PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sorli, SC; Le Gonidec, S; Knibiehler, B; Audigier, Y				Sorli, S. C.; Le Gonidec, S.; Knibiehler, B.; Audigier, Y.			Apelin is a potent activator of tumour neoangiogenesis	ONCOGENE			English	Article						breast cancer; neoangiogenesis; G protein-coupled receptors	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTOR; VASCULAR DEVELOPMENT; ANGIOGENIC FACTOR; HUMAN APJ; X-MSR; EXPRESSION; VEGF; LIGAND; CELLS	Our laboratory has previously shown that apelin is mitogenic for endothelial cells. We have postulated that apelin represents an angiogenic factor secreted by tumour cells in order to promote the formation of new vessels necessary for tumour growth. We first demonstrate that apelin and its receptor are not expressed by the mouse TS/A mammary carcinoma cells. We therefore established clones of this tumoral cell type stably overexpressing the apelin cDNA (TS/A-apelin clones). Comparison of the in vitro proliferation rates between TS/A-mock and TS/A-apelin cells did not reveal any difference and confirmed the lack of receptor expression by tumour cells. On the other hand, apelin overexpression clearly increased the in vivo tumour growth and this increase was associated with an earlier onset of tumour development. In tumours derived from TS/A-apelin clones, the expression of the endothelial marker CD31 was increased and revealed the formation of large intratumoral vessels lined with CD31 positive cells. These data suggest that apelin behaves as a potent activator of tumour neoangiogenesis by a paracrine effect on host vessels. The pathological relevance of this finding is demonstrated by hypoxia-induced upregulation of apelin gene and its overexpression in one-third of human tumours.	[Sorli, S. C.; Le Gonidec, S.; Knibiehler, B.; Audigier, Y.] INSERM, U589, 12MR, Canc Dept, F-31432 Toulouse 4, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Audigier, Y (corresponding author), INSERM, U589, 12MR, Canc Dept, BP 84225,1 Ave Jean Poulhes, F-31432 Toulouse 4, France.	yves.audigier@toulouse.inserm.fr		Le Gonidec, Sophie/0000-0002-8141-690X				AUDIGIER Y, 2006, AFCS NATURE MOL PAGE; BREIER G, 1992, DEVELOPMENT, V114, P521; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Cox CM, 2006, DEV BIOL, V296, P177, DOI 10.1016/j.ydbio.2006.04.452; Devic E, 1996, MECH DEVELOP, V59, P129, DOI 10.1016/0925-4773(96)00585-0; Devic E, 1999, MECH DEVELOP, V84, P199, DOI 10.1016/S0925-4773(99)00081-7; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Graeven U, 2001, CANCER RES, V61, P7282; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Masri B, 2005, CELL SIGNAL, V17, P415, DOI 10.1016/j.cellsig.2004.09.018; Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje; Masri B, 2002, BIOCHEM BIOPH RES CO, V290, P539, DOI 10.1006/bbrc.2001.6230; Masri B, 2006, J BIOL CHEM, V281, P18317, DOI 10.1074/jbc.M600606200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; PLATE KH, 1993, CANCER RES, V53, P5822; Prewett M, 1999, CANCER RES, V59, P5209; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; RAK J, 1995, CANCER RES, V55, P4575; Saint-Geniez M, 2002, MECH DEVELOP, V110, P183, DOI 10.1016/S0925-4773(01)00558-5; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P845; Sorli SC, 2006, DRUG DISCOV TODAY, V11, P1100, DOI 10.1016/j.drudis.2006.10.011; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Wood JM, 2000, CANCER RES, V60, P2178	37	129	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7692	7699		10.1038/sj.onc.1210573	http://dx.doi.org/10.1038/sj.onc.1210573			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563744				2022-12-25	WOS:000251537800011
J	Barbosa, MTP; Soares, SM; Novak, CM; Sinclair, D; Levine, JA; Aksoy, P; Chini, EN				Barbosa, Maria Thereza P.; Soares, Sandra M.; Novak, Colleen M.; Sinclair, David; Levine, James A.; Aksoy, Pinar; Chini, Eduardo Nunes			The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity	FASEB JOURNAL			English	Article						sirtuins; SIRT1; PGC1 alpha; nicotinamide adenine dinucleotide; knockout mice; liver	CYCLIC ADP-RIBOSE; PGC-1-ALPHA; INCREASES; FAMILY; GROWTH; CELL	Obesity is one of the major health problems of our times. Elucidating the signaling mechanisms by which high-fat caloric diet induces obesity is critical for the understanding of this condition and for the development of therapeutic strategies for its treatment. Here, we demonstrate a novel role for protein CD38 as a regulator of body weight during a high-fat diet. CD38 is a ubiquitous enzyme that catalyzes the synthesis of second messengers and has been implicated in the regulation of a wide variety of signaling pathways. We report that CD38-deficient mice are protected against high-fat diet-induced obesity owing to enhanced energy expenditure. In fact, calorimetric studies indicate that CD38-deficient animals have a higher metabolic rate compared to control mice. Analysis of the mechanism revealed that this resistance to diet-induced obesity is mediated at least in part via a NAD-dependent activation of SIRT-PGC1 alpha axis, a well-established cascade, involved in the regulation of mitochondrial biogenesis and energy homeostasis. Thus, together these results identify a novel pathway regulating body weight and clearly show that CD38 is a nearly obligatory component of the cellular cascade that led to diet-induced obesity.	Mayo Clin & Mayo Fdn, Coll Med, Dept Anesthesiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Endocrinol, Rochester, MN 55905 USA; Harvard Univ, Sch Med, Paul F Glenn Labs Biol Mech Aging, Boston, MA USA	Mayo Clinic; Mayo Clinic; Harvard University; Harvard Medical School	Chini, EN (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Anesthesiol, 200 1st St SW, Rochester, MN 55905 USA.	chini.eduardo@mayo.edu		Sinclair, David/0000-0002-9936-436X; Herrmann, Sandra/0000-0002-3700-4537; Novak, Colleen/0000-0002-8542-1677				Aksoy P, 2006, BIOCHEM BIOPH RES CO, V349, P353, DOI 10.1016/j.bbrc.2006.08.066; Aksoy P, 2006, BIOCHEM BIOPH RES CO, V345, P1386, DOI 10.1016/j.bbrc.2006.05.042; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Cai GW, 2004, HUM BIOL, V76, P651, DOI 10.1353/hub.2005.0001; Chini EN, 2002, BRAZ J MED BIOL RES, V35, P543, DOI 10.1590/S0100-879X2002000500005; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fernandez-Zapico ME, 2003, EMBO J, V22, P4748, DOI 10.1093/emboj/cdg470; FOLCH J, 1957, J BIOL CHEM, V226, P497; Galione A, 2000, Sci STKE, V2000, ppe1; Johnson JD, 2006, DIABETES, V55, P2737, DOI 10.2337/db05-1455; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mai A, 2005, J MED CHEM, V48, P7789, DOI 10.1021/jm050100l; Novak CM, 2006, J NEUROENDOCRINOL, V18, P594, DOI 10.1111/j.1365-2826.2006.01454.x; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Puigserver P, 2005, INT J OBESITY, V29, pS5, DOI 10.1038/sj.ijo.0802905; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; Thompson M, 2004, AM J PHYSIOL-ENDOC M, V287, pE1142, DOI 10.1152/ajpendo.00122.2004; Webb DL, 1996, J BIOL CHEM, V271, P19074, DOI 10.1074/jbc.271.32.19074	23	166	175	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3629	3639		10.1096/fj.07-8290com	http://dx.doi.org/10.1096/fj.07-8290com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17585054				2022-12-25	WOS:000250517800025
J	Barraud-Lange, V; Naud-Barriant, N; Bomsel, M; Wolf, JP; Ziyyat, A				Barraud-Lange, Virginie; Naud-Barriant, Nathalie; Bomsel, Morgane; Wolf, Jean-Philippe; Ziyyat, Ahmed			Transfer of oocyte membrane fragments to fertilizing spermatozoa	FASEB JOURNAL			English	Article						trogocytosis; gamete fusion; tetraspanin; lipid transfer; protein transfer	TETRASPANIN WEB; EWI-2; CD9; FUSION; SPERM	Several families of molecules are implicated in the membrane fusion process between sperm and oocyte. Among these, CD9 tetraspanin, a membrane-organizing molecule, plays a crucial role, since the fertilizing ability of CD9-/- oocytes is dramatically impaired. CD9 controls alpha6-beta1 integrin relocation involved in the membrane reorganization that occurs on oocyte fertilization but is not expressed on sperm. We report here that, together with several other proteins, the CD9 tetraspanin is transferred from the oocyte to the fertilizing spermatozoa present in the perivitelline space before fertilization. Transfer of CD9 from oocyte to sperm from CD9-/- male mice still occurs. CD9 acquisition by sperm results from a transfer of membrane fragments from the plasma membrane of the oocyte, in a process similar to trogocytosis, the recently described mechanism of intercellular exchange of membrane patches. Acquisition of CD9 by the sperm may be crucial for the membrane reorganization in sperm required for fusion with the oocyte, a process that is similar to the role CD9 plays in oocyte membrane reorganization.	Univ Paris 13, Reprod Biol Lab, UFR SMBH, F-93017 Bobigny, France; Hop Jean Verdier, AP HP, Bondy, France; INSERM, U567, Paris, France	Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Wolf, JP (corresponding author), Univ Paris 13, Reprod Biol Lab, UFR SMBH, 74 Rue Marcel Cachin, F-93017 Bobigny, France.	jean-philippe.wolf@jvr.ap-hop-paris.fr	Bomsel, Morgane/GSN-1948-2022; ZIYYAT, Ahmed/F-7617-2019; ZIYYAT, Ahmed/ABB-1861-2021	ZIYYAT, Ahmed/0000-0001-9724-3831; ZIYYAT, Ahmed/0000-0001-9724-3831; Barraud-Lange, Virginie/0000-0001-8507-7303; Bomsel, Morgane/0000-0002-9577-7474				Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Charrin S, 2003, BIOCHEM J, V373, P409, DOI 10.1042/BJ20030343; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Joly E, 2003, NAT IMMUNOL, V4, P815, DOI 10.1038/ni0903-815; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; Kolesnikova TV, 2004, BLOOD, V103, P3013, DOI 10.1182/blood-2003-07-2201; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Runge KE, 2007, DEV BIOL, V304, P317, DOI 10.1016/j.ydbio.2006.12.041; Sala-Valdes M, 2006, J BIOL CHEM, V281, P19665, DOI 10.1074/jbc.M602116200; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Toshimori K, 1998, BIOL REPROD, V59, P22, DOI 10.1095/biolreprod59.1.22; Zhu GZ, 2002, DEVELOPMENT, V129, P1995; Ziyyat A, 2006, J CELL SCI, V119, P416, DOI 10.1242/jcs.02730	14	52	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3446	3449		10.1096/fj.06-8035hyp	http://dx.doi.org/10.1096/fj.06-8035hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575263				2022-12-25	WOS:000250517800007
J	Hostettler, N; Naggi, A; Torri, G; Ishai-Michaeli, R; Casu, B; Vlodavsky, I; Borsig, L				Hostettler, Nina; Naggi, Annamaria; Torri, Giangiacomo; Ishai-Michaeli, Riva; Casu, Benito; Vlodavsky, Israel; Borsig, Lubor			P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins	FASEB JOURNAL			English	Article						thrombin generation; LMWH; selectin interactions; heparin derivatives	MOLECULAR-WEIGHT HEPARIN; TISSUE FACTOR PATHWAY; CHEMICALLY-MODIFIED HEPARIN; TUMOR-METASTASIS; VENOUS THROMBOEMBOLISM; MAMMALIAN HEPARANASE; ADVANCED MALIGNANCY; CANCER METASTASIS; ANGIOGENESIS; SURVIVAL	Vascular cell adhesion molecules, P- and L-selectins, facilitate metastasis of cancer cells in mice by mediating interactions with platelets, endothelium, and leukocytes. Heparanase is an endoglycosidase that degrades heparan sulfate of extracellular matrix, thereby promoting tumor invasion and metastasis. Heparin is known to efficiently attenuate metastasis in different tumor models. Here we identified modified, nonanticoagulant species of heparin that specifically inhibit selectin-mediated cell-cell interactions, heparanase enzymatic activity, or both. We show that selective inhibition of selectin interactions or heparanase with specific heparin derivatives in mouse models of MC-38 colon carcinoma and B16-BL6 melanoma attenuates metastasis. Selectin-specific heparin derivatives attenuated metastasis of MC-38 carcinoma, but heparanase-specific derivatives had no effect, in accordance with the virtual absence of heparanase activity in these cells. Heparin derivatives had no further effect on metastasis in mice deficient in P- and L-selectin, indicating that selectins are the primary targets of heparin antimeta-static activity. Selectin-specific and heparanase-specific derivatives attenuated metastasis of B16-BL6 melanomas to a similar extent. When mice were injected with a derivative containing both heparanase and selectin inhibitory activity, no additional attenuation of metastasis could be observed. Thus, selectin-specific heparin derivatives efficiently attenuated metastasis of both tumor cell types whereas inhibition of heparanase led to reduction of metastasis only in tumor cells producing heparanase.	Univ Zurich, Inst Physiol, Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; G Ronzoni Inst Chem & Biochem Res, Milan, Italy; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Borsig, L (corresponding author), Univ Zurich, Inst Physiol, Zurich Ctr Integrat Human Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	lborsig@access.unizh.ch		Torri, Giangiacomo/0000-0002-2077-1203; Borsig, Lubor/0000-0003-2263-9545				Alban S, 2001, SEMIN THROMB HEMOST, V27, P503, DOI 10.1055/s-2001-17952; Altinbas M, 2004, J THROMB HAEMOST, V2, P1266, DOI 10.1111/j.1538-7836.2004.00871.x; BARNER M, 1985, INT J CANCER, V35, P483, DOI 10.1002/ijc.2910350411; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Cohen I, 2006, INT J CANCER, V118, P1609, DOI 10.1002/ijc.21552; Cosgrove RH, 2002, SEMIN THROMB HEMOST, V28, P79, DOI 10.1055/s-2002-20566; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Gao YG, 2005, MOL CELLS, V19, P350; Hettiarachchi RJK, 1999, THROMB HAEMOSTASIS, V82, P947, DOI 10.1055/s-0037-1615937; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Im JH, 2004, CANCER RES, V64, P8613, DOI 10.1158/0008-5472.CAN-04-2078; Jayson GC, 1997, BRIT J CANCER, V75, P9, DOI 10.1038/bjc.1997.3; Kakkar AK, 2004, J CLIN ONCOL, V22, P1944, DOI 10.1200/JCO.2004.10.002; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; Klerk CPW, 2005, J CLIN ONCOL, V23, P2130, DOI 10.1200/JCO.2005.03.134; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kragh M, 2005, ONCOL REP, V14, P99; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; Laubli H, 2006, CANCER RES, V66, P1536, DOI 10.1158/0008-5472.CAN-05-3121; Lazo-Langner A, 2007, J THROMB HAEMOST, V5, P729, DOI 10.1111/j.1538-7836.2007.02427.x; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; Lee AYY, 2005, J CLIN ONCOL, V23, P2123, DOI 10.1200/JCO.2005.03.133; Lever R, 2002, NAT REV DRUG DISCOV, V1, P140, DOI 10.1038/nrd724; Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471-4914(03)00071-6; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Ludwig RJ, 2004, CANCER RES, V64, P2743, DOI 10.1158/0008-5472.CAN-03-1054; MANNORI G, 1995, CANCER RES, V55, P4425; Mousa SA, 2004, THROMB HAEMOSTASIS, V92, P627, DOI 10.1160/TH04-02-0069; Mousa SA, 2004, SEMIN THROMB HEMOST, V30, P25; Mousa SA, 2002, SEMIN THROMB HEMOST, V28, P45, DOI 10.1055/s-2002-20559; NAGASAWA K, 1978, BIOCHIM BIOPHYS ACTA, V544, P430, DOI 10.1016/0304-4165(78)90110-1; Naggi A, 2005, J BIOL CHEM, V280, P12103, DOI 10.1074/jbc.M414217200; Ohyama C, 1999, EMBO J, V18, P1516, DOI 10.1093/emboj/18.6.1516; Ono K, 2002, BRIT J CANCER, V86, P1803, DOI 10.1038/sj.bjc.6600307; Parish CR, 1999, CANCER RES, V59, P3433; Rickles FR, 2006, PATHOPHYSIOL HAEMO T, V35, P103, DOI 10.1159/000093551; Singh R, 2001, CIRC RES, V89, P71, DOI 10.1161/hh1301.092508; Smorenburg SM, 1999, THROMB HAEMOSTASIS, V82, P1600; Smorenburg SM, 2001, PHARMACOL REV, V53, P93; Stevenson JL, 2005, CLIN CANCER RES, V11, P7003, DOI 10.1158/1078-0432.CCR-05-1131; Tobu M, 2005, CLIN APPL THROMB-HEM, V11, P37, DOI 10.1177/107602960501100104; VALENTIN S, 1994, THROMB RES, V75, P173, DOI 10.1016/0049-3848(94)90066-3; Varki NM, 2002, SEMIN THROMB HEMOST, V28, P53, DOI 10.1055/s-2002-20564; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vlodavsky I, 2006, PATHOPHYSIOL HAEMO T, V35, P116, DOI 10.1159/000093553; Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996; Yoshitomi Y, 2004, CANCER LETT, V207, P165, DOI 10.1016/j.canlet.2003.11.037; Zacharski LR, 1998, THROMB HAEMOSTASIS, V80, P10; Zacharski LR, 2000, SEMIN THROMB HEMOST, V26, P69, DOI 10.1055/s-2000-9499; Zacharski LR, 2002, CANCER LETT, V186, P1, DOI 10.1016/S0304-3835(02)00258-6	54	94	100	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3562	3572		10.1096/fj.07-8450com	http://dx.doi.org/10.1096/fj.07-8450com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17557930	Green Accepted			2022-12-25	WOS:000250517800019
J	Jia, SJ; Omelchenko, M; Garland, D; Vasiliou, V; Kanungo, J; Spencer, M; Wolf, Y; Koonin, E; Piatigorsky, J				Jia, Sujuan; Omelchenko, Marina; Garland, Donita; Vasiliou, Vasilis; Kanungo, Jyotshnabala; Spencer, Michael; Wolf, Yuri; Koonin, Eugene; Piatigorsky, Joram			Duplicated gelsolin family genes in zebrafish: a novel scinderin-like gene (scinla) encodes the major corneal crystallin	FASEB JOURNAL			English	Article						gene duplication; evolution; tissue-specific expression	ACTIN-BINDING PROTEINS; FILAMENT-SEVERING PROTEIN; CHROMAFFIN CELL SCINDERIN; RAY-FINNED FISHES; GENOME DUPLICATION; LENS CRYSTALLINS; ALDEHYDE DEHYDROGENASE; RECOMBINANT SCINDERIN; REGULATORY PROTEIN; ANABLEPS-ANABLEPS	We have previously identified a gelsolin-like protein ( C/L-gelsolin) as a corneal crystallin in zebrafish. Here we show by phylogenetic analysis that there are at least six genes encoding gelsolin-like proteins based on their gelsolin domains in zebrafish: gsna and gsnb group with the vertebrate gelsolin gene, scina and scinb group with the scinderin ( adseverin) gene, and scinla ( C/L-gelsolin) and scinlb are novel scinderin-like genes. RT-PCR showed that scinla, scinlb, and gsnb are preferentially expressed in the adult cornea whereas gsna is expressed to a similar extent in cornea, lens, brain, and heart; scina and scinb expression were detectable only in whole zebrafish and not in these adult tissues. Quantitative RT-PCR and 2-dimensional polyacrylamide gel electrophoresis followed by MALDI/TOF mass spectroscopy confirmed high expression of beta-actin and scinla, moderate expression of scinlb, and very low expression of gsna and gsnb in the cornea. Finally, transgenic zebrafish carrying a green fluorescent protein reporter transgene driven by a 4 kb scinla promoter fragment showed expression in the cornea, snout, dorsal fin, and tail fin of 3-day-old zebrafish larvae. Our data suggest that scinla and scinlb are diverged paralogs of the vertebrate scinderin gene and show that scinla encodes the zebrafish corneal crystallin previously called C/L-gelsolin. - Jia, S., Omelchenko, M., Garland, D., Vasiliou, V., Kanungo, J., Spencer, M., Wolf, Y., Koonin, E., Piatigorsky, J. Duplicated gelsolin family genes in zebrafish: a novel scinderin-like gene ( scinla) encodes the major corneal crystallin.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NEI, Lab Retinal Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA; NIH, Natl Lib Med, Bethesda, MD 20892 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, 7 Mem Dr,Bldg 7,Rm 100, Bethesda, MD 20892 USA.	joramp@nei.nih.gov		vasiliou, vasilis/0000-0003-2552-3118; Wolf, Yuri/0000-0002-0247-8708	NATIONAL EYE INSTITUTE [R01EY011490, R29EY011490, Z01EY000259, Z01EY000126] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 EY000126-26] Funding Source: Medline; NEI NIH HHS [EY11490, R01 EY011490, R29 EY011490] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; ADACHI J, 1992, MOLPHYS PROGRAMS MOL; ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Arai M, 1999, DEV DYNAM, V215, P297, DOI 10.1002/(SICI)1097-0177(199908)215:4<297::AID-AJA2>3.3.CO;2-9; Archer SK, 2005, BIOESSAYS, V27, P388, DOI 10.1002/bies.20200; Arora PD, 2004, MOL BIOL CELL, V15, P588, DOI 10.1091/mbc.E03-07-0468; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Christoffels A, 2004, MOL BIOL EVOL, V21, P1146, DOI 10.1093/molbev/msh114; Culp WD, 2006, J PROTEOME RES, V5, P1332, DOI 10.1021/pr060059q; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DELCASTILLO AR, 1990, EMBO J, V9, P43, DOI 10.1002/j.1460-2075.1990.tb08078.x; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Hough RB, 2004, MOL CELL BIOL, V24, P1324, DOI 10.1128/MCB.24.3.1324-1340.2004; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Kanungo J, 2004, EXP EYE RES, V79, P949, DOI 10.1016/j.exer.2004.04.002; Kanungo J, 2003, P NATL ACAD SCI USA, V100, P3287, DOI 10.1073/pnas.0634473100; King G, 1998, J EXP ZOOL, V282, P12; Kurita R, 2003, DEV BIOL, V255, P113, DOI 10.1016/S0012-1606(02)00079-9; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P8239; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Lejen T, 2002, ANN NY ACAD SCI, V971, P248, DOI 10.1111/j.1749-6632.2002.tb04469.x; Lueck A, 1998, J CELL SCI, V111, P3633; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; Marcu MG, 1996, BLOOD, V87, P20; MARCU MG, 1994, MOL CELL BIOCHEM, V141, P153, DOI 10.1007/BF00926179; Marcu MG, 1998, J BIOL CHEM, V273, P3661, DOI 10.1074/jbc.273.6.3661; McGough AM, 2003, FEBS LETT, V552, P75, DOI 10.1016/S0014-5793(03)00932-3; NAKAMURA S, 1994, J BIOL CHEM, V269, P5890; Naruse K, 2004, GENOME RES, V14, P820, DOI 10.1101/gr.2004004; Nees DW, 2002, MOL CELL BIOL, V22, P849, DOI 10.1128/MCB.22.3.849-855.2002; Oberemm A, 2005, TOXICOLOGY, V206, P33, DOI 10.1016/j.tox.2004.06.061; Paunio T, 1997, FEBS LETT, V406, P49, DOI 10.1016/S0014-5793(97)00237-8; Pene TD, 2005, J NEUROCHEM, V92, P780, DOI 10.1111/j.1471-4159.2004.02907.x; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; Postlethwait J, 2004, TRENDS GENET, V20, P481, DOI 10.1016/j.tig.2004.08.001; Robbens J, 1998, MOL CELL BIOL, V18, P4589, DOI 10.1128/MCB.18.8.4589; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SAKURAI T, 1991, J BIOL CHEM, V266, P15979; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; Soules KA, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471-213X-5-12; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Svensson C, 2002, BIOCHEM BIOPH RES CO, V291, P1194, DOI 10.1006/bbrc.2002.6582; Svensson C, 2001, MOL PHARMACOL, V60, P135, DOI 10.1124/mol.60.1.135; Swamynathan SK, 2003, FASEB J, V17, P1996, DOI 10.1096/fj.03-0122com; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Taylor JS, 2001, TRENDS GENET, V17, P299, DOI 10.1016/S0168-9525(01)02318-6; TCHAKAROV L, 1990, FEBS LETT, V268, P209, DOI 10.1016/0014-5793(90)81010-L; Trifaro JM, 2002, NEUROCHEM RES, V27, P1371, DOI 10.1023/A:1021627800918; Vandepoele K, 2004, P NATL ACAD SCI USA, V101, P1638, DOI 10.1073/pnas.0307968100; VASILIOU V, 1992, BIOCHEM BIOPH RES CO, V187, P413, DOI 10.1016/S0006-291X(05)81508-6; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; Waddell Peter J, 2002, Genome Inform, V13, P82; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Woods IG, 2005, GENOME RES, V15, P1307, DOI 10.1101/gr.4134305; Xu YS, 2000, J BIOL CHEM, V275, P24645, DOI 10.1074/jbc.M001159200; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YOSHIKAWA S, 2006, INVEST OPHTHALMOL VI, V47; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9; Zhao XPC, 2006, INVEST OPHTH VIS SCI, V47, P4341, DOI 10.1167/iovs.05-1611; Zhao YX, 2005, ANAL CHEM, V77, P5324, DOI 10.1021/ac050354e; Zieske JD, 2004, INT J DEV BIOL, V48, P903, DOI 10.1387/ijdb.041860jz; Zunino R, 2001, BLOOD, V98, P2210, DOI 10.1182/blood.V98.7.2210	70	16	18	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3318	3328		10.1096/fj.07-8172com	http://dx.doi.org/10.1096/fj.07-8172com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17548429	Green Accepted			2022-12-25	WOS:000249781600032
J	Lehane, AM; Marchetti, RV; Spry, C; van Schalkwyk, DA; Teng, R; Kirk, K; Saliba, KJ				Lehane, Adele M.; Marchetti, Rosa V.; Spry, Christina; van Schalkwyk, Donelly A.; Teng, Rongwei; Kirk, Kiaran; Saliba, Kevin J.			Feedback inhibition of pantothenate kinase regulates pantothenol uptake by the malaria parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; FALCIPARUM IN-VITRO; RENAL BRUSH-BORDER; PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; P-FALCIPARUM; COENZYME-A; TRANSPORT; ACID; ANTIMETABOLITES	To survive, the human malaria parasite Plasmodium falciparum must acquire pantothenate ( vitamin B-5) from the external medium. Pantothenol (provitamin B-5) inhibits parasite growth by competing with pantothenate for pantothenate kinase, the first enzyme in the coenzyme A biosynthesis pathway. In this study we investigated pantothenol uptake by P. falciparum and in doing so gained insights into the regulation of the parasite's coenzyme A biosynthesis pathway. Pantothenol was shown to enter P. falciparum-infected erythrocytes via two routes, the furosemide-inhibited "new permeation pathways" induced by the parasite in the infected erythrocyte membrane ( the sole access route for pantothenate) and a second, furosemide-insensitive pathway. Having entered the erythrocyte, pantothenol is taken up by the intracellular parasite via a mechanism showing functional characteristics distinct from those of the parasite's pantothenate uptake mechanism. On reaching the parasite cytosol, pantothenol is phosphorylated and thereby trapped by pantothenate kinase, shown here to be under feedback inhibition control by coenzyme A. Furosemide reduced this inherent feedback inhibition by competing with coenzyme A for binding to pantothenate kinase, thereby increasing pantothenol uptake.	Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia; Australian Natl Univ, Sch Med, Canberra, ACT 0200, Australia	Australian National University; Australian National University	Saliba, KJ (corresponding author), Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia.	kevin.saliba@anu.edu.au	van Schalkwyk, Donelly/X-6771-2019; van Schalkwyk, Donelly A/A-2499-2008; Kirk, Kiaran/C-8299-2009; Lehane, Adele M/B-4127-2012; Saliba, Kevin J/C-9166-2009	van Schalkwyk, Donelly/0000-0002-7375-3439; van Schalkwyk, Donelly A/0000-0002-7375-3439; Kirk, Kiaran/0000-0002-5613-2622; Lehane, Adele M/0000-0002-0050-9101; Saliba, Kevin J/0000-0003-3345-8440; Spry, Christina/0000-0002-8156-7070				Allen RJW, 2004, J BIOL CHEM, V279, P11264, DOI 10.1074/jbc.M311110200; Andrews KT, 2006, ANTIMICROB AGENTS CH, V50, P639, DOI 10.1128/AAC.50.2.639-648.2006; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; Brand LA, 2005, J BIOL CHEM, V280, P20185, DOI 10.1074/jbc.C500044200; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; Choudhry AE, 2003, ANTIMICROB AGENTS CH, V47, P2051, DOI 10.1128/AAC.47.6.2051-2055.2003; CLIFTON G, 1970, ARCH BIOCHEM BIOPHYS, V137, P523, DOI 10.1016/0003-9861(70)90470-4; DESMEDT H, 1981, BIOCHIM BIOPHYS ACTA, V648, P247, DOI 10.1016/0005-2736(81)90040-7; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; Ellory J C, 1987, Symp Soc Exp Biol, V41, P53; FISHER MN, 1985, J BIOL CHEM, V260, P5745; HORI R, 1982, BIOCHIM BIOPHYS ACTA, V692, P97, DOI 10.1016/0005-2736(82)90506-5; Ivey RA, 2004, J BIOL CHEM, V279, P35622, DOI 10.1074/jbc.M403152200; Kirk K, 2007, CURR DRUG TARGETS, V8, P75, DOI 10.2174/138945007779315560; Lehane AM, 2004, BIOCHEM BIOPH RES CO, V320, P311, DOI 10.1016/j.bbrc.2004.05.164; Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001; Leonardi R, 2007, P NATL ACAD SCI USA, V104, P1494, DOI 10.1073/pnas.0607621104; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; MADINAVEITIA J, 1945, BIOCHEM J, V39, P85, DOI 10.1042/bj0390085; PAUL F, 1981, LANCET, V2, P70; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; Saliba KJ, 1998, J BIOL CHEM, V273, P10190, DOI 10.1074/jbc.273.17.10190; Saliba KJ, 2005, MOL BIOCHEM PARASIT, V141, P129, DOI 10.1016/j.molbiopara.2005.02.003; Saliba KJ, 2005, ANTIMICROB AGENTS CH, V49, P632, DOI 10.1128/AAC.49.2.632-637.2005; Saliba KJ, 2001, J BIOL CHEM, V276, P18115, DOI 10.1074/jbc.M010942200; SNELL EE, 1945, J BIOL CHEM, V158, P551; Spry C, 2005, ANTIMICROB AGENTS CH, V49, P4649, DOI 10.1128/AAC.49.11.4649-4657.2005; Staalsoe T, 1999, CYTOMETRY, V35, P329, DOI 10.1002/(SICI)1097-0320(19990401)35:4&lt;329::AID-CYTO5&gt;3.0.CO;2-Y; Strauss E, 2002, J BIOL CHEM, V277, P48205, DOI 10.1074/jbc.M204560200; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; TRAGER W, 1966, T NEW YORK ACAD SCI, V28, P1094, DOI 10.1111/j.2164-0947.1966.tb02410.x; TRAGER W, 1971, J PROTOZOOL, V18, P232, DOI 10.1111/j.1550-7408.1971.tb03313.x; Virga KG, 2006, BIOORGAN MED CHEM, V14, P1007, DOI 10.1016/j.bmc.2005.09.021	33	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25395	25405		10.1074/jbc.M704610200	http://dx.doi.org/10.1074/jbc.M704610200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17581817	hybrid			2022-12-25	WOS:000249014100025
J	Stahelin, RV; Karathanassis, D; Murray, D; Williams, RL; Cho, W				Stahelin, Robert V.; Karathanassis, Dimitrios; Murray, Diana; Williams, Roger L.; Cho, Wonhwa			Structural and membrane binding analysis of the phox homology domain of bem1p - Basis of phosphatidylinositol 4-phosphate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL KINASE CISK; BUD-SITE SELECTION; PX-DOMAIN; PROTEIN INTERACTIONS; CRYSTAL-STRUCTURE; CELL POLARITY; C2 DOMAIN; YEAST; PHOSPHOINOSITIDES; BAR	Phox homology (PX) domains, which have been identified in a variety of proteins involved in cell signaling and membrane trafficking, have been shown to interact with phosphoinositides (PIs) with different affinities and specificities. To elucidate the structural origin of the diverse PI specificity of PX domains, we determined the crystal structure of the PX domain from Bem1p that has been reported to bind phosphatidylinositol 4-phosphate ( PtdIns( 4) P). We also measured the membrane binding properties of the PX domain and its mutants by surface plasmon resonance and monolayer techniques and calculated the electrostatic potentials for the PX domain in the absence and presence of bound PtdIns( 4) P. The Bem1p PX domain contains a signature PI-binding site optimized for PtdIns( 4) P binding and also harbors basic and hydrophobic residues on the membrane-binding surface. The membrane binding of the Bem1p PX domain is initiated by nonspecific electrostatic interactions between the cationicmembrane- binding surface of the domain and anionic membrane surfaces, followed by the membrane penetration of hydrophobic residues. Unlike other PX domains, the Bem1p PX domain has high intrinsic membrane penetrating activity in the absence of PtdIns(4) P, suggesting that the partial membrane penetration may occur before specific PtdIns( 4) P binding and last after the removal of PtdIns( 4) P under certain conditions. This structural and functional study of the PtdIns( 4) P-binding Bem1p PX domain provides new insight into the diverse PI specificities and membrane-binding mechanisms of PX domains.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Bloomington, IN 47405 USA; Univ Notre Dame, Walther Ctr Canc Res, South Bend, IN 46617 USA; Univ Notre Dame, Dept Chem & Biochem, South Bend, IN 46617 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Indiana University System; Indiana University Bloomington; University of Notre Dame; Walther Cancer Institute; University of Notre Dame; MRC Laboratory Molecular Biology; Cornell University	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863; Williams, Roger/0000-0001-7754-4207	Medical Research Council [MC_U105184308] Funding Source: Medline; NIGMS NIH HHS [GM68849] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068849] Funding Source: NIH RePORTER; MRC [MC_U105184308] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Blatner NR, 2004, J BIOL CHEM, V279, P53818, DOI 10.1074/jbc.M408408200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; Bose I, 2001, J BIOL CHEM, V276, P7176, DOI 10.1074/jbc.M010546200; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carroll K, 2004, NAT REV MOL CELL BIO, V5, P55, DOI 10.1038/nrm1278; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; CHO W, 2006, SCI STKE, pPE7, DOI DOI 10.1126/STKE.3212006PE7; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Cho W, 2006, BBA-MOL CELL BIOL L, V1761, P838, DOI 10.1016/j.bbalip.2006.06.014; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Cremona O, 2001, J CELL SCI, V114, P1041; Czech MP, 2003, ANNU REV PHYSIOL, V65, P791, DOI 10.1146/annurev.physiol.65.092101.142522; Dawson JC, 2006, TRENDS CELL BIOL, V16, P493, DOI 10.1016/j.tcb.2006.08.004; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; DiNitto JP, 2006, BBA-MOL CELL BIOL L, V1761, P850, DOI 10.1016/j.bbalip.2006.04.008; DINITTO JP, 2003, SCI STKE, pRE16, DOI DOI 10.1126/STKE.2132003RE16; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Flesch FM, 2005, BIOCHEM J, V389, P435, DOI 10.1042/BJ20041721; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Irazoqui JE, 2003, NAT CELL BIOL, V5, P1062, DOI 10.1038/ncb1068; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Itoh T, 2002, CELL SIGNAL, V14, P733, DOI 10.1016/S0898-6568(02)00028-1; Itoh T, 2006, BBA-MOL CELL BIOL L, V1761, P897, DOI 10.1016/j.bbalip.2006.06.015; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kutateladze TG, 2006, BBA-MOL CELL BIOL L, V1761, P868, DOI 10.1016/j.bbalip.2006.03.011; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JS, 2005, J CELL SCI, V118, P4405, DOI 10.1242/jcs.02564; Lee SA, 2006, J BIOL CHEM, V281, P37091, DOI 10.1074/jbc.M608610200; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Lu J, 2002, BIOCHEMISTRY-US, V41, P5956, DOI 10.1021/bi020050b; Malkova S, 2006, BIOCHEMISTRY-US, V45, P13566, DOI 10.1021/bi061133l; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Seet LF, 2006, BBA-MOL CELL BIOL L, V1761, P878, DOI 10.1016/j.bbalip.2006.04.011; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stahelin RV, 2006, J BIOL CHEM, V281, P39396, DOI 10.1074/jbc.M607079200; Stahelin RV, 2004, J BIOL CHEM, V279, P54918, DOI 10.1074/jbc.M407798200; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vollert CS, 2004, MOL CELL PROTEOMICS, V3, P1053, DOI 10.1074/mcp.M400081-MCP200; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215; Wera S, 2001, FEMS YEAST RES, V1, P9, DOI 10.1111/j.1567-1364.2001.tb00008.x; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xing Y, 2004, J BIOL CHEM, V279, P30662, DOI 10.1074/jbc.M404107200; Xing Y, 2003, ACTA CRYSTALLOGR D, V59, P1816, DOI 10.1107/S0907444903015567; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; Zhou CZ, 2003, J BIOL CHEM, V278, P50371, DOI 10.1074/jbc.M304392200	89	47	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25737	25747		10.1074/jbc.M702861200	http://dx.doi.org/10.1074/jbc.M702861200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17581820	hybrid			2022-12-25	WOS:000249014100061
J	Subramanian, S; Sijwali, PS; Rosenthal, PJ				Subramanian, Shoba; Sijwali, Puran S.; Rosenthal, Philip J.			Falcipain cysteine proteases require bipartite motifs for trafficking to the Plasmodium falciparum food vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITES; PROTEIN; GENE; HYDROLYSIS; COMPLEX; ROLES	The Plasmodium falciparum cysteine proteases falcipain- 2 and falcipain- 3 hydrolyze hemoglobin in an acidic food vacuole to provide amino acids for erythrocytic malaria parasites. Trafficking to the food vacuole has not been well characterized. To study trafficking of falcipains, which include large membranespanning prodomains, we utilized chimeras with portions of the proteases fused to green fluorescent protein. The prodomains of falcipain- 2 and falcipain- 3 were sufficient to target green fluorescent protein to the food vacuole. Using serial truncations, deletions, and point mutations, we showed that both a 20-amino acid stretch of the lumenal portion and a 10-amino acid stretch of the cytoplasmic portion of the falcipain- 2 prodomain were required for efficient food vacuolar trafficking. Mutants with altered trafficking were arrested at the plasma membrane, implicating trafficking via this structure. Our results indicate that falcipains utilize a previously undescribed bipartite motif-dependent mechanism for targeting to a hydrolytic organelle, suggesting inhibition of this unique mechanism as a new means of antimalarial chemotherapy.	Univ Calif San Francisco, Div Infect Dis, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Rosenthal, PJ (corresponding author), Univ Calif San Francisco, Div Infect Dis, Dept Med, San Francisco, CA 94143 USA.	prosenthal@medsfgh.ucsf.edu		Subramanian, Shoba/0000-0002-4206-3400	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI035800, R01AI035800, P01AI035707, R29AI035800] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35707, AI35800] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adisa A, 2003, J BIOL CHEM, V278, P6532, DOI 10.1074/jbc.M207039200; Dahl EL, 2005, MOL BIOCHEM PARASIT, V139, P205, DOI 10.1016/j.molbiopara.2004.11.009; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Gowda DC, 1999, PARASITOL TODAY, V15, P147, DOI 10.1016/S0169-4758(99)01412-X; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Huete-Perez JA, 1999, J BIOL CHEM, V274, P16249, DOI 10.1074/jbc.274.23.16249; Klemba M, 2004, J CELL BIOL, V164, P47, DOI 10.1083/jcb200307147; Klemba M, 2002, ANNU REV BIOCHEM, V71, P275, DOI 10.1146/annurev.biochem.71.090501.145453; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; Kuhn Y, 2007, CELL MICROBIOL, V9, P1004, DOI 10.1111/j.1462-5822.2006.00847.x; LeBorgne R, 1997, J CELL BIOL, V137, P335; Liu J, 2006, P NATL ACAD SCI USA, V103, P8840, DOI 10.1073/pnas.0601876103; Matsuoka K, 1999, J EXP BOT, V50, P165, DOI 10.1093/jexbot/50.331.165; McIntosh MT, 2007, J BIOL CHEM, V282, P11499, DOI 10.1074/jbc.M610974200; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Rosenthal Philip J., 2001, P3; ROSENTHAL PJ, 1992, MOL BIOCHEM PARASIT, V51, P143, DOI 10.1016/0166-6851(92)90209-3; Rosenthal PJ, 2002, CURR OPIN HEMATOL, V9, P140, DOI 10.1097/00062752-200203000-00010; Rosenthal PJ, 2002, CURR PHARM DESIGN, V8, P1659, DOI 10.2174/1381612023394197; ROSENTHAL PJ, 2005, MOL APPROACHES MALAR, V1, P311; Rug M, 2004, INFECT IMMUN, V72, P6095, DOI 10.1128/IAI.72.10.6095-6105.2004; Sato S, 2003, MOL BIOCHEM PARASIT, V130, P155, DOI 10.1016/S0166-6851(03)00166-X; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P8721, DOI 10.1073/pnas.0402738101; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Sijwali PS, 2006, MOL BIOCHEM PARASIT, V150, P96, DOI 10.1016/j.molbiopara.2006.06.013; Singh N, 2006, EXP PARASITOL, V112, P187, DOI 10.1016/j.exppara.2005.10.007; Struck NS, 2005, J CELL SCI, V118, P5603, DOI 10.1242/jcs.02673; Wickham Mark E., 2001, EMBO (European Molecular Biology Organization) Journal, V20, P5636, DOI 10.1093/emboj/20.20.5636	32	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24961	24969		10.1074/jbc.M703316200	http://dx.doi.org/10.1074/jbc.M703316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17565983	hybrid			2022-12-25	WOS:000248933000052
J	Ghosh, K; Guo, F; Van Duyne, GD				Ghosh, Kaushik; Guo, Feng; Van Duyne, Gregory D.			Synapsis of loxP sites by cre recombinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION INTERMEDIATE; BACTERIOPHAGE-LAMBDA; FLP-RECOMBINASE; ANALYTICAL ULTRACENTRIFUGATION; CRYSTAL-STRUCTURE; STRAND EXCHANGE; SPACER REGION; PROTEIN; INTEGRASE; GEOMETRY	Cre recombinase catalyzes site-specific recombination between 34-bp loxP sites in a variety of topological and cellular contexts. An obligatory step in the recombination reaction is the association, or synapsis, of Cre-bound loxP sites to form a tetrameric protein assembly that is competent for strand exchange. Using analytical ultracentrifugation and electrophoresis approaches, we have studied the energetics of Cre-mediated synapsis of loxP sites. We found that synapsis occurs with a high affinity (Kd = 10 nM) and is pH-dependent but does not require divalent cations. Surprisingly, the catalytically inactive Cre K201A mutant is fully competent for synapsis of loxP sites, yet the inactive Y324F and R173K mutants are defective for synapsis. These findings have allowed us to determine the first crystal structures of a pre-cleavage Cre-loxP synaptic complex in a configuration representing the starting point in the recombination pathway. When combined with a quantitative analysis of synapsis using loxP mutants, the structures explain how the central 8 bp of the loxP site are able to dictate the order of strand exchange in the Cre system.	Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Ghosh, K (corresponding author), Univ Penn, Howard Hughes Med Inst, 242 Anatomy Chem Bldg, Philadelphia, PA 19104 USA.	vanduyne@mail.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055041] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55041] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; Azaro MA., 2002, MOBILE DNA-UK, P118, DOI DOI 10.1128/9781555817954.CH7; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; Biswas T, 2005, NATURE, V435, P1059, DOI 10.1038/nature03657; Bouhassira EE, 1997, BLOOD, V90, P3332, DOI 10.1182/blood.V90.9.3332; Cassell G, 1999, NUCLEIC ACIDS RES, V27, P1145, DOI 10.1093/nar/27.4.1145; Crisona NJ, 1999, J MOL BIOL, V289, P747, DOI 10.1006/jmbi.1999.2771; Ennifar E, 2003, NUCLEIC ACIDS RES, V31, P5449, DOI 10.1093/nar/gkg732; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; Gelato KA, 2005, J MOL BIOL, V354, P233, DOI 10.1016/j.jmb.2005.08.077; Ghosh K, 2005, NAT CHEM BIOL, V1, P275, DOI 10.1038/nchembio733; Ghosh K, 2005, J BIOL CHEM, V280, P8290, DOI 10.1074/jbc.M411668200; Ghosh K, 2002, METHODS, V28, P374, DOI 10.1016/S1046-2023(02)00244-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Grainge I, 2000, J MOL BIOL, V298, P749, DOI 10.1006/jmbi.2000.3679; Grindley NDF, 2006, ANNU REV BIOCHEM, V75, P567, DOI 10.1146/annurev.biochem.73.011303.073908; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; GUO P, 1997, NATURE, V389, P40; HAMILTON DL, 1984, J MOL BIOL, V178, P481, DOI 10.1016/0022-2836(84)90154-2; Hensley P, 1996, STRUCTURE, V4, P367, DOI 10.1016/S0969-2126(96)00042-1; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; HOESS RH, 1990, STRUCTURE METHODS, V1, P203; Huffman KE, 1999, J MOL BIOL, V286, P1, DOI 10.1006/jmbi.1998.2468; Jayaram M., 2002, MOBILE DNA, P192; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Lee L, 2005, PROG NUCLEIC ACID RE, V80, P1, DOI 10.1016/S0079-6603(05)80001-7; Lee L, 2003, J BIOL CHEM, V278, P36905, DOI 10.1074/jbc.M305464200; Lee L, 2003, J BIOL CHEM, V278, P23118, DOI 10.1074/jbc.M302272200; Lee L, 2003, J MOL BIOL, V326, P397, DOI 10.1016/S0022-2836(02)01429-8; Lee L, 2001, J BIOL CHEM, V276, P31092, DOI 10.1074/jbc.M103739200; Martin SS, 2002, J MOL BIOL, V319, P107, DOI 10.1016/S0022-2836(02)00246-2; Mumm JP, 2006, EMBO J, V25, P4586, DOI 10.1038/sj.emboj.7601325; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ringrose L, 1998, J MOL BIOL, V284, P363, DOI 10.1006/jmbi.1998.2149; Rufer A, 2002, ANAL BIOCHEM, V308, P90, DOI 10.1016/S0003-2697(02)00247-6; Sauer B., 2002, MOBILE DNA, P38; Sealy PG, 1990, GEL ELECTROPHORESIS, P51; SEGALL AM, 1993, EMBO J, V12, P4567, DOI 10.1002/j.1460-2075.1993.tb06145.x; Seibler J, 1997, BIOCHEMISTRY-US, V36, P1740, DOI 10.1021/bi962443e; Sherratt DJ, 2004, PHILOS T R SOC B, V359, P61, DOI 10.1098/rstb.2003.1365; Tan S, 2000, J MOL BIOL, V297, P947, DOI 10.1006/jmbi.2000.3606; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; Vetcher AA, 2006, J MOL BIOL, V357, P1089, DOI 10.1016/j.jmb.2006.01.037; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0	53	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24004	24016		10.1074/jbc.M703283200	http://dx.doi.org/10.1074/jbc.M703283200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17573343	hybrid			2022-12-25	WOS:000248686600026
J	McAlinden, A; Liang, L; Mukudai, Y; Imamura, T; Sandell, LJ				McAlinden, Audrey; Liang, Li; Mukudai, Yoshiki; Imamura, Toshihiro; Sandell, Linda J.			Nuclear protein TIA-1 regulates COL2A1 alternative splicing and interacts with precursor mRNA and genomic DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; AU-RICH ELEMENT; BINDING PROTEINS; II-PROCOLLAGEN; POLYMERASE-II; TRANSLATIONAL CONTROL; TERMINAL DOMAIN; IDENTIFICATION; TRANSCRIPTION; ELONGATION	The RNA-binding protein TIA-1 (T-cell-restricted intracellular antigen-1) functions in regulating post-transcriptional mechanisms, including precursor mRNA (pre-mRNA) alternative splicing and mRNA translation. Utilizing a mini-gene consisting of part of the type II procollagen gene (COL2A1), we show that TIA-1 interacts with a conserved AU-rich cis element in COL2A1 intron 2 and modulates alternative splicing of exon 2. This unique, highly conserved cis element containing stem-loop secondary structure was previously identified in our laboratory as an essential motif that controls the developmentally regulated exon 2 splicing switch during chondrogenesis (McAlinden, A., Havlioglu, N., Liang, L., Davies, S. R., and Sandell, L. J. (2005) J. Biol. Chem. 280, 32700-32711). In vivo binding of endogenous TIA-1 to the AU-rich cis element in COL2A1 pre-mRNA was confirmed by the ribonucleoprotein immunoprecipitation assay. Importantly, we also show that TIA-1 interacts with the equivalent DNA sequence with a preference for single-stranded rather than double-stranded DNA. Chromatin immunoprecipitation assays (including an additional RNase step) confirmed this interaction in vivo. Competition assays showed that TIA-1 apparently binds with higher affinity to DNA than to RNA. Finally, we show that this strong DNA-TIA-1 interaction can be disrupted by an RNA polymerase during active transcription. This suggests a potentially novel, dual role for TIA-1 in shuttling between DNA and RNA ligands to coregulate COL2A1 expression at the level of transcription and pre-mRNA alternative splicing.	Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	McAlinden, A (corresponding author), Washington Univ, Sch Med, Dept Orthopaed Surg, 660 S Euclid Ave,Yalem 704,Box8233, St Louis, MO 63110 USA.	mcalindena@wustl.edu	Mukudai, Yoshiki/L-4459-2019; Mukudai, Yoshiki/B-4891-2012	Mukudai, Yoshiki/0000-0002-9600-4430; Mukudai, Yoshiki/0000-0002-9600-4430; McAlinden, Audrey/0000-0001-8433-4224	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR036994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abruzzi KC, 2004, EMBO J, V23, P2620, DOI 10.1038/sj.emboj.7600261; ALAKOKKO L, 1995, BIOCHEM J, V308, P923, DOI 10.1042/bj3080923; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Beck ARP, 1996, NUCLEIC ACIDS RES, V24, P3829, DOI 10.1093/nar/24.19.3829; Burge CB, 1999, RNA WORLD, P525; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; Cramer P, 2001, FEBS LETT, V498, P179, DOI 10.1016/S0014-5793(01)02485-1; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; de Silanes IL, 2005, MOL CELL BIOL, V25, P9520, DOI 10.1128/MCB.25.21.9520-9531.2005; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Derrigo M, 2000, INT J MOL MED, V5, P111; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; ERIE DA, 1993, BIOCHEMISTRY-US, V32, P436, DOI 10.1021/bi00053a008; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Forch P, 2002, EMBO J, V21, P6882, DOI 10.1093/emboj/cdf668; Furger A, 2002, GENE DEV, V16, P2792, DOI 10.1101/gad.983602; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; GROSSO LE, 1985, CANCER RES, V45, P5035; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; IKUTA S, 1986, BIOCHEMISTRY-US, V25, P4840, DOI 10.1021/bi00365a018; Kawai T, 2006, MOL CELL BIOL, V26, P3295, DOI 10.1128/MCB.26.8.3295-3307.2006; KAWAKAMI A, 1994, J IMMUNOL, V152, P4937; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; Kornblihtt AR, 2006, NAT STRUCT MOL BIOL, V13, P5, DOI 10.1038/nsmb0106-5; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Lacadie SA, 2005, MOL CELL, V19, P65, DOI 10.1016/j.molcel.2005.05.006; Larrain J, 2000, DEVELOPMENT, V127, P821; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; Li W, 2002, J VIROL, V76, P11989, DOI 10.1128/JVI.76.23.11989-12000.2002; Listerman I, 2006, NAT STRUCT MOL BIOL, V13, P815, DOI 10.1038/nsmb1135; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; Mazan-Mamczarz K, 2006, MOL CELL BIOL, V26, P2716, DOI 10.1128/MCB.26.7.2716-2727.2006; McAlinden A, 2005, J BIOL CHEM, V280, P32700, DOI 10.1074/jbc.M505940200; MCMURRAY CT, 1994, BIOCHEMISTRY-US, V33, P11960, DOI 10.1021/bi00205a035; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; Phillips K, 2004, P NATL ACAD SCI USA, V101, P2011, DOI 10.1073/pnas.0400148101; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Rothe F, 2006, BIOCHEM BIOPH RES CO, V343, P57, DOI 10.1016/j.bbrc.2006.02.112; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SANDELL LJ, 1994, DEV DYNAM, V199, P129, DOI 10.1002/aja.1001990206; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; SHI YB, 1988, J BIOL CHEM, V263, P527; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; Suswam EA, 2005, NUCLEIC ACIDS RES, V33, P4507, DOI 10.1093/nar/gki763; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhang T, 2005, J CELL SCI, V118, P5453, DOI 10.1242/jcs.02669; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zhu H, 2003, MOL CELL BIOL, V23, P5959, DOI 10.1128/MCB.23.17.5959-5971.2003; Zuccato E, 2004, J BIOL CHEM, V279, P16980, DOI 10.1074/jbc.M313439200	60	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24444	24454		10.1074/jbc.M702717200	http://dx.doi.org/10.1074/jbc.M702717200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17580305	hybrid			2022-12-25	WOS:000248686600071
J	Nishimoto, S; Nishida, E				Nishimoto, Satoko; Nishida, Eisuke			Fibroblast growth factor 13 is essential for neural differentiation in xenopus early embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR HOMOLOGOUS FACTORS; GROWTH-FACTOR; SIGNALING PATHWAY; NERVOUS-SYSTEM; INDUCTION; PROTEIN; EXPRESSION; BMP-4; IDENTIFICATION; FOLLISTATIN	In Xenopus embryonic development, the MEK5- ERK5 pathway, one of the MAPK pathways, lies downstream of SoxD and upstream of Xngnr1 in a signaling pathway regulating neural differentiation. It remains unclear, however, how the MEK5ERK5 pathway is regulated in Xenopus neural development. As SoxD is a transcription factor, we hypothesized that some growth factor should be induced by SoxD and activate the MEK5- ERK5 pathway. As the expression level of fibroblast growth factor 13 ( FGF13) is increased by SoxD, we analyzed the function of FGF13 in neural development. Knockdown of FGF13 with antisense morpholino- oligonucleotides ( MOs) results in the reduced head structure and inhibition of neural differentiation. FGF13 MOs inhibit the SoxD- induced expression of Xngnr1 and the Xngnr1- induced expression of NeuroD, suggesting that FGF13 is necessary both upstream and downstream of Xngnr1 in neural differentiation. In addition, FGF13 MOsinhibit the activation of the MEK5- ERK5 pathway by dominant negative bone morphogenetic protein receptor, a mimicker of neural inducers, indicating that FGF13 is involved in the activation of the MEK5- ERK5 pathway. Together, these results identify a role of FGF13 in Xenopus neural differentiation.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp						Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Goldfarb M, 2005, CYTOKINE GROWTH F R, V16, P215, DOI 10.1016/j.cytogfr.2005.02.002; Hartung H, 1997, MECH DEVELOP, V64, P31, DOI 10.1016/S0925-4773(97)00042-7; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karabagli H, 2002, ANAT EMBRYOL, V205, P365, DOI 10.1007/s00429-002-0264-7; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Mizuseki K, 1998, NEURON, V21, P77, DOI 10.1016/S0896-6273(00)80516-4; Mizuseki K, 1998, DEVELOPMENT, V125, P579; Munoz-Sanjuan I, 1999, DEVELOPMENT, V126, P409; Munoz-Sanjuan I, 2000, J BIOL CHEM, V275, P2589, DOI 10.1074/jbc.275.4.2589; Nishimoto S, 2005, EMBO REP, V6, P1064, DOI 10.1038/sj.embor.7400515; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Wang Q, 2002, NEURON, V35, P25, DOI 10.1016/S0896-6273(02)00744-4; Wozniak DF, 2007, NEUROBIOL DIS, V26, P14, DOI 10.1016/j.nbd.2006.11.014	23	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24255	24261		10.1074/jbc.M704277200	http://dx.doi.org/10.1074/jbc.M704277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584734	hybrid			2022-12-25	WOS:000248686600051
J	Kojima, Y; Miyoshi, H; Clevers, HC; Oshima, M; Aoki, M; Taketo, MM				Kojima, Yasushi; Miyoshi, Hiroyuki; Clevers, Hans C.; Oshima, Masanobu; Aoki, Masahiro; Taketo, Makoto M.			Suppression of tubulin polymerization by the LKB1-microtubule-associated protein/microtubule affinity-regulating kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEUTZ-JEGHERS-SYNDROME; C-ELEGANS PAR-1; PROTEIN-KINASE; MICROTUBULE AFFINITY; VERTEBRATE DEVELOPMENT; EPITHELIAL POLARITY; KNOCKOUT MICE; LKB1; TAU; PHOSPHORYLATION	LKB1, a tumor suppressor gene mutated in the Peutz-Jeghers syndrome, encodes a serine/threonine protein kinase. Recent biochemical studies have shown that LKB1 activates 14 AMP-activated protein kinase-related kinases including MARKs (microtubule-associated protein/microtubule affinity-regulating kinases) that regulate microtubule dynamics. Here we show in vitro that LKB1 phosphorylates and activates MARK2, which in turn phosphorylates microtubule-associated protein Tau at the KXGS motif and suppresses tubulin polymerization. In cells, forced expression of LKB1 suppresses microtubule regrowth, whereas LKB1 knockdown accelerates it. We further show that the phosphorylation of Tau by the LKB1-MARK signaling triggers proteasome-mediated degradation of Tau. These results indicate that LKB1 is involved in the regulation of microtubule dynamics through the activation of MARKs.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Utrecht, NL-3584 CT Utrecht, Netherlands	Kyoto University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Aoki, Masahiro/A-5149-2016; Oshima, Masanobu/F-9958-2014	Aoki, Masahiro/0000-0003-4316-9490; Oshima, Masanobu/0000-0002-3304-0004; Miyoshi, Hiroyuki/0000-0001-7400-0714				Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Chen YM, 2006, P NATL ACAD SCI USA, V103, P8534, DOI 10.1073/pnas.0509955103; Cohen D, 2004, J CELL BIOL, V164, P717, DOI 10.1083/jcb.200308104; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Dickey CA, 2006, J NEUROSCI, V26, P6985, DOI 10.1523/JNEUROSCI.0746-06.2006; Doerflinger H, 2003, DEVELOPMENT, V130, P3965, DOI 10.1242/dev.00616; Drewes G, 2004, TRENDS BIOCHEM SCI, V29, P548, DOI 10.1016/j.tibs.2004.08.001; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kishi M, 2005, SCIENCE, V307, P929, DOI 10.1126/science.1107403; Kosuga S, 2005, J BIOL CHEM, V280, P42715, DOI 10.1074/jbc.M507941200; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Mandelkow EM, 2004, J CELL BIOL, V167, P99, DOI 10.1083/jcb.200401085; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Ossipova O, 2005, DEV CELL, V8, P829, DOI 10.1016/j.devcel.2005.04.011; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sandig V, 2000, P NATL ACAD SCI USA, V97, P1002, DOI 10.1073/pnas.97.3.1002; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schaar BT, 2004, NEURON, V41, P203, DOI 10.1016/S0896-6273(03)00843-2; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; Shulman JM, 2003, GENETICS, V165, P1233; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Timm T, 2006, NEURODEGENER DIS, V3, P207, DOI 10.1159/000095258; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	50	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23532	23540		10.1074/jbc.M700590200	http://dx.doi.org/10.1074/jbc.M700590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17573348	hybrid			2022-12-25	WOS:000248577500055
J	Walbott, H; Auxilien, S; Grosjean, H; Golinelli-Pimpaneau, B				Walbott, Helen; Auxilien, Sylvie; Grosjean, Henri; Golinelli-Pimpaneau, Beatrice			The carboxyl-terminal extension of yeast tRNA m(5)C methyltransferase enhances the catalytic efficiency of the amino-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; PUA DOMAIN; COMPLEX; IDENTIFICATION; MECHANISM; COFACTOR	The human tRNAm(5)C methyltransferase is a potential target for anticancer drugs because it is a novel downstream target of the proto-oncogene myc, mediating Myc-induced cell proliferation. Sequence comparisons of RNA m(5)C methyltransferases indicate that the eukaryotic enzymes possess, in addition to a conserved catalytic domain, a large characteristic carboxyl-terminal extension. To gain insight into the function of this additional domain, the modular architecture of the yeast tRNAm(5)C methyltransferase orthologue, Trm4p, was studied. The yeast enzyme catalyzes the transfer of a methyl group from S-adenosylL- methionine to carbon 5 of cytosine at different positions depending on the tRNAs. By limited proteolysis, Trm4p was shown to be composed of two domains that have been separately produced and purified. Here we demonstrate that the amino-terminal domain, encompassing the active site, binds tRNA with similar affinity as the whole enzyme but shows low catalytic efficiency. The carboxyl-terminal domain displays only weak affinity for tRNA. It is not required for m5C formation and does not appear to contribute to substrate specificity. However, it enhances considerably the catalytic efficiency of the amino-terminal domain.	CNRS, Lab Enzymol & Biochim Struct, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Golinelli-Pimpaneau, B (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Batiment 34,1 Ave Terrasse, F-91190 Gif Sur Yvette, France.	beatrice.golinelli@lebs.cnrs-gif.fr	WALBOTT, Hélène/D-3266-2009; Golinelli, Beatrice/ABB-8347-2021	Golinelli, Beatrice/0000-0001-8248-4704				Agris PF, 2004, NUCLEIC ACIDS RES, V32, P223, DOI 10.1093/nar/gkh185; Agris PF, 1996, PROG NUCLEIC ACID RE, V53, P79, DOI 10.1016/S0079-6603(08)60143-9; Anantharaman V, 2001, FEMS MICROBIOL LETT, V197, P215, DOI 10.1111/j.1574-6968.2001.tb10606.x; Anderson J, 2000, P NATL ACAD SCI USA, V97, P5173, DOI 10.1073/pnas.090102597; Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P215, DOI 10.1016/S0968-0004(01)01826-6; Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; Auxilien S, 2007, J BIOL CHEM, V282, P18711, DOI 10.1074/jbc.M607459200; Basti MM, 1996, NAT STRUCT BIOL, V3, P38, DOI 10.1038/nsb0196-38; Brzezicha B, 2006, NUCLEIC ACIDS RES, V34, P6034, DOI 10.1093/nar/gkl765; Bujnicki JM, 2004, NUCLEIC ACIDS RES, V32, P2453, DOI 10.1093/nar/gkh564; Bussiere DE, 1998, BIOCHEMISTRY-US, V37, P7103, DOI 10.1021/bi973113c; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Chester A, 2004, RNA, V10, P1399, DOI 10.1261/rna.7490704; Constantinesco F, 1998, NUCLEIC ACIDS RES, V26, P3753, DOI 10.1093/nar/26.16.3753; Daujotyte D, 2004, STRUCTURE, V12, P1047, DOI 10.1016/j.str.2004.04.007; Foster PG, 2003, STRUCTURE, V11, P1609, DOI 10.1016/j.str.2003.10.014; Francin M, 2002, J BIOL CHEM, V277, P1762, DOI 10.1074/jbc.M109759200; Frugier M, 2000, EMBO J, V19, P2371, DOI 10.1093/emboj/19.10.2371; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Gabant G, 2006, NUCLEIC ACIDS RES, V34, P2483, DOI 10.1093/nar/gkl145; Garcia MJ, 1997, MICROBIOL-UK, V143, P1125, DOI 10.1099/00221287-143-4-1125; GROSJEAN H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P267, DOI 10.1016/0167-4781(90)90179-6; GROSJEAN H, 2005, FINETUNING RNA FUNCT; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Gu XR, 1999, BIOCHEMISTRY-US, V38, P4053, DOI 10.1021/bi982364y; Hallberg BM, 2006, J MOL BIOL, V360, P774, DOI 10.1016/j.jmb.2006.05.047; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; Kaminska M, 2000, EMBO J, V19, P6908, DOI 10.1093/emboj/19.24.6908; King MY, 2002, BIOCHEMISTRY-US, V41, P11218, DOI 10.1021/bi026055q; Lee TT, 2005, CELL, V120, P599, DOI 10.1016/j.cell.2004.12.037; Losey HC, 2006, NAT STRUCT MOL BIOL, V13, P153, DOI 10.1038/nsmb1047; Maravic G, 2003, NUCLEIC ACIDS RES, V31, P4941, DOI 10.1093/nar/gkg666; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; Pan H, 2003, P NATL ACAD SCI USA, V100, P12648, DOI 10.1073/pnas.2135585100; Reid R, 1999, NUCLEIC ACIDS RES, V27, P3138, DOI 10.1093/nar/27.15.3138; Sabina J, 2006, J BIOL CHEM, V281, P6993, DOI 10.1074/jbc.M512841200; Scheuermann TH, 2004, BIOCHEMISTRY-US, V43, P12198, DOI 10.1021/bi0492556; Schluckebier G, 1999, J MOL BIOL, V289, P277, DOI 10.1006/jmbi.1999.2788; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Takata Y, 2003, BIOCHEMISTRY-US, V42, P8394, DOI 10.1021/bi034245a; Walbott H, 2007, RNA, V13, P967, DOI 10.1261/rna.515707; Waterman DG, 2006, J MOL BIOL, V356, P97, DOI 10.1016/j.jmb.2005.11.013	43	9	10	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23663	23671		10.1074/jbc.M703818200	http://dx.doi.org/10.1074/jbc.M703818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17567576	Green Published, hybrid			2022-12-25	WOS:000248577500069
J	Humphries, KM; Pennypacker, JK; Taylor, SS				Humphries, Kenneth M.; Pennypacker, Juniper K.; Taylor, Susan S.			Redox regulation of cAMP-dependent protein kinase signaling - Kinase versus phosphatase inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; ADENYLYL-CYCLASE; OKADAIC ACID; CYCLIC-AMP; CREB PHOSPHORYLATION; BETA-ADRENOCEPTOR; CALCINEURIN; ACTIVATION; SUPEROXIDE; INHIBITION	Many components of cellular signaling pathways are sensitive to regulation by oxidation and reduction. Previously, we described the inactivation of cAMP-dependent protein kinase (PKA) by direct oxidation of a reactive cysteine in the activation loop of the kinase. In the present study, we demonstrate that in HeLa cells PKA activity follows a biphasic response to thiol oxidation. Under mild oxidizing conditions, or short exposure to oxidants, forskolin-stimulated PKA activity is enhanced. This enhancement was blocked by sulfhydryl reducing agents, demonstrating a reversible mode of activation. In contrast, forskolin-stimulated PKA activity is inhibited by more severe oxidizing conditions. Mild oxidation enhanced PKA activity stimulated by forskolin, isoproterenol, or the cell-permeable analog, 8-bromo-cAMP. When cells were lysed in the presence of serine/threonine phosphatase inhibitor, NaF, the PKA-enhancing effect of oxidation was blunted. These results suggest oxidation of a PKA-counteracting phosphatase may be inhibited, thus enhancing the apparent kinase activity. Using an in vivo PKA activity reporter, we demonstrated that mild oxidation does indeed prolong the PKA signal induced by isoproterenol by inhibiting counteracting phosphatase activity. The results of this study demonstrate in live cells a unique synergistic mechanism whereby the PKA signaling pathway is enhanced in an apparent biphasic manner.	Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, 9500 Gilman Dr,Leichtag Bldg, La Jolla, CA 92093 USA.	staylor@ucsd.edu		Humphries, Kenneth/0000-0002-6167-3175	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019301, R01GM019301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beavo J A, 1975, Adv Cyclic Nucleotide Res, V5, P241; BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bogumil R, 2000, EUR J BIOCHEM, V267, P1407, DOI 10.1046/j.1432-1327.2000.01133.x; Brennan JP, 2006, J BIOL CHEM, V281, P21827, DOI 10.1074/jbc.M603952200; Brushia R. J., 1999, FRONT BIOSCI, V4, pD618; Danila CI, 2004, BIOL RES, V37, P521, DOI 10.4067/s0716-97602004000400005; Ding QM, 2004, MOL PHARMACOL, V66, P921, DOI 10.1124/mol.66.4.921; Fetrow JS, 1999, FASEB J, V13, P1866, DOI 10.1096/fasebj.13.13.1866; Flajolet M, 2003, P NATL ACAD SCI USA, V100, P16006, DOI 10.1073/pnas.2136600100; FOOR F, 1992, NATURE, V360, P682; Goldstein BJ, 2005, ANTIOXID REDOX SIGN, V7, P1021, DOI 10.1089/ars.2005.7.1021; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hensley K, 2005, ANTIOXID REDOX SIGN, V7, P523, DOI 10.1089/ars.2005.7.523; Hongpaisan J, 2003, MOL CELL NEUROSCI, V24, P1103, DOI 10.1016/j.mcn.2003.09.003; Humphries KM, 2005, J BIOL CHEM, V280, P2750, DOI 10.1074/jbc.M410242200; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Li SP, 2004, MOL BRAIN RES, V125, P156, DOI 10.1016/j.molbrainres.2004.02.025; Macala LJ, 1998, KIDNEY INT, V54, P1746, DOI 10.1046/j.1523-1755.1998.00140.x; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Marley AE, 1996, BIOCHEM J, V320, P801, DOI 10.1042/bj3200801; Meinhard M, 2002, PLANTA, V214, P775, DOI 10.1007/s00425-001-0675-3; Meinhard M, 2001, FEBS LETT, V508, P443, DOI 10.1016/S0014-5793(01)03106-4; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; MUKAI H, 1993, J BIOCHEM, V113, P292, DOI 10.1093/oxfordjournals.jbchem.a124041; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Persad S, 1998, MOL CELL BIOCHEM, V186, P99, DOI 10.1023/A:1006823531286; Persad S, 1997, J PHARMACOL EXP THER, V282, P1623; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; RHEE SG, 2000, SCI STKE, pE1; Rogers JP, 2006, J MED CHEM, V49, P1658, DOI 10.1021/jm051033y; Santana LF, 2002, J PHYSIOL-LONDON, V544, P57, DOI 10.1113/jphysiol.2002.020552; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; TAKAI A, 1991, BIOCHEM J, V275, P233, DOI 10.1042/bj2750233; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; Tan CM, 2001, BIOCHEMISTRY-US, V40, P1702, DOI 10.1021/bi0015818; TAN CM, 1995, CIRC RES, V77, P710, DOI 10.1161/01.RES.77.4.710; Tan CM, 1999, CLIN PHARMACOL THER, V66, P275, DOI 10.1016/S0009-9236(99)70035-4; Ullrich V, 2003, TOXICOL LETT, V139, P107, DOI 10.1016/S0378-4274(02)00424-1; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; WEN W, 1994, J BIOL CHEM, V269, P32214; Zhang J, 2005, NATURE, V437, P569, DOI 10.1038/nature04140; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798	57	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22072	22079		10.1074/jbc.M702582200	http://dx.doi.org/10.1074/jbc.M702582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17548350	hybrid			2022-12-25	WOS:000248196800054
J	Watanabe, H; Mizunami, M				Watanabe, Hidehiro; Mizunami, Makoto			Pavlov's Cockroach: Classical Conditioning of Salivation in an Insect	PLOS ONE			English	Article								Secretion of saliva to aid swallowing and digestion is an important physiological function found in many vertebrates and invertebrates. Pavlov reported classical conditioning of salivation in dogs a century ago. Conditioning of salivation, however, has been so far reported only in dogs and humans, and its underlying neural mechanisms remain elusive because of the complexity of the mammalian brain. We previously reported that, in cockroaches Periplaneta americana, salivary neurons that control salivation exhibited increased responses to an odor after conditioning trials in which the odor was paired with sucrose solution. However, no direct evidence of conditioning of salivation was obtained. In this study, we investigated the effects of conditioning trials on the level of salivation. Untrained cockroaches exhibited salivary responses to sucrose solution applied to the mouth but not to peppermint or vanilla odor applied to an antenna. After differential conditioning trials in which an odor was paired with sucrose solution and another odor was presented without pairing with sucrose solution, sucrose-associated odor induced an increase in the level of salivation, but the odor presented alone did not. The conditioning effect lasted for one day after conditioning trials. This study demonstrates, for the first time, classical conditioning of salivation in species other than dogs and humans, thereby providing the first evidence of sophisticated neural control of autonomic function in insects. The results provide a useful model system for studying cellular basis of conditioning of salivation in the simpler nervous system of insects.	[Watanabe, Hidehiro; Mizunami, Makoto] Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi 980, Japan	Tohoku University	Mizunami, M (corresponding author), Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi 980, Japan.	makoto@biology.tohoku.ac.jp		Mizunami, Makoto/0000-0003-4168-2610	Ministry of Education, Science, Culture, Sports and Technology of Japan; Japan Society	Ministry of Education, Science, Culture, Sports and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was supported by grants from the Ministry of Education, Science, Culture, Sports and Technology of Japan and Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists.	Ali DW, 1997, J EXP BIOL, V200, P1941; BALDERRAMA N, 1980, J INSECT PHYSIOL, V26, P499, DOI 10.1016/0022-1910(80)90123-7; Baranov V V, 1983, Neurosci Behav Physiol, V13, P245, DOI 10.1007/BF01150012; Burrows M., 1996, NEUROBIOLOGY INSECT; Daly KC, 2004, P NATL ACAD SCI USA, V101, P10476, DOI 10.1073/pnas.0401902101; DANILOVA LK, 1983, NEUROSCI BEHAV PHYSL, V12, P337; DAVIS NT, 1985, CELL TISSUE RES, V240, P593, DOI 10.1007/BF00216349; Ekstrom J, 1989, Proc Finn Dent Soc, V85, P323; FEATHER BW, 1967, J EXP PSYCHOL, V74, P389, DOI 10.1037/h0024709; GARRETT JR, 1987, J DENT RES, V66, P387, DOI 10.1177/00220345870660020201; Giurfa M, 2003, CURR OPIN NEUROBIOL, V13, P726, DOI 10.1016/j.conb.2003.10.015; HAMMER M, 1993, NATURE, V366, P59, DOI 10.1038/366059a0; HARRIS AH, 1974, ANNU REV PSYCHOL, V25, P107, DOI 10.1146/annurev.ps.25.020174.000543; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; Hermitte G, 2006, J COMP PHYSIOL A, V192, P69, DOI 10.1007/s00359-005-0052-y; HOLLAND R, 1970, ARCH ORAL BIOL, V15, P761, DOI 10.1016/0003-9969(70)90039-7; Just F, 1996, J EXP BIOL, V199, P407; Krontiris-Litowitz J, 1999, J COMP PHYSIOL A, V185, P181, DOI 10.1007/s003590050376; Kwon HW, 2004, J EXP BIOL, V207, P377, DOI 10.1242/jeb.00737; Li YS, 1999, J COMP NEUROL, V409, P647, DOI 10.1002/(SICI)1096-9861(19990712)409:4<647::AID-CNE9>3.0.CO;2-3; MATSUO R, 1999, FRONT ORAL BIOL, V11, P26; MAUELSHAGEN J, 1993, J NEUROPHYSIOL, V69, P609, DOI 10.1152/jn.1993.69.2.609; Menzel R, 2001, LEARN MEMORY, V8, P53, DOI 10.1101/lm.38801; Menzel Randolf, 2006, Behav Cogn Neurosci Rev, V5, P24, DOI 10.1177/1534582306289522; MILLER NE, 1969, SCIENCE, V163, P434, DOI 10.1126/science.163.3866.434; MIZUNAMI M, 1990, J GEN PHYSIOL, V95, P297, DOI 10.1085/jgp.95.2.297; MIZUNAMI M, 1988, J GEN PHYSIOL, V91, P703, DOI 10.1085/jgp.91.5.703; Mizunami M, 1996, J GEN PHYSIOL, V107, P121, DOI 10.1085/jgp.107.1.121; Nishino H, 2003, J COMP NEUROL, V455, P40, DOI 10.1002/cne.10450; Sakura M, 2002, J COMP PHYSIOL A, V188, P787, DOI 10.1007/s00359-002-0366-y; Sakura M, 2001, ZOOL SCI, V18, P21, DOI 10.2108/zsj.18.21; Sato C, 2006, NEUROREPORT, V17, P553, DOI 10.1097/01.wnr.0000209002.17610.79; Strausfeld NJ, 1999, J COMP NEUROL, V409, P603; THON B, 1980, J COMP PHYSIOL PSYCH, V94, P886, DOI 10.1037/h0077821; Walz B, 2006, ARCH INSECT BIOCHEM, V62, P141, DOI 10.1002/arch.20128; Watanabe H, 2003, ZOOL SCI, V20, P1447, DOI 10.2108/zsj.20.1447; Watanabe H, 2006, J EXP BIOL, V209, P766, DOI 10.1242/jeb.02049; WELLS DT, 1968, PSYCHOPHYSIOLOGY, V4, P278, DOI 10.1111/j.1469-8986.1968.tb02768.x; ZERNICKI B., 1961, ACTA BIOL EXPTL, V21, P163	39	29	29	1	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e529	10.1371/journal.pone.0000529	http://dx.doi.org/10.1371/journal.pone.0000529			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565382	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451600017
J	Winkeler, A; Sena-Esteves, M; Paulis, LEM; Li, HF; Waerzeggers, Y; Ruckriem, B; Himmelreich, U; Klein, M; Monfared, P; Rueger, MA; Heneka, M; Vollmar, S; Hoehn, M; Fraefel, C; Graf, R; Wienhard, K; Heiss, WD; Jacobs, AH				Winkeler, Alexandra; Sena-Esteves, Miguel; Paulis, Leonie E. M.; Li, Hongfeng; Waerzeggers, Yannic; Rueckriem, Benedikt; Himmelreich, Uwe; Klein, Markus; Monfared, Parisa; Rueger, Maria A.; Heneka, Michael; Vollmar, Stefan; Hoehn, Mathias; Fraefel, Cornel; Graf, Rudolf; Wienhard, Klaus; Heiss, Wolf D.; Jacobs, Andreas H.			Switching on the Lights for Gene Therapy	PLOS ONE			English	Article								Strategies for non-invasive and quantitative imaging of gene expression in vivo have been developed over the past decade. Non-invasive assessment of the dynamics of gene regulation is of interest for the detection of endogenous disease-specific biological alterations (e. g., signal transduction) and for monitoring the induction and regulation of therapeutic genes (e. g., gene therapy). To demonstrate that non-invasive imaging of regulated expression of any type of gene after in vivo transduction by versatile vectors is feasible, we generated regulatable herpes simplex virus type 1 (HSV-1) amplicon vectors carrying hormone (mifepristone) or antibiotic (tetracycline) regulated promoters driving the proportional co-expression of two marker genes. Regulated gene expression was monitored by fluorescence microscopy in culture and by positron emission tomography (PET) or bioluminescence (BLI) in vivo. The induction levels evaluated in glioma models varied depending on the dose of inductor. With fluorescence microscopy and BLI being the tools for assessing gene expression in culture and animal models, and with PET being the technology for possible application in humans, the generated vectors may serve to non-invasively monitor the dynamics of any gene of interest which is proportionally co-expressed with the respective imaging marker gene in research applications aiming towards translation into clinical application.	[Jacobs, Andreas H.] Max Planck Inst Neurol Res, Ctr Mol Med CMMC, Lab Gene Therapy & Mol Imaging, Cologne, Germany; Univ Cologne, Dept Neurol, Cologne, Germany; Univ Cologne, Dept Radiol, Cologne, Germany	Max Planck Society; University of Cologne; University of Cologne; University of Cologne	Jacobs, AH (corresponding author), Max Planck Inst Neurol Res, Ctr Mol Med CMMC, Lab Gene Therapy & Mol Imaging, Cologne, Germany.	Andreas.Jacobs@nf.mpg.de	Winkeler, Alexandra/B-7436-2014; Jacobs, Andreas H./AAA-6794-2020; Heneka, Michael/AAE-8011-2019; Heneka, Michael/E-8072-2015	Winkeler, Alexandra/0000-0003-3397-2570; Himmelreich, Uwe/0000-0002-2060-8895; Heneka, Michael/0000-0003-4996-1630; Fraefel, Cornel/0000-0001-7221-6706	Deutsche Forschungsgemeinschaft [DFG-Ja98/1-2]; Ministerium fur Schule; Wissenschaft und Forschung NRW [MSWF 516-40000299]; Center for Molecular Medicine Cologne [CMMC-TV46]; 6th FW EU [LSHC-CT-2004-503569]; DiMI [LSHB-CT-2005-512146]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Ministerium fur Schule; Wissenschaft und Forschung NRW; Center for Molecular Medicine Cologne; 6th FW EU; DiMI	This work is supported in part by the Deutsche Forschungsgemeinschaft (DFG-Ja98/1-2), Ministerium fur Schule, Wissenschaft und Forschung NRW (MSWF 516-40000299), Center for Molecular Medicine Cologne (CMMC-TV46), 6th FW EU grant EMIL (LSHC-CT-2004-503569) and DiMI (LSHB-CT-2005-512146).	BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Blasberg RG, 2003, NUCL MED BIOL, V30, P879, DOI 10.1016/S0969-8051(03)00115-X; Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Doubrovin M, 2001, P NATL ACAD SCI USA, V98, P9300, DOI 10.1073/pnas.161091198; Doubrovin M, 2004, BIOCONJUGATE CHEM, V15, P1376, DOI 10.1021/bc0498572; DUMORTIER J, 2005, GENE THER; Fotaki ME, 1997, GENE THER, V4, P901, DOI 10.1038/sj.gt.3300487; Fraefel C, 1996, J VIROL, V70, P7190, DOI 10.1128/JVI.70.10.7190-7197.1996; Freundlieb S, 1999, J GENE MED, V1, P4, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gambhir SS, 1999, NUCL MED BIOL, V26, P481, DOI 10.1016/S0969-8051(99)00021-9; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Green Leeta A, 2002, Mol Imaging Biol, V4, P71, DOI 10.1016/S1095-0397(01)00071-1; Heiss WD, 2004, J NUCL MED, V45, P1811; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; Iyer M, 2004, MOL THER, V10, P545, DOI 10.1016/j.ymthe.2004.06.118; Jacobs A H, 2002, Mol Imaging, V1, P309, DOI 10.1162/153535002321093936; Jacobs AH, 2003, HUM GENE THER, V14, P277, DOI 10.1089/10430340360535823; Jacobs Andreas, 1999, Neoplasia (New York), V1, P154, DOI 10.1038/sj.neo.7900007; Jacobs AH, 2007, CANCER RES, V67, P1706, DOI 10.1158/0008-5472.CAN-06-2418; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Lipshutz GS, 2001, MOL THER, V3, P284, DOI 10.1006/mthe.2001.0267; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; Ponomarev V, 2001, NEOPLASIA, V3, P480, DOI 10.1038/sj.neo.7900204; SAITO Y, 1982, SCIENCE, V217, P1151, DOI 10.1126/science.7112121; Shah K, 2003, ONCOGENE, V22, P6865, DOI 10.1038/sj.onc.1206748; Shockett PE, 1996, P NATL ACAD SCI USA, V93, P5173, DOI 10.1073/pnas.93.11.5173; Sun X, 2001, GENE THER, V8, P1572, DOI 10.1038/sj.gt.3301554; Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016; TJUVAJEV JG, 1995, CANCER RES, V55, P6126; Tjuvajev Juri G., 1999, Neoplasia (New York), V1, P315, DOI 10.1038/sj.neo.7900053; Wang Y, 2002, MOL GENET GENOMICS, V268, P160, DOI 10.1007/s00438-002-0751-9; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Weissleder R, 2006, SCIENCE, V312, P1168, DOI 10.1126/science.1125949; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; Yaghoubi SS, 2001, GENE THER, V8, P1072, DOI 10.1038/sj.gt.3301490; Yu YA, 2002, MOL GENET GENOMICS, V268, P169, DOI 10.1007/s00438-002-0750-x; Yu YJ, 2000, NAT MED, V6, P933, DOI 10.1038/78704	47	19	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e528	10.1371/journal.pone.0000528	http://dx.doi.org/10.1371/journal.pone.0000528			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565381	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451600016
J	Jin, H; Wang, X; Ying, J; Wong, AHY; Li, H; Lee, KY; Srivastava, G; Chan, ATC; Yeo, W; Ma, BBY; Putti, TC; Lung, ML; Shen, ZY; Xu, LY; Langford, C; Tao, Q				Jin, H.; Wang, X.; Ying, J.; Wong, A. H. Y.; Li, H.; Lee, K. Y.; Srivastava, G.; Chan, A. T. C.; Yeo, W.; Ma, B. B. Y.; Putti, T. C.; Lung, M. L.; Shen, Z-Y; Xu, L-Y; Langford, C.; Tao, Q.			Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas	ONCOGENE			English	Article						ADAMTS18; methylation; tumor suppressor gene; carcinoma; promoter	STRESS-RESPONSIVE GENE; METHYLATION STATUS; HUMAN BREAST; CANCER; DNA; EXPRESSION; HYPERMETHYLATION; METALLOPROTEINASES; TRANSFORMATION; TUMORIGENESIS	Tumor suppressor genes (TSGs) often locate at chromosomal regions with frequent deletions in tumors. Loss of 16q23 occurs frequently in multiple tumors, indicating the presence of critical TSGs at this locus, such as the well-studied WWOX. Herein, we found that ADAMTS18, located next to WWOX, was significantly downregulated in multiple carcinoma cell lines. No deletion of ADAMTS18 was detected with multiplex differential DNA-PCR or high-resolution 1-Mb array-based comparative genomic hybridization (CGH) analysis. Instead, methylation of the ADAMTS18 promoter CpG Island was frequently detected with methylation-specific PCR and bisulfite genome sequencing in multiple carcinoma cell lines and primary carcinomas, but not in any nontumor cell line and normal epithelial tissue. Both pharmacological and genetic demethylation dramatically induced the ADAMTS18 expression, indicating that CpG methylation directly contributes to the tumor-specific silencing of ADAMTS18. Ectopic ADAMTS18 expression led to significant inhibition of both anchorage-dependent and - independent growth of carcinoma cells lacking the expression. Thus, through functional epigenetics, we identified ADAMTS18 as a novel functional tumor suppressor, being frequently inactivated epigenetically in multiple carcinomas.	Chinese Univ Hong Kong, Hong Kong Canc Inst & Li Ka Shing Inst Hlth Sci, Dept Clin Oncol, Sir YK Pao Ctr Canc State Key Lab Oncol S China, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore, Singapore; Hong Kong Univ Sci & Technol, Canc Res Ctr, Dept Biol, Hong Kong, Peoples R China; Shantou Univ, Coll Med, SUMC CUHK Joint Epigenet Grp, Shantou, Peoples R China; Well Trust Sanger Inst, Microarray Facil, Cambridge, England	Chinese University of Hong Kong; University of Hong Kong; National University of Singapore; Hong Kong University of Science & Technology; Shantou University; Wellcome Trust Sanger Institute	Tao, Q (corresponding author), Chinese Univ Hong Kong, Dept Clin Oncol, Ctr Canc, PWH, Rm 315, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Jin, Hongchuan/C-3686-2009; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018; Yeo, Winnie/R-4792-2018; B.Y., Brigette/H-4681-2017; Lung, Maria Li/C-4495-2009	Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Yeo, Winnie/0000-0002-0863-8469; B.Y., Brigette/0000-0003-4802-1102; Lung, Maria Li/0000-0003-2559-3626; Jin, Hongchuan/0000-0002-6697-3097; Wang, Xian/0000-0003-0041-7589	Wellcome Trust [079643] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Balsara BR, 2001, GENE CHROMOSOME CANC, V30, P245, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1083>3.0.CO;2-M; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bishop JM, 1996, FASEB J, V10, P362, DOI 10.1096/fasebj.10.2.8641572; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x; Cui Y, 2007, LAB INVEST; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Dunn JR, 2004, BRIT J CANCER, V91, P1149, DOI 10.1038/sj.bjc.6602107; Gius D, 2005, CANCER, V104, P1789, DOI 10.1002/cncr.21395; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lind GE, 2006, CELL ONCOL, V28, P259; Lo KW, 2000, CANCER RES, V60, P3348; Lo PHY, 2007, ONCOGENE, V26, P148, DOI 10.1038/sj.onc.1209767; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Masui T, 2001, CLIN CANCER RES, V7, P3437; Morin D, 1999, PC WEEK, V16, P80; Nakata S, 2006, CANCER-AM CANCER SOC, V106, P2190, DOI 10.1002/cncr.21870; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Riegman PHJ, 2001, CANCER RES, V61, P3164; Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217	35	90	94	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7490	7498		10.1038/sj.onc.1210559	http://dx.doi.org/10.1038/sj.onc.1210559			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546048	Green Accepted			2022-12-25	WOS:000251282000010
J	Alikhani-Koupaei, R; Fouladkou, F; Fustier, P; Cenni, B; Sharma, AM; Deter, HC; Frey, BM; Frey, FJ				Alikhani-Koupaei, Rasoul; Fouladkou, Fatemeh; Fustier, Pierre; Cenni, Bruno; Sharma, Arya M.; Deter, Hans-Christian; Frey, Brigitte M.; Frey, Felix J.			Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity	FASEB JOURNAL			English	Article						hypertension; NF1; glucocorticoid receptor; glucocorticoid responsive element; microsatellite	TRANSCRIPTIONAL ACTIVATION; HYPERTENSION; EXPRESSION; RECEPTOR; ELEMENTS; CELLS	Reduced activity of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) plays a role in essential hypertension and the sensitivity of blood pressure to dietary salt. Nonconservative mutations in the coding region are extremely rare and do not explain the variable 11beta-HSD2 activity. We focused therefore on the 5'-regulatory region and identified and characterized the first promoter polymorphisms. Transfections of variants G-209A and G-126A into SW620 cells reduced promoter activity and affinity for activators nuclear factor 1 ( NF1) and Sp1. Chromatin immunoprecipitation revealed Sp1, NF1, and glucocorticoid receptor (GR) binding to the HSD11B2 promoter. Dexamethasone induced expression of mRNA and activity of HSD11B2. GR and/or NF1 overexpression increased endogenous HSD11B2 mRNA and activity. GR complexes cooperated with NF1 to activate HSD11B2, an effect diminished in the presence of the G-209A variant. When compared to salt-resistant subjects ( 96), salt-sensitive volunteers ( 54) more frequently had the G-209A variant, higher occurrence of alleles A4/A7 of polymorphic microsatellite marker, and higher urinary ratios of cortisol to cortisone metabolites. First, we conclude that the mechanism of glucocorticoid-induced HSD11B2 expression is mainly mediated by cooperation between GR and NF1 on the HSD11B2 promoter and, second, that the newly identified promoter variants reduce activity and cooperation of cognate transcription factors, resulting in diminished HSD11B2 transcription, an effect favoring salt sensitivity.	Univ Hosp Bern, Inselspital, Dept Hypertens & Nephrol, CH-3010 Bern, Switzerland; Univ Hosp Bern, Inst Clin Chem, CH-3010 Bern, Switzerland; McMaster Univ, Hamilton Gen Hosp, Canada Res Chair Cardiovasc Obes Res & Management, Hamilton, ON, Canada; Charite Campus Benjamin Franklin, Dept Psychosomat & Psychotherapy, Berlin, Germany	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; McMaster University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Frey, BM (corresponding author), Univ Hosp Bern, Inselspital, Dept Hypertens & Nephrol, Freiburgstr 15, CH-3010 Bern, Switzerland.	brigitte.frey@dkf.unibe.ch	Deter, Hans-Christian/AAH-4350-2021; Deter, Hans-Christian/ABB-9989-2020	Deter, Hans-Christian/0000-0001-8575-4570; Deter, Hans-Christian/0000-0001-8575-4570; Fustier, Pierre/0000-0003-3220-2582; Cenni, Bruno/0000-0002-8603-2032				Agarwal AK, 2000, ENDOCR RES, V26, P289, DOI 10.3109/07435800009066168; Aittomaki S, 2000, J IMMUNOL, V164, P5689, DOI 10.4049/jimmunol.164.11.5689; ALLAN GF, 1991, J BIOL CHEM, V266, P5905; Brand E, 1999, J HYPERTENS, V17, P1563, DOI 10.1097/00004872-199917110-00009; Carvajal CA, 2005, J HYPERTENS, V23, P71, DOI 10.1097/00004872-200501000-00015; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Darnel AD, 1999, J STEROID BIOCHEM, V70, P203, DOI 10.1016/S0960-0760(99)00116-8; DelMonaco M, 1997, J INVEST DERMATOL, V108, P938, DOI 10.1111/1523-1747.ep12295241; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Hebbar PB, 2003, MOL CELL BIOL, V23, P887, DOI 10.1128/MCB.23.3.887-898.2003; Jain S, 2002, J BIOL CHEM, V277, P36889, DOI 10.1074/jbc.M204732200; Lanz CB, 2001, HYPERTENSION, V37, P160, DOI 10.1161/01.HYP.37.1.160; Liu AG, 2004, J BIOL CHEM, V279, P17449, DOI 10.1074/jbc.M311267200; Luft FC, 2001, DRUG METAB DISPOS, V29, P500; Persu A, 2005, J HYPERTENS, V23, P29, DOI 10.1097/00004872-200501000-00007; Rebuffat A, 2001, NAT BIOTECHNOL, V19, P1155, DOI 10.1038/nbt1201-1155; Schorr U, 2000, J HYPERTENS, V18, P855, DOI 10.1097/00004872-200018070-00006; Sharma AM, 1996, NEPHROL DIAL TRANSPL, V11, P927; Suzuki S, 2003, AM J RESP CRIT CARE, V167, P1244, DOI 10.1164/rccm.200210-1139OC; van Beek JP, 2004, J CLIN ENDOCR METAB, V89, P5614, DOI 10.1210/jc.2004-0113; Williams TA, 2005, KIDNEY INT, V67, P631, DOI 10.1111/j.1523-1755.2005.67119.x	22	40	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3618	3628		10.1096/fj.07-8140com	http://dx.doi.org/10.1096/fj.07-8140com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17551100				2022-12-25	WOS:000250517800024
J	Partridge, J; Carlsen, H; Enesa, K; Chaudhury, H; Zakkar, M; Luong, L; Kinderlerer, A; Johns, M; Blomhoff, R; Mason, JC; Haskard, DO; Evans, PC				Partridge, Jason; Carlsen, Harald; Enesa, Karine; Chaudhury, Hera; Zakkar, Mustafa; Luong, Le; Kinderlerer, Anne; Johns, Mike; Blomhoff, Rune; Mason, Justin C.; Haskard, Dorian O.; Evans, Paul C.			Laminar shear stress acts as a switch to regulate divergent functions of NF-kappa B in endothelial cells	FASEB JOURNAL			English	Article						atherosclerosis; blood flow; proinflammatory activation; cytoprotection	NECROSIS-FACTOR-ALPHA; ADHESION MOLECULE-1 GENE; EXPRESSION; ACTIVATION; APOPTOSIS; PATHWAY; SENSITIVITY; MECHANISM; REGIONS; RABBIT	Regions of the arterial tree exposed to laminar flow, which exerts high shear stress, are protected from inflammation, endothelial cell (EC) death and atherosclerosis. TNF alpha activates NF-kappa B transcription factors, which potentially exert dual functions by inducing both proinflammatory and cytoprotective transcripts. We assessed whether laminar shear stress protects EC by modulating NF-kappa B function. Human umbilical vein EC ( HUVEC) were cultured under shear stress (12 dynes/cm(2) for 16 h) using a parallel-plate flow chamber or were maintained in static conditions. Comparative real-time PCR revealed that preshearing significantly alters transcriptional responses to TNF alpha by enhancing the expression of cytoprotective molecules (Bcl-2, MnSOD, GADD45 beta, A1) and suppressing proinflammatory transcripts (E-selectin, VCAM-1, IL-8). We demonstrated using assays of nuclear localization, NF-kappa B subunit phosphorylation, DNA-binding, and transcriptional activity that NF-kappa B is activated by TNF alpha in presheared HUVEC. Furthermore, a specific inhibitor revealed that NF-kappa B is essential for the induction of cytoprotective transcripts in presheared EC. Finally, we observed that NF-kappa B can be activated in vascular endothelium exposed to laminar shear stress in NF-kappa B-luciferase reporter mice, thus validating our cell culture experiments. We conclude that shear stress primes EC for enhanced NF-alpha B-dependent cytoprotective responsiveness while attenuating proinflammatory activation. Thus modulation of NF-alpha B function may underlie the atheroprotective effects of laminar shear stress.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, BHF Cardiovasc Med Unit, London W12 0NN, England; Univ Oslo, Inst Nutr Res, Oslo, Norway	Imperial College London; University of Oslo	Evans, PC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, BHF Cardiovasc Med Unit, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	paul.evans@imperial.ac.uk		Mason, Justin/0000-0001-7783-1660; Carlsen, Harald/0000-0001-5123-5756				Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Anrather J, 2005, J BIOL CHEM, V280, P244, DOI 10.1074/jbc.M409344200; Aoudjit F, 1997, CELL GROWTH DIFFER, V8, P335; Campbell J, 2004, J IMMUNOL, V173, P6928, DOI 10.4049/jimmunol.173.11.6928; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Cheng C, 2005, BLOOD, V106, P3691, DOI 10.1182/blood-2005-06-2326; Chiu JJ, 2004, ARTERIOSCL THROM VAS, V24, P73, DOI 10.1161/01.ATV.0000106321.63667.24; Cunningham KS, 2005, LAB INVEST, V85, P9, DOI 10.1038/labinvest.3700215; Dai GH, 2004, P NATL ACAD SCI USA, V101, P14871, DOI 10.1073/pnas.0406073101; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Dion C, 2005, INT IMMUNOL, V17, P1257, DOI 10.1093/intimm/dxh302; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Edelstein LC, 2005, J BIOL CHEM, V280, P11192, DOI 10.1074/jbc.M412997200; Evans PC, 2000, TRANSPLANTATION, V70, P928, DOI 10.1097/00007890-200009270-00010; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812; Grabowski EF, 2001, ARTERIOSCL THROM VAS, V21, P157, DOI 10.1161/01.ATV.21.1.157; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Huo Y, 2001, ACTA PHYSIOL SCAND, V173, P35, DOI 10.1046/j.1365-201X.2001.00882.x; Iiyama K, 1999, CIRC RES, V85, P199, DOI 10.1161/01.RES.85.2.199; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Natarajan R, 2001, EXP CELL RES, V266, P203, DOI 10.1006/excr.2001.5218; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Sheikh S, 2003, BLOOD, V102, P2828, DOI 10.1182/blood-2003-01-0080; Sheikh S, 2005, BRIT J PHARMACOL, V145, P1052, DOI 10.1038/sj.bjp.0706281; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Spiecker M, 2000, J IMMUNOL, V164, P3316, DOI 10.4049/jimmunol.164.6.3316; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yamawaki H, 2003, CIRCULATION, V108, P1619, DOI 10.1161/01.CIR.0000089373.49941.C4; Zhang N, 2005, J BIOL CHEM, V280, P21400, DOI 10.1074/jbc.M411952200; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	42	108	109	2	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3553	3561		10.1096/fj.06-8059com	http://dx.doi.org/10.1096/fj.06-8059com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17557931				2022-12-25	WOS:000250517800018
J	Greene, NP; Porcelli, I; Buchanan, G; Hicks, MG; Schermann, SM; Palmer, T; Berks, BC				Greene, Nicholas P.; Porcelli, Ida; Buchanan, Grant; Hicks, Matthew G.; Schermann, Sonya M.; Palmer, Tracy; Berks, Ben C.			Cysteine scanning mutagenesis and disulfide mapping studies of the TatA component of the bacterial twin arginine translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEC-INDEPENDENT PROTEIN; ESCHERICHIA-COLI; SELF-ASSOCIATION; COMPLEXES; SYSTEM; MODEL; FORM; RESIDUES; DISTINCT; PATHWAY	The Tat (twin arginine translocation) system transports folded proteins across the bacterial cytoplasmic membrane and the thylakoid membrane of plant chloroplasts. The integral membrane proteins TatA, TatB, and TatC are essential components of the Tat pathway. TatA forms high order oligomers and is thought to constitute the protein-translocating unit of the Tat system. Cysteine scanning mutagenesis was used to systematically investigate the functional importance of residues in the essential N-terminal transmembrane and amphipathic helices of Escherichia coli TatA. Cysteine substitutions of most residues in the amphipathic helix, including all the residues on the hydrophobic face of the helix, severely compromise Tat function. Glutamine 8 was identified as the only residue in the transmembrane helix that is critical for TatA function. The cysteine variants in the transmembrane helix were used in disulfide mapping experiments to probe the oligomeric arrangement of TatA protomers within the larger TatA complex. Residues in the center of the transmembrane helix (including residues 10-16) show a distinct pattern of cross-linking indicating that this region of the protein forms well defined interactions with other protomers. At least two interacting faces were detected. The results of our TatA studies are compared with analogous data for the homologous, but functionally distinct, TatB protein. This comparison reveals that it is only in TatA that the amphipathic helix is sensitive to amino acid substitutions. The TatA amphipathic helix may play a role in forming and controlling the path of substrate movement across the membrane.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; John Innes Inst, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of East Anglia	Berks, BC (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	ben.berks@bioch.ox.ac.uk	Hicks, Matthew/I-3689-2012	Palmer, Tracy/0000-0001-9043-2592; Berks, Ben/0000-0001-9685-4067; Greene, Nicholas/0000-0002-3631-0380	MRC [G117/519] Funding Source: UKRI; Medical Research Council [G117/519] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Barrett CML, 2005, FEBS J, V272, P2261, DOI 10.1111/j.1742-4658.2005.04654.x; Barrett CML, 2003, FEBS LETT, V537, P42, DOI 10.1016/S0014-5793(03)00068-1; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Blaudeck N, 2005, J BIOL CHEM, V280, P3426, DOI 10.1074/jbc.M411210200; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bruser T, 2003, MICROBIOL RES, V158, P7, DOI 10.1078/0944-5013-00176; Buchanan G, 2002, MOL MICROBIOL, V43, P1457, DOI 10.1046/j.1365-2958.2002.02853.x; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Choma C, 2000, NAT STRUCT BIOL, V7, P161; CLINE K, 2007, IN PRESS ENZYMES; COHEN N, 1956, ANN I PASTEUR PARIS, V91, P693; Dabney-Smith C, 2006, J BIOL CHEM, V281, P5476, DOI 10.1074/jbc.M512453200; Dabney-Smith C, 2003, J BIOL CHEM, V278, P43027, DOI 10.1074/jbc.M307923200; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Gouffi K, 2004, J BIOL CHEM, V279, P11608, DOI 10.1074/jbc.M313187200; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Gust B, 2003, P NATL ACAD SCI USA, V100, P1541, DOI 10.1073/pnas.0337542100; Hicks MG, 2005, J BACTERIOL, V187, P2920, DOI 10.1128/JB.187.8.2920-2925.2005; Hicks MG, 2003, FEBS LETT, V539, P61, DOI 10.1016/S0014-5793(03)00198-4; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lee PA, 2002, J BACTERIOL, V184, P5871, DOI 10.1128/JB.184.21.5871-5879.2002; Lee PA, 2006, J BIOL CHEM, V281, P34072, DOI 10.1074/jbc.M607295200; Lee PA, 2006, ANNU REV MICROBIOL, V60, P373, DOI 10.1146/annurev.micro.60.080805.142212; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McDevitt CA, 2006, FEBS J, V273, P5656, DOI 10.1111/j.1742-4658.2006.05554.x; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Oates J, 2005, J MOL BIOL, V346, P295, DOI 10.1016/j.jmb.2004.11.047; Osborne AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/annurev.cellbio.21.012704.133214; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Russell DW, 2001, MOL CLONING LAB MANU; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; SILVESTRO A, 1988, BIOCHIM BIOPHYS ACTA, V954, P1, DOI 10.1016/0167-4838(88)90049-0; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	45	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23937	23945		10.1074/jbc.M702972200	http://dx.doi.org/10.1074/jbc.M702972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17565984	hybrid			2022-12-25	WOS:000248686600020
J	Plotkin, LI; Manolagas, SC; Bellido, T				Plotkin, Lillian I.; Manolagas, Stavros C.; Bellido, Teresita			Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival - Evidence for inside-out signaling leading to anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; TYROSINE KINASE; BONE-FORMATION; OSTEOBLAST APOPTOSIS; CELL-ADHESION; GENE-EXPRESSION; ANGIOTENSIN-II; PYK2	Bone fragility induced by chronic glucocorticoid excess is due, at least in part, to induction of osteocyte apoptosis through direct actions on these cells. However, the molecular mechanism by which glucocorticoids shorten osteocyte life span has remained heretofore unknown. We report that apoptosis of osteocytic MLO- Y4 cells induced by the synthetic glucocorticoid dexamethasone is abolished by the glucocorticoid receptor antagonist RU486, but not by inhibition of protein or RNA synthesis. Dexamethasone- induced apoptosis is preceded by a decrease in the number of cytoplasmic processes, an indicator of cell detachment. In addition, the focal adhesion kinase FAK prevents dexamethasone- induced apoptosis, whereas the FAK- related kinase Pyk2 increases the basal levels of apoptosis. Dexamethasoneinduced apoptosis is also prevented in cells expressing kinase- deficient or phosphorylation- defective ( Y402F) dominant negative mutants of Pyk2. Consistent with the requirement of tyrosine 402, dexamethasone induces rapid Pyk2 phosphorylation in this residue. Moreover, knocking down Pyk2 expression abolishes apoptosis and cell detachment induced by dexamethasone, and transfection with human Pyk2 rescues both responses. Furthermore, induction of apoptosis as well as cell detachment by dexamethasone is abolished by inhibiting the activity of JNK, a recognized downstream target of Pyk2 activation. These results demonstrate that glucocorticoids promote osteocyte apoptosis via a receptor- mediated mechanism that does not require gene transcription and that is mediated by rapid activation of Pyk2 and JNK, followed by inside- out signaling that leads to cell detachment- induced apoptosis or anoikis.	Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Bellido, T (corresponding author), 4301 W Markham St,Slot 587, Little Rock, AR 72205 USA.	tmbellido@uams.edu		Plotkin, Lilian/0000-0002-9537-4544	NCRR NIH HHS [2 P20 RR 16460] Funding Source: Medline; NIAMS NIH HHS [K02-AR02127] Funding Source: Medline; NIA NIH HHS [P01-AG13918] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL MK, 1987, FEBS LETT, V217, P221, DOI 10.1016/0014-5793(87)80667-1; Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104; Carter CA, 1999, J CELL PHYSIOL, V178, P320, DOI 10.1002/(SICI)1097-4652(199903)178:3<320::AID-JCP6>3.0.CO;2-S; CARY LA, 1999, FRONT BIOSCI, V4, P102; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Cheng SL, 1998, J CELL BIOCHEM, V71, P449, DOI 10.1002/(SICI)1097-4644(19981201)71:3<449::AID-JCB13>3.0.CO;2-D; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DOHERTY WJ, 1995, J BONE JOINT SURG AM, V77A, P396, DOI 10.2106/00004623-199503000-00009; Druilhe A, 2003, APOPTOSIS, V8, P481, DOI 10.1023/A:1025590308147; Engelbrecht Y, 2003, ENDOCRINOLOGY, V144, P412, DOI 10.1210/en.2002-220769; Frank GD, 2000, BIOCHEM BIOPH RES CO, V270, P761, DOI 10.1006/bbrc.2000.2505; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gardai SJ, 2003, J IMMUNOL, V170, P556, DOI 10.4049/jimmunol.170.1.556; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gil-Henn H, 2006, J BONE MINER RES, V21, pS67; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Globus RK, 1998, J CELL SCI, V111, P1385; Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Heidkamp MC, 2005, AM J PHYSIOL-CELL PH, V289, pC471, DOI 10.1152/ajpcell.00130.2005; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Inoue K, 2006, J BIOL CHEM, V281, P33814, DOI 10.1074/jbc.M607290200; Iuchi T, 2003, CIRC RES, V92, P81, DOI 10.1161/01.RES.0000050588.35034.3C; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Karsdal MA, 2004, DNA CELL BIOL, V23, P155, DOI 10.1089/104454904322964751; Karsdal MA, 2002, J BIOL CHEM, V277, P44061, DOI 10.1074/jbc.M207205200; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084; Kogianni G, 2004, LIFE SCI, V75, P2879, DOI 10.1016/j.lfs.2004.04.048; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; Limbourg FP, 2003, J MOL MED-JMM, V81, P168, DOI 10.1007/s00109-003-0418-y; Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009; Miller AL, 2005, MOL ENDOCRINOL, V19, P1569, DOI 10.1210/me.2004-0528; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Necela Brian M, 2004, Proc Am Thorac Soc, V1, P239, DOI 10.1513/pats.200402-005MS; Newell-Price J, 2006, LANCET, V367, P1605, DOI 10.1016/S0140-6736(06)68699-6; O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003-0990; Ohtsu H, 2005, ARTERIOSCL THROM VAS, V25, P1831, DOI 10.1161/01.ATV.0000175749.41799.9b; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Pawate S, 2006, ANTIOXID REDOX SIGN, V8, P903, DOI 10.1089/ars.2006.8.903; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Plotkin LI, 2005, AM J PHYSIOL-CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Sancho D, 2000, J CELL BIOL, V149, P1249, DOI 10.1083/jcb.149.6.1249; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; STELLATO C, 2006, P AM THORAC SOC, V1, P255; Tai LK, 2002, ARTERIOSCL THROM VAS, V22, P1790, DOI 10.1161/01.ATV.0000034475.40227.40; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Touyz RM, 2005, ANTIOXID REDOX SIGN, V7, P1302, DOI 10.1089/ars.2005.7.1302; Tukermann J, 2005, J BONE MINER RES, V20, pS27; van Staa TP, 2006, CALCIFIED TISSUE INT, V79, P129, DOI 10.1007/s00223-006-0019-1; van Wetering S, 2002, J CELL SCI, V115, P1837; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Vertino AM, 2005, J BIOL CHEM, V280, P14130, DOI 10.1074/jbc.M410720200; Weinstein RS, 2006, J BONE MINER RES, V21, pS62; Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; You LD, 2004, ANAT REC PART A, V278A, P505, DOI 10.1002/ar.a.20050; You LD, 2001, J BIOMECH, V34, P1375, DOI 10.1016/S0021-9290(01)00107-5; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang JP, 2000, CLIN EXP IMMUNOL, V122, P20, DOI 10.1046/j.1365-2249.2000.01344.x; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158	85	102	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24120	24130		10.1074/jbc.M611435200	http://dx.doi.org/10.1074/jbc.M611435200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17581824	hybrid			2022-12-25	WOS:000248686600038
J	Eavri, R; Lorberboum-Galski, H				Eavri, Ronen; Lorberboum-Galski, Haya			A novel approach for enzyme replacement therapy - The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMMONIA-LYASE; TRANSDUCTION; ANTAGONIST; CELLS; PKU; MOTILITY; DELIVERY; DISEASE; CANCER; MOUSE	Metabolic diseases arise from mutations in key enzymes of major metabolic pathways. One promising approach for the treatment of such diseases is based on the administration of a wild-type enzyme to substitute the activity of the impaired enzyme by the use of enzyme replacement therapy, yet it is important to deliver this enzyme to the specific deficient tissue. We suggest a new concept for the treatment of metabolic diseases using fusion proteins. We examined the feasibility of this concept in the well characterized metabolic disease, phenylketonuria (PKU), which results from a mutation in the liver enzyme phenylalanine hydroxylase (PAH). PAH is a key enzyme in the metabolic pathway of phenylalanine. Deficiency in PAH leads to high and persistent levels of this amino acid in the plasma of PKU patients, causing permanent neurological damage. Currently a low protein diet is still considered the only effective treatment for most PKU patients. To restore PAH activity in the liver of PKU patients, we constructed PAH-based fusion proteins with delivery moieties based on the HIV-transactivator of transcription peptide, and fragments of human hepatocyte growth factor aiming to specifically target PAH to the liver. We show that these new fusion proteins can be delivered into a variety of human liver cell lines and retain PAH activity after being internalized. We also show that plasma phenylalanine levels were dramatically lowered in mice treated with PAH-based fusion proteins after intravenous administration. We therefore suggest an alternative concept for the treatment of PKU using targeted fusion proteins, which may also be applied to the treatment of other metabolic diseases.	Hebrew Univ Jerusalem, Fac Med, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Lorberboum-Galski, H (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel.	hayalg@md.huji.ac.il	Lorberboum-Galski, Haya/K-8839-2019					ATHERTON ND, 1988, CLIN CHEM, V34, P2241; BERRY MN, 1991, ISOLATED HEPATOCYTES, P14; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Cai SR, 2006, EUR J PHARM SCI, V27, P311, DOI 10.1016/j.ejps.2005.10.011; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chen L, 2005, P NATL ACAD SCI USA, V102, P15581, DOI 10.1073/pnas.0503877102; Ding Z, 2006, GENE THER, V13, P587, DOI 10.1038/sj.gt.3302684; Foss F, 2006, SEMIN ONCOL, V33, pS11, DOI 10.1053/j.seminoncol.2005.12.017; Gamez A, 2004, MOL THER, V9, P124, DOI 10.1016/j.ymthe.2003.11.002; Grabowski GA, 2005, CURR OPIN PEDIATR, V17, P519, DOI 10.1097/01.mop.0000172702.33128.19; Hufton SE, 1998, BBA-PROTEIN STRUCT M, V1382, P295, DOI 10.1016/S0167-4838(97)00171-4; Kaufman S, 1999, P NATL ACAD SCI USA, V96, P3160, DOI 10.1073/pnas.96.6.3160; Levy HL, 1999, P NATL ACAD SCI USA, V96, P1811, DOI 10.1073/pnas.96.5.1811; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; Nechushtan A, 1997, J BIOL CHEM, V272, P11597; Parr C, 2000, INT J CANCER, V85, P563, DOI 10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.0.CO;2-D; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Sarkissian CN, 2005, MOL GENET METAB, V86, pS22, DOI 10.1016/j.ymgme.2005.06.016; Sarkissian CN, 1999, P NATL ACAD SCI USA, V96, P2339, DOI 10.1073/pnas.96.5.2339; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SCRIVER CR, 1995, CLIN BIOCHEM, V28, P137, DOI 10.1016/0009-9120(94)00076-8; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005; Wang L, 2005, MOL GENET METAB, V86, P134, DOI 10.1016/j.ymgme.2005.05.012	24	26	27	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23402	23409		10.1074/jbc.M703367200	http://dx.doi.org/10.1074/jbc.M703367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565982	hybrid			2022-12-25	WOS:000248577500040
J	Rybin, VO; Guo, J; Gertsberg, Z; Elouardighi, H; Steinberg, SF				Rybin, Vitalyi O.; Guo, Jianfen; Gertsberg, Zoya; Elouardighi, Hasnae; Steinberg, Susan F.			Protein kinase C epsilon (PKC epsilon) and src control PKC delta activation loop phosphorylation in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELLS; AUTOPHOSPHORYLATION; FIBROBLASTS; MECHANISMS; ALPHA; PDK1	Protein kinase C delta(PKC delta) is unusual among AGC kinases in that it does not require activation loop (Thr(505)) phosphorylation for catalytic competence. Nevertheless, Thr(505) phosphorylation has been implicated as a mechanism that influences PKC delta activity. This study examines the controls of PKC delta- Thr(505) phosphorylation in cardiomyocytes. We implicate phosphoinositide-dependent kinase-1 and PKC delta autophosphorylation in the "priming" maturational PKC delta-Thr(505) phosphorylation that accompanies de novo enzyme synthesis. In contrast, we show that PKC delta-Thr(505) phosphorylation dynamically increases in cardiomyocytes treated with phorbol 12-myristate 13-acetate or the alpha(1)-adrenergic receptor agonist norepinephrine via a mechanism that requires novel PKC isoform activity and not phosphoinositide-dependent kinase-1. We used a PKC epsilon overexpression strategy as an initial approach to discriminate two possible novel PKC mechanisms, namely PKC delta-Thr(505) autophosphorylation and PKC delta-Thr(505) phosphorylation in trans by PKC epsilon. Our studies show that adenovirus-mediated PKC delta overexpression leads to an increase in PKC delta-Thr(505) phosphorylation. However, this cannot be attributed to an effect of PKC epsilon to function as a direct PKC delta-Thr(505) kinase, since the PKC epsilon-dependent increase in PKC delta-Thr(505) phosphorylation is accompanied by ( and dependent upon) increased PKC phosphorylation at Tyr(311) and Tyr(332). Further studies implicate Src in this mechanism, showing that 1) PKC epsilon overexpression increases PKC delta-Thr(505) phosphorylation in cardiomyocytes and Src+ cells but not in SYF cells (that lack Src, Yes, and Fyn and exhibit a defect in PKC delta-Tyr(311)/Tyr(332) phosphorylation), and 2) in vitro PKC delta-Thr(505) autophosphorylation is augmented in assays performed with Src ( which promotes PKC delta-Tyr(311)/Tyr(332) phosphorylation). Collectively, these results identify a novel PKC delta-Thr(505) autophosphorylation mechanism that is triggered by PKC epsilon overexpression and involves Src-dependent PKC delta-Tyr(311)/Tyr(332) phosphorylation.	Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University	Steinberg, SF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	sfs1@columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL77860, R01 HL077860-04, R01 HL077860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; GRANDAGE VL, 2006, BR J HAEMATOL; Gray MO, 2004, J BIOL CHEM, V279, P3596, DOI 10.1074/jbc.M311459200; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Kiss Z, 1999, ARCH BIOCHEM BIOPHYS, V363, P121, DOI 10.1006/abbi.1998.1066; Klein G, 2005, CIRC RES, V96, P748, DOI 10.1161/01.RES.0000161999.86198.1e; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liu Y, 2006, J BIOL CHEM, V281, P12102, DOI 10.1074/jbc.M600508200; Moore MJ, 2002, J BIOL CHEM, V277, P47878, DOI 10.1074/jbc.M204970200; Porter MJ, 2003, AM J PHYSIOL-CELL PH, V285, pC39, DOI 10.1152/ajpcell.00461.2002; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rybin VO, 2004, J BIOL CHEM, V279, P19350, DOI 10.1074/jbc.M311096200; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; Sabri A, 2002, CIRC RES, V91, P532, DOI 10.1161/01.RES.0000035242.96310.45; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	24	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23631	23638		10.1074/jbc.M701676200	http://dx.doi.org/10.1074/jbc.M701676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17569658	hybrid, Green Accepted			2022-12-25	WOS:000248577500065
J	Lee, S; Jeong, SY; Lim, WC; Kim, S; Park, YY; Sun, X; Youle, RJ; Cho, H				Lee, Seungmin; Jeong, Seon-Yong; Lim, Won-Chung; Kim, Sujeong; Park, Yong-Yea; Sun, Xuejun; Youle, Richard J.; Cho, Hyeseong			Mitochondrial fission and fusion mediators, hFis1 and OPA1, modulate cellular senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED PROTEIN; DOMINANT OPTIC ATROPHY; CYTOCHROME-C RELEASE; MAMMALIAN-CELLS; OXIDATIVE STRESS; APOPTOSIS; MORPHOLOGY; BAX; GTPASE; FIS1	The number and morphology of mitochondria within a cell are precisely regulated by the mitochondrial fission and fusion machinery. The human protein, hFis1, participates in mitochondrial fission by recruiting the Drp1 into the mitochondria. Using short hairpin RNA, we reduced the expression levels of hFis1 in mammalian cells. Cells lacking hFis1 showed sustained elongation of mitochondria and underwent significant cellular morphological changes, including enlargement, flattening, and increased cellular granularity. In these cells, staining for acidic senescence-associated beta-galactosidase activity was elevated, and the rate of cell proliferation was greatly reduced, indicating that cells lacking hFis1 undergo senescence-associated phenotypic changes. Reintroduction of the hFis1 gene into hFis1depleted cells restored mitochondrial fragmentation and suppressed senescence-associated beta-galactosidase activity. Moreover, depletion of both hFis1 and OPA1, a critical component of mitochondrial fusion, resulted in extensive mitochondrial fragmentation and markedly rescued cells from senescence-associated phenotypic changes. Intriguingly, sustained elongation of mitochondria was associated with decreased mitochondrial membrane potential, increased reactive oxygen species production, and DNA damage. The data indicate that sustained mitochondrial elongation induces senescence-associated phenotypic changes that can be neutralized by mitochondrial fragmentation. Thus, one of the key functions of mitochondrial fission might be prevention of the sustained extensive mitochondrial elongation that triggers cellular senescence.	Ajou Univ, Sch Med, Dept Biochem, Suwon 443721, South Korea; Ajou Univ, Sch Med, Dept Med Genet, Suwon 443721, South Korea; Ajou Univ, Grad Sch Mol Sci & Technol, Suwon 443721, South Korea; Cross Canc Inst, Mol Imaging Fac, Edmonton, AB T6G 1Z2, Canada; NIH, NINDS, SNB, Biochem Sect, Bethesda, MD 20892 USA	Ajou University; Ajou University; Ajou University; University of Alberta; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Cho, H (corresponding author), Ajou Univ, Sch Med, Dept Biochem, 5 Wonchon Dong, Suwon 443721, South Korea.	hscho@ajou.ac.kr		Cho, Hyeseong/0000-0002-4672-8887; Lim, Wonchung/0000-0003-4018-7757	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002859, Z01NS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Campisi J, 2000, IN VIVO, V14, P183; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270; Cipolat S, 2006, CELL DEATH DIFFER, V13, P1833, DOI 10.1038/sj.cdd.4402005; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025; Gorsich SW, 2004, MOL BIOL CELL, V15, P4369, DOI 10.1091/mbc.E03-12-0875; Ishikawa F, 2006, CORNEA, V25, pS3, DOI 10.1097/01.ico.0000247206.47897.92; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kijima K, 2005, HUM GENET, V116, P23, DOI 10.1007/s00439-004-1199-2; Lee HC, 2005, INT J BIOCHEM CELL B, V37, P822, DOI 10.1016/j.biocel.2004.09.010; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Meinhardt A, 1999, HUM REPROD UPDATE, V5, P108, DOI 10.1093/humupd/5.2.108; Motta P M, 2000, Hum Reprod, V15 Suppl 2, P129; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Neutzner A, 2005, J BIOL CHEM, V280, P18598, DOI 10.1074/jbc.M500807200; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116; Santel A, 2001, J CELL SCI, V114, P867; Schmitt C, 2006, BIOCHIM BIOPHYS ACTA, V1775, P5; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shin DM, 2004, J BIOL CHEM, V279, P15032, DOI 10.1074/jbc.M308734200; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Verhoeven K, 2006, BRAIN, V129, P2093, DOI 10.1093/brain/awl126; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Yoon YS, 2006, J CELL PHYSIOL, V209, P468, DOI 10.1002/jcp.20753; Yu TZ, 2005, J CELL SCI, V118, P4141, DOI 10.1242/jcs.02537; Zgheib O, 2005, RADIOTHER ONCOL, V76, P119, DOI 10.1016/j.radonc.2005.06.026; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440; Zottini M, 2006, NEW PHYTOL, V172, P239, DOI 10.1111/j.1469-8137.2006.01830.x	45	208	212	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22977	22983		10.1074/jbc.M700679200	http://dx.doi.org/10.1074/jbc.M700679200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17545159	hybrid			2022-12-25	WOS:000248354200074
J	Valkonen, M; Kalkman, ER; Saloheimo, M; Penttila, M; Read, ND; Duncan, RR				Valkonen, Mari; Kalkman, Eric R.; Saloheimo, Markku; Penttilae, Merja; Read, Nick D.; Duncan, Rory R.			Spatially segregated SNARE protein interactions in living fungal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMAGING MICROSCOPY FLIM; TRICHODERMA-REESEI; ASPERGILLUS-NIGER; SECRETORY PATHWAY; PLASMA-MEMBRANE; FLUORESCENT PROTEIN; NEUROSPORA-CRASSA; SWISS-MODEL; YEAST; GENE	The machinery for trafficking proteins through the secretory pathway is well conserved in eukaryotes, from fungi to mammals. We describe the isolation of the snc1, sso1, and sso2 genes encoding exocytic SNARE proteins from the filamentous fungus Trichoderma reesei. The localization and interactions of the T. reesei SNARE proteins were studied with advanced fluorescence imaging methods. The SSOI and SNCI proteins co-localized in sterol-independent clusters on the plasma membrane in subapical but not apical hyphal regions. The vesicle SNARE SNCI also localized to the apical vesicle cluster within the Spitzenkorper of the growing hyphal tips. Using fluorescence lifetime imaging microscopy and Foerster resonance energy transfer analysis, we quantified the interactions between these proteins with high spatial resolution in living cells. Our data showed that the site of ternary SNARE complex formation between SNCI and SSOI or SSOII, respectively, is spatially segregated. SNARE complex formation could be detected between SNCI and SSOI in subapical hyphal compartments along the plasma membrane, but surprisingly, not in growing hyphal tips, previously thought to be the main site of exocytosis. In contrast, SNCI.SSOII complexes were found exclusively in growing apical hyphal compartments. These findings demonstrate spatially distinct sites of plasma membrane SNARE complex formation in fungi and the existence of multiple exocytic SNAREs, which are functionally and spatially segregated. This is the first demonstration of spatially regulated SNARE interactions within the same membrane.	VTT Biotechnol, FIN-02044 Espoo, Finland; Univ Edinburgh, Inst Cell Biol, Fungal Cell Biol Grp, Edinburgh EH9 3JH, Midlothian, Scotland; Univ Edinburgh, Membrane Biol Grp, Edinburgh EH8 9XD, Midlothian, Scotland	VTT Technical Research Center Finland; University of Edinburgh; University of Edinburgh	Valkonen, M (corresponding author), VTT Biotechnol, POB 1000, FIN-02044 Espoo, Finland.	mari.valkonen@vtt.fi	Penttilä, Merja E/A-4710-2013	Kalkman, Eric/0000-0002-1108-6589; Read, Nick/0000-0002-2286-2862; Duncan, Rory/0000-0003-0693-910X; Penttila, Merja/0000-0002-6929-1032	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BAILEY MJ, 1981, ENZYME MICROB TECH, V3, P153, DOI 10.1016/0141-0229(81)90076-4; Bartnicki-Garcia S, 2002, MYCOLOGY S, V15, P29; Beauvais A, 2001, DRUG RESIST UPDATE, V4, P38, DOI 10.1054/drup.2001.0185; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; Borkovich KA, 2004, MICROBIOL MOL BIOL R, V68, P1, DOI 10.1128/MMBR.68.1.1-108.2004; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Diener SE, 2004, FEMS MICROBIOL LETT, V230, P275, DOI 10.1016/S0378-1097(03)00916-9; Duncan RR, 2006, BIOCHEM SOC T, V34, P679, DOI 10.1042/BST0340679; Duncan RR, 2004, J MICROSC-OXFORD, V215, P1, DOI 10.1111/j.0022-2720.2004.01343.x; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Gerst JE, 1997, J BIOL CHEM, V272, P16591, DOI 10.1074/jbc.272.26.16591; Gerst JE, 2003, BBA-MOL CELL RES, V1641, P99, DOI 10.1016/S0167-4889(03)00096-X; Goldstein A, 1975, Methods Enzymol, V42, P504; Goodall AR, 1997, J NEUROCHEM, V68, P1542; Gordon CL, 2000, J MICROBIOL METH, V42, P39, DOI 10.1016/S0167-7012(00)00170-6; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GROVE SN, 1970, J BACTERIOL, V104, P989, DOI 10.1128/JB.104.2.989-1009.1970; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gupta GD, 2003, FUNGAL GENET BIOL, V40, P271, DOI 10.1016/S1087-1845(03)00109-9; Gupta GD, 2002, FUNGAL GENET BIOL, V36, P1, DOI 10.1016/S1087-1845(02)00017-8; Gupta GD, 2000, FUNGAL GENET BIOL, V29, P187, DOI 10.1006/fgbi.2000.1200; HARSAY E, 1995, J CELL BIOL, V131, P297, DOI 10.1083/jcb.131.2.297; HEINTZ K, 1992, MOL GEN GENET, V235, P413, DOI 10.1007/BF00279388; Hickey PC, 2005, METHOD MICROBIOL, V34, P63, DOI 10.1016/S0580-8517(04)3403-1; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jantti J, 2002, J CELL SCI, V115, P409; Kato N, 2003, BIOCHEMISTRY-US, V42, P11808, DOI 10.1021/bi034758h; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Liu F, 1998, BIOTECHNOL LETT, V20, P539, DOI 10.1023/A:1005337325456; MargollesClark E, 1996, APPL ENVIRON MICROB, V62, P3840, DOI 10.1128/AEM.62.10.3840-3846.1996; Martin SW, 2004, EUKARYOT CELL, V3, P675, DOI 10.1128/EC.3.3.675-684.2004; Montenecourt B. S. ., 1979, ACS SYM SER, V181, P289, DOI DOI 10.1021/BA-1979-0181.CH014; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Nykanen M, 1997, APPL ENVIRON MICROB, V63, P4929, DOI 10.1128/AEM.63.12.4929-4937.1997; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PENTTILA M, 1987, GENE, V61, P155, DOI 10.1016/0378-1119(87)90110-7; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Punt PJ, 2001, MOL MICROBIOL, V41, P513, DOI 10.1046/j.1365-2958.2001.02541.x; Rautio JJ, 2006, J MICROBIOL METH, V65, P404, DOI 10.1016/j.mimet.2005.08.010; Rickman C, 2004, J BIOL CHEM, V279, P644, DOI 10.1074/jbc.M310879200; Rickman C, 2007, J BIOL CHEM, V282, P12097, DOI 10.1074/jbc.M700227200; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Salaun C, 2005, J BIOL CHEM, V280, P19449, DOI 10.1074/jbc.M501923200; SALOHEIMO A, 1994, MOL MICROBIOL, V13, P219, DOI 10.1111/j.1365-2958.1994.tb00417.x; Saloheimo M, 1999, MOL GEN GENET, V262, P35, DOI 10.1007/s004380051057; Saloheimo M, 2004, APPL ENVIRON MICROB, V70, P459, DOI 10.1128/AEM.70.1.459-467.2004; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sheehan DJ, 1999, CLIN MICROBIOL REV, V12, P40, DOI 10.1128/CMR.12.1.40; Shoji JY, 2006, EUKARYOT CELL, V5, P411, DOI 10.1128/EC.5.2.411-421.2006; Sieber JJ, 2006, BIOPHYS J, V90, P2843, DOI 10.1529/biophysj.105.079574; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Talabardon M, 2005, BIOTECHNOL PROGR, V21, P1389, DOI 10.1021/bp0501064; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Veldhuisen G, 1997, MOL GEN GENET, V256, P446; Virag A, 2006, MYCOL RES, V110, P4, DOI 10.1016/j.mycres.2005.09.005; Weber RWS, 1997, MYCOL RES, V101, P1431, DOI 10.1017/S0953756297004139; Wedlich-Soldner R, 2000, EMBO J, V19, P1974, DOI 10.1093/emboj/19.9.1974; WOSTEN HAB, 1991, J GEN MICROBIOL, V137, P2017, DOI 10.1099/00221287-137-8-2017	66	47	50	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22775	22785		10.1074/jbc.M700916200	http://dx.doi.org/10.1074/jbc.M700916200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553800	hybrid			2022-12-25	WOS:000248354200055
J	Kato, T; Kitamura, K; Maeda, M; Kimura, Y; Katayama, T; Ashida, H; Yamamoto, K				Kato, Toshihiko; Kitamura, Kumiko; Maeda, Megumi; Kimura, Yoshinobu; Katayama, Takane; Ashida, Hisashi; Yamamoto, Kenji			Free oligosaccharides in the cytosol of Caenorhabditis elegans are generated through endoplasmic reticulum-Golgi trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; FREE POLYMANNOSE OLIGOSACCHARIDES; NEUTRAL ALPHA-MANNOSIDASE; GLYCOPROTEIN-BIOSYNTHESIS; QUALITY-CONTROL; SUBSTRATE-SPECIFICITY; LINKED GLYCANS; SUGAR CHAINS; HEN OVIDUCT; DEGRADATION	Free oligosaccharides (FOSs) in the cytosol of eukaryotic cells are mainly generated during endoplasmic reticulum (ER)-associated degradation (ERAD) of misfolded glycoproteins. We analyzed FOS of the nematode Caenorhabditis elegans to elucidate its detailed degradation pathway. The major FOSs were high mannose-type ones bearing 3-9 Man residues. About 94% of the total FOSs had one GlcNAc at their reducing end (FOS-GN1), and the remaining 6% had two GlcNAc (FOS-GN2). A cytosolic endo-beta-N-acetylglucosaminidase mutant (tm1208) accumulated FOS-GN2, indicating involvement of the enzyme in conversion of FOS-GN2 into FOS-GN1. The most abundant FOS in the wild type was Man(5)GlcNAc(1), the M5A' isomer (Man alpha 1- 3(Man alpha 1-6)Man alpha 1-6(Man alpha 1-3)Man beta 1-4GlcNAc), which is different from the corresponding M5B' (Man alpha 1-2Man alpha 1- 2Man alpha 1-3(Man alpha 1-6)Man beta 1-4GlcNAc) in mammals. Analyses of FOS in worms treated with Golgi alpha-mannosidase I inhibitors revealed decreases in Man(5)GlcNAc(1) and increases in Man(7)GlcNAc(1). These results suggested that Golgi alpha-mannosidase I-like enzyme is involved in the production of Man(5-6)- GlcNAc(1), which is unlike in mammals, in which cytosolic alpha-mannosidase is involved. Thus, we assumed that major FOSs in C. elegans were generated through Golgi trafficking. Analysis of FOSs from a Golgi alpha-mannosidase II mutant (tm1078) supported this idea, because GlcNAc(1)Man(5)GlcNAc(1), which is formed by the Golgi-resident GlcNAc-transferase I, was found as a FOS in the mutant. We concluded that significant amounts of misfolded glycoproteins in C. elegans are trafficked to the Golgi and are directly or indirectly retro-translocated into the cytosol to be degraded.	Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan; Okayama Univ, Grad Sch Nat Sci Technol, Okayama 7008530, Japan	Kyoto University; Okayama University	Ashida, H (corresponding author), Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	ashida@lif.kyoto-u.ac.jp	Ashida, Hisashi/HCI-0293-2022	Ashida, Hisashi/0000-0001-5844-4075				ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; Arai MA, 2005, CHEMBIOCHEM, V6, P2281, DOI 10.1002/cbic.200500143; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; Cacan R, 2000, GLYCOBIOLOGY, V10, P645, DOI 10.1093/glycob/10.7.645; CACAN R, 1980, EUR J BIOCHEM, V106, P473, DOI 10.1111/j.1432-1033.1980.tb04594.x; Chen SH, 1999, J BIOL CHEM, V274, P288, DOI 10.1074/jbc.274.1.288; Cipollo JF, 2002, J BIOL CHEM, V277, P49143, DOI 10.1074/jbc.M208020200; Costanzi E, 2006, BBA-GEN SUBJECTS, V1760, P1580, DOI 10.1016/j.bbagen.2006.06.011; Frenkel Z, 2003, J BIOL CHEM, V278, P34119, DOI 10.1074/jbc.M305929200; Fujita K, 2004, ARCH BIOCHEM BIOPHYS, V432, P41, DOI 10.1016/j.abb.2004.09.013; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; HAEUW JF, 1991, EUR J BIOCHEM, V202, P1257, DOI 10.1111/j.1432-1033.1991.tb16498.x; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HASE S, 1994, METHOD ENZYMOL, V230, P225; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; Hirao K, 2006, J BIOL CHEM, V281, P9650, DOI 10.1074/jbc.M512191200; Iwai K, 1999, J BIOCHEM, V125, P70, DOI 10.1093/oxfordjournals.jbchem.a022270; Kato T, 2002, GLYCOBIOLOGY, V12, P581, DOI 10.1093/glycob/cwf073; KIMURA Y, 1988, J BIOCHEM-TOKYO, V103, P944, DOI 10.1093/oxfordjournals.jbchem.a122391; Kimura Y, 2002, BBA-GEN SUBJECTS, V1570, P38, DOI 10.1016/S0304-4165(02)00149-6; Kimura Y, 2000, J BIOCHEM, V127, P1013, DOI 10.1093/oxfordjournals.jbchem.a022692; Kincaid MM, 2007, MOL BIOL CELL, V18, P455, DOI 10.1091/mbc.E06-08-0696; KMIECIK D, 1995, GLYCOBIOLOGY, V5, P483, DOI 10.1093/glycob/5.5.483; MOORE SEH, 1995, EMBO J, V14, P6034, DOI 10.1002/j.1460-2075.1995.tb00292.x; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; Natsuka S, 2002, J BIOCHEM, V131, P807, DOI 10.1093/oxfordjournals.jbchem.a003169; Ohashi S, 1999, J BIOCHEM-TOKYO, V126, P852, DOI 10.1093/oxfordjournals.jbchem.a022526; OKU H, 1991, J BIOCHEM-TOKYO, V110, P982, DOI 10.1093/oxfordjournals.jbchem.a123700; Olivari S, 2006, BIOCHEM BIOPH RES CO, V349, P1278, DOI 10.1016/j.bbrc.2006.08.186; Paschinger K, 2006, J BIOL CHEM, V281, P28265, DOI 10.1074/jbc.M602878200; Plemper RK, 1999, MOL BIOL REP, V26, P125, DOI 10.1023/A:1006913215484; PRIEM B, 1993, PLANT PHYSIOL, V102, P445, DOI 10.1104/pp.102.2.445; Saint-Pol A, 1999, J BIOL CHEM, V274, P13547, DOI 10.1074/jbc.274.19.13547; Spiro RG, 2004, CELL MOL LIFE SCI, V61, P1025, DOI 10.1007/s00018-004-4037-8; Suzuki T, 2002, P NATL ACAD SCI USA, V99, P9691, DOI 10.1073/pnas.152333599; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; SUZUKI T, 1995, J BIOL CHEM, V270, P15181, DOI 10.1074/jbc.270.25.15181; Suzuki T, 2006, BIOCHEM J, V400, P33, DOI 10.1042/BJ20060945; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Verbert A, 1999, BBA-GEN SUBJECTS, V1473, P137, DOI 10.1016/S0304-4165(99)00174-9; Yamashiro K, 1997, J BIOCHEM-TOKYO, V122, P1174, DOI 10.1093/oxfordjournals.jbchem.a021878; Yanagida K, 2006, GLYCOBIOLOGY, V16, P294, DOI 10.1093/glycob/cwj074; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931	46	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22080	22088		10.1074/jbc.M700805200	http://dx.doi.org/10.1074/jbc.M700805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17537729	hybrid			2022-12-25	WOS:000248196800055
J	Mani, K; Cheng, F; Fransson, LA				Mani, Katrin; Cheng, Fang; Fransson, Lars-Ake			Heparan sulfate degradation products can associate with oxidized proteins and proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROUS-ACID DEAMINATION; NITRIC-OXIDE; DEPENDENT AUTOCLEAVAGE; LATE ENDOSOMES; GLYPICAN-1; CELLS; GLYCOSAMINOGLYCANS; CLEAVAGE; DISEASE; BRAIN	The S-nitrosylated proteoglycan glypican-1 recycles via endosomes where its heparan sulfate chains are degraded into anhydromannose-containing saccharides by NO-catalyzed deaminative cleavage. Because heparan sulfate chains can be associated with intracellular protein aggregates, glypican-1 autoprocessing may be involved in the clearance of misfolded recycling proteins. Here we have arrested and then reactivated NO-catalyzed cleavage in the absence or presence of proteasome inhibitors and analyzed the products present in endosomes or co-precipitating with proteasomes using metabolic radiolabeling and immunomagnet isolation as well as by confocal immunofluorescence microscopy. Upon reactivation of deaminative cleavage in T24 carcinoma cells, [S-35] sulfate-labeled degradation products appeared in Rab7-positive vesicles and co-precipitated with a 20 S proteasome subunit. Simultaneous inhibition of proteasome activity resulted in a sustained accumulation of degradation products. We also demonstrated that the anhydromannose-containing heparan sulfate degradation products are detected by a hydrazide-based method that also identifies oxidized, i.e. carbonylated, proteins that are normally degraded in proteasomes. Upon inhibition of proteasome activity, pronounced colocalization between carbonyl-staining, anhydro-mannosecontaining degradation products, and proteasomes was observed in both T24 carcinoma and N2a neuroblastoma cells. The deaminatively generated products that co-precipitated with the proteasomal subunit contained heparan sulfate but were larger than heparan sulfate oligosaccharides and resistant to both acid and alkali. However, proteolytic degradation released heparan sulfate oligosaccharides. In Niemann-Pick C-1 fibroblasts, where deaminative degradation of heparan sulfate is defective, carbonylated proteins were abundant. Moreover, when glypican-1 expression was silenced in normal fibroblasts, the level of carbonylated proteins increased raising the possibility that deaminative heparan sulfate degradation is involved in the clearance of misfolded proteins.	Lund Univ, Sect Neurosci, Dept Expt Med Sci, SE-22184 Lund, Sweden	Lund University	Fransson, LA (corresponding author), Lund Univ, Sect Neurosci, Dept Expt Med Sci, Biomed Centre A13, SE-22184 Lund, Sweden.	lars-ake.fransson@med.lu.se		Mani, Katrin/0000-0002-1821-0634				Belting M, 2003, J BIOL CHEM, V278, P47181, DOI 10.1074/jbc.M308325200; Cappai R, 2005, J BIOL CHEM, V280, P13913, DOI 10.1074/jbc.M409179200; Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200; Cheng F, 2006, J NEUROCHEM, V98, P1445, DOI 10.1111/j.1471-4159.2006.03981.x; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Dong JB, 2004, J BIOL CHEM, V279, P21334, DOI 10.1074/jbc.M401022200; Fransson LA, 2004, CELL MOL LIFE SCI, V61, P1016, DOI 10.1007/s00018-004-3445-0; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Hernebring M, 2006, P NATL ACAD SCI USA, V103, P7700, DOI 10.1073/pnas.0510944103; HORTON D, 1973, CARBOHYD RES, V30, P367, DOI 10.1016/S0008-6215(00)81823-6; JUNG T, 2007, IN PRESS ARCH BIOCH; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; Mani K, 2004, GLYCOBIOLOGY, V14, P387, DOI 10.1093/glycob/cwh035; Mani K, 2004, J BIOL CHEM, V279, P12918, DOI 10.1074/jbc.M313678200; Mani K, 2003, J BIOL CHEM, V278, P38956, DOI 10.1074/jbc.M300394200; Mani K, 2006, GLYCOBIOLOGY, V16, P1251, DOI 10.1093/glycob/cwl045; Mani K, 2006, GLYCOBIOLOGY, V16, P711, DOI 10.1093/glycob/cwj121; PEJLER G, 1988, J BIOL CHEM, V263, P5197; Vilar RE, 1997, BIOCHEM J, V324, P473, DOI 10.1042/bj3240473; Watanabe N, 2004, FASEB J, V18, P1013, DOI 10.1096/fj.03-1040fje; Wilson JX, 2005, ANNU REV NUTR, V25, P105, DOI 10.1146/annurev.nutr.25.050304.092647; Yogalingam G, 2001, HUM MUTAT, V18, P264, DOI 10.1002/humu.1189	28	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21934	21944		10.1074/jbc.M701200200	http://dx.doi.org/10.1074/jbc.M701200200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17540770	hybrid			2022-12-25	WOS:000248196800041
J	Arrigo, N; Arnold, C				Arrigo, Nils; Arnold, Claire			Naturalised Vitis Rootstocks in Europe and Consequences to Native Wild Grapevine	PLOS ONE			English	Article							GENETIC DIVERSITY; DNA; DIFFERENTIATION; IDENTIFICATION; POPULATIONS; COMMUNITIES; LOCI	The genus Vitis is represented by several coexisting species in Europe. Our study focuses on naturalised rootstocks that originate in viticulture. The consequences of their presence to the landscape and to native European species (Vitis vinifera ssp. silvestris) are evaluated. This study compares ecological traits (seven qualitative and quantitative descriptors) and the genetic diversity (10 SSR markers) of populations of naturalised rootstocks and native wild grapevines. 18 large naturalised rootstock populations were studied in the Rhone watershed. Wild European grapevines are present in four main habitats (screes, alluvial forests, hedges, and streamside hedges). In contrast, naturalised rootstock populations are mainly located in alluvial forests, but they clearly take advantage of alluvial system dynamics and connectivity at the landscape level. These latter populations appear to reproduce sexually, and show a higher genetic diversity than Vitis vinifera ssp. silvestris. The regrouping of naturalised rootstocks in interconnected populations tends to create active hybrid swarms of rootstocks. The rootstocks show characters of invasive plants. The spread of naturalised rootstocks in the environment, the acceleration of the decline of the European wild grapevine, and the propagation of genes of viticultural interest in natural populations are potential consequences that should be kept in mind when undertaking appropriate management measures.	[Arnold, Claire] Univ Neuchatel, Natl Ctr Competence Res Plant Survival, CH-2000 Neuchatel, Switzerland; [Arrigo, Nils] Univ Neuchatel, Lab Evolutionary Bot, CH-2000 Neuchatel, Switzerland	University of Neuchatel; University of Neuchatel	Arnold, C (corresponding author), Univ Neuchatel, Natl Ctr Competence Res Plant Survival, CH-2000 Neuchatel, Switzerland.	claire.arnold@unine.ch	Arnold, Claire/AAC-7330-2022	Arnold, Claire/0000-0002-1179-0728	Swiss Confederation [SER-COST C04.0262]; Laboratory of Evolutionary Botany (University of Neuchatel)	Swiss Confederation; Laboratory of Evolutionary Botany (University of Neuchatel)	Swiss Confederation SER-COST C04.0262, Laboratory of Evolutionary Botany (University of Neuchatel)	Abella SR, 2004, J TORREY BOT SOC, V131, P220, DOI 10.2307/4126952; Amoros C, 2002, FRESHWATER BIOL, V47, P761, DOI 10.1046/j.1365-2427.2002.00905.x; *APPL BIOS, 2001, ABI PRISM GENESCAN 3; *APPL BIOS, 2001, ABI PRISM GEN 3 7 NT; Aradhya MK, 2003, GENET RES, V81, P179, DOI 10.1017/S0016672303006177; Arnold C, 1998, VITIS, V37, P159; Arnold C., 2002, GEOBOTANICA HELVETIC, V76, P256; BELKHIR K, 1996, LAB GENOME P INTERAC; Bowers JE, 1999, AM J ENOL VITICULT, V50, P243; Bowers JE, 1996, GENOME, V39, P628, DOI 10.1139/g96-080; *CRAN, 2005, R PROJ STAT COMP 2 0; CRAWLEY MJ, 1986, PHILOS T ROY SOC B, V314, P711, DOI 10.1098/rstb.1986.0082; DELARZE R, 1998, GUIDE MILIEUX NATURE, P415; Desfayes M, 1989, B MURITHIENNE, V107, P161; Dieringer D, 2003, MOL ECOL NOTES, V3, P167, DOI 10.1046/j.1471-8286.2003.00351.x; *DIREN, 2007, REG DIREN DRIRE; *DIREN RHON ALP, 2001, GAL FOR CONFL AIN RH; *DRIRE PACA, 2007, DONN ENV; Ellstrand NC, 2000, P NATL ACAD SCI USA, V97, P7043, DOI 10.1073/pnas.97.13.7043; ElMousadik A, 1996, THEOR APPL GENET, V92, P832, DOI 10.1007/BF00221895; Falush D, 2003, GENETICS, V164, P1567; FARQUET P, 1928, B MURITHIENNE, V16, P111; Forman R.T.T., 1986, LANDSCAPE ECOLOGY, P640; Goudet J., 2001, FSTAT PROGRAM ESTIMA; Grassi F, 2003, THEOR APPL GENET, V107, P1315, DOI 10.1007/s00122-003-1321-1; LAGUNA E, 2004, TOLL NEGRE, V3, P11; Laguna E., 2003, FLORA MONTIBERICA, V23, P46; LEVADOUX L., 1956, Annales de l'Amelioration des Plantes, V6, P59; LEVADOUX L., 1962, ANN AMELIORATION PLANTES, V12, P19; Lin H, 1998, AM J ENOL VITICULT, V49, P403; LUMBRERAS EL, 2003, TOLL NEGRE, V2, P10; Meadows JS, 2006, NEW FOREST, V32, P335, DOI 10.1007/s11056-006-9007-6; MORANO LD, 1995, AM MIDL NAT, V134, P254, DOI 10.2307/2426296; *NATURA2000, 2007, RES EC EUR NAT 2000; Ocete R, 2002, VITIS, V41, P55; Olmo H., 1995, EVOLUTION CROP PLANT, V1, P485; *ONIVINS, 2007, LIST CLON AGR VAR PO; PlantyTabacchi AM, 1996, CONSERV BIOL, V10, P598, DOI 10.1046/j.1523-1739.1996.10020598.x; Pollefeys P, 2003, GENOME, V46, P1037, DOI 10.1139/G03-076; RIBEREAUGAYON J, 1971, SCI TECHNIQUES VIGNE, P725; Rives M., 1974, Vitis, V13, P186; ROGERS SO, 1985, PLANT MOL BIOL, V5, P69, DOI 10.1007/BF00020088; Schumann F., 1974, Vitis, V13, P198; SCHWARZENBACH H, 1968, Wein-Wissenschaft, V23, P145; Sefc K. M., 2000, Acta Horticulturae, P111; Sefc KM, 1999, GENOME, V42, P367, DOI 10.1139/gen-42-3-367; This P, 2004, THEOR APPL GENET, V109, P1448, DOI 10.1007/s00122-004-1760-3; This P, 2001, GENET SEL EVOL, V33, pS289, DOI 10.1186/BF03500885; This P, 2006, TRENDS GENET, V22, P511, DOI 10.1016/j.tig.2006.07.008; THOMAS MR, 1993, THEOR APPL GENET, V86, P985, DOI 10.1007/BF00211051; VOUILLAMOZ J, 2006, SVMD SWISS VITIS MIC; Ward JV, 1999, REGUL RIVER, V15, P125, DOI 10.1002/(SICI)1099-1646(199901/06)15:1/3&lt;125::AID-RRR523&gt;3.0.CO;2-E	52	51	63	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e521	10.1371/journal.pone.0000521	http://dx.doi.org/10.1371/journal.pone.0000521			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565374	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451600009
J	Barreau, F; Meinzer, U; Chareyre, F; Berrebi, D; Niwa-Kawakita, M; Dussaillant, M; Foligne, B; Ollendorff, V; Heyman, M; Bonacorsi, S; Lesuffleur, T; Sterkers, G; Giovannini, M; Hugot, JP				Barreau, Frederick; Meinzer, Ulrich; Chareyre, Fabrice; Berrebi, Dominique; Niwa-Kawakita, Michiko; Dussaillant, Monique; Foligne, Benoit; Ollendorff, Vincent; Heyman, Martine; Bonacorsi, Stephane; Lesuffleur, Thecla; Sterkers, Ghislaine; Giovannini, Marco; Hugot, Jean-Pierre			CARD15/NOD2 Is Required for Peyer's Patches Homeostasis in Mice	PLOS ONE			English	Article							VERSUS-HOST-DISEASE; INCREASED INTESTINAL PERMEABILITY; NECROSIS-FACTOR-ALPHA; CROHNS-DISEASE; INTERFERON-GAMMA; NOD2 VARIANTS; BARRIER; CELLS; AGE; INFLAMMATION	Background. CARD15/NOD2 mutations are associated with susceptibility to Crohn's Disease (CD) and Graft Versus Host Disease (GVHD). CD and GVHD are suspected to be related with the dysfunction of Peyer's patches (PP) and isolated lymphoid follicles (LFs). Using a new mouse model invalidated for Card15/Nod2 (KO), we thus analysed the impact of the gene in these lymphoid formations together with the development of experimental colitis. Methodology/Principal Findings. At weeks 4, 12 and 52, the numbers of PPs and LFs were higher in KO mice while no difference was observed at birth. At weeks 4 and 12, the size and cellular composition of PPs were analysed by flow cytometry and immunohistochemistry. PPs of KO mice were larger with an increased proportion of M cells and CD4(+) T-cells. KO mice were also characterised by higher concentrations of TNF alpha, IFN gamma, IL12 and IL4 measured by ELISA. In contrast, little differences were found in the PP-free ileum and the spleen of KO mice. By Ussing chamber experiments, we found that this PP phenotype is associated with an increased of both paracellular permeability and yeast/bacterial translocation. Finally, KO mice were more susceptible to the colitis induced by TNBS. Conclusions. Card15/Nod2 deficiency induces an abnormal development and function of the PPs characterised by an exaggerated immune response and an increased permeability. These observations provide a comprehensive link between the molecular defect and the Human CARD15/NOD2 associated disorders: CD and GVHD.	[Barreau, Frederick; Meinzer, Ulrich; Dussaillant, Monique; Lesuffleur, Thecla; Hugot, Jean-Pierre] INSERM, U843, Paris, France; [Barreau, Frederick; Meinzer, Ulrich; Dussaillant, Monique; Lesuffleur, Thecla; Hugot, Jean-Pierre] Univ Paris Diderot, UMR S843, Paris, France; [Meinzer, Ulrich; Hugot, Jean-Pierre] Hop Robert Debre, AP HP, Serv Gastroenterol, F-75019 Paris, France; [Chareyre, Fabrice; Niwa-Kawakita, Michiko; Giovannini, Marco] Univ Paris Diderot, Inst Univ Hematol, Paris, France; [Chareyre, Fabrice; Niwa-Kawakita, Michiko; Giovannini, Marco] INSERM, U674, Paris, France; [Berrebi, Dominique] Univ Paris Diderot, EA3102, Paris, France; [Berrebi, Dominique] Inst Pasteur, Serv Anat Pathol, F-59019 Lille, France; [Foligne, Benoit] Inst Pasteur, Lab Bacteries Lact & Immunite Muqueuses, F-59019 Lille, France; [Ollendorff, Vincent] Univ Paul Cezanne, Fac St Jerome, INRA, UMR 1111, Marseille, France; [Ollendorff, Vincent] Univ Paul Cezanne, Fac St Jerome, IMRN, Marseille, France; [Heyman, Martine] INSERM, U793, Paris, France; [Heyman, Martine] Univ Paris 05, IFR94, Paris, France; [Bonacorsi, Stephane] Univ Paris Diderot, EA3105, Paris, France; [Bonacorsi, Stephane] Hop Robert Debre, AP HP, Microbiol Serv, F-75019 Paris, France; [Sterkers, Ghislaine] Hop Robert Debre, AP HP, Serv Immunol, F-75019 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; INRAE; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Hugot, JP (corresponding author), INSERM, U843, Paris, France.	jean-pierre.hugot@rdb.aphp.fr	Foligne, Benoit/B-2754-2014; Meinzer, Ulrich/N-4282-2019; Hugot, Jean-Pierre/F-6594-2012; lesuffleur, thecla/AAC-2980-2020; berrebi, dominique/B-1419-2014; Bonacorsi, Stéphane/HGB-3185-2022	Foligne, Benoit/0000-0001-9263-9706; Kawakita, Michiko/0000-0002-9450-583X; Barreau, Frederick/0000-0002-7150-9619; Ollendorff, Vincent/0000-0001-9751-2202; Hugot, Jean-Pierre/0000-0002-8446-6056	Institut National de la Sante et de la Recherche Medicale; Broad Medical Research Program; la Mairie de Paris; la Fondation pour la Recherche Medicale; BREMICI; l'association Francois Aupetit and la region Ile de France	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Broad Medical Research Program; la Mairie de Paris; la Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); BREMICI; l'association Francois Aupetit and la region Ile de France(Region Ile-de-France)	This work was supported by the Institut National de la Sante et de la Recherche Medicale, the Broad Medical Research Program, la Mairie de Paris, la Fondation pour la Recherche Medicale, BREMICI, l'association Francois Aupetit and la region Ile de France.	Adachi S, 1998, INT IMMUNOL, V10, P1, DOI 10.1093/intimm/10.1.1; Berin MC, 1999, AM J PHYSIOL-CELL PH, V276, pC1046, DOI 10.1152/ajpcell.1999.276.5.C1046; Borghesi C, 1999, LAB INVEST, V79, P1393; Buhner S, 2006, GUT, V55, P342, DOI 10.1136/gut.2005.065557; Busca A, 2007, AM J HEMATOL, V82, P45, DOI 10.1002/ajh.20752; D'Inca R, 2006, ALIMENT PHARM THER, V23, P1455, DOI 10.1111/j.1365-2036.2006.02916.x; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Devlin SM, 2007, GASTROENTEROLOGY, V132, P576, DOI 10.1053/j.gastro.2006.11.013; Dohi T, 2001, J IMMUNOL, V167, P2781, DOI 10.4049/jimmunol.167.5.2781; Dohi T, 1999, J EXP MED, V189, P1169, DOI 10.1084/jem.189.8.1169; Eckmann L, 2005, IMMUNITY, V22, P661, DOI 10.1016/j.immuni.2005.06.004; Elmaagacli AH, 2006, TRANSPLANTATION, V81, P247, DOI 10.1097/01.tp.0000188671.94646.16; Ferrier L, 2003, GASTROENTEROLOGY, V125, P795, DOI 10.1016/S0016-5085(03)01057-6; Fujimura Y, 1996, GUT, V38, P724, DOI 10.1136/gut.38.5.724; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Granell M, 2006, HAEMATOLOGICA, V91, P1372; Hess DJ, 2002, J SURG RES, V104, P88, DOI 10.1006/jsre.2002.6417; Hill GR, 2000, BLOOD, V95, P2754, DOI 10.1182/blood.V95.9.2754.009k25_2754_2759; Holler E, 2004, BLOOD, V104, P889, DOI 10.1182/blood-2003-10-3543; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Iiyama R, 2003, SCAND J IMMUNOL, V58, P620, DOI 10.1111/j.1365-3083.2003.01346.x; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; KATZ KD, 1989, GASTROENTEROLOGY, V97, P927, DOI 10.1016/0016-5085(89)91499-6; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Lesage S, 2002, AM J HUM GENET, V70, P845, DOI 10.1086/339432; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; McKay DM, 1999, GUT, V44, P283, DOI 10.1136/gut.44.2.283; Meinzer U, 2005, INFLAMM BOWEL DIS, V11, P639, DOI 10.1097/01.MIB.0000165114.10687.bf; Murai M, 2003, NAT IMMUNOL, V4, P154, DOI 10.1038/ni879; Nascimbeni R, 2005, MODERN PATHOL, V18, P681, DOI 10.1038/modpathol.3800343; Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Perdue MH, 1999, AM J PHYSIOL-GASTR L, V277, pG1, DOI 10.1152/ajpgi.1999.277.1.G1; Polito JM, 1996, GASTROENTEROLOGY, V111, P580, DOI 10.1053/gast.1996.v111.pm8780560; TEAHON K, 1992, GUT, V33, P320, DOI 10.1136/gut.33.3.320; Van Kruiningen HJ, 2002, INFLAMM BOWEL DIS, V8, P180, DOI 10.1097/00054725-200205000-00004; VanKruiningen HJ, 1997, J CLIN GASTROENTEROL, V25, P470, DOI 10.1097/00004836-199709000-00017; WALLACE JL, 1990, AM J PHYSIOL, V258, pG527, DOI 10.1152/ajpgi.1990.258.4.G527; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Welniak LA, 2006, BLOOD, V107, P410, DOI 10.1182/blood-2004-11-4565; Youakim A, 1999, AM J PHYSIOL-GASTR L, V276, pG1279, DOI 10.1152/ajpgi.1999.276.5.G1279; Zeissig S, 2004, GUT, V53, P1295, DOI 10.1136/gut.2003.036632	43	114	118	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e523	10.1371/journal.pone.0000523	http://dx.doi.org/10.1371/journal.pone.0000523			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565376	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451600011
J	Vojtech, E; Turnbull, LA; Hector, A				Vojtech, Eva; Turnbull, Lindsay A.; Hector, Andy			Differences in Light Interception in Grass Monocultures Predict Short-Term Competitive Outcomes under Productive Conditions	PLOS ONE			English	Article							ASYMMETRIC COMPETITION; NITROGEN DEPOSITION; SPECIES RICHNESS; FOUNDER CONTROL; PLANT; NUTRIENT; RATIO; COEXISTENCE; MECHANISMS; DIVERSITY	Due to its inherent asymmetry, competition for light is thought to cause loss of diversity from eutrophied systems. However, most of the work on this topic in grasslands has been phenomenological and has not measured light directly. We present the results of one of the few mechanistic experiments investigating the outcome of short-term competition using measurements of light interception from monocultures of five perennial grass species grown under fertilized and irrigated conditions. We found that the level of incident light intercepted by each species in monoculture, a direct measure of resource-reduction ability, was an excellent predictor of the relative competitive effect in pairwise mixtures. Competition for light was asymmetric in relation to differences in light intercepting ability. Our results are consistent with the idea that when light is a limiting resource, competition between species for this resource can be asymmetric, contributing to high dominance and low diversity.	[Vojtech, Eva; Turnbull, Lindsay A.; Hector, Andy] Univ Zurich, Inst Environm Sci, Zurich, Switzerland	University of Zurich	Vojtech, E (corresponding author), Univ Zurich, Inst Environm Sci, Zurich, Switzerland.	vojtech@uwinst.uzh.ch	Hector, Andrew/H-4199-2011; Turnbull, Lindsay A./A-2680-2012	Hector, Andrew/0000-0002-1309-7716; 	Swiss National Foundation [3100A0-107572]	Swiss National Foundation(Swiss National Science Foundation (SNSF))	E.V is funded by the Swiss National Foundation grant 3100A0-107572 to A. H.	BEGON M, 1984, EVOL ECOL, P175; Berendse F, 1999, TRENDS ECOL EVOL, V14, P4, DOI 10.1016/S0169-5347(98)01451-7; Berendse F., 1990, Perspectives on plant competition., P93; Berntson GM, 2000, ECOLOGY, V81, P1072, DOI 10.1890/0012-9658(2000)081[1072:CTSDOR]2.0.CO;2; DYBZINSKI R, AM NATURALI IN PRESS; Fargione J, 2006, FUNCT ECOL, V20, P533, DOI 10.1111/j.1365-2435.2006.01116.x; Foster BL, 1998, ECOLOGY, V79, P2593, DOI 10.1890/0012-9658(1998)079[2593:SRIASG]2.0.CO;2; Freckleton RP, 2001, ECOL LETT, V4, P348, DOI 10.1046/j.1461-0248.2001.00231.x; Harpole WS, 2006, ECOL LETT, V9, P15, DOI 10.1111/j.1461-0248.2005.00836.x; Huisman J, 1999, ECOLOGY, V80, P211, DOI 10.2307/176991; HUISMAN J, 1994, ECOLOGY, V75, P507, DOI 10.2307/1939554; HUSTON MA, 1994, AM NAT, V144, P954, DOI 10.1086/285720; Lauber K., 1996, FLORA HELVETICA; Leps J, 1999, J VEG SCI, V10, P219, DOI 10.2307/3237143; Miller TE, 2005, AM NAT, V165, P439, DOI 10.1086/428681; Nord-Larsen T, 2006, CAN J FOREST RES, V36, P418, DOI 10.1139/X05-255; Perry LG, 2003, J THEOR BIOL, V222, P425, DOI 10.1016/S0022-5193(03)00055-9; Rees M, 1997, J THEOR BIOL, V184, P353, DOI 10.1006/jtbi.1996.0297; REYNOLDS HL, 1993, AM NAT, V141, P51, DOI 10.1086/285460; Roem WJ, 2000, BIOL CONSERV, V92, P151, DOI 10.1016/S0006-3207(99)00049-X; Schwinning S, 1998, OECOLOGIA, V113, P447, DOI 10.1007/s004420050397; Schwinning S, 1996, ANN BOT-LONDON, V77, P47, DOI 10.1006/anbo.1996.0006; SCHWINNING S, 1995, OIKOS, V72, P422, DOI 10.2307/3546128; Silvertown J, 2006, J ECOL, V94, P801, DOI 10.1111/j.1365-2745.2006.01145.x; Stevens CJ, 2006, GLOBAL CHANGE BIOL, V12, P1823, DOI 10.1111/j.1365-2486.2006.01217.x; Stevens CJ, 2004, SCIENCE, V303, P1876, DOI 10.1126/science.1094678; Stevens MHH, 2002, ECOL LETT, V5, P420, DOI 10.1046/j.1461-0248.2002.00333.x; Tilman D., 1982, Monographs in Population Biology, pi; TILMAN D, 1991, ECOLOGY, V72, P1038, DOI 10.2307/1940604; TILMAN D, 1988; TILMAN D, 1991, AM NAT, V138, P1283, DOI 10.1086/285285; Turnbull LA, 2004, J ECOL, V92, P97, DOI 10.1111/j.1365-2745.2004.00856.x; Violle C, 2007, FUNCT ECOL, V21, P185, DOI 10.1111/j.1365-2435.2006.01241.x; WEDIN D, 1993, ECOL MONOGR, V63, P199, DOI 10.2307/2937180; WEINER J, 1990, TRENDS ECOL EVOL, V5, P360, DOI 10.1016/0169-5347(90)90095-U	35	40	41	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e499	10.1371/journal.pone.0000499	http://dx.doi.org/10.1371/journal.pone.0000499			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565366	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451600001
J	Vieux-Rochas, M; Coen, L; Sato, T; Kurihara, Y; Gitton, Y; Barbieri, O; Le Blay, K; Merlo, G; Ekker, M; Kurihara, H; Janvier, P; Levi, G				Vieux-Rochas, Maxence; Coen, Laurent; Sato, Takahiro; Kurihara, Yukiko; Gitton, Yorick; Barbieri, Ottavia; Le Blay, Karine; Merlo, Giorgio; Ekker, Marc; Kurihara, Hiroki; Janvier, Philippe; Levi, Giovanni			Molecular Dynamics of Retinoic Acid-Induced Craniofacial Malformations: Implications for the Origin of Gnathostome Jaws	PLOS ONE			English	Article								Background. Intake of retinoic acid (RA) or of its precursor, vitamin A, during early pregnancy is associated with increased incidence of craniofacial lesions. The origin of these teratogenic effects remains enigmatic as in cranial neural crest cells (CNCCs), which largely contribute to craniofacial structures, the RA-transduction pathway is not active. Recent results suggest that RA could act on the endoderm of the first pharyngeal arch (1stPA), through a RAR beta-dependent mechanism. Methodology/Principal Findings. Here we show that RA provokes dramatically different craniofacial malformations when administered at slightly different developmental times within a narrow temporal interval corresponding to the colonization of the 1(st) PA by CNCCs. We provide evidence showing that RA acts on the signalling epithelium of the 1(st) PA, gradually reducing the expression of endothelin-1 and Fgf8. These two molecular signals are instrumental in activating Dlx genes in incoming CNCCs, thereby triggering the morphogenetic programs, which specify different jaw elements. Conclusions/Significance. The anatomical series induced by RA-treatments at different developmental times parallels, at least in some instances, the supposed origin of modern jaws (e.g., the fate of the incus). Our results might provide a conceptual framework for the rise of jaw morphotypes characteristic of gnathostomes.	[Vieux-Rochas, Maxence; Coen, Laurent; Gitton, Yorick; Le Blay, Karine; Levi, Giovanni] Museum Natl Hist Nat, CNRS, UMR5166, Paris, France; [Sato, Takahiro; Kurihara, Yukiko; Kurihara, Hiroki] Univ Tokyo, Dept Physiol Chem & Metab, Grad Sch Med, Tokyo, Japan; [Barbieri, Ottavia] Univ Genoa, Transgen Unit, Dept Oncol Biol & Genet, IST,CBA, Genoa, Italy; [Merlo, Giorgio] Dulbecco Telethon Inst CNR ITB, Milan, Italy; [Ekker, Marc] Univ Ottawa, Dept Biol, Ctr Adv Res Environm Genom, Ottawa, ON, Canada; [Janvier, Philippe] Museum Natl Hist Nat, CNRS, UMR 5143, Dept Hist Terre, Paris, France; [Janvier, Philippe] Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); University of Tokyo; University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Ottawa; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Natural History Museum London	Levi, G (corresponding author), Museum Natl Hist Nat, CNRS, UMR5166, Paris, France.	glevi@mnhn.fr	Barbieri, Ottavia/E-8768-2011; Levi, Giovanni/B-4416-2013; GITTON, Yorick/M-8524-2019	GITTON, Yorick/0000-0002-6808-6010; Kurihara, Hiroki/0000-0002-6476-5593; Levi, Giovanni/0000-0002-7041-6787	EU [PL503020, LSHM-CT-2005-018652]; French Government; Fondazione Telethon Funding Source: Custom	EU(European Commission); French Government; Fondazione Telethon(Fondazione Telethon)	This work was supported by grants from the EU community: Anabonos PL503020 and Crescendo LSHM-CT-2005-018652. M. V.-R. is recipient of a doctoral fellowship from the French Government.	Abu-Abed S, 2003, DEVELOPMENT, V130, P1449, DOI 10.1242/dev.00357; Acampora D, 1999, DEVELOPMENT, V126, P3795; Alles A J, 1992, Clin Dysmorphol, V1, P187; ALLES AJ, 1990, DEVELOPMENT, V108, P73; Arafa HMM, 2000, ARCH TOXICOL, V73, P547, DOI 10.1007/s002040050007; Beverdam A, 2002, GENESIS, V34, P221, DOI 10.1002/gene.10156; Brondani V, 2002, J MOL BIOL, V319, P715, DOI 10.1016/S0022-2836(02)00376-5; Chai Y, 2006, DEV DYNAM, V235, P2353, DOI 10.1002/dvdy.20833; Charite J, 2001, GENE DEV, V15, P3039, DOI 10.1101/gad.931701; Cheung Chui Shan, 2003, Neuroembryology, V2, P164, DOI 10.1159/000079403; Coberly S, 1996, PEDIATR PATHOL LAB M, V16, P823, DOI 10.1080/107710496175435; Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399; Couly G, 2002, DEVELOPMENT, V129, P1061; Couly G, 1998, DEVELOPMENT, V125, P3445; Creuzet S, 2005, J ANAT, V207, P447, DOI 10.1111/j.1469-7580.2005.00485.x; Depew MJ, 2002, SCIENCE, V298, P381, DOI 10.1126/science.1075703; Depew MJ, 2005, J ANAT, V207, P501, DOI 10.1111/j.1469-7580.2005.00487.x; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Dupe V, 1999, DEVELOPMENT, V126, P5051; Ellies DL, 1997, MECH DEVELOP, V61, P23, DOI 10.1016/S0925-4773(96)00616-8; Elmazar MMA, 2004, ARCH TOXICOL, V78, P660, DOI 10.1007/s00204-004-0586-8; Elmazar MMA, 2001, TOXICOL APPL PHARM, V170, P2, DOI 10.1006/taap.2000.9074; Elmazar MMA, 1996, TERATOLOGY, V53, P158, DOI 10.1002/(SICI)1096-9926(199603)53:3<158::AID-TERA3>3.0.CO;2-0; Escriva H, 2002, DEVELOPMENT, V129, P2905; Gavalas A, 2001, DEVELOPMENT, V128, P3017; GOULDING EH, 1986, J CRAN GENET DEV BIO, V6, P99; Graham A, 2001, BIOESSAYS, V23, P54, DOI 10.1002/1521-1878(200101)23:1<54::AID-BIES1007>3.0.CO;2-5; Haworth KE, 2004, DEVELOPMENT, V131, P4797, DOI 10.1242/dev.01337; Iulianella A, 1997, DEV DYNAM, V209, P92, DOI 10.1002/(SICI)1097-0177(199705)209:1<92::AID-AJA9>3.0.CO;2-S; Iulianella A, 2002, DEV BIOL, V247, P62, DOI 10.1006/dbio.2002.0685; Jiang XB, 2002, MECH DEVELOP, V117, P115, DOI 10.1016/S0925-4773(02)00206-X; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KNUDSEN PA, 1967, ACTA ODONTOL SCAND, V25, P267, DOI 10.3109/00016356709104023; Kochhar DM, 1996, CHEM-BIOL INTERACT, V100, P1, DOI 10.1016/0009-2797(95)03681-4; Kontges G, 1996, DEVELOPMENT, V122, P3229; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEE YM, 1995, DEVELOPMENT, V121, P825; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; Mallo M, 1997, DEV BIOL, V184, P175, DOI 10.1006/dbio.1997.8519; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; Mark M, 2003, PURE APPL CHEM, V75, P1709, DOI 10.1351/pac200375111709; Matt N, 2003, DEVELOPMENT, V130, P2083, DOI 10.1242/dev.00428; MORRISSKAY G, 1993, ANN ANAT, V175, P501, DOI 10.1016/S0940-9602(11)80209-8; Mulder GB, 1998, TERATOLOGY, V58, P263, DOI 10.1002/(SICI)1096-9926(199812)58:6<263::AID-TERA8>3.3.CO;2-1; Nugent P, 1999, INT J DEV BIOL, V43, P567; Ozeki H, 2004, MECH DEVELOP, V121, P387, DOI 10.1016/j.mod.2004.02.002; Park BK, 2004, DEV BIOL, V268, P532, DOI 10.1016/j.ydbio.2004.01.010; PRATT RM, 1987, J CRAN GENET DEV BIO, V7, P205; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruest LB, 2004, DEVELOPMENT, V131, P4413, DOI 10.1242/dev.01291; Saadeddin A, 2004, AAPS PHARMSCI, V6, DOI 10.1208/ps060101; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Santagati F, 2003, NAT REV NEUROSCI, V4, P806, DOI 10.1038/nrn1221; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; Shigetani Y, 2000, DEV BIOL, V228, P73, DOI 10.1006/dbio.2000.9932; Shigetani Y, 2002, SCIENCE, V296, P1316, DOI 10.1126/science.1068310; SIMEONE A, 1995, MECH DEVELOP, V51, P83, DOI 10.1016/0925-4773(95)96241-M; SOPRANO DR, 1995, ANNU REV NUTR, V15, P111, DOI 10.1146/annurev.nu.15.070195.000551; Sucov HM, 1995, DEVELOPMENT, V121, P3997; SULIK KK, 1988, DEVELOPMENT, V103, P213; SULIK KK, 1995, TERATOLOGY, V51, P398, DOI 10.1002/tera.1420510605; Tahayato A, 2003, GENE EXPR PATTERNS, V3, P449, DOI 10.1016/S1567-133X(03)00066-8; Trainor PA, 2003, INT J DEV BIOL, V47, P541; Veitch E, 1999, CURR BIOL, V9, P1481, DOI 10.1016/S0960-9822(00)80118-9; WEBSTER WS, 1986, J CRAN GENET DEV BIO, V6, P211; Wei X, 1999, TERATOLOGY, V60, P83, DOI 10.1002/(SICI)1096-9926(199908)60:2<83::AID-TERA12>3.0.CO;2-O; Wendling O, 2000, DEVELOPMENT, V127, P1553; Yokota J, 2001, ATHEROSCLEROSIS, V159, P491, DOI 10.1016/S0021-9150(01)00530-5; Zerucha T, 2000, J NEUROSCI, V20, P709, DOI 10.1523/JNEUROSCI.20-02-00709.2000	73	36	37	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e510	10.1371/journal.pone.0000510	http://dx.doi.org/10.1371/journal.pone.0000510			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551590	Green Published, gold			2022-12-25	WOS:000207451500019
J	Voisine, C; Varma, H; Walker, N; Bates, EA; Stockwell, BR; Hart, AC				Voisine, Cindy; Varma, Hemant; Walker, Nicola; Bates, Emily A.; Stockwell, Brent R.; Hart, Anne C.			Identification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegans	PLOS ONE			English	Article							HISTONE DEACETYLASE INHIBITORS; HEAT-SHOCK FACTOR; MOUSE MODEL; PROTEIN AGGREGATION; POLYGLUTAMINE; TOXICITY; TRANSCRIPTION; SURVIVAL; DAF-16; SUPPRESSION	Background. The prolonged time course of Huntington's disease (HD) neurodegeneration increases both the time and cost of testing potential therapeutic compounds in mammalian models. An alternative is to initially assess the efficacy of compounds in invertebrate models, reducing time of testing from months to days. Methodology/Principal Findings. We screened candidate therapeutic compounds that were identified previously in cell culture/animal studies in a C. elegans HD model and found that two FDA approved drugs, lithium chloride and mithramycin, independently and in combination suppressed HD neurotoxicity. Aging is a critical contributor to late onset neurodegenerative diseases. Using a genetic strategy and a novel assay, we demonstrate that lithium chloride and mithramycin remain neuroprotective independent of activity of the forkhead transcription factor DAF-16, which mediates the effects of the insulin-like signaling pathway on aging. Conclusions/Significance. These results suggest that pathways involved in polyglutamine-induced degeneration are distinct from specific aging pathways. The assays presented here will be useful for rapid and inexpensive testing of other potential HD drugs and elucidating pathways of drug action. Additionally, the neuroprotection conferred by lithium chloride and mithramycin suggests that these drugs may be useful for polyglutamine disease therapy.	[Voisine, Cindy; Walker, Nicola; Bates, Emily A.; Hart, Anne C.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA; [Varma, Hemant; Stockwell, Brent R.] Columbia Univ, Fairchild Ctr, Dept Biol Sci, New York, NY 10027 USA; [Stockwell, Brent R.] Columbia Univ, Fairchild Ctr, Dept Chem, New York, NY 10027 USA; [Voisine, Cindy; Walker, Nicola; Bates, Emily A.; Hart, Anne C.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Columbia University; Columbia University; Harvard University; Harvard Medical School	Hart, AC (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.	hart@helix.mgh.harvard.edu	Voisine, Cindy/AAG-9045-2019; Stockwell, Brent R/AAE-7200-2019	Stockwell, Brent R/0000-0002-3532-3868; Voisine, Cindy/0000-0001-7165-9636	Hereditary Disease Foundation; Cure Huntington Disease Initiative; High Q Foundation; Ellison Medical Foundation; NIH [NS-040048, T32 AG20506]; Burroughs Wellcome Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG020506] Funding Source: NIH RePORTER	Hereditary Disease Foundation; Cure Huntington Disease Initiative; High Q Foundation; Ellison Medical Foundation(Lawrence Ellison Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We gratefully acknowledge the support of the Hereditary Disease Foundation (C. V. and B. R. S.), Cure Huntington Disease Initiative (B. R. S.), the High Q Foundation (H. V. and B. R. S.), the Ellison Medical Foundation (A. C. H.) and the NIH (NS-040048 for A. C. H. and T32 AG20506 for C. V.). Brent R. Stockwell is supported in part by a Career Award at the Scientific Interface from the Burroughs Wellcome Fund.	Apostol BL, 2003, P NATL ACAD SCI USA, V100, P5950, DOI 10.1073/pnas.2628045100; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Bates EA, 2006, J NEUROSCI, V26, P2830, DOI 10.1523/JNEUROSCI.3344-05.2006; Baugh LR, 2006, CURR BIOL, V16, P780, DOI 10.1016/j.cub.2006.03.021; Berger Z, 2005, HUM MOL GENET, V14, P3003, DOI 10.1093/hmg/ddi331; Butler R, 2006, NAT REV NEUROSCI, V7, P784, DOI 10.1038/nrn1989; Carmichael J, 2002, J BIOL CHEM, V277, P33791, DOI 10.1074/jbc.m204861200; Chamberlain JS, 2000, CURR BIOL, V10, pR795, DOI 10.1016/S0960-9822(00)00768-5; Dedeoglu A, 2002, J NEUROSCI, V22, P8942; Diamond MI, 2000, P NATL ACAD SCI USA, V97, P657, DOI 10.1073/pnas.97.2.657; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; Faber PW, 2002, P NATL ACAD SCI USA, V99, P17131, DOI 10.1073/pnas.262544899; Ferrante RJ, 2004, J NEUROSCI, V24, P10335, DOI 10.1523/JNEUROSCI.2599-04.2004; Fukuyama M, 2006, CURR BIOL, V16, P773, DOI 10.1016/j.cub.2006.02.073; Garigan D, 2002, GENETICS, V161, P1101; Geary TG, 2001, VET PARASITOL, V101, P371, DOI 10.1016/S0304-4017(01)00562-3; Gieseler K, 2000, CURR BIOL, V10, P1092, DOI 10.1016/S0960-9822(00)00691-6; GRANATO M, 1994, DEVELOPMENT, V120, P3005; GUSELLA JF, 1995, CURR OPIN NEUROBIOL, V5, P656, DOI 10.1016/0959-4388(95)80072-7; Hazeki N, 1999, BIOCHEM BIOPH RES CO, V256, P361, DOI 10.1006/bbrc.1999.0337; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hughes RE, 2001, P NATL ACAD SCI USA, V98, P13201, DOI 10.1073/pnas.191498198; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; JONES DE, 1995, ONCOGENE, V10, P2323; Karpuj MV, 2002, NAT MED, V8, P143, DOI 10.1038/nm0202-143; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Nollen EAA, 2004, P NATL ACAD SCI USA, V101, P6403, DOI 10.1073/pnas.0307697101; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Piccioni F, 2004, HUM MOL GENET, V13, P437, DOI 10.1093/hmg/ddh045; Rand JB, 1995, METHOD CELL BIOL, V48, P187; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Tang BL, 2006, NEUROBIOL AGING, V27, P501, DOI 10.1016/j.neurobiolaging.2005.02.001; Van Raamsdonk JM, 2005, J NEUROCHEM, V95, P210, DOI 10.1111/j.1471-4159.2005.03357.x; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Varma H, 2007, NAT CHEM BIOL, V3, P99, DOI 10.1038/nchembio852; Wang J, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-1; Wang WF, 2005, NEUROBIOL DIS, V20, P500, DOI 10.1016/j.nbd.2005.03.026; Wood WB, 1988, NEMATODE CAENORHABDI	46	109	116	1	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e504	10.1371/journal.pone.0000504	http://dx.doi.org/10.1371/journal.pone.0000504			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551584	gold, Green Published			2022-12-25	WOS:000207451500013
J	Frazzetto, G; Di Lorenzo, G; Carola, V; Proietti, L; Sokolowska, E; Siracusano, A; Gross, C; Troisi, A				Frazzetto, Giovanni; Di Lorenzo, Giorgio; Carola, Valeria; Proietti, Luca; Sokolowska, Ewa; Siracusano, Alberto; Gross, Cornelius; Troisi, Alfonso			Early Trauma and Increased Risk for Physical Aggression during Adulthood: The Moderating Role of MAOA Genotype	PLOS ONE			English	Article								Previous research has reported that a functional polymorphism in the monoamine oxidase A (MAOA) gene promoter can moderate the association between early life adversity and increased risk for violence and antisocial behavior. In this study of a combined population of psychiatric outpatients and healthy volunteers (N = 235), we tested the hypothesis that MAOA genotype moderates the association between early traumatic life events (ETLE) experienced during the first 15 years of life and the display of physical aggression during adulthood, as assessed by the Aggression Questionnaire. An ANOVA model including gender, exposure to early trauma, and MAOA genotype as between-subjects factors showed significant MAOA x ETLE (F-1,F-227 = 8.20, P = 0.005) and gender x MAOA x ETLE (F-1,F-227 = 7.04, P = 0.009) interaction effects. Physical aggression scores were higher in men who had experienced early traumatic life events and who carried the low MAOA activity allele (MAOA-L). We repeated the analysis in the subgroup of healthy volunteers (N = 145) to exclude that the observed G x E interactions were due to the inclusion of psychiatric patients in our sample and were not generalizable to the population at large. The results for the subgroup of healthy volunteers were identical to those for the entire sample. The cumulative variance in the physical aggression score explained by the ANOVA effects involving the MAOA polymorphism was 6.6% in the entire sample and 12.1% in the sub-sample of healthy volunteers. Our results support the hypothesis that, when combined with exposure to early traumatic life events, low MAOA activity is a significant risk factor for aggressive behavior during adulthood and suggest that the use of dimensional measures focusing on behavioral aspects of aggression may increase the likelihood of detecting significant gene-by-environment interactions in studies of MAOA-related aggression.	[Frazzetto, Giovanni; Carola, Valeria; Sokolowska, Ewa; Gross, Cornelius] European Mol Biol Lab, Mouse Biol Unit, Monterotondo, Italy; [Di Lorenzo, Giorgio; Proietti, Luca; Siracusano, Alberto; Troisi, Alfonso] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy	European Molecular Biology Laboratory (EMBL); University of Rome Tor Vergata	Gross, C (corresponding author), European Mol Biol Lab, Mouse Biol Unit, Monterotondo, Italy.	gross@embl.it	carola, valeria/J-9724-2014; TROISI, ALFONSO/AAB-8010-2019; Di Lorenzo, Giorgio/B-1308-2013	TROISI, ALFONSO/0000-0002-3483-1318; Di Lorenzo, Giorgio/0000-0002-0576-4064; SIRACUSANO, ALBERTO/0000-0001-8406-093X	Fritz Thyssen Stiftung; Branco Weiss Fellowship	Fritz Thyssen Stiftung; Branco Weiss Fellowship	This work was supported by a grant from the Fritz Thyssen Stiftung (C. G.) and by 'Society in Science'-The Branco Weiss Fellowship (G. F.).	Bandelow B, 2002, COMPR PSYCHIAT, V43, P269, DOI 10.1053/comp.2002.33492; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Chen K, 2007, J BIOL CHEM, V282, P115, DOI 10.1074/jbc.M609830200; Deckert J, 1999, HUM MOL GENET, V8, P621, DOI 10.1093/hmg/8.4.621; Eisenberger NI, 2007, BIOL PSYCHIAT, V61, P1100, DOI 10.1016/j.biopsych.2006.08.007; Fan J, 2003, P NATL ACAD SCI USA, V100, P7406, DOI 10.1073/pnas.0732088100; Feinberg ME, 2007, ARCH GEN PSYCHIAT, V64, P457, DOI 10.1001/archpsyc.64.4.457; First M. B., 1997, STRUCTURED CLIN INTE; Foley DL, 2004, ARCH GEN PSYCHIAT, V61, P738, DOI 10.1001/archpsyc.61.7.738; Freeman B, 2003, BEHAV GENET, V33, P67, DOI 10.1023/A:1021055617738; Haberstick BC, 2005, AM J MED GENET B, V135B, P59, DOI 10.1002/ajmg.b.30176; Harris JA, 1997, BEHAV RES THER, V35, P1047, DOI 10.1016/S0005-7967(97)00064-8; Huizinga D, 2006, BIOL PSYCHIAT, V60, P677, DOI 10.1016/j.biopsych.2005.12.022; Johnson JG, 1999, ARCH GEN PSYCHIAT, V56, P600, DOI 10.1001/archpsyc.56.7.600; Kim-Cohen J, 2006, MOL PSYCHIATR, V11, P903, DOI 10.1038/sj.mp.4001851; Lesch KP, 2000, BEHAV SCI LAW, V18, P581, DOI 10.1002/1099-0798(200010)18:5<581::AID-BSL411>3.0.CO;2-L; LEVY ER, 1989, GENOMICS, V5, P368, DOI 10.1016/0888-7543(89)90072-4; LUNTZ BK, 1994, AM J PSYCHIAT, V151, P670; Meyer-Lindenberg A, 2006, P NATL ACAD SCI USA, V103, P6269, DOI 10.1073/pnas.0511311103; Moffitt TE, 2005, ARCH GEN PSYCHIAT, V62, P473, DOI 10.1001/archpsyc.62.5.473; Nilsson KW, 2006, BIOL PSYCHIAT, V59, P121, DOI 10.1016/j.biopsych.2005.06.024; Nordquist N, 2006, BIOCHEM BIOPH RES CO, V348, P763, DOI 10.1016/j.bbrc.2006.07.131; Pfohl B., 1995, STRUCTURED INTERVIEW; Raine A, 1997, AM J PSYCHIAT, V154, P1265; Raine A, 1996, ARCH GEN PSYCHIAT, V53, P544; REIF A, 2007, NEUROPSYCHO IN PRESS; Renn Paul, 2002, Attach Hum Dev, V4, P294, DOI 10.1080/14616730210167203; Sabol SZ, 1998, HUM GENET, V103, P273, DOI 10.1007/s004390050816; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Suris A, 2004, AGGRESS VIOLENT BEH, V9, P165, DOI 10.1016/S1359-1789(03)00012-0; Troisi A, 2004, J AFFECT DISORDERS, V79, P269, DOI 10.1016/S0165-0327(02)00406-8; Young SE, 2006, AM J PSYCHIAT, V163, P1019, DOI 10.1176/appi.ajp.163.6.1019	35	134	142	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e486	10.1371/journal.pone.0000486	http://dx.doi.org/10.1371/journal.pone.0000486			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534436	Green Published, Green Submitted, gold			2022-12-25	WOS:000207448800016
J	Koch-Nolte, F; Reyelt, J; Schossow, B; Schwarz, N; Scheuplein, F; Rothenburg, S; Haag, F; Alzogaray, V; Cauerhff, A; Goldbaum, FA				Koch-Nolte, Friedrich; Reyelt, Jan; Schoessow, Britta; Schwarz, Nicole; Scheuplein, Felix; Rothenburg, Stefan; Haag, Friedrich; Alzogaray, Vanina; Cauerhff, Ana; Goldbaum, Fernando A.			Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo	FASEB JOURNAL			English	Article						recombinant antibodies; leukocyte ecto-enzymes; enzyme inhibitors; ADP-ribosylation	NICOTINAMIDE ADENINE-DINUCLEOTIDE; HEAVY-CHAIN ANTIBODIES; MEMBRANE-PROTEINS; BACTERIAL TOXINS; SURFACE-PROTEINS; LIGHT-CHAINS; RIBOSYLATION; MOUSE; ACTIVATION; CD38	The purpose of our study was to develop a tool for blocking the function of a specific leukocyte ecto-enzyme in vivo. ART2.2 is a toxin-related ectoenzyme that transfers the ADP-ribose moiety from NAD onto other cell surface proteins. ART2.2 induces T cell death by activating the cytolytic P2 x 7 purinoceptor via ADP-ribosylation. Here, we report the generation of ART2.2-blocking single domain antibodies from an immunized llama. The variable domain of heavy-chain antibodies (VHH domain) represents the smallest known antigen-binding unit generated by adaptive immune responses. Their long CDR3 endows VHH domains with the extraordinary capacity to extend into and block molecular clefts. Following intravenous injection, the ART2.2-specific VHH domains effectively shut off the enzymatic and cytotoxic activities of ART2.2 in lymphatic organs. This blockade was highly specific ( blocking ART2.2 but not the related enzymes ART1 or ART2.1), rapid ( within 15 min after injection), and reversible ( 24 h after injection). Our findings constitute a proof of principle that opens up a new avenue for targeting leukocyte ecto-enzymes in vivo and that can serve as a model also for developing new antidotes against ADP-ribosylating toxins.	Univ Med Ctr Hamburg Eppendorf, Dept Clin Pathol, Inst Immunol, Ctr Diagnost, D-20246 Hamburg, Germany; Consejo Nacl Invest Cient & Tecn, Fdn Inst Leloir, Buenos Aires, DF, Argentina	University of Hamburg; University Medical Center Hamburg-Eppendorf; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute	Koch-Nolte, F (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Clin Pathol, Inst Immunol, Ctr Diagnost, Martinistr 52, D-20246 Hamburg, Germany.	nolte@uke.uni-hamburg.de	Rothenburg, Stefan/A-8340-2008	Goldbaum, Fernando/0000-0001-6235-3002; Cauerhff, Ana/0000-0001-9686-9883; Scheuplein, Felix/0000-0002-2691-0796; Koch-Nolte, Friedrich/0000-0003-1730-6674				Aktories K, 2005, NAT REV MICROBIOL, V3, P397, DOI 10.1038/nrmicro1150; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Bannas P, 2005, BLOOD, V105, P3663, DOI 10.1182/blood-2004-08-3325; Baral TN, 2006, NAT MED, V12, P580, DOI 10.1038/nm1395; BOERSMA WJA, 1992, RES IMMUNOL, V143, P503, DOI 10.1016/0923-2494(92)80061-O; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; Corda D, 2003, EMBO J, V22, P1953, DOI 10.1093/emboj/cdg209; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103; Deaglio S, 2006, BLOOD, V108, P1135, DOI 10.1182/blood-2006-01-013003; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Garton KJ, 2006, J LEUKOCYTE BIOL, V79, P1105, DOI 10.1189/jlb.0106038; Glowacki G, 2002, PROTEIN SCI, V11, P1657, DOI 10.1110/ps.0200602; Goding JW, 1998, IMMUNOL REV, V161, P5, DOI 10.1111/j.1600-065X.1998.tb01567.x; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Harmsen MM, 2000, MOL IMMUNOL, V37, P579, DOI 10.1016/S0161-5890(00)00081-X; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Janssens R, 2006, P NATL ACAD SCI USA, V103, P15130, DOI 10.1073/pnas.0601108103; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Kahl S, 2000, J IMMUNOL, V165, P4463, DOI 10.4049/jimmunol.165.8.4463; Kawamura H, 2005, J IMMUNOL, V174, P1971, DOI 10.4049/jimmunol.174.4.1971; Koch-Nolte F, 1999, J IMMUNOL, V163, P6014; Koch-Nolte F, 2005, CELL IMMUNOL, V236, P66, DOI 10.1016/j.cellimm.2005.08.033; Koch-Nolte F, 2006, ANN MED, V38, P188, DOI 10.1080/07853890600655499; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; Krebs C, 2005, J IMMUNOL, V174, P3298, DOI 10.4049/jimmunol.174.6.3298; Krebs C, 2003, ANAL BIOCHEM, V314, P108, DOI 10.1016/S0003-2697(02)00640-1; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Mueller-Dieckmann C, 2002, J MOL BIOL, V322, P687, DOI 10.1016/S0022-2836(02)00818-5; Muruganandam A, 2001, FASEB J, V15, P240, DOI 10.1096/fj.01-0343fje; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Muyldermans S, 2001, J Biotechnol, V74, P277; Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X; Okazaki IJ, 1996, BLOOD, V88, P915; Reinhold D, 2002, BIOL CHEM, V383, P1133, DOI 10.1515/BC.2002.123; Ritter H, 2003, BIOCHEMISTRY-US, V42, P10155, DOI 10.1021/bi034625w; Salmi M, 2005, NAT REV IMMUNOL, V5, P760, DOI 10.1038/nri1705; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Seman M, 2004, CURR MED CHEM, V11, P857, DOI 10.2174/0929867043455611; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102; Yates SP, 2006, TRENDS BIOCHEM SCI, V31, P123, DOI 10.1016/j.tibs.2005.12.007; Zarebski LM, 2005, J MOL BIOL, V349, P814, DOI 10.1016/j.jmb.2005.03.072; Zolkiewska A, 2005, PHYSIOLOGY, V20, P374, DOI 10.1152/physiol.00028.2005	48	86	113	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3490	3498		10.1096/fj.07-8661com	http://dx.doi.org/10.1096/fj.07-8661com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575259				2022-12-25	WOS:000250517800012
J	Sakao, S; Taraseviciene-Stewart, L; Cool, CD; Tada, Y; Kasahara, Y; Kurosu, K; Tanabe, N; Takiguchi, Y; Tatsumi, K; Kuriyama, T; Voelkel, NF				Sakao, Seiichiro; Taraseviciene-Stewart, Laimute; Cool, Carlyne D.; Tada, Yuji; Kasahara, Yasunori; Kurosu, Katsushi; Tanabe, Nobuhiro; Takiguchi, Yuichi; Tatsumi, Koichiro; Kuriyama, Takayuki; Voelkel, Norbert F.			VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34(+) precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells	FASEB JOURNAL			English	Article						pulmonary hypertension; human pulmonary microvascular endothelial cells	SEVERE PULMONARY-HYPERTENSION; HEMATOPOIETIC STEM-CELLS; ADULT BONE-MARROW; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; IN-VITRO; PROGENITOR CELLS; C-KIT; ATHEROSCLEROTIC LESIONS; ENCODING CD34	Severe pulmonary hypertension (PH) is characterized by complex precapillary arteriolar lesions, which contain phenotypically altered smooth muscle ( SM) and endothelial cells (EC). We have demonstrated that VEGF receptor blockade by SU5416 {3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin 2-one} in combination with chronic hypoxia causes severe angioproliferative PH associated with arterial occlusion in rats. We postulate that endothelial-mesenchymal transdifferentiation can take place in the occlusive lesions and that endothelium-derived mesenchymal cells can further differentiate toward a SM phenotype. To examine this hypothesis, we incubated human pulmonary microvascular endothelial cells (HPMVEC) with SU5416 and analyzed these cells utilizing quantitative-PCR, immunofluorescent staining and flow cytometry analysis. In vitro studies in HPMVEC demonstrated that SU5416 suppressed PGI(2)S gene expression while potently inducing COX-2, VEGF, and TGF-beta(1) expression; and caused transdifferentiation of mature vascular endothelial cells (defined by Dil-ac-LDL, Lectin and Factor VIII) to SM-like (as defined by expression of alpha-SM actin) "transitional" cells, coexpressing both endothelial and SM markers. SU5416 expanded the number of CD34 and/or c-kit positive cells and caused transdifferentiation of CD34 positive cells but not negative cells. In conclusion, our data show that SU5416 generated a selection pressure that killed some EC and expanded progenitor-like cells to transdifferentiate to SM-like and neuronal-like cells.	Chiba Univ, Sch Med, Dept Respirol B2, Grad Sch Med,Chuo Ku, Chiba 2608670, Japan; Univ Colorado, Hlth Sci Ctr, Pulm Hypertens Ctr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO USA	Chiba University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sakao, S (corresponding author), Chiba Univ, Sch Med, Dept Respirol B2, Grad Sch Med,Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	sakaos@faculty.chiba-u.jp			NHLBI NIH HHS [5P01 HL66254-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066254] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCINIEGAS E, 1992, J CELL SCI, V103, P521; ASHMAN LK, 1994, J CELL PHYSIOL, V158, P545, DOI 10.1002/jcp.1041580321; Baluk P, 2004, AM J PATHOL, V165, P1071, DOI 10.1016/S0002-9440(10)63369-X; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Catalano A, 2005, EMBO J, V24, P170, DOI 10.1038/sj.emboj.7600502; Cool C.D., 2004, AM J RESP CRIT CARE, V167, pA844; Cool CD, 1999, AM J PATHOL, V155, P411, DOI 10.1016/S0002-9440(10)65137-1; DELIA D, 1993, BLOOD, V81, P1001; Doyonnas R, 2005, BLOOD, V105, P4170, DOI 10.1182/blood-2004-10-4077; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Frid MG, 2002, CIRC RES, V90, P1189, DOI 10.1161/01.RES.0000021432.70309.28; Geraci MW, 2001, CIRC RES, V88, P555, DOI 10.1161/01.RES.88.6.555; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Glaser R, 2002, CIRCULATION, V106, P17, DOI 10.1161/01.CIR.0000021923.58307.8F; Golpon HA, 2001, AM J PATHOL, V158, P955, DOI 10.1016/S0002-9440(10)64042-4; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guo P, 2001, CANCER RES, V61, P8569; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628; Hu YH, 2002, CIRC RES, V91, pE13, DOI 10.1161/01.RES.0000037090.34760.EE; Hu YH, 2002, CIRCULATION, V106, P1834, DOI 10.1161/01.CIR.0000031333.86845.DD; Jin H, 2006, J CLIN INVEST, V116, P652, DOI 10.1172/JCI24751; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kerosuo L, 2004, BRIT J HAEMATOL, V124, P809, DOI 10.1111/j.1365-2141.2004.04840.x; Koide Y, 2002, J MED CHEM, V45, P4629, DOI 10.1021/jm020080c; Krause DS, 1996, BLOOD, V87, P1; KRAUSE DS, 1994, BLOOD, V84, P691; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEE SL, 1991, CIRC RES, V68, P1362, DOI 10.1161/01.RES.68.5.1362; LERNER NB, 1991, BLOOD, V77, P1876; Licht T, 2003, BLOOD, V102, P2099, DOI 10.1182/blood-2002-12-3634; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Muller AM, 2002, EXP MOL PATHOL, V72, P221, DOI 10.1006/exmp.2002.2424; Okada K, 1998, AM J RESP CRIT CARE, V158, P939, DOI 10.1164/ajrccm.158.3.9710007; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; RUFAIHAH AJ, 2007, J GENE MED; Sakao S, 2005, CHEST, V128, p610S, DOI 10.1378/chest.128.6_suppl.610S-a; Sakao S, 2005, FASEB J, V19, P1178, DOI 10.1096/fj.04-3261fje; Sakao S, 2006, AM J PHYSIOL-LUNG C, V291, pL362, DOI 10.1152/ajplung.00111.2005; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; SATTERTHWAITE AB, 1992, GENOMICS, V12, P788, DOI 10.1016/0888-7543(92)90310-O; Sauter B, 1998, J HISTOCHEM CYTOCHEM, V46, P165, DOI 10.1177/002215549804600205; SCHLINGEMANN RO, 1990, LAB INVEST, V62, P690; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; SIMMONS DL, 1992, J IMMUNOL, V148, P267; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Sugita M, 2002, CANCER RES, V62, P3971; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Tang K, 2004, PHYSIOL GENOMICS, V18, P63, DOI 10.1152/physiolgenomics.00023.2004; Tang KC, 2004, J APPL PHYSIOL, V97, P1559, DOI 10.1152/japplphysiol.00221.2004; Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com; Tuder RM, 1999, AM J RESP CRIT CARE, V159, P1925, DOI 10.1164/ajrccm.159.6.9804054; Tuder RM, 2001, J PATHOL, V195, P367, DOI 10.1002/path.953; Tuder RM, 2001, CLIN CHEST MED, V22, P405, DOI 10.1016/S0272-5231(05)70280-X; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; WYPYCH J, 1995, BLOOD, V85, P66, DOI 10.1182/blood.V85.1.66.bloodjournal85166; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Zamora MR, 1996, AM J PHYSIOL-LUNG C, V270, pL101, DOI 10.1152/ajplung.1996.270.1.L101	61	66	68	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3640	3652		10.1096/fj.07-8432com	http://dx.doi.org/10.1096/fj.07-8432com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567571				2022-12-25	WOS:000250517800026
J	Belloni, D; Scabini, S; Foglieni, C; Veschini, L; Giazzon, A; Colombo, B; Fulgenzi, A; Helle, KB; Ferrero, ME; Corti, A; Ferrero, E				Belloni, Daniela; Scabini, Silvia; Foglieni, Chiara; Veschini, Lorenzo; Giazzon, Alessio; Colombo, Barbara; Fulgenzi, Alessandro; Helle, Karen B.; Ferrero, Maria Elena; Corti, Angelo; Ferrero, Elisabetta			The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration	FASEB JOURNAL			English	Article						ERK/MAPK; capillary-like structures	TUMOR-GROWTH; MAP KINASES; ANGIOGENESIS; IDENTIFICATION; MORPHOGENESIS; ACTIVATION; PHENOTYPE; ADHESION; SYSTEM; MATRIX	A growing body of evidence suggests that chromogranin A (CgA), a secretory protein released by many neuroendocrine cells and frequently used as a diagnostic and prognostic serum marker for a range of neuroendocrine tumors, is a precursor of several bioactive fragments. This work was undertaken to assess whether the N-terminal fragment CgA(1-76) (called vasostatin I) can inhibit the proangiogenic activity of vascular endothelial growth factor (VEGF), a factor involved in tumor growth. The effect of recombinant human vasostatin I (VS-1) on VEGF-induced human umbilical endothelial cells (HUVEC) signaling, proliferation, migration, and organization has been investigated. We have found that VS-1 (3 mu g/ ml; 330 nM) can inhibit VEGF-induced ERK phosphorylation, as well as cell migration, proliferation, morphogenesis, and invasion of collagen gels in various in vitro assays. In addition, VS-1 could inhibit the formation of capillary-like structures in Matrigel plugs in a rat model. VS-1 could also inhibit basal ERK phosphorylation and motility of HUVEC, leading to a more quiescent state in the absence of VEGF, without inducing apoptotic or necrotic effects. Conclusion: These findings suggest that vasostatin I may play a novel role as a regulator of endothelial cell function and homeostasis.	Ist Sci San Raffaele, DIBIT, Cardiovasc Dept, I-20132 Milan, Italy; Ist Sci San Raffaele, Dept Oncol, I-20132 Milan, Italy; Ist Sci San Raffaele, IIT Network Res Unit Mol Neurosci, I-20132 Milan, Italy; Univ Bergen, Dept Biomed, Bergen, Norway; CNR, Inst Gen Pathol, I-20133 Milan, Italy; CNR, Ctr Studies Cellular Pathol, I-20133 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto Italiano di Tecnologia - IIT; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Bergen; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)	Ferrero, E (corresponding author), Ist Sci San Raffaele, DIBIT, Cardiovasc Dept, Via Olgettina 60, I-20132 Milan, Italy.	elisabetta.ferrero@hsr.it	Colombo, Barbara/AAN-5045-2020; Ferrero, Elisabetta/G-5690-2013; fulgenzi, alessandro/AAN-6722-2020; Belloni, Daniela/AAN-6718-2020; Corti, Angelo/F-7046-2012; Foglieni, Chiara/O-2339-2015	Colombo, Barbara/0000-0002-5887-5868; fulgenzi, alessandro/0000-0003-1343-6965; Belloni, Daniela/0000-0002-3487-4203; Corti, Angelo/0000-0002-0893-6191; Foglieni, Chiara/0000-0002-5155-6426; Veschini, Lorenzo/0000-0003-3820-7472; Subba, Rajkrishna/0000-0003-0051-0062				AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bernini GP, 2001, BRIT J CANCER, V84, P636, DOI 10.1054/bjoc.2000.1659; Blois A, 2006, REGUL PEPTIDES, V134, P30, DOI 10.1016/j.regpep.2005.11.003; BLOIS A, 2006, REGUL PEPTIDES, V135, P554; Bullard LE, 2003, INVEST OPHTH VIS SCI, V44, P1722, DOI 10.1167/iovs.01-1193; Cai J, 2006, MICROVASC RES, V71, P20, DOI 10.1016/j.mvr.2005.10.004; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Ceconi C, 2002, EUR HEART J, V23, P967, DOI 10.1053/euhj.2001.2977; Chow S, 2001, CYTOMETRY, V46, P72, DOI 10.1002/cyto.1067; Colombo B, 2002, CANCER RES, V62, P941; Colombo B, 2002, J BIOL CHEM, V277, P45911, DOI 10.1074/jbc.M202637200; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Corti A, 2000, ADV EXP MED BIOL, V482, P351; Corti Angelo, 2004, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V4, P161, DOI 10.2174/1568013043357626; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; Ferrero E, 2004, FASEB J, V18, P554, DOI 10.1096/fj.03-0922fje; FERRERO E, 1995, FEBS LETT, V374, P323, DOI 10.1016/0014-5793(95)01110-Z; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Heissig B, 2003, CURR OPIN HEMATOL, V10, P136, DOI 10.1097/00062752-200303000-00007; HELLE KB, 1994, ACTA PHYSIOL SCAND, V152, P1, DOI 10.1111/j.1748-1716.1994.tb09779.x; Helle KB, 2004, BIOL REV, V79, P769, DOI 10.1017/S146479310400644X; Hoefen RJ, 2002, VASC PHARMACOL, V38, P271, DOI 10.1016/S1537-1891(02)00251-3; HSIAO RJ, 1990, AM J MED, V88, P607, DOI 10.1016/0002-9343(90)90526-J; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; Kang YK, 1997, FEBS LETT, V404, P87, DOI 10.1016/S0014-5793(97)00099-9; Meadows KN, 2004, ONCOGENE, V23, P192, DOI 10.1038/sj.onc.1206921; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; METZBOUTIGUE MH, 2001, CURR MED CHEM IMMUNO, V1, P119; Michiels C, 2003, J CELL PHYSIOL, V196, P430, DOI 10.1002/jcp.10333; OCONNOR DT, 1984, NEW ENGL J MED, V311, P764, DOI 10.1056/NEJM198409203111204; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; Patan S, 2000, J NEURO-ONCOL, V50, P1, DOI 10.1023/A:1006493130855; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Prewett M, 1999, CANCER RES, V59, P5209; Ratti S, 2000, J BIOL CHEM, V275, P29257, DOI 10.1074/jbc.M003796200; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Strasly M, 2004, BLOOD, V103, P40, DOI 10.1182/blood-2003-05-1387; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; White CR, 2005, AM J PHYSIOL-HEART C, V289, pH2350, DOI 10.1152/ajpheart.01229.2004; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; ZIEGLER MG, 1990, KIDNEY INT, V37, P1357, DOI 10.1038/ki.1990.122	49	70	72	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3052	3062		10.1096/fj.06-6829com	http://dx.doi.org/10.1096/fj.06-6829com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17566084				2022-12-25	WOS:000249781600007
J	Avlani, VA; Gregory, KJ; Morton, CJ; Parker, MW; Sexton, PM; Christopoulos, A				Avlani, Vimesh A.; Gregory, Karen J.; Morton, Craig J.; Parker, Michael W.; Sexton, Patrick M.; Christopoulos, Arthur			Critical role for the second extracellular loop in the binding of both orthosteric and allosteric g protein-coupled receptor Ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MECHANISMS; AMINO-ACIDS; ACETYLCHOLINE; SITE; DISTINCT; MODEL; IDENTIFICATION; MODULATION; GALLAMINE	The second extracellular (E2) loop of G protein-coupled receptors (GPCRs) plays an essential but poorly understood role in the binding of non-peptidic small molecules. We have utilized both orthosteric ligands and allosteric modulators of the M2 muscarinic acetylcholine receptor, a prototypical Family A GPCR, to probe possible E2 loop binding dynamics. We developed a homology model based on the crystal structure of bovine rhodopsin and predicted novel cysteine substitutions that should dramatically reduce E2 loop flexibility via disulfide bond formation and significantly inhibit the binding of both types of ligands. This prediction was validated experimentally using radioligand binding, dissociation kinetics, and cell-based functional assays. The results argue for a flexible "gatekeeper" role of the E2 loop in the binding of both allosteric and orthosteric GPCR ligands.	Monash Univ, Dept Pharmacol, Drug Discovery Biol Lab, Clayton, Vic 3800, Australia; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia	Monash University; St. Vincent's Institute of Medical Research	Christopoulos, A (corresponding author), Monash Univ, Dept Pharmacol, Drug Discovery Biol Lab, Clayton, Vic 3800, Australia.	arthur.christopoulos@med.monash.edu.au	Sexton, Patrick M/B-1319-2008; Christopoulos, Arthur/B-6207-2013; Parker, Michael W/F-9069-2013; Morton, Craig/GON-8638-2022	Sexton, Patrick M/0000-0001-8902-2473; Christopoulos, Arthur/0000-0003-4442-3294; Parker, Michael W/0000-0002-3101-1138; Morton, Craig/0000-0001-5452-5193; Gregory, Karen/0000-0002-3833-2137				Avlani V, 2004, J PHARMACOL EXP THER, V308, P1062, DOI 10.1124/jpet.103.059840; Christopoulos A, 1999, BIOCHEM PHARMACOL, V58, P735, DOI 10.1016/S0006-2952(99)00087-8; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Christopoulos A, 1998, CLIN EXP PHARMACOL P, V25, P185, DOI 10.1111/j.1440-1681.1998.t01-4-.x; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gnagey AL, 1999, MOL PHARMACOL, V56, P1245, DOI 10.1124/mol.56.6.1245; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Johren K, 2002, J COMPUT AID MOL DES, V16, P795, DOI 10.1023/A:1023880611709; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Lanzafame A, 1997, J PHARMACOL EXP THER, V282, P278; LAZARENO S, 1995, MOL PHARMACOL, V48, P362; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; LEPPIK RA, 1994, MOL PHARMACOL, V45, P983; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; MATSUI H, 1995, MOL PHARMACOL, V47, P88; May LT, 2007, ANNU REV PHARMACOL, V47, P1, DOI 10.1146/annurev.pharmtox.47.120505.105159; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Neubig RR, 2003, PHARMACOL REV, V55, P597, DOI 10.1124/pr.55.4.4; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Scarselli M, 2007, J BIOL CHEM, V282, P7385, DOI 10.1074/jbc.M610394200; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Voigtlander U, 2003, MOL PHARMACOL, V64, P21, DOI 10.1124/mol.64.1.21; Yan F, 2005, BIOCHEMISTRY-US, V44, P8643, DOI 10.1021/bi050490d	27	119	125	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25677	25686		10.1074/jbc.M702311200	http://dx.doi.org/10.1074/jbc.M702311200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17591774	hybrid			2022-12-25	WOS:000249014100055
J	Lu, M; Ammar, D; Ives, H; Albrecht, F; Gluck, SL				Lu, Ming; Ammar, David; Ives, Harlan; Albrecht, Fred; Gluck, Stephen L.			Physical interaction between aldolase and vacuolar H+-ATPase is essential for the assembly and activity of the proton pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; ESCHERICHIA-COLI; V-ATPASE; SUBUNIT; ACIDIFICATION; GLUCOSE; (H+)-ATPASES; GLYCOLYSIS; EXPRESSION	Vacuolar proton-translocating ATPases (V-ATPases) are a family of highly conserved proton pumps that couple hydrolysis of cytosolic ATP to proton transport out of the cytosol. Although V-ATPases are involved in a number of cellular processes, how the proton pumps are regulated under physiological conditions is not well understood. We have reported that the glycolytic enzyme aldolase mediates V-ATPase assembly and activity by physical association with the proton pump (Lu, M., Holliday, L. S., Zhang, L., Dunn, W. A., and Gluck, S. L. (2001) J. Biol. Chem. 276, 30407-30413 and Lu, M., Sautin, Y., Holliday, L. S., and Gluck, S. L. (2004) J. Biol. Chem. 279, 8732-8739). In this study, we generate aldolase mutants that lack binding to the B subunit of V-ATPase but retain normal catalytic activities. Functional analysis of the aldolase mutants shows that disruption of binding between aldolase and the B subunit of V-ATPase results in disassembly and malfunction of V-ATPase. In contrast, aldolase enzymatic activity is not required for V-ATPase assembly. Taken together, these findings strongly suggest an important role for physical association between aldolase and V-ATPase in the regulation of the proton pump.	Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Lu, M (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, HSE 672,Box 0532,513 Parnassus Ave, San Francisco, CA 94143 USA.	minglu@medicine.ucsf.edu			NIDDK NIH HHS [DK64977, DK64095] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064977, R01DK064095] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY A, 1993, FEBS LETT, V318, P11, DOI 10.1016/0014-5793(93)81317-S; BOLES E, 1993, CURR GENET, V23, P187, DOI 10.1007/BF00351494; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; GORGARTEN JP, 1992, J EXP BIOL, V172, P137; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; HSU SC, 1991, J BIOL CHEM, V266, P21745; Ikemoto A, 2003, J BIOL CHEM, V278, P5929, DOI 10.1074/jbc.M211617200; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; KANE PM, 1995, J BIOL CHEM, V270, P17025; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; LinGoerke JL, 1997, BIOTECHNIQUES, V23, P409, DOI 10.2144/97233bm12; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; MORRIS RC, 1968, J CLIN INVEST, V47, P1389, DOI 10.1172/JCI105830; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Pezza JA, 2003, J BIOL CHEM, V278, P17307, DOI 10.1074/jbc.M209185200; Rellos P, 2000, J BIOL CHEM, V275, P1145, DOI 10.1074/jbc.275.2.1145; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WU L, 1997, P NATL ACAD SCI USA, V94, P13273	29	116	117	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24495	24503		10.1074/jbc.M702598200	http://dx.doi.org/10.1074/jbc.M702598200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17576770	hybrid			2022-12-25	WOS:000248933000003
J	De Biasio, A; Vrana, JA; Zhou, P; Qian, LP; Bieszczad, CK; Braley, KE; Domina, AM; Weintraub, SJ; Neveu, JM; Lane, WS; Craig, RW				De Biasio, Alfredo; Vrana, Julie A.; Zhou, Ping; Qian, Liping; Bieszczad, Christine K.; Braley, Karen E.; Domina, Aaron M.; Weintraub, Steven J.; Neveu, John M.; Lane, William S.; Craig, Ruth W.			N-terminal truncation of antiapoptotic MCL1, but not G(2)/M-induced phosphorylation, is associated with stabilization and abundant expression in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-MYELOMA CELLS; ANTI-APOPTOTIC MCL-1; BH3 MIMETIC ABT-737; BCL-2 FAMILY; CYCLIN-E; GENE-PRODUCT; SURVIVAL; PROTEIN; DIFFERENTIATION; DEGRADATION	The antiapoptotic BCL2 family member MCL1 is normally up-and down-modulated in response to environmental signals and conditions, but is constitutively expressed in cancer where it promotes cell survival and drug resistance. A post-translational modification identified here, truncation at the Nterminus, was found to act along with previously described ERK- and GSK3-induced phosphorylation events to regulate the turnover of the MCL1 protein and thus its availability for antiapoptotic effects. Although both N-terminally truncated and full-length MCL1 contain sequences enriched in proline, glutamic acid, serine, and threonine and were susceptible to proteasomal degradation, the truncated form decayed less rapidly and was maintained for an extended period in the presence of ERK activation. This was associated with extended cell survival because the truncated form of MCL1 (unlike those of BCL2 and BCLX) retained antiapoptotic activity. N-terminal truncation slightly increased the electrophoretic mobility of MCL1 and differed from the phosphorylation/band shift to decreased mobility, which occurs in the G2/M phase and was not found to affect MCL1 turnover. The N-terminally truncated form of MCL1 was expressed to varying extents in normal lymphoid tissues and was the predominant form present in lymphomas from transgenic mice and human tumor lines of B-lymphoid origin. The degradation versus stabilized expression of antiapoptotic MCL1 is thus controlled by N-terminal truncation as well as by ERK- and GSK3 (but not G2/M)-induced phosphorylation. These modifications may contribute to dysregulated MCL1 expression in cancer and represent targets for promoting its degradation to enhance tumor cell death.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Eastern Nazarene Coll, Dept Biol, Quincy, MA 02170 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Harvard Univ, Microchem & Prote Anal Facil, Cambridge, MA 02138 USA	Dartmouth College; Washington University (WUSTL); Washington University (WUSTL); Harvard University	Craig, RW (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	Ruth.W.Craig@dartmouth.edu	Weintraub, Steve/GSE-3366-2022	De Biasio, Alfredo/0000-0003-2139-2958	NCI NIH HHS [R01 CA057359, CA57359, R01 CA098605-05, R01 CA098605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098605, R01CA057359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aartsma-Rus A, 2004, AM J HUM GENET, V74, P83, DOI 10.1086/381039; Asher G, 2006, BIOESSAYS, V28, P844, DOI 10.1002/bies.20447; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; Chen-Kiang S, 2003, IMMUNOL REV, V194, P39, DOI 10.1034/j.1600-065X.2003.00065.x; Coenen S, 2005, HAEMATOLOGICA, V90, P1285; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Day CL, 2005, J BIOL CHEM, V280, P4738, DOI 10.1074/jbc.M411434200; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Ding QQ, 2007, CANCER RES, V67, P4564, DOI 10.1158/0008-5472.CAN-06-1788; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Fleischer B, 2006, INT J ONCOL, V28, P25; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Harwell RM, 2004, J BIOL CHEM, V279, P12695, DOI 10.1074/jbc.M313407200; Hussain SRA, 2007, CLIN CANCER RES, V13, P2144, DOI 10.1158/1078-0432.CCR-06-2294; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kobayashi S, 2007, J BIOL CHEM, V282, P18407, DOI 10.1074/jbc.M610010200; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; KOZOPAS KM, 1990, J CELL PHYSIOL, V145, P575, DOI 10.1002/jcp.1041450326; Le Gouill S, 2004, CELL CYCLE, V3, P1259; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Ma Y, 2007, P NATL ACAD SCI USA, V104, P4089, DOI 10.1073/pnas.0606537104; Marriott HM, 2005, J CLIN INVEST, V115, P359, DOI 10.1172/JCI200521766; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Rapaport D, 2003, EMBO REP, V4, P948, DOI 10.1038/sj.embor.embor937; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Sano M, 2005, HISTOPATHOLOGY, V46, P532, DOI 10.1111/j.1365-2559.2005.02118.x; Shumway SD, 2006, MOL CELL, V23, P149, DOI 10.1016/j.molcel.2006.07.002; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vrana JA, 2002, CANCER RES, V62, P892; Vrana JA, 2006, APOPTOSIS, V11, P1275, DOI 10.1007/s10495-006-7787-y; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yin XM, 2006, GENE, V369, P7, DOI 10.1016/j.gene.2005.10.038; Zhang B, 2003, ONCOGENE, V22, P1848, DOI 10.1038/sj.onc.1206358; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	71	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23919	23936		10.1074/jbc.M700938200	http://dx.doi.org/10.1074/jbc.M700938200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17561513	hybrid			2022-12-25	WOS:000248686600019
J	Inoue, KI; Ito, K; Osato, M; Lee, B; Bae, SC; Ito, Y				Inoue, Ken-ichi; Ito, Kosei; Osato, Motomi; Lee, Bernett; Bae, Suk-Chul; Ito, Yoshiaki			The transcription factor Runx3 represses the neurotrophin receptor TrkB during lineage commitment of dorsal root ganglion neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOCICEPTIVE SENSORY NEURONS; NERVE GROWTH-FACTOR; REGULATES DEVELOPMENT; GENE-EXPRESSION; PRECURSOR CELLS; RETINOIC ACID; IN-VIVO; SURVIVAL; DIFFERENTIATION; CANCER	Runx3, a Runt domain transcription factor, determines neurotrophin receptor phenotype in dorsal root ganglion ( DRG) neurons. Molecular mechanisms by which Runx3 controls distinct neurotrophin receptors are largely unknown. Here, we show that RUNX3 abolished mRNA induction of TRKB expression, and concomitantly altered the neurotrophin response in a differentiating neuroblastoma cell line. In contrast, RUNX3 did not play a significant role in TRKC regulation even under the relevant BMP signaling pathway. We identified putative regulatory elements of Ntrk2/ NTRK2 ( a gene that codes for TrkB) using an unbiased computational approach. One of these elements was a highly conserved intronic sequence that contains a cluster of Runx binding sites. In a primary culture of DRG neurons, endogenous Runx3 bound to the consensus cluster, which had repressor activity against the Ntrk2 promoter under the control of NT- 3 signaling. Consistent with these findings, Runx3- deficient embryos showed an increased number of trkB(+) DRG neurons and failed to maintain trkC expression. Taken together, Runx3 determines TrkC positive sensory neuron identities through the transcriptional repression of TrkB when TrkBTrkC double positive neurons differentiate into TrkC single positive neurons.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117548, Singapore; Bioinformat Inst, Singapore, Singapore; Chungbuk Natl Univ, Sch Med, Inst Tumor Res, Dept Biochem, Cheongju 361763, South Korea	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); Chungbuk National University	Ito, Y (corresponding author), 61 Biopolis Dr,Proteos, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg	Osato, Motomi/N-5056-2014	Osato, Motomi/0000-0003-3982-9054				Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brederlau A, 2004, MOL BIOL CELL, V15, P3863, DOI 10.1091/mbc.E03-08-0584; Chalazonitis A, 2004, J NEUROSCI, V24, P4266, DOI 10.1523/JNEUROSCI.3688-03.2004; Chen CL, 2006, NEURON, V49, P365, DOI 10.1016/j.neuron.2005.10.036; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689; ElShamy WM, 1998, NEURON, V21, P1003, DOI 10.1016/S0896-6273(00)80619-4; ElShamy WM, 1996, NEURON, V16, P963, DOI 10.1016/S0896-6273(00)80119-1; Farinas I, 1998, NEURON, V21, P325, DOI 10.1016/S0896-6273(00)80542-5; Farinas I, 1996, NEURON, V17, P1065, DOI 10.1016/S0896-6273(00)80240-8; Friedel RH, 1997, P NATL ACAD SCI USA, V94, P12670, DOI 10.1073/pnas.94.23.12670; Gruber CA, 1997, MOL CELL BIOL, V17, P2391, DOI 10.1128/MCB.17.5.2391; Hallikas O, 2006, CELL, V124, P47, DOI 10.1016/j.cell.2005.10.042; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Huang EJ, 1999, DEVELOPMENT, V126, P2869; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kramer I, 2006, NEURON, V49, P379, DOI 10.1016/j.neuron.2006.01.008; Lei L, 2005, GENE DEV, V19, P1354, DOI 10.1101/gad.1227705; Lei L, 2001, DEVELOPMENT, V128, P1147; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Liebl DJ, 2000, P NATL ACAD SCI USA, V97, P2297, DOI 10.1073/pnas.040562597; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; Ma L, 2000, DEVELOPMENT, V127, P3777; Ma L, 2003, DEVELOPMENT, V130, P3525, DOI 10.1242/dev.00582; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; Marmigere F, 2006, NAT NEUROSCI, V9, P180, DOI 10.1038/nn1631; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Moqrich A, 2004, NAT NEUROSCI, V7, P812, DOI 10.1038/nn1283; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; O'Connor R, 1999, NEURON, V24, P165, DOI 10.1016/S0896-6273(00)80830-2; O'Neill LP, 2006, NAT GENET, V38, P835, DOI 10.1038/ng1820; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Patel TD, 2000, NEURON, V25, P345, DOI 10.1016/S0896-6273(00)80899-5; Patel TD, 2003, NEURON, V38, P403, DOI 10.1016/S0896-6273(03)00261-7; Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096; Prabhakar S, 2006, GENOME RES, V16, P855, DOI 10.1101/gr.4717506; Rhoades KL, 2000, CURR BIOL, V10, P789, DOI 10.1016/S0960-9822(00)00565-0; Rifkin JT, 2000, DEV BIOL, V227, P465, DOI 10.1006/dbio.2000.9841; Satoh F, 2001, INT J UROL, V8, pS28, DOI 10.1046/j.1442-2042.2001.00331.x; Sclabas GM, 2005, CLIN CANCER RES, V11, P440; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; White FA, 1996, J NEUROSCI, V16, P4662; Yarmus M, 2006, P NATL ACAD SCI USA, V103, P7384, DOI 10.1073/pnas.0602470103; Yoshida T, 2002, AM J HUM GENET, V71, P724, DOI 10.1086/342717; Zhang DM, 1998, J NEUROSCI, V18, P3314; Zou YR, 2001, NAT GENET, V29, P332, DOI 10.1038/ng750	59	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24175	24184		10.1074/jbc.M703746200	http://dx.doi.org/10.1074/jbc.M703746200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584746	hybrid			2022-12-25	WOS:000248686600043
J	Hersleth, HP; Uchida, T; Rohr, AK; Teschner, T; Schuenemann, V; Kitagawa, T; Trautwein, AX; Gorbitz, CH; Andersson, KK				Hersleth, Hans-Petter; Uchida, Takeshi; Rohr, Asmund K.; Teschner, Thomas; Schuenemann, Volker; Kitagawa, Teizo; Trautwein, Alfred X.; Gorbitz, Carl Henrik; Andersson, K. Kristoffer			Crystallographic and spectroscopic studies of peroxide-derived myoglobin compound II and occurrence of protonated Fe-IV-O	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; CYTOCHROME-C PEROXIDASE; X-RAY-ABSORPTION; QUANTUM-CHEMICAL CALCULATIONS; VALENT NONHEME IRON; HIGH-FREQUENCY EPR; HORSERADISH-PEROXIDASE; HYDROGEN-PEROXIDE; MOSSBAUER-SPECTROSCOPY; CRYSTAL-STRUCTURES	High resolution crystal structures of myoglobin in the pH range 5.2-8.7 have been used as models for the peroxide-derived compound II intermediates in heme peroxidases and oxygenases. The observed Fe-O bond length (1.86-1.90 angstrom) is consistent with that of a single bond. The compound II state of myoglobin in crystals was controlled by single-crystal microspectrophotometry before and after synchrotron data collection. We observe some radiation-induced changes in both compound II (resulting in intermediate H) and in the resting ferric state of myoglobin. These radiation-induced states are quite unstable, and compound II and ferric myoglobin are immediately regenerated through a short heating above the glass transition temperature (< 1 s) of the crystals. It is unclear how this influences our compound II structures compared with the unaffected compound II, but some crystallographic data suggest that the influence on the Fe-O bond distance is minimal. Based on our crystallographic and spectroscopic data we suggest that for myoglobin the compound II intermediate consists of an Fe-IV-O species with a single bond. The presence of Fe-IV is indicated by a small isomer shift of delta = 0.07 mm/s from Mossbauer spectroscopy. Earlier quantum refinements (crystallographic refinement where the molecular-mechanics potential is replaced by a quantum chemical calculation) and density functional theory calculations suggest that this intermediate H species is protonated.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; Univ Oslo, Dept Chem, N-0315 Oslo, Norway; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan; Med Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany; Univ Kaiserslautern, Dept Phys, D-67653 Kaiserslautern, Germany	University of Oslo; University of Oslo; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Hokkaido University; University of Lubeck; University of Kaiserslautern	Andersson, KK (corresponding author), Univ Oslo, Dept Mol Biosci, POB 1041, N-0316 Oslo, Norway.	k.k.andersson@imbv.uio.no	Andersson, K Kristoffer/F-9624-2010; Kjendseth, Åsmund Røhr/O-2543-2016; Schünemann, Volker/C-6603-2016; Uchida, Takeshi/A-6455-2017	Kjendseth, Åsmund Røhr/0000-0002-4956-4865; Uchida, Takeshi/0000-0001-9270-8329; Hersleth, Hans-Petter/0000-0002-1142-9983				Alayash AI, 2001, ANTIOXID REDOX SIGN, V3, P313, DOI 10.1089/152308601300185250; ALBEN JO, 1989, PHYSICA B, V158, P87, DOI 10.1016/0921-4526(89)90208-1; ALLENTOFF AJ, 1992, J AM CHEM SOC, V114, P9744, DOI 10.1021/ja00051a003; Andersson KK, 2003, J BIOL INORG CHEM, V8, P235, DOI 10.1007/s00775-002-0429-0; ANDERSSON LA, 1990, STRUCT BOND, V64, P1; ARDUINI A, 1991, OXIDATIVE DAMAGE REP, P406; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barra AL, 2004, BIO MAGN RE, V22, P145; Behan RK, 2006, J INORG BIOCHEM, V100, P448, DOI 10.1016/j.jinorgbio.2005.12.019; Behan RK, 2006, J AM CHEM SOC, V128, P11471, DOI 10.1021/ja062428p; Beitlich T, 2007, J SYNCHROTRON RADIAT, V14, P11, DOI 10.1107/S0909049506049806; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; Bonagura CA, 2003, BIOCHEMISTRY-US, V42, P5600, DOI 10.1021/bi034058c; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Carugo O, 2005, TRENDS BIOCHEM SCI, V30, P213, DOI 10.1016/j.tibs.2005.02.009; CHANCE B, 1984, ARCH BIOCHEM BIOPHYS, V235, P596, DOI 10.1016/0003-9861(84)90234-0; CHANG CS, 1993, BIOCHEMISTRY-US, V32, P923, DOI 10.1021/bi00054a025; Conradie J, 2006, J INORG BIOCHEM, V100, P502, DOI 10.1016/j.jinorgbio.2006.01.027; Denisov IG, 2002, J BIOL CHEM, V277, P42706, DOI 10.1074/jbc.M207949200; Derat E, 2006, J AM CHEM SOC, V128, P8185, DOI 10.1021/ja0600734; Donzello MP, 2001, INORG CHEM, V40, P2963, DOI 10.1021/ic000874m; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engler N, 2000, BIOPHYS J, V78, P2081, DOI 10.1016/S0006-3495(00)76755-5; ERCOLANI C, 1995, INORG CHEM, V34, P2535, DOI 10.1021/ic00114a010; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Everse J, 1998, FREE RADICAL BIO MED, V24, P1338, DOI 10.1016/S0891-5849(97)00451-6; Fenwick CW, 1997, J AM CHEM SOC, V119, P4758, DOI 10.1021/ja963108g; Flogel U, 2004, FASEB J, V18, P1156, DOI 10.1096/fj.03-1382fje; FOOTE N, 1989, BIOCHEM J, V261, P515, DOI 10.1042/bj2610515; FOX JB, 1974, BIOCHEMISTRY-US, V13, P5178, DOI 10.1021/bi00722a020; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GARMAN E, 2006, MACROMOLECULAR CRYST, V2, P1; Garry DJ, 2003, TRENDS CARDIOVAS MED, V13, P111, DOI 10.1016/S1050-1738(02)00256-6; GASYNA Z, 1979, BIOCHIM BIOPHYS ACTA, V577, P207, DOI 10.1016/0005-2795(79)90022-9; GEORGE P, 1951, NATURE, V168, P164, DOI 10.1038/168164b0; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; Ghosh A, 2002, J INORG BIOCHEM, V91, P423, DOI 10.1016/S0162-0134(02)00484-1; GIBSON JF, 1956, NATURE, V178, P871, DOI 10.1038/178871b0; GIULIVI C, 1994, METHOD ENZYMOL, V233, P189; Gouet P, 1996, NAT STRUCT BIOL, V3, P951, DOI 10.1038/nsb1196-951; Green MT, 2006, J AM CHEM SOC, V128, P1902, DOI 10.1021/ja054074s; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; Green MT, 2000, J AM CHEM SOC, V122, P9495, DOI 10.1021/ja994377k; Gunther MR, 2004, FREE RADICAL BIO MED, V36, P1345, DOI 10.1016/j.freeradbiomed.2004.02.018; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; HARAMI T, 1977, J CHEM PHYS, V67, P1164, DOI 10.1063/1.434969; HASHIMOTO S, 1984, P JPN ACAD B-PHYS, V60, P345, DOI 10.2183/pjab.60.345; HASHIMOTO S, 1986, J BIOL CHEM, V261, P1110; Herold S, 2001, J BIOL INORG CHEM, V6, P543, DOI 10.1007/s007750100231; Hersleth HP, 2006, J INORG BIOCHEM, V100, P460, DOI 10.1016/j.jinorgbio.2006.01.018; Hersleth HP, 2002, J BIOL INORG CHEM, V7, P299, DOI 10.1007/s007750100296; Hersleth HP, 2001, J INORG BIOCHEM, V86, P260; HILDEBRANDT P, 1994, BIOCHEMISTRY-US, V33, P12920, DOI 10.1021/bi00209a024; Horner O, 2006, J INORG BIOCHEM, V100, P477, DOI 10.1016/j.jinorgbio.2005.12.010; Ibrahim M, 2004, J PORPHYR PHTHALOCYA, V8, P215, DOI 10.1142/S1088424604000209; Ibrahim M, 2003, J AM CHEM SOC, V125, P13714, DOI 10.1021/ja036949d; Jensen MP, 2005, J AM CHEM SOC, V127, P10512, DOI 10.1021/ja0438765; Jones P, 2001, J BIOL CHEM, V276, P13791, DOI 10.1074/jbc.M011413200; Jouve HM, 1997, BIOCHIMIE, V79, P667, DOI 10.1016/S0300-9084(97)83500-6; KEILIN D, 1950, NATURE, V166, P513, DOI 10.1038/166513a0; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KING NK, 1966, AUST J BIOL SCI, V19, P211, DOI 10.1071/BI9660211; KING NK, 1963, J BIOL CHEM, V238, P1520; Klinker EJ, 2005, ANGEW CHEM INT EDIT, V44, P3690, DOI 10.1002/anie.200500485; Krebs C, 2005, INORG CHEM, V44, P742, DOI 10.1021/ic048523l; Krebs C, 2002, METHOD ENZYMOL, V354, P436; Lamb DC, 1998, EUR BIOPHYS J BIOPHY, V27, P113; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MAEDA Y, 1971, J BIOCHEM, V70, P509, DOI 10.1093/oxfordjournals.jbchem.a129664; MAKINO R, 1986, J BIOL CHEM, V261, P8376; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; MAURUS R, 1997, BIOCHIM BIOPHYS ACTA, P1; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; Millikan GA, 1939, PHYSIOL REV, V19, P503, DOI 10.1152/physrev.1939.19.4.503; Millikan GA, 1937, PROC R SOC SER B-BIO, V123, P218, DOI 10.1098/rspb.1937.0052; Mizutani Y, 1997, SCIENCE, V278, P443, DOI 10.1126/science.278.5337.443; Mizutani Y, 2001, CHEM REC, V1, P258, DOI 10.1002/tcr.1012; Mondal MS, 1996, BBA-PROTEIN STRUCT M, V1296, P174, DOI 10.1016/0167-4838(96)00068-4; Moore KP, 1998, J BIOL CHEM, V273, P31731, DOI 10.1074/jbc.273.48.31731; MUNCK E, 1993, METHOD ENZYMOL, V227, P463, DOI 10.1016/0076-6879(93)27019-D; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Murshudov GN, 2002, ACTA CRYSTALLOGR D, V58, P1972, DOI 10.1107/S0907444902016566; Nakashima S, 1998, CHEM PHYS, V228, P323, DOI 10.1016/S0301-0104(97)00353-4; Neese F, 2003, CURR OPIN CHEM BIOL, V7, P125, DOI 10.1016/S1367-5931(02)00006-6; Nilsson K, 2004, BIOPHYS J, V87, P3437, DOI 10.1529/biophysj.104.041590; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ozaki S, 1997, J AM CHEM SOC, V119, P6666, DOI 10.1021/ja970453c; Ozaki S, 2000, COORDIN CHEM REV, V198, P39, DOI 10.1016/S0010-8545(00)00234-4; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; POULOS TL, 1980, J BIOL CHEM, V255, P8199; Poulos TL, 2005, PHILOS T R SOC A, V363, P793, DOI 10.1098/rsta.2004.1537; Poulos TL, 2005, BIOCHEM BIOPH RES CO, V338, P337, DOI 10.1016/j.bbrc.2005.07.204; Poulos TL, 2005, DRUG METAB DISPOS, V33, P10, DOI 10.1124/dmd.104.002071; POWERS L, 1984, BIOCHEMISTRY-US, V23, P5519, DOI 10.1021/bi00318a021; PRUSAKOV VE, 1995, BIOPHYS J, V68, P2524, DOI 10.1016/S0006-3495(95)80435-2; RECZEK CM, 1989, J MOL STRUCT, V214, P27, DOI 10.1016/0022-2860(89)80004-3; Reeder BJ, 2004, ANTIOXID REDOX SIGN, V6, P954, DOI 10.1089/ars.2004.6.954; Reeder BJ, 2002, BIOCHEMISTRY-US, V41, P367, DOI 10.1021/bi011335b; Rohde JU, 2003, SCIENCE, V299, P1037, DOI 10.1126/science.299.5609.1037; Rovira C, 2005, CHEMPHYSCHEM, V6, P1820, DOI 10.1002/cphc.200400633; Rovira C, 2003, J PHYS CHEM B, V107, P5300, DOI 10.1021/jp0268516; Sanders LK, 2001, J PORPHYR PHTHALOCYA, V5, P323, DOI 10.1002/jpp.319; Schoneboom JC, 2005, J AM CHEM SOC, V127, P5840, DOI 10.1021/ja0424732; Schulz C., 1979, Journal de Physique Colloque, V40, pC2/534, DOI 10.1051/jphyscol:19792185; Schunemann V, 2000, REP PROG PHYS, V63, P263, DOI 10.1088/0034-4885/63/3/202; Shan XP, 2006, J INORG BIOCHEM, V100, P421, DOI 10.1016/j.jinorgbio.2006.01.014; SHERWOOD C, 1987, J MOL BIOL, V193, P227, DOI 10.1016/0022-2836(87)90641-3; Silaghi-Dumitrescu R, 2004, J BIOL INORG CHEM, V9, P471, DOI 10.1007/s00775-004-0543-2; Simaan AJ, 2000, EUR J INORG CHEM, P1627; SITTER AJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P229, DOI 10.1016/0167-4838(85)90301-2; SITTER AJ, 1989, SPIE, V1055, P271; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; SPIRO TG, 1985, ADV PROTEIN CHEM, V37, P111, DOI 10.1016/S0065-3233(08)60064-9; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; Stone KL, 2006, P NATL ACAD SCI USA, V103, P12307, DOI 10.1073/pnas.0603159103; Stone KL, 2006, J AM CHEM SOC, V128, P6147, DOI 10.1021/ja057876w; Stone KL, 2005, P NATL ACAD SCI USA, V102, P16563, DOI 10.1073/pnas.0507069102; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TERNER J, 1985, BIOCHIM BIOPHYS ACTA, V828, P73, DOI 10.1016/0167-4838(85)90011-1; Terner J, 2006, J INORG BIOCHEM, V100, P480, DOI 10.1016/j.jinorgbio.2006.01.008; TRAUTWEIN AX, 1991, STRUCT BOND, V78, P1; VanderZee J, 1997, BIOCHEM J, V322, P633; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; WALTERS MA, 1980, J AM CHEM SOC, V102, P6857, DOI 10.1021/ja00542a037; Watanabe Y, 2003, B CHEM SOC JPN, V76, P1309, DOI 10.1246/bcsj.76.1309; Wilmot CM, 2002, METHOD ENZYMOL, V353, P301; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; WITTENBERG JB, 1978, J BIOL CHEM, V253, P5694; YONETANI T, 1969, J BIOL CHEM, V244, P4580	134	55	53	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23372	23386		10.1074/jbc.M701948200	http://dx.doi.org/10.1074/jbc.M701948200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565988	hybrid			2022-12-25	WOS:000248577500038
J	Khanna, S; Roy, S; Park, HA; Sen, CK				Khanna, Savita; Roy, Sashwati; Park, Han-A; Sen, Chandan K.			Regulation of c-Src activity in glutamate-induced neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; VITAMIN-E ACTION; TYROSINE PHOSPHORYLATION; KINASE CSK; MOLECULAR-BASIS; PROTEIN; SHP-1; TOXICITY; DEATH; 12-LIPOXYGENASE	c-Src is heavily expressed in the brain and in human neural tissues. Our pursuit for characterization of the neuroprotective mechanisms of tocotrienols led to the first evidence demonstrating that rapid c-Src activation plays a central role in executing glutamate-induced neurodegeneration. It is now known that Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Here, we sought to examine the mechanisms that regulate inducible c-Src activity in glutamate-challenged HT4 neural cells and primary cortical neurons. Knockdown of c-Src protected cells against glutamate-induced loss of viability. Consistently, microinjection of siRNA against c-Src protected cells against glutamate. Using overexpression and knockdown approaches, we noted that SHP-1 may be implicated in glutamate-induced c-Src activation. Following such activation, Cbp and caveolin-1 were phosphorylated and associated with Csk. Csk was translocated to the membrane where it down-regulated glutamate-induced c-Src activity by catalyzing the inhibitory phosphorylation of a tyrosine residue in c-Src. Findings of this study present a new paradigm that addresses the regulation of c-Src under neurodegenerative conditions.	Ohio State Univ, Med Ctr, Davis Heart & Lung Res Inst 512, Mol Med Lab, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Sen, CK (corresponding author), Ohio State Univ, Med Ctr, Davis Heart & Lung Res Inst 512, Mol Med Lab, 473 W 12th Ave, Columbus, OH 43210 USA.	Chandan.Sen@osumc.edu	Khanna, Savita/E-3378-2011; Sen, Chandan K/A-8762-2013	Park, Han-A/0000-0001-5563-5255	NINDS NIH HHS [R01 NS042617, R01NS42617] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042617] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beamer CA, 2006, J NEUROSCI RES, V83, P1220, DOI 10.1002/jnr.20825; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Frank C, 2004, J BIOL CHEM, V279, P11375, DOI 10.1074/jbc.M309096200; Gurd JW, 1997, NEUROCHEM INT, V31, P635, DOI 10.1016/S0197-0186(97)00022-3; Han D, 1997, AM J PHYSIOL-REG I, V273, pR1771, DOI 10.1152/ajpregu.1997.273.5.R1771; Huo JZ, 2006, NEUROSCI LETT, V401, P266, DOI 10.1016/j.neulet.2006.03.033; INGRAHAM CA, 1989, MOL CHEM NEUROPATHOL, V10, P1, DOI 10.1007/BF02969481; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Khanna S, 2003, J BIOL CHEM, V278, P43508, DOI 10.1074/jbc.M307075200; Khanna S, 2002, METHOD ENZYMOL, V352, P191; Khanna S, 2006, J NEUROCHEM, V98, P1474, DOI 10.1111/j.1471-4159.2006.04000.x; Khanna Savita, 2005, Stroke, V36, P2258; LAU AF, 2005, SCI STKE; Lennmyr F, 2004, ACTA NEUROL SCAND, V110, P175, DOI 10.1111/j.1600-0404.2004.00306.x; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lu TL, 2006, CELL SIGNAL, V18, P1977, DOI 10.1016/j.cellsig.2006.03.002; Luo Y, 2006, J BIOL CHEM, V281, P16436, DOI 10.1074/jbc.M512430200; Maher P, 2006, ANTIOXID REDOX SIGN, V8, P1941, DOI 10.1089/ars.2006.8.1941; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; Marsh HN, 2003, J CELL BIOL, V163, P999, DOI 10.1083/jcb.200309036; Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; OKADA M, 1991, J BIOL CHEM, V266, P24249; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Shu LM, 2003, J BIOL CHEM, V278, P31419, DOI 10.1074/jbc.M303783200; Sohn H, 2006, FASEB J, V20, P1248, DOI 10.1096/fj.05-4911fje; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sugano M, 2005, FASEB J, V19, P2054, DOI 10.1096/fj.05-4020fje; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tirosh O, 2000, NEUROSCIENCE, V97, P531, DOI 10.1016/S0306-4522(00)00028-2; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Tsui FWL, 2006, IMMUNOL RES, V35, P127, DOI 10.1385/IR:35:1:127; Vega IE, 2005, MOL BRAIN RES, V138, P135, DOI 10.1016/j.molbrainres.2005.04.015; Viviani B, 2006, J BIOL CHEM, V281, P30212, DOI 10.1074/jbc.M602156200	46	53	54	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23482	23490		10.1074/jbc.M611269200	http://dx.doi.org/10.1074/jbc.M611269200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17569670	hybrid			2022-12-25	WOS:000248577500049
J	Konishi, H; Namikawa, K; Shikata, K; Kobatake, Y; Tachibana, T; Kiyama, H				Konishi, Hiroyuki; Namikawa, Kazuhiko; Shikata, Keiji; Kobatake, Yuji; Tachibana, Taro; Kiyama, Hiroshi			Identification of peripherin as a Akt substrate in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; INTERMEDIATE-FILAMENT PROTEIN; P70 S6 KINASE; NEUROTROPHIC FACTORS; PHOSPHORYLATION SITE; AXONAL REGENERATION; NERVE REGENERATION; SIGNALING PATHWAY; MAMMALIAN-CELLS; MAPKAP KINASE-1	Activation of Akt-mediated signaling pathways is crucial for survival and regeneration of injured neurons. In this study, we attempted to identify novel Akt substrates by using an antibody that recognized a consensus motif phosphorylated by Akt. PC12 cells that overexpressed constitutively active Akt were used. Using two-dimensional PAGE, we identified protein spots that exhibited increased immunostaining of the antibody. Mass spectrometry revealed several major spots as the neuronal intermediate filament protein, peripherin. Using several peripherin fragments, the phosphorylation site was determined as Ser(66) in its head domain in vitro. Furthermore, a co-immunoprecipitation experiment revealed that Akt interacted with the head domain of peripherin in HEK 293T cells. An antibody against phosphorylated peripherin was raised, and induction of phosphorylated peripherin was observed not only in Akt-activated cultured cells but also in nerve-injured hypoglossal motor neurons. These results suggest that peripherin is a novel substrate for Akt in vivo and that its phosphorylation may play a role in motor nerve regeneration.	Osaka City Univ, Grad Sch Med, Dept Anat & Neurobiol, Osaka 5458585, Japan; Asahikawa Med Coll, Dept Anat, Asahikawa, Hokkaido 0788510, Japan; Osaka City Univ, Grad Sch Engn, Dept Bioengn, Osaka 5588585, Japan	Osaka Metropolitan University; Asahikawa Medical College; Osaka Metropolitan University	Kiyama, H (corresponding author), Osaka City Univ, Grad Sch Med, Dept Anat & Neurobiol, 1-4-3 Abeno Ku, Osaka 5458585, Japan.	kiyama@med.osaka-cu.ac.jp	KONISHI, Hiroyuki/M-8871-2014; Kiyama, Hiroshi/M-8867-2014	Kiyama, Hiroshi/0000-0001-5963-046X; Konishi, Hiroyuki/0000-0002-4321-8339				Akama KT, 2003, J NEUROSCI, V23, P2333; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Asnaghi L, 2004, PHARMACOL RES, V50, P545, DOI 10.1016/j.phrs.2004.03.007; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Beaulieu JM, 2002, BRAIN RES, V946, P153, DOI 10.1016/S0006-8993(02)02830-5; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Boyd JG, 2003, MOL NEUROBIOL, V27, P277, DOI 10.1385/MN:27:3:277; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BRODY BA, 1989, J NEUROSCI, V9, P2391; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Coffer PJ, 1998, BIOCHEM J, V335, P1; Coulombe PA, 2001, J CELL SCI, V114, P4345; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Djabali K, 1997, J CELL SCI, V110, P2759; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; Giasson BI, 1998, J NEUROCHEM, V70, P1869; Gibb BJM, 1998, J NEUROCHEM, V70, P492; Grant P, 2000, J NEUROCYTOL, V29, P843, DOI 10.1023/A:1010999509251; Grothe C, 2001, ANAT EMBRYOL, V204, P171, DOI 10.1007/s004290100205; Helfand BT, 2003, MOL BIOL CELL, V14, P5069, DOI 10.1091/mbc.E03-06-0376; HUC C, 1989, BIOCHEM BIOPH RES CO, V160, P772, DOI 10.1016/0006-291X(89)92500-X; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Karajannis MA, 2006, LEUKEMIA, V20, P979, DOI 10.1038/sj.leu.2404203; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; KISHIRO Y, 1995, CELL STRUCT FUNCT, V20, P151, DOI 10.1247/csf.20.151; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Konishi H, 2006, GLIA, V53, P723, DOI 10.1002/glia.20327; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; Leung CL, 1999, J CELL BIOL, V144, P435, DOI 10.1083/jcb.144.3.435; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Manabe Y, 2002, APOPTOSIS, V7, P329, DOI 10.1023/A:1016123413038; Markus A, 2002, NEURON, V35, P65, DOI 10.1016/S0896-6273(02)00752-3; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; Nakamura Y, 2000, J NEUROCHEM, V74, P949, DOI 10.1046/j.1471-4159.2000.0740949.x; Namikawa K, 2000, J NEUROSCI, V20, P2875; OBLINGER MM, 1989, J NEUROSCI, V9, P3766; Ohba N, 2004, NEUROSCI LETT, V359, P159, DOI 10.1016/j.neulet.2004.02.029; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; PARYSEK LM, 1988, J NEUROSCI, V8, P555; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Peng Y, 2004, J BIOL CHEM, V279, P28509, DOI 10.1074/jbc.M402294200; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Sato Y, 1998, BIOCHEM BIOPH RES CO, V244, P455, DOI 10.1006/bbrc.1997.8087; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; Sinor AD, 2004, J NEUROSCI, V24, P8531, DOI 10.1523/JNEUROSCI.1470-04.2004; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Strelkov SV, 2003, BIOESSAYS, V25, P243, DOI 10.1002/bies.10246; Terao E, 2000, NEUROSCIENCE, V101, P679, DOI 10.1016/S0306-4522(00)00423-1; Terenghi G, 1999, J ANAT, V194, P1, DOI 10.1046/j.1469-7580.1999.19410001.x; TROY CM, 1990, BRAIN RES, V529, P232, DOI 10.1016/0006-8993(90)90832-V; TROY CM, 1992, J CELL BIOL, V117, P1085, DOI 10.1083/jcb.117.5.1085; Ushijima R, 2005, BIOCHEM BIOPH RES CO, V330, P880, DOI 10.1016/j.bbrc.2005.03.063; Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Yu FS, 2005, NEUROBIOL DIS, V20, P491, DOI 10.1016/j.nbd.2005.04.004; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003; Znamensky V, 2003, J NEUROSCI, V23, P2340	66	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23491	23499		10.1074/jbc.M611703200	http://dx.doi.org/10.1074/jbc.M611703200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17569669	hybrid			2022-12-25	WOS:000248577500050
J	Sachs, UJH; Andrei-Selmer, CL; Maniar, A; Weiss, T; Paddock, C; Orlova, VV; Choi, EY; Newman, PJ; Preissner, KT; Chavakis, T; Santoso, S				Sachs, Ulrich J. H.; Andrei-Selmer, Cornelia L.; Maniar, Amudhan; Weiss, Timo; Paddock, Cathy; Orlova, Valeria V.; Choi, Eun Young; Newman, Peter J.; Preissner, Klaus T.; Chavakis, Triantafyllos; Santoso, Sentot			The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYTHEMIA RUBRA VERA; MIGRATION IN-VITRO; TRANSENDOTHELIAL MIGRATION; UROKINASE RECEPTOR; PECAM-1 CD31; SURFACE GLYCOSAMINOGLYCANS; LEUKOCYTE TRANSMIGRATION; INTERCELLULAR-JUNCTIONS; ALPHA-V-BETA-3 INTEGRIN; MONOCLONAL-ANTIBODY	Human neutrophil-specific CD177 (NB1 and PRV-1) has been reported to be up-regulated in a number of inflammatory settings, including bacterial infection and granulocyte-colonystimulating factor application. Little is known about its function. By flow cytometry and immunoprecipitation studies, we identified platelet endothelial cell adhesion molecule-1 (PECAM-1) as a binding partner of CD177. Real-time protein-protein analysis using surface plasmon resonance confirmed a cation-dependent, specific interaction between CD177 and the heterophilic domains of PECAM-1. Monoclonal antibodies against CD177 and against PECAM-1 domain 6 inhibited adhesion of U937 cells stably expressing CD177 to immobilized PECAM-1. Transendothelial migration of human neutrophils was also inhibited by these antibodies. Our findings provide direct evidence that neutrophil-specific CD177 is a heterophilic binding partner of PECAM-1. This interaction may constitute a new pathway that participates in neutrophil transmigration.	Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53233 USA; NCI, Expt Immunol Branch, Natl Inst Hlth, Bethesda, MD 20892 USA	Justus Liebig University Giessen; Justus Liebig University Giessen; Versiti Blood Center of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Santoso, S (corresponding author), Univ Giessen, Inst Clin Immunol & Transfus Med, Langhansstr 7, D-35392 Giessen, Germany.	Sentot.santoso@med.uni-giessen.de	Chavakis, Triantafyllos/ABE-8845-2020; Orlova, Valeria V/C-6065-2014; Sachs, Ulrich/GSI-7824-2022	Orlova, Valeria V/0000-0002-1169-2802; 	NATIONAL CANCER INSTITUTE [Z01BC010663, ZIABC010663] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Bauer S, 2007, J LEUKOCYTE BIOL, V81, P458, DOI 10.1189/jlb.0806514; BERMAN ME, 1995, J IMMUNOL, V154, P299; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; Caruccio L, 2006, TRANSFUSION, V46, P441, DOI 10.1111/j.1537-2995.2006.00741.x; Caruccio L, 2003, TRANSFUSION, V43, P357, DOI 10.1046/j.1537-2995.2003.00320.x; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 1999, BLOOD, V93, P2976; Chavakis T, 2004, J BIOL CHEM, V279, P55602, DOI 10.1074/jbc.M404676200; Chavakis T, 2002, BIOCHEM SOC T, V30, P168, DOI 10.1042/BST0300168; Chiba R, 1999, BLOOD, V94, P1319, DOI 10.1182/blood.V94.4.1319.416k28_1319_1329; Dangerfield J, 2002, J EXP MED, V196, P1201, DOI 10.1084/jem.20020324; Deaglio S, 1998, J IMMUNOL, V160, P395; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; Gohring K, 2004, BRIT J HAEMATOL, V126, P252, DOI 10.1111/j.1365-2141.2004.05027.x; GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183; Jackson DE, 1997, BIOCHEMISTRY-US, V36, P9395, DOI 10.1021/bi970084x; Kakkar AK, 2004, CURR OPIN PHARMACOL, V4, P154, DOI 10.1016/j.coph.2004.01.003; Kissel K, 2001, EUR J IMMUNOL, V31, P1301, DOI 10.1002/1521-4141(200105)31:5<1301::AID-IMMU1301>3.0.CO;2-J; Kroll H, 2000, BLOOD, V96, P1409, DOI 10.1182/blood.V96.4.1409.h8001409_1409_1414; LALEZARI P, 1971, J CLIN INVEST, V50, P1108, DOI 10.1172/JCI106582; LIAO F, 1995, J EXP MED, V182, P1337, DOI 10.1084/jem.182.5.1337; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; Luu NT, 2003, J VASC RES, V40, P467, DOI 10.1159/000074296; Matsuo K, 2000, TRANSFUSION, V40, P654, DOI 10.1046/j.1537-2995.2000.40060654.x; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McIntyre TM, 2003, CURR OPIN HEMATOL, V10, P150, DOI 10.1097/00062752-200303000-00009; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Plesner T, 1997, STEM CELLS, V15, P398, DOI 10.1002/stem.150398; Sachs UJH, 2006, BLOOD, V107, P1217, DOI 10.1182/blood-2005-04-1744; Sachs UJH, 2006, TRANSFUSION, V46, P1909, DOI 10.1111/j.1537-2995.2006.00996.x; Santoso S, 2002, BLOOD, V99, P1205, DOI 10.1182/blood.V99.4.1205; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Shaw SK, 2004, J EXP MED, V200, P1571, DOI 10.1084/jem.20040965; STRONCEK DF, 1994, J LAB CLIN MED, V123, P247; Stroncek DF, 1996, TRANSFUSION, V36, P168, DOI 10.1046/j.1537-2995.1996.36296181931.x; STRONCEK DF, 1990, BLOOD, V75, P744; Sun QH, 1998, J BIOL CHEM, V273, P11483, DOI 10.1074/jbc.273.19.11483; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; Temerinac S, 2000, BLOOD, V95, P2569; Thompson RD, 2000, J IMMUNOL, V165, P426, DOI 10.4049/jimmunol.165.1.426; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; Wolff JC, 2006, TRANSFUSION, V46, P132, DOI 10.1111/j.1537-2995.2005.00676.x; Wong CWY, 2000, MOL BIOL CELL, V11, P3109, DOI 10.1091/mbc.11.9.3109; YAN HC, 1995, CELL ADHES COMMUN, V3, P45, DOI 10.3109/15419069509081277	50	157	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23603	23612		10.1074/jbc.M701120200	http://dx.doi.org/10.1074/jbc.M701120200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17580308	hybrid			2022-12-25	WOS:000248577500062
J	Eom, TY; Roth, KA; Jope, RS				Eom, Tae-Yeon; Roth, Kevin A.; Jope, Richard S.			Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ENDOTHELIAL GROWTH-FACTOR; ADULT BRAIN NEUROGENESIS; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; HIPPOCAMPAL NEUROGENESIS; DNA-DAMAGE; NEURONAL APOPTOSIS; ALZHEIMERS-DISEASE; PROGENITOR CELLS	Mechanisms controlling the survival of neural precursor cells (NPCs) are critical during brain development, in adults for neuron replenishment, and after transplantation for neuron replacement. This investigation found that glycogen synthase kinase 3 (GSK3) promotes apoptotic signaling in cultured NPCs derived from embryonic mouse brain subjected to two common apoptotic conditions, trophic factor withdrawal and genotoxic stress. Trophic factor withdrawal activated GSK3 and the key apoptosis mediators Bax and caspase-3. Pharmacological inhibition of GSK3 activity produced dramatic reductions in the activation of Bax and caspase-3 and NPC death after trophic factor withdrawal. Trophic factor withdrawal-induced apoptosis was delayed in Bax knock-out NPCs, but GSK3 inhibitors provided additional protection. Genotoxic stress induced by camptothecin treatment of NPCs stabilized p53, which formed a complex with GSK3 beta and activated Bax and caspase-3. Camptothecin-induced activation of caspase-3 was reduced by GSK3 inhibitors in both bax (+/+) and bax (-/-) NPCs. Thus, NPCs are sensitive to loss of trophic factors and genotoxic stress, and inhibitors of GSK3 are capable of enhancing NPC survival.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720 7th Ave S Sparks Ctr 1057, Birmingham, AL 35294 USA.	jope@uab.edu		Roth, Kevin/0000-0002-0643-995X	NATIONAL INSTITUTE OF MENTAL HEALTH [R56MH038752, R01MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041962, R01NS037768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021045] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG021045-05, R01 AG021045, AG021045] Funding Source: Medline; NIMH NIH HHS [R01 MH038752, R01 MH038752-23, R56 MH038752, MH38752] Funding Source: Medline; NINDS NIH HHS [R01 NS037768-08, NS41962, R01 NS037768, R01 NS041962] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aberg MAI, 2000, J NEUROSCI, V20, P2896; Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Akhtar RS, 2006, CELL DEATH DIFFER, V13, P1727, DOI 10.1038/sj.cdd.4401879; Akhtar RS, 2004, BBA-MOL CELL RES, V1644, P189, DOI 10.1016/j.bbamcr.2003.10.013; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Beurel E, 2004, EXP CELL RES, V300, P354, DOI 10.1016/j.yexcr.2004.08.001; Beurel E, 2006, PROG NEUROBIOL, V79, P173, DOI 10.1016/j.pneurobio.2006.07.006; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO;2-B; Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cregan SP, 1999, J NEUROSCI, V19, P7860; D'Sa C, 2003, J NEUROSCI RES, V74, P435, DOI 10.1002/jnr.10738; D'Sa-Eipper C, 2001, DEVELOPMENT, V128, P137; de la Rosa EJ, 2000, TRENDS NEUROSCI, V23, P454, DOI 10.1016/S0166-2236(00)01628-3; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Duman RS, 2000, BIOL PSYCHIAT, V48, P732, DOI 10.1016/S0006-3223(00)00935-5; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Hashimoto R, 2003, NEUROSCIENCE, V117, P55, DOI 10.1016/S0306-4522(02)00577-8; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Imitola J, 2003, PHYSIOL GENOMICS, V14, P171, DOI 10.1152/physiolgenomics.00021.2002; Jacobs BL, 2000, MOL PSYCHIATR, V5, P262, DOI 10.1038/sj.mp.4000712; Jin KL, 2005, P NATL ACAD SCI USA, V102, P18189, DOI 10.1073/pnas.0506375102; Jin KL, 2002, J NEUROSCI, V22, P5365; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kuhn HG, 2005, EUR J NEUROSCI, V22, P1907, DOI 10.1111/j.1460-9568.2005.04377.x; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lazic SE, 2004, NEUROREPORT, V15, P811, DOI 10.1097/00001756-200404090-00014; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; Lichtenwalner RJ, 2001, NEUROSCIENCE, V107, P603, DOI 10.1016/S0306-4522(01)00378-5; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Lossi L, 2003, PROG NEUROBIOL, V69, P287, DOI 10.1016/S0301-0082(03)00051-0; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Manev H, 2001, EUR J PHARMACOL, V411, P67, DOI 10.1016/S0014-2999(00)00904-3; MARTINEZ A, 2006, GLYCOGEN SYNTHASE KI, V3; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Popken GJ, 2004, EUR J NEUROSCI, V19, P2056, DOI 10.1111/j.0953-816X.2004.03320.x; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Shimomura A, 2003, NEUROREPORT, V14, P1779, DOI 10.1097/00001756-200310060-00004; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; Sun YJ, 2006, DEV BIOL, V289, P329, DOI 10.1016/j.ydbio.2005.10.016; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Xiang H, 1998, J NEUROSCI, V18, P1363	63	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22856	22864		10.1074/jbc.M702973200	http://dx.doi.org/10.1074/jbc.M702973200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17548347	hybrid, Green Accepted			2022-12-25	WOS:000248354200063
J	Mathe, C; Weill, CO; Mattioli, TA; Berthomieu, C; Houee-Levin, C; Tremey, E; Niviere, V				Mathe, Christelle; Weill, Claire O.; Mattioli, Tony A.; Berthomieu, Catherine; Houee-Levin, Chantal; Tremey, Emilie; Niviere, Vincent			Assessing the role of the active-site cysteine ligand in the superoxide reductase from Desulfoarculus baarsii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEOGLOBUS-FULGIDUS; OXYGEN DETOXIFICATION; TREPONEMA-PALLIDUM; DESULFOFERRODOXIN; MECHANISM; IDENTIFICATION; KINETICS; REVEALS; MODEL; SIDE	Superoxide reductase is a novel class of non-heme iron proteins that catalyzes the one-electron reduction of O-2((center dot) over bar) to H2O2, providing an antioxidant defense in some bacteria. Its active site consists of an unusual non-heme Fe2+ center in a [His(4) Cys(1)] square pyramidal pentacoordination. In this class of enzyme, the cysteine axial ligand has been hypothesized to be an essential feature in the reactivity of the enzyme. Previous Fourier transform infrared spectroscopy studies on the enzyme from Desulfoarculus baarsii revealed that a protonated carboxylate group, proposed to be the side chain of Glu(114), is in interaction with the cysteine ligand. In this work, using pulse radiolysis, Fourier transform infrared, and resonance Raman spectroscopies, we have investigated to what extent the presence of this Glu(114) carboxylic lateral chain affects the strength of the S-Fe bond and the reaction of the iron active site with superoxide. The E114A mutant shows significantly modified pulse radiolysis kinetics for the protonation process of the first reaction intermediate. Resonance Raman spectroscopy demonstrates that the E114A mutation results in both a strengthening of the S-Fe bond and an increase in the extent of freeze-trapping of a Fe-peroxo species after treatment with H2O2 by a specific strengthening of the Fe-O bond. A fine tuning of the strength of the S-Fe bond by the presence of Glu(114) appears to be an essential factor for both the strength of the Fe-O bond and the pK(a) value of the Fe3+-peroxo intermediate species to form the reaction product H2O2.	Univ Grenoble 1, CNRS, iRTSV CEA Grenoble, Lab Chim & Biol Met, F-38054 Grenoble 9, France; CEA Saclay, CNRS, Lab Stress Oxydant & Detoxicat, SB2SM,iBiTec S, F-91191 Gif Sur Yvette, France; Univ Aix Marseille 2, CNRS, SBVME CEA Cadarache, Lab Interact Prot Met, F-13108 St Paul Les Durance, France; Univ Paris Sud, CNRS, Chim Phys Lab, Ctr Univ, F-91405 Orsay, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Niviere, V (corresponding author), Univ Grenoble 1, CNRS, iRTSV CEA Grenoble, Lab Chim & Biol Met, 17 Ave Martyrs, F-38054 Grenoble 9, France.	vniviere@cea.fr	Berthomieu, Catherine/AAX-9559-2021	Houee Levin, Chantal/0000-0001-8089-796X; Berthomieu, Catherine/0000-0001-8784-5396; Niviere, Vincent/0000-0002-5132-457X				Abreu IA, 2000, MOL MICROBIOL, V38, P322, DOI 10.1046/j.1365-2958.2000.02121.x; Adam V, 2004, STRUCTURE, V12, P1729, DOI 10.1016/j.str.2004.07.013; Berthomieu C, 2002, BIOCHEMISTRY-US, V41, P10360, DOI 10.1021/bi020344x; Brines LM, 2007, EUR J INORG CHEM, P29, DOI 10.1002/ejic.200600461; BUKOWSKI MR, 2005, ANGEW CHEM INT EDIT, V44, P5483; Clay MD, 2003, J BIOL INORG CHEM, V8, P671, DOI 10.1007/s00775-003-0465-4; Clay MD, 2002, J AM CHEM SOC, V124, P788, DOI 10.1021/ja016889g; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Dey A, 2005, J AM CHEM SOC, V127, P12046, DOI 10.1021/ja0519031; Emerson JP, 2003, J BIOL CHEM, V278, P39662, DOI 10.1074/jbc.M306488200; Emerson JP, 2003, P NATL ACAD SCI USA, V100, P3802, DOI 10.1073/pnas.0537177100; Emerson JP, 2002, BIOCHEMISTRY-US, V41, P4348, DOI 10.1021/bi0119159; Horner O, 2004, BIOCHEMISTRY-US, V43, P8815, DOI 10.1021/bi0498151; IOVANOVIC T, 2000, J BIOL CHEM, V275, P28439; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Katona G, 2007, SCIENCE, V316, P449, DOI 10.1126/science.1138885; Kitagawa T, 2006, J AM CHEM SOC, V128, P14448, DOI 10.1021/ja064870d; Kurtz DM, 2004, ACCOUNTS CHEM RES, V37, P902, DOI 10.1021/ar0200091; Lin IJ, 2005, P NATL ACAD SCI USA, V102, P14581, DOI 10.1073/pnas.0505521102; Lombard M, 2000, J BIOL CHEM, V275, P27021; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; Lombard M, 2001, BIOCHEMISTRY-US, V40, P5032, DOI 10.1021/bi0023908; Mathe C, 2006, BIOPHYS CHEM, V119, P38, DOI 10.1016/j.bpc.2005.06.013; Mathe C, 2005, J AM CHEM SOC, V127, P16436, DOI 10.1021/ja053808y; Mathe C, 2002, J AM CHEM SOC, V124, P4966, DOI 10.1021/ja025707v; Niviere V, 2004, J BIOL INORG CHEM, V9, P119, DOI 10.1007/s00775-003-0519-7; Niviere V, 2004, BIOCHEMISTRY-US, V43, P808, DOI 10.1021/bi035698i; Niviere V, 2001, FEBS LETT, V497, P171, DOI 10.1016/S0014-5793(01)02468-1; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; Rodrigues JV, 2007, J BIOL INORG CHEM, V12, P248, DOI 10.1007/s00775-006-0182-x; Rodrigues JV, 2006, BIOCHEMISTRY-US, V45, P9266, DOI 10.1021/bi052489k; Santos-Silva T, 2006, J BIOL INORG CHEM, V11, P548, DOI 10.1007/s00775-006-0104-y; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; [No title captured]	35	29	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22207	22216		10.1074/jbc.M700279200	http://dx.doi.org/10.1074/jbc.M700279200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545670	hybrid			2022-12-25	WOS:000248196800066
J	Mogami, T; Kon, T; Ito, K; Sutoh, K				Mogami, Toshifumi; Kon, Takahide; Ito, Kohji; Sutoh, Kazuo			Kinetic characterization of tail swing steps in the ATPase cycle of Dictyostelium cytoplasmic dynein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE ACTIVITY; MICROTUBULE-BINDING DOMAIN; INTERMEDIATE-CHAIN BINDING; BETA-HEAVY CHAIN; NUCLEOTIDE-BINDING; MOLECULAR MOTOR; ADP RELEASE; PROTEINS; MYOSIN; SITES	According to the power stroke model of dynein deduced from electron microscopic and fluorescence resonance energy transfer studies, the power stroke and the recovery stroke are expected to take place at the two isomerization steps of the ATPase cycle at the primary ATPase site. Here, we have conducted presteady-state kinetic analyses of these two isomerization steps with the single-headed motor domain of Dictyostelium cytoplasmic dynein by employing fluorescence resonance energy transfer to probe ATPase steps at the primary site and tail positions. Our results show that the recovery stroke at the first isomerization step proceeds quickly (similar to 180 s(-1)), whereas the power stroke at the second isomerization step is very slow (similar to 0.2 s(-1)) in the absence of microtubules, and that the presence of microtubules accelerates the second but not the first step. Moreover, a comparison of the microtubule-induced acceleration of the power stroke step and that of steady-state ATP hydrolysis implies the intriguing possibility that microtubules simultaneously accelerate the ATPase activity not only at the primary site but also at other site(s) in the motor domain.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan; Chiba Univ, Dept Biol, Inage Ku, Chiba 2638522, Japan	University of Tokyo; Chiba University	Sutoh, K (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Komaba 3-8-1, Tokyo 1538902, Japan.	sutoh@bio.c.u-tokyo.ac.jp	Ito, Kohji/K-8441-2017; Kon, Takahide/AAG-6975-2021	Ito, Kohji/0000-0001-9573-432X; Kon, Takahide/0000-0002-1231-7609				BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; Blaauw M, 2000, GENE, V252, P71, DOI 10.1016/S0378-1119(00)00227-4; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS IR, 1966, J BIOL CHEM, V241, P5590; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P5577, DOI 10.1021/bi00439a036; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Kon T, 2005, NAT STRUCT MOL BIOL, V12, P513, DOI 10.1038/nsmb930; Kon T, 2004, BIOCHEMISTRY-US, V43, P11266, DOI 10.1021/bi048985a; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; Koonce MP, 2000, MOL BIOL CELL, V11, P523, DOI 10.1091/mbc.11.2.523; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; Neuwald AF, 1999, GENOME RES, V9, P27; Nishiura M, 2004, J BIOL CHEM, V279, P22799, DOI 10.1074/jbc.M313362200; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; OMOTO CK, 1986, BIOCHEMISTRY-US, V25, P419, DOI 10.1021/bi00350a022; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PASCHAL BM, 1987, NATURE, V330, P672, DOI 10.1038/330672a0; Pfister KK, 2006, PLOS GENET, V2, P11, DOI 10.1371/journal.pgen.0020001; Reck-Peterson SL, 2006, CELL, V126, P335, DOI 10.1016/j.cell.2006.05.046; Reck-Peterson SL, 2004, P NATL ACAD SCI USA, V101, P1491, DOI 10.1073/pnas.2637011100; SADHU A, 1992, J BIOL CHEM, V267, P11352; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; Shima T, 2006, P NATL ACAD SCI USA, V103, P17736, DOI 10.1073/pnas.0606794103; Shima T, 2006, J STRUCT BIOL, V156, P182, DOI 10.1016/j.jsb.2006.03.014; Silvanovich A, 2003, MOL BIOL CELL, V14, P1355, DOI 10.1091/mbc.E02-10-0675; SLOBODA RD, 1982, METHOD ENZYMOL, V85, P409; TRENTHAM DR, 1972, BIOCHEM J, V126, P635, DOI 10.1042/bj1260635; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Zeng W, 2006, BIOCHEMISTRY-US, V45, P10482, DOI 10.1021/bi060943u	40	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21639	21644		10.1074/jbc.M701914200	http://dx.doi.org/10.1074/jbc.M701914200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17548361	hybrid			2022-12-25	WOS:000248196800010
J	Pham, TH; Langmann, S; Schwarzfischer, L; El Chartouni, C; Lichtinger, M; Klug, M; Krause, SW; Rehli, M				Pham, Thu-Hang; Langmann, Sabine; Schwarzfischer, Lucia; El Chartouni, Carol; Lichtinger, Monika; Klug, Maja; Krause, Stefan W.; Rehli, Michael			CCAAT enhancer-binding protein beta regulates constitutive gene expression during late stages of monocyte to macrophage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARTILAGE GP-39; PLASMA CHITOTRIOSIDASE ACTIVITY; TRANSCRIPTION FACTOR; C/EBP-BETA; CELLS; PU.1; ALPHA; YKL-40; FAMILY; SERUM	Human monocyte to macrophage differentiation is accompanied by pronounced phenotypical changes and generally proceeds in the absence of proliferation. The molecular events governing this process are poorly understood. Here, we studied the regulation of the macrophage-specific chitotriosidase (CHIT1) gene promoter to gain insights into the mechanisms of transcriptional control during the differentiation of human blood monocytes into macrophages. We used transient transfections to define a cell type-specific minimal promoter that was mainly dependent on a proximal C/EBP motif that bound multiple C/EBP factors in gel shift assays. In depth analysis of occupied promoter elements using in vivo footprinting and chromatin immunoprecipitation analyses demonstrated the differentiation-associated recruitment of C/EBP beta and PU.1 at the proximal promoter in parallel with CHIT1 mRNA induction. Notably, the induction of C/EBP beta promoter binding strongly correlated with increased nuclear levels of Thr-235- phosphorylated C/EBP beta protein during the differentiation process, whereas C/EBP beta mRNA and total protein expression remained relatively stable. Our data suggest an important constitutive gene regulatory function for C/EBP beta in differentiated macrophages but not in human blood monocytes.	Univ Hosp Regensburg, Dept Hematol & Oncol, D-93042 Regensburg, Germany	University of Regensburg	Rehli, M (corresponding author), Univ Hosp Regensburg, Dept Hematol & Oncol, D-93042 Regensburg, Germany.	michael.rehli@klinik.uni-regensburg.de	Rehli, Michael/E-9093-2011	Rehli, Michael/0000-0003-3992-932X; Krause, Stefan/0000-0002-5259-4651				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; ANDREESEN R, 1983, J IMMUNOL METHODS, V56, P295, DOI 10.1016/S0022-1759(83)80019-2; Barone R, 2003, CLIN CHIM ACTA, V331, P79, DOI 10.1016/S0009-8981(03)00089-5; Barone R, 1999, BLOOD CELL MOL DIS, V25, P1, DOI 10.1006/bcmd.1999.0221; Bleau G, 1999, EXS, V87, P211; Boot RG, 2005, J HISTOCHEM CYTOCHEM, V53, P1283, DOI 10.1369/jhc.4A6547.2005; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; Boven LA, 2004, AM J CLIN PATHOL, V122, P359, DOI 10.1309/BG5VA8JRDQH1M7HN; Bradley MN, 2003, MOL CELL BIOL, V23, P4841, DOI 10.1128/MCB.23.14.4841-4858.2003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gorgoni B, 2002, J IMMUNOL, V168, P4055, DOI 10.4049/jimmunol.168.8.4055; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Harvey S, 2000, SCAND J RHEUMATOL, V29, P391; Hume DA, 2002, J LEUKOCYTE BIOL, V72, P621; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; Kirkpatrick RB, 1997, EXP CELL RES, V237, P46, DOI 10.1006/excr.1997.3764; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P223; Kohro Takahide, 2004, J Atheroscler Thromb, V11, P88; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Krause SW, 1996, J LEUKOCYTE BIOL, V60, P540, DOI 10.1002/jlb.60.4.540; Kronborg G, 2002, SCAND J INFECT DIS, V34, P323, DOI 10.1080/00365540110080233; Laiosa CV, 2006, IMMUNITY, V25, P731, DOI 10.1016/j.immuni.2006.09.011; Lehrnbecher T, 2005, LEUKEMIA, V19, P1745, DOI 10.1038/sj.leu.2403922; Malaguarnera L, 2006, GUT, V55, P1313, DOI 10.1136/gut.2005.075697; Malaguarnera L, 2005, J CLIN LAB ANAL, V19, P128, DOI 10.1002/jcla.20063; Maxam A M, 1980, Methods Enzymol, V65, P499; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NATSUKA S, 1992, BLOOD, V79, P460; Nikolic DM, 2007, AM J PHYSIOL-CELL PH, V292, pC1450, DOI 10.1152/ajpcell.00401.2006; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rehli M, 2003, J BIOL CHEM, V278, P44058, DOI 10.1074/jbc.M306792200; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; REHLI M, 1995, J BIOL CHEM, V270, P15644, DOI 10.1074/jbc.270.26.15644; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Rehli M, 1995, BIOCHEM BIOPH RES CO, V217, P661, DOI 10.1006/bbrc.1995.2825; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; Rovida E, 2005, BIOL CHEM, V386, P919, DOI 10.1515/BC.2005.107; SCHEIBENBOGEN C, 1991, J LEUKOCYTE BIOL, V50, P35, DOI 10.1002/jlb.50.1.35; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Tagoh H, 2006, METH MOL B, V325, P285; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; van Eijk M, 2005, INT IMMUNOL, V17, P1505, DOI 10.1093/intimm/dxh328; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2	51	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21924	21933		10.1074/jbc.M611618200	http://dx.doi.org/10.1074/jbc.M611618200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17540774	hybrid			2022-12-25	WOS:000248196800040
J	Shu, L; Shayman, JA				Shu, Liming; Shayman, James A.			Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-GAMMA ACTIVITY; PICK TYPE-C; FABRY-DISEASE; CELLS; CHOLESTEROL; MEMBRANE; GLYCOSPHINGOLIPIDS; FIBROBLASTS; METABOLISM; HEPARIN	Cardiovascular complications, including stroke and myocardial infarction, result in premature mortality in patients with Fabry disease, an X-linked deficiency of alpha-galactosidase A (alpha-Gal A). The enzymatic defect results in the deposition of globotriaosylceramide (Gb3) in the vascular endothelium. To better understand the underlying pathogenesis of Fabry disease, the caveolar lipid content of primary cultured mouse aortic endothelial cells isolated from alpha-Gal A null mice was measured. Lipid mass analysis revealed that the excessive Gb3 in cultured alpha-Gal A-deficient mouse aortic endothelial cells accumulated in endothelial plasma membrane caveolar fractions. The levels of glucosylceramide and lactosylceramide increased in parallel with Gb3 levels in an age-dependent manner, whereas globotetraosylceramide (Gb4) levels reached maximal levels by 6 months of age and then rapidly decreased at older ages. The levels of cholesterol enriched in caveolar membranes declined in parallel with the progressive deposition of Gb3. Depleting Gb3 with recombinant human alpha-Gal A protein or D-threo-ethylenedioxyphenyl-P4, an inhibitor of glucosylceramide synthase, restored cholesterol in cultured alpha-Gal A-deficient mouse aortic endothelial cell caveolae. By contrast, recombinant human alpha-Gal A was less effective in normalizing the cholesterol content. These results demonstrate the caveolar accumulation of glycosphingolipids in an in vitro model of a lysosomal storage disease and raise the possibility that dynamic changes in the composition of plasma membrane lipid microdomains may mediate the endothelial dysfunction seen in Fabry disease.	Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48103 USA	University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Dept Internal Med, Div Nephrol, Rm 1560 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48103 USA.	jshayman@umich.edu						AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; Anderson W., 1898, BRIT J DERMATOL, V10, P113, DOI [10.1111/j.1365-2133.1898.tb16317.x, DOI 10.1111/J.1365-2133.1898.TB16317.X]; Bodary PF, 2005, CIRCULATION, V111, P629, DOI 10.1161/01.CIR.0000154550.15963.80; BREMER EG, 1984, J BIOL CHEM, V259, P6818; CHEN SF, 1995, MICROVASC RES, V50, P119, DOI 10.1006/mvre.1995.1044; CLOWES AW, 1978, J SURG RES, V24, P161, DOI 10.1016/0022-4804(78)90169-5; DAHL NK, 1992, J BIOL CHEM, V267, P4889; Desnick R J, 2001, Adv Nephrol Necker Hosp, V31, P317; DUVE CD, 1975, SCIENCE, V189, P186, DOI 10.1126/science.1138375; Eitzman DT, 2003, J AM SOC NEPHROL, V14, P298, DOI 10.1097/01.ASN.0000043901.45141.D4; Fabry J., 1898, ARCH DERMATOL SYPHIL, V43, P187; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; Ikonen Elina, 2005, Sci STKE, V2005, ppe3; Koike T, 1998, BBA-MOL BASIS DIS, V1406, P327, DOI 10.1016/S0925-4439(98)00019-2; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 2002, J LIPID RES, V43, P198; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Ohshima T, 1997, P NATL ACAD SCI USA, V94, P2540, DOI 10.1073/pnas.94.6.2540; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Shu LM, 2005, J AM SOC NEPHROL, V16, P2636, DOI 10.1681/ASN.2005040383; Shu LM, 2003, J BIOL CHEM, V278, P31419, DOI 10.1074/jbc.M303783200; Shu LM, 2002, J BIOL CHEM, V277, P18447, DOI 10.1074/jbc.M111363200; Shu LM, 2000, ARCH BIOCHEM BIOPHYS, V373, P83, DOI 10.1006/abbi.1999.1553; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; Todeschini AR, 2007, J BIOL CHEM, V282, P8123, DOI 10.1074/jbc.M611407200; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	28	37	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20960	20967		10.1074/jbc.M702436200	http://dx.doi.org/10.1074/jbc.M702436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17535804	hybrid			2022-12-25	WOS:000248047500022
J	Su, X; Kong, C; Stahl, PD				Su, Xiong; Kong, Chen; Stahl, Philip D.			GAPex-5 mediates ubiquitination, trafficking, and degradation of epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; EGF RECEPTOR; C-CBL; TYROSINE PHOSPHORYLATION; ENDOCYTOSIS; RAB5; PROTEIN; BINDING; RIN1; UBIQUITINYLATION	Upon ligand stimulation, epidermal growth factor receptor (EGFR) is rapidly ubiquitinated, internalized, and sorted to lysosomes for degradation. Rab5 has been shown to play an important role in the early stages of EGFR trafficking. GAPex-5 is a newly described Rab5 exchange factor. Herein, we investigate the role of GAPex-5 on EGFR trafficking and degradation. Down-regulation of GAPex-5 by RNA interference decreases epidermal growth factor-stimulated EGFR degradation. Moreover, ubiquitination of EGFR is impaired by depletion of GAPex-5. This inhibitory effect is due to a decrease in the interaction between the adapter protein c-Cbl and EGFR, but not the phosphorylation state of EGFR. Consistently, when examined by immunofluorescence microscopy in cells depleted of GAPex-5, ligand-bound EGFR appeared trapped in early endosomes and the trafficking of internalized receptor from early to late endosomes was impaired. In agreement with the depletion studies, EGFR degradation is enhanced by overexpressing GAPex-5 wild type, but not GAPex-5 Delta GAP, a mutant lacking the Ras GTPase-activating protein (GAP) domain. This is consistent with the finding that c-Cbl binds specifically to the Ras GAP domain. Finally, overexpression of dominant negative Rab5a or depletion of all three isoforms of Rab5 does not inhibit ubiquitination of EGFR, which suggests that GAPex-5-mediated EGFR ubiquitination is independent of Rab5 activation. Collectively, the results suggest a novel mechanism by which EGF-stimulated receptor ubiquitination and trafficking are mediated via GAPex-5.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	pstahl@wustl.edu	Stahl, Philip/D-6315-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01GM42259-33] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agromayor M, 2006, J BIOL CHEM, V281, P23083, DOI 10.1074/jbc.M513803200; Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Hunker CM, 2006, BIOCHEM BIOPH RES CO, V340, P967, DOI 10.1016/j.bbrc.2005.12.099; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kajiho H, 2003, J CELL SCI, V116, P4159, DOI 10.1242/jcs.00718; Kimura T, 2006, J BIOL CHEM, V281, P10598, DOI 10.1074/jbc.M510531200; Kong C, 2007, J BIOL CHEM, V282, P15294, DOI 10.1074/jbc.M611538200; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LI GP, 1994, J BIOL CHEM, V269, P14631; Lodhi IJ, 2007, CELL METAB, V5, P59, DOI 10.1016/j.cmet.2006.12.006; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Ravid T, 2004, J BIOL CHEM, V279, P37153, DOI 10.1074/jbc.M403210200; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; Sato M, 2005, NAT CELL BIOL, V7, P559, DOI 10.1038/ncb1261; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Su X, 2006, J BIOL CHEM, V281, P27982, DOI 10.1074/jbc.M602873200; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	41	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21278	21284		10.1074/jbc.M703725200	http://dx.doi.org/10.1074/jbc.M703725200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17545148	hybrid			2022-12-25	WOS:000248047500056
J	Zhu, PX; Aller, MI; Baron, U; Cambridge, S; Bausen, M; Herb, J; Sawinski, J; Cetin, A; Osten, P; Nelson, ML; Kugler, S; Seeburg, PH; Sprengel, R; Hasan, MT				Zhu, Peixin; Aller, M. Isabel; Baron, Udo; Cambridge, Sidney; Bausen, Melanie; Herb, Jan; Sawinski, Juergen; Cetin, Ali; Osten, Pavel; Nelson, Mark L.; Kuegler, Sebastian; Seeburg, Peter H.; Sprengel, Rolf; Hasan, Mazahir T.			Silencing and Un-silencing of Tetracycline-Controlled Genes in Neurons	PLOS ONE			English	Article								To identify the underlying reason for the controversial performance of tetracycline (Tet)-controlled regulated gene expression in mammalian neurons, we investigated each of the three components that comprise the Tet inducible systems, namely tetracyclines as inducers, tetracycline-transactivator (tTA) and reverse tTA (rtTA), and tTA-responsive promoters (P-tets). We have discovered that stably integrated P-tet becomes functionally silenced in the majority of neurons when it is inactive during development. Ptet silencing can be avoided when it is either not integrated in the genome or stably-integrated with basal activity. Moreover, long-term, high transactivator levels in neurons can often overcome integration-induced Ptet gene silencing, possibly by inducing promoter accessibility.	[Zhu, Peixin; Bausen, Melanie; Herb, Jan; Sawinski, Juergen; Cetin, Ali; Osten, Pavel; Seeburg, Peter H.; Sprengel, Rolf; Hasan, Mazahir T.] Max Planck Inst Med Res, Heidelberg, Germany; [Cambridge, Sidney; Hasan, Mazahir T.] Max Planck Inst Neurobiol, Munich, Germany; [Baron, Udo] Epiontis GmbH, Berlin, Germany; [Aller, M. Isabel] Univ Heidelberg, Dept Clin Neurobiol, Heidelberg, Germany; [Nelson, Mark L.] Paratek Pharmaceut Inc, Boston, MA USA; [Kuegler, Sebastian] Univ Gottingen, Dept Neurol, D-3400 Gottingen, Germany	Max Planck Society; Max Planck Society; Epiontis GmbH; Ruprecht Karls University Heidelberg; University of Gottingen	Hasan, MT (corresponding author), Max Planck Inst Med Res, Heidelberg, Germany.	mhasan@mpimf-heidelberg.mpg.de	Cambridge, Sidney/GYQ-5764-2022; Aller, Isabel/AAY-8409-2020; Hasan, Mazahir/L-3679-2017	Baron, Udo/0000-0001-7432-3601; Hasan, Mazahir/0000-0001-9985-7271; Aller, M.Isabel/0000-0002-6447-9896	Max Planck Society, Volkswagenstiftung; German-Israeli Project [I-663-64.11/2000]; Schloessmann Foundation	Max Planck Society, Volkswagenstiftung(Max Planck SocietyVolkswagen); German-Israeli Project; Schloessmann Foundation	This work was supported by funding from the Max Planck Society, Volkswagenstiftung (M. I. A.), German-Israeli Project (Grant No.: I-663-64.11/2000), and Schloessmann Foundation.	Ali SF, 1999, MOL BRAIN RES, V74, P237, DOI 10.1016/S0169-328X(99)00283-1; Aller MI, 2005, J NEUROSCI, V25, P11455, DOI 10.1523/JNEUROSCI.3153-05.2005; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Bejar R, 2002, J NEUROSCI, V22, P5719; Boger H, 1999, MECH DEVELOP, V83, P141, DOI 10.1016/S0925-4773(99)00042-8; Carpenter AE, 2005, MOL CELL BIOL, V25, P958, DOI 10.1128/MCB.25.3.958-968.2005; CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; Cui ZZ, 2004, NEURON, V41, P781, DOI 10.1016/S0896-6273(04)00072-8; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Eckenstein FP, 2006, EXP NEUROL, V198, P338, DOI 10.1016/j.expneurol.2005.12.020; Ferreira ME, 2005, J BIOL CHEM, V280, P21779, DOI 10.1074/jbc.M502627200; Gogos JA, 2000, CELL, V103, P609, DOI 10.1016/S0092-8674(00)00164-1; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gossen M, 2002, ANNU REV GENET, V36, P153, DOI 10.1146/annurev.genet.36.041002.120114; Grimm D, 2003, MOL THER, V7, P839, DOI 10.1016/S1525-0016(03)00095-9; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; Hasan MT, 2004, PLOS BIOL, V2, P763, DOI 10.1371/journal.pbio.0020163; Hasan MT, 2001, GENESIS, V29, P116, DOI 10.1002/gene.1014; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; Jerecic J, 1999, ANN NY ACAD SCI, V868, P27, DOI 10.1111/j.1749-6632.1999.tb11271.x; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Krestel HE, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e39; Krestel HE, 2004, J NEUROSCI, V24, P10568, DOI 10.1523/JNEUROSCI.4579-03.2004; Kues WA, 2006, FASEB J, V20, P1200, DOI 10.1096/fj.05-5415fje; Lindeberg J, 2002, J NEUROSCI RES, V68, P248, DOI 10.1002/jnr.10213; Mansuy IM, 1998, NEURON, V21, P257, DOI 10.1016/S0896-6273(00)80533-4; Mayford M, 1999, TRENDS GENET, V15, P463, DOI 10.1016/S0168-9525(99)01846-6; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Michalon A, 2005, GENESIS, V43, P205, DOI 10.1002/gene.20175; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Miyawaki A, 2003, CURR OPIN NEUROBIOL, V13, P591, DOI 10.1016/j.conb.2003.09.005; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Pankiewicz R, 2005, J GENE MED, V7, P117, DOI 10.1002/jgm.644; Schnepp BC, 2003, J VIROL, V77, P3495, DOI 10.1128/JVI.77.6.3495-3504.2003; Shevtsova Z, 2005, EXP PHYSIOL, V90, P53, DOI 10.1113/expphysiol.2004.028159; Shimshek DR, 2002, GENESIS, V32, P19, DOI 10.1002/gene.10023; Shimshek DR, 2005, PLOS BIOL, V3, P2017, DOI 10.1371/journal.pbio.0030354; Sprengel R, 2007, Handb Exp Pharmacol, P49; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Tsien Roger Y, 2003, Harvey Lect, V99, P77; Uchida S, 2006, GENES BRAIN BEHAV, V5, P96, DOI 10.1111/j.1601-183X.2005.00139.x; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Yamamoto M, 2003, J NEUROSCI, V23, P6759; Yu TS, 2005, GENESIS, V41, P147, DOI 10.1002/gene.20110	49	63	64	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e533	10.1371/journal.pone.0000533	http://dx.doi.org/10.1371/journal.pone.0000533			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579707	Green Published, gold, Green Accepted			2022-12-25	WOS:000207451700001
J	Bauer, S; Duensing, A; Demetri, GD; Fletcher, JA				Bauer, S.; Duensing, A.; Demetri, G. D.; Fletcher, J. A.			KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway	ONCOGENE			English	Article						KIT; oncogenic signaling; sarcoma; gastrointestinal; neoplasm; PI3-K	C-KIT; ACQUIRED-RESISTANCE; MUTATIONS; INHIBITION; ACTIVATION; MESYLATE; MUTANTS; ABL	Most gastrointestinal stromal tumor (GIST) patients respond to KIT inhibition with imatinib, yet will eventually exhibit resistance. Imatinib-resistance mechanisms are heterogeneous, and little is known about KIT functional roles in imatinib-resistant GIST. Biological consequences of biochemical inhibition of KIT, phospha-tidyl-inositol- 3-kinase (PI3-K), PLC gamma, MAPK/ERK kinase/mitogen-activated protein kinase (MEK/MAPK), mammalian target of rapamycin (mTOR) and JAK were determined by immunoblotting for protein activation, and by cell proliferation and apoptosis assays in GIST cell lines from imatinib-sensitive GIST (GIST882), imatinib-resistant GISTs (GIST430 and GIST48) and KIT-negative GIST (GIST62). KIT activation was 3- to 6-fold higher in GIST430 and GIST48 than in GIST882, whereas total KIT expression was comparable in these three GIST lines. In addition to the higher set point for KIT activation, GIST430 and GIST48 had intrinsic imatinib resistance. After treatment with 1 mu M imatinib, residual KIT activation was 6- and 2.8-fold higher in GIST430 and GIST48, respectively, compared to GIST882. In all GIST lines, cell growth arrest resulted from PI3-K inhibition, and - to a lesser extent - from MEK/MAPK and mTOR inhibition. Inhibition of JAK/STAT or PLC gamma did not affect cell proliferation. Similarly, only PI3-K inhibition resulted in substantial apoptosis in the imatinib-resistant GISTs. We conclude that GIST secondary KIT mutations can be associated with KIT hyperactivation and imatinib resistance. Targeting critical downstream signaling proteins, such as PI3-K, is a promising therapeutic strategy in imatinib-resistant GISTs.	Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; Harvard Med Sch, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Bauer, S (corresponding author), W German Canc Res Ctr, Dept Internal Med, Ctr Canc Res, Hufelandstr 55, D-45122 Essen, Germany.	sebastian.bauer@uni-due.de; jflecher@partners.org	Bauer, Sebastian/HHR-9319-2022; Bauer, Sebastian/D-8120-2012; ravegnini, gloria/K-1330-2016	Bauer, Sebastian/0000-0001-5949-8120; ravegnini, gloria/0000-0002-7774-402X; Duensing, Anette/0000-0002-0168-4067				Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bauer S, 2005, INT J CANCER, V117, P316, DOI 10.1002/ijc.21164; BAUER S, 2005, P AN M AM SOC CLIN, V23, pA9034; Bauer S, 2006, CANCER RES, V66, P9153, DOI 10.1158/0008-5472.CAN-06-0165; Cammenga J, 2005, BLOOD, V106, P3958, DOI 10.1182/blood-2005-02-0583; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; FLETCHER JA, 2003, P AN M AM SOC CLIN, V22, pA3275; Frank DA, 1999, MOL MED, V5, P432; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Ning ZQ, 2001, ONCOGENE, V20, P4528, DOI 10.1038/sj.onc.1204590; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2001, CANCER RES, V61, P8118; Sawka-Verhelle D, 2000, ENDOCRINOLOGY, V141, P1977, DOI 10.1210/en.141.6.1977; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shivas T, 2003, AM J BIOETHICS, V3, P63, DOI 10.1162/152651603321612042; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Wardelmann E, 2006, CLIN CANCER RES, V12, P1743, DOI 10.1158/1078-0432.CCR-05-1211; Wardelmann E, 2005, LANCET ONCOL, V6, P249, DOI 10.1016/S1470-2045(05)70097-8	29	195	205	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7560	7568		10.1038/sj.onc.1210558	http://dx.doi.org/10.1038/sj.onc.1210558			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546049				2022-12-25	WOS:000251282100008
J	Zhou, Y; Zhong, Y; Wang, Y; Zhang, X; Batista, DL; Gejman, R; Ansell, PJ; Zhao, J; Weng, C; Klibanski, A				Zhou, Yunli; Zhong, Ying; Wang, Yingying; Zhang, Xun; Batista, Dalia L.; Gejman, Roger; Ansell, Peter J.; Zhao, Jing; Weng, Catherine; Klibanski, Anne			Activation of p53 by MEG3 non-coding RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA SUPERFAMILY; PTEN TUMOR-SUPPRESSOR; UP-REGULATION; DNA-DAMAGE; GENE NAG-1; MORPHOGENETIC PROTEIN; GROWTH ARREST; CHROMOSOME 12; CANCER-CELLS; EXPRESSION	MEG3 is a maternally expressed imprinted gene suggested to function as a non-coding RNA. Our previous studies suggest that MEG3 has a function of tumor suppression. The tumor suppressor p53 plays a central role in tumor suppression and mediates the functions of many other tumor suppressors. Therefore, we hypothesized that MEG3 functions through activation of p53. We found that transfection of expression constructs for MEG3 and its isoforms results in a significant increase in p53 protein levels and dramatically stimulates p53-dependent transcription from a p53-responsive promoter. Using this as the functional assay, we demonstrated that the open reading frames encoded by MEG3 transcripts are not required for MEG3 function, and the folding of MEG3 RNA is critical to its function, supporting the concept that MEG3 functions as a non-coding RNA. We further found that MEG3 stimulates expression of the growth differentiation factor 15 (GDF15) by enhancing p53 binding to the GDF15 gene promoter. Interestingly, MEG3 does not stimulate p21(CIP1) expression, suggesting that MEG3 can regulate the specificity of p53 transcriptional activation. p53 degradation is mainly mediated by the mouse double minute 2 homolog (MDM2). We found that MDM2 levels were down-regulated in cells transfected with MEG3, suggesting that MDM2 suppression contributes at least in part to p53 accumulation induced by MEG3. Finally, we found that MEG3 is able to inhibit cell proliferation in the absence of p53. These data suggest that MEG3 non-coding RNA may function as a tumor suppressor, whose action is mediated by both p53-dependent and p53-independent pathways.	Massachusetts Gen Hosp, Neuendrocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Neuropathol Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Zhou, Y (corresponding author), Massachusetts Gen Hosp, Neuendrocrine Unit, 55 Fruit St,Bulfinch 457, Boston, MA 02114 USA.	yzhou2@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG026060] Funding Source: NIH RePORTER; NIA NIH HHS [R03AG026060] Funding Source: Medline; NIDDK NIH HHS [R01DK40947] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Astuti D, 2005, BRIT J CANCER, V92, P1574, DOI 10.1038/sj.bjc.6602478; Baek SJ, 2006, GASTROENTEROLOGY, V131, P1553, DOI 10.1053/j.gastro.2006.09.015; Baek SJ, 2005, MOL PHARMACOL, V67, P356, DOI 10.1124/mol.104.005108; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Croteau S, 2003, MAMM GENOME, V14, P231, DOI 10.1007/s00335-002-2244-x; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eling TE, 2006, J BIOCHEM MOL BIOL, V39, P649; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Jacquot C, 2004, INT J ONCOL, V25, P519; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lim JH, 2007, APOPTOSIS, V12, P411, DOI 10.1007/s10495-006-0576-9; Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Matera AG, 2007, NAT REV MOL CELL BIO, V8, P209, DOI 10.1038/nrm2124; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Mattick JS, 2005, HUM MOL GENET, V14, pR121, DOI 10.1093/hmg/ddi101; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Miyoshi N, 2000, GENES CELLS, V5, P211, DOI 10.1046/j.1365-2443.2000.00320.x; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Osada M, 2007, BIOCHEM BIOPH RES CO, V354, P913, DOI 10.1016/j.bbrc.2007.01.089; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pang KC, 2006, TRENDS GENET, V22, P1, DOI 10.1016/j.tig.2005.10.003; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schuster-Gossler K, 1998, DEV DYNAM, V212, P214, DOI 10.1002/(SICI)1097-0177(199806)212:2<214::AID-AJA6>3.0.CO;2-K; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Strelau J, 2000, ADV RES NEURODEGENER, V8, P273; Takada S, 2000, CURR BIOL, V10, P1135, DOI 10.1016/S0960-9822(00)00704-1; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Teodoro JG, 2006, SCIENCE, V313, P968, DOI 10.1126/science.1126391; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALDMAN T, 1995, CANCER RES, V55, P5187; Wei G, 2005, J BIOL CHEM, V280, P12271, DOI 10.1074/jbc.M409522200; Wilson LC, 2003, INT J CANCER, V105, P747, DOI 10.1002/ijc.11173; Wylie AA, 2000, GENOME RES, V10, P1711, DOI 10.1101/gr.161600; YULI C, 2007, IN PRESS ONCOGENE; Zhang X, 2003, J CLIN ENDOCR METAB, V88, P5119, DOI 10.1210/jc.2003-030222; Zhao J, 2005, J CLIN ENDOCR METAB, V90, P2179, DOI 10.1210/jc.2004-1848; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	60	474	516	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24731	24742		10.1074/jbc.M702029200	http://dx.doi.org/10.1074/jbc.M702029200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17569660	hybrid			2022-12-25	WOS:000248933000028
J	Winkler, A; Kutchan, TM; Macheroux, P				Winkler, Andreas; Kutchan, Toni M.; Macheroux, Peter			6-S-cysteinylation of Bi-covalently attached FAD in berberine bridge enzyme tunes the redox potential for optimal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANILLYL-ALCOHOL OXIDASE; P-CRESOL METHYLHYDROXYLASE; TRIMETHYLAMINE DEHYDROGENASE; GLUCOOLIGOSACCHARIDE OXIDASE; PENICILLIUM-SIMPLICISSIMUM; THIAMIN DEHYDROGENASE; ACREMONIUM-STRICTUM; MOLECULAR-CLONING; FLAVIN; FLAVOPROTEINS	A mutagenic analysis of the amino acid residues His-104 and Cys-166, which are involved in the bi-covalent attachment of FAD to berberine bridge enzyme, was performed. Here we present a detailed biochemical characterization of the cysteine link to FAD observed in this recently discovered group of flavoproteins. The C166A mutant protein still has residual activity, but reduced to similar to 6% of the turnover rate observed for wild-type berberine bridge enzyme. A more detailed analysis of single reaction steps by stopped-flow spectrophotometry showed that the reductive half-reaction is greatly influenced by the lack of the 6-S-cysteinyl linkage, resulting in a 370-fold decrease in the rate of flavin reduction. Determination of the redox potentials for both wild type and the C166A mutein revealed that the difference in the redox potential observed can fully account for the change in the kinetic properties. The wild-type protein exhibits a midpoint potential of +132 mV, which is the highest redox potential determined for any flavoenzyme so far. Removal of the cysteine linkage to FAD in the C166A mutein leads to a redox potential of +53 mV, which is in the expected range for flavoproteins with a single covalent attachment of FAD to a His residue via its 8-alpha position. We also show that the biochemical properties of the mutein resemble that of typical flavoprotein oxidases and that deviations from this behavior observed for the wild type are due to the FAD-6-S-cysteinyl bond. In addition, rapid reaction stopped-flow experiments give no indication for a radical mechanism supporting the direct transfer of a hydride from the substrate to the cofactor.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria; Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Graz University of Technology; Donald Danforth Plant Science Center	Macheroux, P (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-11, A-8010 Graz, Austria.	peter.macheroux@tugraz.at	Macheroux, Peter/AAB-5157-2019; Kutchan, Toni/L-4625-2013	Macheroux, Peter/0000-0002-0242-454X; Winkler, Andreas/0000-0001-6221-9671	Austrian Science Fund FWF [W 901] Funding Source: Medline; Austrian Science Fund (FWF) [W 901] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		Alcantara J, 2005, PLANT PHYSIOL, V138, P173, DOI 10.1104/pp.105.059287; Alexeev I, 2007, P NATL ACAD SCI USA, V104, P6170, DOI 10.1073/pnas.0700579104; BARBER MJ, 1988, BIOCHEM J, V256, P657, DOI 10.1042/bj2560657; Binda C, 2002, J BIOL CHEM, V277, P23973, DOI 10.1074/jbc.R200005200; Bock A, 2002, PLANTA, V216, P57, DOI 10.1007/s00425-002-0867-5; CHOI JD, 1983, J BIOL CHEM, V258, P840; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; EDMONDSON DE, 1973, J BIOL CHEM, V248, P8144; Efimov I, 2001, BIOCHEMISTRY-US, V40, P2155, DOI 10.1021/bi001644m; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; Gadda G, 1997, EUR J BIOCHEM, V250, P369, DOI 10.1111/j.1432-1033.1997.0369a.x; GHISLA S, 1980, BIOCHEMISTRY-US, V19, P2537, DOI 10.1021/bi00553a001; GOMEZMORENO C, 1979, J BIOL CHEM, V254, P7630; Huang CH, 2005, J BIOL CHEM, V280, P38831, DOI 10.1074/jbc.M506078200; KENNEY WC, 1976, J BIOL CHEM, V251, P5386; Kim J, 1995, J BIOL CHEM, V270, P31202, DOI 10.1074/jbc.270.52.31202; KUTCHAN TM, 1995, J BIOL CHEM, V270, P24475, DOI 10.1074/jbc.270.41.24475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MH, 2005, APPL ENVIRON MICROB, V71, P8881, DOI 10.1128/AEM.71.12.8881-8887.2005; MACHEROUX P, 1993, EUR J BIOCHEM, V213, P1047, DOI 10.1111/j.1432-1033.1993.tb17852.x; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1991, HAVINS FLAVOPROTEINS, P59; Mattevi A, 2006, TRENDS BIOCHEM SCI, V31, P276, DOI 10.1016/j.tibs.2006.03.003; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Mewies M, 1997, BIOCHEMISTRY-US, V36, P7162, DOI 10.1021/bi970621d; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; Pilone MS, 2000, CELL MOL LIFE SCI, V57, P1732, DOI 10.1007/PL00000655; Rand T, 2006, FEBS J, V273, P2693, DOI 10.1111/j.1742-4658.2006.05285.x; Singer T P, 1980, Methods Enzymol, V66, P253; Sirikantaramas S, 2004, J BIOL CHEM, V279, P39767, DOI 10.1074/jbc.M403693200; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; Taylor JF, 1942, J BIOL CHEM, V144, P15; Winkler A, 2006, J BIOL CHEM, V281, P21276, DOI 10.1074/jbc.M603267200	35	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24437	24443		10.1074/jbc.M703642200	http://dx.doi.org/10.1074/jbc.M703642200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17573342	hybrid			2022-12-25	WOS:000248686600070
J	Bush, CR; Havens, JM; Necela, BM; Su, WD; Chen, L; Yanagisawa, M; Anastasiadis, PZ; Guerra, R; Luxon, BA; Thompson, EA				Bush, Craig R.; Havens, Jennifer M.; Necela, Brian M.; Su, Weidong; Chen, Lu; Yanagisawa, Masahiro; Anastasiadis, Panos Z.; Guerra, Rudy; Luxon, Bruce A.; Thompson, E. Aubrey			Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor gamma and calcium signaling in human colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED COLON CARCINOGENESIS; SYNDROME CRITICAL REGION; POLYUNSATURATED FATTY-ACIDS; INTESTINAL POLYP FORMATION; ABERRANT CRYPT FOCI; DIETARY FISH-OIL; PPAR-GAMMA; DOWN-SYNDROME; INHIBITS CALCINEURIN; GENE ONTOLOGY	Activation of PPAR gamma in MOSER cells inhibits anchorage-dependent and anchorage-independent growth and invasion through Matrigel-coated transwell membranes. We carried out a longitudinal two-class microarray analysis in which mRNA abundance was measured as a function of time in cells treated with a thiazolidinedione PPAR gamma agonist or vehicle. A statistical machine learning algorithm that employs an empirical Bayesian implementation of the multivariate HotellingT2 score was used to identify differentially regulated genes. HotellingT2 scores, MB statistics, and maximum median differences were used as figures of merit to interrogate genomic ontology of these targets. Three major cohorts of genes were regulated: those involved in metabolism, DNA replication, and migration/motility, reflecting the cellular phenotype that attends activation of PPAR gamma. The bioinformatic analysis also inferred that PPAR gamma regulates calcium signaling. This response was unanticipated, because calcium signaling has not previously been associated with PPAR gamma activation. Ingenuity pathway analysis inferred that the nodal point in this cross-talk was Down syndrome critical region 1 (DSCR1). DSCR1 is an endogenous calcineurin inhibitor that blocks dephosphorylation and activation of members of the cytoplasmic component of nuclear factor of activated T cells transcription factors. Lentiviral short hairpin RNA-mediated knockdown of DSCR1 blocks PPAR gamma inhibition of proliferation and invasion, indicating that DSCR1 is required for suppression of transformed properties of early stage colorectal cancer cells by PPAR gamma. These data reveal a novel, heretofore unappreciated link between PPAR gamma and calcium signaling and indicate that DSCR1, which has previously been thought to function by suppression of the angiogenic response in endothelial cells, may also play a direct role in transformation of epithelial cells.	Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA; Texas Childrens Hosp, Canc Genom Ctr, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Rice Univ, Dept Stat, Houston, TX 77251 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77550 USA	Mayo Clinic; Baylor College of Medicine; Baylor College of Medicine; Rice University; University of Texas System; University of Texas Medical Branch Galveston	Thompson, EA (corresponding author), Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Griffin Canc Res Bldg,Rm 304,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	Thompson.aubrey@mayo.edu	Luxon, Bruce A/C-9140-2012		NATIONAL CANCER INSTITUTE [R01CA100467, R03CA121349, R03CA127996] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007093] Funding Source: NIH RePORTER; NCI NIH HHS [CA121349, CA100467, CA127996] Funding Source: Medline; NLM NIH HHS [5 T15-LM07093] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Anti M, 1997, ADV EXP MED BIOL, V400, P605; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bogazzi F, 2002, J CLIN ENDOCR METAB, V87, P2403, DOI 10.1210/jc.87.5.2403; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Caetano MS, 2002, FASEB J, V16, P1940, DOI 10.1096/fj.02-0282fje; CAYGILL CPJ, 1995, EUR J CANCER PREV, V4, P329, DOI 10.1097/00008469-199508000-00008; Chan B, 2005, P NATL ACAD SCI USA, V102, P13075, DOI 10.1073/pnas.0503846102; Chang TH, 2000, CANCER RES, V60, P1129; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; Chen GG, 2002, LIFE SCI, V70, P2631, DOI 10.1016/S0024-3205(02)01510-2; Chen L, 2006, J BIOL CHEM, V281, P24575, DOI 10.1074/jbc.M604147200; Chen L, 2006, MOL CELL ENDOCRINOL, V251, P17, DOI 10.1016/j.mce.2006.02.006; Copland JA, 2006, ONCOGENE, V25, P2304, DOI 10.1038/sj.onc.1209267; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Dubuquoy L, 2003, GASTROENTEROLOGY, V124, P1265, DOI 10.1016/S0016-5085(03)00271-3; Dudoit S, 2003, BIOTECHNIQUES, P45; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Ermak G, 2002, FASEB J, V16, DOI 10.1096/fj.01-0846com; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; FUKITA T, 2004, Patent No. 6706746; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gooch JL, 2004, AM J PATHOL, V165, P1755, DOI 10.1016/S0002-9440(10)63430-X; Gupta RA, 2003, J BIOL CHEM, V278, P7431, DOI 10.1074/jbc.M208076200; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Hampton T, 2005, JAMA-J AM MED ASSOC, V293, P284, DOI 10.1001/jama.293.3.284; Harris CD, 2005, CELL MOL LIFE SCI, V62, P2477, DOI 10.1007/s00018-005-5085-4; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; HUANG S, 1994, INT J CANCER, V57, P742, DOI 10.1002/ijc.2910570522; Ikezoe T, 2001, CANCER RES, V61, P5307; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Katayama K, 2003, GASTROENTEROLOGY, V124, P1315, DOI 10.1016/S0016-5085(03)00262-2; Kato M, 2004, J CANCER RES CLIN, V130, P73, DOI 10.1007/s00432-003-0510-2; Katz S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-464; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kohno H, 2001, JPN J CANCER RES, V92, P396, DOI 10.1111/j.1349-7006.2001.tb01108.x; Kulke MH, 2002, CANCER J, V8, P395, DOI 10.1097/00130404-200209000-00010; Lazar MA, 2005, BIOCHIMIE, V87, P9, DOI 10.1016/j.biochi.2004.10.021; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277; McAlpine CA, 2006, INT J CANCER, V119, P2339, DOI 10.1002/ijc.22115; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; NELSON RL, 1988, NUTR CANCER, V11, P215, DOI 10.1080/01635588809513990; Niho N, 2003, CANCER SCI, V94, P960, DOI 10.1111/j.1349-7006.2003.tb01385.x; Niho N, 2003, CANCER RES, V63, P6090; O'Connell M., 2003, SIGKDD EXPLOR NEWSL, V5, P38, DOI [10.1145/980972.980979, DOI 10.1145/980972.980979]; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Palakurthi SS, 2001, CANCER RES, V61, P6213; Pavlidis P, 2004, NEUROCHEM RES, V29, P1213, DOI 10.1023/B:NERE.0000023608.29741.45; Pavlidis Paul, 2002, Pac Symp Biocomput, P474; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Picard F, 2002, ANNU REV NUTR, V22, P167, DOI 10.1146/annurev.nutr.22.010402.102808; Qin LL, 2006, MOL CANCER RES, V4, P811, DOI 10.1158/1541-7786.MCR-06-0126; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; REDDY BS, 1986, CANCER RES, V46, P3367; REDDY BS, 1988, CANCER RES, V48, P6642; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; SAKAGUCHI M, 1984, CANCER RES, V44, P1472; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658; Shoda R, 1996, AM J CLIN NUTR, V63, P741, DOI 10.1093/ajcn/63.5.741; Stathatos N, 2005, J CLIN ENDOCR METAB, V90, P5432, DOI 10.1210/jc.2005-0963; SU W, 2007, PHYSIOL GENOMICS, DOI DOI 10.1152/PHYSIOLGENOMICS.00042.02007; Sun L, 2005, P NATL ACAD SCI USA, V102, P17130, DOI 10.1073/pnas.0508480102; TAI YC, 2004, 667 DEP STAT J HOPKI; Tanaka T, 2001, CANCER RES, V61, P2424; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; U M, 2004, LEUKEMIA, V18, P1850, DOI 10.1038/sj.leu.2403516; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Vernochet C, 2002, FEBS LETT, V510, P94, DOI 10.1016/S0014-5793(01)03235-5; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WU Z, 2003, TECHNICAL REPORT J H; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; YANG YH, 2005, STAT ANAL GENE EXPRE; Yao YG, 2004, BIOCHEM BIOPH RES CO, V321, P648, DOI 10.1016/j.bbrc.2004.06.176; Yiu GK, 2006, J BIOL CHEM, V281, P12210, DOI 10.1074/jbc.M600184200; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Yoshizumi T, 2004, INT J ONCOL, V25, P631; Zhu X, 2003, CELL MOL LIFE SCI, V60, P212, DOI 10.1007/s000180300015; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	108	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23387	23401		10.1074/jbc.M702708200	http://dx.doi.org/10.1074/jbc.M702708200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565986	hybrid			2022-12-25	WOS:000248577500039
J	Hernandez-Negrete, I; Carretero-Ortega, J; Rosenfeldt, H; Hernandez-Garcia, R; Calderon-Salinas, JV; Reyes-Cruz, G; Gutkind, JS; Vazquez-Prado, J				Hernandez-Negrete, Ivette; Carretero-Ortega, Jorge; Rosenfeldt, Hans; Hernandez-Garcia, Ricardo; Calderon-Salinas, J. Victor; Reyes-Cruz, Guadalupe; Gutkind, J. Silvio; Vazquez-Prado, Jose			P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; ACTIN CYTOSKELETON; BINDING PARTNER; S6 KINASE; MTOR; COMPLEX; RAPTOR; PHOSPHORYLATION; PATHWAY; RICTOR	Polarized cell migration results from the transduction of extracellular cues promoting the activation of Rho GTPases with the intervention of multidomain proteins, including guanine exchange factors. P-Rex1 and P-Rex2 are Rac GEFs connecting G beta gamma and phosphatidylinositol 3-kinase signaling to Rac activation. Their complex architecture suggests their regulation by protein-protein interactions. Novel mechanisms of activation of Rho GTPases are associated with mammalian target of rapamycin ( mTOR), a serine/threonine kinase known as a central regulator of cell growth and proliferation. Recently, two independent multiprotein complexes containing mTOR have been described. mTORC1 links to the classical rapamycin-sensitive pathways relevant for protein synthesis; mTORC2 links to the activation of Rho GTPases and cytoskeletal events via undefined mechanisms. Here we demonstrate that P-Rex1 and P-Rex2 establish, through their tandem DEP domains, interactions with mTOR, suggesting their potential as effectors in the signaling of mTOR to Rac activation and cell migration. This possibility was consistent with the effect of dominant-negative constructs and short hairpin RNA-mediated knockdown of P-Rex1, which decreased mTOR-dependent leucine-induced activation of Rac and cell migration. Rapamycin, a widely used inhibitor of mTOR signaling, did not inhibit Rac activity and cell migration induced by leucine, indicating that P-Rex1, which we found associated to both mTOR complexes, is only active when in the mTORC2 complex. mTORC2 has been described as the catalytic complex that phosphorylates AKT/PKB at Ser-473 and elicits activation of Rho GTPases and cytoskeletal reorganization. Thus, P-Rex1 links mTOR signaling to Rac activation and cell migration.	Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Pharmacol, Mexico City 07000, DF, Mexico; Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Cell Biol, Mexico City 07000, DF, Mexico; Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biochem, Mexico City 07000, DF, Mexico; NIDCR, Oral & Pharyngeal Canc Branch, Natl Inst Hlth, Bethesda, MD 20892 USA	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Vazquez-Prado, J (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Pharmacol, Apartado Postal 14-740, Mexico City 07000, DF, Mexico.	jvazquez@cinvestav.mx	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; VAZQUEZ-PRADO, JOSE/C-1630-2017	Gutkind, J. Silvio/0000-0002-5150-4482; VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643; Hernandez Negrete, Ivette/0000-0003-1097-0038; Carretero-Ortega, Jorge/0000-0003-1295-9596	FIC NIH HHS [R01TW006664] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW006664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Dong XM, 2005, CURR BIOL, V15, P1874, DOI 10.1016/j.cub.2005.09.014; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Joseph RE, 2005, J BIOL CHEM, V280, P27508, DOI 10.1074/jbc.M412495200; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Lee S, 2005, MOL BIOL CELL, V16, P4572, DOI 10.1091/mbc.E05-04-0342; Liu L, 2006, ONCOGENE, V25, P7029, DOI 10.1038/sj.onc.1209691; Lynch CJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE854, DOI 10.1152/ajpendo.00153.2003; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1913, DOI 10.1074/jbc.M506034200; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1921, DOI 10.1074/jbc.M506035200; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Rhoads JM, 2006, AM J PHYSIOL-GASTR L, V291, pG510, DOI 10.1152/ajpgi.00189.2005; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Takahara T, 2006, J BIOL CHEM, V281, P28605, DOI 10.1074/jbc.M606087200; Vazquez-Prado J, 2004, METHOD ENZYMOL, V390, P259; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yoshizawa M, 2005, J NEUROSCI, V25, P4406, DOI 10.1523/JNEUROSCI.4955-04.2005	32	118	121	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23708	23715		10.1074/jbc.M703771200	http://dx.doi.org/10.1074/jbc.M703771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565979	hybrid			2022-12-25	WOS:000248577500074
J	Gladycheva, SE; Lam, AD; Liu, J; D'Andrea-Merrins, M; Yizhar, O; Lentz, SI; Ashery, U; Ernst, SA; Stuenkel, EL				Gladycheva, Svetlana E.; Lam, Alice D.; Liu, Jiang; D'Andrea-Merrins, Matthew; Yizhar, Ofer; Lentz, Stephen I.; Ashery, Uri; Ernst, Stephen A.; Stuenkel, Edward L.			Receptor-mediated regulation of tomosyn-syntaxin 1A interactions in bovine adrenal chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; LARGE DENSE-CORE; NEUROTRANSMITTER RELEASE; CA2+-DEPENDENT EXOCYTOSIS; SECRETORY GRANULES; RECESSIVE ONCOGENE; STRUCTURAL BASIS; BINDING PROTEIN; EXOCYST COMPLEX; MEMBRANE-FUSION	Tomosyn, a soluble R-SNARE protein identified as a binding partner of the Q-SNARE syntaxin 1A, is thought to be critical in setting the level of fusion-competent SNARE complexes for neurosecretion. To date, there has been no direct evaluation of the dynamics in which tomosyn transits through tomosyn-SNARE complexes or of the extent to which tomosyn-SNARE complexes are regulated by secretory demand. Here, we employed biochemical and optical approaches to characterize the dynamic properties of tomosyn- syntaxin 1A complexes in live adrenal chromaffin cells. We demonstrate that secretagogue stimulation results in the rapid translocation of tomosyn from the cytosol to plasma membrane regions and that this translocation is associated with an increase in the tomosyn-syntaxin 1A interaction, including increased cycling of tomosyn into tomosyn-SNARE complexes. The secretagogue-induced interaction was strongly reduced by pharmacological inhibition of the Rho-associated coiled-coil forming kinase, a result consistent with findings demonstrating secretagogue-induced activation of RhoA. Stimulation of chromaffin cells with lysophosphatidic acid, a nonsecretory stimulus that strongly activates RhoA, resulted in effects on tomosyn similar to that of application of the secretagogue. In PC-12 cells overexpressing tomosyn, secretagogue stimulation in the presence of lysophosphatidic acid resulted in reduced evoked secretory responses, an effect that was eliminated upon inhibition of Rho-associated coiled-coil forming kinase. Moreover, this effect required an intact interaction between tomosyn and syntaxin 1A. Thus, modulation of the tomosyn- syntaxin 1A interaction in response to secretagogue activation is an important mechanism allowing for dynamic regulation of the secretory response.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Michigan Diabet Res & Training Ctr, Ann Arbor, MI 48109 USA; Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Tel Aviv University	Stuenkel, EL (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, 7807 Med Sci 2 Bldg, Ann Arbor, MI 48109 USA.	esterm@umich.edu	YIZHAR, OFER/AAV-8497-2021	Ashery, Uri/0000-0001-6338-7888; Stuenkel, Edward/0000-0001-8225-5725; Lentz, Stephen/0000-0003-1686-7998; Yizhar, Ofer/0000-0003-4228-1448; Merrins, Matthew J./0000-0003-1599-9227	NIDDK NIH HHS [P60DK20572, P30DK 34933, 5P60 DK20572] Funding Source: Medline; NIGMS NIH HHS [GM007863] Funding Source: Medline; NINDS NIH HHS [NS39914, NS053978, NS053263] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, P60DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039914, F31NS053263, R01NS053978] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; Baba T, 2005, J CELL BIOL, V170, P1113, DOI 10.1083/jcb.200504055; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; Constable JRL, 2005, J BIOL CHEM, V280, P31615, DOI 10.1074/jbc.M505858200; Dybbs M, 2005, PLOS GENET, V1, P6, DOI 10.1371/journal.pgen.0010002; EauClaire S, 2003, NEURON, V37, P369, DOI 10.1016/S0896-6273(03)00059-X; Elferink LA, 1995, PROG BRAIN RES, V105, P79; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gasman S, 2003, CELL SIGNAL, V15, P893, DOI 10.1016/S0898-6568(03)00052-4; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Gasman S, 1999, J CELL SCI, V112, P4763; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Gladycheva SE, 2004, J PHYSIOL-LONDON, V558, P857, DOI 10.1113/jphysiol.2004.067249; Gracheva EO, 2006, PLOS BIOL, V4, P1426, DOI 10.1371/journal.pbio.0040261; Groffen AJA, 2005, J NEUROCHEM, V92, P554, DOI 10.1111/j.1471-4159.2004.02890.x; Hakoshima T, 2003, J BIOCHEM, V134, P327, DOI 10.1093/jb/mvg149; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hatsuzawa K, 2003, J BIOL CHEM, V278, P31159, DOI 10.1074/jbc.M305500200; Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4; Hsu SC, 2004, INT REV CYTOL, V233, P243, DOI 10.1016/S0074-7696(04)33006-8; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kagami M, 1998, GENETICS, V149, P1717; Katoh M, 2004, INT J ONCOL, V24, P737; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Kim YS, 2003, INT J ONCOL, V23, P229; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Li QW, 2003, J PHYSIOL-LONDON, V550, P431, DOI 10.1113/jphysiol.2003.039073; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Liu J, 2004, J BIOL CHEM, V279, P55924, DOI 10.1074/jbc.M410024200; Martin TFJ, 2002, NEURON, V34, P9, DOI 10.1016/S0896-6273(02)00651-7; Masuda ES, 1998, NEURON, V21, P479, DOI 10.1016/S0896-6273(00)80559-0; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; Pobbati AV, 2004, J BIOL CHEM, V279, P47192, DOI 10.1074/jbc.M408767200; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rowe J, 2001, J CELL SCI, V114, P3323; Rowe J, 1999, J CELL SCI, V112, P1865; Sakisaka T, 2004, J CELL BIOL, V166, P17, DOI 10.1083/jcb.200405002; Scales SJ, 2002, J BIOL CHEM, V277, P28271, DOI 10.1074/jbc.M204929200; Silinsky EM, 2003, BRIT J PHARMACOL, V138, P1191, DOI 10.1038/sj.bjp.0705213; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sollner TH, 1996, CELL STRUCT FUNCT, V21, P407; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Toonen RFG, 2005, J NEUROCHEM, V93, P1393, DOI 10.1111/j.1471-4159.2005.03128.x; Toonen RFG, 2003, BIOCHEM SOC T, V31, P848, DOI 10.1042/BST0310848; TOUTANT M, 1987, FEBS LETT, V215, P339, DOI 10.1016/0014-5793(87)80174-6; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; Vitale N, 2000, BIOCHIMIE, V82, P365, DOI 10.1016/S0300-9084(00)00198-X; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimer RM, 2005, CURR TOP DEV BIOL, V65, P83; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; WICK PF, 1993, J BIOL CHEM, V268, P10983; Widberg CH, 2003, J BIOL CHEM, V278, P35093, DOI 10.1074/jbc.M304261200; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yang XF, 2006, J BIOL CHEM, V281, P15457, DOI 10.1074/jbc.M513246200; Yizhar O, 2004, P NATL ACAD SCI USA, V101, P2578, DOI 10.1073/pnas.0308700100; Zhang W, 2006, DIABETES, V55, P574, DOI 10.2337/diabetes.55.03.06.db05-0015; Zhang XY, 2005, J CELL BIOL, V170, P273, DOI 10.1083/jcb.200502055	67	32	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22887	22899		10.1074/jbc.M701787200	http://dx.doi.org/10.1074/jbc.M701787200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17545156	hybrid			2022-12-25	WOS:000248354200066
J	Pei, WM; Ritz, M; McCarthy, M; Huang, Z; Niu, L				Pei, Weimin; Ritz, Mark; McCarthy, Michael; Huang, Zhen; Niu, Li			Receptor occupancy and channel-opening kinetics - A study of GluR1 L497Y AMPA receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONOTROPIC GLUTAMATE RECEPTORS; FOLDING TRANSITION-STATES; ION CHANNELS; PSI-ANALYSIS; PHI-VALUE; DESENSITIZATION; BINDING; MECHANISM; ACTIVATION; NEURONS	AMPA glutamate ion channels are tetrameric receptors in which activation to form the open channel depends on the binding of possibly multiple glutamate molecules. However, it is unclear whether AMPA receptors bound with a different number of glutamate molecules (i.e. one being the minimal and four being the maximal number of glutamate molecules) open the channels with different kinetic constants. Using a laser pulse photolysis technique that provides microsecond time resolution, we investigated the channel-opening kinetic mechanism of a nondesensitizing AMPA receptor, i.e. GluR1Q(flip) L497Y or a leucine-to-tyrosine substitution mutant, in the entire range of glutamate concentrations to ensure receptor saturation. We found that the minimal number of glutamate molecules required to bind to the receptor and to open the channel is two (or n = 2), and that the entire channel-opening kinetics can be adequately described by just one channel-opening rate constant, k(op), which correlates to n = 2. This result suggests that higher receptor occupancy (n = 3 and 4) does not give rise to different kop values or, at least, not appreciably if the kop values are different. Furthermore, compared with the wild-type receptor (Li, G., and Niu, L. (2004) J. Biol. Chem. 279, 3990-3997), the channel-opening and channel-closing rate constants of the mutant are 1.5- and 13-fold smaller, respectively. Thus, the major effect of this mutation is to decrease the channel-closing rate constant by stabilizing the open channel conformation.	SUNY Albany, Dept Chem, Albany, NY 12222 USA; SUNY Albany, Neurosci Res Ctr, Albany, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Niu, L (corresponding author), SUNY Albany, Dept Chem, Albany, NY 12222 USA.	lniu@albany.edu						Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Chen PE, 2006, BRIT J PHARMACOL, V147, P839, DOI 10.1038/sj.bjp.0706689; Clements JD, 1998, J NEUROSCI, V18, P119; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Diamond JS, 1997, J NEUROSCI, V17, P4672; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fersht AR, 2004, P NATL ACAD SCI USA, V101, P17327, DOI 10.1073/pnas.0407863101; Fersht AR, 2004, P NATL ACAD SCI USA, V101, P7976, DOI 10.1073/pnas.0402684101; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Jin RS, 2002, BIOCHEMISTRY-US, V41, P15635, DOI 10.1021/bi020583k; Li G, 2005, BIOCHEMISTRY-US, V44, P5835, DOI 10.1021/bi047413n; Li G, 2004, J BIOL CHEM, V279, P3990, DOI 10.1074/jbc.M310410200; Li G, 2003, BIOCHEMISTRY-US, V42, P12358, DOI 10.1021/bi0347961; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; Pandit Adarsh D., 2007, V350, P83; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Pei WM, 2007, BIOCHEMISTRY-US, V46, P2027, DOI 10.1021/bi062213s; Plested AJR, 2004, ANESTHESIOLOGY, V100, P347, DOI 10.1097/00000542-200402000-00025; RAMAN IM, 1995, BIOPHYS J, V68, P137, DOI 10.1016/S0006-3495(95)80168-2; Robert A, 2003, J NEUROSCI, V23, P847; Robert A, 2001, J NEUROSCI, V21, P5574, DOI 10.1523/JNEUROSCI.21-15-05574.2001; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Ruiz M, 1997, NATURE, V389, P389, DOI 10.1038/38744; Smith TC, 2000, NAT NEUROSCI, V3, P992, DOI 10.1038/79931; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1988, P NATL ACAD SCI USA, V85, P4562, DOI 10.1073/pnas.85.12.4562-a; WEIBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752	34	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22731	22736		10.1074/jbc.M611821200	http://dx.doi.org/10.1074/jbc.M611821200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17545169	hybrid			2022-12-25	WOS:000248354200050
J	Chang, CR; Blackstone, C				Chang, Chuang-Rung; Blackstone, Craig			Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EFFECTOR DOMAIN; DYNAMIN; FISSION; OLIGOMERIZATION; ENDOCYTOSIS	Mitochondria in cells comprise a tubulovesicular reticulum shaped by dynamic fission and fusion events. The multimeric dynamin-like GTPase Drp1 is a critical protein mediating mitochondrial division. It harbors multiple motifs including GTP-binding, middle, and GTPase effector (GED) domains that are important for both intramolecular and intermolecular interactions. As for other members of the dynamin superfamily, such interactions are critical for assembly of higher-order structures and cooperative increases in GTPase activity. Although the functions of Drp1 in cells have been extensively studied, mechanisms underlying its regulation remain less clear. Here, we have identified cAMP-dependent protein kinase-dependent phosphorylation of Drp1 within the GED domain at Ser(637) that inhibits Drp1 GTPase activity. Mechanistically, this change in GTPase activity likely derives from decreased interaction of GTP-binding/middle domains with the GED domain since the phosphomimetic S637D mutation impairs this intramolecular interaction but not Drp1-Drp1 intermolecular interactions. Using the phosphomimetic S637D substitution, we also demonstrate that mitochondrial fission is prominently inhibited in cells. Thus, protein phosphorylation at Ser(637) results in clear alterations in Drp1 function and mitochondrial morphology that are likely involved in dynamic regulation of mitochondrial division in cells.	NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Blackstone, C (corresponding author), NINDS, Cellular Neurol Unit, NIH, Bldg 35,Rm 2C-913,9000 Rockville Pike, Bethesda, MD 20892 USA.	blackstc@ninds.nih.gov	Chang, Chuang-Rung/C-1815-2012	Chang, Chuang-Rung/0000-0002-6124-5429	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS003025, ZIANS003025] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Chen CH, 2000, BIOCHEM BIOPH RES CO, V268, P893, DOI 10.1006/bbrc.2000.2197; Di Paolo C, 1999, J BIOL CHEM, V274, P32071, DOI 10.1074/jbc.274.45.32071; Fukushima NH, 2001, MOL BIOL CELL, V12, P2756, DOI 10.1091/mbc.12.9.2756; Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004; HOPPINS S, 2007, IN PRESS ANN REV BIO; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Nakamura N, 2006, EMBO REP, V7, P1019, DOI 10.1038/sj.embor.7400790; Narayanan R, 2005, J CELL BIOL, V169, P117, DOI 10.1083/jcb.200502042; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Ramachandran R, 2007, EMBO J, V26, P559, DOI 10.1038/sj.emboj.7601491; Rube DA, 2004, MOL CELL BIOCHEM, V256, P331, DOI 10.1023/B:MCBI.0000009879.01256.f6; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922; Zhu PP, 2004, J BIOL CHEM, V279, P35967, DOI 10.1074/jbc.M404105200	20	560	572	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21583	21587		10.1074/jbc.C700083200	http://dx.doi.org/10.1074/jbc.C700083200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17553808	hybrid			2022-12-25	WOS:000248196800003
J	Krautz-Peterson, G; Camargo, S; Huggel, K; Verrey, F; Shoemaker, CB; Skelly, PJ				Krautz-Peterson, Greice; Camargo, Simone; Huggel, Katja; Verrey, Francois; Shoemaker, Charles B.; Skelly, Patrick J.			Amino acid transport in schistosomes - Characterization of the permease heavy chain SPRM1hc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER; MEMBRANE-TRANSPORT; SYSTEM L; MANSONI; TEGUMENT; EXPRESSION; SURFACE; SUPPRESSION; EXCHANGERS; CLONING	Schistosomes are human parasitic flatworms that constitute an important public health problem globally. Adult parasites live in the bloodstream where they import nutrients such as amino acids across their body surface (the tegument). One amino acid transporter, Schistosome Permease 1 light chain, SPRM1lc, a member of the glycoprotein-associated family of transporters (gpaAT), has been characterized in schistosomes. Only a single member of the SLC3 family of glycoproteins that associate with gpaATs is found following extensive searching of the genomes of Schistosoma mansoni and S. japonicum. In this report, we characterize this schistosome permease heavy chain (SPRM1hc) gene and protein. The 72-kDa gene product is predicted to possess a single transmembrane domain, a (beta alpha)(8) (TIM barrel) conformation and a catalytic triad. Xenopus oocytes functionally expressing SPRM1hc with SPRM1lc import phenylalanine, arginine, lysine, alanine, glutamine, histidine, tryptophan, and leucine. Biochemical characterization demonstrates that in Xenopus extracts and in schistosome extracts SPRM1hc is associated into a high molecular weight complex with SPRM1lc that is disrupted by reducing agents. Quantitative real-time PCR and Western analysis demonstrate that SPRM1hc is expressed in each schistosome life stage examined (eggs, cercariae, schistosomula, adult males and females). SPRM1hc is widely distributed throughout adult male and female worms as determined by immunolocalization. Consistent with the hypothesis that SPRM1hc functions to facilitate nutrient uptake from host blood, immunogold electron microscopy confirms that the protein is distributed on the host-interactive tegumental membranes. We propose that surface-exposed, host-interactive, nutrient-transporting proteins like the SPRM1 heterodimer are promising vaccine candidates.	Tufts Univ, Cummings Sch Vet Med, Dept Biomed Sci, Div Infect Dis,Mol Helminthol Lab, North Grafton, MA 01536 USA; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	Tufts University; University of Zurich	Skelly, PJ (corresponding author), 200 Westboro Rd, North Grafton, MA 01536 USA.	Patrick.Skelly@Tufts.edu		Verrey, Francois/0000-0003-3250-9824; Camargo, Simone/0000-0003-0091-7380	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056273, R01AI030026] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI056273, AI056273, N01 AI30026, R01 AI056273-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASCH HL, 1975, J PARASITOL, V61, P378, DOI 10.2307/3279026; ASCH HL, 1975, EXP PARASITOL, V38, P123, DOI 10.1016/0014-4894(75)90045-4; Bergquist R, 2002, ACTA TROP, V82, P183, DOI 10.1016/S0001-706X(02)00048-7; Braschi S, 2006, PROTEOMICS, V6, P1471, DOI 10.1002/pmic.200500368; Broer S, 2002, CELL BIOCHEM BIOPHYS, V36, P155, DOI 10.1385/CBB:36:2-3:155; Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Da Lage JL, 2004, CELL MOL LIFE SCI, V61, P97, DOI 10.1007/s00018-003-3334-y; FRIPP PJ, 1967, COMP BIOCHEM PHYSIOL, V23, P893, DOI 10.1016/0010-406X(67)90349-0; Hackett F, 1993, Methods Mol Biol, V21, P89; Janecek S, 1997, J MOL EVOL, V45, P322, DOI 10.1007/PL00006236; Jiang JW, 1996, EXP PARASITOL, V82, P201, DOI 10.1006/expr.1996.0025; Krautz-Peterson G, 2007, MOL BIOCHEM PARASIT, V153, P194, DOI 10.1016/j.molbiopara.2007.03.006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; MORRIS GP, 1968, J PARASITOL, V54, P15, DOI 10.2307/3276867; Nagano N, 2002, J MOL BIOL, V321, P741, DOI 10.1016/S0022-2836(02)00649-6; Overhoff M, 2005, J MOL BIOL, V348, P871, DOI 10.1016/j.jmb.2005.03.012; Palacin M, 2005, PHYSIOLOGY, V20, P112, DOI 10.1152/physiol.00051.2004; PAPPAS PW, 1975, EXP PARASITOL, V37, P469, DOI 10.1016/0014-4894(75)90016-8; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; SILK M H, 1969, South African Journal of Medical Sciences, V34, P1; Skelly PJ, 1996, P NATL ACAD SCI USA, V93, P3642, DOI 10.1073/pnas.93.8.3642; SKELLY PJ, 1994, J BIOL CHEM, V269, P4247; Skelly PJ, 2000, INT J PARASITOL, V30, P625, DOI 10.1016/S0020-7519(00)00031-X; Skelly PJ, 2003, INT J PARASITOL, V33, P363, DOI 10.1016/S0020-7519(03)00030-4; Skelly PJ, 2001, PARASITOLOGY, V123, P277, DOI 10.1017/S0031182001008484; Skelly PJ, 2001, PARASITOLOGY, V122, P67, DOI 10.1017/S0031182000007071; Skelly PJ, 1999, PARASITOLOGY, V119, P569, DOI 10.1017/S0031182099005181; Skelly PJ, 1998, PARASITOL TODAY, V14, P402, DOI 10.1016/S0169-4758(98)01319-2; SMITH JH, 1969, AM J TROP MED HYG, V18, P28, DOI 10.4269/ajtmh.1969.18.28; van Balkom BWM, 2005, J PROTEOME RES, V4, P958, DOI 10.1021/pr050036w; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; Verrey F, 2003, PFLUG ARCH EUR J PHY, V445, P529, DOI 10.1007/S00424-002-0973-Z; WARREN KS, 1982, IMMUNOL REV, V61, P189, DOI 10.1111/j.1600-065X.1982.tb00377.x; WILSON RA, 1974, PARASITOLOGY, V68, P239, DOI 10.1017/S0031182000045765; ZHONG C, 1995, PARASITOLOGY, V110, P383, DOI 10.1017/S0031182000064726	39	35	36	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21767	21775		10.1074/jbc.M703512200	http://dx.doi.org/10.1074/jbc.M703512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545149	hybrid, Green Accepted			2022-12-25	WOS:000248196800024
J	Sevostyanova, A; Feklistov, A; Barinova, N; Heyduk, E; Bass, I; Klimasauskas, S; Heyduk, T; Kulbachinskiy, A				Sevostyanova, Anastasiya; Feklistov, Andrey; Barinova, Nataliya; Heyduk, Ewa; Bass, Irina; Klimasauskas, Saulius; Heyduk, Tomasz; Kulbachinskiy, Andrey			Specific recognition of the-10 promoter element by the free RNA polymerase sigma subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC INTERACTION; AROMATIC-AMINO-ACIDS; ESCHERICHIA-COLI; NONTEMPLATE STRAND; TRANSCRIPTION INITIATION; CRYSTAL-STRUCTURE; CROSS-LINKING; ANGSTROM RESOLUTION; CONSERVED REGION-2; STRUCTURAL BASIS	Bacterial RNA polymerase holoenzyme relies on its sigma subunit for promoter recognition and opening. In the holoenzyme, regions 2 and 4 of the sigma subunit are positioned at an optimal distance to allow specific recognition of the -10 and -35 promoter elements, respectively. In free sigma, the promoter binding regions are positioned closer to each other and are masked for interactions with the promoter, with sigma region 1 playing a role in the masking. To analyze the DNA-binding properties of the free sigma, we selected single-stranded DNA aptamers that are specific to primary sigma subunits from several bacterial species, including Escherichia coli and Thermus aquaticus. The aptamers share a consensus motif, TGTAGAAT, that is similar to the extended -10 promoter. We demonstrate that recognition of this motif by sigma region 2 occurs without major structural rearrangements of sigma observed upon the holoenzyme formation and is not inhibited by sigma regions 1 and 4. Thus, the complex process of the -10 element recognition by RNA polymerase holoenzyme can be reduced to a simple system consisting of an isolated sigma subunit and a short aptamer oligonucleotide.	Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia; St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Inst Biotechnol, LT-02241 Vilnius, Lithuania	Russian Academy of Sciences; Saint Louis University; Vilnius University	Kulbachinskiy, A (corresponding author), Russian Acad Sci, Inst Mol Genet, 2 Kurchatov Sq, Moscow 123182, Russia.	akulb@img.ras.ru	Kulbachinskiy, Andrey/P-5401-2016; Sevostiyanova, Anastasia/G-4935-2011; Klimasauskas, Saulius/M-3053-2016	Kulbachinskiy, Andrey/0000-0002-2292-6424; Klimasauskas, Saulius/0000-0002-1395-2030	NIGMS NIH HHS [GM50514] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R21GM050514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; Camarero JA, 2002, P NATL ACAD SCI USA, V99, P8536, DOI 10.1073/pnas.132033899; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; Fedoriw AM, 1998, BIOCHEMISTRY-US, V37, P11971, DOI 10.1021/bi980980o; Feklistov A, 2006, MOL CELL, V23, P97, DOI 10.1016/j.molcel.2006.06.010; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gowrishankar J, 2003, J BACTERIOL, V185, P2673, DOI 10.1128/JB.185.8.2673-2679.2003; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Heyduk E, 2002, BIOCHEMISTRY-US, V41, P2876, DOI 10.1021/bi012133i; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; Kulbachinskiy A, 1999, FEBS LETT, V454, P71, DOI 10.1016/S0014-5793(99)00778-4; Kulbachinskiy A, 2004, J BACTERIOL, V186, P7818, DOI 10.1128/JB.186.22.7818-7820.2004; Lim HM, 2001, P NATL ACAD SCI USA, V98, P14849, DOI 10.1073/pnas.261517398; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Mustaev A, 2003, METHOD ENZYMOL, V371, P191; Roberts CW, 1996, CELL, V86, P495; Rudakova EA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P640; Sanderson A, 2003, FEBS LETT, V544, P199, DOI 10.1016/S0014-5793(03)00500-3; SAVINKOVA L K, 1988, Molekulyarnaya Biologiya (Moscow), V22, P807; SETHI VS, 1970, FEBS LETT, V8, P236, DOI 10.1016/0014-5793(70)80274-5; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; Sorenson MK, 2006, P NATL ACAD SCI USA, V103, P16722, DOI 10.1073/pnas.0606482103; Sorenson MK, 2004, MOL CELL, V14, P127, DOI 10.1016/S1097-2765(04)00150-9; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; Young BA, 2001, CELL, V105, P935, DOI 10.1016/S0092-8674(01)00398-1; Zenkin N, 2007, EMBO J, V26, P955, DOI 10.1038/sj.emboj.7601555	41	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22033	22039		10.1074/jbc.M702495200	http://dx.doi.org/10.1074/jbc.M702495200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17535803	hybrid			2022-12-25	WOS:000248196800050
J	Van Acker, GJD; Perides, G; Weiss, ER; Das, S; Tsichlis, PN; Steer, ML				Van Acker, Gijs J. D.; Perides, George; Weiss, Eric R.; Das, Santasabuj; Tsichlis, Philip N.; Steer, Michael L.			Tumor progression locus-2 is a critical regulator of pancreatic and lung inflammation during acute pancreatitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; ACTIVATION; MODEL; NF-KAPPA-B1/P105; PHOSPHORYLATION; MACROPHAGES; INDUCTION; CELLS	Pancreatic and lung inflammation during acute pancreatitis is a poorly understood, but clinically important, phenomenon. The proto-oncogene Tpl2 (tumor progression locus-2) has recently been shown to have important immunomodulatory effects on some inflammatory processes, but its importance to pancreatitis has not been previously examined. Our studies were designed to (a) define the effects of Tpl2 on pancreatic and lung inflammation during pancreatitis and (b) identify mechanisms and cell types responsible for those effects. We examined pancreatitis-associated Tpl2 effects in wild type and Tpl2(-/-) mice subjected to either secretagogue-induced or bile salt-induced pancreatitis. To determine the myeloid or non-myeloid lineage of cells responsible for the Tpl2 effects, we used Tpl2(-/-) chimeric mice generated by lethal irradiation followed by bone marrow transplantation. Mechanisms responsible for the effects of Tpl2 ablation on caerulein-induced proinflammatory events were evaluated under in vivo and in vitro conditions using the techniques of electrophoretic mobility shift assay, immunoblot analysis, and quantitative reverse transcription-PCR. We found that Tpl2 ablation markedly reduced pancreatic and lung inflammation in these two dissimilar models of pancreatitis, but it did not alter pancreatic injury/necrosis in either model. The reduction in caerulein-induced pancreatic inflammation is dependent upon Tpl2 ablation in non-myeloid cells and is associated with both in vivo and in vitro inhibition of MEK, JNK, and AP-1 activation and the expression of MCP-1, MIP-2, and interleukin-6. Non-myeloid cell expression of Tpl2 regulates pancreatic inflammation during pancreatitis by mediating proinflammatory signals and the generation of neutrophil chemoattracting factors.	Tufts Univ, New England Med Ctr, Dept Surg, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Tufts University	Steer, ML (corresponding author), Tufts Univ, New England Med Ctr, Dept Surg, 860 Washington St, Boston, MA 02111 USA.	msteer@tufts-nemc.org			NATIONAL CANCER INSTITUTE [R01CA095431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031396, R37DK031396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA015410] Funding Source: NIH RePORTER; NCI NIH HHS [CA095431] Funding Source: Medline; NIAAA NIH HHS [AA015410] Funding Source: Medline; NIDDK NIH HHS [DK031396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Algul H, 2002, PANCREATOLOGY, V2, P503, DOI 10.1159/000066090; Babu GR, 2006, BBA-MOL CELL RES, V1763, P174, DOI 10.1016/j.bbamcr.2005.12.010; Blinman TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1993, DOI 10.1152/ajpcell.2000.279.6.C1993; Chen XQ, 2002, GASTROENTEROLOGY, V122, P448, DOI 10.1053/gast.2002.31060; Cho JH, 2005, P NATL ACAD SCI USA, V102, P2350, DOI 10.1073/pnas.0409856102; Cui YZ, 2002, BONE MARROW TRANSPL, V30, P843, DOI 10.1038/sj.bmt.1703766; Das S, 2005, J BIOL CHEM, V280, P23748, DOI 10.1074/jbc.M412837200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Han XN, 2004, AM J PHYSIOL-LUNG C, V286, pL259, DOI 10.1152/ajplung.00187.2003; Haqqani AS, 1999, ANAL BIOCHEM, V273, P126, DOI 10.1006/abio.1999.4206; Hietaranta AJ, 2001, BIOCHEM BIOPH RES CO, V280, P388, DOI 10.1006/bbrc.2000.4120; Jaffrey C, 1999, PANCREAS, V19, P377, DOI 10.1097/00006676-199911000-00009; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281; LAMPEL M, 1977, VIRCHOWS ARCH A, V373, P97, DOI 10.1007/BF00432156; Matute-Bello G, 2004, J IMMUNOL METHODS, V292, P25, DOI 10.1016/j.jim.2004.05.010; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Perides G, 2005, GUT, V54, P1461, DOI 10.1136/gut.2004.062919; Perides G, 2005, AM J PHYSIOL-GASTR L, V289, pG713, DOI 10.1152/ajpgi.00519.2004; POWERS RE, 1986, J CLIN INVEST, V77, P1668, DOI 10.1172/JCI112484; Sharma A, 2005, AM J PHYSIOL-GASTR L, V288, pG388, DOI 10.1152/ajpgi.00341.2004; Steinle AU, 1999, GASTROENTEROLOGY, V116, P420, DOI 10.1016/S0016-5085(99)70140-X; Van Acker GJ, 2006, GASTROENTEROLOGY, V130, pA708; Yamanaka K, 1997, AM J PHYSIOL-GASTR L, V272, pG23, DOI 10.1152/ajpgi.1997.272.1.G23	27	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22140	22149		10.1074/jbc.M702225200	http://dx.doi.org/10.1074/jbc.M702225200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17537724	hybrid			2022-12-25	WOS:000248196800060
J	Wu, DF; Koch, T; Liang, YJ; Stumm, R; Schulz, S; Schroder, H; Hollt, V				Wu, Dai-Fei; Koch, Thomas; Liang, Ying-Jian; Stumm, Ralf; Schulz, Stefan; Schroeder, Helmut; Hoellt, Volker			Membrane glycoprotein M6a interacts with the mu-opioid receptor and facilitates receptor endocytosis and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MORPHINE-INDUCED ANALGESIA; MESSENGER-RNA EXPRESSION; CENTRAL-NERVOUS-SYSTEM; PHYSIOLOGICAL ADAPTATION; DEPENDENT ENDOCYTOSIS; PHOSPHOLIPASE D2; OPIATE DRUGS; GENE FAMILY; RAT CNS	Using a yeast two-hybrid screen, the neuronal membrane glycoprotein M6a, a member of the proteolipid protein family, was identified to be associated with the mu-opioid receptor (MOPr). Bioluminescence resonance energy transfer and co-immuno-precipitation experiments confirmed that M6a interacts agonist-independently with MOPr in human embryonic kidney 293 cells co-expressing MOPr and M6a. Co-expression of MOPr with M6a, but not with M6b or DM20, exists in many brain regions, further supporting a specific interaction between MOPr and M6a. After opioid treatment M6a co-internalizes and then co-recycles with MOPr to cell surface in transfected human embryonic kidney 293 cells. Moreover, the interaction of M6a and MOPr augments constitutive and agonist-dependent internalization as well as the recycling rate of mu-opioid receptors. On the other hand, overexpression of a M6a-negative mutant prevents mu-opioid receptor endocytosis, demonstrating an essential role of M6a in receptor internalization. In addition, we demonstrated the interaction of M6a with a number of other G protein-coupled receptors (GPCRs) such as the delta-opioid receptor, cannabinoid receptor CB1, and somatostatin receptor sst2A, suggesting that M6a might play a general role in the regulation of certain GPCRs. Taken together, these data provide evidence that M6a may act as a scaffolding molecule in the regulation of GPCR endocytosis and intracellular trafficking.	Otto Von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Koch, T (corresponding author), Otto Von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany.	thomas.koch@Medizin.Uni-Magdeburg.de	Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Alfonso J, 2005, P NATL ACAD SCI USA, V102, P17196, DOI 10.1073/pnas.0504262102; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Feng GJ, 2003, J BIOL CHEM, V278, P33400, DOI 10.1074/jbc.M305866200; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Guang W, 2004, MOL PHARMACOL, V66, P1285, DOI 10.1124/mol.66.5.; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Heydorn A, 2004, J BIOL CHEM, V279, P54291, DOI 10.1074/jbc.M406169200; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Ko MCH, 2003, J PHARMACOL EXP THER, V306, P179, DOI 10.1124/jpet.103.050625; Koch T, 2006, J NEUROCHEM, V97, P365, DOI 10.1111/j.1471-4159.2006.03736.x; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Koch T, 2003, J BIOL CHEM, V278, P9979, DOI 10.1074/jbc.M206709200; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; LAGENAUR C, 1992, J NEUROBIOL, V23, P71, DOI 10.1002/neu.480230108; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Liang YJ, 2007, MOL PHARMACOL, V71, P123, DOI 10.1124/mol.106.026062; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; MANSOUR A, 1994, BRAIN RES, V643, P245, DOI 10.1016/0006-8993(94)90031-0; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Mukobata S, 2002, BIOCHEM BIOPH RES CO, V297, P722, DOI 10.1016/S0006-291X(02)02284-2; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Pfeiffer M, 2003, J BIOL CHEM, V278, P51630, DOI 10.1074/jbc.M307095200; Qiu Y, 2003, J BIOL CHEM, V278, P36733, DOI 10.1074/jbc.M305857200; Roussel G, 1998, J NEUROCYTOL, V27, P695, DOI 10.1023/A:1006924400768; Shenoy Sudha K, 2005, Sci STKE, V2005, pcm10, DOI 10.1126/stke.2005/308/cm10; Stumm RK, 2004, J COMP NEUROL, V469, P107, DOI 10.1002/cne.10997; Stumm RK, 2001, J NEUROSCI, V21, P798, DOI 10.1523/JNEUROSCI.21-03-00798.2001; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; von Zastrow M, 2004, NEUROPHARMACOLOGY, V47, P286, DOI 10.1016/j.neuropharm.2004.05.007; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; Wang W, 2003, J BIOL CHEM, V278, P36848, DOI 10.1074/jbc.M301540200; Werner H, 2001, MOL CELL NEUROSCI, V18, P593, DOI 10.1006/mcne.2001.1044; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Williams JT, 2001, PHYSIOL REV, V81, P299, DOI 10.1152/physrev.2001.81.1.299; YAN YM, 1993, NEURON, V11, P423, DOI 10.1016/0896-6273(93)90147-J; Yan YM, 1996, J COMP NEUROL, V370, P465, DOI 10.1002/(SICI)1096-9861(19960708)370:4<465::AID-CNE4>3.0.CO;2-2; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	49	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22239	22247		10.1074/jbc.M700941200	http://dx.doi.org/10.1074/jbc.M700941200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17548356	hybrid			2022-12-25	WOS:000248196800069
J	Jin, W; Yun, C; Kwak, MK; Kim, TA; Kim, SJ				Jin, W.; Yun, C.; Kwak, M-K; Kim, T-A; Kim, S-J			TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling	ONCOGENE			English	Article						neurotrophin receptors; TrkC; TGF-beta; cancer; signaling; ETV6-NTRK3	ETV6-NTRK3 GENE FUSION; GASTRIC-CANCER CELLS; HUMAN NEUROBLASTOMAS; EXPRESSION; TUMORS; NEUROTROPHINS; INHIBITOR; PROGNOSIS; PROSTATE; COMPLEX	Growing evidence suggests that overexpression of TrkC, a member of the Trk family of neurotrophin receptors, could drive tumorigenesis, invasion and metastatic capability in cancer cells. However, relatively little is known about the mechanism of TrkC-mediated oncogenesis. The TrkC gene is a partner of the Tel-TrkC (ETV6-NTRK3) chimeric tyrosine kinase, a potent oncoprotein expressed in tumors derived from multiple cell lineages. Recently, we have shown that ETV6-NTRK3 suppresses transforming growth factor-beta (TGF-beta) signaling by directly binding to the type II TGF-beta receptor (TbRII). Here, we report that expression of TrkC also suppresses TGF-beta-induced Smad2/3 phosphorylation and transcriptional activation. Silencing TrkC expression by small interfering RNA in the highly metastatic 4T1 mammary tumor cell line expressing endogenous TrkC significantly enhanced TGF-beta-induced Smad2/3 phosphorylation and restored TGF-b growth inhibitory activity. In contrast, expression of TrkC in 67NR cells, in which TrkC is not expressed, suppressed TGF-beta transcriptional activation. Moreover, we show that TrkC directly binds to the TbRII, thereby preventing it from interacting with the type I TGF-beta receptor (T beta RI). These results indicate that TrkC is an inhibitor of TGF-beta tumor suppressor activity.	[Jin, W.; Yun, C.; Kwak, M-K; Kim, T-A; Kim, S-J] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Kim, S-J] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Lab Cell Regulat & Carcinogenesis, Inchon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Gachon University	Kim, SJ (corresponding author), NCI, Lab Canc Biol & Genet, NIH, Bldg 37,Room 5046D,9000 Rockville Pike, Bethesda, MD 20892 USA.	kims@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Chang J, 1997, CANCER RES, V57, P2856; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; Guate JL, 1999, BJU INT, V84, P495; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hisaoka M, 2002, J PATHOL, V197, P661, DOI 10.1002/path.1138; Horton CD, 2001, J NEUROCHEM, V76, P201, DOI 10.1046/j.1471-4159.2001.00017.x; Jin W, 2005, P NATL ACAD SCI USA, V102, P16239, DOI 10.1073/pnas.0503137102; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Lee BI, 2001, CANCER RES, V61, P931; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Rickert CH, 2004, J NEUROPATH EXP NEUR, V63, P1211, DOI 10.1093/jnen/63.12.1211; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; Ryden M, 1996, BRIT J CANCER, V74, P773, DOI 10.1038/bjc.1996.435; Satoh F, 2001, INT J UROL, V8, pS28, DOI 10.1046/j.1442-2042.2001.00331.x; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamashiro DJ, 1997, EUR J CANCER, V33, P2054, DOI 10.1016/S0959-8049(97)00309-2; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	32	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7684	7691		10.1038/sj.onc.1210571	http://dx.doi.org/10.1038/sj.onc.1210571			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17546043				2022-12-25	WOS:000251537800010
J	Yang, HY; Wen, YY; Lin, YI; Pham, L; Su, CH; Yang, H; Chen, J; Lee, MH				Yang, H-Y; Wen, Y-Y; Lin, Y-I; Pham, L.; Su, C-H; Yang, H.; Chen, J.; Lee, M-H			Roles for negative cell regulator 14-3-3 sigma in control of MDM2 activities	ONCOGENE			English	Article						MDM2; 14-3-3; NEDDylation; p53; RB	NUCLEAR EXPORT; DNA-DAMAGE; P53; PROTEIN; CANCER; DOMAIN; AMPLIFICATION; PROGRESSION; INHIBITOR	The 14-3-3 sigma, upregulated by p53 in response to DNA damage, can have a positive-feedback impact driving p53 activities and is a human cancer epithelial marker downregulated in various tumors. However, the precise roles of 14-3-3 sigma during tumorigenesis are not well characterized. Here, we show that 14-3-3 sigma is a critical regulator of murine double minute oncogene (MDM2). 14-3-3 sigma interacts with MDM2 at the RING domain. The C-terminal region of 14-3-3 sigma binds to MDM2 very efficiently. Importantly, 14-3-3 sigma overexpression leads to destabilization of MDM2 through enhancing MDM2 self-ubiquitination and accelerating turnover rate. Conversely, loss of 14-3-3 sigma results in a significant increase in MDM2 protein. Moreover, live-cell images indicated that 14-3-3 sigma can affect the location of MDM2 from the nucleus to the cytoplasm, and that MDM2-mediated cytoplasmic localization of p53 can be reversed by the presence of 14-3-3 sigma. Significantly, we further showed that 14-3-3 sigma causes MDM2 downregulation, thereby stabilizing p53 and inhibiting tumor growth in animal tumors. Also, 14-3-3 sigma blocks MDM2-mediated retinoblastoma degradation and p53 NEDDylation. Our results provide evidence that 14-3-3 sigma is a pivotal MDM2 regulator involved in blocking a variety of activities of MDM2.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Gen & Dev, Houston, TX USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA; Zhongshan Univ, Dept Pathophysiol, Guangzhou, Peoples R China; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; Sun Yat Sen University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhlee@mdanderson.org		Phan, Liem/0000-0003-1194-216X; Lee, Mong-Hong/0000-0001-8675-8215	NATIONAL CANCER INSTITUTE [R01CA089266, P30CA016672, R56CA089266] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA089266, R56 CA089266, R01CA089266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MH, 2006, SEMIN CANCER BIOL, V16, P225, DOI 10.1016/j.semcancer.2006.03.009; Miwa S, 2006, BIOCHEM BIOPH RES CO, V340, P54, DOI 10.1016/j.bbrc.2005.11.148; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Wang LK, 2005, HANDB ENVIRON ENG, V2, P1; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang HL, 2006, CANCER RES, V66, P3096, DOI 10.1158/0008-5472.CAN-05-3620; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	23	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7355	7362		10.1038/sj.onc.1210540	http://dx.doi.org/10.1038/sj.onc.1210540			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17546054				2022-12-25	WOS:000250955700007
J	Zeira, E; Manevitch, A; Manevitch, Z; Kedar, E; Gropp, M; Daudi, N; Barsuk, R; Harati, M; Yotvat, H; Troilo, PJ; Griffiths, TG; Pacchione, SJ; Roden, DF; Niu, Z; Nussbaum, O; Zamir, G; Papo, O; Hemo, I; Lewis, A; Galun, E				Zeira, Evelyne; Manevitch, Alexandra; Manevitch, Zakharia; Kedar, Eli; Gropp, Michal; Daudi, Nili; Barsuk, Rimma; Harati, Menahem; Yotvat, Hagit; Troilo, Philip J.; Griffiths, Thomas G., II; Pacchione, Stephen J.; Roden, Dana F.; Niu, Zhutian; Nussbaum, Ofer; Zamir, Gideon; Papo, Orit; Hemo, Izhack; Lewis, Aaron; Galun, Eithan			Femtosecond laser: a new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization	FASEB JOURNAL			English	Article						gene delivery; vaccination; HBV; antitumor	ELECTROPORATION; THERAPY; SKIN; VACCINATION; VACCINES; BIOLOGY; MOUSE; MODEL; CELL	A femtosecond laser beam gene transduction (SG-LBGT) system is described as a novel and efficient method of intradermal (i.d.)non viralgene delivery in mice by permeabilizing cells utilizing femtosecond laser pulses. Using this approach, significant gene expression and efficient dermal transduction lasting for > 7 months were obtained. The ability of this new DNA gene transfer method to enhance genetic vaccination was tested in BALB/C mice. A single i.d. injection of a plasmid (10 mu g) containing the hepatitis B virus (HBV) surface antigen (HBsAg), followed by pulses of laser, induced high titers of HBsAg-specific antibodies lasting for > 210 days and increased levels of IgG1, IgG2a, IFN gamma, and IL-4, indicating the activation of both Th1 and Th2 cells. Moreover, mice vaccinated using the SG-LBGT followed by challenge with pHBV showed increased protection against viral challenge, as detected by decreased levels of HBV DNA, suggesting an efficient Th1 effect against HBV-infected replicating cells. Tumor growth retardation was induced in vaccinated mice challenged with an HBsAg-expressing syngeneic tumor. In most of the parameters tested, administration of plasmid followed by laser application was significantly more effective and prolonged than that of plasmid alone. Tissue damage was not detected and integration of the plasmid into the host genomic DNA probably did not occur. We suggest that the LBGT method is an efficient and safe technology for in vivo gene expression and vaccination and emphasizes its potential therapeutic applications for i.d. nonviral gene delivery.	Hadassah Hebrew Univ Hosp, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem Engn & Comp Sci, Selim & Rachel Benin Sch, Dept Appl Phys, Fac Nat Sci, Jerusalem, Israel; Hadassah Laser Ctr, Dept Ophthalmol, Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Liver Unit, Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91010 Jerusalem, Israel; Merck & Co Inc, Merck Res Labs, Dept Biol Safety Assessment, West Point, PA USA; XTL Biopharmaceut Ltd, Rehovot, Israel; Hadassah Hebrew Univ Hosp, Dept Surg, Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Dept Pathol, Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Merck & Company; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Galun, E (corresponding author), Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, POB 12000, IL-91120 Jerusalem, Israel.	eithang@hadassah.org.il	Galun, Eithan/AAD-9117-2022	Galun, Eithan/0000-0002-6243-6702				BERNS MW, 1981, SCIENCE, V213, P505, DOI 10.1126/science.7017933; BERNS MW, 1991, INT REV CYTOL, V129, P1; Chow YH, 1998, J IMMUNOL, V160, P1320; Donnelly JJ, 1995, ANN NY ACAD SCI, V772, P40, DOI 10.1111/j.1749-6632.1995.tb44730.x; Duguez S, 2002, AM J PHYSIOL-ENDOC M, V282, pE802, DOI 10.1152/ajpendo.00343.2001; Glasspool-Malone J, 2000, MOL THER, V2, P140, DOI 10.1006/mthe.2000.0107; Haupt K, 2002, EXP BIOL MED, V227, P227, DOI 10.1177/153537020222700403; Honigman A, 2001, MOL THER, V4, P239, DOI 10.1006/mthe.2001.0437; Ilan E, 1999, HEPATOLOGY, V29, P553, DOI 10.1002/hep.510290228; Ilan Y, 2000, BONE MARROW TRANSPL, V26, P633, DOI 10.1038/sj.bmt.1702571; Ketzinel-Gilad M, 2006, HEPATOL RES, V34, P228, DOI 10.1016/j.hepres.2006.01.008; Kim JJ, 2001, CLIN CANCER RES, V7, p882S; Kwissa M, 2000, VACCINE, V18, P2337, DOI 10.1016/S0264-410X(00)00030-X; Ledwith BJ, 2000, INTERVIROLOGY, V43, P258, DOI 10.1159/000053993; Lee WR, 2006, J CONTROL RELEASE, V115, P344, DOI 10.1016/j.jconrel.2006.08.012; Lucas ML, 2001, DNA CELL BIOL, V20, P183, DOI 10.1089/104454901300069040; Pavselj N, 2005, J CONTROL RELEASE, V106, P407, DOI 10.1016/j.jconrel.2005.05.003; Regnier V, 2000, J CONTROL RELEASE, V67, P337, DOI 10.1016/S0168-3659(00)00223-6; ROBERTSON JS, 1994, VACCINE, V12, P1526, DOI 10.1016/0264-410X(94)90077-9; SMITH HA, 1994, VACCINE, V12, P1515, DOI 10.1016/0264-410X(94)90075-2; Spirito F, 2001, J GENE MED, V3, P21, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM156>3.0.CO;2-I; Stevenson D, 2006, OPT EXPRESS, V14, P7125, DOI 10.1364/OE.14.007125; Tirlapur UK, 2002, NATURE, V418, P290, DOI 10.1038/418290a; van Slooten ML, 2001, BBA-MOL CELL BIOL L, V1531, P99, DOI 10.1016/S1388-1981(01)00092-0; Vogel JC, 2000, HUM GENE THER, V11, P2253, DOI 10.1089/104303400750035780; WEICHSELBAUM RR, 1994, CANCER RES, V54, P4266; Weiss L, 2002, CYTOKINE, V19, P85, DOI 10.1006/cyto.2002.1956; Wells DJ, 2004, GENE THER, V11, P1363, DOI 10.1038/sj.gt.3302337; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Zeira E, 2003, MOL THER, V8, P342, DOI 10.1016/S1525-0016(03)00184-9	30	33	36	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3522	3533		10.1096/fj.06-7528com	http://dx.doi.org/10.1096/fj.06-7528com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575264				2022-12-25	WOS:000250517800015
J	Chen, M; Margittai, M; Chen, J; Langen, R				Chen, Min; Margittai, Martin; Chen, Jeannie; Langen, Ralf			Investigation of alpha-synuclein fibril structure by site-directed spin labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARALLEL BETA-SHEET; ALZHEIMERS-DISEASE; T4 LYSOZYME; PARKINSONS; PROTEIN; AGGREGATION; FILAMENTS; MUTATION; RESONANCE; RESIDUES	The misfolding and fibril formation of alpha- synuclein plays an important role in neurodegenerative diseases such as Parkinson disease. Here we used electron paramagnetic resonance spectroscopy, together with site-directed spin labeling, to investigate the structural features of alpha- synuclein fibrils. We generated fibrils from a total of 83 different spin- labeled derivatives and observed single-line, exchange-narrowed EPR spectra for the majority of all sites located within the core region of alpha- synuclein fibrils. Such exchange narrowing requires the orbital overlap between multiple spin labels in close contact. The core region of alpha- synuclein fibrils must therefore be arranged in a parallel, inregister structure wherein same residues from different molecules are stacked on top of each other. This parallel, in-register core region extends from residue 36 to residue 98 and is tightly packed. Only a few sites within the core region, such as residues 62-67 located at the beginning of the NAC region, as well as the N- and C- terminal regions outside the core region, are significantly less ordered. Together with the accessibility measurements that suggest the location of potential alpha- sheet regions within the fibril, the data provide significant structural constraints for generating three-dimensional models. Furthermore, the data support the emerging view that parallel, in-register structure is a common feature shared by a number of naturally occurring amyloid fibrils.	Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Langen, R (corresponding author), Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, 1501 San Pablo St, Los Angeles, CA 90033 USA.	langen@usc.edu	Margittai, Martin/D-5039-2014	Margittai, Martin/0000-0003-1903-5927	NIA NIH HHS [P50 AG05142] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005142] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Berriman J, 2003, P NATL ACAD SCI USA, V100, P9034, DOI 10.1073/pnas.1530287100; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chan JCC, 2005, BIOCHEMISTRY-US, V44, P10669, DOI 10.1021/bi050724t; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Dedmon MM, 2005, J AM CHEM SOC, V127, P476, DOI 10.1021/ja044834j; Del Mar C, 2005, P NATL ACAD SCI USA, V102, P15477, DOI 10.1073/pnas.0507405102; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Duda JE, 2000, J NEUROPATH EXP NEUR, V59, P830, DOI 10.1093/jnen/59.9.830; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Hanson P, 1996, J AM CHEM SOC, V118, P7618, DOI 10.1021/ja961025u; Heise H, 2005, P NATL ACAD SCI USA, V102, P15871, DOI 10.1073/pnas.0506109102; Hoyer W, 2004, BIOCHEMISTRY-US, V43, P16233, DOI 10.1021/bi048453u; Hoyer WG, 2004, J MOL BIOL, V340, P127, DOI 10.1016/j.jmb.2004.04.051; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hustedt EJ, 1997, BIOPHYS J, V72, P1861, DOI 10.1016/S0006-3495(97)78832-5; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IWATA K, 2006, P NATL ACAD SCI US; Jayasinghe SA, 2004, J BIOL CHEM, V279, P48420, DOI 10.1074/jbc.M406853200; Jellinger KA, 2003, ACTA NEUROPATHOL, V106, P191, DOI 10.1007/s00401-003-0725-y; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lajzerowicz-Bonneteau J., 1976, SPIN LABELING, P239, DOI [10.1016/B978-0-12-092350-2.50011-4, DOI 10.1016/B978-0-12-092350-2.50011-4]; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Li WX, 2005, P NATL ACAD SCI USA, V102, P2162, DOI 10.1073/pnas.0406976102; Liu CW, 2005, J BIOL CHEM, V280, P22670, DOI 10.1074/jbc.M501508200; LUCKHURST GR, 1966, MOL PHYS, V10, P543, DOI 10.1080/00268976600101481; Margittai M, 2004, P NATL ACAD SCI USA, V101, P10278, DOI 10.1073/pnas.0401911101; Margittai M, 2006, J BIOL CHEM, V281, P37820, DOI 10.1074/jbc.M605336200; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Masuda M, 2006, FEBS LETT, V580, P1775, DOI 10.1016/j.febslet.2006.02.032; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Miake H, 2002, J BIOL CHEM, V277, P19213, DOI 10.1074/jbc.M110551200; Molin Y. N., 1980, SPIN EXCHANGE; Murray IVJ, 2003, BIOCHEMISTRY-US, V42, P8530, DOI 10.1021/bi027363r; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Norris EH, 2004, CURR TOP DEV BIOL, V60, P17; PAKE GE, 1948, J CHEM PHYS, V16, P327, DOI 10.1063/1.1746878; Pawar AP, 2005, J MOL BIOL, V350, P379, DOI 10.1016/j.jmb.2005.04.016; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Shewmaker F, 2006, P NATL ACAD SCI USA, V103, P19754, DOI 10.1073/pnas.0609638103; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Smith D, 2001, LAB ANIM-UK, V35, P117, DOI 10.1258/0023677011911444; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	69	188	191	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24970	24979		10.1074/jbc.M700368200	http://dx.doi.org/10.1074/jbc.M700368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17573347	hybrid			2022-12-25	WOS:000248933000053
J	Marshall-Clarke, S; Downes, JE; Haga, IR; Bowie, AG; Borrow, P; Pennock, JL; Grencis, RK; Rothwell, P				Marshall-Clarke, Stuart; Downes, Joan E.; Haga, Ismar R.; Bowie, Andrew G.; Borrow, Persephone; Pennock, Joanne L.; Grencis, Richard K.; Rothwell, Paul			Polyinosinic acid is a ligand for toll-like receptor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; HOST-DEFENSE; ACTIVATION; RECOGNITION; VIRUS; CELLS; INTERFERON; INFECTION; RESPONSES	Innate immune responses are critical in controlling viral infections. Viral proteins and nucleic acids have been shown to be recognized by pattern recognition receptors of the Toll-like receptor (TLR) family, triggering downstream signaling cascades that lead to cellular activation and cytokine production. Viral DNA is sensed by TLR9, and TLRs 3, 7, and 8 have been implicated in innate responses to RNA viruses by virtue of their ability to sense double-stranded (ds) RNA (TLR3) or single-stranded RNA (murine TLR7 and human TLR8). Viral and synthetic dsRNAs have also been shown to be a potent adjuvant, promoting enhanced adaptive immune responses, and this property is also dependent on their recognition by TLR3. It has recently been shown that mRNA that is largely single-stranded is a ligand for TLR3. Here we have investigated the ability of single-stranded homopolymeric nucleic acids to induce innate responses by murine immune cells. We show for the first time that polyinosinic acid (poly(I)) activates B lymphocytes, dendritic cells, and macrophages and that these responses are dependent on the expression of both TLR3 and the adaptor molecule, Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta(TRIF). We therefore conclude that TLR3 is able to sense both single-stranded RNA and dsRNA.	Univ Liverpool, Dept Human Anat & Cell Biol, Liverpool L69 3GE, Merseyside, England; Trinity Coll Dublin, Sch Biochem & Immunol, Dublin 2, Ireland; Univ Oxford, Jenner Inst, Oxford RG20 7NN, England; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Liverpool; Trinity College Dublin; University of Oxford; Jenner Institute; University of Manchester	Marshall-Clarke, S (corresponding author), Univ Liverpool, Dept Human Anat & Cell Biol, Ashton St, Liverpool L69 3GE, Merseyside, England.	stumc@liv.ac.uk	Haga, Ismar/C-7754-2013; Pennock, Jo/AGZ-1209-2022; Pennock, Joanne/O-7353-2014	Pennock, Jo/0000-0002-8304-2905; Pennock, Joanne/0000-0002-8304-2905; Borrow, Persephone/0000-0002-3877-9780; Bowie, Andrew/0000-0001-5316-4373; Downes, Joni/0000-0001-7135-8956				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Bieback K, 2002, J VIROL, V76, P8729, DOI 10.1128/JVI.76.17.8729-8736.2002; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Bowie AG, 2005, MOL IMMUNOL, V42, P859, DOI 10.1016/j.molimm.2004.11.007; Campa VM, 2005, INFLAMM RES, V54, P328, DOI 10.1007/s00011-005-1359-4; CARTER WA, 1974, SCIENCE, V186, P1172, DOI 10.1126/science.186.4170.1172; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; FIELD AK, 1967, P NATL ACAD SCI USA, V58, P2102, DOI 10.1073/pnas.58.5.2102; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lee HK, 2006, IMMUNITY, V24, P153, DOI 10.1016/j.immuni.2005.12.012; Loseke S, 2006, SCAND J IMMUNOL, V63, P264, DOI 10.1111/j.1365-3083.2006.01736.x; Marshall-Clarke S, 2006, EUR J IMMUNOL, V36, P95, DOI 10.1002/eji.200535331; Matsumoto M, 2004, MICROBIOL IMMUNOL, V48, P147, DOI 10.1111/j.1348-0421.2004.tb03500.x; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Tasker L, 1997, INT IMMUNOL, V9, P475, DOI 10.1093/intimm/9.4.475; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	27	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24759	24766		10.1074/jbc.M700188200	http://dx.doi.org/10.1074/jbc.M700188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17573354	hybrid			2022-12-25	WOS:000248933000031
J	Seo, MR; Lee, MJ; Heo, JH; Lee, YI; Kim, Y; Kim, SY; Lee, ES; Juhnn, YS				Seo, MiRan; Lee, Mi-Jeong; Heo, Jin Hee; Lee, Yun-Il; Kim, Yeni; Kim, So-Young; Lee, Eun-So; Juhnn, Yong-Sung			G protein beta gamma subunits augment UVB-induced apoptosis by stimulating the release of soluble heparin-binding epidermal growth factor from human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-INDUCED APOPTOSIS; FACTOR RECEPTOR TRANSACTIVATION; P38 MAPK; COUPLED RECEPTORS; TYROSINE KINASES; ULTRAVIOLET-IRRADIATION; EPITHELIAL-CELLS; PROHB-EGF; ACTIVATION; MEMBRANE	UV radiation induces various cellular responses by regulating the activity of many UV- responsive enzymes, including MAPKs. The beta gamma subunit of the heterotrimeric GTP-binding protein (G beta gamma) was found to mediate UV-induced p38 activation via epidermal growth factor receptor (EGFR). However, it is not known how G beta gamma mediates the UVB-induced activation of EGFR, and thus we undertook this study to elucidate the mechanism. Treatment of HaCaT-immortalized human keratinocytes with conditioned medium obtained from UVB-irradiated cells induced the phosphorylations of EGFR, p38, and ERK but not that of JNK. Blockade of heparin-binding EGF-like growth factor (HB-EGF) by neutralizing antibody or CRM197 toxin inhibited the UVB-induced activations of EGFR, p38, and ERK in normal human epidermal keratinocytes and in HaCaT cells. Treatment with HB-EGF also activated EGFR, p38, and ERK. UVB radiation stimulated the processing of pro-HB-EGF and increased the secretion of soluble HB-EGF in medium, which was quantified by immunoblotting and protein staining. In addition, treatment with CRM179 toxin blocked UV-induced apoptosis, but HB-EGF augmented this apoptosis. Moreover, UVB-induced apoptosis was reduced by inhibiting EGFR or p38. The overexpression of G beta(1)gamma(2) increased EGFR-activating activity and soluble HB-EGF content in conditioned medium, but the sequestration of G beta gamma by the carboxyl terminus of G protein-coupled receptor kinase 2 (GRK2ct) produced the opposite effect. The activation of Src increased UVB-induced, G beta gamma-mediated HB-EGF secretion, but the inhibition of Src blocked that. Overexpression of G beta gamma increased UVB-induced apoptosis, and the overexpression of GRK2ct decreased this apoptosis. We conclude that G beta gamma mediates UVB-induced human keratinocyte apoptosis by augmenting the ectodomain shedding of HB-EGF, which sequentially activates EGFR and p38.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Canc Res Inst, Seoul 110799, South Korea; Ajou Univ, Sch Med, Dept Dermatol, Seoul 433749, South Korea	Seoul National University (SNU); Ajou University	Juhnn, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Canc Res Inst, 28 Yong Dong, Seoul 110799, South Korea.	juhnn@snu.ac.kr	Juhnn, Yong-Sung/J-2790-2012	Lee, Eun-So/0000-0003-0232-7704				Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bachelor MA, 2004, J BIOL CHEM, V279, P42658, DOI 10.1074/jbc.M406626200; BODE AM, 2003, SCI STKE, pRE2; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; Cadet J, 2001, CURR PROBL DERMATOL, V29, P62; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; Chouinard N, 2002, BIOCHEM J, V365, P133, DOI 10.1042/BJ20020072; Dlugosz A, 2002, J INVEST DERM SYMP P, V7, P17, DOI 10.1046/j.1523-1747.2002.19631.x; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; ELLEM KAO, 1988, CARCINOGENESIS, V9, P797, DOI 10.1093/carcin/9.5.797; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; GAHRING L, 1984, P NATL ACAD SCI-BIOL, V81, P1198, DOI 10.1073/pnas.81.4.1198; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Hildesheim J, 2004, J INVEST DERMATOL, V122, P497, DOI 10.1111/j.1523-1747.2004.22229.x; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRAMER M, 1993, J BIOL CHEM, V268, P6734; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lewis DA, 2003, J INVEST DERMATOL, V120, P483, DOI 10.1046/j.1523-1747.2003.12060.x; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Lin JQ, 2001, J BIOL CHEM, V276, P30127, DOI 10.1074/jbc.M010237200; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Nanba D, 2004, CYTOKINE GROWTH F R, V15, P13, DOI 10.1016/j.cytogfr.2003.10.002; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nolan TM, 2003, AM J PATHOL, V162, P567, DOI 10.1016/S0002-9440(10)63850-3; Pan BC, 2002, MOL HUM REPROD, V8, P734, DOI 10.1093/molehr/8.8.734; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SCHWARZ T, 1989, J PHOTOCH PHOTOBIO B, V4, P1, DOI 10.1016/1011-1344(89)80097-1; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Seo M, 2002, J BIOL CHEM, V277, P24197, DOI 10.1074/jbc.M201717200; Seo MR, 2004, J BIOL CHEM, V279, P17366, DOI 10.1074/jbc.M312442200; Steinbach JP, 2004, CANCER RES, V64, P1575, DOI 10.1158/0008-5472.CAN-03-3775; Takenobu H, 2003, J BIOL CHEM, V278, P17255, DOI 10.1074/jbc.M211835200; Van Laethem A, 2004, FASEB J, V18, P1946, DOI 10.1096/fj.04-2285fje; Wang Q, 2005, INT J MOL MED, V15, P633; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xu KP, 2006, INVEST OPHTH VIS SCI, V47, P2832, DOI 10.1167/iovs.05-1361; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	53	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24720	24730		10.1074/jbc.M702343200	http://dx.doi.org/10.1074/jbc.M702343200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17548351	hybrid			2022-12-25	WOS:000248933000027
J	van Slegtenhorst, M; Khabibullin, D; Hartman, TR; Nicolas, E; Kruger, WD; Henske, EP				van Slegtenhorst, Marjon; Khabibullin, Damir; Hartman, Tiffiney R.; Nicolas, Emmanuelle; Kruger, Warren D.; Henske, Elizabeth Petri			The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; BHD GENE; SPONTANEOUS PNEUMOTHORAX; NITROGEN STARVATION; DIRECT TARGET; CELL-GROWTH; RHEB GTPASE; MTOR; MUTATIONS; TSC2	Birt-Hogg-Dube (BHD) is a tumor suppressor gene disorder characterized by skin hamartomas, cystic lung disease, and renal cell carcinoma. The fact that hamartomas, lung cysts, and renal cell carcinoma can also occur in tuberous sclerosis complex (TSC) suggests that the BHD and TSC proteins may function within a common pathway. To evaluate this hypothesis, we deleted the BHD homolog in Schizosaccharomyces pombe. Expression profiling revealed that six permease and transporter genes, known to be down-regulated in Delta tsc1 and Delta tsc2, were up-regulated in Delta bhd, and levels of specific intracellular amino acids known to be low in Delta tsc1 and Delta tsc2 were elevated in Delta bhd. This "opposite" profile was unexpected, given the overlapping clinical phenotypes. The TSC1/2 proteins inhibit Rheb in mammals, and Tsc1/Tsc2 inhibit Rhb1 in S. pombe. Expression of a hypomorphic allele of rhb1(+) dramatically increased permease expression levels in Delta bhd but not in wild-type yeast. Loss of Bhd sensitized yeast to rapamycin-induced increases in permease expression levels, and rapamycin induced lethality in Delta bhd yeast expressing the hypomorphic Rhb1 allele. In S. pombe, it is known that Rhb1 binds Tor2, and Tor2 inhibition leads to up-regulation of permeases including those that are regulated by Bhd. Our data, therefore, suggest that Bhd activates Tor2. If the mammalian BHD protein, folliculin, similarly activates mammalian target of rapamycin, it will be of great interest to determine how mammalian target of rapamycin inhibition in BHD patients and mammalian target of rapamycin activation in TSC patients lead to overlapping clinical phenotypes.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Henske, EP (corresponding author), 333 Cottman Ave, Philadelphia, PA 19111 USA.	Henske@FCCC.edu	albert, karen/B-1882-2008; Kruger, Warren/Y-2541-2018; kruger, warren/A-6407-2008	kruger, warren/0000-0002-4990-3695	NHLBI NIH HHS [R21 HL82746] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL082746] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; FRIEDMAN MA, 1977, CANCER LETT, V3, P71, DOI 10.1016/S0304-3835(77)94272-0; Fujii H, 2006, J PATHOL, V209, P328, DOI 10.1002/path.1992; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; GRIMM C, 1988, MOL GEN GENET, V215, P87, DOI 10.1007/BF00331308; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Khoo SK, 2002, J MED GENET, V39, P906, DOI 10.1136/jmg.39.12.906; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; Lingaas F, 2003, HUM MOL GENET, V12, P3043, DOI 10.1093/hmg/ddg336; Matsuo T, 2007, MOL CELL BIOL, V27, P3154, DOI 10.1128/MCB.01039-06; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Painter JN, 2005, AM J HUM GENET, V76, P522, DOI 10.1086/428455; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmidt LS, 2005, AM J HUM GENET, V76, P1023, DOI 10.1086/430842; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Toro JR, 1999, ARCH DERMATOL, V135, P1195, DOI 10.1001/archderm.135.10.1195; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; Uritani M, 2006, GENES CELLS, V11, P1367, DOI 10.1111/j.1365-2443.2006.01025.x; van Slegtenhorst M, 2005, HUM MOL GENET, V14, P2851, DOI 10.1093/hmg/ddi317; van Slegtenhorst M, 2004, J BIOL CHEM, V279, P12706, DOI 10.1074/jbc.M313874200; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154; Weisman R, 2004, Curr Top Microbiol Immunol, V279, P85; Weisman R, 2005, GENETICS, V169, P539, DOI 10.1534/genetics.104.034983; Weisman R, 2007, GENETICS, V175, P1153, DOI 10.1534/genetics.106.064170; Yang WL, 2000, J BIOL CHEM, V275, P429, DOI 10.1074/jbc.275.1.429; Zbar B, 2002, CANCER EPIDEM BIOMAR, V11, P393; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	33	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24583	24590		10.1074/jbc.M700857200	http://dx.doi.org/10.1074/jbc.M700857200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17556368	hybrid			2022-12-25	WOS:000248933000012
J	Cheong, N; Zhang, H; Madesh, M; Zhao, M; Yu, K; Dodia, C; Fisher, AB; Savani, RC; Shuman, H				Cheong, Naeun; Zhang, Huayan; Madesh, Muniswamy; Zhao, Ming; Yu, Kevin; Dodia, Chandra; Fisher, Aron B.; Savani, Rashmin C.; Shuman, Henry			ABCA3 is critical for lamellar body biogenesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-B; HUMAN FETAL LUNG; PULMONARY SURFACTANT; GLUCOCORTICOID REGULATION; SP-C; DEFICIENCY; MICE; EXPRESSION; MUTATIONS; DISEASE	Mutations in ATP-binding cassette transporter A3 (human ABCA3) protein are associated with fatal respiratory distress syndrome in newborns. We therefore characterized mice with targeted disruption of the ABCA3 gene. Homozygous Abca3(-/-) knock-out mice died soon after birth, whereas most of the wild type, Abca3(+/+), and heterozygous, Abca3(+/-), neonates survived. The lungs from E18.5 and E19.5 Abca3(-/-) mice were less mature than wild type. Alveolar type 2 cells from Abca3(-/-) embryos contained no lamellar bodies, and expression of mature SP-B protein was disrupted when compared with the normal lung surfactant system of wild type embryos. Small structural and functional differences in the surfactant system were seen in adult Abca3(+/-) compared with Abca3(+/+) mice. The heterozygotes had fewer lamellar bodies, and the incorporation of radiolabeled substrates into newly synthesized disaturated phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, and phosphatidylserine in both lamellar bodies and surfactant was lower than in Abca3(+/+) mouse lungs. In addition, since the fraction of near term Abca3(-/-) embryos was significantly lower than expected from Mendelian inheritance ABCA3 probably plays roles in development unrelated to surfactant. Collectively, these findings strongly suggest that ABCA3 is necessary for lamellar body biogenesis, surfactant protein-B processing, and lung development late in gestation.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shuman, H (corresponding author), Univ Penn, Sch Med, Dept Physiol, B400 Richards,, Philadelphia, PA 19104 USA.	shuman@mail.med.upenn.edu	Rashmin C. Savani, MBChB/AAG-2041-2021	Rashmin C. Savani, MBChB/0000-0002-9533-5422				Amin RS, 2001, J PEDIATR-US, V139, P85, DOI 10.1067/mpd.2001.114545; Ban N, 2007, J BIOL CHEM, V282, P9628, DOI 10.1074/jbc.M611767200; BEERS MF, 1995, PEDIATR RES, V38, P668, DOI 10.1203/00006450-199511000-00007; Brasch F, 2004, AM J RESP CELL MOL, V30, P449, DOI 10.1165/rcmb.2003-0262OC; Brasch F, 2006, AM J RESP CRIT CARE, V174, P571, DOI 10.1164/rccm.200509-1535OC; Bullard JE, 2005, AM J RESP CRIT CARE, V172, P1026, DOI 10.1164/rccm.200503-504OC; Cheong N, 2006, J BIOL CHEM, V281, P9791, DOI 10.1074/jbc.M507515200; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; DEMELLO DE, 1994, J PEDIATR-US, V125, P43, DOI 10.1016/S0022-3476(94)70119-9; Edwards V, 2005, ULTRASTRUCT PATHOL, V29, P503, DOI 10.1080/01913120500323480; Fisher AB, 2005, J LIPID RES, V46, P1248, DOI 10.1194/jlr.M400499-JLR200; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V280, pL748, DOI 10.1152/ajplung.2001.280.4.L748; Fitzgerald ML, 2007, J LIPID RES, V48, P621, DOI 10.1194/jlr.M600449-JLR200; Foster CD, 2003, AM J RESP CELL MOL, V29, P259, DOI 10.1165/rcmb.2002-0149OC; Garmany TH, 2006, PEDIATR RES, V59, P801, DOI 10.1203/01.pdr.0000219311.14291.df; Guttentag S, 2003, AM J RESP CELL MOL, V28, P69, DOI 10.1165/rcmb.2002-0111OC; Guttentag SH, 1998, AM J PHYSIOL-LUNG C, V275, pL559, DOI 10.1152/ajplung.1998.275.3.L559; Johansson J, 1997, EUR J BIOCHEM, V244, P675, DOI 10.1111/j.1432-1033.1997.00675.x; Korimilli A, 2000, J BIOL CHEM, V275, P8672, DOI 10.1074/jbc.275.12.8672; MASON RJ, 1976, J LIPID RES, V17, P281; McCormack FX, 1998, BBA-MOL BASIS DIS, V1408, P109, DOI 10.1016/S0925-4439(98)00062-3; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; Nagata K, 2004, BIOCHEM BIOPH RES CO, V324, P262, DOI 10.1016/j.bbrc.2004.09.043; Nogee LM, 2006, CURR OPIN PEDIATR, V18, P287, DOI 10.1097/01.mop.0000193310.22462.1f; Nogee LM, 2004, ANNU REV PHYSIOL, V66, P601, DOI 10.1146/annurev.physiol.66.032102.134711; Perez-Gil J, 2001, PEDIATR PATHOL MOL M, V20, P445, DOI 10.1080/15227950152625783; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Solarin KO, 1997, PEDIATR RES, V42, P356, DOI 10.1203/00006450-199709000-00017; Stahlman MT, 2007, J HISTOCHEM CYTOCHEM, V55, P71, DOI 10.1369/jhc.6A6962.2006; Stahlman MT, 2000, LAB INVEST, V80, P395, DOI 10.1038/labinvest.3780044; Weaver TE, 2001, ANNU REV PHYSIOL, V63, P555, DOI 10.1146/annurev.physiol.63.1.555; Weaver TE, 1998, BBA-MOL BASIS DIS, V1408, P173, DOI 10.1016/S0925-4439(98)00066-0; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; Zen K, 1998, AM J PHYSIOL-LUNG C, V275, pL172, DOI 10.1152/ajplung.1998.275.1.L172	35	116	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23811	23817		10.1074/jbc.M703927200	http://dx.doi.org/10.1074/jbc.M703927200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17540762	hybrid			2022-12-25	WOS:000248686600009
J	Naiki, T; Saijou, E; Miyaoka, Y; Sekine, K; Miyajima, A				Naiki, Takahiro; Saijou, Eiko; Miyaoka, Yuichiro; Sekine, Keisuke; Miyajima, Atsushi			TRB2, a mouse tribbles ortholog, suppresses adipocyte differentiation by inhibiting AKT and C/EBP beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; MESSENGER-RNA; MICE LACKING; PPAR-GAMMA; CELL-LINE; IN-VITRO; ADIPOGENESIS; INSULIN; PROTEIN; DROSOPHILA	Adipocyte differentiation is regulated by a complex array of extracelluar signals, intracellular mediators and transcription factors. Here we describe suppression of adipocyte differentiation by TRBs, mammalian orthologs of Drosophila Tribbles. Whereas all the three TRBs were expressed in 3T3- L1 preadipocytes, TRB2 and TRB3, but not TRB1, were immediately down-regulated by differentiation stimuli. Forced expression of TRB2 and TRB3 inhibited adipocyte differentiation at an early stage. Akt activation is a key event in adipogenesis and was severely inhibited by TRB3 in 3T3- L1 cells. However, the inhibition by TRB2 was mild compared with severe inhibition by TRB3, though TRB2 suppressed adipogenesis as strongly as TRB3. Interestingly, TRB2 but not TRB3 reduced the level of C/ EBP beta, a transcription factor required for an early stage of adipogenesis, through a proteasome- dependent mechanism. Furthermore, knockdown of endogenous TRB2 by siRNA allowed 3T3- L1 cells to differentiate without full differentiation stimuli. These results suggest that inhibition of Akt activation in combination with degradation of C/ EBP beta is the basis for the strong inhibitory effect of TRB2 on adipogenesis.	Univ Tokyo, Inst Mol & Cell Biosci, Lab Cell Growth & Differentiat, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Miyajima, A (corresponding author), Univ Tokyo, Inst Mol & Cell Biosci, Lab Cell Growth & Differentiat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	miyajima@iam.u-tokyo.ac.jp		Miyaoka, Yuichiro/0000-0002-8874-4738; Sekine, Keisuke/0000-0001-5133-0876				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; Bost F, 2005, BIOCHIMIE, V87, P51, DOI 10.1016/j.biochi.2004.10.018; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kiss-Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Miyaoka Y, 2006, J BIOL CHEM, V281, P37913, DOI 10.1074/jbc.M606089200; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Rorth P, 2000, MOL CELL, V6, P23; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Schwarzer R, 2006, CELL SIGNAL, V18, P899, DOI 10.1016/j.cellsig.2005.08.002; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Smas CM, 1996, INT J OBESITY, V20, pS65; Smas CM, 1999, J BIOL CHEM, V274, P12632, DOI 10.1074/jbc.274.18.12632; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tseng YH, 2005, NAT CELL BIOL, V7, P601, DOI 10.1038/ncb1259; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Wilkin F, 1997, EUR J BIOCHEM, V248, P660, DOI 10.1111/j.1432-1033.1997.t01-1-00660.x; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8	39	70	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24075	24082		10.1074/jbc.M701409200	http://dx.doi.org/10.1074/jbc.M701409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17576771	hybrid			2022-12-25	WOS:000248686600033
J	Perier, A; Chassaing, A; Raffestin, S; Pichard, S; Masella, M; Menez, A; Forge, V; Chenal, A; Gillet, D				Perier, Aurelie; Chassaing, Anne; Raffestin, Stephanie; Pichard, Sylvain; Masella, Michel; Menez, Andre; Forge, Vincent; Chenal, Alexandre; Gillet, Daniel			Concerted protonation of key histidines triggers membrane interaction of the diphtheria toxin T domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH; PROTEIN; TRANSLOCATION; FUSION; INSERTION; BACTERIA; BEHAVIOR; HELICES	The translocation domain (T domain) of the diphtheria toxin contributes to the transfer of the catalytic domain from the cell endosome to the cytosol, where it blocks protein synthesis. Translocation is initiated when endosome acidification induces the interaction of the T domain with the membrane of the compartment. We found that the protonation of histidine side chains triggers the conformational changes required for membrane interaction. All histidines are involved in a concerted manner, but none is indispensable. However, the preponderance of each histidine varies according to the transition observed. The pair His(223) - His(257) and His(251) are the most sensitive triggers for the formation of the molten globule state in solution, whereas His(322) - His(323) and His(251) are the most sensitive triggers for membrane binding. Interestingly, the histidines are located at key positions throughout the structure of the protein, in hinges and at the interface between each of the three layers of helices forming the domain. Their protonation induces local destabilizations, disrupting the tertiary structure and favoring membrane interaction. We propose that the selection of histidine residues as triggers of membrane interaction enables the T domain to initiate translocation at the rather mild pH found in the endosome, contributing to toxin efficacy.	CEA, Inst Biol & Technol Saclay, Serv Ingn Mol Prot, F-91191 Gif Sur Yvette, France; Inst Rech Technol & Sci Vivant, Lab Chim Biol Met, F-38054 Grenoble, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Chenal, A (corresponding author), Inst Pasteur, Dept Biol Struct & Chim, CNRS URA 2185, Unit Biochim Interact Macromol, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	chenal@pasteur.fr; daniel.gillet@cea.fr	Gillet, Daniel/C-5592-2008; Chenal, Alexandre/C-2240-2009; Masella, Michel/I-8367-2019	Gillet, Daniel/0000-0003-0477-3599; Chenal, Alexandre/0000-0002-4959-1003; Masella, Michel/0000-0003-1073-4457				BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; Chenal A, 2002, J BIOL CHEM, V277, P43425, DOI 10.1074/jbc.M204148200; Chenal A, 2002, PROTEIN ENG, V15, P383, DOI 10.1093/protein/15.5.383; Chenal A, 2002, J TOXICOL-TOXIN REV, V21, P321, DOI 10.1081/TXR-120014408; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Geierstanger B, 1998, BIOCHEMISTRY-US, V37, P4254, DOI 10.1021/bi972516+; Kampmann T, 2006, STRUCTURE, V14, P1481, DOI 10.1016/j.str.2006.07.011; Koriazova LK, 2003, NAT STRUCT BIOL, V10, P13, DOI 10.1038/nsb879; Krantz BA, 2006, J MOL BIOL, V355, P968, DOI 10.1016/j.jmb.2005.11.030; Mason AJ, 2006, ANTIMICROB AGENTS CH, V50, P3305, DOI 10.1128/AAC.00490-06; Menetrey J, 2005, TOXICON, V45, P129, DOI 10.1016/j.toxicon.2004.09.004; Mere J, 2005, J BIOL CHEM, V280, P21194, DOI 10.1074/jbc.M412656200; Montagner C, 2007, BIOCHEMISTRY-US, V46, P1878, DOI 10.1021/bi602381z; Nizard P, 1998, FEBS LETT, V433, P83, DOI 10.1016/S0014-5793(98)00890-4; Nizard P, 2001, PROTEIN ENG, V14, P439, DOI 10.1093/protein/14.6.439; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; Srivastava J, 2007, PHYSIOLOGY, V22, P30, DOI 10.1152/physiol.00035.2006; Wang J, 2006, BIOCHEMISTRY-US, V45, P8124, DOI 10.1021/bi060587f; Wang Y, 1997, J BIOL CHEM, V272, P25091, DOI 10.1074/jbc.272.40.25091; Wei Z, 2005, J MOL BIOL, V348, P205, DOI 10.1016/j.jmb.2005.02.028; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	21	53	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24239	24245		10.1074/jbc.M703392200	http://dx.doi.org/10.1074/jbc.M703392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584737	hybrid			2022-12-25	WOS:000248686600049
J	Sbrissa, D; Ikonomov, OC; Fu, ZY; Ijuin, T; Gruenberg, J; Takenawa, T; Shisheva, A				Sbrissa, Diego; Ikonomov, Ognian C.; Fu, Zhiyao; Ijuin, Takeshi; Gruenberg, Jean; Takenawa, Tadaomi; Shisheva, Assia			Core protein machinery for mammalian phosphatidylinositol 3,5-bisphosphate synthesis and turnover that regulates the progression of endosomal transport - Novel sac phosphatase joins the arpikfyve-pikfyve complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-KINASE PIKFYVE; LIPID KINASE; PHOSPHOINOSITIDE; PATHWAY; TRAFFICKING; BIOGENESIS; VESICLES; DYNAMICS; LOCALIZATION; EXPRESSION	Perturbations in phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P-2)-synthesizing enzymes result in enlarged endocytic organelles from yeast to humans, indicating evolutionarily conserved function of PtdIns(3,5)P-2 in endosome-related events. This is reinforced by the structural and functional homology of yeast Vac14 and human Vac14 (ArPIKfyve), which activate yeast and mammalian PtdIns(3,5)P-2-producing enzymes, Fab1 and PIKfyve, respectively. In yeast, PtdIns(3,5)P-2-specific phosphatase, Fig4, in association with Vac14, turns over PtdIns(3,5)P-2, but whether such a mechanism operates in mammalian cells and what the identity of mammalian Fig4 may be are unknown. Here we have identified and characterized Sac3, a Sac domain phosphatase, as the Fig4 mammalian counterpart. Endogenous Sac3, a widespread 97-kDa protein, formed a stable ternary complex with ArPIKfyve and PIKfyve. Concordantly, Sac3 cofractionated and colocalized with ArPIKfyve and PIKfyve. The intrinsic Sac3(WT) phosphatase activity preferably hydrolyzed PtdIns(3,5)P-2 in vitro, although the other D5-phosphorylated polyphosphoinositides were also substrates. Ablation of endogenous Sac3 by short interfering RNAs elevated PtdIns(3,5)P-2 in P-32-labeled HEK293 cells. Ectopically expressed Sac3(WT) in COS cells colocalized with and dilated EEA1-positive endosomes, consistent with the PtdIns(3,5)P-2 requirement in early endosome dynamics. In vitro reconstitution of carrier vesicle formation from donor early endosomes revealed a gain of function upon Sac3 loss, whereas PIKfyve or ArPIKfyve protein depletion produced a loss of function. These data demonstrate a coupling between the machinery for PtdIns(3,5)P-2 synthesis and turnover achieved through a physical assembly of PIKfyve, ArPIKfyve, and Sac3. We suggest that the tight regulation in PtdIns(3,5)P-2 homeostasis is mechanistically linked to early endosome dynamics in the course of cargo transport.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Tokyo, Inst Mol Sci, Dept Biochem, Tokyo 1130032, Japan	Wayne State University; University of Geneva; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); University of Tokyo	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.	ashishev@med.wayne.edu	Ijuin, Takeshi/H-7016-2017	Ijuin, Takeshi/0000-0002-0618-1776	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058058] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58058] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Balla T, 2006, J ENDOCRINOL, V188, P135, DOI 10.1677/joe.1.06595; Bonangelino CJ, 2002, J CELL BIOL, V156, P1015, DOI 10.1083/jcb.200201002; CALA SE, 1994, J BIOL CHEM, V269, P5926; Clague MJ, 2005, TRAFFIC, V6, P1063, DOI 10.1111/j.1600-0854.2005.00338.x; Corvera S, 2001, TRAFFIC, V2, P859, DOI 10.1034/j.1600-0854.2001.21201.x; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Dove SK, 2002, CURR BIOL, V12, P885, DOI 10.1016/S0960-9822(02)00891-6; Duex JE, 2006, EUKARYOT CELL, V5, P723, DOI 10.1128/EC.5.4.723-731.2006; Duex JE, 2006, J CELL BIOL, V172, P693, DOI 10.1083/jcb.200512105; Efe JA, 2005, CURR OPIN CELL BIOL, V17, P402, DOI 10.1016/j.ceb.2005.06.002; Fedorov Y, 2005, NAT METHODS, V2, P241, DOI 10.1038/nmeth0405-241; Gary JD, 2002, MOL BIOL CELL, V13, P1238, DOI 10.1091/mbc.01-10-0498; Griffiths G, 1996, PROTOPLASMA, V195, P37, DOI 10.1007/BF01279185; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Hughes WE, 2000, BIOCHEM J, V350, P337, DOI 10.1042/0264-6021:3500337; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Ikonomov NC, 2007, EXP CELL RES, V313, P2404, DOI 10.1016/j.yexcr.2007.03.024; Ikonomov OC, 2003, J BIOL CHEM, V278, P50863, DOI 10.1074/jbc.M307260200; Ikonomov OC, 2003, MOL BIOL CELL, V14, P4581, DOI 10.1091/mbc.E03-04-0222; Ikonomov OC, 2002, ENDOCRINOLOGY, V143, P4742, DOI 10.1210/en.2002-220615; Ikonomov OC, 2002, J BIOL CHEM, V277, P9206, DOI 10.1074/jbc.M108750200; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Ikonomov OC, 2006, AM J PHYSIOL-CELL PH, V291, pC393, DOI 10.1152/ajpcell.00019.2006; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Luzio JP, 2003, MOL MEMBR BIOL, V20, P141, DOI 10.1080/0968768031000089546; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Michell RH, 2006, TRENDS BIOCHEM SCI, V31, P52, DOI 10.1016/j.tibs.2005.11.013; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Minagawa T, 2001, J BIOL CHEM, V276, P22011, DOI 10.1074/jbc.M101579200; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; Nemoto Y, 2000, J BIOL CHEM, V275, P34293, DOI 10.1074/jbc.M003923200; Nicot AS, 2006, MOL BIOL CELL, V17, P3062, DOI 10.1091/mbc.e05-12-1120; Owen DJ, 2004, ANNU REV CELL DEV BI, V20, P153, DOI 10.1146/annurev.cellbio.20.010403.104543; Petiot A, 2003, J CELL BIOL, V162, P971, DOI 10.1083/jcb.200303018; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Prestwich GD, 2004, CHEM BIOL, V11, P619, DOI 10.1016/j.chembiol.2004.03.025; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Robinson FL, 2006, TRENDS CELL BIOL, V16, P403, DOI 10.1016/j.tcb.2006.06.001; ROBINSON LJ, 1998, CELL BIOL LAB HDB, V2, P201; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Rudge SA, 2004, MOL BIOL CELL, V15, P24, DOI 10.1091/mbc.E03-05-0297; Rusten TE, 2006, MOL BIOL CELL, V17, P3989, DOI 10.1091/mbc.E06-03-0239; Rutherford AC, 2006, J CELL SCI, V119, P3944, DOI 10.1242/jcs.03153; Sbrissa D, 2005, J BIOL CHEM, V280, P7883, DOI 10.1074/jbc.M412729200; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2004, MOL CELL BIOL, V24, P10437, DOI 10.1128/MCB.24.23.10437-10447.2004; Sbrissa D, 2002, J BIOL CHEM, V277, P47276, DOI 10.1074/jbc.M207576200; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 2003, FRONT BIOSCI-LANDMRK, V8, pS945, DOI 10.2741/1101; Shisheva A, 2001, METHOD ENZYMOL, V329, P39; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Slagsvold T, 2006, TRENDS CELL BIOL, V16, P317, DOI 10.1016/j.tcb.2006.04.004; Takenawa T, 2006, IUBMB LIFE, V58, P296, DOI 10.1080/15216540600732039; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; Tsujita K, 2004, J BIOL CHEM, V279, P13817, DOI 10.1074/jbc.M312294200; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X	65	136	143	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23878	23891		10.1074/jbc.M611678200	http://dx.doi.org/10.1074/jbc.M611678200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17556371	hybrid			2022-12-25	WOS:000248686600015
J	Banci, L; Bertini, I; Cantini, F; Della-Malva, N; Migliardi, M; Rosato, A				Banci, Lucia; Bertini, Ivano; Cantini, Francesca; Della-Malva, Nunzia; Migliardi, Manuele; Rosato, Antonio			The different intermolecular interactions of the soluble copper-binding domains of the Menkes protein, ATP7A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN WILSON PROTEIN; METAL-BINDING; DISEASE PROTEIN; CANDIDATE GENE; INTRACELLULAR TRAFFICKING; ATPASE; CHAPERONE; CU(I); MECHANISMS; TRANSPORT	ATP7A is a P-type ATPase involved in copper(I) homeostasis in humans. It possesses a long N-terminal cytosolic tail containing six domains that are individually folded and capable of binding one copper(I) ion each. We investigated the entire N-terminal tail (MNK1 - 6) in solution by NMR spectroscopy and addressed its interaction with copper(I) and with copper(I)-HAH1, the physiological partner of ATP7A. At copper(I)-HAH1:MNK1 - 6 ratios of up to 3:1, thus encompassing the range of protein ratios in vivo, both the first and fourth domain of the tail formed a metal-mediated adduct with HAH1 whereas the sixth domain was simultaneously able to partly remove copper(I) from HAH1. These processes are not dependent on one another. In particular, formation of the adducts is not necessary for copper(I) transfer from HAH1 to the sixth domain. The present data, together with available in vivo studies, suggest that the localization of ATP7A between the trans-Golgi network and the plasma membrane may be regulated by the accumulation of the adducts with HAH1, whereas the main role of domains 5 and 6 is to assist copper(I) translocation.	Magnet Resonance Ctr, I-50019 Sesto Fiorentino, Italy; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; Fiorgen Fdn, I-50019 Sesto Fiorentino, Italy	University of Florence	Bertini, I (corresponding author), Magnet Resonance Ctr, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.	ivanobertini@cerm.unifi.it	Rosato, Antonio/D-8548-2011; Cantini, Francesca/O-1220-2015; Rosato, Antonio/M-3250-2019	Rosato, Antonio/0000-0001-6172-0368; Cantini, Francesca/0000-0003-0526-6732; Rosato, Antonio/0000-0001-6172-0368; BANCI, LUCIA/0000-0003-0562-5774				Achila D, 2006, P NATL ACAD SCI USA, V103, P5729, DOI 10.1073/pnas.0504472103; Anastassopoulou I, 2004, BIOCHEMISTRY-US, V43, P13046, DOI 10.1021/bi0487591; Banci L, 2005, J BIOL CHEM, V280, P38259, DOI 10.1074/jbc.M506219200; Banci L, 2005, J MOL BIOL, V352, P409, DOI 10.1016/j.jmb.2005.07.034; Banci L, 2005, FEBS J, V272, P865, DOI 10.1111/j.1742-4658.2004.04526.x; Banci L, 2004, BIOCHEMISTRY-US, V43, P3396, DOI 10.1021/bi036042s; Banci L, 2003, ACCOUNTS CHEM RES, V36, P215, DOI 10.1021/ar010120r; Banci L, 2006, J BIOL CHEM, V281, P29141, DOI 10.1074/jbc.M603176200; Banci L, 2006, NAT CHEM BIOL, V2, P367, DOI 10.1038/nchembio797; Bertini I, 2006, J BIOMOL NMR, V36, P111, DOI 10.1007/s10858-006-9068-z; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Cater MA, 2004, BIOCHEM J, V380, P805, DOI 10.1042/BJ20031804; Cater MA, 2007, BIOCHEM J, V401, P143, DOI 10.1042/BJ20061055; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; DeSilva TM, 2005, PROTEINS, V61, P1038, DOI 10.1002/prot.20639; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963; Jones CE, 2003, J STRUCT BIOL, V143, P209, DOI 10.1016/j.jsb.2003.08.008; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Mercer JFB, 2003, BIOMETALS, V16, P175, DOI 10.1023/A:1020719016675; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Voskoboinik I, 2002, J BIOENERG BIOMEMBR, V34, P363, DOI 10.1023/A:1021250003104; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Yatsunyk LA, 2007, J BIOL CHEM, V282, P8622, DOI 10.1074/jbc.M609533200	39	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23140	23146		10.1074/jbc.M700695200	http://dx.doi.org/10.1074/jbc.M700695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17545667	hybrid			2022-12-25	WOS:000248577500016
J	Cavanaugh, LF; Chen, X; Richardson, BC; Ungar, D; Pelczer, I; Rizo, J; Hughson, FM				Cavanaugh, Lorraine F.; Chen, Xiaocheng; Richardson, Brian C.; Ungar, Daniel; Pelczer, Istvan; Rizo, Josep; Hughson, Frederick M.			Structural analysis of conserved oligomeric golgi complex subunit 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; RETROGRADE TRANSPORT; TETHERING COMPLEXES; VESICLE DOCKING; SHUTTLE VECTORS; COG COMPLEX; PROTEIN; EXOCYST; NMR	The (c) under bar onserved (o) under bar ligomeric (G) under bar olgi (COG) complex is strongly implicated in retrograde vesicular trafficking within the Golgi apparatus. Although its mechanism of action is poorly understood, it has been proposed to function by mediating the initial physical contact between transport vesicles and their membrane targets. An analogous role in tethering vesicles has been suggested for at least six additional large multisubunit complexes, including the exocyst, a complex essential for trafficking to the plasma membrane. Here we report the solution structure of a large portion of yeast Cog2p, one of eight subunits composing the COG complex. The structure reveals a six-helix bundle with few conserved surface features but a general resemblance to recently determined crystal structures of four different exocyst subunits. This finding provides the first structural evidence that COG, like the exocyst and potentially other tethering complexes, is constructed from helical bundles. These structures may represent platforms for interaction with other trafficking proteins including SNAREs (soluble N-ethylmaleimide factor attachment protein receptors) and Rabs.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Princeton University; Princeton University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hughson, FM (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	hughson@princeton.edu	Ungar, Daniel/A-5302-2012	Ungar, Daniel/0000-0002-9852-6160; Richardson, Brian/0000-0002-5434-1500	NIGMS NIH HHS [GM071574] Funding Source: Medline; NINDS NIH HHS [NS37200] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037200] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bruinsma P, 2004, J BIOL CHEM, V279, P39814, DOI 10.1074/jbc.M405500200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai HQ, 2005, J CELL BIOL, V171, P823, DOI 10.1083/jcb.200505145; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dong G, 2005, NAT STRUCT MOL BIOL, V12, P1094, DOI 10.1038/nsmb1017; Fotso P, 2005, J BIOL CHEM, V280, P27613, DOI 10.1074/jbc.M504597200; Fukai S, 2003, EMBO J, V22, P3267, DOI 10.1093/emboj/cdg329; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Hamburger ZA, 2006, J MOL BIOL, V356, P9, DOI 10.1016/j.jmb.2005.09.099; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Jang SB, 2002, J BIOL CHEM, V277, P49863, DOI 10.1074/jbc.M207436200; Kim DW, 2001, TRAFFIC, V2, P820, DOI 10.1034/j.1600-0854.2001.21111.x; Kim YG, 2006, CELL, V127, P817, DOI 10.1016/j.cell.2006.09.029; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; Koumandou VL, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-29; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Loh E, 2004, J BIOL CHEM, V279, P24640, DOI 10.1074/jbc.M400662200; Lupashin V, 2005, BBA-MOL CELL RES, V1744, P325, DOI 10.1016/j.bbamcr.2005.03.013; Mott HR, 2003, J BIOL CHEM, V278, P17053, DOI 10.1074/jbc.M300155200; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Munson M, 2006, NAT STRUCT MOL BIOL, V13, P577, DOI 10.1038/nsmb1097; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oka T, 2005, J BIOL CHEM, V280, P32736, DOI 10.1074/jbc.M505558200; Oka T, 2005, J BIOCHEM, V137, P109, DOI 10.1093/jb/mvi024; Oka T, 2004, MOL BIOL CELL, V15, P2423, DOI 10.1091/mbc.E03-09-0699; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Ram RJ, 2002, MOL BIOL CELL, V13, P1484, DOI 10.1091/mbc.01-10-0495; ROSEN H, 1957, ARCH BIOCHEM BIOPHYS, V67, P10, DOI 10.1016/0003-9861(57)90241-2; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Shestakova A, 2006, TRAFFIC, V7, P191, DOI 10.1111/j.1600-0854.2005.00376.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Sivaram MVS, 2006, NAT STRUCT MOL BIOL, V13, P555, DOI 10.1038/nsmb1096; Suvorova ES, 2002, J CELL BIOL, V157, P631, DOI 10.1083/jcb.200111081; Sztul E, 2006, AM J PHYSIOL-CELL PH, V290, pC11, DOI 10.1152/ajpcell.00293.2005; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ungar D, 2006, TRENDS CELL BIOL, V16, P113, DOI 10.1016/j.tcb.2005.12.004; Ungar D, 2005, J BIOL CHEM, V280, P32729, DOI 10.1074/jbc.M504590200; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Walter DM, 1998, J BIOL CHEM, V273, P29565, DOI 10.1074/jbc.273.45.29565; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wu SY, 2005, NAT STRUCT MOL BIOL, V12, P879, DOI 10.1038/nsmb987; Wuestehube LJ, 1996, GENETICS, V142, P393; Zolov SN, 2005, J CELL BIOL, V168, P747, DOI 10.1083/jcb.200412003; [No title captured]	58	35	39	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23418	23426		10.1074/jbc.M703716200	http://dx.doi.org/10.1074/jbc.M703716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565980	hybrid			2022-12-25	WOS:000248577500042
J	Chun, W; Johnson, GVW				Chun, Wanjoo; Johnson, Gail V. W.			Activation of glycogen synthase kinase 3 beta promotes the intermolecular association of tau - The use of fluorescence resonance energy transfer microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; PROTEIN-TAU; CASPASE-CLEAVAGE; PHOSPHORYLATION; AGGREGATION; HYPERPHOSPHORYLATION; TANGLES; APOPTOSIS; ANTIBODY	Tau is hyperphosphorylated and undergoes proteolysis in Alzheimer disease brain. Caspase-cleaved tau efficiently forms fibrillary structures in vitro and in situ. Glycogen synthase kinase 3 beta (GSK3 beta) phosphorylates tau and induces the aggregation of caspase-cleaved tau in situ. Given the hypothesis that increased association of tau precedes the formation of fibrillar structures, we generated a cell model to quantitate the extent of tau association in situ using fluorescence resonance energy transfer (FRET) microscopy. The cyan and yellow fluorescent proteins were attached to full-length (T4) and caspase-cleaved (T4C3) tau at either the N or C termini, and a pair of cyan and yellow fluorescent protein-tagged tau were co-transfected into human embryonic kidney cells. The FRET efficiency was examined in the presence of a constitutively active or a kinase-dead GSK3 beta. Active GSK3 beta significantly increased FRET efficiency with both T4 and T4C3, indicating that GSK3 beta activation resulted in an increase in the self-association of both T4 and T4C3, but interestingly only T4 is efficiently phosphorylated by GSK3 beta. There was no significant difference in FRET efficiency between T4 and T4C3, although only T4C3 in the presence of active GSK3 beta leads to the formation of Sarkosyl-insoluble inclusions. These FRET studies demonstrate that GSK3 beta facilitates the association of T4 and T4C3, and the presence of caspase-cleaved tau is necessary for the evolution of tau oligomers into Sarkosyl-insoluble inclusions even though it is not extensively phosphorylated. These data imply that increased association of tau should not be regarded as a direct indicator of the formation of insoluble tau aggregates.	Univ Alabama Birmingham, Sch Med, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Rochester, Med Ctr, Dept Anesthesiol, 601 Elmwood Ave,Box 604, Rochester, NY 14642 USA.	gail_johnsonvoll@urmc.rochester.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NINDS NIH HHS [NS051279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraha A, 2000, J CELL SCI, V113, P3737; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Avila J, 2006, FEBS LETT, V580, P2922, DOI 10.1016/j.febslet.2006.02.067; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Cabantous S, 2005, NAT BIOTECHNOL, V23, P102, DOI 10.1038/nbt1044; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chan SL, 1999, J NEUROSCI RES, V57, P315, DOI 10.1002/(SICI)1097-4547(19990801)57:3<315::AID-JNR3>3.3.CO;2-R; Cho JH, 2004, J BIOL CHEM, V279, P54716, DOI 10.1074/jbc.M403364200; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Chun W, 2007, FRONT BIOSCI-LANDMRK, V12, P733, DOI 10.2741/2097; Cotman CW, 2005, J NEUROPATH EXP NEUR, V64, P104, DOI 10.1093/jnen/64.2.104; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Ding HP, 2006, J BIOL CHEM, V281, P19107, DOI 10.1074/jbc.M511697200; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Galvan M, 2001, J ALZHEIMERS DIS, V3, P417, DOI 10.3233/JAD-2001-3409; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Gotz J, 2004, MOL PSYCHIATR, V9, P664, DOI 10.1038/sj.mp.4001508; Grober E, 1999, NEUROBIOL AGING, V20, P573, DOI 10.1016/S0197-4580(99)00063-9; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Haase C, 2004, J NEUROCHEM, V88, P1509, DOI 10.1046/j.1471-4159.2003.02287.x; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Iqbal K, 2005, ACTA NEUROPATHOL, V109, P25, DOI 10.1007/s00401-004-0951-y; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kang HJ, 2005, NEUROBIOL DIS, V18, P450, DOI 10.1016/j.nbd.2004.12.004; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Kuret J, 2005, BBA-MOL BASIS DIS, V1739, P167, DOI 10.1016/j.bbadis.2004.06.016; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leroy K, 2002, ACTA NEUROPATHOL, V103, P91; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Meares GP, 2007, J BIOL CHEM, V282, P16989, DOI 10.1074/jbc.M700610200; Mendelsohn AR, 1999, SCIENCE, V284, P1948, DOI 10.1126/science.284.5422.1948; Necula M, 2005, FEBS LETT, V579, P1453, DOI 10.1016/j.febslet.2005.01.047; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rankin CA, 2005, MOL BRAIN RES, V138, P84, DOI 10.1016/j.molbrainres.2005.04.012; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Schneider A, 2004, J BIOL CHEM, V279, P55833, DOI 10.1074/jbc.M409954200; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Toth PT, 2004, J PHARMACOL EXP THER, V310, P8, DOI 10.1124/jpet.103.064956; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; von Bergen M, 2005, BBA-MOL BASIS DIS, V1739, P158, DOI 10.1016/j.bbadis.2004.09.010; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhou JY, 2003, J PHARMACOL EXP THER, V305, P460, DOI 10.1124/jpet.102.048637	63	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23410	23417		10.1074/jbc.M703706200	http://dx.doi.org/10.1074/jbc.M703706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565981	hybrid			2022-12-25	WOS:000248577500041
J	Harada, N; Yasunaga, R; Higashimura, Y; Yamaji, R; Fujimoto, K; Moss, J; Inui, H; Nakano, Y				Harada, Naoki; Yasunaga, Ryoko; Higashimura, Yasuki; Yamaji, Ryoichi; Fujimoto, Katsumi; Moss, Joel; Inui, Hiroshi; Nakano, Yoshihisa			Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COREGULATOR ARA70; GENE; EXPRESSION; DOMAIN; HYPOXIA; IDENTIFICATION; COACTIVATORS; MECHANISMS; PROMOTER; PROTEIN	Androgen receptor (AR) functions as a transcriptional factor for genes involved in proliferation and differentiation of normal and cancerous prostate cells. Coactivators that bind to AR are required for maximal androgen action. Here we report that increasing the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in a prostate cancer cell line by as little as 1.8-fold enhances transcriptional activity of AR ( but not the transcriptional activity of glucocorticoid receptor or estrogen receptor alpha) in a ligand-dependent manner and results in an increased expression of prostate-specific antigen. Small interference RNA-mediated knockdown of GAPDH significantly attenuated ligand-activated AR transactivation. Immunoprecipitation analysis revealed the presence of an endogenous protein complex containing GAPDH and AR in both the cytoplasm and nucleus. Addition of a nuclear localization signal (NLS) to GAPDH (GAPDH-NLS) completely abolished the ability of GAPDH to transactivate AR. Neither wild-type GAPDH nor GAPDH-NLS enhanced transcriptional activity of mutant AR (AR Delta C-Nuc) that is a constitutively active form of AR in the nucleus, even though GAPDH-NLS formed a complex with wild-type AR or AR Delta C-Nuc. AR transactivation was enhanced by a mutant GAPDH lacking dehydrogenase activity. GAPDH enhanced the transcriptional activity of AR(T875A) activated by an antagonist such as hydroxyflutamide or cyproterone acetate. These results indicate that GAPDH functions as a coactivator with high selectivity for AR and enhances AR transactivation independent of its glycolytic activity. Further, these data suggest that formation of a GAPDH center dot AR complex in the cytoplasm rather than nucleus is essential for GAPDH to enhance AR transactivation.	Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Div Appl Life Sci, Naka Ku, Osaka 5998531, Japan; Hiroshima Univ, Grad Sch Biochem Sci, Dept Dent, Hiroshima 7348553, Japan; Hiroshima Univ, Grad Sch Biochem Sci, Dept Med Biochem, Hiroshima 7348553, Japan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Hiroshima University; Hiroshima University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Yamaji, R (corresponding author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Div Appl Life Sci, Naka Ku, 1-1 Gakuen Cho, Osaka 5998531, Japan.	yamaji@biochem.osakafu-u.ac.jp	Harada, Naoki/AAP-2868-2020; Inui, Hiroshi/C-7721-2011	Harada, Naoki/0000-0003-3846-388X; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000659, ZIAHL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown VM, 2004, J BIOL CHEM, V279, P5984, DOI 10.1074/jbc.M307071200; BURKE JR, 1996, NAT MED, V347, P350; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Dehm SM, 2006, J BIOL CHEM, V281, P27882, DOI 10.1074/jbc.M605002200; EPNER DE, 1993, CANCER RES, V53, P1995; Epner DE, 1996, PROSTATE, V28, P372; Escoubet B, 1999, BIOCHEM BIOPH RES CO, V266, P156, DOI 10.1006/bbrc.1999.1798; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Hu YC, 2004, J BIOL CHEM, V279, P33438, DOI 10.1074/jbc.M401781200; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; KUZMINSKAYA EV, 1991, BIOCHIM BIOPHYS ACTA, V1075, P123, DOI 10.1016/0304-4165(91)90241-8; Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Lu S, 2002, BBA-GENE STRUCT EXPR, V1574, P152, DOI 10.1016/S0167-4781(01)00359-1; MacLean HE, 1997, J STEROID BIOCHEM, V62, P233, DOI 10.1016/S0960-0760(97)00049-6; Masiello D, 2004, MOL ENDOCRINOL, V18, P2388, DOI 10.1210/me.2003-0436; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; RIPPLE MO, 1995, CANCER RES, V55, P4234; Rondinelli RH, 1997, PROSTATE CANCER P D, V1, P66, DOI 10.1038/sj.pcan.4500208; Roy AK, 1999, VITAM HORM, V55, P309; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Yamaji R, 2003, BBA-MOL CELL RES, V1593, P269, DOI 10.1016/S0167-4889(02)00397-X; Yamaji R, 2005, BBA-GEN SUBJECTS, V1726, P261, DOI 10.1016/j.bbagen.2005.07.013; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	37	84	86	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22651	22661		10.1074/jbc.M610724200	http://dx.doi.org/10.1074/jbc.M610724200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553795	hybrid			2022-12-25	WOS:000248354200042
J	Iwasaki, K; Hailemariam, K; Tsuji, Y				Iwasaki, Kenta; Hailemariam, Kiros; Tsuji, Yoshiaki			PIAS3 interacts with ATF1 and regulates the human ferritin H gene through an antioxidant-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMAD TRANSCRIPTIONAL ACTIVITY; BINDING-PROTEIN-BETA; LABILE IRON POOL; OXIDATIVE STRESS; MESSENGER-RNA; DNA-BINDING; FACTOR-I; DEPENDENT TRANSCRIPTION; MEDIATED EXPRESSION; MOLECULAR CONTROL	Gene transcription is coordinately regulated by the balance between activation and repression mechanisms in response to various external stimuli. Ferritin, composed of Hand L subunits, is the major intracellular iron storage protein involved in iron homeostasis. We previously identified an enhancer, termed antioxidant-responsive element (ARE), in the human ferritin H gene and its respective transcriptional activators including Nrf2 and JunD. Here we found that ATF1 (activating transcription factor 1) is a transcriptional repressor of the ferritin H ARE. Subsequent yeast two-hybrid screening identified PIAS3 (protein inhibitor of activated STAT3) as an ATF1-binding protein. Further investigation of the human ferritin H ARE regulation showed that 1) PIAS3 reversed ATF1-mediated repression of the ferritin H ARE; 2) ATF1 was sumoylated, but PIAS3, a SUMO E3 ligase, did not appear to play a major role in SUMO1-mediated ATF1 sumoylation or ATF1 transcription activating function; 3) PIAS3 decreased ATF1 binding to the ARE; and 4) ATF1 knockdown with siRNA increased ferritin H expression, whereas PIAS3 knockdown decreased basal expression and oxidative stress-mediated induction of ferritin H. These results suggest that PIAS3 antagonizes the repressor function of ATF1, at least in part by blocking its DNA binding, and ultimately activates the ARE. Collectively our results suggest that PIAS3 is a new regulator of ATF1 that regulates the ARE-mediated transcription of the ferritin H gene.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Tsuji, Y (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	yoshiaki_tsuji@ncsu.edu		Iwasaki, Kenta/0000-0003-3229-5192	NIDDK NIH HHS [DK-60007S, R01 DK060007-03, R01 DK060007, DK-60007] Funding Source: Medline; NIEHS NIH HHS [ES-007046] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007046] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Arora T, 2003, J BIOL CHEM, V278, P21327, DOI 10.1074/jbc.C300119200; Arosio P, 2002, FREE RADICAL BIO MED, V33, P457, DOI 10.1016/S0891-5849(02)00842-0; Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; Belmonte N, 2001, MOL ENDOCRINOL, V15, P2037, DOI 10.1210/me.15.11.2037; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; Chenais B, 2000, FREE RADICAL BIO MED, V28, P18, DOI 10.1016/S0891-5849(99)00195-1; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Dong Y, 2002, EXP CELL RES, V276, P328, DOI 10.1006/excr.2002.5534; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Ferreira C, 2001, BLOOD, V98, P525, DOI 10.1182/blood.V98.3.525; Ganz T, 2006, BBA-MOL CELL RES, V1763, P690, DOI 10.1016/j.bbamcr.2006.03.014; Guo B, 1997, BIOCHEMISTRY-US, V36, P14447, DOI 10.1021/bi971781s; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hintze KJ, 2005, P NATL ACAD SCI USA, V102, P15048, DOI 10.1073/pnas.0505148102; HSUEH YP, 1995, J IMMUNOL, V154, P5675; Huang CY, 2005, MOL ENDOCRINOL, V19, P2915, DOI 10.1210/me.2005-0097; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Iwasaki K, 2006, MOL CELL BIOL, V26, P2845, DOI 10.1128/MCB.26.7.2845-2856.2006; Jaiswal AK, 2004, METHOD ENZYMOL, V378, P221; James P, 1996, GENETICS, V144, P1425; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; Kakhlon O, 2002, BIOCHEM J, V363, P431, DOI 10.1042/0264-6021:3630431; Kakhlon O, 2001, BIOCHEM J, V356, P311, DOI 10.1042/0264-6021:3560311; Kingsley-Kallesen ML, 1999, J BIOL CHEM, V274, P34020, DOI 10.1074/jbc.274.48.34020; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee MG, 2003, J BIOL CHEM, V278, P41047, DOI 10.1074/jbc.M307031200; Li J, 2004, METHOD ENZYMOL, V378, P238; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Lyst MJ, 2006, EMBO J, V25, P5317, DOI 10.1038/sj.emboj.7601404; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Okuyama Y, 1996, FEBS LETT, V397, P219, DOI 10.1016/S0014-5793(96)01178-7; Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241; Papanikolaou G, 2005, TOXICOL APPL PHARM, V202, P199, DOI 10.1016/j.taap.2004.06.021; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Salnikow K, 1997, CANCER RES, V57, P5060; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Theil EC, 2003, J NUTR, V133, p1549S, DOI 10.1093/jn/133.5.1549S; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Tsuji Y, 2005, ONCOGENE, V24, P7567, DOI 10.1038/sj.onc.1208901; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; TSUJI Y, 1993, J BIOL CHEM, V268, P7270; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Tsuji Y, 1998, J BIOL CHEM, V273, P2984, DOI 10.1074/jbc.273.5.2984; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Zaman K, 1999, J NEUROSCI, V19, P9821; Zhang JW, 2004, J BIOL CHEM, V279, P4471, DOI 10.1074/jbc.M311327200; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	72	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22335	22343		10.1074/jbc.M701477200	http://dx.doi.org/10.1074/jbc.M701477200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17565989	Green Accepted, hybrid			2022-12-25	WOS:000248354200011
J	Liebert, K; Horton, JR; Chahar, S; Orwick, M; Cheng, XD; Jeltsch, A				Liebert, Kirsten; Horton, John R.; Chahar, Sanjay; Orwick, Marcella; Cheng, Xiaodong; Jeltsch, Albert			Two alternative conformations of S-Adenosyl-L-homocysteine bound to Escherichia coli DNA adenine methyltransferase and the implication of conformational changes in regulating the catalytic cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; DAM METHYLTRANSFERASE; SUBSTRATE-RECOGNITION; L-METHIONINE; METHYLATION; BINDING; ADENOSYLMETHIONINE; SPECIFICITY; SEQUENCE; COMPLEX	The crystal structure of the Escherichia coli DNA adenine methyltransferase( EcoDam) in a binary complex with the cofactor product S-adenosyl-L-homocysteine ( AdoHcy) unexpectedly showed the bound AdoHcy in two alternative conformations, extended or folded. The extended conformation represents the catalytically competent conformation, identical to that of EcoDam-DNA-AdoHcy ternary complex. The folded conformation prevents catalysis, because the homocysteine moiety occupies the target Ade binding pocket. The largest difference between the binary and ternary structures is in the conformation of the N-terminal hexapeptide ( (9)KWAGGK(14)). Cofactor binding leads to a strong change in the fluorescence of Trp(10), whose indole ring approaches the cofactor by 3.3 angstrom. Stopped-flow kinetics andAdoMetcross-linking studies indicate that the cofactor prefers binding to the enzyme after preincubation with DNA. In the presence of DNA, AdoMet binding is similar to 2-fold stronger than AdoHcy binding. In the binary complex the side chain of Lys(14) is disordered, whereas Lys(14) stabilizes the active site in the ternary complex. Fluorescence stopped-flow experiments indicate that Lys(14) is important for EcoDam binding of the extrahelical target base into the active site pocket. This suggests that the hexapeptide couples specific DNA binding (Lys(9)), AdoMet binding (Trp(10)), and insertion of the flipped target base into the active site pocket (Lys(14)).	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Jacobs Univ Bremen, Sch Sci & Engn, Biochem Lab, D-28759 Bremen, Germany; Jacobs Univ Bremen, Sch Sci & Engn, BioRec Grad Program, D-28759 Bremen, Germany	Emory University; Jacobs University; Jacobs University	Jeltsch, A (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	a.jeltsch@jacobs-university.de	Horton, John/F-2375-2010; Horton, John R/ABB-4770-2020; Jeltsch, Albert/O-7404-2014	Jeltsch, Albert/0000-0001-6113-9290; Horton, John/0000-0001-9749-8068	NIGMS NIH HHS [R01 GM068680, GM068680] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068680] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BERGERAT A, 1990, NUCLEIC ACIDS RES, V18, P4369, DOI 10.1093/nar/18.15.4369; BERGERAT A, 1991, P NATL ACAD SCI USA, V88, P6394, DOI 10.1073/pnas.88.15.6394; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; CHENG XD, 1995, CURR OPIN STRUC BIOL, V5, P4, DOI 10.1016/0959-440X(95)80003-J; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gowher H, 2006, J MOL BIOL, V357, P928, DOI 10.1016/j.jmb.2006.01.035; HATTMAN S, 1978, J MOL BIOL, V126, P367, DOI 10.1016/0022-2836(78)90046-3; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Horton JR, 2006, J MOL BIOL, V358, P559, DOI 10.1016/j.jmb.2006.02.028; Horton JR, 2005, CELL, V121, P349, DOI 10.1016/j.cell.2005.02.021; Jeltsch Albert, 2002, Methods Mol Biol, V182, P85; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LACKS S, 1977, J MOL BIOL, V114, P153, DOI 10.1016/0022-2836(77)90289-3; Liebert K, 2004, J MOL BIOL, V341, P443, DOI 10.1016/j.jmb.2004.05.033; Lobner-Olesen A, 2005, CURR OPIN MICROBIOL, V8, P154, DOI 10.1016/j.mib.2005.02.009; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; Roth M, 1998, J BIOL CHEM, V273, P17333, DOI 10.1074/jbc.273.28.17333; Roth M, 2000, BIOL CHEM, V381, P269, DOI 10.1515/BC.2000.035; Roth M, 2001, NUCLEIC ACIDS RES, V29, P3137, DOI 10.1093/nar/29.15.3137; Sankpal UT, 2002, NUCLEIC ACIDS RES, V30, P2628, DOI 10.1093/nar/gkf380; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Thomas CB, 2003, J BIOL CHEM, V278, P26094, DOI 10.1074/jbc.M303751200; Tong L, 1997, METHOD ENZYMOL, V276, P594, DOI 10.1016/S0076-6879(97)76080-4; Urig S, 2002, J MOL BIOL, V319, P1085, DOI 10.1016/S0022-2836(02)00371-6; WENZEL C, 1993, NUCLEIC ACIDS RES, V21, P4604, DOI 10.1093/nar/21.19.4604; Yang Z, 2003, NAT STRUCT BIOL, V10, P849, DOI 10.1038/nsb973	34	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22848	22855		10.1074/jbc.M700926200	http://dx.doi.org/10.1074/jbc.M700926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17545164	hybrid			2022-12-25	WOS:000248354200062
J	Mueller, GP; Driscoll, WJ				Mueller, Gregory P.; Driscoll, William J.			In vitro synthesis of oleoylglycine by cytochrome c points to a novel pathway for the production of lipid signaling molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION COMMUNICATION; ACID N-ACYLTRANSFERASE; ACYL-COA; INDUCE SLEEP; BRAIN LIPIDS; FATTY-ACIDS; CELL INJURY; RAT-LIVER; MITOCHONDRIA; OLEAMIDE	Long chain fatty acyl glycines represent a new class of signaling molecules whose biosynthetic pathway is unknown. Here we report that cytochrome c catalyzes the formation of oleoylglycine from oleoyl-CoA and glycine, in the presence of hydrogen peroxide. The identity of oleoylglycine product was confirmed by isotope labeling and fragmentation mass spectrometry. Synthesis of oleoylglycine by cytochrome c was dependent upon substrate concentration and time. Other heme-containing proteins, myoglobin and hemoglobin, did not catalyze oleoylglycine synthesis. The functional properties of the reaction closely resemble those observed for the ability of cytochrome c to mediate the synthesis of oleamide from oleoyl-CoA and ammonia, in the presence of hydrogen peroxide (Driscoll, W. J., Chaturvedi., S., and Mueller, G. P. (2007) J. Biol. Chem. 282). The ability of cytochrome c to catalyze the formation of oleoylglycine experimentally indicates the potential importance of cytochrome c as a novel mechanism for the generation of long chain fatty acyl glycine messengers in vivo.	Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Mueller, GP (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gmueller@usuhs.mil			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038050] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS38050-03] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAFAT ES, 1989, LIFE SCI, V45, P1679, DOI 10.1016/0024-3205(89)90278-6; Barros MH, 2003, FREE RADICAL BIO MED, V35, P179, DOI 10.1016/S0891-5849(03)00307-1; Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002; Boger DL, 1998, P NATL ACAD SCI USA, V95, P4810, DOI 10.1073/pnas.95.9.4810; Bonafe L, 2000, MOL GENET METAB, V69, P302, DOI 10.1006/mgme.2000.2982; Chaturvedi S, 2006, PROSTAG OTH LIPID M, V81, P136, DOI 10.1016/j.prostaglandins.2006.09.001; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; Driscoll WJ, 2007, J BIOL CHEM, V282, P22353, DOI 10.1074/jbc.M610070200; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Garcia-Dorado D, 2004, CARDIOVASC RES, V61, P386, DOI 10.1016/j.cardiores.2003.11.039; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Huang SM, 2001, J BIOL CHEM, V276, P42639, DOI 10.1074/jbc.M107351200; HuidobroToro JP, 1996, P NATL ACAD SCI USA, V93, P8078, DOI 10.1073/pnas.93.15.8078; Huitron-Resendiz S, 2001, EXP NEUROL, V172, P235, DOI 10.1006/exnr.2001.7792; Ito A, 2004, CARCINOGENESIS, V25, P2015, DOI 10.1093/carcin/bgh208; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; KASE BF, 1989, J BIOL CHEM, V264, P9220; KASE BF, 1986, BIOCHEM BIOPH RES CO, V138, P167, DOI 10.1016/0006-291X(86)90261-5; KELLEY M, 1994, J BIOCHEM TOXICOL, V9, P153, DOI 10.1002/jbt.2570090307; Kohno M, 2006, BIOCHEM BIOPH RES CO, V347, P827, DOI 10.1016/j.bbrc.2006.06.175; LERNER RA, 1994, P NATL ACAD SCI USA, V91, P9505, DOI 10.1073/pnas.91.20.9505; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; MAWAL YR, 1994, BIOCHEM BIOPH RES CO, V205, P1373, DOI 10.1006/bbrc.1994.2817; Merkler DJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P430, DOI 10.1006/abbi.1996.0272; Merkler DJ, 2004, BIOCHEMISTRY-US, V43, P12667, DOI 10.1021/bi049529p; O'Byrne J, 2003, J BIOL CHEM, V278, P34237, DOI 10.1074/jbc.M300987200; Soltys BJ, 2001, CELL BIOL INT, V25, P331, DOI 10.1006/cbir.2000.0651; Stewart JM, 2000, BIOCHEM CELL BIOL, V78, P675, DOI 10.1139/bcb-78-6-675; Sultana T, 2006, J CHROMATOGR A, V1101, P278, DOI 10.1016/j.chroma.2005.10.027; Wang ZB, 2003, PROTEIN PEPTIDE LETT, V10, P247, DOI 10.2174/0929866033479013; Zhao YG, 2004, BIOCHEM BIOPH RES CO, V317, P980, DOI 10.1016/j.bbrc.2004.03.144; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200	35	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22364	22369		10.1074/jbc.M701801200	http://dx.doi.org/10.1074/jbc.M701801200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17537719	hybrid			2022-12-25	WOS:000248354200014
J	Nakanishi, M; Ozaki, T; Yamamoto, H; Hanamoto, T; Kikuchi, H; Furuya, K; Asaka, M; Delia, D; Nakagawara, A				Nakanishi, Mitsuru; Ozaki, Toshinori; Yamamoto, Hideki; Hanamoto, Takayuki; Kikuchi, Hironobu; Furuya, Kazushige; Asaka, Masahiro; Delia, Domenico; Nakagawara, Akira			NFBD1/MDC1 associates with p53 and regulates its function at the crossroad between cell survival and death in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BRCT DOMAIN; TRANSCRIPTIONAL ACTIVATION; IONIZING-RADIATION; WILD-TYPE; PHOSPHORYLATION; CHECKPOINT; MDM2; PROTEIN; ATM	NFBD1/MDC1, which belongs to the BRCT superfamily, has an anti-apoptotic activity and contributes to the early cellular responses to DNA damage. Here we found that NFBD1 protects cells from apoptotic cell death by inhibiting phosphorylation of p53 at Ser-15 under steady state as well as early phase of DNA damage, thereby blocking its transcriptional and pro-apoptotic activities. During late phase of DNA damage, a remarkable reduction of NFBD1 was observed in dying but not in surviving A549 cells bearing wild-type p53. Small interference RNA-mediated knockdown of the endogenous NFBD1 resulted in an increase in sensitivity to adriamycin in A549 cells but not in p53-deficient H1299 cells. Immunoprecipitation and luciferase reporter analyses demonstrated that NFBD1 binds to the NH2-terminal region of p53 and strongly inhibits its transcriptional activity. Additionally, BRCT domains, which can interact with p53, reduced the adriamycin-induced phosphorylation levels of p53 at Ser-15 and also suppressed the transcriptional activity of p53. Thus, our present findings strongly suggest that NFBD1 plays an important role in the decision of cell survival and death after DNA damage through the regulation of p53.	Chiba Canc Ctr Res Inst, Div Biochem, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Gastroenterol, Sapporo, Hokkaido 0608638, Japan; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy	Chiba Cancer Center; Hokkaido University; Fondazione IRCCS Istituto Nazionale Tumori Milan	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Asaka, Masahiro/A-5948-2012					Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chehab NH, 2000, GENE DEV, V14, P278; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; HIRAO A, 2003, SCIENCE, V287, P37536; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lou ZK, 2004, J BIOL CHEM, V279, P46359, DOI 10.1074/jbc.C400375200; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ozaki T, 2000, DNA CELL BIOL, V19, P475, DOI 10.1089/10445490050128403; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Peng AM, 2005, CANCER RES, V65, P1158, DOI 10.1158/0008-5472.CAN-04-2508; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rodicker F, 2003, CANCER RES, V63, P2737; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stuck M, 2004, DNA REPAIR, V3, P953, DOI 10.1016/j.dnarep.2004.03.007; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Townsend PA, 2005, J CELL SCI, V118, P1629, DOI 10.1242/jcs.01728; VAN AD, 1996, SCIENCE, V274, P787; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xu XZ, 2003, FASEB J, V17, P1842, DOI 10.1096/fj.03-0310com; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	51	42	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22993	23004		10.1074/jbc.M611412200	http://dx.doi.org/10.1074/jbc.M611412200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17535811	hybrid			2022-12-25	WOS:000248354200076
J	Berdichevsky, Y; Mizrahi, A; Ugolev, Y; Molshanski-Mor, S; Pick, E				Berdichevsky, Yevgeny; Mizrahi, Ariel; Ugolev, Yelena; Molshanski-Mor, Shahar; Pick, Edgar			Tripartite chimeras comprising functional domains derived from the cytosolic NADPH oxidase components p47(phox), p67(phox), and Rac1 elicit activator-independent superoxide production by phagocyte membranes - An essential role for anionic membrane phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; SODIUM DODECYL-SULFATE; ADENINE-DINUCLEOTIDE PHOSPHATE; SRC HOMOLOGY-3 DOMAINS; GTP-BINDING PROTEIN; POLYMORPHONUCLEAR LEUKOCYTES; MOLECULAR-BASIS; LIPID PRODUCTS; NUCLEOTIDE	The superoxide-generating NADPH oxidase is converted to an active state by the assembly of a membrane-localized cytochrome b(559) with three cytosolic components: p47(phox), p67(phox), and GTPase Rac1 or Rac2. Assembly involves two sets of protein-protein interactions: among cytosolic components and among cytosolic components and cytochrome b559 within its lipid habitat. We circumvented the need for interactions among cytosolic components by constructing a recombinant tripartite chimera (trimera) consisting of the Phox homology (PX) and Src homology 3 (SH3) domains of p47(phox), the tetratricopeptide repeat and activation domains of p67(phox), and full-length Rac1. Upon addition to phagocyte membrane, the trimera was capable of oxidase activation in vitro in the presence of an anionic amphiphile. The trimera had a higher affinity (lower EC50) for and formed a more stable complex (longer half-life) with cytochrome b559 compared with the combined individual components, full-length or truncated. Supplementation of membrane with anionic but not neutral phospholipids made activation by the trimera amphiphile-independent. Mutagenesis, truncations, and domain replacements revealed that oxidase activation by the trimera was dependent on the following interactions: 1) interaction with anionic membrane phospholipids via the polybasic stretch at the C terminus of the Rac1 segment; 2) interaction with p22(phox) via Trp(193) in the N-terminal SH3 domain of the p47(phox) segment, supplementing the electrostatic attraction; and 3) an intrachimeric bond among the p67(phox) and Rac1 segments complementary to their physical fusion. The PX domain of the p47(phox) segment and the insert domain of the Rac1 segment made only minor contributions to oxidase assembly.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Ela Kodesz Inst Host Def Infect Dis, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel.	epick@post.tau.ac.il	Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233; Berdichevsky, Yevgeny/0000-0002-5038-6816				ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1992, J BIOL CHEM, V267, P16767; AHARONI I, 1990, J LEUKOCYTE BIOL, V48, P107, DOI 10.1002/jlb.48.2.107; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; *BIORAD LAB, 1984, BIORAD TECHN B; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Dang PMC, 2002, P NATL ACAD SCI USA, V99, P4262, DOI 10.1073/pnas.072345299; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DeCoursey TE, 2005, CELL MOL LIFE SCI, V62, P2173, DOI 10.1007/s00018-005-5177-1; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Diebold BA, 2004, J BIOL CHEM, V279, P28136, DOI 10.1074/jbc.M313891200; Ebisu K, 2001, J BIOL CHEM, V276, P24498, DOI 10.1074/jbc.M101122200; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Finkielstein CV, 2006, J BIOL CHEM, V281, P27317, DOI 10.1074/jbc.M605560200; Foubert TR, 2002, BBA-BIOMEMBRANES, V1567, P221, DOI 10.1016/S0005-2736(02)00619-3; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; Henriques C, 2003, PARASITOL RES, V89, P123, DOI 10.1007/s00436-002-0728-y; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Miyano K, 2004, ARCH BIOCHEM BIOPHYS, V431, P129, DOI 10.1016/j.abb.2004.08.004; Miyano K, 2003, BIOCHEMISTRY-US, V42, P184, DOI 10.1021/bi0269052; Miyano K, 2001, BIOCHEMISTRY-US, V40, P14089, DOI 10.1021/bi010882u; Mizrahi A, 2005, J BIOL CHEM, V280, P3802, DOI 10.1074/jbc.M410257200; Mizrahi A, 2006, J LEUKOCYTE BIOL, V79, P881, DOI 10.1189/jlb.1005553; Molshanski-Mor Shahar, 2007, V412, P385, DOI 10.1007/978-1-59745-467-4_25; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Peng GH, 2003, BIOCHEM J, V373, P221, DOI 10.1042/BJ20021629; Perisic O, 2004, ADV ENZYME REGUL, V44, P279, DOI 10.1016/j.advenzreg.2003.11.003; PICK E, 1987, J BIOL CHEM, V262, P16476; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Sambrook J, 2001, MOL CLONING LAB MANU; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; Sigal N, 2003, INFLAMMATION, V27, P147, DOI 10.1023/A:1023869828688; Sigal N, 2003, J BIOL CHEM, V278, P4854, DOI 10.1074/jbc.M211011200; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith Susan J M, 2002, Methods Mol Biol, V189, P13; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; TAMURA M, 1992, J BIOL CHEM, V267, P7529; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; Ueyama T, 2005, J IMMUNOL, V175, P2381, DOI 10.4049/jimmunol.175.4.2381; Ugolev Y, 2006, J BIOL CHEM, V281, P19204, DOI 10.1074/jbc.M600042200; van Bruggen R, 2004, J BIOL CHEM, V279, P9097, DOI 10.1074/jbc.M309284200	81	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22122	22139		10.1074/jbc.M701497200	http://dx.doi.org/10.1074/jbc.M701497200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17548354	hybrid			2022-12-25	WOS:000248196800059
J	Jerga, A; Lu, YJ; Schujman, GE; de Mendoza, D; Rock, CO				Jerga, Agoston; Lu, Ying-Jie; Schujman, Gustavo E.; de Mendoza, Diego; Rock, Charles O.			Identification of a soluble diacylglycerol kinase required for lipoteichoic acid production in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-DERIVED OLIGOSACCHARIDES; BACTERIAL CELL WALLS; ESCHERICHIA-COLI; DIGLYCERIDE KINASE; STAPHYLOCOCCUS-AUREUS; C55-ISOPRENOID ALCOHOL; STREPTOCOCCUS-MUTANS; BIOSYNTHESIS; GENE; PHOSPHATIDYLGLYCEROL	Diacylglycerol kinases (DagKs) are key enzymes in lipid metabolism that function to reintroduce diacylglycerol formed from the hydrolysis of phospholipids into the biosynthetic pathway. Bacillus subtilis is a prototypical Gram-positive bacterium with a lipoteichoic acid structure containing repeating units of sn-glycerol-1-P groups derived from phosphatidylglycerol head groups. The B. subtilis homolog of the prokaryotic DagK gene family (dgkA; Pfam01219) was not a DagK but rather was an undecaprenol kinase. The three members of the soluble DagK protein family (Pfam00781) in B. subtilis were tested by complementation of an E. coli dgkA mutant, and only the essential yerQ gene possessed DagK activity. This gene was dubbed dgkB, and the soluble protein product was purified, and its DagK activity was verified in vitro. Conditional inactivation of dgkB led to the accumulation of diacylglycerol and the cessation of lipoteichoic acid formation in B. subtilis. This study identifies a soluble protein encoded by the dgkB (yerQ) gene as an essential kinase in the diacylglycerol cycle that drives lipoteichoic acid production.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Mol & Celular Rosario, RA-2000 Rosario, Argentina; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol, RA-2000 Rosario, Argentina	St Jude Children's Research Hospital; National University of Rosario; National University of Rosario	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale, Memphis, TN 38105 USA.	charles.rock@stjude.org			NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amiteye S, 2003, J BACTERIOL, V185, P5306, DOI 10.1128/JB.185.17.5306-5309.2003; Bakali HMA, 2007, J BIOL CHEM, V282, P19644, DOI 10.1074/jbc.M604852200; BEHR T, 1992, EUR J BIOCHEM, V207, P1063, DOI 10.1111/j.1432-1033.1992.tb17143.x; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; BISHOP DG, 1967, EUR J BIOCHEM, V2, P448, DOI 10.1111/j.1432-1033.1967.tb00158.x; CABACUNGAN E, 1981, J BACTERIOL, V147, P75, DOI 10.1128/JB.147.1.75-79.1981; CAIN BD, 1993, J BACTERIOL, V175, P3784, DOI 10.1128/JB.175.12.3784-3789.1993; Chen P, 1998, J BACTERIOL, V180, P167, DOI 10.1128/JB.180.1.167-170.1998; EL GM, 2004, J BIOL CHEM, V279, P30106; FIEDLER W, 1985, J BIOL CHEM, V260, P4799; GOLDBERG DE, 1981, P NATL ACAD SCI-BIOL, V78, P5513, DOI 10.1073/pnas.78.9.5513; HIGASHI Y, 1970, J BIOL CHEM, V245, P3683; HIGASHI Y, 1970, J BIOL CHEM, V245, P3697; JACKSON BJ, 1984, J BACTERIOL, V160, P976, DOI 10.1128/JB.160.3.976-981.1984; KENNEDY EP, 1982, P NATL ACAD SCI-BIOL, V79, P1092, DOI 10.1073/pnas.79.4.1092; Kiriukhin MY, 2001, J BACTERIOL, V183, P3506, DOI 10.1128/JB.183.11.3506-3514.2001; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; KOCH HU, 1984, EUR J BIOCHEM, V138, P357, DOI 10.1111/j.1432-1033.1984.tb07923.x; KOGA Y, 1984, BIOCHIM BIOPHYS ACTA, V793, P86; LACROIX JM, 1991, MOL MICROBIOL, V5, P1745, DOI 10.1111/j.1365-2958.1991.tb01924.x; Lau FW, 1999, BIOCHEMISTRY-US, V38, P5521, DOI 10.1021/bi982763t; Lis M, 2003, FEMS MICROBIOL LETT, V229, P179, DOI 10.1016/S0378-1097(03)00818-8; Lis M, 2003, INFECT IMMUN, V71, P1938, DOI 10.1128/IAI.71.4.1938-1943.2003; Neuhaus FC, 2003, MICROBIOL MOL BIOL R, V67, P686, DOI 10.1128/MMBR.67.4.686-723.2003; Nguyen HD, 2005, PLASMID, V54, P241, DOI 10.1016/j.plasmid.2005.05.001; NOTO T, 1982, J ANTIBIOT, V35, P401, DOI 10.7164/antibiotics.35.401; Owens RM, 2006, MOL MICROBIOL, V60, P1152, DOI 10.1111/j.1365-2958.2006.05174.x; Oxenoid K, 2002, BIOCHEMISTRY-US, V41, P12876, DOI 10.1021/bi020335o; RAETZ CRH, 1978, J BIOL CHEM, V253, P3882; RAETZ CRH, 1979, J BACTERIOL, V137, P860, DOI 10.1128/JB.137.2.860-868.1979; RUMLEY MK, 1992, J BIOL CHEM, V267, P11806; SANDERMA.H, 1971, P NATL ACAD SCI USA, V68, P2441, DOI 10.1073/pnas.68.10.2441; SCHNEIDER EG, 1976, BIOCHIM BIOPHYS ACTA, V441, P201, DOI 10.1016/0005-2760(76)90163-6; SCHNEIDER EG, 1973, J BIOL CHEM, V248, P3739; SCHULMAN H, 1977, J BIOL CHEM, V252, P4250; SMITH RL, 1994, J BACTERIOL, V176, P5459, DOI 10.1128/JB.176.17.5459-5465.1994; TARON DJ, 1983, J BACTERIOL, V154, P1110, DOI 10.1128/JB.154.3.1110-1116.1983; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; WALSH JP, 1986, J BIOL CHEM, V261, P6239; Wen JA, 1996, NAT STRUCT BIOL, V3, P141, DOI 10.1038/nsb0296-141	41	50	59	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21738	21745		10.1074/jbc.M703536200	http://dx.doi.org/10.1074/jbc.M703536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17535816	hybrid			2022-12-25	WOS:000248196800021
J	Andres-Enguix, I; Caley, A; Yustos, R; Schumacher, MA; Spanu, PD; Dickinson, R; Maze, M; Franks, NP				Andres-Enguix, Isabelle; Caley, Alex; Yustos, Raquel; Schumacher, Mark A.; Spanu, Pietro D.; Dickinson, Robert; Maze, Mervyn; Franks, Nicholas P.			Determinants of the anesthetic sensitivity of two-pore domain acid-sensitive potassium channels - Molecular cloning of an anesthetic-activated potassium channel from Lymnaea stagnalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACKGROUND K+ CHANNELS; GENERAL-ANESTHETICS; VOLATILE ANESTHETICS; INHALED ANESTHETICS; APLYSIA-CALIFORNICA; K-2P CHANNELS; TASK-3; MECHANISMS; NEUROPROTECTION; MODULATION	Certain two-pore domain K+ channels are plausible targets for volatile general anesthetics, yet little is known at the molecular level about how these simple agents cause channel activation. The first anesthetic-activated K+ current I-K(An) that was characterized was discovered in the mollusk Lymnaea stagnalis and is remarkable for both its sensitivity to general anesthetics and its stereo-selective responses to anesthetic enantiomers (Franks, N. P., and Lieb, W. R. (1988) Nature 333, 662-664 and Franks, N. P., and Lieb, W. R. (1991) Science 254, 427-430). Here we report the molecular cloning of a two-pore domain K+ channel LyTASK from L. stagnalis and show that, when expressed in HEK-293 cells, it displays the same biophysical characteristics as the anesthetic-activated K+ current I-K(An). Sequence analysis and functional properties show it to be a member of the TASK family of channels with similar to 47% identity at the amino acid level when compared with human TASK-1 and TASK-3. By using chimeric channel constructs and site-directed mutagenesis we have identified the specific amino acid 159 to be a critical determinant of anesthetic sensitivity, which, when mutated to alanine, essentially eliminates anesthetic activation in the human channels and greatly reduces activation in LyTASK. The L159A mutation in LyTASK disrupts the stereo-selective response to isoflurane while having no effect on the pH sensitivity of the channel, suggesting this critical amino acid may form part of an anesthetic binding site.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Div Biol, London SW7 2AZ, England; Chelsea & Westminster Hosp, Imperial Coll Sch Med, Dept Anaesthet Pain Med & Intens Care, London SW10 9NH, England	Imperial College London; Imperial College London; Imperial College London	Franks, NP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Prince Consort Rd, London SW7 2AZ, England.	n.franks@imperial.ac.uk	Spanu, Pietro/P-5859-2019	Spanu, Pietro/0000-0001-8928-6049; Franks, Nicholas/0000-0003-4874-4212				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Clarke CE, 2004, J PHYSIOL-LONDON, V560, P51, DOI 10.1113/jphysiol.2004.070292; DICKINSON R, 1994, BIOPHYS J, V66, P2019, DOI 10.1016/S0006-3495(94)80994-4; FIRESTONE LL, 1986, MOL CELLULAR MECH AN, P455; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; Franks NP, 2004, TRENDS PHARMACOL SCI, V25, P601, DOI 10.1016/j.tips.2004.09.003; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; Franks NP, 1999, NAT NEUROSCI, V2, P395, DOI 10.1038/8054; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; FRANKS NP, 1991, ANN NY ACAD SCI, V625, P54, DOI 10.1111/j.1749-6632.1991.tb33829.x; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Gruss M, 2004, MOL PHARMACOL, V66, P530; Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234; Hille B, 2001, ION CHANNELS EXCITAB, V3rd, P445; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Honore E, 2007, NAT REV NEUROSCI, V8, P251, DOI 10.1038/nrn2117; Jezzini SH, 2006, BRAIN RES, V1094, P47, DOI 10.1016/j.brainres.2006.03.122; Jezzini SH, 2004, MOL BRAIN RES, V127, P27, DOI 10.1016/j.molbrainres.2004.05.007; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Linden AM, 2006, J PHARMACOL EXP THER, V317, P615, DOI 10.1124/jpet.105.098525; Lopes CMB, 1998, BRIT J PHARMACOL, V125, P309, DOI 10.1038/sj.bjp.0702069; Morton MJ, 2003, PFLUG ARCH EUR J PHY, V445, P577, DOI 10.1007/s00424-002-0901-2; NICOLL RA, 1982, SCIENCE, V217, P1055, DOI 10.1126/science.7112112; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Patel AJ, 2001, ANESTHESIOLOGY, V95, P1013, DOI 10.1097/00000542-200110000-00034; Rajan S, 2001, J BIOL CHEM, V276, P7302, DOI 10.1074/jbc.M008985200; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; RAVENTOS J, 1956, BRIT J PHARM CHEMOTH, V11, P394, DOI 10.1111/j.1476-5381.1956.tb00007.x; Reynolds DS, 2003, J NEUROSCI, V23, P8608; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Sambrook J., 2001, MOL CLONING; Sonner JM, 2003, ANESTH ANALG, V97, P718, DOI 10.1213/01.ANE.0000081063.76651.33; Talley EM, 2003, NEUROSCIENTIST, V9, P46, DOI 10.1177/1073858402239590; Talley EM, 2002, J BIOL CHEM, V277, P17733, DOI 10.1074/jbc.M200502200; Yost CS, 2003, CURR DRUG TARGETS, V4, P347, DOI 10.2174/1389450033491091; Yuill K, 2004, PFLUG ARCH EUR J PHY, V448, P63, DOI 10.1007/s00424-003-1218-5	40	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20977	20990		10.1074/jbc.M610692200	http://dx.doi.org/10.1074/jbc.M610692200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17548360	hybrid			2022-12-25	WOS:000248047500024
J	Ideo, H; Seko, A; Yamashita, K				Ideo, Hiroko; Seko, Akira; Yamashita, Katsuko			Recognition mechanism of galectin-4 for cholesterol 3-sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; SITE-DIRECTED MUTAGENESIS; ADHERENS JUNCTION PROTEIN; RAY CRYSTAL-STRUCTURE; CARBOHYDRATE-RECOGNITION; STRUCTURAL BASIS; HIGH-AFFINITY; SULFATE; MEMBRANE; LACTOSE	Galectin-4 binds to glycosphingolipids carrying 3-O-sulfated Gal residues, and it co-localizes on the cell surface of human colonic adenocarcinoma cells with glycosphingolipids carrying SO3--->3Gal beta 1-->3(GalNAc) residues (Ideo, H., Seko, A., and Yamashita, K. (2005) J. Biol. Chem. 280, 4730-4737). In the present study, it was found that galectin-4 also binds to cholesterol 3-sulfate, which has no beta-galactoside moiety. This characteristic of galectin-4 is unique within the galectin family. The site-directed mutated galectin-4-R45A had diminished binding ability toward cholesterol 3-sulfate, suggesting that Arg(45) of galectin-4 is indispensable for cholesterol 3-sulfate recognition. Gel filtration and chemical cross-linking experiments revealed that some galectin-4 exists as dimers, and this multivalency seemed to enhance its avidity for cholesterol 3-sulfate binding. Cholesterol 3-sulfate and sulfatide co-existed with galectin-4 in detergent-insoluble fractions of porcine esophagus and intestine, respectively. These results suggested that not only sulfated glycosphingolipids but also cholesterol 3-sulfate are endogenous ligands for galectin-4 in vivo.	Tokyo Inst Technol, Innovat Res Initiat, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Yamashita, K (corresponding author), Tokyo Inst Technol, Innovat Res Initiat, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268503, Japan.	kyamashi@bio.titech.ac.jp						Allen HJ, 1998, GLYCOCONJUGATE J, V15, P691, DOI 10.1023/A:1006988515346; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Braccia A, 2003, J BIOL CHEM, V278, P15679, DOI 10.1074/jbc.M211228200; CHIU ML, 1992, J CELL BIOL, V119, P1689, DOI 10.1083/jcb.119.6.1689; CHIU ML, 1994, J BIOL CHEM, V269, P31770; Cui YX, 1997, LIPIDS, V32, P599, DOI 10.1007/s11745-997-0076-2; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; Delacour D, 2005, J CELL BIOL, V169, P491, DOI 10.1083/jcb.200407073; Hansen GH, 2001, J BIOL CHEM, V276, P32338, DOI 10.1074/jbc.M102667200; Henrick K, 1998, GLYCOBIOLOGY, V8, P45, DOI 10.1093/glycob/8.1.45; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1994, GLYCOCONJUGATE J, V11, P437, DOI 10.1007/BF00731280; HOLT GD, 1990, J BIOL CHEM, V265, P2852; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Ideo H, 2005, J BIOL CHEM, V280, P4730, DOI 10.1074/jbc.M410362200; Ideo H, 2003, GLYCOBIOLOGY, V13, P713, DOI 10.1093/glycob/cwg094; Ideo H, 2002, GLYCOBIOLOGY, V12, P199, DOI 10.1093/glycob/12.3.199; IIDA N, 1989, J BIOL CHEM, V264, P5974; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; Kojima K, 1996, J BIOL CHEM, V271, P7679, DOI 10.1074/jbc.271.13.7679; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; Lingwood C, 2005, J BIOL CHEM, V280, P12542, DOI 10.1074/jbc.M413724200; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; NAGAKAWA M, 1976, J BIOCHEM-TOKYO, V80, P729; ODA Y, 1993, J BIOL CHEM, V268, P5929; RODRIGUEZA WV, 1995, BIOCHEMISTRY-US, V34, P6208, DOI 10.1021/bi00018a025; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Seko A, 2005, GLYCOBIOLOGY, V15, P943, DOI 10.1093/glycob/cwi082; Seko A, 2002, JPN J CANCER RES, V93, P507, DOI 10.1111/j.1349-7006.2002.tb01285.x; Strott CA, 2003, J LIPID RES, V44, P1268, DOI 10.1194/jlr.R300005-JLR200; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WILLIAMS ML, 1985, BIOCHIM BIOPHYS ACTA, V845, P349, DOI 10.1016/0167-4889(85)90198-3	33	42	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21081	21089		10.1074/jbc.M703770200	http://dx.doi.org/10.1074/jbc.M703770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17545668	hybrid			2022-12-25	WOS:000248047500034
J	Liu, D; Ding, X; Du, J; Cai, X; Huang, YJ; Ward, T; Shaw, A; Yang, Y; Hu, R; Jin, CJ; Yao, X				Liu, Dan; Ding, Xia; Du, Jian; Cai, Xin; Huang, Yuejia; Ward, Tarsha; Shaw, Andrew; Yang, Yong; Hu, Renming; Jin, Changjiang; Yao, Xuebiao			Human NUF2 interacts with centromere-associated protein E and is essential for a stable spindle microtubule-kinetochore attachment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENP-E; MITOTIC CHECKPOINT; NDC80 COMPLEX; BUDDING YEAST; CHROMOSOME CONGRESSION; VERTEBRATE CELLS; HEC1; COMPONENTS; METAPHASE; LOCALIZATION	Chromosome segregation in mitosis is orchestrated by dynamic interaction between spindle microtubules and the kinetochore, a multiprotein complex assembled onto centromeric DNA of the chromosome. Here, we show that Homo sapiens (Hs) NUF2 is required for stable kinetochore localization of centromere-associated protein E (CENP-E) in HeLa cells. HsNUF2 specifies the kinetochore association of CENP-E by interacting with its C-terminal domain. The region of HsNUF2 binding to CENP-E was mapped to its C-terminal domain by glutathione S-transferase pulldown and yeast two-hybrid assays. Suppression of synthesis of HsNUF2 by small interfering RNA abrogated the localization of CENP-E to the kinetochore, demonstrating the requirement of HsNUF2 for CENP-E kinetochore localization. In addition, depletion of HsNUF2 caused aberrant chromosome segregation. These HsNUF2-suppressed cells displayed reduced tension at kinetochores of bi-orientated chromosomes. Double knockdown of CENP-E and HsNUF2 further abolished the tension at the kinetochores. Our results indicate that HsNUF2 and CENP-E are required for organization of stable microtubule-kinetochore attachment that is essential for faithful chromosome segregation in mitosis.	Univ Sci & Technol China, Lab Cellular Dynam, Hefei 230027, Peoples R China; Natl Lab Phys Sci, Hefei 230027, Peoples R China; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA; Morehouse Sch Med, Canc Biol Program, Atlanta, GA 30310 USA; Beijing Univ Chinese Med, Dept Med, Beijing 100029, Peoples R China; Fudan Univ, Dept Endocrinol & Metab, Shanghai 200040, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine; Morehouse School of Medicine; Beijing University of Chinese Medicine; Fudan University	Jin, CJ (corresponding author), Univ Sci & Technol China, Lab Cellular Dynam, Hefei 230027, Peoples R China.	jincj@ustc.edu.cn	Yang, Yong/U-4781-2019; Yang, Yong/P-8322-2018					Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009; Bharadwaj R, 2004, J BIOL CHEM, V279, P13076, DOI 10.1074/jbc.M310224200; Cao XW, 2005, J BIOL CHEM, V280, P13584, DOI 10.1074/jbc.M411941200; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; DeLuca JG, 2002, J CELL BIOL, V159, P549, DOI 10.1083/jcb.200208159; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Fukagawa T, 2004, EXP CELL RES, V296, P21, DOI 10.1016/j.yexcr.2004.03.004; Gillett ES, 2004, J CELL BIOL, V164, P535, DOI 10.1083/jcb.200308100; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; Johnson VL, 2004, J CELL SCI, V117, P1577, DOI 10.1242/jcs.01006; Kapoor TM, 2006, SCIENCE, V311, P388, DOI 10.1126/science.1122142; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lin YT, 2006, ONCOGENE, V25, P6901, DOI 10.1038/sj.onc.1209687; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Maiato H, 2004, J CELL SCI, V117, P5461, DOI 10.1242/jcs.01536; Mao YH, 2005, J CELL BIOL, V170, P873, DOI 10.1083/jcb.200505040; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McCleland ML, 2004, CURR BIOL, V14, P131, DOI 10.1016/j.cub.2003.12.058; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; Mikami Y, 2005, MOL CELL BIOL, V25, P1958, DOI 10.1128/MCB.25.5.1958-1970.2005; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; Wei RR, 2005, P NATL ACAD SCI USA, V102, P5363, DOI 10.1073/pnas.0501168102; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; Xue Y, 2006, CHINESE SCI BULL, V51, P1836, DOI 10.1007/s11434-006-2054-8; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x	37	66	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21415	21424		10.1074/jbc.M609026200	http://dx.doi.org/10.1074/jbc.M609026200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17535814	hybrid			2022-12-25	WOS:000248047500069
J	Tanaka, A; Takahashi, H; Shimizu, T				Tanaka, Atsunari; Takahashi, Hiroto; Shimizu, Toru			Critical role of the heme axial ligand, Met(95), in locking catalysis of the phosphodiesterase from Escherichia coli (Ec DOS) toward cyclic diGMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT OXYGEN SENSOR; 3',5'-CYCLIC DIGUANYLIC ACID; C-DI-GMP; REGULATED PHOSPHODIESTERASE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; PAS DOMAINS; BINDING; PROTEIN; 2ND-MESSENGER	Heme-regulated phosphodiesterase from Escherichia coli (Ec DOS) is a gas-sensor enzyme that hydrolyzes cyclic dinucleotide-GMP, and it is activated by O-2 or CO binding to the Fe(II) heme. In contrast to other well known heme-regulated gas-sensor enzymes or proteins, Ec DOS is not specific for a single gas ligand. Because Arg(97) in the heme distal side in Ec DOS interacts with the O-2 molecule and Met(95) serves as the axial ligand on the distal side of the Fe(II) heme-bound PAS domain of Ec DOS, we explored the effect of mutating these residues on the activity and gas specificity of Ec DOS. We found that R97A, R97I, and R97E mutations do not significantly affect regulation of the phosphodiesterase activities of the Fe(II)-CO and Fe(II)-NO complexes. The phosphodiesterase activities of the Fe(II)-O-2 complexes of the mutants could not be detected due to rapid autoxidation and/or low affinity for O2. In contrast, the activities even of the gas-free M95A and M95L mutants were similar to that of the gas-activated wild-type enzyme. Interestingly, the activity of the M95H mutant was partially activated by O-2, CO, and NO. Spectroscopic analysis indicated that the Fe(II) heme is in the 5-coordinated high-spin state in the M95A and M95L mutants but that in the M95H mutant, like wild-type Ec DOS, it is in the 6-coordinated low-spin state. These results suggest that Met(95) coordination to the Fe(II) heme is critical for locking the system and that global structural changes around Met(95) caused by the binding of the external ligands or mutations at Met(95) releases the catalytic lock and activates catalysis.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan	Tohoku University	Shimizu, T (corresponding author), Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@tagen.tohoku.ac.jp	Tanaka, Atsunari/F-4950-2013	Shimizu, Toru/0000-0002-3950-5554				Akimoto S, 2003, BIOCHEM BIOPH RES CO, V304, P136, DOI 10.1016/S0006-291X(03)00556-4; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Dunham CM, 2003, BIOCHEMISTRY-US, V42, P7701, DOI 10.1021/bi0343370; El-Mashtoly SF, 2007, J AM CHEM SOC, V129, P3556, DOI 10.1021/ja0669777; Galperin MY, 2004, ENVIRON MICROBIOL, V6, P552, DOI 10.1111/j.1462-2920.2004.00633.x; Gilles-Gonzalez MA, 2005, J INORG BIOCHEM, V99, P1, DOI 10.1016/j.jinorgbio.2004.11.006; Gong WM, 2000, BIOCHEMISTRY-US, V39, P3955, DOI 10.1021/bi992346w; Hirata S, 2003, EUR J BIOCHEM, V270, P4771, DOI 10.1046/j.1432-1033.2003.03879.x; Hoffman LR, 2005, NATURE, V436, P1171, DOI 10.1038/nature03912; Jain R, 2003, J BIOL INORG CHEM, V8, P1, DOI 10.1007/s00775-002-0405-8; Karaolis DKR, 2005, BIOCHEM BIOPH RES CO, V329, P40, DOI 10.1016/j.bbrc.2005.01.093; KULESEKARA H, 2006, P NATL ACAD SCI USA, V103, P92844; Kurokawa H, 2004, J BIOL CHEM, V279, P20186, DOI 10.1074/jbc.M314199200; Mendez-Ortiz MM, 2006, J BIOL CHEM, V281, P8090, DOI 10.1074/jbc.M510701200; Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p; Romling U, 2006, CURR OPIN MICROBIOL, V9, P218, DOI 10.1016/j.mib.2006.02.010; Ryjenkov DA, 2006, J BIOL CHEM, V281, P30310, DOI 10.1074/jbc.C600179200; Sasakura Y, 2006, ACCOUNTS CHEM RES, V39, P37, DOI 10.1021/ar0501525; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Taguchi S, 2004, J BIOL CHEM, V279, P3340, DOI 10.1074/jbc.M301013200; Takahashi H, 2006, CHEM LETT, V35, P970, DOI 10.1246/cl.2006.970; Tamayo R, 2005, J BIOL CHEM, V280, P33324, DOI 10.1074/jbc.M506500200; Tanaka A, 2006, BIOCHEMISTRY-US, V45, P2515, DOI 10.1021/bi051989a; Vreede J, 2003, J BIOL CHEM, V278, P18434, DOI 10.1074/jbc.M301701200; Watanabe M, 2002, BIOCHEM BIOPH RES CO, V299, P169, DOI 10.1016/S0006-291X(02)02621-9; Yang JS, 2005, J BIOL CHEM, V280, P36047, DOI 10.1074/jbc.M501755200; Yoshimura-Suzuki T, 2005, J BACTERIOL, V187, P6678, DOI 10.1128/JB.187.19.6678-6682.2005	34	57	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21301	21307		10.1074/jbc.M701920200	http://dx.doi.org/10.1074/jbc.M701920200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17535805	hybrid			2022-12-25	WOS:000248047500058
J	Yi, L; Ragsdale, SW				Yi, Li; Ragsdale, Stephen W.			Evidence that the heme regulatory motifs in heme oxygenase-2 serve as a Thiol/Disulfide redox switch regulating heme binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SULFENIC ACID; IRR PROTEIN; OXIDATIVE STRESS; CARBON-MONOXIDE; IRON LIGAND; K+-CHANNELS; DEGRADATION; HEMOPROTEIN; EXPRESSION; REDUCTASE	Heme oxygenase (HO) catalyzes the O-2- and NADPH-dependent conversion of heme to biliverdin, CO, and iron. The two forms of HO (HO-1 and HO-2) share similar physical properties but are differentially regulated and exhibit dissimilar physiological roles and tissue distributions. Unlike HO-1, HO-2 contains heme regulatory motifs (HRMs) (McCoubrey, W. K., Jr., Huang, T. J., and Maines, M. D. (1997) J. Biol. Chem. 272, 12568-12574). Here we describe UV-visible, EPR, and differential scanning calorimetry experiments on human HO-2 variants containing single, double, and triple mutations in the HRMs. Oxidized HO-2, which contains an intramolecular disulfide bond linking Cys(265) of HRM1 and Cys(282) of HRM2, binds heme tightly. Reduction of the disulfide bond increases the K-d for ferric heme from 0.03 to 0.3 mu M, which is much higher than the concentration of the free heme pool in cells. Although the HRMs markedly affect the K-d for heme, they do not alter the k(cat) for heme degradation and do not bind additional hemes. Because HO-2 plays a key role in CO generation and heme homeostasis, reduction of the disulfide bond would be expected to increase intracellular free heme and decrease CO concentrations. Thus, we propose that the HRMs in HO-2 constitute a thiol/ disulfide redox switch that regulates the myriad physiological functions of HO-2, including its involvement in the hypoxic response in the carotid body, which involves interactions with a Ca2+-activated potassium channel.	Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Ragsdale, SW (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr, 1901 Vine St, Lincoln, NE 68588 USA.	sragsdale1@unl.edu	Yi, Li/A-3967-2013		NCRR NIH HHS [1P20RR17675, P20 RR017675] Funding Source: Medline; NHLBI NIH HHS [R21 HL089837] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL089837] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; Chefalo PJ, 1998, EUR J BIOCHEM, V258, P820, DOI 10.1046/j.1432-1327.1998.2580820.x; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; DOU Y, 1995, J BIOL CHEM, V270, P15993, DOI 10.1074/jbc.270.27.15993; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; Galbraith R, 1999, P SOC EXP BIOL MED, V222, P299, DOI 10.1046/j.1525-1373.1999.d01-147.x; Garrick MD, 1999, BBA-MOL CELL RES, V1449, P125, DOI 10.1016/S0167-4889(99)00006-3; Hen T, 2000, BIOCHEM BIOPH RES CO, V273, P584, DOI 10.1006/bbrc.2000.2995; Hoshi T, 2004, SCIENCE, V306, P2050, DOI 10.1126/science.1107069; Huang TJ, 2001, ANTIOXID REDOX SIGN, V3, P685, DOI 10.1089/15230860152543023; Ishikawa K, 1998, J BIOL CHEM, V273, P4317, DOI 10.1074/jbc.273.8.4317; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; Jaggar JH, 2005, CIRC RES, V97, P805, DOI 10.1161/01.RES.0000186180.47148.7b; Kim HP, 2006, ANNU REV PHARMACOL, V46, P411, DOI 10.1146/annurev.pharmtox.46.120604.141053; KIRSCHNERZILBER I, 1982, BIOCHIM BIOPHYS ACTA, V690, P20, DOI 10.1016/0005-2736(82)90234-6; Lee HC, 2003, MOL CELL BIOL, V23, P5857, DOI 10.1128/MCB.23.16.5857-5866.2003; LeLean JE, 2000, BIOCHEM BIOPH RES CO, V276, P762, DOI 10.1006/bbrc.2000.3539; LIU SC, 1988, BLOOD, V71, P1755; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; Maines MD, 2005, PHYSIOLOGY, V20, P382, DOI 10.1152/physiol.00029.2005; Maines MD, 2004, ANTIOXID REDOX SIGN, V6, P797, DOI 10.1089/1523086041798105; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1992, CLIN APPL FUNCTIONS; McCartney CE, 2005, P NATL ACAD SCI USA, V102, P17870, DOI 10.1073/pnas.0505270102; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; Migita CT, 2003, EUR J BIOCHEM, V270, P687, DOI 10.1046/j.1432-1033.2003.03421.x; Munakata H, 2004, J BIOCHEM, V136, P233, DOI 10.1093/jb/mvh112; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Qi ZH, 1999, P NATL ACAD SCI USA, V96, P13056, DOI 10.1073/pnas.96.23.13056; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sassa S, 2004, ANTIOXID REDOX SIGN, V6, P819, DOI 10.1089/ars.2004.6.819; SASSA S, 2006, ANTIOXID REDOX SIGN, V38, P138; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; TAKAHASHI S, 1995, J BIOL CHEM, V270, P1010; Tang XD, 2003, NATURE, V425, P531, DOI 10.1038/nature02003; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; Yang J, 2006, MOL MICROBIOL, V60, P209, DOI 10.1111/j.1365-2958.2006.05087.x; Yang JH, 2005, J BIOL CHEM, V280, P7671, DOI 10.1074/jbc.M411664200; Zhang YZ, 2006, FEBS J, V273, P3136, DOI 10.1111/j.1742-4658.2006.05319.x	51	71	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21056	21067		10.1074/jbc.M700664200	http://dx.doi.org/10.1074/jbc.M700664200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17540772	Green Accepted, hybrid			2022-12-25	WOS:000248047500032
J	Calzolari, D; Paternostro, G; Harrington, PL; Piermarocchi, C; Duxbury, PM				Calzolari, Diego; Paternostro, Giovanni; Harrington, Patrick L., Jr.; Piermarocchi, Carlo; Duxbury, Phillip M.			Selective Control of the Apoptosis Signaling Network in Heterogeneous Cell Populations	PLOS ONE			English	Article								Background. Selective control in a population is the ability to control a member of the population while leaving the other members relatively unaffected. The concept of selective control is developed using cell death or apoptosis in heterogeneous cell populations as an example. Control of apoptosis is essential in a variety of therapeutic environments, including cancer where cancer cell death is a desired outcome and Alzheimer's disease where neuron survival is the desired outcome. However, in both cases these responses must occur with minimal response in other cells exposed to treatment; that is, the response must be selective. Methodology and Principal Findings. Apoptosis signaling in heterogeneous cells is described by an ensemble of gene networks with identical topology but different link strengths. Selective control depends on the statistics of signaling in the ensemble of networks, and we analyze the effects of superposition, non-linearity and feedback on these statistics. Parallel pathways promote normal statistics while series pathways promote skew distributions, which in the most extreme cases become log-normal. We also show that feedback and non-linearity can produce bimodal signaling statistics, as can discreteness and non-linearity. Two methods for optimizing selective control are presented. The first is an exhaustive search method and the second is a linear programming based approach. Though control of a single gene in the signaling network yields little selectivity, control of a few genes typically yields higher levels of selectivity. The statistics of gene combinations susceptible to selective control in heterogeneous apoptosis networks is studied and is used to identify general control strategies. Conclusions and Significance. We have explored two methods for the study of selectivity in cell populations. The first is an exhaustive search method limited to three node perturbations. The second is an effective linear model, based on interpolation of single node sensitivity, in which the selective combinations can be found by linear programming optimization. We found that selectivity is promoted by acting on the least sensitive nodes in the case of weak populations, while selective control of robust populations is optimized through perturbations of more sensitive nodes. High throughput experiments with heterogeneous cell lines could be designed in an analogous manner, with the further possibility of incorporating the selectivity optimization process into a closed-loop control system.	[Harrington, Patrick L., Jr.; Piermarocchi, Carlo; Duxbury, Phillip M.] Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA; [Calzolari, Diego; Paternostro, Giovanni] Burnham Inst Med Res, La Jolla, CA USA	Michigan State University; Sanford Burnham Prebys Medical Discovery Institute	Duxbury, PM (corresponding author), Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA.	duxbury@pa.msu.edu	Piermarocchi, Carlo/A-2427-2008; Piermarocchi, Carlo/AAH-2162-2019	Piermarocchi, Carlo/0000-0003-2762-8562; Piermarocchi, Carlo/0000-0003-2762-8562; duxbury, Phillip/0000-0003-4549-4764	Burnham Institute; Michigan State University	Burnham Institute; Michigan State University	The work was supported by the Burnham Institute and by Michigan State University. The funders had no role in the work described in the manuscript or in its preparation.	Albert R, 2003, J THEOR BIOL, V223, P1, DOI 10.1016/S0022-5193(03)00035-3; Aldridge BB, 2006, NAT CELL BIOL, V8, P1195, DOI 10.1038/ncb1497; Ankarcrona M, 2005, INT J GERIATR PSYCH, V20, P101, DOI 10.1002/gps.1260; Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122; Barrett CL, 2006, PLOS COMPUT BIOL, V2, P429, DOI 10.1371/journal.pcbi.0020052; Buchler NE, 2005, P NATL ACAD SCI USA, V102, P9559, DOI 10.1073/pnas.0409553102; Colizza V, 2005, PHYSICA A, V352, P1, DOI 10.1016/j.physa.2004.12.030; Covert MW, 2001, J THEOR BIOL, V213, P73, DOI 10.1006/jtbi.2001.2405; Dealy S, 2005, COMPLEXITY, V11, P52, DOI 10.1002/cplx.20100; Drossel B, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.016110; Duarte NC, 2007, P NATL ACAD SCI USA, V104, P1777, DOI 10.1073/pnas.0610772104; Eissing T, 2005, IEE P SYST BIOL, V152, P221, DOI 10.1049/ip-syb:20050046; Feng XJ, 2004, BIOPHYS J, V87, P2195, DOI 10.1529/biophysj.104.044131; Feng XJ, 2004, BIOPHYS J, V86, P1270, DOI 10.1016/S0006-3495(04)74201-0; Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817; Huang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128701; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kauffman S.A., 1993, ORIGINS ORDER; Kholodenko BN, 2006, NAT REV MOL CELL BIO, V7, P165, DOI 10.1038/nrm1838; Klein S, 2006, CURR SIGNAL TRANSD T, V1, P1, DOI 10.2174/157436206775269244; Klemm K, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.055101; Ku J, 2004, J COMPUT BIOL, V11, P642, DOI 10.1089/cmb.2004.11.642; Lee JM, 2006, BRIEF BIOINFORM, V7, P140, DOI 10.1093/bib/bbl007; Leiserson CE, 2001, INTRO ALGORITHMS; Li FT, 2004, P NATL ACAD SCI USA, V101, P4781, DOI 10.1073/pnas.0305937101; Lu KP, 2004, TRENDS BIOCHEM SCI, V29, P200, DOI 10.1016/j.tibs.2004.02.002; Perkins TJ, 2006, PLOS COMPUT BIOL, V2, P417, DOI 10.1371/journal.pcbi.0020051; Petak I, 2006, CURR SIGNAL TRANSD T, V1, P113, DOI 10.2174/157436206775269217; Pompl PN, 2003, ARCH NEUROL-CHICAGO, V60, P369, DOI 10.1001/archneur.60.3.369; Reed JC, 2005, BLOOD, V106, P408, DOI 10.1182/blood-2004-07-2761; Shmulevich I, 2005, P NATL ACAD SCI USA, V102, P13439, DOI 10.1073/pnas.0506771102; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; Zhou HJ, 2005, P NATL ACAD SCI USA, V102, P10052, DOI 10.1073/pnas.0409296102	33	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e547	10.1371/journal.pone.0000547	http://dx.doi.org/10.1371/journal.pone.0000547			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579719	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451700013
J	Gilbert, MTP; Haselkorn, T; Bunce, M; Sanchez, JJ; Lucas, SB; Jewell, LD; Van Marck, E; Worobey, M				Gilbert, M. Thomas P.; Haselkorn, Tamara; Bunce, Michael; Sanchez, Juan J.; Lucas, Sebastian B.; Jewell, Laurence D.; Van Marck, Eric; Worobey, Michael			The Isolation of Nucleic Acids from Fixed, Paraffin-Embedded Tissues-Which Methods Are Useful When?	PLOS ONE			English	Article								Museums and pathology collections around the world represent an archive of genetic material to study populations and diseases. For preservation purposes, a large portion of these collections has been fixed in formalin-containing solutions, a treatment that results in cross-linking of biomolecules. Cross-linking not only complicates isolation of nucleic acid but also introduces polymerase "blocks" during PCR. A wide variety of methods exists for the recovery of DNA and RNA from archival tissues, and although a number of previous studies have qualitatively compared the relative merits of the different techniques, very few have undertaken wide scale quantitative comparisons. To help address this issue, we have undertaken a study that investigates the quality of nucleic acids recovered from a test panel of fixed specimens that have been manipulated following a number of the published protocols. These include methods of pre-treating the samples prior to extraction, extraction and nucleic acid purification methods themselves, and a post-extraction enzymatic repair technique. We find that although many of the published methods have distinct positive effects on some characteristics of the nucleic acids, the benefits often come at a cost. In addition, a number of the previously published techniques appear to have no effect at all. Our findings recommend that the extraction methodology adopted should be chosen carefully. Here we provide a quick reference table that can be used to determine appropriate protocols for particular aims.	[Gilbert, M. Thomas P.; Haselkorn, Tamara; Worobey, Michael] Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ USA; [Bunce, Michael] Murdoch Univ, Ancient DNA Lab, Sch Biol Sci & Biotechnol, Perth, WA, Australia; [Sanchez, Juan J.] Natl Inst Toxicol & Forens Sci, Tenerife, Spain; [Lucas, Sebastian B.] St Thomas Hosp, Dept Pathol, London, England; [Jewell, Laurence D.] Univ Alberta Hosp, Dept Lab Med & Pathol, Edmonton, AB T6G 2R7, Canada; [Van Marck, Eric] Univ Antwerp, Dept Pathol, Univ Hosp, B-2020 Antwerp, Belgium	University of Arizona; Murdoch University; Guy's & St Thomas' NHS Foundation Trust; University of Alberta; University of Antwerp	Gilbert, MTP (corresponding author), Univ Copenhagen, Ancient DNA & Evolut, Niels Bohr Inst, Copenhagen, Denmark.	mtpgilbert@gmail.com	Gilbert, Marcus TP/A-8936-2013	Gilbert, Marcus TP/0000-0002-5805-7195; Bunce, Michael/0000-0002-0302-4206	NIAID/NIH [5-R21-AI065371]; Packard Foundation; FORMAPLEX [FP6-MEIF-CT-2005-025002]; University of Arizona NSF Integrative Graduate Training [DGE-0114420]; Ellen and Aage Andersen's Foundation; European Commission [G6RD-CT-2002-00844]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI065371] Funding Source: NIH RePORTER	NIAID/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Packard Foundation(The David & Lucile Packard Foundation); FORMAPLEX; University of Arizona NSF Integrative Graduate Training; Ellen and Aage Andersen's Foundation; European Commission(European CommissionEuropean Commission Joint Research Centre); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by NIAID/NIH grant 5-R21-AI065371 and the Packard Foundation (MW), a Marie Curie Actions FP6-MEIF-CT-2005-025002 "FORMAPLEX" grant (MTPG), a University of Arizona NSF Integrative Graduate Training (IGERT) grant Genomics Initiative DGE-0114420 (TSH) and the Ellen and Aage Andersen's Foundation and the European Commission (G6RD-CT-2002-00844) (JJS).	ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BANERJEE SK, 1995, BIOTECHNIQUES, V18, P768; Benavides J, 2006, J VIROL METHODS, V137, P317, DOI 10.1016/j.jviromet.2006.07.009; BONI J, 1993, J VIROL METHODS, V42, P309, DOI 10.1016/0166-0934(93)90042-P; Bonin S, 2005, J CLIN PATHOL, V58, P313, DOI 10.1136/jcp.2004.016477; Bonin S, 2003, J CLIN PATHOL-MOL PA, V56, P184, DOI 10.1136/mp.56.3.184; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRUTLAG D, 1969, BIOCHEMISTRY-US, V8, P3214, DOI 10.1021/bi00836a013; Coura R, 2005, J CLIN PATHOL, V58, P894, DOI 10.1136/jcp.2004.021352; DELAMBALLERIE X, 1994, J CLIN PATHOL, V47, P466, DOI 10.1136/jcp.47.5.466; Fang SG, 2002, BIOTECHNIQUES, V33, P604, DOI 10.2144/02333rr03_11827a; Feldman M Y, 1973, Prog Nucleic Acid Res Mol Biol, V13, P1, DOI 10.1016/S0079-6603(08)60099-9; Gilbert MTP, 2007, NUCLEIC ACIDS RES, V35, P1, DOI 10.1093/nar/gkl483; Gilbert MTP, 2005, TRENDS ECOL EVOL, V20, P541, DOI 10.1016/j.tree.2005.07.005; GILBERT MTP, ELECTROPHOR IN PRESS; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; Hofreiter M, 2001, NAT REV GENET, V2, P353, DOI 10.1038/35072071; ILYIN YV, 1969, J MOL BIOL, V41, P299, DOI 10.1016/0022-2836(69)90395-7; ISOLA J, 1994, AM J PATHOL, V145, P1301; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; JACKSON V, 1981, P NATL ACAD SCI-BIOL, V78, P6081, DOI 10.1073/pnas.78.10.6081; Krafft AE, 1995, J WILDLIFE DIS, V32, P410; Legrand B, 2002, FORENSIC SCI INT, V125, P205, DOI 10.1016/S0379-0738(01)00641-7; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Longy M, 1997, DIAGN MOL PATHOL, V6, P167, DOI 10.1097/00019606-199706000-00007; Miething F, 2006, J HISTOCHEM CYTOCHEM, V39, P351; MOLLER K, 1977, EUR J BIOCHEM, V76, P175, DOI 10.1111/j.1432-1033.1977.tb11583.x; Pattyn F, 2006, NUCLEIC ACIDS RES, V34, pD684, DOI 10.1093/nar/gkj155; Rohland N, 2007, BIOTECHNIQUES, V42, P343, DOI 10.2144/000112383; Romero RL, 1997, J FORENSIC SCI, V42, P708; ROSENTHAL R, 1978, PSYCHOL BULL, V85, P185, DOI 10.1037/0033-2909.85.1.185; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez JJ, 2006, ELECTROPHORESIS, V27, P1713, DOI 10.1002/elps.200500671; Shedlock AM, 1997, BIOTECHNIQUES, V22, P394, DOI 10.2144/97223bm03; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Shi SR, 2004, HISTOCHEM CELL BIOL, V122, P211, DOI 10.1007/s00418-004-0693-x; Shi SR, 2002, J HISTOCHEM CYTOCHEM, V50, P1005, DOI 10.1177/002215540205000802; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; STANTA G, 1991, BIOTECHNIQUES, V11, P304; Stiller M, 2006, P NATL ACAD SCI USA, V103, P13578, DOI 10.1073/pnas.0605327103; SULLIVAN KM, 1993, BIOTECHNIQUES, V15, P636; VARSHAVSKY AJ, 1979, CELL, V16, P453, DOI 10.1016/0092-8674(79)90021-7; VARSHAVSKY AJ, 1974, BIOCHIM BIOPHYS ACTA, V340, P207, DOI 10.1016/0005-2787(74)90114-2; Vince A, 1998, BRIT J HAEMATOL, V101, P349, DOI 10.1046/j.1365-2141.1998.00702.x; Wickham CL, 2000, J CLIN PATHOL-MOL PA, V53, P19, DOI 10.1136/mp.53.1.19; Wu L, 2002, APPL IMMUNOHISTO M M, V10, P269, DOI 10.1097/00022744-200209000-00015	47	281	331	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e537	10.1371/journal.pone.0000537	http://dx.doi.org/10.1371/journal.pone.0000537			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579711	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451700005
J	Melov, S; Adlard, PA; Morten, K; Johnson, F; Golden, TR; Hinerfeld, D; Schilling, B; Mavros, C; Masters, CL; Volitakis, I; Li, QX; Laughton, K; Hubbard, A; Cherny, RA; Gibson, B; Bush, AI				Melov, Simon; Adlard, Paul A.; Morten, Karl; Johnson, Felicity; Golden, Tamara R.; Hinerfeld, Doug; Schilling, Birgit; Mavros, Christine; Masters, Colin L.; Volitakis, Irene; Li, Qiao-Xin; Laughton, Katrina; Hubbard, Alan; Cherny, Robert A.; Gibson, Brad; Bush, Ashley I.			Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau	PLOS ONE			English	Article								Age-related neurodegenerative disease has been mechanistically linked with mitochondrial dysfunction via damage from reactive oxygen species produced within the cell. We determined whether increased mitochondrial oxidative stress could modulate or regulate two of the key neurochemical hallmarks of Alzheimer's disease (AD): tau phosphorylation, and beta-amyloid deposition. Mice lacking superoxide dismutase 2 (SOD2) die within the first week of life, and develop a complex heterogeneous phenotype arising from mitochondrial dysfunction and oxidative stress. Treatment of these mice with catalytic antioxidants increases their lifespan and rescues the peripheral phenotypes, while uncovering central nervous system pathology. We examined sod2 null mice differentially treated with high and low doses of a catalytic antioxidant and observed striking elevations in the levels of tau phosphorylation (at Ser-396 and other phospho-epitopes of tau) in the low-dose antioxidant treated mice at AD-associated residues. This hyperphosphorylation of tau was prevented with an increased dose of the antioxidant, previously reported to be sufficient to prevent neuropathology. We then genetically combined a well-characterized mouse model of AD (Tg2576) with heterozygous sod2 knockout mice to study the interactions between mitochondrial oxidative stress and cerebral A beta load. We found that mitochondrial SOD2 deficiency exacerbates amyloid burden and significantly reduces metal levels in the brain, while increasing levels of Ser-396 phosphorylated tau. These findings mechanistically link mitochondrial oxidative stress with the pathological features of AD.	[Melov, Simon; Morten, Karl; Johnson, Felicity; Golden, Tamara R.; Hinerfeld, Doug; Schilling, Birgit; Gibson, Brad] Buck Inst Age Res, Novato, CA USA; [Adlard, Paul A.; Mavros, Christine; Masters, Colin L.; Volitakis, Irene; Li, Qiao-Xin; Laughton, Katrina; Cherny, Robert A.; Bush, Ashley I.] Univ Melbourne, Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; [Adlard, Paul A.; Mavros, Christine; Masters, Colin L.; Volitakis, Irene; Li, Qiao-Xin; Laughton, Katrina; Cherny, Robert A.; Bush, Ashley I.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Hubbard, Alan] Univ Calif Berkeley, Sch Publ Hlth, EHS Biostat, Berkeley, CA 94720 USA; [Bush, Ashley I.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA	Buck Institute for Research on Aging; University of Melbourne; University of Melbourne; University of California System; University of California Berkeley; Harvard University; Massachusetts General Hospital	Melov, S (corresponding author), Buck Inst Age Res, Novato, CA USA.	smelov@buckinsti-tute.org; bush@helix.mgh.harvard.edu	Bush, Ashley/Y-2457-2019; Melov, Simon/AAC-9469-2020; MORTEN, Karl/GXM-6291-2022; Bush, Ashley I/A-1186-2007	Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069; Melov, Simon/0000-0001-8554-2834; Sommerville, Christine/0000-0002-9226-1691; Morten, Karl/0000-0001-6926-6550; Volitakis, Irene/0000-0003-0766-817X	National Institutes of Health [AG18679, PO1 AG25901, AG12686]; American Health Assistance Foundation; Institute for the Study of Aging; Ellison Medical Foundation; Australian Research Council; National Health and Medical Research Council; NATIONAL INSTITUTE ON AGING [P01AG025901, R01AG012686, R29AG012686, R01AG018679] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Health Assistance Foundation; Institute for the Study of Aging; Ellison Medical Foundation(Lawrence Ellison Foundation); Australian Research Council(Australian Research Council); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institutes of Health grants AG18679 and PO1 AG25901 (S. M), AG12686 (A. I. B.), and a grant from the American Health Assistance Foundation (A. I. B.). It was also supported by an award from the Institute for the Study of Aging and an Ellison Medical Foundation award (S. M); the Australian Research Council Federation Fellowship (A. I. B.); the National Health and Medical Research Council Howard Florey Centenary Research Fellowship (P. A). We would like to thank Nicole Nagulko and Lawreen Asuncion for excellent animal work, and Sue Doctrow for helpful comments.	Ali SS, 2004, FREE RADICAL BIO MED, V37, P1191, DOI 10.1016/j.freeradbiomed.2004.07.002; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bancroft G.D., 1996, THEORY PRACTICE PATH, V4th ed.; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; Bellingham SA, 2004, J NEUROCHEM, V91, P423, DOI 10.1111/j.1471-4159.2004.02731.x; Blass JP, 2001, J NEUROSCI RES, V66, P851, DOI 10.1002/jnr.10087; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Crouch PJ, 2006, DRUG NEWS PERSPECT, V19, P469, DOI 10.1358/dnp.2006.19.8.1021492; Dewachter I, 2000, EXP GERONTOL, V35, P831, DOI 10.1016/S0531-5565(00)00149-2; Dias-Santagata D, 2007, J CLIN INVEST, V117, P236, DOI 10.1172/JCI28769; Esposito L, 2006, J NEUROSCI, V26, P5167, DOI 10.1523/JNEUROSCI.0482-06.2006; Friedman JS, 2004, BLOOD, V104, P2565, DOI 10.1182/blood-2003-11-3858; Friedman JS, 2001, J EXP MED, V193, P925, DOI 10.1084/jem.193.8.925; Galas MC, 2006, J BIOL CHEM, V281, P19296, DOI 10.1074/jbc.M601849200; Golden TR, 2005, FREE RADICAL BIO MED, V39, P152, DOI 10.1016/j.freeradbiomed.2005.03.002; Hinerfeld D, 2004, J NEUROCHEM, V88, P657, DOI 10.1046/j.1471-4159.2003.02195.x; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huang TT, 2001, FREE RADICAL BIO MED, V31, P1101, DOI 10.1016/S0891-5849(01)00694-3; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; KOBAYASHI K, 1992, BIOTECH HISTOCHEM, V67, P256, DOI 10.3109/10520299209110033; Li B, 2007, ACTA NEUROPATHOL, V113, P501, DOI 10.1007/s00401-007-0207-8; Li F, 2004, J NEUROCHEM, V89, P1308, DOI 10.1111/j.1471-4159.2004.02455.x; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Marcus DL, 2006, MED SCI MONITOR, V12, pBR8; Maynard CJ, 2006, J INORG BIOCHEM, V100, P952, DOI 10.1016/j.jinorgbio.2006.02.010; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Melov S, 2001, J NEUROSCI, V21, P8348, DOI 10.1523/JNEUROSCI.21-21-08348.2001; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Phinney AL, 2003, P NATL ACAD SCI USA, V100, P14193, DOI 10.1073/pnas.2332851100; Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864; Richardson James A, 2002, ILAR J, V43, P89; Samper E, 2003, AGING CELL, V2, P277, DOI 10.1046/j.1474-9728.2003.00062.x; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Schonheit B, 2004, NEUROBIOL AGING, V25, P697, DOI 10.1016/j.neurobioalging.2003.09.009; Smith MA, 1999, DRUG DEVELOP RES, V46, P26, DOI 10.1002/(SICI)1098-2299(199901)46:1<26::AID-DDR5>3.0.CO;2-8; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Strassburger M, 2005, FREE RADICAL BIO MED, V38, P1458, DOI 10.1016/j.freeradbiomed.2005.02.009; Takuma K, 2005, FASEB J, V19, P597, DOI 10.1096/fj.04-2582fje; van Leuven F, 2000, PROG NEUROBIOL, V61, P305, DOI 10.1016/S0301-0082(99)00055-6; Van Remmen H, 2001, AM J PHYSIOL-HEART C, V281, pH1422, DOI 10.1152/ajpheart.2001.281.3.H1422; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6	55	252	255	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e536	10.1371/journal.pone.0000536	http://dx.doi.org/10.1371/journal.pone.0000536			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579710	Green Published, gold			2022-12-25	WOS:000207451700004
J	Olah, Z; Josvay, K; Pecze, L; Letoha, T; Babai, N; Budai, D; Otvos, F; Szalma, S; Vizler, C				Olah, Zoltan; Josvay, Katalin; Pecze, Laszlo; Letoha, Tamas; Babai, Norbert; Budai, Denes; Otvos, Ferenc; Szalma, Sandor; Vizler, Csaba			Anti-calmodulins and Tricyclic Adjuvants in Pain Therapy Block the TRPV1 Channel	PLOS ONE			English	Article								Ca2+-loaded calmodulin normally inhibits multiple Ca2+-channels upon dangerous elevation of intracellular Ca2+ and protects cells from Ca2+-cytotoxicity, so blocking of calmodulin should theoretically lead to uncontrolled elevation of intracellular Ca2+. Paradoxically, classical anti-psychotic, anti-calmodulin drugs were noted here to inhibit Ca2+-uptake via the vanilloid inducible Ca2+-channel/inflamatory pain receptor 1 (TRPV1), which suggests that calmodulin inhibitors may block pore formation and Ca2+ entry. Functional assays on TRPV1 expressing cells support direct, dose-dependent inhibition of vanilloid-induced Ca-45(2+)-uptake at mu M concentrations: calmidazolium (broad range)>= trifluoperazine (narrow range)>chlorpromazine/amitriptyline>"' fluphenazine>>W-7 and W-13 (only partially). Most likely a short acidic domain at the pore loop of the channel orifice functions as binding site either for Ca2+ or anti-calmodulin drugs. Camstatin, a selective peptide blocker of calmodulin, inhibits vanilloid-induced Ca2+-uptake in intact TRPV1(+) cells, and suggests an extracellular site of inhibition. TRPV1+, inflammatory pain-conferring nociceptive neurons from sensory ganglia, were blocked by various anti-psychotic and anti-calmodulin drugs. Among them, calmidazolium, the most effective calmodulin agonist, blocked Ca2+-entry by a non-competitive kinetics, affecting the TRPV1 at a different site than the vanilloid binding pocket. Data suggest that various calmodulin antagonists dock to an extracellular site, not found in other Ca2+-channels. Calmodulin antagonist-evoked inhibition of TRPV1 and NMDA receptors/Ca2+-channels was validated by microiontophoresis of calmidazolium to laminectomised rat monitored with extracellular single unit recordings in vivo. These unexpected findings may explain empirically noted efficacy of clinical pain adjuvant therapy that justify efforts to develop hits into painkillers, selective to sensory Ca2+-channels but not affecting motoneurons.	[Olah, Zoltan; Josvay, Katalin; Pecze, Laszlo; Otvos, Ferenc; Vizler, Csaba] Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, H-6701 Szeged, Hungary; [Olah, Zoltan; Letoha, Tamas] Acheuron Hungary Ltd, Szeged, Hungary; [Olah, Zoltan; Szalma, Sandor] Acheuron Pharmaceut Inc, San Diego, CA USA; [Letoha, Tamas] Univ Szeged, Dept Med Chem, Fac Gen Med, Szeged, Hungary; [Babai, Norbert] Univ Pecs, Dept Expt Zool & Neurobiol, Pecs, Hungary; [Budai, Denes] Univ Szeged, Dept Biol, Gyula Juhsz Fac Educ, Szeged, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Szeged University; University of Pecs; Szeged University	Olah, Z (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, H-6701 Szeged, Hungary.	zolah@brc.hu	Letoha, Tamas/ABG-6348-2020; Babai, Norbert/T-2952-2019	Szalma, Sandor/0000-0001-7591-3902	Jedlik Program [NKFP-1-00019/2005]; GVOP; National Office for Research and Technology [OM-00051/2005, OMFB-01575/2006]; Hungarian Ministry of Health [552/2006];  [MC-IRG030854-PAINKILLER];  [GVOP-3.3.1-05/1.-2005-05-0057/3.0]	Jedlik Program; GVOP; National Office for Research and Technology(National Office for Research and TechnologyTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Hungarian Ministry of Health; ; 	ZO was supported by MC-IRG030854-PAINKILLER; Anyos Jedlik Program NKFP-1-00019/2005; GVOP-3.3.1-05/1.-2005-05-0057/3.0. DB was also supported by GVOP, CV was also supported by grants the National Office for Research and Technology (OM-00051/2005 and OMFB-01575/2006) and the Hungarian Ministry of Health (552/2006).	ACS G, 1995, J PHARMACOL EXP THER, V274, P1090; Bhave G, 2003, P NATL ACAD SCI USA, V100, P12480, DOI 10.1073/pnas.2032100100; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; Brown DC, 2005, ANESTHESIOLOGY, V103, P1052, DOI 10.1097/00000542-200511000-00020; Bruening-Wright A, 2002, J NEUROSCI, V22, P6499; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Del Carlo B, 2002, BBA-BIOMEMBRANES, V1558, P133, DOI 10.1016/S0005-2736(01)00419-9; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Douglass PM, 2002, BIOCONJUGATE CHEM, V13, P1186, DOI 10.1021/bc010080b; Fang L, 2002, J NEUROSCI, V22, P4196, DOI 10.1523/JNEUROSCI.22-10-04196.2002; Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/jgp.200208783; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harper JL, 2000, BIOCHEM PHARMACOL, V60, P317, DOI 10.1016/S0006-2952(00)00349-X; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Johanson RA, 2000, J NEUROSCI, V20, P2860; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361; Jung J, 1999, J NEUROSCI, V19, P529; JUNG J, 2003, J BIOL CHEM; Karai L, 2004, J CLIN INVEST, V113, P1344, DOI 10.1172/JCI200420449; KARAI L, 1994, J BIOL CHEM; Karai LJ, 2004, J BIOL CHEM, V279, P16377, DOI 10.1074/jbc.M310891200; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; KHOROMI S, 2006, PAIN; Kieburtz K, 1998, NEUROLOGY, V51, P1682, DOI 10.1212/WNL.51.6.1682; Kitaguchi T, 2005, BIOCHEMISTRY-US, V44, P15544, DOI 10.1021/bi051494l; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Likic VA, 2005, PROTEIN SCI, V14, P2955, DOI 10.1110/ps.051681605; Liu M, 2003, J BIOL CHEM, V278, P5462, DOI 10.1074/jbc.M209111200; Marshall ICB, 2003, BRIT J PHARMACOL, V138, P172, DOI 10.1038/sj.bjp.0705003; MAX MB, 1994, ANN NEUROL, V35, pS50, DOI 10.1002/ana.410350715; Menendez L, 1996, BRAIN RES, V731, P114, DOI 10.1016/S0006-8993(96)00480-5; Mohapatra DP, 2003, MOL CELL NEUROSCI, V23, P314, DOI 10.1016/S1044-7431(03)00054-X; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Olah Z, 2002, J BIOL CHEM, V277, P35752, DOI 10.1074/jbc.M201551200; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Rigden DJ, 2003, FEMS MICROBIOL LETT, V221, P103, DOI 10.1016/S0378-1097(03)00160-5; Robinson LR, 2004, ARCH PHYS MED REHAB, V85, P1, DOI 10.1016/S0003-9993(03)00476-3; Rosenbaum T, 2004, J GEN PHYSIOL, V123, P53, DOI 10.1085/jgp.200308906; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Slemmon JR, 1996, J BIOL CHEM, V271, P15911, DOI 10.1074/jbc.271.27.15911; Soldatov MM, 2003, TRENDS PHARMACOL SCI, V24, P167, DOI 10.1016/S0165-6147(03)00065-8; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tender GC, 2005, J NEUROSURG, V102, P522, DOI 10.3171/jns.2005.102.3.0522; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Williams M, 1999, J MED CHEM, V42, P1481, DOI 10.1021/jm9805034; Zhang T, 2001, INFORM RETRIEVAL, V4, P5, DOI 10.1023/A:1011441423217; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	57	21	23	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e545	10.1371/journal.pone.0000545	http://dx.doi.org/10.1371/journal.pone.0000545			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579717	gold, Green Submitted, Green Published			2022-12-25	WOS:000207451700011
J	Bergsten, J; Miller, KB				Bergsten, Johannes; Miller, Kelly B.			Phylogeny of Diving Beetles Reveals a Coevolutionary Arms Race between the Sexes	PLOS ONE			English	Article								Background. Darwin illustrated his sexual selection theory with male and female morphology of diving beetles, but maintained a cooperative view of their interaction. Present theory suggests that instead sexual conflict should be a widespread evolutionary force driving both intersexual coevolutionary arms races and speciation. Methodology/Principal Findings. We combined Bayesian phylogenetics, complete taxon sampling and a multi-gene approach to test the arms race scenario on a robust diving beetle phylogeny. As predicted, suction cups in males and modified dorsal surfaces in females showed a pronounced coevolutionary pattern. The female dorsal modifications impair the attachment ability of male suction cups, but each antagonistic novelty in females corresponds to counter-differentiation of suction cups in males. Conclusions. A recently diverged sibling species pair in Japan is possibly one consequence of this arms race and we suggest that future studies on hypoxia might reveal the key to the extraordinary selection for female counter-adaptations in diving beetles.	[Bergsten, Johannes] Nat Hist Museum, Dept Entomol, London SW7 5BD, England; [Bergsten, Johannes] Imperial Coll London, Div Biol, Ascot, Berks, England; [Miller, Kelly B.] Univ New Mexico, Museum SW Biol, Dept Entomol, Albuquerque, NM 87131 USA	Natural History Museum London; Imperial College London; University of New Mexico	Bergsten, J (corresponding author), Nat Hist Museum, Dept Entomol, Cromwell Rd, London SW7 5BD, England.	j.bergsten@nhm.ac.uk	Miller, Kelly/I-6651-2012		US National Science Foundation	US National Science Foundation(National Science Foundation (NSF))	support came from US National Science Foundation, Stiftelsen J.C. Kempes Minnes Stipendiefond and Helge Axson Johnsons Stiftelse.	AIKEN RB, 1992, ETHOL ECOL EVOL, V4, P245, DOI 10.1080/08927014.1992.9523136; AIKEN RB, 1992, CAN J ZOOL, V70, P1321, DOI 10.1139/z92-185; Arnqvist G, 2002, NATURE, V415, P787, DOI 10.1038/415787a; Arnqvist G, 2002, EVOLUTION, V56, P936; Arnqvist G., 2005, SEXUAL CONFLICT, P360; Barraclough TG, 2001, TRENDS ECOL EVOL, V16, P391, DOI 10.1016/S0169-5347(01)02161-9; Bergsten J, 2006, SYST ENTOMOL, V31, P145, DOI 10.1111/j.1365-3113.2005.00309.x; Bergsten J, 2005, CLADISTICS, V21, P163, DOI 10.1111/j.1096-0031.2005.00059.x; Bergsten J, 2001, BIOL J LINN SOC, V73, P221, DOI 10.1006/bijl.2001.0540; BROOKS R, 2005, TREE, V20, P294; Brower AVZ, 1997, P ROY SOC B-BIOL SCI, V264, P969, DOI 10.1098/rspb.1997.0134; Chapman T, 2003, TRENDS ECOL EVOL, V18, P41, DOI 10.1016/S0169-5347(02)00004-6; Chapman T, 2001, HEREDITY, V87, P511, DOI 10.1046/j.1365-2540.2001.00961.x; Colgan DJ, 1998, AUST J ZOOL, V46, P419, DOI 10.1071/ZO98048; Cordero C, 2003, J EVOLUTION BIOL, V16, P1, DOI 10.1046/j.1420-9101.2003.00506.x; Darwin G., 1871, P423; DOBSON M, 1994, MAMMAL REV, V24, P91, DOI 10.1111/j.1365-2907.1994.tb00137.x; Eberhard WG, 2004, EVOLUTION, V58, P1947; Edvardsson M, 2006, BEHAV GENET, V36, P775, DOI 10.1007/s10519-005-9043-6; Gavrilets S, 2000, NATURE, V403, P886, DOI 10.1038/35002564; GOLOBOFF P, 2003, TNT SOFTWARE VER 1 0; Holland B, 1999, P NATL ACAD SCI USA, V96, P5083, DOI 10.1073/pnas.96.9.5083; Hosken D, 2005, AM NAT, V165, pS1, DOI 10.1086/429355; Huelsenbeck JP, 2004, SYST BIOL, V53, P904, DOI 10.1080/10635150490522629; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; Huelsenbeck JP, 2000, SCIENCE, V288, P2349, DOI 10.1126/science.288.5475.2349; Koene JM, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-25; Kolaczkowski B, 2004, NATURE, V431, P980, DOI 10.1038/nature02917; Lewis PO, 2001, SYST BIOL, V50, P913, DOI 10.1080/106351501753462876; Martin OY, 2003, NATURE, V423, P979, DOI 10.1038/nature01752; Miller KB, 2003, BIOL J LINN SOC, V79, P359, DOI 10.1046/j.1095-8312.2003.00195.x; NAUMANN H, 1955, GELBRANDKAFER, P80; Pischedda A, 2006, PLOS BIOL, V4, P2099, DOI 10.1371/journal.pbio.0040356; Pizzari T, 2003, EVOLUTION, V57, P1223, DOI 10.1111/j.0014-3820.2003.tb00331.x; Rice WR, 1998, ENDLESS FORMS, P261; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Ronquist F, 2004, TRENDS ECOL EVOL, V19, P475, DOI 10.1016/j.tree.2004.07.002; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; SIMON C, 1994, ANN ENTOMOL SOC AM, V87, P651, DOI 10.1093/aesa/87.6.651; Tregenza T, 2006, PHILOS T R SOC B, V361, P229, DOI 10.1098/rstb.2005.1796; WESENBERGLUND C, 1912, BIOL STUDIEN DYTISCI, P129; Wichard W., 2002, Biological atlas of aquatic insects	42	54	56	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e522	10.1371/journal.pone.0000522	http://dx.doi.org/10.1371/journal.pone.0000522			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565375	gold, Green Published			2022-12-25	WOS:000207451600010
J	Wang, Q; Pang, YP				Wang, Qi; Pang, Yuan-Ping			Accurate Reproduction of 161 Small-Molecule Complex Crystal Structures using the EUDOC Program: Expanding the Use of EUDOC to Supramolecular Chemistry	PLOS ONE			English	Article							CHEMICAL DATABASE; DRUG-LEAD; INHIBITORS; IDENTIFICATION; QUINOXALINE; DISCOVERY; GENOME	EUDOC is a docking program that has successfully predicted small-molecule-bound protein complexes and identified drug leads from chemical databases. To expand the application of the EUDOC program to supramolecular chemistry, we tested its ability to reproduce crystal structures of small-molecule complexes. Of 161 selected crystal structures of small-molecule guest-host complexes, EUDOC reproduced all these crystal structures with guest structure mass-weighted root mean square deviations (mwRMSDs) of < 1.0 angstrom relative to the corresponding crystal structures. In addition, the average interaction energy of these 161 guest-host complexes (-50.1 kcal/mol) was found to be nearly half of that of 153 previously tested small-molecule-bound protein complexes (-108.5 kcal/mol), according to the interaction energies calculated by EUDOC. 31 of the 161 complexes could not be reproduced with mwRMSDs of < 1.0 angstrom if neighboring hosts in the crystal structure of a guest-host complex were not included as part of the multimeric host system, whereas two of the 161 complexes could not be reproduced with mwRMSDs of < 1.0 angstrom if water molecules were excluded from the host system. These results demonstrate the significant influence of crystal packing on small molecule complexation and suggest that EUDOC is able to predict small-molecule complexes and that it is useful for the design of new materials, molecular sensors, and multimeric inhibitors of protein-protein interactions.	[Wang, Qi; Pang, Yuan-Ping] Mayo Clin, Comp Aided Mol Design Lab, Rochester, MN 55905 USA	Mayo Clinic	Pang, YP (corresponding author), Mayo Clin, Comp Aided Mol Design Lab, Rochester, MN 55905 USA.	pang@mayo.edu		Pang, Yuan-Ping/0000-0003-0838-2560	U. S. Army Medical Research Acquisition Activity [W81XWH-04-2-0001]; National Institutes of Health [5R01AI054574-03]; Mayo Graduate School; Mayo Foundation for Medical Education and Research	U. S. Army Medical Research Acquisition Activity; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Graduate School; Mayo Foundation for Medical Education and Research	This work was supported by the U. S. Army Medical Research Acquisition Activity (W81XWH-04-2-0001), the National Institutes of Health (5R01AI054574-03), Mayo Graduate School, and the Mayo Foundation for Medical Education and Research.	Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; Dooley AJ, 2006, BIOORG MED CHEM LETT, V16, P830, DOI 10.1016/j.bmcl.2005.11.018; DUFFY EM, 1994, J AM CHEM SOC, V116, P6337, DOI 10.1021/ja00093a038; Eyal E, 2005, J MOL BIOL, V351, P431, DOI 10.1016/j.jmb.2005.05.066; Frisch M., 2016, GAUSSIAN 16 REVISION; LEHN JM, 1993, SCIENCE, V260, P1762, DOI 10.1126/science.8511582; Miller MA, 2002, NAT REV DRUG DISCOV, V1, P220, DOI 10.1038/nrd745; Pang YP, 2007, CLIN PHARMACOL THER, V81, P30, DOI 10.1038/sj.clpt.6100030; Pang YP, 2001, J COMPUT CHEM, V22, P1750, DOI 10.1002/jcc.1129; Pang YP, 2001, FEBS LETT, V502, P93, DOI 10.1016/S0014-5793(01)02672-2; PANG YP, 2007, IBM J RES D IN PRESS; Park JG, 2006, BIOORGAN MED CHEM, V14, P395, DOI 10.1016/j.bmc.2005.08.018; PASCAL RA, 1993, J AM CHEM SOC, V115, P8507, DOI 10.1021/ja00071a094; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Perola E, 2000, J MED CHEM, V43, P401, DOI 10.1021/jm990408a; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; REBEK J, 1986, J AM CHEM SOC, V108, P5637, DOI 10.1021/ja00278a052; Sun H, 2002, MOL PHARMACOL, V62, P220, DOI 10.1124/mol.62.2.220	21	14	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e531	10.1371/journal.pone.0000531	http://dx.doi.org/10.1371/journal.pone.0000531			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565384	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451600019
J	Selman, M; Carrillo, G; Estrada, A; Mejia, M; Becerril, C; Cisneros, J; Gaxiola, M; Perez-Padilla, R; Navarro, C; Richards, T; Dauber, J; King, TE; Pardo, A; Kaminski, N				Selman, Moises; Carrillo, Guillermo; Estrada, Andrea; Mejia, Mayra; Becerril, Carina; Cisneros, Jose; Gaxiola, Miguel; Perez-Padilla, Rogelio; Navarro, Carmen; Richards, Thomas; Dauber, James; King, Talmadge E., Jr.; Pardo, Annie; Kaminski, Naftali			Accelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern	PLOS ONE			English	Article							LUNG-FUNCTION; PATHOGENESIS; SURVIVAL; MATRIX-METALLOPROTEINASE-9; THERAPY; MARKER	Background. Idiopathic pulmonary fibrosis (IPF) is characterized by the insidious onset of dyspnea or cough. However, a subset of patients has a short duration of symptoms with rapid progression to end-stage disease. In this study, we evaluated clinical and molecular features of "rapid'' and "slow'' progressors with IPF. Methods and Findings. 26 patients with,6 months of symptoms before first presentation [rapid progressors] and 88 patients with >24 months of symptoms [slow progressors] were studied. Survival was analyzed by the Kaplan-Meyer method and proportional hazard's model. Lung microarrays and tissue proteins were measured in a subset of patients. No differences were found in age, physiologic impairment and bronchoalveolar lavage (BAL) cellular profile. There were more males (OR = 6.5; CI: 1.4-29.5; p = 0.006) and smokers (OR = 3.04; CI: 1.1-8.3; p = 0.04) in the rapid progressors group. Survival from the beginning of symptoms was significantly reduced in rapid progressors (HR = 9.0; CI: 4.48-18.3; p<0.0001) and there was a tendency for decreased survival from the time of diagnosis (HR = 1.5; CI: 0.81-2.87; p = 0.18). We identified 437 differentially expressed genes. Lungs of rapid progressors overexpressed genes involved in morphogenesis, oxidative stress, migration/proliferation, and genes from fibroblasts/smooth muscle cells. Upregulation of two of these genes, adenosine-2B receptor and prominin-1/CD133, was validated by immunohistochemistry and were expressed by alveolar epithelial cells. BAL from rapid progressors showed a >2-fold increase of active matrix metalloproteinase-9, and induced a higher fibroblast migration compared with slow progressors and controls [238 +/- 98% versus 123 +/- 29% (p < 0.05) and 30 +/- 17% (p < 0.01)]. Conclusions/Significance. A subgroup of IPF patients, predominantly smoking males, display an accelerated clinical course and have a gene expression pattern that is different from those with slower progression and longer survival. These findings highlight the variability in the progression of IPF, and may explain, in part, the difficulty in obtaining significant and reproducible results in studies of therapeutic interventions in patients with IPF.	[Selman, Moises; Carrillo, Guillermo; Estrada, Andrea; Mejia, Mayra; Becerril, Carina; Cisneros, Jose; Gaxiola, Miguel; Perez-Padilla, Rogelio; Navarro, Carmen] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico; [Richards, Thomas; Dauber, James; Kaminski, Naftali] Univ Pittsburgh, Dorothy P & Richard P Simmons Ctr Interstitial Lu, Pittsburgh, PA USA; [King, Talmadge E., Jr.] San Francisco Gen Hosp, Div Pulm & Crit Care Med, Dept Med, San Francisco, CA 94110 USA; [Pardo, Annie] Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City 04510, DF, Mexico	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; San Francisco General Hospital Medical Center; Universidad Nacional Autonoma de Mexico	Selman, M (corresponding author), Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico.	mselmanl@yahoo.com.mx		Cisneros, Jose/0000-0002-4592-4464; Kaminski, Naftali/0000-0001-5917-4601	Universidad Nacional Autonoma de Mexico [SDI.PTID.05.6]; NIH [HL073745, HL079394]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL079394, R01HL073745] Funding Source: NIH RePORTER	Universidad Nacional Autonoma de Mexico(Universidad Nacional Autonoma de Mexico); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was partially supported by Universidad Nacional Autonoma de Mexico Grant SDI.PTID.05.6. Naftali Kaminski's work was supported by NIH grant HL073745, HL079394 and by a generous donation from the Simmons family. Funding sources were not involved in study design, performance, analysis or manuscript preparation.	*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; Ambrosini V, 2003, EUR RESPIR J, V22, P821, DOI 10.1183/09031936.03.00022703; Atkinson JJ, 2003, AM J RESP CELL MOL, V28, P12, DOI 10.1165/rcmb.2002-0166TR; Ben-Dor A, 2000, J COMPUT BIOL, V7, P559, DOI 10.1089/106652700750050943; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolton WK, 2001, NEPHRON, V88, P6, DOI 10.1159/000045952; Carr BA, 2003, J BIOL CHEM, V278, P15473, DOI 10.1074/jbc.M300319200; Chunn JL, 2006, AM J PHYSIOL-LUNG C, V290, pL579, DOI 10.1152/ajplung.00258.2005; Cisneros-Lira J, 2003, AM J PHYSIOL-LUNG C, V285, pL949, DOI 10.1152/ajplung.00074.2003; Collard HR, 2004, CHEST, V125, P2169, DOI 10.1378/chest.125.6.2169; Demling N, 2006, CELL TISSUE RES, V323, P475, DOI 10.1007/s00441-005-0069-0; Egan JJ, 2005, THORAX, V60, P270, DOI 10.1136/thx.2004.035436; Fukuda Y, 1998, LAB INVEST, V78, P687; Gahl WA, 2002, MOL GENET METAB, V76, P234, DOI 10.1016/S1096-7192(02)00044-6; Gay SE, 1998, AM J RESP CRIT CARE, V157, P1063, DOI 10.1164/ajrccm.157.4.9703022; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Hanford LE, 2003, AM J RESP CELL MOL, V29, pS77; Harvey BG, 2007, J MOL MED, V85, P39, DOI 10.1007/s00109-006-0103-z; He JQ, 2002, AM J RESP CRIT CARE, V166, P323, DOI 10.1164/rccm.2111059; Heguy A, 2006, J MOL MED, V84, P318, DOI 10.1007/s00109-005-0008-2; Hogan CM, 2001, ANN INTERN MED, V134, P761, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00013; HYDE DM, 1992, AM REV RESPIR DIS, V146, P1042, DOI 10.1164/ajrccm/146.4.1042; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Kania G, 2005, STEM CELLS, V23, P791, DOI 10.1634/stemcells.2004-0232; Kazerooni EA, 1997, AM J ROENTGENOL, V169, P977, DOI 10.2214/ajr.169.4.9308447; King TE, 2001, AM J RESP CRIT CARE, V164, P1171, DOI 10.1164/ajrccm.164.7.2003140; Marshall A, 2005, LIVER TRANSPLANT, V11, P427, DOI 10.1002/lt.20347; Martinez FJ, 2005, ANN INTERN MED, V142, P963, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00005; MCCORMAC FX, 1995, AM J RESP CRIT CARE, V152, P751, DOI 10.1164/ajrccm.152.2.7633738; Ning W, 2004, P NATL ACAD SCI USA, V101, P14895, DOI 10.1073/pnas.0401168101; Pardo A, 2005, PLOS MED, V2, P891, DOI 10.1371/journal.pmed.0020251; Pardo A, 2003, AM J RESP CRIT CARE, V167, P925, DOI 10.1164/rccm.200209-1007OC; PEREZPADILLA R, 1993, AM REV RESPIR DIS, V148, P49, DOI 10.1164/ajrccm/148.1.49; Radom-Aizik S, 2005, MED SCI SPORT EXER, V37, P1680, DOI 10.1249/01.mss.0000181838.96815.4d; Raghu G, 2004, NEW ENGL J MED, V350, P125, DOI 10.1056/NEJMoa030511; Segal E, 2005, NAT GENET, V37, pS38, DOI 10.1038/ng1561; Selman M, 2000, AM J PHYSIOL-LUNG C, V279, pL562, DOI 10.1152/ajplung.2000.279.3.L562; Selman M, 2006, AM J RESP CRIT CARE, V173, P188, DOI 10.1164/rccm.200504-644OC; Selman M, 1998, CHEST, V114, P507, DOI 10.1378/chest.114.2.507; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Shmelkov SV, 2005, INT J BIOCHEM CELL B, V37, P715, DOI 10.1016/j.biocel.2004.08.010; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Woodruff PG, 2005, AM J RESP CRIT CARE, V172, P1383, DOI 10.1164/rccm.200505-686OC; Yu Q, 2000, GENE DEV, V14, P163; Zhong HY, 2005, AM J RESP CELL MOL, V32, P2, DOI 10.1165/rcmb.2004-0103OC	45	196	203	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e482	10.1371/journal.pone.0000482	http://dx.doi.org/10.1371/journal.pone.0000482			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534432	Green Accepted, gold, Green Published			2022-12-25	WOS:000207448800012
J	Sundquist, A; Ronaghi, M; Tang, HX; Pevzner, P; Batzoglou, S				Sundquist, Andreas; Ronaghi, Mostafa; Tang, Haixu; Pevzner, Pavel; Batzoglou, Serafim			Whole-Genome Sequencing and Assembly with High-Throughput, Short-Read Technologies	PLOS ONE			English	Article								While recently developed short-read sequencing technologies may dramatically reduce the sequencing cost and eventually achieve the $1000 goal for re-sequencing, their limitations prevent the de novo sequencing of eukaryotic genomes with the standard shotgun sequencing protocol. We present SHRAP (SHort Read Assembly Protocol), a sequencing protocol and assembly methodology that utilizes high-throughput short-read technologies. We describe a variation on hierarchical sequencing with two crucial differences: (1) we select a clone library from the genome randomly rather than as a tiling path and (2) we sample clones from the genome at high coverage and reads from the clones at low coverage. We assume that 200 bp read lengths with a 1% error rate and inexpensive random fragment cloning on whole mammalian genomes is feasible. Our assembly methodology is based on first ordering the clones and subsequently performing read assembly in three stages: (1) local assemblies of regions significantly smaller than a clone size, (2) clone-sized assemblies of the results of stage 1, and (3) chromosome-sized assemblies. By aggressively localizing the assembly problem during the first stage, our method succeeds in assembling short, unpaired reads sampled from repetitive genomes. We tested our assembler using simulated reads from D. melanogaster and human chromosomes 1, 11, and 21, and produced assemblies with large sets of contiguous sequence and a misassembly rate comparable to other draft assemblies. Tested on D. melanogaster and the entire human genome, our clone-ordering method produces accurate maps, thereby localizing fragment assembly and enabling the parallelization of the subsequent steps of our pipeline. Thus, we have demonstrated that truly inexpensive de novo sequencing of mammalian genomes will soon be possible with high-throughput, short-read technologies using our methodology.	[Sundquist, Andreas; Batzoglou, Serafim] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Ronaghi, Mostafa] Stanford Genome Technol Ctr, Stanford, CA USA; [Tang, Haixu] Indiana Univ, Sch Informat, Bloomington, IN USA; [Pevzner, Pavel] Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA	Stanford University; Stanford University; Indiana University System; Indiana University Bloomington; University of California System; University of California San Diego	Sundquist, A (corresponding author), Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA.	asundqui@cs.stanford.edu			NIH [R01HG003571-02]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003571] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This project was supported in part by NIH grant R01HG003571-02. AS was partly supported by an SAP Labs Stanford Graduate Fellowship.	Batzoglou S, 1999, GENOME RES, V9, P1163, DOI 10.1101/gr.9.12.1163; Batzoglou S, 2002, GENOME RES, V12, P177, DOI 10.1101/gr.208902; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chaisson M, 2004, BIOINFORMATICS, V20, P2067, DOI 10.1093/bioinformatics/bth205; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; ELTOUKHY H, 2006, 2006 IEEE INT C AC S, P1032; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Havlak P, 2004, GENOME RES, V14, P721, DOI 10.1101/gr.2264004; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Pevzner P.A., 2001, P 5 ANN INT C COMP M, P256; Pevzner PA, 2001, P NATL ACAD SCI USA, V98, P9748, DOI 10.1073/pnas.171285098; Pop M, 2004, GENOME RES, V14, P149; Ramanathan A, 2004, ANAL BIOCHEM, V330, P227, DOI 10.1016/j.ab.2004.03.029; ROACH JC, 1995, GENOMICS, V26, P345, DOI 10.1016/0888-7543(95)80219-C; Roach JC, 2000, GENOME RES, V10, P1020, DOI 10.1101/gr.10.7.1020; Rogers YH, 2005, NATURE, V437, P326, DOI 10.1038/437326a; Ronaghi M, 1996, ANAL BIOCHEM, V242, P84, DOI 10.1006/abio.1996.0432; Ronaghi M, 1999, ANAL BIOCHEM, V267, P65, DOI 10.1006/abio.1998.2978; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Siegel AF, 2000, GENOMICS, V68, P237, DOI 10.1006/geno.2000.6303; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Zhou SG, 2003, GENOME RES, V13, P2142, DOI 10.1101/gr.1128803	35	86	98	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e484	10.1371/journal.pone.0000484	http://dx.doi.org/10.1371/journal.pone.0000484			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534434	gold, Green Published			2022-12-25	WOS:000207448800014
J	Fujino, H; Hiramatsu, H; Tsuchiya, A; Niwa, A; Noma, H; Shiota, M; Umeda, K; Yoshimoto, M; Ito, M; Heike, T; Nakahata, T				Fujino, Hisanori; Hiramatsu, Hidefumi; Tsuchiya, Atsunori; Niwa, Akira; Noma, Haruyoshi; Shiota, Mitsutaka; Umeda, Katsutsugu; Yoshimoto, Momoko; Ito, Mamoru; Heike, Toshio; Nakahata, Tatsutoshi			Human cord blood CD34(+) cells develop into hepatocytes in the livers of NOD/SCID/gamma(null)(c) mice through cell fusion	FASEB JOURNAL			English	Article						liver regeneration; hematopoietic stem/progenitor cell; mature hepatocyte; bone marrow-derived cell	HEMATOPOIETIC STEM-CELLS; BONE-MARROW; MYELOMONOCYTIC CELLS; PROGENITOR CELLS; C-MET; DIFFERENTIATE; MOUSE; REGENERATION; RECRUITMENT; EXPRESSION	Several studies have shown that hepatocytes can be generated from hematopoietic stem cells, but this event is believed to be rare and to require hepatic damage. To investigate this phenomenon in human cells, we used a NOD/SCID/gamma(null)(c) ( NOG) mouse model that can achieve a tremendously high level of chimerism when transplanted with human hematopoietic cells. Even without hepatotoxic treatment other than irradiation, human albumin and alpha-1-antitrypsin-positive cells were invariably detected in the livers of NOG mice after i.v. transplantation of human cord blood CD34(+) cells. Human albumin was detected in the murine sera, indicating functional maturation of the human hepatocytes. Flow cytometric analysis of recipient liver cells in single-cell suspension demonstrated that human albumin-positive cells were also positive for both murine and human MHC and were negative for human CD45. PCR analysis of recipient livers revealed the expression of a wide variety of human hepatocyte- or cholangiocyte-specific mRNAs. These results show that human CD34(+) cells fuse with hepatocytes of NOG mice without liver injury, lose their hematopoietic phenotype, and begin hepatocyte-specific gene transcription. These phenomena were not observed when CD34(+) cells were transplanted. Thus, our model revealed a previously unidentified pathway of human hematopoietic stem/progenitor cell differentiation.	Kyoto Univ, Dept Pediat, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; Cent Inst Expt Anim, Kawasaki, Kanagawa, Japan	Kyoto University	Nakahata, T (corresponding author), Kyoto Univ, Dept Pediat, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	tnakaha@kuhp.kyoto-u.ac.jp	Yoshimoto, Momoko/AFP-3523-2022; Yoshimoto, Momoko/N-4238-2014	Yoshimoto, Momoko/0000-0002-7272-6682; Yoshimoto, Momoko/0000-0002-7272-6682				Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Camargo FD, 2004, J CLIN INVEST, V113, P1266, DOI 10.1172/JCI200421301; Cramer T, 2004, LIVER INT, V24, P335, DOI 10.1111/j.1478-3231.2004.0926.x; Fausto N, 2004, HEPATOLOGY, V39, P1477, DOI 10.1002/hep.20214; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; Ishikawa F, 2003, ANN NY ACAD SCI, V996, P174, DOI 10.1111/j.1749-6632.2003.tb03245.x; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Kakinuma S, 2003, STEM CELLS, V21, P217, DOI 10.1634/stemcells.21-2-217; Kambe N, 2004, BLOOD, V103, P860, DOI 10.1182/blood-2003-04-1160; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Ljubimova JY, 1997, J HISTOCHEM CYTOCHEM, V45, P79, DOI 10.1177/002215549704500111; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; Newsome PN, 2003, GASTROENTEROLOGY, V124, P1891, DOI 10.1016/S0016-5085(03)00401-3; Ng IOL, 2003, HEPATOLOGY, V38, P989, DOI 10.1053/jhep.2003.50395; Nonome K, 2005, AM J PHYSIOL-GASTR L, V289, pG1091, DOI 10.1152/ajpgi.00049.2005; Selzner N, 2003, GASTROENTEROLOGY, V124, P692, DOI 10.1053/gast.2003.50098; Sharma AD, 2005, AM J PATHOL, V167, P555, DOI 10.1016/S0002-9440(10)62997-5; Tanabe Y, 2004, BIOCHEM BIOPH RES CO, V324, P711, DOI 10.1016/j.bbrc.2004.09.115; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; TOMITA M, 1994, HEPATOLOGY, V20, P317, DOI 10.1002/hep.1840200208; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2002, AM J PATHOL, V161, P565, DOI 10.1016/S0002-9440(10)64212-5; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wang XL, 2003, BLOOD, V101, P4201, DOI 10.1182/blood-2002-05-1338; Willenbring H, 2004, NAT MED, V10, P744, DOI 10.1038/nm1062; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	32	37	44	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3499	3510		10.1096/fj.06-6109com	http://dx.doi.org/10.1096/fj.06-6109com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17576850	Green Submitted			2022-12-25	WOS:000250517800013
J	Rodrigues, T; de Franca, LP; Kawai, C; de Faria, PA; Mugnol, KCU; Braga, FM; Tersariol, ILS; Smaili, SS; Nantes, IL				Rodrigues, Tiago; de Franca, Lucimar P.; Kawai, Cintia; de Faria, Priscila A.; Mugnol, Katia C. U.; Braga, Fernanda M.; Tersariol, Ivarne L. S.; Smaili, Soraya S.; Nantes, Iseli L.			Protective role of mitochondrial unsaturated lipids on the preservation of the apoptotic ability of cytochrome c exposed to singlet oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; MOLECULAR-OXYGEN; METHYLENE-BLUE; DNA-REPAIR; PHOTOSENSITIZED OXIDATION; CELLULAR-DNA; DAMAGE; HYDROPEROXIDE; PEROXIDATION; MUTAGENESIS	Cytochrome c-mediated apoptosis in cells submitted to photodynamic therapy raises the question about the ability of photodynamically oxidized cytochrome c ( cytc405) to trigger apoptosis as well as the effect of membranes on protein photo-oxidation. Cytochrome c was submitted to irradiation in the presence of MB+ in phosphate buffer and in the presence of four types of phosphatidylcholine/phosphatidylethanolamine/cardiolipin ( PCPECL) liposomes ( 50/30/20%): totally saturated lipids ( tsPCPECL), totally unsaturated lipids ( tuPCPECL), partially unsaturated ( 80%) lipids, with unsaturation in the PC and PE content ( puPCPECL80), and partially unsaturated ( 20%) lipids, with unsaturation in the CL content ( puPCPECL20). Cytc405 was formed by irradiation in buffered water and in tsPCPECL and puPCPECL20 liposomes. In the presence of tuPCPECL and puPCPECL80, cytochrome c was protected from photodynamic damage ( lipid-protected cytochrome c). In CL liposomes, 25% unsaturated lipids were enough to protect cytochrome c. The presence of unsaturated lipids, in amounts varying according to the liposome composition, are crucial to protect cytochrome c. Interesting findings corroborating the unsaturated lipids as cytochrome c protectors were obtained from the analysis of the lipid-oxidized derivatives of the samples. Native cytochrome c, lipid-protected cytochrome c, and cytc405 were microinjected in aortic smooth muscle cells. Apoptosis, characterized by nucleus blebbing and chromatin condensation, was detected in cells loaded with native and lipid protected cytochrome c but not in cells loaded with cytc405. These results suggest that photodynamic therapy-promoted apoptosis is feasible due to the protective effect of the mitochondrial lipids on the cytochrome c structure and function.	Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, BR-08780911 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Farmacol, Sao Paulo, Brazil	Universidade de Mogi das Cruzes; Universidade Federal de Sao Paulo (UNIFESP)	Nantes, IL (corresponding author), Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, Sala 1S-15, BR-08780911 Sao Paulo, Brazil.	ilnantes@umc.br	Nantes, Iseli Lourenço/B-9517-2012; Smaili, Soraya/AAH-2129-2019; Rodrigues, Tiago/AAG-1121-2020; Dos Santos Tersariol, Ivarne Luis/G-4042-2012; Kawai, Cintia/H-2979-2013; Mugnol, Katia C. U./K-7128-2012; Rodrigues, Tiago/B-8459-2012	Nantes, Iseli Lourenço/0000-0003-1434-3154; Smaili, Soraya/0000-0001-5844-1368; Rodrigues, Tiago/0000-0003-1277-0224; Dos Santos Tersariol, Ivarne Luis/0000-0002-8399-4535; Mugnol, Katia C. U./0000-0002-1760-9440; Rodrigues, Tiago/0000-0003-1277-0224				Agnez LF, 1996, CARCINOGENESIS, V17, P1183, DOI 10.1093/carcin/17.5.1183; Agnez-Lima LF, 2001, NUCLEIC ACIDS RES, V29, P2899, DOI 10.1093/nar/29.13.2899; Agnez-Lima LF, 2001, BIOL CHEM, V382, P1071, DOI 10.1515/BC.2001.134; Almeida AM, 1999, FREE RADICAL BIO MED, V27, P744, DOI 10.1016/S0891-5849(99)00136-7; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; Cavalcante AKD, 2002, DNA REPAIR, V1, P1051, DOI 10.1016/S1568-7864(02)00164-7; Cosso RG, 2002, J BIOENERG BIOMEMBR, V34, P157, DOI 10.1023/A:1016075218162; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DESAI ID, 1963, J LIPID RES, V4, P204; Estevam ML, 2004, J BIOL CHEM, V279, P39214, DOI 10.1074/jbc.M402093200; FOOTE CS, 1968, SCIENCE, V162, P963, DOI 10.1126/science.162.3857.963; FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x; Gabrielli D, 2004, PHOTOCHEM PHOTOBIOL, V79, P227, DOI 10.1562/BE-03-27.1; Grijalba MT, 1996, PHOTOCHEM PHOTOBIOL, V63, P697, DOI 10.1111/j.1751-1097.1996.tb09617.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Iwahashi H, 2002, BIOCHEM J, V361, P57, DOI 10.1042/0264-6021:3610057; Jass J, 2003, METHOD ENZYMOL, V367, P199; Kawai C, 2005, J BIOL CHEM, V280, P34709, DOI 10.1074/jbc.M412532200; KELLOGG EW, 1975, J BIOL CHEM, V250, P8812; KLUCK RM, 1997, SCIENCE, V275, P7770; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Martinez GR, 2004, J AM CHEM SOC, V126, P3056, DOI 10.1021/ja039111z; Martinez GR, 2002, BIOL CHEM, V383, P607, DOI 10.1515/BC.2002.063; Martinez GR, 2003, MUTAT RES-REV MUTAT, V544, P115, DOI 10.1016/j.mrrev.2003.05.005; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; MICHAELI A, 1995, PHOTOCHEM PHOTOBIOL, V61, P255, DOI 10.1111/j.1751-1097.1995.tb03968.x; MICHAELI A, 1997, PHOTOCHEM PHOTOBIOL, V51, P299; MISKOSKI S, 1993, PHOTOCHEM PHOTOBIOL, V57, P447, DOI 10.1111/j.1751-1097.1993.tb02317.x; MONOROE BM, 1985, SINGLET O2, V1, P177; Nantes IL, 1998, FREE RADICAL BIO MED, V25, P546, DOI 10.1016/S0891-5849(98)00082-3; NANTES IL, 1995, PHOTOCHEM PHOTOBIOL, V62, P522, DOI 10.1111/j.1751-1097.1995.tb02378.x; Nantes IL, 2000, FREE RADICAL BIO MED, V28, P786, DOI 10.1016/S0891-5849(00)00170-2; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PETIT JM, 1994, EUR J BIOCHEM, V220, P871, DOI 10.1111/j.1432-1033.1994.tb18690.x; Pierlot C, 2000, METHOD ENZYMOL, V319, P3; Ravanat JL, 2004, ARCH BIOCHEM BIOPHYS, V423, P23, DOI 10.1016/j.abb.2003.10.018; Ravanat JL, 2004, BIOL CHEM, V385, P17, DOI 10.1515/BC.2004.003; Ravanat JL, 2000, J BIOL CHEM, V275, P40601, DOI 10.1074/jbc.M006681200; Ravanat JL, 2001, HELV CHIM ACTA, V84, P3702, DOI 10.1002/1522-2675(20011219)84:12<3702::AID-HLCA3702>3.0.CO;2-Y; Ruozi B, 2005, EUR J PHARM SCI, V25, P81, DOI 10.1016/j.ejps.2005.01.020; Severino D, 2003, PHOTOCHEM PHOTOBIOL, V77, P459, DOI 10.1562/0031-8655(2003)077<0459:IONCIO>2.0.CO;2; TANIELIAN C, 1994, PHOTOCHEM PHOTOBIOL, V59, P263, DOI 10.1111/j.1751-1097.1994.tb05032.x; TANIELIAN C, 1992, J PHOTOCH PHOTOBIO A, V64, P191, DOI 10.1016/1010-6030(92)85106-5; Tanielian C, 2000, PHOTOCHEM PHOTOBIOL, V71, P12, DOI 10.1562/0031-8655(2000)071<0012:MAKAOP>2.0.CO;2; TUIETE EM, 1993, J PHOTOCHEM PHOTOBIO, V21, P103; Veeramasuneni S, 1996, J COLLOID INTERF SCI, V184, P594, DOI 10.1006/jcis.1996.0656; YANG J, 1997, SCIENCE, V275, P1132	47	28	32	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25577	25587		10.1074/jbc.M700009200	http://dx.doi.org/10.1074/jbc.M700009200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17567586	hybrid			2022-12-25	WOS:000249014100044
J	Yang, LK; Bae, JS; Manithody, C; Rezaie, AR				Yang, Likui; Bae, Jong-Sup; Manithody, Chandrashekhara; Rezaie, Alireza R.			Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; FACTOR VA; ANTICOAGULANT FUNCTION; DEPENDENT REGULATION; COAGULATION-FACTOR; BLOOD-COAGULATION; HEPARIN-BINDING; BASIC RESIDUES	Activated protein C ( APC) is a vitamin K-dependent plasma serine protease which down-regulates the clotting cascade by inactivating procoagulant factors Va and VIIIa by limited proteolysis. In addition to its anticoagulant effect, APC also exhibits cytoprotective and antiinflammatory activity through the endothelial protein C receptor-dependent cleavage of protease activated receptor 1 ( PAR-1) on endothelial cells. Recent mutagenesis data have indicated that the basic residues of two surface loops including those on 39 and the Ca2+-binding 70-80 loops constitute interactive sites for both factors Va and VIIIa, thereby mediating the interaction of APC specifically with these procoagulant cofactors. The basic residues of both loops have been discovered to be dispensable for the interaction of APC with PAR-1. It is not known if a similar exosite-dependent interaction contributes to the specificity of APC recognition of PAR-1 on endothelial cells. In this study, we have identified two acidic residues on helix-162 ( Glu-167 and Glu-170) on the protease domain of APC which are required for the protease interaction with PAR-1, but not for its interaction with the procoagulant cofactors. Thus, the substitution of either Glu-167 or Glu-170 with Ala eliminated the cytoprotective signaling properties of APC without affecting its anticoagulant activity. These mutants provide useful tools for initiating in vivo studies to understand the extent to which the anticoagulant versus antiinflammatory activity of APC contributes to its beneficial effect in treating severe sepsis.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu	Bae, Jong-Sup/AAU-9724-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R01HL068571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62565, HL 68571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKESON AL, 1993, J IMMUNOL METHODS, V163, P181, DOI 10.1016/0022-1759(93)90121-M; Bae JS, 2007, J BIOL CHEM, V282, P9251, DOI 10.1074/jbc.M610547200; Bae JS, 2007, P NATL ACAD SCI USA, V104, P2867, DOI 10.1073/pnas.0611493104; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Feistritzer C, 2006, J BIOL CHEM, V281, P20077, DOI 10.1074/jbc.M600506200; Friedrich U, 2001, J BIOL CHEM, V276, P23105, DOI 10.1074/jbc.M103138200; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Manithody C, 2003, BLOOD, V101, P4802, DOI 10.1182/blood-2003-01-0126; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; Mizutani A, 2000, BLOOD, V95, P3781; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Oganesyan V, 2002, J BIOL CHEM, V277, P24851, DOI 10.1074/jbc.C200163200; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Regan LM, 1996, J BIOL CHEM, V271, P17499, DOI 10.1074/jbc.271.29.17499; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rezaie AR, 2003, TRENDS CARDIOVAS MED, V13, P8, DOI 10.1016/S1050-1738(02)00191-3; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; STENFLO J, 1984, SEMIN THROMB HEMOST, V10, P109, DOI 10.1055/s-2007-1004413; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; Yang LK, 2006, P NATL ACAD SCI USA, V103, P879, DOI 10.1073/pnas.0507700103; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r	37	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25493	25500		10.1074/jbc.M702131200	http://dx.doi.org/10.1074/jbc.M702131200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17580306	hybrid			2022-12-25	WOS:000249014100035
J	Januszyk, K; Li, PWL; Villareal, V; Branciforte, D; Wu, H; Xie, Y; Feigon, J; Loo, JA; Martin, SL; Clubb, RT				Januszyk, Kurt; Li, Patrick Wai-Lun; Villareal, Valerie; Branciforte, Dan; Wu, Haihong; Xie, Yongming; Feigon, Juli; Loo, Joseph A.; Martin, Sandra L.; Clubb, Robert T.			Identification and solution structure of a highly conserved C-terminal domain within ORF1p required for retrotransposition of long interspersed nuclear element-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTOPICALLY ENRICHED PROTEINS; EMBRYONAL CARCINOMA-CELLS; TRIPLE-RESONANCE NMR; L1 RETROTRANSPOSITION; RNA-BINDING; LINE-1 RETROTRANSPOSITION; LARGER PROTEINS; REVERSE TRANSCRIPTION; CHAPERONE ACTIVITY; ACID INTERACTIONS	Long interspersed nuclear element-1 (LINE-1 or L1) retro-transposons comprise a large fraction of the human and mouse genomes. The mobility of these successful elements requires the protein encoded by open reading frame-1 (ORF1p), which binds single-stranded RNA with high affinity and functions as a nucleic acid chaperone. In this report, we have used limited proteolysis, filter binding, and NMR spectroscopy to characterize the global structure of ORF1p and the three-dimensional structure of a highly conserved RNA binding domain. ORF1p contains three structured regions, a coiled-coil domain, a middle domain of unknown function, and a C-terminal domain (CTD). We show that high affinity RNA binding by ORF1p requires the CTD and residues within an amino acid protease-sensitive segment that joins the CTD to the middle domain. Insights in the mechanism of RNA binding were obtained by determining the solution structure of the CTD, which is shown to adopt a novel fold consisting of a three-stranded beta sheet that is packed against three alpha-helices. An RNA binding surface on the CTD has been localized using chemical shift perturbation experiments and is proximal to residues previously shown to be essential for retro-transposition, RNA binding, and chaperone activity. A similar structure and mechanism of RNA binding is expected for all vertebrate long interspersed nuclear element-1 elements, since residues encoding the middle, protease-sensitive segment, and CTD are highly conserved.	Univ Colorado, Sch Med, Dept Cell & Dev Biol, Aurora, CO 80045 USA; Univ Calif Los Angeles, Dept Energy, Dept Energy Inst Genom & Proteom, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Martin, SL (corresponding author), Univ Colorado, Sch Med, Dept Cell & Dev Biol, POB 6511,MS 8108, Aurora, CO 80045 USA.	sandy.martin@uchsc.edu			NIGMS NIH HHS [GM40367, GM57487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040367, R01GM057487, R29GM040367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Bailey JA, 2000, P NATL ACAD SCI USA, V97, P6634, DOI 10.1073/pnas.97.12.6634; Basame S, 2006, J MOL BIOL, V357, P351, DOI 10.1016/j.jmb.2005.12.063; BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BAX A, 1992, J AM CHEM SOC, V114, P6923, DOI 10.1021/ja00043a052; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Chen JM, 2005, HUM GENET, V117, P411, DOI 10.1007/s00439-005-1321-0; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104; Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delano W. L., 2003, PYMOL MOL GENETICS G; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Dieckmann T, 1997, J BIOMOL NMR, V9, P259, DOI 10.1023/A:1018622708674; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Fujimoto H, 2004, NUCLEIC ACIDS RES, V32, P1555, DOI 10.1093/nar/gkh304; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Goodier JL, 2001, GENOME RES, V11, P1677, DOI 10.1101/gr.198301; GRZESIEK S, 1993, J BIOMOL NMR, V3, P487; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; Hakansson-McReynolds S, 2006, J BIOL CHEM, V281, P11965, DOI 10.1074/jbc.M601174200; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; Hu JS, 1997, J AM CHEM SOC, V119, P6360, DOI 10.1021/ja970067v; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kolosha VO, 2003, J BIOL CHEM, V278, P8112, DOI 10.1074/jbc.M210487200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kulpa DA, 2005, HUM MOL GENET, V14, P3237, DOI 10.1093/hmg/ddi354; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Martin SL, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/45621; Martin SL, 2000, J MOL BIOL, V304, P11, DOI 10.1006/jmbi.2000.4182; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Martin SL, 2005, J MOL BIOL, V348, P549, DOI 10.1016/j.jmb.2005.03.003; Martin SL, 2003, P NATL ACAD SCI USA, V100, P13815, DOI 10.1073/pnas.2336221100; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; MORAN JV, 2002, MOBILE DNA, V2; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Naas TP, 1998, EMBO J, V17, P590, DOI 10.1093/emboj/17.2.590; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1991, COMPUTATIONAL ASPECT; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Ramachandran P, 2006, J PROTEOME RES, V5, P1493, DOI 10.1021/pr050492k; Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866; Sambrook J., 2002, MOL CLONING LAB MANU; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Wu HH, 2004, P NATL ACAD SCI USA, V101, P8307, DOI 10.1073/pnas.0402627101; Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141; Zhang WX, 1996, J BIOMOL NMR, V7, P247	70	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24893	24904		10.1074/jbc.M702023200	http://dx.doi.org/10.1074/jbc.M702023200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17569664	hybrid			2022-12-25	WOS:000248933000046
J	Pahlman, LI; Marx, PF; Morgelin, M; Lukomski, S; Meijers, JCM; Herwald, H				Pahlman, Lisa I.; Marx, Pauline F.; Morgelin, Matthias; Lukomski, Slawomir; Meijers, Joost C. M.; Herwald, Heiko			Thrombin-activatable fibrinolysis inhibitor binds to Streptococcus pyogenes by interacting with collagen-like proteins A and B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PROCARBOXYPEPTIDASE-B; SURFACE PROTEIN; CARBOXYPEPTIDASE-R; PLASMINOGEN; COAGULATION; IDENTIFICATION; PLASMIN(OGEN); INACTIVATION; FIBRINOGEN; RECEPTOR	Regulation of proteolysis is a critical element of the host immune system and plays an important role in the induction of pro- and anti-inflammatory reactions in response to infection. Some bacterial species take advantage of these processes and recruit host proteinases to their surface in order to counteract the host attack. Here we show that Thrombin-activatable Fibrinolysis Inhibitor (TAFI), a zinc-dependent procarboxypeptidase, binds to the surface of group A streptococci of an M41 serotype. The interaction is mediated by the streptococcal collagen-like surface proteins A and B (Sc1A and Sc1B), and the streptococcal-associated TAFI is then processed at the bacterial surface via plasmin and thrombin-thrombomodulin. These findings suggest an important role for TAFI in the modulation of host responses by streptococci.	Lund Univ, Dept Clin Sci, Sect Clin & Expt Infect Med, BMC B14, SE-22184 Lund, Sweden; Acad Med Ctr, Dept Vasc, NL-1100 DD Amsterdam, Netherlands; Acad Med Ctr, Dept Expt Vasc Med, NL-1100 DD Amsterdam, Netherlands; W Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA	Lund University; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; West Virginia University	Pahlman, LI (corresponding author), Lund Univ, Dept Clin Sci, Sect Clin & Expt Infect Med, BMC B14, Tornavagen 10, SE-22184 Lund, Sweden.	Lisa.Pahlman@med.lu.se	Herwald, Heiko/AAN-3708-2021; Meijers, J.C.M./S-5981-2019	Herwald, Heiko/0000-0002-8111-2842; Meijers, J.C.M./0000-0002-4198-6780	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050666] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50666] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BERGE A, 1993, J BIOL CHEM, V268, P25417; Bouma BN, 2003, J THROMB HAEMOST, V1, P1566, DOI 10.1046/j.1538-7836.2003.00329.x; BRODER CC, 1991, J BIOL CHEM, V266, P4922; Brummel KE, 1999, J BIOL CHEM, V274, P22862, DOI 10.1074/jbc.274.32.22862; Campbell WD, 2002, MICROBIOL IMMUNOL, V46, P131, DOI 10.1111/j.1348-0421.2002.tb02669.x; Courtney HS, 2002, ANN MED, V34, P77, DOI 10.1080/07853890252953464; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; DECHATEAU M, 1994, J BIOL CHEM, V269, P12147; DESJARDIN LE, 1989, THROMB RES, V55, P187, DOI 10.1016/0049-3848(89)90435-0; EATON DL, 1991, J BIOL CHEM, V266, P21833; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FAULMANN EL, 1991, PREP BIOCHEM, V21, P75, DOI 10.1080/10826069108021517; FUCHS H, 1994, P NATL ACAD SCI USA, V91, P12594, DOI 10.1073/pnas.91.26.12594; Han RL, 2006, MOL MICROBIOL, V61, P351, DOI 10.1111/j.1365-2958.2006.05237.x; Han RL, 2006, APPL MICROBIOL BIOT, V72, P109, DOI 10.1007/s00253-006-0387-5; Herwald H, 2003, SCAND J INFECT DIS, V35, P604, DOI 10.1080/00365540310016268; Herwald H, 2003, J THROMB HAEMOST, V1, P284, DOI 10.1046/j.1538-7836.2003.00105.x; Humtsoe JO, 2005, J BIOL CHEM, V280, P13848, DOI 10.1074/jbc.M410605200; Kawamura T, 2002, MICROBIOL IMMUNOL, V46, P225, DOI 10.1111/j.1348-0421.2002.tb02690.x; LOTTENBERG R, 1987, INFECT IMMUN, V55, P1914, DOI 10.1128/IAI.55.8.1914-1918.1987; Lukomski S, 2001, INFECT IMMUN, V69, P1729, DOI 10.1128/IAI.69.3.1729-1738.2001; Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Marx PF, 2002, BIOCHEMISTRY-US, V41, P6688, DOI 10.1021/bi015982e; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; Myles T, 2003, J BIOL CHEM, V278, P51059, DOI 10.1074/jbc.M306977200; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; Panizzi P, 2006, J BIOL CHEM, V281, P1179, DOI 10.1074/jbc.M507956200; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; Rasmussen M, 2001, MOL MICROBIOL, V40, P1427, DOI 10.1046/j.1365-2958.2001.02493.x; Santala A, 1999, FEBS LETT, V461, P153, DOI 10.1016/S0014-5793(99)01440-4; Schatteman KA, 1999, CLIN CHEM, V45, P807; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Tapper H, 2000, BLOOD, V96, P2329; van Gorp ECM, 1999, J INFECT DIS, V180, P176, DOI 10.1086/314829; WANG H, 1995, J INFECT DIS, V171, P85, DOI 10.1093/infdis/171.1.85; Whatmore AM, 2001, MICROBIOL-UK, V147, P419, DOI 10.1099/00221287-147-2-419; Willemse J, 2005, ANAL BIOCHEM, V340, P106, DOI 10.1016/j.ab.2005.01.039; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x	41	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24873	24881		10.1074/jbc.M610015200	http://dx.doi.org/10.1074/jbc.M610015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17553807	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000248933000044
J	Lai, AL; Tamm, LK				Lai, Alex L.; Tamm, Lukas K.			Locking the kink in the influenza hemagglutinin fusion domain structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; PROTEINS; DISTANCE; PROGRAM; PEPTIDE; SYSTEM	We have previously identified Trp(14) as a critical residue that stabilizes the kink in the boomerang structure of the influenza fusion domain and found that cells expressing hemagglutinin with a Trp14 to Ala mutation cannot fuse with red blood cells. However, mutating another aromatic residue, Phe(9), on the other side of the kink did not have a significant effect on fusion or the ability of the mutant fusion peptide to bind to or perturb the bilayer structure of lipid model membranes. We reasoned that Phe is not as potent to contribute to the kink as the larger Trp and that the cooperation of Phe(9) and Ile(10) might be needed to elicit the same effect. Indeed, the double mutant F9A/I10A diminished cell-cell fusion and the ability of the fusion domain to bind to and perturb lipid bilayers in a similar fashion as the W14A mutant. A structure determination of F9A in lipid micelles by solution NMR shows that F9A adopts a similarly kinked structure as wild type. Distances between the two arms of the boomerang structure of wild type, F9A, W14A, and F9A/I10A in lipid bilayers were measured by double electron-electron resonance spectroscopy and showed that the kinks of W14A and F9A/I10A are more flexible than those of wild type and F9A. These results underscore the importance of large hydrophobic residues on both sides of the kink region of the influenza hemagglutinin fusion domain to fix the angle of the boomerang structure and thereby confer fusion function to this critical domain.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Tamm, LK (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA.	lkt2e@virginia.edu	Lai, Alex/G-8668-2014		NIAID NIH HHS [R37 AI030557, R37 AI30557] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030557] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HELM CA, 1989, SCIENCE, V246, P919, DOI 10.1126/science.2814514; Hong HD, 2007, J AM CHEM SOC, V129, P8320, DOI 10.1021/ja068849o; Jeschke G, 2002, CHEMPHYSCHEM, V3, P927, DOI 10.1002/1439-7641(20021115)3:11<927::AID-CPHC927>3.0.CO;2-Q; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lai AL, 2006, J BIOL CHEM, V281, P5760, DOI 10.1074/jbc.M512280200; Lai AL, 2005, PROTEIN-LIPID INTERACTIONS: FROM MEMBRANE DOMAINS TO CELLULAR NETWORKS, P279; Li YL, 2003, BIOCHEMISTRY-US, V42, P7245, DOI 10.1021/bi0341760; Luginbuhl P, 1996, J BIOMOL NMR, V8, P136; Pannier M, 2000, J MAGN RESON, V142, P331, DOI 10.1006/jmre.1999.1944; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Tamm LK, 2003, BBA-BIOMEMBRANES, V1614, P14, DOI 10.1016/S0005-2736(03)00159-7; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; TATULIAN SA, 1995, EMBO J, V14, P5514, DOI 10.1002/j.1460-2075.1995.tb00238.x; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Yang L, 2003, BIOCHEMISTRY-US, V42, P6631, DOI 10.1021/bi0344836	22	53	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23946	23956		10.1074/jbc.M704008200	http://dx.doi.org/10.1074/jbc.M704008200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17567572	hybrid			2022-12-25	WOS:000248686600021
J	Mammoto, T; Parikh, SM; Mammoto, A; Gallagher, D; Chan, B; Mostoslavsky, G; Ingber, DE; Sukhatme, VP				Mammoto, Tadanori; Parikh, Samir M.; Mammoto, Akiko; Gallagher, Diana; Chan, Barden; Mostoslavsky, Gustavo; Ingber, Donald E.; Sukhatme, Vikas P.			Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL PERMEABILITY; LEUKOCYTE ADHESION; TYROSINE KINASES; INDUCED INCREASE; PLASMA LEAKAGE; TIE2 RECEPTOR; CELLS; RAC; RHOA; EXPRESSION	Angiopoietin-1 ( Ang-1), a ligand of the endothelium-specific receptor Tie-2, inhibits permeability in the mature vasculature, but the mechanism remains unknown. Here we show that Ang-1 signals Rho family GTPases to organize the cytoskeleton into a junction-fortifying arrangement that enhances the permeability barrier function of the endothelium. Ang-1 phosphorylates Tie-2 and its downstream effector phosphatidylinositol 3-kinase. This induces activation of one endogenous GTPase, Rac1, and inhibition of another, RhoA. Loss of either part of this dual effect abrogates the cytoskeletal and anti-permeability actions of Ang-1, suggesting that coordinated GTPase regulation is necessary for the vessel-sealing effects of Ang-1. p190 RhoGAP, a GTPase regulatory protein, provides this coordinating function as it is phosphorylated by Ang-1 treatment, requires Rac1 activation, and is necessary for RhoA inhibition. Ang-1 prevents the cytoskeletal and pro-permeability effects of endotoxin but requires p190 RhoGAP to do so. Treatment with p190 RhoGAP small interfering RNA completely abolishes the ability of Ang-1 to rescue endotoxemia-induced pulmonary vascular leak and inflammation in mice. We conclude that Ang-1 prevents vascular permeability by regulating the endothelial cytoskeleton through coordinated and opposite effects on the Rho GTPases Rac1 and RhoA. By linking Rac1 activation and RhoA inhibition, p190 RhoGAP is critical to the protective effects of Ang-1 against endotoxin. These results provide mechanistic evidence that targeting the endothelium through Tie-2 may offer specific therapeutic strategies in life-threatening endotoxemic conditions such as sepsis and acute respiratory distress syndrome.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Vasc Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program, Boston, MA USA; Harvard Univ, Sch Med, Harvard Inst Med, Dept Genet, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Sukhatme, VP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Interdisciplinary Med & Biotechnol, 330 Brookline Ave,RW 563, Boston, MA 02215 USA.	vsukhatm@bidmc.harvard.edu	Sukhatme, Vikas/W-2776-2019; Ingber, Donald E/AAC-5894-2019	Mostoslavsky, Gustavo/0000-0002-0784-2169	NCI NIH HHS [CA55833, CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055833, P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Amerongen GPV, 2000, ARTERIOSCL THROM VAS, V20, pE127, DOI 10.1161/01.ATV.20.12.e127; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH107, DOI 10.1152/ajpheart.00542.2005; Bhandari V, 2006, NAT MED, V12, P1286, DOI 10.1038/nm1494; Broman MT, 2006, CIRC RES, V98, P73, DOI 10.1161/01.RES.0000198387.44395.e9; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5553, DOI 10.1073/pnas.0307575101; Clements RT, 2005, AM J PHYSIOL-LUNG C, V288, pL294, DOI 10.1152/ajplung.00213.2004; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Daly C, 2006, P NATL ACAD SCI USA, V103, P15491, DOI 10.1073/pnas.0607538103; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200; Jho D, 2005, CIRC RES, V96, P1282, DOI 10.1161/01.RES.0000171894.03801.03; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Li XC, 2004, BLOOD, V104, P1716, DOI 10.1182/blood-2003-11-3744; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; LUM H, 1989, J APPL PHYSIOL, V66, P1471, DOI 10.1152/jappl.1989.66.3.1471; Millan J, 2005, BIOCHEM J, V385, P329, DOI 10.1042/BJ20041584; Mostoslavsky G, 2005, MOL THER, V11, P932, DOI 10.1016/j.ymthe.2005.01.005; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046; Pizurki L, 2003, BRIT J PHARMACOL, V139, P329, DOI 10.1038/sj.bjp.0705259; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Seebach J, 2005, THROMB HAEMOSTASIS, V94, P620, DOI 10.1160/TH05-01-0015; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thorlacius K, 2006, J LEUKOCYTE BIOL, V79, P923, DOI 10.1189/jlb.0705406; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Witzenbichler B, 2005, CIRCULATION, V111, P97, DOI 10.1161/01.CIR.0000151287.08202.8E; Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011	52	140	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23910	23918		10.1074/jbc.M702169200	http://dx.doi.org/10.1074/jbc.M702169200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17562701	Green Published, hybrid			2022-12-25	WOS:000248686600018
J	Marella, M; Seo, BB; Matsuno-Yagi, A; Yagi, T				Marella, Mathieu; Seo, Byoung Boo; Matsuno-Yagi, Akemi; Yagi, Takao			Mechanism of cell death caused by complex I defects in a rat dopaminergic cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY-OPTIC-NEUROPATHY; NADH-QUINONE OXIDOREDUCTASE; PARKINSONS-DISEASE; REACTIVE OXYGEN; INTERMEMBRANE SPACE; SIGNAL-TRANSDUCTION; NEURONAL APOPTOSIS; OXIDATIVE DAMAGE; ALPHA-SYNUCLEIN; ENDONUCLEASE-G	Defects in the proton- translocating NADH- quinone oxidoreductase (complex I) of mammalian mitochondria are linked to neurodegenerative disorders. The mechanism leading to cell death elicited by complex I deficiency remains elusive. We have shown that expression of a rotenone- insensitive yeast NADHquinone oxidoreductase ( Ndi1) can rescue mammalian cells from complex I dysfunction. By using the Ndi1 enzyme, we have investigated the key events in the process of cell death using a rat dopaminergic cell line, PC12. We found that complex I inhibition provokes the following events: 1) activation of specific kinase pathways; 2) release of mitochondrial proapoptotic factors, apoptosis inducing factor, and endonuclease G. AS601245, a kinase inhibitor, exhibited significant protection against these apoptotic events. The traditional caspase pathway does not seems to be involved because caspase 3 activation was not observed. Our data suggest that overproduction of reactive oxygen species ( ROS) caused by complex I inhibition is responsible for triggering the kinase activation, for the release of the proapoptotic factors, and then for cell death. Nearly perfect prevention of apoptotic cell death by Ndi1 agrees with our earlier observation that the presence of Ndi1 diminishes rotenone- induced ROS generation from complex I. In fact, this study demonstrated that Ndi1 keeps the redox potential high even in the presence of rotenone. Under these conditions, ROS formation by complex I is known to be minimal. Possible use of our cellular model is discussed with regard to development of therapeutic strategies for neurodegenerative diseases caused by complex I defects.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA	Scripps Research Institute	Yagi, T (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, MEM-256,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	yagi@scripps.edu			NIDDK NIH HHS [R01DK053244] Funding Source: Medline; NINDS NIH HHS [R01NS048441] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048441] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Alam M, 2002, BEHAV BRAIN RES, V136, P317, DOI 10.1016/S0166-4328(02)00180-8; Betarbet R, 2006, NEUROBIOL DIS, V22, P404, DOI 10.1016/j.nbd.2005.12.003; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bogoyevitch MA, 2006, BIOESSAYS, V28, P923, DOI 10.1002/bies.20458; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; Dukes AA, 2005, ANTIOXID REDOX SIGN, V7, P630, DOI 10.1089/ars.2005.7.630; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HIRSCH EC, 2003, J NEURAL TRANSM, V65, pS89; Kabir J, 2002, BIOCHEM J, V367, P145, DOI 10.1042/BJ20020665; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; King MA, 2002, CYTOMETRY, V49, P106, DOI 10.1002/cyto.10156; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Kussmaul L, 2006, P NATL ACAD SCI USA, V103, P7607, DOI 10.1073/pnas.0510977103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Newhouse K, 2004, TOXICOL SCI, V79, P137, DOI 10.1093/toxsci/kfh089; Novikova L, 2006, NEUROSCIENCE, V140, P67, DOI 10.1016/j.neuroscience.2006.02.007; Ooe H, 2005, TOXICOL SCI, V88, P114, DOI 10.1093/toxsci/kfi278; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Perier C, 2005, P NATL ACAD SCI USA, V102, P19126, DOI 10.1073/pnas.0508215102; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V135, P269, DOI 10.1016/0006-291X(86)90972-1; Robinson KM, 2006, P NATL ACAD SCI USA, V103, P15038, DOI 10.1073/pnas.0601945103; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674; Seo BB, 2006, FEBS LETT, V580, P6105, DOI 10.1016/j.febslet.2006.10.008; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Sherer TB, 2002, J NEUROSCI, V22, P7006; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimizu S, 1996, ONCOGENE, V13, P21; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wang XD, 2001, GENE DEV, V15, P2922; Yagi T, 2006, REJUV RES, V9, P191, DOI 10.1089/rej.2006.9.191; Yagi T, 2001, J BIOENERG BIOMEMBR, V33, P233, DOI 10.1023/A:1010787004053; Yagi T, 2006, BBA-BIOENERGETICS, V1757, P708, DOI 10.1016/j.bbabio.2006.01.011; Zanna C, 2005, APOPTOSIS, V10, P997, DOI 10.1007/s10495-005-0742-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	49	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24146	24156		10.1074/jbc.M701819200	http://dx.doi.org/10.1074/jbc.M701819200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17581813	hybrid			2022-12-25	WOS:000248686600040
J	Pelzer, C; Kassner, I; Matentzoglu, K; Singh, RK; Wollscheid, HP; Scheffner, M; Schmidtke, G; Groettrup, M				Pelzer, Christiane; Kassner, Ingrid; Matentzoglu, Konstantin; Singh, Rajesh K.; Wollscheid, Hans-Peter; Scheffner, Martin; Schmidtke, Gunter; Groettrup, Marcus			UBE1L2, a novel E1 enzyme specific for ubiquitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE MUTANT TS85; ACTIVATING ENZYME; MOLECULAR-CLONING; CONJUGATING ENZYMES; PROTEIN LIGASE; SYSTEM; IDENTIFICATION; DEGRADATION; EXPRESSION; COMPONENTS	\UBE1 is known as the human ubiquitin-activating enzyme (E1), which activates ubiquitin in an ATP-dependent manner. Here, we identified a novel human ubiquitin-activating enzyme referred to as UBE1L2, which also shows specificity for ubiquitin. The UBE1L2 sequence displays a 40% identity to UBE1 and also contains an ATP-binding domain and an active site cysteine conserved among E1 family proteins. UBE1L2 forms a covalent link with ubiquitin in vitro and in vivo, which is sensitive to reducing conditions. In an in vitro polyubiquitylation assay, recombinant UBE1L2 could activate ubiquitin and transfer it onto the ubiquitin-conjugating enzyme UbcH5b. Ubiquitin activated by UBE1L2 could be used for ubiquitylation of p53 by MDM2 and supported the autoubiquitylation of the E3 ubiquitin ligases HectH9 and E6-AP. The UBE1L2 mRNA is most abundantly expressed in the testis, suggesting an organ-specific regulation of ubiquitin activation.	Univ Konstanz, Dept Biol, Div Immunol, D-78457 Constance, Germany; Univ Konstanz, Dept Biol, Div Biochem, D-78457 Constance, Germany	University of Konstanz; University of Konstanz	Groettrup, M (corresponding author), Univ Konstanz, Dept Biol, Div Immunol, Univ Str 10, D-78457 Constance, Germany.	marcus.groettrup@uni-konstanz.de	Groettrup, Marcus/AAT-2623-2020; Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Komatsu M, 2004, EMBO J, V23, P1977, DOI 10.1038/sj.emboj.7600205; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Singh RK, 2007, J BIOL CHEM, V282, P10901, DOI 10.1074/jbc.M610879200; Swanson R, 2000, FEBS LETT, V477, P193, DOI 10.1016/S0014-5793(00)01802-0; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x; Zhu H, 2004, ACTA BIOCH BIOPH SIN, V36, P227, DOI 10.1093/abbs/36.3.227	26	120	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23010	23014		10.1074/jbc.C700111200	http://dx.doi.org/10.1074/jbc.C700111200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17580310	hybrid, Green Published			2022-12-25	WOS:000248577500003
J	Xu, S; Benoff, B; Liou, HL; Lobel, P; Stock, AM				Xu, Sujuan; Benoff, Brian; Liou, Heng-Ling; Lobel, Peter; Stock, Ann M.			Structural basis of sterol binding by NPC2, a lysosomal protein deficient in Niemann-Pick type C2 disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GM2-ACTIVATOR PROTEIN; MAJOR SECRETORY PROTEIN; CHOLESTEROL-BINDING; CRYSTAL-STRUCTURE; MITE ALLERGEN; RESOLUTION; TRANSPORT; HE-1; REFINEMENT; MECHANISM	NPC2 is a small lysosomal glycoprotein that binds cholesterol with submicromolar affinity. Deficiency in NPC2 is the cause of Niemann-Pick type C2 disease, a fatal neurovisceral disorder characterized by accumulation of cholesterol in lysosomes. Here we report the crystal structure of bovine NPC2 bound to cholesterol-3-O-sulfate, an analog that binds with greater apparent affinity than cholesterol. Structures of both apo-bound and sterol-bound NPC2 were observed within the same crystal lattice, with an asymmetric unit containing one molecule of apoNPC2 and two molecules of sterol-bound NPC2. As predicted from a previously determined structure of apoNPC2, the sterol binds in a deep hydrophobic pocket sandwiched between the two beta- sheets of NPC2, with only the sulfate substituent of the ligand exposed to solvent. In the two available structures of apoNPC2, the incipient ligand-binding pocket, which ranges from a loosely packed hydrophobic core to a small tunnel, is too small to accommodate cholesterol. In the presence of sterol, the pocket expands, facilitated by a slight separation of the beta- strands and substantial reorientation of some side chains, resulting in a perfect molding of the pocket around the hydrocarbon portion of cholesterol. A notable feature is the repositioning of two aromatic residues at the tunnel entrance that are essential for NPC2 function. The NPC2 structures provide evidence of a malleable binding site, consistent with the previously documented broad range of sterol ligand specificity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Pharmacol, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Stock, AM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Ctr Adv Biotechnol & Med, 679 Hoes, Piscataway, NJ 08854 USA.	stock@cabm.rutgers.edu		Stock, Ann/0000-0002-0446-8079	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047958] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIDDK NIH HHS [R01 DK054317, DK54317] Funding Source: Medline; NIGMS NIH HHS [R37 GM047958] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheruku SR, 2006, J BIOL CHEM, V281, P31594, DOI 10.1074/jbc.M602765200; Choinowski T, 2000, BIOCHEMISTRY-US, V39, P1897, DOI 10.1021/bi992742e; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; Ichikawa S, 1998, J BIOL CHEM, V273, P356, DOI 10.1074/jbc.273.1.356; Im YJ, 2005, NATURE, V437, P154, DOI 10.1038/nature03923; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Kallen J, 2004, J BIOL CHEM, V279, P14033, DOI 10.1074/jbc.M400302200; Kirchhoff C, 1996, BIOL REPROD, V54, P847, DOI 10.1095/biolreprod54.4.847; Klunemann HH, 2002, ANN NEUROL, V52, P743, DOI 10.1002/ana.10366; Ko DC, 2003, P NATL ACAD SCI USA, V100, P2518, DOI 10.1073/pnas.0530027100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen LB, 1997, EUR J BIOCHEM, V243, P437, DOI 10.1111/j.1432-1033.1997.0437a.x; Liou HL, 2006, J BIOL CHEM, V281, P36710, DOI 10.1074/jbc.M608743200; Malinina L, 2004, NATURE, V430, P1048, DOI 10.1038/nature02856; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Van Bambeke F, 2000, LIPIDS, V35, P213, DOI 10.1007/BF02664772; Wendeler M, 2004, EUR J BIOCHEM, V271, P614, DOI 10.1111/j.1432-1033.2003.03964.x; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225; Wu F, 2001, BIOCHEMISTRY-US, V40, P1976, DOI 10.1021/bi002252i; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6	35	156	162	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23525	23531		10.1074/jbc.M703848200	http://dx.doi.org/10.1074/jbc.M703848200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17573352	Green Accepted, hybrid			2022-12-25	WOS:000248577500054
J	Campana, V; Caputo, A; Sarnataro, D; Paladino, S; Tivodar, S; Zurzolo, C				Campana, Vincenza; Caputo, Anna; Sarnataro, Daniela; Paladino, Simona; Tivodar, Simona; Zurzolo, Chiara			Characterization of the properties and trafficking of an anchorless form of the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID RAFTS; SCRAPIE ISOFORM; EPITHELIAL-CELLS; CULTURED-CELLS; ENDOPLASMIC-RETICULUM; MEMBRANE DOMAINS; PRP; CONVERSION; SURFACE; ASSOCIATION	Conversion of PrPC into PrPSc is the central event in the pathogenesis of transmissible prion diseases. Although the molecular basis of this event and the intracellular compartment where it occurs are not yet understood, the association of PrP with cellular membranes and in particular its presence in detergent-resistant microdomains appears to be of critical importance. In addition it appears that scrapie conversion requires membrane-bound glycosylphosphatidylinositol (GPI)-linked PrP. The GPI anchor may affect either the conformation, the intracellular localization, or the association of the prion protein with specific membrane domains. However, how this occurs is not known. To understand the relevance of the GPI anchor for the cellular behavior of PrP, we have studied the biosynthesis and localization of a PrP version which lacks the GPI anchor attachment signal (PrP Delta GPI). We found that PrP Delta GPI is tethered to cell membranes and associates to membrane detergent-resistant microdomains but does not assume a transmembrane topology. Differently to PrPC, this protein does not localize at the cell surface but is mainly released in the culture media in a fully glycosylated soluble form. The cellular behavior of anchor-less PrP explains why PrP Delta GPI Tg mice can be infected but do not show the classical signs of the disorder, thus indicating that the plasma membrane localization of PrPC and/or of the converted scrapie form might be necessary for the development of a symptomatic disease.	Inst Pasteur, Unite Traf Membranaire & Pathogenese, F-75724 Paris, France; Univ Naples Federico 2, Centro Biotecnol Avanzate, Ctr Eccellenza Ingn Genet, I-80131 Naples, Italy; Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Naples Federico II; University of Naples Federico II	Zurzolo, C (corresponding author), Inst Pasteur, Unite Traf Membranaire & Pathogenese, 25 Rue Dr Roux, F-75724 Paris, France.	zurzolo@pasteur.fr	Zurzolo, Chiara/AAH-5225-2019; Paladino, Simona/ABH-7826-2020; Sarnataro, Daniela/X-5629-2019; Paladino, Simona/J-5383-2018	Sarnataro, Daniela/0000-0002-6094-8384; Paladino, Simona/0000-0001-5332-6774; ZURZOLO, Chiara/0000-0001-6048-6602	Telethon [GGP04147] Funding Source: Medline	Telethon(Fondazione Telethon)		Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baumann F, 2007, EMBO J, V26, P538, DOI 10.1038/sj.emboj.7601510; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Campana V, 2006, J CELL SCI, V119, P433, DOI 10.1242/jcs.02768; Campana V, 2005, TRENDS CELL BIOL, V15, P102, DOI 10.1016/j.tcb.2004.12.002; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Harris B, 2003, CLIO MED, V71, P85; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kazlauskaite J, 2005, BIOCHEM SOC SYMP, V72, P211, DOI 10.1042/bss0720211; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Lee KS, 2001, J NEUROCHEM, V79, P79, DOI 10.1046/j.1471-4159.2001.00529.x; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Marella M, 2002, J BIOL CHEM, V277, P25457, DOI 10.1074/jbc.M203248200; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Paquet S, 2004, J VIROL, V78, P7148, DOI 10.1128/JVI.78.13.7148-7152.2004; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Prinetti A, 2000, J BIOL CHEM, V275, P11658, DOI 10.1074/jbc.275.16.11658; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Sarnataro D, 2004, MOL BIOL CELL, V15, P4031, DOI 10.1091/mbc.E03-05-0271; Sarnataro D, 2002, TRAFFIC, V3, P810, DOI 10.1034/j.1600-0854.2002.31106.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Stewart RS, 2003, J BIOL CHEM, V278, P45960, DOI 10.1074/jbc.M307833200; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Tivodar S, 2006, FEBS LETT, V580, P5705, DOI 10.1016/j.febslet.2006.09.022; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; Zurzolo C, 2003, EMBO REP, V4, P1117, DOI 10.1038/sj.embor.7400032; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	46	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22747	22756		10.1074/jbc.M701468200	http://dx.doi.org/10.1074/jbc.M701468200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17556367	hybrid			2022-12-25	WOS:000248354200052
J	Johnson, MP; Havaux, M; Triantaphylides, C; Ksas, B; Pascal, AA; Robert, B; Davison, PA; Ruban, AV; Horton, P				Johnson, Matthew P.; Havaux, Michel; Triantaphylides, Christian; Ksas, Brigitte; Pascal, Andrew A.; Robert, Bruno; Davison, Paul A.; Ruban, Alexander V.; Horton, Peter			Elevated zeaxanthin bound to oligomeric LHCII enhances the resistance of Arabidopsis to photooxidative stress by a lipid-protective, antioxidant mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; BETA-CAROTENE HYDROXYLASE; HIGHER-PLANT CHLOROPLASTS; PROTEINS IN-VIVO; PHOTOSYSTEM-II; XANTHOPHYLL CYCLE; SINGLET OXYGEN; CHLAMYDOMONAS-REINHARDTII; PHOTOSYNTHETIC APPARATUS; THYLAKOID MEMBRANES	xanthophyll cycle has a major role in protecting plants from photooxidative stress, although the mechanism of its action is unclear. Here, we have investigated Arabidopsis plants overexpressing a gene encoding beta-carotene hydroxylase, containing nearly three times the amount of xanthophyll cycle carotenoids present in the wild-type. In high light at low temperature wild- type plants exhibited symptoms of severe oxidative stress: lipid peroxidation, chlorophyll bleaching, and photoinhibition. In transformed plants, which accumulate over twice as much zeaxanthin as the wild-type, these symptoms were significantly ameliorated. The capacity of non-photochemical quenching is not significantly different in transformed plants compared with wild-type and therefore an enhancement of this process cannot be the cause of the stress tolerant phenotype. Rather, it is concluded that it results from the antioxidant effect of zeaxanthin. 80-90% of violaxanthin and zeaxanthin in wildtype and transformed plants was localized to an oligomeric LHCII fraction prepared from thylakoid membranes. The binding of these pigments in intact membranes was confirmed by resonance Raman spectroscopy. Based on the structural model of LHCII, we suggest that the protein/lipid interface is the active site for the antioxidant activity of zeaxanthin, which mediates stress tolerance by the protection of bound lipids.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Aix Marseille, CEA, CNRS UMR 6191,CEA Cadarache, Lab Ecophysiol Mol Plantes,Inst Biol Environm & B, F-13108 St Paul Les Durance, France; CEA, Inst Biol & Technol Saclay, URA 2096, F-91191 Gif Sur Yvette, France; Univ London Queen Mary Coll, Sch Biol & Chem Sci, London E1 4NS, England	University of Sheffield; CEA; UDICE-French Research Universities; Aix-Marseille Universite; CEA; University of London; Queen Mary University London	Horton, P (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	p.horton@sheffield.ac.uk	Robert, Bruno/D-1264-2012; pascal, andrew a/B-6186-2014; Horton, Peter/A-3958-2012	Robert, Bruno/0000-0001-5999-4538; pascal, andrew a/0000-0002-1844-6065; Horton, Peter/0000-0002-6095-1460; Johnson, Matthew/0000-0002-1663-0205				Adams WW, 2002, PLANT BIOLOGY, V4, P545, DOI 10.1055/s-2002-35434; Adamska I, 1999, EUR J BIOCHEM, V260, P453, DOI 10.1046/j.1432-1327.1999.00178.x; ALEXANDERNORTH LS, 1994, J LIPID RES, V35, P1773; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Asada K, 1996, PHOTOSYNTHESIS ENV, P123, DOI DOI 10.1007/0-306-48135-9_5; Ballottari M, 2007, J BIOL CHEM, V282, P8947, DOI 10.1074/jbc.M606417200; Baroli I, 2003, PLANT CELL, V15, P992, DOI 10.1105/tpc.010405; Baroli I, 2004, J BIOL CHEM, V279, P6337, DOI 10.1074/jbc.M312919200; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002; Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200; Bohm F, 1997, J AM CHEM SOC, V119, P621, DOI 10.1021/ja962512c; Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6; Davison PA, 2002, NATURE, V418, P203, DOI 10.1038/nature00861; Dekker JP, 2002, PHOTOSYNTH RES, V72, P203, DOI 10.1023/A:1016188818591; Demmig-Adams B, 2002, SCIENCE, V298, P2149, DOI 10.1126/science.1078002; Demmig-Adams B, 2006, PHYSIOL PLANTARUM, V127, P670, DOI 10.1111/j.1399-3054.2006.00698.x; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; Depka B, 1998, FEBS LETT, V424, P267, DOI 10.1016/S0014-5793(98)00188-4; Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4; Fiore A, 2006, FEBS LETT, V580, P4718, DOI 10.1016/j.febslet.2006.07.055; GANETOG U, 2004, PLANT PHYSIOL, V127, P150; Girotti AW, 2004, ANTIOXID REDOX SIGN, V6, P301, DOI 10.1089/152308604322899369; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; GRUSZECKI WI, 1991, BIOCHIM BIOPHYS ACTA, V1060, P310, DOI 10.1016/S0005-2728(05)80322-6; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 2004, J BIOL CHEM, V279, P13878, DOI 10.1074/jbc.M311154200; Havaux M, 2003, TRENDS PLANT SCI, V8, P409, DOI 10.1016/S1360-1385(03)00185-7; Havaux M, 2005, PLANT CELL, V17, P3451, DOI 10.1105/tpc.105.037036; Havaux M, 1998, TRENDS PLANT SCI, V3, P147, DOI 10.1016/S1360-1385(98)01200-X; Havaux M, 2000, PLANT PHYSIOL, V124, P273, DOI 10.1104/pp.124.1.273; Havaux M, 2006, TRENDS PLANT SCI, V11, P480, DOI 10.1016/j.tplants.2006.08.001; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; Heddad M, 2006, PLANT PHYSIOL, V142, P75, DOI 10.1104/pp.106.081489; Holt NE, 2004, BIOCHEMISTRY-US, V43, P8281, DOI 10.1021/bi0494020; Horton P, 2005, FEBS LETT, V579, P4201, DOI 10.1016/j.febslet.2005.07.003; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HORTON P, 1991, FEBS LETT, V292, P1, DOI 10.1016/0014-5793(91)80819-O; Horton P, 2001, NOVART FDN SYMP, V236, P117; Hutin C, 2003, P NATL ACAD SCI USA, V100, P4921, DOI 10.1073/pnas.0736939100; Jahns P, 2000, PLANT PHYSIOL BIOCH, V38, P371, DOI 10.1016/S0981-9428(00)00753-1; JOHNSON GN, 1993, PLANT CELL ENVIRON, V16, P673, DOI 10.1111/j.1365-3040.1993.tb00485.x; Kim J, 2006, P NATL ACAD SCI USA, V103, P3474, DOI 10.1073/pnas.0511207103; Kopsell DA, 2006, TRENDS PLANT SCI, V11, P499, DOI 10.1016/j.tplants.2006.08.006; Kovacs L, 2006, PLANT CELL, V18, P3106, DOI 10.1105/tpc.106.045641; Ledford HK, 2005, PLANT CELL ENVIRON, V28, P1037, DOI 10.1111/j.1365-3040.2005.01374.x; Li XP, 2002, P NATL ACAD SCI USA, V99, P15222, DOI 10.1073/pnas.232447699; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Montillet JL, 2004, PLANT J, V40, P439, DOI 10.1111/j.1365-313X.2004.02223.x; Morosinotto T, 2002, J BIOL CHEM, V277, P36913, DOI 10.1074/jbc.M205339200; Muller-Moule P, 2003, PLANT PHYSIOL, V133, P748, DOI 10.1104/pp.103.026252; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; op den Camp RGL, 2003, PLANT CELL, V15, P2320, DOI 10.1105/tpc.014662; Oquist G, 2003, ANNU REV PLANT BIOL, V54, P329, DOI 10.1146/annurev.arplant.54.072402 .115741; Pascal AA, 2005, NATURE, V436, P134, DOI 10.1038/nature03795; PETER GF, 1991, J BIOL CHEM, V266, P16745; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REMY R, 1984, PHOTOBIOCH PHOTOBIOP, V7, P267; Robert B, 2004, TRENDS PLANT SCI, V9, P385, DOI 10.1016/j.tplants.2004.06.006; Rossini S, 2006, PLANT PHYSIOL, V141, P1264, DOI 10.1104/pp.106.083055; Ruban AV, 2006, J BIOL CHEM, V281, P14981, DOI 10.1074/jbc.M511415200; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Ruban AV, 2002, J BIOL CHEM, V277, P42937, DOI 10.1074/jbc.M207823200; Ruban AV, 1997, BIOCHEMISTRY-US, V36, P7855, DOI 10.1021/bi9630725; Ruban AV, 2001, J BIOL CHEM, V276, P24862, DOI 10.1074/jbc.M103263200; RUBAN AV, 1993, J PHOTOCH PHOTOBIO B, V21, P229, DOI 10.1016/1011-1344(93)80188-F; SARRY JE, 1994, FEBS LETT, V353, P147, DOI 10.1016/0014-5793(94)01028-5; Sun ZR, 1996, J BIOL CHEM, V271, P24349, DOI 10.1074/jbc.271.40.24349; Tardy F, 1997, BBA-BIOMEMBRANES, V1330, P179, DOI 10.1016/S0005-2736(97)00168-5; Tian L, 2003, PLANT CELL, V15, P1320, DOI 10.1105/tpc.011403; Vavilin DV, 1998, J PHOTOCH PHOTOBIO B, V42, P233, DOI 10.1016/S1011-1344(98)00076-1; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; Wehner A, 2006, J BIOL CHEM, V281, P21924, DOI 10.1074/jbc.M602915200; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965	78	142	147	3	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22605	10.1074/jbc.M702831200	http://dx.doi.org/10.1074/jbc.M702831200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553786	hybrid			2022-12-25	WOS:000248354200038
J	Jonckheere, N; Vincent, A; Perrais, M; Ducourouble, MP; Korteland-van Male, A; Aubert, JP; Pigny, P; Carraway, KL; Freund, JN; Renes, IB; Van Seuningen, I				Jonckheere, Nicolas; Vincent, Audrey; Perrais, Michael; Ducourouble, Marie-Paule; Korteland-van Male, Anita; Aubert, Jean-Pierre; Pigny, Pascal; Carraway, Kermit L.; Freund, Jean-Noel; Renes, Ingrid B.; Van Seuningen, Isabelle			The human mucin MUC4 is transcriptionally regulated by caudal-related homeobox, hepatocyte nuclear factors, forkhead box A, and GATA endodermal transcription factors in epithelial cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY DIGESTIVE GLANDS; HUMAN RESPIRATORY-TRACT; CDX2 MUTANT MICE; GENE-EXPRESSION; PANCREATIC-CANCER; DEVELOPMENTAL EXPRESSION; FUNCTIONAL INTERACTION; INTESTINAL DEVELOPMENT; GASTRODUODENAL TRACT; GASTRIC-CARCINOMA	The human gene MUC4 encodes a large transmembrane mucin that is developmentally regulated and expressed along the undifferfetal development. Immunohistochemical analysis of Muc4 expression inentiated pseudostratified epithelium, as early as 6.5 weeks during developing mouse lung and gastrointestinal tract showed a different spatio-temporal pattern of expression before and after cytodifferentiation. The molecular mechanisms governing MUC4 expression during development are, however, unknown. Hepatocyte nuclear factors (HNF), forkhead box A (FOXA), GATA, and caudal-related homeobox transcription factors (TFs) are known to control cell differentiation of gut endoderm derived-tissues during embryonic development. They also control the expression of cell- and tissue-specific genes and may thus control MUC4 expression. To test this hypothesis, we studied and deciphered the molecular mechanisms responsible for MUC4 transcriptional regulation by these TFs. Experiments using small interfering RNA, cell co-transfection, and site-directed mutagenesis indicated that MUC4 is regulated at the transcriptional level by CDX-1 and -2, HNF-1 alpha and -1 beta, FOXA1/A2, HNF-4 alpha and -4 gamma, and GATA-4, -5, and -6 factors in a cell- specific manner. Binding of TFs was assessed by chromatin immunoprecipitation, and gel-shift assays. Altogether, these results demonstrate that MUC4 is a target gene of endodermal TFs and thus point out an important role for these TFs in regulating MUC4 expression during epithelial differentiation during development, cancer, and repair.	INSERM, U560, F-59045 Lille, France; Erasmus MC, Dept Pediat, Div Gastroenterol, NL-3015 GE Rotterdam, Netherlands; Erasmus MC, Dept Pediat, Div Nutr, NL-3015 GE Rotterdam, Netherlands; Erasmus MC, Div Neonatol, NL-3015 GE Rotterdam, Netherlands; Sophia Childrens Univ Hosp, NL-3015 GE Rotterdam, Netherlands; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA; INSERM, U682, F-67200 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; University of Miami; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Van Seuningen, I (corresponding author), INSERM, U560, Pl Verdun, F-59045 Lille, France.	isabelvs@lille.inserm.fr	VAN SEUNINGEN, Isabelle/N-6176-2016; Freund, Jean-Noel/R-4383-2016; Renes, Ingrid/C-4801-2013; Vincent, Audrey/I-2934-2016; Jonckheere, Nicolas/J-6028-2013	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Freund, Jean-Noel/0000-0002-0971-3774; Vincent, Audrey/0000-0003-0058-2058; Jonckheere, Nicolas/0000-0002-0496-0661	NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER; NCI NIH HHS [CA52498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Besnard V, 2004, GENE EXPR PATTERNS, V5, P193, DOI 10.1016/j.modgep.2004.08.006; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Buisine MP, 1998, GUT, V43, P519, DOI 10.1136/gut.43.4.519; Buisine MP, 2000, J HISTOCHEM CYTOCHEM, V48, P1667, DOI 10.1177/002215540004801210; Buisine MP, 2000, J HISTOCHEM CYTOCHEM, V48, P1657, DOI 10.1177/002215540004801209; Buisine MP, 1999, AM J RESP CELL MOL, V20, P209, DOI 10.1165/ajrcmb.20.2.3259; Calon A, 2007, NUCLEIC ACIDS RES, V35, P175, DOI 10.1093/nar/gkl1034; CARDOSO WV, 1995, AM J PHYSIOL-LUNG C, V269, pL429, DOI 10.1152/ajplung.1995.269.4.L429; Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Copin MC, 2001, FRONT BIOSCI, V6, pD1264, DOI 10.2741/Copin; Corfield AP, 2001, FRONT BIOSCI-LANDMRK, V6, pD1321, DOI 10.2741/Corfield; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Fang RX, 2006, GENE EXPR PATTERNS, V6, P426, DOI 10.1016/j.modgep.2005.09.003; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Gendron FP, 2006, AM J PHYSIOL-GASTR L, V290, pG310, DOI 10.1152/ajpgi.00217.2005; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Hackett BP, 1996, ANNU REV PHYSIOL, V58, P51, DOI 10.1146/annurev.physiol.58.1.51; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769; JONCKHEERE N, 2002, GASTROENTEROLOGY, V122, P247; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Leteurtre E, 2004, BIOL CELL, V96, P145, DOI 10.1016/j.biolcel.2003.12.005; Lin L, 2002, CANCER RES, V62, P5273; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mesquita P, 2003, J BIOL CHEM, V278, P51549, DOI 10.1074/jbc.M309019200; Mesquita Patricia, 2006, Critical Reviews in Oncogenesis, V12, P3; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Ozeki T, 2001, BIOCHEM J, V355, P537, DOI 10.1042/0264-6021:3550537; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Pontoglio M, 2000, J AM SOC NEPHROL, V11, pS140; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Price-Schiavi A, 1998, BIOCHEM J, V335, P457, DOI 10.1042/bj3350457; Reid CJ, 1998, GUT, V42, P220, DOI 10.1136/gut.42.2.220; Reid CJ, 1997, AM J RESP CELL MOL, V17, P592, DOI 10.1165/ajrcmb.17.5.2798; Rong M, 2005, J CELL PHYSIOL, V202, P275, DOI 10.1002/jcp.20121; Sauvaget D, 2002, J BIOL CHEM, V277, P34540, DOI 10.1074/jbc.M206074200; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; Shah RNH, 2002, ONCOGENE, V21, P8251, DOI 10.1038/sj.onc.1206020; Shimakura J, 2006, BIOCHEM PHARMACOL, V71, P1581, DOI 10.1016/j.bcp.2006.03.001; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Traber Peter G., 1995, P21; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; van der Sluis M, 2004, BIOCHEM BIOPH RES CO, V325, P952, DOI 10.1016/j.bbrc.2004.10.108; Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020; Van Seuningen I, 2000, BIOCHEM J, V348, P675; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Whitsett JA, 2002, J CLIN INVEST, V109, P565, DOI 10.1172/JCI200215209; Zhang J, 2006, TISSUE CELL, V38, P271, DOI 10.1016/j.tice.2006.06.004	70	39	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22638	22650		10.1074/jbc.M700905200	http://dx.doi.org/10.1074/jbc.M700905200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553805	Green Published, hybrid			2022-12-25	WOS:000248354200041
J	Zhou, Y; Muh, U; Hanzelka, BL; Bartels, DJ; Wei, YY; Rao, BG; Brennan, DL; Tigges, AM; Swenson, L; Kwong, AD; Lin, C				Zhou, Yi; Mueh, Ute; Hanzelka, Brian L.; Bartels, Doug J.; Wei, Yunyi; Rao, B. Govinda; Brennan, Debra L.; Tigges, Ann M.; Swenson, Lora; Kwong, Ann D.; Lin, Chao			Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg(155) variants - Sensitivity to telaprevir (VX-950) and interferon alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONS CONFERRING RESISTANCE; SERINE-TYPE PROTEINASE; IN-VITRO; ANTIVIRAL EFFICACY; PLUS RIBAVIRIN; NS4A COFACTOR; INHIBITOR; RNA; CLEAVAGE; POTENT	Telaprevir (VX-950) is a highly selective, potent inhibitor of the hepatitis C virus (HCV) NS3 center dot 4A serine protease. It has demonstrated strong antiviral activity in patients chronically infected with genotype 1 HCV when dosed alone or in combination with peginterferon alfa-2a. Substitutions of Arg(155) of the HCV NS3 protease domain have been previously detected in HCV isolates from some patients during telaprevir dosing. In this study, Arg(155) was replaced with various residues in genotype 1a protease domain proteins and in genotype 1b HCV subgenomic replicons. Characterization of both the purified enzymes and reconstituted replicon cells demonstrated that substitutions of Arg(155) with these residues conferred low level resistance to telaprevir (< 25-fold). An x-ray structure of genotype 1a HCV protease domain with the R155K mutation, in a complex with an NS4A co-factor peptide, was determined at a resolution of 2.5 angstrom. The crystal structure of the R155K protease is essentially identical to that of the wild-type apoenzyme ( Protein Data Bank code 1A1R) except for the side chain of mutated residue 155. Telaprevir was docked into the x-ray structure of the R155K protease, and modeling analysis suggests that the P2 group of telaprevir loses several hydrophobic contacts with the Lys(155) side chain. It was demonstrated that replicon cells containing substitutions at NS3 protease residue 155 remain fully sensitive to interferon alpha or ribavirin. Finally, these variant replicons were shown to have reduced replication capacity compared with the wild-type HCV replicon in cells.	Vertex Pharmaceut Inc, Dept Infect Dis, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	Lin, C (corresponding author), Vertex Pharmaceut Inc, Dept Infect Dis, 130 Waverly St, Cambridge, MA 02139 USA.	chao_lin@vrtx.com						Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 1998, ANTIVIR THER, V3, P71; Chander G, 2002, HEPATOLOGY, V36, pS135, DOI 10.1053/jhep.2002.37146; Di Marco S, 2000, J BIOL CHEM, V275, P7152, DOI 10.1074/jbc.275.10.7152; FAILLA C, 1995, J VIROL, V69, P1769, DOI 10.1128/JVI.69.3.1769-1777.1995; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; Hinrichsen H, 2004, GASTROENTEROLOGY, V127, P1347, DOI 10.1053/j.gastro.2004.08.002; Kenny-Walsh E, 2001, Clin Liver Dis, V5, P969, DOI 10.1016/S1089-3261(05)70204-X; Kieffer T, 2005, HEPATOLOGY, V42, p537A; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Landro JA, 1997, BIOCHEMISTRY-US, V36, P9340, DOI 10.1021/bi963054n; LAWITZ E, 2006, 37 ANN DIG DIS WEEK; Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200; Lin C, 2005, J BIOL CHEM, V280, P36784, DOI 10.1074/jbc.M506462200; Lin C., 2006, Infectious Disorders - Drug Targets, V6, P3, DOI 10.2174/187152606776056706; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; Lin K, 2006, ANTIMICROB AGENTS CH, V50, P1813, DOI 10.1128/AAC.50.5.1813-1822.2006; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lu LJ, 2004, ANTIMICROB AGENTS CH, V48, P2260, DOI 10.1128/AAC.48.6.2260-2266.2004; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Mo HM, 2005, ANTIMICROB AGENTS CH, V49, P4305, DOI 10.1128/AAC.49.10.4305-4314.2005; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Perni RB, 2006, ANTIMICROB AGENTS CH, V50, P899, DOI 10.1128/AAC.50.3.899-909.2006; Perni RB, 2004, BIOORG MED CHEM LETT, V14, P1441, DOI 10.1016/j.bmcl.2004.01.022; Reesink HW, 2006, J HEPATOL, V44, pS272, DOI 10.1016/S0168-8278(06)80737-3; Reesink HW, 2006, GASTROENTEROLOGY, V131, P997, DOI 10.1053/j.gastro.2006.07.013; Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1767, DOI 10.1053/j.gastro.2007.02.037; Seiwert S, 2007, REV ANTIVIRAL THER, V1, P56; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Taliani M, 1996, ANAL BIOCHEM, V240, P60, DOI 10.1006/abio.1996.0331; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Tong X, 2006, ANTIVIR RES, V70, P28, DOI 10.1016/j.antiviral.2005.12.003; Trozzi C, 2003, J VIROL, V77, P3669, DOI 10.1128/JVI.77.6.3669-3679.2003; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Yi MK, 2006, J BIOL CHEM, V281, P8205, DOI 10.1074/jbc.M510246200; Zeuzem S, 2005, HEPATOLOGY, V42, p233A	46	71	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22619	22628		10.1074/jbc.M610207200	http://dx.doi.org/10.1074/jbc.M610207200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17556358	hybrid			2022-12-25	WOS:000248354200039
J	Basu, I; Cordovano, G; Das, I; Belbin, TJ; Guha, C; Schramm, VL				Basu, Indranil; Cordovano, Grace; Das, Ishita; Belbin, Thomas J.; Guha, Chandan; Schramm, Vern L.			A transition state analogue of 5'-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOSIDE PHOSPHORYLASE; METHYLTHIOADENOSINE PHOSPHORYLASE; 5'-METHYLTHIOADENOSINE/S-ADENOSYLHOMOCYSTEINE NUCLEOSIDASE; HOMOZYGOUS DELETIONS; POLYAMINE ANALOGS; ESCHERICHIA-COLI; TUMOR-SUPPRESSOR; INHIBITORS; 5'-METHYLTHIOADENOSINE; DECARBOXYLASE	Methylthio-DADMe-immucillin-A (MT-DADMe-ImmA) is an 86-pM inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP). The sole function of MTAP is to recycle 5'-methylthioadenosine (MTA) to S-adenosylmethionine. Treatment of cultured cells with MT-DADMe-ImmA and MTA inhibited MTAP, increased cellular MTA concentrations, decreased polyamines, and induced apoptosis in FaDu and Cal27, two head and neck squamous cell carcinoma cell lines. The same treatment did not induce apoptosis in normal human fibroblast cell lines (CRL2522 and GM02037) or in MCF7, a breast cancer cell line with an MTAP gene deletion. MT-DADMe-ImmA alone did not induce apoptosis in any cell line, implicating MTA as the active agent. Treatment of sensitive cells caused loss of mitochondrial inner membrane potential, G(2)/M arrest, activation of mitochondria-dependent caspases, and apoptosis. Changes in cellular polyamines and MTA levels occurred in both responsive and nonresponsive cells, suggesting cell-specific epigenetic effects. A survey of aberrant DNA methylation in genomic DNA using a microarray of 12,288 CpG island clones revealed decreased CpG island methylation in treated FaDu cells compared with untreated cells. FaDu tumors in a mouse xenograft model were treated with MT-DADMe-ImmA, resulting in tumor remission. The selective action of MT-DADMe-ImmA on head and neck squamous cell carcinoma cells suggests potential as an agent for treatment of cancers sensitive to reduced CpG island methylation.	Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Schramm, VL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	vern@aecom.yu.edu			NCI NIH HHS [P30 CA013330, CA85953] Funding Source: Medline; NIGMS NIH HHS [GM41916] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA085953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041916, R01GM041916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adrien LR, 2006, CYTOGENET GENOME RES, V114, P16, DOI 10.1159/000091923; CARTENIFARINA M, 1984, BIOCHIM BIOPHYS ACTA, V805, P158, DOI 10.1016/0167-4889(84)90163-0; Casero RA, 2005, P W PHARMACOL SOC, V48, P24; Chattopadhyay S, 2006, MOL CANCER THER, V5, P2549, DOI 10.1158/1535-7163.MCT-06-0313; Chen ZH, 1996, CANCER RES, V56, P1083; Chow WA, 2006, CANCER GENET CYTOGEN, V166, P95, DOI 10.1016/j.cancergencyto.2005.10.009; Christopher SA, 2002, CANCER RES, V62, P6639; Evans GB, 2005, J MED CHEM, V48, P4679, DOI 10.1021/jm050269z; FISCHER D, 1976, J CLIN INVEST, V58, P399, DOI 10.1172/JCI108484; Gaboriau F, 2002, J PHARMACOL TOXICOL, V47, P33, DOI 10.1016/S1056-8719(02)00187-9; Gandhi V, 2005, BLOOD, V106, P4253, DOI 10.1182/blood-2005-03-1309; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Karikari CA, 2005, MOL CANCER THER, V4, P1860, DOI 10.1158/1535-7163.MCT-05-0103; KIM MS, 1993, ANTICANCER RES, V13, P1405; KLINE PC, 1992, BIOCHEMISTRY-US, V31, P5964, DOI 10.1021/bi00141a003; KLINE PC, 1995, BIOCHEMISTRY-US, V34, P1153, DOI 10.1021/bi00004a008; KLINE PC, 1993, BIOCHEMISTRY-US, V32, P13212, DOI 10.1021/bi00211a033; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; MITCHELL BS, 1980, ANN INTERN MED, V92, P826, DOI 10.7326/0003-4819-92-6-826; PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6; PEGG AE, 1983, METHOD ENZYMOL, V94, P239; PEGG AE, 1981, BIOCHEM J, V194, P79, DOI 10.1042/bj1940079; Rinaldo-Matthis A, 2007, BIOCHEMISTRY-US, V46, P659, DOI 10.1021/bi061515r; Ringia EAT, 2005, CURR TOP MED CHEM, V5, P1237, DOI 10.2174/156802605774463088; Sauve AA, 2005, MOL CELL, V17, P595, DOI 10.1016/j.molcel.2004.12.032; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Schramm VL, 2005, ARCH BIOCHEM BIOPHYS, V433, P13, DOI 10.1016/j.abb.2004.08.035; Seiler N, 2003, CURR DRUG TARGETS, V4, P565, DOI 10.2174/1389450033490876; Singh V, 2005, BIOCHEMISTRY-US, V44, P11647, DOI 10.1021/bi050863a; Singh V, 2005, J BIOL CHEM, V280, P18265, DOI 10.1074/jbc.M414472200; Singh V, 2004, BIOCHEMISTRY-US, V43, P9, DOI 10.1021/bi0358420; Singh V, 2006, J AM CHEM SOC, V128, P14691, DOI 10.1021/ja065419p; Subhi AL, 2004, CLIN CANCER RES, V10, P7290, DOI 10.1158/1078-0432.CCR-04-0972; Wallace HM, 2003, BIOCHEM SOC T, V31, P393, DOI 10.1042/BST0310393; Wallace HM, 1996, P NUTR SOC, V55, P419, DOI 10.1079/PNS19960039; Wang XT, 2004, CANCER RES, V64, P1377, DOI 10.1158/0008-5472.CAN-03-2428; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; WOLFORD RW, 1981, CANCER RES, V41, P3035	40	61	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21477	21486		10.1074/jbc.M702287200	http://dx.doi.org/10.1074/jbc.M702287200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17548352	hybrid			2022-12-25	WOS:000248047500075
J	Skiniotis, G; Moazed, D; Walz, T				Skiniotis, Georgios; Moazed, Danesh; Walz, Thomas			Acetylated histone tail peptides induce structural rearrangements in the RSC chromatin remodeling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; TILT; RECONSTRUCTION; BROMODOMAINS	Post-translational acetylation of histone tails is often required for the recruitment of ATP-dependent chromatin remodelers, which in turn mobilize nucleosomes on the chromatin fiber. Here we show that the lower lobe of the ATP-dependent chromatin remodeler RSC exists in a dynamic equilibrium and can be found extended away or retracted against the tripartite upper lobe of the complex. Extension of the lower lobe increases the size of a central cavity that has been proposed to be the nucleosome binding site. We show that the presence of acetylated histone 3N-terminal tail peptides stabilizes the lower lobe of RSC in the retracted state, suggesting that domains recognizing the acetylated histone tails reside at the interface between the two lobes. Based on three-dimensional reconstructions, we propose a model for the interaction of RSC with acetylated nucleosomes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walz, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	twalz@hms.harvard.edu		Walz, Thomas/0000-0003-2606-2835; Skiniotis, Georgios/0000-0003-0238-7846				Asturias FJ, 2002, P NATL ACAD SCI USA, V99, P13477, DOI 10.1073/pnas.162504299; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Carey M, 2006, MOL CELL, V24, P481, DOI 10.1016/j.molcel.2006.09.012; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Grigorieff N, 2007, J STRUCT BIOL, V157, P117, DOI 10.1016/j.jsb.2006.05.004; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kasten M, 2004, EMBO J, V23, P1348, DOI 10.1038/sj.emboj.7600143; Leschziner AE, 2005, STRUCTURE, V13, P267, DOI 10.1016/j.str.2004.12.008; Leschziner AE, 2007, P NATL ACAD SCI USA, V104, P4913, DOI 10.1073/pnas.0700706104; Mindell JA, 2003, J STRUCT BIOL, V142, P334, DOI 10.1016/S1047-8477(03)00069-8; Mohrmann L, 2005, BBA-GENE STRUCT EXPR, V1681, P59, DOI 10.1016/j.bbaexp.2004.10.005; Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; Saha A, 2005, NAT STRUCT MOL BIOL, V12, P747, DOI 10.1038/nsmb973; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Smith CL, 2005, CURR TOP DEV BIOL, V65, P115; Verger A, 2004, CELL MOL LIFE SCI, V61, P2154, DOI 10.1007/s00018-004-4176-y; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7	22	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20804	20808		10.1074/jbc.C700081200	http://dx.doi.org/10.1074/jbc.C700081200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17535815	hybrid			2022-12-25	WOS:000248047500005
J	Marino, S; Nusse, R				Marino, Susan; Nusse, Roel			Mutants in the Mouse NuRD/Mi2 Component P66 alpha Are Embryonic Lethal	PLOS ONE			English	Article							DNA METHYLATION; HISTONE; COMPLEX; BINDING; IDENTIFICATION; PROTEIN; ROLES; MBD2; LOCALIZATION; DEACETYLASES	Background. The NuRD/Mi2 chromatin complex is involved in histone modifications and contains a large number of subunits, including the p66 protein. There are two mouse and human p66 paralogs, p66 alpha and p66 beta. The functions of these genes are not clear, in part because there are no mutants available, except in invertebrate model systems. Methodology. We made loss of function mutants in the mouse p66 alpha gene (mp66 alpha, official name Gatad2a, MGI:2384585). We found that mp66 alpha is essential for development, as mutant embryos die around day 10 of embryogenesis. The gene is not required for normal blastocyst development or for implantation. The phenotype of mutant embryos and the pattern of gene expression in mutants are consistent with a role of mp66 alpha in gene silencing. Conclusion. mp66 alpha is an essential gene, required for early mouse development. The lethal phenotype supports a role in execution of methylated DNA silencing.	[Marino, Susan; Nusse, Roel] Stanford Univ, Beckman Ctr, Sch Med, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Nusse, R (corresponding author), Stanford Univ, Beckman Ctr, Sch Med, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA.	rnusse@stanford.edu			Howard Hughes Medical Institute; US ARMY Medical Research and Material Command [DAMD17-99-1-9386]	Howard Hughes Medical Institute(Howard Hughes Medical Institute); US ARMY Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC))	The work was supported by the Howard Hughes Medical Institute and a grant from the US ARMY Medical Research and Material Command (DAMD17-99-1-9386).	Brackertz M, 2006, NUCLEIC ACIDS RES, V34, P397, DOI 10.1093/nar/gkj437; Brackertz M, 2002, J BIOL CHEM, V277, P40958, DOI 10.1074/jbc.M207467200; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Crook JM, 2006, NAT CELL BIOL, V8, P212, DOI 10.1038/ncb0306-212; Drewell RA, 2002, NUCLEIC ACIDS RES, V30, P1139, DOI 10.1093/nar/30.5.1139; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Feng Q, 2001, GENE DEV, V15, P827; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hogan B, 1994, MANIPULATING MOUSE E; Joyner AL, 2000, GENE TARGETING PRACT; Kaji K, 2006, NAT CELL BIOL, V8, P285, DOI 10.1038/ncb1372; Kantor B, 2003, GENE EXPR PATTERNS, V3, P697, DOI 10.1016/j.modgep.2003.07.003; Kon C, 2005, GENETICS, V169, P2087, DOI 10.1534/genetics.104.034595; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Le Guezennec X, 2006, MOL CELL BIOL, V26, P843, DOI 10.1128/MCB.26.3.843-851.2006; Lei H, 1996, DEVELOPMENT, V122, P3195; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang HB, 2001, NUCLEIC ACIDS RES, V29, P2517, DOI 10.1093/nar/29.12.2517; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	34	21	22	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e519	10.1371/journal.pone.0000519	http://dx.doi.org/10.1371/journal.pone.0000519			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565372	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451600007
J	Andrews, R; Ahringer, J				Andrews, Robert; Ahringer, Julie			Asymmetry of Early Endosome Distribution in C. elegans Embryos	PLOS ONE			English	Article							ANTERIOR-POSTERIOR POLARITY; CAENORHABDITIS-ELEGANS; ANTEROPOSTERIOR AXIS; CYTOPLASMIC DYNEIN; CELL POLARITY; PROTEIN; POLARIZATION; PAR-3; GENE; TRANSPORT	Background. Endocytosis is involved in the regulation of many cellular events, including signalling, cell migration, and cell polarity. To begin to investigate roles for endocytosis in early C. elegans development, we examined the distribution and dynamics of early endosomes (EEs) in embryos. Methodology/Principal Findings. EEs are primarily found at the cell periphery with an initially uniform distribution after fertilization. Strikingly, we find that during the first cell cycle, EEA-1 positive EEs become enriched at the anterior cortex. In contrast, the Golgi compartment shows no asymmetry in distribution. Asymmetric enrichment of EEs depends on acto-myosin contractility and embryonic PAR polarity. In addition to their localization at the cortex, EEs are also found around the centrosome. These EEs move rapidly (1.3um/s) from the cortex directly to the centrosome, a speed comparable to that of the minus end directed motor dynein. Conclusions/Significance. We speculate that the asymmetry of early endosomes might play a role in cell asymmetries or fate decisions.	[Ahringer, Julie] Univ Cambridge, Gurdon Inst, Cambridge, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Cambridge; University of Cambridge	Ahringer, J (corresponding author), Univ Cambridge, Gurdon Inst, Cambridge, England.	jaa@mole.bio.cam.ac.uk		Ahringer, Julie/0000-0002-7074-4051	Wellcome Trust	Wellcome Trust(Wellcome Trust)	The work was funded by the Wellcome Trust. They had no role in the study.	Ahringer J., 2006, WORMBOOK, P1, DOI [DOI 10.1895/WORMBOOK.1.47.1, 10.1895/wormbook.1.47.1]; BRENNER S, 1974, GENETICS, V77, P71; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cowan CR, 2004, NATURE, V431, P92, DOI 10.1038/nature02825; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Cuenca AA, 2003, DEVELOPMENT, V130, P1255, DOI 10.1242/dev.00284; Emery G, 2005, CELL, V122, P763, DOI 10.1016/j.cell.2005.08.017; Emery G, 2006, CURR OPIN CELL BIOL, V18, P407, DOI 10.1016/j.ceb.2006.06.009; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gillingham AK, 2002, MOL BIOL CELL, V13, P3761, DOI 10.1091/mbc.E02-06-0349; Goldstein B, 1996, DEVELOPMENT, V122, P1467; Hung TJ, 1999, DEVELOPMENT, V126, P127; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Munro E, 2004, DEV CELL, V7, P413, DOI 10.1016/j.devcel.2004.08.001; Nishiura M, 2004, J BIOL CHEM, V279, P22799, DOI 10.1074/jbc.M313362200; O'Connell KF, 2000, DEV BIOL, V222, P55, DOI 10.1006/dbio.2000.9714; Patton A, 2005, CURR BIOL, V15, P1045, DOI 10.1016/j.cub.2005.04.057; Poteryaev D, 2005, MOL BIOL CELL, V16, P2139, DOI 10.1091/mbc.E04-08-0726; Praitis V, 2001, GENETICS, V157, P1217; Roggo L, 2002, EMBO J, V21, P1673, DOI 10.1093/emboj/21.7.1673; Rolls MM, 2002, MOL BIOL CELL, V13, P1778, DOI 10.1091/mbc.01-10-0514; Sadler PL, 2000, DEVELOPMENT, V127, P355; Sato K, 2006, MOL BIOL CELL, V17, P3085, DOI 10.1091/mbc.E06-03-0211; Sato M, 2005, NAT CELL BIOL, V7, P559, DOI 10.1038/ncb1261; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; Shelton CA, 1999, J CELL BIOL, V146, P439, DOI 10.1083/jcb.146.2.439; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; Tabuse Y, 1998, DEVELOPMENT, V125, P3607	31	42	45	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e493	10.1371/journal.pone.0000493	http://dx.doi.org/10.1371/journal.pone.0000493			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551574	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451500003
J	Massone, C; Hofmann-Wellenhof, R; Ahlgrimm-Siess, V; Gabler, G; Ebner, C; Soyer, HP				Massone, Cesare; Hofmann-Wellenhof, Rainer; Ahlgrimm-Siess, Verena; Gabler, Gerald; Ebner, Christoph; Soyer, H. Peter			Melanoma Screening with Cellular Phones	PLOS ONE			English	Article								Background. Mobile teledermatology has recently been shown to be suitable for teledermatology despite limitations in image definition in preliminary studies. The unique aspect of mobile teledermatology is that this system represents a filtering or triage system, allowing a sensitive approach for the management of patients with emergent skin diseases. Methodology/Principal Findings. In this study we investigated the feasibility of teleconsultation using a new generation of cellular phones in pigmented skin lesions. 18 patients were selected consecutively in the Pigmented Skin Lesions Clinic of the Department of Dermatology, Medical University of Graz, Graz (Austria). Clinical and dermoscopic images were acquired using a Sony Ericsson with a built-in two-megapixel camera. Two teleconsultants reviewed the images on a specific web application (http://www.dermahandy.net/default.asp) where images had been uploaded in JPEG format. Compared to the face-to-face diagnoses, the two teleconsultants obtained a score of correct telediagnoses of 89% and of 91.5% reporting the clinical and dermoscopic images, respectively. Conclusions/Significance. The present work is the first study performing mobile teledermoscopy using cellular phones. Mobile teledermatology has the potential to become an easy applicable tool for everyone and a new approach for enhanced self-monitoring for skin cancer screening in the spirit of the eHealth program of the European Commission Information for Society and Media.	[Massone, Cesare; Hofmann-Wellenhof, Rainer; Ahlgrimm-Siess, Verena; Ebner, Christoph; Soyer, H. Peter] Med Univ Graz, Dept Dermatol, Graz, Austria; [Gabler, Gerald] Graz Univ Clin & Gen Hosp, Dept IT & Telecommun, Graz, Austria	Medical University of Graz	Soyer, HP (corresponding author), Med Univ Graz, Dept Dermatol, Graz, Austria.	peter.soyer@meduni-graz.at	Soyer, H. Peter/E-6000-2010; Soyer, H. Peter/W-3791-2017	Soyer, H. Peter/0000-0002-4770-561X; Soyer, H. Peter/0000-0002-4770-561X; massone, cesare/0000-0002-0996-643X				Argenziano G, 2001, LANCET ONCOL, V2, P443, DOI 10.1016/S1470-2045(00)00422-8; Balch CM, 2004, CA-CANCER J CLIN, V54, P131, DOI 10.3322/canjclin.54.3.131; Braun RP, 2005, ARCH DERMATOL, V141, P254, DOI 10.1001/archderm.141.2.254; Braun RP, 2000, J AM ACAD DERMATOL, V42, P770, DOI 10.1067/mjd.2000.103977; Burg G, 2005, DERMATOLOGY, V210, P169, DOI 10.1159/000082573; Carli P, 2004, J AM ACAD DERMATOL, V50, P683, DOI 10.1016/j.jaad.2003.09.009; Diepgen TL, 2002, BRIT J DERMATOL, V146, P1, DOI 10.1046/j.1365-2133.146.s61.2.x; Eedy DJ, 2001, BRIT J DERMATOL, V144, P696, DOI 10.1046/j.1365-2133.2001.04124.x; *EUR COMM INF SOC, 2006, ICT HLTH I2010 TRANS, P9; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; Grob JJ, 1998, ARCH DERMATOL, V134, P103, DOI 10.1001/archderm.134.1.103-a; Kittler H, 2002, LANCET ONCOL, V3, P159, DOI 10.1016/S1470-2045(02)00679-4; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Massone C, 2006, BRIT J DERMATOL, V154, P801, DOI 10.1111/j.1365-2133.2006.07175.x; Massone C, 2005, ARCH DERMATOL, V141, P1319, DOI 10.1001/archderm.141.10.1319; Massone C, 2005, CURR OPIN ONCOL, V17, P147, DOI 10.1097/01.cco.0000152627.36243.26; Meystre S, 2005, TELEMED J E-HEALTH, V11, P63, DOI 10.1089/tmj.2005.11.63; Moreno-Ramirez D, 2005, J TELEMED TELECARE, V11, P298, DOI 10.1258/1357633054893364; Piccolo D, 1999, ARCH DERMATOL, V135, P1467, DOI 10.1001/archderm.135.12.1467; Piccolo D, 2000, J TELEMED TELECARE, V6, P132, DOI 10.1258/1357633001935202; Provost N, 1998, DERMATOLOGY, V196, P299, DOI 10.1159/000017925; Schaffer JV, 2004, J AM ACAD DERMATOL, V51, pS65, DOI 10.1016/j.jaad.2004.01.030; Shapiro M, 2004, ARCH DERMATOL, V140, P525, DOI 10.1001/archderm.140.5.525; Soyer HP, 2005, PLOS MED, V2, P293, DOI 10.1371/journal.pmed.0020087; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Wolf IH, 1998, MELANOMA RES, V8, P425, DOI 10.1097/00008390-199810000-00007	26	96	97	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e483	10.1371/journal.pone.0000483	http://dx.doi.org/10.1371/journal.pone.0000483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534433	gold, Green Published, Green Submitted			2022-12-25	WOS:000207448800013
J	Rieg, T; Bundey, RA; Chen, Y; Deschenes, G; Junger, W; Insel, PA; Vallon, V				Rieg, Timo; Bundey, Richard A.; Chen, Yu; Deschenes, George; Junger, Wolfgang; Insel, Paul A.; Vallon, Volker			Mice lacking P2Y(2) receptors have salt-resistant hypertension and facilitated renal Na+ and water reabsorption	FASEB JOURNAL			English	Article						aTP; epithelial sodium channel ENaC; vasopressin	AVP-INDEPENDENT REGULATION; MEDULLARY COLLECTING DUCT; P2 RECEPTORS; PROSTAGLANDIN E-2; EPITHELIAL-CELLS; DEHYDRATED RATS; LUMINAL P2Y(2); INNER MEDULLA; IMCD FUNCTION; MOUSE KIDNEY	Extracellular nucleotides (e. g., ATP) regulate many physiological and pathophysiological processes through activation of nucleotide (P2) receptors in the plasma membrane. Here we report that genetargeted (knockout) mice that lack P2Y(2) receptors have salt-resistant arterial hypertension in association with an inverse relationship between salt intake and heart rate, indicating intact baroreceptor function. Knockout mice have multiple alterations in their handling of salt and water: these include suppressed plasma renin and aldosterone concentrations, lower renal expression of the aldosterone-induced epithelial sodium channel alpha-ENaC, greater medullary expression of the Na-K-2Cl-cotransporter NKCC2, and greater furosemide-sensitive Na+ reabsorption in association with greater renal medullary expression of aquaporin-2 and vasopressin-dependent renal cAMP formation and water reabsorption despite similar vasopressin levels compared with wild type. Of note, smaller increases in plasma aldosterone were required to adapt renal Na+ excretion to restricted intake in knockout mice, suggesting a facilitation in renal Na+ retention. The results thus identify a previously unrecognized role for P2Y(2) receptors in blood pressure regulation that is linked to an inhibitory influence on renal Na+ and water reabsorption. Based on these findings in knockout mice, we propose that a blunting in P2Y(2) receptor expression or activity is a new mechanism for salt-resistant arterial hypertension.	Univ Calif San Diego, Dept Med, La Jolla, CA 92161 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; Hop Trousseau, Dept Pediat Nephrol, F-75571 Paris, France	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University of California System; University of California San Diego; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite	Vallon, V (corresponding author), Univ Calif San Diego, Dept Med, 3350 La Jolla Village Dr 9151, La Jolla, CA 92161 USA.	vvallon@ucsd.edu	Rieg, Timo/W-7478-2019; Junger, Wolfgang G/I-1932-2013	Rieg, Timo/0000-0001-6082-662X; Junger, Wolfgang G/0000-0003-3350-8452; Vallon, Volker/0000-0002-9211-2063; deschenes, georges/0000-0002-5158-2915	NIDDK NIH HHS [DK-28602, DK-56248] Funding Source: Medline; NIGMS NIH HHS [GM-66232] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028602, R01DK056248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066232] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akizuki N, 2001, AM J PHYSIOL-RENAL, V280, pF79, DOI 10.1152/ajprenal.2001.280.1.F79; Arthur DB, 2005, P NATL ACAD SCI USA, V102, P19138, DOI 10.1073/pnas.0505913102; Bailey MA, 2000, KIDNEY INT, V58, P1893, DOI 10.1111/j.1523-1755.2000.00361.x; Bailey MA, 2004, NEPHRON PHYSIOL, V96, P79, DOI [10.1159/000076753, DOI 10.1159/000076753]; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; Buscher R, 2006, PHARMACOGENET GENOM, V16, P199; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Capasso G, 2005, AM J PHYSIOL-RENAL, V288, pF1173, DOI 10.1152/ajprenal.00228.2004; CHASE LR, 1967, P NATL ACAD SCI USA, V58, P518, DOI 10.1073/pnas.58.2.518; Chen Y, 2004, J LEUKOCYTE BIOL, V76, P245, DOI 10.1189/jlb.0204066; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF78, DOI 10.1152/ajprenal.1995.269.1.F78; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; Deetjen P, 2000, J AM SOC NEPHROL, V11, P1798, DOI 10.1681/ASN.V11101798; Erb L, 2006, PFLUG ARCH EUR J PHY, V452, P552, DOI 10.1007/s00424-006-0069-2; FERRANDI M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P13, DOI 10.1016/0005-2736(90)90377-Z; Folkow Bjorn, 1998, Blood Pressure, V7, P133; GORDON FJ, 1983, AM J PHYSIOL, V245, pH210, DOI 10.1152/ajpheart.1983.245.2.H210; Guns PJDF, 2006, BRIT J PHARMACOL, V147, P569, DOI 10.1038/sj.bjp.0706642; GUYTON AC, 1992, HYPERTENSION, V19, pI2, DOI 10.1161/01.HYP.19.1_Suppl.I2; Hoagland KM, 2004, HYPERTENSION, V43, P860, DOI 10.1161/01.HYP.0000120123.44945.47; Homolya L, 1999, J BIOL CHEM, V274, P26454, DOI 10.1074/jbc.274.37.26454; Huang DY, 2006, AM J PHYSIOL-REG I, V290, pR935, DOI 10.1152/ajpregu.00382.2005; Huang DY, 2004, J AM SOC NEPHROL, V15, P885, DOI 10.1097/01.ASN.0000120368.59693.A8; Huang DY, 2000, N-S ARCH PHARMACOL, V362, P201, DOI 10.1007/s002100000282; Hummler E, 2005, J AM SOC NEPHROL, V16, P3160, DOI 10.1681/ASN.2005040450; Jackson EK, 2004, ANNU REV PHYSIOL, V66, P571, DOI 10.1146/annurev.physiol.66.032102.111604; Kishore BK, 2005, AM J PHYSIOL-RENAL, V288, pF1164, DOI 10.1152/ajprenal.00199.2004; Kishore BK, 1995, AM J PHYSIOL-RENAL, V269, pF863, DOI 10.1152/ajprenal.1995.269.6.F863; Kishore BK, 2000, AM J PHYSIOL-RENAL, V278, pF43, DOI 10.1152/ajprenal.2000.278.1.F43; Kunzelmann K, 2005, FASEB J, V19, P969, DOI 10.1096/fj.04-2469fje; Lehrmann H, 2002, J AM SOC NEPHROL, V13, P10, DOI 10.1681/ASN.V13110; Leipziger J, 2003, AM J PHYSIOL-RENAL, V284, pF419, DOI 10.1152/ajprenal.00075.2002; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lu M, 2000, J GEN PHYSIOL, V116, P299, DOI 10.1085/jgp.116.2.299; Ma HP, 2002, AM J PHYSIOL-RENAL, V282, pF501, DOI 10.1152/ajprenal.00147.2001; Ma XY, 2002, AM J PHYSIOL-REG I, V283, pR1033, DOI 10.1152/ajpregu.00768.2001; MANNING CJ, 2002, HDB VIBRATIONAL SPEC, V1, P283; Matos JE, 2005, J PHYSIOL-LONDON, V564, P269, DOI 10.1113/jphysiol.2004.080002; McDonough AA, 2003, ANN NY ACAD SCI, V986, P669, DOI 10.1111/j.1749-6632.2003.tb07281.x; MIYAJIMA E, 1986, CLIN EXP HYPERTENS A, V8, P1049, DOI 10.3109/10641968609044085; NADLER SP, 1992, AM J PHYSIOL, V262, pF229, DOI 10.1152/ajprenal.1992.262.2.F229; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Rieg T, 2005, J PHARMACOL EXP THER, V313, P403, DOI 10.1124/jpet.104.080432; Rieg T, 2007, EUR J PHARMACOL, V555, P174, DOI 10.1016/j.ejphar.2006.10.039; ROMAN RJ, 1981, AM J PHYSIOL, V241, pF53; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; ROSE BD, 1986, AM J MED, V81, P1033, DOI 10.1016/0002-9343(86)90401-8; Rouch AJ, 2000, AM J PHYSIOL-RENAL, V279, pF294, DOI 10.1152/ajprenal.2000.279.2.F294; ROUSE D, 1994, AM J PHYSIOL, V267, pF289, DOI 10.1152/ajprenal.1994.267.2.F289; Rubera I, 2003, J CLIN INVEST, V112, P554, DOI 10.1172/JCI200316956; Sabirov RZ, 2004, JPN J PHYSIOL, V54, P7, DOI 10.2170/jjphysiol.54.7; Schwiebert EM, 2001, AM J PHYSIOL-RENAL, V280, pF945, DOI 10.1152/ajprenal.2001.280.6.F945; Shirley DG, 2005, AM J PHYSIOL-RENAL, V288, pF1243, DOI 10.1152/ajprenal.00152.2004; Sonalker PA, 2004, J PHARMACOL EXP THER, V311, P1052, DOI 10.1124/jpet.104.071209; Sun RJ, 2005, AM J PHYSIOL-RENAL, V289, pF585, DOI 10.1152/ajprenal.00050.2005; THORNTON RM, 1989, HYPERTENSION, V14, P518, DOI 10.1161/01.HYP.14.5.518; Unwin RJ, 2003, NEWS PHYSIOL SCI, V18, P237, DOI 10.1152/nips.01436.2003; Vallon V, 2005, P NATL ACAD SCI USA, V102, P17864, DOI 10.1073/pnas.0505860102; Vallon V, 2005, AM J PHYSIOL-REG I, V289, pR395, DOI 10.1152/ajpregu.00731.2004; VALLON V, 2003, NEPHRON PHYSIOL, V94, P1; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Welch BD, 2003, AM J PHYSIOL-RENAL, V285, pF711, DOI 10.1152/ajprenal.00096.2003	63	133	134	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3717	3726		10.1096/fj.07-8807com	http://dx.doi.org/10.1096/fj.07-8807com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575258				2022-12-25	WOS:000250517800033
J	Guttmann-Raviv, N; Shraga-Heled, N; Varshavsky, A; Guimaraes-Sternberg, C; Kessler, O; Neufeld, G				Guttmann-Raviv, Noga; Shraga-Heled, Niva; Varshavsky, Asya; Guimaraes-Sternberg, Cinthya; Kessler, Ofra; Neufeld, Gera			Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPILIN-1; RECEPTOR; VEGF; EXPRESSION; VEGF(121); KINASES; BINDING; SEMA3F; FAMILY; REGION	Semaphorin-3A (sema3A) is a neuropilin-1 (np1) agonist. It inhibits the binding of the 165-amino acid form of VEGF (VEGF(165)) to np1 and was reported to inhibit angiogenesis as a result. However, we find that sema3A concentrations that inhibit the mitogenic effects of VEGF(165) do not inhibit VEGF(165) induced phosphorylation of VEGF receptor-2 (VEGFR-2). Furthermore, sema3A inhibits the biological effects of VEGF(121), a VEGF form that does not bind to neuropilins and basic fibroblast growth factor, a growth factor whose activity, unlike that of VEGF, is not inhibited by small interfering RNA directed against np1. Therefore, the mechanism by which sema3A inhibits VEGF165 activity does not depend on competition with VEGF165 for binding to np1. Sema3A induced rapid disappearance of focal contacts followed by collapse of the actin cytoskeleton in human umbilical vein-derived endothelial cells. HEK293 cells expressing sema3A repel human endothelial cells and at high concentrations induce their death by apoptosis. Furthermore, sema3A inhibited the formation of tubes from endothelial cells in an in vitro angiogenesis assay. Similar effects are induced by the neuropilin-2 (np2) agonist sema3F. These inhibitory effects are abrogated by small interfering RNAs directed against np1 or np2, respectively. The anti-proliferative effects of sema3A and sema3F are additive when the semaphorins are added as pure proteins. However, when sema3A and sema3F were co-expressed in HEK293 cells their pro-apoptotic and cell repellant activities appeared to be synergistic. These observations suggest that combinations of sema3A and sema3F may be able to inhibit tumor angiogenesis more effectively than single semaphorins.	Technion Israel Inst Technol, Rappaport Res Inst Med Sci, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Neufeld, G (corresponding author), Technion Israel Inst Technol, Rappaport Res Inst Med Sci, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, 1 Efron St,POB 9679, IL-31096 Haifa, Israel.	gera@tx.technion.ac.il	Neufeld, Gera/F-1524-2019; Sternberg, Cinthya/K-4038-2012	Sternberg, Cinthya/0000-0002-4760-6339				Bagnard D, 2004, MOL CELL NEUROSCI, V25, P722, DOI 10.1016/j.mcn.2003.12.007; Bates D, 2003, DEV BIOL, V255, P77, DOI 10.1016/S0012-1606(02)00045-3; Bielenberg DR, 2004, J CLIN INVEST, V114, P1260, DOI 10.1172/JCI200421378; Boguslawski G, 2004, J BIOL CHEM, V279, P5716, DOI 10.1074/jbc.M308625200; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Duan WR, 2003, J PATHOL, V199, P221, DOI 10.1002/path.1289; Eichmann A, 2005, INT J DEV BIOL, V49, P259, DOI 10.1387/ijdb.041941ae; Ferro D, 1996, HEPATOLOGY, V23, P1377, DOI 10.1053/jhep.1996.v23.pm0008675154; Gherardi E, 2004, CURR OPIN STRUC BIOL, V14, P669, DOI 10.1016/j.sbi.2004.10.010; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kessler O, 2004, CANCER RES, V64, P1008, DOI 10.1158/0008-5472.CAN-03-3090; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Lafleur MA, 2002, J CELL SCI, V115, P3427; Lamm GM, 1997, NUCLEIC ACIDS RES, V25, P4855, DOI 10.1093/nar/25.23.4855; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Narazaki M, 2006, BLOOD, V107, P3892, DOI 10.1182/blood-2005-10-4113; Nasarre P, 2005, NEOPLASIA, V7, P180, DOI 10.1593/neo.04481; Nasarre P, 2003, NEOPLASIA, V5, P83, DOI 10.1016/S1476-5586(03)80020-9; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; SHARMA S K, 1986, Biotechnology and Applied Biochemistry, V8, P5; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; Shraga-Heled N, 2007, FASEB J, V21, P915, DOI 10.1096/fj.06-6277com; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; Xiang RH, 2002, CANCER RES, V62, P2637	39	176	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26294	26305		10.1074/jbc.M609711200	http://dx.doi.org/10.1074/jbc.M609711200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17569671	hybrid			2022-12-25	WOS:000249239600034
J	Bhatnagar, S; Schorey, JS				Bhatnagar, Sanchita; Schorey, Jeffrey S.			Exosomes released from infected macrophages contain mycobacterium avium glycopeptidolipids and are proinflammatory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE-RESPONSES; DENDRITIC CELLS; K562 CELLS; T-CELLS; APOPTOSIS; TUBERCULOSIS; LYMPHOCYTES; ACTIVATION; MATURATION; PATHWAY	Mycobacterium avium is a major opportunistic pathogen in HIV-positive individuals and is responsible for increased morbidity and mortality in AIDS patients. M. avium express glycopeptidolipids (GPLs) as a major cell wall constituent, and recent studies suggest that GPLs play an important role in M. avium pathogenesis. In the present study we show that M. avium-infected macrophages release GPLs, which are trafficked from the phagosome through the endocytic network to multivesicular bodies. Prior studies have shown that multivesicular bodies can fuse with the plasma membrane releasing small 50 to 100 nm vesicles known as exosomes. We found that M. avium-infected macrophages release exosomes containing GPLs leading to the transfer of GPLs from infected to uninfected macrophages. Interestingly, exosomes isolated from M. avium-infected but not from uninfected macrophages can stimulate a proinflammatory response in resting macrophages. This proinflammatory response is dependent on Toll like receptor (TLR) 2, TLR4, and MyD88 suggesting that released exosomes contain M. avium-expressed TLR ligands. Our studies are the first to demonstrate that exosomes isolated from mycobacteria-infected macrophages can induce a proinflammatory response, and we hypothesize that exosomes play an important role in immune surveillance during intracellular bacteria infections.	Univ Notre Dame, Dept Biol, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Biol Sci, Ctr Global Hlth & Infect Dis, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame	Schorey, JS (corresponding author), Univ Notre Dame, Dept Biol, 130 Galvin Life Sci Ctr, Notre Dame, IN 46556 USA.	Schorey.1@nd.edu		Bhatnagar, Sanchita/0000-0002-3588-7874	NIAID NIH HHS [R01 AI052439-04, R01 AI052439-05, R01 AI052439, AI056979, AI052439, R01 AI056979, R01 AI056979-04, R01 AI056979-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052439, R01AI056979] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andre F, 2004, ANN ONCOL, V15, P141, DOI 10.1093/annonc/mdh918; Aniento F, 1995, COLD SPRING HARB SYM, V60, P205, DOI 10.1101/SQB.1995.060.01.023; BARROW WW, 1982, J BACTERIOL, V150, P381, DOI 10.1128/JB.150.1.381-384.1982; Beatty WL, 2000, TRAFFIC, V1, P235, DOI 10.1034/j.1600-0854.2000.010306.x; Beatty WL, 2001, EUR J CELL BIOL, V80, P31, DOI 10.1078/0171-9335-00131; Bhatnagar S, 2006, CELL MICROBIOL, V8, P85, DOI 10.1111/j.1462-5822.2005.00602.x; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Chatterjee D, 2001, CELL MOL LIFE SCI, V58, P2018, DOI 10.1007/PL00000834; Denzer K, 2000, J CELL SCI, V113, P3365; DRAPER P, 1970, NATURE, V228, P860, DOI 10.1038/228860a0; Fan XX, 2004, MOL BIOL CELL, V15, P2863, DOI 10.1091/mbc.E03-09-0670; Farsad Khashayar, 2002, Yale Journal of Biology and Medicine, V75, P95; Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100; Fratti RA, 2000, ELECTROPHORESIS, V21, P3378, DOI 10.1002/1522-2683(20001001)21:16<3378::AID-ELPS3378>3.0.CO;2-B; FREHEL C, 1986, INFECT IMMUN, V52, P252, DOI 10.1128/IAI.52.1.252-262.1986; Geisel RE, 2005, J IMMUNOL, V174, P5007, DOI 10.4049/jimmunol.174.8.5007; Horgen L, 2000, MICROB PATHOGENESIS, V29, P9, DOI 10.1006/mpat.2000.0358; Horsburgh CR, 1999, J INFECT DIS, V179, pS461; Houben ENG, 2006, CURR OPIN MICROBIOL, V9, P76, DOI 10.1016/j.mib.2005.12.014; Huesmann GR, 2006, NEURON, V52, P1061, DOI 10.1016/j.neuron.2006.10.033; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Katoh N, 2000, J CLIN INVEST, V105, P183, DOI 10.1172/JCI6895; Krzywinska E, 2005, MOL MICROBIOL, V56, P1262, DOI 10.1111/j.1365-2958.2005.04608.x; Li XB, 2006, J CELL MOL MED, V10, P364, DOI 10.1111/j.1582-4934.2006.tb00405.x; Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876; Mise K, 2005, INFECT IMMUN, V73, P4846, DOI 10.1128/IAI.73.8.4846-4852.2005; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824; Quesniaux V, 2004, MICROBES INFECT, V6, P946, DOI 10.1016/j.micinf.2004.04.016; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rhoades E, 2003, MOL MICROBIOL, V48, P875, DOI 10.1046/j.1365-2958.2003.03473.x; Roach SK, 2002, INFECT IMMUN, V70, P3040, DOI 10.1128/IAI.70.6.3040-3052.2002; Roth KA, 1996, J NEUROSCI, V16, P1753; RULONG S, 1991, INFECT IMMUN, V59, P3895, DOI 10.1128/IAI.59.11.3895-3902.1991; Rusin P A, 1997, Rev Environ Contam Toxicol, V152, P57; Savina A, 2003, J BIOL CHEM, V278, P20083, DOI 10.1074/jbc.M301642200; Savina A, 2002, J CELL SCI, V115, P2505; Schaible UE, 2003, NAT MED, V9, P1039, DOI 10.1038/nm906; Segura E, 2005, BLOOD CELL MOL DIS, V35, P89, DOI 10.1016/j.bcmd.2005.05.003; Sweet L, 2006, J LEUKOCYTE BIOL, V80, P415, DOI 10.1189/jlb.1205702; TERELETSKY MJ, 1983, INFECT IMMUN, V41, P1312, DOI 10.1128/IAI.41.3.1312-1321.1983; Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Ulett GC, 2005, J IMMUNOL, V175, P2555, DOI 10.4049/jimmunol.175.4.2555; van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128; VERGNE I, 1995, FEBS LETT, V375, P254, DOI 10.1016/0014-5793(95)01219-5; Vidal M, 1997, J CELL SCI, V110, P1867; Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438	49	236	249	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25779	25789		10.1074/jbc.M702277200	http://dx.doi.org/10.1074/jbc.M702277200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17591775	Green Accepted, hybrid			2022-12-25	WOS:000249014100065
J	Hanes, JW; Zhu, Y; Parris, DS; Johnson, KA				Hanes, Jeremiah W.; Zhu, Yali; Parris, Deborah S.; Johnson, Kenneth A.			Enzymatic therapeutic index of acyclovir - Viral versus human polymerase gamma specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 DNA-POLYMERASE; MITOCHONDRIAL TOXICITY; REVERSE-TRANSCRIPTASE; ANTIHERPETIC AGENT; BINDING PROTEIN; NUCLEOSIDE; EXONUCLEASE; SELECTIVITY; FIDELITY; CELLS	We have examined the kinetics of incorporation of acyclovir triphosphate by the herpes simplex virus-1 DNA polymerase holoenzyme ( Pol- UL42)andthe human mitochondrial DNA polymerase using transient kinetic methods. For each enzyme, we compared the kinetic parameters for acyclovir to those governing incorporation of dGTP. The favorable ground state dissociation constant ( 6 mu M) and rate of polymerization ( 10 s(-1)) afford efficient incorporation of acyclovir triphosphate by the Pol- UL42 enzyme. A discrimination factor of similar to 50 favors dGTP over acyclovir triphosphate, mostly due to a faster maximum rate of dGTP incorporation. Once incorporated, acyclovir is removed with a half-life of similar to 1 h in the presence of a normal concentration of deoxynucleoside triphosphates, leading to a high toxicity index ( 16,000) toward viral replication. To assess the potential for toxicity toward the host we examined the incorporation and removal of acyclovir triphosphate by the human mitochondrial DNA polymerase. These results suggest moderate inhibition of mitochondrial DNA replication defining a toxicity index of 380. This value is much higher than the value of 1.5 determined for tenofovir, another acyclic nucleoside analog. The enzymatic therapeutic index is only 42 in favoring inhibition of the viral polymerase over polymerase gamma, whereas that for tenofovir is greater than 1,200. Mitochondrial toxicity is relatively low because acyclovir is activated only in infected cells by the promiscuous viral thymidine kinase and otherwise, mitochondrialtoxicity would accumulate during long term treatment.	Univ Texas, Inst Cell & Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University of Texas System; University of Texas Austin; University System of Ohio; Ohio State University	Johnson, KA (corresponding author), Univ Texas, Inst Cell & Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu			NCI NIH HHS [CA09338] Funding Source: Medline; NIGMS NIH HHS [GM034930, GM073832, GM044613] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073832, R01GM044613, R01GM034930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P716, DOI 10.1128/AAC.46.3.716-723.2002; Brandis JW, 1996, BIOCHEMISTRY-US, V35, P2189, DOI 10.1021/bi951682j; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Chaudhuri M, 2003, J BIOL CHEM, V278, P8996, DOI 10.1074/jbc.M210023200; Chaudhuri M, 2002, J VIROL, V76, P10270, DOI 10.1128/JVI.76.20.10270-10281.2002; CHEN MS, 1978, J BIOL CHEM, V253, P1325; COEN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2265, DOI 10.1073/pnas.77.4.2265; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; De Clercq E, 2006, BRIT J PHARMACOL, V147, P1, DOI 10.1038/sj.bjp.0706446; De Clercq Eric, 2003, Expert Rev Anti Infect Ther, V1, P21, DOI 10.1586/14787210.1.1.21; DERSE D, 1981, J BIOL CHEM, V256, P1447; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Dragovic Gordana, 2003, Antiviral Chemistry & Chemotherapy, V14, P281; Elion GB, 1999, REV MED VIROL, V9, P147, DOI 10.1002/(SICI)1099-1654(199907/09)9:3<147::AID-RMV255>3.3.CO;2-G; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; Feng JY, 2004, ANTIMICROB AGENTS CH, V48, P1300, DOI 10.1128/AAC.48.4.1300-1306.2004; Foti M, 1997, BIOCHEMISTRY-US, V36, P5336, DOI 10.1021/bi962604e; FURMAN PA, 1979, J VIROL, V32, P72, DOI 10.1128/JVI.32.1.72-77.1979; FURMAN PA, 1984, J BIOL CHEM, V259, P9575; GALLO ML, 1988, J VIROL, V62, P2874, DOI 10.1128/JVI.62.8.2874-2883.1988; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; HALL JD, 1995, J GEN VIROL, V76, P2999, DOI 10.1099/0022-1317-76-12-2999; Herraiz M, 2003, HUM GENE THER, V14, P463, DOI 10.1089/104303403321467225; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Kimberlin David, 2004, Herpes, V11 Suppl 2, p65A; Kuhn FJP, 1996, J BIOL CHEM, V271, P29245; Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Moyle G, 2000, CLIN THER, V22, P911, DOI 10.1016/S0149-2918(00)80064-8; PARRIS DS, 1988, J VIROL, V62, P818, DOI 10.1128/JVI.62.3.818-825.1988; Rylova SN, 2005, BIOCHEM PHARMACOL, V69, P951, DOI 10.1016/j.bcp.2004.12.010; Song LP, 2004, J BIOL CHEM, V279, P18535, DOI 10.1074/jbc.M309848200; Squires KE, 2001, ANTIVIR THER, V6, P1; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; van der Eb MM, 2003, J GENE MED, V5, P1018, DOI 10.1002/jgm.450	40	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25159	25167		10.1074/jbc.M703972200	http://dx.doi.org/10.1074/jbc.M703972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17573351	hybrid			2022-12-25	WOS:000248933000071
J	Murtazina, R; Kovbasnjuk, O; Zachos, NC; Li, XH; Chen, YP; Hubbard, A; Hogema, BM; Steplock, D; Seidler, U; Hoque, KM; Tse, CM; De Jonge, HR; Weinman, EJ; Donowitz, M				Murtazina, Rakhilya; Kovbasnjuk, Olga; Zachos, Nicholas C.; Li, Xuhang; Chen, Yueping; Hubbard, Ann; Hogema, Boris M.; Steplock, Deborah; Seidler, Ursula; Hoque, Kazi M.; Tse, Chung Ming; De Jonge, Hugo R.; Weinman, Edward J.; Donowitz, M.			Tissue-specific regulation of Sodium/Proton exchanger isoform 3 activity in Na+/H+ exchanger regulatory factor 1 (NHERF1) null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL PROXIMAL TUBULE; PARATHYROID-HORMONE REGULATION; PROTEIN-COUPLED RECEPTORS; BRUSH-BORDER; NHE3 REQUIRES; CA2+-DEPENDENT INHIBITION; TARGETED DISRUPTION; ANCHORING PROTEIN; CELL-LINE; NAPI-IIA	The multi-PDZ domain containing protein Na+/ H+ Exchanger Regulatory Factor 1 ( NHERF1) binds to Na+/ H+ exchanger 3 ( NHE3) and is associated with the brush border ( BB) membrane of murine kidney and small intestine. Although studies in BB isolated from kidney cortex of wild type and NHERF1(-/-) mice have shown that NHERF1 is necessary for cAMP inhibition of NHE3 activity, a role of NHERF1 in NHE3 regulation in small intestine and in intact kidney has not been established. Here a method using multi-photon microscopy with the pH- sensitive dye SNARF- 4F ( carboxyseminaphthorhodafluors-4F) to measure BB NHE3 activity in intact murine tissue and use it to examine the role of NHERF1 in regulation of NHE3 activity. NHE3 activity in wild type and NHERF1(-/-) ileum and wild type kidney cortex were inhibited by cAMP, whereas the cAMP effect was abolished in kidney cortex of NHERF1(-/-) mice. cAMP inhibition of NHE3 activity in these two tissues is mediated by different mechanisms. In ileum, a protein kinase A ( PKA)- dependent mechanism accounts for all cAMP inhibition of NHE3 activity since the PKA antagonist H-89 abolished the inhibitory effect of cAMP. In kidney, both PKA-dependent and non-PKA-dependent mechanisms were involved, with the latter reproduced by the effect on an EPAC ( exchange protein directly activated by cAMP) agonist ( 8-( 4- chlorophenylthio)- 2'O-MecAMP). In contrast, the EPAC agonist had no effect in proximal tubules in NHERF1-/- mice. These data suggest that in proximal tubule, NHERF1 is required for all cAMP inhibition of NHE3, which occurs through both EPAC- dependent and PKA- dependent mechanisms; in contrast, cAMP inhibits ileal NHE3 only by a PKA-dependent pathway, which is independent of NHERF1 and EPAC.	Johns Hopkins Univ, Sch Med, Dept Med, GI Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Erasmus Univ, Med Ctr, Dept Biochem, NL-3000 CA Rotterdam, Netherlands; Univ Maryland, Sch Med & Med Staff, Dept Med, Dept Vet Affairs, Baltimore, MD 21201 USA; Leibniz Univ Hannover, Sch Med, Dept Med, D-30419 Hannover, Germany	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Erasmus University Rotterdam; Erasmus MC; University System of Maryland; University of Maryland Baltimore; Leibniz University Hannover	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, GI Div, 720 Rutland Ave,925 Ross Res Bldg, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu	Seidler, Ursula/HII-8049-2022; Zachos, Nicholas/GWC-7914-2022; Kazi, Mirajul Hoque/AAR-5291-2021	Seidler, Ursula/0000-0002-9600-2769; 	NIDDK NIH HHS [R01-DK26523, P01-DK44484, P01-DK72084, R24-DK64388, R01-DK61765, K08 DK088950] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061765, R24DK064388, P01DK044484, P01DK072084, R01DK026523, K08DK088950] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Capuano P, 2005, PFLUG ARCH EUR J PHY, V449, P392, DOI 10.1007/s00424-004-1351-9; Cha B, 2005, J BIOL CHEM, V280, P16642, DOI 10.1074/jbc.M500505200; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; Chu SY, 1996, J PHYSIOL-LONDON, V494, P783, DOI 10.1113/jphysiol.1996.sp021532; Collins JF, 1997, AM J PHYSIOL-CELL PH, V273, pC1937, DOI 10.1152/ajpcell.1997.273.6.C1937; Cunninghan R, 2004, J BIOL CHEM, V279, P37815, DOI 10.1074/jbc.M405893200; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; Donowitz M, 2005, J PHYSIOL-LONDON, V567, P3, DOI 10.1113/jphysiol.2005.090399; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; EMAMI S, 1986, PEPTIDES, V7, P121, DOI 10.1016/0196-9781(86)90174-9; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; Gage RM, 2005, J BIOL CHEM, V280, P3305, DOI 10.1074/jbc.M406934200; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Guggino WB, 2006, NAT REV MOL CELL BIO, V7, P426, DOI 10.1038/nrm1949; Hernando N, 2005, J PHYSIOL-LONDON, V567, P21, DOI 10.1113/jphysiol.2005.087049; Honegger KJ, 2006, P NATL ACAD SCI USA, V103, P803, DOI 10.1073/pnas.0503562103; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; Khundmiri SJ, 2005, J AM SOC NEPHROL, V16, P2598, DOI 10.1681/ASN.2004121049; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Kocher O, 2003, J BIOL CHEM, V278, P52820, DOI 10.1074/jbc.M310482200; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lee-Kwon W, 2003, AM J PHYSIOL-CELL PH, V285, pC1527, DOI 10.1152/ajpcell.00017.2003; Lee-Kwon W, 2003, J BIOL CHEM, V278, P16494, DOI 10.1074/jbc.M300580200; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; Li XH, 2004, J PHYSIOL-LONDON, V556, P791, DOI 10.1113/jphysiol.2004.060921; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; McDonough AA, 2003, CURR OPIN NEPHROL HY, V12, P533, DOI 10.1097/00041552-200309000-00009; Morales FC, 2004, P NATL ACAD SCI USA, V101, P17705, DOI 10.1073/pnas.0407974101; Puthenveedu MA, 2006, CELL, V127, P113, DOI 10.1016/j.cell.2006.08.035; Shenolikar S, 2004, PHYSIOLOGY, V19, P362, DOI 10.1152/physiol.00020.2004; Shenolikar S, 2002, P NATL ACAD SCI USA, V99, P11470, DOI 10.1073/pnas.162232699; STEINBERG TH, 1987, J CELL BIOL, V105, P2695, DOI 10.1083/jcb.105.6.2695; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Thelin WR, 2005, J PHYSIOL-LONDON, V567, P13, DOI 10.1113/jphysiol.2005.091041; Wade JB, 2003, AM J PHYSIOL-CELL PH, V285, pC1494, DOI 10.1152/ajpcell.00092.2003; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Weinman EJ, 2005, J PHYSIOL-LONDON, V567, P27, DOI 10.1113/jphysiol.2005.086777; Weinman EJ, 2003, FEBS LETT, V536, P141, DOI 10.1016/S0014-5793(03)00043-7; Yun CC, 2005, AM J PHYSIOL-CELL PH, V289, pC2, DOI 10.1152/ajpcell.00610.2004; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; ZACHOS NC, 2005, GASTROENTEROLOGY, V128, P177; ZHAO J, 2006, THESIS BOS LAB; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	47	59	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25141	25151		10.1074/jbc.M701910200	http://dx.doi.org/10.1074/jbc.M701910200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17580307	hybrid			2022-12-25	WOS:000248933000069
J	Frank, S; Deery, E; Brindley, AA; Leech, HK; Lawrence, A; Heathcote, P; Schubert, HL; Brocklehurst, K; Rigby, SEJ; Warren, MJ; Pickersgill, RW				Frank, Stefanie; Deery, Evelyne; Brindley, Amanda A.; Leech, Helen K.; Lawrence, Andrew; Heathcote, Peter; Schubert, Heidi L.; Brocklehurst, Keith; Rigby, Steve E. J.; Warren, Martin J.; Pickersgill, Richard W.			Elucidation of substrate specificity in the cobalamin (vitamin B-12) biosynthetic methyltransferases - Structure and function of the C20 methyltransferase (Cbil) from methanothermobacter thermautotrophicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; DEFINITION; CORRINOIDS; SIROHAEM; PATHWAY; ENZYMES; GENES	Ring contraction during cobalamin (vitamin B-12) biosynthesis requires a seemingly futile methylation of the C20 position of the tetrapyrrole framework. Along the anaerobic route, this reaction is catalyzed by CbiL, which transfers a methyl group from S-adenosyl-L-methionine to cobalt factor II to generate cobalt factor III. CbiL belongs to the class III methyltransferases and displays similarity to other cobalamin biosynthetic methyltransferases that are responsible for the regiospecific methylation of a number of positions on the tetrapyrrole molecular canvas. In an attempt to understand how CbiL selectively methylates the C20 position, a detailed structure function analysis of the enzyme has been undertaken. In this paper, we demonstrate that the enzyme methylates the C20 position, that its preferred substrate is cobalt factor II, and that the metalion does not undergo any oxidation change during the course of the reaction. The enzyme was crystallized, and its structure was determined by x-ray crystallography, revealing that the 26-kDa protein has a similar overall topology to other class III enzymes. This helped in the identification of some key amino acid residues (Asp(104), Lys(176), and Tyr(220)). Analysis of mutant variants of these groups has allowed us to suggest potential roles that these side chains may play in substrate binding and catalysis. EPR analysis of binary and ternary complexes indicate that the protein donates a fifth ligand to the cobalt ion via a gated mechanism to prevent transfer of the methyl group to water. The chemical logic underpinning the methylation is discussed.	Univ Kent, Dept Biosci, Protein Sci Grp, Canterbury CT2 7NJ, Kent, England; Queen Mary Univ London, Sch Biol & Chem Sci, London E1 4NS, England; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA	University of Kent; University of London; Queen Mary University London; Utah System of Higher Education; University of Utah	Warren, MJ (corresponding author), Univ Kent, Dept Biosci, Protein Sci Grp, Canterbury CT2 7NJ, Kent, England.	m.j.warren@kent.ac.uk; r.w.pickersgill@qmul.ac.uk	Heathcote, Peter/B-3749-2011	Heathcote, Peter/0000-0003-0189-3552; Frank, Stefanie/0000-0003-3153-6417; Warren, Martin/0000-0002-6028-6456	Biotechnology and Biological Sciences Research Council [BB/E002137/1, BBS/B/04145/2] Funding Source: Medline; BBSRC [BB/E002137/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAYSTON JH, 1970, BIOCHEMISTRY-US, V9, P2164, DOI 10.1021/bi00812a020; BLANCHE F, 1993, ANGEW CHEM INT EDIT, V32, P1651, DOI 10.1002/anie.199316511; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; Brindley AA, 2003, J BIOL CHEM, V278, P22388, DOI 10.1074/jbc.M302468200; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; ESCHENMOSER A, 1988, ANGEW CHEM INT EDIT, V27, P5, DOI 10.1002/anie.198800051; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kajiwara Y, 2006, J AM CHEM SOC, V128, P9971, DOI 10.1021/ja062940a; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Raux E, 2003, BIOCHEM J, V370, P505, DOI 10.1042/BJ20021443; Raux E, 1999, BIOCHEM J, V338, P701, DOI 10.1042/0264-6021:3380701; Raux E, 1999, BIOORG CHEM, V27, P100, DOI 10.1006/bioo.1998.1125; Raux E, 1996, J BACTERIOL, V178, P753, DOI 10.1128/jb.178.3.753-767.1996; ROESSNER CA, 1995, PROTEIN EXPRES PURIF, V6, P155, DOI 10.1006/prep.1995.1019; Roessner CA, 2006, J BACTERIOL, V188, P7331, DOI 10.1128/JB.00918-06; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; Santander PJ, 1997, CHEM BIOL, V4, P659, DOI 10.1016/S1074-5521(97)90221-0; Santander PJ, 2006, BIOORGAN MED CHEM, V14, P724, DOI 10.1016/j.bmc.2005.08.062; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Schubert HL, 1998, NAT STRUCT BIOL, V5, P585, DOI 10.1038/846; SCOTT AI, 1994, HETEROCYCLES, V39, P471; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Spencer P, 1998, BIOCHEMISTRY-US, V37, P14917, DOI 10.1021/bi981366f; Stroupe ME, 2003, NAT STRUCT BIOL, V10, P1064, DOI 10.1038/nsb1007; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vevodova J, 2004, J MOL BIOL, V344, P419, DOI 10.1016/j.jmb.2004.09.020; Wada K, 2007, FEBS J, V274, P563, DOI 10.1111/j.1742-4658.2006.05611.x; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	34	20	21	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23957	23969		10.1074/jbc.M703827200	http://dx.doi.org/10.1074/jbc.M703827200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17567575	hybrid			2022-12-25	WOS:000248686600022
J	Xue, B; Kim, YB; Lee, A; Toschi, E; Bonner-Weir, S; Kahn, CR; Neel, BG; Kahn, BB				Xue, Bingzhong; Kim, Young-Bum; Lee, Anna; Toschi, Elena; Bonner-Weir, Susan; Kahn, C. Ronald; Neel, Benjamin G.; Kahn, Barbara B.			Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; RECEPTOR SUBSTRATE-1; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; OBESE SUBJECTS; LEPTIN ACTION; OB/OB MICE; MUSCLE; SENSITIVITY; ACTIVATION	Mice heterozygous for insulin receptor (IR) and IR substrate (IRS)-1 deficiency provide a model of polygenic type 2 diabetes in which early-onset, genetically programmed insulin resistance leads to diabetes. Protein-tyrosine phosphatase 1B (PTP1B) dephosphorylates tyrosine residues in IR and possibly IRS proteins, thereby inhibiting insulin signaling. Mice lacking PTP1B are lean and have increased insulin sensitivity. To determine whether PTP1B can modify polygenic insulin resistance, we crossed PTP1B(-/-) mice with mice with a (d) under bar ouble (het) under bar erozygous deficiency of IR and IRS-1 alleles (DHet). DHet mice weighed slightly less than wild-type mice and exhibited severe insulin resistance and hyperglycemia, with similar to 35% of DHet males developing diabetes by 9-10 weeks of age. Body weight in DHet mice with PTP1B deficiency was similar to that in DHet mice. However, absence of PTP1B in DHet mice markedly improved glucose tolerance and insulin sensitivity at 10-11 weeks of age and reduced the incidence of diabetes and hyperplastic pancreatic islets at 6 months of age. Insulin-stimulated phosphorylation of IR, IRS proteins, Akt/protein kinase B, glycogen synthase kinase 3 beta, and p70(S6K) was impaired in DHet mouse muscle and liver and was differentially improved by PTP1B deficiency. In addition, increased phosphoenolpyruvate carboxykinase expression in DHet mouse liver was reversed by PTP1B deficiency. In summary, PTP1B deficiency reduces insulin resistance and hyperglycemia without altering body weight in a model of polygenic type 2 diabetes. Thus, even in the setting of high genetic risk for diabetes, reducing PTP1B is partially protective, further demonstrating its attractiveness as a target for prevention and treatment of type 2 diabetes.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.	bkahn@bidmc.harvard.edu	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; Bonner-Weir, Susan/0000-0003-4682-0656	NIDDK NIH HHS [R01 DK043051, DK57521, DK33201, DK60839, DK31036, DK66056, DK60838] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060838, R37DK031036, R01DK031036, R01DK033201, R01DK060839, R01DK066056, P30DK057521] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1997, METABOLISM, V46, P1140, DOI 10.1016/S0026-0495(97)90206-7; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; AHMAD F, 1995, METABOLISM, V44, P1175, DOI 10.1016/0026-0495(95)90012-8; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAR RS, 1976, J CLIN INVEST, V58, P1123, DOI 10.1172/JCI108565; Bence KK, 2006, NAT MED, V12, P917, DOI 10.1038/nm1435; Bento JL, 2004, DIABETES, V53, P3007, DOI 10.2337/diabetes.53.11.3007; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Di Paola R, 2002, AM J HUM GENET, V70, P806, DOI 10.1086/339270; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Esposito DL, 2001, ENDOCRINOLOGY, V142, P2833, DOI 10.1210/en.142.7.2833; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Galic S, 2005, MOL CELL BIOL, V25, P819, DOI 10.1128/MCB.25.2.819-829.2005; Goldstein Barry J., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P265, DOI 10.2174/1568008013341163; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; Gum RJ, 2003, MOL ENDOCRINOL, V17, P1131, DOI 10.1210/me.2002-0288; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim YB, 2005, MOL CELL BIOL, V25, P9713, DOI 10.1128/MCB.25.21.9713-9723.2005; Kipfer-Coudreau S, 2004, DIABETOLOGIA, V47, P1278, DOI 10.1007/s00125-004-1432-5; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; Kulkarni RN, 2003, DIABETES, V52, P1528, DOI 10.2337/diabetes.52.6.1528; Kushner JA, 2004, DIABETES, V53, P61, DOI 10.2337/diabetes.53.1.61; Lamia KA, 2004, MOL CELL BIOL, V24, P5080, DOI 10.1128/MCB.24.11.5080-5087.2004; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; OLEFSKY JM, 1976, AM J MED, V60, P89, DOI 10.1016/0002-9343(76)90537-4; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Rondinone CM, 2002, DIABETES, V51, P2405, DOI 10.2337/diabetes.51.8.2405; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Shimizu S, 2003, J BIOL CHEM, V278, P43095, DOI 10.1074/jbc.M306880200; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; WHITE MF, 1988, J BIOL CHEM, V263, P2969; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zabolotny JM, 2004, J BIOL CHEM, V279, P24844, DOI 10.1074/jbc.M310688200; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	54	47	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23829	23840		10.1074/jbc.M609680200	http://dx.doi.org/10.1074/jbc.M609680200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17545163	hybrid			2022-12-25	WOS:000248686600011
J	Baek, JH; Liu, YV; McDonald, KR; Wesley, JB; Hubbi, ME; Byun, H; Semenza, GL				Baek, Jin Hyen; Liu, Ye V.; McDonald, Karin R.; Wesley, Jacob B.; Hubbi, Maimon E.; Byun, Hweejo; Semenza, Gregg L.			Spermidine/spermine-N-1-acetyltransferase 2 is an essential component of the ubiquitin ligase complex that regulates hypoxia-inducible factor 1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE-FACTOR; OXYGEN-DEPENDENT DEGRADATION; N-EPSILON-ACETYLTRANSFERASE; FACTOR 1-ALPHA; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVITY; HIF-1-ALPHA; FACTOR-1; HIF; PROTEIN	Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that functions as a master regulator of oxygen homeostasis. The HIF-1 subunit is subjected to O-2-dependent prolyl hydroxylation leading to ubiquitination by the von Hippel-Lindau protein (VHL)-Elongin C ubiquitin-ligase complex and degradation by the 26 S proteasome. In this study, we demonstrate that spermidine/spermine-N-1-acetyltransferase (SSAT) 2 plays an essential role in this process. SSAT2 binds to HIF-1 alpha, VHL, and Elongin C and promotes ubiquitination of hydroxylated HIF-1 alpha by stabilizing the interaction of VHL and Elongin C. Multivalent interactions by SSAT2 provide a mechanism to ensure efficient complex formation, which is necessary for the extremely rapid ubiquitination and degradation of HIF-1 alpha that is observed in oxygenated cells.	Johns Hopkins Univ, Sch Med, Vasc Biol Program, Inst Cell Engn,Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Vasc Biol Program, Inst Cell Engn,Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Vasc Biol Program, Inst Cell Engn,Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Vasc Biol Program, Inst Cell Engn,Dept Radiat Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), 733 North Broadway, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu		Hubbi, Maimon/0000-0001-9763-287X	NHLBI NIH HHS [R01-HL55338] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055338] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; CASERO RA, 1991, J BIOL CHEM, V266, P810; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chen Y, 2003, BIOCHEM J, V373, P661, DOI 10.1042/BJ20030734; Coleman CS, 2004, BIOCHEM J, V384, P139, DOI 10.1042/BJ20040790; Compernolle V, 2003, CARDIOVASC RES, V60, P569, DOI 10.1016/j.cardiores.2003.07.003; Ehrismann D, 2007, BIOCHEM J, V401, P227, DOI 10.1042/BJ20061151; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; FISHER SA, 2007, IN PRESS ANTIOXID RE; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Han BW, 2006, PROTEINS, V64, P288, DOI 10.1002/prot.20967; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Koivunen P, 2006, J BIOL CHEM, V281, P28712, DOI 10.1074/jbc.M604628200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Luersen K, 2005, FEBS LETT, V579, P5347, DOI 10.1016/j.febslet.2005.08.063; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nardini M, 2003, J CHROMATOGR B, V795, P319, DOI 10.1016/S1570-0232(03)00597-X; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Patel TH, 2005, CARDIOVASC RES, V68, P144, DOI 10.1016/j.cardiores.2005.05.002; PITARI G, 1992, BIOCHIM BIOPHYS ACTA, V1116, P27, DOI 10.1016/0304-4165(92)90124-D; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389; Semenza GL, 2006, EXP PHYSIOL, V91, P803, DOI 10.1113/expphysiol.2006.033498; Smith TG, 2006, PLOS MED, V3, P1178, DOI 10.1371/journal.pmed.0030290; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Vogel NL, 2006, BBA-GENE STRUCT EXPR, V1759, P470, DOI 10.1016/j.bbaexp.2006.08.005; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; YU AY, 1998, AM J PHYSIOL, V275, P6818; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhong H, 1999, CANCER RES, V59, P5830	56	46	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23572	23580		10.1074/jbc.M703504200	http://dx.doi.org/10.1074/jbc.M703504200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17558023	hybrid			2022-12-25	WOS:000248577500059
J	Zhang, FX; Hu, Y; Huang, P; Toleman, CA; Paterson, AJ; Kudlow, JE				Zhang, Fengxue; Hu, Yong; Huang, Ping; Toleman, Clifford A.; Paterson, Andrew J.; Kudlow, Jeffrey E.			Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; UBIQUITIN SYSTEM; 26S PROTEASOME; GENERATING SYSTEMS; ENZYME-ACTIVITY; DEGRADATION; PROTEOLYSIS; PATHWAY; ACTIVATION; FORSKOLIN	Dysregulation of the proteasome has been documented in a variety of human diseases such as Alzheimer, muscle atrophy, cataracts etc. Proteolytic activity of 26 S proteasome is ATP-and ubiquitin-dependent. O-GlcNAcylation of Rpt2, one of the AAA ATPases in the 19 S regulatory cap, shuts off the proteasome through the inhibition of ATPase activity. Thus, through control of the flux of glucose into O-GlcNAc, the function of the proteasome is coupled to glucose metabolism. In the present study we found another metabolic control of the proteasome via cAMP-dependent protein kinase (PKA). Contrary to O-GlcNAcylation, PKA activated proteasomes both in vitro and in vivo in association with the phosphorylation at Ser(120) of another AAA ATPase subunit, Rpt6. Mutation of Ser(120) to Ala blocked proteasome function. The stimulatory effect of PKA and the phosphorylation of Rpt6 were reversible by protein phosphatase 1 gamma. Thus, hormones using the PKA system can also regulate proteasomes often in concert with glucose metabolism. This finding might lead to novel strategies for the treatment of proteasome-related diseases.	Univ Alabama, Div Endocrinol Diabet & Metab, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Div Endocrinol Diabet & Metab, Dept Med, BDB 767,1808 7th Ave S, Birmingham, AL 35294 USA.	kudlow@uab.edu			NATIONAL CANCER INSTITUTE [T32CA009502] Funding Source: NIH RePORTER; NCI NIH HHS [CA09502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Andersson M, 1998, EXP EYE RES, V67, P231, DOI 10.1006/exer.1998.0519; Bardag-Gorce F, 2004, LIFE SCI, V75, P585, DOI 10.1016/j.lfs.2003.12.027; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bose S, 2004, BIOCHEM J, V378, P177, DOI 10.1042/BJ20031122; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Chang Q, 2000, J BIOL CHEM, V275, P21981, DOI 10.1074/jbc.M001049200; Cohen PTW, 2002, J CELL SCI, V115, P241; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; DAHLMANN B, 1985, BIOCHEM J, V228, P161, DOI 10.1042/bj2280161; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DALY JW, 1982, J NEUROCHEM, V38, P532, DOI 10.1111/j.1471-4159.1982.tb08660.x; Ding QX, 2003, J ALZHEIMERS DIS, V5, P241, DOI 10.3233/JAD-2003-5307; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; Glickman MH, 1999, MOL BIOL REP, V26, P21, DOI 10.1023/A:1006928316738; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hershko A, 2005, CELL DEATH DIFFER, V12, P1191, DOI 10.1038/sj.cdd.4401702; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hu Y, 2004, J BIOL CHEM, V279, P29988, DOI 10.1074/jbc.M401547200; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Kierszenbaum AL, 2000, MOL REPROD DEV, V57, P109, DOI 10.1002/1098-2795(200010)57:2<109::AID-MRD1>3.3.CO;2-0; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; KREBS EG, 1989, JAMA-J AM MED ASSOC, V262, P1815, DOI 10.1001/jama.262.13.1815; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Maki CG, 1996, CANCER RES, V56, P2649; Marambaud P, 1996, J NEUROCHEM, V67, P2616; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Murray EJB, 1998, EXP CELL RES, V242, P460, DOI 10.1006/excr.1998.4090; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Owen O E, 1979, Adv Exp Med Biol, V111, P169; Price S R, 1998, Curr Opin Clin Nutr Metab Care, V1, P79, DOI 10.1097/00075197-199801000-00013; RICHTERRUOFF B, 1993, FEBS LETT, V336, P34, DOI 10.1016/0014-5793(93)81603-W; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Russell SJ, 2001, CHEM BIOL, V8, P941, DOI 10.1016/S1074-5521(01)00060-6; Satoh K, 2001, BIOCHEMISTRY-US, V40, P314, DOI 10.1021/bi001815n; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Su KH, 2000, BIOCHEM J, V348, P281, DOI 10.1042/0264-6021:3480281; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; TEMPARIS S, 1994, CANCER RES, V54, P5568; Varshavsky A, 2005, TRENDS BIOCHEM SCI, V30, P283, DOI 10.1016/j.tibs.2005.04.005; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	47	153	156	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22460	22471		10.1074/jbc.M702439200	http://dx.doi.org/10.1074/jbc.M702439200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17565987	hybrid			2022-12-25	WOS:000248354200024
J	Kebache, S; Ash, J; Annis, MG; Hagan, J; Huber, M; Hassard, J; Stewart, CL; Whiteway, M; Nantel, A				Kebache, Sem; Ash, Josee; Annis, Matthew G.; Hagan, John; Huber, Maria; Hassard, Jennifer; Stewart, Colin L.; Whiteway, Malcolm; Nantel, Andre			Grb10 and active Raf-1 kinase promote bad-dependent cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PROTEIN-KINASE; ADAPTER PROTEIN; SIGNALING PATHWAYS; C-RAF-1 GENE; PHOSPHORYLATION; APOPTOSIS; DEATH; RECEPTOR; AKT	The proapoptotic protein Bad is a key player in cell survival decisions, and is regulated post-translationally by several signaling networks. We expressed Bad in mouse embryonic fibroblasts to sensitize them to apoptosis, and tested cell lines derived from knock-out mice to establish the significance of the interaction between the adaptor protein Grb10 and the Raf-1 protein kinase in anti-apoptotic signaling pathways targeting Bad. When compared with wild-type cells, both Grb10 and Raf-1 deficient cells exhibit greatly enhanced sensitivity to apoptosis in response to Bad expression. Structure-function analysis demonstrates that, in this cellular model, the SH2, proline-rich, and pleckstrin homology domains of Grb10, as well as its Akt phosphorylation site and consequent binding by 14-3-3, are all necessary for its anti-apoptotic functions. As for Raf-1, its kinase activity, its ability to be phosphorylated by Src on Tyr-340/341 and the binding of its Ras-associated domain to the Grb10 SH2 domain are all necessary to promote cell survival. Silencing the expression of either Grb10 or Raf-1 by small interfering RNAs as well as mutagenesis of specific serine residues on Bad, coupled with signaling inhibitor studies, all indicate that Raf-1 and Grb10 are required for the ability of both the phosphatidylinositol 3-kinase/Akt and MAP kinase pathways to modulate the phosphorylation and inactivation of Bad. Because total Raf-1, ERK,andAktkinaseactivities are not impaired in the absence of Grb10, we propose that this adapter protein creates a subpopulation of Raf-1 with specific anti-apoptotic activity.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Anat, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Cell Biol, Montreal, PQ H3A 2B2, Canada; NCI, NIH, Canc & Dev Biol Lab, Ft Detrick, MD 21702 USA	National Research Council Canada; McGill University; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nantel, A (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	andre.nantel@cnrc-nrc.gc.ca		Hagan, John/0000-0003-0295-4898; Annis, Matthew/0000-0002-8776-004X	NATIONAL CANCER INSTITUTE [Z01BC010377] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Cattanach BM, 1998, CYTOGENET CELL GENET, V80, P41, DOI 10.1159/000014955; Charalambous M, 2003, P NATL ACAD SCI USA, V100, P8292, DOI 10.1073/pnas.1532175100; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cooney GJ, 2004, EMBO J, V23, P582, DOI 10.1038/sj.emboj.7600082; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Depetris RS, 2005, MOL CELL, V20, P325, DOI 10.1016/j.molcel.2005.09.001; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holt LJ, 2005, BIOCHEM J, V388, P393, DOI 10.1042/BJ20050216; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Le Mellay V, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-14; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Lim MA, 2004, FRONT BIOSCI-LANDMRK, V9, P387, DOI 10.2741/1226; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Majewski M, 1999, CANCER RES, V59, P2815; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Nantel Andre, 2003, Methods Mol Biol, V218, P269; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Oliviero R, 1997, BIOCHEM J, V324, P75, DOI 10.1042/bj3240075; OOI J, 1995, ONCOGENE, V10, P1621; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Riedel H, 2004, FRONT BIOSCI-LANDMRK, V9, P603, DOI 10.2741/1227; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Urschel S, 2005, J BIOL CHEM, V280, P16987, DOI 10.1074/jbc.M501477200; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamaguchi O, 2004, J CLIN INVEST, V114, P937, DOI 10.1172/JCI200420317; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	58	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21873	21883		10.1074/jbc.M611066200	http://dx.doi.org/10.1074/jbc.M611066200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17535812	hybrid			2022-12-25	WOS:000248196800035
J	Melowic, HR; Stahelin, RV; Blatner, NR; Tian, W; Hayashi, K; Altman, A; Cho, WH				Melowic, Heather R.; Stahelin, Robert V.; Blatner, Nichole R.; Tian, Wen; Hayashi, Keitaro; Altman, Amnon; Cho, Wonhwa			Mechanism of diacylglycerol-induced membrane targeting and activation of protein kinase C theta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; PKC-THETA; BINDING; DOMAINS; ALPHA; DELTA; PHOSPHORYLATION; AFFINITY; EPSILON; LYMPHOCYTES	Protein kinase C (PKC) theta is a novel PKC that plays a key role in T lymphocyte activation. PKC theta has been shown to be specifically recruited to the immunological synapse in response to T cell receptor activation. To understand the basis of its unique subcellular localization properties, we investigated the mechanism of in vitro and cellular sn-1,2-diacylglycerol (DAG)-mediated membrane binding of PKC theta. PKC theta showed phosphatidylserine selectivity in membrane binding and kinase action, which contributes to its translocation to the phosphatidylserine-rich plasma membrane in HEK293 cells. Unlike any other PKCs characterized so far, the isolated C1B domain of PKC theta had much higher affinity for DAG-containing membranes than the C1A domain. Also, the mutational analysis indicates that the C1B domain plays a predominant role in the DAG-induced membrane binding and activation of PKC theta. Furthermore, the Ca2+-independent C2 domain of PKC theta has significant affinity for anionic membranes, and the truncation of the C2 domain greatly enhanced the membrane affinity and enzyme activity of PKC theta. In addition, membrane binding properties of Y90E and Y90F mutants indicate that phosphorylation of Tyr(90) of the C2 domain enhances the affinity of PKC theta for model and cell membranes. Collectively, these results show that PKC theta has a unique membrane binding and activation mechanism that may account for its subcellular targeting properties.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; La Jolla Inst Allergy & Immunol, Div Cell Biol, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; La Jolla Institute for Immunology	Cho, WH (corresponding author), Univ Illinois, Dept Chem, 845 W Taylor St,MC 111, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076581] Funding Source: NIH RePORTER; NCI NIH HHS [CA35299] Funding Source: Medline; NIGMS NIH HHS [GM76581] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman A, 2003, IMMUNOL REV, V192, P53, DOI 10.1034/j.1600-065X.2003.00027.x; Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhardwaj N, 2006, J MOL BIOL, V359, P486, DOI 10.1016/j.jmb.2006.03.039; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho W, 2006, BBA-MOL CELL BIOL L, V1761, P838, DOI 10.1016/j.bbalip.2006.06.014; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Giorgione JR, 2006, J BIOL CHEM, V281, P1660, DOI 10.1074/jbc.M510251200; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SEDWICK CE, 2002, SCI STKE, pRE2; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Stahelin RV, 2005, J BIOL CHEM, V280, P36452, DOI 10.1074/jbc.M506224200; Stahelin RV, 2005, J BIOL CHEM, V280, P19784, DOI 10.1074/jbc.M411285200; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003	40	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21467	21476		10.1074/jbc.M700119200	http://dx.doi.org/10.1074/jbc.M700119200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17548359	hybrid			2022-12-25	WOS:000248047500074
J	Raine, NE; Chittka, L				Raine, Nigel E.; Chittka, Lars			The Adaptive Significance of Sensory Bias in a Foraging Context: Floral Colour Preferences in the Bumblebee Bombus terrestris	PLOS ONE			English	Article								Innate sensory biases could play an important role in helping naive animals to find food. As inexperienced bees are known to have strong innate colour biases we investigated whether bumblebee (Bombus terrestris) colonies with stronger biases for the most rewarding flower colour (violet) foraged more successfully in their local flora. To test the adaptive significance of variation in innate colour bias, we compared the performance of colour-naive bees, from nine bumblebee colonies raised from local wild-caught queens, in a laboratory colour bias paradigm using violet (bee UV-blue) and blue (bee blue) artificial flowers. The foraging performance of the same colonies was assessed under field conditions. Colonies with a stronger innate bias for violet over blue flowers in the laboratory harvested more nectar per unit time under field conditions. In fact, the colony with the strongest bias for violet (over blue) brought in 41% more nectar than the colony with the least strong bias. As violet flowers in the local area produce more nectar than blue flowers (the next most rewarding flower colour), these data are consistent with the hypothesis that local variation in flower traits could drive selection for innate colour biases.	[Raine, Nigel E.; Chittka, Lars] Univ London, Sch Biol & Chem Sci, London, England	University of London	Raine, NE (corresponding author), Univ London, Sch Biol & Chem Sci, London, England.	n.e.raine@qmul.ac.uk	Chittka, Lars/C-3110-2012; Raine, Nigel/AAK-6425-2020	Chittka, Lars/0000-0001-8153-1732; Raine, Nigel/0000-0001-6343-2829	Natural Environment Research Council [NER/A/S/2003/00469]; German Research Foundation (Deutsche Forschungsgemeinschaft) [Ch 147/3-1]	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG))	Financial support for this work was provided by grants from the Natural Environment Research Council (NER/A/S/2003/00469) and the German Research Foundation (Deutsche Forschungsgemeinschaft: Ch 147/3-1). The study funders played no role in designing the study, data collection/analysis or preparation of the manuscript.	ALLEN T, 1978, Journal of the Kansas Entomological Society, V51, P329; BANSCHBACH VS, 1994, J COMP PHYSIOL A, V175, P107, DOI 10.1007/BF00217441; BASOLO AL, 1995, TRENDS ECOL EVOL, V10, P489, DOI 10.1016/S0169-5347(00)89196-X; Briscoe AD, 2001, ANNU REV ENTOMOL, V46, P471, DOI 10.1146/annurev.ento.46.1.471; Bruce MJ, 2001, J EVOLUTION BIOL, V14, P786, DOI 10.1046/j.1420-9101.2001.00326.x; Cakmak Ibrahim, 1995, BeeScience, V3, P165; Chittka L, 2004, POPUL ECOL, V46, P243, DOI 10.1007/s10144-004-0180-1; CHITTKA L, 1992, J COMP PHYSIOL A, V170, P533; Chittka L, 1996, J THEOR BIOL, V181, P179, DOI 10.1006/jtbi.1996.0124; Chittka L, 2001, COGNITIVE ECOLOGY OF POLLINATION: ANIMAL BEHAVIOUR AND FLORAL EVOLUTION, P106, DOI 10.1017/CBO9780511542268.007; Chittka L., 2005, PRACTICAL POLLINATIO, P157; Chittka L., 2001, ECOLOGY SENSING, P19; Chittka L, 2006, CURR OPIN PLANT BIOL, V9, P428, DOI 10.1016/j.pbi.2006.05.002; Chittka Lars, 2004, P165; Collins SA, 1999, P ROY SOC B-BIOL SCI, V266, P2309, DOI 10.1098/rspb.1999.0924; Dawkins MS, 1996, AM NAT, V148, P937, DOI 10.1086/285964; Dyer AG, 2006, ENTOMOL GEN, V28, P257; Dyer AG, 2006, NATURE, V442, P525, DOI 10.1038/442525a; Dyer AG, 2004, J COMP PHYSIOL A, V190, P105, DOI 10.1007/s00359-003-0475-2; Endler JA, 1998, TRENDS ECOL EVOL, V13, P415, DOI 10.1016/S0169-5347(98)01471-2; FISHER RA, 1954, STAT METHODS RES WOR, P356; Gegear RJ, 2004, CAN J ZOOL, V82, P587, DOI 10.1139/Z04-029; GIURFA M, 1995, J COMP PHYSIOL A, V177, P247; Gumbert A, 2000, BEHAV ECOL SOCIOBIOL, V48, P36, DOI 10.1007/s002650000213; HEINRICH B, 1977, BEHAV ECOL SOCIOBIOL, V2, P247, DOI 10.1007/BF00299738; Heinrich B., 1979, BUMBLEBEE EC; Ings TC, 2006, J APPL ECOL, V43, P940, DOI 10.1111/j.1365-2664.2006.01199.x; Ings TC, 2005, OECOLOGIA, V144, P508, DOI 10.1007/s00442-005-0081-9; LAVERTY TM, 1994, ANIM BEHAV, V47, P531, DOI 10.1006/anbe.1994.1077; LUNAU K, 1995, J COMP PHYSIOL A, V177, P1; Lunau K, 1996, J COMP PHYSIOL A, V178, P477, DOI 10.1007/BF00190178; Menzel R, 1985, EXPT BEHAV ECOLOGY, P55; PEITSCH D, 1992, J COMP PHYSIOL A, V170, P23, DOI 10.1007/BF00190398; Pelletier L, 2003, OIKOS, V103, P688, DOI 10.1034/j.1600-0706.2003.12592.x; Raine NE, 2005, ENTOMOL GEN, V28, P81; RAINE NE, 2007, ENTOMOL GEN IN PRESS; Raine NE, 2007, NATURWISSENSCHAFTEN, V94, P459, DOI 10.1007/s00114-006-0184-0; Raine NE, 2006, ADV STUD BEHAV, V36, P305, DOI 10.1016/S0065-3454(06)36007-X; Raine NE, 2007, ENTOMOL GEN, V29, P179; Raine NE, 2006, ENTOMOL GEN, V28, P241; RAUH W, 1987, FLORA DEUTSCHLAND SE, P606; Schmid-Hempel P, 1998, ANIM BEHAV, V55, P819, DOI 10.1006/anbe.1997.0661; Schmid-Hempel P., 1990, NATURWISSENSCHAFTEN, V27, P50; Schmid-Hempel R, 1998, FUNCT ECOL, V12, P22, DOI 10.1046/j.1365-2435.1998.00153.x; SCHMIDHEMPEL R, 1991, ANIM BEHAV, V41, P910, DOI 10.1016/S0003-3472(05)80362-8; Smith C, 2004, P ROY SOC B-BIOL SCI, V271, P949, DOI 10.1098/rspb.2004.2690; Spaethe J, 2003, J EXP BIOL, V206, P3447, DOI 10.1242/jeb.00570; Spaethe J, 2002, INSECT SOC, V49, P142, DOI 10.1007/s00040-002-8293-z; Willmer PG, 2004, ADV STUD BEHAV, V34, P347, DOI 10.1016/S0065-3454(04)34009-X	49	168	172	1	93	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e556	10.1371/journal.pone.0000556	http://dx.doi.org/10.1371/journal.pone.0000556			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579727	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451700021
J	Munoz-Alarcon, A; Pavlovic, M; Wismar, J; Schmitt, B; Eriksson, M; Kylsten, P; Dushay, MS				Munoz-Alarcon, Andres; Pavlovic, Maja; Wismar, Jasmine; Schmitt, Bertram; Eriksson, Maria; Kylsten, Per; Dushay, Mitchell S.			Characterization of lamin Mutation Phenotypes in Drosophila and Comparison to Human Laminopathies	PLOS ONE			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; HUTCHINSON-GILFORD-PROGERIA; NUCLEAR LAMINS; A/C GENE; PARTIAL LIPODYSTROPHY; MOLECULAR ANALYSIS; MELANOGASTER; EXPRESSION; PROTEIN; MUSCLE	Lamins are intermediate filament proteins that make up the nuclear lamina, a matrix underlying the nuclear membrane in all metazoan cells that is important for nuclear form and function. Vertebrate A-type lamins are expressed in differentiating cells, while B-type lamins are expressed ubiquitously. Drosophila has two lamin genes that are expressed in A-and B-type patterns, and it is assumed that similarly expressed lamins perform similar functions. However, Drosophila and vertebrate lamins are not orthologous, and their expression patterns evolved independently. It is therefore of interest to examine the effects of mutations in lamin genes. Mutations in the mammalian lamin A/C gene cause a range of diseases, collectively called laminopathies, that include muscular dystrophies and premature aging disorders. We compared the sequences of lamin genes from different species, and we have characterized larval and adult phenotypes in Drosophila bearing mutations in the lam gene that is expressed in the B-type pattern. Larvae move less and show subtle muscle defects, and surviving lam adults are flightless and walk like aged wild-type flies, suggesting that lam phenotypes might result from neuromuscular defects, premature aging, or both. The resemblance of Drosophila lam phenotypes to human laminopathies suggests that some lamin functions may be performed by differently expressed genes in flies and mammals. Such still-unknown functions thus would not be dependent on lamin gene expression pattern, suggesting the presence of other lamin functions that are expression dependent. Our results illustrate a complex interplay between lamin gene expression and function through evolution.	[Dushay, Mitchell S.] Uppsala Univ, EBC, Dept Comparat Physiol, Uppsala, Sweden; [Munoz-Alarcon, Andres; Pavlovic, Maja; Kylsten, Per; Dushay, Mitchell S.] Sodertorns Hogskola, Dept Life Sci, Huddinge, Sweden; [Munoz-Alarcon, Andres; Pavlovic, Maja; Eriksson, Maria] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Wismar, Jasmine; Schmitt, Bertram] Max Planck Inst Hirnforsch, Neurochem Abt, D-60528 Frankfurt, Germany	Uppsala University; Sodertorn University; Karolinska Institutet; Max Planck Society	Dushay, MS (corresponding author), Uppsala Univ, EBC, Dept Comparat Physiol, Uppsala, Sweden.	mitch.dushay@ebc.uu.se			Graduate Research School in Genomics and Bioinformatics; Swedish Animal Welfare Agency; Sodetorns hogskola and Uppsala University	Graduate Research School in Genomics and Bioinformatics; Swedish Animal Welfare Agency; Sodetorns hogskola and Uppsala University	`A. M. A. and M. P. were supported by grants from the Graduate Research School in Genomics and Bioinformatics (awarded to PK and MD, respectively), and MSD was supported by grants from the Swedish Animal Welfare Agency, and by Sodetorns hogskola and Uppsala University	Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Bechert K, 2003, EXP CELL RES, V286, P75, DOI 10.1016/S0014-4827(03)00104-6; Beremendi A, 2005, NEUROSCIENCE, V134, P397, DOI 10.1016/j.neuroscience.2005.04.046; Bonne G, 2000, ANN NEUROL, V48, P170, DOI 10.1002/1531-8249(200008)48:2<170::AID-ANA6>3.0.CO;2-J; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brodsky GL, 2000, CIRCULATION, V101, P473, DOI 10.1161/01.CIR.101.5.473; Broers JLV, 2006, PHYSIOL REV, V86, P967, DOI 10.1152/physrev.00047.2005; BURKE B, 2006, HUM GENET, V7, P369; Canki-Klain N, 2000, CROAT MED J, V41, P389; Casares P, 1997, GENET SEL EVOL, V29, P589, DOI 10.1051/gse:19970504; Crossley A.C., 1978, P499; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; Erber A, 1999, J MOL EVOL, V49, P260, DOI 10.1007/PL00006548; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Favreau C, 2003, EXP CELL RES, V282, P14, DOI 10.1006/excr.2002.5669; Goddeeris MM, 2003, AGING CELL, V2, P257, DOI 10.1046/j.1474-9728.2003.00060.x; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Grotewiel MS, 2005, AGEING RES REV, V4, P372, DOI 10.1016/j.arr.2005.04.001; Gruenbaum Y, 2003, INT REV CYTOL, V226, P1, DOI 10.1016/S0074-7696(03)01001-5; Haithcock E, 2005, P NATL ACAD SCI USA, V102, P16690, DOI 10.1073/pnas.0506755102; HAMILTON BA, 1991, P NATL ACAD SCI USA, V88, P2731, DOI 10.1073/pnas.88.7.2731; Hegele RA, 2007, EXP CELL RES, V313, P2134, DOI 10.1016/j.yexcr.2007.03.023; Hidalgo A, 2000, DEVELOPMENT, V127, P393; Iyengar B, 1999, GENETICS, V153, P1809; Kurucz E, 2003, P NATL ACAD SCI USA, V100, P2622, DOI 10.1073/pnas.0436940100; Leal SM, 2002, J NEUROBIOL, V50, P245, DOI 10.1002/neu.10030; LenzBohme B, 1997, J CELL BIOL, V137, P1001, DOI 10.1083/jcb.137.5.1001; Maraldi NM, 2005, J CELL PHYSIOL, V203, P319, DOI 10.1002/jcp.20217; Melcer S, 2007, EXP CELL RES, V313, P2157, DOI 10.1016/j.yexcr.2007.03.004; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; OSMAN M, 1990, GENOMICS, V8, P217, DOI 10.1016/0888-7543(90)90274-X; Osouda S, 2005, DEV BIOL, V284, P219, DOI 10.1016/j.ydbio.2005.05.022; Padiath QS, 2006, NAT GENET, V38, P1114, DOI 10.1038/ng1872; Prufert K, 2004, J CELL SCI, V117, P6105, DOI 10.1242/jcs.01532; Riemer D, 2000, GENE, V255, P317, DOI 10.1016/S0378-1119(00)00323-1; RIEMER D, 1995, J CELL SCI, V108, P3189; RIEMER D, 1994, EUR J CELL BIOL, V63, P299; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulze SR, 2005, GENETICS, V171, P185, DOI 10.1534/genetics.105.043208; Shcherbata HR, 2007, EMBO J, V26, P481, DOI 10.1038/sj.emboj.7601503; Shumaker DK, 2003, CURR OPIN CELL BIOL, V15, P358, DOI 10.1016/S0955-0674(03)00050-4; Stuurman N, 1999, EXP CELL RES, V248, P350, DOI 10.1006/excr.1999.4396; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; TULLY T, 1990, COLD SPRING HARB SYM, V55, P203; Varga R, 2006, P NATL ACAD SCI USA, V103, P3250, DOI 10.1073/pnas.0600012103; Vytopil M, 2002, NEUROMUSCULAR DISORD, V12, P958, DOI 10.1016/S0960-8966(02)00178-5; Worman HJ, 2007, EXP CELL RES, V313, P2121, DOI 10.1016/j.yexcr.2007.03.028; Yang P, 2000, GENETICS, V155, P1161	49	24	24	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e532	10.1371/journal.pone.0000532	http://dx.doi.org/10.1371/journal.pone.0000532			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565385	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451600020
J	Broor, S; Parveen, S; Bharaj, P; Prasad, VS; Srinivasulu, KN; Sumanth, KM; Kapoor, SK; Fowler, K; Sullender, WM				Broor, Shobha; Parveen, Shama; Bharaj, Preeti; Prasad, Velisetty S.; Srinivasulu, Kavalu N.; Sumanth, Krishna M.; Kapoor, Suresh Kumar; Fowler, Karen; Sullender, Wayne M.			A Prospective Three-Year Cohort Study of the Epidemiology and Virology of Acute Respiratory Infections of Children in Rural India	PLOS ONE			English	Article							SYNCYTIAL VIRUS-INFECTION; RAPID DETECTION; ETIOLOGY	Background. Acute respiratory infection (ARI) is a major killer of children in developing countries. Although the frequency of ARI is similar in both developed and developing countries, mortality due to ARI is 10-50 times higher in developing countries. Viruses are common causes of ARI among such children, yet the disease burden of these infections in rural communities is unknown. Methodology/Principal Findings. A prospective longitudinal study was carried out in children enrolled from two rural Indian villages at birth and followed weekly for the development of ARI, classified as upper respiratory infection, acute lower respiratory infection (ALRI), or severe ALRI. Respiratory syncytial virus (RSV), influenza, parainfluenza viruses and adenoviruses in nasopharyngeal aspirates were detected by direct fluorescent antibody testing (DFA) and, in addition, centrifugation enhanced culture for RSV was done. 281 infants enrolled in 39 months and followed until 42 months. During 440 child years of follow-up there were 1307 ARIs, including 236 ALRIs and 19 severe ALRIs. Virus specific incidence rates per 1000 child years for RSV were total ARI 234, ALRI 39, and severe ALRI 9; for influenza A total ARI 141, ALRI 39; for INF B total ARI 37; for PIV1 total ARI 23, for PIV2 total ARI 28, ALRI 5; for parainfluenza virus 3 total ARI 229, ALRI 48, and severe ALRI 5 and for adenovirus total ARI 18, ALRI 5. Repeat infections with RSV were seen in 18 children. Conclusions/Significance. RSV, influenza A and parainfluenza virus 3 were important causes of ARI among children in rural communities in India. These data will be useful for vaccine design, development and implementation purposes.	[Broor, Shobha; Parveen, Shama; Bharaj, Preeti; Prasad, Velisetty S.; Srinivasulu, Kavalu N.; Sumanth, Krishna M.] All India Inst Med Sci, Dept Microbiol, New Delhi 110029, India; [Kapoor, Suresh Kumar] All India Inst Med Sci, Comprehens Rural Hlth Serv Project, Ctr Community Med, New Delhi 110029, India; [Fowler, Karen; Sullender, Wayne M.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA; [Fowler, Karen] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA; [Fowler, Karen] Univ Alabama Birmingham, Dept Maternal & Child Hlth, Birmingham, AL USA; [Sullender, Wayne M.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Broor, S (corresponding author), All India Inst Med Sci, Dept Microbiol, New Delhi 110029, India.	shobha.broor@gmail.com	Broor, Shobha/AAX-4163-2021; Bharaj, Preeti/AAX-7394-2020	Broor, Shobha/0000-0001-9679-4180; Bharaj, Preeti/0000-0002-9411-9373	Indo-U.S. Vaccine Action Program; Department of Biotechnology (India); National Institute for Allergy and Infectious Disease (USA) [R03 AI50693]; Council of Scientific and Industrial Research (India); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI050693] Funding Source: NIH RePORTER	Indo-U.S. Vaccine Action Program; Department of Biotechnology (India)(Department of Biotechnology (DBT) India); National Institute for Allergy and Infectious Disease (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Council of Scientific and Industrial Research (India)(Council of Scientific & Industrial Research (CSIR) - India); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding for the study was received from Indo-U.S. Vaccine Action Program, Department of Biotechnology (India) and National Institute for Allergy and Infectious Disease, R03 AI50693 (USA). Support for Shama Parveen was received from the Council of Scientific and Industrial Research (India).	BOSHCIPINTO C, 2002, 1 M 6 7 FEBR 2002 MA; *CHERG, 2001, 5074 CHERG UN POP DI; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; HILLIS WD, 1971, INDIAN J MED RES, V59, P1354; JAIN A, 1991, J MED MICROBIOL, V35, P219, DOI 10.1099/00222615-35-4-219; Jennings LC, 2004, PEDIATR INFECT DIS J, V23, P1003, DOI 10.1097/01.inf.0000143648.04673.6c; JOHN TJ, 1991, REV INFECT DIS, V13, pS463; Kapoor SK, 2001, J EPIDEMIOL COMMUN H, V55, P366, DOI 10.1136/jech.55.5.366; KLOENE W, 1970, AM J EPIDEMIOL, V92, P307, DOI 10.1093/oxfordjournals.aje.a121212; Landry ML, 2000, J CLIN MICROBIOL, V38, P708, DOI 10.1128/JCM.38.2.708-711.2000; Maitreyi RS, 2000, J CLIN VIROL, V16, P41, DOI 10.1016/S1386-6532(99)00075-X; Nokes DJ, 2004, J INFECT DIS, V190, P1828, DOI 10.1086/425040; Parveen S, 2006, J MED VIROL, V78, P659, DOI 10.1002/jmv.20590; Parveen S, 2006, J CLIN MICROBIOL, V44, P3055, DOI 10.1128/JCM.00187-06; Rajala MS, 2003, J CLIN MICROBIOL, V41, P2311, DOI 10.1128/JCM.41.6.2311-2316.2003; REDDAIAH V P, 1988, Indian Journal of Pediatrics, V55, P424, DOI 10.1007/BF02810367; Robertson SE, 2004, B WORLD HEALTH ORGAN, V82, P914; Scott PD, 2006, J INFECT DIS, V193, P59, DOI 10.1086/498246; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; Shann F, 1999, LANCET, V354, pS7, DOI 10.1016/S0140-6736(99)90250-7; *WHO, 2000, INT MAN CHILDH ILL H; WHO, 1994, MOTH BAB PACK IMPL S; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0; WOLONTIS S, 1969, Scandinavian Journal of Infectious Diseases, V1, P119, DOI 10.3109/inf.1969.1.issue-2.08	25	105	106	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e491	10.1371/journal.pone.0000491	http://dx.doi.org/10.1371/journal.pone.0000491			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551572	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451500001
J	van der Sande, MAB; Kaye, S; Miles, DJC; Waight, P; Jeffries, DJ; Ojuola, OO; Palmero, M; Pinder, M; Ismaili, J; Flanagan, KL; Aveika, AA; Zaman, A; Rowland-Jones, S; McConkey, SJ; Whittle, HC; Marchant, A				van der Sande, Marianne A. B.; Kaye, Steve; Miles, David J. C.; Waight, Pauline; Jeffries, David J.; Ojuola, Olubukola O.; Palmero, Melba; Pinder, Margaret; Ismaili, Jamila; Flanagan, Katie L.; Aveika, Akum A.; Zaman, Akram; Rowland-Jones, Sarah; McConkey, Samuel J.; Whittle, Hilton C.; Marchant, Arnaud			Risk Factors for and Clinical Outcome of Congenital Cytomegalovirus Infection in a Peri-Urban West-African Birth Cohort	PLOS ONE			English	Article								Background. Congenital cytomegalovirus (CMV) infection is the most prevalent congenital infection worldwide. Epidemiology and clinical outcomes are known to vary with socio-economic background, but few data are available from developing countries, where the overall burden of infectious diseases is frequently high. Methodology/Principal Findings. As part of an ongoing birth cohort study in The Gambia among term infants, urine samples were collected at birth and tested by PCR for the presence of CMV DNA. Risk factors for transmission and clinical outcome were assessed, including placental malaria infection. Babies were followed up at home monthly for morbidity and anthropometry, and at one year of age a clinical evaluation was performed. The prevalence of congenital CMV infection was 5.4% (40/741). A higher prevalence of hepatomegaly was the only significant clinical difference at birth. Congenitally infected children were more often first born babies (adjusted odds ratio (OR) 5.3, 95% confidence interval (CI) 2.0-13.7), more frequently born in crowded compounds (adjusted OR 2.9, 95% CI 1.0-8.3) and active placental malaria was more prevalent (adjusted OR 2.9, 95% CI 1.0-8.4). These associations were corrected for maternal age, bed net use and season of birth. During the first year of follow up, mothers of congenitally infected children reported more health complaints for their child. Conclusions/Significance. In this study, the prevalence of congenital CMV among healthy neonates was much higher than previously reported in industrialised countries, and was associated with active placental malaria infection. There were no obvious clinical implications during the first year of life. The effect of early life CMV on the developing infant in the Gambia could be mitigated by environmental factors, such as the high burden of other infections.	[van der Sande, Marianne A. B.; Kaye, Steve; Miles, David J. C.; Waight, Pauline; Jeffries, David J.; Ojuola, Olubukola O.; Palmero, Melba; Pinder, Margaret; Ismaili, Jamila; Flanagan, Katie L.; Aveika, Akum A.; Zaman, Akram; Rowland-Jones, Sarah; McConkey, Samuel J.; Whittle, Hilton C.; Marchant, Arnaud] MRC Labs, Fajara, Gambia	MRC Laboratory Molecular Biology	van der Sande, MAB (corresponding author), MRC Labs, Fajara, Gambia.	Marianne.van.der.Sande@rivm.nl	McConkey, Samuel/E-7307-2012	Flanagan, Katie/0000-0002-1575-1953; van der Sande, Marianne AB/0000-0002-4778-6739; McConkey, Samuel/0000-0001-9085-7793	Glaxo Smith Kline Biologicals (Belgium); Medical Research Council (UK); Medical Research Council [MC_U190088483, MC_U190081978, MC_U190085854] Funding Source: researchfish; MRC [MC_U190085854, MC_U190081978, MC_U190088483] Funding Source: UKRI	Glaxo Smith Kline Biologicals (Belgium)(GlaxoSmithKline); Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by Glaxo Smith Kline Biologicals (Belgium), and the Medical Research Council (UK). The funders of the study were not involved in design, conduct, collection-analysis-interpretetation of data, nor in the preparation-review-approval of the manuscript.	Barbi M, 2003, PEDIATR INFECT DIS J, V22, P39, DOI 10.1097/00006454-200301000-00012; BELLO C, 1991, J CLIN PATHOL, V44, P366, DOI 10.1136/jcp.44.5.366; Boppana SB, 2005, J PEDIATR-US, V146, P817, DOI 10.1016/j.jpeds.2005.01.059; Boppana SB, 1999, PEDIATRICS, V104, P55, DOI 10.1542/peds.104.1.55; BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007; Boppana SB, 2001, NEW ENGL J MED, V344, P1366, DOI 10.1056/NEJM200105033441804; BURNY W, 2004, EXPERT REV ANTI-INFE, V2, P6; Chow SSW, 2006, J MED VIROL, V78, P747, DOI 10.1002/jmv.20618; Doyle M, 1996, PEDIATR INFECT DIS J, V15, P1102, DOI 10.1097/00006454-199612000-00010; Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5; Fowler KB, 2003, JAMA-J AM MED ASSOC, V289, P1008, DOI 10.1001/jama.289.8.1008; FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003; Gaytant MA, 2005, J MED VIROL, V76, P71, DOI 10.1002/jmv.20325; Gaytant MA, 2003, EUR J PEDIATR, V162, P248, DOI 10.1007/s00431-002-1115-3; Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8; Ismaili J, 2003, CLIN EXP IMMUNOL, V133, P414, DOI 10.1046/j.1365-2249.2003.02243.x; Iwasaki S, 2007, AUDIOL NEURO-OTOL, V12, P31, DOI 10.1159/000096156; Looney RJ, 1999, CLIN IMMUNOL, V90, P213, DOI 10.1006/clim.1998.4638; Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI17470; Marin Gabriel M A, 2005, An Pediatr (Barc), V62, P38; Moore SE, 2006, P NUTR SOC, V65, P311, DOI 10.1079/PNS2006503; Moutaftsi M, 2002, BLOOD, V99, P2913, DOI 10.1182/blood.V99.8.2913; Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9; NICKELL SP, 1987, PARASITE IMMUNOL, V9, P161, DOI 10.1111/j.1365-3024.1987.tb00497.x; Numazaki K, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-22; Okoko BJ, 2003, ACTA TROP, V87, P193, DOI 10.1016/S0001-706X(03)00097-4; Olsson J, 2000, MECH AGEING DEV, V121, P187; Pass Robert F, 2005, Herpes, V12, P50; Pawelec G, 2005, IMMUNOL REV, V205, P257, DOI 10.1111/j.0105-2896.2005.00271.x; Picone O, 2005, PRENATAL DIAG, V25, P34, DOI 10.1002/pd.944; Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1; Ross SA, 2006, J PEDIATR-US, V148, P332, DOI 10.1016/j.jpeds.2005.09.003; Schleiss MR, 2005, EXPERT REV VACCINES, V4, P381, DOI 10.1586/14760584.4.3.381; Schleiss Mark R, 2004, Expert Rev Anti Infect Ther, V2, P389, DOI 10.1586/14787210.2.3.389; Schlesinger Y, 2005, ISR MED ASSOC J, V7, P237; van der Loeff MFS, 2003, AIDS, V17, P1841, DOI [10.1097/00002030-200308150-00014, 10.1097/01.aids.0000076303.76477.49]; Vochem M, 1998, PEDIATR INFECT DIS J, V17, P53, DOI 10.1097/00006454-199801000-00012; WHITTLE HC, 1984, NATURE, V312, P449, DOI 10.1038/312449a0; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; Wreghitt TG, 2003, CLIN INFECT DIS, V37, P1603, DOI 10.1086/379711; Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014	41	61	63	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e492	10.1371/journal.pone.0000492	http://dx.doi.org/10.1371/journal.pone.0000492			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551573	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451500002
J	Ehrchen, J; Helming, L; Varga, G; Pasche, B; Loser, K; Gunzer, M; Sunderkotter, C; Sorg, C; Roth, J; Lengeling, A				Ehrchen, Jan; Helming, Laura; Varga, Georg; Pasche, Bastian; Loser, Karin; Gunzer, Matthias; Sunderkoetter, Cord; Sorg, Clemens; Roth, Johannes; Lengeling, Andreas			Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major	FASEB JOURNAL			English	Article						interferon-gamma; host resistance; macrophage; knockout mice; parasite	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; MACROPHAGE ACTIVATION; IN-VIVO; 1,25-DIHYDROXYVITAMIN D-3; DENDRITIC CELLS; T-CELLS; REACTIVE NITROGEN; IMMUNE-RESPONSES; MANNOSE RECEPTOR	We have previously reported that 1 alpha, 25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) can selectively suppress key functions of interferon-gamma (IFN-gamma) activated macrophages. To further explore this mechanism for its relevance in vivo, we investigated an infection model that crucially depends on the function of IFN-gamma activated macrophages, the infection with the intracellular protozoan Leishmania major. 1 alpha, 25(OH)(2)D-3 treatment of L. major infected macrophages demonstrated a vitamin D receptor (Vdr) dependent inhibition of macrophage killing activity. Further analysis showed that this was a result of decreased production of nitric oxide by 1 alpha,25(OH)(2)D-3-treated macrophages due to Vdr-dependent up-regulation of arginase 1 expression, which overrides NO production by Nos2. When analyzing the course of infection in vivo, we found that Vdr-knockout (Vdr-KO) mice were more resistant to L. major infection than their wild-type littermates. This result is in agreement with an inhibitory influence of 1 alpha, 25(OH)(2)D-3 on the macrophage mediated host defense. Further investigation showed that Vdr-KO mice developed an unaltered T helper cell type 1 (Th1) response on infection as indicated by normal production of IFN-gamma by CD4+ and CD8+ T cells. Therefore, we propose that the absence of 1 alpha, 25(OH)(2)D-3-mediated inhibition of macrophage microbicidal activity in Vdr-KO mice results in increased resistance to Leishmania infection.	Helmholtz Ctr Infect Res, Dept Expt Mouse Genet, Res Grp Infect Genet, D-38124 Braunschweig, Germany; Helmholtz Ctr Infect Res, Junior Res Grp Immunodynam, D-38124 Braunschweig, Germany; Univ Munster, Inst Expt Dermatol, D-4400 Munster, Germany; Univ Munster, Dept Dermatol, D-4400 Munster, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; University of Munster; University of Munster	Ehrchen, J (corresponding author), Helmholtz Ctr Infect Res, Dept Expt Mouse Genet, Res Grp Infect Genet, Inhoffenstr 7, D-38124 Braunschweig, Germany.		Gunzer, Matthias/AAW-7026-2021	Gunzer, Matthias/0000-0002-5534-6055; Sunderkotter, Cord/0000-0002-2929-145X				Adorini L, 2005, CELL IMMUNOL, V233, P115, DOI 10.1016/j.cellimm.2005.04.013; Ashcroft DM, 2000, BMJ-BRIT MED J, V320, P963, DOI 10.1136/bmj.320.7240.963; Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Cantorna MT, 2000, J NUTR, V130, P2648, DOI 10.1093/jn/130.11.2648; Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861; Cantorna MT, 1998, J NUTR, V128, P68, DOI 10.1093/jn/128.1.68; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; Diefenbach A, 1999, SCIENCE, V284, P951, DOI 10.1126/science.284.5416.951; DING AH, 1988, J IMMUNOL, V141, P2407; Ehrchen J, 2004, INFECT IMMUN, V72, P5106, DOI 10.1128/IAI.72.9.5106-5114.2004; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Froicu M, 2003, MOL ENDOCRINOL, V17, P2386, DOI 10.1210/me.2003-0281; Gauzzi MC, 2005, J IMMUNOL, V174, P270, DOI 10.4049/jimmunol.174.1.270; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Handman E, 2002, TRENDS PARASITOL, V18, P332, DOI 10.1016/S1471-4922(02)02352-8; Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood-2005-03-1029; Holscher C, 2006, J IMMUNOL, V176, P1115, DOI 10.4049/jimmunol.176.2.1115; Iniesta V, 2005, INFECT IMMUN, V73, P6085, DOI 10.1128/IAI.73.9.6085-6090.2005; Iniesta V, 2001, J EXP MED, V193, P777, DOI 10.1084/jem.193.6.777; Kang S, 1998, BRIT J DERMATOL, V138, P77; KOEFFLER HP, 1985, BIOCHEM BIOPH RES CO, V127, P596; Kropf P, 2005, FASEB J, V19, P1000, DOI 10.1096/fj.04-3416fje; Lehmann B, 2004, EXP DERMATOL, V13, P11, DOI 10.1111/j.1600-0625.2004.00257.x; LEMIRE JM, 1992, AUTOIMMUNITY, V12, P143, DOI 10.3109/08916939209150321; LEMIRE JM, 1991, J CLIN INVEST, V87, P1103, DOI 10.1172/JCI115072; LEMIRE JM, 1985, J IMMUNOL, V134, P3032; LEMIRE JM, 1992, J CELL BIOCHEM, V49, P26, DOI 10.1002/jcb.240490106; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Loke H, 2002, AM J TROP MED HYG, V67, P102, DOI 10.4269/ajtmh.2002.67.102; Loke P'ng, 2002, BMC Immunol, V3, P7, DOI 10.1186/1471-2172-3-7; Mahon BD, 2003, J CELL BIOCHEM, V89, P922, DOI 10.1002/jcb.10580; Meehan TF, 2002, P NATL ACAD SCI USA, V99, P5557, DOI 10.1073/pnas.082100699; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Munder M, 1998, J IMMUNOL, V160, P5347; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004-0002; O'Kelly J, 2002, J CLIN INVEST, V109, P1091, DOI 10.1172/JCI200212392; Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405; Piemonti L, 2000, J IMMUNOL, V164, P4443, DOI 10.4049/jimmunol.164.9.4443; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; REICHEL H, 1987, J BIOL CHEM, V262, P10931; Roth DE, 2004, J INFECT DIS, V190, P920, DOI 10.1086/423212; Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; Schonlau F, 2003, J LEUKOCYTE BIOL, V73, P564, DOI 10.1189/jlb.12011003; Schonlau F, 2000, EUR J IMMUNOL, V30, P2729, DOI 10.1002/1521-4141(200009)30:9&lt;2729::AID-IMMU2729&gt;3.0.CO;2-3; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; SUNDERKOTTER C, 1993, J IMMUNOL, V151, P4891; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; Veldman CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334, DOI 10.1006/abbi.1999.1605; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6; Wittke A, 2004, J IMMUNOL, V173, P3432, DOI 10.4049/jimmunol.173.5.3432; Zella JB, 2003, ARCH BIOCHEM BIOPHYS, V417, P77, DOI 10.1016/S0003-9861(03)00338-2	60	69	70	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3208	3218		10.1096/fj.06-7261com	http://dx.doi.org/10.1096/fj.06-7261com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17551101				2022-12-25	WOS:000249781600021
J	Freitas, MS; Gaspar, LP; Lorenzoni, M; Almeida, FCL; Tinoco, LW; Almeida, MS; Maia, LF; Degreve, L; Valente, AP; Silva, JL				Freitas, Monica S.; Gaspar, Luciane P.; Lorenzoni, Marcos; Almeida, Fabio C. L.; Tinoco, Luzineide W.; Almeida, Marcius S.; Maia, Lenize F.; Degreve, Leo; Valente, Ana Paula; Silva, Jerson L.			Structure of the Ebola fusion peptide in a membrane-mimetic environment and the interaction with lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; PROTEIN; SIMULATION; DOMAIN; SUBUNIT; GP2; PH	The fusion peptide EBO16 (GAAIGLAWIPYFGPAA) comprises the fusion domain of an internal sequence located in the envelope fusion glycoprotein (GP2) of the Ebola virus. This region interacts with the cellular membrane of the host and leads to membrane fusion. To gain insight into the mechanism of the peptide-membrane interaction and fusion, insertion of the peptide was modeled by experiments in which the tryptophan fluorescence and (HNMR)-H-1 were monitored in the presence of sodium dodecyl sulfate micelles or in the presence of detergent-resistant membrane fractions. In the presence of SDS micelles, EBO16 undergoes a random coil-helix transition, showing a tendency to self-associate. The three-dimensional structure displays a 3(10)-helix in the central part of molecule, similar to the fusion peptides of many known membrane fusion proteins. Our results also reveal that EBO16 can interact with detergent-resistant membrane fractions and strongly suggest that Trp-8 and Phe-12 are important for structure maintenance within the membrane bilayer. Replacement of tryptophan 8 with alanine (W8A) resulted in dramatic loss of helical structure, proving the importance of the aromatic ring in stabilizing the helix. Molecular dynamics studies of the interaction between the peptide and the target membrane also corroborated the crucial participation of these aromatic residues. The aromatic-aromatic interaction may provide a mechanism for the free energy coupling between random coil-helical transition and membrane anchoring. Our data shed light on the structural "domains" of fusion peptides and provide a clue for the development of a drug that might block the early steps of viral infection.	Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Jiri Jonas, Inst Bioquim Med, Programa biol Estrutural, BR-21941590 Rio De Janeiro, Brazil; Inst Oswaldo Cruz, Dept Virol, BR-21040360 Rio De Janeiro, Brazil; Univ Sao Paulo, Fac Filosofia Ciencias & Letras Ribeirao Pret, Dept Quim, BR-14040901 Ribeirao Preto, SP, Brazil; Univ Fed Rio de Janeiro, Lab Analise & Desenvolvimento Inibidores, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; Universidade Federal do Rio de Janeiro	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Jiri Jonas, Inst Bioquim Med, Programa biol Estrutural, BR-21941590 Rio De Janeiro, Brazil.	jerson@bioqmed.ufrj.br	Almeida, Fabio/O-4989-2018; Tinoco, Luzineide W/G-3630-2014; Maia, Lenize F./N-9420-2013; SILVA, JERSON Lima/GRF-1442-2022; de Freitas, Mônica Santos/E-8540-2015; Valente, Ana Paula/J-3010-2017; Silva, Jerson/J-8984-2014	Almeida, Fabio/0000-0001-6046-7006; Tinoco, Luzineide W/0000-0002-1299-6242; Maia, Lenize F./0000-0002-7433-4156; SILVA, JERSON Lima/0000-0001-9523-9441; de Freitas, Mônica Santos/0000-0003-3105-7918; Valente, Ana Paula/0000-0001-7219-1123; Silva, Jerson/0000-0001-9523-9441; almeida, marcius/0000-0003-4921-8185				Bar S, 2006, J VIROL, V80, P2815, DOI 10.1128/JVI.80.6.2815-2822.2006; Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Feldmann H, 1993, Arch Virol Suppl, V7, P81; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Ito H, 1999, J VIROL, V73, P8907, DOI 10.1128/JVI.73.10.8907-8912.1999; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Maia LF, 2006, J BIOL CHEM, V281, P29278, DOI 10.1074/jbc.M604689200; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Malashkevich VN, 2001, P NATL ACAD SCI USA, V98, P8502, DOI 10.1073/pnas.151254798; MILLHAUSER GL, 1995, BIOCHEMISTRY-US, V34, P3873, DOI 10.1021/bi00012a001; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Peters C.J., 1996, FIELDS VIROLOGY, P1161; Ruiz-Arguello MB, 1998, J VIROL, V72, P1775; Schweighofer KJ, 1997, J PHYS CHEM B, V101, P3793, DOI 10.1021/jp963460g; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; SHEINERMAN FB, 1995, J AM CHEM SOC, V117, P10098, DOI 10.1021/ja00145a022; Suarez T, 2003, FEBS LETT, V535, P23, DOI 10.1016/S0014-5793(02)03847-4; Tamm LK, 2002, BIOPOLYMERS, V66, P249, DOI 10.1002/bip.10261; Tieleman DP, 2000, J PHYS CHEM B, V104, P6380, DOI 10.1021/jp001268f; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wong TC, 2003, BBA-BIOMEMBRANES, V1609, P45, DOI 10.1016/S0005-2736(02)00652-1; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yao Y, 2003, VIROLOGY, V310, P319, DOI 10.1016/S0042-6822(03)00146-6	33	41	41	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27306	27314		10.1074/jbc.M611864200	http://dx.doi.org/10.1074/jbc.M611864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17545161	hybrid			2022-12-25	WOS:000249304900072
J	Chen, Q; Sivakumar, P; Barley, C; Peters, DM; Gomes, RR; Farach-Carson, MC; Dallas, SL				Chen, Qian; Sivakumar, Pitchumani; Barley, Craig; Peters, Donna M.; Gomes, Ronald R.; Farach-Carson, Mary C.; Dallas, Sarah L.			Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-beta(TGF-beta) by modulating assembly of latent TGF-beta-binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; FIBRONECTIN; ACTIVATION; CELLS; BONE; LTBP-1; GROWTH-FACTOR-BETA-1; MICROFIBRILS; TGF-BETA-1; FIBRILLIN	Latent transforming growth factor-beta-binding proteins (LTBPs) are extracellular matrix (ECM) glycoproteins that play a major role in storage of latent TGF-beta in the ECM and regulate its availability. We have previously identified fibronectin as a key molecule for incorporation of LTBP1 and TGF-beta into the ECM of osteoblasts and fibroblasts. Here we provide evidence that heparan sulfate proteoglycans may mediate binding between LTBP1 and fibronectin. We have localized critical domains in the N terminus of LTBP1 that are required for colocalization with fibronectin in osteoblast cultures and have identified heparin binding sites in the N terminus of LTBP1 between residues 345 and 487. Solid-phase binding assays suggest that LTBP1 does not bind directly to fibronectin but that the binding is indirect. Heparin coupled to bovine serum albumin (heparin-BSA) was able to mediate binding between fibronectin and LTBP1. Treatment of primary osteoblast cultures with heparin or heparin-BSA but not with chondroitin sulfate impaired LTBP1 deposition onto fibronectin without inhibiting expression of LTBP1. Inhibition of LTBP1 incorporation was accompanied by reduced incorporation of latent TGF-beta into the ECM, with increased amounts of soluble latent TGF-beta. Inhibition of attachment of glycosaminoglycans to the core proteins of proteoglycans by beta-D-xylosides also reduced incorporation of LTBP1 into the ECM. These studies suggest that heparan sulfate proteoglycans may play a critical role in regulating TGF-beta availability by controlling the deposition of LTBP1 into the ECM in association with fibronectin.	Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Delaware, Penn State Coll Med, Dept Orthoped & Rehabil, Newark, DE 19716 USA	University of Missouri System; University of Missouri Kansas City; University of Manchester; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Delaware	Dallas, SL (corresponding author), Univ Missouri, Sch Dent, Dept Oral Biol, 650 E 25th Str, Kansas City, MO 64108 USA.	dallass@umkc.edu	Sivakumar, Pitchumani/AAA-8199-2022	Farach-Carson, Mary/0000-0002-4526-3088; Sivakumar, Pitchumani/0000-0002-1157-8831	NATIONAL CANCER INSTITUTE [K01CA075387, P01CA098912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051517, R56AR051517] Funding Source: NIH RePORTER; NCI NIH HHS [CA75387, CA098912] Funding Source: Medline; NIAMS NIH HHS [AR051517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bi YM, 2005, J BIOL CHEM, V280, P30481, DOI 10.1074/jbc.M500573200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Charbonneau Noe L, 2004, Birth Defects Res C Embryo Today, V72, P37, DOI 10.1002/bdrc.20000; Dabovic B, 2002, J CELL BIOL, V156, P227, DOI 10.1083/jcb.200111080; Dallas SL, 2005, J BIOL CHEM, V280, P18871, DOI 10.1074/jbc.M410762200; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200; DALTON BA, 1995, J CELL SCI, V108, P2083; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Fontana L, 2005, FASEB J, V19, P1798, DOI 10.1096/fj.05-4134com; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; GODYNA S, 1995, MATRIX BIOL, V14, P467, DOI 10.1016/0945-053X(95)90004-7; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hyytiainen M, 2004, CRIT REV CL LAB SCI, V41, P233, DOI 10.1080/10408360490460933; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1991, CIBA F SYMP, V157, P81; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; MOULD AP, 1994, J BIOL CHEM, V269, P27224; Nakajima Y, 1997, J CELL BIOL, V136, P193, DOI 10.1083/jcb.136.1.193; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Oklu R, 1998, FEBS LETT, V425, P281, DOI 10.1016/S0014-5793(98)00257-9; Pereira M, 2002, J CELL SCI, V115, P609; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121; Raghunath M, 1998, J INVEST DERMATOL, V111, P559, DOI 10.1046/j.1523-1747.1998.00339.x; Ramirez F, 2004, PHYSIOL GENOMICS, V19, P151, DOI 10.1152/physiolgenomics.00092.2004; Ritty TM, 2003, BIOCHEM J, V375, P425, DOI 10.1042/BJ20030649; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Sterner-Kock A, 2002, GENE DEV, V16, P2264, DOI 10.1101/gad.229102; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; Unsold C, 2001, J CELL SCI, V114, P187; Yang WD, 2005, TISSUE ENG, V11, P76, DOI 10.1089/ten.2005.11.76	48	83	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26418	26430		10.1074/jbc.M703341200	http://dx.doi.org/10.1074/jbc.M703341200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17580303	hybrid			2022-12-25	WOS:000249239600047
J	Koch, HP; Hubbard, JM; Larsson, HP				Koch, Hans P.; Hubbard, Jeffrey M.; Larsson, H. Peter			Voltage-independent sodium-binding events reported by the 4B-4C loop in the human glutamate transporter excitatory amino acid transporter 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; ASPARTATE TRANSPORTER; INDIVIDUAL SUBUNITS; ANION CONDUCTANCE; GLT-1; EXPRESSION; TOPOLOGY; CURRENTS; CARRIER; EAAC1	Glutamate transporters (excitatory amino acid transporter (EAATs)) are critical for normal excitatory signaling and maintaining subtoxic glutamate concentrations in mammalian central nervous system. Recently, a crystal structure for a homologous transporter in bacteria was reported. Still, little is understood regarding the mechanism of substrate uptake. In transmembrane domain 4, the mammalian EAATs contain a stretch of over 50 amino acids (4B-4C loop) that are absent in the bacterial protein. These residues have been suggested to be located in the large extracellular vestibule seen in the crystal structure. State-dependent trypsin-cleavage sites have been reported in this region, suggesting that the 4B-4C loop undergoes significant conformational changes. Here we employed substituted cysteine accessibility, voltage clamp fluorometry, and fluorescence resonance energy transfer on oocytes expressing mutant EAAT3 transporters to determine the location and functionality of the 4B-4C loop. We find that this loop extends from near the center of the protein and that the majority of the residues are positioned on the outer perimeter of the protein, rather than inside the vestibule. Our fluorescence resonance energy transfer measurements demonstrated that these residues do not undergo large scale motions during glutamate uptake. However, our voltage clamp fluorometry studies indicate that these residues report on Na+ and glutamate binding-induced conformational changes, including a previously un-described voltage-independent component of Na+ binding to the transporter. The finding that residues far from the glutamate-binding site report on several different types of binding events suggests that the series of small conformational changes that accomplish glutamate uptake extend throughout the transporter structure.	Oregon Hlth & Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Larsson, HP (corresponding author), Oregon Hlth & Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA.	larssonp@ohsu.edu		Hubbard, Jeffrey/0000-0003-2619-2242	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051169, T32NS045553] Funding Source: NIH RePORTER; NCRR NIH HHS [RR016858] Funding Source: Medline; NINDS NIH HHS [NS051169, NS45553, R01 NS051169] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auger C, 2000, NEURON, V28, P547, DOI 10.1016/S0896-6273(00)00132-X; Bergles DE, 2002, J NEUROSCI, V22, P10153; Billups B, 1996, J NEUROSCI, V16, P6722; Boudker O, 2007, NATURE, V445, P387, DOI 10.1038/nature05455; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Grewer C, 2005, BIOCHEMISTRY-US, V44, P11913, DOI 10.1021/bi050987n; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; Koch HP, 2007, J NEUROSCI, V27, P2943, DOI 10.1523/JNEUROSCI.0118-07.2007; Koch HP, 2005, J NEUROSCI, V25, P1730, DOI 10.1523/JNEUROSCI.4138-04.2005; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Otis TS, 1998, J NEUROSCI, V18, P7099; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Raunser S, 2005, J MOL BIOL, V351, P598, DOI 10.1016/j.jmb.2005.06.036; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Voros J, 2004, BIOPHYS J, V87, P553, DOI 10.1529/biophysj.103.030072; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Watzke N, 2001, J GEN PHYSIOL, V117, P547, DOI 10.1085/jgp.117.6.547; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	28	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24547	24553		10.1074/jbc.M704087200	http://dx.doi.org/10.1074/jbc.M704087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17588938	hybrid			2022-12-25	WOS:000248933000008
J	Aguado, T; Romero, E; Monory, K; Palazuelos, J; Sendtner, M; Marsicano, G; Lutz, B; Guzman, M; Galve-Roperh, I				Aguado, Tania; Romero, Eva; Monory, Krisztina; Palazuelos, Javier; Sendtner, Michael; Marsicano, Giovanni; Lutz, Beat; Guzman, Manuel; Galve-Roperh, Ismael			The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; STEM-CELLS; ADULT NEUROGENESIS; BRAIN; SYSTEM; HIPPOCAMPUS; PRECURSORS; PLASTICITY; EGF; FGF	Endocannabinoids are lipid signaling mediators that exert an important neuromodulatory role and confer neuroprotection in several types of brain injury. Excitotoxicity and stroke can induce neural progenitor (NP) proliferation and differentiation as an attempt of neuroregeneration after damage. Here we investigated the mechanism of hippocampal progenitor cell engagement upon excitotoxicity induced by kainic acid administration and the putative involvement of the CB1 cannabinoid receptor in this process. Adult NPs express kainate receptors that mediate proliferation and neurosphere generation in vitro via CB1 cannabinoid receptors. Similarly, in vivo studies showed that excitotoxicity-induced hippocampal NPs proliferation and neurogenesis are abrogated in CB1-deficient mice and in wildtype mice administered with the selective CB1 antagonist rimonabant (N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)4-methyl-3-pyrazolecarboxamide; SR141716). Kainate stimulation increased basic fibroblast growth factor (bFGF) expression in cultured NPs in a CB1-dependent manner as this response was prevented by rimonabant and mimicked by endocannabinoids. Likewise, in vivo analyses showed that increased hippocampal expression of bFGF, as well as of brain-derived neurotrophic factor and epidermal growth factor, occurs upon excitotoxicity and that CB1 receptor ablation prevents this induction. Moreover, excitotoxicity increased the number of CB1 (+)bFGF(+) cells, and this up-regulation preceded NP proliferation. In summary, our results show the involvement of the CB1 cannabinoid receptor in NP proliferation and neurogenesis induced by excitotoxic injury and support a role for bFGF signaling in this process.	Univ Complutense, Sch Biol, Dept Biochem & Mol Biol, E-28040 Madrid, Spain; Univ Complutense, Ctr Invest Biomed & Redsobre Enfermedades Neurode, E-28040 Madrid, Spain; Johannes Gutenberg Univ Mainz, Dept Physiol Chem, D-55099 Mainz, Germany; Univ Wurzburg, Inst Clin Neurobiol, D-97078 Wurzburg, Germany; Inst Francois Magendie, INSERM, U862, F-33076 Bordeaux, France	Complutense University of Madrid; Complutense University of Madrid; Johannes Gutenberg University of Mainz; University of Wurzburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Galve-Roperh, I (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol, E-28040 Madrid, Spain.	igr@quim.ucm.es	AGUADO SANCHEZ, TANIA/ABD-6975-2021; Sendtner, Michael/J-1542-2012; Marsicano, Giovanni/I-9603-2016; Galve-Roperh, Ismael/AAG-2369-2020; Lutz, Beat/AAG-4538-2022; PALAZUELOS, JAVIER/AAD-7313-2020; Sendtner, Michael/M-8137-2014; Lutz, Beat/AFK-6229-2022; Aguado, Tania/AAE-3972-2019; PALAZUELOS, JAVIER/D-1211-2013	AGUADO SANCHEZ, TANIA/0000-0003-4339-0443; Sendtner, Michael/0000-0002-4737-2974; PALAZUELOS, JAVIER/0000-0002-0409-1398; Sendtner, Michael/0000-0002-4737-2974; Guzman, Manuel/0000-0001-7475-118X; Marsicano, Giovanni/0000-0003-3804-1951				AGRADO T, 2006, J NEUROSCI, V26, P1551; Aguado T, 2005, FASEB J, V19, P1704, DOI 10.1096/fj.05-3995fje; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Berghuis P, 2005, P NATL ACAD SCI USA, V102, P19115, DOI 10.1073/pnas.0509494102; Chevaleyre V, 2006, ANNU REV NEUROSCI, V29, P37, DOI 10.1146/annurev.neuro.29.051605.112834; Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001; Guan XL, 2006, FASEB J, V20, P1152, DOI 10.1096/fj.05-5362com; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Harkany T, 2007, TRENDS PHARMACOL SCI, V28, P83, DOI 10.1016/j.tips.2006.12.004; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Jin KL, 2000, ANN NEUROL, V48, P257, DOI 10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.0.CO;2-P; Jin KL, 2004, MOL PHARMACOL, V66, P204, DOI 10.1124/mol.66.2.204; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jordan JD, 2005, J BIOL CHEM, V280, P11413, DOI 10.1074/jbc.M411521200; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Khaspekov LG, 2004, EUR J NEUROSCI, V19, P1691, DOI 10.1111/j.1460-9568.2004.03285.x; Kim E, 2006, J BIOL CHEM, V281, P33749, DOI 10.1074/jbc.M603862200; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; Makara JK, 2005, NAT NEUROSCI, V8, P1139, DOI 10.1038/nn1521; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Palazuelos J, 2006, FASEB J, V20, P2405, DOI 10.1096/fj.06-6164fje; Palmer TD, 1999, J NEUROSCI, V19, P8487; Parent JM, 1997, J NEUROSCI, V17, P3727; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Svetlov SI, 2004, STEM CELLS DEV, V13, P685, DOI 10.1089/scd.2004.13.685; Toda H, 2003, J BIOL CHEM, V278, P35491, DOI 10.1074/jbc.M305342200; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Unzicker C, 2005, NEUROCHEM RES, V30, P1305, DOI 10.1007/s11064-005-8802-3; Williams EJ, 2003, J CELL BIOL, V160, P481, DOI 10.1083/jcb.200210164; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhu YH, 2003, FASEB J, V17, P186, DOI 10.1096/fj.02-0515com	43	123	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23892	23898		10.1074/jbc.M700678200	http://dx.doi.org/10.1074/jbc.M700678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17556369	hybrid			2022-12-25	WOS:000248686600016
J	Ballou, LM; Selinger, ES; Choi, JY; Drueckhammer, DG; Lin, RZ				Ballou, Lisa M.; Selinger, Elzbieta S.; Choi, Jun Yong; Drueckhammer, Dale G.; Lin, Richard Z.			Inhibition of mammalian target of rapamycin signaling by 2-(Morpholin-1-yl) pyrimido[2,1-alpha]isoquinolin-4-one	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS COMPLEX; HUMAN BREAST-CANCER; PHOSPHOINOSITIDE 3-KINASE INHIBITORS; DEPENDENT PROTEIN-KINASE; P70 S6 KINASE; BINDING PARTNER; HIGH-FREQUENCY; TUMOR-GROWTH; PIK3CA GENE; CELL-LINE	Signaling through the mammalian target of rapamycin (mTOR) is hyperactivated in many human tumors, including hamartomas associated with tuberous sclerosis complex (TSC). Several small molecules such as LY294002 inhibit mTOR kinase activity, but they also inhibit phosphatidylinositol 3-kinase (PI3K) at similar concentrations. Compound 401 is a synthetic inhibitor of DNA-dependent protein kinase (DNA-PK) that also targets mTOR but not PI3K in vitro (Griffin, R. J., Fontana, G., Golding, B. T., Guiard, S., Hardcastle, I. R., Leahy, J. J., Martin, N., Richardson, C., Rigoreau, L., Stockley, M., and Smith, G. C. (2005) J. Med. Chem. 48, 569-585). We used 401 to test the cellular effect of mTOR inhibition without the complicating side effects on PI3K. Treatment of cells with 401 blocked the phosphorylation of sites modified by mTOR-Raptor and mTOR-Rictor complexes (ribosomal protein S6 kinase 1 Thr(389) and Akt Ser(473), respectively). By contrast, there was no direct inhibition of Akt Thr(308) phosphorylation, which is dependent on PI3K. Similar effects were also observed in cells that lack DNA-PK. The proliferation of TSC1(-/-) fibroblasts was inhibited in the presence of 401, but TSC1(-/-) cells were resistant. In contrast to rapamycin, long-term treatment of TSC1(-/-) cells with 401 did not up-regulate phospho-Akt Ser(473). Because increased Akt activity promotes survival, this may explain why the level of apoptosis was increased in the presence of 401 but not rapamycin. These results suggest that mTOR kinase inhibitors might be more effective than rapamycins in controlling the growth of TSC hamartomas and other tumors that depend on elevated mTOR activity.	SUNY Stony Brook, Dept Med, Div Hematol Oncol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Chem Biol & Drug Discovery, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Phys & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Mol Cardiol, Stony Brook, NY 11794 USA; Dept Vet Affairs Med Ctr, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ballou, LM (corresponding author), SUNY Stony Brook, Dept Med, Div Hematol Oncol, Stony Brook, NY 11794 USA.	lisa.ballou@sunysb.edu	Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059568, R01DK062722] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59568, DK62722] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Ballou LM, 2003, FEBS LETT, V550, P51, DOI 10.1016/S0014-5793(03)00816-0; Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Chiang Gary G, 2004, Methods Mol Biol, V281, P125; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; DeFeo-Jones D, 2005, MOL CANCER THER, V4, P271; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Franz DN, 2006, ANN NEUROL, V59, P490, DOI 10.1002/ana.20784; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Griffin RJ, 2005, J MED CHEM, V48, P569, DOI 10.1021/jm049526a; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardcastle IR, 2005, J MED CHEM, V48, P7829, DOI 10.1021/jm050444b; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jiang YP, 2001, J BIOL CHEM, V276, P10943, DOI 10.1074/jbc.M007758200; Kenny BA, 1996, BRIT J PHARMACOL, V118, P871, DOI 10.1111/j.1476-5381.1996.tb15480.x; Knight ZA, 2004, BIOORGAN MED CHEM, V12, P4749, DOI 10.1016/j.bmc.2004.06.022; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Parcells BW, 2006, STEM CELLS, V24, P1174, DOI 10.1634/stemcells.2005-0519; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yang Q, 2006, P NATL ACAD SCI USA, V103, P6811, DOI 10.1073/pnas.0602282103	61	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24463	24470		10.1074/jbc.M704741200	http://dx.doi.org/10.1074/jbc.M704741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17562705	hybrid			2022-12-25	WOS:000248686600073
J	Chisari, M; Saini, DK; Kalyanaraman, V; Gautam, N				Chisari, Mariangela; Saini, Deepak Kumar; Kalyanaraman, Vani; Gautam, Narasimhan			Shuttling of G protein subunits between the plasma membrane and intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMERIC G-PROTEINS; BETA-GAMMA COMPLEX; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; GOLGI-APPARATUS; CELLS; RAS; PALMITOYLATION; RECEPTOR; TRANSLOCATION	Heterotrimeric G proteins ( alpha beta gamma) mediate the majority of signaling pathways in mammalian cells. It is long held that G protein function is localized to the plasma membrane. Here we examined the spatiotemporal dynamics of G protein localization using fluorescence recovery after photobleaching, fluorescence loss in photobleaching, and a photoswitchable fluorescent protein, Dronpa. Unexpectedly, G protein subunits shuttle rapidly ( t(1/2) < 1 min) between the plasma membrane and intracellular membranes. We show that consistent with such shuttling, G proteins constitutively reside in endomembranes. Furthermore, we show that shuttling is inhibited by 2- bromopalmitate. Thus, contrary to present thought, G proteins do not reside permanently on the plasma membrane but are constantly testing the cytoplasmic surfaces of the plasma membrane and endomembranes to maintain G protein pools in intracellular membranes to establish direct communication between receptors and endomembranes.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.	gautam@wustl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069027] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 69027, R01 GM069027-02, R01 GM069027] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akgoz M, 2006, CELL SIGNAL, V18, P1758, DOI 10.1016/j.cellsig.2006.01.016; Ando R, 2004, SCIENCE, V306, P1370, DOI 10.1126/science.1102506; Azpiazu I, 2004, J BIOL CHEM, V279, P27709, DOI 10.1074/jbc.M403712200; Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; Fivaz M, 2005, J CELL BIOL, V170, P429, DOI 10.1083/jcb.200409157; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goodwin JS, 2005, J CELL BIOL, V170, P261, DOI 10.1083/jcb.200502063; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Le-Niculescu H, 2005, J BIOL CHEM, V280, P22012, DOI 10.1074/jbc.M501833200; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Mikic I, 2006, METHOD ENZYMOL, V414, P150, DOI 10.1016/S0076-6879(06)14010-0; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; Punnonen EL, 1998, EUR J CELL BIOL, V75, P344, DOI 10.1016/S0171-9335(98)80067-8; Quatela SE, 2006, CURR OPIN CELL BIOL, V18, P162, DOI 10.1016/j.ceb.2006.02.004; Resh MD, 2006, METHODS, V40, P191, DOI 10.1016/j.ymeth.2006.04.013; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rocks O, 2006, CURR OPIN CELL BIOL, V18, P351, DOI 10.1016/j.ceb.2006.06.007; Saini DK, 2007, J BIOL CHEM, V282, P24099, DOI 10.1074/jbc.M701191200; Sato M, 2006, ANNU REV PHARMACOL, V46, P151, DOI 10.1146/annurev.pharmtox.46.120604.141115; Schechtman D, 2004, J BIOL CHEM, V279, P15831, DOI 10.1074/jbc.M310696200; Schroeder H, 1997, BIOCHEMISTRY-US, V36, P13102, DOI 10.1021/bi9709497; Silvius JR, 2006, MOL BIOL CELL, V17, P192, DOI 10.1091/mbc.e05-05-0408; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Vukmirica J, 2003, J BIOL CHEM, V278, P14153, DOI 10.1074/jbc.M211995200; Wang YR, 1999, J BIOL CHEM, V274, P37435, DOI 10.1074/jbc.274.52.37435; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1; ZHANG GF, 1993, J CELL SCI, V104, P819	41	67	69	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24092	24098		10.1074/jbc.M704246200	http://dx.doi.org/10.1074/jbc.M704246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17576765	Green Accepted, hybrid			2022-12-25	WOS:000248686600035
J	Pankiv, S; Clausen, TH; Lamark, T; Brech, A; Bruun, JA; Outzen, H; Overvatn, A; Bjorkoy, G; Johansen, T				Pankiv, Serhiy; Clausen, Terje Hoyvarde; Lamark, Trond; Brech, Andreas; Bruun, Jack-Ansgar; Outzen, Heidi; Overvatn, Aud; Bjorkoy, Geir; Johansen, Terje			p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURODEGENERATIVE DISEASE; FLUORESCENT PROTEINS; INTERACTION NETWORK; MAMMALIAN HOMOLOG; PAGETS-DISEASE; P62; DOMAIN; CELLS; MICE; LC3	Protein degradation by basal constitutive autophagy is important to avoid accumulation of polyubiquitinated protein aggregates and development of neurodegenerative diseases. The polyubiquitinbinding protein p62/ SQSTM1 is degraded by autophagy. It is found in cellular inclusion bodies together with polyubiquitinated proteins and in cytosolic protein aggregates that accumulate in various chronic, toxic, and degenerative diseases. Here we show for the first time a direct interaction between p62 and the autophagic effector proteins LC3A and - B and the related gamma- aminobutyrate receptor- associated protein and gamma- aminobutyrate receptor- associated like proteins. The binding is mediated by a 22- residue sequence of p62 containing an evolutionarily conserved motif. To monitor the autophagic sequestration of p62- and LC3- positive bodies, we developed a novel pH- sensitive fluorescent tag consisting of a tandem fusion of the red, acid- insensitive mCherry and the acid- sensitive green fluorescent proteins. This approach revealed that p62- and LC3- positive bodies are degraded in autolysosomes. Strikingly, even rather large p62- positive inclusion bodies ( 2 mu m diameter) become degraded by autophagy. The specific interaction between p62 and LC3, requiring the motif we have mapped, is instrumental in mediating autophagic degradation of the p62- positive bodies. We also demonstrate that the previously reported aggresome- like induced structures containing ubiquitinated proteins in cytosolic bodies are dependent on p62 for their formation. In fact, p62 bodies and these structures are indistinguishable. Taken together, our results clearly suggest that p62 is required both for the formation and the degradation of polyubiquitin- containing bodies by autophagy.	Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway; Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway	UiT The Arctic University of Tromso; University of Oslo	Johansen, T (corresponding author), Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway.	terjej@fagmed.uit.no	Johansen, Terje/N-2971-2015; Johansen, Terje/AAY-1753-2021	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Bruun, Jack-Ansgar/0000-0003-0614-2790; Pankiv, Serhiy/0000-0001-7953-2445; Bjorkoy, Geir/0000-0003-0031-8361; Brech, Andreas/0000-0002-9803-1774; Lamark, Trond/0000-0001-6338-3342				Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Cavey JR, 2005, J BONE MINER RES, V20, P619, DOI 10.1359/JBMR.041205; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Daroszewska A, 2006, NAT CLIN PRACT RHEUM, V2, P270, DOI 10.1038/ncprheum0172; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hammarstrom M, 2002, PROTEIN SCI, V11, P313, DOI 10.1110/ps.22102; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Hosokawa N, 2006, FEBS LETT, V580, P2623, DOI 10.1016/j.febslet.2006.04.008; Ishii T, 1997, BIOCHEM BIOPH RES CO, V232, P33, DOI 10.1006/bbrc.1997.6221; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; KIELIAN MC, 1982, J CELL BIOL, V93, P875, DOI 10.1083/jcb.93.3.875; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kouno T, 2005, J BIOL CHEM, V280, P24610, DOI 10.1074/jbc.M413565200; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Lelouard H, 2004, J CELL BIOL, V164, P667, DOI 10.1083/jcb.200312073; Lelouard H, 2002, NATURE, V417, P177, DOI 10.1038/417177a; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mizushima N, 2006, AUTOPHAGY, V2, P302, DOI 10.4161/auto.2945; Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simonsen A, 2004, J CELL SCI, V117, P4239, DOI 10.1242/jcs.01287; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Sou Y, 2006, J BIOL CHEM, V281, P3017, DOI 10.1074/jbc.M505888200; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x; Szeto J, 2006, AUTOPHAGY, V2, P189, DOI 10.4161/auto.2731; Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Wang QJ, 2006, J NEUROSCI, V26, P8057, DOI 10.1523/JNEUROSCI.2261-06.2006; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Xin YR, 2001, GENOMICS, V74, P408, DOI 10.1006/geno.2001.6555; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	55	3162	3277	13	337	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24131	24145		10.1074/jbc.M702824200	http://dx.doi.org/10.1074/jbc.M702824200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17580304	hybrid			2022-12-25	WOS:000248686600039
J	Keskanokwong, T; Shandro, HJ; Johnson, DE; Kittanakom, S; Vilas, GL; Thorner, P; Reithmeier, RAF; Akkarapatumwong, V; Yenchitsomanus, PT; Casey, JR				Keskanokwong, Thitima; Shandro, Haley J.; Johnson, Danielle E.; Kittanakom, Saranya; Vilas, Gonzalo L.; Thorner, Paul; Reithmeier, Reinhart A. F.; Akkarapatumwong, Varaporn; Yenchitsomanus, Pa-thai; Casey, Joseph R.			Interaction of integrin-linked kinase with the kidney chloride/bicarbonate exchanger, kAE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; REGULATES CELL-ADHESION; ANION-EXCHANGER; PLASMA-MEMBRANE; ACTIN-BINDING; ERYTHROCYTE-MEMBRANE; CYTOPLASMIC DOMAIN; PROTEIN-KINASE; BAND-3 GENE; AE1	Kidney anion exchanger 1 (kAE1) mediates chloride/bicarbonate exchange at the basolateral membrane of kidney alpha-intercalated cells, thereby facilitating bicarbonate reabsorption into the blood. Human kAE1 lacks the N-terminal 65 residues of the erythroid form (AE1, band 3), which are essential for binding of cytoskeletal and cytosolic proteins. Yeast two-hybrid screening identified integrin-linked kinase (ILK), a serine/threonine kinase, and an actin-binding protein as an interacting partner with the N-terminal domain of kAE1. Interaction between kAE1 and ILK was confirmed in co-expression experiments in HEK 293 cells and is mediated by a previously unidentified calponin homology domain in the kAE1 N-terminal region. The calponin homology domain of kAE1 binds the C-terminal catalytic domain of ILK to enhance association of kAE1 with the actin cytoskeleton. Overexpression of ILK increased kAE1 levels at the cell surface as shown by flow cytometry, cell surface biotinylation, and anion transport activity assays. Pulse-chase experiments revealed that ILK associates with kAE1 early in biosynthesis, likely in the endoplasmic reticulum. ILK co-localized with kAE1 at the basolateral membrane of polarized Madin-Darby canine kidney cells and in alpha-intercalated cells of human kidneys. Taken together these results suggest that ILK and kAE1 traffic together from the endoplasmic reticulum to the basolateral membrane. ILK may provide a linkage between kAE1 and the underlying actin cytoskeleton to stabilize kAE1 at the basolateral membrane, resulting in higher levels of cell surface expression.	Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Mahidol Univ, Inst Mol Biol & Genet, Nakhon Pathom 73170, Thailand; Mahidol Univ, Siriraj Hosp, Fac Med, Dept Res & Dev, Bangkok 10700, Thailand; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	University of Alberta; University of Alberta; Mahidol University; Mahidol University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				Adair-Kirk TL, 2003, J CELL SCI, V116, P655, DOI 10.1242/jcs.00260; ALPER SL, 1994, J CLIN INVEST, V93, P1430, DOI 10.1172/JCI117120; Alvarez BV, 2005, EMBO J, V24, P2499, DOI 10.1038/sj.emboj.7600736; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Bastani B, 1996, MINER ELECTROL METAB, V22, P396; Bramham J, 2002, STRUCTURE, V10, P249, DOI 10.1016/S0969-2126(02)00703-7; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; Chen JH, 1998, J BIOL CHEM, V273, P1038, DOI 10.1074/jbc.273.2.1038; Cheung JC, 2005, BIOCHEM J, V390, P137, DOI 10.1042/BJ20050315; Cordat E, 2003, TRAFFIC, V4, P642, DOI 10.1034/j.1600-0854.2003.00123.x; CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DING Y, 1994, J BIOL CHEM, V269, P32201; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fujinaga J, 2003, BIOCHEM J, V371, P687, DOI 10.1042/BJ20030007; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Godinich M J, 1995, Curr Opin Nephrol Hypertens, V4, P398, DOI 10.1097/00041552-199509000-00004; Guo LD, 2001, AM J PATHOL, V159, P1735, DOI 10.1016/S0002-9440(10)63020-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Kittanakom S, 2004, MOL MEMBR BIOL, V21, P395, DOI 10.1080/09687860400011365; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; Leung-Hagesteijn C, 2005, MOL CELL BIOL, V25, P3648, DOI 10.1128/MCB.25.9.3648-3657.2005; Matsuda C, 2005, J NEUROPATH EXP NEUR, V64, P334, DOI 10.1093/jnen/64.4.334; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Quilty JA, 2002, BIOCHEM J, V368, P895, DOI 10.1042/BJ20020574; Quilty JA, 2000, TRAFFIC, V1, P987, DOI 10.1034/j.1600-0854.2000.011208.x; Rodriguez-Soriano J, 2000, PEDIATR NEPHROL, V14, P1121, DOI 10.1007/s004670000407; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SCHOFIELD AE, 1994, BLOOD, V84, P2000; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; Tanner MJA, 1997, MOL MEMBR BIOL, V14, P155, DOI 10.3109/09687689709048178; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Toye AM, 2004, J CELL SCI, V117, P1399, DOI 10.1242/jcs.00974; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; WAGNER S, 1987, AM J PHYSIOL, V253, P213; WANG CC, 1995, J BIOL CHEM, V270, P17892, DOI 10.1074/jbc.270.30.17892; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zhang DC, 2000, BLOOD, V96, P2925; Zhu QS, 2004, J BIOL CHEM, V279, P23565, DOI 10.1074/jbc.M401380200; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200	47	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23205	23218		10.1074/jbc.M702139200	http://dx.doi.org/10.1074/jbc.M702139200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17553790	hybrid			2022-12-25	WOS:000248577500022
J	Beeson, JG; Andrews, KT; Boyle, M; Duffy, MF; Choong, EK; Byrne, TJ; Chesson, JM; Lawson, AM; Chai, W				Beeson, James G.; Andrews, Katherine T.; Boyle, Michelle; Duffy, Michael F.; Choong, Ee Ken; Byrne, Tim J.; Chesson, Joanne M.; Lawson, Alexander M.; Chai, Wengang			Structural basis for binding of Plasmodium falciparum erythrocyte membrane protein 1 to chondroitin sulfate and placental tissue and the influence of protein polymorphisms on binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; INFECTED ERYTHROCYTES; VAR GENE; HYALURONIC-ACID; PARASITE ADHESION; DISTINCT ADHESIVE; IN-VITRO; ADHERENCE; MALARIA; RECEPTOR	Chondroitin sulfate ( CS) A is a key receptor for adhesion of Plasmodium falciparum-infected erythrocytes (IEs) in the placenta and can also mediate adhesion to microvascular endothelial cells. IEs that adhere to CSA express var2csa-type genes, which encode specific variants of the IE surface antigen P. falciparum erythrocyte membrane protein 1 (PfEMP1). We report direct binding of native PfEMP1, isolated from IEs and encoded by var2csa, to immobilized CSA. Binding of PfEMP1 was dependent on 4-O-sulfated disaccharides and glucuronic acid rather than iduronic acid, consistent with the specificity of intact IEs. Using immobilized CS oligosaccharides as neoglycolipid probes, the minimum chain length for direct binding of PfEMP1 was eight monosaccharide units. Similarly for IE adhesion to placental tissue there was a requirement for 4-O-sulfated GalNAc and glucuronic acid mixed with non-sulfated disaccharides; 6-O-sulfation interfered with the interaction between placental CSA and IEs. The minimum chain length for maximal inhibition of adhesion was 10 monosaccharide residues. Partially 4-O-sulfated CS oligosaccharides (45-55% sulfation) were highly effective inhibitors of placental adhesion (IC50, 0.15 mu g/ml) and may have potential for therapeutic development. We used defined P. falciparum isolates expressing different variants of var2csa in adhesion assays and found that there were isolate-specific differences in the preferred structural motifs for adhesion to CSA that correlated with polymorphisms in PfEMP1 encoded by var2csa-type genes. This may influence sites of IE sequestration or parasite virulence. These findings have significant implications for understanding the pathogenesis and biology of malaria, particularly during pregnancy, and the development of targeted interventions.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Queensland Inst Med Res, Clin Trop Med Lab, Brisbane, Qld 4066, Australia; Queensland Inst Med Res, Griffith Med Res Coll, Brisbane, Qld 4066, Australia; Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia; Univ London Imperial Coll Sci Technol & Med, Glycosci Lab, Harrow HA1 3UJ, Middx, England	Royal Melbourne Hospital; Walter & Eliza Hall Institute; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; Royal Melbourne Hospital; University of Melbourne; Imperial College London	Beeson, JG (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	beeson@wehi.edu.au; w.chai@imperial.ac.uk	Boyle, Michelle/P-7297-2019; Boyle, Michelle/D-4223-2018; Andrews, Katherine/F-9586-2011; Duffy, Michael/A-8618-2012	Boyle, Michelle/0000-0002-0268-232X; Boyle, Michelle/0000-0002-0268-232X; Andrews, Katherine/0000-0002-1591-8979; Duffy, Michael/0000-0001-5635-4033; CHOONG, KEN/0000-0001-5266-4683	MRC [G9601454] Funding Source: UKRI; Medical Research Council [G9601454] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Achur RN, 2003, J BIOL CHEM, V278, P11705, DOI 10.1074/jbc.M211015200; Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200; Andrews KT, 2005, INFECT IMMUN, V73, P4288, DOI 10.1128/IAI.73.7.4288-4294.2005; Andrews KT, 2003, MOL MICROBIOL, V49, P655, DOI 10.1046/j.1365-2958.2003.03595.x; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; Beeson JG, 2002, CELL MOL LIFE SCI, V59, P258, DOI 10.1007/s00018-002-8421-y; Beeson JG, 2006, J INFECT DIS, V193, P721, DOI 10.1086/500145; Beeson JG, 2005, CURR TOP MICROBIOL, V297, P187; Beeson JG, 2004, J INFECT DIS, V189, P169, DOI 10.1086/380975; Beeson JG, 2004, J INFECT DIS, V189, P540, DOI 10.1086/381186; Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899; Beeson JG, 1998, INFECT IMMUN, V66, P3397, DOI 10.1128/IAI.66.7.3397-3402.1998; Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582; BEESON JG, 2007, IN PRESS AM J TROP M; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BIGGS BA, 1992, J IMMUNOL, V149, P2047; Bobardt MD, 2004, J VIROL, V78, P6567, DOI 10.1128/JVI.78.12.6567-6584.2004; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; Chai WG, 2003, METHOD ENZYMOL, V362, P160; Chai WG, 2002, J BIOL CHEM, V277, P22438, DOI 10.1074/jbc.M111401200; Chai WG, 2001, INFECT IMMUN, V69, P420, DOI 10.1128/IAI.69.1.420-425.2001; Chai WG, 1998, ANAL CHEM, V70, P2060, DOI 10.1021/ac9712761; Chaiyaroj SC, 1996, AM J TROP MED HYG, V55, P76, DOI 10.4269/ajtmh.1996.55.76; Chen Q, 1998, J EXP MED, V187, P15, DOI 10.1084/jem.187.1.15; CONTE A, 1991, ARZNEIMITTEL-FORSCH, V41-2, P768; Duffy MF, 2005, MOL MICROBIOL, V56, P774, DOI 10.1111/j.1365-2958.2005.04577.x; Duffy MF, 2006, INFECT IMMUN, V74, P4875, DOI 10.1128/IAI.01978-05; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; Elliott SR, 2005, INFECT IMMUN, V73, P2848, DOI 10.1128/IAI.73.5.2848-2856.2005; Enghild JJ, 1999, BIOCHEMISTRY-US, V38, P11804, DOI 10.1021/bi9908540; Feizi T, 2004, NAT REV MOL CELL BIO, V5, P582, DOI 10.1038/nrm1428; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fukui S, 2002, NAT BIOTECHNOL, V20, P1011, DOI 10.1038/nbt735; Fusai T, 2000, MOL BIOCHEM PARASIT, V108, P25, DOI 10.1016/S0166-6851(00)00199-7; Gamain B, 2005, J INFECT DIS, V191, P1010, DOI 10.1086/428137; Gamain B, 2004, MOL MICROBIOL, V53, P445, DOI 10.1111/j.1365-2958.2004.04145.x; Gamain B, 2001, BLOOD, V97, P3268, DOI 10.1182/blood.V97.10.3268; Gowda ASP, 2007, J BIOL CHEM, V282, P916, DOI 10.1074/jbc.M604741200; Gysin J, 1999, INFECT IMMUN, V67, P6596; Kamwendo DD, 2002, T ROY SOC TROP MED H, V96, P145, DOI 10.1016/S0035-9203(02)90284-1; KARAMANOS NK, 1994, ANAL BIOCHEM, V221, P189, DOI 10.1006/abio.1994.1396; Kraemer SM, 2003, MOL MICROBIOL, V50, P1527, DOI 10.1046/j.1365-2958.2003.03814.x; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Muthusamy A, 2004, EXP PARASITOL, V107, P183, DOI 10.1016/j.exppara.2004.05.003; Ndam NGT, 2005, J INFECT DIS, V192, P331, DOI 10.1086/430933; Noviyanti R, 2001, MOL BIOCHEM PARASIT, V114, P227, DOI 10.1016/S0166-6851(01)00266-3; Petersen F, 1998, J IMMUNOL, V161, P4347; Piepkorn M, 1997, BIOCHEM J, V327, P499, DOI 10.1042/bj3270499; Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; Rogerson SJ, 1997, EXP PARASITOL, V86, P8, DOI 10.1006/expr.1996.4142; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; Rostand KS, 1997, INFECT IMMUN, V65, P1; Rowe JA, 2004, MOL MICROBIOL, V53, P1011, DOI 10.1111/j.1365-2958.2004.04256.x; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Smith JD, 2000, P NATL ACAD SCI USA, V97, P1766, DOI 10.1073/pnas.040545897; Trimnell AR, 2006, MOL BIOCHEM PARASIT, V148, P169, DOI 10.1016/j.molbiopara.2006.03.012; Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466; VOLPI N, 1995, BBA-GEN SUBJECTS, V1243, P49, DOI 10.1016/0304-4165(94)00123-F; [No title captured]	66	29	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22426	22436		10.1074/jbc.M700231200	http://dx.doi.org/10.1074/jbc.M700231200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17562715	hybrid			2022-12-25	WOS:000248354200021
J	Buczynski, MW; Stephens, DL; Bowers-Gentry, RC; Grkovich, A; Deems, RA; Dennis, EA				Buczynski, Matthew W.; Stephens, Daren L.; Bowers-Gentry, Rebecca C.; Grkovich, Andrej; Deems, Raymond A.; Dennis, Edward A.			TLR-4 and sustained calcium agonists synergistically produce eicosanoids independent of protein synthesis in RAW264.7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); PLATELET-ACTIVATING-FACTOR; TANDEM MASS-SPECTROMETRY; ARACHIDONIC-ACID RELEASE; MACROPHAGE-LIKE CELLS; GROUP-SPECIFIC ASSAYS; P388D(1) MACROPHAGES; ELECTROSPRAY; INFLAMMATION; METABOLISM	Arachidonic acid is released by phospholipase A(2) and converted into hundreds of distinct bioactive mediators by a variety of cyclooxygenases ( COX), lipoxygenases (LO), and cytochrome P450s. Because of the size and diversity of the eicosanoid class of signaling molecules produced, a thorough and systematic investigation of these biological processes requires the simultaneous quantitation of a large number of eicosanoids in a single analysis. We have developed a robust liquid chromatography/tandem mass spectrometry method that can identify and quantitate over 60 different eicosanoids in a single analysis, and we applied it to agonist-stimulated RAW264.7 murine macrophages. Fifteen different eicosanoids produced through COX and 5-LO were detected either intracellularly or in the media following stimulation with 16 different agonists of Toll-like receptors (TLR), Gprotein-coupled receptors, and purinergic receptors. No significant differences in the COX metabolite profiles were detected using the different agonists; however, we determined that only agonists creating a sustained Ca2+ influx were capable of activating the 5-LO pathway in these cells. Synergy between Ca2+ and TLR pathways was detected and discovered to be independent of NF- kappa B-induced protein synthesis. This demonstrates that TLR induction of protein synthesis and priming for enhanced phospholipase A2-mediated eicosanoid production work through two distinct pathways.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	edennis@ucsd.edu	Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NIDDK NIH HHS [T32 DK007202] Funding Source: Medline; NIGMS NIH HHS [GM64611, GM069338] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338, R01GM064611] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM AA, 1986, CIBA F SYMP, V118, P196, DOI 10.1002/9780470720998.ch13; ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; ASMIS R, 1994, BIOCHEM J, V298, P543, DOI 10.1042/bj2980543; Balboa MA, 2000, BIOCHEM BIOPH RES CO, V267, P145, DOI 10.1006/bbrc.1999.1964; Balboa MA, 1999, J BIOL CHEM, V274, P36764, DOI 10.1074/jbc.274.51.36764; Balsinde J, 1997, BIOCHEM J, V321, P805, DOI 10.1042/bj3210805; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Baranowski R, 2002, MINI-REV MED CHEM, V2, P135, DOI 10.2174/1389557024605465; Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161/01.ATV.0000133192.39901.be; Coffey MJ, 2000, J IMMUNOL, V165, P3592, DOI 10.4049/jimmunol.165.7.3592; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Funk CD, 2002, PROSTAG OTH LIPID M, V68-9, P303, DOI 10.1016/S0090-6980(02)00036-9; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; Grkovich A, 2006, J BIOL CHEM, V281, P32978, DOI 10.1074/jbc.M605935200; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; Huwiler A, 2001, FASEB J, V15, P7; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Kita Y, 2005, ANAL BIOCHEM, V342, P134, DOI 10.1016/j.ab.2005.03.048; Klapisz E, 2000, J LIPID RES, V41, P1680; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lucas KK, 2005, PROSTAG OTH LIPID M, V77, P235, DOI 10.1016/j.prostaglandins.2005.02.004; Margalit A, 1996, ANAL BIOCHEM, V235, P73, DOI 10.1006/abio.1996.0093; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murphy RC, 2005, ANAL BIOCHEM, V346, P1, DOI 10.1016/j.ab.2005.04.042; Nakamura H, 2006, BIOCHEM PHARMACOL, V71, P850, DOI 10.1016/j.bcp.2005.12.027; Natarajan M, 2006, NAT CELL BIOL, V8, P571, DOI 10.1038/ncb1418; Peters-Golden M, 2003, PROSTAG LEUKOTR ESS, V69, P99, DOI 10.1016/S0952-3278(03)00070-X; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Qi HY, 2005, J BIOL CHEM, V280, P38969, DOI 10.1074/jbc.M509352200; Raetz CRH, 2006, J LIPID RES, V47, P1097, DOI 10.1194/jlr.M600027-JLR200; REINKE M, 1992, AM J PHYSIOL, V262, pE658, DOI 10.1152/ajpendo.1992.262.5.E658; Sacerdoti D, 2003, PROSTAG OTH LIPID M, V72, P51, DOI 10.1016/S1098-8823(03)00077-7; Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011; Schaloske RH, 2005, BBA-MOL CELL BIOL L, V1687, P64, DOI 10.1016/j.bbalip.2004.11.005; Seeds MC, 1998, BBA-LIPID LIPID MET, V1394, P224, DOI 10.1016/S0005-2760(98)00111-8; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; SHONO F, 1988, ANAL BIOCHEM, V168, P284, DOI 10.1016/0003-2697(88)90320-X; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Six DA, 2003, J BIOL CHEM, V278, P23842, DOI 10.1074/jbc.M301386200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spokas EG, 1999, METH MOL B, V120, P213; Takabatake M, 2002, PROSTAG LEUKOTR ESS, V67, P51, DOI 10.1054/plef.2002.0381; Trebino CE, 2005, J BIOL CHEM, V280, P16579, DOI 10.1074/jbc.M412075200; Wang M, 2006, P NATL ACAD SCI USA, V103, P14507, DOI 10.1073/pnas.0606586103; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053	55	78	79	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22834	22847		10.1074/jbc.M701831200	http://dx.doi.org/10.1074/jbc.M701831200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17535806	hybrid, Green Published			2022-12-25	WOS:000248354200061
J	Chen, Z; Akin, BL; Jones, LR				Chen, Zhenhui; Akin, Brandy L.; Jones, Larry R.			Mechanism of reversal of phospholamban inhibition of the cardiac Ca2+-ATPase by protein kinase a and by anti-phospholamban monoclonal antibody 2D12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CA2+ PUMP; FUNCTIONAL INTERACTIONS; CROSS-LINKING; CALCIUM-TRANSPORT; CA-2+ PUMP; PHOSPHORYLATION; ATPASE; STIMULATION; DOMAIN	Our model of phospholamban (PLB) regulation of the cardiac Ca2+ -ATPase in sarcoplasmic reticulum (SERCA2a) states that PLB binds to the Ca2+ -free, E2 conformation of SERCA2a and blocks it from transitioning from E2 to E1, the Ca2+ -bound state. PLB and Ca2+ binding to SERCA2a are mutually exclusive, and PLB inhibition of SERCA2a is manifested as a decreased apparent affinity of SERCA2a for Ca2+. Here we extend this model to explain the reversal of SERCA2a inhibition that occurs after phosphorylation of PLB at Ser(16) by protein kinase A (PKA) and after binding of the anti-PLB monoclonal antibody 2D12, which recognizes residues 7-13 of PLB. Site-specific cysteine variants of PLB were co-expressed with SERCA2a, and the effects of PKA phosphorylation and 2D12 on Ca2+- ATPase activity and cross-linking to SERCA2a were monitored. In Ca2+- ATPase assays, PKA phosphorylation and 2D12 partially and completely reversed SERCA2a inhibition by decreasing K-Ca values for enzyme activation, respectively. In cross-linking assays, cross-linking of PKA-phosphorylated PLB to SERCA2a was inhibited at only two of eight sites when conducted in the absence of Ca2+ favoring E2. However, at a subsaturating Ca2+ concentration supporting some E1, cross-linking of phosphorylated PLB to SERCA2a was attenuated at all eight sites. KCa values for cross-linking inhibition were decreased nearly 2-fold at all sites by PLB phosphorylation, demonstrating that phosphorylated PLB binds more weakly to SERCA2a than dephosphorylated PLB. In parallel assays, 2D12 blocked PLB cross-linking to SERCA2a at all eight sites regardless of Ca2+ concentration. Our results demonstrate that 2D12 restores maximal Ca2+-ATPase activity by physically disrupting the binding interaction between PLB and SERCA2a. Phosphorylation of PLB by PKA weakens the binding interaction between PLB and SERCA2a ( yielding more PLB-free SERCA2a molecules at intermediate Ca2+ concentrations), only partially restoring Ca2+ affinity and Ca2+- ATPase activity.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Jones, LR (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, 1800 N Capitol Ave, Indianapolis, IN 46202 USA.	lrjones@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049428, R01HL049428] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49428] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahi M, 2000, J BIOL CHEM, V275, P15034, DOI 10.1074/jbc.275.20.15034; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Chen ZH, 2005, J BIOL CHEM, V280, P10530, DOI 10.1074/jbc.M414007200; Chen ZH, 2003, J BIOL CHEM, V278, P48348, DOI 10.1074/jbc.M309545200; Chen ZH, 2006, J BIOL CHEM, V281, P14163, DOI 10.1074/jbc.M601338200; COLYER J, 1991, J BIOL CHEM, V266, P17486; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; Haghighi K, 2004, BIOCHEM BIOPH RES CO, V322, P1214, DOI 10.1016/j.bbrc.2004.07.164; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; Jones LR, 2002, J BIOL CHEM, V277, P28319, DOI 10.1074/jbc.M204085200; Karim CB, 2006, J MOL BIOL, V358, P1032, DOI 10.1016/j.jmb.2006.02.051; KIMURA Y, 1991, J MOL CELL CARDIOL, V23, P1223, DOI 10.1016/0022-2828(91)90080-6; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; Li JH, 2004, BIOCHEMISTRY-US, V43, P455, DOI 10.1021/bi035424v; Li JH, 2003, BIOCHEMISTRY-US, V42, P10674, DOI 10.1021/bi034708c; Mattiazzi A, 2005, CARDIOVASC RES, V68, P366, DOI 10.1016/j.cardiores.2005.08.010; Mueller B, 2004, BIOCHEMISTRY-US, V43, P8754, DOI 10.1021/bi049732k; Pantano S, 2007, PROTEINS, V66, P930, DOI 10.1002/prot.21239; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; Schmidt AG, 2001, CARDIOVASC DRUG THER, V15, P387, DOI 10.1023/A:1013381204658; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1974, J BIOL CHEM, V249, P6174; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WEGENER AD, 1989, J BIOL CHEM, V264, P11468	34	49	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20968	20976		10.1074/jbc.M703516200	http://dx.doi.org/10.1074/jbc.M703516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17548345	hybrid			2022-12-25	WOS:000248047500023
J	McNaghten, AD; Wolfe, MI; Onorato, I; Nakashima, AK; Valdiserri, RO; Mokotoff, E; Romaguera, RA; Kroliczak, A; Janssen, RS; Sullivan, PS				McNaghten, A. D.; Wolfe, Mitchell I.; Onorato, Ida; Nakashima, Allyn K.; Valdiserri, Ronald O.; Mokotoff, Eve; Romaguera, Raul A.; Kroliczak, Alice; Janssen, Robert S.; Sullivan, Patrick S.			Improving the Representativeness of Behavioral and Clinical Surveillance for Persons with HIV in the United States: The Rationale for Developing a Population-Based Approach	PLOS ONE			English	Article							PNEUMOCYSTIS-CARINII-PNEUMONIA; NATIONAL PROBABILITY SAMPLES; LOW-PREVALENCE DISEASES; CRACK COCAINE USE; ANTIRETROVIRAL THERAPY; RISK BEHAVIORS; AIDS; CHEMOPROPHYLAXIS; SURVIVAL; MEN	The need for a new surveillance approach to understand the clinical outcomes and behaviors of people in care for HIV evolved from the new challenges for monitoring clinical outcomes in the HAART era, the impact of the epidemic on an increasing number of areas in the US, and the need for representative data to describe the epidemic and related resource utilization and needs. The Institute of Medicine recommended that the Centers for Disease Control and Prevention and the Heath Resources and Services Administration coordinate efforts to survey a random sample of HIV-infected persons in care, in order to more accurately measure the need for prevention and care services. The Medical Monitoring Project (MMP) was created to meet these needs. This manuscript describes the evolution and design of MMP, a new nationally representative clinical outcomes and behavioral surveillance system, and describes how MMP data will be used locally and nationally to identify care and treatment utilization needs, and to plan for prevention interventions and services.	[McNaghten, A. D.; Wolfe, Mitchell I.; Onorato, Ida; Nakashima, Allyn K.; Valdiserri, Ronald O.; Romaguera, Raul A.; Janssen, Robert S.; Sullivan, Patrick S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; [Mokotoff, Eve] Michigan Dept Community Hlth, Detroit, MI USA; [Kroliczak, Alice] US Hlth Resources & Serv Adm, Rockville, MD 20857 USA	Centers for Disease Control & Prevention - USA; United States Health Resources & Service Administration (HRSA)	McNaghten, AD (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.	aom5@cdc.gov		Sullivan, Patrick Sean/0000-0002-7728-0587				Buehler JW, 1996, PUBLIC HEALTH REP, V111, P133; Campsmith Michael L, 2003, Health Qual Life Outcomes, V1, P12, DOI 10.1186/1477-7525-1-12; Campsmith ML, 2000, J ACQ IMMUN DEF SYND, V25, P192, DOI 10.1097/00126334-200010010-00015; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; *CDCP, 2003, GUID HIV PREV COMM P; *CDCP, 2001, HIV PREV STRAT PLAN; *CDCP, 2006, HIV AIDS SURV REP 20, V17, P1; *CDCP, 2004, HIV AIDS SURV REP 20, V15, P1; *CDCP, 2003, HIPAA PRIV RUL PUBL; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P329; Centers for Disease Control and Prevention, 2003, MMWR MORB MORTAL WKL, V52, P581; Centers for Disease Control and Prevention, 1985, MMWR-MORBID MORTAL W, V34, P373; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; CHAISSON RE, 1993, AIDS, V7, P857, DOI 10.1097/00002030-199306000-00015; DIAZ T, 1993, AIDS, V7, P1227, DOI 10.1097/00002030-199309000-00012; DIAZ T, 1993, JAMA-J AM MED ASSOC, V269, P2845, DOI 10.1001/jama.1993.03500220031012; Dworkin MS, 2001, J INFECT DIS, V183, P1409, DOI 10.1086/319866; Dworkin MS, 2000, J INFECT DIS, V182, P611, DOI 10.1086/315734; Dybul Mark, 2002, MMWR Recomm Rep, V51, P1; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; Fleming PL, 2000, AM J PUBLIC HEALTH, V90, P1037, DOI 10.2105/AJPH.90.7.1037; Frankel MR, 1999, HEALTH SERV RES, V34, P969; Gange SJ, 2007, INT J EPIDEMIOL; Glynn MK, 2007, PUBLIC HEALTH REP, V122, P63, DOI 10.1177/00333549071220S110; GOSTIN LO, LEG SURV STAT CONF L; Hall HI, 2005, J RURAL HEALTH, V21, P245, DOI 10.1111/j.1748-0361.2005.tb00090.x; HANSON DL, 1995, ARCH INTERN MED, V155, P1537, DOI 10.1001/archinte.155.14.1537; *HLTH ED RES TRUST, HIV LAWS IND STAT; *HLTH RES SERV ADM, GOV PERF RES ACT FIN; *HLTH RES SERV ADM, TITL 1 GRANTS EL MET; Holmberg SD, 1998, JAMA-J AM MED ASSOC, V279, P384, DOI 10.1001/jama.279.5.384; *I MED, 2004, MEAS WHAT MATT ALL P, P1; Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026; Jones JL, 2000, J ACQ IMMUN DEF SYND, V24, P270; *KAIS FAM FDN, TOT RYAN WHIT CARE A; Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1; Karon JM, 1997, J ACQ IMMUN DEF SYND, V16, P116, DOI 10.1097/00042560-199710010-00007; Kellerman SE, 2002, JAIDS-J ACQ IMM DEF, V31, P202, DOI 10.1097/00126334-200210010-00011; Kitahata MM, 2003, J GEN INTERN MED, V18, P95, DOI 10.1046/j.1525-1497.2003.11049.x; Lansky A, 2000, SEX TRANSM DIS, V27, P483, DOI 10.1097/00007435-200009000-00012; Matthews GW, 2000, PRINCIPLES PRACTICE, P215; McNaghten AD, 2003, JAIDS-J ACQ IMM DEF, V32, P499, DOI 10.1097/00126334-200304150-00006; McNaghten AD, 1999, AIDS, V13, P1687, DOI 10.1097/00002030-199909100-00012; Montgomery JP, 2003, AIDS CARE, V15, P829, DOI 10.1080/09540120310001618676; Moorman AC, 1998, J ACQ IMMUN DEF SYND, V19, P182, DOI 10.1097/00042560-199810010-00013; Moorman AC, 1999, ANN EPIDEMIOL, V9, P349, DOI 10.1016/S1047-2797(99)00005-8; Nakashima AK, 2003, JAIDS-J ACQ IMM DEF, V32, pS68, DOI 10.1097/00126334-200302011-00011; NEAL JJ, 2002, 9 C RETR OPP INF; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Rosenberg PS, 1998, JAMA-J AM MED ASSOC, V279, P1894, DOI 10.1001/jama.279.23.1894; Shapiro MF, 1999, HEALTH SERV RES, V34, P951; Sullivan PS, 2005, PUBLIC HEALTH REP, V120, P230, DOI 10.1177/003335490512000304; Sullivan PS, 1998, J ACQ IMMUN DEF SYND, V19, P266, DOI 10.1097/00042560-199811010-00009; United States Department of Health and Human Services, 2000, HLTH PEOPL 2010, V1; Weidle PJ, 1999, AIDS, V13, pS61	55	57	58	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e550	10.1371/journal.pone.0000550	http://dx.doi.org/10.1371/journal.pone.0000550			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579722	Green Published, gold			2022-12-25	WOS:000207451700016
J	Yap, JS; Wang, CG; Wu, RL				Yap, John Stephen; Wang, Chenguang; Wu, Rongling			A Computational Approach for Functional Mapping of Quantitative Trait Loci That Regulate Thermal Performance Curves	PLOS ONE			English	Article								Whether and how thermal reaction norm is under genetic control is fundamental to understand the mechanistic basis of adaptation to novel thermal environments. However, the genetic study of thermal reaction norm is difficult because it is often expressed as a continuous function or curve. Here we derive a statistical model for dissecting thermal performance curves into individual quantitative trait loci (QTL) with the aid of a genetic linkage map. The model is constructed within the maximum likelihood context and implemented with the EM algorithm. It integrates the biological principle of responses to temperature into a framework for genetic mapping through rigorous mathematical functions established to describe the pattern and shape of thermal reaction norms. The biological advantages of the model lie in the decomposition of the genetic causes for thermal reaction norm into its biologically interpretable modes, such as hotter-colder, faster-slower and generalist-specialist, as well as the formulation of a series of hypotheses at the interface between genetic actions/interactions and temperature-dependent sensitivity. The model is also meritorious in statistics because the precision of parameter estimation and power of QTLdetection can be increased by modeling the mean-covariance structure with a small set of parameters. The results from simulation studies suggest that the model displays favorable statistical properties and can be robust in practical genetic applications. The model provides a conceptual platform for testing many ecologically relevant hypotheses regarding organismic adaptation within the Eco-Devo paradigm.	[Yap, John Stephen; Wang, Chenguang; Wu, Rongling] Univ Florida, Dept Stat, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Wu, RL (corresponding author), Univ Florida, Dept Stat, Gainesville, FL 32611 USA.	rwu@mail.ifas.ufl.edu			NSF [0540745]; NIH [R01 NS041670]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041670] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The preparation of this manuscript is supported by NSF grant (0540745) and NIH grant (R01 NS041670) to R. W.	Angilletta MJ, 2003, TRENDS ECOL EVOL, V18, P234, DOI 10.1016/S0169-5347(03)00087-9; Arthur W, 2002, NATURE, V415, P757, DOI 10.1038/415757a; Brett JR, 1979, FISH PHYSIOL, V8, P599, DOI DOI 10.1016/S1546-5098(08)60033-3; CARROLL RJ, 1984, J AM STAT ASSOC, V79, P321, DOI 10.2307/2288271; Cronk QCB, 2005, NEW PHYTOL, V166, P39, DOI 10.1111/j.1469-8137.2005.01369.x; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Diggle P., 2002, ANAL LONGITUDINAL DA, DOI DOI 10.2307/2983303; Dusheck J, 2002, NATURE, V418, P578, DOI 10.1038/418578a; Elliott J.M., 1994, QUANTITATIVE ECOLOGY; GILCHRIST GW, 1995, AM NAT, V146, P252, DOI 10.1086/285797; GOMULKIEWICZ R, 1992, EVOLUTION, V46, P390, DOI [10.2307/2409860, 10.1111/j.1558-5646.1992.tb02047.x]; HUEY RB, 1979, AM ZOOL, V19, P357; HUEY RB, 1993, AM NAT, V142, pS21, DOI 10.1086/285521; HUEY RB, 1989, TRENDS ECOL EVOL, V4, P131, DOI 10.1016/0169-5347(89)90211-5; Izem R, 2005, AM NAT, V166, P277, DOI 10.1086/431314; JANSEN RC, 1994, GENETICS, V136, P1447; JIANG CJ, 1995, GENETICS, V140, P1111; Kingsolver JG, 2004, EVOLUTION, V58, P1521, DOI 10.1111/j.0014-3820.2004.tb01732.x; Kingsolver JG, 2001, GENETICA, V112, P87, DOI 10.1023/A:1013323318612; KOROL AB, 1995, GENETICS, V140, P1137; LANDER ES, 1989, GENETICS, V121, P185; Lynch M., 1998, GENETICS ANAL QUANTI; Ma CX, 2002, GENETICS, V161, P1751; Ojanguren AF, 2001, J THERM BIOL, V26, P165, DOI 10.1016/S0306-4565(00)00038-3; PELLETIER D, 1995, J EXP BIOL, V198, P1493; SCHEINER SM, 1993, ANNU REV ECOL SYST, V24, P35, DOI 10.1146/annurev.es.24.110193.000343; Schlichting CD, 1998, PHENOTYPIC EVOLUTION; Somero G. N., 1996, ANIMALS TEMPERATURE, P53; STEARNS SC, 1989, BIOSCIENCE, V39, P436, DOI 10.2307/1311135; VIA S, 1995, TRENDS ECOL EVOL, V10, P212, DOI 10.1016/S0169-5347(00)89061-8; VONBERTALANFFY L, 1957, Q REV BIOL, V32, P217, DOI 10.1086/401873; West GB, 2001, NATURE, V413, P628, DOI 10.1038/35098076; Wu RL, 2006, NAT REV GENET, V7, P229, DOI 10.1038/nrg1804; Wu RL, 2004, BIOMETRICS, V60, P729, DOI 10.1111/j.0006-341X.2004.00223.x; XU SH, 1995, GENETICS, V141, P1189; YANG RQ, 2006, GENETICS; ZENG ZB, 1994, GENETICS, V136, P1457; Zhao W, 2005, BIOINFORMATICS, V21, P2469, DOI 10.1093/bioinformatics/bti382; Zimmerman DL, 2001, TEST-SPAIN, V10, P1, DOI 10.1007/BF02595823	39	9	9	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e554	10.1371/journal.pone.0000554	http://dx.doi.org/10.1371/journal.pone.0000554			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579725	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451700019
J	Shin, SL; Hoebeek, FE; Schonewille, M; De Zeeuw, CI; Aertsen, A; De Schutter, E				Shin, Soon-Lim; Hoebeek, Freek E.; Schonewille, Martijn; De Zeeuw, Chris I.; Aertsen, Ad; De Schutter, Erik			Regular Patterns in Cerebellar Purkinje Cell Simple Spike Trains	PLOS ONE			English	Article							LONG-TERM DEPRESSION; IN-VITRO; NEURONS; RAT; RESPONSES; SYNAPSES; COMPLEX; LTD; SYNCHRONIZATION; TRANSMISSION	Background. Cerebellar Purkinje cells (PC) in vivo are commonly reported to generate irregular spike trains, documented by high coefficients of variation of interspike-intervals (ISI). In strong contrast, they fire very regularly in the in vitro slice preparation. We studied the nature of this difference in firing properties by focusing on short-term variability and its dependence on behavioral state. Methodology/Principal Findings. Using an analysis based on CV2 values, we could isolate precise regular spiking patterns, lasting up to hundreds of milliseconds, in PC simple spike trains recorded in both anesthetized and awake rodents. Regular spike patterns, defined by low variability of successive ISIs, comprised over half of the spikes, showed a wide range of mean ISIs, and were affected by behavioral state and tactile stimulation. Interestingly, regular patterns often coincided in nearby Purkinje cells without precise synchronization of individual spikes. Regular patterns exclusively appeared during the up state of the PC membrane potential, while single ISIs occurred both during up and down states. Possible functional consequences of regular spike patterns were investigated by modeling the synaptic conductance in neurons of the deep cerebellar nuclei (DCN). Simulations showed that these regular patterns caused epochs of relatively constant synaptic conductance in DCN neurons. Conclusions/Significance. Our findings indicate that the apparent irregularity in cerebellar PC simple spike trains in vivo is most likely caused by mixing of different regular spike patterns, separated by single long intervals, over time. We propose that PCs may signal information, at least in part, in regular spike patterns to downstream DCN neurons.	[Shin, Soon-Lim; De Schutter, Erik] Univ Antwerp, B-2020 Antwerp, Belgium; [Hoebeek, Freek E.; Schonewille, Martijn; De Zeeuw, Chris I.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; [Aertsen, Ad] Univ Freiburg, Fac Biol, Freiburg, Germany; [Aertsen, Ad] Univ Freiburg, Bernstein Ctr Computat Neurosci, Freiburg, Germany; [De Schutter, Erik] Okinawa Inst Sci & Technol, Computat Neurosci Unit, Okinawa, Japan	University of Antwerp; Erasmus University Rotterdam; Erasmus MC; University of Freiburg; University of Freiburg; Okinawa Institute of Science & Technology Graduate University	De Schutter, E (corresponding author), Univ Antwerp, B-2020 Antwerp, Belgium.	erik@tnb.ua.ac.be	De Schutter, Erik/G-8460-2011; Schonewille, Martijn/E-6170-2013	De Schutter, Erik/0000-0001-8618-5138; 	European Commission; IUAP; GSKE; FWO; NOW; NeuroBsik; Prinses Beatrix Fonds; BMBF	European Commission(European CommissionEuropean Commission Joint Research Centre); IUAP; GSKE; FWO(FWO); NOW; NeuroBsik; Prinses Beatrix Fonds; BMBF(Federal Ministry of Education & Research (BMBF))	This study was funded by the European Commission, in Belgium by IUAP, GSKE, FWO, in the Netherlands by NOW, NeuroBsik, Prinses Beatrix Fonds, and in Germany by the BMBF. These organisations had not influence on the study design, collection, analysis, interpretation of data; or writing of the paper; and on the decision to submit it for publication to PloS One.	Abbott LF, 2004, NATURE, V431, P796, DOI 10.1038/nature03010; Aizenman CD, 1999, J NEUROPHYSIOL, V82, P1697, DOI 10.1152/jn.1999.82.4.1697; Chan-Palay V, 1977, CEREBELLAR DENTATE N; Coltz JD, 1999, J NEUROSCI, V19, P1782; DEZEEUW CI, 1994, J COMP NEUROL, V349, P428, DOI 10.1002/cne.903490308; EGGERMONT JJ, 1995, NEUROREPORT, V6, P2125, DOI 10.1097/00001756-199511000-00007; Gauck V, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-15-j0004.2001; Goossens HHLM, 2004, EUR J NEUROSCI, V19, P687, DOI 10.1111/j.0953-816X.2003.03173.x; Goossens J, 2001, J NEUROSCI, V21, P5813, DOI 10.1523/JNEUROSCI.21-15-05813.2001; Hausser M, 1997, NEURON, V19, P665, DOI 10.1016/S0896-6273(00)80379-7; Heil P, 2004, CURR OPIN NEUROBIOL, V14, P461, DOI 10.1016/j.conb.2004.07.002; Hoebeek FE, 2005, NEURON, V45, P953, DOI 10.1016/j.neuron.2005.02.012; Holt GR, 1996, J NEUROPHYSIOL, V75, P1806, DOI 10.1152/jn.1996.75.5.1806; Ito M, 2001, PHYSIOL REV, V81, P1143, DOI 10.1152/physrev.2001.81.3.1143; Ivry RB, 2004, CURR OPIN NEUROBIOL, V14, P225, DOI 10.1016/j.conb.2004.03.013; JAEGER D, 1994, EXP BRAIN RES, V100, P200; Jorntell H, 2003, J NEUROSCI, V23, P9620; Kistler WM, 2002, NEURAL COMPUT, V14, P2597, DOI 10.1162/089976602760407991; Kitazawa S, 1998, NATURE, V392, P494, DOI 10.1038/33141; Koch Christof, 1999, P1; Koekkoek SKE, 2005, NEURON, V47, P339, DOI 10.1016/j.neuron.2005.07.005; Koekkoek SKE, 2003, SCIENCE, V301, P1736, DOI 10.1126/science.1088383; Konishi M, 2003, ANNU REV NEUROSCI, V26, P31, DOI 10.1146/annurev.neuro.26.041002.131123; LeDoux MS, 1998, NEUROSCIENCE, V86, P533, DOI 10.1016/S0306-4522(98)00007-4; Loewenstein Y, 2005, NAT NEUROSCI, V8, P202, DOI 10.1038/nn1393; Maex R, 2000, J PHYSIOL-LONDON, V523, P175, DOI 10.1111/j.1469-7793.2000.t01-1-00175.x; Ohyama T, 2003, TRENDS NEUROSCI, V26, P222, DOI 10.1016/S0166-2236(03)00054-7; Pedroarena CM, 2003, J NEUROPHYSIOL, V89, P704, DOI 10.1152/jn.00558.2002; Raman IM, 1999, J NEUROSCI, V19, P1663; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; Rieke F., 1997, SPIKES EXPLORING NEU; Schonewille M, 2006, NAT NEUROSCI, V9, P459, DOI 10.1038/nn0406-459; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; Shin SL, 2007, EUR J NEUROSCI, V25, P785, DOI 10.1111/j.1460-9568.2007.05308.x; Shin SL, 2006, J NEUROPHYSIOL, V96, P3485, DOI 10.1152/jn.00570.2006; SOFTKY WR, 1993, J NEUROSCI, V13, P334; Steuber V, 2007, NEURON, V54, P121, DOI 10.1016/j.neuron.2007.03.015; Telgkamp P, 2002, J NEUROSCI, V22, P8447; Telgkamp P, 2004, NEURON, V41, P113, DOI 10.1016/S0896-6273(03)00802-X; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; VanRullen R, 2005, TRENDS NEUROSCI, V28, P1, DOI 10.1016/j.tins.2004.10.010; Vos BP, 1999, EUR J NEUROSCI, V11, P2621, DOI 10.1046/j.1460-9568.1999.00678.x; Vos BP, 1999, J NEUROSCI, V19; Walter JT, 2006, NAT NEUROSCI, V9, P389, DOI 10.1038/nn1648	44	84	84	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e485	10.1371/journal.pone.0000485	http://dx.doi.org/10.1371/journal.pone.0000485			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534435	Green Published, gold			2022-12-25	WOS:000207448800015
J	Reif, R; Sales, S; Hettwer, S; Dreier, B; Gisler, C; Wolfel, J; Luscher, D; Zurlinden, A; Stephan, A; Ahmed, S; Baici, A; Ledermann, B; Kunz, B; Sonderegger, P				Reif, Raymond; Sales, Susanne; Hettwer, Stefan; Dreier, Birgit; Gisler, Claudio; Woelfel, Jens; Luescher, Daniel; Zurlinden, Andreas; Stephan, Alexander; Ahmed, Shaheen; Baici, Antonio; Ledermann, Birgit; Kunz, Beat; Sonderegger, Peter			Specific cleavage of agrin by neurotrypsin, a synaptic protease linked to mental retardation	FASEB JOURNAL			English	Article						serine peptidase; extracellular matrix; cognitive function; nervous system	PRO-ARG CHLOROMETHYLKETONE; HUMAN ALPHA-THROMBIN; CRYSTAL-STRUCTURE; ACTIVE-SITE; SUBSTRATE-SPECIFICITY; DENDRITIC SPINES; GROWTH; COAGULATION; MECHANISMS; FILOPODIA	The synaptic serine protease neurotrypsin is thought to be important for adaptive synaptic processes required for cognitive functions, because humans deficient in neurotrypsin suffer from severe mental retardation. In the present study, we describe the biochemical characterization of neurotrypsin and its so far unique substrate agrin. In cell culture experiment as well as in neurotrypsin-deficient mice, we showed that agrin cleavage depends on neurotrypsin and occurs at two conserved sites. Neurotrypsin and agrin were expressed recombinantly,purified, and assayed in vitro. A catalytic efficiency of 1.3 x 10(4) M-1 s(-1) was determined. Neurotrypsin activity was shown to depend on calcium with an optimal activity in the pH range of 7-8.5. Mutagenesis analysis of the amino acids flanking the scissile bonds showed that cleavage is highly specific due to the unique substrate recognition pocket of neurotrypsin at the active site. The C-terminal agrin fragment released after cleavage has recently been identified as an inactivating ligand of the Na+ / K+-ATPase at CNS synapses, and its binding has been demonstrated to regulate presynaptic excitability. Therefore, dysregulation of agrin processing is a good candidate for a pathogenetic mechanism underlying mental retardation. In turn, these results may also shed light on mechanisms involved in cognitive functions.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Lab Anim Res, CH-8057 Zurich, Switzerland; Neurotune AG, Schlieren, Switzerland	University of Zurich; University of Zurich	Sonderegger, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	peter.sonderegger@bioc.uzh.ch		Baici, Antonio/0000-0002-2980-0541				ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Annies M, 2006, MOL CELL NEUROSCI, V31, P515, DOI 10.1016/j.mcn.2005.11.005; Baldi L, 2005, BIOTECHNOL PROGR, V21, P148, DOI 10.1021/bp049830x; Bezakova G, 2003, NAT REV MOL CELL BIO, V4, P295, DOI 10.1038/nrm1074; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; Bode W, 2006, SEMIN THROMB HEMOST, V32, P16, DOI 10.1055/s-2006-939551; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Chelly J, 2001, NAT REV GENET, V2, P669, DOI 10.1038/35088558; Coombs GS, 1996, J BIOL CHEM, V271, P4461; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; Hilgenberg LGW, 2006, CELL, V125, P359, DOI 10.1016/j.cell.2006.01.052; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Kardos J, 1999, BIOCHEMISTRY-US, V38, P12248, DOI 10.1021/bi990764v; Knott GW, 2006, NAT NEUROSCI, V9, P1117, DOI 10.1038/nn1747; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; Kummer TT, 2006, CURR OPIN NEUROBIOL, V16, P74, DOI 10.1016/j.conb.2005.12.003; Lin YR, 2005, CRYST GROWTH DES, V5, P579, DOI 10.1021/cg049747h; Matus A, 2005, CURR OPIN NEUROBIOL, V15, P67, DOI 10.1016/j.conb.2005.01.015; McCroskery S, 2006, MOL CELL NEUROSCI, V33, P15, DOI 10.1016/j.mcn.2006.06.004; Misgeld T, 2005, P NATL ACAD SCI USA, V102, P11088, DOI 10.1073/pnas.0504806102; Molinari F, 2002, SCIENCE, V298, P1779, DOI 10.1126/science.1076521; Nimchinsky EA, 2002, ANNU REV PHYSIOL, V64, P313, DOI 10.1146/annurev.physiol.64.081501.160008; Proba K, 1998, BBA-GENE STRUCT EXPR, V1396, P143, DOI 10.1016/S0167-4781(97)00205-4; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; Ropers HH, 2006, CURR OPIN GENET DEV, V16, P260, DOI 10.1016/j.gde.2006.04.017; Ropers HH, 2005, NAT REV GENET, V6, P46, DOI 10.1038/nrg1501; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6	35	77	85	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3468	3478		10.1096/fj.07-8800com	http://dx.doi.org/10.1096/fj.07-8800com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586728				2022-12-25	WOS:000250517800010
J	Meplan, C; Crosley, LK; Nicol, F; Beckett, GJ; Howie, AF; Hill, KE; Horgan, G; Mathers, JC; Arthur, JR; Hesketh, JE				Meplan, Catherine; Crosley, Lynne K.; Nicol, Fergus; Beckett, Geoffrey J.; Howie, Alexander F.; Hill, Kristina E.; Horgan, Graham; Mathers, John C.; Arthur, John R.; Hesketh, John E.			Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study)	FASEB JOURNAL			English	Article						nutrient-gene interaction; 3 ' untranslated region; BMI	GLUTATHIONE-PEROXIDASE; CANCER PREVENTION; OXIDATIVE DAMAGE; EXPRESSION; HEALTH; DEFICIENCY; MORTALITY; DELETION; TISSUES; MOUSE	Selenium (Se), a micronutrient essential for human health, is incorporated into at least 25 selenoproteins including selenoprotein P (SePP), which transports Se within the body. This research identified two single nucleotide polymorphisms (SNPs) in the SePP gene, one in the coding region (position 24731, causing an Ala to Thr change) and one in the 3 ' untranslated region (position 25191). Their frequency was similar in Caucasian, Chinese, and South Asian populations. Prospectively genotyped volunteers were supplemented for 6 wk with 100 mu g sodium selenite/ day. Blood samples were analyzed for plasma Se and selenoprotein biomarkers at baseline, after supplementation, and during a washout period. Plasma Se, SePP, and glutathione peroxidase 3 (GPx3) levels increased with supplementation. Baseline plasma Se content depended on both SePP genotypes and body mass index. Pre-supplementation SePP concentration was associated with gender and genotype at SNP 24731 and post-supplementation concentration with SNP 25191. Both SNPs and gender were associated with differences in GPx3 activity, plasma, and erythrocyte thioredoxin reductase 1 concentrations and lymphocyte glutathione peroxidase 1 and 4 activities and concentrations. In conclusion, the data reveal two common functional SNPs within the human SePP gene that may predict behavior of biomarkers of Se status and response to supplementation and thus susceptibility to disease.	Univ Newcastle, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle, Sch Med, Human Nutr Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle, Sch Med, Sch Clin Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Edinburgh, Dept Clin Biochem, Edinburgh, Midlothian, Scotland; Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA; BioSS, Aberdeen, Scotland; Rowett Res Inst, Aberdeen, Scotland	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; University of Edinburgh; Vanderbilt University; James Hutton Institute; University of Aberdeen	Hesketh, JE (corresponding author), Univ Newcastle, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.e.hesketh@ncl.ac.uk	Horgan, Graham/J-3738-2013	Mathers, John/0000-0003-3406-3002	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058763] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-58763] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akbaraly NT, 2005, CLIN CHEM, V51, P2117, DOI 10.1373/clinchem.2005.055301; Al-Taie OH, 2004, NUTR CANCER, V48, P6, DOI 10.1207/s15327914nc4801_2; Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Beckett GJ, 2005, J ENDOCRINOL, V184, P455, DOI 10.1677/joe.1.05971; BERMANO G, 1995, BIOCHEM J, V311, P425, DOI 10.1042/bj3110425; Bhopal R, 1999, BRIT MED J, V319, P215, DOI 10.1136/bmj.319.7204.215; Broome CS, 2004, AM J CLIN NUTR, V80, P154; Brown KM, 2000, CLIN SCI, V98, P593, DOI 10.1042/CS19990276; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; Burk RF, 2006, CANCER EPIDEM BIOMAR, V15, P804, DOI 10.1158/1055-9965.EPI-05-0950; Combs GF, 2005, J NUTR, V135, P343, DOI 10.1093/jn/135.2.343; Fischbacher C M, 2002, J Epidemiol Community Health, V56, P79, DOI 10.1136/jech.56.1.79; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2004, J NUTR, V134, P157, DOI 10.1093/jn/134.1.157; Hirashima M, 2003, BIOL PHARM BULL, V26, P794; Maehara S, 2004, INT J CANCER, V112, P184, DOI 10.1002/ijc.20304; Meplan C., 2006, Nutritional genomics: impact on health and disease, P132, DOI 10.1002/3527608109.ch8; Miller S, 2001, CLIN SCI, V100, P543, DOI 10.1042/CS20000299; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Ray AL, 2006, J NUTR, V136, P172, DOI 10.1093/jn/136.1.172; Rayman MP, 2004, BRIT J NUTR, V92, P557, DOI 10.1079/BJN20041251; Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Riese C, 2006, ENDOCRINOLOGY, V147, P5883, DOI 10.1210/en.2006-0689; Saito Y, 2004, BIOCHEM J, V381, P841, DOI 10.1042/BJ20040328; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; Schweizer U, 2004, BRAIN RES REV, V45, P164, DOI 10.1016/j.brainresrev.2004.03.004; Schweizer U, 2005, BIOCHEM J, V386, P221, DOI 10.1042/BJ20041973; Small-Howard AL, 2005, BIOCHEM SOC T, V33, P1493, DOI 10.1042/BST0331493; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; Steinbrenner H, 2006, FREE RADICAL BIO MED, V40, P1513, DOI 10.1016/j.freeradbiomed.2005.12.022; Weiss SL, 1996, J NUTR, V126, P2260, DOI 10.1093/jn/126.9.2260; WEITZEL F, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88, DOI 10.1016/0304-4165(90)90018-R; Whanger PD, 2004, BRIT J NUTR, V91, P11, DOI 10.1079/BJN20031015; Wolters M, 2006, EUR J CLIN NUTR, V60, P85, DOI 10.1038/sj.ejcn.1602271; Xia YM, 2005, AM J CLIN NUTR, V81, P829, DOI 10.1093/ajcn/81.4.829	36	168	174	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3063	3074		10.1096/fj.07-8166com	http://dx.doi.org/10.1096/fj.07-8166com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17536041				2022-12-25	WOS:000249781600008
J	Farin, HF; Bussen, M; Schmidt, MK; Singh, MK; Schuster-Gossler, K; Kispert, A				Farin, Henner F.; Bussen, Markus; Schmidt, Martina K.; Singh, Manvendra K.; Schuster-Gossler, Karin; Kispert, Andreas			Transcriptional repression by the T-box proteins tbx18 and tbx15 depends on groucho corepressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; EXPRESSION ANALYSIS; PRESOMITIC MESODERM; CIONA-INTESTINALIS; PARAXIAL MESODERM; TARGET GENES; HEART; MOUSE; BRACHYURY; INTERACTS	Tbox18 (Tbx18) and Tbox15 (Tbx15) encode a closely related pair of vertebrate-specific T-box (Tbx) transcription factors. Functional analyses in the mouse have proven the requirement of Tbx15 in skin and skeletal development and of Tbx18 in the formation of the vertebral column, the ureter, and the posterior pole of the heart. Despite the accumulation of genetic data concerning the embryological roles of these genes, it is currently unclear how Tbx18 and Tbx15 exert their function on the molecular level. Here, we have initiated a molecular analysis of Tbx18 and Tbx15 proteins and have characterized functional domains for nuclear localization, DNA binding, and transcriptional modulation. We show that both proteins homo- and heterodimerize, bind to various combinations of T half-sites, and repress transcription in a Groucho-dependent manner. Competition with activating T-box proteins may constitute one mode of action as we show that Tbx18 interacts with Gata4 and Nkx2-5 and competes Tbx5-mediated activation of the cardiac Natriuretic peptide precursor type a-promoter and that ectopic expression of Tbx18 down-regulates Tbx6-activated Delta-like 1 expression in the somitic mesoderm in vivo.	Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany	Hannover Medical School	Kispert, A (corresponding author), Hannover Med Sch, Inst Mol Biol, OES250,Carl Neuberg Str 1, D-30625 Hannover, Germany.	kispert.andreas@mh-hannover.de	Singh, Manvendra K./AHE-0676-2022; Farin, Henner/AAC-2574-2021	Farin, Henner/0000-0003-1558-5366; Singh, Manvendra K./0000-0002-2884-0074				Agulnik SI, 1998, GENOMICS, V51, P68, DOI 10.1006/geno.1998.5278; Airik R, 2006, J CLIN INVEST, V116, P663, DOI 10.1172/JCI26027; ANDREOU AM, 2007, IN PRESS AM J HUM GE; Aulehla A, 2004, GENE DEV, V18, P2060, DOI 10.1101/gad.1217404; Barrantes ID, 1999, CURR BIOL, V9, P470, DOI 10.1016/S0960-9822(99)80212-7; Beaster-Jones L, 2006, EVOL DEV, V8, P119, DOI 10.1111/j.1525-142X.2006.00083.x; Beckers J, 2000, MECH DEVELOP, V95, P35, DOI 10.1016/S0925-4773(00)00323-3; Beckers J, 2000, MECH DEVELOP, V95, P23, DOI 10.1016/S0925-4773(00)00322-1; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Bush JO, 2002, DEV DYNAM, V225, P322, DOI 10.1002/dvdy.10154; Bussen M, 2004, GENE DEV, V18, P1209, DOI 10.1101/gad.300104; Candille SI, 2004, PLOS BIOL, V2, P30, DOI 10.1371/journal.pbio.0020003; Casey ES, 1998, DEVELOPMENT, V125, P3887; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Christoffels VM, 2006, CIRC RES, V98, P1555, DOI 10.1161/01.RES.0000227571.84189.65; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Conlon FL, 2001, DEVELOPMENT, V128, P3749; Copley RR, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-169; Davidson B, 2005, DEVELOPMENT, V132, P4811, DOI 10.1242/dev.02051; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; Harrelson Z, 2004, DEVELOPMENT, V131, P5041, DOI 10.1242/dev.01378; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Hofmann M, 2004, GENE DEV, V18, P2712, DOI 10.1101/gad.1248604; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Kraus F, 2001, MECH DEVELOP, V100, P83, DOI 10.1016/S0925-4773(00)00494-9; Kusch T, 2002, GENE DEV, V16, P518, DOI 10.1101/gad.213002; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Leconte L, 2004, J BIOL CHEM, V279, P47272, DOI 10.1074/jbc.M406624200; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; Leitges M, 2000, DEVELOPMENT, V127, P2259; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Naiche LA, 2005, ANNU REV GENET, V39, P219, DOI 10.1146/annurev.genet.39.073003.105925; Nowotschin S, 2006, DEVELOPMENT, V133, P1565, DOI 10.1242/dev.02309; Packham EA, 2003, HUM MOL GENET, V12, pR37, DOI 10.1093/hmg/ddg077; Plageman TF, 2004, J BIOL CHEM, V279, P19026, DOI 10.1074/jbc.M314041200; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Singh MK, 2005, MECH DEVELOP, V122, P131, DOI 10.1016/j.mod.2004.10.011; Sinha S, 2000, GENE, V258, P15, DOI 10.1016/S0378-1119(00)00417-0; Smith ST, 1996, DEVELOPMENT, V122, P3141; Stennard FA, 2003, DEV BIOL, V262, P206, DOI 10.1016/S0012-1606(03)00385-3; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Takatori N, 2004, DEV DYNAM, V230, P743, DOI 10.1002/dvdy.20082; Takeuchi JK, 2005, DEVELOPMENT, V132, P2463, DOI 10.1242/dev.01827; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; White PH, 2005, GENESIS, V42, P193, DOI 10.1002/gene.20140; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wissmuller S, 2006, NUCLEIC ACIDS RES, V34, P1735, DOI 10.1093/nar/gkl105; Yarmus M, 2006, P NATL ACAD SCI USA, V103, P7384, DOI 10.1073/pnas.0602470103	56	71	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25748	25759		10.1074/jbc.M703724200	http://dx.doi.org/10.1074/jbc.M703724200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17584735	hybrid			2022-12-25	WOS:000249014100062
J	Xu, J; Peng, H; Kang, N; Zhao, Z; Lin, JHC; Stanton, PK; Kang, J				Xu, Jun; Peng, Hong; Kang, Ning; Zhao, Zhuo; Lin, Jane H. -C.; Stanton, Patric K.; Kang, Jian			Glutamate-induced exocytosis of glutamate from astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; EXCITATORY AMINO-ACIDS; IN-SITU; MULTIVESICULAR RELEASE; SYNAPTIC-TRANSMISSION; NMDA RECEPTORS; GLIAL-CELLS; MECHANISM; CLEFT; NEUROEXOCYTOSIS	Recent studies indicate that astrocytes can play a much more active role in neuronal circuits than previously believed, by releasing neurotransmitters such as glutamate and ATP. Here we report that local application of glutamate or glutamine synthetase inhibitors induces astrocytic release of glutamate, which activates a slowly decaying transient inward current (SIC) in CA1 pyramidal neurons and a transient inward current in astrocytes in hippocampal slices. The occurrence of SICs was accompanied by an appearance of large vesicles around the puffing pipette. The frequency of SICs was positively correlated with [ glutamate] (0). EM imaging of anti-glial fibrillary acid proteinlabeled astrocytes showed glutamate-induced large astrocytic vesicles. Imaging of FM 1- 43 fluorescence using two- photon laser scanning microscopy detected glutamate- induced formation and fusion of large vesicles identified as FM 1- 43- negative structures. Fusion of large vesicles, monitored by collapse of vesicles with a high intensity FM 1- 43 stain in the vesicular membrane, coincided with SICs. Glutamate induced two types of large vesicles with high and low intravesicular [ Ca2(+) ]. The high [ Ca2 (+)] vesicle plays a major role in astrocytic release of glutamate. Vesicular fusion was blocked by infusing the Ca2 (+) chelator, 1,2- bis( 2-aminophenoxy) ethane- N, N, N ', N '-tetraacetic acid, or the SNARE blocker, tetanus toxin, suggesting Ca2 (+)-and SNARE- dependent fusion. Infusion of the vesicular glutamate transport inhibitor, Rose Bengal, reduced astrocytic glutamate release, suggesting the involvement of vesicular glutamate transports in vesicular transport of glutamate. Our results demonstrate that local [glutamate] (0) increases induce formation and exocytotic fusion of glutamate-containing large astrocytic vesicles. These large vesicles could play important roles in the feedback control of neuronal circuits and epileptic seizures.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; China Med Univ, Dept Physiol, Shenyang 110001, Peoples R China	New York Medical College; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; China Medical University	Kang, J (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Basic Sci bldg,Rm 220, Valhalla, NY 10595 USA.	jian_kang@NYMC.edu		Peng, Hong/0000-0001-5522-072X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039997] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 39997] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHNERTHILGER G, 1995, PROG NEUROBIOL, V46, P83, DOI 10.1016/0301-0082(95)00003-E; Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Araque A, 2001, ANNU REV PHYSIOL, V63, P795, DOI 10.1146/annurev.physiol.63.1.795; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Araque A, 1998, J NEUROSCI, V18, P6822; Auger C, 1998, J NEUROSCI, V18, P4532; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Carmignoto G, 2006, J PHYSIOLOGY-PARIS, V99, P98, DOI 10.1016/j.jphysparis.2005.12.008; Cavelier P, 2005, J PHYSIOL-LONDON, V564, P397, DOI 10.1113/jphysiol.2004.082131; Chen XK, 2005, J NEUROSCI, V25, P9236, DOI 10.1523/JNEUROSCI.1640-05.2005; Choi S, 2000, NAT NEUROSCI, V3, P330, DOI 10.1038/73895; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; Crippa D, 2006, J PHYSIOL-LONDON, V570, P567, DOI 10.1113/jphysiol.2005.094052; Diamond JS, 1997, J NEUROSCI, V17, P4672; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; Fellin T, 2006, J BIOL CHEM, V281, P4274, DOI 10.1074/jbc.M510679200; Fellin T, 2004, J PHYSIOL-LONDON, V559, P3, DOI 10.1113/jphysiol.2004.063214; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fiacco TA, 2007, NEURON, V54, P611, DOI 10.1016/j.neuron.2007.04.032; Haas K, 2001, NEURON, V29, P583, DOI 10.1016/S0896-6273(01)00235-5; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.3.CO;2-E; Jeftinija SD, 1996, J NEUROCHEM, V66, P676; Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kang N, 2005, J NEUROPHYSIOL, V94, P4121, DOI 10.1152/jn.00448.2005; Kleinle J, 1996, BIOPHYS J, V71, P2413, DOI 10.1016/S0006-3495(96)79435-3; KRESSIN K, 1995, GLIA, V15, P173, DOI 10.1002/glia.440150210; Lalo U, 2006, J NEUROSCI, V26, P2673, DOI 10.1523/JNEUROSCI.4689-05.2006; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; Matthias K, 2003, J NEUROSCI, V23, P1750; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Panatier A, 2006, CELL, V125, P775, DOI 10.1016/j.cell.2006.02.051; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Parri HR, 2001, NEUROREPORT, V12, P3897, DOI 10.1097/00001756-200112210-00008; Parri HR, 2001, NAT NEUROSCI, V4, P803, DOI 10.1038/90507; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Rossetto O, 2002, CURR PROBL DERMATOL, V30, P117; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rutledge EM, 1996, J NEUROSCI, V16, P7803; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Schote U, 1998, BBA-BIOMEMBRANES, V1415, P135, DOI 10.1016/S0005-2736(98)00188-6; Shigeri Yasushi, 2003, Nihon Yakurigaku Zasshi, V122, P253; Takano T, 2005, P NATL ACAD SCI USA, V102, P16466, DOI 10.1073/pnas.0506382102; Tian GF, 2005, NAT MED, V11, P973, DOI 10.1038/nm1277; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Wang XH, 2006, NAT NEUROSCI, V9, P816, DOI 10.1038/nn1703; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zoccarato F, 1999, J NEUROCHEM, V72, P625, DOI 10.1046/j.1471-4159.1999.0720625.x	55	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24185	24197		10.1074/jbc.M700452200	http://dx.doi.org/10.1074/jbc.M700452200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584743	hybrid			2022-12-25	WOS:000248686600044
J	De, M; Ciccotosto, GD; Mains, RE; Eipper, BA				De, Mithu; Ciccotosto, Giuseppe D.; Mains, Richard E.; Eipper, Betty A.			Trafficking of a secretory granule membrane protein is sensitive to copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; PEPTIDE PROCESSING ENZYME; GDP/GTP EXCHANGE FACTOR; CYTOSOLIC DOMAIN; HYDROXYLATING MONOOXYGENASE; MENKES PROTEIN; PROHORMONE CONVERTASES; REGULATED TRAFFICKING; ROUTING DETERMINANTS; MOLECULAR-MECHANISMS	We explored the effect of copper availability on the synthesis and trafficking of peptidylglycine alpha-amidating monooxygenase (PAM), an essential cuproenzyme whose catalytic domains function in the lumen of peptide-containing secretory granules. Corticotrope tumor cell lines expressing integral membrane and soluble forms of PAM were depleted of copper using bathocuproinedisulfonic acid or loaded with copper by incubation with CuCl2. Depleting cellular copper stimulates basal secretion of soluble enzyme produced by endoproteolytic cleavage of PAM in secretory granules and transit of membrane PAM though the endocytic pathway and back into secretory granules. Unlike many cuproenzymes, lack of copper does not lead to instability of PAM. Copper loading decreases cleavage of PAM in secretory granules, secretion of soluble enzyme, and the return of internalized PAM to secretory granules. The trafficking and stability of the soluble, luminal domain of PAM and truncated membrane PAM lacking a cytosolic domain are not affected by copper availability. Taken together, our data demonstrate a role for copper-sensitive cytosolic machinery in directing endocytosed membrane PAM back to secretory granules or to a degradative pathway. The response of PAM to lack of copper suggests that it facilitates copper homeostasis.	Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA; Univ Melbourne, Melbourne, Vic 3010, Australia	University of Connecticut; University of Melbourne	Eipper, BA (corresponding author), 263 Farmington Ave, Farmington, CT 06030 USA.	eipper@uchc.edu			NIDDK NIH HHS [DK-32949] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R37DK032949, R01DK032949] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 2001, MOL BIOL CELL, V12, P629, DOI 10.1091/mbc.12.3.629; Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; Caldwell BD, 1999, J BIOL CHEM, V274, P34646, DOI 10.1074/jbc.274.49.34646; Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; Cater MA, 2007, BIOCHEM J, V401, P143, DOI 10.1042/BJ20061055; Ciccotosto GD, 1999, J CELL BIOL, V144, P459, DOI 10.1083/jcb.144.3.459; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1986, J BIOL CHEM, V261, P8686; Francis MJ, 1999, J CELL SCI, V112, P1721; Francis MJ, 1998, HUM MOL GENET, V7, P1245, DOI 10.1093/hmg/7.8.1245; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Gordge MP, 1996, BRIT J PHARMACOL, V119, P533, DOI 10.1111/j.1476-5381.1996.tb15704.x; HALBAN PA, 1994, BIOCHEM J, V299, P1; Hansel DE, 2001, J HISTOCHEM CYTOCHEM, V49, P833, DOI 10.1177/002215540104900704; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Hellman NE, 2002, J BIOL CHEM, V277, P46632, DOI 10.1074/jbc.M206246200; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; Klinman JP, 2006, J BIOL CHEM, V281, P3013, DOI 10.1074/jbc.R500011200; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; LI S, 1997, MATRIX BIOL, V16, P387; Linder MC, 1996, AM J CLIN NUTR, V63, P797; Ma XM, 2001, J COMP NEUROL, V429, P388, DOI 10.1002/1096-9861(20010115)429:3<388::AID-CNE3>3.0.CO;2-I; Madsen E, 2007, CURR OPIN GASTROEN, V23, P187, DOI 10.1097/MOG.0b013e32801421bb; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; Nittis T, 2004, J BIOL CHEM, V279, P25696, DOI 10.1074/jbc.M401151200; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Prigge ST, 1999, NAT STRUCT BIOL, V6, P976; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Qin ZY, 2006, FASEB J, V20, P334, DOI 10.1096/fj.05-4564fje; Rees EM, 2004, CURR OPIN MICROBIOL, V7, P175, DOI 10.1016/j.mib.2004.02.004; SATO M, 1991, J BIOL CHEM, V266, P5128; SATO SM, 1985, ENDOCRINOLOGY, V117, P773, DOI 10.1210/endo-117-2-773; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Steveson TC, 2003, ENDOCRINOLOGY, V144, P188, DOI 10.1210/en.2002-220716; Steveson TC, 2001, J BIOL CHEM, V276, P40326, DOI 10.1074/jbc.M011460200; Steveson TC, 1999, J BIOL CHEM, V274, P21128, DOI 10.1074/jbc.274.30.21128; Voskoboinik I, 2002, ADV PROTEIN CHEM, V60, P123; Wang N, 2006, PIGM CELL RES, V19, P3, DOI 10.1111/j.1600-0749.2005.00288.x; YUN HY, 1995, J BIOL CHEM, V270, P30075; ZHOU A, 1993, J BIOL CHEM, V268, P1763; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	55	23	23	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23362	23371		10.1074/jbc.M702891200	http://dx.doi.org/10.1074/jbc.M702891200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17562710	hybrid			2022-12-25	WOS:000248577500037
J	Ieguchi, K; Ueda, S; Kataoka, T; Satoh, T				Ieguchi, Katsuaki; Ueda, Shuji; Kataoka, Tohru; Satoh, Takaya			Role of the guanine nucleotide exchange factor Ost in negative regulation of receptor endocytosis by the small GTPase Rac1*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOJANIN 2; RHO-GTPASES; PROTEIN; MEMBRANE; RAC1; MIGRATION; GABARAP; CELLS; LC3	The Rho family of GTPases has been implicated in the regulation of intracellular vesicle trafficking. Here, we investigated the mechanism underlying the negative regulation of clathrin-mediated endocytosis of cell surface receptors mediated by the Rho family protein Rac1. Contrary to previous reports, only the activated mutant of Rac1, but not other Rho family members including RhoA and Cdc42, suppressed internalization of the transferrin receptor. On the other hand, down-regulation of Rac1 expression by RNA interference resulted in enhanced receptor internalization, suggesting that endogenous Rac1 in fact functions as a negative regulator. We identified a guanine nucleotide exchange factor splice variant designated Ost-III, which contains a unique C-terminal region including an Src homology 3 domain, as a regulator of Rac1 involved in the inhibition of receptor endocytosis. In contrast, other splice variants Ost-I and Ost-II exerted virtually no effect on receptor endocytosis. We also examined subcellular localization of synaptojanin 2, a putative Rac1 effector implicated in negative regulation of receptor endocytosis. Each Ost splice variant induced distinct subcellular localization of synaptojanin 2, depending on Rac1 activation. Furthermore, we isolated gamma-aminobutyric acid type A receptor-associated protein ( GABARAP) as a protein that binds to the C-terminal region of Ost-III. When ectopically expressed, GABARAP was co-localized with Ost-III and potently suppressed the Ost-III-dependent Rac1 activation and the inhibition of receptor endocytosis. Lipid modification of GABARAP was necessary for the suppression of Ost-III. These results are discussed in terms of subcellular region-specific regulation of the Rac1-dependent signaling pathway that negatively regulates clathrin-mediated endocytosis.	Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Mol Biol, Kobe, Hyogo 6500017, Japan	Kobe University	Satoh, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Mol Biol, Kobe, Hyogo 6500017, Japan.	tkysato@med.kobe-u.ac.jp	Satoh, Takaya/K-2628-2014					Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cremona O, 2001, J CELL SCI, V114, P1041; de Toledo M, 2003, MOL BIOL CELL, V14, P4846, DOI 10.1091/mbc.E03-04-0254; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Green F, 2002, FEBS LETT, V518, P101, DOI 10.1016/S0014-5793(02)02655-8; Jou TS, 2000, MOL BIOL CELL, V11, P287, DOI 10.1091/mbc.11.1.287; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Leung SM, 1999, MOL BIOL CELL, V10, P4369, DOI 10.1091/mbc.10.12.4369; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Meng WX, 2004, EMBO J, V23, P760, DOI 10.1038/sj.emboj.7600095; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nemoto Y, 2001, J BIOL CHEM, V276, P41133, DOI 10.1074/jbc.M106404200; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ray RM, 2007, CELL MOTIL CYTOSKEL, V64, P143, DOI 10.1002/cm.20172; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Rusk N, 2003, CURR BIOL, V13, P659, DOI 10.1016/S0960-9822(03)00241-0; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Sunaguchi M, 2003, BRAIN RES, V984, P21, DOI 10.1016/S0006-8993(03)03004-X; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Ueda S, 2004, CELL SIGNAL, V16, P899, DOI 10.1016/j.cellsig.2004.01.007; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Yamaguchi K, 2006, BIOCHEM BIOPH RES CO, V346, P484, DOI 10.1016/j.bbrc.2006.05.136	37	9	9	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23296	23305		10.1074/jbc.M700950200	http://dx.doi.org/10.1074/jbc.M700950200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17562712	hybrid			2022-12-25	WOS:000248577500030
J	Schnell, R; Oehlmann, W; Singh, M; Schneider, G				Schnell, Robert; Oehlmann, Wulf; Singh, Mahavir; Schneider, Gunter			Structural insights into catalysis and inhibition of O-acetylserine sulfhydrylase from Mycobacterium tuberculosis - Crystal structures of the enzyme alpha-aminoacrylate intermediate and an enzyme-inhibitor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE ACETYLTRANSFERASE; 3-DIMENSIONAL STRUCTURE; TRYPTOPHAN SYNTHASE; INTERNAL ALDIMINE; MECHANISM; CYSTEINE; TRANSIMINATION; BIOSYNTHESIS; MACROPHAGES; PERSISTENCE	Cysteine biosynthetic genes are up-regulated in the persistent phase of Mycobacterium tuberculosis, and the corresponding enzymes are therefore of interest as potential targets for novel anti-bacterial agents. cysK1 is one of these genes and has been annotated as coding for an O-acetylserine sulfhydrylase. Recombinant CysK1 is a pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the conversion of O-acetylserine to cysteine. The crystal structure of the enzyme was determined to 1.8 angstrom resolution. CysK1 belongs to the family of fold type II PLP enzymes and is similar in structure to other O-acetylserine sulfhydrylases. We were able to trap the alpha-aminoacrylate reaction intermediate and determine its structure by cryocrystallography. Formation of the amino acrylate complex is accompanied by a domain rotation resulting in active site closure. The aminoacrylate moiety is bound in the active site via the covalent linkage to the PLP cofactor and by hydrogen bonds of its carboxyl group to several enzyme residues. The catalytic lysine residue is positioned such that it can protonate the C alpha-carbon atom of the aminoacrylate only from the si-face, resulting in the formation of L-cysteine. CysK1 is competitively inhibited by a four-residue peptide derived from the C-terminal of serine acetyl transferase. The crystallographic analysis reveals that the peptide binds to the enzyme active site, suggesting that CysK1 forms an bi-enzyme complex with serine acetyl transferase, in a similar manner to other bacterial and plant O-acetylserine sulfhydrylases. The structure of the enzyme-peptide complex provides a framework for the design of strong binding inhibitors.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; LIONEX GmbH, D-38124 Braunschweig, Germany; Helmholtz Ctr Infect Res, D-38124 Braunschweig, Germany	Karolinska Institutet; Helmholtz Association; Helmholtz-Center for Infection Research	Schneider, G (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	Gunter.Schneider@ki.se		SCHNELL, ROBERT/0000-0001-7530-3629; Schneider, Gunter/0000-0003-0622-5713				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bonner ER, 2005, J BIOL CHEM, V280, P38803, DOI 10.1074/jbc.M505313200; Bornemann C, 1997, BIOCHEM J, V325, P623, DOI 10.1042/bj3250623; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; Claus MT, 2005, BIOCHEMISTRY-US, V44, P8620, DOI 10.1021/bi050485+; Cornish-Bowden A, 2012, FUNDAMENTALS ENZYME, V4th; Droux M, 1998, EUR J BIOCHEM, V255, P235, DOI 10.1046/j.1432-1327.1998.2550235.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ericsson UB, 2006, ANAL BIOCHEM, V357, P289, DOI 10.1016/j.ab.2006.07.027; Francois JA, 2006, PLANT CELL, V18, P3647, DOI 10.1105/tpc.106.047316; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Hampshire T, 2004, TUBERCULOSIS, V84, P228, DOI 10.1016/j.tube.2003.12.010; Huang B, 2005, J BACTERIOL, V187, P3201, DOI 10.1128/JB.187.9.3201-3205.2005; Hwang CC, 1996, BIOCHEMISTRY-US, V35, P6358, DOI 10.1021/bi9602472; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Karsten WE, 2002, METHOD ENZYMOL, V354, P223; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LU ZC, 1993, J BIOL CHEM, V268, P8727; Maier THP, 2003, NAT BIOTECHNOL, V21, P422, DOI 10.1038/nbt807; Manganelli R, 2002, MOL MICROBIOL, V45, P365, DOI 10.1046/j.1365-2958.2002.03005.x; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Mino K, 2000, BIOSCI BIOTECH BIOCH, V64, P1874, DOI 10.1271/bbb.64.1874; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAMURA T, 1984, J BACTERIOL, V158, P1122, DOI 10.1128/JB.158.3.1122-1127.1984; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Pinto R, 2004, MICROBIOL-SGM, V150, P1681, DOI 10.1099/mic.0.26894-0; Rabeh WM, 2005, BIOCHEMISTRY-US, V44, P5541, DOI 10.1021/bi047479i; Rabeh WM, 2004, J BIOL CHEM, V279, P26803, DOI 10.1074/jbc.R400001200; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rege VD, 1996, BIOCHEMISTRY-US, V35, P13485, DOI 10.1021/bi961517j; Rhee KY, 2005, P NATL ACAD SCI USA, V102, P467, DOI 10.1073/pnas.0406133102; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; TAI CH, 1995, BIOCHEMISTRY-US, V34, P12311, DOI 10.1021/bi00038a027; Tai CH, 2001, ACCOUNTS CHEM RES, V34, P49, DOI 10.1021/ar990169l; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139; Wooff E, 2002, MOL MICROBIOL, V43, P653, DOI 10.1046/j.1365-2958.2002.02771.x	45	76	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23473	23481		10.1074/jbc.M703518200	http://dx.doi.org/10.1074/jbc.M703518200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17567578	hybrid, Green Submitted			2022-12-25	WOS:000248577500048
J	Panis, G; Mejean, V; Ansaldi, M				Panis, Gael; Mejean, Vincent; Ansaldi, Mireille			Control and regulation of KplE1 prophage site-specific recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; LAMBDA-INTEGRASE; BACTERIOPHAGE-LAMBDA; SHIGELLA-FLEXNERI; TEMPERATE BACTERIOPHAGE; NUCLEOTIDE-SEQUENCE; BINDING-SITES; DNA COMPLEX; C-TERMINUS; INT GENE	KplE1 is one of the 10 prophage regions of Escherichia coli K12, located at 2464 kb on the chromosome. KplE1 is defective for lysis, but it is fully competent for excisive recombination. In this study, we have mapped the binding sites of the recombination proteins, namely IntS, TorI, and IHF on attL and attR, and the organization of these sites suggests that the intasome is architecturally different from the lambda canonical form. We also measured the relative contribution of these proteins to both excisive and integrative recombination by using a quantitative in vitro assay. These experiments show a requirement of the TorI excisionase for excisive recombination and of the IntS integrase for both integration and excision. Moreover, we observed a strong influence of the supercoiled state of the substrates. The KplE1 recombination module, composed of the integrase and excisionase genes together with the attL and attR DNA regions, is highly similar to that of several phages infecting various E. coli strains as well as Shigella flexneri and Shigella sonnei. The in vitro recombination data reveal that HK620 and KplE1 att sequences are exchangeable. This study thus defines a new site-specific recombination module, and implications for the mechanism and regulation of recombination are discussed.	CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Ansaldi, M (corresponding author), CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	ansaldi@ibsm.cnrs-mrs.fr		ANSALDI, Mireille/0000-0002-2878-0702; Mejean, Vincent/0000-0001-6533-5846				Abbani MA, 2007, P NATL ACAD SCI USA, V104, P2109, DOI 10.1073/pnas.0607820104; ABREMSKI K, 1982, J BIOL CHEM, V257, P9658; Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; Allison GE, 2002, J BACTERIOL, V184, P1974, DOI 10.1128/JB.184.7.1974-1987.2002; Ansaldi M, 2004, P NATL ACAD SCI USA, V101, P9423, DOI 10.1073/pnas.0401927101; Ansaldi M, 2000, J BACTERIOL, V182, P961, DOI 10.1128/JB.182.4.961-966.2000; Biswas T, 2005, NATURE, V435, P1059, DOI 10.1038/nature03657; Brussow H, 2004, MICROBIOL MOL BIOL R, V68, P560, DOI 10.1128/MMBR.68.3.560-602.2004; Calendar R., 2006, BACTERIOPHAGES; CAMPBELL A, 1992, GENETICA, V86, P259, DOI 10.1007/BF00133724; Campbell A. M., 1996, ESCHERICHIA COLI SAL, P2041; Canchaya C, 2003, CURR OPIN MICROBIOL, V6, P417, DOI 10.1016/S1369-5274(03)00086-9; Casjens S, 2004, J MOL BIOL, V339, P379, DOI 10.1016/j.jmb.2004.03.068; Casjens S, 2003, MOL MICROBIOL, V49, P277, DOI 10.1046/j.1365-2958.2003.03580.x; Casjens SR, 2005, CURR OPIN MICROBIOL, V8, P451, DOI 10.1016/j.mib.2005.06.014; Clark AJ, 2001, J MOL BIOL, V311, P657, DOI 10.1006/jmbi.2001.4868; Court DL, 2007, J BACTERIOL, V189, P298, DOI 10.1128/JB.01215-06; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dhillon TS, 1998, FEMS MICROBIOL LETT, V161, P129, DOI 10.1111/j.1574-6968.1998.tb12938.x; Dorgai L, 1998, J MOL BIOL, V277, P1059, DOI 10.1006/jmbi.1998.1642; ElAntak L, 2005, J BIOL CHEM, V280, P36802, DOI 10.1074/jbc.M507409200; Ellenberger T, 1997, STRUCTURE, V5, P153, DOI 10.1016/S0969-2126(97)00174-3; ERASO JM, 1992, J BACTERIOL, V174, P5101, DOI 10.1128/JB.174.15.5101-5109.1992; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GUARNEROS G, 1982, P NATL ACAD SCI-BIOL, V79, P238, DOI 10.1073/pnas.79.2.238; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Huan PT, 1997, GENE, V195, P207, DOI 10.1016/S0378-1119(97)00144-3; Kazmierczak RA, 2002, NUCLEIC ACIDS RES, V30, P5193, DOI 10.1093/nar/gkf652; KITTS PA, 1988, NUCLEIC ACIDS RES, V16, P6839, DOI 10.1093/nar/16.14.6839; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lewis JA, 2001, NUCLEIC ACIDS RES, V29, P2205, DOI 10.1093/nar/29.11.2205; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MILLER HI, 1979, COLD SPRING HARB SYM, V43, P1121, DOI 10.1101/SQB.1979.043.01.125; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; Moreau PL, 2007, J BACTERIOL, V189, P2249, DOI 10.1128/JB.01306-06; Mumm JP, 2006, EMBO J, V25, P4586, DOI 10.1038/sj.emboj.7601325; Murtin C, 1998, J MOL BIOL, V284, P949, DOI 10.1006/jmbi.1998.2256; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NASH HA, 1981, J BIOL CHEM, V256, P9246; NUMRYCH TE, 1992, EMBO J, V11, P3797, DOI 10.1002/j.1460-2075.1992.tb05465.x; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; Oppenheim AB, 2005, ANNU REV GENET, V39, P409, DOI 10.1146/annurev.genet.39.073003.113656; Piazzolla D, 2006, J GEN VIROL, V87, P2423, DOI 10.1099/vir.0.81875-0; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Rudd KE, 1999, RES MICROBIOL, V150, P653, DOI 10.1016/S0923-2508(99)00126-6; SCHINDLER D, 1981, P NATL ACAD SCI-BIOL, V78, P4475, DOI 10.1073/pnas.78.7.4475; SMITHMUNGO L, 1994, J BIOL CHEM, V269, P20798; Stummeyer K, 2006, MOL MICROBIOL, V60, P1123, DOI 10.1111/j.1365-2958.2006.05173.x; Sun XM, 2006, MOL CELL, V24, P569, DOI 10.1016/j.molcel.2006.10.006; Swalla BM, 2003, MOL MICROBIOL, V50, P89, DOI 10.1046/j.1365-2958.2003.03687.x; Swalla BM, 2003, NUCLEIC ACIDS RES, V31, P805, DOI 10.1093/nar/gkg142; Tirumalai RS, 1998, J MOL BIOL, V279, P513, DOI 10.1006/jmbi.1998.1786; Wojciak JM, 2002, P NATL ACAD SCI USA, V99, P3434, DOI 10.1073/pnas.052017999	53	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21798	21809		10.1074/jbc.M701827200	http://dx.doi.org/10.1074/jbc.M701827200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545146	hybrid			2022-12-25	WOS:000248196800027
J	Schnitger, AKD; Kafatos, FC; Osta, MA				Schnitger, Anna K. D.; Kafatos, Fotis C.; Osta, Mike A.			The melanization reaction is not required for survival of Anopheles gambiae mosquitoes after bacterial infections	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLOTRICHIA-DIOMPHALIA LARVAE; PROPHENOLOXIDASE ACTIVATION; SERINE-PROTEASE; AEDES-AEGYPTI; PLASMODIUM; HEMOCYTES; DROSOPHILA; IMMUNITY; SYSTEM; GENES	The melanization reaction of insects requires activation of pro-phenoloxidase by a proteolytic cascade leading to melanin production. Studies in adult mosquitoes have shown that bacteria are efficiently melanized in the hemocoel, but the contribution of melanization to survival after bacterial infections has not been established. Here we show that the Anopheles gambiae noncatalytic serine protease CLIPA8, an essential factor for Plasmodium ookinete melanization, is also required for melanization of bacteria in adult mosquitoes. CLIPA8 silencing by RNA interference inhibits pro-phenoloxidase activation and melanization of bacteria in the hemolymph following microbial challenge. However, CLIPA8 is not required for wound melanization nor for melanotic pseudotumor formation in serpin2 knockdown mosquitoes, suggesting a specific role for pathogen melanization. Surprisingly, CLIPA8 knockdown mosquitoes are as resistant to bacterial challenge as controls, indicating that melanization is not essential for defense against bacteria and questions its precise role in mosquito immunity.	Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, London SW7 2AZ, England	Imperial College London	Osta, MA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Exhibit Rd, London SW7 2AZ, England.	m.osta@imperial.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Blandin S, 2004, CELL, V116, P661, DOI 10.1016/S0092-8674(04)00173-4; Blandin S, 2002, EMBO REP, V3, P852, DOI 10.1093/embo-reports/kvf180; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Danielli A, 2000, P NATL ACAD SCI USA, V97, P7136, DOI 10.1073/pnas.97.13.7136; De Masi F, 2005, PROTEOMICS, V5, P4070, DOI 10.1002/pmic.200401279; Hernandez-Martinez S, 2002, J MED ENTOMOL, V39, P61, DOI 10.1603/0022-2585-39.1.61; Hillyer JF, 2004, MICROBES INFECT, V6, P448, DOI 10.1016/j.micinf.2004.01.005; Hillyer JF, 2003, J PARASITOL, V89, P62, DOI 10.1645/0022-3395(2003)089[0062:RPAMOB]2.0.CO;2; Jiravanichpaisal P, 2006, IMMUNOBIOLOGY, V211, P213, DOI 10.1016/j.imbio.2005.10.015; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Leclerc V, 2006, EMBO REP, V7, P231, DOI 10.1038/sj.embor.7400592; Meister S, 2005, P NATL ACAD SCI USA, V102, P11420, DOI 10.1073/pnas.0504950102; Michel K, 2005, EMBO REP, V6, P891, DOI 10.1038/sj.embor.7400478; Michel K, 2006, P NATL ACAD SCI USA, V103, P16858, DOI 10.1073/pnas.0608033103; Niare O, 2002, SCIENCE, V298, P213, DOI 10.1126/science.1073420; Osta MA, 2004, SCIENCE, V303, P2030, DOI 10.1126/science.1091789; Piao S, 2005, EMBO J, V24, P4404, DOI 10.1038/sj.emboj.7600891; Schrodel A, 2005, J BIOTECHNOL, V120, P2, DOI 10.1016/j.jbiotec.2005.04.028; Tang HP, 2006, J BIOL CHEM, V281, P28097, DOI 10.1074/jbc.M601642200; Volz J, 2005, J BIOL CHEM, V280, P40161, DOI 10.1074/jbc.M506191200; Volz J, 2006, CELL MICROBIOL, V8, P1392, DOI 10.1111/j.1462-5822.2006.00718.x; Yu XQ, 2003, INSECT BIOCHEM MOLEC, V33, P197, DOI 10.1016/S0965-1748(02)00191-1	25	69	75	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21884	21888		10.1074/jbc.M701635200	http://dx.doi.org/10.1074/jbc.M701635200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17537726	hybrid			2022-12-25	WOS:000248196800036
J	Sekulic, N; Konrad, M; Lavie, A				Sekulic, Nikolina; Konrad, Manfred; Lavie, Arnon			Structural mechanism for substrate inhibition of the adenosine 5 '-phosphosulfate kinase domain of human 3 '-phosphoadenosine 5 '-phosphosulfate synthetase 1 and its ramifications for enzyme regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPS SYNTHETASE-1; PENICILLIUM-CHRYSOGENUM; CRYSTAL-STRUCTURE; KINETIC MECHANISM; APS-KINASE; PURIFICATION; SYNTHASE; CONFORMATION; SULFURYLASE; MOUSE	In mammals, the universal sulfuryl group donor molecule 3'-phosphoadenosine 5'-phosphosulfate (PAPS) is synthesized in two steps by a bifunctional enzyme called PAPS synthetase. The APS kinase domain of PAPS synthetase catalyzes the second step in which APS, the product of the ATP-sulfurylase domain, is phosphorylated on its 3'-hydroxyl group to yield PAPS. The substrate APS acts as a strong uncompetitive inhibitor of the APS kinase reaction. We generated truncated and point mutants of the APS kinase domain that are active but devoid of substrate inhibition. Structural analysis of these mutant enzymes reveals the intrasubunit rearrangements that occur upon substrate binding. We also observe intersubunit rearrangements in this dimeric enzyme that result in asymmetry between the two monomers. Our work elucidates the structural elements required for the ability of the substrate APS to inhibit the reaction at micromolar concentrations. Because the ATP-sulfurylase domain of PAPS synthetase influences these elements in the APS kinase domain, we propose that this could be a communication mechanism between the two domains of the bifunctional enzyme.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Max Planck Society	Lavie, A (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave,MBRB Room 1108, Chicago, IL 60607 USA.	lavie@uic.edu	Lavie, Arnon/H-4927-2012; Sekulic, Nikolina/N-5550-2016; Sekulic, Nikolina/F-8911-2013	Sekulic, Nikolina/0000-0001-7555-3222; Lavie, Arnon/0000-0001-5591-8722	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046943] Funding Source: NIH RePORTER; NIAID NIH HHS [AI046943] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beynon JD, 2001, BIOCHEMISTRY-US, V40, P14509, DOI 10.1021/bi015643l; Brundiers R, 1999, J BIOL CHEM, V274, P35289, DOI 10.1074/jbc.274.50.35289; Colletier JP, 2006, EMBO J, V25, P2746, DOI 10.1038/sj.emboj.7601175; Harjes S, 2005, J MOL BIOL, V347, P623, DOI 10.1016/j.jmb.2005.01.005; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HOMMES FA, 1987, BIOCHIM BIOPHYS ACTA, V924, P270, DOI 10.1016/0304-4165(87)90022-5; KABASH W, 1993, J APPL CRYSTALLOGR, V26, P795; Klaassen CD, 1997, FASEB J, V11, P404, DOI 10.1096/fasebj.11.6.9194521; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; Lansdon EB, 2004, BIOCHEMISTRY-US, V43, P4356, DOI 10.1021/bi049827m; Lansdon EB, 2002, BIOCHEMISTRY-US, V41, P13672, DOI 10.1021/bi026556b; LiCata VJ, 1997, BIOPHYS CHEM, V64, P225, DOI 10.1016/S0301-4622(96)02204-1; Lillig CH, 2001, ARCH BIOCHEM BIOPHYS, V392, P303, DOI 10.1006/abbi.2001.2453; LYLE S, 1994, BIOCHEM J, V301, P355, DOI 10.1042/bj3010355; MacRae IJ, 2000, BIOCHEMISTRY-US, V39, P1613, DOI 10.1021/bi9924157; MacRae IJ, 1999, ARCH BIOCHEM BIOPHYS, V361, P277, DOI 10.1006/abbi.1998.0993; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; SATISHCHANDRAN C, 1989, J BIOL CHEM, V264, P15012; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; Segura-Pena D, 2004, J BIOL CHEM, V279, P33882, DOI 10.1074/jbc.M401989200; Sekulic N, 2002, J BIOL CHEM, V277, P30236, DOI 10.1074/jbc.M204668200; Sekulic N, 2007, J MOL BIOL, V367, P488, DOI 10.1016/j.jmb.2007.01.025; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Venkatachalam KV, 1998, J BIOL CHEM, V273, P19311, DOI 10.1074/jbc.273.30.19311; Venkatachalam KV, 2003, IUBMB LIFE, V55, P1, DOI 10.1080/1521654031000072148; Xu HY, 2006, BIOCHEMISTRY-US, V45, P12156, DOI 10.1021/bi0610808	27	15	15	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22112	22121		10.1074/jbc.M701713200	http://dx.doi.org/10.1074/jbc.M701713200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17540769	Green Published, hybrid			2022-12-25	WOS:000248196800058
J	Lyon, RC; Johnston, SM; Watson, DG; McGarvie, G; Ellis, EM				Lyon, Robert C.; Johnston, Stuart M.; Watson, David G.; McGarvie, Gail; Ellis, Elizabeth M.			Synthesis and catabolism of gamma-hydroxybutyrate in SH-SY5Y human neuroblastoma cells - Role of the aldo-keto reductase AKR7A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYACID-OXOACID TRANSHYDROGENASE; SUCCINIC SEMIALDEHYDE REDUCTASE; B-1 ALDEHYDE REDUCTASE; ALCOHOL-DEHYDROGENASE; SEMI-ALDEHYDE; HUMAN-BRAIN; RAT-BRAIN; GAS-CHROMATOGRAPHY; ENERGY-METABOLISM; ACID	gamma-Hydroxybutyrate ( GHB) is an endogenous metabolite synthesized in the brain. There is strong evidence to suggest that GHB has an important role as a neurotransmitter or neuro-modulator. The human aldo-keto reductase AKR7A2 has been proposed previously to catalyze the NADPH-dependent reduction of succinic semialdehyde ( SSA) to GHB in human brain. In this study we have used RNA interference to evaluate the role of AKR7A2 in GHB biosynthesis in human neuroblastoma SH-SY5Y cells. Quantitative reverse transcription-PCR analysis and immunoblotting revealed that short interfering RNA molecules directed against AKR7A2 led to a significant reduction in both AKR7A2 transcript and protein levels 72 h post-transfection. We have shown that reduced expression of AKR7A2 results in a 90% decrease in SSA reductase activity of cell extracts. Furthermore, we have shown using gas chromatography-mass spectrometry that a decrease in the level of AKR7A2 was paralleled with a significant reduction in intracellular GHB concentration. This provides conclusive evidence that AKR7A2 is the major SSA reductase in these cells. In contrast, short interfering RNA-dependent reduction in AKR7A2 levels had no effect on the GHB dehydrogenase activity of the extracts, and inhibitor studies suggest that another enzyme characteristic of an NAD-dependent alcohol dehydrogenase may be responsible for catalyzing this reverse reaction. Together these findings delineate pathways for GHB metabolism in the brain and will enable a better understanding of the relationship between GHB biosynthesis and catabolism in disease states and in drug overdose.	Univ Strathclyde, Stratclyde Inst Pharm & Biomed Sci, Glasgow G1 1XW, Lanark, Scotland; Bell Coll, Sch Sci & Technol, Hamilton ML3 0JB, Scotland	University of Strathclyde; University of West Scotland	Ellis, EM (corresponding author), Univ Strathclyde, Stratclyde Inst Pharm & Biomed Sci, 204 George St, Glasgow G1 1XW, Lanark, Scotland.	elizabeth.ellis@strath.ac.uk						BARKER SA, 1985, BIOCHEM PHARMACOL, V34, P1849, DOI 10.1016/0006-2952(85)90662-8; BARSKI OA, 1995, BIOCHEMISTRY-US, V34, P11264, DOI 10.1021/bi00035a036; BESSMAN SP, 1963, NATURE, V200, P1207, DOI 10.1038/2001207a0; Bhattacharya I, 2004, J PHARMACOL EXP THER, V311, P92, DOI 10.1124/jpet.104.069682; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buzzi A, 2006, BRAIN RES, V1090, P15, DOI 10.1016/j.brainres.2006.02.131; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; CASH CD, 1979, J NEUROCHEM, V33, P1169, DOI 10.1111/j.1471-4159.1979.tb05261.x; Crichton PG, 2007, BIOCHEM J, V401, P459, DOI 10.1042/BJ20061181; CROMLISH JA, 1985, J NEUROCHEM, V44, P1485, DOI 10.1111/j.1471-4159.1985.tb08786.x; Deng YF, 2002, DNA SEQUENCE, V13, P301, DOI 10.1080/1042517021000011636; DOHERTY JD, 1975, ANAL BIOCHEM, V69, P268, DOI 10.1016/0003-2697(75)90586-2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gervasi N, 2003, J NEUROSCI, V23, P11469; Gibson KM, 1998, NEUROPEDIATRICS, V29, P14, DOI 10.1055/s-2007-973527; GOLD BI, 1977, J NEUROCHEM, V28, P1069, DOI 10.1111/j.1471-4159.1977.tb10670.x; HOFFMAN PL, 1980, J NEUROCHEM, V35, P354, DOI 10.1111/j.1471-4159.1980.tb06272.x; Ireland LS, 1998, BIOCHEM J, V332, P21, DOI 10.1042/bj3320021; Kardon T, 2006, FEBS LETT, V580, P2347, DOI 10.1016/j.febslet.2006.02.082; KAUFMAN EE, 1988, J BIOL CHEM, V263, P16872; KAUFMAN EE, 1983, J NEUROCHEM, V40, P1639, DOI 10.1111/j.1471-4159.1983.tb08137.x; KAUFMAN EE, 1979, J NEUROCHEM, V32, P699, DOI 10.1111/j.1471-4159.1979.tb04552.x; Kleinschmidt S, 1999, EUR J ANAESTH, V16, P23, DOI 10.1046/j.1365-2346.1999.00393.x; Kuhla B, 2006, J NEUROSCI RES, V83, P1591, DOI 10.1002/jnr.20838; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li D, 2006, TOXICOLOGY, V226, P172, DOI 10.1016/j.tox.2006.06.013; MAMELAK M, 1989, NEUROSCI BIOBEHAV R, V13, P187, DOI 10.1016/S0149-7634(89)80053-3; Mamelak M, 2007, NEUROBIOL AGING, V28, P1340, DOI 10.1016/j.neurobiolaging.2006.06.008; Montella C, 2005, J BACTERIOL, V187, P4957, DOI 10.1128/JB.187.14.4957-4966.2005; Muller C, 2002, J NEUROCHEM, V80, P899, DOI 10.1046/j.0022-3042.2002.00780.x; NELSON T, 1981, J NEUROCHEM, V37, P1345, DOI 10.1111/j.1471-4159.1981.tb04689.x; Nicholson KL, 2001, DRUG ALCOHOL DEPEN, V63, P1, DOI 10.1016/S0376-8716(00)00191-5; O'Connor T, 1999, BIOCHEM J, V343, P487, DOI 10.1042/0264-6021:3430487; PARK J, 1993, J BIOL CHEM, V268, P7636; Picklo MJ, 2001, BRAIN RES, V916, P229, DOI 10.1016/S0006-8993(01)02897-9; ROTH R. H., 1966, INT J NEUROPHARMACOL, V5, P421; ROTH RH, 1970, BIOCHEM PHARMACOL, V19, P1087, DOI 10.1016/0006-2952(70)90370-9; ROTH RH, 1968, BIOCHEM PHARMACOL, V17, P735, DOI 10.1016/0006-2952(68)90010-5; Schaller M, 1999, EUR J BIOCHEM, V265, P1056, DOI 10.1046/j.1432-1327.1999.00826.x; Short DM, 2006, TOXICOL APPL PHARM, V210, P163, DOI 10.1016/j.taap.2005.09.017; Snead OC, 2000, J NEUROCHEM, V75, P1986, DOI 10.1046/j.1471-4159.2000.0751986.x; Sohling B, 1996, J BACTERIOL, V178, P871; Struys EA, 2006, METABOLISM, V55, P353, DOI 10.1016/j.metabol.2005.09.009; Struys EA, 2005, J INHERIT METAB DIS, V28, P921, DOI 10.1007/s10545-005-0114-x; TABAKOFF B, 1975, BIOCHEM BIOPH RES CO, V63, P957, DOI 10.1016/0006-291X(75)90662-2; Tunnicliff Godfrey, 2002, Curr Opin Investig Drugs, V3, P278; VAYER P, 1985, FEBS LETT, V190, P55, DOI 10.1016/0014-5793(85)80426-9; Villain M, 2003, J CHROMATOGR B, V792, P83, DOI 10.1016/S1570-0232(03)00307-6; WALKENSTEIN SS, 1964, BIOCHIM BIOPHYS ACTA, V86, P640, DOI 10.1016/0304-4165(64)90107-2	50	26	31	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					25986	25992		10.1074/jbc.M702465200	http://dx.doi.org/10.1074/jbc.M702465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17591773	hybrid			2022-12-25	WOS:000249239600002
J	Malecova, B; Gross, P; Boyer-Guittaut, M; Yavuz, S; Oelgeschlager, T				Malecova, Barbora; Gross, Petra; Boyer-Guittaut, Michael; Yavuz, Sevil; Oelgeschlaeger, Thomas			The initiator core promoter element antagonizes repression of TATA-directed transcription by negative cofactor NC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BINDING PROTEIN; BASAL TRANSCRIPTION; GENE; TFIIA; MECHANISM; BOX; REQUIREMENT; ACTIVATION; COMPLEXES	Core promoter regions of protein-coding genes in metazoan genomes are structurally highly diverse and can contain several distinct core promoter elements, which direct accurate transcription initiation and determine basal promoter strength. Diversity in core promoter structure is an important aspect of transcription regulation in metazoans as it provides a basis for gene-selective function of activators and repressors. The basal activity of TATA box-containing promoters is dramatically enhanced by the initiator element (INR), which can function in concert with the TATA box in a synergistic manner. Here we report that a functional INR provides resistance to NC2 (Dr1/DRAP1), a general repressor of TATA promoters. INR-mediated resistance to NC2 is established during transcription initiation complex assembly and requires TBP-associated factors (TAFs) and TAF-and INR-dependent cofactor activity. Remarkably, the INR appears to stimulate TATA-dependent transcription similar to activators by strongly enhancing recruitment of TFIIA and TFIIB and, at the same time, by compromising NC2 binding.	Marie Curie Res Inst, Transcript Lab, Surrey RH8 0TL, England		Oelgeschlager, T (corresponding author), Marie Curie Res Inst, Transcript Lab, Chart Oxted, Surrey RH8 0TL, England.	t.oelgeschlager@mcri.ac.uk	Guittaut, Michael/ABE-4274-2021	Guittaut, Michael/0000-0001-9540-5593; Oelgeschlager, Thomas/0000-0002-4086-719X; Malecova, Barbora/0000-0001-5334-3195				Bajic Vladimir B., 2004, In Silico Biology, V4, P109; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; Caswell R, 1996, J VIROL, V70, P4028, DOI 10.1128/JVI.70.6.4028-4037.1996; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; Deng WS, 2005, GENE DEV, V19, P2418, DOI 10.1101/gad.342405; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRABENT B, 1986, NUCLEIC ACIDS RES, V14, P8933, DOI 10.1093/nar/14.22.8933; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; Evans R, 2001, GENE DEV, V15, P2945, DOI 10.1101/gad.206901; Gadbois EL, 1997, P NATL ACAD SCI USA, V94, P3145, DOI 10.1073/pnas.94.7.3145; Gershenzon NI, 2005, BIOINFORMATICS, V21, P1295, DOI 10.1093/bioinformatics/bti172; Gilfillan S, 2005, J BIOL CHEM, V280, P6222, DOI 10.1074/jbc.M406343200; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Goppelt A, 1996, NUCLEIC ACIDS RES, V24, P4450, DOI 10.1093/nar/24.22.4450; Gross P, 2006, BIOCHEM SOC SYMP, V73, P225; Guermah M, 2001, MOL CELL BIOL, V21, P6882, DOI 10.1128/MCB.21.20.6882-6894.2001; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; INOSTROZA JA, 1992, CELL, V70, P477; Johnson KM, 2002, GENE DEV, V16, P1852, DOI 10.1101/gad.995702; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Kim J, 1996, J BIOL CHEM, V271, P18405, DOI 10.1074/jbc.271.31.18405; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Ohler U, 2002, GENOME BIOL, V3, DOI [10.1186/gb-2002-3-12-research0087, DOI 10.1186/GB-2002-3-12-RESEARCH0087]; Ohtsuki S, 1998, GENE DEV, V12, P547, DOI 10.1101/gad.12.4.547; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Suzuki Y, 2001, GENOME RES, V11, P677, DOI 10.1101/gr.GR-1640R; Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; Xie J, 2000, EMBO J, V19, P672, DOI 10.1093/emboj/19.4.672; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	61	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24767	24776		10.1074/jbc.M702776200	http://dx.doi.org/10.1074/jbc.M702776200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17584739	hybrid			2022-12-25	WOS:000248933000032
J	Einholm, AP; Andersen, JP; Vilsen, B				Einholm, Anja Pernille; Andersen, Jens Peter; Vilsen, Bente			Importance of Leu(99) in transmembrane segment M1 of the Na+, K+-ATPase in the binding and occlusion of K+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; NA,K-ATPASE ALPHA-SUBUNIT; CALCIUM-PUMP; SARCOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; CATION-BINDING; CONFORMATIONAL-CHANGES; POTASSIUM-IONS; SODIUM-PUMP; PHOSPHOENZYME INTERMEDIATE	Twenty-six point mutations were introduced into the N-terminal and middle parts of transmembrane segment M1 of the Na+, K+-ATPase and its cytosolic extension. None of the alterations to charged and polar residues in the N-terminal part of M1 and its cytosolic extension had any major effect on the cation binding properties, thus rejecting the hypothesis that these residues are involved in cation selectivity. By contrast, specific residues in the middle part of M1, particularly Leu(99), were found critical to K+ interaction of the enzyme. Hence, mutation L99A reduced the affinity for K+ activation of E2P dephosphorylation 17-fold, and L99F reduced the equilibrium level of the K+-oc-cluded intermediate [K-2]E-2 and increased the rate of K+ deocclusion 39-fold, i.e. more than seen for mutation E329Q of the cation-binding glutamate in M4. L99Q affected K+ interaction in yet another way, the equilibrium level of [K-2]E-2 being slightly increased despite an increased rate of K+ deocclusion, suggesting that the K+ ions leave and enter the occlusion pocket more frequently than in the wild type. L99Q furthermore affected the ability to discriminate between Na+ and K+ on the extracellular side. Our findings can be explained by a structural model in which Leu99 and Glu(329) interact and cooperate in K+ binding and gating of the K+ sites. The disturbance of K+ interaction in mutants with alteration to Leu(91), Phe(95), Ser(96), or Leu(98) could be a consequence of the roles of these residues in positioning the M1 helix optimally for the interaction between Leu99 and Glu329. Phe95 may serve to stabilize the pivot for movement of M1 through interaction with Ile(287) in M3.	Univ Aarhus, Inst Physiol & Biophys, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Vilsen, B (corresponding author), Univ Aarhus, Inst Physiol & Biophys, Dept Physiol, 1160 Ole Worms Alle, DK-8000 Aarhus C, Denmark.	bv@fi.au.dk		Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; Einholm AP, 2005, P NATL ACAD SCI USA, V102, P11254, DOI 10.1073/pnas.0501201102; Einholm AP, 2004, J BIOL CHEM, V279, P15888, DOI 10.1074/jbc.M400158200; EISNER DA, 1981, J PHYSIOL-LONDON, V319, P403, DOI 10.1113/jphysiol.1981.sp013917; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; Forbush B 3rd, 1988, Prog Clin Biol Res, V268A, P229; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Gropp T, 1998, BBA-BIOMEMBRANES, V1368, P184, DOI 10.1016/S0005-2736(97)00162-4; HANSEN O, 1984, PHARMACOL REV, V36, P143; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Imagawa T, 2005, J BIOL CHEM, V280, P18736, DOI 10.1074/jbc.M500137200; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; Li CM, 2005, P NATL ACAD SCI USA, V102, P12706, DOI 10.1073/pnas.0505980102; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; Lipkind GM, 2001, BIOCHEMISTRY-US, V40, P6786, DOI 10.1021/bi010269a; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; POST RL, 1965, J BIOL CHEM, V240, P1437; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; POST RL, 1972, J BIOL CHEM, V247, P6530; Schneeberger A, 1999, J MEMBRANE BIOL, V168, P221, DOI 10.1007/s002329900511; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toustrup-Jensen M, 2002, J BIOL CHEM, V277, P38607, DOI 10.1074/jbc.M203665200; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; VILSEN B, 1995, ACTA PHYSIOL SCAND, V154, P1; WALL SM, 1994, AM J PHYSIOL-RENAL, V267, pF660, DOI 10.1152/ajprenal.1994.267.4.F660	50	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23854	23866		10.1074/jbc.M702259200	http://dx.doi.org/10.1074/jbc.M702259200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17553789	hybrid			2022-12-25	WOS:000248686600013
J	Li, YF; Poole, S; Rasulova, F; McVeigh, AL; Savarino, SJ; Xia, D				Li, Yong-Fu; Poole, Steven; Rasulova, Fatima; McVeigh, Annette L.; Savarino, Stephen J.; Xia, Di			Receptor-binding site as revealed by the crystal structure of CfaE, the colonization factor antigen I fimbrial adhesin of enterotoxigenic Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIMH ADHESIN; CS1 PILI; ERYTHROCYTE RECEPTOR; DEVELOPING-COUNTRIES; PROTEIN STRUCTURES; DIARRHEA; CHILDREN; ARCHITECTURE; BIOGENESIS; RESOLUTION	CfaE is the minor, tip-localized adhesive subunit of colonization factor antigen I fimbriae (CFA/I) of enterotoxigenic Escherichia coli and is thought to be essential for the attachment of enterotoxigenic E. coli to the human small intestine early in diarrhea pathogenesis. The crystal structure of an in cis donor strand complemented CfaE was determined, providing the first atomic view of a fimbrial subunit assembled by the alternate chaperone pathway. The in cis donor strand complemented variant of CfaE structure consists of an N-terminal adhesin domain and a C-terminal pilin domain of similar size, each featuring a variable immunoglobulin-like fold. Extensive interactions exist between the two domains and appear to rigidify the molecule. The upper surface of the adhesin domain distal to the pilin domain reveals a depression consisting of conserved residues including Arg(181), previously shown to be necessary for erythrocyte adhesion. Mutational analysis revealed a cluster of conserved, positively charged residues that are required for CFA/I-mediated hemagglutination, implicating this as the receptor-binding pocket. Mutations in a few subclass-specific residues that surround the cluster displayed differential effects on the two red cell species used in hemagglutination, suggesting that these residues play a role in host or cell specificity. The C-terminal donor strand derived from the major subunit CfaB is folded as a beta-strand and fits into a hydrophobic groove in the pilin domain to complete the immunoglobulin fold. The location of this well ordered donor strand suggests the positioning and orientation of the subjacent major fimbrial subunit CfaB in the native assembly of CFA/I fimbriae.	USN, Med Res Ctr, Enter DIs Dept, Infect Dis Directorate, Silver Spring, MD 20910 USA; NCI, Ctr Canc Res, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA	United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA	Savarino, SJ (corresponding author), USN, Med Res Ctr, Enter DIs Dept, Infect Dis Directorate, 503 Robert Grant Ave,Silver Spring, Silver Spring, MD 20910 USA.	savarinos@nmrc.navy.mil; dixia@helix.nih.gov	Savarino, Stephen/A-8030-2011		Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Anantha RP, 2004, INFECT IMMUN, V72, P7190, DOI 10.1128/IAI.72.12.7190-7201.2004; Anderson KL, 2004, MOL CELL, V15, P647, DOI 10.1016/j.molcel.2004.08.003; BARTUS H, 1985, J CLIN MICROBIOL, V21, P951, DOI 10.1128/JCM.21.6.951-954.1985; BINSZTEIN N, 1991, J CLIN MICROBIOL, V29, P1893, DOI 10.1128/JCM.29.9.1893-1898.1991; BLACK RE, 1981, LANCET, V1, P141; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Bouckaert J, 2005, MOL MICROBIOL, V55, P441, DOI 10.1111/j.1365-2958.2004.04415.x; BUHLER T, 1991, INFECT IMMUN, V59, P3876; CHENEY CP, 1983, INFECT IMMUN, V39, P1280, DOI 10.1128/IAI.39.3.1280-1284.1983; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; DARFEUILLE-MICHAUD A, 1990, INFECT IMMUN, V58, P893, DOI 10.1128/IAI.58.4.893-902.1990; Dodson KW, 2001, CELL, V105, P733, DOI 10.1016/S0092-8674(01)00388-9; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; EVANS DG, 1979, INFECT IMMUN, V25, P738, DOI 10.1128/IAI.25.2.738-748.1979; EVANS DJ, 1979, INFECT IMMUN, V23, P336, DOI 10.1128/IAI.23.2.336-346.1979; FROEHLICH BJ, 1994, MOL MICROBIOL, V12, P387, DOI 10.1111/j.1365-2958.1994.tb01028.x; Gaastra W, 2002, INT J MED MICROBIOL, V292, P43, DOI 10.1078/1438-4221-00189; HIBBERD ML, 1991, J GEN MICROBIOL, V137, P1963, DOI 10.1099/00221287-137-8-1963; HUILAN S, 1991, B WORLD HEALTH ORGAN, V69, P549; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; Jedrzejczak R, 2006, ACTA CRYSTALLOGR D, V62, P157, DOI 10.1107/S0907444905036747; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jonson Ann-Beth, 2005, V12, P67, DOI 10.1159/000081690; Knudsen TB, 1998, MICROBIOL-SGM, V144, P1919, DOI 10.1099/00221287-144-7-1919; KNUTTON S, 1984, INFECT IMMUN, V44, P514, DOI 10.1128/IAI.44.2.514-518.1984; KNUTTON S, 1985, INFECT IMMUN, V48, P824, DOI 10.1128/IAI.48.3.824-831.1985; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; LABIGNEROUSSEL A, 1988, J BACTERIOL, V170, P1704, DOI 10.1128/jb.170.4.1704-1708.1988; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Li YF, 2006, ACTA CRYSTALLOGR F, V62, P121, DOI 10.1107/S1744309105043198; LOW D, 1998, ESCHERICHIA COLI SAL, P146; MARRON MB, 1995, MICROBIOL-SGM, V141, P2849, DOI 10.1099/13500872-141-11-2849; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; Merckel MC, 2003, J MOL BIOL, V331, P897, DOI 10.1016/S0022-2836(03)00841-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy B, 1999, VET RES, V30, P259; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pettigrew D, 2004, J BIOL CHEM, V279, P46851, DOI 10.1074/jbc.M409284200; PIERONI P, 1988, INFECT IMMUN, V56, P1334, DOI 10.1128/IAI.56.5.1334-1340.1988; Poole ST, 2007, MOL MICROBIOL, V63, P1372, DOI 10.1111/j.1365-2958.2007.05612.x; Qadri F, 2005, CLIN MICROBIOL REV, V18, P465, DOI 10.1128/CMR.18.3.465-483.2005; Sakellaris H, 1998, MOL MICROBIOL, V30, P681, DOI 10.1046/j.1365-2958.1998.01088.x; Sakellaris H, 1996, MOL MICROBIOL, V21, P529, DOI 10.1111/j.1365-2958.1996.tb02562.x; Sakellaris H, 1999, P NATL ACAD SCI USA, V96, P12828, DOI 10.1073/pnas.96.22.12828; Sauer FG, 2000, CURR OPIN MICROBIOL, V3, P65, DOI 10.1016/S1369-5274(99)00053-3; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Sommerfelt H, 1996, J INFECT DIS, V174, P768, DOI 10.1093/infdis/174.4.768; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; Starks AM, 2006, J BACTERIOL, V188, P231, DOI 10.1128/JB.188.1.231-239.2006; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Thomas WE, 2002, CELL, V109, P913, DOI 10.1016/S0092-8674(02)00796-1; Westerlund-Wikstrom B, 2005, INT J MED MICROBIOL, V295, P479, DOI 10.1016/j.ijmm.2005.06.010; Wolf MK, 1997, CLIN MICROBIOL REV, V10, P569, DOI 10.1128/CMR.10.4.569; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9	59	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23970	23980		10.1074/jbc.M700921200	http://dx.doi.org/10.1074/jbc.M700921200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17569668	hybrid			2022-12-25	WOS:000248686600023
J	Saini, DK; Kalyanaraman, V; Chisari, M; Gautam, N				Saini, Deepak Kumar; Kalyanaraman, Vani; Chisari, Mariangela; Gautam, Narasimhan			A family of G protein beta gamma subunits translocate reversibly from the plasma membrane to endomembranes on receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; RESONANCE ENERGY-TRANSFER; ENDOPLASMIC-RETICULUM; CONFORMATIONAL SWITCH; MUSCARINIC RECEPTOR; FLUORESCENT PROTEIN; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; DIMER FORMATION; GOLGI-COMPLEX	The present model of G protein activation by G protein- coupled receptors exclusively localizes their activation and function to the plasma membrane ( PM). Observation of the spatiotemporal response of G protein subunits in a living cell to receptor activation showed that 6 of the 12 members of the G protein gamma subunit family translocate specifically from the PM to endomembranes. The gamma subunits translocate as beta gamma complexes, whereas the alpha subunit is retained on the PM. Depending on the gamma subunit, translocation occurs predominantly to the Golgi complex or the endoplasmic reticulum. The rate of translocation also varies with the gamma subunit type. Different gamma subunits, thus, confer distinct spatiotemporal properties to translocation. A striking relationship exists between the amino acid sequences of various gamma subunits and their translocation properties. gamma subunits with similar translocation properties are more closely related to each other. Consistent with this relationship, introducing residues conserved in translocating subunits into a non-translocating subunit results in a gain of function. Inhibitors of vesicle- mediated trafficking and palmitoylation suggest that translocation is diffusion- mediated and controlled by acylation similar to the shuttling of G protein subunits ( Chisari, M., Saini, D. K., Kalyanaraman, V., and Gautam, N. ( 2007) J. Biol. Chem. 282, 24092 - 24098). These results suggest that the continual testing of cytosolic surfaces of cell membranes by G protein subunits facilitates an activated cell surface receptor to direct potentially active G protein beta gamma subunits to intracellular membranes.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.	gautam@wustl.edu			NIGMS NIH HHS [R01 GM069027, R01 GM069027-02, GM 69027] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069027] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akgoz M, 2004, J BIOL CHEM, V279, P51541, DOI 10.1074/jbc.M410639200; Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; Akgoz M, 2006, CELL SIGNAL, V18, P1758, DOI 10.1016/j.cellsig.2006.01.016; Azpiazu I, 2004, J BIOL CHEM, V279, P27709, DOI 10.1074/jbc.M403712200; Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Carroll RC, 1998, EMBO J, V17, P3036, DOI 10.1093/emboj/17.11.3036; Chisari M, 2007, J BIOL CHEM, V282, P24092, DOI 10.1074/jbc.M704246200; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dingus J, 2005, BIOCHEMISTRY-US, V44, P11882, DOI 10.1021/bi0504254; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Downes GB, 1999, GENOMICS, V62, P544, DOI 10.1006/geno.1999.5992; Downes GB, 1998, GENOMICS, V53, P220, DOI 10.1006/geno.1998.5508; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; Gautam N, 2003, STRUCTURE, V11, P359, DOI 10.1016/S0969-2126(03)00054-6; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Gibson SK, 2006, P NATL ACAD SCI USA, V103, P212, DOI 10.1073/pnas.0509763102; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Hynes TR, 2004, J BIOL CHEM, V279, P30279, DOI 10.1074/jbc.M401432200; Kassai H, 2005, NEURON, V47, P529, DOI 10.1016/j.neuron.2005.07.025; Kenworthy AK, 2006, METHODS, V40, P198, DOI 10.1016/j.ymeth.2006.06.021; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; Kisselev OG, 2003, STRUCTURE, V11, P367, DOI 10.1016/S0969-2126(03)00045-5; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Le-Niculescu H, 2005, J BIOL CHEM, V280, P22012, DOI 10.1074/jbc.M501833200; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; Lim WK, 2001, BIOCHEMISTRY-US, V40, P10532, DOI 10.1021/bi010950c; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; Luttrell LM, 2005, J MOL NEUROSCI, V26, P253, DOI 10.1385/JMN:26:2-3:253; Luttrell LM, 2003, J MOL ENDOCRINOL, V30, P117, DOI 10.1677/jme.0.0300117; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; McIntire WE, 2001, J BIOL CHEM, V276, P15801, DOI 10.1074/jbc.M011233200; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; Punnonen EL, 1998, EUR J CELL BIOL, V75, P344, DOI 10.1016/S0171-9335(98)80067-8; Resh MD, 2006, METHODS, V40, P191, DOI 10.1016/j.ymeth.2006.04.013; Robishaw JD, 2004, CURR OPIN CELL BIOL, V16, P206, DOI 10.1016/j.ceb.2004.02.007; Sato M, 2006, ANNU REV PHARMACOL, V46, P151, DOI 10.1146/annurev.pharmtox.46.120604.141115; Sbalzarini IF, 2005, BIOPHYS J, V89, P1482, DOI 10.1529/biophysj.104.057885; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Takida S, 2004, FEBS LETT, V567, P209, DOI 10.1016/j.febslet.2004.04.062; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Wang Q, 2001, J BIOL CHEM, V276, P39386, DOI 10.1074/jbc.M104981200; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; Yang WL, 2006, CELL SIGNAL, V18, P194, DOI 10.1016/j.cellsig.2005.04.011; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	65	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24099	24108		10.1074/jbc.M701191200	http://dx.doi.org/10.1074/jbc.M701191200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17581822	Green Accepted, hybrid			2022-12-25	WOS:000248686600036
J	Salvi, M; Battaglia, V; Brunati, AM; La Rocca, N; Tibaldi, E; Pietrangeli, P; Marcocci, L; Mondovi, B; Rossi, CA; Toninello, A				Salvi, Mauro; Battaglia, Valentina; Brunati, Anna Maria; La Rocca, Nicoletta; Tibaldi, Elena; Pietrangeli, Paola; Marcocci, Lucia; Mondovi, Bruno; Rossi, Carlo A.; Toninello, Antonio			Catalase takes part in rat liver mitochondria oxidative stress Defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION INDUCTION; MEMBRANE; PHOSPHORYLATION; GLUTATHIONE; MECHANISMS; NECROSIS; PATHWAY; OXIDASE; INJURY; DAMAGE	Highly purified rat liver mitochondria (RLM) when exposed to tert-butylhydroperoxide undergo matrix swelling, membrane potential collapse, and oxidation of glutathione and pyridine nucleotides, all events attributable to the induction of mitochondrial permeability transition. Instead, RLM, if treated with the same or higher amounts of H2O2 or tyramine, are insensitive or only partially sensitive, respectively, to mitochondrial permeability transition. In addition, the block of respiration by antimycin A added to RLM respiring in state 4 conditions, or the addition of H2O2, results in O-2 generation, which is blocked by the catalase inhibitors aminotriazole or KCN. In this regard, H2O2 decomposition yields molecular oxygen in a 2: 1 stoichiometry, consistent with a catalatic mechanism with a rate constant of 0.0346 s(-1). The rate of H2O2 consumption is not influenced by respiratory substrates, succinate or glutamate-malate, nor by N-ethylmaleimide, suggesting that cytochrome c oxidase and the glutathione-glutathione peroxidase system are not significantly involved in this process. Instead, H2O2 consumption is considerably inhibited by KCN or aminotriazole, indicating activity by a hemoprotein. All these observations are compatible with the presence of endogenous heme-containing catalase with an activity of 825 +/- 15 units, which contributes to mitochondrial protection against endogenous or exogenous H2O2. Mitochondrial catalase in liver most probably represents regulatory control of bioenergetic metabolism, but it may also be proposed for new therapeutic strategies against liver diseases. The constitutive presence of catalase inside mitochondria is demonstrated by several methodological approaches as follows: biochemical fractionating, proteinase K sensitivity, and immunogold electron microscopy on isolated RLM and whole rat liver tissue.	Univ Padua, Dipartimento Chim Biol, CNR, Ist Neurosci, I-35121 Padua, Italy; Univ Padua, Dipartimento Biol, I-35131 Padua, Italy; Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Sapienza University Rome	Toninello, A (corresponding author), Univ Padua, Dipartimento Chim Biol, CNR, Ist Neurosci, Viale G Colombo 3, I-35121 Padua, Italy.	antonio.toninello@unipd.it	Brunati, Anna Maria/I-8136-2018; La Rocca, Nicoletta/AAA-2241-2021	Brunati, Anna Maria/0000-0002-3481-9503; La Rocca, Nicoletta/0000-0003-4866-5952; Salvi, Mauro/0000-0003-3448-6048; Marcocci, Lucia/0000-0003-2301-7166				Afanas'ev IB, 2005, BIOGERONTOLOGY, V6, P283, DOI 10.1007/s10522-005-2626-z; Angelini R, 1996, PLANT SCI, V119, P103, DOI 10.1016/0168-9452(96)04453-6; ARITA Y, 2005, AM J PHYSIOL, V290, pL978; Bai JX, 2001, BIOL SIGNAL RECEPT, V10, P189; Battaglia V, 2005, J BIOL CHEM, V280, P33864, DOI 10.1074/jbc.M502391200; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fiore C, 2004, BBA-BIOENERGETICS, V1658, P195, DOI 10.1016/j.bbabio.2004.05.012; FREEMAN BA, 1982, LAB INVEST, V47, P412; Goossens V, 1999, ANTIOXID REDOX SIGN, V1, P285, DOI 10.1089/ars.1999.1.3-285; GREENFIELD RE, 1954, J BIOL CHEM, V209, P355; HODNICK WF, 1988, BIOCHEM PHARMACOL, V37, P2607, DOI 10.1016/0006-2952(88)90253-5; Jiang XS, 2005, MOL CELL PROTEOMICS, V4, P12, DOI 10.1074/mcp.M400079-MCP200; Joly E, 2005, FEBS LETT, V579, P6581, DOI 10.1016/j.febslet.2005.10.050; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Marcocci L, 2002, J MEMBRANE BIOL, V188, P23, DOI 10.1007/s00232-001-0169-z; MATHAI JC, 1994, J BIOL CHEM, V269, P17784; NEUBERT D, 1962, P NATL ACAD SCI USA, V48, P1651, DOI 10.1073/pnas.48.9.1651; Nicholls P, 2001, ADV INORG CHEM, V51, P51; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; ORII Y, 1982, J BIOL CHEM, V257, P9246; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Petrova VY, 2004, BIOCHEM J, V380, P393, DOI 10.1042/BJ20040042; RADI R, 1991, J BIOL CHEM, V266, P22028; Salvi M, 2003, BIOCHEM PHARMACOL, V66, P2375, DOI 10.1016/j.bcp.2003.08.023; Salvi M, 2005, ENDOCRINOLOGY, V146, P2306, DOI 10.1210/en.2004-1128; Salvi M, 2002, BBA-BIOENERGETICS, V1556, P187, DOI 10.1016/S0005-2728(02)00361-4; Salvi M, 2002, BBA-MOL CELL RES, V1589, P181, DOI 10.1016/S0167-4889(02)00174-X; Schild L, 2005, FEBS J, V272, P5844, DOI 10.1111/j.1742-4658.2005.04978.x; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; TAPPEL AL, 1973, FED PROC, V32, P1870; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Toninello A, 2004, CURR MED CHEM, V11, P2349, DOI 10.2174/0929867043364559; VanVeldhoven PP, 1996, ANAL BIOCHEM, V237, P17, DOI 10.1006/abio.1996.0194; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	42	161	166	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24407	24415		10.1074/jbc.M701589200	http://dx.doi.org/10.1074/jbc.M701589200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17576767	hybrid			2022-12-25	WOS:000248686600067
J	Turski, ML; Thiele, DJ				Turski, Michelle L.; Thiele, Dennis J.			Drosophila Ctr1A functions as a copper transporter essential for development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SUPEROXIDE-DISMUTASE; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; EMBRYONIC-DEVELOPMENT; METAL; HOMEOSTASIS; CARDIOMYOPATHY; NEUROPEPTIDES	Copper is an essential trace element required by all aerobic organisms as a cofactor for enzymes involved in normal growth, development, and physiology. Ctr1 proteins are members of a highly conserved family of copper importers responsible for copper uptake across the plasma membrane. Mice lacking Ctr1 die during embryogenesis from widespread developmental defects, demonstrating the need for adequate copper acquisition in the development of metazoan organisms via as yet uncharacterized mechanisms. Whereas the fruit fly, Drosophila melanogaster, expresses three Ctr1 genes, ctr1A, ctr1B, and ctr1C, little is known about their protein isoform- specific roles. Previous studies demonstrated that Ctr1B localizes to the plasma membrane and is not essential for development unless flies are severely copper- deficient or are subjected to copper toxicity. Here we demonstrate that Ctr1A also resides on the plasma membrane and is the primary Drosophila copper transporter. Loss of Ctr1A results in copper- remedial developmental arrest at early larval stages. Ctr1A mutants are deficient in the activity of copper- dependent enzymes, including cytochrome c oxidase and tyrosinase. Amidation of Phe- Met- Arg- Pheamides, a group of cardiomodulatory neuropeptide hormones that are matured via the action of peptidylglycine alpha- hydroxylating monooxygenase, is defective in neuroendocrine cells of Ctr1A mutant larvae. Moreover, both the Phe- Met- Arg- Pheamide maturation and heart beat rate defects observed in Ctr1A mutant larvae can be partially rescued by exogenous copper. These studies establish clear physiological distinctions between two Drosophila plasma membrane copper transport proteins and demonstrate that copper import by Ctr1A is required to drive neuropeptide maturation during normal growth and development.	Duke Univ, Program Genet & Genom, Durham, NC 27706 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Turski, ML (corresponding author), 3813 Res Dr,LSRC C-351, Durham, NC 27710 USA.	dennis.thiele@duke.edu			NIEHS NIH HHS [5P42ES010356] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010356] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aller SG, 2006, P NATL ACAD SCI USA, V103, P3627, DOI 10.1073/pnas.0509929103; Andrews NC, 2002, CURR OPIN CHEM BIOL, V6, P181, DOI 10.1016/S1367-5931(02)00307-1; Arredondo M, 2003, AM J PHYSIOL-CELL PH, V284, pC1525, DOI 10.1152/ajpcell.00480.2002; Balamurugan K, 2007, EMBO J, V26, P1035, DOI 10.1038/sj.emboj.7601543; Bertinato J, 2003, J BIOL CHEM, V278, P35071, DOI 10.1074/jbc.M302242200; Bertinato J, 2003, J NUTR, V133, P28, DOI 10.1093/jn/133.1.28; Bier E, 2004, GENE, V342, P1, DOI 10.1016/j.gene.2004.07.018; Caruano-Yzermans AL, 2006, J BIOL CHEM, V281, P13581, DOI 10.1074/jbc.M601580200; CHOU TB, 1992, GENETICS, V131, P643; Cobine PA, 2006, BBA-MOL CELL RES, V1763, P759, DOI 10.1016/j.bbamcr.2006.03.002; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; Cohen SM., 1993, DEV DROSOPHILA MELAN; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Culotta VC, 2006, BBA-MOL CELL RES, V1763, P747, DOI 10.1016/j.bbamcr.2006.05.003; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DEMEREC M, 1994, BIOL DROSOPHILA, P283; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Eisses JF, 2005, J BIOL CHEM, V280, P9635, DOI 10.1074/jbc.M500116200; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; Elsherif L, 2003, EXP BIOL MED, V228, P811, DOI 10.1177/15353702-0322807-06; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; Eto Tanenao, 2001, Trends in Endocrinology and Metabolism, V12, P91, DOI 10.1016/S1043-2760(01)00374-5; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; Jiang N, 2000, DEV BIOL, V226, P118, DOI 10.1006/dbio.2000.9832; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Leary SC, 2007, CELL METAB, V5, P9, DOI 10.1016/j.cmet.2006.12.001; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Li Y, 2005, J NUTR, V135, P2130, DOI 10.1093/jn/135.9.2130; Linder M, 1991, BIOCH COPPER; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Medeiros DM, 1997, P SOC EXP BIOL MED, V215, P299, DOI 10.3181/00379727-215-44141; Mendelsohn BA, 2006, CELL METAB, V4, P155, DOI 10.1016/j.cmet.2006.05.001; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Nassel DR, 2002, PROG NEUROBIOL, V68, P1, DOI 10.1016/S0301-0082(02)00057-6; Nichols R, 2003, ANNU REV ENTOMOL, V48, P485, DOI 10.1146/annurev.ento.48.091801.112525; NOSE Y, 2006, CELL METAB, V4, P1; Nose Y, 2006, TRENDS BIOCHEM SCI, V31, P604, DOI 10.1016/j.tibs.2006.09.003; Orgad S, 1998, J EXP BIOL, V201, P115; Papadopoulou LC, 1999, NAT GENET, V23, P333; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; PRICE DA, 1977, PREP BIOCHEM, V7, P261, DOI 10.1080/00327487708061643; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rees EM, 2004, J BIOL CHEM, V279, P54221, DOI 10.1074/jbc.M411669200; Rees EM, 2004, CURR OPIN MICROBIOL, V7, P175, DOI 10.1016/j.mib.2004.02.004; Schlief ML, 2005, J NEUROSCI, V25, P239, DOI 10.1523/JNEUROSCI.3699-04.2005; Selvaraj A, 2005, GENE DEV, V19, P891, DOI 10.1101/gad.1301805; Sen CK, 2002, AM J PHYSIOL-HEART C, V282, pH1821, DOI 10.1152/ajpheart.01015.2001; Steveson TC, 2003, ENDOCRINOLOGY, V144, P188, DOI 10.1210/en.2002-220716; SULLIVAN W, 2000, DROSOPHILA PROTOCOLS, P141; TAGHERT PH, 1990, J NEUROSCI, V10, P1929; Taghert PH, 2003, ADV GENET, V49, P1, DOI 10.1016/S0065-2660(03)01001-0; TAGHERT PH, 2003, ENCY HORMONES, P421; Takahashi Y, 2002, MOL CELL BIOL, V22, P7614, DOI 10.1128/MCB.22.21.7614-7621.2002; Valnot I, 2000, AM J HUM GENET, V67, P1104; West EC, 2004, EXP BIOL MED, V229, P756, DOI 10.1177/153537020422900807; Wildman REC, 1996, BIOL TRACE ELEM RES, V55, P55, DOI 10.1007/BF02784168; Wolf MJ, 2006, P NATL ACAD SCI USA, V103, P1394, DOI 10.1073/pnas.0507359103; Zhou H, 2003, J BIOL CHEM, V278, P48210, DOI 10.1074/jbc.M309820200	70	53	55	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24017	24026		10.1074/jbc.M703792200	http://dx.doi.org/10.1074/jbc.M703792200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17573340	hybrid			2022-12-25	WOS:000248686600027
J	Bondensgaard, K; Breinholt, J; Madsen, D; Omkvist, DH; Kang, L; Worsaae, A; Becker, P; Schiodt, CB; Hjorth, SA				Bondensgaard, Kent; Breinholt, Jens; Madsen, Dennis; Omkvist, Diana Hojmark; Kang, Lishan; Worsaae, Anne; Becker, Peter; Schiodt, Christine Bruun; Hjorth, Siv A.			The existence of multiple conformers of interleukin-21 directs engineering of a superpotent analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 NMR RELAXATION; CRYSTAL-STRUCTURE; ALPHA-RECEPTOR; PROTEIN; BINDING; ASSIGNMENT; GAMMA(C)-RECEPTOR; RESTRAINTS; CYTOKINES; RESPONSES	The high resolution three-dimensional structure of human interleukin (hIL)-21 has been resolved by heteronuclear NMR spectroscopy. Overall, the hIL-21 structure is dominated by a well defined central four-helical bundle, arranged in an up-up-down-down topology, as observed for other cytokines. A segment of the hIL-21 molecule that includes the third helical segment, helix C, is observed to exist in two distinct and interchangeable states. In one conformer, the helix C segment is presented in a regular, alpha-helical conformation, whereas in the other conformer, this segment is largely disordered. A structure-based sequence alignment of hIL-21 with receptor complexes of the related cytokines, interleukin-2 and -4, implied that this particular segment is involved in receptor binding. An hIL-21 analog was designed to stabilize the region around helix C through the introduction of a segment grafted from hIL-4. This novel hIL-21 analog was demonstrated to exhibit a 10-fold increase in potency in a cellular assay.	Novo Nordisk AS, Biopharmaceut Res Unit, DK-2760 Malov, Denmark; Novo Nordisk R&D, Beijing 10228, Peoples R China	Novo Nordisk; Novo Nordisk	Bondensgaard, K (corresponding author), Novo Nordisk AS, Biopharmaceut Res Unit, Novo Nordisk Pk, DK-2760 Malov, Denmark.	kbaa@novonordisk.com		Hjorth, Siv Annegrethe/0000-0002-6470-650X				BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; Cheetham JC, 1998, NAT STRUCT BIOL, V5, P861, DOI 10.1038/2302; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Eisenmesser EZ, 2001, J MOL BIOL, V310, P231, DOI 10.1006/jmbi.2001.4765; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hill EE, 2002, J MOL BIOL, V322, P205, DOI 10.1016/S0022-2836(02)00653-8; Hyberts SG, 2003, J BIOMOL NMR, V26, P335, DOI 10.1023/A:1024078926886; Kallen KJ, 1999, J BIOL CHEM, V274, P11859, DOI 10.1074/jbc.274.17.11859; KLEYWEGT GJ, 2006, FROM 1 MAP TO FINAL, P59; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; MADESEN D, 2005, INDONESIA INTEGRATED; MOTT HR, 1995, J MOL BIOL, V247, P979, DOI 10.1006/jmbi.1994.0194; Parrish-Novak J, 2002, J LEUKOCYTE BIOL, V72, P856; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; REDFIELD C, 1992, BIOCHEMISTRY-US, V31, P10431, DOI 10.1021/bi00158a003; REDFIELD C, 1994, J MOL BIOL, V238, P23, DOI 10.1006/jmbi.1994.1265; Rickert M, 2004, J MOL BIOL, V339, P1115, DOI 10.1016/j.jmb.2004.04.038; Rickert M, 2005, SCIENCE, V308, P1477, DOI 10.1126/science.1109745; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; WALTER MR, 1992, J BIOL CHEM, V267, P20371; Wang XQ, 2005, SCIENCE, V310, P1159, DOI 10.1126/science.1117893; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WLODAVER A, 1992, FEBS LETT, V309, P59, DOI 10.1016/0014-5793(92)80739-4; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	33	26	38	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23326	23336		10.1074/jbc.M701313200	http://dx.doi.org/10.1074/jbc.M701313200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565991	hybrid			2022-12-25	WOS:000248577500033
J	KueperO, T; Grune, T; PrahlO, S; Lenz, H; Welge, V; Biernoth, T; Vogt, Y; Muhr, GM; Gaemlich, A; Jung, T; BoemkeO, G; Elsaser, HP; Wittern, KP; Wenck, H; Stab, F; Blatt, T				Kueper, Thomas; Grune, Tilman; Prahl, Stefanie; Lenz, Holger; Welge, Vivienne; Biernoth, Tanja; Vogt, Yvonne; Muhr, Gesa-Meike; Gaemlich, Astrid; Jung, Tobias; Boemke, Gerrit; Elsaesser, Hans-Peter; Wittern, Klaus-Peter; Wenck, Horst; Staeb, Franz; Blatt, Thomas			Vimentin is the specific target in skin glycation - Structural prerequisites, functional consequences, and role in skin aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-DEPENDENT ACCUMULATION; END-PRODUCTS AGES; INTERMEDIATE-FILAMENTS; CHEMICAL-MODIFICATION; MECHANICAL FORCES; MAILLARD REACTION; INCLUSION-BODIES; SERUM-ALBUMIN; LENS PROTEINS; IN-VITRO	Until now, the glycation reaction was considered to be a nonspecific reaction between reducing sugars and amino groups of random proteins. We were able to identify the intermediate filament vimentin as the major target for the AGE modification N-epsilon-(carboxymethyl)lysine (CML) in primary human fibroblasts. This glycation of vimentin is neither based on a slow turnover of this protein nor on an extremely high intracellular expression level, but remarkably it is based on structural properties of this protein. Glycation of vimentin was predominantly detected at lysine residues located at the linker regions using nanoLC-ESIMS/MS. This modification results in a rigorous redistribution of vimentin into a perinuclear aggregate, which is accompanied by the loss of contractile capacity of human skin fibroblasts. CML-induced rearrangement of vimentin was identified as an aggresome. This is the first evidence that CML-vimentin represents a damaged protein inside the aggresome, linking the glycation reaction directly to aggresome formation. Strikingly, we were able to prove that the accumulation of modified vimentin can be found in skin fibroblasts of elderly donors in vivo, bringing AGE modifications in human tissues such as skin into strong relationship with loss of organ contractile functions.	Univ Hamburg, Dept Biochem & Mol Biol, D-20146 Hamburg, Germany; Beiersdorf AG, R&D, D-20253 Hamburg, Germany; Univ Hohenheim, Dept Biol Chem & Nutr, D-70593 Stuttgart, Germany; Univ Marburg, Dept Cytobiol & Cytopathol, D-35033 Marburg, Germany	University of Hamburg; Beiersdorf AG; University Hohenheim; Philipps University Marburg	KueperO, T (corresponding author), Stephanstr 28, D-48734 Reken, Germany.	thomas_kueper@arcor.de		Grune, Tilman/0000-0003-4775-9973; Jung, Tobias/0000-0002-9159-8444				Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Ahmed N, 2005, J BIOL CHEM, V280, P5724, DOI 10.1074/jbc.M410973200; Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Brown RA, 1996, J CELL PHYSIOL, V169, P439, DOI 10.1002/(SICI)1097-4652(199612)169:3<439::AID-JCP4>3.0.CO;2-P; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bucala R, 1992, Adv Pharmacol, V23, P1; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; Cervantes-Laurean D, 2005, FREE RADICAL BIO MED, V38, P786, DOI 10.1016/j.freeradbiomed.2004.11.030; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Cloos PAC, 2002, MATRIX BIOL, V21, P39, DOI 10.1016/S0945-053X(01)00188-3; Degenhardt TP, 1998, CELL MOL BIOL, V44, P1139; DELVOYE P, 1991, J INVEST DERMATOL, V97, P898, DOI 10.1111/1523-1747.ep12491651; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; ESUE O, 2006, J BIOL CHEM; Fujii Takenori, 1999, Medical Electron Microscopy, V32, P43, DOI 10.1007/s007950050007; Goedert M, 2001, CLIN CHEM LAB MED, V39, P308, DOI 10.1515/CCLM.2001.047; Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Hipkiss AR, 2006, EXP GERONTOL, V41, P464, DOI 10.1016/j.exger.2006.03.004; Ho CL, 1998, J CELL SCI, V111, P1767; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; ITO S, 1968, J CELL BIOL, V39, pA168; Jeanmaire C, 2001, BRIT J DERMATOL, V145, P10, DOI 10.1046/j.1365-2133.2001.04275.x; JOHNSON AB, 1989, AM J ANAT, V185, P335, DOI 10.1002/aja.1001850228; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kasper M, 2001, ARCH GERONTOL GERIAT, V32, P233, DOI 10.1016/S0167-4943(01)00103-0; Kim SS, 2005, J BIOMED MATER RES B, V75B, P369, DOI 10.1002/jbm.b.30302; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lenz H, 2005, J INVEST DERMATOL, V124, P443, DOI 10.1111/j.0022-202X.2004.23522.x; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; Miyata T, 1996, P NATL ACAD SCI USA, V93, P2353, DOI 10.1073/pnas.93.6.2353; Munch G, 1999, NAT BIOTECHNOL, V17, P1006, DOI 10.1038/13704; Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355; Nishio K, 2001, HISTOCHEM CELL BIOL, V116, P321, DOI 10.1007/s004180100325; Radfar AJ, 2000, WOUND REPAIR REGEN, V8, P503, DOI 10.1046/j.1524-475x.2000.00503.x; Reichenberg E, 2005, J PERIODONTOL, V76, P1645, DOI 10.1902/jop.2005.76.10.1645; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Smith TA, 2002, J STRUCT BIOL, V137, P128, DOI 10.1006/jsbi.2002.4438; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stitt AW, 1997, AM J PATHOL, V150, P523; Stolzing A, 2006, FREE RADICAL BIO MED, V40, P1017, DOI 10.1016/j.freeradbiomed.2005.10.061; Strelkov SV, 2002, EMBO J, V21, P1255, DOI 10.1093/emboj/21.6.1255; Strelkov SV, 2002, J STRUCT BIOL, V137, P54, DOI 10.1006/jsbi.2002.4454; Suzuki K, 1998, J BIOCHEM-TOKYO, V123, P353; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; Unver N, 2006, BRIT J DERMATOL, V155, P119, DOI 10.1111/j.1365-2133.2006.07210.x; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; van Heijst JWJ, 2006, CANCER LETT, V241, P309, DOI 10.1016/j.canlet.2005.10.042; Vlassara H, 2005, ANN NY ACAD SCI, V1043, P452, DOI 10.1196/annals.1333.051; Wang N, 2002, J MUSCLE RES CELL M, V23, P535, DOI 10.1023/A:1023470709071; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; Yao DC, 2006, CELL, V124, P275, DOI 10.1016/j.cell.2005.11.024; Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009	60	85	91	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23427	23436		10.1074/jbc.M701586200	http://dx.doi.org/10.1074/jbc.M701586200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17567584	hybrid			2022-12-25	WOS:000248577500043
J	Sharma, O; Yamashita, E; Zhalnina, MV; Zakharov, SD; Datsenko, KA; Wanner, BL; Cramer, WA				Sharma, Onkar; Yamashita, Eiki; Zhalnina, Mariya V.; Zakharov, Stanislav D.; Datsenko, Kirill A.; Wanner, Barry L.; Cramer, William A.			Structure of the complex of the colicin E2 R-domain and its BtuB receptor - The outer membrane colicin translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; IMMUNITY PROTEIN; COBALAMIN TRANSPORTER; CRYSTAL-STRUCTURE; CROSS-RESISTANCE; CELL ENTRY; IN-VITRO; GROUP-A; IMPORT; MECHANISM	The crystal structure of the complex of the BtuB receptor and the 135-residue coiled-coil receptor-binding R-domain of colicin E3 (E3R135) suggested a novel mechanism for import of colicin proteins across the outer membrane. It was proposed that one function of the R-domain, which extends along the outer membrane surface, is to recruit an additional outer membrane protein(s) to form a translocon for passage colicin activity domain. A 3.5-angstrom crystal structure of the complex of E2R135 and BtuB (E2R135-BtuB) was obtained, which revealed E2R135 bound to BtuB in an oblique orientation identical to that previously found for E3R135. The only significant difference between the two structures was that the bound coiled-coil R-domain of colicin E2, compared with that of colicin E3, was extended by two and five residues at the N and C termini, respectively. There was no detectable displacement of the BtuB plug domain in either structure, implying that colicin is not imported through the outer membrane by BtuB alone. It was concluded that the oblique orientation of the R-domain of the nuclease E colicins has a function in the recruitment of another member(s) of an outer membrane translocon. Screening of porin knock-out mutants showed that either OmpF or OmpC can function in such a translocon. Arg(452) at the R/C-domain interface in colicin E2 was found have an essential role at a putative site of protease cleavage, which would liberate the C-terminal activity domain for passage through the outer membrane translocon.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Cramer, WA (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	waclab@purdue.edu	Sharma, Onkar/K-4532-2013; Yamashita, Eiki/V-6758-2019	Yamashita, Eiki/0000-0002-4278-0039	NIGMS NIH HHS [GM18457, GM62662] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018457, R01GM062662] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENEDETTI H, 1989, J GEN MICROBIOL, V135, P3413; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BOON T, 1972, P NATL ACAD SCI USA, V69, P549, DOI 10.1073/pnas.69.3.549; Bouveret E, 1997, MOL MICROBIOL, V23, P909, DOI 10.1046/j.1365-2958.1997.2751640.x; BOWMAN CM, 1971, NATURE-NEW BIOL, V234, P133, DOI 10.1038/newbio234133a0; Braun V, 2002, BIOCHIMIE, V84, P365, DOI 10.1016/S0300-9084(02)01427-X; Buchanan SK, 2007, EMBO J, V26, P2594, DOI 10.1038/sj.emboj.7601693; Cao Z, 2002, BIOCHIMIE, V84, P399, DOI 10.1016/S0300-9084(02)01455-4; Carr S, 2000, STRUCT FOLD DES, V8, P57, DOI 10.1016/S0969-2126(00)00079-4; Cherezov V, 2006, J MOL BIOL, V364, P716, DOI 10.1016/j.jmb.2006.09.022; Chimento DP, 2003, J MOL BIOL, V332, P999, DOI 10.1016/j.jmb.2003.07.005; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DAVIES JK, 1975, J BACTERIOL, V123, P102, DOI 10.1128/JB.123.1.102-117.1975; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; DEZWAIG RN, 1967, J BACTERIOL, V94, P1112, DOI 10.1128/JB.94.4.1112-1123.1967; Duche D, 2006, J BACTERIOL, V188, P8593, DOI 10.1128/JB.00941-06; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Hands SL, 2005, J BACTERIOL, V187, P6733, DOI 10.1128/JB.187.19.6733-6741.2005; Housden NG, 2005, P NATL ACAD SCI USA, V102, P13849, DOI 10.1073/pnas.0503567102; JAKES KS, 1974, P NATL ACAD SCI USA, V71, P3380, DOI 10.1073/pnas.71.9.3380; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuhlmann UC, 2000, J MOL BIOL, V301, P1163, DOI 10.1006/jmbi.2000.3945; Kurisu G, 2003, NAT STRUCT BIOL, V10, P948, DOI 10.1038/nsb997; Law CJ, 2003, FEBS LETT, V545, P127, DOI 10.1016/S0014-5793(03)00511-8; LAZDUNSKI CJ, 1995, MOL MICROBIOL, V16, P1059, DOI 10.1111/j.1365-2958.1995.tb02331.x; Lazzaroni JC, 2002, BIOCHIMIE, V84, P391, DOI 10.1016/S0300-9084(02)01419-0; Loftus SR, 2006, P NATL ACAD SCI USA, V103, P12353, DOI 10.1073/pnas.0603433103; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOCK M, 1982, J BACTERIOL, V150, P1069, DOI 10.1128/JB.150.3.1069-1076.1982; Mokranjac D, 2005, BIOCHEM SOC T, V33, P1019, DOI 10.1042/BST0331019; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; OTSUJI N, 1982, MOL GEN GENET, V187, P30, DOI 10.1007/BF00384379; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YH, 2006, J BIOL CHEM, V281, P13083, DOI 10.1074/jbc.M511365200; Pfanner N, 2004, NAT STRUCT MOL BIOL, V11, P1044, DOI 10.1038/nsmb852; Pommer AJ, 2001, J MOL BIOL, V314, P735, DOI 10.1006/jmbi.2001.5189; PUGSLEY AP, 1978, J BACTERIOL, V135, P1118, DOI 10.1128/JB.135.3.1118-1129.1978; Riley MA, 1999, TRENDS MICROBIOL, V7, P129, DOI 10.1016/S0966-842X(99)01459-6; Sharma O, 2006, HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES, P115, DOI 10.1016/B978-012369442-3/50021-0; Shi ZH, 2005, J BIOL CHEM, V280, P24663, DOI 10.1074/jbc.M501216200; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; Song JM, 1998, BBA-BIOMEMBRANES, V1370, P289, DOI 10.1016/S0005-2736(97)00279-4; Taylor R, 1998, J BIOL CHEM, V273, P31113, DOI 10.1074/jbc.273.47.31113; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; Zakharov SD, 2004, BIOPHYS J, V87, P3901, DOI 10.1529/biophysj.104.046151; Zakharov SD, 2004, FRONT BIOSCI-LANDMRK, V9, P1311, DOI 10.2741/1334; Zakharov SD, 2006, BIOCHEMISTRY-US, V45, P10199, DOI 10.1021/bi060694+	50	50	50	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23163	23170		10.1074/jbc.M703004200	http://dx.doi.org/10.1074/jbc.M703004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17548346	hybrid			2022-12-25	WOS:000248577500018
J	Olayioye, MA; Buchholz, M; Schmid, S; Schoffler, P; Hoffmann, P; Pomorski, T				Olayioye, Monilola A.; Buchholz, Michael; Schmid, Simone; Schoeffler, Patrik; Hoffmann, Peter; Pomorski, Thomas			Phosphorylation of StarD10 on serine 284 by casein kinase II modulates its lipid transfer activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE TRANSFER PROTEIN; BREAST-CANCER; DOMAIN; BINDING; CK2; TRAFFICKING; APOPTOSIS; CLEAVAGE; SITES; CELLS	StarD10 is a dual specificity lipid transfer protein capable of shuttling phosphatidylcholine and phosphatidylethanolamine between membranes in vitro. We now provide evidence that, in vivo, StarD10 is phosphorylated on serine 284. This novel phosphorylation site was identified by tandem mass spectrometry of immunoaffinity-purified StarD10 from lysates of HEK293T cells transiently expressing the protein. In vitro kinase assays revealed that casein kinase II was capable of phosphorylating wild-type StarD10 but not a S284A mutant protein. Interestingly, hypotonic extracts prepared from HEK293T cells expressing the serine to alanine mutant exhibited increased lipid transfer activity compared with those from wild-type StarD10-expressing cells, suggesting that, in a cellular context, phosphorylation on serine 284 negatively regulates StarD10 activity. Because casein kinase II phosphorylation also inhibited lipid transfer activity of the purified recombinant StarD10 protein, inhibition is not dependent on any cellular cofactors. Instead, our data show that C-terminal StarD10 phosphorylation on serine 284 regulates its association with cellular membranes.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany; Free Univ Berlin, Dept Biol Chem & Pharm, D-14195 Berlin, Germany; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	University of Stuttgart; Humboldt University of Berlin; Free University of Berlin; University of Adelaide	Olayioye, MA (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	monilola.olayioye@izi.uni-stuttgart.de; thomas.pomorski@rz.hu-berlin.de	Pomorski, Thomas Günther/G-4804-2014; Hoffmann, Peter/U-5996-2017	Pomorski, Thomas Günther/0000-0002-4889-0829; Hoffmann, Peter/0000-0001-8493-2208				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; de Brouwer APM, 2002, EXP CELL RES, V274, P100, DOI 10.1006/excr.2001.5460; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Feng L, 2000, BIOCHEMISTRY-US, V39, P15399, DOI 10.1021/bi001076a; FUGMANN T, 2007, IN PRESS J CELL BIOL; GORDESKY SE, 1973, MEMBR BIOL, V14, P229; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hoffmann P, 2005, ELECTROPHORESIS, V26, P1029, DOI 10.1002/elps.200406197; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Levine T, 2006, CURR OPIN CELL BIOL, V18, P371, DOI 10.1016/j.ceb.2006.06.011; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Olayioye MA, 2005, J BIOL CHEM, V280, P27436, DOI 10.1074/jbc.M413330200; Olayioye MA, 2004, CANCER RES, V64, P3538, DOI 10.1158/0008-5472.CAN-03-3731; Olsten MEK, 2004, BIOCHEM CELL BIOL, V82, P681, DOI 10.1139/O04-116; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Snoek GT, 2004, BIOCHIMIE, V86, P857, DOI 10.1016/j.biochi.2004.09.021; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; SOMERHARJU PJ, 1992, METHOD ENZYMOL, V209, P495; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Strauss JF, 2003, MOL CELL ENDOCRINOL, V202, P59, DOI 10.1016/S0303-7207(03)00063-7; van Helvoort A, 1999, P NATL ACAD SCI USA, V96, P11501, DOI 10.1073/pnas.96.20.11501; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Voelker DR, 2005, TRENDS BIOCHEM SCI, V30, P396, DOI 10.1016/j.tibs.2005.05.008; Wirtz KWA, 2006, FEBS LETT, V580, P5436, DOI 10.1016/j.febslet.2006.06.065	28	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22492	10.1074/jbc.M701990200	http://dx.doi.org/10.1074/jbc.M701990200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17561512	hybrid			2022-12-25	WOS:000248354200027
J	Shen, JP; Zhang, LD; Zhao, R				Shen, Jingping; Zhang, Lingdi; Zhao, Rui			Biochemical characterization of the ATPase and helicase activity of UAP56, an essential pre-mRNA splicing and mRNA export factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION-FACTORS; JUNCTION CORE COMPLEX; BOX PROTEIN FAMILY; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; DEPENDENT ATPASE; PENTA-SNRNP; FACTOR 4A; TRANSLATION; SPLICEOSOME	DEXD/H-box protein UAP56 is an essential pre-mRNA splicing factor required for the first ATP-dependent spliceosome assembly step. UAP56 is also essential for the export of the majority of mRNAs from the nucleus to the cytoplasm. We performed biochemical characterization of UAP56's ATPase and helicase activity, which is important for further understanding the role of these activities in UAP56's function. We showed that UAP56 is an RNA-stimulated ATPase that can only hydrolyze ATP. We demonstrated that UAP56 is an ATP-dependent RNA helicase that can unwind substrates with 5 ' or 3 ' overhangs or blunt ends in vitro. We showed that U2AF(65) and Aly, two proteins known to interact with UAP56, do not influence UAP56's ATPase or helicase activity. We also demonstrated that several mutants in the conserved helicase motifs I, II, and III abolish UAP56's ATPase and/or helicase activity, providing tools for future investigation of the role of UAP56's ATPase and helicase activity in spliceosome assembly and mRNA export.	Univ Colorado, Dept Biochem & Mol Genet, Aurora, CO 80045 USA; Hlth Sci Ctr, Dept Biochem & Mol Genet, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Zhao, R (corresponding author), Univ Colorado, Dept Biochem & Mol Genet, MS 8101,POB 6511, Aurora, CO 80045 USA.	rui.zhao@uchsc.edu						ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; Andersen CBF, 2006, SCIENCE, V313, P1968, DOI 10.1126/science.1131981; Ballut L, 2005, NAT STRUCT MOL BIOL, V12, P861, DOI 10.1038/nsmb990; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; Bizebard T, 2004, BIOCHEMISTRY-US, V43, P7857, DOI 10.1021/bi049852s; Bono F, 2006, CELL, V126, P713, DOI 10.1016/j.cell.2006.08.006; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Herold A, 2003, EMBO J, V22, P2472, DOI 10.1093/emboj/cdg233; Huang YL, 2002, J BIOL CHEM, V277, P12810, DOI 10.1074/jbc.M200182200; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; MacMorris M, 2003, RNA, V9, P847, DOI 10.1261/rna.5480803; Malca H, 2003, MOL CELL BIOL, V23, P3442, DOI 10.1128/MCB.23.10.3442-3455.2003; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Moore M., 1993, RNA WORLD, P303; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Nilsen TW, 2002, MOL CELL, V9, P8, DOI 10.1016/S1097-2765(02)00430-6; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Richter-Cook NJ, 1998, J BIOL CHEM, V273, P7579, DOI 10.1074/jbc.273.13.7579; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Rogers GW, 2001, J BIOL CHEM, V276, P12598, DOI 10.1074/jbc.M007560200; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Sengoku T, 2006, CELL, V125, P287, DOI 10.1016/j.cell.2006.01.054; Shi H, 2004, P NATL ACAD SCI USA, V101, P17628, DOI 10.1073/pnas.0408172101; Sonenberg Nahum, 1993, Gene Expression, V3, P317; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Svitkin YV, 2001, RNA, V7, P1743; Tanaka N, 2006, BIOCHEMISTRY-US, V45, P6510, DOI 10.1021/bi052656g; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; Weirich CS, 2006, NAT CELL BIOL, V8, P668, DOI 10.1038/ncb1424; Yang QS, 2006, NAT STRUCT MOL BIOL, V13, P981, DOI 10.1038/nsmb1165; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zhao R, 2004, STRUCTURE, V12, P1373, DOI 10.1016/j.str.2004.06.006	51	63	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22544	10.1074/jbc.M702304200	http://dx.doi.org/10.1074/jbc.M702304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17562711	hybrid			2022-12-25	WOS:000248354200032
J	Ho, ELY; Parent, M; Satoh, MS				Ho, Erick L. Y.; Parent, Marianne; Satoh, Masahiko S.			Induction of base damages representing a high risk site for double-strand DNA break formation in genomic DNA by exposure of cells to DNA damaging agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER MUTATIONAL HOTSPOTS; ATAXIA-TELANGIECTASIA; EXCISION-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; IONIZING-RADIATION; REPLICATION; FAMILIES; LIGASE; HYPERSENSITIVITY; INTERRUPTIONS	DNA repair is known as a defense mechanism against genotoxic insults. However, the most lethal type of DNA damages, double-strand DNA breaks (DSBs), can be produced by DNA repair. We have previously demonstrated that when long patch base excision repair attempts to repair a synthetic substrate containing two uracils, the repair produces DSBs (Vispe, S. and Satoh, M. S. (2000) J. Biol. Chem. 275, 27386-27392 and Vispe, S., Ho, E. L., Yung, T. M., and Satoh, M. S. (2003) J. Biol. Chem. 278, 35279-35285). In this synthetic substrate, the two uracils are located on the opposite DNA strands (separated by an intervening sequence stable at 37 degrees C) and represent a high risk site for DSB formation. It is not clear, however, whether similar high risk sites are also induced in genomic DNA by exposure to DNA damaging agents. Thus, to investigate the mechanisms of DSB formation, we have modified the DSB formation assay developed previously and demonstrated that high risk sites for DSB formation are indeed generated in genomic DNA by exposure of cells to alkylating agents. In fact, genomic DNA containing alkylated base damages, which could represent high risk sites, are converted into DSBs by enzymes present in extracts prepared from cells derived from clinically normal individuals. Furthermore, DSBs are also produced by extracts from cells derived from ataxia-telangiectasia patients who show cancer proneness due to an impaired response to DSBs. These results suggest the presence of a novel link between base damage formation and DSBs and between long patch base excision repair and human diseases that occur due to an impaired response to DSB.	Univ Laval, Med Ctr, CHUL, Div Hlth & Environm Res, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Anat & Physiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Satoh, MS (corresponding author), Univ Laval, Med Ctr, CHUL, Div Hlth & Environm Res, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	masahiko.sato@crchul.ulaval.ca						BARFKNECHT TR, 1982, MUTAT RES, V94, P369, DOI 10.1016/0027-5107(82)90299-8; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Braithwaite E, 1998, CARCINOGENESIS, V19, P1239, DOI 10.1093/carcin/19.7.1239; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; CHAUDHRY MA, 1995, J MOL BIOL, V249, P914; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DIANOV GL, 1991, MOL GEN GENET, V225, P448, DOI 10.1007/BF00261686; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Gatei M, 2001, ONCOGENE, V20, P289, DOI 10.1038/sj.onc.1204111; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; Ho ELY, 2003, NUCLEIC ACIDS RES, V31, P7032, DOI 10.1093/nar/gkg892; HOPPER JL, 1992, AM J EPIDEMIOL, V136, P1138, DOI 10.1093/oxfordjournals.aje.a116580; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; KHANNA K, 1998, DNA DAMAGE REPAIR; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kouzminova EA, 2006, J MOL BIOL, V355, P20, DOI 10.1016/j.jmb.2005.10.044; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8241, DOI 10.1073/pnas.131009198; Lavin MF, 2006, EMBO REP, V7, P154, DOI 10.1038/sj.embor.7400629; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Lundin C, 2005, NUCLEIC ACIDS RES, V33, P3799, DOI 10.1093/nar/gki681; Matsumoto Y, 2001, PROG NUCLEIC ACID RE, V68, P129; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; MORRELL D, 1990, CANCER GENET CYTOGEN, V50, P119, DOI 10.1016/0165-4608(90)90245-6; OSBORNE M, 1985, CHEM-BIOL INTERACT, V53, P183, DOI 10.1016/S0009-2797(85)80095-8; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; PHEIFFER BH, 1983, NUCLEIC ACIDS RES, V11, P7853, DOI 10.1093/nar/11.22.7853; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; Saleh-Gohari N, 2005, MOL CELL BIOL, V25, P7158, DOI 10.1128/MCB.25.16.7158-7169.2005; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SCUDIERO DA, 1980, CANCER RES, V40, P984; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; Sonntag C.V, 1989, CHEM BASIS RAD BIOL; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TEO IA, 1982, CARCINOGENESIS, V3, P33, DOI 10.1093/carcin/3.1.33; Tomkinson AE, 2001, PROG NUCLEIC ACID RE, V68, P151; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vispe S, 2000, J BIOL CHEM, V275, P27386; Vispe S, 2003, J BIOL CHEM, V278, P35279, DOI 10.1074/jbc.M303448200; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	61	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21913	21923		10.1074/jbc.M610651200	http://dx.doi.org/10.1074/jbc.M610651200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545165	hybrid			2022-12-25	WOS:000248196800039
J	Kohli, R; Pan, XM; Malladi, P; Wainwright, MS; Whitington, PF				Kohli, Rohit; Pan, Xiaomin; Malladi, Padmini; Wainwright, Mark S.; Whitington, Peter F.			Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONALCOHOLIC STEATOHEPATITIS; PHOSPHOINOSITIDE 3-KINASE; OXIDATIVE STRESS; INSULIN-RESISTANCE; HEPATIC STEATOSIS; RAT HEPATOCYTES; DOWN-REGULATION; KINASE-B; PTEN; MICE	Abnormal dietary intake of macronutrients is implicated in the development of obesity and fatty liver disease. Steatosis develops in cultured hepatocytes exposed to medium containing either a high concentration of long chain free fatty acids (HFFA) or medium deficient in methionine and choline (MCD). This study examined the mitochondrial reactive oxygen species (ROS)-dependent regulation of the phosphoinositol (PI) 3-kinase pathway in steatosis induced by exposure of AML-12 mouse hepatocytes to MCD or HFFA medium. Exposure to either MCD or HFFA medium resulted in increased production of superoxide anions and H2O2, transduction of the PI 3-kinase pathway and steatosis. Inhibition of PI 3-kinase with LY294002 prevented steatosis. Pharmacologically inhibiting electron transport chain complex III production of ROS prevented activation of PI 3-kinase during macronutrient perturbation, whereas pharmacologically promoting electron transport chain complex III ROS production activated PI 3-kinase independent of nutrient input. The data suggest that H2O2 is the ROS species involved in signal transduction; promoting the rapid conversion of superoxide to H2O2 does not inhibit PI 3-kinase pathway activation during nutrient perturbation, and exogenous H2O2 activates it independent of nutrient input. In addition to transducing PI 3-kinase, the ROS-dependent signal cascade amplifies the PI 3-kinase signal by maintaining phosphatase and tensin homolog in its inactive phosphorylated state. Knockdown of phosphatase and tensin homolog by small interfering RNA independently activated the PI 3-kinase pathway. Our findings suggest a common path for response to altered nutrition involving mitochondrial ROS-dependent PI 3-kinase pathway regulation, leading to steatosis.	Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Childrens Mem Hosp,Dept Pediat, Chicago, IL 60614 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Whitington, PF (corresponding author), Childrens Mem Res Ctr, 2300 Childrens Plaza, Chicago, IL 60614 USA.	p-whitington@northwestern.edu	kohli, Rohit/H-3020-2013	kohli, Rohit/0000-0002-0198-7703				Ahima RS, 2007, GASTROENTEROLOGY, V132, P444, DOI 10.1053/j.gastro.2006.11.048; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barthel A, 2005, BIOL CHEM, V386, P207, DOI 10.1515/BC.2005.026; Benani A, 2007, DIABETES, V56, P152, DOI 10.2337/db06-0440; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Brunt EM, 2004, SEMIN LIVER DIS, V24, P3; Cai ZQ, 2005, CIRC RES, V97, P1351, DOI 10.1161/01.RES.0000195656.52760.30; Caldwell SH, 1999, J HEPATOL, V31, P430, DOI 10.1016/S0168-8278(99)80033-6; Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927; Day CP, 2006, GASTROENTEROLOGY, V130, P207, DOI 10.1053/j.gastro.2005.11.017; Deng QG, 2005, HEPATOLOGY, V42, P905, DOI 10.1002/hep.20877; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; Hoehn KL, 2004, AM J PHYSIOL-REG I, V286, pR498, DOI 10.1152/ajpregu.00509.2003; Javadi M, 2004, J NUTR BIOCHEM, V15, P680, DOI 10.1016/j.jnutbio.2004.06.005; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932; Lee SB, 2005, CELL SIGNAL, V17, P197, DOI 10.1016/j.cellsig.2004.07.001; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leloup C, 2006, DIABETES, V55, P2084, DOI 10.2337/db06-0086; Lieber CS, 2004, AM J CLIN NUTR, V79, P502; Perez-Carreras M, 2003, HEPATOLOGY, V38, P999, DOI 10.1053/jhep.2003.50398; Pessayre D, 2001, SEMIN LIVER DIS, V21, P57, DOI 10.1055/s-2001-12929; Rizki G, 2006, J LIPID RES, V47, P2280, DOI 10.1194/jlr.M600198-JLR200; Rosseland CM, 2005, HEPATOLOGY, V42, P200, DOI 10.1002/hep.20762; Sahai A, 2004, AM J PHYSIOL-GASTR L, V287, pG264, DOI 10.1152/ajpgi.00002.2004; Sahai A, 2006, AM J PHYSIOL-GASTR L, V291, pG55, DOI 10.1152/ajpgi.00360.2005; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Schattenberg JRM, 2005, J BIOL CHEM, V280, P9887, DOI 10.1074/jbc.M410310200; Taniguchi CM, 2006, P NATL ACAD SCI USA, V103, P12093, DOI 10.1073/pnas.0604628103; Vankoningsloo S, 2006, J CELL SCI, V119, P1266, DOI 10.1242/jcs.02848; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vazquez F, 2006, CELL CYCLE, V5, P1523, DOI 10.4161/cc.5.14.3005; Venkatesan B, 2007, J CELL PHYSIOL, V211, P457, DOI 10.1002/jcp.20953; Wang YJ, 2004, J BIOL CHEM, V279, P31089, DOI 10.1074/jbc.M404170200; Watanabe S, 2005, HEPATOL RES, V33, P161, DOI 10.1016/j.hepres.2005.09.026; Weltman MD, 1996, GASTROENTEROLOGY, V111, P1645, DOI 10.1016/S0016-5085(96)70028-8; Yamagishi SI, 2001, J BIOL CHEM, V276, P25096, DOI 10.1074/jbc.M007383200	46	54	54	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21327	21336		10.1074/jbc.M701759200	http://dx.doi.org/10.1074/jbc.M701759200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17540768	hybrid			2022-12-25	WOS:000248047500061
J	Hastings, ML; Allemand, E; Duelli, DM; Myers, MP; Krainer, AR				Hastings, Michelle L.; Allemand, Eric; Duelli, Dominik M.; Myers, Michael P.; Krainer, Adrian R.			Control of Pre-mRNA Splicing by the General Splicing Factors PUF60 and U2AF(65)	PLOS ONE			English	Article								Pre-mRNA splicing is a crucial step in gene expression, and accurate recognition of splice sites is an essential part of this process. Splice sites with weak matches to the consensus sequences are common, though it is not clear how such sites are efficiently utilized. Using an in vitro splicing-complementation approach, we identified PUF60 as a factor that promotes splicing of an intron with a weak 39 splice-site. PUF60 has homology to U2AF(65), a general splicing factor that facilitates 39 splice-site recognition at the early stages of spliceosome assembly. We demonstrate that PUF60 can functionally substitute for U2AF(65) in vitro, but splicing is strongly stimulated by the presence of both proteins. Reduction of either PUF60 or U2AF(65) in cells alters the splicing pattern of endogenous transcripts, consistent with the idea that regulation of PUF60 and U2AF(65) levels can dictate alternative splicing patterns. Our results indicate that recognition of 39 splice sites involves different U2AF-like molecules, and that modulation of these general splicing factors can have profound effects on splicing.	[Hastings, Michelle L.; Allemand, Eric; Duelli, Dominik M.; Myers, Michael P.; Krainer, Adrian R.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Krainer, AR (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	krainer@cshl.edu	Hastings, MICHELLE L./AAK-6627-2021; allemand, eric/ABE-4272-2021	allemand, eric/0000-0002-9617-5336; Krainer, Adrian/0000-0001-9024-9501; Hastings, Michelle L./0000-0002-4253-9261	American Cancer Society; NCI [CA45508]; NIH [GM42699]; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042699, R37GM042699] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	M. L. H. was supported by a postdoctoral fellowship from the American Cancer Society. M. P. M was supported by NCI grant CA45508. This work was supported by NIH grant GM42699 to A. R. K.	Andreadis A, 2005, BBA-MOL BASIS DIS, V1739, P91, DOI 10.1016/j.bbadis.2004.08.010; Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Bouffard P, 2000, RNA, V6, P66, DOI 10.1017/S1355838200990277; Cartegni L, 2006, AM J HUM GENET, V78, P63, DOI 10.1086/498853; Cazalla D, 2005, MOL CELL BIOL, V25, P2969, DOI 10.1128/MCB.25.8.2969-2980.2005; Chen XG, 2004, J MOL MED, V82, P232, DOI 10.1007/s00109-004-0529-0; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; Dowhan DH, 2005, MOL CELL, V17, P429, DOI 10.1016/j.molcel.2004.12.025; Duelli DM, 2005, J CELL BIOL, V171, P493, DOI 10.1083/jcb.200507069; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Gozani O, 1998, MOL CELL BIOL, V18, P4752, DOI 10.1128/MCB.18.8.4752; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Guth S, 2001, MOL CELL BIOL, V21, P7673, DOI 10.1128/MCB.21.22.7673-7681.2001; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hastings ML, 2001, RNA, V7, P471, DOI 10.1017/S1355838201002552; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; HOLTZMAN DM, 1991, TRENDS BIOCHEM SCI, V16, P140, DOI 10.1016/0968-0004(91)90056-2; IMAI H, 1993, J CLIN INVEST, V92, P2419, DOI 10.1172/JCI116848; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kielkopf CL, 2004, GENE DEV, V18, P1513, DOI 10.1101/gad.1206204; Konarska MM, 2005, GENE DEV, V19, P2255, DOI 10.1101/gad.1363105; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Kralovicova J, 2005, NUCLEIC ACIDS RES, V33, P4882, DOI 10.1093/nar/gki811; Licatalosi DD, 2006, NEURON, V52, P93, DOI 10.1016/j.neuron.2006.09.017; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; Lim SR, 2001, J BIOL CHEM, V276, P45476, DOI 10.1074/jbc.M107632200; LIN CH, 1995, RNA, V1, P234; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; Lutzelberger M, 2005, J BIOL CHEM, V280, P25478, DOI 10.1074/jbc.M413737200; MacMillan AM, 1997, P NATL ACAD SCI USA, V94, P133, DOI 10.1073/pnas.94.1.133; MacMorris M, 2003, RNA, V9, P847, DOI 10.1261/rna.5480803; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Mayeda A, 1999, METH MOL B, V118, P309; McCurrach ME, 2001, METHOD CELL BIOL, V66, P197; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Murray MV, 1999, GENE DEV, V13, P87, DOI 10.1101/gad.13.1.87; Page-McCaw PS, 1999, RNA, V5, P1548, DOI 10.1017/S1355838299991938; Park JW, 2004, P NATL ACAD SCI USA, V101, P15974, DOI 10.1073/pnas.0407004101; Poleev A, 2000, EUR J BIOCHEM, V267, P4002, DOI 10.1046/j.1432-1327.2000.01431.x; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Roca X, 2003, NUCLEIC ACIDS RES, V31, P6321, DOI 10.1093/nar/gkg830; Rudner DZ, 1998, MOL CELL BIOL, V18, P4004, DOI 10.1128/MCB.18.7.4004; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SAKAMOTO H, 1987, J BIOCHEM-TOKYO, V102, P1289, DOI 10.1093/oxfordjournals.jbchem.a122167; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Tanackovic G, 2005, MOL BIOL CELL, V16, P1366, DOI 10.1091/mbc.E04-11-1034; TRESS ML, 2007, P NATL ACAD SCI US; Van Buskirk C, 2002, DEV CELL, V2, P343, DOI 10.1016/S1534-5807(02)00128-4; Will CL, 2002, EMBO J, V21, P4978, DOI 10.1093/emboj/cdf480; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; Xu YZ, 2004, EMBO J, V23, P376, DOI 10.1038/sj.emboj.7600050; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597	66	89	101	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e538	10.1371/journal.pone.0000538	http://dx.doi.org/10.1371/journal.pone.0000538			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579712	Green Published, Green Accepted, gold			2022-12-25	WOS:000207451700006
J	Becherer, U; Pasche, M; Nofal, S; Hof, D; Matti, U; Rettig, J				Becherer, Ute; Pasche, Mathias; Nofal, Shahira; Hof, Detlef; Matti, Ulf; Rettig, Jens			Quantifying Exocytosis by Combination of Membrane Capacitance Measurements and Total Internal Reflection Fluorescence Microscopy in Chromaffin Cells	PLOS ONE			English	Article								Total internal reflection fluorescence microscopy (TIRF-Microscopy) allows the observation of individual secretory vesicles in real-time during exocytosis. In contrast to electrophysiological methods, such as membrane capacitance recording or carbon fiber amperometry, TIRF-Microscopy also enables the observation of vesicles as they reside close to the plasma membrane prior to fusion. However, TIRF-Microscopy is limited to the visualization of vesicles that are located near the membrane attached to the glass coverslip on which the cell grows. This has raised concerns as to whether exocytosis measured with TIRF-Microscopy is comparable to global secretion of the cell measured with membrane capacitance recording. Here we address this concern by combining TIRF-Microscopy and membrane capacitance recording to quantify exocytosis from adrenal chromaffin cells. We found that secretion measured with TIRF-Microscopy is representative of the overall secretion of the cells, thereby validating for the first time the TIRF method as a measure of secretion. Furthermore, the combination of these two techniques provides a new tool for investigating the molecular mechanism of synaptic transmission with combined electrophysiological and imaging techniques.	[Becherer, Ute; Pasche, Mathias; Nofal, Shahira; Hof, Detlef; Matti, Ulf; Rettig, Jens] Univ Saarland, Inst Physiol, Homburg, Saar, Germany	Saarland University	Becherer, U (corresponding author), Univ Saarland, Inst Physiol, Homburg, Saar, Germany.	ute.becherer@uks.eu; jrettig@uks.eu	Becherer, Ute/AGW-2576-2022; Rettig, Jens/K-5103-2013; Becherer, Ute/F-6711-2010	Rettig, Jens/0000-0001-6160-3954; Becherer, Ute/0000-0001-6005-7517; Matti, Ulf/0000-0001-5548-1081; Nofal, Shahira/0000-0003-0405-9002	Deutsche Forschungsgemeinschaft [SFB 530]; HOMFOR	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); HOMFOR	This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB 530 to U. B. and J. R.) and HOMFOR.	Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; Angleson JK, 1997, TRENDS NEUROSCI, V20, P281, DOI 10.1016/S0166-2236(97)01083-7; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; Beaumont V, 2003, BIOCHEM SOC T, V31, P819, DOI 10.1042/BST0310819; Becherer U, 2003, NAT NEUROSCI, V6, P846, DOI 10.1038/nn1087; Dernick G, 2005, NAT METHODS, V2, P699, DOI 10.1038/nmeth0905-699; Eitzen G, 2003, BBA-MOL CELL RES, V1641, P175, DOI 10.1016/S0167-4889(03)00087-9; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; Johns LM, 2001, J CELL BIOL, V153, P177, DOI 10.1083/jcb.153.1.177; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nofal S, 2007, J NEUROSCI, V27, P1386, DOI 10.1523/JNEUROSCI.4714-06.2007; Oheim M, 1998, EUR BIOPHYS J BIOPHY, V27, P83, DOI 10.1007/s002490050114; Oheim M, 2000, EUR BIOPHYS J BIOPHY, V29, P67, DOI 10.1007/s002490050253; Perrais D, 2004, J PHYSIOL-LONDON, V560, P413, DOI 10.1113/jphysiol.2004.064410; Plattner H, 1997, J CELL BIOL, V139, P1709, DOI 10.1083/jcb.139.7.1709; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Sankaranarayanan S, 2000, BIOPHYS J, V79, P2199, DOI 10.1016/S0006-3495(00)76468-X; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; Steyer JA, 1999, BIOPHYS J, V76, P2262, DOI 10.1016/S0006-3495(99)77382-0; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; Toonen RF, 2006, EMBO J, V25, P3725, DOI 10.1038/sj.emboj.7601256; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; Zenisek D, 2000, NATURE, V406, P849, DOI 10.1038/35022500; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7	27	31	32	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e505	10.1371/journal.pone.0000505	http://dx.doi.org/10.1371/journal.pone.0000505			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551585	gold, Green Published			2022-12-25	WOS:000207451500014
J	Graziano, A; d'Aquino, R; Cusella-De Angelis, MG; Laino, G; Piattelli, A; Pacifici, M; De Rosa, A; Papaccio, G				Graziano, Antonio; d'Aquino, Riccardo; Cusella-De Angelis, Maria Gabriella; Laino, Gregorio; Piattelli, Adriano; Pacifici, Maurizio; De Rosa, Alfredo; Papaccio, Gianpaolo			Concave Pit-Containing Scaffold Surfaces Improve Stem Cell-Derived Osteoblast Performance and Lead to Significant Bone Tissue Formation	PLOS ONE			English	Article							VASCULAR-PERMEABILITY FACTOR; OSTEOGENIC DIFFERENTIATION; TYROSINE KINASE; GROWTH-FACTORS; RECEPTOR; TRANSDUCTION; DEGRADATION; SECRETE; BMP-2	Background. Scaffold surface features are thought to be important regulators of stem cell performance and endurance in tissue engineering applications, but details about these fundamental aspects of stem cell biology remain largely unclear. Methodology and Findings. In the present study, smooth clinical-grade lactide-coglyolic acid 85: 15 (PLGA) scaffolds were carved as membranes and treated with NMP (N-metil-pyrrolidone) to create controlled subtractive pits or microcavities. Scanning electron and confocal microscopy revealed that the NMP-treated membranes contained: (i) large microcavities of 80120 mu m in diameter and 40-100 mu m in depth, which we termed primary; and (ii) smaller microcavities of 10-20 mu m in diameter and 3-10 mu m in depth located within the primary cavities, which we termed secondary. We asked whether a microcavity-rich scaffold had distinct bone-forming capabilities compared to a smooth one. To do so, mesenchymal stem cells derived from human dental pulp were seeded onto the two types of scaffold and monitored over time for cytoarchitectural characteristics, differentiation status and production of important factors, including bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF). We found that the microcavity-rich scaffold enhanced cell adhesion: the cells created intimate contact with secondary microcavities and were polarized. These cytological responses were not seen with the smooth-surface scaffold. Moreover, cells on the microcavity-rich scaffold released larger amounts of BMP-2 and VEGF into the culture medium and expressed higher alkaline phosphatase activity. When this type of scaffold was transplanted into rats, superior bone formation was elicited compared to cells seeded on the smooth scaffold. Conclusion. In conclusion, surface microcavities appear to support a more vigorous osteogenic response of stem cells and should be used in the design of therapeutic substrates to improve bone repair and bioengineering applications in the future.	[Graziano, Antonio; d'Aquino, Riccardo; Papaccio, Gianpaolo] Secondo Ateneo Napoli, Dipartimento Med Sperimentale, Sez Istol & Embriol, Naples, Italy; [d'Aquino, Riccardo; Laino, Gregorio; De Rosa, Alfredo] Secondo Ateneo Napoli, Dipartimento Discipline Odontostomatol Ortodontic, Naples, Italy; [Cusella-De Angelis, Maria Gabriella] Univ Pavia, Dipartimento Med Sperimentale, Sez Anat Umana, I-27100 Pavia, Italy; [Piattelli, Adriano] Univ G DAnnunzio, Dipartimento Sci Odontostomatol, Chieti, Italy; [Pacifici, Maurizio] Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA	University of Pavia; G d'Annunzio University of Chieti-Pescara; Jefferson University	Graziano, A (corresponding author), Secondo Ateneo Napoli, Dipartimento Med Sperimentale, Sez Istol & Embriol, Naples, Italy.	gianpaolo.papaccio@unina2.it	; Papaccio, Gianpaolo/B-7150-2014	Cusella De Angelis, Maria Gabriella/0000-0003-2642-3346; Papaccio, Gianpaolo/0000-0002-4014-5306	2nd University of Naples; MIUR	2nd University of Naples; MIUR(Ministry of Education, Universities and Research (MIUR))	This study was supported by the 2nd University of Naples (2004-5 to G.P.) and MIUR (Project of relevant interest 2005 to G. P.) grants.	BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169-6009(91)90100-E; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; COOMBES AGA, 1992, BIOMATERIALS, V13, P297, DOI 10.1016/0142-9612(92)90053-Q; d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121; De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Erickson DM, 1997, J ORTHOP RES, V15, P371, DOI 10.1002/jor.1100150309; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gomes ME, 2006, TISSUE ENG, V12, P801, DOI 10.1089/ten.2006.12.801; Huang YC, 2005, J BONE MINER RES, V20, P848, DOI 10.1359/JBMR.041226; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirschner P., 2000, RES DIALOGUE LEARNIN, V2, P1; Knaus P, 2001, BIOL CHEM, V382, P1189, DOI 10.1515/BC.2001.149; Laino G, 2006, J CELL PHYSIOL, V206, P693, DOI 10.1002/jcp.20526; Laino G, 2005, J BONE MINER RES, V20, P1394, DOI 10.1359/JBMR.050325; LIU F, 1995, MOL CELL BIOL, V15, P3479; Marletta G, 2007, BIOMATERIALS, V28, P1132, DOI 10.1016/j.biomaterials.2006.10.027; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; Oliveira JM, 2006, BIOMATERIALS, V27, P6123, DOI 10.1016/j.biomaterials.2006.07.034; Papaccio G, 2006, J CELL PHYSIOL, V208, P319, DOI 10.1002/jcp.20667; Park BS, 2005, J BIOMED MATER RES A, V74A, P640, DOI 10.1002/jbm.a.30326; Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Reddi AH, 2000, TISSUE ENG, V6, P351, DOI 10.1089/107632700418074; SAITOH H, 1994, J ORAL REHABIL, V21, P431, DOI 10.1111/j.1365-2842.1994.tb01157.x; SCHOTT RJ, 1993, CARDIOVASC RES, V27, P1155, DOI 10.1093/cvr/27.7.1155; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shen Francis H, 2006, Spine J, V6, P615, DOI 10.1016/j.spinee.2006.03.006; Stahelin AC, 1997, ARTHROSCOPY, V13, P238, DOI 10.1016/S0749-8063(97)90162-6; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Velema J, 2006, ADV BIOCHEM ENG BIOT, V102, P187, DOI 10.1007/10_013; Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953; WINET H, 1993, J BIOMED MATER RES, V27, P667, DOI 10.1002/jbm.820270514; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1	42	55	55	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e496	10.1371/journal.pone.0000496	http://dx.doi.org/10.1371/journal.pone.0000496			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551577	gold, Green Submitted, Green Published			2022-12-25	WOS:000207451500006
J	Zhou, D; Xue, J; Chen, JM; Morcillo, P; Lambert, JD; White, KP; Haddad, GG				Zhou, Dan; Xue, Jin; Chen, Jianming; Morcillo, Patrick; Lambert, J. David; White, Kevin P.; Haddad, Gabriel G.			Experimental Selection for Drosophila Survival in Extremely Low O-2 Environment	PLOS ONE			English	Article								Background. Cellular hypoxia, if severe enough, results usually in injury or cell death. Our research in this area has focused on the molecular mechanisms underlying hypoxic tissue injury to explore strategies to prevent injury or enhance tolerance. The current experiments were designed to determine the genetic basis for adaptation to long term low O-2 environments. Methodology/Principal Findings. With long term experimental selection over many generations, we obtained a Drosophila melanogaster strain that can live perpetually in extremely low, normally lethal, O-2 condition (as low as 4% O-2). This strain shows a dramatic phenotypic divergence from controls, including a decreased recovery time from anoxic stupor, a higher rate of O-2 consumption in hypoxic conditions, and a decreased body size and mass due to decreased cell number and size. Expression arrays showed that about 4% of the Drosophila genome altered in expression and about half of the alteration was down-regulation. The contribution of some altered transcripts to hypoxia tolerance was examined by testing the survival of available corresponding P-element insertions (and their excisions) under extremely low O-2 conditions. We found that down-regulation of several candidate genes including Best1, broad, CG7102, dunce, lin19-like and sec6 conferred severe hypoxia tolerance in Drosophila. Conclusions/Significance. We have identified a number of genes that play an important role in the survival of a selected Drosophila strain in extremely low O-2 conditions, selected by decreasing O-2 availability over many generations. Because of conservation of pathways, we believe that such genes are critical in hypoxia adaptation in physiological or pathological conditions not only in Drosophila but also in mammals.	[White, Kevin P.] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA; [White, Kevin P.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [White, Kevin P.] Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; [Zhou, Dan; Xue, Jin; Haddad, Gabriel G.] Univ Calif San Diego, Dept Pediat, Sect Resp Med, La Jolla, CA 92093 USA; [Zhou, Dan; Xue, Jin; Haddad, Gabriel G.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Chen, Jianming] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; [Morcillo, Patrick] Yeshiva Univ, Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY USA; [Lambert, J. David] Univ Rochester, Dept Biol, Rochester, NY 14627 USA; [Zhou, Dan; Xue, Jin; Haddad, Gabriel G.] Rady Childrens Hosp San Diego, San Diego, CA USA	University of Chicago; University of Chicago; University of Chicago; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute; Yeshiva University; Albert Einstein College of Medicine; University of Rochester; Rady Childrens Hospital San Diego	White, KP (corresponding author), Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA.	kpwhite@uchicago.edu; ghaddad@ucsd.edu	Zhou, Dan/T-7203-2017	Lambert, J. David/0000-0002-7005-0244; Zhou, Dan/0000-0001-6401-9040; Morcillo, Patrick/0000-0001-9543-2487	National Institutes of Health [RO1NS037756, PO1HD032573]; Helen Hay Whitney Foundation; W.M. Keck Foundation; Beckman Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD032573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037756] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Helen Hay Whitney Foundation; W.M. Keck Foundation(W.M. Keck Foundation); Beckman Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by National Institutes of Health grants to GGH (RO1NS037756 and PO1HD032573), a postdoctoral fellowship from the Helen Hay Whitney Foundation to JDL and by grants from the W.M. Keck Foundation, the Beckman Foundation and the NIH to KPW.	ALBERGHINA M, 1982, J NEUROSCI RES, V7, P147, DOI 10.1002/jnr.490070206; Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29; Bayer CA, 1997, DEV BIOL, V187, P267, DOI 10.1006/dbio.1997.8620; Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427; Bruder ED, 2004, ENDOCRINOLOGY, V145, P5364, DOI 10.1210/en.2004-0582; Carini R, 2004, GASTROENTEROLOGY, V127, P914, DOI 10.1053/j.gastro.2004.06.018; Chen QF, 2002, J BIOL CHEM, V277, P3274, DOI 10.1074/jbc.M109479200; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; DAVIS RL, 1981, J CELL BIOL, V90, P101, DOI 10.1083/jcb.90.1.101; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Douglas RM, 2003, J APPL PHYSIOL, V94, P2068, DOI 10.1152/japplphysiol.01029.2002; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Filippov V, 2000, J EXP BIOL, V203, P2747; Greenway SC, 2000, J EXP ZOOL, V287, P477, DOI 10.1002/1097-010X(20001201)287:7<477::AID-JEZ3>3.0.CO;2-4; GREKSA LP, 1988, AM J PHYS ANTHROPOL, V75, P77, DOI 10.1002/ajpa.1330750109; GREKSA LP, 1985, ANN HUM BIOL, V12, P225, DOI 10.1080/03014468500007721; GROOTHUIS JR, 1987, AM J DIS CHILD, V141, P992, DOI 10.1001/archpedi.1987.04460090069028; HADDAD GG, 1993, PROG NEUROBIOL, V40, P277, DOI 10.1016/0301-0082(93)90014-J; Haddad GG, 1997, P NATL ACAD SCI USA, V94, P10809, DOI 10.1073/pnas.94.20.10809; HADDAD GG, 1997, J INSECT PHYSL, V43, P203; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Henry JR, 2004, J EXP BIOL, V207, P3559, DOI 10.1242/jeb.01189; Jacobs EGJ, 2000, J PEDIATR ENDOCR MET, V13, P387; Jones NM, 2004, J NEUROCHEM, V89, P157, DOI 10.1111/j.1471-4159.2004.02324.x; KISS I, 1988, GENETICS, V118, P247; Li TR, 2003, DEV CELL, V5, P59, DOI 10.1016/S1534-5807(03)00192-8; Lloyd TE, 2000, NEURON, V26, P45, DOI 10.1016/S0896-6273(00)81136-8; Ma E, 2001, J CLIN INVEST, V107, P685, DOI 10.1172/JCI11625; Ma EB, 1999, MOL BRAIN RES, V63, P217, DOI 10.1016/S0169-328X(98)00265-4; MONGE C, 1991, PHYSIOL REV, V71, P1135, DOI 10.1152/physrev.1991.71.4.1135; Neckar J, 2005, AM J PHYSIOL-HEART C, V288, pH1566, DOI 10.1152/ajpheart.00586.2004; Pachori AS, 2004, P NATL ACAD SCI USA, V101, P12282, DOI 10.1073/pnas.0404616101; Raval AP, 2003, J NEUROSCI, V23, P384, DOI 10.1523/JNEUROSCI.23-02-00384.2003; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Toma DP, 2002, NAT GENET, V31, P349, DOI 10.1038/ng893; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vartiainen N, 2002, J NEUROCHEM, V82, P329, DOI 10.1046/j.1471-4159.2002.00959.x; White KP, 2001, NAT REV GENET, V2, P528, DOI 10.1038/35080565; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Xi L, 2006, MOL CELL BIOCHEM, V291, P205, DOI 10.1007/s11010-006-9194-7	42	68	70	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e490	10.1371/journal.pone.0000490	http://dx.doi.org/10.1371/journal.pone.0000490			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534440	gold, Green Published, Green Submitted			2022-12-25	WOS:000207448800020
J	Lufei, C; Koh, TH; Uchida, T; Cao, X				Lufei, C.; Koh, T. H.; Uchida, T.; Cao, X.			Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity	ONCOGENE			English	Article						Pin1; serine phosphorylation; Stat3; transcriptional activity	PROLYL ISOMERASE PIN1; SERINE PHOSPHORYLATION; CARCINOMA CELLS; BREAST-CANCER; ACTIVATION; ISOMERIZATION; TRANSCRIPTION; DETACHMENT; ONCOGENE; PROTEINS	Signal transducer and activator of transcription 3 (Stat3) belongs to a family of latent cytoplasmic transcription factors important for cytokine signaling. Stat3 is constitutively activated in various tumors, and activated Stat3 itself also acts as an oncogene. Transcriptional activity of Stat3 is controlled by Tyr-phosphorylation, followed by dimerization and nuclear translocation. However, phosphorylation on Ser727 is indispensable for its maximal transcriptional activity with unclear mechanism. Here, we report that peptidyl-prolyl cis/trans isomerase 1 (Pin1), which specifically recognizes the pSer/Thr-Pro motifs on its target proteins, interacts with Stat3 upon cytokine/growth factor stimulation. Overexpression of Pin1 promotes Stat3 transcriptional activity and target gene expression, as well as recruitment of transcription coactivator, p300. These effects, however, were compromised in the Pin1-deficient cells, and were totally dependent on the Ser727 phosphorylation site. Finally, we showed that Pin1 enhances Stat3-mediated epithelial mesenchymal transition in breast cancer cells induced by oncostatin M. Our data reveal a novel, Ser727 phosphorylation-dependent, post-translational regulation mechanism for Stat3.	[Lufei, C.; Koh, T. H.; Cao, X.] Inst Mol & Cell Biol, Signal Transduct Lab, Singapore, Singapore; [Uchida, T.] Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 980, Japan	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Tohoku University	Cao, X (corresponding author), Inst Mol & Cell Biol, Cell Signaling Lab, 61 Proteos Bldg,61 Biopolis Dr, Singapore 138673, Singapore.	mcbcaoxm@imcb.a-star.edu.sg		Uchida, Takafumi/0000-0003-3665-4906				Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Holzer RG, 2004, CLIN EXP METASTAS, V21, P167, DOI 10.1023/B:CLIN.0000024760.02667.db; Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WINKLER S, 2000, P SOC PHOTO-OPT INS, V1, P287; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhanel George G, 2002, Expert Opin Pharmacother, V3, P277; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	32	84	85	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7656	7664		10.1038/sj.onc.1210567	http://dx.doi.org/10.1038/sj.onc.1210567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563747				2022-12-25	WOS:000251537800007
J	Glaros, S; Cirrincione, GM; Muchardt, C; Kleer, CG; Michael, CW; Reisman, D				Glaros, S.; Cirrincione, G. M.; Muchardt, C.; Kleer, C. G.; Michael, C. W.; Reisman, D.			The reversible epigenetic silencing of BRM: implications for clinical targeted therapy	ONCOGENE			English	Article						Brahma; Brahma-related gene 1; BRG1/BRM-associated factor; tumor suppressor; lung cancer; SWI/SNF complex	CHROMATIN REMODELING FACTORS; HUMAN LUNG-CANCER; TUMOR-CELL LINES; SWI/SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; CD44 EXPRESSION; GROWTH; BRG1; TRANSCRIPTION	The SWI/SNF chromatin- remodeling complex serves as a master switch that directs and limits the execution of specific cellular programs, such as differentiation and growth control. SWI/SNF function requires one of two paralogous ATPase subunits, Brahma (BRM) or BRMrelated gene 1 (BRG1), which we previously found are lost together in cancer cell lines and primary lung cancers. Although BRG1 has been found to be mutated in cancer cell lines, the mechanisms underlying BRM silencing are not known. To address this question, we sequenced BRM in 10 BRM/BRG10 deficient cancer cell lines and found that BRM was devoid of abrogating mutations. Moreover, histone deacetylase (HDAC) inhibitors restored BRM expression in each of these BRG1/BRM-defficient cancer cell lines, indicating that epigenetic silencing is a major mechanism underlying the loss of BRM expression. Despite their ability restore BRM expression, these HDAC inhibitors also blocked BRM function when present. However, after their removal, we observed that BRM expression remained elevated for several days, and during this period, BRM activity was detected. We also found that the suppression of BRM occurs in a broad range of human tumor types and that loss of one or both BRM alleles potentiated tumor development in mice. Thus, BRG1 and BRM are silenced by different mechanisms, and it may be possible to clinically target and reexpress BRM in a number of tumor types, potentially impacting tumor development.	Univ Michigan, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI 48103 USA; Inst Pasteur, Dept Dev Biol, CNRS, URA1644, Paris, France; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Michigan System; University of Michigan	Reisman, D (corresponding author), Univ Michigan, Div Hematol Oncol, Dept Internal Med, MRSB2,B570B, Ann Arbor, MI 48103 USA.	dreisman@umich.edu			NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572, P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [CA092149-03, 5-P30-CA46592] Funding Source: Medline; NIDDK NIH HHS [DK20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Coisy-Quivy M, 2006, CANCER RES, V66, P5069, DOI 10.1158/0008-5472.CAN-05-0596; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; STROBECK MW, 2002, J BIOL CHEM, V21, P21; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716	20	111	116	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					7058	7066		10.1038/sj.onc.1210514	http://dx.doi.org/10.1038/sj.onc.1210514			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17546055				2022-12-25	WOS:000250412200011
J	Egerer, M; Giesemann, T; Jank, T; Satchell, KJF; Aktories, K				Egerer, Martina; Giesemann, Torsten; Jank, Thomas; Satchell, Karla J. Fullner; Aktories, Klaus			Auto-catalytic cleavage of Clostridium difficile toxins a and B depends on cysteine protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLTRANSFERASES; DOMAIN; CELLS; GENE; CYTOTOXINS; EPIDEMIC; PROTEINS; COLITIS; DISEASE; STRAIN	The action of Clostridium difficile toxins A and B depends on processing and translocation of the catalytic glucosyltransferase domain into the cytosol of target cells where Rho GTPases are modified. Here we studied the processing of the toxins. Dithiothreitol and beta-mercaptoethanol induced auto-cleavage of purified native toxin A and toxin B into similar to 250/210- and similar to 63-kDa fragments. The similar to 63-kDa fragment was identified by mass spectrometric analysis as the N-terminal glucosyltransferase domain. This cleavage was blocked by N-ethylmaleimide or iodoacetamide. Exchange of cysteine 698, histidine 653, or aspartate 587 of toxin B prevented cleavage of full-length recombinant toxin B and of an N-terminal fragment covering residues 1-955 and inhibited cytotoxicity of full-length toxin B. Dithiothreitol synergistically increased the effect of myo-inositol hexakisphosphate, which has been reported to facilitate auto-cleavage of toxin B (Reineke, J., Tenzer, S., Rupnik, M., Koschinski, A., Hasselmayer, O., Schrattenholz, A., Schild, H., and Von Eichel-Streiber, C. ( 2007) Nature 446, 415-419). N-Ethylmaleimide blocked auto-cleavage induced by the addition of myo-inositol hexakisphosphate, suggesting that cysteine residues are essential for the processing of clostridial glucosylating toxins. Our data indicate that clostridial glucosylating cytotoxins possess an inherent cysteine protease activity related to the cysteine protease of Vibrio cholerae RTX toxin, which is responsible for auto-cleavage of glucosylating toxins.	Univ Freiburg, Otto Krayer Haus, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Northwestern Univ, Feinberg Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA	University of Freiburg; Northwestern University; Feinberg School of Medicine	Aktories, K (corresponding author), Univ Freiburg, Otto Krayer Haus, Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Satchell, Karla/GSN-3100-2022; Aktories, Klaus/CAJ-5682-2022; Jank, Thomas/R-9627-2017	Aktories, Klaus/0000-0002-5397-0436; 	NIAID NIH HHS [AI051490, R01 AI051490, R01 AI051490-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051490] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; Barth H, 2001, J BIOL CHEM, V276, P10670, DOI 10.1074/jbc.M009445200; BARTLETT JG, 1977, J INFECT DIS, V136, P701, DOI 10.1093/infdis/136.5.701; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Datta SAK, 2007, J MOL BIOL, V365, P799, DOI 10.1016/j.jmb.2006.10.072; DOVE CH, 1990, INFECT IMMUN, V58, P480, DOI 10.1128/IAI.58.2.480-488.1990; Genth H, 2006, FEBS LETT, V580, P3565, DOI 10.1016/j.febslet.2006.04.100; Greco A, 2006, NAT STRUCT MOL BIOL, V13, P460, DOI 10.1038/nsmb1084; Ho JGS, 2005, P NATL ACAD SCI USA, V102, P18373, DOI 10.1073/pnas.0506391102; Jank T, 2007, GLYCOBIOLOGY, V17, p15R, DOI 10.1093/glycob/cwm004; Just I, 2005, REV PHYSIOL BIOCH P, V152, P23, DOI 10.1007/s10254-004-0033-5; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Just I., 1997, BACTERIAL TOXINS TOO, P159; KRIVAN HC, 1987, INFECT IMMUN, V55, P1873, DOI 10.1128/IAI.55.8.1873-1877.1987; Lorenz IC, 2006, NATURE, V442, P831, DOI 10.1038/nature04975; McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590; Novikova EG, 1999, J BIOL CHEM, V274, P28887, DOI 10.1074/jbc.274.41.28887; Pepin J, 2005, CAN MED ASSOC J, V173, P1037, DOI 10.1503/cmaj.050978; Pfeifer G, 2003, J BIOL CHEM, V278, P44535, DOI 10.1074/jbc.M307540200; Pop M, 2004, J BIOL CHEM, V279, P35840, DOI 10.1074/jbc.M404346200; Reineke J, 2007, NATURE, V446, P415, DOI 10.1038/nature05622; Reinert DJ, 2005, J MOL BIOL, V351, P973, DOI 10.1016/j.jmb.2005.06.071; RIFKIN GD, 1977, LANCET, V2, P1103; Rupnik M, 2005, MICROBIOL-SGM, V151, P199, DOI 10.1099/mic.0.27474-0; Sheahan KL, 2007, EMBO J, V26, P2552, DOI 10.1038/sj.emboj.7601700; VONEICHELSTREIBER C, 1990, GENE, V96, P107, DOI 10.1016/0378-1119(90)90348-U; VONEICHELSTREIBER C, 1992, J BACTERIOL, V174, P6707, DOI 10.1128/JB.174.20.6707-6710.1992; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Voth DE, 2005, CLIN MICROBIOL REV, V18, P247, DOI 10.1128/CMR.18.2.247-263.2005; WEI L, 1991, J BIOL CHEM, V266, P9002	30	147	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25314	25321		10.1074/jbc.M703062200	http://dx.doi.org/10.1074/jbc.M703062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17591770	hybrid			2022-12-25	WOS:000249014100017
J	Er, E; Lalier, L; Cartron, PF; Oliver, L; Vallette, FM				Er, Emine; Lalier, Lisenn; Cartron, Pierre-Francois; Oliver, Lisa; Vallette, Francois M.			Control of Bax homodimerization by its carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; SUBCELLULAR-LOCALIZATION; TARGETING SIGNAL; PROTEIN BAX; CELL-DEATH; MITOCHONDRIA; APOPTOSIS; OLIGOMERIZATION; MEMBRANE	The regulated oligomerization of proteins is increasingly understood to be an important step in many cellular processes, including signaling, transcription, and protein degradation. The activity of Bax, which is essential for the completion of apoptosis, has been shown to be associated with its oligomerization: homodimerization that appears to facilitate mitochondrial permeabilization during apoptosis and heterodimerization with multidomain anti-apoptotic members of the Bcl-2 family inhibiting this process. Several domains have been identified to be crucial in the homo-/heterodimerization or oligomerization of Bax, especially the so-called Bax homology 3 domain. In this study we show that although the carboxyl terminus of Bax is not implicated in its mitochondrial localization, it has a role in the dimerization process and thus in its activity.	INSERM, U601, Dept Rec Cancerol Nantes, F-44035 Nantes, France; Univ Nantes, Fac Med, F-44035 Nantes 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Vallette, FM (corresponding author), INSERM, U601, Dept Rec Cancerol Nantes, F-44035 Nantes, France.	francois.vallette@univ-nantes.fr	Vallette, Francois M/K-9047-2015; Cartron, Pierre Francois/K-9802-2015; Vallette, Francois/N-2361-2018; Oliver, Lisa J/L-3070-2015; Lalier, Lisenn/K-9230-2015	Vallette, Francois M/0000-0002-3296-8572; Oliver, Lisa J/0000-0002-5588-7564; Cartron, Pierre-Francois/0000-0002-3393-784X; Vallette, Francois/0000-0003-0802-0519				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Cartron PF, 2004, FEBS LETT, V578, P41, DOI 10.1016/j.febslet.2004.10.080; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Cassinelli G, 2004, BIOCHEM PHARMACOL, V68, P923, DOI 10.1016/j.bcp.2004.06.002; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Er E, 2006, BBA-BIOENERGETICS, V1757, P1301, DOI 10.1016/j.bbabio.2006.05.032; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Frank K, 2006, ELECTROPHORESIS, V27, P2759; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; John GB, 2002, EXP CELL RES, V278, P198, DOI 10.1006/excr.2002.5586; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; O'Neill JW, 2006, J MOL BIOL, V356, P367, DOI 10.1016/j.jmb.2005.11.032; Oliver L, 2000, FEBS LETT, V487, P161, DOI 10.1016/S0014-5793(00)02330-9; Pagliari LJ, 2005, P NATL ACAD SCI USA, V102, P17975, DOI 10.1073/pnas.0506712102; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Zha HB, 1996, MOL CELL BIOL, V16, P6494	32	17	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24938	24947		10.1074/jbc.M703823200	http://dx.doi.org/10.1074/jbc.M703823200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17556360	hybrid			2022-12-25	WOS:000248933000050
J	Philips, AS; Kwok, JC; Chong, BH				Philips, Alana S.; Kwok, Juliana C.; Chong, Beng H.			Analysis of the signals and mechanisms mediating nuclear trafficking of GATA-4 - Loss of DNA binding is associated with localization in intranuclear speckles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-4; GREEN FLUORESCENT PROTEIN; IMPORTIN-ALPHA; MISSENSE MUTATIONS; CARDIAC MYOCYTES; TRANSPORT FACTOR; PORE COMPLEX; CELL-NUCLEUS; IDENTIFICATION; EXPRESSION	Nucleocytoplasmic transport of GATA-4 is important in maintaining and regulating normal cardiogenesis and heart function. This report investigates the detailed mechanisms of GATA-4 nuclear transport. We characterized a nonclassical nuclear localization signal between amino acids 270 and 324 that actively transports GATA-4 into the nucleus of both HeLa cells and cardiac myocytes. Fine mapping studies revealed four crucial arginine residues within this region that mediate active transport predominately through the nonclassical pathway via interaction with importin beta. These four residues were also essential for the DNA binding activity of GATA-4 and transcriptional activation of cardiac-specific genes. Interestingly, mutation of these residues not only inhibited DNA binding and gene transcription but also resulted in a preferential accumulation of the GATA-4 protein in distinct subnuclear speckles. A cardiac myocyte-specific, chromosome maintenance region 1-dependent nuclear export signal consisting of three essential leucine residues was also identified. The current study provides detailed information on the nuclear shuttling pathways of GATA-4 that represents an additional mechanism of gene regulation.	St George Hosp, Dept Med, Kogarah, NSW 2217, Australia; Univ New S Wales, St Geo Clin Sch, Dept Med, Ctr Vasc Res, Sydney, NSW 2052, Australia	St George Hospital; University of New South Wales Sydney	Kwok, JC (corresponding author), St George Hosp, Dept Med, Wr Pitney Bldg,Gray St, Kogarah, NSW 2217, Australia.	j.kwok@unsw.edu.au	Chong, Beng/AAM-9010-2021; Chong, Beng/AAE-2617-2019					ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Bayliss R, 2000, TRAFFIC, V1, P448, DOI 10.1034/j.1600-0854.2000.010602.x; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; Chen M, 2002, MOL BIOL CELL, V13, P3576, DOI 10.1091/mbc.02-05-0083; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fan C, 2003, J BIOL CHEM, V278, P8780, DOI 10.1074/jbc.M208120200; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; Fernandez-Martinez J, 2003, J MOL BIOL, V334, P667, DOI 10.1016/j.jmb.2003.09.072; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorisch S, 2005, HISTOCHEM CELL BIOL, V123, P217, DOI 10.1007/s00418-005-0752-y; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; Hallhuber M, 2006, CIRC RES, V99, P626, DOI 10.1161/01.RES.0000243208.59795.d8; Harreman MT, 2004, J BIOL CHEM, V279, P20613, DOI 10.1074/jbc.M401720200; He Q, 2002, AM J PHYSIOL-ENDOC M, V283, pE50, DOI 10.1152/ajpendo.00274.2001; Hu W, 2005, MOL CELL BIOL, V25, P3087, DOI 10.1128/MCB.25.8.3087-3108.2005; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; HUANG WY, 1995, GENE, V155, P219, DOI 10.1016/0378-1119(94)00893-W; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; Kaiser FJ, 2004, EUR J HUM GENET, V12, P121, DOI 10.1038/sj.ejhg.5201094; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kwok JC, 2003, MOL PHARMACOL, V63, P849, DOI 10.1124/mol.63.4.849; Lee SJ, 2005, NATURE, V435, P693, DOI 10.1038/nature03578; Liu JY, 2006, FEBS LETT, V580, P1405, DOI 10.1016/j.febslet.2006.01.064; Lyman SK, 2002, J CELL BIOL, V159, P55, DOI 10.1083/jcb.200204163; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; McBride K, 2001, CAN J PHYSIOL PHARM, V79, P673, DOI 10.1139/cjpp-79-8-673; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; Nikolaev I, 2003, EUKARYOT CELL, V2, P209, DOI 10.1128/EC.2.2.209-221.2003; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; PRENDERGAST FG, 1978, BIOCHEMISTRY-US, V17, P3448, DOI 10.1021/bi00610a004; Quadrini KJ, 2002, J BIOL CHEM, V277, P32243, DOI 10.1074/jbc.M205677200; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rockel TD, 2005, J CELL SCI, V118, P5231, DOI 10.1242/jcs.02642; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; Terman A, 1998, MECH AGEING DEV, V100, P145, DOI 10.1016/S0047-6374(97)00129-2; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Zaffran S, 2002, CIRC RES, V91, P457, DOI 10.1161/01.RES.0000034152.74523.A8; Zhu QS, 2004, BBA-GENE STRUCT EXPR, V1676, P251, DOI 10.1016/j.bbaexp.2004.01.002	59	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24915	24927		10.1074/jbc.M701789200	http://dx.doi.org/10.1074/jbc.M701789200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17548362	hybrid			2022-12-25	WOS:000248933000048
J	Saheki, T; Iijima, M; Li, MX; Kobayashi, K; Horiuchi, M; Ushikai, M; Okumura, F; Meng, XJ; Inoue, I; Tajima, A; Moriyama, M; Eto, K; Kadowaki, T; Sinasac, DS; Tsui, LC; Tsuji, M; Okano, A; Kobayashi, T				Saheki, Takeyori; Iijima, Mikio; Li, Meng Xian; Kobayashi, Keiko; Horiuchi, Masahisa; Ushikai, Miharu; Okumura, Fumihiko; Meng, Xiao Jian; Inoue, Ituro; Tajima, Atsushi; Moriyama, Mitsuaki; Eto, Kazuhiro; Kadowaki, Takashi; Sinasac, David S.; Tsui, Lap-Chee; Tsuji, Mihoko; Okano, Akira; Kobayashi, Tsuyoshi			Citrin/Mitochondrial glycerol-3-phosphate dehydrogenase double knock-out mice recapitulate features of human citrin deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOZYGOUS SLC25A13 MUTATION; SECRETORY TRYPSIN-INHIBITOR; ADULT-ONSET CITRULLINEMIA; II CITRULLINEMIA; ARGININOSUCCINATE SYNTHETASE; UREA CYCLE; LIVER; GENE; IDENTIFICATION; GLUTAMATE	Citrin is the liver-type mitochondrial aspartate-glutamate carrier that participates in urea, protein, and nucleotide biosynthetic pathways by supplying aspartate from mitochondria to the cytosol. Citrin also plays a role in transporting cytosolic NADH reducing equivalents into mitochondria as a component of the malate-aspartate shuttle. In humans, loss-of-function mutations in the SLC25A13 gene encoding citrin cause both adult-onset type II citrullinemia and neonatal intrahepatic cholestasis, collectively referred to as human citrin deficiency. Citrin knock-out mice fail to display features of human citrin deficiency. Based on the hypothesis that an enhanced glycerol phosphate shuttle activity may be compensating for the loss of citrin function in the mouse, we have generated mice with a combined disruption of the genes for citrin and mitochondrial glycerol 3-phosphate dehydrogenase. The resulting double knock- out mice demonstrated citrullinemia, hyperammonemia that was further elevated by oral sucrose administration, hypoglycemia, and a fatty liver, all features of human citrin deficiency. An increased hepatic lactate/ pyruvate ratio in the double knock- out mice compared with controls was also further elevated by the oral sucrose administration, suggesting that an altered cytosolic NADH/NAD(+) ratio is closely associated with the hyperammonemia observed. Microarray analyses identified over 100 genes that were differentially expressed in the double knock- out mice compared with wild- type controls, revealing genes potentially involved in compensatory or downstream effects of the combined mutations. Together, our data indicate that the more severe phenotype present in the citrin/ mitochondrial glycerol-3-phosphate dehydrogenase double knock- out mice represents a more accurate model of human citrin deficiency than citrin knock- out mice.	Tokushima Bunri Univ, Inst Hlth Sci, Tokushima 7708514, Japan; Kagoshima Univ, Grad Sch Med & Dental Sci, Dept Mol Metab & Biochem Genet, Kagoshima 8908544, Japan; Tokai Univ, Sch Med, Div Mol Life Sci, Isehara, Kanagawa 2591193, Japan; Osaka Prefecture Univ, Lab Integrated Physiol Vet Sci, Sakai, Osaka 5998531, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ Hong Kong, Vice Chancellors Off, Hong Kong, Hong Kong, Peoples R China; Ajinomoto Co Inc, Pharmaceut Res Labs, Exploratory & Appl Pharmaceut Res Dept, Kawasaki, Kanagawa 2108681, Japan	Tokushima Bunri University; Kagoshima University; Tokai University; Osaka Metropolitan University; University of Tokyo; Case Western Reserve University; University of Hong Kong; Ajinomoto Co Inc	Saheki, T (corresponding author), Tokushima Bunri Univ, Inst Hlth Sci, Yamashiro, Tokushima 7708514, Japan.	takesah@tokushima.bunri-u.ac.jp	Tajima, Atsushi/C-1053-2008; Tsui, Lap-chee/A-1081-2010	Tajima, Atsushi/0000-0001-6808-5491; Sinasac, David/0000-0002-3749-5989; Moriyama, Mitsuaki/0000-0001-8123-8835				Begum L, 2002, BBA-GENE STRUCT EXPR, V1574, P283, DOI 10.1016/S0167-4781(01)00376-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown LJ, 2002, J BIOL CHEM, V277, P32892, DOI 10.1074/jbc.M202408200; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; del Arco A, 2000, BIOCHEM J, V345, P725, DOI 10.1042/0264-6021:3450725; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; Dimmock D, 2007, PEDIATRICS, V119, pE773, DOI 10.1542/peds.2006-1950; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Gao HZ, 2003, HUM MUTAT, V22, P24, DOI 10.1002/humu.10230; Hachisu M, 2005, EUR J PEDIATR, V164, P109, DOI 10.1007/s00431-004-1549-z; Hagiwara N, 2003, INTERNAL MED, V42, P978, DOI 10.2169/internalmedicine.42.978; Iijima M, 2001, ADV ENZYME REGUL, V41, P325, DOI 10.1016/S0065-2571(00)00022-4; Ikeda S, 2001, J NEUROL NEUROSUR PS, V71, P663, DOI 10.1136/jnnp.71.5.663; Ikeda Shu-ichi, 2004, Ann Intern Med, V141, pW109; Imamura Y, 2003, HEPATOL RES, V26, P68, DOI 10.1016/S1386-6346(02)00331-5; INUI Y, 1994, GASTROENTEROLOGY, V107, P1154, DOI 10.1016/0016-5085(94)90241-0; Kasahara M, 2001, TRANSPLANTATION, V71, P157, DOI 10.1097/00007890-200101150-00027; KOBAYASHI K, 1986, AM J HUM GENET, V38, P667; KOBAYASHI K, 1995, FEBS LETT, V372, P69, DOI 10.1016/0014-5793(95)00948-9; Kobayashi K, 1997, HEPATOLOGY, V25, P1160, DOI 10.1002/hep.510250519; KOBAYASHI K, 1993, AM J HUM GENET, V53, P1024; Kobayashi K, 2004, SEIKAGAKU, V76, P1543; KOBAYASHI K, 1990, J BIOL CHEM, V265, P11361; Kobayashi K, 1999, NAT GENET, V22, P159, DOI 10.1038/9667; Kobayashi K, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P565; Lamprecht W., 1988, METHOD ENZYMAT AN, VVI, P570; MILMAN HA, 1974, BIOCHEM J, V142, P27, DOI 10.1042/bj1420027; Moriyama M, 2006, J HEPATOL, V44, P930, DOI 10.1016/j.jhep.2005.09.018; NAKABAYASHI H, 2001, JPN J INHERIT METAB, V17, P124; Ohura T, 2001, HUM GENET, V108, P87, DOI 10.1007/s004390000448; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; PIERSON DL, 1977, J BIOL CHEM, V252, P6464; RUEGG UT, 1980, ANAL BIOCHEM, V102, P206, DOI 10.1016/0003-2697(80)90340-1; SADAVA D, 1987, BIOL NEONATE, V52, P26, DOI 10.1159/000242681; Saheki T, 2005, HEPATOL RES, V33, P181, DOI 10.1016/j.hepres.2005.09.031; SAHEKI T, 1987, REV PHYSIOL BIOCH P, V108, P21, DOI 10.1007/BFb0034071; SAHEKI T, 1981, CLIN CHIM ACTA, V109, P325, DOI 10.1016/0009-8981(81)90318-1; Saheki T, 2002, J HUM GENET, V47, P333, DOI 10.1007/s100380200046; SAHEKI T, 1985, J INHERIT METAB DIS, V8, P155, DOI 10.1007/BF01819306; Sameshima Y., 1986, J CLIN BIOCHEM NUTR, V1, P129; SCHIMKE RT, 1962, J BIOL CHEM, V237, P459; Sinasac DS, 2004, MOL CELL BIOL, V24, P527, DOI 10.1128/MCB.24.2.527-536.2004; STOLL B, 1991, HEPATOLOGY, V13, P247, DOI 10.1002/hep.1840130208; SU TS, 1982, J CLIN INVEST, V70, P1334, DOI 10.1172/JCI110736; Takagi H, 2006, J HEPATOL, V44, P236, DOI 10.1016/j.jhep.2005.08.024; Takahashi H, 2006, MED SCI MONITOR, V12, pCS13; Tamakawa S, 1994, J JPN SOC INTENSIVE, V1, P37, DOI DOI 10.3918/JSICM.1.37; Tamamori A, 2004, PEDIATR RES, V56, P608, DOI 10.1203/01.PDR.0000139713.64264.BC; Tamamori A, 2002, EUR J PEDIATR, V161, P609, DOI 10.1007/s00431-002-1045-2; Tanaka N, 2007, CLIN GASTROENTEROL H, V5, pXXXII, DOI 10.1016/j.cgh.2006.06.014; Tanaka T, 2002, TOHOKU J EXP MED, V198, P89, DOI 10.1620/tjem.198.89; Tazawa Y, 2001, J PEDIATR-US, V138, P735, DOI 10.1067/mpd.2001.113264; Terada R, 2006, J GASTROEN HEPATOL, V21, P1634, DOI 10.1111/j.1440-1746.2006.04339.x; Tomomasa T, 2001, J PEDIATR-US, V138, P741, DOI 10.1067/mpd.2001.113361; Tsai CW, 2006, J FORMOS MED ASSOC, V105, P852, DOI 10.1016/S0929-6646(09)60274-6; WILLIAMS MT, 1986, BIOCHEM J, V233, P595, DOI 10.1042/bj2330595; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; YAGI Y, 1988, AM J CLIN PATHOL, V89, P735, DOI 10.1093/ajcp/89.6.735; YAJIMA Y, 1982, TOHOKU J EXP MED, V137, P213, DOI 10.1620/tjem.137.213; Yamaguchi N, 2002, HUM MUTAT, V19, P122, DOI 10.1002/humu.10022; Yasuda T, 2000, HUM GENET, V107, P537, DOI 10.1007/s004390000430; Yazaki M, 2005, INTERNAL MED, V44, P188, DOI 10.2169/internalmedicine.44.188	63	58	62	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25041	25052		10.1074/jbc.M702031200	http://dx.doi.org/10.1074/jbc.M702031200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17591776	hybrid			2022-12-25	WOS:000248933000060
J	Xu, MH; Yamada, M; Li, M; Liu, HQ; Chen, SG; Han, YPW				Xu, Minghua; Yamada, Mitsunori; Li, Mei; Liu, Hongqi; Chen, Shu G.; Han, Yiping W.			FadA from Fusobacterium nucleatum utilizes both secreted and nonsecreted forms for functional oligomerization for attachment and invasion of host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSE-BINDING ADHESIN; IDENTIFICATION; COAGGREGATION; BACTERIA; PK1594; LECTIN; MECHANISM; INFECTION; ADHERES	Fusobacterium nucleatum is a Gram-negative anaerobe associated with various human infections, including periodontal diseases and preterm birth. A novel FadA adhesin was recently identified for host-cell binding. It consists of 129 amino acid residues, with an 18-amino acid signal peptide. Expression of FadA in Escherichia coli enhanced bacterial binding to host epithelial and endothelial cells. In both E. coli and F. nucleatum, FadA exists in two forms, the intact pre- FadA and the secreted mature FadA ( mFadA), with pre- FadA anchored in the inner membrane and mFadA secreted outside the bacteria. Pre- FadA and mFadA formed high M-r complexes. When each form was purified to a single species, mFadA was soluble at neutral pH, whereas pre- FadA was insoluble. Pre- FadA became soluble when mixed with mFadA or under acidic pH. When fluorescence-labeled mFadA alone was added to the epithelial cells, no binding was detected. However, when mixed with nonlabeled pre- FadA, binding and invasion of mFadA into epithelial cells was observed. FadA is a unique bacterial adhesin/ invasin in that it utilizes its own two forms for both structural and functional purposes. The pre- FadA-mFadA complex is probably anchored in the inner membrane and protrudes through the outer membrane. Internalization of the pre- FadA- mFadA ensures invasion of the bacteria into the host cells.	Case Western Reserve Univ, Dept Sci Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Periodont, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Han, YPW (corresponding author), Case Western Reserve Univ, Dept Sci Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	yiping.han@case.edu	Chen, Shu/Z-2943-2019; Chen, Shu G./O-4750-2014; Chen, Shu G./AAK-7301-2021	Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001	NIDCR NIH HHS [R01DE14924] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014924] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CHAIM W, 1992, ARCH GYNECOL OBSTET, V251, P1, DOI 10.1007/BF02718272; Desvaux M, 2005, BBA-BIOMEMBRANES, V1713, P92, DOI 10.1016/j.bbamem.2005.05.002; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Guo M, 2000, ORAL MICROBIOL IMMUN, V15, P119, DOI 10.1034/j.1399-302x.2000.150208.x; Han YPW, 2004, INFECT IMMUN, V72, P2272, DOI 10.1128/IAI.72.4.2272-2279.2004; Han YW, 2005, J BACTERIOL, V187, P5330, DOI 10.1128/JB.187.15.5330-5340.2005; Han YW, 2000, INFECT IMMUN, V68, P3140, DOI 10.1128/IAI.68.6.3140-3146.2000; HAN YW, 2006, CURRENT PROTOCOLS MI; Hill G B, 1998, Ann Periodontol, V3, P222, DOI 10.1902/annals.1998.3.1.222; HILL GB, 1993, CLIN INFECT DIS, V16, P423, DOI DOI 10.1093/CLINIDS/16.SUPPLEMENT_; KAUFMAN J, 1989, INFECT IMMUN, V57, P331, DOI 10.1128/IAI.57.2.331-337.1989; KINDER SA, 1993, J BACTERIOL, V175, P840, DOI 10.1128/JB.175.3.840-850.1993; KOLENBRANDER PE, 1993, J BACTERIOL, V175, P3247, DOI 10.1128/jb.175.11.3247-3252.1993; MANGAN DF, 1989, INFECT IMMUN, V57, P3601, DOI 10.1128/IAI.57.11.3601-3611.1989; Mattick JS, 1996, GENE, V179, P147, DOI 10.1016/S0378-1119(96)00441-6; Moore W E, 1994, Periodontol 2000, V5, P66, DOI 10.1111/j.1600-0757.1994.tb00019.x; MURRAY PA, 1988, INFECT IMMUN, V56, P1314, DOI 10.1128/IAI.56.5.1314-1319.1988; Nithianantham S, 2006, ACTA CRYSTALLOGR F, V62, P1215, DOI 10.1107/S1744309106045593; Shaniztki B, 1997, INFECT IMMUN, V65, P5231, DOI 10.1128/IAI.65.12.5231-5237.1997; Shaniztki B, 1998, ORAL MICROBIOL IMMUN, V13, P47, DOI 10.1111/j.1399-302X.1998.tb00750.x; Skerker JM, 2001, P NATL ACAD SCI USA, V98, P6901, DOI 10.1073/pnas.121171698; TUTTLE RS, 1992, ORAL MICROBIOL IMMUN, V7, P78, DOI 10.1111/j.1399-302X.1992.tb00513.x; WATTS DH, 1992, OBSTET GYNECOL, V79, P351; Weiss EI, 2000, ORAL MICROBIOL IMMUN, V15, P371, DOI 10.1034/j.1399-302x.2000.150606.x	24	87	97	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25000	25009		10.1074/jbc.M611567200	http://dx.doi.org/10.1074/jbc.M611567200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17588948	hybrid			2022-12-25	WOS:000248933000056
J	Kanayama, M; Yamaguchi, S; Shibata, T; Shibata, N; Kobayashi, M; Nagai, R; Arai, H; Takahashi, K; Uchida, K				Kanayama, Masaya; Yamaguchi, Satoru; Shibata, Takahiro; Shibata, Noriyuki; Kobayashi, Makio; Nagai, Ryoji; Arai, Hiroyuki; Takahashi, Kazuhiko; Uchida, Koji			Identification of a serum component that regulates cyclooxygenase-2 gene expression in cooperation with 4-hydroxy-2-nonenal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; OXIDIZED LDL; LIPID-PEROXIDATION; PPAR-GAMMA; MACROPHAGES; CD36; RECEPTOR; ATHEROSCLEROSIS; ACTIVATION; PROTEIN	Atherosclerosis is a disorder of lipid metabolism as well as a chronic inflammatory disease. Cyclooxygenase- 2 ( COX- 2), an inducible isoform responsible for high levels of prostaglandin production during inflammation and immune responses, mediates a variety of biological actions involved in vascular pathophysiology. We have previously shown that COX- 2 gene expression is dramatically induced by a lipid- derived endogenous electrophile, 4- hydroxy- 2- nonenal ( HNE) ( Kumagai, T., Matsukawa, N., Kaneko, Y., Kusumi, Y., Mitsumata, M., and Uchida, K. ( 2004) J. Biol. Chem. 279, 48389 - 48396). In the present study, based on the finding that HNE induced COX- 2 expression only in the serum- containing media, we characterized a serum component essential for the HNE- induced COX- 2 induction and found that low density lipoprotein ( LDL) that had been denatured by freeze- thawing or oxidized LDL might be involved in the COX- 2 induction. Moreover, we characterized the cellular events triggered by the combined stimulus of HNE and oxidized LDL and established that COX- 2 induction is regulated by two sets of signaling mechanisms, one for the up- regulation of the scavenger receptor CD36 by HNE and one for the CD36mediated COX induction by oxidized LDL. These findings represent a demonstration of a link between lipoprotein modification and activation of the inflammatory potential of macrophages.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Tokyo Womens Med Univ, Dept Pathol, Tokyo 1628666, Japan; Kumamoto Univ, Fac Med & Pharmaceut Sci, Kumamoto 8608556, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan; Hokkaido Pharmaceut Univ, Dept Nutr Biochem, Otaru, Hokkaido 0470264, Japan	Nagoya University; Tokyo Women's Medical University; Kumamoto University; University of Tokyo	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp	; Shibata, Takahiro/I-6872-2014	Uchida, Koji/0000-0003-3894-5299; Shibata, Takahiro/0000-0003-3194-607X				BASU SK, 1982, J BIOL CHEM, V257, P9788; Bonen A, 2004, P NUTR SOC, V63, P245, DOI 10.1079/PNS2004331; Campbell SE, 2004, J BIOL CHEM, V279, P36235, DOI 10.1074/jbc.M400566200; Chen CC, 1999, J BIOL CHEM, V274, P31559, DOI 10.1074/jbc.274.44.31559; Escargueil-Blanc I, 2001, CIRCULATION, V104, P1814, DOI 10.1161/hc4001.097179; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FitzGerald GA, 2000, ANN MED, V32, P21; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Hirano K, 2003, TRENDS CARDIOVAS MED, V13, P136, DOI 10.1016/S1050-1738(03)00026-4; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Koki A, 2002, ADV EXP MED BIOL, V507, P177; Kumagai T, 2004, J BIOL CHEM, V279, P48389, DOI 10.1074/jbc.M409935200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Medeiros LA, 2004, J BIOL CHEM, V279, P10643, DOI 10.1074/jbc.M311735200; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Roepstorff C, 2004, P NUTR SOC, V63, P239, DOI 10.1079/PNS2004332; Sevanian A, 1997, J LIPID RES, V38, P419; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; Sevanian A, 1999, BLOOD PURIFICAT, V17, P66, DOI 10.1159/000014378; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TOYOKUNI S, 1995, FEBS LETT, V359, P189, DOI 10.1016/0014-5793(95)00033-6; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Ziouzenkova O, 1999, J BIOL CHEM, V274, P18916, DOI 10.1074/jbc.274.27.18916	37	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24166	24174		10.1074/jbc.M703212200	http://dx.doi.org/10.1074/jbc.M703212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17581812	hybrid			2022-12-25	WOS:000248686600042
J	Yassin, A; Mankin, AS				Yassin, Aymen; Mankin, Alexander S.			Potential new antibiotic sites in the ribosome revealed by deleterious mutations in RNA of the large ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-TRANSFERASE CENTER; ESCHERICHIA-COLI; A-SITE; ERYTHROMYCIN RESISTANCE; ANGSTROM RESOLUTION; SARCIN/RICIN DOMAIN; CELLULAR-REGULATION; BACTERIAL RIBOSOME; FUNCTIONAL SITES; CONSERVED LOOP	The ribosome is the main target for antibiotics that inhibit protein biosynthesis. Despite the chemical diversity of the known antibiotics that affect functions of the large ribosomal subunit, these drugs act on only a few sites corresponding to some of the known functional centers. We have used a genetic approach for identifying structurally and functionally critical sites in the ribosome that can be used as new antibiotic targets. By using randomly mutagenized rRNA genes, we mapped rRNA sites where nucleotide alterations impair the ribosome function or assembly and lead to a deleterious phenotype. A total of 77 single-point deleterious mutations were mapped in 23 S rRNA and ranked according to the severity of their deleterious phenotypes. Many of the mutations mapped to familiar functional sites that are targeted by known antibiotics. However, a number of mutations were located in previously unexplored regions. The distribution of the mutations in the spatial structure of the ribosome showed a strong bias, with the strongly deleterious mutations being mainly localized at the interface of the large subunit and the mild ones on the solvent side. Five sites where deleterious mutations tend to cluster within discrete rRNA elements were identified as potential new antibiotic targets. One of the sites, the conserved segment of helix 38, was studied in more detail. Although the ability of the mutant 50 S subunits to associate with 30 S subunits was impaired, the lethal effect of mutations in this rRNA element was unrelated to its function as an intersubunit bridge. Instead, mutations in this region had a profound deleterious effect on the ribosome assembly.	Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mankin, AS (corresponding author), Univ Illinois, Ctr Pharmaceut Biotechnol, MC 870,900 S Ashland Ave, Chicago, IL 60607 USA.	shura@uic.edu	Yassin, Aymen/N-8490-2016	Yassin, Aymen/0000-0002-4423-164X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056575] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI56575] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adrian PV, 2000, ANTIMICROB AGENTS CH, V44, P3101, DOI 10.1128/AAC.44.11.3101-3106.2000; Belova L, 2001, P NATL ACAD SCI USA, V98, P3726, DOI 10.1073/pnas.071527498; Berisio R, 2003, NAT STRUCT BIOL, V10, P366, DOI 10.1038/nsb915; Bogdanov AA, 1995, BIOCHEM CELL BIOL, V73, P869, DOI 10.1139/o95-094; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-2; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Chan YL, 2000, J MOL BIOL, V298, P795, DOI 10.1006/jmbi.2000.3720; Chernyaeva NS, 1999, J BACTERIOL, V181, P5257, DOI 10.1128/JB.181.17.5257-5262.1999; CHITTUM HS, 1995, CURR MICROBIOL, V30, P273, DOI 10.1007/BF00295501; Comartin DJ, 2006, CURR OPIN PHARMACOL, V6, P453, DOI 10.1016/j.coph.2006.05.005; DESTASIO EA, 1989, EMBO J, V8, P1213, DOI 10.1002/j.1460-2075.1989.tb03494.x; Deuerling E, 2004, CRIT REV BIOCHEM MOL, V39, P261, DOI 10.1080/10409230490892496; Dinos G, 2004, MOL CELL, V13, P113, DOI 10.1016/S1097-2765(04)00002-4; DOHME F, 1976, P NATL ACAD SCI USA, V73, P2221, DOI 10.1073/pnas.73.7.2221; DOUTHWAITE S, 1989, J MOL BIOL, V209, P655, DOI 10.1016/0022-2836(89)93000-3; ENDO Y, 1982, J BIOL CHEM, V257, P9054; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; Franceschi F, 2006, BIOCHEM PHARMACOL, V71, P1016, DOI 10.1016/j.bcp.2005.12.026; Francois B, 2005, NUCLEIC ACIDS RES, V33, P5677, DOI 10.1093/nar/gki862; Fredrick K, 2000, J MOL BIOL, V298, P379, DOI 10.1006/jmbi.2000.3563; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; Gao HX, 2003, CELL, V113, P789, DOI 10.1016/S0092-8674(03)00427-6; Gregory ST, 2001, COLD SPRING HARB SYM, V66, P101, DOI 10.1101/sqb.2001.66.101; Hansen JL, 2003, J MOL BIOL, V330, P1061, DOI 10.1016/S0022-2836(03)00668-5; Hobbie SN, 2006, BIOCHIMIE, V88, P1033, DOI 10.1016/j.biochi.2006.04.008; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Khaitovich P, 1999, J MOL BIOL, V291, P1025, DOI 10.1006/jmbi.1999.3030; Komoda T, 2006, J BIOL CHEM, V281, P32303, DOI 10.1074/jbc.M607058200; Laios E, 2004, ARCH PATHOL LAB MED, V128, P1351; LIEBERMAN KR, 1994, J BIOL CHEM, V269, P16163; Liiv A, 2006, J BIOL CHEM, V281, P29850, DOI 10.1074/jbc.M603013200; Macbeth MR, 1999, J MOL BIOL, V285, P965, DOI 10.1006/jmbi.1998.2388; Maeder C, 2006, BIOCHEMISTRY-US, V45, P6635, DOI 10.1021/bi052544p; Mitra K, 2006, NAT STRUCT MOL BIOL, V13, P957, DOI 10.1038/nsmb1166; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MURGOLA EJ, 1988, P NATL ACAD SCI USA, V85, P4162, DOI 10.1073/pnas.85.12.4162; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; NIERHAUS KH, 1991, BIOCHIMIE, V73, P739, DOI 10.1016/0300-9084(91)90054-5; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; PACE B, 1982, P NATL ACAD SCI-BIOL, V79, P36, DOI 10.1073/pnas.79.1.36; Poehlsgaard J, 2005, NAT REV MICROBIOL, V3, P870, DOI 10.1038/nrmicro1265; Polacek N, 2000, MOL CELL, V6, P159, DOI 10.1016/S1097-2765(00)00017-4; Porse BT, 1998, J MOL BIOL, V276, P391, DOI 10.1006/jmbi.1997.1541; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1990, P NATL ACAD SCI USA, V87, P1042, DOI 10.1073/pnas.87.3.1042; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; Rodriguez-Correa D, 2004, RNA, V10, P28, DOI 10.1261/rna.5172104; RON EZ, 1966, SCIENCE, V153, P1119, DOI 10.1126/science.153.3740.1119; ROTTMANN N, 1988, EUR J BIOCHEM, V177, P81, DOI 10.1111/j.1432-1033.1988.tb14347.x; Russell RJM, 2003, J AM CHEM SOC, V125, P3410, DOI 10.1021/ja029736h; Sato NS, 2006, P NATL ACAD SCI USA, V103, P15386, DOI 10.1073/pnas.0605970103; Schluenzen F, 2006, NAT STRUCT MOL BIOL, V13, P871, DOI 10.1038/nsmb1145; Schlunzen F, 2001, NATURE, V413, P814, DOI 10.1038/35101544; Schoolnik GK, 2002, CURR OPIN MICROBIOL, V5, P20, DOI 10.1016/S1369-5274(02)00280-1; Schroeder SJ, 2007, J MOL BIOL, V367, P1471, DOI 10.1016/j.jmb.2007.01.081; Schuwirth BS, 2006, NAT STRUCT MOL BIOL, V13, P879, DOI 10.1038/nsmb1150; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Sergiev P, 1998, NUCLEIC ACIDS RES, V26, P2519, DOI 10.1093/nar/26.11.2519; Sergiev PV, 2005, J MOL BIOL, V353, P116, DOI 10.1016/j.jmb.2005.08.006; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; Stelzl U, 2000, P NATL ACAD SCI USA, V97, P4597, DOI 10.1073/pnas.090009297; Tenson T, 2006, MOL MICROBIOL, V59, P1664, DOI 10.1111/j.1365-2958.2006.05063.x; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; Thomson CJ, 2004, CURR OPIN MICROBIOL, V7, P445, DOI 10.1016/j.mib.2004.08.009; Tor Y, 2006, BIOCHIMIE, V88, P1045, DOI 10.1016/j.biochi.2006.03.005; Treede I, 2003, MOL MICROBIOL, V49, P309, DOI 10.1046/j.1365-2958.2003.03558.x; Triman KL, 1999, ADV GENET, V41, P157, DOI 10.1016/S0065-2660(08)60153-4; Tu D, 2005, CELL, V121, P257, DOI 10.1016/j.cell.2005.02.005; Wild K, 2004, NAT STRUCT MOL BIOL, V11, P1049, DOI 10.1038/nsmb853; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; Yassin A, 2005, P NATL ACAD SCI USA, V102, P16620, DOI 10.1073/pnas.0508444102; Yonath A, 2005, ANNU REV BIOCHEM, V74, P649, DOI 10.1146/annurev.biochem.74.082803.133130; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zhou YF, 2005, ANTIMICROB AGENTS CH, V49, P4942, DOI 10.1128/AAC.49.12.4942-4949.2005; Zvereva MI, 1998, FEBS LETT, V421, P249, DOI 10.1016/S0014-5793(97)01578-0	78	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24329	24342		10.1074/jbc.M703106200	http://dx.doi.org/10.1074/jbc.M703106200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17591769	hybrid			2022-12-25	WOS:000248686600059
J	Xie, M; Kobayashi, I; Kiyoshima, T; Yamaza, H; Honda, JY; Takahashi, K; Enoki, N; Akamine, A; Sakai, H				Xie, Ming; Kobayashi, Ieyoshi; Kiyoshima, Tamotsu; Yamaza, Haruyoshi; Honda, Jun-ya; Takahashi, Keiko; Enoki, Norio; Akamine, Akifumi; Sakai, Hidetaka			Functional implication of nucleolin in the mouse first molar development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING TOOTH GERM; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; MESSENGER-RNA; UP-REGULATION; MIDKINE MK; EXPRESSION; PROTEIN; BINDING; GROWTH	We examined the functional implication of nucleolin in the mouse first molar development. Both the nucleolin mRNA and protein expressions were demonstrated in the odontogenic epithelial cells in the early stage and in the inner enamel epithelial layer in the late stage. The expression pattern of nucleolin corresponded to the proliferating cells in the tooth germ, thus showing that nucleolin could possibly be related to cell proliferation. No in situ signal of nucleolin was found in the primary enamel knot (PEK). Furthermore, nucleolin protein was demonstrated in the PEK by immunohistochemistry. The existence of nucleolin protein in the PEK may possibly be related to the apoptosis in the PEK cells. An inhibition assay using the hemagglutinating virus of Japan-liposome containing nucleolin antisense phosphorothioated oligonucleotide (AS S-ODN) in cultured mouse mandibles at embryonic day (E) 11.0 showed a marked growth inhibition of tooth germ. Moreover, no developmental arrest was found in the cultured tooth germ at E15.0 treated with nucleolin AS S-ODN. Real time PCR was performed to examine the mRNA expression of nucleolin-related genes, and a significant reduction in the midkine mRNA expression was thus observed in the mouse mandible after being treated with nucleolin AS S-ODN. This inhibition assay indicated that nucleolin could thus be involved in the early stage of tooth germ initiation and morphogenesis, possibly by regulating the midkine expression.	Kyushu Univ, Grad Sch Dent Sci, Lab Oral Pathol & Med, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Dent Sci, Dept Endodontol & Operat Dent, Fukuoka 8128582, Japan; Nagasaki Univ, Sch Med, Dept Resp & Digest Med, Div Expt Med Pathol & Gerontol, Nagasaki 8528523, Japan; Kyushu Univ, Grad Sch Dent Sci, Dept Orthodont, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Dent Sci, Dept Fixed Prothodont, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Nagasaki University; Kyushu University; Kyushu University	Xie, M (corresponding author), Kyushu Univ, Grad Sch Dent Sci, Lab Oral Pathol & Med, Fukuoka 8128582, Japan.	ikoba@dent.kyushu-u.ac.jp	Yamaza, Haruyoshi/AAD-4011-2019	Yamaza, Haruyoshi/0000-0003-1138-3943				Akhter M, 2005, HISTOCHEM CELL BIOL, V124, P207, DOI 10.1007/s00418-005-0040-x; Bjerregaard B, 2004, BIOL REPROD, V70, P867, DOI 10.1095/biolreprod.103.021683; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CAIZERGUESFERRER M, 1989, GENE DEV, V3, P324, DOI 10.1101/gad.3.3.324; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; Fahling M, 2005, BBA-GENE STRUCT EXPR, V1731, P32, DOI 10.1016/j.bbaexp.2005.08.005; Ginisty H, 2000, J BIOL CHEM, V275, P18845, DOI 10.1074/jbc.M002350200; Hoffmann H, 2000, J CELL BIOCHEM, V80, P156; Huang Y, 2006, BLOOD, V107, P3564, DOI 10.1182/blood-2005-07-2961; Huddleson JP, 2006, J BIOL CHEM, V281, P15121, DOI 10.1074/jbc.M513406200; Inazumi T, 1997, ARCH DERMATOL RES, V289, P471, DOI 10.1007/s004030050223; KANEDA Y, 1987, EXP CELL RES, V173, P56, DOI 10.1016/0014-4827(87)90331-4; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; Kim SK, 2003, DNA CELL BIOL, V22, P171, DOI 10.1089/104454903321655792; Kito S, 2003, BIOCHEM BIOPH RES CO, V300, P950, DOI 10.1016/S0006-291X(02)02942-X; Klibanov SA, 2001, J CELL SCI, V114, P1867; Kobayashi I, 2006, BONE, V38, P836, DOI 10.1016/j.bone.2005.10.026; KONISHI T, 1995, J BIOCHEM-TOKYO, V117, P1170, DOI 10.1093/oxfordjournals.jbchem.a124840; MITSIADIS TA, 1995, J CELL BIOL, V129, P267, DOI 10.1083/jcb.129.1.267; OHMORI H, 1990, EXP CELL RES, V189, P227, DOI 10.1016/0014-4827(90)90240-B; Otake Y, 2005, MOL PHARMACOL, V67, P319, DOI 10.1124/mol.104.006080; Pispa J, 2003, GENE EXPR PATTERNS, V3, P675, DOI 10.1016/S1567-133X(03)00092-9; Randall LE, 2002, CONNECT TISSUE RES, V43, P205, DOI 10.1080/03008200290000538; Roger B, 2003, CHROMOSOMA, V111, P399, DOI 10.1007/s00412-002-0221-5; Saeki Y, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P123; Said EA, 2002, J BIOL CHEM, V277, P37492, DOI 10.1074/jbc.M201194200; Salazar-Ciudad I, 2002, P NATL ACAD SCI USA, V99, P8116, DOI 10.1073/pnas.132069499; Sawada T, 1998, EUR J ORAL SCI, V106, P126, DOI 10.1111/j.1600-0722.1998.tb02164.x; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Shigemura N, 2001, HISTOCHEM J, V33, P253, DOI 10.1023/A:1017900305661; Shigemura N, 1999, HISTOCHEM J, V31, P367, DOI 10.1023/A:1003796023992; Sirri V, 1997, CYTOMETRY, V28, P147, DOI 10.1002/(SICI)1097-0320(19970601)28:2<147::AID-CYTO8>3.3.CO;2-G; Slavkin H, 2000, METH MOL B, V136, P45; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Wada H, 2002, HISTOCHEM J, V34, P105, DOI 10.1023/A:1020930228303; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001; Yamaza H, 2001, HISTOCHEM J, V33, P437, DOI 10.1023/A:1014491111628; Yamaza H, 2001, INT J DEV BIOL, V45, P675; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Ying GG, 2000, J BIOL CHEM, V275, P4152, DOI 10.1074/jbc.275.6.4152; Zheng X, 2005, BIOCHEM BIOPH RES CO, V329, P95, DOI 10.1016/j.bbrc.2005.01.105	46	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23275	23283		10.1074/jbc.M610779200	http://dx.doi.org/10.1074/jbc.M610779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17562718	hybrid			2022-12-25	WOS:000248577500028
J	Pedram, A; Razandi, M; Sainson, RCA; Kim, JK; Hughes, CC; Levin, ER				Pedram, Ali; Razandi, Mahnaz; Sainson, Richard C. A.; Kim, Jin K.; Hughes, Christopher C.; Levin, Ellis R.			A conserved mechanism for steroid receptor translocation to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ESTROGEN-RECEPTOR; BINDING-SITES; ALPHA; PALMITOYLATION; IDENTIFICATION; LOCALIZATION; INTEGRATION; ACTIVATION; CELLS	Multiple steroid receptors (SR) have been proposed to localize to the plasma membrane. Some structural elements for membrane translocation of the estrogen receptor alpha( ER alpha) have been described, but the mechanisms relevant to other steroid receptors are entirely unknown. Here, we identify a highly conserved 9 amino acid motif in the ligand binding domains (E domains) of human/mouse ER alpha and ER beta, progesterone receptors A and B, and the androgen receptor. Mutation of the phenylalanine or tyrosine at position -2, cysteine at position 0, and hydrophobic isoleucine/leucine or leucine/leucine combinations at positions +5/6, relative to cysteine, significantly reduced membrane localization, MAP and PI 3-kinase activation, thymidine incorporation into DNA, and cell viability, stimulated by specific SR ligands. The localization sequence mediated palmitoylation of each SR, which facilitated caveolin-1 association, subsequent membrane localization, and steroid signaling. Palmitoylation within the E domain is therefore a crucial modification for membrane translocation and function of classical sex steroid receptors.	Univ Calif Irvine, Long Beach Vet Affairs Med Ctr, Med Serv 111 1, Long Beach, CA 90822 USA; Vet Affairs Med Ctr, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Univ Calif Irvine, Long Beach Vet Affairs Med Ctr, Med Serv 111 1, 5901 E 7th St, Long Beach, CA 90822 USA.	ellis.levin@med.va.gov	Levin, Ellis/J-5402-2013		NATIONAL CANCER INSTITUTE [R01CA100366] Funding Source: NIH RePORTER; NCI NIH HHS [CA-100366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acconcia F, 2005, MOL BIOL CELL, V16, P231, DOI 10.1091/mbc.e04-07-0547; Basu J, 2004, CURR SCI INDIA, V87, P212; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Drisdel RC, 2006, METHODS, V40, P127, DOI 10.1016/j.ymeth.2006.04.015; Duvernay MT, 2004, J BIOL CHEM, V279, P30741, DOI 10.1074/jbc.M313881200; HAGVE TA, 1987, BIOCHIM BIOPHYS ACTA, V917, P333, DOI 10.1016/0005-2760(87)90138-X; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; JENSEN EV, 1962, RECENT PROG HORM RES, V18, P387; Kelly MJ, 1999, TRENDS ENDOCRIN MET, V10, P369, DOI 10.1016/S1043-2760(99)00190-3; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kim JK, 2006, J BIOL CHEM, V281, P6760, DOI 10.1074/jbc.M511024200; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Lange CA, 2007, ANNU REV PHYSIOL, V69, P171, DOI 10.1146/annurev.physiol.69.031905.160319; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200; Pedram A, 2006, MOL ENDOCRINOL, V20, P1996, DOI 10.1210/me.2005-0525; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; PIETRAS RJ, 1975, NATURE, V253, P357, DOI 10.1038/253357a0; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004-0115; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Roth AF, 2006, CELL, V125, P1003, DOI 10.1016/j.cell.2006.03.042; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Skildum A, 2005, MOL ENDOCRINOL, V19, P327, DOI 10.1210/me.2004-0306; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	33	340	351	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22278	22288		10.1074/jbc.M611877200	http://dx.doi.org/10.1074/jbc.M611877200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17535799	hybrid			2022-12-25	WOS:000248354200005
J	Williams, C; van den Berg, M; Sprenger, RR; Distel, B				Williams, Chris; van den Berg, Marlene; Sprenger, Richard R.; Distel, Ben			A conserved cysteine is essential for Pex4p-dependent ubiquitination of the peroxisomal import receptor Pex5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN IMPORT; TARGETING SIGNAL TYPE-1; N-TERMINAL RESIDUE; SACCHAROMYCES-CEREVISIAE; PICHIA-PASTORIS; PTS1 RECEPTOR; CONJUGATING ENZYME; BIOGENESIS FACTORS; CYCLING RECEPTOR; MEMBRANE	The peroxisomal protein import receptor Pex5p is modified by ubiquitin, both in an Ubc4p-dependent and -independent manner. Here we show that the two types of ubiquitination target different residues in the NH2-terminal region of Pex5p and we identify Pex4p (Ubc10p) as the ubiquitin-conjugating enzyme required for Ubc4p-independent ubiquitination. Whereas Ubc4p-dependent ubiquitination occurs on two lysine residues, Pex4p-dependent ubiquitination neither requires lysine residues nor the NH2-terminal alpha-NH2 group. Instead, a conserved cysteine residue appears to be essential for both the Pex4p-dependent ubiquitination and the overall function of Pex5p. In addition, we show that this form of ubiquitinated Pex5p is susceptible to the reducing agent beta-mercaptoethanol, a compound that is unable to break ubiquitin-NH2 group linkages. Together, our results strongly suggest that Pex4p-dependent ubiquitination of Pex5p occurs on a cysteine residue.	Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Distel, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.distel@amc.uva.nl	Williams, Chris/C-4216-2012	Williams, Chris/0000-0003-1757-6156; Sprenger, Richard/0000-0002-3947-1606				Albertini M, 2001, EUR J CELL BIOL, V80, P257, DOI 10.1078/0171-9335-00164; Ben-Saadon R, 2004, J BIOL CHEM, V279, P41414, DOI 10.1074/jbc.M407201200; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Cadwell K, 2005, SCIENCE, V309, P127, DOI 10.1126/science.1110340; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Costa-Rodrigues J, 2004, J BIOL CHEM, V279, P46573, DOI 10.1074/jbc.M406399200; CRANE DI, 1994, J BIOL CHEM, V269, P21835; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kiel JAKW, 2005, BBA-MOL CELL RES, V1745, P176, DOI 10.1016/j.bbamcr.2005.01.004; Kiel JAKW, 2005, J BIOL CHEM, V280, P1921, DOI 10.1074/jbc.M403632200; Klein ATJ, 2002, J BIOL CHEM, V277, P25011, DOI 10.1074/jbc.M203254200; Klein ATJ, 2001, J BIOL CHEM, V276, P15034, DOI 10.1074/jbc.M010776200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Koller A, 1999, J CELL BIOL, V146, P99, DOI 10.1083/jcb.146.1.99; Kragt A, 2005, J BIOL CHEM, V280, P7867, DOI 10.1074/jbc.M413553200; KRAGT A, 2006, PROTEIN DEGRADATION, P1; Leon S, 2006, J CELL BIOL, V172, P67, DOI 10.1083/jcb.200508096; Leon S, 2007, J BIOL CHEM, V282, P7424, DOI 10.1074/jbc.M611627200; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Platta H, 2004, BIOCHEM J, V384, P37, DOI 10.1042/BJ20040572; Platta HW, 2005, NAT CELL BIOL, V7, P817, DOI 10.1038/ncb1281; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Purdue PE, 2001, J BIOL CHEM, V276, P47684, DOI 10.1074/jbc.M106823200; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Saidowsky J, 2001, J BIOL CHEM, V276, P34524, DOI 10.1074/jbc.M104647200; Schafer A, 2004, MOL CELL BIOL, V24, P8895, DOI 10.1128/MCB.24.20.8895-8906.2004; Sprenger RR, 2004, ELECTROPHORESIS, V25, P156, DOI 10.1002/elps.200305675; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	42	157	162	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22534	10.1074/jbc.M702038200	http://dx.doi.org/10.1074/jbc.M702038200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17550898	hybrid			2022-12-25	WOS:000248354200031
J	Lyons, TR; Thorburn, J; Ryan, PW; Thorburn, A; Anderson, SM; Kassenbrock, CK				Lyons, Traci R.; Thorburn, Jackie; Ryan, Philip W.; Thorburn, Andrew; Anderson, Steven M.; Kassenbrock, C. Kenneth			Regulation of the pro-apoptotic scaffolding protein POSH by Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; NF-KAPPA-B; GROWTH-FACTOR; NEGATIVE REGULATION; SIGNALING PATHWAY; SURVIVAL SIGNALS; JNK ACTIVATION; CELL-SURVIVAL; KINASE-B; PHOSPHORYLATION	POSH (Plenty of SH3 domains) binds to activated Rac and promotes apoptosis by acting as a scaffold to assemble a signal transduction pathway leading from Rac to JNK activation. Overexpression of POSH induces apoptosis in a variety of cell types, but apoptosis can be prevented by co-expressing the pro-survival protein kinase Akt. We report here that POSH is a direct substrate for phosphorylation by Akt in vivo and in vitro, and we identify a major site of Akt phosphorylation as serine 304 of POSH, which lies within the Rac-binding domain. We further show that phosphorylation of POSH results in a decreased ability to bind activated Rac, as does phosphomimetic S304D and S304E mutation of POSH. S304D mutant POSH also shows a strongly reduced ability to induce apoptosis. These findings identify a novel mechanism by which Akt promotes cell survival.	Univ Colorado, Dept Pathol, Denver, CO 80202 USA; Univ Colorado, Dept Pharmacol, Denver, CO 80202 USA; Colorado State Univ, Ft Collins, CO 80523 USA; Hlth Sci Ctr, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver; Colorado State University	Kassenbrock, CK (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, Mailstop 8104,POB 6511, Aurora, CO 80045 USA.	Ken.Kassenbrock@uchsc.edu			NCI NIH HHS [CA111421] Funding Source: Medline; NIDDK NIH HHS [DK063674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; BELLACOSA A, 1993, ONCOGENE, V8, P745; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen PL, 2002, PROTEIN EXPRES PURIF, V24, P481, DOI 10.1006/prep.2001.1599; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Figueroa C, 2003, J BIOL CHEM, V278, P47922, DOI 10.1074/jbc.M307357200; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Hui L, 2005, BRAIN RES, V1052, P1, DOI 10.1016/j.brainres.2005.05.043; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kim AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kim GH, 2006, CELL SIGNAL, V18, P553, DOI 10.1016/j.cellsig.2005.05.026; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kukekov NV, 2006, J BIOL CHEM, V281, P15517, DOI 10.1074/jbc.M601056200; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Xu ZH, 2005, MOL CELL BIOL, V25, P9949, DOI 10.1128/MCB.25.22.9949-9959.2005; Xu ZH, 2006, METHOD ENZYMOL, V406, P479, DOI 10.1016/S0076-6879(06)06036-8; Xu ZH, 2006, J BIOL CHEM, V281, P303, DOI 10.1074/jbc.M509060200; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang QG, 2005, J NEUROCHEM, V95, P784, DOI 10.1111/j.1471-4159.2005.03435.x	35	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21987	21997		10.1074/jbc.M704321200	http://dx.doi.org/10.1074/jbc.M704321200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17535800	hybrid			2022-12-25	WOS:000248196800046
J	Schulz, T; Schumacher, U; Prehm, P				Schulz, Tobias; Schumacher, Udo; Prehm, Peter			Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; CULTURED-MAMMALIAN-CELLS; RESISTANCE PROTEIN 5; CYCLIC-NUCLEOTIDES; RNA INTERFERENCE; OSMOTIC LYSIS; EXPRESSION; MACROMOLECULES; INHIBITION; METABOLISM	Hyaluronan must be exported from its site of synthesis, the inner side of plasma membrane, to the extracellular matrix. Here, we identified the multidrug-associated protein MRP5 as the principle hyaluronan exporter from fibroblasts. The expression of the MRP5 (ABC-C5) transporter was silenced in fibroblasts using RNA interference, and a dose-dependent inhibition of hyaluronan export was observed. Hyaluronan oligosaccharides introduced into the cytosol competed with the export of endogenously labeled hyaluronan and the MRP5 substrate fluorescein. Because cGMP is a physiological substrate of MRP5, the intracellular concentrations of cGMP were modulated by the drugs 3-isobutyl-1-methylxanthin, propentofyllin, L-NAME, zaprinast, and bromo-cGMP, and the effects on hyaluronan export were analyzed. Increasing the cGMP levels inhibited hyaluronan export and decreasing it afforded higher concentrations of zaprinast to inhibit the export. Thus, cGMP may be a physiological regulator of hyaluronan export at the level of the export MRP5.	Muenster Univ Hosp, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Med Ctr Hamburg Eppendorf, Inst Anat, D-20246 Hamburg, Germany	University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf	Prehm, P (corresponding author), Muenster Univ Hosp, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.	prehm@uni-muenster.de		Prehm, Peter/0000-0002-8063-311X				Al'Qteishat A, 2006, BRAIN, V129, P2158, DOI 10.1093/brain/awl139; Andric SA, 2006, ENDOCRINOLOGY, V147, P3435, DOI 10.1210/en.2006-0091; Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; CHAKRABARTI R, 1989, J BIOL CHEM, V264, P8214; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gerdin B, 1997, J INTERN MED, V242, P49, DOI 10.1046/j.1365-2796.1997.00173.x; Ghosh C, 2000, ANTISENSE NUCLEIC A, V10, P263, DOI 10.1089/108729000421448; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; LAURENT UBG, 1991, EXP PHYSIOL, V76, P695, DOI 10.1113/expphysiol.1991.sp003536; LEE G, 1993, CYTOMETRY, V14, P265, DOI 10.1002/cyto.990140305; Melin J, 2006, NEPHRON EXP NEPHROL, V103, pE86, DOI 10.1159/000092193; Nakane M, 2003, CLIN CHEM LAB MED, V41, P865, DOI 10.1515/CCLM.2003.131; OKADA CY, 1982, CELL, V29, P33, DOI 10.1016/0092-8674(82)90087-3; Ouskova G, 2004, GLYCOBIOLOGY, V14, P931, DOI 10.1093/glycob/cwh115; PARKINSON FE, 1994, GEN PHARMACOL, V25, P1053, DOI 10.1016/0306-3623(94)90119-8; Prehm P, 2004, BIOCHEM PHARMACOL, V68, P1401, DOI 10.1016/j.bcp.2004.06.017; Prehm P, 2005, J RHEUMATOL, V32, P690; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM P, 1985, BIOCHEM J, V225, P699, DOI 10.1042/bj2250699; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; PREHM P, 2002, BIOPOLYMERS, V15, P379; Prehm P, 2006, BIOCHEM J, V398, P469, DOI 10.1042/BJ20060431; RECHSTEINER M, 1987, METHOD ENZYMOL, V149, P42; Reid G, 2003, P NATL ACAD SCI USA, V100, P9244, DOI 10.1073/pnas.1033060100; Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2; Seyfried NT, 2005, GLYCOBIOLOGY, V15, P303, DOI 10.1093/glycob/cwi008; Sundkvist E, 2002, BIOCHEM PHARMACOL, V63, P945, DOI 10.1016/S0006-2952(01)00940-6; TAMMI R, 1994, ARCH DERMATOL RES, V286, P21, DOI 10.1007/BF00375839; TEDER P, 1995, AM J RESP CELL MOL, V12, P181, DOI 10.1165/ajrcmb.12.2.7532420; WALDENSTROM A, 1991, J CLIN INVEST, V88, P1622, DOI 10.1172/JCI115475; Wielinga PR, 2003, J BIOL CHEM, V278, P17664, DOI 10.1074/jbc.M212723200; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197	34	71	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20999	21004		10.1074/jbc.M700915200	http://dx.doi.org/10.1074/jbc.M700915200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17540771	hybrid			2022-12-25	WOS:000248047500026
J	Hooper, SB; Kitchen, MJ; Wallace, MJ; Yagi, N; Uesugi, K; Morgan, MJ; Hall, C; Siu, KKW; Williams, IM; Siew, M; Irvine, SC; Pavlov, K; Lewis, RA				Hooper, Stuart B.; Kitchen, Marcus J.; Wallace, Megan J.; Yagi, Naoto; Uesugi, Kentaro; Morgan, Michael J.; Hall, Chris; Siu, Karen K. W.; Williams, Ivan M.; Siew, Melissa; Irvine, Sarah C.; Pavlov, Konstantin; Lewis, Robert A.			Imaging lung aeration and lung liquid clearance at birth	FASEB JOURNAL			English	Article						phase contrast X-ray imaging; fetus; neonate; airways	RAY PHASE-CONTRAST; NEWBORN RABBITS; FETAL SHEEP; SYNCHROTRON-RADIATION; EXPANSION; PRESSURE; FLUID; LAMBS; LABOR	Aeration of the lung and the transition to air-breathing at birth is fundamental to mammalian life and initiates major changes in cardiopulmonary physiology. However, the dynamics of this process and the factors involved are largely unknown, because it has not been possible to observe or measure lung aeration on a breath-by-breath basis. We have used the high contrast and spatial resolution of phase contrast X-ray imaging to study lung aeration at birth in spontaneously breathing neonatal rabbits. As the liquid-filled fetal lungs provide little absorption or phase contrast, they are not visible and only become visible as they aerate, allowing a detailed examination of this process. Pups were imaged live from birth to determine the timing and spatial pattern of lung aeration, and relative levels of lung aeration were measured from the images using a power spectral analysis. We report the first detailed observations and measurements of lung aeration, demonstrating its dependence on inspiratory activity and body position; dependent regions aerated at much slower rates. The air/liquid interface moved toward the distal airways only during inspiration, with little proximal movement during expiration, indicating that transpulmonary pressures play an important role in airway liquid clearance at birth. Using these imaging techniques, the dynamics of lung aeration and the critical role it plays in regulating the physiological changes at birth can be fully explored. - Hooper, S. B., Kitchen, M. J., Wallace, M. J., Yagi, N., Uesugi, K., Morgan, M. J., Hall, C., Siu, K. K. W., Williams, I. M., Siew, M., Irvine, S. C., Pavlov, K., Lewis, R. A. Imaging lung aeration and lung liquid clearance at birth.	Monash Univ, Dept Physiol, Melbourne, Vic 3800, Australia; Monash Univ, Sch Phys, Melbourne, Vic 3800, Australia; Monash Univ, Monash Ctr Synchrotron Sci, Melbourne, Vic 3800, Australia; Monash Univ, Dept Med Imaging & Radiat Sci, Melbourne, Vic 3800, Australia; JASRI, SPring 8, Sayo, Japan	Monash University; Monash University; Monash University; Monash University	Hooper, SB (corresponding author), Monash Univ, Dept Physiol, Melbourne, Vic 3800, Australia.	stuart.hooper@med.monash.edu.au	Kitchen, Marcus/A-1355-2008; Pavlov, Konstantin M/A-3802-2008; Siu, Karen K W/C-1472-2008; Irvine, Sarah/J-4411-2013	Kitchen, Marcus/0000-0002-0029-6660; Pavlov, Konstantin M/0000-0002-1756-4406; Wallace, Megan/0000-0001-5785-5120; Siew, Melissa/0000-0003-3014-2379; Hooper, Stuart/0000-0003-1676-4825				Barker PM, 2002, J APPL PHYSIOL, V93, P1542, DOI 10.1152/japplphysiol.00092.2002; BLAND RD, 1979, AM J OBSTET GYNECOL, V135, P364, DOI 10.1016/0002-9378(79)90706-3; BLAND RD, 1980, J APPL PHYSIOL, V49, P171, DOI 10.1152/jappl.1980.49.2.171; Bland RD, 2001, AM J PHYSIOL-LUNG C, V280, pL602, DOI 10.1152/ajplung.2001.280.4.L602; Davey MG, 1998, RESP PHYSIOL, V113, P83, DOI 10.1016/S0034-5687(98)00036-X; Dawes GS, 1968, FETAL NEONATAL PHYSL; FAWCITT J, 1960, Acta Paediatr Suppl, V49(Suppl 123), P5, DOI 10.1111/j.1651-2227.1960.tb05965.x; Goto S, 2001, NUCL INSTRUM METH A, V467, P682, DOI 10.1016/S0168-9002(01)00445-4; Harding R, 1996, REPROD FERT DEVELOP, V8, P117, DOI 10.1071/RD9960117; Harding R, 1996, J APPL PHYSIOL, V81, P209, DOI 10.1152/jappl.1996.81.1.209; HIRVONEN L, 1975, ANN CHIR GYNAECOL FE, V64, P170; Hooper SB, 2005, CURR RESPIR MED REV, V1, P185, DOI 10.2174/1573398054023037; Joyce BJ, 2003, AM J PHYSIOL-LUNG C, V284, pL643, DOI 10.1152/ajplung.00090.2002; Kitchen MJ, 2005, BRIT J RADIOL, V78, P1018, DOI 10.1259/bjr/13024611; Kitchen MJ, 2004, PHYS MED BIOL, V49, P4335, DOI 10.1088/0031-9155/49/18/010; Kovar J, 2002, J APPL PHYSIOL, V93, P629, DOI 10.1152/japplphysiol.01044.2001; Lewis RA, 2005, PHYS MED BIOL, V50, P5031, DOI 10.1088/0031-9155/50/21/006; MISEROCCHI G, 1994, J APPL PHYSIOL, V77, P2260, DOI 10.1152/jappl.1994.77.5.2260; Nardo L, 2000, EXP LUNG RES, V26, P105, DOI 10.1080/019021400269907; Olver RE, 2004, ANNU REV PHYSIOL, V66, P77, DOI 10.1146/annurev.physiol.66.071702.145229; RAJ JU, 1986, AM REV RESPIR DIS, V134, P305; RIMMER S, 1982, ARCH DIS CHILD, V57, P63; RUDOLPH AM, 1985, CIRC RES, V57, P811, DOI 10.1161/01.RES.57.6.811; Snigirev A, 1995, REV SCI INSTRUM, V66, P5486, DOI 10.1063/1.1146073; Stocks J, 1999, Monaldi Arch Chest Dis, V54, P358; SUKI B, 1994, NATURE, V368, P615, DOI 10.1038/368615a0; Suzuki Y, 2002, J SYNCHROTRON RADIAT, V9, P160, DOI 10.1107/S090904950200554X; Yagi N, 1999, MED PHYS, V26, P2190, DOI 10.1118/1.598735	28	143	145	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3329	3337		10.1096/fj.07-8208com	http://dx.doi.org/10.1096/fj.07-8208com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17536040				2022-12-25	WOS:000249781600033
J	Gazaryan, IG; Krasinskaya, IP; Kristal, BS; Brown, AM				Gazaryan, Irina G.; Krasinskaya, Inna P.; Kristal, Bruce S.; Brown, Abraham M.			Zinc irreversibly damages major enzymes of energy production and antioxidant Defense prior to mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; RAT-LIVER MITOCHONDRIA; INNER MEMBRANE; CELL-DEATH; COMPLEX; BRAIN; PORE; DEHYDROGENASE; RESPIRATION; MODULATION	Recent observations point to the role played by Zn2+ as an inducer of neuronal death. Two Zn2+ targets have been identified that result in inhibition of mitochondrial respiration: the bc(1) center and, more recently, alpha-ketoglutarate dehydrogenase. Zn2+ is also a mediator of oxidative stress, leading to mitochondrial failure, release of apoptotic peptides, and neuronal death. We now present evidence, by means of direct biochemical assays, that Zn2+ is imported through the Ca2+ uniporter and directly targets major enzymes of energy production (lipoamide dehydrogenase) and antioxidant defense (thioredoxin reductase and glutathione reductase). We demonstrate the following. (a) These matrix enzymes are rapidly inhibited by application of Zn2+ to intact mitochondria. (b) Delayed treatment with membrane-impermeable chelators has no effect, indicating rapid transport of biologically relevant quantities of Zn2+ into the matrix. (c) Membrane-permeable chelators stop but do not reverse enzyme inactivation. (d) Enzyme inhibition is rapid and irreversible and precedes the major changes associated with the mitochondrial permeability transition (MPT). (e) The extent and rate of enzyme inactivation linearly correlates with the MPT onset and propagation. (f) The Ca2+ uniporter blocker, Ruthenium Red, protects enzyme activities and delays pore opening up to 2 mu M Zn2+. An additional, unidentified import route functions at higher Zn2+ concentrations. (g) No enzyme inactivation is observed for Ca2+-induced MPT. These observations strongly suggest that, unlike Ca2+, exogenous Zn2+ interferes with mitochondrial NADH production and directly alters redox protection in the matrix, contributing to mitochondrial dysfunction. Inactivation of these enzymes by Zn2+ is irreversible, and thus only their de novo synthesis can restore function, which may underlie persistent loss of oxidative carbohydrate metabolism following transient ischemia.	Burke Med Res Inst, Dementia Res Serv, White Plains, NY 10605 USA; Cornell Univ, Weill Med Coll, Dept Neurosci, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Cornell University; Cornell University	Brown, AM (corresponding author), Burke Med Res Inst, Dementia Res Serv, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	ambrown@med.cornell.edu	Gazaryan, Irina G/T-8578-2017; brown, abraham/R-8823-2019	Gazaryan, Irina G/0000-0002-9670-5579; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038741] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK040561-12] Funding Source: Medline; NINDS NIH HHS [NS38741, R01 NS038741] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; Bonanni L, 2006, J NEUROSCI, V26, P6851, DOI 10.1523/JNEUROSCI.5444-05.2006; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Brown AM, 2000, J BIOL CHEM, V275, P13441, DOI 10.1074/jbc.275.18.13441; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; CROMPTON M, 1994, BIOCHEM J, V302, P181, DOI 10.1042/bj3020181; Cuajungco MP, 2003, BRAIN RES REV, V41, P44, DOI 10.1016/S0165-0173(02)00219-9; Dedov VN, 1999, BIOCHEMISTRY-MOSCOW+, V64, P809; Dineley KE, 2005, MITOCHONDRION, V5, P55, DOI 10.1016/j.mito.2004.11.001; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Frederickson CJ, 2004, NEUROSCIENTIST, V10, P18, DOI 10.1177/1073858403255840; Gazaryan IG, 2002, J BIOL CHEM, V277, P10064, DOI 10.1074/jbc.M108264200; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; LINK TA, 1995, J BIOL CHEM, V270, P25001, DOI 10.1074/jbc.270.42.25001; LORUSSO M, 1991, EUR J BIOCHEM, V197, P555, DOI 10.1111/j.1432-1033.1991.tb15944.x; Massari S, 1996, J BIOL CHEM, V271, P31942; Pong K, 2002, BRAIN RES, V950, P218, DOI 10.1016/S0006-8993(02)03040-8; Religa D, 2006, NEUROLOGY, V67, P69, DOI 10.1212/01.wnl.0000223644.08653.b5; Ricchelli F, 2005, INT J BIOCHEM CELL B, V37, P1858, DOI 10.1016/j.biocel.2005.04.001; Ryu JR, 2002, EXP BRAIN RES, V143, P257, DOI 10.1007/s00221-001-0991-7; SARIS NEL, 1994, FEBS LETT, V356, P195, DOI 10.1016/0014-5793(94)01256-3; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; SIMS NR, 1991, J NEUROCHEM, V56, P1836, DOI 10.1111/j.1471-4159.1991.tb03438.x; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; SKULACHE.VP, 1967, BIOCHEM BIOPH RES CO, V26, P1, DOI 10.1016/0006-291X(67)90242-2; Stavrovskaya IG, 2004, J EXP MED, V200, P211, DOI 10.1084/jem.20032053; Verrier F, 2003, ANN NY ACAD SCI, V1010, P126, DOI 10.1196/annals.1299.022; Wudarczyk J, 1999, ARCH BIOCHEM BIOPHYS, V363, P1, DOI 10.1006/abbi.1998.1058; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	37	122	124	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24373	24380		10.1074/jbc.M611376200	http://dx.doi.org/10.1074/jbc.M611376200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17565998	hybrid			2022-12-25	WOS:000248686600063
J	Fanara, P; Banerjee, J; Hueck, RV; Harper, MR; Awada, M; Turner, H; Husted, KH; Brandt, R; Hellerstein, MK				Fanara, Patrizia; Banerjee, Jayee; Hueck, Rommel V.; Harper, Macha R.; Awada, Mohamad; Turner, Holly; Husted, Kristofor H.; Brandt, Roland; Hellerstein, Marc K.			Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC-MOUSE MODEL; ALS-LINKED SOD1; SLOW AXONAL-TRANSPORT; IN-VIVO; STABLE-TUBULE; LIVING CELLS; HEAVY-WATER; TAU; NEURONS; PROTEIN	Mutations in copper/zinc superoxide dismutase 1 (SOD1), a genetic cause of human amyotrophic lateral sclerosis, trigger motoneuron death through unknown toxic mechanisms. We report that transgenic SOD1G93A mice exhibit striking and progressive changes in neuronal microtubule dynamics from an early age, associated with impaired axonal transport. Pharmacologic administration of a microtubule-modulating agent alone or in combination with a neuroprotective drug to symptomatic SOD1G93A mice reduced microtubule turnover, preserved spinal cord neurons, normalized axonal transport kinetics, and delayed the onset of symptoms, while prolonging life by up to 26%. The degree of reduction of microtubule turnover was highly predictive of clinical responses to different treatments. These data are consistent with the hypothesis that hyperdynamic microtubules impair axonal transport and accelerate motor neuron degeneration in amyotrophic lateral sclerosis. Measurement of microtubule dynamics in vivo provides a sensitive biomarker of disease activity and therapeutic response and represents a new pharmacologic target in neurodegenerative disorders.	KineMed Inc, Emeryville, CA 94608 USA; Univ Osnabruck, Dept Neurobiol, D-49076 Osnabruck, Germany; Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA	University Osnabruck; University of California System; University of California Berkeley; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Fanara, P (corresponding author), KineMed Inc, 5980 Horton St,Ste 400, Emeryville, CA 94608 USA.	pfanara@kinemed.com		Brandt, Roland/0000-0003-0101-1257				Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Baas PW, 2004, J NEUROBIOL, V58, P3, DOI 10.1002/neu.10281; BAAS PW, 1991, J NEUROSCI RES, V30, P134, DOI 10.1002/jnr.490300115; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BINET S, 1988, NEUROLOGY, V38, P1596, DOI 10.1212/WNL.38.10.1596; Brandt R, 2005, BBA-MOL BASIS DIS, V1739, P331, DOI 10.1016/j.bbadis.2004.06.018; BRANDT R, 1993, J BIOL CHEM, V268, P3414; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Busch R, 2006, BBA-GEN SUBJECTS, V1760, P730, DOI 10.1016/j.bbagen.2005.12.023; Cairns NJ, 2004, J PATHOL, V204, P438, DOI 10.1002/path.1650; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; EDSON KJ, 1993, CELL MOTIL CYTOSKEL, V25, P59, DOI 10.1002/cm.970250108; Fanara P, 1999, EMBO J, V18, P565, DOI 10.1093/emboj/18.3.565; Fanara P, 2004, J BIOL CHEM, V279, P49940, DOI 10.1074/jbc.M409660200; Farah CA, 2003, J NEUROCHEM, V84, P77, DOI 10.1046/j.1471-4159.2003.01505.x; Goldstein LSB, 2003, NEURON, V40, P415, DOI 10.1016/S0896-6273(03)00630-5; Gurney ME, 1998, NEUROLOGY, V50, P62, DOI 10.1212/WNL.50.1.62; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; He Y, 2002, J NEUROSCI, V22, P5982; Hirokawa N, 1997, CURR OPIN NEUROBIOL, V7, P605, DOI 10.1016/S0959-4388(97)80079-7; Inglefield JR, 2002, NEUROSCIENCE, V115, P559, DOI 10.1016/S0306-4522(02)00343-3; Irving EA, 1996, ACTA NEUROPATHOL, V92, P186, DOI 10.1007/s004010050507; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007; Kikuchi H, 1999, ACTA NEUROPATHOL, V97, P13, DOI 10.1007/s004010050950; Kirkpatrick LL, 2001, J NEUROSCI, V21, P2288, DOI 10.1523/JNEUROSCI.21-07-02288.2001; Kwei SL, 1998, NEUROREPORT, V9, P1035, DOI 10.1097/00001756-199804200-00015; Landen JW, 2004, CLIN CANCER RES, V10, P5187, DOI 10.1158/1078-0432.CCR-04-0360; Landen JW, 2002, CANCER RES, V62, P4109; Letournel F, 2003, J NEUROPATH EXP NEUR, V62, P1211, DOI 10.1093/jnen/62.12.1211; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; McMurray CT, 2000, CELL DEATH DIFFER, V7, P861, DOI 10.1038/sj.cdd.4400764; PIROLLET F, 1992, BIOCHEMISTRY-US, V31, P8849, DOI 10.1021/bi00152a022; POSTMA TJ, 1995, ANN ONCOL, V6, P489, DOI 10.1093/oxfordjournals.annonc.a059220; Roos J, 2000, NAT NEUROSCI, V3, P415, DOI 10.1038/74773; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Samsonov A, 2004, J CELL SCI, V117, P6129, DOI 10.1242/jcs.01531; Sasaki S, 1996, NEUROLOGY, V47, P535, DOI 10.1212/WNL.47.2.535; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Slaughter T, 2003, J NEUROCYTOL, V32, P399, DOI 10.1023/B:NEUR.0000011334.70648.87; Strey CW, 2004, AM J PATHOL, V165, P1701, DOI 10.1016/S0002-9440(10)63426-8; Tashiro T, 1997, J NEUROSCI RES, V50, P81, DOI 10.1002/(SICI)1097-4547(19971001)50:1<81::AID-JNR9>3.0.CO;2-H; TASHIRO T, 1989, J NEUROSCI, V9, P760; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7	46	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23465	23472		10.1074/jbc.M703434200	http://dx.doi.org/10.1074/jbc.M703434200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17567579	hybrid			2022-12-25	WOS:000248577500047
J	Woods, A; Wang, GY; Dupuis, H; Shao, ZH; Beier, F				Woods, Anita; Wang, Guoyan; Dupuis, Holly; Shao, Zhuhong; Beier, Frank			Rac1 signaling stimulates N-cadherin expression, mesenchymal condensation, and chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTROPHIC CHONDROCYTE DIFFERENTIATION; IN-VITRO CHONDROGENESIS; CELL-CELL CONTACT; RETINOIC ACID; INDUCED REEXPRESSION; LIMB CHONDROGENESIS; CARTILAGE FORMATION; ACTIN ORGANIZATION; GENE-EXPRESSION; FOCAL ADHESIONS	The molecular mechanisms controlling differentiation of mesenchymal precursor cells into chondrocytes (chondrogenesis) are not completely understood. We have recently shown that the small GTPase RhoA inhibits this process. Here we demonstrate that a different Rho GTPase family member, Rac1, promotes chondrogenesis. Pharmacological inhibition of Rac1 expression in micromass culture resulted in reduced mRNA levels of the chondrogenic markers collagen II and aggrecan, and decreased accumulation of glycosaminoglycans. Expression of the essential chondrogenic transcription factors Sox9, Sox5, and Sox6 was also reduced upon inhibition of Rac1 signaling. In contrast, overexpression of Rac1 in the chondrogenic ATDC5 cell line increased mRNA transcripts of Sox9, 5, and 6, collagen II, and aggrecan. Inhibition of Rac1 resulted in a reduction in the number, size, and organization of cellular condensations and decreased expression of N-cadherin. Overexpression of Rac1 resulted in an increase in N-cadherin expression levels. Furthermore, genetic ablation of Rac1 in primary micromass cultures resulted in reduced expression of chondrogenic markers. Additionally, we provide evidence that Cdc42 also promotes chondrogenesis. Overexpression of Cdc42 in ATDC5 cells resulted in increased expression of Sox5, Sox9, and collagen II but not Sox6, aggrecan, or N-cadherin. Therefore, we demonstrate that Rac1 and Cdc42 are positive regulators of chondrogenesis, but act at least in part through different cellular and molecular mechanisms.	Univ Western Ontario, Dept Physiol & Pharmacol, CIHR Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Beier, F (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, CIHR Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada.	fbeier@uwo.ca	Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Allen WE, 1997, J CELL SCI, V110, P707; BENYA PD, 1988, J CELL BIOL, V106, P161, DOI 10.1083/jcb.106.1.161; BENYA PD, 1993, EXP CELL RES, V204, P268, DOI 10.1006/excr.1993.1033; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BROWN PD, 1988, J CELL BIOL, V106, P171, DOI 10.1083/jcb.106.1.171; Charite J, 2000, DEVELOPMENT, V127, P2461; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; Delise AM, 2002, DEV DYNAM, V225, P195, DOI 10.1002/dvdy.10151; Denning MF, 2004, INT J BIOCHEM CELL B, V36, P1141, DOI 10.1016/j.biocel.2003.12.004; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; FURUKAWA F, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P802, DOI 10.1111/j.1346-8138.1994.tb03294.x; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; James CG, 2005, MOL BIOL CELL, V16, P5316, DOI 10.1091/mbc.E05-01-0084; James CG, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-30; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654; Kluppel M, 2005, DEVELOPMENT, V132, P3989, DOI 10.1242/dev.01948; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LOTY S, 1995, BIOL CELL, V83, P149, DOI 10.1016/0248-4900(96)81303-7; Mammoto A, 2004, J BIOL CHEM, V279, P26323, DOI 10.1074/jbc.M402725200; Modarresi R, 2005, J CELL BIOCHEM, V95, P53, DOI 10.1002/jcb.20396; MUIR H, 1995, BIOESSAYS, V17, P1039, DOI 10.1002/bies.950171208; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Nishiyama T, 2004, J BIOL CHEM, V279, P47311, DOI 10.1074/jbc.M403546200; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noritake J, 2004, MOL BIOL CELL, V15, P1065, DOI 10.1091/mbc.E03-08-0582; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Seasholtz TM, 2004, J NEUROCHEM, V91, P501, DOI 10.1111/j.1471-4159.2004.02749.x; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Shum L, 2002, ARTHRITIS RES, V4, P94, DOI 10.1186/ar396; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Storey NM, 2002, CURR BIOL, V12, P27, DOI 10.1016/S0960-9822(01)00625-X; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAVELLA S, 1994, EXP CELL RES, V215, P354, DOI 10.1006/excr.1994.1352; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Thiele H, 2004, P NATL ACAD SCI USA, V101, P10155, DOI 10.1073/pnas.0400334101; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Wang GY, 2005, J BONE MINER RES, V20, P1022, DOI 10.1359/JBMR.050113; Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224; Woods A, 2005, J BIOL CHEM, V280, P11626, DOI 10.1074/jbc.M409158200; Woods A, 2006, J BIOL CHEM, V281, P13134, DOI 10.1074/jbc.M509433200; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115	57	103	106	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23500	23508		10.1074/jbc.M700680200	http://dx.doi.org/10.1074/jbc.M700680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17573353	hybrid			2022-12-25	WOS:000248577500051
J	Bandwar, RP; Ma, N; Emanuel, SA; Anikin, M; Vassylyev, DG; Patel, SS; McAllister, WT				Bandwar, Rajiv P.; Ma, Na; Emanuel, Steven A.; Anikin, Michael; Vassylyev, Dmitry G.; Patel, Smita S.; McAllister, William T.			The transition to an elongation complex by T7 RNA polymerase is a multistep process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CONFORMATIONAL-CHANGES; INITIAL BUBBLE COLLAPSE; LAC UV5 PROMOTER; TRANSCRIPTION INITIATION; STRUCTURAL BASIS; RELEASE; BACTERIOPHAGE-T7; TERMINATION; MECHANISM; T7-RNA-POLYMERASE	During the transition from an initiation complex to an elongation complex (EC), T7 RNA polymerase undergoes major conformational changes that involve reorientation of a "core" subdomain as a rigid body and extensive refolding of other elements in the 266 residue N-terminal domain. The pathway and timing of these events is poorly understood. To examine this, we introduced proline residues into regions of the N-terminal domain that become alpha-helical during the reorganization and changed the charge of a key residue that interacts with the RNA: DNA hybrid 5 bp upstream of the active site in the EC but not in the initiation complex. These alterations resulted in a diminished ability to make products > 5 - 7 nt and/or a slow transition through this point. The results indicate that the transition to an EC is a multistep process and that the movement of the core subdomain and reorganization of certain elements in the N-terminal domain commence prior to promoter release ( at 8 - 9 nt).	Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Cell Biol, Stratford, NJ 08084 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Suny Downstate Med Ctr, Grad Program Mol & Cell Biol, Brooklyn, NY 11203 USA; Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Patel, SS (corresponding author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Cell Biol, 42 E Laurel Rd, Stratford, NJ 08084 USA.	patelss@umdnj.edu; mcalliwt@umdnj.edu	Vassylyev, Dmitry/A-9005-2008	Bandwar, Rajiv/0000-0002-8081-8958	NIGMS NIH HHS [R37 GM051966, R37 GM051966-13, R01 GM038147, GM74252, R01 GM038147-16, R01 GM074252, R01 GM051966, GM38147, GM51966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051966, R01GM038147, R01GM051966, R01GM074252] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandwar RP, 2006, J MOL BIOL, V360, P466, DOI 10.1016/j.jmb.2006.05.029; Borukhov S, 2003, CURR OPIN MICROBIOL, V6, P93, DOI 10.1016/S1369-5274(03)00036-5; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Brieba LG, 2001, J BIOL CHEM, V276, P10306, DOI 10.1074/jbc.M009866200; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Gong P, 2004, J BIOL CHEM, V279, P44277, DOI 10.1074/jbc.M409118200; Gong P, 2006, J BIOL CHEM, V281, P23533, DOI 10.1074/jbc.M604023200; Guillerez J, 2005, P NATL ACAD SCI USA, V102, P5958, DOI 10.1073/pnas.0407141102; Guo Q, 2005, J MOL BIOL, V353, P256, DOI 10.1016/j.jmb.2005.08.016; Guo Q, 2005, J BIOL CHEM, V280, P14956, DOI 10.1074/jbc.M500518200; Guo Q, 2005, J BIOL CHEM, V280, P3474, DOI 10.1074/jbc.M412287200; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; He B, 1997, J MOL BIOL, V265, P275, DOI 10.1006/jmbi.1996.0741; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jiang ML, 2004, MOL CELL, V15, P777, DOI 10.1016/j.molcel.2004.07.019; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Ma KY, 2005, P NATL ACAD SCI USA, V102, P17612, DOI 10.1073/pnas.0508865102; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; STRANEY DC, 1987, J MOL BIOL, V193, P279, DOI 10.1016/0022-2836(87)90219-1; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2002, J BIOL CHEM, V277, P47035, DOI 10.1074/jbc.M208923200; Theis K, 2004, BIOCHEMISTRY-US, V43, P12709, DOI 10.1021/bi0486987; Turingan RS, 2007, BIOCHEMISTRY-US, V46, P6165, DOI 10.1021/bi700058b; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	33	15	17	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22879	22886		10.1074/jbc.M702589200	http://dx.doi.org/10.1074/jbc.M702589200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17548349	Green Accepted, hybrid			2022-12-25	WOS:000248354200065
J	Covian, R; Kleinschroth, T; Ludwig, B; Trumpower, BL				Covian, Raul; Kleinschroth, Thomas; Ludwig, Bernd; Trumpower, Bernard L.			Asymmetric binding of stigmatellin to the dimeric Paracoccus denitrificans bc(1) complex - Evidence for anti-cooperative ubiquinol oxidation and communication between center P ubiquinol oxidation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; IRON-SULFUR PROTEIN; C OXIDOREDUCTASE COMPLEX; CYTOCHROME BC(1); QUINOL OXIDATION; ELECTRON-TRANSFER; INHIBITORS; PURIFICATION; MECHANISM; REDUCTASE	We have investigated the mechanism responsible for half-of-the-sites activity in the dimeric cytochrome bc(1) complex from Paracoccus denitrificans by characterizing the kinetics of inhibitor binding to the ubiquinol oxidation site at center P. Both myxothiazol and stigmatellin induced a 2-3 nm shift of the visible absorbance spectrum of the b(L) heme. The shift generated by myxothiazol was symmetric, with monophasic kinetics that indicate equal binding of this inhibitor to both center P sites. In contrast, stigmatellin generated an asymmetric shift in the b(L) spectrum, with biphasic kinetics in which each phase contributed approximately half of the total magnitude of the spectral change. The faster binding phase corresponded to a more symmetrical shift of the b(L) spectrum relative to the slower binding phase, indicating that approximately half of the center P sites bound stigmatellin more slowly and in a different position relative to the b(L) heme, generating a different effect on its electronic environment. Significantly, the slow stigmatellin binding phase was lost as the inhibitor concentration was increased. This implies that a conformational change is transmitted from one center P site in the dimer to the other upon stigmatellin binding to one monomer, rendering the second site less accessible to the inhibitor. Because the position that stigmatellin occupies at center P is considered to be analogous to that of the quinol substrate at the moment of electron transfer, these results indicate that the productive enzyme-substrate configuration is prevented from occurring in both monomers simultaneously.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Goethe Univ Frankfurt, Inst Biochem, D-60439 Frankfurt, Germany; Cluster Excellence Macromol Complexes, D-60439 Frankfurt, Germany	Dartmouth College; Goethe University Frankfurt	Trumpower, BL (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERKA O, 2005, THESIS JOHANN WOLFGA; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Berry EA, 2004, PHOTOSYNTH RES, V81, P251, DOI 10.1023/B:PRES.0000036888.18223.0e; Berry EA, 2003, FEBS LETT, V555, P13, DOI 10.1016/S0014-5793(03)01099-8; Bowman MK, 2004, BIOCHEMISTRY-US, V43, P430, DOI 10.1021/bi034620z; BUTLER J, 1975, BIOCHIM BIOPHYS ACTA, V408, P215, DOI 10.1016/0005-2728(75)90124-3; Covian R, 2005, J BIOL CHEM, V280, P22732, DOI 10.1074/jbc.M413592200; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Covian R, 2002, J BIOL CHEM, V277, P48449, DOI 10.1074/jbc.M208060200; Covian R, 2006, J BIOL CHEM, V281, P30925, DOI 10.1074/jbc.M604694200; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; KORN M, 1994, THESIS JOHANN WOLFGA; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Margoliash E, 1967, METHOD ENZYMOL, V10, P339; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; OHNISHI T, 1988, EUR J BIOCHEM, V176, P385, DOI 10.1111/j.1432-1033.1988.tb14293.x; Pfitzner U, 1998, J BIOENERG BIOMEMBR, V30, P89, DOI 10.1023/A:1020515713103; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Ritter M, 2003, BIOCHEMISTRY-US, V42, P12391, DOI 10.1021/bi035103j; Schroter T, 1998, EUR J BIOCHEM, V255, P100, DOI 10.1046/j.1432-1327.1998.2550100.x; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Wenz T, 2006, BIOCHEMISTRY-US, V45, P9042, DOI 10.1021/bi060280g; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG XH, 1986, J BIOL CHEM, V261, P2282; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	32	14	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22289	22297		10.1074/jbc.M702132200	http://dx.doi.org/10.1074/jbc.M702132200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17561507	hybrid			2022-12-25	WOS:000248354200006
J	Horwitz, AA; Navon, A; Groll, M; Smith, DM; Reis, C; Goldberg, AL				Horwitz, Andrew A.; Navon, Ami; Groll, Michael; Smith, David M.; Reis, Christian; Goldberg, Alfred L.			ATP-induced structural transitions in PAN, the proteasome-regulatory ATPase complex in Archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; 26 S PROTEASOME; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 20S PROTEASOME; DEPENDENT OLIGOMERIZATION; CORE PARTICLE; DEGRADATION; CHAPERONE; SUBUNIT	ATP binding to the PAN-ATPase complex in Archaea or the homologous 19 S protease-regulatory complex in eukaryotes induces association with the 20 S proteasome and opening of its substrate entry channel, whereas ATP hydrolysis allows unfolding of globular substrates. To clarify the conformational changes associated with ATP binding and hydrolysis, we used protease sensitivity to monitor the conformations of the PAN ATPase from Methanococcus jannischii. Exhaustive trypsin treatment of PAN generated five distinct fragments, two of which differed when a nucleotide ( either ATP, ATP gamma S, or ADP) was bound. Surprisingly, the nucleotide concentrations altering protease sensitivity were much lower (K-a 20-40 mu M) than are required for ATP-dependent protein breakdown by the PAN-20S proteasome complex (K-m similar to 300-500 mu M). Unlike trypsin, proteinase K yielded several fragments that differed in the ATP gamma S and ADP-bound forms, and thus revealed conformational transitions associated with ATPhydrolysis. Mapping the fragments generated by each revealed that nucleotide binding and hydrolysis induce local conformational changes, affecting the Walker A and B nucleotide-binding motif, as well as global changes extending to its carboxyl terminus. The location and overlap of the fragments also suggest that the conformation of the six subunits is not identical, probably because they do not all bind ATP simultaneously. Partial nucleotide occupancy was supported by direct assays, which demonstrated that, at saturating conditions, only four nucleotides are bound to hexameric PAN. Using the protease protection maps, we modeled the conformational changes associated with ATP binding and hydrolysis in PAN based on the x-ray structures of the homologous AAA ATPase, HslU.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA; Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel; Charite Univ Med Berlin CCM, Inst Biochem, D-10117 Berlin, Germany	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Weizmann Institute of Science; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	alfred_goldberg@hms.harvard.edu	Smith, David/AAL-7662-2020; Groll, Michael/C-1174-2010; Groll, Michael/F-5572-2015	Smith, David/0000-0002-1502-676X; 	NIGMS NIH HHS [R01 GM051923-12, R01 GM051923] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051923] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081; BENAROUDJ N, 2006, UBIQUITIN PROTEASOME; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hartman JJ, 1999, SCIENCE, V286, P782, DOI 10.1126/science.286.5440.782; Hartmann-Petersen R, 2001, ARCH BIOCHEM BIOPHYS, V386, P89, DOI 10.1006/abbi.2000.2178; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MENON AS, 1987, J BIOL CHEM, V262, P14921; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Smith DM, 2005, MOL CELL, V20, P687, DOI 10.1016/j.molcel.2005.10.019; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Wilson HL, 2000, J BACTERIOL, V182, P1680, DOI 10.1128/JB.182.6.1680-1692.2000; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008	39	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22921	22929		10.1074/jbc.M702846200	http://dx.doi.org/10.1074/jbc.M702846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553803	hybrid			2022-12-25	WOS:000248354200069
J	Lehen'kyi, V; Beck, B; Polakowska, R; Charveron, M; Bordat, P; Skryma, R; Prevarskaya, N				Lehen'kyi, V'yacheslav; Beck, Benjamin; Polakowska, Renata; Charveron, Maria; Bordat, Pascal; Skryma, Roman; Prevarskaya, Natalia			TRPV6 is a Ca2+ entry channel essential for Ca2+-induced differentiation of human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE EPIDERMAL DIFFERENTIATION; CULTURED HUMAN KERATINOCYTES; EXTRACELLULAR CALCIUM; TERMINAL DIFFERENTIATION; PROSTATE-CANCER; EXPRESSION; RECEPTOR; FAMILY; GROWTH; 1,25-DIHYDROXYVITAMIN-D	Ca2+ is an essential factor inducing keratinocyte differentiation due to the natural Ca2+ gradient in the skin. However, the membrane mechanisms that mediate calcium entry and trigger keratinocyte differentiation had not previously been elucidated. In this study we demonstrate that Ca2+-induced differentiation up-regulates both mRNA and protein expression of a transient receptor potential highly Ca2+-selective channel, TRPV6. The latter mediates Ca2+ uptake and accounts for the basal [Ca2+] (i) in human keratinocytes. Our results show that TRPV6 is a prerequisite for keratinocyte entry into differentiation, because the silencing of TRPV6 in human primary keratinocytes led to the development of impaired differentiated phenotype triggered by Ca2+. The expression of such differentiation markers as involucrin, transglutaminase-1, and cytokeratin-10 was significantly inhibited by small interfering RNA-TRPV6 as compared with differentiated control cells. TRPV6 silencing affected cell morphology and the development of intercellular contacts, as well as the ability of cells to stratify. 1,25-Dihydroxyvitamin D3, a cofactor of differentiation, dose-dependently increased TRPV6 mRNA and protein expression in human keratinocytes. This TRPV6 up-regulation led to a significant increase in Ca2+ uptake in both undifferentiated and differentiated keratinocytes. We conclude that TRPV6 mediates, at least in part, the pro-differentiating effects of 1,25-dihydroxyvitamin D3 by increasing Ca2+ entry, thereby promoting differentiation. Taken together, these data suggest that the TRPV6 channel is a key element in Ca2+/1,25-dihydroxyvitamin D3-induced differentiation of human keratinocytes.	Univ Sci & Tech Lille Flandres Artois, INSERM, U800, Equip Lab Ligue Natl Contre Canc, F-59655 Villeneuve Dascq, France; Univ Lille 2, Fac Med, INSERM,U837, Ctr Rech Jean Pierre Aubert, F-59045 Lille, France; Dermocosmet Res Ctr Pierre Fabre, F-31322 Castanet Tolosan, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prevarskaya, N (corresponding author), Univ Sci & Tech Lille Flandres Artois, INSERM, U800, Lab Cell Physiol, F-59650 Villeneuve Dascq, France.	natacha.prevarskaya@univ-lille1.fr	LEHEN'KYI, V'yacheslav/AAJ-6008-2020	LEHEN'KYI, V'yacheslav/0000-0003-0806-8766; Beck, Benjamin/0000-0001-8162-7566; Prevarskaya, natacha/0000-0003-0316-197X				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Bianco SDC, 2007, J BONE MINER RES, V22, P274, DOI 10.1359/JBMR.061110; BIKLE DD, 1993, J INVEST DERMATOL, V101, P713, DOI 10.1111/1523-1747.ep12371681; Bikle DD, 1996, J CLIN INVEST, V97, P1085, DOI 10.1172/JCI118501; Bodding M, 2003, J BIOL CHEM, V278, P50872, DOI 10.1074/jbc.M308800200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Hines MD, 1999, J CELL SCI, V112, P4569; Hoenderop JGJ, 2004, KIDNEY INT, V66, P1082, DOI 10.1111/j.1523-1755.2004.00858.x; Hoenderop JGJ, 2003, PFLUG ARCH EUR J PHY, V446, P304, DOI 10.1007/s00424-003-1045-8; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; MAURO TM, 1990, J CELL PHYSIOL, V143, P13, DOI 10.1002/jcp.1041430103; MAURO TM, 1993, J MEMBRANE BIOL, V132, P201; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; Nijenhuis T, 2003, J AM SOC NEPHROL, V14, P2731, DOI 10.1097/01.ASN.0000094081.78893.E8; Oda Y, 2000, J BIOL CHEM, V275, P1183, DOI 10.1074/jbc.275.2.1183; Peng JB, 2000, BIOCHEM BIOPH RES CO, V278, P326, DOI 10.1006/bbrc.2000.3716; Peng JB, 2002, CURR OPIN NEPHROL HY, V11, P555, DOI 10.1097/00041552-200209000-00012; PILLAI S, 1988, J BIOL CHEM, V263, P5390; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; Solomon C, 2001, RADIAT RES, V155, P156, DOI 10.1667/0033-7587(2001)155[0156:VDRIRT]2.0.CO;2; SU MJ, 1994, J BIOL CHEM, V269, P14723; Tamiji S, 2005, J INVEST DERMATOL, V125, P647, DOI 10.1111/j.0022-202X.2005.23885.x; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; van de Graaf SFJ, 2006, AM J PHYSIOL-RENAL, V290, pF1295, DOI 10.1152/ajprenal.00443.2005; van de Graaf SFJ, 2006, MOL CELL BIOL, V26, P303, DOI 10.1128/MCB.26.1.303-312.2006; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Walters JRF, 2004, J STEROID BIOCHEM, V89-90, P317, DOI 10.1016/j.jsbmb.2004.03.028; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Xie ZJ, 2002, J INVEST DERMATOL, V118, P11, DOI 10.1046/j.1523-1747.2002.01644.x; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	39	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22582	10.1074/jbc.M611398200	http://dx.doi.org/10.1074/jbc.M611398200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17550901	hybrid			2022-12-25	WOS:000248354200036
J	Choi, J; Kim, B; Heo, K; Kim, K; Kim, H; Zhan, YX; Ranish, JA; An, WJ				Choi, Jongkyu; Kim, Bong; Heo, Kyu; Kim, Kyunghwan; Kim, Hyunjung; Zhan, Yuxia; Ranish, Jeffrey A.; An, Woojin			Purification and characterization of cellular proteins associated with histone H4 tails	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODED AFFINITY TAGS; RNA-POLYMERASE-II; NUCLEOSOME CORE; ACTIVE GENES; TRANSCRIPTIONAL ACTIVATION; CHROMATIN MODIFICATIONS; ARGININE METHYLATION; EPIGENETIC CONTROL; STATISTICAL-MODEL; LYSINE 9	The histone H4 N-terminal tail has long been regarded as a major regulator in chromatin structure and function. Although the underlying mechanism has not been unraveled, an emerging body of evidence supports that H4 tail and its post-translational modification function as a recruitment motif for key factors required for proper regulation of chromatin transcription. To investigate these aspects, we have generated HeLa cell lines that constitutively express ectopic H4 tail domain for biochemical purification of proteins associated with H4 tail. We found that expressed H4 tails stably associate with sets of transcription regulatory factors and histone methyltransferases distinct from those that associate with histone H3 tails. Importantly, point mutations of four major lysine substrates to block cellular acetylation of ectopic H4 tail significantly inhibited the association of histone methyltransferases and sets of transcription-activating factors, supporting a major role of acetylation on recruitment-based action of H4 tail during transcription. Further, our transcription analysis revealed that the proteins associated with wild-type/acetylated H4 tail, but not with mutant/unacetylated H4 tail, can enhance p300-dependent chromatin transcription. Taken together, these findings demonstrate novel roles for H4 tail and its acetylation in mediating recruitment of multiple regulatory factors that can change chromatin states for transcription regulation.	Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90033 USA; Inst Syst Biol, Seattle, WA 98103 USA	University of Southern California; Institute for Systems Biology (ISB)	An, WJ (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Keck Sch Med, 1501 San Pablo St,ZNI Rm 241, Los Angeles, CA 90033 USA.	woojinan@usc.edu		Heo, Kyu/0000-0001-8833-4731				An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Ancelin K, 2006, NAT CELL BIOL, V8, P623, DOI 10.1038/ncb1413; Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bitoun E, 2007, HUM MOL GENET, V16, P92, DOI 10.1093/hmg/ddl444; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cosgrove MS, 2005, BIOCHEM CELL BIOL, V83, P468, DOI 10.1139/O05-137; Dacwag CS, 2007, MOL CELL BIOL, V27, P384, DOI 10.1128/MCB.01528-06; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Heo K, 2007, J BIOL CHEM, V282, P15476, DOI 10.1074/jbc.M610270200; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Karachentsev D, 2007, DEV BIOL, V304, P46, DOI 10.1016/j.ydbio.2006.12.019; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee JH, 2005, MOL CELLS, V19, P289; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Malik S, 2003, METHOD ENZYMOL, V364, P257; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Richard S, 2005, BIOCHEM J, V388, P379, DOI 10.1042/BJ20040373; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Sims JK, 2006, J BIOL CHEM, V281, P12760, DOI 10.1074/jbc.M513462200; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Holde K.E., 1988, CHROMATIN; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	58	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21024	21031		10.1074/jbc.M703883200	http://dx.doi.org/10.1074/jbc.M703883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17548343	hybrid			2022-12-25	WOS:000248047500029
J	Amela, I; Cedano, J; Querol, E				Amela, Isaac; Cedano, Juan; Querol, Enrique			Pathogen Proteins Eliciting Antibodies Do Not Share Epitopes with Host Proteins: A Bioinformatics Approach	PLOS ONE			English	Article								The best way to prevent diseases caused by pathogens is by the use of vaccines. The advent of genomics enables genome-wide searches of new vaccine candidates, called reverse vaccinology. The most common strategy to apply reverse vaccinology is by designing subunit recombinant vaccines, which usually generate an humoral immune response due to B-cell epitopes in proteins. A major problem for this strategy is the identification of protective immunogenic proteins from the surfome of the pathogen. Epitope mimicry may lead to auto-immune phenomena related to several human diseases. A sequence-based computational analysis has been carried out applying the BLASTP algorithm. Therefore, two huge databases have been created, one with the most complete and current linear B-cell epitopes, and the other one with the surface-protein sequences of the main human respiratory bacterial pathogens. We found that none of the 7353 linear B-cell epitopes analysed shares any sequence identity region with human proteins capable of generating antibodies, and that only 1% of the 2175 exposed proteins analysed contain a stretch of shared sequence with the human proteome. These findings suggest the existence of a mechanism to avoid autoimmunity. We also propose a strategy for corroborating or warning about the viability of a protein linear B-cell epitope as a putative vaccine candidate in a reverse vaccinology study; so, epitopes without any sequence identity with human proteins should be very good vaccine candidates, and the other way around.	[Querol, Enrique] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Querol, E (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.	enric.querol@uab.es		Cedano, Juan/0000-0003-1380-8036	European Union [LSHB-CT-2006-037325]; MEC (Ministerio de Educacion y Ciencia, Spain) [BFU2004-06377-CO2-01]; Centre de Referencia de R+D de Biotecnologia de la Generalitat de Catalunya; UAB (Universitat Autonoma de Barcelona)	European Union(European Commission); MEC (Ministerio de Educacion y Ciencia, Spain)(Spanish Government); Centre de Referencia de R+D de Biotecnologia de la Generalitat de Catalunya(Generalitat de Catalunya); UAB (Universitat Autonoma de Barcelona)	This research was supported by Grants LSHB-CT-2006-037325 funded under the Sixth Research Framework Programme of the European Union; BFU2004-06377-CO2-01 from the MEC (Ministerio de Educacion y Ciencia, Spain); and by the Centre de Referencia de R+D de Biotecnologia de la Generalitat de Catalunya. I. Amela is a predoctoral fellowship recipient from the UAB (Universitat Autonoma de Barcelona).	Abdissa A, 2006, CLIN INFECT DIS, V42, P1362, DOI 10.1086/503422; Adamou JE, 2001, INFECT IMMUN, V69, P949, DOI 10.1128/IAI.69.2.949-958.2001; ALAALDEEN DAA, 1994, INFECT IMMUN, V62, P2984, DOI 10.1128/IAI.62.7.2984-2990.1994; AlaAldeen DAA, 1996, VACCINE, V14, P49, DOI 10.1016/0264-410X(95)00136-O; Aloy P, 1997, COMPUT APPL BIOSCI, V13, P231; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASKELOF P, 1990, P NATL ACAD SCI USA, V87, P1347, DOI 10.1073/pnas.87.4.1347; Banks DJ, 2004, J INFECT DIS, V190, P727, DOI 10.1086/422697; Bannantine JP, 2000, CELL MICROBIOL, V2, P35; Beghetto E, 2006, FEMS MICROBIOL LETT, V262, P14, DOI 10.1111/j.1574-6968.2006.00360.x; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Benner GE, 1999, INFECT IMMUN, V67, P1922; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; Birkeland HCG, 2004, CURR TOP MICROBIOL, V282, P89; Borchardt JK, 2004, DRUG NEWS PERSPECT, V17, P219, DOI 10.1358/dnp.2004.17.3.829020; Cazalet C, 2004, NAT GENET, V36, P1165, DOI 10.1038/ng1447; Chang B, 2005, INFECT IMMUN, V73, P4272, DOI 10.1128/IAI.73.7.4272-4280.2005; Chatenoud L, 2000, Rev Prat, V50, P1497; Chiavolini D, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-14; Corech R, 2005, J CLIN MICROBIOL, V43, P3956, DOI 10.1128/JCM.43.8.3956-3962.2005; DIAS WO, 1994, BRAZ J MED BIOL RES, V27, P2607; DUCHENE M, 1989, J BACTERIOL, V171, P4130; El-Adhami W, 1999, INFECT IMMUN, V67, P1935; Erkkila L, 2004, ATHEROSCLEROSIS, V177, P321, DOI 10.1016/j.atherosclerosis.2004.08.021; Finco O, 2005, VACCINE, V23, P1178, DOI 10.1016/j.vaccine.2004.07.045; Fitzpatrick DA, 2005, J MOL EVOL, V61, P90, DOI 10.1007/s00239-004-0290-6; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gattiker A, 2003, COMPUT BIOL CHEM, V27, P49, DOI 10.1016/S1476-9271(02)00094-4; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; Goure J, 2005, J INFECT DIS, V192, P218, DOI 10.1086/430932; Guzman CA, 1999, J INFECT DIS, V179, P901, DOI 10.1086/314655; Hausman SZ, 2000, INFECT IMMUN, V68, P3763, DOI 10.1128/IAI.68.6.3763-3767.2000; JANSON H, 1993, INFECT IMMUN, V61, P4546, DOI 10.1128/IAI.61.11.4546-4552.1993; Keil DJ, 1999, VACCINE, V18, P860, DOI 10.1016/S0264-410X(99)00322-9; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Li B, 2005, INFECT IMMUN, V73, P3734, DOI 10.1128/IAI.73.6.3734-3739.2005; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Liu DF, 2004, INFECT IMMUN, V72, P6961, DOI 10.1128/IAI.72.12.6961-6968.2004; LUGTENBERG B, 1986, INFECT IMMUN, V52, P175, DOI 10.1128/IAI.52.1.175-182.1986; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Mascarell L, 2005, J VIROL, V79, P9872, DOI 10.1128/JVI.79.15.9872-9884.2005; Mattoo S, 2000, INFECT IMMUN, V68, P2024, DOI 10.1128/IAI.68.4.2024-2033.2000; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; McArthur JD, 2006, MOL MICROBIOL, V59, P1, DOI 10.1111/j.1365-2958.2005.04967.x; McMillan DJ, 2004, FEMS IMMUNOL MED MIC, V40, P249, DOI 10.1016/S0928-8244(04)00003-3; Miyamoto Y, 2007, EXP CELL RES, V313, P791, DOI 10.1016/j.yexcr.2006.11.017; Montigiani S, 2002, INFECT IMMUN, V70, P368, DOI 10.1128/IAI.70.1.368-379.2002; Moss J, 2001, INFECT IMMUN, V69, P1185, DOI 10.1128/IAI.69.2.1185-1188.2001; Moyle PM, 2006, J ORG CHEM, V71, P6846, DOI 10.1021/jo060960p; Murphy TF, 2006, INFECT IMMUN, V74, P5169, DOI 10.1128/IAI.00692-06; Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009; NOVOTNY P, 1991, J INFECT DIS, V164, P114, DOI 10.1093/infdis/164.1.114; NOVOTNY P, 1991, DEV BIOLOGICALS, V73, P243; Okamoto S, 2005, VACCINE, V23, P4852, DOI 10.1016/j.vaccine.2005.02.035; Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091; Philipovskiy AV, 2005, INFECT IMMUN, V73, P1532, DOI 10.1128/IAI.73.3.1532-1542.2005; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; POOLMAN JT, 1995, INFECT AGENT DIS, V4, P13; Price BM, 2001, INFECT IMMUN, V69, P3510, DOI 10.1128/IAI.69.5.3510-3515.2001; Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3; Rappuoli R, 2003, SCIENCE, V302, P602, DOI 10.1126/science.1092329; Ring G O, 1927, Trans Am Ophthalmol Soc, V25, P93; Rodriguez-Ortega MJ, 2006, NAT BIOTECHNOL, V24, P191, DOI 10.1038/nbt1179; Saha S, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-79; Saha S., 2004, BCEPRED PREDICTION C; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Sambri V, 2004, VACCINE, V22, P1131, DOI 10.1016/j.vaccine.2003.09.035; Seepersaud R, 2005, INFECT IMMUN, V73, P1671, DOI 10.1128/IAI.73.3.1671-1683.2005; Thomas LD, 2003, FEMS IMMUNOL MED MIC, V37, P155, DOI 10.1016/S0928-8244(03)00073-7; Toseland Christopher P, 2005, Immunome Res, V1, P4, DOI 10.1186/1745-7580-1-4; Turner PC, 2001, MICROBIOL-SGM, V147, P1277, DOI 10.1099/00221287-147-5-1277; Umelo-Njaka E, 2001, VACCINE, V19, P1406, DOI 10.1016/S0264-410X(00)00362-5; van den Elsen J, 1999, J BIOL CHEM, V274, P1495, DOI 10.1074/jbc.274.3.1495; Vermont C, 2002, FEMS IMMUNOL MED MIC, V34, P89, DOI 10.1111/j.1574-695X.2002.tb00608.x; Viau M, 2005, MOL IMMUNOL, V42, P849, DOI 10.1016/j.molimm.2004.07.047; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Vohra H, 2005, RES MICROBIOL, V156, P575, DOI 10.1016/j.resmic.2004.12.009; Vytvytska O, 2002, PROTEOMICS, V2, P580, DOI 10.1002/1615-9861(200205)2:5<580::AID-PROT580>3.0.CO;2-G; WEERATNA R, 1994, INFECT IMMUN, V62, P3454, DOI 10.1128/IAI.62.8.3454-3462.1994; Weichhart T, 2003, INFECT IMMUN, V71, P4633, DOI 10.1128/IAI.71.8.4633-4641.2003; Welsch JA, 2004, J IMMUNOL, V172, P5606, DOI 10.4049/jimmunol.172.9.5606; Wizemann TM, 2001, INFECT IMMUN, V69, P1593, DOI 10.1128/IAI.69.3.1593-1598.2001; Worgall S, 2005, J CLIN INVEST, V115, P1281, DOI 10.1172/JCI200523135; Zagursky RJ, 2000, INFECT IMMUN, V68, P2525, DOI 10.1128/IAI.68.5.2525-2534.2000	84	26	27	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e512	10.1371/journal.pone.0000512	http://dx.doi.org/10.1371/journal.pone.0000512			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551592	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451500021
J	Rong, R; Jiang, LY; Sheikh, MS; Huang, Y				Rong, R.; Jiang, L. Y.; Sheikh, M. S.; Huang, Y.			Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation	ONCOGENE			English	Article						tumor suppressor; mitotic kinase; RASSF1A; Aurora-A; cell cycle; microtubules	TUMOR-SUPPRESSOR RASSF1A; CENTROSOME AMPLIFICATION; CDC2 KINASE; PROTEIN; OVEREXPRESSION; SITES; MAP4	RASSF1A (RAS-association domain family 1, isoform A) is a newer tumor suppressor that binds to and stabilizes microtubules as well as induces M-phase cell cycle arrest. Several other proteins that interact with and stabilize microtubules also undergo mitotic phase phosphorylation to regulate microtubule dynamics and M-phase cell cycle progression. Currently, however, there is a paucity of information regarding the phosphorylation status of RASSF1A and its regulation during mitosis. In this study, for the first time, we demonstrate that Aurora-A is a RASSF1A kinase and, to the best of our knowledge, this is also the first study reporting the identification of a kinase for RASSF1A. We show that the mitotic kinase Aurora-A directly interacts with and phosphorylates RASSF1 and that RASSF1A is phosphorylated by Aurora-A during mitosis. These findings therefore link an important oncogenic mitotic kinase to regulate RASSF1A tumor suppressor. Aurora-A appears to phosphorylate RASSF1A at Threonine202 and/or Serine203 that reside within the known microtubule-binding domain of RASSF1A. Substitutions of these residues with glutamic acid at both positions, mimicking constitutive phosphorylation of RASSF1A, disrupt RASSF1A interactions with microtubules and abolish its ability to induce M-phase cell cycle arrest. Our results further demonstrate that Aurora-A overexpression also interferes with RASSF1A-mediated growth suppression. In view of our results, we propose that Aurora-A-mediated phosphorylation of RASSF1A is a novel mechanism that regulates the ability of this tumor suppressor to interact with microtubules and modulate M-phase cell cycle progression.	[Rong, R.; Jiang, L. Y.; Sheikh, M. S.; Huang, Y.] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			NATIONAL CANCER INSTITUTE [R21CA113868, R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067271] Funding Source: NIH RePORTER; NCI NIH HHS [CA113868, CA86945] Funding Source: Medline; NIDDK NIH HHS [DK067271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; FARUKI S, 1992, J CELL SCI, V101, P69; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Ookata K, 1997, BIOCHEMISTRY-US, V36, P15873, DOI 10.1021/bi971251w; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Shiina N, 1999, MOL BIOL CELL, V10, P597, DOI 10.1091/mbc.10.3.597; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Trzepacz C, 1997, J BIOL CHEM, V272, P21681, DOI 10.1074/jbc.272.35.21681; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wang XX, 2006, CELL RES, V16, P356, DOI 10.1038/sj.cr.7310046; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	19	66	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7700	7708		10.1038/sj.onc.1210575	http://dx.doi.org/10.1038/sj.onc.1210575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563743				2022-12-25	WOS:000251537800012
J	Yuan, TC; Lin, FF; Veeramani, S; Chen, SJ; Earp, HS; Lin, MF				Yuan, T-C; Lin, F-F; Veeramani, S.; Chen, S-J; Earp, H. S., III; Lin, M-F			ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells	ONCOGENE			English	Article						prostate cancer; cell adhesion; PYK2; ErbB-2	PROTEIN-TYROSINE-PHOSPHATASE; ACID-PHOSPHATASE; KINASE; PROLIFERATION; EXPRESSION; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; PAXILLIN; INVASION	Aberrant regulation in the adhesive ability of cancer cells is closely associated with their metastatic activity. In this study, we examine the role of ErbB-2 in regulating the adhesive ability of androgen receptor (AR)-positive human prostate cancer (PCa) cells, the major cell population of PCa. Utilizing different LNCaP and MDA PCa2b cells as model systems, we found that ErbB-2 activity was correlated with PYK2 activity and adhesive ability in those cells. Increased ErbB-2 expression or activity in LNCaP C-33 cells enhanced PYK2 activation and cell adhesion, while the high PYK2 activity and the rapid adhesion of LNCaP C-81 cells were decreased by diminishing ErbB-2 expression or activity. Knockdown studies revealed the predominant role of ErbB-2 in regulating LNCaP C-81 cell adhesion. Coimmunoprecipitation showed that C-81 cells had increased interaction between ErbB-2 and PYK2. Elevated ErbB-2 activity in LNCaP cells correlated with increased ERK/MAPK activity and enhanced adhesive ability, which were abolished by the expression of K457A-PYK2 mutant or the treatment of PD98059, a MEK inhibitor. In summary, our data suggested that ErbB-2, via PYK2-ERK/MAPK, upregulates the adhesive ability of AR-positive human PCa cells.	Univ Nebraska Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA; Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	mlin@unmc.edu	Veeramani, Suresh/P-7838-2019	Veeramani, Suresh/0000-0001-9217-0872	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Chen SJ, 2007, PROSTATE, V67, P557, DOI 10.1002/pros.20551; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haier J, 2001, APMIS, V109, P241, DOI 10.1034/j.1600-0463.2001.d01-118.x; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Knudsen BS, 2006, J CELL BIOCHEM, V99, P345, DOI 10.1002/jcb.20934; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Lipinski CA, 2005, NEOPLASIA, V7, P435, DOI 10.1593/neo.04712; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Park SY, 2007, CELL SIGNAL, V19, P289, DOI 10.1016/j.cellsig.2006.07.005; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Vafa A, 1998, INT J ONCOL, V13, P1191; van der Horst EH, 2005, INT J CANCER, V113, P689, DOI 10.1002/ijc.20643; Veeramani S, 2005, ENDOCR-RELAT CANCER, V12, P805, DOI 10.1677/erc.1.00950; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	29	21	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7552	7559		10.1038/sj.onc.1210570	http://dx.doi.org/10.1038/sj.onc.1210570			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563746				2022-12-25	WOS:000251282100007
J	Taneja, P; Mallakin, A; Matise, LA; Frazier, DP; Choudhary, M; Inoue, K				Taneja, P.; Mallakin, A.; Matise, L. A.; Frazier, D. P.; Choudhary, M.; Inoue, K.			Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-kappa B subunit p65	ONCOGENE			English	Article						Dmp1; Arf; p53; NF-kappa B; anthracyclin; UV-C	CELL-CYCLE ARREST; TUMOR SUPPRESSION; GENE-EXPRESSION; P53; RAS; TRANSFORMATION; RESPONSES; CANCER	Both genotoxic and oncogenic stress activates the nuclear factor-kappa B (NF-kappa B) and p53 proteins however the p53 activity is antagonized by NF-kappa B signaling. Dmp1 is a Myb-like transcription factor that activates the Arf-p53 pathway. The Dmp1 promoter was activated by a classical NF-kappa B activator tumor necrosis factor a but repressed by treatment of cells with non classical NF-kappa B activators anthracyclins and UV-C. p65 and other subsets of NF-kappa B proteins were bound to the Dmp1 promoter following anthracyclin/UV-C treatment of rodent. broblasts. This resulted in the downregulation of Dmp1 mRNA and protein. Repression of the Dmp1 transcription by anthracyclins depended on the unique NF-kappa B site on the promoter. Downregulation of p65 significantly attenuated the repression of the Dmp1 promoter by anthracyclins/UV-C. The amount of Dmp1 bound to the Arf promoter decreased significantly upon anthracyclin treatment this in turn downregulated the Arf levels. Repression of the Arf promoter by p65 or anthracyclins depended on Dmp1 which was significantly attenuated in Dmp1(-/-) cells. Both Dmp1(-/-) and Arf(-/-) cells showed resistance to anthracyclin-induced cell death compared to wild-type cells non-immortalized p65-knockdown cells were much more sensitive. Thus the Dmp1-Arf pathway is repressed by p65 in response to genotoxic stress which implicates a novel mechanism of p53 inactivation by NF-kappa B.	Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC USA; Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Pathol & Canc Biol, 2102 Gray Bldg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	kinoue@wfubmc.edu	Choudhary, Mayur/AAU-3497-2021	Choudhary, Mayur/0000-0001-8056-011X	NCI NIH HHS [5R01CA106314, R01 CA106314-03, R01 CA106314-02, R01 CA106314, P30 CA012197, CA12197-31] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106314, P30CA012197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; DeVita V. T., 2005, CANC PRINCIPLES PRAC; Gallagher S, 2005, CELL CYCLE, V4, P465, DOI 10.4161/cc.4.3.1526; Gapuzan MER, 2005, ONCOGENE, V24, P6574, DOI 10.1038/sj.onc.1208809; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Huang DB, 2005, STRUCTURE, V13, P1365, DOI 10.1016/j.str.2005.06.018; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; INOUE K, 2007, ONCOGENE        0122; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Mallakin A, 2006, ONCOGENE, V25, P7703, DOI 10.1038/sj.onc.1209750; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	28	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7457	7466		10.1038/sj.onc.1210568	http://dx.doi.org/10.1038/sj.onc.1210568			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546045	Green Accepted			2022-12-25	WOS:000251282000007
J	Peculis, BA; Reynolds, K; Cleland, M				Peculis, Brenda A.; Reynolds, Kristen; Cleland, Megan			Metal determines efficiency and substrate specificity of the nuclear NUDIX decapping proteins X29 and H29K (Nudt16)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DECAY; CYTOPLASMIC PROCESSING BODIES; SNORNA-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; MAMMALIAN EXOSOME; ESCHERICHIA-COLI; ENZYME; YEAST; HYDROLASE	The Xenopus X29 protein was identified by its high affinity binding to U8 small nucleolar RNA, a small nucleolar RNA required for ribosome biogenesis. X29 and its human homologue H29K (Nudt16) are nuclear nucleoside diphosphatase proteins localized within foci in the nucleolus and nucleoplasm. These proteins can remove m(7)G and m(227)G caps from RNAs, rendering them substrates for 5'-3' exonucleases for degradation in vivo. Here, a more complete characterization of these metal-dependent decapping proteins demonstrates that the metal identity determines both the efficiency of decapping and the RNA substrate specificity. In Mg+2 the proteins hydrolyze the 5' cap from only one RNA substrate: U8 small nucleolar RNA. However, in the presence of Mn+2 or Co+2 all RNAs are substrates and the decapping efficiency is higher. The x-ray crystal structure of X29 facilitated structure-based mutagenesis. Mutation of single amino acids coordinating metal in the active site yielded mutant proteins confirming essential residues. In vitro assays with purified components are consistent with a lack of protein turnover, apparently due to an inability of the protein to release the decapped RNA, implicating critical in vivo interacting factors. Collectively, these studies indicate that the metal that binds the X29/H29K proteins in vivo may determine whether these decapping proteins function solely as a negative regulator of ribosome biogenesis or can decap a wider variety of nuclear-limited RNAs. With the potential broader RNA substrate specificity, X29/H29K may be the nuclear counterparts of the cytoplasmic decapping machinery, localized in specialized bodies involved in RNA decay.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Peculis, BA (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.	peculisb@missouri.edu		Harwig, Megan/0000-0003-2140-5739				Abdelraheim SR, 2003, BIOCHEM J, V374, P329, DOI 10.1042/BJ20030441; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Bail S, 2006, NAT STRUCT MOL BIOL, V13, P7, DOI 10.1038/nsmb0106-7; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BURGE C, 1999, SPLICING PRECURSORS; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Cougot N, 2004, TRENDS BIOCHEM SCI, V29, P436, DOI 10.1016/j.tibs.2004.06.008; Decker CJ, 2002, P NATL ACAD SCI USA, V99, P12512, DOI 10.1073/pnas.212518099; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Dunckley T, 2001, METHOD ENZYMOL, V342, P226, DOI 10.1016/S0076-6879(01)42547-X; Fenger-Gron M, 2005, MOL CELL, V20, P905, DOI 10.1016/j.molcel.2005.10.031; Gabelli SB, 2002, BIOCHEMISTRY-US, V41, P9279, DOI 10.1021/bi0259296; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; Ghosh T, 2004, MOL CELL, V13, P817, DOI 10.1016/S1097-2765(04)00127-3; GREEN SM, 1990, BIOCHEMISTRY-US, V29, P9159, DOI 10.1021/bi00491a009; Gu MG, 2004, MOL CELL, V14, P67, DOI 10.1016/S1097-2765(04)00180-7; Iwai T, 2004, J BIOL CHEM, V279, P21732, DOI 10.1074/jbc.M312018200; Legler PM, 2002, BIOCHEMISTRY-US, V41, P10834, DOI 10.1021/bi020362e; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; Liu SW, 2004, RNA, V10, P1412, DOI 10.1261/rna.7660804; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; Maksel D, 2001, BIOCHEM J, V357, P399, DOI 10.1042/0264-6021:3570399; Mildvan AS, 2005, ARCH BIOCHEM BIOPHYS, V433, P129, DOI 10.1016/j.abb.2004.08.017; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Peculis BA, 2004, ACTA CRYSTALLOGR D, V60, P1668, DOI 10.1107/S0907444904016051; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; Peculis BA, 2001, RNA, V7, P207, DOI 10.1017/S1355838201001625; Piccirillo C, 2003, RNA, V9, P1138, DOI 10.1261/rna.5690503; Rehwinkel J, 2005, RNA, V11, P1640, DOI 10.1261/rna.2191905; Saguez C, 2005, CURR OPIN CELL BIOL, V17, P287, DOI 10.1016/j.ceb.2005.04.009; Scarsdale JN, 2006, STRUCTURE, V14, P331, DOI 10.1016/j.str.2005.11.010; Sharma S, 2006, NEURON, V52, P574, DOI 10.1016/j.neuron.2006.11.005; She MP, 2006, NAT STRUCT MOL BIOL, V13, P63, DOI 10.1038/nsmb1033; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Sheth U, 2006, CELL, V125, P1095, DOI 10.1016/j.cell.2006.04.037; Simon E, 2006, TRENDS BIOCHEM SCI, V31, P241, DOI 10.1016/j.tibs.2006.03.001; Steiger M, 2003, RNA, V9, P231, DOI 10.1261/rna.2151403; Tharun S, 1999, GENETICS, V151, P1273; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Tomasevic N, 1999, J BIOL CHEM, V274, P35914, DOI 10.1074/jbc.274.50.35914; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; van Dijk E, 2003, P NATL ACAD SCI USA, V100, P12081, DOI 10.1073/pnas.1635192100; Vasudevan S, 2003, CURR OPIN CELL BIOL, V15, P332, DOI 10.1016/S0955-0674(03)00051-6; Wagner D, 2005, J IMMUNOL, V174, P1491, DOI 10.4049/jimmunol.174.3.1491; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Wilusz CJ, 2001, RNA, V7, P1416; Yang XN, 1999, J BIOL CHEM, V274, P35434, DOI 10.1074/jbc.274.50.35434; Yu JH, 2005, RNA, V11, P1795, DOI 10.1261/rna.2142405; Zhang S, 1999, METHODS, V17, P46, DOI 10.1006/meth.1998.0706	60	21	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24792	24805		10.1074/jbc.M704179200	http://dx.doi.org/10.1074/jbc.M704179200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17567574	hybrid			2022-12-25	WOS:000248933000035
J	Laugel, B; van den Berg, HA; Gostick, E; Cole, DK; Wooldridge, L; Boulter, J; Milicic, A; Price, DA; Sewell, AK				Laugel, Bruno; van den Berg, Hugo A.; Gostick, Emma; Cole, David K.; Wooldridge, Linda; Boulter, Jonathan; Milicic, Anita; Price, David A.; Sewell, Andrew K.			Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ANTIGEN RECOGNITION; CROSS-REACTIVITY; ALPHA-3 DOMAIN; AVIDITY; CTL; CD8-ALPHA-ALPHA; IDENTIFICATION; COMPLEXES; MOLECULES	T cells have evolved a unique system of ligand recognition involving an antigen T cell receptor (TCR) and a coreceptor that integrate stimuli provided by the engagement of peptide-major histocompatibility complex (pMHC) antigens. Here, we use altered pMHC class I (pMHCI) molecules with impaired CD8 binding (CD8-null) to quantify the contribution of coreceptor extracellular binding to (i) the engagement of soluble tetrameric pMHCI molecules, (ii) the kinetics of TCR/pMHCI interactions on live cytotoxic T lymphocytes (CTLs), and (iii) the activation of CTLs by cell-surface antigenic determinants. Our data indicate that the CD8 coreceptor substantially enhances binding efficiency at suboptimal TCR/pMHCI affinities through effects on both association and dissociation rates. Interestingly, coreceptor requirements for efficient tetramer labeling of CTLs or for CTL activation by determinants displayed on the cell surface operated in different TCR/pMHCI affinity ranges. Wild-type and CD8-null pMHCI tetramers required monomeric affinities for cognate TCRs of K-D < similar to 80 mu M and similar to 35 mu M, respectively, to label human CTLs at 37 degrees C. In contrast, activation by cellular pMHCI molecules was strictly dependent on CD8 binding only for TCR/pMHCI interactions with K-D values > 200 mu M. Altogether, our data provide information on the binding interplay between CD8 and the TCR and support a model of CTL activation in which the extent of coreceptor dependence is inversely correlated to TCR/pMHCI affinity. In addition, the results reported here define the range of TCR/pMHCI affinities required for the detection of antigen-specific CTLs by flow cytometry.	Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; Univ Warwick, Warwick Syst Biol Ctr, Coventry CU4 7AC, W Midlands, England	Cardiff University; University of Oxford; University of Warwick	Sewell, AK (corresponding author), Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Henry Wellcome Bldg,Heath Pk,S Parks Rd, Cardiff CF14 4XN, S Glam, Wales.	sewellak@cardiff.ac.uk	Sewell, Andrew/GPT-4220-2022; Price, David A/C-7876-2013; Cole, David/C-8387-2012; Milicic, Anita/B-7693-2011	Sewell, Andrew/0000-0003-3194-3135; Price, David A/0000-0001-9416-2737; Milicic, Anita/0000-0002-7984-1317; Wooldridge, Linda/0000-0002-6213-347X; van den Berg, Hugo/0000-0002-8230-6227; Cole, David/0000-0003-0028-9396	MRC [G0501963] Funding Source: UKRI; Medical Research Council [G0501963] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALRAMADI BK, 1995, J IMMUNOL, V155, P662; Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; BLOK R, 1992, INT IMMUNOL, V4, P455, DOI 10.1093/intimm/4.4.455; Boulter JM, 2003, PROTEIN ENG, V16, P707, DOI 10.1093/protein/gzg087; Burrows SR, 2000, J IMMUNOL, V165, P6229, DOI 10.4049/jimmunol.165.11.6229; Busch DH, 1999, J EXP MED, V189, P701, DOI 10.1084/jem.189.4.701; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; Buslepp J, 2003, J IMMUNOL, V170, P373, DOI 10.4049/jimmunol.170.1.373; Callender GG, 2006, HEPATOLOGY, V43, P973, DOI 10.1002/hep.21157; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; Chang HC, 2005, IMMUNITY, V23, P661, DOI 10.1016/j.immuni.2005.11.002; Cho BK, 2001, P NATL ACAD SCI USA, V98, P1723, DOI 10.1073/pnas.98.4.1723; Choi EML, 2003, J IMMUNOL, V171, P5116, DOI 10.4049/jimmunol.171.10.5116; Couedel C, 1999, J IMMUNOL, V162, P6351; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; Demotte N, 2002, EUR J IMMUNOL, V32, P1688, DOI 10.1002/1521-4141(200206)32:6<1688::AID-IMMU1688>3.0.CO;2-9; Drake DR, 2005, J IMMUNOL, V175, P1507, DOI 10.4049/jimmunol.175.3.1507; Drake DR, 2001, J IMMUNOL, V166, P7009, DOI 10.4049/jimmunol.166.12.7009; Fahmy TM, 2001, IMMUNITY, V14, P135, DOI 10.1016/S1074-7613(09)00099-5; Falta MT, 2005, ARTHRITIS RHEUM-US, V52, P1885, DOI 10.1002/ART.21098; Gakamsky DM, 2005, BIOPHYS J, V89, P2121, DOI 10.1529/biophysj.105.061671; Gangadharan D, 2004, CURR OPIN IMMUNOL, V16, P264, DOI 10.1016/j.coi.2004.03.015; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Glick M, 2002, J BIOL CHEM, V277, P20840, DOI 10.1074/jbc.M201819200; Guimezanes A, 2003, EUR J IMMUNOL, V33, P3060, DOI 10.1002/eji.200324249; Hernandez J, 2000, J IMMUNOL, V164, P596, DOI 10.4049/jimmunol.164.2.596; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; Hutchinson SL, 2003, J BIOL CHEM, V278, P24285, DOI 10.1074/jbc.M300633200; Kao C, 2005, INT IMMUNOL, V17, P1607, DOI 10.1093/intimm/dxh340; Kerry SE, 2003, J IMMUNOL, V171, P4493, DOI 10.4049/jimmunol.171.9.4493; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Laugel B, 2005, J BIOL CHEM, V280, P1882, DOI 10.1074/jbc.M409427200; Leishman AJ, 2001, SCIENCE, V294, P1936, DOI 10.1126/science.1063564; Lyons GE, 2006, CANCER RES, V66, P11455, DOI 10.1158/0008-5472.CAN-06-2379; Maile R, 2005, J IMMUNOL, V174, P619, DOI 10.4049/jimmunol.174.2.619; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; Pecht I, 2005, FEBS LETT, V579, P3336, DOI 10.1016/j.febslet.2005.04.025; Pittet MJ, 2003, J IMMUNOL, V171, P1844, DOI 10.4049/jimmunol.171.4.1844; Price DA, 2005, J EXP MED, V202, P1349, DOI 10.1084/jem.20051357; Purbhoo MA, 2001, J BIOL CHEM, V276, P32786, DOI 10.1074/jbc.M102498200; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Viola A, 1997, J EXP MED, V186, P1775, DOI 10.1084/jem.186.10.1775; Wooldridge L, 2005, J BIOL CHEM, V280, P27491, DOI 10.1074/jbc.M500555200; Wooldridge L, 2003, J IMMUNOL, V171, P6650, DOI 10.4049/jimmunol.171.12.6650; Wooldridge L, 2006, EUR J IMMUNOL, V36, P1847, DOI 10.1002/eji.200635886; Yachi PP, 2006, IMMUNITY, V25, P203, DOI 10.1016/j.immuni.2006.05.015; Yee C, 1999, J IMMUNOL, V162, P2227; Zamoyska R, 1998, CURR OPIN IMMUNOL, V10, P82, DOI 10.1016/S0952-7915(98)80036-8	58	156	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23799	23810		10.1074/jbc.M700976200	http://dx.doi.org/10.1074/jbc.M700976200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17540778	Green Accepted, hybrid			2022-12-25	WOS:000248686600008
J	Zhong, J; Kyriakis, JM				Zhong, Jian; Kyriakis, John M.			Dissection of a signaling pathway by which pathogen-associated molecular patterns recruit the JNK and p38 MAPKs and trigger cytokine release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; N-TERMINAL KINASE; KAPPA-B; RECEPTOR; ACTIVATION; STRESS; INNATE; INTERLEUKIN-1; RECOGNITION; EXPRESSION	Pathogen-associated molecular patterns ( PAMPs), molecular moieties produced by invading microbial pathogens, initiate innate immune responses by binding to pattern recognition receptors ( PRRs). Engagement of PRRs elicits a wide variety of responses, including the production and release of cytokines and chemokines. These responses require the activation of several parallel signaling pathways, including NF- kappa B, the interferon regulatory factors, and the MAPKs. The JNK and p38 MAPK groups are major PRR effectors and are key to the PRR-dependent induction and release of proinflammatory cytokines such as tumor necrosis factor and interleukin- 8. The mammalian Ste20 orthologue germinal center kinase ( GCK) is required for the activation of JNK by a subset of PAMPs; however, the mechanisms by which GCK couples to downstream events remain unclear. Here we show thatGCKis required for JNK and, unexpectedly, p38 activation by three bacterial PAMPs, lipopolysaccharide, peptidoglycan, and flagellin ( FliC). We show that these same PAMPs, in a GCK- dependent manner, activate mixed lineage kinases- 2 and - 3, MAPK kinase kinases upstream of JNK, and p38. We also show that MLK2 and - 3 are required for activation of JNK and p38 by ectopically expressed GCK. Finally, we show that MLK2 and - 3 are required for lipopolysaccharide, peptidoglycan, and FliC recruitment of JNK and p38 as well as for PAMP recruitment of the transcription factor c- Jun, and for the induction of interleukin- 8. Our results define a signaling pathway whereby PAMPs can trigger MAPK activation and gene expression.	Tufts Univ, New England Med Ctr, Dept Med, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University	Kyriakis, JM (corresponding author), Tufts Univ, New England Med Ctr, Dept Med, Mol Cardiol Res Inst, 750 Washington St,Box 8486, Boston, MA 02111 USA.	jkyriakis@tufts-nemc.org			NHLBI NIH HHS [T32-HL069770] Funding Source: Medline; NIGMS NIH HHS [R01-GM46577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brancho D, 2005, MOL CELL BIOL, V25, P3670, DOI 10.1128/MCB.25.9.3670-3681.2005; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Di Bartolo V, 2007, J EXP MED, V204, P681, DOI 10.1084/jem.20062066; Doyle SL, 2006, BIOCHEM PHARMACOL, V72, P1102, DOI 10.1016/j.bcp.2006.07.010; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Kyriakis JM, 2007, BBA-MOL CELL RES, V1773, P1238, DOI 10.1016/j.bbamcr.2006.11.003; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; Michelsen KS, 2006, CURR OPIN HEMATOL, V13, P163, DOI 10.1097/01.moh.0000219662.88409.7c; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shi CS, 2006, MOL CELL BIOL, V26, P6511, DOI 10.1128/MCB.00209-06; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Wan YSY, 2006, NAT IMMUNOL, V7, P851, DOI 10.1038/ni1355; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhong J, 2004, MOL CELL BIOL, V24, P9165, DOI 10.1128/MCB.24.20.9165-9175.2004	35	47	52	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24246	24254		10.1074/jbc.M703422200	http://dx.doi.org/10.1074/jbc.M703422200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584736	hybrid			2022-12-25	WOS:000248686600050
J	Gutierrrez, P; Kozlov, G; Gabrielli, L; Elias, D; Osborne, MJ; Gallouzi, IE; Gehring, K				Gutierrrez, Pablo; Kozlov, Guennadi; Gabrielli, Lisa; Elias, Demetra; Osborne, Michael J.; Gallouzi, Imed E.; Gehring, Kalle			Solution structure of YaeO, a Rho-specific inhibitor of transcription termination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; ESCHERICHIA-COLI; ANTIBIOTIC BICYCLOMYCIN; DIPOLAR COUPLINGS; ESSENTIAL GENES; PROTEIN PSU; MACROMOLECULES; MECHANISM; HOMOLOGY; HELICASE	Rho-dependent transcription termination is an essential process for the regulation of bacterial gene expression. Thus far, only two Rho-specific inhibitors of bacterial transcription termination have been described, the psu protein from the satellite bacteriophage P4 and YaeO from Escherichia coli. Here, we report the solution structure of YaeO, the first of a Rho-specific inhibitor of transcription termination. YaeO is an acidic protein composed of an N-terminal helix and a seven-stranded beta sandwich. NMR chemical shift perturbation experiments revealed that YaeO binds proximal to the primary nucleic acid binding site of Rho. Based on the NMR titrations, a docked model of the YaeO-Rho complex was calculated. These results suggest that YaeO binds outside the Rho hexamer, acting as a competitive inhibitor of RNA binding. In vitro gel shift assays confirmed the inhibition of nucleic acid binding to Rho. Site-directed mutagenesis showed that the negative character of YaeO is essential for its function in vivo.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Gehring, K (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	kalle.gehring@mcgill.ca	Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184; Osborne, Michael John/0000-0003-1028-4038				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BRENDEL V, 1986, J BIOMOL STRUCT DYN, V3, P705, DOI 10.1080/07391102.1986.10508457; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; Briercheck DM, 1996, J BIOMOL NMR, V8, P429; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; BROWN S, 1981, J BACTERIOL, V146, P422, DOI 10.1128/JB.146.1.422-425.1981; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Hitchens TK, 2006, J BIOL CHEM, V281, P33697, DOI 10.1074/jbc.M605312200; KAMIYA T, 1972, J ANTIBIOT, V25, P576, DOI 10.7164/antibiotics.25.576; Kim DE, 2001, J BIOL CHEM, V276, P13902, DOI 10.1074/jbc.M011043200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINDEROTH NA, 1991, J BACTERIOL, V173, P6722, DOI 10.1128/jb.173.21.6722-6731.1991; Linderoth NA, 1997, VIROLOGY, V227, P131, DOI 10.1006/viro.1996.8325; Magyar A, 1996, J BIOL CHEM, V271, P25369, DOI 10.1074/jbc.271.41.25369; Malliavin TE, 1998, BIOINFORMATICS, V14, P624, DOI 10.1093/bioinformatics/14.7.624; Miller JH., 1972, EXPT MOL GENETICS; MIYAMURA S, 1972, J ANTIBIOT, V25, P610, DOI 10.7164/antibiotics.25.610; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pani B, 2006, J BIOL CHEM, V281, P26491, DOI 10.1074/jbc.M603982200; Pasman Z, 2000, BIOCHEMISTRY-US, V39, P5573, DOI 10.1021/bi992658z; Pichoff S, 1998, MOL MICROBIOL, V29, P859, DOI 10.1046/j.1365-2958.1998.00981.x; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; Skordalakes E, 2005, STRUCTURE, V13, P99, DOI 10.1016/j.str.2004.10.013; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Skordalakes E, 2006, CELL, V127, P553, DOI 10.1016/j.cell.2006.08.051; Wuthrich K, 1986, NMR PROTEINS NUCL AC	38	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23348	23353		10.1074/jbc.M702010200	http://dx.doi.org/10.1074/jbc.M702010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565995	hybrid			2022-12-25	WOS:000248577500035
J	Donigian, JR; de Lange, T				Donigian, Jill R.; de Lange, Titia			The role of the poly(ADP-ribose) polymerase tankyrase1 in telomere length control by the TRF1 component of the shelterin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POT1; INTERACTS; LOCALIZATION; REGULATOR; DOMAIN; MOTIF; TIN2; IRAP; PARP	Tankyrase1 is a multifunctional poly(ADP-ribose) polymerase that can localize to telomeres through its interaction with the shelterin component TRF1. Tankyrase1 poly(ADP-ribosyl) ates TRF1 in vitro, and its nuclear overexpression leads to loss of TRF1 and telomere elongation, suggesting that tankyrase1 is a positive regulator of telomere length. In agreement with this proposal, we show that tankyrase1 RNA interference results in telomere shortening proportional to the level of knockdown. Furthermore, we show that a tankyrase1-resistant form of TRF1 enforced normal telomere length control, indicating that tankyrase1 is not required downstream of TRF1 in this pathway. Thus, in human cells, tankyrase1 appears to act upstream of TRF1, promoting telomere elongation through the removal of TRF1. This pathway appears absent from mouse cells. We show that murine TRF1, which lacks the canonical tankyrase1-binding site, is not a substrate for tankyrase1 poly(ADP-ribosyl)sylation in vitro. Furthermore, overexpression of tankyrase1 in mouse nuclei did not remove TRF1 from telomeres and had no detectable effect on other components of mouse shelterin. We propose that the tankyrase1-controlled telomere extension is a human-specific elaboration that allows additional control over telomere length in telomerase positive cells.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, Box 159,1230 York Ave, New York, NY 10021 USA.	delange@mail.rockefeller.edu	de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NATIONAL CANCER INSTITUTE [R01CA076027, K08CA000966] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA0096673, CA076027] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Chang P, 2004, NATURE, V432, P645, DOI 10.1038/nature03061; Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; Cristofari G, 2006, EMBO J, V25, P565, DOI 10.1038/sj.emboj.7600952; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; De Rycker M, 2003, BIOCHEM J, V372, P87, DOI 10.1042/BJ20021450; Dynek JN, 2004, SCIENCE, V304, P97, DOI 10.1126/science.1094754; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kelleher C, 2005, MOL CELL BIOL, V25, P808, DOI 10.1128/MCB.25.2.808-818.2005; Lei M, 2005, J BIOL CHEM, V280, P20449, DOI 10.1074/jbc.M502212200; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Sbodio JI, 2002, J BIOL CHEM, V277, P31887, DOI 10.1074/jbc.M203916200; Seimiya H, 2005, CANCER CELL, V7, P25, DOI 10.1016/j.ccr.2004.11.021; Seimiya H, 2004, MOL CELL BIOL, V24, P1944, DOI 10.1128/MCB.24.5.1944-1955.2004; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Ye JZS, 2004, NAT GENET, V36, P618, DOI 10.1038/ng1360	27	52	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22662	22667		10.1074/jbc.M702620200	http://dx.doi.org/10.1074/jbc.M702620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17561506	hybrid			2022-12-25	WOS:000248354200043
J	Hoffmann, SC; Schellack, C; Textor, S; Konold, S; Schmitz, D; Cerwenka, A; Pflanz, S; Watzl, C				Hoffmann, Sabrina C.; Schellack, Carola; Textor, Sonja; Konold, Stephanie; Schmitz, Debora; Cerwenka, Adelheid; Pflanz, Stefan; Watzl, Carsten			Identification of CLEC12B, an inhibitory receptor on myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE RECEPTORS; NATURAL-KILLER-CELLS; LECTIN-LIKE RECEPTOR; CYTOTOXICITY; ACTIVATION	Activation of immune cells has to be tightly controlled to prevent detrimental hyperactivation. In this regulatory process molecules of the C-type lectin-like family play a central role. Here we describe a new member of this family, CLEC12B. The extracellular domain of CLEC12B shows considerable homology to the activating natural killer cell receptor NKG2D, but unlike NKG2D, CLEC12B contains an immunoreceptor tyrosine-based inhibition motif in its intracellular domain. Despite the homology, CLEC12B does not appear to bind NKG2D ligands and therefore does not represent the inhibitory counterpart of NKG2D. However, CLEC12B has the ability to counteract NKG2D-mediated signaling, and we show that this function is dependent on the immunoreceptor tyrosine-based inhibition motif and the recruitment of the phosphatases SHP-1 and SHP-2. Using monoclonal anti-CLEC12B antibodies we found de novo expression of this receptor on in vitro generated human macrophages and on the human myelo-monocytic cell line U937 upon phorbol 12-myristate 13-acetate treatment, suggesting that this receptor plays a role in myeloid cell function.	Univ Heidelberg, Inst Immunol, D-6912 Heidelberg, Germany; German Canc Res Ctr D080, Div Innate Immun, D-69120 Heidelberg, Germany; Micromet AG, D-81477 Munich, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Amgen; Amgen Research Munich GmbH; Micromet AG	Watzl, C (corresponding author), Univ Heidelberg, Inst Immunol, Im Neuenheimer Feld 305, D-6912 Heidelberg, Germany.	Carsten.watzl@urz.uni-heidelberg.de	Watzl, Carsten/B-4911-2013	Watzl, Carsten/0000-0001-5195-0995; Cerwenka, Adelheid/0000-0001-6977-3536				Bakker ABH, 2004, CANCER RES, V64, P8443, DOI 10.1158/0008-5472.CAN-04-1659; Bhat R, 2006, J LEUKOCYTE BIOL, V79, P417, DOI 10.1189/jlb.0905537; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; Eissmann P, 2005, BLOOD, V105, P4722, DOI 10.1182/blood-2004-09-3796; Eissmann P, 2006, J IMMUNOL, V177, P3170, DOI 10.4049/jimmunol.177.5.3170; Han YM, 2004, BLOOD, V104, P2858, DOI 10.1182/blood-2004-03-0878; Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105-2896.2005.00325.x; Jabri B, 2006, CURR TOP MICROBIOL, V298, P139; Lanier LL, 2001, CURR OPIN IMMUNOL, V13, P326, DOI 10.1016/S0952-7915(00)00222-3; Long EO, 2001, IMMUNOL REV, V181, P223, DOI 10.1034/j.1600-065X.2001.1810119.x; Lopez-Botet M, 2000, HUM IMMUNOL, V61, P7, DOI 10.1016/S0198-8859(99)00161-5; Marshall ASJ, 2004, J BIOL CHEM, V279, P14792, DOI 10.1074/jbc.M313127200; Moretta L, 2004, CURR OPIN IMMUNOL, V16, P626, DOI 10.1016/j.coi.2004.07.010; Nedvetzki S, 2007, BLOOD, V109, P3776, DOI 10.1182/blood-2006-10-052977; Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417; Sobanov Y, 2001, EUR J IMMUNOL, V31, P3493, DOI 10.1002/1521-4141(200112)31:12<3493::AID-IMMU3493>3.0.CO;2-9; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Stewart CA, 2005, P NATL ACAD SCI USA, V102, P13224, DOI 10.1073/pnas.0503594102; Taylor L S, 2000, Rev Immunogenet, V2, P204; Watzl C, 2000, TISSUE ANTIGENS, V56, P240, DOI 10.1034/j.1399-0039.2000.560306.x	20	32	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22370	22375		10.1074/jbc.M704250200	http://dx.doi.org/10.1074/jbc.M704250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17562706	hybrid			2022-12-25	WOS:000248354200015
J	Lee, H; Hubbert, ML; Osborne, TF; Woodford, K; Zerangue, N; Edwards, PA				Lee, Hans; Hubbert, Melissa L.; Osborne, Timothy F.; Woodford, Katherine; Zerangue, Noa; Edwards, Peter A.			Regulation of the sodium/sulfate co-transporter by farnesoid X receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC SOLUTE TRANSPORTER; BASOLATERAL BILE-ACID; NUCLEAR RECEPTOR; OST-BETA; ACTIVATED RECEPTOR; VITAMIN-D; SULFATE HOMEOSTASIS; FXR; IDENTIFICATION; TARGET	Fxr alpha is known to regulate a variety of metabolic processes, including bile acid, cholesterol, and carbohydrate metabolism. In this study, we show direct evidence that Fxr alpha is a key player in maintaining sulfate homeostasis. We identified and characterized the sodium/sulfate co-transporter (NaS-1; Slc13a1) as an Fxr alpha target gene expressed in the kidney and intestine. Electromobility shift assays, chromatin immunoprecipitation, and promoter reporter studies identified a single functional Fxr alpha response element in the second intron of the mouse Slc13a1 gene. Treatment of wild-type mice with GW4064, a synthetic Fxr alpha agonist, induced Slc13a1 mRNA in the intestine and kidney. Slc13a1 mRNA was also induced in the kidney and intestine of wild-type, but not Fxr alpha(-/-) mice, after treatment with the hepatotoxin alpha-naphthylisothiocyanate, which is known to result in elevated blood bile acid levels. Finally, we observed a decrease in Slc13a1 mRNA in the kidney and intestine of Fxr alpha(-/-) mice and a corresponding increase in urinary excretion of free sulfates as compared with wild-type mice. These results demonstrate that mouse Slc13a1 is a novel Fxr alpha target gene expressed in the kidney and intestine and that in the absence of Fxr alpha, mice waste sulfate into the urine. Thus, Fxr alpha is necessary for normal sulfate homeostasis in vivo.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; XenoPort Inc, Santa Clara, CA 95051 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Irvine	Edwards, PA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, 10833 Conte Ave,33-257 CHS, Los Angeles, CA 90095 USA.	pedwards@mednet.ucla.edu			NHLBI NIH HHS [HL30568, HL68445] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, R01HL068445] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anisfeld AM, 2003, J BIOL CHEM, V278, P20420, DOI 10.1074/jbc.M302505200; Ballatori N, 2005, HEPATOLOGY, V42, P1270, DOI 10.1002/hep.20961; Bolt MJG, 2004, AM J PHYSIOL-ENDOC M, V287, pE744, DOI 10.1152/ajpendo.00151.2004; Boyer JL, 2006, AM J PHYSIOL-GASTR L, V290, pG1124, DOI 10.1152/ajpgi.00539.2005; Cariou B, 2007, TRENDS PHARMACOL SCI, V28, P236, DOI 10.1016/j.tips.2007.03.002; Dawson PA, 2003, P NATL ACAD SCI USA, V100, P13704, DOI 10.1073/pnas.2231298100; Dawson PA, 2002, PFLUG ARCH EUR J PHY, V444, P353, DOI 10.1007/s00424-002-0789-x; Dawson PA, 2005, J BIOL CHEM, V280, P6960, DOI 10.1074/jbc.M412752200; Downes M, 2003, MOL CELL, V11, P1079, DOI 10.1016/S1097-2765(03)00104-7; Dussault I, 2003, J BIOL CHEM, V278, P7027, DOI 10.1074/jbc.M209863200; Echchgadda I, 2004, MOL PHARMACOL, V65, P720, DOI 10.1124/mol.65.3.720; Edwards PA, 2002, J LIPID RES, V43, P2; Falany CN, 1997, FASEB J, V11, P1; FAROOQUI AA, 1980, CLIN CHIM ACTA, V100, P285, DOI 10.1016/0009-8981(80)90278-8; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Frankenberg T, 2006, AM J PHYSIOL-GASTR L, V290, pG912, DOI 10.1152/ajpgi.00479.2005; Huber RM, 2002, GENE, V290, P35, DOI 10.1016/S0378-1119(02)00557-7; Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Landrier JF, 2006, AM J PHYSIOL-GASTR L, V290, pG476, DOI 10.1152/ajpgi.00430.2005; Lee A, 2005, INT J BIOCHEM CELL B, V37, P1350, DOI 10.1016/j.biocel.2005.02.013; Lee FY, 2006, TRENDS BIOCHEM SCI, V31, P572, DOI 10.1016/j.tibs.2006.08.002; Lee FY, 2005, J BIOL CHEM, V280, P31792, DOI 10.1074/jbc.M503182200; Lee H, 2006, J LIPID RES, V47, P201, DOI 10.1194/jlr.M500417-JLR200; Lee S, 2006, HEPATOLOGY, V43, P1241, DOI 10.1002/hep.21207; Liu YP, 2003, J CLIN INVEST, V112, P1678, DOI 10.1172/JCI200318945; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; Markovich D, 2001, PHYSIOL REV, V81, P1499, DOI 10.1152/physrev.2001.81.4.1499; Markovich D, 2007, ANNU REV PHYSIOL, V69, P361, DOI 10.1146/annurev.physiol.69.040705.141319; Matsukuma KE, 2006, J LIPID RES, V47, P2754, DOI 10.1194/jlr.M600342-JLR200; Morris ME, 2001, J MEMBRANE BIOL, V181, P1; Nakada T, 2005, AM J PHYSIOL-REG I, V289, pR575, DOI 10.1152/ajpregu.00725.2004; Nicolaou KC, 2003, ORG BIOMOL CHEM, V1, P908, DOI 10.1039/b300525a; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Willson TM, 2001, MED RES REV, V21, P513, DOI 10.1002/med.1023; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200; Zollner G, 2006, AM J PHYSIOL-GASTR L, V290, pG923, DOI 10.1152/ajpgi.00490.2005	44	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21653	21661		10.1074/jbc.M700897200	http://dx.doi.org/10.1074/jbc.M700897200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545158	hybrid			2022-12-25	WOS:000248196800012
J	Wygrecka, M; Morty, RE; Markart, P; Kanse, SM; Andreasen, PA; Wind, T; Guenther, A; Preissner, KT				Wygrecka, Malgorzata; Morty, Rory E.; Markart, Philipp; Kanse, Sandip M.; Andreasen, Peter A.; Wind, Troels; Guenther, Andreas; Preissner, Klaus T.			Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; SERINE-PROTEASE; CELL-PROLIFERATION; BINDING-PROTEIN; HUMAN-PLASMA; MECHANISM; TYPE-1; COAGULATION; VITRONECTIN; FIBRIN	Factor VII-activating protease (FSAP) is a novel plasma-derived serine protease structurally homologous to tissue-type and urokinase-type plasminogen activators. We demonstrate that plasminogen activator inhibitor-1 (PAI-1), the predominant inhibitor of tissue-type and urokinase-type plasminogen activators in plasma and tissues, is an inhibitor of FSAP as well. We detected PAI-1.FSAP complexes in addition to high levels of extracellular RNA, an important FSAP cofactor, in bronchoal-veolar lavage fluids from patients with acute respiratory distress syndrome. Hydrolytic activity of FSAP was inhibited by PAI-1 with a second-order inhibition rate constant (K-a) of 3.38 +/- 1.12 x 105 M-1.s(-1). Residue Arg(346) was a critical recognition element on PAI-1 for interaction with FSAP. RNA, but not DNA, fragments (>400 nucleotides in length) dramatically enhanced the reactivity of PAI-1 with FSAP, and 4 mu g.ml(-1) RNA increased the K-a to 1.61 +/- 0.94 x 106 M-1.s(-1). RNA also stabilized the active conformation of PAI-1, increasing the half-life for spontaneous conversion of active to latent PAI-1 from 48.4 +/- 8 min to 114.6 +/- 5 min. In contrast, little effect of DNA on PAI-1 stability was apparent. Residues Arg(76) and Lys(80) in PAI-1 were key elements mediating binding of nucleic acids to PAI-1. FSAP-driven inhibition of vascular smooth muscle cell proliferation was antagonized by PAI-1, suggesting functional consequences for the FSAP-PAI-1 interaction. These data indicate that extracellular RNA and PAI-1 can regulate FSAP activity, thereby playing a potentially important role in hemostasis and cell functions under various pathophysiological conditions, such as acute respiratory distress syndrome.	Univ Giessen, Fac Med, Dept Biochem, D-35392 Giessen, Germany; Univ Giessen, Fac Med, Dept Internal Med, D-35392 Giessen, Germany; Univ Aarhus, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark	Justus Liebig University Giessen; Justus Liebig University Giessen; Aarhus University	Wygrecka, M (corresponding author), Univ Giessen, Fac Med, Dept Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	malgorzata.wygrecka@innere.med.uni-giessen.de	Wygrecka, Malgorzata/AAZ-3679-2020	Wygrecka, Malgorzata/0000-0002-3656-2932; Kanse, Sandip/0000-0003-0782-9957				Altincicek B, 2006, BIOCHEM J, V394, P687, DOI 10.1042/BJ20051563; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; Battmann A., 2002, ANN HEMATOL, V81, pA 42; Beiter K, 2006, CURR BIOL, V16, P401, DOI 10.1016/j.cub.2006.01.056; Belorgey D, 1998, BIOCHEMISTRY-US, V37, P16416, DOI 10.1021/bi981536o; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304; Choi-Miura NH, 2001, BIOL PHARM BULL, V24, P221, DOI 10.1248/bpb.24.221; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Duranton J, 2000, J BIOL CHEM, V275, P3787, DOI 10.1074/jbc.275.6.3787; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; EMMETT M, 1987, P SOC EXP BIOL MED, V184, P74; Etscheid M, 2004, EUR J CELL BIOL, V82, P597, DOI 10.1078/0171-9335-00349; Etscheid M, 2000, BIOL CHEM, V381, P1223, DOI 10.1515/BC.2000.150; Futamura A, 2000, J BIOL CHEM, V275, P4092, DOI 10.1074/jbc.275.6.4092; Gunther A, 2000, AM J RESP CRIT CARE, V161, P454; Gunther A, 1996, AM J RESP CRIT CARE, V153, P176; Hunfeld A, 1999, FEBS LETT, V456, P290, DOI 10.1016/S0014-5793(99)00959-X; Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB; IDELL S, 1991, AM J PHYSIOL, V261, pL240, DOI 10.1152/ajplung.1991.261.4.L240; IDELL S, 1989, J CLIN INVEST, V84, P695, DOI 10.1172/JCI114217; Kannemeier C, 2004, FASEB J, V18, P728, DOI 10.1096/fj.03-0898fje; Kannemeier C, 2001, EUR J BIOCHEM, V268, P3789, DOI 10.1046/j.1432-1327.2001.02285.x; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; LINDAHL TL, 1990, BIOCHEM J, V265, P109, DOI 10.1042/bj2650109; MANCHANDA N, 1995, J BIOL CHEM, V270, P20032, DOI 10.1074/jbc.270.34.20032; MIMURO J, 1989, J BIOL CHEM, V264, P5058; Moraes TJ, 2003, CRIT CARE MED, V31, pS189, DOI 10.1097/01.CCM.0000057842.90746.1E; Nakazawa F, 2005, BIOCHEM J, V385, P831, DOI 10.1042/BJ20041021; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; POTTER JL, 1969, AM REV RESPIR DIS, V99, P909; Rezaie AR, 2001, J BIOL CHEM, V276, P15567, DOI 10.1074/jbc.C100123200; Romisch J, 1999, BLOOD COAGUL FIBRIN, V10, P471; Romisch J, 1999, HAEMOSTASIS, V29, P292; Schermuly RT, 2001, AM J PHYSIOL-LUNG C, V280, pL792, DOI 10.1152/ajplung.2001.280.4.L792; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHERMAN PM, 1995, J BIOL CHEM, V270, P9301, DOI 10.1074/jbc.270.16.9301; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VELASCO F, 1986, THROMB HAEMOSTASIS, V55, P357; Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288; Welty-Wolf KE, 2001, AM J RESP CRIT CARE, V164, P1988, DOI 10.1164/ajrccm.164.10.2105027; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Willeit J, 2003, CIRCULATION, V107, P667, DOI 10.1161/01.CIR.0000055189.18831.B1; Wind T, 2003, EUR J BIOCHEM, V270, P1680, DOI 10.1046/j.1432-1033.2003.03524.x	53	40	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21671	21682		10.1074/jbc.M610748200	http://dx.doi.org/10.1074/jbc.M610748200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17540775	Green Published, hybrid			2022-12-25	WOS:000248196800014
J	Hildebrand, ME; David, LS; Hamid, J; Mulatz, K; Garcia, E; Zamponi, GW; Snutch, TP				Hildebrand, Michael E.; David, Laurence S.; Hamid, Jawed; Mulatz, Kirk; Garcia, Esperanza; Zamponi, Gerald W.; Snutch, Terrance P.			Selective inhibition of Cav3.3 T-type calcium channels by G alpha(q/11)-coupled muscarinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHILDHOOD ABSENCE EPILEPSY; RETICULAR THALAMIC NEURONS; CA2+ CHANNELS; OLFACTORY-BULB; FUNCTIONAL-CHARACTERIZATION; GRANULE CELLS; GENE FAMILY; BETA-GAMMA; RAT-BRAIN; MODULATION	T-type calcium channels play critical roles in controlling neuronal excitability, including the generation of complex spiking patterns and the modulation of synaptic plasticity, although the mechanisms and extent to which T-type Ca2+ channels are modulated by G-protein-coupled receptors (GPCRs) remain largely unexplored. To examine specific interactions between T-type Ca2+ channel subtypes and muscarinic acetylcholine receptors (mAChRS), the Cav3.1 (alpha(1G)), Cav3.2 (alpha(1H)), and Cav3.3 (alpha(1I)) T-type Ca2+ channels were co-expressed with the M1 G alpha(q/11)-coupled mAChR. Perforated patch recordings demonstrate that activation of M1 receptors has a strong inhibitory effect on Cav3.3 T-type Ca2+ currents but either no effect or a moderate stimulating effect on Cav3.1 and Cav3.2 peak current amplitudes. This differential modulation was observed for both rat and human T-type Ca2+ channel variants. The inhibition of Cav3.3 channels by M1 receptors is reversible, use-independent, and associated with a concomitant increase in inactivation kinetics. Loss-of-function experiments with genetically encoded antagonists of G alpha and G beta gamma proteins and gain-of-function experiments with genetically encoded G alpha subtypes indicate that M1 receptor-mediated inhibition of Cav3.3 occurs through G alpha(q/11). This is supported by experiments showing that activation of the M3 and M5 G alpha(q/11)-coupled mAChRs also causes inhibition of Cav3.3 currents, although G alpha(i)-coupled mAChRs (M2 and M4) have no effect. Examining Cav3.1-Cav3.3 chimeric channels demonstrates that two distinct regions of the Cav3.3 channel are necessary and sufficient for complete M1 receptor-mediated channel inhibition and represent novel sites not previously implicated in T-type channel modulation.	Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada	University of British Columbia; University of Calgary	Snutch, TP (corresponding author), Univ British Columbia, Michael Smith Labs, 2185 East Mall, Vancouver, BC V6T 1Z4, Canada.	snutch@msl.ubc.ca	Hildebrand, Michael E/J-9102-2012; Snutch, Terrance P/L-3464-2019	Hildebrand, Michael E/0000-0002-6845-8013; Snutch, Terrance P/0000-0001-5182-1296; Zamponi, Gerald W./0000-0002-0644-9066				ALLEN TGJ, 1993, J PHYSIOL-LONDON, V466, P173; Anderson MP, 2005, P NATL ACAD SCI USA, V102, P1743, DOI 10.1073/pnas.0409644102; Bannister RA, 2002, BIOPHYS J, V83, P3256, DOI 10.1016/S0006-3495(02)75327-7; Bian JS, 2001, CIRC RES, V89, P1168, DOI 10.1161/hh2401.101375; Bourinet E, 2005, EMBO J, V24, P315, DOI 10.1038/sj.emboj.7600515; Castillo PE, 1999, J NEUROSCI, V19, P9180; Chemin J, 2002, J PHYSIOL-LONDON, V540, P3, DOI 10.1113/jphysiol.2001.013269; Chemin J, 2001, EMBO J, V20, P7033, DOI 10.1093/emboj/20.24.7033; Chemin J, 2006, CELL CALCIUM, V40, P121, DOI 10.1016/j.ceca.2006.04.015; Chevalier M, 2006, EUR J NEUROSCI, V23, P2321, DOI 10.1111/j.1460-9568.2006.04761.x; CHRISTIE BR, 1995, J NEUROPHYSIOL, V73, P2553, DOI 10.1152/jn.1995.73.6.2553; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Depuy SD, 2006, P NATL ACAD SCI USA, V103, P14590, DOI 10.1073/pnas.0603945103; Destexhe A, 2003, PHYSIOL REV, V83, P1401, DOI 10.1152/physrev.00012.2003; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; Egger V, 2005, J NEUROSCI, V25, P3521, DOI 10.1523/JNEUROSCI.4746-04.2005; Egger V, 2003, J NEUROSCI, V23, P7551; FISHER R, 1990, J NEUROPHYSIOL, V64, P1291, DOI 10.1152/jn.1990.64.4.1291; FRASER DD, 1991, J NEUROSCI, V11, P2812; Gamper N, 2004, J NEUROSCI, V24, P10980, DOI 10.1523/JNEUROSCI.3869-04.2004; Hamid J, 2006, NEUROSCIENCE, V143, P717, DOI 10.1016/j.neuroscience.2006.08.023; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hildebrand M.E., 2006, DRUG DISCOVERY TODAY, V3, P335; HILDEBRAND ME, 2005, BIOPH SOC 49 ANN M L; HOGGER P, 1995, J BIOL CHEM, V270, P7405; HUGUENARD JR, 1992, J NEUROSCI, V12, P3804, DOI 10.1523/jneurosci.12-10-03804.1992; Joksovic PM, 2006, J PHYSIOL-LONDON, V574, P415, DOI 10.1113/jphysiol.2006.110395; Joksovic PM, 2005, J PHYSIOL-LONDON, V566, P125, DOI 10.1113/jphysiol.2005.086579; Kammermeier PJ, 2000, J NEUROSCI, V20, P5623, DOI 10.1523/JNEUROSCI.20-15-05623.2000; Khosravani H, 2005, ANN NEUROL, V57, P745, DOI 10.1002/ana.20458; Khosravani H, 2004, J BIOL CHEM, V279, P9681, DOI 10.1074/jbc.C400006200; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; Lee JH, 1999, J NEUROSCI, V19, P1912; LEVEY AI, 1995, J NEUROSCI, V15, P4077; LEVEY AI, 1994, NEUROSCIENCE, V63, P207, DOI 10.1016/0306-4522(94)90017-5; McKay BE, 2006, EUR J NEUROSCI, V24, P2581, DOI 10.1111/j.1460-9568.2006.05136.x; McRory JE, 2001, J BIOL CHEM, V276, P3999, DOI 10.1074/jbc.M008215200; Melliti K, 2000, J NEUROSCI, V20, P7167; Mittman S, 1999, NEUROSCI LETT, V269, P121, DOI 10.1016/S0304-3940(99)00319-5; Monteil A, 2000, J BIOL CHEM, V275, P16530, DOI 10.1074/jbc.C000090200; Murbartian J, 2004, J NEUROPHYSIOL, V92, P3399, DOI 10.1152/jn.00498.2004; Murbartian J, 2002, FEBS LETT, V528, P272, DOI 10.1016/S0014-5793(02)03341-0; Park JY, 2006, J PHYSIOL-LONDON, V577, P513, DOI 10.1113/jphysiol.2006.117440; Peloquin JB, 2006, EPILEPSIA, V47, P655, DOI 10.1111/j.1528-1167.2006.00482.x; Pemberton KE, 2000, PFLUG ARCH EUR J PHY, V440, P452, DOI 10.1007/s004240000303; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Plummer KL, 1999, J COMP NEUROL, V404, P408; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Santi CM, 2002, J NEUROSCI, V22, P396, DOI 10.1523/JNEUROSCI.22-02-00396.2002; SCHWARZ RD, 1993, LIFE SCI, V52, P465, DOI 10.1016/0024-3205(93)90303-K; Suh BC, 2005, CURR OPIN NEUROBIOL, V15, P370, DOI 10.1016/j.conb.2005.05.005; Suh BC, 2004, J GEN PHYSIOL, V123, P663, DOI 10.1085/jgp.200409029; Talley EM, 1999, J NEUROSCI, V19, P1895; THOMPSON SM, 1991, J PHYSIOL-LONDON, V439, P671, DOI 10.1113/jphysiol.1991.sp018687; Tombler E, 2006, J BIOL CHEM, V281, P1827, DOI 10.1074/jbc.M508829200; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; Vitko I, 2005, J NEUROSCI, V25, P4844, DOI 10.1523/JNEUROSCI.0847-05.2005; Wan XD, 1996, ENDOCRINOLOGY, V137, P2514, DOI 10.1210/en.137.6.2514; WEI J, 1994, J NEUROCHEM, V63, P815; Welsby PJ, 2003, J NEUROSCI, V23, P10116, DOI 10.1523/jneurosci.23-31-10116.2003; Wolfe JT, 2003, NATURE, V424, P209, DOI 10.1038/nature01772; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Yunker AMR, 2003, NEUROSCIENCE, V117, P321, DOI 10.1016/S0306-4522(02)00936-3; Zamponi Gerald W, 2002, Mol Interv, V2, P476, DOI 10.1124/mi.2.8.476	65	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21043	21055		10.1074/jbc.M611809200	http://dx.doi.org/10.1074/jbc.M611809200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17535809	Green Published, hybrid			2022-12-25	WOS:000248047500031
J	Rayapuram, N; Hagenmuller, J; Grienenberger, JM; Giege, P; Bonnard, G				Rayapuram, Naganand; Hagenmuller, Jeremie; Grienenberger, Jean-Michel; Giege, Philippe; Bonnard, Geraldine			AtCCMA interacts with AtCcmB to form a novel mitochondrial ABC transporter involved in cytochrome c maturation in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HEME CHAPERONE; IN-VITRO; SUBCELLULAR-LOCALIZATION; WHEAT MITOCHONDRIA; HISTIDINE PERMEASE; PLANT-MITOCHONDRIA; BIOGENESIS SYSTEM; FERROCHELATASE-I; APOCYTOCHROME-C	ABC transporters make a large and diverse family of proteins found in all phylae. AtCCMA is the nucleotide binding domain of a novel Arabidopsis mitochondrial ABC transporter. It is encoded in the nucleus and imported into mitochondria. Suborganellar and topology studies find AtCCMA bound to the mitochondrial inner membrane, facing the matrix. AtCCMA exhibits an ATPase activity, and ATP/Mg2+ can facilitate its dissociation from membranes. Blue Native PAGE shows that it is part of a 480-kDa complex. Yeast two-hybrid assays reveal interactions between AtCCMA and domains of CcmB, the mitochondria-encoded transmembrane protein of a conserved ABC transporter. All these properties designate the protein as the ortholog in plant mitochondria of the bacterial CcmA required for cytochrome c maturation. The transporter that involves AtCCMA defines a new category of eukaryotic ABC proteins because its transmembrane and nucleotide binding domains are encoded by separate genomes.	Univ Strasbourg, CNRS, Inst Mol Biol Plantes, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bonnard, G (corresponding author), Univ Strasbourg, CNRS, Inst Mol Biol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.	geraldine.bonnard@ibmp-ulp.u-strasbg.fr		Giege, Philippe/0000-0003-2285-8190				AMES GFL, 1992, INT REV CYTOL, V137A, P1; Balk J, 2005, TRENDS PLANT SCI, V10, P324, DOI 10.1016/j.tplants.2005.05.002; BECKMAN DL, 1992, GENE DEV, V6, P268, DOI 10.1101/gad.6.2.268; Bernard DG, 2005, J BIOL CHEM, V280, P39852, DOI 10.1074/jbc.M508574200; BONNARD G, 1995, MOL GEN GENET, V246, P91, DOI 10.1007/BF00290137; Chow KS, 1997, J BIOL CHEM, V272, P27565, DOI 10.1074/jbc.272.44.27565; Christensen O, 2007, FEBS J, V274, P2322, DOI 10.1111/j.1742-4658.2007.05769.x; Cianciotto NP, 2005, MOL MICROBIOL, V56, P1408, DOI 10.1111/j.1365-2958.2005.04650.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P9703, DOI 10.1073/pnas.152120699; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; Dieterle M, 2005, PLANT J, V41, P386, DOI 10.1111/j.1365-313X.2004.02302.x; Faivre-Nitschke SE, 2001, BBA-GENE STRUCT EXPR, V1519, P199, DOI 10.1016/S0167-4781(01)00239-1; Feissner RE, 2006, MOL MICROBIOL, V60, P563, DOI 10.1111/j.1365-2958.2006.05132.x; Feissner RE, 2006, MOL MICROBIOL, V61, P219, DOI 10.1111/j.1365-2958.2006.05221.x; Fey J, 1999, FEBS LETT, V458, P124, DOI 10.1016/S0014-5793(99)01140-0; Giege P, 2004, FEBS LETT, V563, P165, DOI 10.1016/S0014-5793(04)00291-1; Goldman BS, 1997, J MOL BIOL, V268, P724, DOI 10.1006/jmbi.1997.0992; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Goldman BS, 2001, RES MICROBIOL, V152, P323, DOI 10.1016/S0923-2508(01)01203-7; GONZALEZ DH, 1993, CURR GENET, V24, P248, DOI 10.1007/BF00351799; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; LAMATTINA L, 1993, EUR J BIOCHEM, V217, P831, DOI 10.1111/j.1432-1033.1993.tb18311.x; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; Lee DH, 2005, J AM CHEM SOC, V127, P3716, DOI 10.1021/ja044658e; Lill R, 2001, RES MICROBIOL, V152, P331, DOI 10.1016/S0923-2508(01)01204-9; Lister R, 2001, FEBS LETT, V506, P291, DOI 10.1016/S0014-5793(01)02925-8; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; MACDONALD PN, 2001, METHODS MOL BIOL SER, V177; Masuda T, 2003, PLANTA, V217, P602, DOI 10.1007/s00425-003-1019-2; Meyer EH, 2005, P NATL ACAD SCI USA, V102, P16113, DOI 10.1073/pnas.0503473102; Mourez M, 1998, MOL MICROBIOL, V30, P353, DOI 10.1046/j.1365-2958.1998.01070.x; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; Ohta N, 1998, NUCLEIC ACIDS RES, V26, P5190, DOI 10.1093/nar/26.22.5190; RAMSEIER TM, 1991, J BIOL CHEM, V266, P7793; Sabar M, 2005, PLANT J, V44, P893, DOI 10.1111/j.1365-313X.2005.02577.x; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Saurin W, 1999, J MOL EVOL, V48, P22, DOI 10.1007/PL00006442; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Schulz H, 2000, MOL MICROBIOL, V37, P1379, DOI 10.1046/j.1365-2958.2000.02083.x; Spielewoy N, 2001, J BIOL CHEM, V276, P5491, DOI 10.1074/jbc.M008853200; Stevens JM, 2004, ACCOUNTS CHEM RES, V37, P999, DOI 10.1021/ar030266l; Thony-Meyer L, 2003, BIOCHEMISTRY-US, V42, P13099, DOI 10.1021/bi035598c; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; THONYMEYER L, 1989, CELL, V57, P683, DOI 10.1016/0092-8674(89)90137-2; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThroneHolst M, 1997, FEBS LETT, V410, P351, DOI 10.1016/S0014-5793(97)00656-X; van Lis R, 2005, PLANT PHYSIOL, V139, P1946, DOI 10.1104/pp.105.069732; Werhahn W, 2001, PLANT PHYSIOL, V125, P943, DOI 10.1104/pp.125.2.943	56	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21015	21023		10.1074/jbc.M704091200	http://dx.doi.org/10.1074/jbc.M704091200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17550895	hybrid, Green Published			2022-12-25	WOS:000248047500028
J	Shiomi, Y; Masutani, C; Hanaoka, F; Kimura, H; Tsurimoto, T				Shiomi, Yasushi; Masutani, Chikahide; Hanaoka, Fumio; Kimura, Hiroshi; Tsurimoto, Toshiki			A second proliferating cell nuclear antigen loader complex, Ctf18-replication factor C, stimulates DNA polymerase eta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; REPLICATION FACTOR-C; THYMINE-THYMINE DIMER; SIMIAN VIRUS-40 DNA; TRANSLESION SYNTHESIS; LARGE SUBUNIT; CLAMP-LOADER; CHROMOSOME TRANSMISSION; PROTEIN; BYPASS	Replication factor C (RFC) loads the clamp protein PCNA onto DNA structures. Ctf18-RFC, which consists of the chromosome cohesion factors Ctf18, Dcc1, and Ctf8 and four small RFC subunits, functions as a second proliferating cell nuclear antigen (PCNA) loader. To identify potential targets of Ctf18-RFC, human cell extracts were assayed for DNA polymerase activity specifically stimulated by Ctf18-RFC in conjunction with PCNA. After several chromatography steps, an activity stimulated by Ctf18-RFC but not by RFC was identified. Liquid chromatography/ tandem mass spectrometry (LC/ MS/ MS) analysis revealed the presence of two DNA polymerases, eta and lambda, in the most purified fraction, but experiments with purified recombinant proteins demonstrated that only polymerase (pol) eta was responsible for activity. Ctf18-RFC alone stimulated pol eta, and the addition of PCNA cooperatively increased stimulation. Furthermore, Ctf18-RFC interacted physically with pol eta, as indicated by co-precipitation in human cells. We propose that this novel loader-DNA polymerase interaction allows DNA replication forks to overcome interference by various template structures, including damaged DNA and DNA-protein complexes that maintain chromosome cohesion.	Kyushu Univ, Sch Sci, Dept Biol, Higashi Ku, Fukuoka 8128581, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Kyoto Univ, Sch Med, Horizontal Med Res Org, Sakyo Ku, Kyoto 6068501, Japan	Kyushu University; Osaka University; Japan Science & Technology Agency (JST); Kyoto University	Tsurimoto, T (corresponding author), Kyushu Univ, Sch Sci, Dept Biol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	ttsurscb@mbox.nc.kyushu-u.ac.jp	Kimura, Hiroshi/B-9524-2015; Masutani, Chikahide/I-6160-2014	Kimura, Hiroshi/0000-0003-0854-083X; Masutani, Chikahide/0000-0002-8600-8227; Tsurimoto, Toshiki/0000-0001-7597-2216				Anderson LA, 2003, MOL CELL BIOL, V23, P721, DOI 10.1128/MCB.23.2.721-732.2003; Anderson LA, 2002, J BIOL CHEM, V277, P29550, DOI 10.1074/jbc.M200513200; Bemark M, 2000, CURR BIOL, V10, P1213, DOI 10.1016/S0960-9822(00)00724-7; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P10237, DOI 10.1073/pnas.1434308100; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Edwards S, 2003, MOL CELL BIOL, V23, P2733, DOI 10.1128/MCB.23.8.2733-2748.2003; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Franco AA, 2005, GENE DEV, V19, P1365, DOI 10.1101/gad.1305005; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; Hong SH, 2001, J BIOL CHEM, V276, P28098, DOI 10.1074/jbc.M010912200; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Ivanov D, 2005, CELL, V122, P849, DOI 10.1016/j.cell.2005.07.018; Ivanov D, 2002, CURR BIOL, V12, P323, DOI 10.1016/S0960-9822(02)00681-4; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kawamoto T, 2005, MOL CELL, V20, P793, DOI 10.1016/j.molcel.2005.10.016; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Kim JY, 2003, CURR BIOL, V13, pR873, DOI 10.1016/j.cub.2003.10.048; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; KOUPRINA N, 1993, YEAST, V9, P11, DOI 10.1002/yea.320090103; KOUPRINA N, 1994, GENETICS, V138, P1067; Lehmann AR, 2005, FEBS LETT, V579, P873, DOI 10.1016/j.febslet.2004.11.029; Levin DS, 2004, J BIOL CHEM, V279, P55196, DOI 10.1074/jbc.M409250200; Madril AC, 2001, J BIOL CHEM, V276, P42857, DOI 10.1074/jbc.M106917200; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsumoto M, 2005, PROTEOMICS, V5, P4145, DOI 10.1002/pmic.200401280; McDonald JP, 1997, GENETICS, V147, P1557; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Miyata T, 2004, NAT STRUCT MOL BIOL, V11, P632, DOI 10.1038/nsmb788; Naiki T, 2001, MOL CELL BIOL, V21, P5838, DOI 10.1128/MCB.21.17.5838-5845.2001; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; Ohashi E, 2004, GENES CELLS, V9, P523, DOI 10.1111/j.1356-9597.2004.00747.x; Ohta S, 2002, J BIOL CHEM, V277, P40362, DOI 10.1074/jbc.M206194200; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Rattray AJ, 2005, MOL CELL, V20, P658, DOI 10.1016/j.molcel.2005.11.018; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; Shiomi Y, 2004, GENES CELLS, V9, P279, DOI 10.1111/j.1356-9597.2004.00724.x; Shiomi Y, 2002, GENES CELLS, V7, P861, DOI 10.1046/j.1365-2443.2002.00566.x; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; Tanaka K, 2000, MOL CELL BIOL, V20, P3459, DOI 10.1128/MCB.20.10.3459-3469.2000; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; Wilson TM, 2005, J EXP MED, V201, P637, DOI 10.1084/jem.20042066; Yamada A, 2000, NUCLEIC ACIDS RES, V28, P2473, DOI 10.1093/nar/28.13.2473; Yuasa MS, 2006, GENES CELLS, V11, P731, DOI 10.1111/j.1365-2443.2006.00974.x; Zhou YJ, 2004, MOL CELL BIOL, V24, P9568, DOI 10.1128/MCB.24.21.9568-9579.2004	68	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20906	20914		10.1074/jbc.M610102200	http://dx.doi.org/10.1074/jbc.M610102200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17545166	hybrid			2022-12-25	WOS:000248047500016
J	Ster, IC; Ferguson, NM				Ster, Irina Chis; Ferguson, Neil M.			Transmission Parameters of the 2001 Foot and Mouth Epidemic in Great Britain	PLOS ONE			English	Article							ALTERNATIVE CONTROL STRATEGIES; DISEASE EPIDEMIC; MODELS; IMPACT; LIKELIHOOD	Despite intensive ongoing research, key aspects of the spatial-temporal evolution of the 2001 foot and mouth disease (FMD) epidemic in Great Britain (GB) remain unexplained. Here we develop a Markov Chain Monte Carlo (MCMC) method for estimating epidemiological parameters of the 2001 outbreak for a range of simple transmission models. We make the simplifying assumption that infectious farms were completely observed in 2001, equivalent to assuming that farms that were proactively culled but not diagnosed with FMD were not infectious, even if some were infected. We estimate how transmission parameters varied through time, highlighting the impact of the control measures on the progression of the epidemic. We demonstrate statistically significant evidence for assortative contact patterns between animals of the same species. Predictive risk maps of the transmission potential in different geographic areas of GB are presented for the fitted models.	[Ster, Irina Chis; Ferguson, Neil M.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England	Imperial College London	Ster, IC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, Norfolk Pl, London, England.	irina.chisster@imperial.ac.uk	Ferguson, Neil/B-8578-2008; Ster, Irina Chis/AAJ-3217-2021	Ferguson, Neil/0000-0002-1154-8093; Ster, Irina Chis/0000-0003-2637-1259	Department of Environmental and Rural Affairs (DEFRA), UK BBRSC, UK	Department of Environmental and Rural Affairs (DEFRA), UK BBRSC, UK(Department for Environment, Food & Rural Affairs (DEFRA))	Department of Environmental and Rural Affairs (DEFRA), UK BBRSC, UK	Alexandersen S, 2003, J COMP PATHOL, V129, P1, DOI 10.1016/S0021-9975(03)00041-0; Cressie N.A.C, 1993, WILEY SERIES PROBABI, Vxx, P900; Diggle PJ, 2006, STAT METHODS MED RES, V15, P325, DOI 10.1191/0962280206sm454oa; Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116; Ferguson NM, 2001, SCIENCE, V292, P1155, DOI 10.1126/science.1061020; Finkenstadt BF, 2005, STAT MED, V24, P3447, DOI 10.1002/sim.2196; Gelman A., 2000, BAYESIAN DATA ANAL; Gibson GJ, 1998, IMA J MATH APPL MED, V15, P19; Gibson GJ, 1997, J R STAT SOC C-APPL, V46, P215, DOI 10.1111/1467-9876.00061; Gibson GJ, 2001, STAT COMPUT, V11, P347, DOI 10.1023/A:1011973120681; Gilks W.R., 1996, MARKOV CHAIN MONTE C; Green LE, 2002, RES VET SCI, V73, P201, DOI 10.1016/S0034-5288(02)00106-6; HASTINGS WK, 1970, BIOMETRIKA, V57, P97, DOI 10.2307/2334940; Howard SC, 2000, RES VET SCI, V69, P189, DOI 10.1053/rvsc.2000.0415; Kao RR, 2003, P ROY SOC B-BIOL SCI, V270, P2557, DOI 10.1098/rspb.2003.2546; Kao RR, 2002, TRENDS MICROBIOL, V10, P279, DOI 10.1016/S0966-842X(02)02371-5; Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973; Keeling MJ, 2005, P ROY SOC B-BIOL SCI, V272, P1195, DOI 10.1098/rspb.2004.3046; Keeling MJ, 2003, NATURE, V421, P136, DOI 10.1038/nature01343; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Morris RS, 2001, VET REC, V149, P137, DOI 10.1136/vr.149.5.137; O'Neill PD, 1999, J ROY STAT SOC A STA, V162, P121, DOI 10.1111/1467-985X.00125; ONEILL PD, 2003, HIGHLY STRUCTURED ST, P354; ROBERT CP, 2003, HIGHLY STRUCTURED ST, P167; Roberts GO, 1997, ANN APPL PROBAB, V7, P110, DOI 10.1214/aoap/1034625254; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; Streftaris G, 2004, P ROY SOC B-BIOL SCI, V271, P1111, DOI 10.1098/rspb.2004.2715; Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255	28	78	78	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e502	10.1371/journal.pone.0000502	http://dx.doi.org/10.1371/journal.pone.0000502			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551582	Green Published, Green Submitted, Green Accepted, gold			2022-12-25	WOS:000207451500011
J	Messina, S; Mazzeo, A; Bitto, A; Aguennouz, M; Migliorato, A; De Pasquale, MG; Minutoli, L; Altavilla, D; Zentilin, L; Giacca, M; Squadrito, F; Vita, G				Messina, Sonia; Mazzeo, Anna; Bitto, Alessandra; Aguennouz, M'hammed; Migliorato, Alba; De Pasquale, Maria G.; Minutoli, Letteria; Altavilla, Domenica; Zentilin, Lorena; Giacca, Mauro; Squadrito, Francesco; Vita, Giuseppe			VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice	FASEB JOURNAL			English	Article						dystrophin gene; muscle necrosis; rAAV; Duchenne muscular dystrophy	ENDOTHELIAL GROWTH-FACTOR; MUSCULAR-DYSTROPHY; BONE-MARROW; SIGNAL-TRANSDUCTION; SATELLITE CELLS; STEM-CELLS; MOUSE; EXPRESSION; NEOVASCULARIZATION; AKT	Vascular endothelial growth factor (VEGF) is a major regulator of physiological and pathological angiogenesis. Recently it was reported that the delivery of VEGF using recombinant adeno-associated virus (rAAV) vectors reduces muscle damage and promotes muscle regeneration in different experimental models of muscle necrosis. We demonstrate that intramuscular administration of rAAV-VEGF improved pathophysiology of the mdx mouse, a model of Duchenne muscular dystrophy (DMD). One month after injection, rAAV-VEGF-treated muscles showed augmented expression of VEGF and immunolocalization of its receptor, VEGFR-2. VEGF-treated mdx mice showed increased forelimb strength and strength normalized to weight. Treatment reduced necrotic fibers area and increased regenerating fibers area with an augmented number of myogenin-positive satellite cells and myonuclei, and of developmental myosin heavy chain-positive fibers. Only the regenerating area showed increased capillary density. This study provides novel evidence of a VEGF beneficial effect in mdx mice that is exerted mainly by a proregenerative and angiogenic effect. It opens new therapeutic prospectives in DMD and other types of muscular disorders.	Univ Messina, Dept Neurosci Psychiat & Anaesthesiol, Unit Clin Neurobiol & Neuromuscular Dis, AOU Policlin G Martino, I-98125 Messina, Italy; Univ Messina, Dept Expt Med & Pharmacol, Messina, Italy; ICGEB, Mol Med Lab, Trieste, Italy; Univ Trieste, Fac Med, Dept Clin & Biomed Sci, I-34127 Trieste, Italy	AOU Policlinico Gaetano Martino; University of Messina; University of Messina; International Center for Genetic Engineering & Biotechnology (ICGEB); University of Trieste	Vita, G (corresponding author), Univ Messina, Dept Neurosci Psychiat & Anaesthesiol, Unit Clin Neurobiol & Neuromuscular Dis, AOU Policlin G Martino, I-98125 Messina, Italy.	giuseppe.vita@unime.it	Aguennouz, M'hammed/O-9520-2019; Giacca, Mauro/J-9287-2016	Aguennouz, M'hammed/0000-0003-0440-0354; Giacca, Mauro/0000-0003-2927-7225; Vita, Giuseppe/0000-0002-5204-7826; MAZZEO, Anna/0000-0003-1914-6184; MIGLIORATO, Alba/0000-0002-9256-6524; Messina, Sonia/0000-0001-7994-3391				Abadie J, 2002, GENE THER, V9, P1037, DOI 10.1038/sj.gt.3301773; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007; Arsic N, 2003, MOL THER, V7, P450, DOI 10.1016/S1525-0016(03)00034-0; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Connolly AM, 2001, NEUROMUSCULAR DISORD, V11, P703, DOI 10.1016/S0960-8966(01)00232-2; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; De Angelis L, 1999, J CELL BIOL, V147, P869, DOI 10.1083/jcb.147.4.869; Deodato B, 2002, GENE THER, V9, P777, DOI 10.1038/sj.gt.3301697; Dubowitz V., 1995, MUSCLE DISORDERS CHI; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Granchelli JA, 2000, NEUROMUSCULAR DISORD, V10, P235, DOI 10.1016/S0960-8966(99)00126-1; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Inagaki K, 2006, MOL THER, V14, P45, DOI 10.1016/j.ymthe.2006.03.014; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lescaudron L, 1999, NEUROMUSCULAR DISORD, V9, P72, DOI 10.1016/S0960-8966(98)00111-4; Matecki S, 2004, AM J PHYSIOL-REG I, V287, pR961, DOI 10.1152/ajpregu.00146.2004; MCARDLE A, 1995, NEUROMUSCULAR DISORD, V5, P445, DOI 10.1016/0960-8966(95)00001-4; Merly F, 1999, MUSCLE NERVE, V22, P724, DOI 10.1002/(SICI)1097-4598(199906)22:6<724::AID-MUS9>3.0.CO;2-O; Messina S, 2006, AM J PATHOL, V168, P918, DOI 10.2353/ajpath.2006.050673; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; SCHMALBRUCH H, 1977, ANAT REC, V189, P169, DOI 10.1002/ar.1091890204; Shavlakadze T, 2004, MOL THER, V10, P829, DOI 10.1016/j.ymthe.2004.07.026; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Stupka N, 2006, NEUROMUSCULAR DISORD, V16, P337, DOI 10.1016/j.nmd.2006.03.003; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; Tuomisto TT, 2004, ATHEROSCLEROSIS, V174, P111, DOI 10.1016/j.atherosclerosis.2004.01.015; Wagatsuma A, 2006, PHYSIOL RES, V55, P633, DOI 10.33549/physiolres.930811; ZACCHIGNA S, 2007, IN PRESS HUM GENE TH; Zentilin L, 2006, BLOOD, V107, P3546, DOI 10.1182/blood-2005-08-3215	44	73	82	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3737	3746		10.1096/fj.07-8459com	http://dx.doi.org/10.1096/fj.07-8459com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575261				2022-12-25	WOS:000250517800035
J	Morales, ME; Mann, VH; Kines, KJ; Gobert, GN; Fraser, MJ; Kalinna, BH; Correnti, JM; Pearce, EJ; Brindley, PJ				Morales, Maria E.; Mann, Victoria H.; Kines, Kristine J.; Gobert, Geoffrey N.; Fraser, Malcolm J., Jr.; Kalinna, Bernd H.; Correnti, Jason M.; Pearce, Edward J.; Brindley, Paul J.			piggyBac transposon mediated transgenesis of the human blood fluke, Schistosoma mansoni	FASEB JOURNAL			English	Article						schistosome; gene manipulation; electroporation; parasitic helminth; functional genomics; reverse genetics	SOIL-TRANSMITTED HELMINTHIASIS; RNA INTERFERENCE; PARTICLE BOMBARDMENT; BACULOVIRUS GENOME; MAMMALIAN-CELLS; SLEEPING-BEAUTY; IN-VITRO; DNA; EXPRESSION; TRANSFORMATION	The transposon piggyBac from the genome of the cabbage looper moth Trichoplusia ni has been observed in the laboratory to jump into the genomes of key model and pathogenic eukaryote organisms including mosquitoes, planarians, human and other mammalian cells, and the malaria parasite Plasmodium falciparum. Introduction of exogenous transposons into schistosomes has not been reported but transposon-mediated transgenesis of schistosomes might supersede current methods for functional genomics of this important human pathogen. In the present study we examined whether the piggyBac transposon could deliver reporter transgenes into the genome of Schistosoma mansoni parasites. A piggyBac donor plasmid modified to encode firefly luciferase under control of schistosome gene promoters was introduced along with 7-methylguanosine capped RNAs encoding piggyBac transposase into cultured schistosomula by square wave electroporation. The activity of the helper transposase mRNA was confirmed by Southern hybridization analysis of genomic DNA from the transformed schistosomes, and hybridization signals indicated that the piggyBac transposon had integrated into numerous sites within the parasite chromosomes. piggyBac integrations were recovered by retrotransposon-anchored PCR, revealing characteristic piggyBac TTAA footprints in the vicinity of the endogenous schistosome retrotransposons Boudicca, SR1, and SR2. This is the first report of chromosomal integration of a transgene and somatic transgenesis of this important human pathogen, in this instance accomplished by mobilization of the piggyBac transposon.	Tulane Univ, Hlth Sci Ctr, Dept Trop Med, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Program Biomed Sci, New Orleans, LA 70112 USA; Queensland Inst Med Res, Div Infect Dis & Immunol, Brisbane, Qld 4006, Australia; Univ Notre Dame, Dept Biol Sci, South Bend, IN USA; Univ Melbourne, Fac Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3052, Australia; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	Tulane University; Tulane University; QIMR Berghofer Medical Research Institute; University of Notre Dame; University of Melbourne; University of Pennsylvania	Brindley, PJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Trop Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.	paul.brindley@tulane.edu	Fraser, Malcolm J/C-9100-2009; Gobert, Geoffrey/A-1468-2011; Gobert, Geoffrey/V-2985-2019	Gobert, Geoffrey/0000-0001-5884-6453; Brindley, Paul J./0000-0003-1765-0002	PHS HHS [N0155270] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Balu B, 2005, P NATL ACAD SCI USA, V102, P16391, DOI 10.1073/pnas.0504679102; BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; Brindley PJ, 2007, INT J PARASITOL, V37, P465, DOI 10.1016/j.ijpara.2006.12.012; Brindley PJ, 2005, TRENDS PARASITOL, V21, P533, DOI 10.1016/j.pt.2005.08.015; Brindley PJ, 2003, TRENDS PARASITOL, V19, P79, DOI 10.1016/S1471-4922(02)00061-2; CARY LC, 1989, VIROLOGY, V172, P156, DOI 10.1016/0042-6822(89)90117-7; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Copeland CS, 2003, J VIROL, V77, P6153, DOI 10.1128/JVI.77.11.6153-6166.2003; Correnti JA, 2005, MOL BIOCHEM PARASIT, V143, P209, DOI 10.1016/j.molbiopara.2005.06.007; Correnti JM, 2004, MOL BIOCHEM PARASIT, V137, P75, DOI 10.1016/j.molbiopara.2004.04.015; CORRENTI JM, 2007, IN PRESS INT J PARAS; Crabb BS, 2007, TRENDS MICROBIOL, V15, P3, DOI 10.1016/j.tim.2006.11.006; Davis RE, 1999, P NATL ACAD SCI USA, V96, P8687, DOI 10.1073/pnas.96.15.8687; DeMarco R, 2005, BIOCHEM BIOPH RES CO, V333, P230, DOI 10.1016/j.bbrc.2005.05.080; Ding S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013; Dinguirard N, 2006, MOL BIOCHEM PARASIT, V146, P219, DOI 10.1016/j.molbiopara.2005.12.010; Drew AC, 1999, MOL BIOL EVOL, V16, P1256, DOI 10.1093/oxfordjournals.molbev.a026216; Drew AC, 1997, MOL BIOL EVOL, V14, P602, DOI 10.1093/oxfordjournals.molbev.a025799; Dupuy AJ, 2002, P NATL ACAD SCI USA, V99, P4495, DOI 10.1073/pnas.062630599; Elick TA, 1996, GENETICA, V97, P127, DOI 10.1007/BF00054620; Elick TA, 1996, GENETICA, V98, P33, DOI 10.1007/BF00120216; Franz AWE, 2006, P NATL ACAD SCI USA, V103, P4198, DOI 10.1073/pnas.0600479103; FRASER MJ, 1995, VIROLOGY, V211, P397, DOI 10.1006/viro.1995.1422; Fraser MJ, 1996, INSECT MOL BIOL, V5, P141, DOI 10.1111/j.1365-2583.1996.tb00048.x; Gonzalez-Estevez C, 2003, P NATL ACAD SCI USA, V100, P14046, DOI 10.1073/pnas.2335980100; Grevelding CG, 2006, PARASITIC FLATWORMS: MOLECULAR BIOLOGY, BIOCHEMISTRY, IMMUNOLOGY AND PHYSIOLOGY, P149, DOI 10.1079/9780851990279.0149; Handler AM, 2002, INSECT BIOCHEM MOLEC, V32, P1211, DOI 10.1016/S0965-1748(02)00084-X; Hedges DJ, 2005, PLOS COMPUT BIOL, V1, P333, DOI 10.1371/journal.pcbi.0010044; Heyers O, 2003, EXP PARASITOL, V105, P174, DOI 10.1016/j.exppara.2003.11.001; Hirai H, 2000, INT J PARASITOL, V30, P441, DOI 10.1016/S0020-7519(99)00186-1; Hotez PJ, 2006, PLOS MED, V3, P576, DOI 10.1371/journal.pmed.0030102; Hu W, 2003, NAT GENET, V35, P139, DOI 10.1038/ng1236; Kines KJ, 2006, EXP PARASITOL, V112, P209, DOI 10.1016/j.exppara.2006.02.003; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Korswagen HC, 1996, P NATL ACAD SCI USA, V93, P14680, DOI 10.1073/pnas.93.25.14680; Laha T, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-154; Laha T, 2004, INT J PARASITOL, V34, P1365, DOI 10.1016/j.ijpara.2004.08.007; LAZDINS JK, 1982, EXP PARASITOL, V53, P39, DOI 10.1016/0014-4894(82)90090-X; Li X, 2005, INSECT MOL BIOL, V14, P17, DOI 10.1111/j.1365-2583.2004.00525.x; Liu F, 2006, PLOS PATHOG, V2, P268, DOI 10.1371/journal.ppat.0020029; Maragathavally KJ, 2006, FASEB J, V20, P1880, DOI 10.1096/fj.05-5485fje; McCarthy E, 2004, INT J PARASITOL, V34, P703, DOI 10.1016/j.ijpara.2004.01.008; MCLAREN DJ, 1977, NATURE, V269, P147, DOI 10.1038/269147a0; Nabekura T, 2006, MOL THER, V13, P301, DOI 10.1016/j.ymthe.2005.09.021; Osman A, 2006, PLOS PATHOG, V2, P536, DOI 10.1371/journal.ppat.0020054; Pritham EJ, 2005, MOL BIOL EVOL, V22, P1751, DOI 10.1093/molbev/msi169; Sarkar A, 2003, MOL GENET GENOMICS, V270, P173, DOI 10.1007/s00438-003-0909-0; Savioli L, 2004, PARASITOL INT, V53, P103, DOI 10.1016/j.parint.2004.01.001; Shinmyo Y, 2004, DEV GROWTH DIFFER, V46, P343, DOI 10.1111/j.1440-169x.2004.00751.x; Skelly PJ, 2003, INT J PARASITOL, V33, P363, DOI 10.1016/S0020-7519(03)00030-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPOTILA LD, 1989, CHROMOSOMA, V97, P421, DOI 10.1007/BF00295025; Utzinger J, 2004, EXPERT OPIN PHARMACO, V5, P263, DOI 10.1517/eoph.5.2.263.26469; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; Wang PC, 2001, J VIROL METHODS, V92, P83, DOI 10.1016/S0166-0934(00)00278-0; Wilber A, 2006, MOL THER, V13, P625, DOI 10.1016/j.ymthe.2005.10.014; Wilson MH, 2007, MOL THER, V15, P139, DOI 10.1038/sj.mt.6300028; Wilson RA, 2007, TRENDS PARASITOL, V23, P14, DOI 10.1016/j.pt.2006.10.002; Wippersteg V, 2005, INT J PARASITOL, V35, P583, DOI 10.1016/j.ijpara.2005.02.002; Wu P, 1998, J VIROL, V72, P5919, DOI 10.1128/JVI.72.7.5919-5926.1998; Wu SCY, 2006, P NATL ACAD SCI USA, V103, P15008, DOI 10.1073/pnas.0606979103; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Ziegler K, 2004, J VIROL METHODS, V122, P123, DOI 10.1016/j.jviromet.2004.08.012	63	74	80	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3479	3489		10.1096/fj.07-8726com	http://dx.doi.org/10.1096/fj.07-8726com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586730				2022-12-25	WOS:000250517800011
J	Lee, JS; Ellis, BE				Lee, Jin Suk; Ellis, Brian E.			Arabidopsis MAPK phosphatase 2 (MKP2) positively regulates oxidative stress tolerance and inactivates the MPK3 and MPK6 MAPKs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NEGATIVE REGULATOR; ABSCISIC-ACID; CATALYTIC ACTIVATION; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; PLANT MAPK; RESPONSES; THALIANA; OZONE	Two closely related Arabidopsis mitogen- activated protein kinases ( MAPKs), MPK3 and MPK6, are rapidly but transiently activated in plants exposed to ozone. Although the contribution of these MAPKs to control of redox stress has been examined extensively, it remains unclear whether the dual-specificity MKPs play an essential role in the regulation of these processes. To explore this question, specific knockdown of each of the five putative MKPs in Arabidopsis was performed, and the ozone sensitivity phenotype of each MKP-suppressed line was assessed. Silencing of only one previously uncharacterized MKP, designated AtMKP2, rendered the plants hypersensitive to oxidative stress. AtMKP2- suppressed plants displayed significantly prolonged MPK3 and MPK6 activation during ozone treatment, and recombinant AtMKP2 was able to dephosphorylate both phospho-MPK3 and phospho-MPK6 in vitro, providing direct evidence that AtMKP2 may target these oxidantactivated MAPKs. In addition, the in vitro phosphatase activity of AtMKP2 was enhanced by co-incubation with either recombinant MPK3 or MPK6. In AtMKP2: YFP-expressing plants, the fusion protein was localized predominantly in the nucleus, the same compartment into which ozone-activated MPK3 and MPK6 have previously been shown to be translocated. Taken together, these data suggest that AtMKP2, a novel MKP protein in Arabidopsis, acts upon MPK3 and - 6, and serves as a positive regulator of the cellular response to oxidant challenge.	Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Ellis, BE (corresponding author), Univ British Columbia, Michael Smith Labs, 2185 E Mall, Vancouver, BC V6T 1Z4, Canada.	bee@interchange.ubc.ca						Ahlfors R, 2004, PLANT J, V40, P512, DOI 10.1111/j.1365-313X.2004.02229.x; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Boldt R, 1997, FREE RADICAL BIO MED, V23, P505, DOI 10.1016/S0891-5849(97)00111-1; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Desikan R, 1999, PLANTA, V210, P97, DOI 10.1007/s004250050658; Desikan R, 2001, PLANT PHYSIOL, V126, P1579, DOI 10.1104/pp.126.4.1579; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; Duque P, 2003, PLANT J, V35, P787, DOI 10.1046/j.1365-313X.2003.01848.x; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Gupta R, 1998, PLANT J, V16, P581, DOI 10.1046/j.1365-313x.1998.00327.x; Hamel LP, 2006, TRENDS PLANT SCI, V11, P192, DOI 10.1016/j.tplants.2006.02.007; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Hirt H, 2000, RES PRO CEL, V27, P1; Jonak C, 2002, CURR OPIN PLANT BIOL, V5, P415, DOI 10.1016/S1369-5266(02)00285-6; Kang HG, 1999, PLANT J, V20, P127, DOI 10.1046/j.1365-313X.1999.00575.x; Katou S, 2005, J BIOL CHEM, V280, P39569, DOI 10.1074/jbc.M508115200; Kerk D, 2002, PLANT PHYSIOL, V129, P908, DOI 10.1104/pp.004002; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lee J, 2001, PLANT CELL, V13, P1079, DOI 10.1105/tpc.13.5.1079; Leitner M, 2005, NEW PHYTOL, V167, P597, DOI 10.1111/j.1469-8137.2005.01426.x; Liu YD, 2004, PLANT CELL, V16, P3386, DOI 10.1105/tpc.104.026609; Meskiene I, 1998, P NATL ACAD SCI USA, V95, P1938, DOI 10.1073/pnas.95.4.1938; Meskiene I, 2003, J BIOL CHEM, V278, P18945, DOI 10.1074/jbc.M300878200; Miles GP, 2005, ENVIRON POLLUT, V138, P230, DOI 10.1016/j.envpol.2005.04.017; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Monroe-Augustus M, 2003, PLANT CELL, V15, P2979, DOI 10.1105/tpc.017046; Naoi K, 2004, PLANT CELL, V16, P1841, DOI 10.1105/tpc.021865; Pellinen R, 1999, PLANT J, V20, P349, DOI 10.1046/j.1365-313X.1999.00613.x; Quettier AL, 2006, PLANT J, V47, P711, DOI 10.1111/j.1365-313X.2006.02823.x; Samaj J, 2002, EMBO J, V21, P3296, DOI 10.1093/emboj/cdf349; Samuel MA, 2005, PLANT J, V42, P406, DOI 10.1111/j.1365-313X.2005.02382.x; Samuel MA, 2000, PLANT J, V22, P367, DOI 10.1046/j.1365-313x.2000.00741.x; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Ulm R, 2002, EMBO J, V21, P6483, DOI 10.1093/emboj/cdf646; Ulm R, 2001, GENE DEV, V15, P699, DOI 10.1101/gad.192601; Wang HC, 2007, PLANT CELL, V19, P63, DOI 10.1105/tpc.106.048298; Wrzaczek M, 2001, BIOL CELL, V93, P81, DOI 10.1016/S0248-4900(01)01121-2; Zhang X, 2001, PLANT PHYSIOL, V126, P1438, DOI 10.1104/pp.126.4.1438	45	100	112	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25020	25029		10.1074/jbc.M701888200	http://dx.doi.org/10.1074/jbc.M701888200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17586809	hybrid			2022-12-25	WOS:000248933000058
J	Parfenova, LV; Abarca-Heidemann, K; Crane, BM; Rothberg, BS				Parfenova, Lyubov V.; Abarca-Heidemann, Karin; Crane, Brittany M.; Rothberg, Brad S.			Molecular architecture and divalent cation activation of TvoK, a prokaryotic potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; BK CHANNEL; RCK DOMAIN; LARGE-CONDUCTANCE; INITIATION CODON; SKELETAL-MUSCLE; GATING RING; IN-VIVO; MTHK; BINDING	RCK (regulator of conductance of potassium) domains form a family of ligand-binding domains found in many prokaryotic K+ channels and transport proteins. Although many RCK domains contain an apparent nucleotide binding motif, some are known instead to bind Ca2+, which can then facilitate channel opening. Here we report on the molecular architecture and ligand activation properties of an RCK-containing potassium channel cloned from the prokaryote Thermoplasma volcanium. This channel, called TvoK, is of an apparent molecular mass and subunit composition that is consistent with the hetero-octameric configuration hypothesized for the related MthK (Methanobacterium thermoautotrophicum potassium) channel, in which four channel-tethered RCK domains coassemble with four soluble (untethered) RCK domains. The expression of soluble TvoK RCK subunits arises from an unconventional UUG start codon within the TvoK gene; silent mutagenesis of this alternative start codon abolishes expression of the soluble form of the TvoK RCK domain. Using single channel recording of purified, reconstituted TvoK, we found that the channel is activated by Ca2+ as well as Mg2+, Mn2+, and Ni2+. This non-selective divalent activation is in contrast with the activation properties of MthK, which is selectively activated by Ca2+. Transplantation of the TvoK RCK domain into MthK generates a channel that can be activated by Mg2+, illustrating that the Mg2+ binding site is likely contained within the RCK domain. We present a working hypothesis for TvoK gating in which the binding of either Ca2+ or Mg2+ can contribute similar to 5 kcal/mol toward stabilization of the open conformation of the channel.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Rothberg, BS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, MC7756,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	rothberg@uthscsa.edu	Rothberg, Brad/AAD-1260-2022	Rothberg, Brad/0000-0003-1982-2269	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068523] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM068523, GM68523, R01 GM068523-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright RA, 2006, CELL, V126, P1147, DOI 10.1016/j.cell.2006.08.028; ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Cox DH, 2005, J GEN PHYSIOL, V125, P253, DOI 10.1085/jgp.200509270; Dong JB, 2005, J BIOL CHEM, V280, P41716, DOI 10.1074/jbc.M508144200; Dudev T, 2003, CHEM REV, V103, P773, DOI 10.1021/cr020467n; FERGUSON WB, 1991, J GEN PHYSIOL, V98, P163, DOI 10.1085/jgp.98.1.163; FILES JG, 1975, J MOL BIOL, V95, P327, DOI 10.1016/0022-2836(75)90398-8; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kroning N, 2007, J BIOL CHEM, V282, P14018, DOI 10.1074/jbc.M609084200; Kuo MMC, 2007, P NATL ACAD SCI USA, V104, P2151, DOI 10.1073/pnas.0609085104; Kuo MMC, 2003, EMBO J, V22, P4049, DOI 10.1093/emboj/cdg409; Li Y, 2007, J GEN PHYSIOL, V129, P109, DOI 10.1085/jgp.200609655; OBERHAUSER A, 1988, J GEN PHYSIOL, V92, P67, DOI 10.1085/jgp.92.1.67; Parfenova LV, 2006, J BIOL CHEM, V281, P21131, DOI 10.1074/jbc.M603109200; REDDY P, 1985, P NATL ACAD SCI USA, V82, P5656, DOI 10.1073/pnas.82.17.5656; Roosild TP, 2004, TRENDS BIOCHEM SCI, V29, P39, DOI 10.1016/j.tibs.2003.11.008; Roosild TP, 2002, CELL, V109, P781, DOI 10.1016/S0092-8674(02)00768-7; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; SCHLOSSER A, 1993, MOL MICROBIOL, V9, P533, DOI 10.1111/j.1365-2958.1993.tb01714.x; Shi JY, 2002, NATURE, V418, P876, DOI 10.1038/nature00941; Stingl K, 2007, EMBO J, V26, P232, DOI 10.1038/sj.emboj.7601471; Torarinsson E, 2005, ENVIRON MICROBIOL, V7, P47, DOI 10.1111/j.1462-2920.2004.00674.x; Xia XM, 2002, NATURE, V418, P880, DOI 10.1038/nature00956; Zadek B, 2006, J GEN PHYSIOL, V127, P673, DOI 10.1085/jgp.200609534; Zeng XH, 2005, J GEN PHYSIOL, V125, P273, DOI 10.1085/jgp.200409239; Zhang X, 2001, J GEN PHYSIOL, V118, P607, DOI 10.1085/jgp.118.5.607	31	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24302	24309		10.1074/jbc.M703650200	http://dx.doi.org/10.1074/jbc.M703650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17588939	Green Accepted, hybrid			2022-12-25	WOS:000248686600056
J	Porto, BN; Alves, LS; Fernandez, PL; Dutra, TP; Figueiredo, RT; Graca-Souza, AV; Bozza, MT				Porto, Barbara N.; Alves, Leticia S.; Fernandez, Patricia L.; Dutra, Tatiana P.; Figueiredo, Rodrigo T.; Graca-Souza, Aurelio V.; Bozza, Marcelo T.			Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACTIVATION; IDENTIFICATION; INFLAMMATION; TRANSPORTER; INDUCTION; CHANNELS; ALPHA; CELLS; MAPK	Hemolysis or extensive cell damage can lead to high concentrations of free heme, causing oxidative stress and inflammation. Considering that heme induces neutrophil chemotaxis, we hypothesize that heme activates a G protein-coupled receptor. Here we show that similar to heme, several heme analogs were able to induce neutrophil migration in vitro and in vivo. Mesoporphyrins, molecules lacking the vinyl groups in their rings, were not chemotactic for neutrophils and selectively inhibited heme-induced migration. Moreover, migration of neutrophils induced by heme was abolished by pretreatment with pertussis toxin, an inhibitor of G alpha inhibitory protein, and with inhibitors of phosphoinositide 3-kinase, phospholipase C beta, mitogen-activated protein kinases, or Rho kinase. The induction of reactive oxygen species by heme was dependent of G beta, inhibitory protein and phosphoinositide 3-kinase and partially dependent of phospholipase C beta, protein kinase C, mitogen-activated protein kinases, and Rho kinase. Together, our results indicate that heme activates neutrophils through signaling pathways that are characteristic of chemoattractant molecules and suggest that mesoporphyrins might prove valuable in the treatment of the inflammatory consequences of hemorrhagic and hemolytic disorders.	Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, BR-21941590 Rio De Janeiro, Brazil; Inst Adv Sci Invest & High Technol Serv, Panama City 081602852, Panama; Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Biotecnol & Biol Mol, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, CCS Bloco 1,Ave Carlos Chagas Filho,337 Cidade Un, BR-21941590 Rio De Janeiro, Brazil.	mbozza@micro.ufrj.br	; Figueiredo, Rodrigo/F-5176-2016	Bozza, Marcelo/0000-0003-3683-7550; Llanes Fernandez, Patricia/0000-0002-0762-0566; Figueiredo, Rodrigo/0000-0002-7551-8782				Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023; Balla J, 2000, BLOOD, V95, P3442, DOI 10.1182/blood.V95.11.3442.011k51_3442_3450; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Coxon PY, 2003, CELL SIGNAL, V15, P993, DOI 10.1016/S0898-6568(03)00074-3; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DAVENPORT RD, 1994, TRANSFUS MED REV, V8, P157, DOI 10.1016/S0887-7963(94)70108-5; DAVENPORT RD, 1990, BLOOD, V76, P2439; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200; GALBRAITH RA, 1990, J HEPATOL, V10, P305, DOI 10.1016/0168-8278(90)90137-G; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160; Gudi SRP, 1998, AM J PHYSIOL-CELL PH, V274, pC1424, DOI 10.1152/ajpcell.1998.274.5.C1424; Haeger M, 1996, ACTA OBSTET GYN SCAN, V75, P695, DOI 10.3109/00016349609065729; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; JACOB HS, 1994, J LAB CLIN MED, V123, P808; Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879; KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811; MULLEREBERHARD U, 1993, AM J HEMATOL, V42, P59, DOI 10.1002/ajh.2830420112; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586; Quigley JG, 2004, CELL, V118, P757, DOI 10.1016/j.cell.2004.08.014; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Suchyna TM, 2004, PHYS BIOL, V1, P1, DOI 10.1088/1478-3967/1/1/001; Tang XD, 2003, NATURE, V425, P531, DOI 10.1038/nature02003; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Worthington MT, 2001, AM J PHYSIOL-GASTR L, V280, pG1172, DOI 10.1152/ajpgi.2001.280.6.G1172	34	119	119	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24430	24436		10.1074/jbc.M703570200	http://dx.doi.org/10.1074/jbc.M703570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17581818	hybrid			2022-12-25	WOS:000248686600069
J	Takahashi, Y; Okamoto, Y; Popiel, HA; Fujikake, N; Toda, T; Kinjo, M; Nagai, Y				Takahashi, Yasuo; Okamoto, Yuma; Popiel, H. Akiko; Fujikake, Nobuhiro; Toda, Tatsushi; Kinjo, Masataka; Nagai, Yoshitaka			Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; HEAT-SHOCK-PROTEIN; HUNTINGTONS-DISEASE; NEURODEGENERATIVE DISEASE; MISFOLDING DISEASES; COMMON MECHANISM; LIVING CELLS; IN-VIVO; AGGREGATION; PEPTIDES	Abnormal aggregation of misfolded proteins and their deposition as inclusion bodies in the brain have been implicated as a common molecular pathogenesis of neurodegenerative diseases including Alzheimer, Parkinson, and the polyglutamine ( poly( Q)) diseases, which are collectively called the conformational diseases. The poly( Q) diseases, including Huntington disease and various types of spinocerebellar ataxia, are caused by abnormal expansions of the poly( Q) stretch within disease-causing proteins, which triggers the disease- causing proteins to aggregate into insoluble beta- sheet- rich amyloid fibrils. Although oligomeric structures formed in vitro are believed to be more toxic than mature amyloid fibrils in these diseases, the existence of oligomers in vivo has remained controversial. To explore oligomer formation in cells, we employed fluorescence correlation spectroscopy ( FCS), which is a highly sensitive technique for investigating the dynamics of fluorescent molecules in solution. Here we demonstrate direct evidence for oligomer formation of poly( Q)- green fluorescent protein ( GFP) fusion proteins expressed in cultured cells, by showing a time- dependent increase in their diffusion time and particle size by FCS. We show that the poly( Q)- binding peptide QBP1 inhibits poly( Q)GFP oligomer formation, whereas Congo red only inhibits the growth of oligomers, but not the initial formation of the poly( Q)- GFP oligomers, suggesting that FCS is capable of identifying poly( Q) oligomer inhibitors. We therefore conclude that FCS is a useful technique to monitor the oligomerization of disease-causing proteins in cells as well as its inhibition in the conformational diseases.	Osaka Univ, Grad Sch Med, Dept Med Genet, Div Clin Genet, Suita, Osaka 5650871, Japan; Hokkaido Univ, Res Inst Elect Sci, Lab Supramol Biophys, Sapporo, Hokkaido 0600812, Japan; Olympus Corp, Tokyo 1928512, Japan; Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Mol Biol & Cell Informat, Osaka 5998531, Japan	Osaka University; Hokkaido University; Olympus Corporation; Osaka Metropolitan University	Nagai, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Med Genet, Div Clin Genet, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	nagai@clgene.med.osaka-u.ac.jp	Kinjo, Masataka/F-5267-2011	Kinjo, Masataka/0000-0001-8889-8369				Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chai YH, 1999, J NEUROSCI, V19, P10338; Colby DW, 2004, P NATL ACAD SCI USA, V101, P17616, DOI 10.1073/pnas.0408134101; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Elson EL, 2001, TRAFFIC, V2, P789, DOI 10.1034/j.1600-0854.2001.21107.x; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Heiser V, 2002, P NATL ACAD SCI USA, V99, P16400, DOI 10.1073/pnas.182426599; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Hirose M, 2005, J BIOL CHEM, V280, P32586, DOI 10.1074/jbc.M504121200; Jankevics H, 2005, BIOCHEMISTRY-US, V44, P11676, DOI 10.1021/bi050744v; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Kitamura A, 2006, NAT CELL BIOL, V8, P1163, DOI 10.1038/ncb1478; Klein WL, 2004, NEUROBIOL AGING, V25, P569, DOI 10.1016/j.neurobiolaging.2004.02.010; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lecerf JM, 2001, P NATL ACAD SCI USA, V98, P4764, DOI 10.1073/pnas.071058398; Levin MK, 2004, DIFFERENTIATION, V72, P1, DOI 10.1111/j.1432-0436.2004.07201002.x; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Nagai Y, 2003, HUM MOL GENET, V12, P1253, DOI 10.1093/hmg/ddg144; Nagai Y, 1999, EXP NEUROL, V155, P195, DOI 10.1006/exnr.1998.6991; Nagai Y, 2000, J BIOL CHEM, V275, P10437, DOI 10.1074/jbc.275.14.10437; Nagai Y, 2007, NAT STRUCT MOL BIOL, V14, P332, DOI 10.1038/nsmb1215; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Pollitt SK, 2003, NEURON, V40, P685, DOI 10.1016/S0896-6273(03)00697-4; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Popiel HA, 2007, MOL THER, V15, P303, DOI 10.1038/sj.mt.6300045; Popiel HA, 2004, BIOCHEM BIOPH RES CO, V317, P1200, DOI 10.1016/j.bbrc.2004.03.161; Ren H, 2001, BIOCHEM BIOPH RES CO, V288, P703, DOI 10.1006/bbrc.2001.5783; Ross CA, 2005, NAT REV MOL CELL BIO, V6, P891, DOI 10.1038/nrm1742; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Takahashi Y, 2005, CURR PHARM BIOTECHNO, V6, P159, DOI 10.2174/1389201053642330; Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Terada S, 2000, CELL, V103, P141, DOI 10.1016/S0092-8674(00)00094-5; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wood NI, 2007, NEUROBIOL DIS, V25, P342, DOI 10.1016/j.nbd.2006.09.015; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	50	83	85	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24039	24048		10.1074/jbc.M704789200	http://dx.doi.org/10.1074/jbc.M704789200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17573338	hybrid			2022-12-25	WOS:000248686600029
J	Maresso, AW; Wu, RY; Kern, JW; Zhang, RG; Janik, D; Missiakas, DM; Duban, ME; Joachimiak, A; Schneewind, O				Maresso, Anthony W.; Wu, Ruiying; Kern, Justin W.; Zhang, Rongguang; Janik, Dorota; Missiakas, Dominique M.; Duban, Mark-Eugene; Joachimiak, Andrzej; Schneewind, Olaf			Activation of inhibitors by sortase triggers irreversible modification of the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS SORTASE; PROTEIN ANCHORING TRANSPEPTIDASE; SURFACE-PROTEINS; BACILLUS-ANTHRACIS; MANNICH-BASES; DRUG-LIKE; SRTA; PREDICTION; RESISTANCE; DISCOVERY	Sortases anchor surface proteins to the cell wall of Gram-positive pathogens through recognition of specific motif sequences. Loss of sortase leads to large reductions in virulence, which identifies sortase as a target for the development of antibacterials. By screening 135,625 small molecules for inhibition, we report here that aryl (beta-amino) ethyl ketones inhibit sortase enzymes from staphylococci and bacilli. Inhibition of sortases occurs through an irreversible, covalent modification of their active site cysteine. Sortases specifically activate this class of molecules via beta-elimination, generating a reactive olefin intermediate that covalently modifies the cysteine thiol. Analysis of the three-dimensional structure of Bacillusanthracis sortase B with and without inhibit or provides insights into the mechanism of inhibition and reveals binding pockets can be exploited for drug discovery.	Univ Chicago, Dept Microbiol, Chicago, IL 60637 USA; Argonne Natl Lab, Biosci Div, Midwest Ctr Struct Genom & Struct Biol Ctr, Argonne, IL 60439 USA; Chicago State Univ, Dept Chem & Phys, Lab Design Bioact Mol, Chicago, IL 60628 USA	University of Chicago; United States Department of Energy (DOE); Argonne National Laboratory; Chicago State University	Schneewind, O (corresponding author), Univ Chicago, Dept Microbiol, 920 E 58th St, Chicago, IL 60637 USA.	oschnee@bsd.uchicago.edu	Duban, Mark-Eugene/K-2762-2012		NIAID NIH HHS [AI38897, AI057153, 1-U54-AI-057153, R21 AI146481, R01 AI038897, U54 AI057153] Funding Source: Medline; NIGMS NIH HHS [U54 GM074942-04S2, P50 GM062414-02, P50 GM062414, U54 GM074942, GM62414, GM08043, GM074942, S06 GM008043] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057153, R01AI038897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414, S06GM008043, U54GM074942] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali A, 2004, J MED CHEM, V47, P2441, DOI 10.1021/jm030585i; ANDRISANO R, 1967, J CHEM SOC C, P2307, DOI 10.1039/j39670002307; Bryskier A, 2002, CLIN MICROBIOL INFEC, V8, P467, DOI 10.1046/j.1469-0691.2002.00527.x; Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056/NEJMoa025025; Copeland R. A., 2005, EVALUATION ENZYME IN; Davioud-Charvet E, 2003, BIOCHEMISTRY-US, V42, P13319, DOI 10.1021/bi0353629; Davis AM, 2005, CURR TOP MED CHEM, V5, P421, DOI 10.2174/1568026053828411; Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184; Frankel BA, 2004, J AM CHEM SOC, V126, P3404, DOI 10.1021/ja0390294; Gul HI, 2002, ARZNEIMITTEL-FORSCH, V52, P773; Gul M, 2005, ARZNEIMITTELFORSCH, V55, P332; Jung ME, 2005, BIOORG MED CHEM LETT, V15, P5076, DOI 10.1016/j.bmcl.2005.07.073; Kang SK, 1998, SYNTHESIS-STUTTGART, P823; Kaplan SL, 2005, CLIN INFECT DIS, V40, P1785, DOI 10.1086/430312; Kim SH, 2004, BIOSCI BIOTECH BIOCH, V68, P421, DOI 10.1271/bbb.68.421; Kim SH, 2003, BIOSCI BIOTECH BIOCH, V67, P2477, DOI 10.1271/bbb.67.2477; Kim SW, 2002, BIOSCI BIOTECH BIOCH, V66, P2751, DOI 10.1271/bbb.66.2751; Kruger RG, 2004, BIOORGAN MED CHEM, V12, P3723, DOI 10.1016/j.bmc.2004.03.066; LEVY SB, 1976, NATURE, V260, P40, DOI 10.1038/260040a0; Lipinski C, 2004, NATURE, V432, P855, DOI 10.1038/nature03193; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Lowy FD, 2003, J CLIN INVEST, V111, P1265, DOI 10.1172/JC1200318535; Marraffini LA, 2006, MICROBIOL MOL BIOL R, V70, P192, DOI 10.1128/MMBR.70.1.192-221.2006; MARTIN YC, 2006, 232 NAT M AM CHEM SO; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; MOLLICA JA, 1970, J PHARM SCI, V59, P1770, DOI 10.1002/jps.2600591213; MORRILL C, 2006, J ORG CHEM, V71, pS10; Morrill C, 2006, J ORG CHEM, V71, P7813, DOI 10.1021/jo061436l; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Muegge I, 2003, MED RES REV, V23, P302, DOI 10.1002/med.10041; Naidu BN, 2003, J ORG CHEM, V68, P10098, DOI 10.1021/jo034762z; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Oh KB, 2005, BIOORG MED CHEM LETT, V15, P4927, DOI 10.1016/j.bmcl.2005.08.021; Oh KB, 2004, J MED CHEM, V47, P2418, DOI 10.1021/jm0498708; Perez JJ, 2005, CHEM SOC REV, V34, P143, DOI 10.1039/b209064n; Rishton GM, 2003, DRUG DISCOV TODAY, V8, P86, DOI 10.1016/S1359644602025722; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; Scott CJ, 2002, BIOCHEM J, V366, P953, DOI 10.1042/BJ20020602; Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r; SMITH AB, 2007, MARCHS ADV ORGANIC C; Sun HM, 2004, J CHEM INF COMP SCI, V44, P1506, DOI 10.1021/ci049917y; Tenover FC, 2006, J CLIN MICROBIOL, V44, P108, DOI 10.1128/JCM.44.1.108-118.2006; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; TRAMONTINI M, 1990, TETRAHEDRON, V46, P1791, DOI 10.1016/S0040-4020(01)89752-0; Trost B. M., 2002, ANGEW CHEM, V114, P1101; Walsh MA, 1999, ACTA CRYSTALLOGR D, V55, P1168, DOI 10.1107/S0907444999003698; Wunberg T, 2006, DRUG DISCOV TODAY, V11, P175, DOI 10.1016/S1359-6446(05)03700-1; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang RG, 2004, STRUCTURE, V12, P1147, DOI 10.1016/j.str.2004.06.001; Zong YN, 2004, J BIOL CHEM, V279, P31383, DOI 10.1074/jbc.M401374200	55	82	92	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23129	23139		10.1074/jbc.M701857200	http://dx.doi.org/10.1074/jbc.M701857200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17545669	Green Accepted, hybrid			2022-12-25	WOS:000248577500015
J	Bjorkhaug, L; Molnes, J; Sovik, O; Njolstad, PR; Flatmark, T				Bjorkhaug, Lise; Molnes, Janne; Sovik, Oddmund; Njolstad, Pal Rasmus; Flatmark, Torgeir			Allosteric activation of human glucokinase by free polyubiquitin chains and its ubiquitin-dependent cotranslational proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SUBCELLULAR-LOCALIZATION; PROTEOLYTIC PATHWAY; INSULIN-SECRETION; PROTEIN; GLUCOSE; BINDING; SYSTEM; ATP; UBIQUITYLATION	Human glucokinase (hGK) is a monomeric enzyme highly regulated in pancreatic beta-cells (isoform 1) and hepatocytes (isoforms 2 and 3). Although certain cellular proteins are known to either stimulate or inhibit its activity, little is known about post-translational modifications of this enzyme and their possible regulatory functions. In this study, we have identified isoforms 1 and 2 of hGK as novel substrates for the ubiquitin-conjugating enzyme system of the rabbit reticulocyte lysate. Both isoforms were polyubiquitinated on at least two lysine residues, and mutation analysis indicated that multiple lysine residues functioned as redundant acceptor sites. Deletion of its C-terminal alpha- helix, as part of a ubiquitin-interacting motif, affected the polyubiquitination at one of the sites and resulted in a completely inactive enzyme. Evidence is presented that poly/multiubiquitination of hGK in vitro serves as a signal for proteasomal degradation of the newly synthesized protein. Moreover, the recombinant hGK was found to interact with and to be allosterically activated up to similar to 1.4-fold by purified free pentaubiquitin chains at similar to 100 nM(with an apparent EC50 of 93 nM), and possibly also by unidentified polyubiquitinated proteins assigned to their equilibrium binding to the ubiquitin-interacting motif site. The affinity of pentaubiquitin binding to hGK is regulated by the ligand ( D-glucose)-dependent conformational state of the site. Both ubiquitination of hGK and its activation by polyubiquitin chains potentially represent physiological regulatory mechanisms for glucokinase-dependent insulin secretion in pancreatic beta-cells.	Univ Bergen, Dept Biomed, N-5009 Bergen, Norway; Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway; Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital	Flatmark, T (corresponding author), Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.	torgeir.flatmark@biomed.uib.no	Bjørkhaug, Lise/AAA-4356-2021	Bjørkhaug, Lise/0000-0002-9695-4559				Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Baltrusch S, 2001, J BIOL CHEM, V276, P43915, DOI 10.1074/jbc.M105470200; Charbonnier S, 2006, PROTEIN EXPRES PURIF, V50, P89, DOI 10.1016/j.pep.2006.06.010; Dai Q, 2005, J BIOL CHEM, V280, P38673, DOI 10.1074/jbc.M507986200; Davydov IV, 2005, METHOD ENZYMOL, V399, P415, DOI 10.1016/S0076-6879(05)99029-0; de la Iglesia N, 1999, FEBS LETT, V456, P332, DOI 10.1016/S0014-5793(99)00971-0; EYTAN E, 1984, BIOCHEM BIOPH RES CO, V122, P116, DOI 10.1016/0006-291X(84)90447-9; Flick K, 2006, NAT CELL BIOL, V8, P509, DOI 10.1038/ncb1402; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gloyn AL, 2003, HUM MUTAT, V22, P353, DOI 10.1002/humu.10277; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; JAHNGEN JJ, 1986, CURR EYE RES, V5, P725, DOI 10.3109/02713688609000012; Jungbauer LM, 2006, J MOL BIOL, V357, P1121, DOI 10.1016/j.jmb.2006.01.012; Kamata K, 2004, STRUCTURE, V12, P429, DOI 10.1016/j.str.2004.02.005; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kawaguchi M, 2006, J BIOL CHEM, V281, P13015, DOI 10.1074/jbc.M601228200; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Kitiphongspattana K, 2005, J BIOL CHEM, V280, P15727, DOI 10.1074/jbc.M410876200; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Lopez-Avalos MD, 2006, DIABETES, V55, P1223, DOI 10.2337/db05-0450; MEDA P, 1978, DIABETOLOGIA, V14, P305, DOI 10.1007/BF01223021; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Murata S, 2005, METHOD ENZYMOL, V398, P271, DOI 10.1016/S0076-6879(05)98022-1; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Njolstad PR, 2003, DIABETES, V52, P2854, DOI 10.2337/diabetes.52.11.2854; Olejnicka BT, 1997, REDOX REP, V3, P311, DOI 10.1080/13510002.1997.11747128; Pedelini L, 2005, PROTEIN SCI, V14, P2080, DOI 10.1110/ps.051485205; Pickart CM, 2005, METHOD ENZYMOL, V399, P21, DOI 10.1016/S0076-6879(05)99002-2; RILEY DA, 1988, J HISTOCHEM CYTOCHEM, V36, P621, DOI 10.1177/36.6.2835410; Rizzo MA, 2002, J BIOL CHEM, V277, P34168, DOI 10.1074/jbc.M112478200; Sagen JV, 2006, DIABETES, V55, P1713, DOI 10.2337/db05-1513; SCHNELL AH, 1985, CELL TISSUE RES, V239, P537; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Stubbs M, 2000, DIABETES, V49, P2048, DOI 10.2337/diabetes.49.12.2048; Toyoda Y, 1999, HISTOCHEM CELL BIOL, V112, P35, DOI 10.1007/s004180050389; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; Yan FF, 2005, AM J PHYSIOL-CELL PH, V289, pC1351, DOI 10.1152/ajpcell.00240.2005	44	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22757	22764		10.1074/jbc.M700517200	http://dx.doi.org/10.1074/jbc.M700517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17561510	Green Published, hybrid			2022-12-25	WOS:000248354200053
J	Daus, ML; Grote, M; Muller, P; Doebber, M; Herrmann, A; Steinhoff, HJ; Dassa, E; Schneider, E				Daus, Martin L.; Grote, Mathias; Mueller, Peter; Doebber, Meike; Herrmann, Andreas; Steinhoff, Heinz-Juergen; Dassa, Elie; Schneider, Erwin			ATP-driven Malk dimer closure and reopening and conformational changes of the "EAA" motifs are crucial for function of the maltose ATP-binding cassette transporter (MalFGK(2))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; NUCLEOTIDE-BINDING; ABC TRANSPORTER; ESCHERICHIA-COLI; SUBUNIT INTERACTIONS; MEMBRANE-PROTEIN; SIGNATURE MOTIFS; TRANSITION-STATE; CATALYTIC CYCLE; CROSS-LINKING	We have investigated conformational changes of the purified maltose ATP-binding cassette transporter (MalFGK(2)) upon binding of ATP. The transport complex is composed of a heterodimer of the hydrophobic subunits MalF and MalG constituting the translocation pore and of a homodimer of MalK, representing the ATP-hydrolyzing subunit. Substrate is delivered to the transporter in complex with periplasmic maltose-binding protein ( MalE). Cross-linking experiments with a variant containing an A85C mutation within the Q-loop of each MalK monomer indicated an ATP-induced shortening of the distance between both monomers. Cross-linking caused a substantial inhibition of MalE-maltose-stimulated ATPase activity. We further demonstrated that a mutation affecting the "catalytic carboxylate" (E159Q) locks the MalK dimer in the closed state, whereas a transporter containing the "ABC signature" mutation Q140K permanently resides in the resting state. Cross-linking experiments with variants containing the A85C mutation combined with cysteine substitutions in the conserved EAA motifs of MalF and MalG, respectively, revealed close proximity of these residues in the resting state. The formation of a MalK-MalG heterodimer remained unchanged upon the addition of ATP, indicating that MalG-EAA moves along with MalK during dimer closure. In contrast, the yield of MalK-MalF dimers was substantially reduced. This might be taken as further evidence for asymmetric functions of both EAA motifs. Cross-linking also caused inhibition of ATPase activity, suggesting that transporter function requires conformational changes of both EAA motifs. Together, our data support ATP-driven MalK dimer closure and reopening as crucial steps in the translocation cycle of the intact maltose transporter and are discussed with respect to a current model.	Humboldt Univ, Inst Biol Bakterienphysiol, D-10115 Berlin, Germany; Humboldt Univ, Inst Biol Biophy, D-10115 Berlin, Germany; Univ Osnabruck, Fachbereich Phys, D-49069 Osnabruck, Germany; Inst Pasteur, Dept Microbiol Fondamentale & Med, CNRS URA 2172, Unite Mem Bacteriennes, F-75724 Paris 15, France	Humboldt University of Berlin; Humboldt University of Berlin; University Osnabruck; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Schneider, E (corresponding author), Humboldt Univ, Inst Biol Bakterienphysiol, Chausseestr 117, D-10115 Berlin, Germany.	erwin.schneider@rz.hu-berlin.de	Steinhoff, Heinz-Juergen/H-3791-2014	Steinhoff, Heinz-Juergen/0000-0002-5888-0157				Austermuhle MI, 2004, J BIOL CHEM, V279, P28243, DOI 10.1074/jbc.M403508200; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; Braun TF, 2001, BIOCHEMISTRY-US, V40, P13051, DOI 10.1021/bi011264g; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; Dalmas O, 2005, J BIOL CHEM, V280, P36857, DOI 10.1074/jbc.M503266200; Dassa E., 2003, ABC PROTEINS BACTERI, P3; Daus ML, 2006, J BIOL CHEM, V281, P3856, DOI 10.1074/jbc.M511953200; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; HOLLAND EB, 2003, ABC PROTEINS BACTERI; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hunke S, 1999, FEBS LETT, V448, P131, DOI 10.1016/S0014-5793(99)00356-7; Hunke S, 2000, J BIOL CHEM, V275, P15526, DOI 10.1074/jbc.275.20.15526; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; Landmesser H, 2002, BBA-BIOMEMBRANES, V1565, P64, DOI 10.1016/S0005-2736(02)00506-0; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Lu G, 2005, P NATL ACAD SCI USA, V102, P17969, DOI 10.1073/pnas.0506039102; Mannering DE, 2001, J BIOL CHEM, V276, P12362, DOI 10.1074/jbc.M011686200; Melin P, 2005, J MEMBRANE BIOL, V208, P203, DOI 10.1007/s00232-005-7001-0; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Pinkett HW, 2007, SCIENCE, V315, P373, DOI 10.1126/science.1133488; Pretz MG, 2006, BIOCHEMISTRY-US, V45, P15056, DOI 10.1021/bi061230e; Scheffel F, 2005, FEBS LETT, V579, P2953, DOI 10.1016/j.febslet.2005.04.017; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Schneider E, 2001, RES MICROBIOL, V152, P303, DOI 10.1016/S0923-2508(01)01201-3; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; SCHNEIDER E, 2003, ABC PROTEINS BACTERI, P157; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sonne J, 2007, BIOPHYS J, V92, P2727, DOI 10.1529/biophysj.106.097972; Szentpetery Z, 2004, J BIOL CHEM, V279, P41670, DOI 10.1074/jbc.M406484200; Tombline G, 2005, J BIOENERG BIOMEMBR, V37, P497, DOI [10.1007/s10863-005-9498-4, 10.1007/s10863-005-9498/4]; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P11921, DOI 10.1021/bi001220s; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zaitseva J, 2005, EMBO J, V24, P1901, DOI 10.1038/sj.emboj.7600657; Zaitseva J, 2006, EMBO J, V25, P3432, DOI 10.1038/sj.emboj.7601208	54	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22387	22396		10.1074/jbc.M701979200	http://dx.doi.org/10.1074/jbc.M701979200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17545154	hybrid			2022-12-25	WOS:000248354200017
J	Jankowsky, JL; Younkin, LH; Gonzales, V; Fadale, DJ; Slunt, HH; Lester, HA; Younkin, SG; Borchelt, DR				Jankowsky, Joanna L.; Younkin, Linda H.; Gonzales, Victoria; Fadale, Daniel J.; Slunt, Hilda H.; Lester, Henry A.; Younkin, Steven G.; Borchelt, David R.			Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; SENILE PLAQUES; LONDON MUTANT; MOUSE HOMOLOG; BRAIN; PEPTIDES; EXPRESSION; AGGREGATION	The amino acid sequence of amyloid precursor protein (APP) is highly conserved, and age-related A beta aggregates have been described in a variety of vertebrate animals, with the notable exception of mice and rats. Three amino acid substitutions distinguish mouse and human A beta that might contribute to their differing properties in vivo. To examine the amyloidogenic potential of mouse A beta, we studied several lines of transgenic mice overexpressing wild-type mouse amyloid precursor protein (moAPP) either alone or in conjunction with mutant PS1 (PS1dE9). Neither overexpression of moAPP alone nor co-expression with PS1dE9 caused mice to develop Alzheimer-type amyloid pathology by 24 months of age. We further tested whether mouse A beta could accelerate the deposition of human A beta by crossing the moAPP transgenic mice to a bigenic line expressing human APPswe with PS1dE9. The triple transgenic animals (moAPP x APPswe/PS1dE9) produced 20% more A beta but formed amyloid deposits no faster and to no greater extent than APPswe/PS1dE9 siblings. Instead, the additional mouse A beta increased the detergent solubility of accumulated amyloid and exacerbated amyloid deposition in the vasculature. These findings suggest that, although mouse A beta does not influence the rate of amyloid formation, the incorporation of A beta peptides with differing sequences alters the solubility and localization of the resulting aggregates.	Univ Florida, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	State University System of Florida; University of Florida; California Institute of Technology; Mayo Clinic; Johns Hopkins University	Jankowsky, JL (corresponding author), Univ Florida, McKnight Brain Inst, Dept Neurosci, 100 Newell Dr,Rm L1-100H,POB 100244, Gainesville, FL 32610 USA.	jlj2@caltech.edu; borchelt@mbi.ufl.edu	Longo, Kenneth A/A-5631-2010		NATIONAL INSTITUTE ON AGING [P01AG014248, R01AG006656, K01AG026144] Funding Source: NIH RePORTER; NIA NIH HHS [K01 AG026144-05, K01 AG026144-02, 1 P01 AG-98-003, K01 AG-26144-01, K01 AG026144, AG-06-656, 1 P50 AG-14-248, K01 AG026144-04, K01 AG026144-03, K01 AG026144-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Bitan G, 2003, J BIOL CHEM, V278, P34882, DOI 10.1074/jbc.M300825200; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; Fung J, 2004, J NEUROCHEM, V91, P1398, DOI 10.1111/j.1471-4159.2004.02828.x; Gouras GK, 1998, J NEUROCHEM, V71, P1920; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Herzig MC, 2004, NAT NEUROSCI, V7, P954, DOI 10.1038/nn1302; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HILBICH C, 1991, EUR J BIOCHEM, V201, P61, DOI 10.1111/j.1432-1033.1991.tb16256.x; HIRANO A, 1962, ARCH NEUROL-CHICAGO, V6, P114, DOI 10.1001/archneur.1962.00450200028003; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Jankowsky JL, 2005, PLOS MED, V2, P1318, DOI 10.1371/journal.pmed.0020355; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; Kalback W, 2002, BIOCHEMISTRY-US, V41, P922, DOI 10.1021/bi015685+; KANG J, 1989, NUCLEIC ACIDS RES, V17, P2130, DOI 10.1093/nar/17.5.2130; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kim J, 2007, J NEUROSCI, V27, P627, DOI 10.1523/JNEUROSCI.4849-06.2007; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Lesuisse C, 2001, HUM MOL GENET, V10, P2525, DOI 10.1093/hmg/10.22.2525; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; McLaurin J, 2000, EUR J BIOCHEM, V267, P6353, DOI 10.1046/j.1432-1327.2000.01725.x; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Pype S, 2003, J NEUROCHEM, V84, P602, DOI 10.1046/j.1471-4159.2003.01556.x; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STRUBLE RG, 1985, BRAIN RES, V361, P267, DOI 10.1016/0006-8993(85)91298-3; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Van Dooren T, 2006, AM J PATHOL, V168, P245, DOI 10.2353/ajpath.2006.050752; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; Wang J, 2003, NEUROBIOL DIS, V14, P318, DOI 10.1016/j.nbd.2003.08.009; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WISNIEWSKI H, 1970, LAB INVEST, V23, P287; WISNIEWSKI HM, 1973, J NEUROPATH EXP NEUR, V32, P566, DOI 10.1097/00005072-197310000-00007; Xu GL, 2002, ALZ DIS ASSOC DIS, V16, P191, DOI 10.1097/00002093-200207000-00010; YAMADA T, 1989, BIOCHEM BIOPH RES CO, V158, P906, DOI 10.1016/0006-291X(89)92808-8; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YAMAMOTO T, 1986, NEUROPATH APPL NEURO, V12, P3, DOI 10.1111/j.1365-2990.1986.tb00677.x; Yang DS, 2000, EUR J BIOCHEM, V267, P6692, DOI 10.1046/j.1432-1327.2000.01767.x	55	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22707	22720		10.1074/jbc.M611050200	http://dx.doi.org/10.1074/jbc.M611050200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17556372	Green Accepted, hybrid			2022-12-25	WOS:000248354200048
J	Renna, M; Caporaso, MG; Bonatti, S; Kaufman, RJ; Remondelli, P				Renna, Maurizio; Caporaso, Maria Gabriella; Bonatti, Stefano; Kaufman, Randal J.; Remondelli, Paolo			Regulation of ERGIC-53 gene transcription in response to endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-Y; LECTIN ERGIC-53; MESSENGER-RNA; FACTOR YY1; PROTEIN; ELEMENT; ATF6; INDUCTION; IDENTIFICATION; RECEPTOR	Accumulation of unfolded proteins within the endoplasmic reticulum (ER) activates the unfolded protein response, also known as the ER stress response. We previously demonstrated that ER stress induces transcription of the ER Golgi intermediate compartment protein ERGIC-53. To investigate the molecular events that regulate unfolded protein response-mediated induction of the gene, we have analyzed the transcriptional regulation of ERGIC-53. We found that the ERGIC-53 promoter contains a single cis-acting element that mediates induction of the gene by thapsigargin and other ER stress-causing agents. This ER stress response element proved to retain a novel structure and to be highly conserved in mammalian ERGIC-53 genes. The ER stress response element identified contains a 5 '-end CCAAT sequence that constitutively binds NFY/CBF and, 9 nucleotides away, a 3 '-end region (5 '-CCCTGTTGGCCATC- 3 ') that is equally important for ER stress-mediated induction of the gene. This sequence is the binding site for endogenous YY1 at the 5 '-CCCTGTTGG-3 ' part and for undefined factors at the CCATC 3 '-end. ATF6 alpha-YY1, but not XBP1, interacted with the ERGIC-53 regulatory region and activated ERGIC-53 ER stress response element-dependent transcription. A molecular model for the transcriptional regulation of the ERGIC-53 gene is proposed.	Univ Salerno, Dipartimento Sci Farmaceut, I-84034 Fisciano Salerno, Italy; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Michigan, Ctr Med, Dept Biol Chem & Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Salerno; University of Naples Federico II; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Remondelli, P (corresponding author), Univ Salerno, Dipartimento Sci Farmaceut, Via Ponte Don Melillo, I-84034 Fisciano Salerno, Italy.	premondelli@unisa.it	Remondelli, Paolo/X-7805-2019	REMONDELLI, Paolo/0000-0002-3698-3497	NHLBI NIH HHS [HL52173, HL057346] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057346, R01HL052173] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelrahim M, 2005, J BIOL CHEM, V280, P16508, DOI 10.1074/jbc.C500030200; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Baumeister P, 2005, MOL CELL BIOL, V25, P4529, DOI 10.1128/MCB.25.11.4529-4540.2005; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHAO CCK, 1992, NUCLEIC ACIDS RES, V20, P6481, DOI 10.1093/nar/20.24.6481; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hauri HP, 2000, J CELL SCI, V113, P587; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hori O, 2004, GENES CELLS, V9, P457, DOI 10.1111/j.1356-9597.2004.00735.x; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; Klumperman J, 1998, J CELL SCI, V111, P3411; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Nyfeler B, 2003, BIOCHEM BIOPH RES CO, V304, P599, DOI 10.1016/S0006-291X(03)00634-X; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Renna M, 2006, INT J BIOCHEM CELL B, V38, P2040, DOI 10.1016/j.biocel.2006.05.016; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Schulze A, 2005, J MOL BIOL, V354, P1021, DOI 10.1016/j.jmb.2005.10.020; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Spatuzza C, 2004, J BIOL CHEM, V279, P42535, DOI 10.1074/jbc.M401860200; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yamamoto K, 2004, J BIOCHEM, V136, P343, DOI 10.1093/jb/mvh122; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang B, 2005, J BIOL CHEM, V280, P25881, DOI 10.1074/jbc.M502160200; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	45	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22499	10.1074/jbc.M703778200	http://dx.doi.org/10.1074/jbc.M703778200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17535801	hybrid			2022-12-25	WOS:000248354200028
J	Whitaker, GM; Angoli, D; Nazzari, H; Shigemoto, R; Accili, EA				Whitaker, Gina M.; Angoli, Damiano; Nazzari, Hamed; Shigemoto, Ryuichi; Accili, Eric A.			HCN2 and HCN4 isoforms self-assemble and co-assemble with equal preference to form functional pacemaker channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; HYPERPOLARIZATION-ACTIVATED CHANNEL; SINOATRIAL NODE; I-F; BINDING DOMAIN; CATION CHANNEL; EXPRESSION; PROTEIN; HEART; HETEROMERIZATION	Hyperpolarization-activated cyclic nucleotide-modulated (HCN) "pacemaker" channel subunits are integral membrane proteins that assemble as tetramers to form channels in cardiac conduction tissue and nerve cells. Previous studies have suggested that the HCN2 and HCN4 channel isoforms physically interact when overexpressed in mammalian cells, but whether they are able to co-assemble and form functional channels remains unclear. The extent to which co-assembly occurs over self-assembly and whether HCN2-HCN4 heteromeric channels are formed in native tissue are not known. In this study, we show co-assembly of HCN2 and HCN4 in live Chinese hamster ovary cells using bioluminescence resonance energy transfer (BRET2), a novel approach for studying tetramerization of ion channel subunits. Together with results from electrophysiological and imaging approaches, the BRET2 data show that HCN2 and HCN4 subunits self-assemble and co-assemble with equal preference. We also demonstrate colocalization of HCN2 and HCN4 and a positive correlation of their intensities in the embryonic mouse heart using immunohistochemistry, as well as physical interactions between these isoforms in the rat thalamus by co-immunoprecipitation. Together, these data support the formation of HCN2-HCN4 heteromeric channels in native tissue.	Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; Natl Inst Physiol Sci, Div Cerebral Struct, Okazaki, Aichi 4448787, Japan	University of British Columbia; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Accili, EA (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	eaaccili@interchange.ubc.ca	Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				Abbas SY, 2006, NEUROSCIENCE, V141, P1811, DOI 10.1016/j.neuroscience.2006.05.034; Accili EA, 2002, NEWS PHYSIOL SCI, V17, P32, DOI 10.1152/physiologyonline.2002.17.1.32; Altomare C, 2003, J PHYSIOL-LONDON, V549, P347, DOI 10.1113/jphysiol.2002.027698; Altomare C, 2001, J GEN PHYSIOL, V117, P519, DOI 10.1085/jgp.117.6.519; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; DEKKER JP, 2006, J GEN PHYSIOL, V112, pE72; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DIFRANCESCO D, 2006, CIRCULATION; Ehrlich JR, 2004, J BIOL CHEM, V279, P1233, DOI 10.1074/jbc.M309087200; Er F, 2003, CIRCULATION, V107, P485, DOI 10.1161/01.CIR.0000045672.32920.CB; Garcia-Frigola C, 2003, GENE EXPR PATTERNS, V3, P777, DOI 10.1016/S1567-133X(03)00125-X; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Ghavanini AA, 2005, NEUROPHARMACOLOGY, V49, P338, DOI 10.1016/j.neuropharm.2005.03.013; Hebert TE, 2006, CELL BIOCHEM BIOPHYS, V45, P85, DOI 10.1385/CBB:45:1:85; HILLE B, 2001, IONIC CHANNELS EXCIT, P427; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Jackson HA, 2007, PHYSIOL GENOMICS, V29, P231, DOI 10.1152/physiolgenomics.00142.2006; Johnson JP, 2005, P NATL ACAD SCI USA, V102, P2742, DOI 10.1073/pnas.0408323102; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Michels G, 2005, CIRCULATION, V111, P399, DOI 10.1161/01.CIR.0000153799.65783.3A; Milligan G, 2005, FEBS J, V272, P2914, DOI 10.1111/j.1742-4658.2005.04731.x; Mommersteeg MTM, 2007, CIRC RES, V100, P354, DOI 10.1161/01.RES.0000258019.74591.b3; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Notomi T, 2004, J COMP NEUROL, V471, P241, DOI 10.1002/cne.11039; Proenza C, 2002, J BIOL CHEM, V277, P29634, DOI 10.1074/jbc.M200504200; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Stieber J, 2003, J BIOL CHEM, V278, P33672, DOI 10.1074/jbc.M305318200; Tran N, 2002, J BIOL CHEM, V277, P43588, DOI 10.1074/jbc.M208477200; Ulens C, 2003, NEURON, V40, P959, DOI 10.1016/S0896-6273(03)00753-0; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Yasui K, 2001, CIRC RES, V88, P536, DOI 10.1161/01.RES.88.5.536	40	42	50	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22900	22909		10.1074/jbc.M610978200	http://dx.doi.org/10.1074/jbc.M610978200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553794	hybrid			2022-12-25	WOS:000248354200067
J	Rachid, S; Krug, D; Weissman, KJ; Muller, R				Rachid, Shwan; Krug, Daniel; Weissman, Kira J.; Mueller, Rolf			Biosynthesis of (R)-beta-tyrosine and its incorporation into the highly cytotoxic chondramides produced by Chondromyces crocatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR ANTIBIOTIC C-1027; 4-METHYLIDENEIMIDAZOLE-5-ONE-CONTAINING TYROSINE AMINOMUTASE; NONRIBOSOMAL PEPTIDE-SYNTHESIS; ADENYLATION DOMAINS; COMBINATORIAL BIOSYNTHESIS; LYSINE 2,3-AMINOMUTASE; STRUCTURE ELUCIDATION; MODULAR STRUCTURE; SYNTHETASES; ANTIFUNGAL	The chondramides are mixed non-ribosomal peptide/polyketide secondary metabolites produced by the myxobacterium Chondromyces crocatus Cm c5, which exhibit strong cytotoxic activity. On the basis of their striking structural similarity to the marine depsipeptides jaspamides, the chondramides have been assumed to incorporate a (R)-beta-tyrosine moiety, an expectation we confirm here. Thus, the recent sequencing of the chondramide biosynthetic gene cluster provided the opportunity to probe the shared origin of this unusual beta-amino acid. We demonstrate here that (R)-beta-tyrosine is produced directly from L-tyrosine by the aminomutase CmdF. Along with the tyrosine aminomutase SgcC4 from the C-1027 enediyne pathway, this enzyme belongs to a novel family of tyrosine aminomutases related to the ammonium lyase family of enzymes but exhibits opposite facial selectivity for the hydroxycinnamate intermediate. We also show that the adenylation (A) domain in the chondramide pathway, which activates the beta-tyrosine building block, exhibits the required preference for (R)-beta-tyrosine, further arguing against alternative origins for the moiety in the chondramides. Comparison to the (S)-beta-tyrosine specific A domain SgcC1 should enhance our understanding of the structural and stereochemical determinants guiding amino acid selection by non-ribosomal peptide synthetase multienzymes.	Univ Saarland, Inst Pharmaceut Biotechnol, D-66041 Saarbrucken, Germany	Saarland University	Muller, R (corresponding author), Univ Saarland, Inst Pharmaceut Biotechnol, POB 151150, D-66041 Saarbrucken, Germany.	rom@mx.uni-saarland.de	Müller, Rolf/B-1559-2008	Müller, Rolf/0000-0002-1042-5665; Krug, Daniel/0000-0002-3664-1884; Rachid, Shwan/0000-0003-0834-5153				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Berner M, 2006, J BACTERIOL, V188, P2666, DOI 10.1128/JB.188.7.2666-2673.2006; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK RH, 2006, CHROMATOGRAPHIA, V387, P667; Calabrese JC, 2004, BIOCHEMISTRY-US, V43, P11403, DOI 10.1021/bi049053+; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; Chen DW, 2000, BIOCHEM J, V348, P539, DOI 10.1042/0264-6021:3480539; Chiba H, 1999, J ANTIBIOT, V52, P700, DOI 10.7164/antibiotics.52.700; Christenson SD, 2003, BIOCHEMISTRY-US, V42, P12708, DOI 10.1021/bi035223r; Christenson SD, 2003, J AM CHEM SOC, V125, P6062, DOI 10.1021/ja034609m; HU J, 1988, J ANTIBIOT, V41, P1575, DOI 10.7164/antibiotics.41.1575; Jansen R, 1996, LIEBIGS ANN, P285; Keller U, 2003, COMB CHEM HIGH T SCR, V6, P527; KOZARICH J W, 1988, Biofactors, V1, P123; KUNZE B, 1995, J ANTIBIOT, V48, P1262, DOI 10.7164/antibiotics.48.1262; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Mootz HD, 2002, CHEMBIOCHEM, V3, P490, DOI 10.1002/1439-7633(20020603)3:6<490::AID-CBIC490>3.0.CO;2-N; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; Poppe L., 2005, ANGEW CHEM, V117, P3734; Rachid S, 2006, CHEM BIOL, V13, P667, DOI 10.1016/j.chembiol.2006.06.002; Sambrook J, 2001, MOL CLONING LAB MANU; Sasse F, 1998, J NATL CANCER I, V90, P1559, DOI 10.1093/jnci/90.20.1559; Schwarzer D, 2003, NAT PROD REP, V20, P275, DOI 10.1039/b111145k; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; Thorson JS, 1999, BIOORG CHEM, V27, P172, DOI 10.1006/bioo.1998.1122; Van Lanen SG, 2005, J AM CHEM SOC, V127, P11594, DOI 10.1021/ja052871k; Van Lanen SG, 2006, J BIOL CHEM, V281, P29633, DOI 10.1074/jbc.M605887200; Walsh CT, 2002, CHEMBIOCHEM, V3, P125; ZABRISKIE TM, 1986, J AM CHEM SOC, V108, P3123, DOI 10.1021/ja00271a062	32	39	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21810	21817		10.1074/jbc.M703439200	http://dx.doi.org/10.1074/jbc.M703439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545150	hybrid			2022-12-25	WOS:000248196800028
J	Kreis, P; Thevenot, E; Rousseau, V; Boda, B; Muller, D; Barnier, JV				Kreis, Patricia; Thevenot, Emmanuel; Rousseau, Veronique; Boda, Bernadett; Muller, Dominique; Barnier, Jean-Vianney			The p21-activated kinase 3 implicated in mental retardation regulates spine morphogenesis through a Cdc42-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISSENSE MUTATION; ALZHEIMER-DISEASE; SYNAPSE FORMATION; ACTIVATED KINASE; DENDRITIC SPINES; CDC42; PAK3; PROTEIN; ACTIN; HIPPOCAMPUS	The p21-activated kinase 3 (PAK3) is one of the recently identified genes for which mutations lead to nonsyndromic mental retardation. PAK3 is implicated in dendritic spine morphogenesis and is a key regulator of synaptic functions. However, the underlying roles of PAK3 in these processes remain poorly understood. We report here that the three mutations R419X, A365E, and R67C, responsible for mental retardation have different effects on the biological functions of PAK3. The R419X and A365E mutations completely abrogate the kinase activity. The R67C mutation drastically decreases the binding of PAK3 to the small GTPase Cdc42 and impairs its subsequent activation by this GTPase. We also report that PAK3 binds significantly more Cdc42 than Rac1 and is selectively activated by endogenous Cdc42, suggesting that PAK3 is a specific effector of Cdc42. Interestingly, the expression of the three mutated proteins in hippocampal neurons affects spinogenesis differentially. Both kinase-dead mutants slightly decrease the number of spines but profoundly alter spine morphology, whereas expression of the R67C mutant drastically decreases spine density. These results demonstrate that the Cdc42/PAK3 is a key module in dendritic spine formation and synaptic plasticity.	Inst Neurobiol Alfred Fessard, CNRS, FRC 2118, Neurobiol Cellulaire & Mol Lab,UPR 9040, F-91198 Gif Sur Yvette, France; Centre Med Univ, Dept Basic Neurosci, CH-1211 Geneva 4, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Geneva	Barnier, JV (corresponding author), Inst Neurobiol Alfred Fessard, CNRS, FRC 2118, Neurobiol Cellulaire & Mol Lab,UPR 9040, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	barnier@nbcm.cnrs-gif.fr	Kreis, Patricia/GYJ-3521-2022	Boda, Bernadett/0000-0002-4563-4088; Kreis, Patricia/0000-0002-1702-4805				Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bienvenu T, 2000, AM J MED GENET, V93, P294, DOI 10.1002/1096-8628(20000814)93:4<294::AID-AJMG8>3.0.CO;2-F; Boda B, 2004, J NEUROSCI, V24, P10816, DOI 10.1523/JNEUROSCI.2931-04.2004; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Chelly J, 2001, NAT REV GENET, V2, P669, DOI 10.1038/35088558; Choi J, 2005, J NEUROSCI, V25, P869, DOI 10.1523/JNEUROSCI.3212-04.2005; Czuchra A, 2005, MOL BIOL CELL, V16, P4473, DOI 10.1091/mbc.E05-01-0061; Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Gedeon AK, 2003, AM J MED GENET A, V120A, P509, DOI 10.1002/ajmg.a.20131; Goslin K., 1998, CULTURING NERVE CELL, P339; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Hanks SK, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-111; Hayashi ML, 2004, NEURON, V42, P773, DOI 10.1016/j.neuron.2004.05.003; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Irie F, 2002, NAT NEUROSCI, V5, P1117, DOI 10.1038/nn964; Johnson OL, 2006, BRAIN RES, V1113, P1, DOI 10.1016/j.brainres.2006.06.116; Jung JH, 2005, J BIOL CHEM, V280, P40025, DOI 10.1074/jbc.M509075200; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; McPhie DL, 2003, J NEUROSCI, V23, P6914; Meng JS, 2005, J NEUROSCI, V25, P6641, DOI 10.1523/JNEUROSCI.0028-05.2005; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Ong WY, 2002, EXP BRAIN RES, V144, P189, DOI 10.1007/s00221-002-1016-x; Ortutay C, 2005, HUM MUTAT, V25, P435, DOI 10.1002/humu.20166; Poea-Guyon S, 2006, J BIOL CHEM, V281, P17164, DOI 10.1074/jbc.M600927200; PURPURA DP, 1974, SCIENCE, V186, P1126, DOI 10.1126/science.186.4169.1126; Rex CS, 2007, J NEUROSCI, V27, P3017, DOI 10.1523/JNEUROSCI.4037-06.2007; Rousseau V, 2003, J BIOL CHEM, V278, P3912, DOI 10.1074/jbc.M207251200; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Tada T, 2006, CURR OPIN NEUROBIOL, V16, P95, DOI 10.1016/j.conb.2005.12.001; van Galen EJM, 2005, PROG BRAIN RES, V147, P295, DOI 10.1016/S0079-6123(04)47022-8; Yuste R, 2004, NAT REV NEUROSCI, V5, P24, DOI 10.1038/nrn1300; Zhang HY, 2005, J NEUROSCI, V25, P3379, DOI 10.1523/JNEUROSCI.3553-04.2005; Zhao LX, 2006, NAT NEUROSCI, V9, P234, DOI 10.1038/nn1630; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	43	77	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21497	21506		10.1074/jbc.M703298200	http://dx.doi.org/10.1074/jbc.M703298200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17537723	hybrid			2022-12-25	WOS:000248047500077
J	Figuerola, J				Figuerola, Jordi			Climate and Dispersal: Black-Winged Stilts Disperse Further in Dry Springs	PLOS ONE			English	Article								Climate affects the abundance and distribution of many species of wildlife. Nevertheless, the potential effects of climate on dispersive behaviour remain unstudied. Here, I combine data from (i) a long-term Black-winged Stilt (Himantopus himantopus) monitoring program, (ii) a capture-recapture marking program in Donana, and (iii) reports from the Rare Birds Committee in the United Kingdom to analyse at different geographical scales the relationship between climate, survival, philopatry, and dispersive behaviour. Black-winged Stilt populations varied in size in consonance with changes in both the North Atlantic Oscillation (NAO) and local rainfall during the breeding season. Changes in population size are related to changes in philopatry and increases in dispersal beyond the traditional range of the species. The results indicate that climatic conditions influence the dispersive behaviour of individual birds, explaining rapid changes in the local population of this species breeding in unstable Mediterranean wetlands.	CSIC, Estac Biol Donana, Dept Wetland Ecol, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD)	Figuerola, J (corresponding author), CSIC, Estac Biol Donana, Dept Wetland Ecol, E-41080 Seville, Spain.	jordi@ebd.csic.es	Figuerola, Jordi/B-7917-2008	Figuerola, Jordi/0000-0002-4664-9011	Las aves acuaticas de Donana y el cultivo del arroz: la interaccion entre la agricultura y la conservacion de las zonas humedas; Spanish Ministry of Science and Technology	Las aves acuaticas de Donana y el cultivo del arroz: la interaccion entre la agricultura y la conservacion de las zonas humedas; Spanish Ministry of Science and Technology(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	The Junta de Andalucia funded this study via the project contract 'Las aves acuaticas de Donana y el cultivo del arroz: la interaccion entre la agricultura y la conservacion de las zonas humedas'. The Spanish Ministry of Science and Technology provides support for my research with a Ramon y Cajal contract for young researchers.	ANDERSON DR, 1994, ECOLOGY, V75, P1780, DOI 10.2307/1939637; Araujo MB, 2007, TRENDS ECOL EVOL, V22, P42, DOI 10.1016/j.tree.2006.09.010; Blums P, 2002, J ANIM ECOL, V71, P438, DOI 10.1046/j.1365-2656.2002.00613.x; Burnham K. P., 1998, MODEL SELECTION INFE; BURNHAM KP, 1987, AM FISH SOC MONOGR, V5; COOCH E, 2004, PROGRAM MARK GENTLE; Danchin E, 2002, BEHAV ECOL SOCIOBIOL, V51, P153, DOI 10.1007/s00265-001-0423-5; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; IPCC, 2002, CLIMATE CHANGE BIODI; IPCC, 2001, ADV CLIM CHANG RES; Kendall WL, 1997, ECOLOGY, V78, P563; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; Moller AP, 2006, GLOBAL CHANGE BIOL, V12, P2005, DOI 10.1111/j.1365-2486.2006.01216.x; Saether BE, 2004, ADV ECOL RES, V35, P185, DOI 10.1016/S0065-2504(04)35009-9; Sibley CG, 1990, DISTRIBUTION TAXONOM; Skalski J.R., 1993, P9; Stenseth NC, 2002, SCIENCE, V297, P1292, DOI 10.1126/science.1071281; THORUP O, 2006, BREEDING WATERS EURO; Travis JMJ, 2002, EVOL ECOL RES, V4, P1119; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; Weatherhead PJ, 2005, OECOLOGIA, V144, P168, DOI 10.1007/s00442-005-0009-4	21	23	32	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e539	10.1371/journal.pone.0000539	http://dx.doi.org/10.1371/journal.pone.0000539			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579713	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451700007
J	Robida, MD; Rahn, A; Singh, R				Robida, Mark D.; Rahn, Andrew; Singh, Ravinder			Genome-Wide Identification of Alternatively Spliced mRNA Targets of Specific RNA-Binding Proteins	PLOS ONE			English	Article								Background. Alternative splicing plays an important role in generating molecular and functional diversity in multi-cellular organisms. RNA binding proteins play crucial roles in modulating splice site choice. The majority of known binding sites for regulatory proteins are short, degenerate consensus sequences that occur frequently throughout the genome. This poses an important challenge to distinguish between functionally relevant sequences and a vast array of those occurring by chance. Methodology/Principal Findings. Here we have used a computational approach that combines a series of biological constraints to identify uridine-rich sequence motifs that are present within relevant biological contexts and thus are potential targets of the Drosophila master sex-switch protein Sex-lethal (SXL). This strategy led to the identification of one novel target. Moreover, our systematic analysis provides a starting point for the molecular and functional characterization of an additional target, which is dependent on SXL activity, either directly or indirectly, for regulation in a germline-specific manner. Conclusions/Significance. This approach has successfully identified previously known, new, and potential SXL targets. Our analysis suggests that only a subset of potential SXL sites are regulated by SXL. Finally, this approach should be directly relevant to the large majority of splicing regulatory proteins for which bonafide targets are unknown.	[Robida, Mark D.; Rahn, Andrew; Singh, Ravinder] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Singh, R (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	rsingh@colorado.edu			National Institutes of Health; American Cancer Society; Butcher Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Butcher Foundation	National Institutes of Health, the American Cancer Society, and the Butcher Foundation	Abaza I, 2006, GENE DEV, V20, P380, DOI 10.1101/gad.371906; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blanchette M, 2005, GENE DEV, V19, P1306, DOI 10.1101/gad.1314205; Bopp D, 1999, DEVELOPMENT, V126, P5785; Burge CB, 1999, RNA WORLD, P525; Deng WM, 1999, J CELL SCI, V112, P3677; Doberstein SK, 1997, J CELL BIOL, V136, P1249, DOI 10.1083/jcb.136.6.1249; DORER DR, 1990, NUCLEIC ACIDS RES, V18, P5489, DOI 10.1093/nar/18.18.5489; Duncan K, 2006, GENE DEV, V20, P368, DOI 10.1101/gad.371406; Eisen A, 1998, BBA-GENE STRUCT EXPR, V1397, P131, DOI 10.1016/S0167-4781(97)00213-3; Forch P, 2003, Prog Mol Subcell Biol, V31, P127; Fujii S, 2002, EMBO J, V21, P5353, DOI 10.1093/emboj/cdf556; FYRBERG EA, 1980, CELL, V19, P365, DOI 10.1016/0092-8674(80)90511-5; Gawande B, 2006, EMBO J, V25, P1263, DOI 10.1038/sj.emboj.7601022; Hager JH, 1997, DEVELOPMENT, V124, P5033; Hamady M, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-1; HERTZ GZ, 1990, COMPUT APPL BIOSCI, V6, P81; Hicks JL, 1999, MOL BIOL CELL, V10, P4341, DOI 10.1091/mbc.10.12.4341; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kabat JL, 2006, PLOS COMPUT BIOL, V2, P734, DOI 10.1371/journal.pcbi.0020086; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; Lallena MJ, 2002, CELL, V109, P285, DOI 10.1016/S0092-8674(02)00730-4; Lasko P, 2000, J CELL BIOL, V150, pF51, DOI 10.1083/jcb.150.2.F51; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Manak JR, 2006, NAT GENET, V38, P1151, DOI 10.1038/ng1875; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Nagengast AA, 2003, DEVELOPMENT, V130, P463, DOI 10.1242/dev.00274; Nilsen TW, 2002, MOL CELL, V9, P8, DOI 10.1016/S1097-2765(02)00430-6; Park JW, 2004, P NATL ACAD SCI USA, V101, P15974, DOI 10.1073/pnas.0407004101; Robida MD, 2003, EMBO J, V22, P2924, DOI 10.1093/emboj/cdg301; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SALZ HK, 1987, GENETICS, V117, P221; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Schroter RH, 2004, DEVELOPMENT, V131, P4501, DOI 10.1242/dev.01309; SCHUPBACH T, 1985, GENETICS, V109, P529; Schutt C, 2000, DEVELOPMENT, V127, P667; Singh R, 2000, RNA, V6, P901, DOI 10.1017/S1355838200000376; Singh R, 2005, NAT STRUCT MOL BIOL, V12, P645, DOI 10.1038/nsmb961; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Singh R, 2006, CURR GENOMICS, V7, P97, DOI 10.2174/138920206777304669; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STEINMANNZWICKY M, 1989, CELL, V57, P157, DOI 10.1016/0092-8674(89)90181-5; TAYLOR BJ, 1992, GENETICS, V132, P179; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VALCARCEL J, 1995, MECH REGULATED PREMR	50	16	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e520	10.1371/journal.pone.0000520	http://dx.doi.org/10.1371/journal.pone.0000520			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565373	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451600008
J	Marsche, G; Weigle, B; Sattler, W; Malle, E				Marsche, Gunther; Weigle, Bernd; Sattler, Wolfgang; Malle, Ernst			Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein	FASEB JOURNAL			English	Article						myeloperoxidase; inflammation; oxidized LDL; foam cells	GLYCATION END-PRODUCTS; MYELOPEROXIDASE-CATALYZED OXIDATION; HUMAN ATHEROSCLEROTIC LESIONS; FOAM CELL-FORMATION; E-NULL MICE; B TYPE-I; MODIFIED PROTEINS; OXIDIZED PHOSPHOLIPIDS; ENDOTHELIAL-CELLS; DIABETIC-NEPHROPATHY	Engagement of the receptor for advanced glycation end products (RAGE) by its signal transduction ligands evokes inflammatory cell infiltration and activation of the vessel wall. However, soluble RAGE (sRAGE), the truncated form spanning the extracellular binding domain of RAGE, has potent anti-inflammatory properties by acting as a decoy for RAGE ligands. We now show that sRAGE binds with high affinity to atherogenic low-density lipoprotein (LDL) modified by hypochlorous acid (HOCl), the major oxidant generated by the myeloperoxidase-H2O2-chloride system of phagocytes activated during inflammation. We further demonstrate that sRAGE can be co-precipitated with HOCl-LDL from spiked serum. To determine the functional significance of sRAGE binding to HOCl-LDL, cell association studies with macrophages were performed. sRAGE effectively inhibited cellular uptake of HOCl-LDL and subsequent lipid accumulation. Using Chinese hamster ovary cells over-expressing class B scavenger receptor CD36 or SR-BI, two preferential scavenger receptors for HOCl-LDL, we demonstrate that sRAGE only interferes with CD36-mediated uptake of HOCl-LDL. The present findings indicate that sRAGE acts as a sink for HOCl-LDL, which is abundantly present in human atherosclerotic lesions. We propose that sRAGE represents a physiological antagonist that interferes with scavenger receptor-mediated cholesterol accumulation and foam cell formation of macrophages.	Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, A-8010 Graz, Austria; Eucodis GmbH, Vienna, Austria	Medical University of Graz	Malle, E (corresponding author), Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, Harrachgasse 21, A-8010 Graz, Austria.	ernst.malle@meduni-graz.at	Malle, Ernst/D-3071-2013	Marsche, Gunther/0000-0002-2422-5381	Austrian Science Fund FWF [F 3007, P 17013, P 19074] Funding Source: Medline; Austrian Science Fund (FWF) [F 3007] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; Capeillere-Blandin C, 2004, BBA-MOL BASIS DIS, V1689, P91, DOI 10.1016/j.bbadis.2004.02.008; Carr AC, 2000, FEBS LETT, V487, P176, DOI 10.1016/S0014-5793(00)02227-4; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Cuccurullo C, 2006, ARTERIOSCL THROM VAS, V26, P2716, DOI 10.1161/01.ATV.0000249630.02085.12; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Geroldi D, 2006, CURR MED CHEM, V13, P1971, DOI 10.2174/092986706777585013; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Han JH, 1999, J LIPID RES, V40, P830; Hartwich J, 2002, PLATELETS, V13, P141, DOI 10.1080/09533710022149368; Hasegawa T, 2005, AM J PHYSIOL-GASTR L, V289, pG760, DOI 10.1152/ajpgi.00141.2005; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hirano K, 1999, CIRC RES, V85, P108; Hsieh HL, 2004, BIOCHEM BIOPH RES CO, V316, P949, DOI 10.1016/j.bbrc.2004.02.135; Huh HY, 1996, BLOOD, V87, P2020; Kislinger T, 2001, ARTERIOSCL THROM VAS, V21, P905, DOI 10.1161/01.ATV.21.6.905; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Liu SX, 2006, ARTERIOSCL THROM VAS, V26, P1156, DOI 10.1161/01.ATV.0000214960.85469.68; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; Malle E, 2003, KIDNEY INT, V64, P1956, DOI 10.1046/j.1523-1755.2003.00336.x; Malle E, 2006, BBA-MOL CELL BIOL L, V1761, P392, DOI 10.1016/j.bbalip.2006.03.024; Marsche G, 2003, J BIOL CHEM, V278, P47562, DOI 10.1074/jbc.M308428200; Marsche G, 2007, FASEB J, V21, P1145, DOI 10.1096/fj.06-7439com; Naka Y, 2004, ARTERIOSCL THROM VAS, V24, P1342, DOI 10.1161/01.ATV.0000133191.71196.90; Opper C, 1998, PLATELETS, V9, P339, DOI 10.1080/09537109876582; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Rahaman SO, 2006, CELL METAB, V4, P211, DOI 10.1016/j.cmet.2006.06.007; Ramasamy R, 2005, TRENDS CARDIOVAS MED, V15, P237, DOI 10.1016/j.tcm.2005.08.003; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; TAKATA K, 1988, J BIOL CHEM, V263, P14819; Tiruppathi C, 2004, P NATL ACAD SCI USA, V101, P7699, DOI 10.1073/pnas.0401712101; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Wendt TM, 2003, AM J PATHOL, V162, P1123, DOI 10.1016/S0002-9440(10)63909-0; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	47	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3075	3082		10.1096/fj.07-8316com	http://dx.doi.org/10.1096/fj.07-8316com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17536039	Green Accepted			2022-12-25	WOS:000249781600009
J	Borland, G; Edkins, AL; Acharya, M; Matheson, J; White, LJ; Allen, JM; Bonnefoy, JY; Ozanne, BW; Cushley, W				Borland, Gillian; Edkins, Adrienne L.; Acharya, Mridu; Matheson, Johanne; White, Lindsey J.; Allen, Janet M.; Bonnefoy, Jean-Yves; Ozanne, Bradford W.; Cushley, William			alpha v beta 5 integrin sustains growth of human pre-B cells through an RGD-independent interaction with a basic domain of the CD23 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOBLASTIC-LEUKEMIA CELLS; AFFINITY IGE RECEPTOR; BONE-MARROW STROMA; FC-EPSILON-RII; CRYSTAL-STRUCTURE; BINDING-SITE; INTEGRIN ALPHA-V-BETA-3; EXTRACELLULAR SEGMENT; SOLUBLE CD23; VITRONECTIN	CD23 is a type II transmembrane glycoprotein synthesized by hematopoietic cells that has biological activity in both membrane-bound and freely soluble forms, acting via a number of receptors, including integrins. We demonstrate here that soluble CD23 (sCD23) sustains growth of human B cell precursors via an RGD-independent interaction with the alpha v beta 5 integrin. The integrin recognizes a tripeptide motif in a small disulfide-bonded loop at the N terminus of the lectin head region of CD23, centered around Arg(172), Lys(173), and Cys(174) (RKC). This RKC motif is present in all forms of sCD23 with cytokine-like activity, and cytokine activity is independent of the lectin head, an "inverse RGD" motif, and the CD21 and IgE binding sites. RKC-containing peptides derived from this region of CD23 bind alpha v beta 5 and are biologically active. The binding and activity of these peptides is unaffected by inclusion of a short peptide containing the classic RGD sequence recognized by integrins, and, in far-Western analyses, RKC-containing peptides bind to the beta subunit of the alpha v beta 5 integrin. The interaction between alpha v beta 5 and sCD23 indicates that integrins deliver to cells important signals initiated by soluble ligands without the requirement for interactions with RGD motifs in their common ligands. This mode of integrin signaling may not be restricted to alpha v beta 5.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Canc Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Coll Dublin, Conway Inst, Dublin 4, Ireland; Transgene SA, F-67028 Strasbourg, France	University of Glasgow; Beatson Institute; University College Dublin; Transgene SA	Cushley, W (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Univ Ave, Glasgow G12 8QQ, Lanark, Scotland.	W.Cushley@bio.gla.ac.uk	Edkins, Adrienne L/C-8704-2012	Edkins, Adrienne L/0000-0002-3615-6651	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bailey S, 1998, BIOORG MED CHEM LETT, V8, P23, DOI 10.1016/S0960-894X(97)10148-2; Bonnefoy J Y, 1997, Int Rev Immunol, V16, P113, DOI 10.3109/08830189709045705; BONNEFOY JY, 1993, EUR J IMMUNOL, V23, P969; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; Fourcade C, 1992, Eur Cytokine Netw, V3, P539; FUJIWARA H, 1994, P NATL ACAD SCI USA, V91, P6835, DOI 10.1073/pnas.91.15.6835; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756-3282(00)00424-5; Hermann P, 1999, J CELL BIOL, V144, P767, DOI 10.1083/jcb.144.4.767; Hewson J, 1996, BRIT J HAEMATOL, V92, P77, DOI 10.1046/j.1365-2141.1996.00291.x; Hibbert RG, 2005, J EXP MED, V202, P751, DOI 10.1084/jem.20050811; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; Kijimoto-Ochiai S, 2000, BIOCHEM BIOPH RES CO, V267, P686, DOI 10.1006/bbrc.1999.2021; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7; Lin CG, 2005, J BIOL CHEM, V280, P8229, DOI 10.1074/jbc.M404903200; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MAKRYNIKOLA V, 1994, LEUKEMIA, V8, P1734; MAKRYNIKOLA V, 1993, LEUKEMIA, V7, P86; Marolewski AE, 1998, BIOCHEM J, V333, P573, DOI 10.1042/bj3330573; Marshall JF, 1996, SEMIN CANCER BIOL, V7, P129, DOI 10.1006/scbi.1996.0018; MOSSALAYI MD, 1990, J EXP MED, V171, P959, DOI 10.1084/jem.171.3.959; MOSSALAYI MD, 1992, EMBO J, V11, P4323, DOI 10.1002/j.1460-2075.1992.tb05531.x; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Podolnikova NP, 2005, BIOCHEMISTRY-US, V44, P16920, DOI 10.1021/bi051581d; Schober JM, 2003, J BIOL CHEM, V278, P25808, DOI 10.1074/jbc.M301534200; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; SMITH RG, 1984, CANCER, V54, P471, DOI 10.1002/1097-0142(19840801)54:3<471::AID-CNCR2820540315>3.0.CO;2-4; Stuiver I, 1995, HYBRIDOMA, V14, P545, DOI 10.1089/hyb.1995.14.545; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; White LJ, 1997, BLOOD, V90, P234; Wu PL, 2006, J BIOL CHEM, V281, P7937, DOI 10.1074/jbc.M513035200; Wurzburg BA, 2006, STRUCTURE, V14, P1049, DOI 10.1016/j.str.2006.03.017; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0	42	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27315	27326		10.1074/jbc.M609335200	http://dx.doi.org/10.1074/jbc.M609335200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17540777	hybrid			2022-12-25	WOS:000249304900073
J	Lassen, N; Bateman, JB; Estey, T; Kuszak, JR; Nees, DW; Piatigorsky, J; Duester, G; Day, BJ; Huang, J; Hines, LM; Vasiliou, V				Lassen, Natalie; Bateman, J. Bronwyn; Estey, Tia; Kuszak, Jer R.; Nees, David W.; Piatigorsky, Joram; Duester, Gregg; Day, Brian J.; Huang, Jie; Hines, Lisa M.; Vasiliou, Vasilis			Multiple and additive functions of ALDH3A1 and ALDH1A1 - Cataract phenotype and ocular oxidative damage in Aldh3a1(-/-)/Aldh1a1(-/-) knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL ALDEHYDE DEHYDROGENASE; ULTRAVIOLET-LIGHT; OXIDIZED PROTEINS; LENS CRYSTALLINS; EPITHELIAL-CELLS; STRESS; RECRUITMENT; ENZYMES; DEGRADATION; SENSITIVITY	ALDH3A1 ( aldehyde dehydrogenase 3A1) is abundant in the mouse cornea but undetectable in the lens, and ALDH1A1 is present at lower ( catalytic) levels in the cornea and lens. To test the hypothesis that ALDH3A1 and ALDH1A1 protect the anterior segment of the eye against environmentally induced oxidative damage, Aldh1a1(-/ -)/Aldh3a1( -/ -) double knock-out and Aldh1a1(-/-) and Aldh3a1(-/-) single knock-out mice were evaluated for biochemical changes and cataract formation ( lens opacification). The Aldh1a1/ Aldh3a1- and Aldh3a1- null mice develop cataracts in the anterior and posterior subcapsular regions as well as punctate opacities in the cortex by 1 month of age. The Aldh1a1-null mice also develop cataracts later in life ( 6 - 9 months of age). One-to three-month-old Aldh-null mice exposed to UVB exhibited accelerated anterior lens subcapsular opacification, which was more pronounced in Aldh3a1(-/-) and Aldh3a1(-/-)/ Aldh1a1(-/-) mice compared with Aldh1a1(-/-) and wild type animals. Cataract formation was associated with decreased proteasomal activity, increased protein oxidation, increased GSH levels, and increased levels of 4-hydroxy-2-nonenal- and malondialdehyde-protein adducts. In conclusion, these findings support the hypothesis that corneal ALDH3A1 and lens ALDH1A1 protect the eye against cataract formation via nonenzymatic ( light filtering) and enzymatic ( detoxification) functions.	Univ Colorado, Sch Pharm, Dept Pharmaceut Sci,Rocky Mt Lions Eye Inst, Mol Toxicol & Environm Hlth Sci Program,Childrens, Denver, CO 80262 USA; Univ Colorado, Sch Pharm, Childrens Hosp, Rocky Mt Lions Eye Inst,Dept Ophthalmol & Pediat, Denver, CO 80262 USA; Rush Univ, Ctr Med, Dept Ophthalm & Pathol, Chicago, IL 60612 USA; NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Burnham Inst, OncoDev Biol Program, La Jolla, CA 92037 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Dept Biol, Colorado Springs, CO 80933 USA	University of Colorado System; University of Colorado Denver; Children's Hospital Colorado; University of Colorado System; University of Colorado Denver; Rush University; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Sanford Burnham Prebys Medical Discovery Institute; National Jewish Health; University of Colorado System; University of Colorado at Colorado Springs	Vasiliou, V (corresponding author), Univ Colorado, Sch Pharm, Dept Pharmaceut Sci,Rocky Mt Lions Eye Inst, Mol Toxicol & Environm Hlth Sci Program,Childrens, Denver, CO 80262 USA.	vasilis.vasiliou@uchsc.edu		Duester, Gregg/0000-0003-4335-3650; vasiliou, vasilis/0000-0003-2552-3118	NATIONAL EYE INSTITUTE [Z01EY000126, R01EY008282, R29EY011490, R01EY013969, R01EY011490] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY013969-05A2, EY13969, R29 EY011490, R01 EY013969, EY08282, R01 EY011490, R01 EY008282, EY11490] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; Alizadeh A, 2004, INVEST OPHTH VIS SCI, V45, P884, DOI 10.1167/iovs.03-0677; Ansari NH, 1996, BIOCHEM MOL MED, V58, P25, DOI 10.1006/bmme.1996.0028; Ates NA, 2004, EYE, V18, P785, DOI 10.1038/sj.eye.6700718; Atherton SJ, 1999, PHOTOCHEM PHOTOBIOL, V70, P823, DOI 10.1111/j.1751-1097.1999.tb08289.x; Buddi R, 2002, J HISTOCHEM CYTOCHEM, V50, P341, DOI 10.1177/002215540205000306; Bulteau AL, 2002, FREE RADICAL BIO MED, V32, P1157, DOI 10.1016/S0891-5849(02)00816-X; Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037; CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658; Dalton TP, 2004, FREE RADICAL BIO MED, V37, P1511, DOI 10.1016/j.freeradbiomed.2004.06.040; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Day BJ, 2004, INFECT IMMUN, V72, P2045, DOI 10.1128/IAI.72.4.2045-2051.2004; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; DOWNES JE, 1994, CORNEA, V13, P67, DOI 10.1097/00003226-199401000-00011; DRENCKHAHN D, 1977, EXP EYE RES, V24, P621, DOI 10.1016/0014-4835(77)90120-8; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Estey T, 2007, EXP EYE RES, V84, P3, DOI 10.1016/j.exer.2006.04.010; Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; Ganea E, 2006, CURR EYE RES, V31, P1, DOI 10.1080/02713680500477347; Gerido DA, 2003, INVEST OPHTH VIS SCI, V44, P2669, DOI 10.1167/iovs.02-1311; Graham C, 1996, J BIOL CHEM, V271, P15623, DOI 10.1074/jbc.271.26.15623; Graves PR, 2002, MOL PHARMACOL, V62, P1364, DOI 10.1124/mol.62.6.1364; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Iles KE, 2005, FREE RADICAL BIO MED, V38, P547, DOI 10.1016/j.freeradbiomed.2004.11.012; King G, 1998, J EXP ZOOL, V282, P12; Kirkman HN, 1999, J BIOL CHEM, V274, P13908, DOI 10.1074/jbc.274.20.13908; Kirsch M, 2001, FASEB J, V15, P1569, DOI 10.1096/fj.00-0823hyp; Lassen N, 2006, FREE RADICAL BIO MED, V41, P1459, DOI 10.1016/j.freeradbiomed.2006.08.009; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Lou MF, 2003, PROG RETIN EYE RES, V22, P657, DOI 10.1016/S1350-9462(03)00050-8; Manzer R, 2003, DNA CELL BIOL, V22, P329, DOI 10.1089/104454903322216671; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MITCHELL J, 1995, CORNEA, V14, P266, DOI 10.1097/00003226-199505000-00007; MONTGOMERY MK, 1992, J BIOL CHEM, V267, P20999; Nees DW, 2003, INVEST OPHTH VIS SCI, V44, P3339, DOI 10.1167/iovs.02-1161; Nees DW, 2002, MOL CELL BIOL, V22, P849, DOI 10.1128/MCB.22.3.849-855.2002; Pappa A, 2003, BIOCHEM J, V376, P615, DOI 10.1042/BJ20030810; Pappa A, 2003, FREE RADICAL BIO MED, V34, P1178, DOI 10.1016/S0891-5849(03)00070-4; Pappa A, 2001, CHEM-BIOL INTERACT, V130, P181, DOI 10.1016/S0009-2797(00)00233-7; Piatigorsky J, 2000, J OCUL PHARMACOL TH, V16, P173, DOI 10.1089/jop.2000.16.173; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; Piatigorsky J, 2000, J BIOL CHEM, V275, P41064, DOI 10.1074/jbc.M005625200; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; Ringvold A, 1998, ACTA OPHTHALMOL SCAN, V76, P149, DOI 10.1034/j.1600-0420.1998.760205.x; Ringvold A, 1998, INVEST OPHTH VIS SCI, V39, P2774; Shiao T, 1999, PHARMACOGENETICS, V9, P145; Shinohara T, 2000, J OCUL PHARMACOL TH, V16, P181, DOI 10.1089/jop.2000.16.181; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; Spector A, 2000, J OCUL PHARMACOL TH, V16, P193, DOI 10.1089/jop.2000.16.193; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; Truscott RJW, 2000, OPHTHALMIC RES, V32, P185, DOI 10.1159/000055612; van Haaften RIM, 2003, DRUG METAB REV, V35, P215, DOI 10.1081/DMR-120024086; Vasiliou VK, 2004, INVEST OPHTH VIS SCI, V45, pU314; Verdejo C, 1999, EYE, V13, P183, DOI 10.1038/eye.1999.48; Xu ZP, 2002, MOL CELL BIOL, V22, P6142, DOI 10.1128/MCB.22.17.6142-6147.2002; Yang Y, 2002, J BIOL CHEM, V277, P49446, DOI 10.1074/jbc.M209372200; ZINOVIEVA RD, 1993, J BIOL CHEM, V268, P11449	61	128	131	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25668	25676		10.1074/jbc.M702076200	http://dx.doi.org/10.1074/jbc.M702076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17567582	Green Accepted, hybrid			2022-12-25	WOS:000249014100054
J	Dunford, AJ; McLean, KJ; Sabri, M; Seward, HE; Heyes, DJ; Scrutton, NS; Munro, AW				Dunford, Adrian J.; McLean, Kirsty J.; Sabri, Muna; Seward, Harriet E.; Heyes, Derren J.; Scrutton, Nigel S.; Munro, Andrew W.			Rapid P450 heme iron reduction by laser photoexcitation of Mycobacterium tuberculosis CYP121 and CYP51B1 - Analysis of CO complexation reactions and reversibility of the P450/P420 equilibrium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL 14-ALPHA-DEMETHYLASE; AZOLE ANTIFUNGALS; CRYSTAL-STRUCTURE; CYTOCHROME-P450; BINDING; PURIFICATION; REVEALS; LIGAND; AGENTS; NADH	We demonstrate that photoexcitation of NAD(P) H reduces heme iron of Mycobacterium tuberculosis P450s CYP121 and CYP51B1 on the microsecond time scale. Rates of formation for the ferrous-carbonmonoxy (Fe-II-CO) complex were determined across a range of coenzyme/CO concentrations. CYP121 reaction transients were biphasic. A hyperbolic dependence on CO concentration was observed, consistent with the presence of a CO binding site in ferric CYP121. CYP51B1 absorption transients for Fe-II-CO complex formation were monophasic. The reaction rate was second order with respect to [CO], suggesting the absence of a CO-binding site in ferric CYP51B1. In the absence of CO, heme iron reduction by photoexcited NAD(P)H is fast (similar to 10,000-11,000 s(-1)) with both P450s. For CYP121, transients revealed initial production of the thiolate-coordinated (P450) complex (absorbance maximum at 448 nm), followed by a slower phase reporting partial conversion to the thiol-coordinated P420 species (at 420 nm). The slow phase amplitude increased at lower pH values, consistent with heme cysteinate protonation underlying the transition. Thus, CO binding occurs to the thiolate-coordinated ferrous form prior to cysteinate protonation. For CYP51B1, slow conversions of both the ferrous/Fe-II-CO forms to species with spectral maxima at 423/421.5 nm occurred following photoexcitation in the absence/presence of CO. This reflected conversion from ferrous thiolate-to thiol-coordinated forms in both cases, indicating instability of the thiolate-coordinated ferrous CYP51B1. CYP121 Fe-II-CO complex pH titrations revealed reversible spectral transitions between P450 and P420 forms. Our data provide strong evidence for P420 formation linked to reversible heme thiolate protonation, and demonstrate key differences in heme chemistry and CO binding for CYP121 and CYP51B1.	Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Biocentre, Manchester M1 7DN, Lancs, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England	University of Manchester; University of Leicester	Munro, AW (corresponding author), Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Biocentre, 131 Princess St, Manchester M1 7DN, Lancs, England.	Andrew.Munro@manchester.ac.uk	McLean, Kirsty J/GXI-2853-2022; Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X; Heyes, Derren/0000-0002-7453-1571; McLean, Kirsty/0000-0002-7193-5044	BBSRC [BB/F002521/1, BB/D01963X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D01963X/1, BB/F002521/1, C19757/2] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ahmad Z, 2006, FEMS MICROBIOL LETT, V261, P181, DOI 10.1111/j.1574-6968.2006.00350.x; Aoyama Y, 1998, J BIOCHEM-TOKYO, V124, P694; Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937; Cargill R., 1990, CARBON MONOXIDE, V43, P5; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CZOCHRALSKA B, 1983, CHEM PHYS LETT, V101, P297, DOI 10.1016/0009-2614(83)87016-X; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; Estabrook RW, 2003, DRUG METAB DISPOS, V31, P1461, DOI 10.1124/dmd.31.12.1461; Girvan HM, 2007, J AM CHEM SOC, V129, P6647, DOI 10.1021/ja071355m; Guardiola-Diaz HM, 2001, BIOCHEM PHARMACOL, V61, P1463, DOI 10.1016/S0006-2952(01)00571-8; Jackson CJ, 2000, FEMS MICROBIOL LETT, V192, P159, DOI 10.1111/j.1574-6968.2000.tb09375.x; Lepesheva GI, 2004, MOL CELL ENDOCRINOL, V215, P165, DOI 10.1016/j.mce.2003.11.016; Leys D, 2003, J BIOL CHEM, V278, P5141, DOI 10.1074/jbc.M209928200; Matsuura K, 2005, J BIOL CHEM, V280, P9088, DOI 10.1074/jbc.M413042200; McLean KJ, 2006, BIOCHEMISTRY-US, V45, P8427, DOI 10.1021/bi0601609; McLean KJ, 2002, MICROBIOL-SGM, V148, P2937, DOI 10.1099/00221287-148-10-2937; McLean KJ, 2002, J INORG BIOCHEM, V91, P527, DOI 10.1016/S0162-0134(02)00479-8; MILES JS, 1992, BIOCHEM J, V288, P503, DOI 10.1042/bj2880503; Munro AW, 1996, BBA-PROTEIN STRUCT M, V1296, P127, DOI 10.1016/0167-4838(96)00061-1; Ogura H, 2004, BIOCHEMISTRY-US, V43, P14712, DOI 10.1021/bi048980d; OMURA T, 1964, J BIOL CHEM, V239, P2370; ORII Y, 1993, BIOCHEMISTRY-US, V32, P11910, DOI 10.1021/bi00095a021; Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Podust LM, 2004, STRUCTURE, V12, P1937, DOI 10.1016/j.str.2004.08.009; Seward HE, 2006, J BIOL CHEM, V281, P39437, DOI 10.1074/jbc.M607665200; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; Waterman MR, 2005, BIOCHEM BIOPH RES CO, V338, P418, DOI 10.1016/j.bbrc.2005.08.118; *WHO, 2007, 104 WHO	29	40	40	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24816	24824		10.1074/jbc.M702958200	http://dx.doi.org/10.1074/jbc.M702958200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17553785	hybrid			2022-12-25	WOS:000248933000037
J	Lee, JY; Feldman, AR; Delmas, B; Paetzel, M				Lee, Jaeyong; Feldman, Anat R.; Delmas, Bernard; Paetzel, Mark			Crystal structure of the VP4 protease from infectious pancreatic necrosis virus reveals the acyl-enzyme complex for an intermolecular self-cleavage reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL SIGNAL PEPTIDASE; SER-LYS DYAD; CATALYTIC DYAD; SUBSTRATE; DOMAIN; BIRNAVIRUS; PROGRAM; BINDING; MODEL; SITES	Infectious pancreatic necrosis virus (IPNV), an aquatic birnavirus that infects salmonid fish, encodes a large polyprotein (NH2-pVP2-VP4-VP3-COOH) that is processed through the proteolytic activity of its own protease, VP4, to release the proteins pVP2 and VP3. pVP2 is further processed to give rise to the capsid protein VP2 and three peptides that are incorporated into the virion. Reported here are two crystal structures of the IPNV VP4 protease solved from two different crystal symmetries. The electron density at the active site in the triclinic crystal form, refined to 2.2-angstrom resolution, reveals the acyl-enzyme complex formed with an internal VP4 cleavage site. The complex was generated using a truncated enzyme in which the general base lysine was substituted. Inside the complex, the nucleophilic Ser(633)O gamma forms an ester bond with the main-chain carbonyl of the C-terminal residue, Ala(716), of a neighboring VP4. The structure of this substrate-VP4 complex allows us to identify the S1, S3, S5, and S6 substrate binding pockets as well as other substrate-VP4 interactions and therefore provides structural insights into the substrate specificity of this enzyme. The structure from the hexagonal crystal form, refined to 2.3-angstrom resolution, reveals the free-binding site of the protease. Three-dimensional alignment with the VP4 of blotched snakehead virus, another birnavirus, shows that the overall structure of VP4 is conserved despite a low level of sequence identity (similar to 19%). The structure determinations of IPNV VP4, the first of an acyl-enzyme complex for a Ser/Lys dyad protease, provide insights into the catalytic mechanism and substrate recognition of this type of protease.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; INRA, Unit Virol & Immunol Mol, F-78350 Jouy En Josas, France	Simon Fraser University; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Paetzel, M (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, S Sci Bldg,8888, Burnaby, BC V5A 1S6, Canada.	mpaetzel@sfu.ca		Paetzel, Mark/0000-0002-7408-5487				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ALBER T, 1976, NATURE, V263, P297, DOI 10.1038/263297a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell CE, 2000, CELL, V101, P801, DOI 10.1016/S0092-8674(00)80891-0; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Birghan C, 2000, EMBO J, V19, P114, DOI 10.1093/emboj/19.1.114; Botos I, 2005, J MOL BIOL, V351, P144, DOI 10.1016/j.jmb.2005.06.008; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coulibaly F, 2005, CELL, V120, P761, DOI 10.1016/j.cell.2005.01.009; Da Costa B, 2003, J VIROL, V77, P719, DOI 10.1128/JVI.77.1.719-725.2003; DELANO WL, 2002, PYMOL MOL USERS MANU; DELMAS B, 2000, VIRUS TAXONOMY, P561; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; DING XC, 1994, BIOCHEMISTRY-US, V33, P9285, DOI 10.1021/bi00197a032; DOBOS P, 1995, VIROLOGY, V208, P19, DOI 10.1006/viro.1995.1125; DOBOS P, 1979, J VIROL, V32, P593, DOI 10.1128/JVI.32.2.593-605.1979; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Espinoza JC, 2000, ARCH VIROL, V145, P739, DOI 10.1007/s007050050667; Feldman AR, 2006, J MOL BIOL, V358, P1378, DOI 10.1016/j.jmb.2006.02.045; Galloux M, 2004, J GEN VIROL, V85, P2231, DOI 10.1099/vir.0.80012-0; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Katona G, 2002, J BIOL CHEM, V277, P21962, DOI 10.1074/jbc.M200676200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee J, 2006, ACTA CRYSTALLOGR F, V62, P1235, DOI 10.1107/S1744309106046070; Lejal N, 2000, J GEN VIROL, V81, P983, DOI 10.1099/0022-1317-81-4-983; Lemieux MJ, 2007, P NATL ACAD SCI USA, V104, P750, DOI 10.1073/pnas.0609981104; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Luo Y, 2001, CELL, V106, P585, DOI 10.1016/S0092-8674(01)00479-2; Maiti R, 2004, NUCLEIC ACIDS RES, V32, pW590, DOI 10.1093/nar/gkh477; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; MENARD R, 1992, BIOL CHEM H-S, V373, P393, DOI 10.1515/bchm3.1992.373.2.393; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paetzel M, 1999, PROTEIN SCI, V8, P2533; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; Paetzel M, 2004, J BIOL CHEM, V279, P30781, DOI 10.1074/jbc.M401686200; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Petit S, 2000, J VIROL, V74, P2057, DOI 10.1128/JVI.74.5.2057-2066.2000; Radisky ES, 2006, P NATL ACAD SCI USA, V103, P6835, DOI 10.1073/pnas.0601910103; Rawlings ND, 1999, NUCLEIC ACIDS RES, V27, P325, DOI 10.1093/nar/27.1.325; RENO PW, 1999, FISH DIS DISORDERS, V3, P1; Roberts RJ, 2005, J FISH DIS, V28, P383, DOI 10.1111/j.1365-2761.2005.00642.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215; Weiss MS, 2001, J APPL CRYSTALLOGR, V34, P130, DOI 10.1107/S0021889800018227; Wilmouth RC, 1997, NAT STRUCT BIOL, V4, P456, DOI 10.1038/nsb0697-456; Wilmouth RC, 1998, BIOCHEMISTRY-US, V37, P17506, DOI 10.1021/bi9816249; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	62	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24928	24937		10.1074/jbc.M701551200	http://dx.doi.org/10.1074/jbc.M701551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17553791	Green Published, hybrid			2022-12-25	WOS:000248933000049
J	O'Mahony, F; Alzamora, R; Betts, V; LaPaix, F; Carter, D; Irnaten, M; Harvey, BJ				O'Mahony, Fiona; Alzamora, Rodrigo; Betts, Vicki; LaPaix, Franck; Carter, Derek; Irnaten, Mustapha; Harvey, Brian J.			Female gender-specific inhibition of KCNQ1 channels and chloride secretion by 17 beta-estradiol in rat distal colonic crypts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HEART POTASSIUM CHANNEL; STEROID-HORMONES; K+ CHANNELS; CELLS; WATER; ACTIVATION; EPITHELIUM; DELTA; REQUIREMENT	The estrogen sex steroid 17 beta-estradiol rapidly inhibits secretagogue-stimulated cAMP-dependent Cl- secretion in the female rat distal colonic crypt by the inhibition of basolateral K+ channels. In Ussing chamber studies, both the anti-secretory response and inhibition of basolateral K+ current was shown to be attenuated by pretreatment with rottlerin, a PKC delta-specific inhibitor. In whole cell patch-clamp analysis, 17 beta-estradiol inhibited a chromanol 293B-sensitive KCNQ1 channel current in isolated female rat distal colonic crypts. Estrogen had no effect on KCNQ1 channel currents in colonic crypts isolated from male rats. Female distal colonic crypts expressed a significantly higher amount of PKC delta in comparison to male tissue. PKC delta and PKA were activated at 5 min in response to 17 beta-estradiol in female distal colonic crypts only. Both PKC delta- and PKA-associated with the KCNQ1 channel in response to 17 beta-estradiol in female distal colonic crypts, and no associations were observed in crypts from males. PKA activation, association with KCNQ1, and phosphorylation of the channel were regulated by PKC delta as the responses were blocked by pretreatment with rottlerin. Taken together, our experiments have identified the molecular targets underlying the anti-secretory response to estrogen involving the inhibition of KCNQ1 channel activity via PKC delta- and PKA-dependent signaling pathways. This is a novel gender-specific mechanism of regulation of an ion channel by estrogen. The anti-secretory response described in this study provides molecular insights whereby estrogen causes fluid retention effects in the female during periods of high circulating plasma estrogen levels.	Royal Coll Surgeons Ireland, Beaumont Hosp, Dept Mol Med, Dublin 9, Ireland	Royal College of Surgeons - Ireland	O'Mahony, F (corresponding author), Royal Coll Surgeons Ireland, Beaumont Hosp, Dept Mol Med, Smurfit Bldg,POB 9063, Dublin 9, Ireland.	fomahony@rcsi.ie	Harvey, Brian/AAJ-4085-2020; Harvey, Brian J/A-5120-2010	Harvey, Brian/0000-0002-7388-8034; Harvey, Brian J/0000-0002-7388-8034	Wellcome Trust [06379/z/01/z, 06089/z/00/z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ATHERTON JC, 1982, J PHYSIOL-LONDON, V330, P81, DOI 10.1113/jphysiol.1982.sp014330; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; BLAHD WH, 1974, J REPROD MED, V13, P223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Condliffe SB, 2001, J PHYSIOL-LONDON, V530, P47, DOI 10.1111/j.1469-7793.2001.0047m.x; Cooper DMF, 2005, BIOCHEM SOC T, V33, P1319, DOI 10.1042/BST0331319; CROCKER AD, 1971, J PHYSIOL-LONDON, V214, P257, DOI 10.1113/jphysiol.1971.sp009431; CUTLER RE, 1993, BIOCHIM BIOPHYS ACTA, V1179, P260, DOI 10.1016/0167-4889(93)90081-Y; Di Mari JF, 2005, GASTROENTEROLOGY, V128, P2131, DOI 10.1053/j.gastro.2004.09.078; Doolan CM, 2000, BRIT J PHARMACOL, V129, P1375, DOI 10.1038/sj.bjp.0703193; Doolan CM, 1996, J BIOL CHEM, V271, P8763, DOI 10.1074/jbc.271.15.8763; Falkenstein E, 2000, PHARMACOL REV, V52, P513; FIELD M, 1993, ANNU REV PHYSIOL, V55, P631, DOI 10.1146/annurev.ph.55.030193.003215; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HALRN ST, 2006, AM J PHYSIOL-CELL PH, V291, pC636; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harvey BJ, 2001, NEWS PHYSIOL SCI, V16, P174; Hubscher CH, 2005, BIOTECH HISTOCHEM, V80, P79, DOI 10.1080/10520290500138422; Jespersen T, 2005, PHYSIOLOGY, V20, P408, DOI 10.1152/physiol.00031.2005; Kunzelmann K, 2001, J MEMBRANE BIOL, V179, P155, DOI 10.1007/s002320010045; Kurokawa J, 2004, P NATL ACAD SCI USA, V101, P16374, DOI 10.1073/pnas.0405583101; Kurokawa J, 2003, P NATL ACAD SCI USA, V100, P2122, DOI 10.1073/pnas.0434935100; Liao TJ, 2005, AM J PHYSIOL-CELL PH, V289, pC564, DOI 10.1152/ajpcell.00561.2004; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; McNamara B, 1999, J PHYSIOL-LONDON, V519, P251, DOI 10.1111/j.1469-7793.1999.0251o.x; MICHELL AR, 1981, Q J EXP PHYSIOL CMS, V66, P515, DOI 10.1113/expphysiol.1981.sp002592; Moller C, 2006, EUR J PHARMACOL, V532, P44, DOI 10.1016/j.ejphar.2006.01.006; NEQUIN LG, 1979, BIOL REPROD, V20, P659, DOI 10.1095/biolreprod20.3.659; REENSTRA WW, 1993, AM J PHYSIOL, V264, pC161, DOI 10.1152/ajpcell.1993.264.1.C161; Schultheiss Gerhard, 2002, Biological Procedures Online, V3, P70, DOI 10.1251/bpo25; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; Singh AE, 1998, AM J PHYSIOL-CELL PH, V275, pC562, DOI 10.1152/ajpcell.1998.275.2.C562; Smith FD, 2006, TRENDS BIOCHEM SCI, V31, P316, DOI 10.1016/j.tibs.2006.04.009; Song JC, 2001, AM J PHYSIOL-CELL PH, V281, pC649, DOI 10.1152/ajpcell.2001.281.2.C649; Steagall WK, 1998, AM J PHYSIOL-CELL PH, V274, pC819, DOI 10.1152/ajpcell.1998.274.3.C819; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Stevenson John C, 2006, J Br Menopause Soc, V12 Suppl 1, P8, DOI 10.1258/136218006775992167; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; THOMAS ML, 1993, ENDOCRINOLOGY, V132, P426, DOI 10.1210/en.132.1.426; Unsold B, 2000, PFLUG ARCH EUR J PHY, V441, P368, DOI 10.1007/s004240000434; Warth R, 2000, REV PHYSIOL BIOCH P, V140, P1, DOI 10.1007/BFb0035550; ZANGAR RC, 1995, CARCINOGENESIS, V16, P2593, DOI 10.1093/carcin/16.10.2593	42	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24563	24573		10.1074/jbc.M611682200	http://dx.doi.org/10.1074/jbc.M611682200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17556370	hybrid			2022-12-25	WOS:000248933000010
J	Akai, S; Hosomi, H; Minami, K; Tsuneyama, K; Katoh, M; Nakajima, M; Yokoi, T				Akai, Sho; Hosomi, Hiroko; Minami, Keiichi; Tsuneyama, Koichi; Katoh, Miki; Nakajima, Miki; Yokoi, Tsuyoshi			Knock down of gamma-glutamylcysteine synthetase in rat causes acetaminophen-induced hepatotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE SYNTHESIS; OXIDATIVE STRESS; DRUG-METABOLISM; CELL-GROWTH; LIVER; MICE; PARACETAMOL; SUBUNIT; MOUSE; ADENOVIRUSES	Drug-induced hepatotoxicity is mainly caused by hepatic glutathione (GSH) depletion. In general, the activity of rodent glutathione S-transferase is 10 to 20 times higher than that of humans, which could make the prediction of drug-induced hepatotoxicity in human more difficult. gamma-Glutamylcysteine synthetase (gamma-GCS) mainly regulates de novo synthesis of GSH in mammalian cells and plays a central role in the antioxidant capacity of cells. In this study, we constructed a GSH-depletion experimental rat model for the prediction of human hepatotoxicity. An adenovirus vector with short hairpin RNA against rat gamma-GCS heavy chain subunit (GCSh) (AdGCSh-shRNA) was constructed and used to knock down the GCSh. In in vitro study in H4IIE cells, a rat hepatoma cell line, GCSh mRNA and protein were significantly decreased by 80% and GSH was significantly decreased by 50% 3 days after AdGCSh-shRNA infection. In the in vivo study in rat, the hepatic GSH level was decreased by 80% 14 days after a single dose of AdGCSh-shRNA (2 x 10(11) pfu/ml/body), and this depletion continued for at least 2 weeks. Using this GSH knockdown rat model, acetaminophen-induced hepatotoxicity was shown to be significantly potentiated compared with normal rats. This is the first report of a GSH knockdown rat model, which could be useful for highly sensitive tests of acute and subacute toxicity for drug candidates in preclinical drug development.	Kanazawa Univ, Div Pharmaceut Sci, Grad Sch Med Sci, Kanazawa, Ishikawa 9201192, Japan; Toyama Univ, Grad Sch Med & Pharmaceut Sci Res, Dept Diagnost Pathol, Toyama 930, Japan	Kanazawa University; University of Toyama	Yokoi, T (corresponding author), Kanazawa Univ, Div Pharmaceut Sci, Grad Sch Med Sci, Kanazawa, Ishikawa 9201192, Japan.	tyokoi@kenroku.kanazawa-u.ac.jp	Nakajima, Miki/C-3990-2015; yokoi, tsuyoshi/I-7115-2014	Tsuneyama, Koichi/0000-0002-0670-9868; Yokoi, Tsuyoshi/0000-0002-3239-2817				ALBANO E, 1985, MOL PHARMACOL, V28, P306; Callahan SM, 2006, J GENE MED, V8, P566, DOI 10.1002/jgm.884; Chu RL, 2004, CLIN CANCER RES, V10, P5299, DOI 10.1158/1078-0432.CCR-0349-03; Crettaz J, 2006, HEPATOLOGY, V44, P623, DOI 10.1002/hep.21292; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; Farkas D, 2005, CURR DRUG METAB, V6, P111, DOI 10.2174/1389200053586118; GROVER PL, 1964, BIOCHEM J, V90, P603, DOI 10.1042/bj0900603; GUENGERICH FP, 1994, ENVIRON HEALTH PERSP, V102, P49, DOI 10.1289/ehp.94102s949; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayder H, 1999, J IMMUNOL, V163, P1516; Henderson CJ, 2000, P NATL ACAD SCI USA, V97, P12741, DOI 10.1073/pnas.220176997; HINSON JA, 1981, LIFE SCI, V29, P107, DOI 10.1016/0024-3205(81)90278-2; HOWIE D, 1977, J PHARM PHARMACOL, V29, P235, DOI 10.1111/j.2042-7158.1977.tb11295.x; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Huang KC, 2005, INT J CANCER, V113, P738, DOI 10.1002/ijc.20623; JAESCHKE H, 1985, BIOCHEM PHARMACOL, V34, P1029, DOI 10.1016/0006-2952(85)90606-9; JOHANSSON I, 1990, BIOCHEM BIOPH RES CO, V173, P331, DOI 10.1016/S0006-291X(05)81061-7; Fukushima Tamio, 2006, Journal of Toxicological Sciences, V31, P419, DOI 10.2131/jts.31.419; Kim YC, 1998, TOXICOLOGY, V128, P53, DOI 10.1016/S0300-483X(98)00046-8; Kim YW, 2006, CHEM-BIOL INTERACT, V161, P125, DOI 10.1016/j.cbi.2006.03.008; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Merrick BA, 2006, J PHARMACOL EXP THER, V318, P792, DOI 10.1124/jpet.106.102681; MINER DJ, 1979, BIOCHEM PHARMACOL, V28, P3285, DOI 10.1016/0006-2952(79)90123-0; MOLDEUS P, 1982, BIOCHEM PHARMACOL, V31, P1363, DOI 10.1016/0006-2952(82)90029-6; Morishita Katsumi, 2006, Journal of Toxicological Sciences, V31, P491, DOI 10.2131/jts.31.491; OMURA T, 1964, J BIOL CHEM, V239, P2370; Peng ZH, 2005, HUM GENE THER, V16, P1016, DOI 10.1089/hum.2005.16.1016; PESSAYRE D, 1980, BIOCHEM PHARMACOL, V29, P2219, DOI 10.1016/0006-2952(80)90201-4; REED DJ, 1986, BIOCHEM PHARMACOL, V35, P7, DOI 10.1016/0006-2952(86)90545-9; Sekine S, 2006, FREE RADICAL BIO MED, V40, P2166, DOI 10.1016/j.freeradbiomed.2006.02.015; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TONE Y, 1990, J PHARMACOBIO-DYNAM, V13, P327, DOI 10.1248/bpb1978.13.327; VANDESTRAAT R, 1988, CHEM-BIOL INTERACT, V64, P267, DOI 10.1016/0009-2797(88)90102-0; Xiong H, 2000, J PHARMACOL EXP THER, V295, P512; Xu HY, 2006, BIOCHEM BIOPH RES CO, V349, P439, DOI 10.1016/j.bbrc.2006.08.071; Yang Y, 2002, J BIOL CHEM, V277, P49446, DOI 10.1074/jbc.M209372200; Yoshitomi S, 2001, TOXICOL IN VITRO, V15, P245, DOI 10.1016/S0887-2333(01)00011-X; Zhou Q, 2003, SCIENCE, V302, P1179, DOI 10.1126/science.1088313	43	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23996	24003		10.1074/jbc.M702819200	http://dx.doi.org/10.1074/jbc.M702819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17573345	hybrid			2022-12-25	WOS:000248686600025
J	Vanpouille, C; Deligny, A; Delehedde, M; Denys, A; Melchior, A; Lienard, X; Lyon, M; Mazurier, J; Fernig, DG; Allain, F				Vanpouille, Christophe; Deligny, Audrey; Delehedde, Maryse; Denys, Agnes; Melchior, Aurelie; Lienard, Xavier; Lyon, Malcolm; Mazurier, Joel; Fernig, David G.; Allain, Fabrice			The Heparin/Heparan sulfate sequence that interacts with cyclophilin B contains a 3-O-sulfated N-unsubstituted glucosamine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; FIBROBLAST-GROWTH-FACTOR; HEPARIN-DERIVED OLIGOSACCHARIDES; BINDING-SITES; CELL-SURFACE; L-SELECTIN; RECEPTOR; PROTEIN; ENTRY; EXPRESSION	Many of the biological functions of heparan sulfate (HS) proteoglycans can be attributed to specialized structures within HS moieties, which are thought to modulate binding and function of various effector proteins. Cyclophilin B (CyPB), which was initially identified as a cyclosporin A-binding protein, triggers migration and integrin-mediated adhesion of peripheral blood T lymphocytes by a mechanism dependent on interaction with cell surface HS. Here we determined the structural features of HS that are responsible for the specific binding of CyPB. In addition to the involvement of 2-O, 6-O, and N-sulfate groups, we also demonstrated that binding of CyPB was dependent on the presence of N-unsubstituted glucosamine residues (GlcNH2), which have been reported to be precursors for sulfation by 3-Osulfotransferases-3 (3-OST-3). Interestingly, 3-OST-3B isoform was found to be the main 3-OST isoenzyme expressed in peripheral blood T lymphocytes and Jurkat T cells. Moreover, down-regulation of the expression of 3-OST-3 by RNA interference potently reduced CyPB binding and consequent activation of p44/42 mitogen-activated protein kinases. Altogether, our results strongly support the hypothesis that 3-O-sulfation of GlcNH2 residues could be a key modification that provides specialized HS structures for CyPB binding to responsive cells. Given that 3-O-sulfation of GlcNH2-containing HS by 3-OST-3 also provides binding sites for glycoprotein gD of herpes simplex virus type I, these findings suggest an intriguing structural linkage between the HS sequences involved in CyPB binding and viral infection.	Univ Sci & Technol Lille, Unite Glycobiol Struct & Fonctionnelle, Unite Mixte Rech Number 8576, CNRS,Inst Rech Federatif 147, F-59655 Villeneuve Dascq, France; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; University of Liverpool; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Allain, F (corresponding author), Univ Sci & Technol Lille, Unite Glycobiol Struct & Fonctionnelle, Unite Mixte Rech Number 8576, CNRS,Inst Rech Federatif 147, F-59655 Villeneuve Dascq, France.	fabrice.allain@univ-lille1.fr	Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Allain, Fabrice/0000-0002-4484-6302; Lyon, Malcolm/0000-0001-9575-6879; DELEHEDDE, Maryse/0000-0003-2724-143X				Allain F, 2002, P NATL ACAD SCI USA, V99, P2714, DOI 10.1073/pnas.052284899; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Arora K, 2005, J IMMUNOL, V175, P517, DOI 10.4049/jimmunol.175.1.517; Beattie J, 2005, J MOL ENDOCRINOL, V34, P163, DOI 10.1677/jme.1.01656; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Carpentier M, 1999, J BIOL CHEM, V274, P10990, DOI 10.1074/jbc.274.16.10990; Carpentier M, 2002, BIOCHEMISTRY-US, V41, P5222, DOI 10.1021/bi015951j; Celie JWAM, 2005, J BIOL CHEM, V280, P26965, DOI 10.1074/jbc.M502188200; De Ceuninck F, 2003, ARTHRITIS RHEUM, V48, P2197, DOI 10.1002/art.11099; Delehedde M, 2002, BIOCHEM J, V366, P235, DOI 10.1042/BJ20011718; Delehedde M, 2002, J BIOL CHEM, V277, P12456, DOI 10.1074/jbc.M111345200; Denys A, 1997, IMMUNOLOGY, V91, P609, DOI 10.1046/j.1365-2567.1997.00296.x; Denys A, 1998, BIOCHEM J, V336, P689, DOI 10.1042/bj3360689; Ding K, 2001, J BIOL CHEM, V276, P3885, DOI 10.1074/jbc.M005238200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fernig D G, 2001, Methods Mol Biol, V171, P505; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Gwinn WM, 2006, J IMMUNOL, V177, P4870, DOI 10.4049/jimmunol.177.7.4870; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; KE LD, 1992, PROTEIN EXPRES PURIF, V3, P497, DOI 10.1016/1046-5928(92)90067-7; Kinsella L, 1998, GLYCOCONJUGATE J, V15, P419, DOI 10.1023/A:1006986104865; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LYON M, 1990, ANAL BIOCHEM, V185, P63, DOI 10.1016/0003-2697(90)90255-8; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; O'Donnell CD, 2006, VIROLOGY, V346, P452, DOI 10.1016/j.virol.2005.11.003; Osmond RIW, 2002, ANAL BIOCHEM, V310, P199, DOI 10.1016/S0003-2697(02)00396-2; Pakula R, 2007, GLYCOBIOLOGY, V17, P492, DOI 10.1093/glycob/cwm009; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; SASAKI H, 1987, J CHROMATOGR, V400, P123, DOI 10.1016/S0021-9673(01)81605-8; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003; SPIK G, 1991, J BIOL CHEM, V266, P10735; Tegeder I, 1997, J CLIN IMMUNOL, V17, P380, DOI 10.1023/A:1027364207544; Tiwari V, 2005, BIOCHEM BIOPH RES CO, V338, P930, DOI 10.1016/j.bbrc.2005.10.056; Tiwari V, 2006, J VIROL, V80, P8970, DOI 10.1128/JVI.00296-06; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; van den Born J, 2005, J BIOL CHEM, V280, P20516, DOI 10.1074/jbc.M502065200; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Vanpouille C, 2004, BIOCHEM J, V382, P733, DOI 10.1042/BJ20031453; Wei Z, 2005, J BIOL CHEM, V280, P15742, DOI 10.1074/jbc.M501102200; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200; Xu D, 2005, BIOCHEM J, V385, P451, DOI 10.1042/BJ20040908; YAMADA S, 1995, J BIOL CHEM, V270, P8696; Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200	56	54	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24416	24429		10.1074/jbc.M701835200	http://dx.doi.org/10.1074/jbc.M701835200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17588944	hybrid			2022-12-25	WOS:000248686600068
J	Noguchi, A; Saito, A; Homma, Y; Nakao, M; Sasaki, N; Nishino, T; Takahashi, S; Nakayama, T				Noguchi, Akio; Saito, Atsushi; Homma, Yu; Nakao, Masahiro; Sasaki, Nobuhiro; Nishino, Tokuzo; Takahashi, Seiji; Nakayama, Toru			A UDP-glucose : isoflavone 7-O-glucosyltransferase from the roots of soybean (Glycine max) seedlings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOMENCLATURE UPDATE; GLYCOSYLTRANSFERASES; CLONING; EXPRESSION; GLUCOSYLTRANSFERASE; BIOSYNTHESIS; ARABIDOPSIS; ACID; CLASSIFICATION; PHYLOGENETICS	Isoflavones, a class of flavonoids, play very important roles in plant-microbe interactions in certain legumes such as soybeans (Glycine max L. Merr.). G. max UDP-glucose:isoflavone 7-Oglucosyltransferase (GmIF7GT) is a key enzyme in the synthesis of isoflavone conjugates, which accumulate in large amounts in vacuoles and serve as an isoflavonoid pool that allows for interaction with microorganisms. In this study, the 14,000-fold purification of GmIF7GT from the roots of G. max seedlings was accomplished. The purified enzyme is a monomeric protein of 46 kDa, catalyzing regiospecific glucosyl transfer from UDPglucose to isoflavones to produce isoflavone 7-O-beta-D- glucosides (k(cat) = 0.74 s(-1), K-m for genistein = 3.6 mu M, and K-m for UDPglucose = 190 mu M). The GmIF7GT cDNA was isolated based on the amino acid sequence of the purified enzyme. Phylogenetic analysis showed that GmIF7GT is a novel member of glycosyltransferase family 1 and is distantly related to Glycyrrhiza echinata UDP-glucose: isoflavonoid 7-O-glucosyltransferase. The purified enzyme was unexpectedly devoid of the N-terminal 49-residue segment and thus lacks the histidine residue corresponding to the proposed catalytic residue of glycosyltransferases from Medicago truncatula (UGT71G1) and Vitis vinifera (VvGT1). The results of kinetic studies of site-directed mutants of GmIF7GT showed that both His-15 and Asp-125, which correspond to the catalytic residues of UGT71G1 and VvGT1, are not important for GmIF7GT activity. The results also suggest that an acidic residue at position 392 is very important for primary catalysis of GmIF7GT. These results led to the proposal that GmIF7GTutilizes a strategy of catalysis that is distinct from those proposed for UGT71G1 and VvGT1.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Suntory Res Ctr, Osaka 6188503, Japan	Tohoku University; Suntory Holdings Ltd	Nakayama, T (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Yama 6-6-11, Sendai, Miyagi 9808579, Japan.	nakayama@seika.che.tohoku.ac.jp		Takahashi, Seiji/0000-0002-2288-4340				Akashi T, 1999, PLANT PHYSIOL, V121, P821, DOI 10.1104/pp.121.3.821; Akashi T, 2005, PLANT PHYSIOL, V137, P882, DOI 10.1104/pp.104.056747; BARZ W, 1992, RECENT ADV PHYTOCHEM, V26, P139; Bowles D, 2005, CURR OPIN PLANT BIOL, V8, P254, DOI 10.1016/j.pbi.2005.03.007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burbulis IE, 1999, P NATL ACAD SCI USA, V96, P12929, DOI 10.1073/pnas.96.22.12929; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Graham TL, 2000, PLANT MIC I, V5, P181; He XZ, 2006, J BIOL CHEM, V281, P34441, DOI 10.1074/jbc.M605767200; Hefner T, 2003, EUR J BIOCHEM, V270, P533, DOI 10.1046/j.1432-1033.2003.03409.x; Hungria M, 1997, SOIL BIOL BIOCHEM, V29, P819, DOI 10.1016/S0038-0717(96)00239-8; Jones P, 2001, PLANTA, V213, P164, DOI 10.1007/s004250000492; Keegstra K, 2001, CURR OPIN PLANT BIOL, V4, P219, DOI 10.1016/S1369-5266(00)00164-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; Lim EK, 2004, EMBO J, V23, P2915, DOI 10.1038/sj.emboj.7600295; Mackenzie PI, 2005, PHARMACOGENET GENOM, V15, P677, DOI 10.1097/01.fpc.0000173483.13689.56; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Milkowski C, 2000, PLANTA, V211, P883, DOI 10.1007/s004250000411; Nagashima S, 2004, PLANTA, V218, P456, DOI 10.1007/s00425-003-1118-0; Nagashima S, 2000, PHYTOCHEMISTRY, V53, P533, DOI 10.1016/S0031-9422(99)00593-2; Nakayama T, 2000, SCIENCE, V290, P1163, DOI 10.1126/science.290.5494.1163; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Ogata J, 2005, NATURE, V435, P757, DOI 10.1038/nature435757a; Ono E, 2007, TRANSGENIC PLANT J, V1, P66; Ono E, 2006, P NATL ACAD SCI USA, V103, P11075, DOI 10.1073/pnas.0604246103; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PHILLIPS DA, 1992, RECENT ADV PHYTOCHEM, V26, P201; Pueppke SG, 1998, PLANT PHYSIOL, V117, P599, DOI 10.1104/pp.117.2.599; Sawada S, 2005, J BIOL CHEM, V280, P899, DOI 10.1074/jbc.M410537200; Segel I. H., 1975, ENZYME KINETICS BEHA, P505; Shao H, 2005, PLANT CELL, V17, P3141, DOI 10.1105/tpc.105.035055; Steele CL, 1999, ARCH BIOCHEM BIOPHYS, V367, P146, DOI 10.1006/abbi.1999.1238; Suzuki H, 2007, PHYTOCHEMISTRY, V68, P2035, DOI 10.1016/j.phytochem.2007.05.017; Suzuki H, 2006, J BIOL CHEM, V281, P30251, DOI 10.1074/jbc.M605726200; Taguchi G, 2003, ARCH BIOCHEM BIOPHYS, V420, P95, DOI 10.1016/j.abb.2003.09.027; Tohge T, 2005, PLANT J, V42, P218, DOI 10.1111/j.1365-313X.2005.02371.x; Vogt T, 1997, PLANTA, V203, P349, DOI 10.1007/s004250050201; Vogt T, 2000, TRENDS PLANT SCI, V5, P380, DOI 10.1016/S1360-1385(00)01720-9; Wiseman H., 2006, Flavonoids: chemistry, biochemistry and applications, P371; Yonekura-Sakakibara K, 2007, J BIOL CHEM, V282, P14932, DOI 10.1074/jbc.M611498200	42	96	108	1	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23581	23590		10.1074/jbc.M702651200	http://dx.doi.org/10.1074/jbc.M702651200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565994	hybrid			2022-12-25	WOS:000248577500060
J	Odriozola, L; Singh, G; Hoang, T; Chan, AM				Odriozola, Leticia; Singh, Gobind; Hoang, Thuong; Chan, Andrew M.			Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; PHOSPHATASE-ACTIVITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHORYLATION SITES; PROTEIN STABILITY; CANDIDATE PROTEIN; BINDING MOTIF; C2 DOMAIN; ACTIVATION; INHIBITION	The regulation of PTEN intrinsic biochemical properties has not been fully elucidated. In this report, we investigated the role of the PTEN carboxyl-terminal tail domain in regulating its membrane targeting and catalytic functions. Characterization of a panel of PTEN phosphorylation site mutants revealed that mutating Ser-385 to alanine (S385A) promoted membrane localization in vivo and phosphatase activity in vitro. Furthermore, S385A mutation was associated with a substantial reduction in the phosphorylation of the Ser-380/Thr-382/Thr-383 cluster. Therefore, Ser-385 could prime additional dephosphorylation events to regulate PTEN catalytic activity. Moreover, substituting Ser-380/Thr-382/Thr-383 to phosphomimic residues reversed the phosphatase activity of the S385A mutation. Next, we further defined the underlying mechanisms responsible for the COOH-terminal tail region in modulating PTEN biological activity. We have identified an interaction between the 71-amino acid carboxyl-terminal tail region and the CBRIII motif of the C2 domain, which has been implicated in membrane binding. In addition, a synthetic phosphomimic peptide encompassing the phosphorylation site cluster between amino acids 368 and 390 within the tail region mediated the suppression of PTEN catalytic activity in vitro. This same peptide when expressed in cultured cells also impeded PTEN membrane localization and enhanced phospho-Akt levels. Thus, our data suggest that the COOH-terminal tail can act as an autoinhibitory domain to control both PTEN membrane recruitment and phosphatase activity.	CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Chan, AM (corresponding author), CUNY Mt Sinai Sch Med, Dept Oncol Sci, 1425 Madison Ave,Box 1130, New York, NY 10029 USA.	andrew.chan@mssm.edu	Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464	NATIONAL CANCER INSTITUTE [R01CA095063] Funding Source: NIH RePORTER; NCI NIH HHS [CA095063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheong JW, 2003, BRIT J HAEMATOL, V122, P454, DOI 10.1046/j.1365-2141.2003.04452.x; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Georgescu MM, 2000, CANCER RES, V60, P7033; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Kovacs KA, 2007, J STEROID BIOCHEM, V103, P196, DOI 10.1016/j.jsbmb.2006.08.006; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2004, BIOCHEM SOC T, V32, P343, DOI 10.1042/BST0320343; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; NIGH K, 2006, EMBO J, V25, P2377; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Omori N, 2002, BRAIN RES, V954, P317, DOI 10.1016/S0006-8993(02)03366-8; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Sagoo JK, 1996, BIOCHEM J, V320, P879, DOI 10.1042/bj3200879; Solari F, 2005, ONCOGENE, V24, P20, DOI 10.1038/sj.onc.1207978; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vazquez F, 2006, CELL CYCLE, V5, P1523, DOI 10.4161/cc.5.14.3005; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839	39	131	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23306	23315		10.1074/jbc.M611240200	http://dx.doi.org/10.1074/jbc.M611240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565999	hybrid			2022-12-25	WOS:000248577500031
J	Rosser, MFN; Washburn, E; Muchowski, PJ; Patterson, C; Cyr, DM				Rosser, Meredith F. N.; Washburn, Erin; Muchowski, Paul J.; Patterson, Cam; Cyr, Douglas M.			Chaperone functions of the E3 ubiquitin ligase CHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-QUALITY CONTROL; HEAT-SHOCK PROTEINS; CO-CHAPERONE; MOLECULAR CHAPERONES; IN-VIVO; PROTEASOMAL DEGRADATION; CARBOXYL-TERMINUS; HSP70 CHAPERONES; REACTION CYCLE; DNAJ HOMOLOG	The carboxyl terminus of the Hsc70-interacting protein (CHIP) is an Hsp70 co-chaperone as well as an E3 ubiquitin ligase that protects cells from proteotoxic stress. The abilities of CHIP to interact with Hsp70 and function as a ubiquitin ligase place CHIP at a pivotal position in the protein quality control system, where its entrance into Hsp70-substrate complexes partitions nonnative proteins toward degradation. However, the manner by which Hsp70 substrates are selected for ubiquitination by CHIP is not well understood. We discovered that CHIP possesses an intrinsic chaperone activity that enables it to selectively recognize and bind nonnative proteins. Interestingly, the chaperone function of CHIP is temperature-sensitive and is dramatically enhanced by heat stress. The ability of CHIP to recognize nonnative protein structure may aid in selection of slow folding or misfolded polypeptides for ubiquitination.	Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Ctr, Chapel Hill, NC 27599 USA; Univ Calif San Francisco, Gladstone Inst Neurol Dis, Dept Biochem & Biophys, San Francisco, CA 94158 USA; Univ Calif San Francisco, Gladstone Inst Neurol Dis, Dept Neurol, San Francisco, CA 94158 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes	Cyr, DM (corresponding author), Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	DMCYR@med.unc.edu		Cyr, Douglas/0000-0002-4928-3414	NIGMS NIH HHS [GM 056981, GM 000678-08, R01 GM056981, GM 061728] Funding Source: Medline; NINDS NIH HHS [NS 054753, NS 047237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061728, R01GM056981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054753, R01NS047237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberti S, 2004, MOL BIOL CELL, V15, P4003, DOI 10.1091/mbc.E04-04-0293; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2005, J BIOL CHEM, V280, P38673, DOI 10.1074/jbc.M507986200; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Easton DP, 2000, CELL STRESS CHAPERON, V5, P276, DOI 10.1379/1466-1268(2000)005<0276:THAGSP>2.0.CO;2; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Graf PCF, 2002, CELL MOL LIFE SCI, V59, P1624, DOI 10.1007/PL00012489; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; HOHFELD J, 1995, CELL, V83, P589; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Li LY, 2004, MOL CELL BIOL, V24, P856, DOI 10.1128/MCB.24.2.856-864.2004; Li RF, 2005, COLLOID SURFACE B, V40, P133, DOI 10.1016/j.colsurfb.2004.10.013; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Morishima Y, 2003, J BIOL CHEM, V278, P48754, DOI 10.1074/jbc.M309814200; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nemoto TK, 2001, BIOCHEM J, V354, P663, DOI 10.1042/0264-6021:3540663; Nikolay R, 2004, J BIOL CHEM, V279, P2673, DOI 10.1074/jbc.M311112200; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; Peng HM, 2004, J BIOL CHEM, V279, P52970, DOI 10.1074/jbc.M406926200; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Rosser MFN, 2004, BIOCHEMISTRY-US, V43, P8835, DOI 10.1021/bi049539q; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Sahara N, 2005, J NEUROCHEM, V94, P1254, DOI 10.1111/j.1471-4159.2005.03272.x; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Thammavongsa V, 2005, J BIOL CHEM, V280, P33497, DOI 10.1074/jbc.M503648200; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; Welch WJ, 2004, SEMIN CELL DEV BIOL, V15, P31, DOI 10.1016/j.semcdb.2003.12.011; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wiederkehr T, 2002, CURR BIOL, V12, pR26, DOI 10.1016/S0960-9822(01)00644-3; Winter J, 2004, CRIT REV BIOCHEM MOL, V39, P297, DOI 10.1080/10409230490900658; Xu Z, 2006, BIOCHEMISTRY-US, V45, P4749, DOI 10.1021/bi0601508; Yamagishi N, 2003, FEBS LETT, V555, P390, DOI 10.1016/S0014-5793(03)01292-4; Yan JQ, 2003, PLANT PHYSIOL, V132, P861, DOI 10.1104/pp.103.020800; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023	59	99	104	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22267	22277		10.1074/jbc.M700513200	http://dx.doi.org/10.1074/jbc.M700513200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17545168	Green Published, hybrid			2022-12-25	WOS:000248354200004
J	Sabeva, NS; Rouse, EJ; Graf, GA				Sabeva, Nadezhda S.; Rouse, Eric J.; Graf, Gregory A.			Defects in the leptin axis reduce abundance of the ABCG5-ABCG8 sterol transporter in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIARY CHOLESTEROL SECRETION; RESISTANT OBESE MICE; X-RECEPTOR; GALLSTONE FORMATION; DIETARY-CHOLESTEROL; HEPATIC EXPRESSION; MOUSE MODEL; ABCG5; SITOSTEROLEMIA; DEGRADATION	ABGG5 (G5) and ABCG8 (G8) are ABC half-transporters that dimerize within the endoplasmic reticulum, traffic to the cell surface, and mediate cholesterol excretion into bile. Mice harboring defects in the leptin axis (db/db and ob/ob) have reduced biliary cholesterol concentrations. Rapid weight loss brought about by administration of leptin or dietary restriction increases biliary cholesterol excretion. We hypothesized that the reduction in biliary cholesterol in mice harboring defects in the leptin axis is associated with a reduction in G5G8 transporters and that levels of the transporter would increase with leptin administration and dietary restriction. We examined mRNA and protein levels for G5 and G8 in db/db and ob/ob mice. In both models G5 and G8 protein levels were reduced. In ob/ob mice, both leptin administration and dietary restriction increased G5 and G8 protein and biliary cholesterol concentrations. Finally, we examined the effects of tauroursodeoxycholate, which has been shown to increase biliary cholesterol excretion and function as a molecular chaperone. Tauroursodeoxycholate increased G5 and G8 protein and biliary cholesterol concentrations in both wild-type and db/db mice. Our results indicate that the mechanism for reduced biliary cholesterol excretion in db/db and ob/ob mice involves reductions in G5 and G8 protein levels and that this may occur at the level of G5G8 heterodimer assembly within the endoplasmic reticulum.	Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA; Univ Kentucky, Cardiovasc Res Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Graf, GA (corresponding author), Univ Kentucky, Dept Pharmaceut Sci, 725 Rose St, Lexington, KY 40536 USA.	Gregory.Graf@uky.edu		Sabeva, Nadezhda/0000-0002-7714-4884; Graf, Gregory/0000-0002-0130-9929				Albrecht C, 2002, BBA-BIOMEMBRANES, V1567, P133, DOI 10.1016/S0005-2736(02)00608-9; Attili AF, 1997, HEPATOLOGY, V26, P809, DOI 10.1002/hep.510260401; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bouchard G, 2002, J LIPID RES, V43, P1105, DOI 10.1194/jlr.M200102-JLR200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COCKFIELD SM, 1989, J IMMUNOL, V142, P1120; Elferink RPJO, 1996, J LIPID RES, V37, P1065; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Geuken E, 2005, HEPATOLOGY, V42, P1166, DOI 10.1002/hep.20886; Goldblatt MI, 2002, J GASTROINTEST SURG, V6, P438, DOI 10.1016/S1091-255X(01)00046-4; Graewin SJ, 2004, J SURG RES, V122, P145, DOI 10.1016/j.jss.2004.04.012; Graf GA, 2004, J BIOL CHEM, V279, P24881, DOI 10.1074/jbc.M402634200; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Hyogo H, 2003, J LIPID RES, V44, P1232, DOI 10.1194/jlr.M300029-JLR200; Hyogo H, 2002, J BIOL CHEM, V277, P34117, DOI 10.1074/jbc.M203912200; JOHNSTON DE, 1993, NEW ENGL J MED, V328, P412, DOI 10.1056/NEJM199302113280608; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Klett EL, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-5; Kosters A, 2005, HEPATOLOGY, V41, P141, DOI 10.1002/hep.20540; Kosters A, 2003, J HEPATOL, V38, P710, DOI 10.1016/S0168-8278(03)00093-X; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Loo TW, 2005, MOL PHARMACEUT, V2, P407, DOI 10.1021/mp0500521; Loo TW, 2005, J BIOENERG BIOMEMBR, V37, P501, DOI 10.1007/s10863-005-9499-3; Lyons MA, 2006, GASTROENTEROLOGY, V131, P1943, DOI 10.1053/j.gastro.2006.10.024; Maliepaard M, 2001, CANCER RES, V61, P3458; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Okiyoneda T, 2006, BIOCHEM BIOPH RES CO, V347, P67, DOI 10.1016/j.bbrc.2006.06.032; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Plosch T, 2004, GASTROENTEROLOGY, V126, P290, DOI 10.1053/j.gastro.2003.10.074; Plosch T, 2006, AM J PHYSIOL-GASTR L, V291, pG414, DOI 10.1152/ajpgi.00557.2005; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Tran KQ, 2003, SURGERY, V134, P372, DOI 10.1067/msy.2003.234; TURLEY SD, 1991, METABOLISM, V40, P1063, DOI 10.1016/0026-0495(91)90131-F; Wang J, 2006, J BIOL CHEM, V281, P27894, DOI 10.1074/jbc.M605603200; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang Y, 2006, MOL PHARMACOL, V70, P297, DOI 10.1124/mol.106.023994; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Wang ZL, 2006, BIOCHEMISTRY-US, V45, P9929, DOI 10.1021/bi0608055; Wittenburg H, 2005, MAMM GENOME, V16, P495, DOI 10.1007/s00335-005-0006-2; Wittenburg H, 2003, GASTROENTEROLOGY, V125, P868, DOI 10.1016/S0016-5085(03)01053-9; Wittenburg H, 2006, J LIPID RES, V47, P1780, DOI 10.1194/jlr.M500544-JLR200; Yie Q, 2002, HEPATOLOGY, V36, P592, DOI 10.1053/jhep.2002.35441; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Yu LQ, 2005, J BIOL CHEM, V280, P8742, DOI 10.1074/jbc.M411080200	51	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22397	22405		10.1074/jbc.M702236200	http://dx.doi.org/10.1074/jbc.M702236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17561514	hybrid			2022-12-25	WOS:000248354200018
J	Chen, M; Cai, MY; Aprahamian, CJ; Georgeson, KE; Hruby, V; Harmon, CM; Yang, YK				Chen, Min; Cai, Minying; Aprahamian, Charles J.; Georgeson, Keith E.; Hruby, Victor; Harmon, Carroll M.; Yang, Yingkui			Contribution of the conserved amino acids of the melanocortin-4 receptor in D-[Nle(4), Phe(7)]-alpha-melanocyte-stimulating hormone binding and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGOUTI-RELATED PROTEIN; MOLECULAR DETERMINANTS; COUPLED RECEPTORS; LIGAND-BINDING; IN-VITRO; OBESITY; ANTAGONIST; AGONISTS; MUTAGENESIS; NONPEPTIDE	Melanocortin 4 receptor (MC4R) plays an important role in the regulation of food intake and body weight. To determine the molecular basis of human MC4R (hMC4R) responsible for alpha-melanocortin-stimulating hormone (alpha-MSH) binding, in this study, we utilized both receptor domain exchange and site-directed mutagenesis studies to investigate the molecular determinants of hMC4R responsible for alpha-MSH binding and signaling. alpha-MSH is a potent agonist at hMC4R but not at hMC2R. Cassette substitutions of the second, third, fourth, fifth, and sixth transmembrane regions (TM) of the hMC4R with the homologous regions of hMC2R were performed and alpha-MSH binding and signaling were examined. Our results indicate that each chimeric receptor was expressed at the cell surface and the expression levels remain similar to that of the wild-type receptor. The cassette substitutions of the second, fourth, fifth, and sixth TMs of the hMC4R with homologous regions of the hMC2R did not significantly alter alpha-MSH binding affinity and potency except substitution of the TM3 of the hMC4R, suggesting that the conserved residues in TMs of the hMC4R are crucial for alpha-MSH binding and signaling. Further mutagenesis studies indicate that conserved residues Glu(100) in TM2, Asp(122), Asp(126) in TM3 and Trp(258), Phe(261), His(264) in TM6 are involved in alpha-MSHbinding and signaling. In conclusion, our results suggest that the conserved residues in the TM2, TM3, and TM6 of the hMC4R are responsible for alpha-MSH binding and signaling.	Univ Alabama, Dept Surg, Birmingham, AL 35205 USA; Univ Alabama, Dept Nutr, Birmingham, AL 35205 USA; Univ Arizona, Dept Chem, Tucson, AZ USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Arizona	Yang, YK (corresponding author), Div Pediat Surg, Volker Hall G100M,1670 Univ Blvd, Birmingham, AL USA.	ying-kui.yang@ccc.uab.edu	Cai, Minying/H-6712-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD047312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017420] Funding Source: NIH RePORTER; NICHD NIH HHS [R03 HD047312, R03 HD047312-01A1] Funding Source: Medline; NIDDK NIH HHS [R01 DK017420-32, DK17420, R01 DK017420] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Cone RD, 1999, TRENDS ENDOCRIN MET, V10, P211, DOI 10.1016/S1043-2760(99)00153-8; Conrad DM, 2004, J CELL BIOCHEM, V92, P387, DOI 10.1002/jcb.20064; Damcott CM, 2004, METABOLISM, V53, P303, DOI 10.1016/j.metabol.2003.10.010; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Fisher SL, 1999, INT J OBESITY, V23, P54, DOI 10.1038/sj.ijo.0800796; Fleck BA, 2005, BIOCHEMISTRY-US, V44, P14494, DOI 10.1021/bi051316s; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fong TM, 1997, BIOCHEM BIOPH RES CO, V237, P629, DOI 10.1006/bbrc.1997.7200; Geller F, 2004, AM J HUM GENET, V74, P572, DOI 10.1086/382490; Giraudo SQ, 1998, BRAIN RES, V809, P302, DOI 10.1016/S0006-8993(98)00837-3; Haskell-Luevano C, 1996, Drug Des Discov, V14, P197; Haskell-Luevano C, 2001, BIOCHEMISTRY-US, V40, P6164, DOI 10.1021/bi010025q; Hogan K, 2006, J MED CHEM, V49, P911, DOI 10.1021/jm050780s; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kowalski TJ, 2004, APPETITE, V42, P11, DOI 10.1016/j.appet.2002.12.001; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Lubrano-Berthelier C, 2003, ANN NY ACAD SCI, V994, P49, DOI 10.1111/j.1749-6632.2003.tb03161.x; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Pogozheva ID, 2005, BIOCHEMISTRY-US, V44, P11329, DOI 10.1021/bi0501840; Rugg Katy, 2004, Nurs Times, V100, P28; Yang Y, 2000, BIOCHEMISTRY-US, V39, P14900, DOI 10.1021/bi001684q; Yang YK, 1997, J BIOL CHEM, V272, P23000, DOI 10.1074/jbc.272.37.23000; Yang YK, 1999, J BIOL CHEM, V274, P14100, DOI 10.1074/jbc.274.20.14100; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; Yang YK, 2002, J BIOL CHEM, V277, P20328, DOI 10.1074/jbc.M201343200; Yang YK, 2001, AM J PHYSIOL-REG I, V281, pR1877, DOI 10.1152/ajpregu.2001.281.6.R1877; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148; Zimmermann-Belsing T, 2004, ENDOCRINOLOGY, V145, P1501, DOI 10.1210/en.2004-0078	34	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21712	21719		10.1074/jbc.M702285200	http://dx.doi.org/10.1074/jbc.M702285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545153	Green Accepted, hybrid			2022-12-25	WOS:000248196800018
J	Holm, GH; Zurney, J; Tumilasci, V; Leveille, S; Danthi, P; Hiscott, J; Sherry, B; Dermody, TS				Holm, Geoffrey H.; Zurney, Jennifer; Tumilasci, Vanessa; Leveille, Simon; Danthi, Pranav; Hiscott, John; Sherry, Barbara; Dermody, Terence S.			Retinoic acid-inducible gene-I and interferon-beta promoter stimulator-1 augment proapoptotic responses following mammalian reovirus infection via interferon regulatory factor-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTOR-3; CARDIAC MYOCYTE CULTURES; INDUCED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; RIG-I; INDUCED APOPTOSIS; ANTIVIRAL RESPONSES; ATTACHMENT PROTEIN	During viral infection, cells initiate antiviral responses to contain replication and inhibit virus spread. One protective mechanism involves activation of transcription factors interferon regulatory factor-3 (IRF-3) and NF-kappa B, resulting in secretion of the antiviral cytokine, interferon-beta. Another is induction of apoptosis, killing the host cell before virus disseminates. Mammalian reovirus induces both interferon-beta and apoptosis, raising the possibility that both pathways are initiated by a common cellular sensor. We show here that reovirus activates IRF-3 with kinetics that parallel the activation of NF-kappa B, a known mediator of reovirus-induced apoptosis. Activation of IRF-3 requires functional retinoic acid inducible gene-I and interferon-beta promoter stimulator-1, but these intracellular sensors are dispensable for activation of NF-kappa B. Interferon-beta promoter stimulator-1 and IRF-3 are required for efficient apoptosis following reovirus infection, suggesting a common mechanism of antiviral cytokine induction and activation of the cell death response.	Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA; N Carolina State Univ, Dept Microbiol, Raleigh, NC 27606 USA; N Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC 27606 USA; McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; Lady Davis Institute; McGill University	Dermody, TS (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, D7235 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	terry.dermody@vanderbilt.edu	Holm, Geoffrey H./C-3188-2009; Danthi, Pranav/H-6330-2019	Danthi, Pranav/0000-0001-6199-6022; Sherry, Barbara/0000-0001-9858-6094	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI071440, R01AI050080, T32AI049824, R01AI062657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA68485] Funding Source: Medline; NIAID NIH HHS [F32 AI071440, R01 AI50080, T32 AI49824, R01 AI62657] Funding Source: Medline; NIDDK NIH HHS [P60 DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Baer GS, 1997, J VIROL, V71, P4921, DOI 10.1128/JVI.71.7.4921-4928.1997; BANERJEE AK, 1971, J MOL BIOL, V61, P643, DOI 10.1016/0022-2836(71)90069-6; BELLAMY AR, 1967, P NATL ACAD SCI USA, V58, P1389, DOI 10.1073/pnas.58.4.1389; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Coffey CM, 2006, J VIROL, V80, P8422, DOI 10.1128/JVI.02601-05; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Connolly JL, 2002, J VIROL, V76, P1632, DOI 10.1128/JVI.76.4.1632-1641.2002; DeBiasi RL, 2001, J VIROL, V75, P351, DOI 10.1128/JVI.75.1.351-361.2001; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; FURUICHI Y, 1975, P NATL ACAD SCI USA, V72, P742, DOI 10.1073/pnas.72.2.742; Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; GUPTA SL, 1982, VIROLOGY, V120, P495, DOI 10.1016/0042-6822(82)90051-4; Hansberger MW, 2007, J VIROL, V81, P1360, DOI 10.1128/JVI.01860-06; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HENDERSON DR, 1978, VIROLOGY, V91, P389, DOI 10.1016/0042-6822(78)90386-0; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kirshner JR, 2005, J VIROL, V79, P9320, DOI 10.1128/JVI.79.14.9320-9324.2005; Kobayashi T, 2007, CELL HOST MICROBE, V1, P147, DOI 10.1016/j.chom.2007.03.003; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LOO YM, 2005, AM SOC VIR 24 ANN M; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Mogensen TH, 2005, J MOL MED, V83, P180, DOI 10.1007/s00109-004-0620-6; MORGAN EM, 1975, VIROLOGY, V68, P455, DOI 10.1016/0042-6822(75)90286-X; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; Nibert ML., 2001, FIELDS VIROLOGY, P1679; NILSEN TW, 1982, J BIOL CHEM, V257, P4593; Noah DL, 1999, J VIROL, V73, P10208, DOI 10.1128/JVI.73.12.10208-10213.1999; O'Donnell SM, 2006, J VIROL, V80, P1077, DOI 10.1128/JVI.80.3.1077-1086.2006; O'Donnell SM, 2005, J CLIN INVEST, V115, P2341, DOI 10.1172/JCI22428; Oberhaus SM, 1997, J VIROL, V71, P2100, DOI 10.1128/JVI.71.3.2100-2106.1997; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; RANKIN JT, 1989, VIROLOGY, V168, P147, DOI 10.1016/0042-6822(89)90413-3; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Selleri C, 1997, BLOOD, V89, P957, DOI 10.1182/blood.V89.3.957; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Sherry B, 1998, J VIROL, V72, P1314, DOI 10.1128/JVI.72.2.1314-1323.1998; Smith JA, 2005, J VIROL, V79, P2240, DOI 10.1128/JVI.79.4.2240-2250.2005; Stewart MJ, 2005, J VIROL, V79, P2979, DOI 10.1128/JVI.79.5.2979-2987.2005; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; Tyler K.L., 2001, FIELDS VIROLOGY, P1729; TYLER KL, 1995, J VIROL, V69, P6972, DOI 10.1128/JVI.69.11.6972-6979.1995; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 1996, J BIOCHEM-TOKYO, V120, P160; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	64	96	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21953	21961		10.1074/jbc.M702112200	http://dx.doi.org/10.1074/jbc.M702112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17540767	hybrid			2022-12-25	WOS:000248196800043
J	Huarte, M; Lan, F; Kim, T; Vaughn, MW; Zaratiegui, M; Martienssen, RA; Buratowski, S; Shi, Y				Huarte, Maite; Lan, Fei; Kim, Taesoo; Vaughn, Matthew W.; Zaratiegui, Mikel; Martienssen, Robert A.; Buratowski, Stephen; Shi, Yang			The fission yeast Jmj2 reverses histone H3 lysine 4 trimethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEINS; DNA-BINDING PROPERTIES; METHYLATION PATTERNS; DEMETHYLATION; TRANSCRIPTION; HETEROCHROMATIN; FAMILY; GENE; DERNETHYLASE; ACETYLATION	Histone methylation regulates transcription, chromatin structure, and the epigenetic state of the cell. Recent studies identified the JmjC domain as a catalytic module for histone demethylation. Schizosaccharomyces pombe contains seven JmjC proteins, but it was unclear whether any of them functioned as histone demethylases. In this report, we show that the JmjC protein Jmj2, which is evolutionarily conserved from yeast to human, reversed trimethylated H3-Lys-4 to di- and mono-but not unmethylated products. Overexpression of Jmj2 but not a catalytically inactive mutant reduced H3-Lys-4 trimethylation levels in vivo and suppressed the toxicity caused by overexpression of the H3-Lys-4-me3-binding protein Yng1 in budding yeast. Genome-wide analysis showed that the loss of jmj2 was associated with an increase in the H3-Lys-4-me3 signal, which was enriched near the transcriptional start sites and the coding regions. At the mating-type locus, the loss of jmj2 or substitution of jmj2 with a catalytically inactive form is correlated with increased reporter gene transcription and H3-Lys-4-me3/2 levels, suggesting that Jmj2 and its demethylase activity may play a role in heterochromatin biology. Our findings identified a novel S. pombe histone demethylase with specificity toward di- and trimethylated histone H3-Lys-4 and a possible role in heterochromatin regulation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Cold Spring Harbor Laboratory	Shi, Y (corresponding author), Harvard Univ, Sch Med, Dept Pathol, NRB Rm 854B,77 Ave Louis Pasteur, Boston, MA 02115 USA.	yang_shi@hms.harvard.edu	Huarte, Maite/J-6903-2014	Huarte, Maite/0000-0003-3753-6493; Kim, TaeSoo/0000-0002-3902-1058; Vaughn, Matthew/0000-0002-1384-4283; Zaratiegui, Mikel/0000-0002-0342-0268	NCI NIH HHS [CA118487] Funding Source: Medline; NIGMS NIH HHS [R01 GM076396, GM071004, R01 GM076396-04, GM46498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA118487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046498, R01GM046498, R01GM071004, R01GM076396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed S, 2004, MOL CELL BIOL, V24, P3660, DOI 10.1128/MCB.24.9.3660-3669.2004; Ayoub N, 2003, MOL CELL BIOL, V23, P4356, DOI 10.1128/MCB.23.12.4356-4370.2003; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Eissenberg JC, 2007, NAT STRUCT MOL BIOL, V14, P344, DOI 10.1038/nsmb1217; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Grewal SIS, 1997, GENETICS, V146, P1221; Howe L, 2002, MOL CELL BIOL, V22, P5047, DOI 10.1128/MCB.22.14.5047-5053.2002; Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004; Lee N, 2007, NAT STRUCT MOL BIOL, V14, P341, DOI 10.1038/nsmb1216; Liang G, 2007, NAT STRUCT MOL BIOL, V14, P243, DOI 10.1038/nsmb1204; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Seward DJ, 2007, NAT STRUCT MOL BIOL, V14, P240, DOI 10.1038/nsmb1200; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026; Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wilsker D, 2004, NUCLEIC ACIDS RES, V32, P1345, DOI 10.1093/nar/gkh277; Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zofall M, 2006, MOL CELL, V22, P681, DOI 10.1016/j.molcel.2006.05.010	46	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21662	21670		10.1074/jbc.M703897200	http://dx.doi.org/10.1074/jbc.M703897200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17550896	hybrid			2022-12-25	WOS:000248196800013
J	Immeln, D; Schlesinger, R; Heberle, J; Kottke, T				Immeln, Dominik; Schlesinger, Ramona; Heberle, Joachim; Kottke, Tilman			Blue light induces radical formation and autophosphorylation in the light-sensitive domain of Chlamydomonas cryptochrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ELECTRON-TRANSFER; ARABIDOPSIS CRYPTOCHROMES; ESCHERICHIA-COLI; DNA PHOTOLYASE; 2ND CHROMOPHORE; IN-VIVO; PHOTORECEPTORS; IDENTIFICATION; PHOSPHORYLATION; PROTEIN	Cryptochromes are sensory blue light receptors mediating various responses in plants and animals. Studies on the mechanism of plant cryptochromes have been focused on the flowering plant Arabidopsis. In the genome of the unicellular green alga Chlamydomonas reinhardtii, a single plant cryptochrome, Chlamydomonas photolyase homologue 1 (CPH1), has been identified. The N-terminal 500 amino acids comprise the light-sensitive domain of CPH1 linked to a C-terminal extension of similar size. We have expressed the light-sensitive domain heterologously in Escherichia coli in high yield and purity. The 59-kDa protein bears exclusively flavin adenine dinucleotide in its oxidized state. Illumination with blue light induces formation of a neutral flavin radical with absorption maxima at 540 and 580 nm. The reaction proceeds aerobically even in the absence of an exogenous electron donor, which suggests that it reflects a physiological response. The process is completely reversible in the dark and exhibits a decay time constant of 200 s in the presence of oxygen. Binding of ATP strongly stabilizes the radical state after illumination and impedes the dark recovery. Thus, ATP binding has functional significance for plant cryptochromes and does not merely result from structural homology to DNA photolyase. The light-sensitive domain responds to illumination by an increase in phosphorylation. The autophosphorylation takes place although the protein is lacking its native C-terminal extension. This finding indicates that the extension is dispensable for autophosphorylation, despite the role it has been assigned in mediating signal transduction in Arabidopsis.	Forschungszentrum Julich, Inst Neurosci & Biophys Mol Biophys 2, D-52425 Julich, Germany; Univ Bielefeld, Dept Chem, D-33615 Bielefeld, Germany	Helmholtz Association; Research Center Julich; University of Bielefeld	Kottke, T (corresponding author), Forschungszentrum Julich, Inst Neurosci & Biophys Mol Biophys 2, Postfach 1913, D-52425 Julich, Germany.	tilman.kottke@uni-bielefeld.de	Heberle, Joachim/D-8605-2016; Kottke, Tilman/B-7102-2011; Schlesinger, Ramona/W-2620-2018	Heberle, Joachim/0000-0001-6321-2615; Kottke, Tilman/0000-0001-8080-9579; Schlesinger, Ramona/0000-0002-7716-4439				AHMAD M, 1995, PLANT J, V8, P653, DOI 10.1046/j.1365-313X.1995.08050653.x; Banerjee R, 2007, J BIOL CHEM, V282, P14916, DOI 10.1074/jbc.M700616200; Berndt A, 2007, J BIOL CHEM, V282, P13011, DOI 10.1074/jbc.M608872200; Bouly JP, 2007, J BIOL CHEM, V282, P9383, DOI 10.1074/jbc.M609842200; Bouly JP, 2003, EUR J BIOCHEM, V270, P2921, DOI 10.1046/j.1432-1033.2003.03691.x; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Cashmore AR, 2003, CELL, V114, P537, DOI 10.1016/j.cell.2003.08.004; Daiyasu H, 2004, GENES CELLS, V9, P479, DOI 10.1111/j.1356-9597.2004.00738.x; Danon A, 2006, P NATL ACAD SCI USA, V103, P17036, DOI 10.1073/pnas.0608139103; Durr H, 2005, BIOCHEMISTRY-US, V44, P3050, DOI 10.1021/bi0478897; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Gindt YM, 2005, J AM CHEM SOC, V127, P10472, DOI 10.1021/ja051441r; Giovani B, 2003, NAT STRUCT BIOL, V10, P489, DOI 10.1038/nsb933; Holzer W, 2005, J LUMIN, V112, P444, DOI 10.1016/j.jlumin.2004.09.069; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Imaizumi T, 2000, PLANT CELL, V12, P81, DOI 10.1105/tpc.12.1.81; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; Kleine T, 2003, PLANT J, V35, P93, DOI 10.1046/j.1365-313X.2003.01787.x; Kottke T, 2006, BIOCHEMISTRY-US, V45, P2472, DOI 10.1021/bi051964b; Laan W, 2004, PHOTOCH PHOTOBIO SCI, V3, P1011, DOI 10.1039/b410923f; Lariguet P, 2005, J MOL EVOL, V61, P559, DOI 10.1007/s00239-004-0294-2; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Lorenz B, 2001, BBA-PROTEIN STRUCT M, V1547, P254, DOI 10.1016/S0167-4838(01)00193-5; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Mao J, 2005, P NATL ACAD SCI USA, V102, P12270, DOI 10.1073/pnas.0501011102; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Ozgur S, 2006, BIOCHEMISTRY-US, V45, P13369, DOI 10.1021/bi061556n; Partch CL, 2005, METHOD ENZYMOL, V393, P726, DOI 10.1016/S0076-6879(05)93038-3; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; Pokorny R, 2005, ACTA CRYSTALLOGR F, V61, P935, DOI 10.1107/S1744309105028897; Reisdorph NA, 2004, PLANT PHYSIOL, V134, P1546, DOI 10.1104/pp.103.031930; Sambrook J, 2001, MOL CLONING LAB MANU; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Schaffer S, 2001, ELECTROPHORESIS, V22, P4404, DOI 10.1002/1522-2683(200112)22:20<4404::AID-ELPS4404>3.0.CO;2-2; Schulenberg B, 2003, J BIOL CHEM, V278, P27251, DOI 10.1074/jbc.C300189200; Selby CP, 2006, P NATL ACAD SCI USA, V103, P17696, DOI 10.1073/pnas.0607993103; Shalitin D, 2003, PLANT CELL, V15, P2421, DOI 10.1105/tpc.013011; Shalitin D, 2002, NATURE, V417, P763, DOI 10.1038/nature00815; Siegel L M, 1978, Methods Enzymol, V53, P419; SMALL GD, 1995, PLANT MOL BIOL, V28, P443, DOI 10.1007/BF00020393; Song SH, 2006, J PHOTOCH PHOTOBIO B, V85, P1, DOI 10.1016/j.jphotobiol.2006.03.007; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suetsugu N, 2003, CURR OPIN PLANT BIOL, V6, P91, DOI 10.1016/S1369526602000067; Wang HY, 2001, SCIENCE, V294, P154, DOI 10.1126/science.1063630; Worthington EN, 2003, J BIOL CHEM, V278, P39143, DOI 10.1074/jbc.M305792200; Yang HQ, 2001, PLANT CELL, V13, P2573, DOI 10.1105/tpc.13.12.2573; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; Zeugner A, 2005, J BIOL CHEM, V280, P19437, DOI 10.1074/jbc.C500077200; Zueva N N, 1993, Biokhimiia, V58, P1009	53	59	62	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21720	21728		10.1074/jbc.M700849200	http://dx.doi.org/10.1074/jbc.M700849200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17548357	hybrid			2022-12-25	WOS:000248196800019
J	Rees, EM; Thiele, DJ				Rees, Erin M.; Thiele, Dennis J.			Identification of a vacuole-associated metalloreductase and its role in Ctr2-mediated intracellular copper mobilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FERRIC REDUCTASE; MOLECULAR CHARACTERIZATION; IRON UPTAKE; TRANSCRIPTIONAL CONTROL; PLASMA-MEMBRANE; REGULATED GENES; YEAST; TRANSPORTER; PROTEIN	Copper is an essential trace metal whose biological utility is derived from its ability to cycle between oxidized Cu(II) and reduced Cu(I). Ctr1 is a high affinity plasma membrane copper permease, conserved from yeast to humans, that mediates the physiological uptake of Cu(I) from the extracellular environment. In the baker's yeast Saccharomyces cerevisiae, extracellular Cu(II) is reduced to Cu(I) via the action of the cell surface metalloreductase Fre1, similar to the human gp(91phox) subunit of the NADPH oxidase complex, which utilizes heme and flavins to catalyze electron transfer. The S. cerevisiae Ctr2 protein is structurally similar to Ctr1, localizes to the vacuole membrane, and mobilizes vacuolar copper stores to the cytosol via a mechanism that is not well understood. Here we show that Ctr2-1, a mutant form of Ctr2 that mislocalizes to the plasma membrane, requires the Fre1 plasma membrane metalloreductase for Cu(I) import. The conserved methionine residues that are essential for Ctr1 function at the plasma membrane are also essential for Ctr2-1-mediated Cu(I) uptake. We demonstrate that Fre6, a member of the yeast Fre1 metalloreductase protein family, resides on the vacuole membrane and functions in Ctr2-mediated vacuolar copper export, and cells lacking Fre6 phenocopy the Cu-deficient growth defect of ctr2 Delta cells. Furthermore, both CTR2 and FRE6 mRNA levels are regulated by iron availability. Taken together these studies suggest that copper movement across intracellular membranes is mechanistically similar to that at the plasma membrane. This work provides a model for communication between the extracellular Cu(I) uptake and the intracellular Cu(I) mobilization machinery.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA	Duke University; Duke University	Thiele, DJ (corresponding author), 3813 Res Dr,LSRC C-351, Durham, NC 27710 USA.	dennis.thiele@duke.edu			NIGMS NIH HHS [GM41840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aller SG, 2006, P NATL ACAD SCI USA, V103, P3627, DOI 10.1073/pnas.0509929103; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; Bellemare DR, 2002, J BIOL CHEM, V277, P46676, DOI 10.1074/jbc.M206444200; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Cobine PA, 2006, J BIOL CHEM, V281, P36552, DOI 10.1074/jbc.M606839200; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Field LS, 2002, J BIOENERG BIOMEMBR, V34, P373, DOI 10.1023/A:1021202119942; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Froissard Marine, 2006, Biotechnology Journal, V1, P308, DOI 10.1002/biot.200500034; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Georgatsou E, 1999, YEAST, V15, P573, DOI 10.1002/(SICI)1097-0061(199905)15:7<573::AID-YEA404>3.3.CO;2-Z; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; Guisbert KSK, 2007, PLOS BIOL, V5, P15, DOI 10.1371/journal.pbio.0050006; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; Hammacott JE, 2000, MICROBIOL-SGM, V146, P869, DOI 10.1099/00221287-146-4-869; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Knight SAB, 2006, MICROBIOL-SGM, V152, P2301, DOI 10.1099/mic.0.28843-0; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Linder M, 1991, BIOCH COPPER; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MacDiarmid CW, 2002, J BIOL CHEM, V277, P39187, DOI 10.1074/jbc.M205052200; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; Nose Y, 2006, TRENDS BIOCHEM SCI, V31, P604, DOI 10.1016/j.tibs.2006.09.003; Nose Y, 2006, CELL METAB, V4, P235, DOI 10.1016/j.cmet.2006.08.009; Ohgami RS, 2006, BLOOD, V108, P1388, DOI 10.1182/blood-2006-02-003681; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; PROHASKA JR, 2000, J NUTR, V8, P502; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rees EM, 2004, J BIOL CHEM, V279, P54221, DOI 10.1074/jbc.M411669200; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; Sancenon V, 2003, PLANT MOL BIOL, V51, P577, DOI 10.1023/A:1022345507112; Severance S, 2004, BIOCHEM J, V380, P487, DOI 10.1042/BJ20031921; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; Shim H, 2003, J NUTR, V133, p1527S, DOI 10.1093/jn/133.5.1527S; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Wang TP, 2003, J BIOL INORG CHEM, V8, P611, DOI 10.1007/s00775-003-0456-5; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2003, J BIOL CHEM, V278, P48210, DOI 10.1074/jbc.M309820200; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	72	80	86	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21629	21638		10.1074/jbc.M703397200	http://dx.doi.org/10.1074/jbc.M703397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17553781	hybrid			2022-12-25	WOS:000248196800009
J	Bedard, J; Kubis, S; Bimanadham, S; Jarvis, P				Bedard, Jocelyn; Kubis, Sybille; Bimanadham, Sarat; Jarvis, Paul			Functional similarity between the chloroplast translocon component, Tic40, and the human co-chaperone, Hsp70-interacting protein (Hip)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER ENVELOPE MEMBRANE; MOLECULAR-CHAPERONE; IN-VIVO; ARABIDOPSIS-THALIANA; IMPORT MACHINERY; HSP90; HOP; COCHAPERONE; PLASTIDS; HSP70	Tic40 is a component of the protein import apparatus of the inner envelope of chloroplasts, but its role in the import mechanism has not been clearly defined. The C terminus of Tic40 shares weak similarity with the C-terminal Sti1 domains of the mammalian Hsp70-interacting protein (Hip) and Hsp70/Hsp90-organizing protein (Hop) co-chaperones. Additionally, Tic40 may possess a tetratricopeptide repeat (TPR) protein-protein interaction domain, another characteristic feature of Hip/Hop co-chaperones. To investigate the functional importance of different parts of the Tic40 protein and to determine whether the homology between Tic40 and co-chaperones is functionally significant, different Tic40 deletion and Tic40:Hip fusion constructs were generated and assessed for complementation activity in the Arabidopsis Tic40 knock-out mutant, tic40. Interestingly, all Tic40 deletion constructs failed to complement tic40, indicating that each part removed is essential for Tic40 function; these included a construct lacking the Sti1-like domain (Delta Sti1), a second lacking a central region, including the putative TPR domain (Delta TPR), and a third lacking the predicted transmembrane anchor region. Moreover, the Delta Sti1 and Delta TPR constructs caused strong dominant-negative, albino phenotypes in tic40 transformants, indicating that the truncated Tic40 proteins interfere with the residual chloroplast protein import that occurs in tic40 plants. Remarkably, the Tic40:Hip fusion constructs showed that the Sti1 domain of human Hip is functionally equivalent to the Sti1-like region of Tic40, strongly suggesting a co-chaperone role for the Tic40 protein. Supporting this notion, yeast two-hybrid and bimolecular fluorescence complementation assays demonstrated the in vivo interaction of Tic40 with Tic110, a protein believed to recruit stromal chaperones to protein import sites.	Univ Leicester, Dept Biol, Leicester LE1 7RH, Leics, England	University of Leicester	Jarvis, P (corresponding author), Univ Leicester, Dept Biol, Univ Rd, Leicester LE1 7RH, Leics, England.	rpj3@le.ac.uk						Abbas-Terki T, 2001, MOL CELL BIOL, V21, P7569, DOI 10.1128/MCB.21.22.7569-7575.2001; Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; Aronsson H, 2002, FEBS LETT, V529, P215, DOI 10.1016/S0014-5793(02)03342-2; Bedard J, 2005, J EXP BOT, V56, P2287, DOI 10.1093/jxb/eri243; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Bruce BD, 1997, EUR J BIOCHEM, V245, P738, DOI 10.1111/j.1432-1033.1997.00738.x; Cao DS, 2003, PLANT J, V33, P107, DOI 10.1046/j.1365-313X.2003.016011.x; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chou ML, 2006, J CELL BIOL, V175, P893, DOI 10.1083/jcb.200609172; Chou ML, 2003, EMBO J, V22, P2970, DOI 10.1093/emboj/cdg281; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Fan GH, 2002, J BIOL CHEM, V277, P6590, DOI 10.1074/jbc.M110588200; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; HOHFELD J, 1995, CELL, V83, P589; Inaba T, 2005, PLANT CELL, V17, P1482, DOI 10.1105/tpc.105.030700; Inaba T, 2003, J BIOL CHEM, V278, P38617, DOI 10.1074/jbc.M306367200; Irmer H, 1997, J BIOL CHEM, V272, P2230; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Kessler F, 2006, TRAFFIC, V7, P248, DOI 10.1111/j.1600-0854.2005.00382.x; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; Ko K, 2004, FUNCT PLANT BIOL, V31, P285, DOI 10.1071/FP03195; KO K, 1995, J BIOL CHEM, V270, P28601, DOI 10.1074/jbc.270.48.28601; Kost B, 1998, PLANT J, V16, P393, DOI 10.1046/j.1365-313x.1998.00304.x; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kovacheva S, 2005, PLANT J, V41, P412, DOI 10.1111/j.1365-313X.2004.02307.x; Kovacheva S, 2007, PLANT J, V50, P364, DOI 10.1111/j.1365-313X.2007.03060.x; Kubis S, 2004, PLANT CELL, V16, P2059, DOI 10.1105/tpc.104.023309; Kubis S, 2003, PLANT CELL, V15, P1859, DOI 10.1105/tpc.012955; Li M, 2006, J CELL BIOL, V175, P249, DOI 10.1083/jcb.200605162; Maple J, 2005, PLANT J, V43, P811, DOI 10.1111/j.1365-313X.2005.02493.x; Nelson GM, 2003, CELL STRESS CHAPERON, V8, P125, DOI 10.1379/1466-1268(2003)008<0125:COTCDR>2.0.CO;2; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Prapapanich V, 1996, MOL CELL BIOL, V16, P6200; Reumann S, 2005, MOL MEMBR BIOL, V22, P73, DOI 10.1080/09687860500041916; Soll J, 2004, NAT REV MOL CELL BIO, V5, P198, DOI 10.1038/nrm1333; Stahl T, 1999, J BIOL CHEM, V274, P37467, DOI 10.1074/jbc.274.52.37467; Velten M, 2002, J BIOL CHEM, V277, P259, DOI 10.1074/jbc.M106881200; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; Walter M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x; Webb MA, 2001, CELL STRESS CHAPERON, V6, P247, DOI 10.1379/1466-1268(2001)006<0247:OIATOT>2.0.CO;2; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; WU CB, 1994, J BIOL CHEM, V269, P32264	48	51	55	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21404	21414		10.1074/jbc.M611545200	http://dx.doi.org/10.1074/jbc.M611545200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17535810	hybrid			2022-12-25	WOS:000248047500068
J	Campbell, PA; Perez-Iratxeta, C; Andrade-Navarro, MA; Rudnicki, MA				Campbell, Pearl A.; Perez-Iratxeta, Carolina; Andrade-Navarro, Miguel A.; Rudnicki, Michael A.			Oct4 Targets Regulatory Nodes to Modulate Stem Cell Function	PLOS ONE			English	Article							SELF-RENEWAL; ES CELLS; DIFFERENTIATION; EXPRESSION; CHROMATIN; POLYCOMB; NETWORKS; CANCER; CYCLE; REST	Stem cells are characterized by two defining features, the ability to self-renew and to differentiate into highly specialized cell types. The POU homeodomain transcription factor Oct4(Pou5f1) is an essential mediator of the embryonic stem cell state and has been implicated in lineage specific differentiation, adult stem cell identity, and cancer. Recent description of the regulatory networks which maintain 'ES' have highlighted a dual role for Oct4 in the transcriptional activation of genes required to maintain self-renewal and pluripotency while concomitantly repressing genes which facilitate lineage specific differentiation. However, the molecular mechanism by which Oct4 mediates differential activation or repression at these loci to either maintain stem cell identity or facilitate the emergence of alternate transcriptional programs required for the realization of lineage remains to be elucidated. To further investigate Oct4 function, we employed gene expression profiling together with a robust statistical analysis to identify genes highly correlated to Oct4. Gene Ontology analysis to categorize overrepresented genes has led to the identification of themes which may prove essential to stem cell identity, including chromatin structure, nuclear architecture, cell cycle control, DNA repair, and apoptosis. Our experiments have identified previously unappreciated roles for Oct4 for firstly, regulating chromatin structure in a state consistent with self-renewal and pluripotency, and secondly, facilitating the expression of genes that keeps the cell poised to respond to cues that lead to differentiation. Together, these data define the mechanism by which Oct4 orchestrates cellular regulatory pathways to enforce the stem cell state and provides important insight into stem cell function and cancer.	[Campbell, Pearl A.; Perez-Iratxeta, Carolina; Andrade-Navarro, Miguel A.; Rudnicki, Michael A.] Ottawa Hlth Res Inst, Sprott Ctr Stem Cell Res, Ottawa, ON, Canada; [Campbell, Pearl A.; Andrade-Navarro, Miguel A.; Rudnicki, Michael A.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Rudnicki, MA (corresponding author), Ottawa Hlth Res Inst, Sprott Ctr Stem Cell Res, Ottawa, ON, Canada.	mrudnicki@ohri.ca	Andrade, Miguel A/B-6565-2008	Andrade, Miguel A/0000-0001-6650-1711; Rudnicki, Michael/0000-0002-3866-5249; Campbell, Pearl/0000-0001-9502-7318				Arias AM, 2006, NAT REV GENET, V7, P34, DOI 10.1038/nrg1750; Babaie Y, 2007, STEM CELLS, V25, P500, DOI 10.1634/stemcells.2006-0426; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Beissbarth T, 2004, BIOINFORMATICS, V20, P1464, DOI 10.1093/bioinformatics/bth088; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Broceno C, 2002, P NATL ACAD SCI USA, V99, P14200, DOI 10.1073/pnas.212519499; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cairns BR, 2005, CURR OPIN GENET DEV, V15, P185, DOI 10.1016/j.gde.2005.01.003; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chickarmane V, 2006, PLOS COMPUT BIOL, V2, P1080, DOI 10.1371/journal.pcbi.0020123; Fernandez-Capetillo O, 2004, P NATL ACAD SCI USA, V101, P1427, DOI 10.1073/pnas.0307342101; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Hemberger M, 2003, DEV BIOL, V257, P371, DOI 10.1016/S0012-1606(03)00097-6; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jin TR, 1999, INT J CANCER, V81, P104, DOI 10.1002/(SICI)1097-0215(19990331)81:1<104::AID-IJC18>3.0.CO;2-Q; Kim JY, 2004, EUR J HAEMATOL, V73, P75, DOI 10.1111/j.1600-0609.2004.00268.x; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Matoba R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000026; Mikkers H, 2005, EMBO J, V24, P2715, DOI 10.1038/sj.emboj.7600749; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Perez-Iratxeta C, 2005, FEBS LETT, V579, P1795, DOI 10.1016/j.febslet.2005.02.020; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reim G, 2004, DEV CELL, V6, P91, DOI 10.1016/S1534-5807(03)00396-4; Remenyi A, 2003, GENE DEV, V17, P2048, DOI 10.1101/gad.269303; SELL S, 1994, LAB INVEST, V70, P6; Shimozaki K, 2003, DEVELOPMENT, V130, P2505, DOI 10.1242/dev.00476; Sissons J, 2004, J MED MICROBIOL, V53, P711, DOI 10.1099/jmm.0.45604-0; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Stucki M, 2004, NAT CELL BIOL, V6, P1150, DOI 10.1038/ncb1204-1150; Sun YM, 2005, MOL BIOL CELL, V16, P5630, DOI 10.1091/mbc.E05-07-0687; Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321; Tamrakar S, 2000, FRONT BIOSCI-LANDMRK, V5, pD121, DOI 10.2741/Tamrakar; Trounson AO, 2001, REPROD FERT DEVELOP, V13, P523, DOI 10.1071/Rd01101; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Van Eynde A, 2004, MOL CELL BIOL, V24, P5863, DOI 10.1128/MCB.24.13.5863-5874.2004; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Zhang Wen, 2004, J Biol, V3, P21, DOI 10.1186/jbiol16; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020	58	75	79	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e553	10.1371/journal.pone.0000553	http://dx.doi.org/10.1371/journal.pone.0000553			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579724	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451700018
J	Gray, MA; Harrison, NA; Wiens, S; Critchley, HD				Gray, Marcus A.; Harrison, Neil A.; Wiens, Stefan; Critchley, Hugo D.			Modulation of Emotional Appraisal by False Physiological Feedback during fMRI	PLOS ONE			English	Article							FACIAL EXPRESSIONS; AMYGDALA; CORTEX; FEAR; INTEROCEPTION; AROUSAL; REPRESENTATIONS; DETERMINANTS; RECOGNITION; ATTRIBUTION	Background. James and Lange proposed that emotions are the perception of physiological reactions. Two-level theories of emotion extend this model to suggest that cognitive interpretations of physiological changes shape self-reported emotions. Correspondingly false physiological feedback of evoked or tonic bodily responses can alter emotional attributions. Moreover, anxiety states are proposed to arise from detection of mismatch between actual and anticipated states of physiological arousal. However, the neural underpinnings of these phenomena previously have not been examined. Methodology/Principal Findings. We undertook a functional brain imaging (fMRI) experiment to investigate how both primary and second-order levels of physiological (viscerosensory) representation impact on the processing of external emotional cues. 12 participants were scanned while judging face stimuli during both exercise and non-exercise conditions in the context of true and false auditory feedback of tonic heart rate. We observed that the perceived emotional intensity/salience of neutral faces was enhanced by false feedback of increased heart rate. Regional changes in neural activity corresponding to this behavioural interaction were observed within included right anterior insula, bilateral mid insula, and amygdala. In addition, right anterior insula activity was enhanced during by asynchronous relative to synchronous cardiac feedback even with no change in perceived or actual heart rate suggesting this region serves as a comparator to detect physiological mismatches. Finally, BOLD activity within right anterior insula and amygdala predicted the corresponding changes in perceived intensity ratings at both a group and an individual level. Conclusions/Significance. Our findings identify the neural substrates supporting behavioural effects of false physiological feedback, and highlight mechanisms that underlie subjective anxiety states, including the importance of the right anterior insula in guiding second-order "cognitive" representations of bodily arousal state.	[Gray, Marcus A.; Critchley, Hugo D.] Univ Sussex, Brighton Sussex Med Sch, Clin Imaging Sci Ctr, Brighton, E Sussex, England; [Gray, Marcus A.] UCL, Wellcome Trust Ctr Neuroimaging, Inst Neurol, London, England; [Harrison, Neil A.] UCL, Inst Cognit Neurosci, London, England; [Wiens, Stefan] Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden	University of Brighton; University of Sussex; University of London; University College London; University of London; University College London; Stockholm University	Gray, MA (corresponding author), Univ Sussex, Brighton Sussex Med Sch, Clin Imaging Sci Ctr, Brighton, E Sussex, England.	m.gray@bsms.ac.uk	Gray, Marcus/F-6521-2013; critchley, hugo d/G-9267-2011	Gray, Marcus/0000-0001-8671-6939; critchley, hugo d/0000-0002-2445-9284; Harrison, Neil/0000-0002-9584-3769	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	This research was supported by a Wellcome Trust fellowship grant to HDC and conducted at the Wellcome Trust Centre for Neuroimaging, Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London, 12 Queen Square, London WC1N 3BG.	Adolphs R, 2005, NATURE, V433, P68, DOI 10.1038/nature03086; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; BAREFOOT JC, 1971, J PERS SOC PSYCHOL, V2, P154; CANTOR JR, 1975, J PERS SOC PSYCHOL, V32, P69, DOI 10.1037/h0076784; Carver C. S., 1977, MOTIV EMOTION, V1, P61, DOI 10.1007/BF00997581; Corden B, 2006, J COGNITIVE NEUROSCI, V18, P889, DOI 10.1162/jocn.2006.18.6.889; Craig AD, 2003, CURR OPIN NEUROBIOL, V13, P500, DOI 10.1016/S0959-4388(03)00090-4; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Craig AD, 2005, TRENDS COGN SCI, V9, P566, DOI 10.1016/j.tics.2005.10.005; Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176; Critchley HD, 2001, NAT NEUROSCI, V4, P207, DOI 10.1038/84048; Critchley HD, 2004, P NATL ACAD SCI USA, V101, P6333, DOI 10.1073/pnas.0401510101; Critchley HD, 2005, J COMP NEUROL, V493, P154, DOI 10.1002/cne.20749; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Critchley HD, 2002, NEURON, V33, P653, DOI 10.1016/S0896-6273(02)00588-3; Crucian GP, 2000, CORTEX, V36, P623, DOI 10.1016/S0010-9452(08)70542-2; Damasio A, 2003, ANN NY ACAD SCI, V1001, P253, DOI 10.1196/annals.1279.014; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; Deichmann R, 2003, NEUROIMAGE, V19, P430, DOI 10.1016/S1053-8119(03)00073-9; Feinstein JS, 2006, SOC COGN AFFECT NEUR, V1, P136, DOI 10.1093/scan/nsl016; Fitzgerald DA, 2004, NEUROSCI LETT, V370, P91, DOI 10.1016/j.neulet.2004.08.007; Friston KJ, 1999, NEUROIMAGE, V10, P607, DOI 10.1006/nimg.1999.0498; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; GOLDSTEIN D, 1972, J PERS SOC PSYCHOL, V21, P41, DOI 10.1037/h0031873; Henson RNA, 2005, J COGNITIVE NEUROSCI, V17, P1058, DOI 10.1162/0898929054475208; JAMES W, 1994, PSYCHOL REV, V101, P205, DOI 10.1037/0033-295X.101.2.205; Kano M, 2003, BRAIN, V126, P1474, DOI 10.1093/brain/awg131; Katkin ES, 2001, PSYCHOL SCI, V12, P366, DOI 10.1111/1467-9280.00368; KERBER KW, 1978, J EXP SOC PSYCHOL, V14, P419, DOI 10.1016/0022-1031(78)90039-2; Lane RD, 1997, NEUROREPORT, V8, P3969, DOI 10.1097/00001756-199712220-00024; Lange C, 1885, EMOTIONS; LIEBHART EH, 1979, EUR J SOC PSYCHOL, V9, P19, DOI 10.1002/ejsp.2420090103; Liu TT, 2004, NEUROIMAGE, V21, P401, DOI 10.1016/j.neuroimage.2003.09.031; Lundqvist D., 1998, KAROLINSKA DIRECTED; MISOVICH S, 1974, J EXP SOC PSYCHOL, V10, P274, DOI 10.1016/0022-1031(74)90073-0; Morris JS, 1999, P NATL ACAD SCI USA, V96, P1680, DOI 10.1073/pnas.96.4.1680; PARKINSON B, 1985, PSYCHOL BULL, V98, P471, DOI 10.1037/0033-2909.98.3.471; PARKINSON B, 1981, J PERS SOC PSYCHOL, V40, P239; Paulus MP, 2006, BIOL PSYCHIAT, V60, P383, DOI 10.1016/j.biopsych.2006.03.042; Penny W., 2003, HUMAN BRAIN FUNCTION; Phillips ML, 1998, P ROY SOC B-BIOL SCI, V265, P1809, DOI 10.1098/rspb.1998.0506; Pollatos O, 2004, PSYCHOPHYSIOLOGY, V41, P476, DOI 10.1111/1469-8986.2004.00170.x; Puce A, 1998, J NEUROSCI, V18, P2188; Reiman EM, 1997, AM J PSYCHIAT, V154, P918; ROSENTHAL R, 1965, HUM RELAT, V18, P389, DOI 10.1177/001872676501800407; Russell JA, 2003, PSYCHOL REV, V110, P145, DOI 10.1037/0033-295X.110.1.145; Saper CB, 1996, PROG BRAIN RES, V107, P537; SCHACHTER S, 1962, PSYCHOL REV, V69, P379, DOI 10.1037/h0046234; Shaw P, 2005, J COGNITIVE NEUROSCI, V17, P1410, DOI 10.1162/0898929054985491; STERN RM, 1972, PSYCHOPHYSIOLOGY, V9, P21, DOI 10.1111/j.1469-8986.1972.tb00739.x; TAYLOR SE, 1978, ADV EXPT SOCIAL PSYC, V11, P250; THORNTON EW, 1976, BRIT J SOC PSYCHOL, V67, P400; TRUAX SR, 1983, MOTIV EMOTION, V7, P41; VALINS S, 1966, J PERS SOC PSYCHOL, V4, P400, DOI 10.1037/h0023791; Whalen PJ, 1998, J NEUROSCI, V18, P411; Wiens S, 2005, CURR OPIN NEUROL, V18, P442, DOI 10.1097/01.wco.0000168079.92106.99; Winston JS, 2004, J NEUROPHYSIOL, V92, P1830, DOI 10.1152/jn.00155.2004; Yovel G, 2005, CURR BIOL, V15, P2256, DOI 10.1016/j.cub.2005.10.072; ZILLMANN D, 1971, J EXP SOC PSYCHOL, V7, P419, DOI 10.1016/0022-1031(71)90075-8	59	102	102	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e546	10.1371/journal.pone.0000546	http://dx.doi.org/10.1371/journal.pone.0000546			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579718	Green Published, Green Submitted, Green Accepted, gold			2022-12-25	WOS:000207451700012
J	Wexler-Cohen, Y; Shai, Y				Wexler-Cohen, Yael; Shai, Yechiel			Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition	FASEB JOURNAL			English	Article						HIV-1 inhibition; lipopeptides; coiled coil; T-20; virus entry; envelope protein; heptad repeat; peptide-membrane interaction	VIRAL MEMBRANE-FUSION; VIRUS TYPE-1 GP41; CELL-CELL FUSION; IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; SYNTHETIC PEPTIDE; MECHANISM; ENTRY; SURFACE; ECTODOMAIN	The core complex is a structure involved in the fusion mechanism of many viruses, as well as in intracellular vesicle fusion. A powerful approach for studying the dynamic stages of HIV-1-cell fusion utilizes DP178, a core complex inhibitory peptide derived from the known sequence of the virus. Strikingly, we show that fatty acids can replace the entire C-terminal region of DP178, known to play a crucial role in the activity of the peptide. The inhibitory activity correlated with the length of the fatty acid, with the direction of fatty acid attachment (N-or C-terminus) and, as envisioned by a new triple staining assay, with the concentration of the peptides on cells. Our findings indicate, for the first time, the C-terminal boundary of the endogenous core structure in situ and establish that the C-terminal region of DP178 functions mainly as an anchor to the cell membrane. Apart from the mechanistic implications, such short lipopeptides provide new, promising fusion inhibitors. Because the fusion mechanism of HIV-1 is shared by other pathogen-enveloped viruses and by intracellular vesicle fusion, our results might influence the research and therapeutic efforts in these systems as well.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	yechiel.shai@weizmann.ac.il						Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/0022-1317-83-8-1809; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gerber D, 2004, J BIOL CHEM, V279, P48224, DOI 10.1074/jbc.M403436200; Huerta L, 2002, CYTOMETRY, V47, P100, DOI 10.1002/cyto.10051; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; LaBranche CC, 2001, ANTIVIR RES, V50, P95, DOI 10.1016/S0166-3542(01)00130-9; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200; Melikyan GB, 2006, J VIROL, V80, P3249, DOI 10.1128/JVI.80.7.3249-3258.2006; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Peisajovich SG, 2003, J BIOL CHEM, V278, P21012, DOI 10.1074/jbc.M212773200; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Ryu JR, 1999, BIOCHEM BIOPH RES CO, V265, P625, DOI 10.1006/bbrc.1999.1739; Sal-Man N, 2004, J MOL BIOL, V344, P855, DOI 10.1016/j.jmb.2004.09.066; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Sollner TH, 2004, CURR OPIN CELL BIOL, V16, P429, DOI 10.1016/j.ceb.2004.06.015; Steger HK, 2006, J BIOL CHEM, V281, P25813, DOI 10.1074/jbc.M601457200; WEISS A, 1984, J IMMUNOL, V133, P123; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wexler-Cohen Y, 2006, J BIOL CHEM, V281, P9005, DOI 10.1074/jbc.M512475200; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Zanetti G, 2006, PLOS PATHOG, V2, DOI 10.1371/journal.ppat.0020083; Zhang CWH, 2001, J BIOL CHEM, V276, P39577, DOI 10.1074/jbc.M107147200; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817	33	74	80	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3677	3684		10.1096/fj.07-8582com	http://dx.doi.org/10.1096/fj.07-8582com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575260				2022-12-25	WOS:000250517800029
J	Sarkisov, DV; Gelber, SE; Walker, JW; Wang, SSH				Sarkisov, Dmitry V.; Gelber, Shari E.; Walker, Jeffery W.; Wang, Samuel S. -H.			Synapse specificity of calcium release probed by chemical two-photon uncaging of inositol 1,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE NEURONS; LONG-TERM DEPRESSION; DENDRITIC SPINES; MYOINOSITOL 1,4,5-TRISPHOSPHATE; CAGED COMPOUNDS; SMOOTH-MUSCLE; CELL DENDRITES; CA-2+ RELEASE; CA2+ RELEASE; IP3 RECEPTOR	Biological messengers can be "caged" by adding a single photosensitive group that can be photolyzed by a light flash to achieve spatially and temporally precise biochemical control. Here we report that photolysis of a double-caged form of the second messenger inositol 1,4,5-trisphosphate ( IP3) triggers focal calcium release in Purkinje cell somata, dendrites, and spines as measured by two-photon microscopy. In calbindin knock-out Purkinje cells, peak calcium increased with flash energy with higher cooperativity for double-caged IP3 than for conventional single-caged IP3, consistent with a chemical two-photon effect. Spine photolysis of double-caged IP3 led to local calcium release. Uncaging of glycerophosphoryl-myo-inositol 4,5-bisphosphate ( gPIP(2)), a poorly metabolizable IP3 analog, led to less well localized release. Thus, IP3 breakdown is necessary for spine-specificity. IP3- and gPIP(2)-evoked signals declined from peak with similar, slow time courses, indicating that release lasts hundreds of milliseconds and is terminated not by IP3 degradation but by intrinsic receptor dynamics. Based on measurements of spine-dendrite coupling, IP3- evoked calcium signals are expected to be at least 2.4-fold larger in their spine of origin than in nearby spines, allowing IP3 to act as a synapse-specific second messenger. Unexpectedly, single-caged IP3 led to less release in somata and was ineffective in dendrites and spines. Calcium release using caged gPIP(2) was inhibited by the addition of single-caged IP3, suggesting that single-caged IP3 is an antagonist of calcium release. Caging at multiple sites may be an effective general approach to reducing residual receptor interaction.	Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Program Neurosci, Princeton, NJ 08544 USA; Cornell Weill Med Coll, Div Maternal & Fetal Med, New York, NY 10021 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	Princeton University; Princeton University; Princeton University; Cornell University; University of Wisconsin System; University of Wisconsin Madison	Wang, SSH (corresponding author), Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA.	sswang@princeton.edu			NINDS NIH HHS [NS045193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045193] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.ph.55.030193.003543; BIRD GS, 1992, J BIOL CHEM, V267, P17722; Bosanac I, 2004, BBA-MOL CELL RES, V1742, P89, DOI 10.1016/j.bbamcr.2004.09.016; Carafoli E, 1999, CALCIUM CELLULAR REG; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; Fierro L, 1998, J PHYSIOL-LONDON, V510, P499, DOI 10.1111/j.1469-7793.1998.499bk.x; Fierro L, 1996, J PHYSIOL-LONDON, V496, P617, DOI 10.1113/jphysiol.1996.sp021713; Finch EA, 1998, NATURE, V396, P753, DOI 10.1038/25541; Fujiwara A, 2001, NEUROREPORT, V12, P2647, DOI 10.1097/00001756-200108280-00012; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GO M, 1993, NEUROSCI LETT, V158, P135, DOI 10.1016/0304-3940(93)90247-I; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Ito M, 2002, NAT REV NEUROSCI, V3, P896, DOI 10.1038/nrn962; KHODAKHAH K, 1995, J PHYSIOL-LONDON, V487, P343, DOI 10.1113/jphysiol.1995.sp020884; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; Lee SH, 2000, J PHYSIOL-LONDON, V525, P419, DOI 10.1111/j.1469-7793.2000.t01-2-00419.x; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; LESTER HA, 1982, ANNU REV BIOPHYS BIO, V11, P151, DOI 10.1146/annurev.bb.11.060182.001055; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; Maeda H, 1999, NEURON, V24, P989, DOI 10.1016/S0896-6273(00)81045-4; Mayr GW, 2005, J BIOL CHEM, V280, P13229, DOI 10.1074/jbc.M500545200; McCarron JG, 2004, J BIOL CHEM, V279, P8417, DOI 10.1074/jbc.M311797200; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; Nakanishi W, 2002, BIOORG MED CHEM LETT, V12, P911, DOI 10.1016/S0960-894X(02)00044-6; Nerbonne JM, 1996, CURR OPIN NEUROBIOL, V6, P379, DOI 10.1016/S0959-4388(96)80123-1; NILSSON T, 1988, FEBS LETT, V229, P211, DOI 10.1016/0014-5793(88)80829-9; Ogden D, 1997, J GEN PHYSIOL, V109, P741, DOI 10.1085/jgp.109.6.741; Parker I, 1996, BIOPHYS J, V70, P222, DOI 10.1016/S0006-3495(96)79565-6; Pettit DL, 1997, NEURON, V19, P465, DOI 10.1016/S0896-6273(00)80361-X; Sarkisov DV, 2006, NAT PROTOC, V1, P828, DOI 10.1038/nprot.2006.124; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; Schmidt H, 2003, J PHYSIOL-LONDON, V551, P13, DOI 10.1113/jphysiol.2002.035824; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Takechi H, 1998, NATURE, V396, P757, DOI 10.1038/25547; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; WANG SSH, 1995, NEURON, V15, P755, DOI 10.1016/0896-6273(95)90167-1; Wang SSH, 2000, NAT NEUROSCI, V3, P1266, DOI 10.1038/81792; Wilcox RA, 1997, FEBS LETT, V402, P241, DOI 10.1016/S0014-5793(96)01540-2; Wilcox RA, 1998, TRENDS PHARMACOL SCI, V19, P467, DOI 10.1016/S0165-6147(98)01260-7; Womack MD, 2000, J GEN PHYSIOL, V115, P339, DOI 10.1085/jgp.115.3.339; YAMADA M, 1993, BRAIN RES, V606, P335, DOI 10.1016/0006-8993(93)91004-C	54	10	10	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25517	25526		10.1074/jbc.M609672200	http://dx.doi.org/10.1074/jbc.M609672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17540776	hybrid			2022-12-25	WOS:000249014100038
J	Askew, DJ; Cataltepe, S; Kumar, V; Edwards, C; Pace, SM; Howarth, RN; Pak, SC; Askew, YS; Bromme, D; Luke, CJ; Whisstock, JC; Silverman, GA				Askew, David J.; Cataltepe, Sule; Kumar, Vasantha; Edwards, Christopher; Pace, Serena M.; Howarth, Rica N.; Pak, Stephen C.; Askew, Yuko S.; Broemme, Dieter; Luke, Cliff J.; Whisstock, James C.; Silverman, Gary A.			SERPINB11 is a new noninhibitory intracellular serpin - Common single nucleotide polymorphisms in the scaffold impair conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR MASPIN; MESSENGER-RNA DECAY; ANTIGEN GENE LOCUS; FUNCTIONAL EXPRESSION; PROTEINASE-INHIBITOR; RELAXED TRANSITION; SERINE PROTEINASES; ANTITHROMBIN-III; REACTIVE CENTER	SERPINB11, the last of 13 human clade B serpins to be described, gave rise to seven different isoforms. One cDNA contained a premature termination codon, two contained splice variants, and four contained full-length open reading frames punctuated by eight single nucleotide polymorphisms ( SNPs). The SNPs encoded amino acid variants located within the serpin scaffold but not the reactive site loop ( RSL). Although the mouse orthologue, Serpinb11, could inhibit trypsin-like peptidases, SERPINB11 showed no inhibitory activity. To determine whether the human RSL targeted a different class of peptidases or the serpin scaffold was unable to support inhibitory activity, we synthesized chimeric human and mouse proteins, in which the RSLs had been swapped. The human RSL served as a trypsin inhibitor when supported by mouse scaffold sequences. Conversely, the mouse RSL on the human scaffold showed no inhibitory activity. These findings suggested that variant residues in the SERPINB11 scaffold impaired serpin function. SDS-PAGE analysis supported this notion as RSL-cleaved SERPINB11 was unable to undergo the stressed-to-relaxed transition typical of inhibitory type serpins. Mutagenesis studies supported this hypothesis, since the reversion of amino acid sequences in helices D and I to those conserved in other clade B serpins partially restored the ability of SERPINB11 to form covalent complexes with trypsin. Taken together, these findings suggested that SERPINB11 SNPs encoded amino acids in the scaffold that impaired RSL mobility, and HapMap data showed that the majority of genomes in different human populations harbored these noninhibitory SERPINB11 alleles. Like several other serpin superfamily members, SERPINB11 has lost inhibitory activity and may have evolved a noninhibitory function.	Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat,UPMC Newborn Med Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Pittsburgh, PA 15213 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Univ British Columbia, Inst Life Sci, Fac Dent, Vancouver, BC V6T 1Z3, Canada; Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Harvard University; Harvard Medical School; University of British Columbia; Monash University	Silverman, GA (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat,UPMC Newborn Med Program, 300 Halket St, Pittsburgh, PA 15213 USA.	gsilverman@mail.magee.edu	Silverman, Gary/AAJ-1269-2020	Pak, Stephen/0000-0002-8089-3237; Whisstock, James/0000-0003-4200-5611	NATIONAL CANCER INSTITUTE [R01CA086002, R01CA087006] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R10HL052636, U01HL075904, U10HL052636, U01HL052636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046182] Funding Source: NIH RePORTER; NCI NIH HHS [CA86002, CA87006] Funding Source: Medline; NHLBI NIH HHS [HL004403, HL52636, HL075904] Funding Source: Medline; NIAMS NIH HHS [AR46182] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Askew DJ, 2004, GENOMICS, V84, P166, DOI 10.1016/j.ygeno.2004.01.014; Askew DJ, 2004, GENOMICS, V84, P176, DOI 10.1016/j.ygeno.2004.01.015; Askew YS, 2001, J BIOL CHEM, V276, P49320, DOI 10.1074/jbc.M108879200; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bird CH, 2001, MOL CELL BIOL, V21, P5396, DOI 10.1128/MCB.21.16.5396-5407.2001; BIRD PI, 2003, NATURE ENCY HUMAN GE, V4, P462; Blouse GE, 2003, BIOCHEMISTRY-US, V42, P12260, DOI 10.1021/bi034737n; Briand C, 2001, FEBS LETT, V505, P18, DOI 10.1016/S0014-5793(01)02764-8; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; Dafforn TR, 2001, J BIOL CHEM, V276, P49310, DOI 10.1074/jbc.M108896200; Fulton KF, 2005, J BIOL CHEM, V280, P8435, DOI 10.1074/jbc.M410206200; Gao F, 2004, DEVELOPMENT, V131, P1479, DOI 10.1242/dev.01048; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; GRUNDY CB, 1992, HUM GENET, V88, P707, DOI 10.1007/BF02265306; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Izuhara K, 2003, CLIN CHEM LAB MED, V41, P860, DOI 10.1515/CCLM.2003.130; Kaiserman D, 2002, GENOMICS, V79, P349, DOI 10.1006/geno.2002.6716; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law RHP, 2005, J BIOL CHEM, V280, P22356, DOI 10.1074/jbc.M412043200; Law RHP, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-216; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Luke C, 2000, BIOCHEMISTRY-US, V39, P7081, DOI 10.1021/bi000050g; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Maquat LE, 2005, J CELL SCI, V118, P1773, DOI 10.1242/jcs.01701; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SCHELLENBERGER V, 1994, BIOCHEMISTRY-US, V33, P4251, DOI 10.1021/bi00180a020; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; Silverman GA, 2004, CELL MOL LIFE SCI, V61, P301, DOI 10.1007/s00018-003-3240-3; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; Uemura Y, 2000, INT J CANCER, V89, P368, DOI 10.1002/1097-0215(20000720)89:4<368::AID-IJC9>3.0.CO;2-6; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972; Zhou AW, 2006, P NATL ACAD SCI USA, V103, P13321, DOI 10.1073/pnas.0604080103; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	56	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24948	24960		10.1074/jbc.M703182200	http://dx.doi.org/10.1074/jbc.M703182200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17562709	hybrid			2022-12-25	WOS:000248933000051
J	Chen, FH; Herndon, ME; Patel, N; Hecht, JT; Tuan, RS; Lawler, J				Chen, Faye Hui; Herndon, Mary E.; Patel, Nichlesh; Hecht, Jacqueline T.; Tuan, Rocky S.; Lawler, Jack			Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; ARTICULAR-CARTILAGE; PSEUDOACHONDROPLASIA; COMP; BINDING; MUTATIONS; AFFINITY; COLLAGEN; CALCIUM; TENDON	Cartilage oligomeric matrix protein/thrombospondin 5 (COMP/TSP5) is a major component of the extracellular matrix (ECM) of the musculoskeletal system. Its importance is underscored by its association with several growth disorders. In this report, we investigated its interaction with aggrecan, a major component of cartilage ECM. We also tested a COMP/TSP5 mutant, designated MUT3 that accounts for 30% of human pseudoachon-droplasia cases, to determine if the mutation affects function. Using a solid-phase binding assay, we have shown that COMP/TSP5 can bind aggrecan. This binding was decreased with MUT3, or when COMP/TSP5 was treated with EDTA, indicating the presence of a conformation-dependent aggrecan binding site. Soluble glycosaminoglycans (GAGs) partially inhibited binding, suggesting that the interaction was mediated in part through aggrecan GAG side chains. Using affinity co-electrophoresis, we showed that COMP/TSP5, in its calcium-replete conformation, bound to heparin, chondroitin sulfates, and heparan sulfate; this binding was reduced with EDTA treatment of COMP/TSP5. MUT3 showed weaker binding than calcium-repleted COMP/TSP5. Using recombinant COMP/TSP5 fragments, we found that the "signature domain" could bind to aggrecan, suggesting that this domain can mediate the interaction of COMP/TSP5 and aggrecan. In summary, our data indicate that COMP/TSP5 is an aggrecan-binding protein, and this interaction is regulated by the calcium-sensitive conformation of COMP/TSP5; interaction of COMP with aggrecan can be mediated through the GAG side chains on aggrecan and the "signature domain" of COMP/TSP5. Our results suggest that COMP/TSP5 may function to support matrix interactions in cartilage ECM.	NIAMS, Cartilage Biol & Orthopaed Branch, NIH, Bethesda, MD 20892 USA; Columbia Univ, Dept Orthopaed Surg, New York, NY 10032 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Div Tumor Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX 77225 USA; Shriners Hosp Children, Houston, TX 77225 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Columbia University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Texas System	Chen, FH (corresponding author), NIAMS, Cartilage Biol & Orthopaed Branch, NIH, Bethesda, MD 20892 USA.	chenf1@mail.nih.gov	Lawler, Jack/AAJ-1379-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041131] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [R01 HL049081-10, R01 HL049081, HL49081] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Carlson CB, 2005, NAT STRUCT MOL BIOL, V12, P910, DOI 10.1038/nsmb997; Chen FH, 2005, J BIOL CHEM, V280, P32655, DOI 10.1074/jbc.M504778200; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; Di Cesare PE, 2000, J ORTHOPAED RES, V18, P713, DOI 10.1002/jor.1100180506; Di Cesare PE, 2002, MATRIX BIOL, V21, P461, DOI 10.1016/S0945-053X(02)00015-X; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DiCesare PE, 1996, J ORTHOPAED RES, V14, P946, DOI 10.1002/jor.1100140615; DICESARE PE, 1995, J ORTHOPAED RES, V13, P422, DOI 10.1002/jor.1100130316; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; Hauser N, 1995, ACTA ORTHOP SCAND, V266, P71; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; Hecht JT, 1998, MATRIX BIOL, V17, P625, DOI 10.1016/S0945-053X(98)90113-5; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; HERNDON ME, 1997, LAB GUIDE GLYCOCONJG, P379; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIM WA, 1991, METHOD ENZYMOL, V208, P196; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; MAYNARD JA, 1972, LAB INVEST, V26, P40; Mow V.C., 2005, BASIC ORTHOPAEDIC BI; Murphy JM, 1999, MATRIX BIOL, V18, P487, DOI 10.1016/S0945-053X(99)00042-6; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Petersson IF, 1998, BRIT J RHEUMATOL, V37, P46; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2	40	107	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24591	24598		10.1074/jbc.M611390200	http://dx.doi.org/10.1074/jbc.M611390200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17588949	Green Accepted, hybrid			2022-12-25	WOS:000248933000013
J	Yanamadala, V; Negoro, H; Gunaratnam, L; Kong, TQ; Denker, BM				Yanamadala, Vijay; Negoro, Hideyuki; Gunaratnam, Lakshman; Kong, Tianqing; Denker, Bradley M.			G alpha(12) stimulates apoptosis in epithelial cells through JNK1-mediated Bcl-2 degradation and up-regulation of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; N-TERMINAL KINASE; RHO-DEPENDENT ACTIVATION; NEOPLASTIC TRANSFORMATION; LYSOPHOSPHATIDIC ACID; PHOSPHATASE 2A; G13 PROTEINS; FAMILY; DEATH; JNK	Apoptosis is an essential mechanism for the maintenance of somatic tissues, and when dysregulated can lead to numerous pathological conditions. G proteins regulate apoptosis in addition to other cellular functions, but the roles of specific G proteins in apoptosis signaling are not well characterized. G alpha(12) stimulates protein phosphatase 2A (PP2A), a serine/threonine phosphatase that modulates essential signaling pathways, including apoptosis. Herein, we examined whether G alpha(12) regulates apoptosis in epithelial cells. Inducible expression of G alpha(12) or constitutively active (QL)alpha(12) in Madin-Darby canine kidney cells led to increased apoptosis with expression of QL alpha(12), but not G alpha(12). Inducing QL alpha(12) led to degradation of the anti-apoptotic protein Bcl-2 (via the proteasome pathway), increased JNK activity, and up-regulated I kappa B alpha protein levels, a potent stimulator of apoptosis. Furthermore, the QL alpha(12)-stimulated activation of JNK was blocked by inhibiting PP2A. To characterize endogenous G alpha(12) signaling pathways, non-transfected MDCK-II and HEK293 cells were stimulated with thrombin. Thrombin activated endogenous G alpha(12) (confirmed by GST-tetratricopeptide repeat (TPR) pull-downs) and stimulated apoptosis in both cell types. The mechanisms of thrombin-stimulated apoptosis through endogenous G alpha(12) were nearly identical to the mechanisms identified in QL alpha(12)-MDCK cells and included loss of Bcl-2, JNK activation, and up-regulation of I kappa B alpha. Knockdown of the PP2A catalytic subunit in HEK293 cells inhibited thrombin-stimulated apoptosis, prevented JNK activation, and blocked Bcl-2 degradation. In summary, G alpha(12) has a major role in regulating epithelial cell apoptosis through PP2A and JNK activation leading to loss of Bcl-2 protein expression. Targeting these pathways in vivo may lead to new therapeutic strategies for a variety of disease processes.	Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Denker, BM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Renal, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	bdenker@rics.bwh.harvard.edu	Gunaratnam, Lakshman/G-3299-2011	Gunaratnam, Lakshman/0000-0002-8845-1126	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK074030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055223, R01GM055223] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK074030] Funding Source: Medline; NIGMS NIH HHS [GM-55223] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adarichev VA, 2003, AM J PHYSIOL-CELL PH, V285, pC922, DOI 10.1152/ajpcell.00115.2003; Al-Rasheed NM, 2006, J AM SOC NEPHROL, V17, P986, DOI 10.1681/ASN.2005080797; Ashton AW, 2003, J BIOL CHEM, V278, P11858, DOI 10.1074/jbc.M210766200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Bianchi P, 2003, J AM SOC NEPHROL, V14, P855, DOI 10.1097/01.ASN.0000058909.00567.5C; Brichese L, 2004, CELL CYCLE, V3, P1312, DOI 10.4161/cc.3.10.1166; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chang YH, 2007, J CELL PHYSIOL, V211, P174, DOI 10.1002/jcp.20926; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Choi SH, 2003, NEUROBIOL DIS, V14, P181, DOI 10.1016/S0969-9961(03)00085-8; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Dermott JM, 2004, ONCOGENE, V23, P226, DOI 10.1038/sj.onc.1207009; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Garcia A, 2003, BIOCHIMIE, V85, P721, DOI 10.1016/j.biochi.2003.09.004; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Graham B, 2005, CELL CYCLE, V4, P1342, DOI 10.4161/cc.4.10.2047; Guan QH, 2005, BRAIN RES, V1035, P51, DOI 10.1016/j.brainres.2004.11.050; Hains MD, 2006, MOL PHARMACOL, V69, P2068, DOI 10.1124/mol.105.017921; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Howes AL, 2006, J MOL CELL CARDIOL, V40, P597, DOI 10.1016/j.yjmcc.2005.12.003; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Ki SH, 2007, J BIOL CHEM, V282, P1938, DOI 10.1074/jbc.M606080200; Kumar RN, 2006, ONCOGENE, V25, P899, DOI 10.1038/sj.onc.1209132; Kumar RN, 2004, CELL BIOCHEM BIOPHYS, V41, P63, DOI 10.1385/CBB:41:1:063; Lin HH, 1999, KIDNEY INT, V55, P168, DOI 10.1046/j.1523-1755.1999.00249.x; Lin SS, 2006, J BIOL CHEM, V281, P23003, DOI 10.1074/jbc.M602648200; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Ma FY, 2007, J AM SOC NEPHROL, V18, P472, DOI 10.1681/ASN.2006060604; Maudsley S, 2004, CANCER RES, V64, P7533, DOI 10.1158/0008-5472.CAN-04-1360; Meyer TN, 2003, AM J PHYSIOL-CELL PH, V285, pC1281, DOI 10.1152/ajpcell.00548.2002; Meyer TN, 2002, J BIOL CHEM, V277, P24855, DOI 10.1074/jbc.C200240200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagamatsu Y, 2006, J PHARMACOL SCI, V101, P144, DOI 10.1254/jphs.FP0051036; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Radhika V, 2005, ONCOGENE, V24, P4597, DOI 10.1038/sj.onc.1208665; Ray RM, 2005, J BIOL CHEM, V280, P31091, DOI 10.1074/jbc.M503041200; Sorenson CM, 2004, BBA-MOL CELL RES, V1644, P169, DOI 10.1016/j.bbamcr.2003.08.010; Tobin AB, 2003, BIOCHEM SOC T, V31, P1182; Ueda H, 2004, EXP CELL RES, V298, P207, DOI 10.1016/j.yexcr.2004.04.015; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wiren KM, 2006, BONE, V38, P637, DOI 10.1016/j.bone.2005.10.029; WOO D, 1995, NEW ENGL J MED, V333, P18, DOI 10.1056/NEJM199507063330104; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yuasa T, 2004, GENOMICS, V84, P126, DOI 10.1016/j.ygeno.2004.02.008; Zhao CN, 2006, J NEUROSCI RES, V84, P389, DOI 10.1002/jnr.20875; Zhu DG, 2007, MOL PHARMACOL, V71, P1268, DOI 10.1124/mol.106.033555; Zhu DG, 2004, J BIOL CHEM, V279, P54983, DOI 10.1074/jbc.C400508200; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	64	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24352	24363		10.1074/jbc.M702804200	http://dx.doi.org/10.1074/jbc.M702804200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17565996	hybrid			2022-12-25	WOS:000248686600061
J	Dormond, O; Madsen, JC; Briscoe, DM				Dormond, Olivier; Madsen, Joren C.; Briscoe, David M.			The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GROWTH-FACTOR; CYCLE PROGRESSION; MAMMALIAN TARGET; S6 KINASE; RAPAMYCIN; PATHWAY; PHOSPHORYLATION; ANGIOGENESIS; SURVIVAL	Recent studies have determined that mTOR mediates the activation of the protein kinase Akt in several cell types, but little is known about the association between mTOR and Akt in vascular endothelial cells. Furthermore, the functional significance of mTOR/Akt signaling has not been characterized in the endothelium. In these studies we treated endothelial cells with the mTOR inhibitor rapamycin, and we found that it decreases Akt phosphorylation and activity, as determined by phosphorylation of its substrate glycogen synthase kinase-3. This effect of rapamycin on Akt phosphorylation could not be demonstrated in endothelial cells transfected with a rapamycin-resistant mTOR construct. Also, in the presence of rapamycin, vascular endothelial growth factor, tumor necrosis factor, and insulin failed to phosphorylate Akt, further indicating that mTOR regulates Akt activation in endothelial cells. The activation of Akt is well established to mediate pro-survival signals. In part this is mediated via the phosphorylation and inactivation of the proapoptotic Akt substrates Foxo1 and Foxo3a. We find that rapamycin totally blocks vascular endothelial growth factor and Aktinducible phosophorylation of these transcription factors in endothelial cells. Furthermore, inhibition of Akt activity by rapamycin increased the number of endothelial cells undergoing apoptosis after serum withdrawal as well as after stimulation by vascular endothelial growth factor or tumor necrosis factor. Taken together these observations demonstrate first, that mTOR regulates the phosphorylation and activation of Akt in endothelial cells and, second, that a major effect of mTOR inhibition in endothelial cells is to suppress Akt-inducible pro-survival signals.	Childrens Hosp, Div Nephrol, Dept Med, Transplant Res Ctr, Boston, MA 02115 USA; Massachusetts Gen Hosp, Transplant Biol Res Ctr, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital	Briscoe, DM (corresponding author), Childrens Hosp, Div Nephrol, Dept Med, Transplant Res Ctr, 300 Longwood Ave, Boston, MA 02115 USA.	david.biscoe@childrens.harvard	Dormond, Olivier/B-5347-2017	Dormond, Olivier/0000-0002-6418-1782; Briscoe, David/0000-0003-4135-5417	NIAID NIH HHS [R01 AI046756, R01AI046756, R01 AI046756-06A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046756] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; BROWN LF, 1997, EXS, V79, P233; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Datta K, 2004, CANCER RES, V64, P456, DOI 10.1158/0008-5472.CAN-03-2706; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dimmeler S, 2000, CIRC RES, V87, P434; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Flaxenburg JA, 2004, J IMMUNOL, V172, P7503, DOI 10.4049/jimmunol.172.12.7503; Fosbrink M, 2006, J BIOL CHEM, V281, P19009, DOI 10.1074/jbc.M602055200; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Kwon YS, 2005, INVEST OPHTH VIS SCI, V46, P454, DOI 10.1167/iovs.04-0753; Liu L, 2006, ONCOGENE, V25, P7029, DOI 10.1038/sj.onc.1209691; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	51	115	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23679	23686		10.1074/jbc.M700563200	http://dx.doi.org/10.1074/jbc.M700563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17553806	Green Accepted, hybrid			2022-12-25	WOS:000248577500071
J	Hanger, DP; Byers, HL; Wray, S; Leung, KY; Saxton, MJ; Seereeram, A; Reynolds, CH; Ward, MA; Anderton, BH				Hanger, Diane P.; Byers, Helen L.; Wray, Selina; Leung, Kit-Yi; Saxton, Malcolm J.; Seereeram, Anjan; Reynolds, C. Hugh; Ward, Malcolm A.; Anderton, Brian H.			Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED-HELICAL FILAMENTS; CASEIN KINASE-I; GLYCOGEN-SYNTHASE KINASE-3-BETA; DEPENDENT PROTEIN-KINASE; NANOELECTROSPRAY MASS-SPECTROMETRY; N-TERMINAL KINASE; ABNORMAL PHOSPHORYLATION; REQUIRES PHOSPHORYLATION; NEUROFIBRILLARY TANGLES; HYPERPHOSPHORYLATED TAU		Inst Psychiat, Dept Neurosci, MRC Ctr Neurodegenerat Tes, London SE5 8AF, England; Inst Psychiat, Univ London Kings Coll, Proteome Sci Plc, London SE5 8AF, England	University of London; King's College London; University of London; King's College London	Anderton, BH (corresponding author), Inst Psychiat, Dept Neurosci, MRC Ctr Neurodegenerat Tes, De Crespigny Pk, London SE5 8AF, England.	d.hanger@iop.kcl.ac.uk	Wray, Selina/C-3682-2009; Hanger, Diane/C-5697-2009	Wray, Selina/0000-0003-3062-7050; Hanger, Diane/0000-0002-3044-9816; Ward, Malcolm/0000-0003-2164-6938	Medical Research Council [G0300408] Funding Source: Medline; Alzheimers Research UK [ART-EG2004A-1] Funding Source: researchfish; MRC [G0300408] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alonso AD, 2001, J BIOL CHEM, V276, P37967; Bandyopadhyay B, 2007, J BIOL CHEM, V282, P16454, DOI 10.1074/jbc.M700192200; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Brion J. P., 1985, ARCH BIOL BRUX, V95, P229; BRION JP, 1993, J NEUROCHEM, V60, P1372, DOI 10.1111/j.1471-4159.1993.tb03298.x; BRION JP, 1991, BIOCHEM J, V279, P831, DOI 10.1042/bj2790831; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; CHAUHAN A, 1993, BRAIN RES, V629, P47, DOI 10.1016/0006-8993(93)90479-7; Cox David M, 2005, J Biomol Tech, V16, P83; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Feijoo C, 2005, J CELL SCI, V118, P397, DOI 10.1242/jcs.01655; Ferrari A, 2003, J BIOL CHEM, V278, P40162, DOI 10.1074/jbc.M308243200; Flajolet M, 2007, P NATL ACAD SCI USA, V104, P4159, DOI 10.1073/pnas.0611236104; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Ghoshal N, 1999, AM J PATHOL, V155, P1163, DOI 10.1016/S0002-9440(10)65219-4; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GREENWOOD JA, 1994, J BIOL CHEM, V269, P4373; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Hanger DP, 2002, FEBS LETT, V531, P538, DOI 10.1016/S0014-5793(02)03611-6; Hasegawa M, 1996, FEBS LETT, V384, P25, DOI 10.1016/0014-5793(96)00271-2; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Hernandez F, 2003, NEUROBIOL AGING, V24, P1087, DOI 10.1016/j.neurobiolaging.2003.04.002; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; Ishiguro K, 1995, NEUROSCI LETT, V202, P81, DOI 10.1016/0304-3940(95)12206-0; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Kuret J, 1997, J NEUROCHEM, V69, P2506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau Lit-Fui, 2002, Current Topics in Medicinal Chemistry, V2, P395, DOI 10.2174/1568026024607526; Lee G, 2004, J NEUROSCI, V24, P2304, DOI 10.1523/JNEUROSCI.4162-03.2004; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu F, 2002, FEBS LETT, V512, P101, DOI 10.1016/S0014-5793(02)02228-7; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; MORISHIMAKAWASHIMA M, 1995, NEUROBIOL AGING, V16, P365, DOI 10.1016/0197-4580(95)00027-C; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MULOT SFC, 1994, FEBS LETT, V349, P359, DOI 10.1016/0014-5793(94)00702-0; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Pastorino L, 2002, MOL CELL NEUROSCI, V19, P175, DOI 10.1006/mcne.2001.1065; Perkinton MS, 2004, J BIOL CHEM, V279, P22084, DOI 10.1074/jbc.M311479200; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sato S, 2006, J NEUROCHEM, V98, P1573, DOI 10.1111/j.1471-4159.2006.04059.x; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Schwab C, 2000, NEUROBIOL AGING, V21, P503, DOI 10.1016/S0197-4580(00)00110-X; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; Shahani N, 2002, CELL MOL LIFE SCI, V59, P1668, DOI 10.1007/PL00012495; Singh TJ, 1996, MOL CELL BIOCHEM, V154, P143, DOI 10.1007/BF00226782; Utton MA, 2002, J NEUROSCI, V22, P6394; Vega IE, 2005, MOL BRAIN RES, V138, P135, DOI 10.1016/j.molbrainres.2005.04.015; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Watanabe A, 2004, J NEUROCHEM, V90, P1302, DOI 10.1111/j.1471-4159.2004.02611.x; Watanabe A, 1999, J BIOL CHEM, V274, P7368, DOI 10.1074/jbc.274.11.7368; Yamamoto H, 2005, J NEUROCHEM, V94, P1438, DOI 10.1111/j.1471-4159.2005.03307.x; Yasojima K, 2000, BRAIN RES, V865, P116, DOI 10.1016/S0006-8993(00)02200-9; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	75	316	342	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23645	23654		10.1074/jbc.M703269200	http://dx.doi.org/10.1074/jbc.M703269200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17562708	hybrid			2022-12-25	WOS:000248577500067
J	Usatyuk, PV; Romer, LH; He, DH; Parinandi, NL; Kleinberg, ME; Zhan, S; Jacobson, JR; Dudek, SM; Pendyala, S; Garcia, JGN; Natarajan, V				Usatyuk, Peter V.; Romer, Lewis H.; He, Donghong; Parinandi, Narasimham L.; Kleinberg, Michael E.; Zhan, Steve; Jacobson, Jeffrey R.; Dudek, Steven M.; Pendyala, Srikanth; Garcia, Joe G. N.; Natarajan, Viswanathan			Regulation of hyperoxia-induced NADPH oxidase activation in human lung endothelial cells by the actin cytoskeleton and cortactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RESPIRATORY BURST OXIDASE; TYROSINE PHOSPHORYLATION; BINDING PROTEIN; SUPEROXIDE GENERATION; MUSCLE-CELLS; P47(PHOX); SITES; LOCALIZATION; COMPONENT	Although the actin cytoskeleton has been implicated in the control of NADPH oxidase in phagocytosis, very little is known about the cytoskeletal regulation of endothelial NADPH oxidase assembly and activation. Here, we report a role for cortactin and the tyrosine phosphorylation of cortactin in hyperoxia-induced NADPH oxidase activation and ROS production in human pulmonary artery ECs (HPAECs). Exposure of HPAECs to hyperoxia for 3 h induced NADPH oxidase activation, as demonstrated by enhanced superoxide production. Hyperoxia also caused a thickening of the subcortical dense peripheral F-actin band and increased the localization of cortactin in the cortical regions and lamellipodia at cell-cell borders that protruded under neighboring cells. Pretreatment of HPAECs with the actin-stabilizing agent phallacidin attenuated hyperoxia-induced cortical actin thickening and ROS production, whereas cytochalasin D and latrunculin A enhanced basal and hyperoxia-induced ROS formation. In HPAECs, a 3-h hyperoxic exposure enhanced the tyrosine phosphorylation of cortactin and interaction between cortactin and p47(phox), a subcomponent of the EC NADPH oxidase, when compared with normoxic cells. Furthermore, transfection of HPAECs with cortactin small interfering RNA or myristoylated cortactin Src homology domain 3 blocking peptide attenuated ROS production and the hyperoxia-induced translocation of p47(phox) to the cell periphery. Similarly, down-regulation of Src with Src small interfering RNA attenuated the hyperoxia-mediated phosphorylation of cortactin tyrosines and blocked the association of cortactin with actin and p47(phox). In addition, the hyperoxia-induced generation of ROS was significantly lower in ECs expressing a tyrosine-deficient mutant of cortactin than in vector control or wild-type cells. These data demonstrate a novel function for cortactin and actin in hyperoxia-induced activation of NADPH oxidase and ROS generation in human lung endothelial cells.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care, Baltimore, MD 21205 USA; Ohio State Univ, Dept Med, Columbus, OH 43210 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University of Chicago; Johns Hopkins University; University System of Ohio; Ohio State University; University System of Maryland; University of Maryland Baltimore	Usatyuk, PV (corresponding author), Ctr Integrat Sci Bldg,Rm 408B,929 E 57th St, Chicago, IL 60637 USA.	vnataraj@medicine.bsd.uchicago.edu	Garcia, Joe GN/E-8862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069909, P01HL058064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI061042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL69909, P01 HL 58064] Funding Source: Medline; NIAID NIH HHS [AI061042] Funding Source: Medline; NIDCR NIH HHS [DE13079-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BENGTSSON T, 1991, J LEUKOCYTE BIOL, V49, P236, DOI 10.1002/jlb.49.3.236; Bengtsson T, 2006, CELL BIOL INT, V30, P154, DOI 10.1016/j.cellbi.2005.10.017; Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725; Cai H, 2005, CIRC RES, V96, P818, DOI 10.1161/01.RES.0000163631.07205.fb; Cave AC, 2006, ANTIOXID REDOX SIGN, V8, P691, DOI 10.1089/ars.2006.8.691; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chowdhury AK, 2005, J BIOL CHEM, V280, P20700, DOI 10.1074/jbc.M411722200; Clempus RE, 2006, CARDIOVASC RES, V71, P216, DOI 10.1016/j.cardiores.2006.02.033; Cosen-Binker LI, 2006, PHYSIOLOGY, V21, P352, DOI 10.1152/physiol.00012.2006; Didichenko SA, 2000, FEBS LETT, V485, P147, DOI 10.1016/S0014-5793(00)02220-1; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Dudek SM, 2002, BIOCHEM BIOPH RES CO, V298, P511, DOI 10.1016/S0006-291X(02)02492-0; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Frey RS, 2006, J BIOL CHEM, V281, P16128, DOI 10.1074/jbc.M508810200; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Grogan A, 1997, J CELL SCI, V110, P3071; Guzik TJ, 2006, DRUG DISCOV TODAY, V11, P524, DOI 10.1016/j.drudis.2006.04.003; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Hordijk PL, 2006, CIRC RES, V98, P453, DOI 10.1161/01.RES.0000204727.46710.5e; HU T, 2005, AM J PHYSIOL, V289, pF660; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Krause KH, 2004, JPN J INFECT DIS, V57, pS28; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Lee JY, 2006, TOXICOL LETT, V166, P212, DOI 10.1016/j.toxlet.2006.07.305; Li JM, 2004, AM J PHYSIOL-REG I, V287, pR1014, DOI 10.1152/ajpregu.00124.2004; Li QA, 2006, MOL CELL BIOL, V26, P140, DOI 10.1128/MCB.26.1.140-154.2006; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Martin KH, 2006, J CELL SCI, V119, P2851, DOI 10.1242/jcs03034; May RC, 2001, J CELL SCI, V114, P1061; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Morimatsu T, 1997, BIOCHEM BIOPH RES CO, V230, P206, DOI 10.1006/bbrc.1996.5881; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; PARINANDI NL, 2002, AM J PHYSIOL, V284, pL26; Qian Y, 2005, J BIOL CHEM, V280, P3875, DOI 10.1074/jbc.M403788200; Suzuki M, 2003, J ALLERGY CLIN IMMUN, V112, P126, DOI 10.1067/mai.2003.1515; Tamura M, 2000, BIOCHEM BIOPH RES CO, V276, P1186, DOI 10.1006/bbrc.2000.3598; Tamura M, 2006, FEBS LETT, V580, P261, DOI 10.1016/j.febslet.2005.11.080; Therade-Matharan S, 2005, AM J PHYSIOL-REG I, V289, pR1756, DOI 10.1152/ajpregu.00480.2004; Touyz RM, 2005, ARTERIOSCL THROM VAS, V25, P512, DOI 10.1161/01.ATV.0000154141.66879.98; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Usatyuk PV, 2006, J BIOL CHEM, V281, P35554, DOI 10.1074/jbc.M607305200; Utomo A, 2006, J IMMUNOL, V177, P6388, DOI 10.4049/jimmunol.177.9.6388; Waki K, 2006, FREE RADICAL RES, V40, P359, DOI 10.1080/10715760500539121; Wang JS, 2005, CELL MOTIL CYTOSKEL, V62, P35, DOI 10.1002/cm.20083; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WIELAND T, 1978, CRC CR REV BIOCH MOL, V5, P185, DOI 10.3109/10409237809149870; Wolin MS, 2004, ARTERIOSCL THROM VAS, V24, P625, DOI 10.1161/01.ATV.0000117201.14603.5d; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yang L, 2006, CIRC RES, V98, P394, DOI 10.1161/01.RES.0000201958.59020.1a; Yung Lai Ming, 2006, Cardiovascular & Hematological Disorders - Drug Targets, V6, P1; Zhan Y, 2004, J CELL BIOCHEM, V92, P795, DOI 10.1002/jcb.20084	59	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23284	23295		10.1074/jbc.M700535200	http://dx.doi.org/10.1074/jbc.M700535200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17562703	hybrid			2022-12-25	WOS:000248577500029
J	Meyer, MB; Zella, LA; Nerenz, RD; Pike, JW				Meyer, Mark B.; Zella, Lee A.; Nerenz, Robert D.; Pike, J. Wesley			Characterizing early events associated with the activation of target genes by 1,25-dihydroxyvitamin D-3 in mouse kidney and intestine in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; KNOCKOUT MICE; REGULATED TRANSCRIPTION; CALCIUM-ABSORPTION; CA2+ TRANSPORT; DNA-BINDING; CHANNEL; EXPRESSION; CELLS; DIFFERENTIATION	In this report, we explore the interaction of the vitamin D receptor (VDR) at regulatory sites within both the Cyp24a1 and the Trpv6 genes using chromatin immunoprecipitation techniques in a mouse model in vivo. We show that exogenous 1,25(OH)(2)D-3 induces rapid VDR and RXR (retinoid X receptor) binding to the Cyp24a1 gene in both the kidney and the intestine and to the Trpv6 gene in the intestine. Separate studies of Trpv6 in vitro suggest that VDR binding occurs directly to VDR response elements located -2 and -4 kb upstream of the TSS. VDR binding is dose-dependent, demonstrating EC50 values that are comparable with those for the induction of both Cyp24a1 and Trpv6mRNA. Importantly, interaction of the VDR with these targets results in rapid changes in histone 4 acetylation as well as the recruitment of RNA polymerase II. The presence of both VDR and RNA polymerase II at these sites declines between 3-6 h, whereas the changes observed in acetylation decrease more slowly. Finally, we show that whereas mediator protein 1 is recruited to the Cyp24a1 promoter in the intestine, this coactivator is apparently not required for Trpv6 activation. These studies provide the first evidence for 1,25( OH)(2)D-3-induced VDR interaction at key target genes in vivo, revealing the consequences of that interaction on the Cyp24a1 and Trpv6 genes.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Pike, JW (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	pike@biochem.wisc.edu			NIDDK NIH HHS [DK052459, DK072281] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072281] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCO SD, 2006, J BONE MINER RES; BRONNER F, 1986, AM J PHYSIOL, V250, pG561, DOI 10.1152/ajpgi.1986.250.5.G561; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DENKKER E, 2003, CELL CALCIUM, V33, P497; FEHER JJ, 1983, AM J PHYSIOL, V244, P303; Fretz JA, 2006, MOL ENDOCRINOL, V20, P2215, DOI 10.1210/me.2006-0102; Gkika D, 2006, J AM SOC NEPHROL, V17, P3020, DOI 10.1681/ASN.2006060676; Hoenderop JGJ, 2002, BBA-PROTEINS PROTEOM, V1600, P6, DOI 10.1016/S1570-9639(02)00438-7; Hoenderop JGJ, 2002, FASEB J, V16, P1398, DOI 10.1096/fj.02-0225com; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; JIANG HP, 1994, ONCOGENE, V9, P3397; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kim S, 2005, J BONE MINER RES, V20, P305, DOI 10.1359/JBMR.041112; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Meyer MB, 2006, MOL ENDOCRINOL, V20, P1447, DOI 10.1210/me.2006-0031; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Renkema KY, 2005, J AM SOC NEPHROL, V16, P3188, DOI 10.1681/ASN.2005060632; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Song YR, 2003, ENDOCRINOLOGY, V144, P3885, DOI 10.1210/en.2003-0314; Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002-0363; van Abel M, 2003, AM J PHYSIOL-GASTR L, V285, pG78, DOI 10.1152/ajpgi.00036.2003; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Warming S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni035; Wasserman R. H., 1997, Vitamin D., P259; Yamamoto H, 2003, J BIOL CHEM, V278, P31756, DOI 10.1074/jbc.M304737200; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	32	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22344	22352		10.1074/jbc.M703475200	http://dx.doi.org/10.1074/jbc.M703475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17556365	hybrid			2022-12-25	WOS:000248354200012
J	McNutt, MC; Lagace, TA; Horton, JD				McNutt, Markey C.; Lagace, Thomas A.; Horton, Jay D.			Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN CONVERTASE; PRECURSOR PROTEINS; LDL RECEPTORS; MUTATIONS; MUTANTS; FURIN; MICE; HYPERCHOLESTEROLEMIA; IDENTIFICATION; TRAFFICKING	Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K subfamily of subtilases, promotes internalization and degradation of low density lipoprotein receptors (LDLRs) after binding the receptor on the surface of hepatocytes. PCSK9 has autocatalytic activity that releases the prodomain at the N terminus of the protein. The prodomain remains tightly associated with the catalytic domain as the complex transits the secretory pathway. It is not known whether enzymatic activity is required for the LDLR-reducing effects of PCSK9. Here we expressed the prodomain together with a catalytically inactive protease domain in cells and purified the protein from the medium. The ability of the catalytically inactive PCSK9 to bind and degrade LDLRs when added to culture medium of human hepatoma HepG2 cells at physiological concentrations was similar to that seen using wild-type protein. Similarly, a catalytic-dead version of a gain-of-function mutant, PCSK9(D374Y), showed no loss of activity compared with a catalytically active counterpart; both proteins displayed similar to 10-fold increased activity in degradation of cell surface LDLRs compared with wild-type PCSK9. We conclude that the ability of PCSK9 to degrade LDLRs is independent of catalytic activity and suggest that PCSK9 functions as a chaperone to prevent LDLR recycling and/or to target LDLRs for lysosomal degradation.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horton, JD (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	jay.horton@southwestern.edu			NIGMS NIH HHS [GM08014] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; Cameron J, 2006, HUM MOL GENET, V15, P1551, DOI 10.1093/hmg/ddl077; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Cunningham D, 2007, NAT STRUCT MOL BIOL, V14, P413, DOI 10.1038/nsmb1235; Lagace TA, 2006, J CLIN INVEST, V116, P2995, DOI 10.1172/JCI29383; Lalanne F, 2005, J LIPID RES, V46, P1312, DOI 10.1194/jlr.M400396-JLR200; Maxwell KN, 2005, P NATL ACAD SCI USA, V102, P2069, DOI 10.1073/pnas.0409736102; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nassoury N, 2007, TRAFFIC, V8, P718, DOI 10.1111/j.1600-0854.2007.00562.x; Naureckiene S, 2003, ARCH BIOCHEM BIOPHYS, V420, P55, DOI 10.1016/j.abb.2003.09.011; Park SW, 2004, J BIOL CHEM, V279, P50630, DOI 10.1074/jbc.M410077200; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Reeves PJ, 1996, P NATL ACAD SCI USA, V93, P11487, DOI 10.1073/pnas.93.21.11487; Seidah NG, 2006, BIOL CHEM, V387, P871, DOI 10.1515/BC.2006.110; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SEIDAH NG, 2007, IN PRESS J MOL MED; Zhang DW, 2007, J BIOL CHEM, V282, P18602, DOI 10.1074/jbc.M702027200; Zhao ZZ, 2006, AM J HUM GENET, V79, P514, DOI 10.1086/507488	27	218	255	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20799	20803		10.1074/jbc.C700095200	http://dx.doi.org/10.1074/jbc.C700095200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17537735	hybrid			2022-12-25	WOS:000248047500004
J	Methot, N; Rubin, J; Guay, D; Beaulieu, C; Ethier, D; Reddy, TJ; Riendeau, D; Percival, MD				Methot, Nathalie; Rubin, Joel; Guay, Daniel; Beaulieu, Christian; Ethier, Diane; Reddy, T. Jagadeeswar; Riendeau, Denis; Percival, M. David			Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL-PEPTIDASE-I; NEUTROPHIL ELASTASE; PROMYELOCYTIC LEUKEMIA; MOLECULAR-CLONING; LUNG-DISEASE; RAT LIVER; DIFFERENTIATION; PROTEINASE-3; CYSTEINE; CELLS	Cathepsin C is a cysteine protease required for the activation of several pro-inflammatory serine proteases and, as such, is of interest as a therapeutic target. In cathepsin C-deficient mice and humans, the N-terminal processing and activation of neutrophil elastase, cathepsin G, and proteinase-3 is abolished and is accompanied by a reduction of protein levels. Pharmacologically, the consequence of cathepsin C inhibition on the activation of these serine proteases has not been described, due to the lack of stable and non-toxic inhibitors and the absence of appropriate experimental cell systems. Using novel reversible peptide nitrile inhibitors of cathepsin C, and cell-based assays with U937 and EcoM-G cells, we determined the effects of pharmacological inhibition of cathepsin C on serine protease activity. We show that indirect and complete inhibition of neutrophil elastase, cathepsin G, and proteinase-3 is achievable in intact cells with selective and non-cytotoxic cathepsin C inhibitors, at concentrations similar to 10-fold higher than those required to inhibit purified cathepsin C. The concentration of inhibitor needed to block processing of these three serine proteases was similar, regardless of the cell system used. Importantly, cathepsin C inhibition must be sustained to maintain serine protease inhibition, because removal of the reversible inhibitors resulted in the activation of pro-enzymes in intact cells. These findings demonstrate that near complete inhibition of multiple serine proteases can be achieved with cathepsin Cinhibitors and that cathepsin C inhibition represents a viable but challenging approach for the treatment of neutrophil-based inflammatory diseases.	Merck Res Labs, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H9H 3L1, Canada; Merck Res Labs, Merck Frosst Ctr Therapeut Res, Dept Med Chem, Kirkland, PQ H9H 3L1, Canada	Merck & Company; Merck & Company	Percival, MD (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, 16711 Trans Canada Hwy, Montreal, PQ H9H 2L1, Canada.	david_percival@merck.com						Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Bondebjerg J, 2005, BIOORGAN MED CHEM, V13, P4408, DOI 10.1016/j.bmc.2005.04.048; Bondebjerg J, 2006, BIOORG MED CHEM LETT, V16, P3614, DOI 10.1016/j.bmcl.2006.01.102; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BOUMA JMW, 1966, BIOCHIM BIOPHYS ACTA, V113, P350, DOI 10.1016/S0926-6593(66)80074-7; BRANTLY ML, 1988, AM REV RESPIR DIS, V138, P327, DOI 10.1164/ajrccm/138.2.327; Cairns JA, 2005, PULM PHARMACOL THER, V18, P55, DOI 10.1016/j.pupt.2004.09.032; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; COFFEY JW, 1968, J BIOL CHEM, V243, P3255; Conese Massimo, 2003, J Cyst Fibros, V2, P129, DOI 10.1016/S1569-1993(03)00063-8; DAVIES P, 1991, ANN NY ACAD SCI, V624, P219; de Haar Susanne F, 2004, Hum Mutat, V23, P524, DOI 10.1002/humu.9243; Falgueyret JP, 2004, ANAL BIOCHEM, V335, P218, DOI 10.1016/j.ab.2004.09.005; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; Garwicz D, 2005, HAEMATOLOGICA, V90, P38; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; Henningsson F, 2003, BIOL CHEM, V384, P1527, DOI 10.1515/BC.2003.169; Hu Y, 2005, ARTHRITIS RHEUM-US, V52, P2553, DOI 10.1002/art.21192; ISHIDOH K, 1991, J BIOL CHEM, V266, P16312; Kam CM, 2004, ARCH BIOCHEM BIOPHYS, V427, P123, DOI 10.1016/j.abb.2004.04.011; Koehl C, 2003, J BIOL CHEM, V278, P12609, DOI 10.1074/jbc.M210074200; Kohri K, 2002, AM J PHYSIOL-LUNG C, V283, pL531, DOI 10.1152/ajplung.00455.2001; Korver GE, 2001, INT IMMUNOPHARMACOL, V1, P21, DOI 10.1016/S0162-3109(00)00267-8; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; MacIvor DM, 1999, BLOOD, V94, P4282, DOI 10.1182/blood.V94.12.4282.424k45_4282_4293; MCDONALD JK, 1969, J BIOL CHEM, V244, P234; McGuire MJ, 1997, BBA-GENE STRUCT EXPR, V1351, P267, DOI 10.1016/S0167-4781(97)00021-3; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; Methot N, 2004, J BIOL CHEM, V279, P27905, DOI 10.1074/jbc.M400247200; Mezyk-Kopec R, 2005, BIOL CHEM, V386, P801, DOI 10.1515/BC.2005.094; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Pham CTN, 2004, J IMMUNOL, V173, P7277, DOI 10.4049/jimmunol.173.12.7277; Pham CTN, 1997, J BIOL CHEM, V272, P10695, DOI 10.1074/jbc.272.16.10695; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v; RABILLOUD T, 1992, ELECTROPHORESIS, V13, P429, DOI 10.1002/elps.1150130190; Rao NV, 1996, J BIOL CHEM, V271, P2972, DOI 10.1074/jbc.271.6.2972; Rao NV, 1997, J BIOL CHEM, V272, P10260; Raptis SZ, 2005, IMMUNITY, V22, P679, DOI 10.1016/j.immuni.2005.03.015; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Robichaud J, 2003, J MED CHEM, V46, P3709, DOI 10.1021/jm0301078; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; Sheth PD, 2003, BIOCHEM PHARMACOL, V66, P2251, DOI 10.1016/j.bcp.2003.08.002; Sugawara S, 2001, J IMMUNOL, V167, P6568, DOI 10.4049/jimmunol.167.11.6568; Sun ZF, 2004, LANCET ONCOL, V5, P182, DOI 10.1016/S1470-2045(04)01414-7; Sykes DB, 2003, LEUKEMIA LYMPHOMA, V44, P1187, DOI 10.1080/1042819031000090273; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; Taggart CC, 2005, AM J RESP CRIT CARE, V171, P1070, DOI 10.1164/rccm.200407-881PP; Tran TV, 2002, ARCH BIOCHEM BIOPHYS, V403, P160, DOI 10.1016/S0003-9861(02)00217-5; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; WALKER RI, 1980, REV INFECT DIS, V2, P282; Witko-Sarsat V, 2002, J BIOL CHEM, V277, P47338, DOI 10.1074/jbc.M202789200; Wolters PJ, 2001, J BIOL CHEM, V276, P18551, DOI 10.1074/jbc.M100223200	57	62	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20836	20846		10.1074/jbc.M702615200	http://dx.doi.org/10.1074/jbc.M702615200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17535802	hybrid			2022-12-25	WOS:000248047500009
J	Rogaeva, A; Ou, XM; Jafar-Nejad, H; Lemonde, S; Albert, PR				Rogaeva, Anastasia; Ou, Xiao-Ming; Jafar-Nejad, Hamed; Lemonde, Sylvie; Albert, Paul R.			Differential repression by Freud-1/CC2D1A at a polymorphic site in the dopamine-D2 receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN IMMUNOPRECIPITATION; TRANSCRIPTION FACTOR; MENTAL-RETARDATION; MAJOR DEPRESSION; PROMOTER REGION; D-2 RECEPTORS; SCHIZOPHRENIA; D2; BINDING; FAMILY	Freud-1/CC2D1A is a transcriptional repressor of the serotonin-1A receptor gene and was recently genetically linked to non-syndromic mental retardation. To identify new Freud-1 gene targets, data base mining for Freud-1 recognition sequences was done. A highly homologous intronic element (D2-DRE) was identified in the human dopamine-D2 receptor (DRD2) gene, and the role of Freud-1 in regulating the gene at this site was assessed. Recombinant Freud-1 bound specifically to the D2-DRE, and a major protein-D2-DRE complex was identified in nuclear extracts that was super-shifted using Freud-1-specific antibodies. Endogenous Freud-1 binding to the D2-DRE in cells was detected using chromatin immunoprecipitation. The D2-DRE conferred strong repressor activity in transcriptional reporter assays that was dependent on the Freud-1 recognition sequence. In three different human cell lines, the level of Freud-1 protein was inversely related to DRD2 expression. Knockdown of endogenous Freud-1 using small interfering RNA resulted in an up-regulation of DRD2 RNA and binding sites, demonstrating a crucial role for Freud-1 in DRD2 regulation. A previously uncharacterized single nucleotide A/G polymorphism (rs2734836) was located adjacent to the D2-DRE and conferred allele-specific Freud-1 binding and repression, with the major G-allele having reduced activity. These studies demonstrate a key role for Freud-1 to regulate DRD2 expression and provide the first mechanistic insights into its transcriptional regulation. Allele-specific regulation of DRD2 expression by Freud-1 may possibly associate with psychiatric disorders or mental retardation.	Univ Ottawa, Ottawa Hlth Res Inst Neurosci, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ So Calif, Dept Pharm, Los Angeles, CA 90033 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Southern California; Baylor College of Medicine	Albert, PR (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst Neurosci, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	palbert@uottawa.ca	Albert, Paul/E-4804-2010; Jafar-Nejad, Hamed/B-9216-2008	Albert, Paul/0000-0002-1809-3554; 				Abi-Dargham A, 2000, P NATL ACAD SCI USA, V97, P8104, DOI 10.1073/pnas.97.14.8104; Adell A, 2004, NEUROSCI BIOBEHAV R, V28, P415, DOI 10.1016/j.neubiorev.2004.05.001; Ainscough JFX, 2000, DEVELOPMENT, V127, P3923; Albert PR, 2004, NEUROSCIENTIST, V10, P575, DOI 10.1177/1073858404267382; Arinami T, 1997, HUM MOL GENET, V6, P577, DOI 10.1093/hmg/6.4.577; Ausio J, 2003, CLIN GENET, V64, P83, DOI 10.1034/j.1399-0004.2003.00124.x; Basel-Vanagaite L, 2006, J MED GENET, V43, P203, DOI 10.1136/jmg.2005.035709; Bobb AJ, 2005, AM J MED GENET B, V134B, P67, DOI 10.1002/ajmg.b.30142; Caballero IM, 2005, HUM MOL GENET, V14, pR19, DOI 10.1093/hmg/ddi102; Czesak M, 2006, J NEUROSCI, V26, P1864, DOI 10.1523/JNEUROSCI.2643-05.2006; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Fan GP, 2005, CELL RES, V15, P255, DOI 10.1038/sj.cr.7290294; Gainetdinov RR, 2001, TRENDS NEUROSCI, V24, P527, DOI 10.1016/S0166-2236(00)01886-5; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P7558, DOI 10.1073/pnas.121635798; Kapur S, 2001, AM J PSYCHIAT, V158, P360, DOI 10.1176/appi.ajp.158.3.360; Kellendonk C, 2006, NEURON, V49, P603, DOI 10.1016/j.neuron.2006.01.023; Kushwaha N, 2006, MOL PHARMACOL, V69, P1518, DOI 10.1124/mol.105.019844; Lemonde S, 2004, J NEUROCHEM, V88, P857, DOI 10.1046/j.1471-4159.2003.02223.x; Lemonde S, 2003, J NEUROSCI, V23, P8788; Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MANSOUR A, 1990, J NEUROSCI, V10, P2587; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MINOWA T, 1994, J BIOL CHEM, V269, P11656; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Miyamoto S, 2005, MOL PSYCHIATR, V10, P79, DOI 10.1038/sj.mp.4001556; Noble E P, 2000, Pharmacogenomics, V1, P309, DOI 10.1517/14622416.1.3.309; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Ogbourne S, 1998, BIOCHEM J, V331, P1; Ou XM, 2000, J BIOL CHEM, V275, P8161, DOI 10.1074/jbc.275.11.8161; Ou XM, 2003, J NEUROSCI, V23, P7415; Parsey RV, 2006, NEUROPSYCHOPHARMACOL, V31, P1745, DOI 10.1038/sj.npp.1300992; Parsey RV, 2006, BIOL PSYCHIAT, V59, P106, DOI 10.1016/j.biopsych.2005.06.016; ROGAEVA A, 2007, IN PRESS J NEUROSCI; Samad TA, 1997, P NATL ACAD SCI USA, V94, P14349, DOI 10.1073/pnas.94.26.14349; Seeman P, 2000, P NATL ACAD SCI USA, V97, P7673, DOI 10.1073/pnas.97.14.7673; Seeman P, 2005, P NATL ACAD SCI USA, V102, P3513, DOI 10.1073/pnas.0409766102; Storring JM, 1999, J NEUROCHEM, V72, P2238, DOI 10.1046/j.1471-4159.1999.0722238.x; VALDENAIRE O, 1994, EUR J BIOCHEM, V220, P577, DOI 10.1111/j.1432-1033.1994.tb18658.x; Wang J, 2005, J NEUROCHEM, V93, P474, DOI 10.1111/j.1471-4159.2005.03051.x; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Yajima S, 1997, J NEUROSCI, V17, P8657; Yajima S, 1998, DNA CELL BIOL, V17, P471, DOI 10.1089/dna.1998.17.471	46	30	32	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20897	20905		10.1074/jbc.M610038200	http://dx.doi.org/10.1074/jbc.M610038200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17535813	hybrid			2022-12-25	WOS:000248047500015
J	Forneris, F; Binda, C; Adamo, A; Battaglioli, E; Mattevi, A				Forneris, Federico; Binda, Claudia; Adamo, Antonio; Battaglioli, Elena; Mattevi, Andrea			Structural basis of LSD1-CoREST selectivity in histone H3 recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; LSD1; DEMETHYLATION; METHYLATION; COREST	Histone demethylase LSD1 regulates transcription by demethylating Lys(4) of histone H3. The crystal structure of the enzyme in complex with CoREST and a substrate-like peptide inhibitor highlights an intricate network of interactions and a folded conformation of the bound peptide. The core of the peptide structure is formed by Arg(2), Gln(5), and Ser(10), which are engaged in specific intramolecular H-bonds. Several charged side chains on the surface of the substrate- binding pocket establish electrostatic interactions with the peptide. The three-dimensional structure predicts that methylated Lys4 binds in a solvent inaccessible position in front of the flavin cofactor. This geometry is fully consistent with the demethylation reaction being catalyzed through a flavin-mediated oxidation of the substrate amino-methyl group. These features dictate the exquisite substrate specificity of LSD1 and provide a structural framework to explain the fine tuning of its catalytic activity and the active role of CoREST in substrate recognition.	Univ Milan, Dipartimento Biol & Genet Scienze Mediche, I-20133 Milan, Italy	University of Milan	Mattevi, A (corresponding author), Univ Pavia, Dipartimento Genet & Microbiol, Via Ferrata 1, I-27100 Pavia, Italy.	mattevi@ipvgen.unipv.it	Forneris, Federico/B-1145-2011; battaglioli, elena/H-9350-2017; Forneris, Federico/AAL-5361-2020; Mattevi, Andrea/R-4469-2019; mattevi, andrea/K-5464-2012	Forneris, Federico/0000-0002-7818-1804; Forneris, Federico/0000-0002-7818-1804; Mattevi, Andrea/0000-0002-9523-7128; mattevi, andrea/0000-0002-9523-7128; Battaglioli, Elena/0000-0001-9168-7212; Binda, Claudia/0000-0003-2038-9845; Adamo, Antonio/0000-0003-1080-3547				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Chen Y, 2006, P NATL ACAD SCI USA, V103, P13956, DOI 10.1073/pnas.0606381103; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Forneris F, 2005, FEBS LETT, V579, P2203, DOI 10.1016/j.febslet.2005.03.015; Forneris F, 2005, J BIOL CHEM, V280, P41360, DOI 10.1074/jbc.M509549200; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; FRONERIS F, 2006, J BIOL CHEM, V281, P26389; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Stavropoulos P, 2006, NAT STRUCT MOL BIOL, V13, P626, DOI 10.1038/nsmb1113; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012	22	175	205	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20070	20074		10.1074/jbc.C700100200	http://dx.doi.org/10.1074/jbc.C700100200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17537733	hybrid, Green Published			2022-12-25	WOS:000247819300007
J	Hawkins, RD; Bashiardes, S; Powder, KE; Sajan, SA; Bhonagiri, V; Alvarado, DM; Speck, J; Warchol, ME; Lovett, M				Hawkins, R. David; Bashiardes, Stavros; Powder, Kara E.; Sajan, Samin A.; Bhonagiri, Veena; Alvarado, David M.; Speck, Judith; Warchol, Mark E.; Lovett, Michael			Large Scale Gene Expression Profiles of Regenerating Inner Ear Sensory Epithelia	PLOS ONE			English	Article							HAIR CELL REGENERATION; GROUP PROTEIN EZH2; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTORS; GUINEA-PIGS; PROLIFERATION; TRANSCRIPTION; HEARING; ADULT; FATE	Loss of inner ear sensory hair cells (HC) is a leading cause of human hearing loss and balance disorders. Unlike mammals, many lower vertebrates can regenerate these cells. We used cross-species microarrays to examine this process in the avian inner ear. Specifically, changes in expression of over 1700 transcription factor (TF) genes were investigated in hair cells of auditory and vestibular organs following treatment with two different damaging agents and regeneration in vitro. Multiple components of seven distinct known signaling pathways were clearly identifiable: TGF beta, PAX, NOTCH, WNT, NFKappaB, INSULIN/IGF1 and AP1. Numerous components of apoptotic and cell cycle control pathways were differentially expressed, including p27(KIP) and TFs that regulate its expression. A comparison of expression trends across tissues and treatments revealed identical patterns of expression that occurred at identical times during regenerative proliferation. Network analysis of the patterns of gene expression in this large dataset also revealed the additional presence of many components (and possible network interactions) of estrogen receptor signaling, circadian rhythm genes and parts of the polycomb complex (among others). Equal numbers of differentially expressed genes were identified that have not yet been placed into any known pathway. Specific time points and tissues also exhibited interesting differences: For example, 45 zinc finger genes were specifically up-regulated at later stages of cochlear regeneration. These results are the first of their kind and should provide the starting point for more detailed investigations of the role of these many pathways in HC recovery, and for a description of their possible interactions.	[Hawkins, R. David; Bashiardes, Stavros; Powder, Kara E.; Sajan, Samin A.; Bhonagiri, Veena; Alvarado, David M.; Lovett, Michael] Washington Univ, Sch Med, Dept Genet, Div Human Genet, St Louis, MO 63110 USA; [Speck, Judith; Warchol, Mark E.] Washington Univ, Sch Med, Dept Otolaryngol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Lovett, M (corresponding author), Washington Univ, Sch Med, Dept Genet, Div Human Genet, St Louis, MO 63110 USA.	lovett@genetics.wustl.edu		Powder, Kara/0000-0001-7415-4262	National Organization for Hearing Research Foundation [O1-DC05632, R01 DC006283, P30 DC04665, 5T32HG000045, 5T32GM007067]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005632, P30DC004665, R01DC006283] Funding Source: NIH RePORTER	National Organization for Hearing Research Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by a major grant from the National Organization for Hearing Research Foundation (to ML and MW) and by RO1-DC05632 (ML), R01 DC006283 and P30 DC04665 (MW) and by training grant 5T32HG000045 (supporting DMA) and training grant 5T32GM007067 (supporting KEP).	Antoch MP, 2005, CELL CYCLE, V4, P901, DOI 10.4161/cc.4.7.1792; Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Bermingham-McDonogh O, 2001, DEV BIOL, V238, P247, DOI 10.1006/dbio.2001.0412; Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chen P, 1999, DEVELOPMENT, V126, P1581; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; Duncan LJ, 2006, J COMP NEUROL, V499, P691, DOI 10.1002/cne.21114; Etchegaray JP, 2006, J BIOL CHEM, V281, P21209, DOI 10.1074/jbc.M603722200; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; Fritzsch B, 2003, BRAIN RES BULL, V60, P423, DOI 10.1016/S0361-9230(03)00048-0; Hawkins RD, 2003, HUM MOL GENET, V12, P1261, DOI 10.1093/hmg/ddg150; Hayes KR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-5-219; Hillier LW, 2005, NATURE, V434, P724, DOI 10.1038/nature03466; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Hudspeth AJ, 1997, NEURON, V19, P947, DOI 10.1016/S0896-6273(00)80385-2; Ide T, 2003, MOL ENDOCRINOL, V17, P1255, DOI 10.1210/me.2002-0191; Ikeda S, 2005, MOL GENET METAB, V86, P314, DOI 10.1016/j.ymgme.2005.05.011; Izumikawa M, 2005, NAT MED, V11, P271, DOI 10.1038/nm1193; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; JORGENSEN JM, 1988, NATURWISSENSCHAFTEN, V75, P319, DOI 10.1007/BF00367330; Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585; Kawamoto K, 2003, J NEUROSCI, V23, P4395; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; Ledford AW, 2002, DEV BIOL, V245, P157, DOI 10.1006/dbio.2002.0636; Li CG, 2002, J BIOL CHEM, V277, P38399, DOI 10.1074/jbc.M203188200; Li X, 2002, SCIENCE, V297, P1180; Liu Chenglong, 2006, AIDS Res Ther, V3, P6, DOI 10.1186/1742-6405-3-6; Matsui JI, 2004, J NEUROBIOL, V61, P250, DOI 10.1002/neu.20054; Matsui JI, 2000, JARO-J ASSOC RES OTO, V1, P46, DOI 10.1007/s101620010005; Medina KL, 2005, CURR OPIN HEMATOL, V12, P203, DOI 10.1097/01.moh.0000160735.67596.a0; Messina DN, 2004, GENOME RES, V14, P2041, DOI 10.1101/gr.2584104; Oesterle EC, 2003, J COMP NEUROL, V463, P177, DOI 10.1002/cne.10756; Pawar A, 2003, J BIOL CHEM, V278, P40736, DOI 10.1074/jbc.M307973200; RAPHAEL Y, 1988, DEV BIOL, V128, P222, DOI 10.1016/0012-1606(88)90284-9; Reich M, 2004, BIOINFORMATICS, V20, P1797, DOI 10.1093/bioinformatics/bth138; Renn SCP, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-42; ROBERSON DW, 1994, AM J OTOL, V15, P28; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Singh H, 2005, P NATL ACAD SCI USA, V102, P4949, DOI 10.1073/pnas.0500480102; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; Stenberg AE, 2001, HEARING RES, V157, P87, DOI 10.1016/S0378-5955(01)00280-5; Stone JS, 1999, DEVELOPMENT, V126, P961; Stone JS, 2004, DEV DYNAM, V230, P597, DOI 10.1002/dvdy.20087; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Thompson Emma E., 2005, Human Genomics, V2, P168; Trueba SS, 2005, J CLIN ENDOCR METAB, V90, P455, DOI 10.1210/jc.2004-1358; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wagner RA, 2005, DEV BIOL, V288, P595, DOI 10.1016/j.ydbio.2005.09.036; Wang B, 2004, DEVELOPMENT, V131, P4477, DOI 10.1242/dev.01287; Warchol ME, 1996, J NEUROSCI, V16, P5466; Warchol ME, 2001, J NEUROCYTOL, V30, P253, DOI 10.1023/A:1012705925437; Warchol ME, 2002, J NEUROSCI, V22, P2607, DOI 10.1523/JNEUROSCI.22-07-02607.2002; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285; Warchol ME, 1999, J NEUROCYTOL, V28, P889, DOI 10.1023/A:1007026306730; WARCHOL ME, 2007, HEARING RES IN PRESS; White PM, 2006, NATURE, V441, P984, DOI 10.1038/nature04849; YAMASHITA H, 1995, P NATL ACAD SCI USA, V92, P3152, DOI 10.1073/pnas.92.8.3152; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; ZHANG W, 1995, MOL CELL BIOL, V15, P6055	66	58	60	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e525	10.1371/journal.pone.0000525	http://dx.doi.org/10.1371/journal.pone.0000525			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565378	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451600013
J	Rodriguez-Almazan, C; Torner, FJ; Costas, M; Perez-Montfort, R; de Gomez-Puyou, MT; Puyou, AG				Rodriguez-Almazan, Claudia; Torner, Francisco J.; Costas, Miguel; Perez-Montfort, Ruy; de Gomez-Puyou, Marieta Tuena; Puyou, Armando Gomez			The Stability and Formation of Native Proteins from Unfolded Monomers Is Increased through Interactions with Unrelated Proteins	PLOS ONE			English	Article								The intracellular concentration of protein may be as high as 400 mg per ml; thus it seems inevitable that within the cell, numerous protein-protein contacts are constantly occurring. A basic biochemical principle states that the equilibrium of an association reaction can be shifted by ligand binding. This indicates that if within the cell many protein-protein interactions are indeed taking place, some fundamental characteristics of proteins would necessarily differ from those observed in traditional biochemical systems. Accordingly, we measured the effect of eight different proteins on the formation of homodimeric triosephosphate isomerase from Trypanosoma brucei (TbTIM) from guanidinium chloride unfolded monomers. The eight proteins at concentrations of micrograms per ml induced an important increase on active dimer formation. Studies on the mechanism of this phenomenon showed that the proteins stabilize the dimeric structure of TbTIM, and that this is the driving force that promotes the formation of active dimers. Similar data were obtained with TIM from three other species. The heat changes that occur when TbTIM is mixed with lysozyme were determined by isothermal titration calorimetry; the results provided direct evidence of the weak interaction between apparently unrelated proteins. The data, therefore, are strongly suggestive that the numerous protein-protein interactions that occur in the intracellular space are an additional control factor in the formation and stability of proteins.	[Rodriguez-Almazan, Claudia; Perez-Montfort, Ruy; de Gomez-Puyou, Marieta Tuena; Puyou, Armando Gomez] Univ Nacl Autonoma Mexico, Dept Bioquim, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; [Torner, Francisco J.; Costas, Miguel] Univ Nacl Autonoma Mexico, Lab Biofisicoquim, Dept Fisicoquim, Fac Quim, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Puyou, AG (corresponding author), Univ Nacl Autonoma Mexico, Dept Bioquim, Inst Fisiol Celular, Mexico City 04510, DF, Mexico.	apuyou@ifc.unam.mx		Perez-Montfort, Ruy/0000-0003-0810-1159; Costas, Miguel/0000-0001-8604-6381	PAPIIT UNAM [IN203805]; CONACYT, Mexico [G27551, 42328Q]	PAPIIT UNAM(Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico); CONACYT, Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was supported by grant number IN203805 from PAPIIT UNAM to AGP, and grants G27551 and 42328Q from CONACYT, Mexico to AGP and MC, respectively.	ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; BANERJEE SK, 1975, J BIOL CHEM, V250, P8260; BORCHERT TV, 1993, EUR J BIOCHEM, V211, P703, DOI 10.1111/j.1432-1033.1993.tb17599.x; Bulone D, 2001, BIOPHYS CHEM, V91, P61, DOI 10.1016/S0301-4622(01)00155-7; Chebotareva NA, 2004, BIOCHEMISTRY-MOSCOW+, V69, P1239, DOI 10.1007/s10541-005-0070-y; Dhar-Chowdhury P, 2005, J BIOL CHEM, V280, P38464, DOI 10.1074/jbc.M508744200; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Evans MS, 2005, PROTEIN PEPTIDE LETT, V12, P189, DOI 10.2174/0929866053005908; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; Hall D, 2003, BBA-PROTEINS PROTEOM, V1649, P127, DOI 10.1016/S1570-9639(03)00167-5; HAMPE OG, 1982, BIOPHYS J, V40, P77, DOI 10.1016/S0006-3495(82)84460-3; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KNULL HR, 1992, CURR TOP CELL REGUL, V33, P15; KOHL L, 1994, EUR J BIOCHEM, V220, P331, DOI 10.1111/j.1432-1033.1994.tb18629.x; Li J, 2001, J BIOL CHEM, V276, P34396, DOI 10.1074/jbc.M103392200; Maruyama T, 2001, BIOTECHNOL BIOENG, V75, P233, DOI 10.1002/bit.10001; MCVITTIE JD, 1977, EUR J BIOCHEM, V81, P307, DOI 10.1111/j.1432-1033.1977.tb11953.x; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Najera H, 2003, BIOCHEM J, V370, P785, DOI 10.1042/BJ20021439; Orosz F, 2000, P NATL ACAD SCI USA, V97, P1026, DOI 10.1073/pnas.97.3.1026; Orosz F, 2001, BLOOD, V98, P3106, DOI 10.1182/blood.V98.10.3106; OstoaSaloma P, 1997, EUR J BIOCHEM, V244, P700, DOI 10.1111/j.1432-1033.1997.00700.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rakus D, 2004, BIOCHEMISTRY-US, V43, P14948, DOI 10.1021/bi048886x; Ren GP, 2003, J PROTEIN CHEM, V22, P431, DOI 10.1023/B:JOPC.0000005458.08802.11; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; Srere PA, 2000, TRENDS BIOCHEM SCI, V25, P150, DOI 10.1016/S0968-0004(00)01550-4; SRERE PA, 1990, FEBS LETT, V268, P360, DOI 10.1016/0014-5793(90)81286-W; van den Berg B, 2000, EMBO J, V19, P3870, DOI 10.1093/emboj/19.15.3870; Vazquez-Contreras E, 2000, PROTEIN PEPTIDE LETT, V7, P57; Walden H, 2004, BIOCHEM SOC T, V32, P305, DOI 10.1042/BST0320305; Walden H, 2004, J MOL BIOL, V342, P861, DOI 10.1016/j.jmb.2004.07.067; WALEY SG, 1973, BIOCHEM J, V135, P165, DOI 10.1042/bj1350165; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9; WANG Z, 1992, PROTEIN SCI, V1, P522; WILLIAMS JC, 1995, BIOCHEMISTRY-US, V34, P8309, DOI 10.1021/bi00026a012; Xiang JY, 2004, BIOCHEMISTRY-US, V43, P11436, DOI 10.1021/bi049208d; ZABORI S, 1980, Z NATURFORSCH C, V35, P999; Zhou BR, 2004, J BIOL CHEM, V279, P55109, DOI 10.1074/jbc.M409086200; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331; Zomosa-Signoret V, 2003, BIOCHEMISTRY-US, V42, P3311, DOI 10.1021/bi0206560	45	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e497	10.1371/journal.pone.0000497	http://dx.doi.org/10.1371/journal.pone.0000497			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551578	gold, Green Submitted, Green Published			2022-12-25	WOS:000207451500007
J	Kobel, M; Weidensdorfer, D; Reinke, C; Lederer, M; Schmitt, WD; Zeng, K; Thomssen, C; Hauptmann, S; Huettelmaier, S				Koebel, M.; Weidensdorfer, D.; Reinke, C.; Lederer, M.; Schmitt, W. D.; Zeng, K.; Thomssen, C.; Hauptmann, S.; Huettelmaier, S.			Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma	ONCOGENE			English	Article						IMP1; ovarian carcinoma; c-myc	MYC MESSENGER-RNA; C-MYC; CRD-BP; FAMILY; CANCER; TUMORS; OVEREXPRESSION; TRANSLATION; CELLS; ZBP1	The IMP (IGFII mRNA-binding protein) family comprises a group of three RNA-binding proteins involved in the regulation of cytoplasmic mRNA-fate. Recent studies identified IMP proteins as oncofetal factors in various neoplasias, but knowledge of a potential role in ovarian carcinomas is still lacking. The immunohistochemical analysis of 107 ovarian carcinomas, 30 serous borderline tumors of the ovary and five normal ovaries revealed de novo synthesis of IMP1 in 69% of ovarian carcinomas. Elevated IMP1 expression was observed preferentially in high-grade and high-stage cases and was a significant prognostic indicator for reduced recurrence-free and overall survival. Phenotypic studies in ovarian carcinoma-derived ES-2 cells demonstrated that IMP1 knockdown affects proliferation and cell survival. Reduced proliferation was associated with decreased c-myc mRNA half-life, suggesting IMP1 as an oncogenic factor that is involved in promoting elevated proliferation by stabilizing the c-myc mRNA in ovarian carcinoma cells.	Univ Halle Wittenberg, Dept Med, D-06120 Halle, Germany; Univ Halle Wittenberg, Inst Pathol, Dept Med, Halle, Germany; Univ Halle Wittenberg, Dept Gynecol, Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Huettelmaier, S (corresponding author), Univ Halle Wittenberg, Dept Med, Halle-Wittenberg Heinrich-Damerow-St 1, D-06120 Halle, Germany.	hauptmann@medizin.uni-halle.de; stefan.huettelmaier@medizin.uni-halle.de	Hüttelmaier, Stefan/AAQ-1203-2021; Köbel, Martin/A-7373-2011; Thomssen, Christoph/ABC-3102-2021; Schmitt, Wolfgang D/B-4729-2008	Schmitt, Wolfgang D/0000-0002-7870-138X; Kobel, Martin/0000-0002-6615-2037				Chen CH, 2005, INT J GYNECOL CANCER, V15, P878, DOI 10.1111/j.1525-1438.2005.00150.x; Dimova I, 2006, EUR J CANCER, V42, P674, DOI 10.1016/j.ejca.2005.11.022; Farina KL, 2003, J CELL BIOL, V160, P77, DOI 10.1083/jcb.200206003; Gu LJ, 2004, INT J ONCOL, V24, P671; Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Ioannidis P, 2005, J BIOL CHEM, V280, P20086, DOI 10.1074/jbc.M410036200; Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015; Ioannidis P, 2003, ANTICANCER RES, V23, P2179; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; Kobel M, 2006, INT J GYNECOL PATHOL, V25, P121, DOI 10.1097/01.pgp.0000185410.39050.ac; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Liao BS, 2004, J BIOL CHEM, V279, P48716, DOI 10.1074/jbc.M405853200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mueller-Pillasch F, 1999, MECH DEVELOP, V88, P95, DOI 10.1016/S0925-4773(99)00160-4; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Sparanese D, 2007, NUCLEIC ACIDS RES, V35, P1209, DOI 10.1093/nar/gkl1148; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Yaniv K, 2003, DEVELOPMENT, V130, P5649, DOI 10.1242/dev.00810; Yaniv K, 2002, GENE, V287, P49, DOI 10.1016/S0378-1119(01)00866-6; Yisraeli JK, 2005, BIOL CELL, V97, P87	24	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2007	26	54					7584	7589		10.1038/sj.onc.1210563	http://dx.doi.org/10.1038/sj.onc.1210563			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546046				2022-12-25	WOS:000251282100011
J	Bodo, E; Kromminga, A; Funk, W; Laugsch, M; Duske, U; Jelkmann, WG; Paus, R				Bodo, Eniko; Kromminga, Arno; Funk, Wolfgang; Laugsch, Magdalena; Duske, Ute; Jelkmann, Wolfgang; Paus, Ralf			Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin	FASEB JOURNAL			English	Article						anagen hair follicles; tissue protection; hemoglobin alpha-1; kinesin light chain 3; aminase oxidase; calmegin; RAS-like family 10	CORTICOTROPIN-RELEASING HORMONE; INDUCIBLE FACTOR-I; PROTECTS NEURONS; GROWTH-FACTOR; RECEPTOR; HYPOXIA; EXPRESSION; BIOLOGY; INVOLVEMENT; APOPTOSIS	Erythropoietin primarily serves as an essential growth factor for erythrocyte precursor cells. However, there is increasing evidence that erythropoietin ( EPO)/EPO receptor ( EPO-R) signaling operates as a potential tissue-protective system outside the bone marrow. Arguing that growing hair follicles ( HF) are among the most rapidly proliferating tissues, we have here explored whether human HFs are sources of EPO and targets of EPO-R-mediated signaling. Human scalp skin and microdissected HFs were assessed for EPO and EPO-R expression, and the effects of EPO on organ-cultured HFs were assessed in the presence/absence of a classical apoptosis-inducing chemotherapeutic agent. Here, we show that human scalp HFs express EPO on the mRNA and protein level in situ, up-regulate EPO transcription under hypoxic conditions, and express transcripts for EPO-R and the EPO-stimulatory transcriptional cofactor hypoxia-inducible factor-1 alpha. Although EPO does not significantly alter human hair growth in vitro, it significantly down-regulates chemotherapy-induced intrafollicular apoptosis and changes the gene expression program of the HFs. The current study points to intriguing targets of EPO beyond the erythropoietic system: human HFs are an extrarenal site of EPO production and an extrahematopoietic site of EPO-R expression. They may recruit EPO/EPO-R signaling e. g., for modulating HF apoptosis under conditions of hypoxia and chemotherapy-induced stress. - Bodo, E., Kromminga, A., Funk, W., Laugsch, M, Duske, U., Jelkmann, W., Paus, R. Human hair follicles are an extrarenal source and a non-hematopoietic target of erythropoietin.	Univ Lubeck, Dept Dermatol, Lubeck, Germany; Inst Immunol Clin Pathol Mol Med, Hamburg, Germany; Klin Dr Kozlowski, Munich, Germany; Univ Lubeck, Dept Physiol, Lubeck, Germany	University of Lubeck; University of Lubeck	Paus, R (corresponding author), Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	ralf.paus@uk-sh.de	Laugsch, Magdalena/AAH-8170-2021; Paus, Ralf/F-6243-2011; Jelkmann, Wolfgang/AAF-8897-2019					Bodo E, 2005, AM J PATHOL, V166, P985, DOI 10.1016/S0002-9440(10)62320-6; BODO E, 2006, J INVEST DERMATOL SU, V126, pP126; Braun S, 2006, J CELL SCI, V119, P4841, DOI 10.1242/jcs.03259; Brines M, 2006, KIDNEY INT, V70, P246, DOI 10.1038/sj.ki.5001546; Bruegge K, 2007, CURR MED CHEM, V14, P1853; Carlini RG, 1999, KIDNEY INT, V55, P546, DOI 10.1046/j.1523-1755.1999.00266.x; Dame C, 2003, MIL DRUG TH, P35; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Elliott S, 2006, BLOOD, V107, P1892, DOI 10.1182/blood-2005-10-4066; Foitzik K, 2006, AM J PATHOL, V168, P748, DOI 10.2353/ajpath.2006.050468; Galeano M, 2006, CRIT CARE MED, V34, P1139, DOI 10.1097/01.CCM.0000206468.18653.EC; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Hara M, 2000, J INVEST DERMATOL, V114, P438, DOI 10.1046/j.1523-1747.2000.00894.x; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Isogai R, 2006, ARCH DERMATOL RES, V297, P389, DOI 10.1007/s00403-005-0615-3; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Ito T, 2004, AM J PATHOL, V164, P623, DOI 10.1016/S0002-9440(10)63151-3; Jahoda CAB, 2001, LANCET, V358, P1445, DOI 10.1016/S0140-6736(01)06532-1; Jelkmann W, 2004, INTERNAL MED, V43, P649, DOI 10.2169/internalmedicine.43.649; Juul SE, 1998, EARLY HUM DEV, V52, P235, DOI 10.1016/S0378-3782(98)00030-9; Kaushansky K, 2006, NEW ENGL J MED, V354, P2034, DOI 10.1056/NEJMra052706; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Kumar SM, 2005, AM J PATHOL, V166, P823, DOI 10.1016/S0002-9440(10)62303-6; LeBaron MJ, 2007, ENDOCRINOLOGY, V148, P989, DOI 10.1210/en.2006-1219; Lindner G, 1997, AM J PATHOL, V151, P1601; Liu RQ, 2006, J NEUROCHEM, V96, P1101, DOI 10.1111/j.1471-4159.2005.03597.x; Liu T C, 1990, Gaoxiong Yi Xue Ke Xue Za Zhi, V6, P181; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; MASUDA S, 1993, J BIOL CHEM, V268, P11208; *NATL COMM CLIN LA, 1992, NCCLS DOCUM C28 P, V12, P1; Paus R, 2006, TRENDS IMMUNOL, V27, P32, DOI 10.1016/j.it.2005.10.002; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PHILPOTT MP, 1991, J INVEST DERMATOL, V96, P875, DOI 10.1111/1523-1747.ep12475232; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Rossert J, 2005, NEPHROL DIAL TRANSPL, V20, P1025, DOI 10.1093/ndt/gfh800; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Savino R, 2004, CELL DEATH DIFFER, V11, pS2, DOI 10.1038/sj.cdd.4401469; Selzer E, 2000, MELANOMA RES, V10, P421, DOI 10.1097/00008390-200010000-00003; Sharpies EJ, 2006, SEMIN NEPHROL, V26, P325, DOI 10.1016/j.semnephrol.2006.05.010; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2003, EUR J BIOCHEM, V270, P3335, DOI 10.1046/j.1432-1033.2003.03708.x; Slominski A, 2002, J INVEST DERMATOL, V119, P1449, DOI 10.1046/j.1523-1747.2002.19617.x; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Zou HF, 2006, BIOTECHNOL LETT, V28, P1901, DOI 10.1007/s10529-006-9176-6; Zouboulis CC, 2002, P NATL ACAD SCI USA, V99, P7148, DOI 10.1073/pnas.102180999	58	60	60	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3346	3354		10.1096/fj.07-8628com	http://dx.doi.org/10.1096/fj.07-8628com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17540710				2022-12-25	WOS:000249781600035
J	van Tuyn, J; Pijnappels, DA; de Vries, AAF; de Vries, I; Dijke, IVDVV; Knaan-Shanzer, S; van der Laarse, A; Schalij, MJ; Atsma, DE				van Tuyn, John; Pijnappels, Daniel A.; de Vries, Antoine A. F.; de Vries, Ingrid; Velde-van Dijke, Ietje van der; Knaaen-Shanzer, Shoshan; van der Laarse, Arnoud; Schalij, Martin J.; Atsma, Douwe E.			Fibroblasts from human postmyocardial infarction scars acquire properties of cardiomyocytes after transduction with a recombinant myocardin gene	FASEB JOURNAL			English	Article						conduction (block); fibrosis; gene transfer; heart infarction; myocytes	SMOOTH-MUSCLE; LIPOMATOUS METAPLASIA; STEM-CELLS; EXPRESSION; HEART; ACTIVATION; CONDUCTION	Myocardial scar formation impairs heart function by inducing cardiac remodeling, decreasing myocardial compliance, and compromising normal electrical conduction. Conversion of myocardial scar fibroblasts ( MSFs) into ( functional) cardiomyocytes may be an effective alternative treatment to limit loss of cardiac performance after myocardial injury. In this study, we investigated whether the phenotype of MSFs can be modified by gene transfer into cells with properties of cardiomyocytes. To this end, fibroblasts from postmyocardial infarction scars of human left ventricles were isolated and characterized by cell biological, immunological, and molecular biological assays. Cultured human MSFs express GATA4 and connexin 43 and display adipogenic differentiation potential. Infection of human MSFs with a lentivirus vector encoding the potent cardiogenic transcription factor myocardin renders them positive for a wide variety of cardiomyocyte-specific proteins, including sarcomeric components, transcription factors, and ion channels, and induces the expression of several smooth muscle marker genes. Forced myocardin expression also endowed human MSFs with the ability to transmit an action potential and to repair an artificially created conduction block in cardiomyocyte cultures. These finding indicate that in vivo myocardin gene transfer may potentially limit cardiomyocyte loss, myocardial fibrosis, and disturbances in electrical conduction caused by myocardial infarction. - van Tuyn, J., Pijnappels, D. A., de Vries, A. A. F., de Vries, I., van der Velde-van Dijke, I., Knaan-Shanzer, S., van der Laarse, A., Schalij, M. J., Atsma, D. E. Fibroblasts from human postmyocardial infarction scars acquire properties of cardiomyocytes after transduction with a recombinant myocardin gene.	Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, Virus & Stem Cell Biol Lab, NL-2300 RC Leiden, Netherlands; Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Interuniversity Cardiology Institute of the Netherlands; Utrecht University	Atsma, DE (corresponding author), Leiden Univ, Med Ctr, Dept Cardiol, POB 9600, NL-2300 RC Leiden, Netherlands.	d.e.atsma@lumc.nl	de Vries, Antoine/ABG-5787-2021; van Tuyn, John/R-3939-2019; van Tuyn, John/D-1342-2009; Pijnappels, Daniël/AAA-2304-2022	van Tuyn, John/0000-0001-5989-5185; van Tuyn, John/0000-0001-5989-5185; Pijnappels, Daniël/0000-0001-6731-4125				Baroldi G, 1997, CAN J CARDIOL, V13, P65; Brown RD, 2005, ANNU REV PHARMACOL, V45, P657, DOI 10.1146/annurev.pharmtox.45.120403.095802; Camelliti P, 2006, ADV CARDIOL, V42, P132, DOI 10.1159/000092566; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Chien KR, 2006, J CLIN INVEST, V116, P1838, DOI 10.1172/JCI29050; Creemers EE, 2006, MOL CELL, V23, P83, DOI 10.1016/j.molcel.2006.05.026; de Muinck ED, 2006, GENE THER, V13, P659, DOI 10.1038/sj.gt.3302680; Dimmeler S, 2005, J CLIN INVEST, V115, P572, DOI 10.1172/JCI200524283; Donello JE, 1998, J VIROL, V72, P5085, DOI 10.1128/JVI.72.6.5085-5092.1998; Dunwoodie SL, 2007, SEMIN CELL DEV BIOL, V18, P54, DOI 10.1016/j.semcdb.2006.12.003; Etzion S, 2002, CIRCULATION, V106, pI125, DOI 10.1161/01.cir.0000032888.55215.b8; Frangogiannis NG, 2006, ANTIOXID REDOX SIGN, V8, P1907, DOI 10.1089/ars.2006.8.1907; Fukushige T, 2006, GENE DEV, V20, P3395, DOI 10.1101/gad.1481706; Gaudesius G, 2003, CIRC RES, V93, P421, DOI 10.1161/01.RES.0000089258.40661.0C; GONZALEZSANCHEZ A, 1990, DEV BIOL, V139, P197, DOI 10.1016/0012-1606(90)90288-T; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Huang XP, 1999, CIRC RES, V84, P1; Jain MK, 1998, CIRC RES, V83, P980, DOI 10.1161/01.RES.83.10.980; Kizana E, 2006, GENE THER, V13, P1611, DOI 10.1038/sj.gt.3302813; Kizana E, 2005, CIRCULATION, V111, P394, DOI 10.1161/01.CIR.0000153812.64956.EF; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Miragoli M, 2006, CIRC RES, V98, P801, DOI 10.1161/01.RES.0000214537.44195.a3; Mitchell JA, 2004, AM J PHYSIOL-ENDOC M, V287, pE439, DOI 10.1152/ajpendo.00275.2003; Murry CE, 1996, J CLIN INVEST, V98, P2209, DOI 10.1172/JCI119030; Murry CE, 2006, J AM COLL CARDIOL, V47, P1777, DOI 10.1016/j.jacc.2006.02.002; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Parmacek MS, 2004, PROG CARDIOVASC DIS, V47, P159, DOI 10.1016/j.pcad.2004.07.003; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pijnappels DA, 2006, CARDIOVASC RES, V72, P282, DOI 10.1016/j.cardiores.2006.07.016; REISER PJ, 1994, AM J PHYSIOL-HEART C, V267, pH1589; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; Srivastava D, 2006, CELL, V126, P1037, DOI 10.1016/j.cell.2006.09.003; Sun Y, 2002, BASIC RES CARDIOL, V97, P343, DOI 10.1007/s00395-002-0365-8; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Takemura H, 2005, CIRC J, V69, P1405, DOI 10.1253/circj.69.1405; van Tuyn J, 2005, CARDIOVASC RES, V67, P245, DOI 10.1016/j.cardiores.2005.04.013; van Tuyn J, 2007, STEM CELLS, V25, P271, DOI 10.1634/stemcells.2006-0366; Vellinga J, 2006, J GENE MED, V8, P147, DOI 10.1002/jgm.844; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Winer-Muram HT, 2004, J COMPUT ASSIST TOMO, V28, P455, DOI 10.1097/00004728-200407000-00004; Wu SM, 2006, CELL, V127, P1137, DOI 10.1016/j.cell.2006.10.028; Yasui K, 2001, CIRC RES, V88, P536, DOI 10.1161/01.RES.88.5.536	43	33	36	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3369	3379		10.1096/fj.07-8211com	http://dx.doi.org/10.1096/fj.07-8211com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17579192				2022-12-25	WOS:000249781600037
J	Mus, F; Dubini, A; Seibert, M; Posewitz, MC; Grossman, AR				Mus, Florence; Dubini, Alexandra; Seibert, Michael; Posewitz, Matthew C.; Grossman, Arthur R.			Anaerobic acclimation in Chlamydomonas reinhardtii - Anoxic gene expression, hydrogenase induction, and metabolic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; DESULFOVIBRIO-DESULFURICANS ATCC-27774; HYBRID CLUSTER PROTEIN; X-RAY STRUCTURES; GREEN-ALGA; ESCHERICHIA-COLI; FERMENTATIVE METABOLISM; VULGARIS HILDENBOROUGH; SYNCHROTRON-RADIATION; PROLYL 4-HYDROXYLASE	Both prokaryotic and eukaryotic photosynthetic microbes experience conditions of anoxia, especially during the night when photosynthetic activity ceases. In Chlamydomonas reinhardtii, dark anoxia is characterized by the activation of an extensive set of fermentation pathways that act in concert to provide cellular energy, while limiting the accumulation of potentially toxic fermentative products. Metabolite analyses, quantitative PCR, and high density Chlamydomonas DNA microarrays were used to monitor changes in metabolite accumulation and gene expression during acclimation of the cells to anoxia. Elevated levels of transcripts encoding proteins associated with the production of H-2, organic acids, and ethanol were observed in congruence with the accumulation of fermentation products. The levels of over 500 transcripts increased significantly during acclimation of the cells to anoxic conditions. Among these were transcripts encoding transcription/translation regulators, prolyl hydroxylases, hybrid cluster proteins, proteases, transhydrogenase, catalase, and several putative proteins of unknown function. Overall, this study uses metabolite, genomic, and transcriptome data to provide genome-wide insights into the regulation of the complex metabolic networks utilized by Chlamydomonas under the anaerobic conditions associated with H-2 production.	Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA; Natl Renewable Energy Lab, Golden, CO 80401 USA; Colorado Sch Mines, Environm Sci & Engn Div, Golden, CO 80401 USA	Carnegie Institution for Science; United States Department of Energy (DOE); National Renewable Energy Laboratory - USA; Colorado School of Mines	Grossman, AR (corresponding author), Carnegie Inst Washington, Dept Plant Biol, 290 Panama St, Stanford, CA 94305 USA.	arthurg@stanford.edu	dubini, alexandra/A-7252-2016; dubini, alexandra/Q-6277-2019	dubini, alexandra/0000-0001-8825-3915; dubini, alexandra/0000-0001-8825-3915; Mus, Florence/0000-0002-1655-1267				Almeida CC, 2006, J BIOL CHEM, V281, P32445, DOI 10.1074/jbc.M605888200; Antal TK, 2003, BBA-BIOENERGETICS, V1607, P153, DOI 10.1016/j.bbabio.2003.09.008; Aragao D, 2003, J BIOL INORG CHEM, V8, P540, DOI 10.1007/s00775-003-0443-x; Atteia A, 2006, J BIOL CHEM, V281, P9909, DOI 10.1074/jbc.M507862200; BENAMOTZ A, 1972, PLANT PHYSIOL, V49, P240, DOI 10.1104/pp.49.2.240; Bohne AV, 2006, CURR GENET, V49, P333, DOI 10.1007/s00294-006-0060-7; Buis JM, 2005, ARCH BIOCHEM BIOPHYS, V433, P288, DOI 10.1016/j.abb.2004.09.028; Dauvillee D, 2003, EMBO J, V22, P6378, DOI 10.1093/emboj/cdg591; Dent RM, 2005, PLANT PHYSIOL, V137, P545, DOI 10.1104/pp.104.055244; Douce R, 1999, CURR OPIN PLANT BIOL, V2, P214, DOI 10.1016/S1369-5266(99)80038-7; Eberhard S, 2006, CURR GENET, V49, P106, DOI 10.1007/s00294-005-0041-2; Eichel J, 1999, J BACTERIOL, V181, P572, DOI 10.1128/JB.181.2.572-576.1999; Fedorov AS, 2005, APPL BIOCHEM BIOTECH, V121, P403, DOI 10.1385/ABAB:121:1-3:0403; Forestier M, 2003, EUR J BIOCHEM, V270, P2750, DOI 10.1046/j.1432-1033.2003.03656; GFELLER RP, 1984, PLANT PHYSIOL, V75, P212, DOI 10.1104/pp.75.1.212; GFELLER RP, 1985, PLANT PHYSIOL, V77, P509, DOI 10.1104/pp.77.2.509; Ghirardi ML, 2007, ANNU REV PLANT BIOL, V58, P71, DOI 10.1146/annurev.arplant.58.032806.103848; Ghirardi ML, 2005, BIOCHEM SOC T, V33, P70, DOI 10.1042/BST0330070; Ghirardi ML, 1997, APPL BIOCHEM BIOTECH, V63-5, P141, DOI 10.1007/BF02920420; Gonzali S, 2005, ANN BOT-LONDON, V96, P661, DOI 10.1093/aob/mci218; GRAVES DA, 1989, PHOTOCHEM PHOTOBIOL, V50, P571, DOI 10.1111/j.1751-1097.1989.tb05566.x; GREENBAUM E, 1983, PHOTOCHEM PHOTOBIOL, V37, P649, DOI 10.1111/j.1751-1097.1983.tb04534.x; Grossman AR, 2007, CURR OPIN PLANT BIOL, V10, P190, DOI 10.1016/j.pbi.2007.01.012; Happe T, 2002, TRENDS PLANT SCI, V7, P246, DOI 10.1016/S1360-1385(02)02274-4; HAPPE T, 1993, EUR J BIOCHEM, V214, P475, DOI 10.1111/j.1432-1033.1993.tb17944.x; HAPPE T, 1994, EUR J BIOCHEM, V222, P769, DOI 10.1111/j.1432-1033.1994.tb18923.x; Happe T, 2002, EUR J BIOCHEM, V269, P1022, DOI 10.1046/j.0014-2956.2001.02743.x; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; Harris EH, 2001, ANNU REV PLANT PHYS, V52, P363, DOI 10.1146/annurev.arplant.52.1.363; Hemschemeier A, 2005, BIOCHEM SOC T, V33, P39, DOI 10.1042/BST0330039; Hieta R, 2002, J BIOL CHEM, V277, P23965, DOI 10.1074/jbc.M201865200; Im CS, 2006, PLANT J, V48, P1, DOI 10.1111/j.1365-313X.2006.02852.x; Im CS, 2003, PHOTOSYNTH RES, V75, P111, DOI 10.1023/A:1022800630430; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; KASKA DD, 1987, BIOCHEM J, V241, P483, DOI 10.1042/bj2410483; KENNEDY RA, 1992, PLANT PHYSIOL, V100, P1, DOI 10.1104/pp.100.1.1; KESSLER E, 1974, ALGAL PHYSIOLOGY BIO, V10, P456; King PW, 1999, J BACTERIOL, V181, P5250, DOI 10.1128/JB.181.17.5250-5256.1999; KLEIN U, 1978, PLANT PHYSIOL, V61, P953, DOI 10.1104/pp.61.6.953; Klok EJ, 2002, PLANT CELL, V14, P2481, DOI 10.1105/tpc.004747; Kosourov S, 2005, PHOTOSYNTH RES, V85, P295, DOI 10.1007/s11120-005-5105-0; Kosourov S, 2003, PLANT CELL PHYSIOL, V44, P146, DOI 10.1093/pcp/pcg020; Kosourov S, 2002, BIOTECHNOL BIOENG, V78, P731, DOI 10.1002/bit.10254; KREUZBERG K, 1984, PHYSIOL PLANTARUM, V61, P87, DOI 10.1111/j.1399-3054.1984.tb06105.x; Kruse O, 2005, J BIOL CHEM, V280, P34170, DOI 10.1074/jbc.M503840200; Liu FL, 2005, PLANT PHYSIOL, V137, P1115, DOI 10.1104/pp.104.055475; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Macedo S, 2002, J BIOL INORG CHEM, V7, P514, DOI 10.1007/s00775-001-0326-y; McDonough MA, 2006, P NATL ACAD SCI USA, V103, P9814, DOI 10.1073/pnas.0601283103; Melis A, 2000, PLANT PHYSIOL, V122, P127, DOI 10.1104/pp.122.1.127; Moseley J, 2000, EMBO J, V19, P2139, DOI 10.1093/emboj/19.10.2139; Moseley JL, 2006, EUKARYOT CELL, V5, P26, DOI 10.1128/EC.5.1.26-44.2006; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; MULLER M, 1998, EVOLUTIONARY RELATIO; OHTA S, 1987, PLANT PHYSIOL, V83, P1022, DOI 10.1104/pp.83.4.1022; Posewitz MC, 2004, PLANT CELL, V16, P2151, DOI 10.1105/tpc.104.021972; Posewitz MC, 2004, J BIOL CHEM, V279, P25711, DOI 10.1074/jbc.M403206200; Posewitz MC, 2005, BIOCHEM SOC T, V33, P102, DOI 10.1042/BST0330102; Quinn JM, 2002, PLANT PHYSIOL, V128, P463, DOI 10.1104/pp.010694; Ragsdale SW, 2004, CRIT REV BIOCHEM MOL, V39, P165, DOI 10.1080/10409230490496577; Reymond P, 2000, PLANT CELL, V12, P707, DOI 10.1105/tpc.12.5.707; Rochaix JD, 2004, BIOCHEM SOC T, V32, P567, DOI 10.1042/BST0320567; Rochaix JD, 2004, PLANT CELL, V16, P1650, DOI 10.1105/tpc.160770; Rochaix JD, 2002, FEBS LETT, V529, P34, DOI 10.1016/S0014-5793(02)03181-2; ROESSLER PG, 1984, PLANT PHYSIOL, V76, P1086, DOI 10.1104/pp.76.4.1086; Schenk PM, 2000, P NATL ACAD SCI USA, V97, P11655, DOI 10.1073/pnas.97.21.11655; Sedbrook JC, 1996, PLANT PHYSIOL, V111, P243, DOI 10.1104/pp.111.1.243; Seki M, 2001, PLANT CELL, V13, P61, DOI 10.1105/tpc.13.1.61; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Snell WJ, 2004, CELL, V117, P693, DOI 10.1016/j.cell.2004.05.019; Steunou AS, 2006, P NATL ACAD SCI USA, V103, P2398, DOI 10.1073/pnas.0507513103; Tedin K, 2001, J BACTERIOL, V183, P6184, DOI 10.1128/JB.183.21.6184-6196.2001; VALENTINE RC, 1963, J BACTERIOL, V85, P1114, DOI 10.1128/JB.85.5.1114-1120.1963; Vignais PM, 2004, CURR ISSUES MOL BIOL, V6, P159; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WANKA F, 1970, ARCH MIKROBIOL, V75, P25, DOI 10.1007/BF00412091; WEAVER PF, 1980, SOL ENERGY, V24, P3, DOI 10.1016/0038-092X(80)90018-3; Wolfe MT, 2002, J BACTERIOL, V184, P5898, DOI 10.1128/JB.184.21.5898-5902.2002; Wykoff DD, 1998, PLANT PHYSIOL, V117, P129, DOI 10.1104/pp.117.1.129; Zhang LP, 2002, PLANTA, V214, P552, DOI 10.1007/s004250100660	80	218	221	1	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25475	25486		10.1074/jbc.M701415200	http://dx.doi.org/10.1074/jbc.M701415200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17565990	hybrid			2022-12-25	WOS:000249014100033
J	Burnett, JR; Zhong, SM; Jiang, ZHG; Hooper, AJ; Fisher, EA; McLeod, RS; Zhao, Y; Barrett, PHR; Hegele, RA; van Bockxmeer, FM; Zhang, H; Vance, DE; McKnight, CJ; Yao, Z				Burnett, John R.; Zhong, Shumei; Jiang, Zhenghui G.; Hooper, Amanda J.; Fisher, Eric A.; McLeod, Roger S.; Zhao, Yang; Barrett, P. Hugh R.; Hegele, Robert A.; van Bockxmeer, Frank M.; Zhang, Hongyu; Vance, Dennis E.; McKnight, C. James; Yao, Zemin			Missense mutations in APOB within the beta alpha 1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; HUMAN APOLIPOPROTEIN-B; N-TERMINAL DOMAIN; TRUNCATED APOLIPOPROTEIN; AMINO-TERMINUS; DECREASED PRODUCTION; STRUCTURAL-ANALYSIS; INITIATING DOMAIN; LIPID DISORDERS	Familial hypobetalipoproteinemia (FHBL) is associated with mutations in the APOB gene. We reported the first missense APOB mutation, R463W, in an FHBL kindred (Burnett, J. R., Shan, J., Miskie, B. A., Whitfield, A. J., Yuan, J., Tran, K., McKnight, C. J., Hegele, R. A., and Yao, Z. (2003) J. Biol. Chem. 278, 13442-13452). Here we identified a second nonsynonymous APOB mutation, L343V, in another FHBL kindred. Heterozygotes for L343V (n = 10) had a mean plasma apoB at 0.31 g/liter as compared with 0.80 g/liter in unaffected family members (n = 22). The L343V mutation impaired secretion of apoB-100 and very low density lipoproteins. The secretion efficiency was 20% for B100wt and 10% for B100LV and B100RW. Decreased secretion of mutant apoB-100 was associated with increased endoplasmic reticulum retention and increased binding to microsomal triglyceride transfer protein and BiP. Reduced secretion efficiency was also observed with B48LV and B17LV. Biochemical and biophysical analyses of apoB domain constructs showed that L343V and R463W altered folding of the alpha-helical domain within the N terminus of apoB. Thus, proper folding of the alpha-helical domain of apoB-100 is essential for efficient secretion.	Univ Western Australia, Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6847, Australia; Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6847, Australia; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 1X5, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Robarts Res Lab, London, ON N6A 5K8, Canada; Univ Western Australia, Sch Surg & Pathol, Perth, WA 6847, Australia	Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Ottawa; Boston University; Dalhousie University; University of Alberta; Western University (University of Western Ontario); University of Western Australia	Burnett, JR (corresponding author), Univ Western Australia, Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6847, Australia.	john.burnett@health.wa.gov.au	Hooper, Amanda J/H-7757-2014; Barrett, Hugh/B-2745-2011; Hegele, Robert/AAF-6482-2020; Barrett, Hugh/ABF-1714-2020; McLeod, Roger/F-8014-2015; Jiang, Z. Gordon/U-5256-2017; Hegele, Robert/G-3301-2011	Hegele, Robert/0000-0003-2861-5325; Barrett, Hugh/0000-0003-3223-6125; McLeod, Roger/0000-0002-6740-5569; Jiang, Z. Gordon/0000-0003-0495-9940; McKnight, Christopher/0000-0002-3237-0896	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26335] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILARSALINAS CA, 1995, ARTERIOSCL THROM VAS, V15, P71, DOI 10.1161/01.ATV.15.1.71; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; BAKER ME, 1988, BIOCHEM J, V255, P1057, DOI 10.1042/bj2551057; BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; Burch WL, 2000, J BIOL CHEM, V275, P16267, DOI 10.1074/jbc.M000446200; Burnett JR, 2003, J BIOL CHEM, V278, P13442, DOI 10.1074/jbc.M300235200; Cavallo D, 1998, J BIOL CHEM, V273, P33397, DOI 10.1074/jbc.273.50.33397; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; Clarke MW, 2006, CLIN CHEM, V52, P1339, DOI 10.1373/clinchem.2006.068692; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Elias N, 1999, ARTERIOSCL THROM VAS, V19, P2714, DOI 10.1161/01.ATV.19.11.2714; ELOVSON J, 1988, J LIPID RES, V29, P1461; Gabelli C, 1996, ARTERIOSCL THROM VAS, V16, P1189, DOI 10.1161/01.ATV.16.9.1189; GLUECK CJ, 1976, J LAB CLIN MED, V88, P941; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hegele RA, 2001, AM J HUM GENET, V69, P1161, DOI 10.1086/324647; Herscovitz H, 2001, J LIPID RES, V42, P51; HIXSON JE, 1990, J LIPID RES, V31, P545; Hooper AJ, 2005, CRIT REV CL LAB SCI, V42, P515, DOI 10.1080/10408360500295113; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; INNERARITY TL, 1990, J LIPID RES, V31, P1337; Jiang ZG, 2005, BIOCHEMISTRY-US, V44, P1163, DOI 10.1021/bi048286y; Jiang ZG, 2007, BIOPHYS J, V92, P4097, DOI 10.1529/biophysj.106.101105; Jiang ZHG, 2006, BIOCHEMISTRY-US, V45, P11799, DOI 10.1021/bi060600w; Kane J, 2001, METAB MOL BASES INHE, P2717; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lapierre LR, 2004, J LIPID RES, V45, P366, DOI 10.1194/jlr.M300104-JLR200; Ledford AS, 2006, J BIOL CHEM, V281, P8871, DOI 10.1074/jbc.M507657200; LINTON MF, 1993, J LIPID RES, V34, P521; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MCCORMICK SPA, 1992, BIOCHIM BIOPHYS ACTA, V1138, P290, DOI 10.1016/0925-4439(92)90006-9; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; PARHOFER KG, 1992, J CLIN INVEST, V89, P1931, DOI 10.1172/JCI115799; Pulai JI, 1998, AM J MED GENET, V76, P79, DOI 10.1002/(SICI)1096-8628(19980226)76:1<79::AID-AJMG15>3.3.CO;2-E; Richardson PE, 2005, BIOPHYS J, V88, P2789, DOI 10.1529/biophysj.104.046235; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sankatsing RR, 2005, ARTERIOSCL THROM VAS, V25, P1979, DOI 10.1161/01.ATV.0000176191.64314.07; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schonfeld G, 2005, CELL MOL LIFE SCI, V62, P1372, DOI 10.1007/s00018-005-4473-0; Schonfeld G, 2003, J LIPID RES, V44, P878, DOI 10.1194/jlr.R300002-JLR200; Segrest JP, 1999, J LIPID RES, V40, P1401; Segrest JP, 2001, J LIPID RES, V42, P1346; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARROCK WJ, 1992, J MOL BIOL, V226, P903, DOI 10.1016/0022-2836(92)90642-W; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; Tanoli T, 2004, J LIPID RES, V45, P941, DOI 10.1194/jlr.M300508-JLR200; Tarugi P, 2000, J HEPATOL, V33, P361, DOI 10.1016/S0168-8278(00)80270-6; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; Vukmirica J, 2003, J BIOL CHEM, V278, P14153, DOI 10.1074/jbc.M211995200; Vukmirica J, 2002, J LIPID RES, V43, P1496, DOI 10.1194/jlr.M200077-JLR200; Welty FK, 1997, ARTERIOSCL THROM VAS, V17, P881, DOI 10.1161/01.ATV.17.5.881; WETTERAU JR, 1992, SCIENCE, V258, P999; Whitfield AJ, 2005, CLIN CHEM, V51, P266; Whitfield AJ, 2004, CLIN CHEM, V50, P1725, DOI 10.1373/clinchem.2004.038026; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; Yue P, 2005, ATHEROSCLEROSIS, V178, P107, DOI 10.1016/j.atherosclerosis.2004.06.020	72	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24270	24283		10.1074/jbc.M702442200	http://dx.doi.org/10.1074/jbc.M702442200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17588943	hybrid			2022-12-25	WOS:000248686600053
J	Cheng, IH; Scearce-Levie, K; Legleiter, J; Palop, JJ; Gerstein, H; Bien-Ly, N; Puolivali, J; Lesne, S; Ashe, KH; Muchowski, PJ; Mucke, L				Cheng, Irene H.; Scearce-Levie, Kimberly; Legleiter, Justin; Palop, Jorge J.; Gerstein, Hilary; Bien-Ly, Nga; Puolivali, Jukka; Lesne, Sylvain; Ashe, Karen H.; Muchowski, Paul J.; Mucke, Lennart			Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; APP TRANSGENIC MICE; A-BETA; PRECURSOR-PROTEIN; BEHAVIORAL-CHANGES; NEURONAL LOSS; WILD-TYPE; PEPTIDE; AGGREGATION; DEPOSITION	Many proteins suspected of causing neurodegenerative diseases exist in diverse assembly states. For most, it is unclear whether shifts from one state to another would be helpful or harmful. We used mutagenesis to change the assembly state of Alzheimer disease (AD)-associated amyloid-beta (A beta) peptides. In vitro, the "Arctic" mutation (A beta E22G) accelerated A beta fibrillization but decreased the abundance of nonfibrillar A beta assemblies, compared with wild-type A beta. In human amyloid precursor protein (hAPP) transgenic mice carrying mutations adjacent to A beta that increase A beta production, addition of the Arctic mutation markedly enhanced the formation of neuritic amyloid plaques but reduced the relative abundance of a specific nonfibrillar A beta assembly (A beta*56). Mice overexpressing Arctic mutant or wildtype A beta had similar behavioral and neuronal deficits when they were matched for A beta*56 levels but had vastly different plaque loads. Thus, A beta*56 is a likelier determinant of functional deficits in hAPP mice than fibrillar A beta deposits. Therapeutic interventions that reduce A beta fibrils at the cost of augmenting nonfibrillar A beta assemblies could be harmful.	Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Minnesota, Sch Med, Dept Neurol, Minneapolis, MN 55455 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities	Mucke, L (corresponding author), 1650 Owens St, San Francisco, CA 94158 USA.	lmucke@gladstone.ucsf.edu	Palop, Jorge/AAH-9014-2020; Palop, Jorge J./D-8128-2011; Gerstein, Hertzel C/B-1235-2013	Gerstein, Hertzel C/0000-0001-8072-2836; Lesne, Sylvain/0000-0001-9411-1868; Palop, Jorge/0000-0001-6086-1070; Legleiter, Justin/0000-0002-5262-1867	NCRR NIH HHS [RR 18928-01] Funding Source: Medline; NIA NIH HHS [AG023501, AG011385, AG022074] Funding Source: Medline; NINDS NIH HHS [NS33249] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011385, R37AG011385, P50AG023501, P01AG022074] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x; Belzung C, 2001, BEHAV BRAIN RES, V125, P141, DOI 10.1016/S0166-4328(01)00291-1; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; BURDICK D, 1992, J BIOL CHEM, V267, P546; Cheng IH, 2004, NAT MED, V10, P1190, DOI 10.1038/nm1123; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Chin J, 2005, J NEUROSCI, V25, P9694, DOI 10.1523/JNEUROSCI.2980-05.2005; Chin J, 2004, J NEUROSCI, V24, P4692, DOI 10.1523/JNEUROSCI.0277-04.2004; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Esposito L, 2006, J NEUROSCI, V26, P5167, DOI 10.1523/JNEUROSCI.0482-06.2006; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Galvan V, 2006, P NATL ACAD SCI USA, V103, P7130, DOI 10.1073/pnas.0509695103; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Holcomb LA, 1999, BEHAV GENET, V29, P177, DOI 10.1023/A:1021691918517; Hori Y, 2007, J BIOL CHEM, V282, P4916, DOI 10.1074/jbc.M608220200; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Ji ZS, 2006, J BIOL CHEM, V281, P2683, DOI 10.1074/jbc.M506646200; Johansson AS, 2006, FEBS J, V273, P2618, DOI 10.1111/j.1742-4658.2006.05263.x; Kerr ML, 2005, J NEUROSCI RES, V80, P151, DOI 10.1002/jnr.20408; Kim J, 2007, J NEUROSCI, V27, P627, DOI 10.1523/JNEUROSCI.4849-06.2007; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Klyubin I, 2004, EUR J NEUROSCI, V19, P2839, DOI 10.1111/j.1460-9568.2004.03389.x; Knowles RB, 1998, J NEUROPATH EXP NEUR, V57, P1122, DOI 10.1097/00005072-199812000-00003; Kobayashi DT, 2005, GENES BRAIN BEHAV, V4, P173, DOI 10.1111/j.1601-183X.2005.00124.x; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee KW, 2006, NEUROBIOL DIS, V22, P10, DOI 10.1016/j.nbd.2005.09.011; Legleiter J, 2004, J COLLOID INTERF SCI, V278, P96, DOI 10.1016/j.jcis.2004.05.009; Legleiter J, 2004, J MOL BIOL, V335, P997, DOI 10.1016/j.jmb.2003.11.019; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lleo A, 2006, ANNU REV MED, V57, P513, DOI 10.1146/annurev.med.57.121304.131442; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Mucke L, 2000, AM J PATHOL, V157, P2003, DOI 10.1016/S0002-9440(10)64839-0; Murakami K, 2003, J BIOL CHEM, V278, P46179, DOI 10.1074/jbc.M301874200; Neve RL, 2007, BBA-MOL BASIS DIS, V1772, P430, DOI 10.1016/j.bbadis.2006.10.008; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Palop JJ, 2005, J NEUROSCI, V25, P9686, DOI 10.1523/JNEUROSCI.2829-05.2005; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; Rockenstein E, 2005, J BIOL CHEM, V280, P32957, DOI 10.1074/jbc.M507016200; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Skovronsky DM, 2006, ANNU REV PATHOL-MECH, V1, P151, DOI 10.1146/annurev.pathol.1.110304.100113; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; Stern EA, 2004, J NEUROSCI, V24, P4535, DOI 10.1523/JNEUROSCI.0462-04.2004; STEWARD O, 1977, BRAIN RES BULL, V2, P41, DOI 10.1016/0361-9230(77)90023-5; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tsai J, 2004, NAT NEUROSCI, V7, P1181, DOI 10.1038/nn1335; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Whalen BM, 2005, NEUROBIOL DIS, V20, P254, DOI 10.1016/j.nbd.2005.03.007; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303; Zheng H, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-5	69	341	348	1	25	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23818	23828		10.1074/jbc.M701078200	http://dx.doi.org/10.1074/jbc.M701078200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17548355	hybrid			2022-12-25	WOS:000248686600010
J	Walker, VE; Atanasiu, R; Lam, H; Shrier, A				Walker, Valerie E.; Atanasiu, Roxana; Lam, Hung; Shrier, Alvin			Co-chaperone FKBP38 promotes HERG trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PEPTIDYLPROLYL ISOMERASE DOMAIN; FK-506 BINDING-PROTEIN-38; GLUCOCORTICOID-RECEPTOR; MOLECULAR CHAPERONES; IMMUNOPHILIN FKBP52; CARDIAC-ARRHYTHMIA; SEQUENCE DATABASES; DYNEIN INTERACTION; QUALITY-CONTROL	The Long QT Syndrome is a cardiac disorder associated with ventricular arrhythmias that can lead to syncope and sudden death. One prominent form of the Long QT syndrome has been linked to mutations in the HERG gene (KCNH2) that encodes the voltage-dependent delayed rectifier potassium channel (I-Kr). In order to search for HERG-interacting proteins important for HERG maturation and trafficking, we conducted a proteomics screen using myc-tagged HERG transfected into cardiac (HL-1) and non-cardiac (human embryonic kidney 293) cell lines. A partial list of putative HERG-interacting proteins includes several known components of the cytosolic chaperone system, including Hsc70 (70-kDa heat shock cognate protein), Hsp90 (90-kDa heat shock protein), Hdj-2, Hop (Hsp-organizing protein), and Bag-2 (BCL-associated athanogene 2). In addition, two membrane-integrated proteins were identified, calnexin and FKBP38 (38-kDa FK506-binding protein, FKBP8). Weshow that FKBP38 immunoprecipitates and co-localizes with HERG in our cellular system. Importantly, small interfering RNA knock down of FKBP38 causes a reduction of HERG trafficking, and overexpression of FKBP38 is able to partially rescue the LQT2 trafficking mutant F805C. We propose that FKBP38 is a co-chaperone of HERG and contributes via the Hsc70/Hsp90 chaperone system to the trafficking of wild type and mutant HERG potassium channels.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Shrier, A (corresponding author), McGill Univ, Dept Physiol, 3655 Rue Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	alvin.shrier@mcgill.ca						Akhavan A, 2003, J BIOL CHEM, V278, P40105, DOI 10.1074/jbc.M307837200; Anderson CL, 2006, CIRCULATION, V113, P365, DOI 10.1161/CIRCULATIONAHA.105.570200; Arndt V, 2005, MOL BIOL CELL, V16, P5891, DOI 10.1091/mbc.E05-07-0660; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Delisle BP, 2003, J BIOL CHEM, V278, P35749, DOI 10.1074/jbc.M305787200; Edlich F, 2005, EMBO J, V24, P2688, DOI 10.1038/sj.emboj.7600739; Edlich F, 2007, J BIOL CHEM, V282, P15341, DOI 10.1074/jbc.M611594200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Ficker E, 2002, J BIOL CHEM, V277, P4989, DOI 10.1074/jbc.M107345200; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Gong QM, 2006, J BIOL CHEM, V281, P4069, DOI 10.1074/jbc.M511765200; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Kang CB, 2005, BIOCHEM BIOPH RES CO, V337, P30, DOI 10.1016/j.bbrc.2005.09.023; Kang CB, 2005, FEBS LETT, V579, P1469, DOI 10.1016/j.febslet.2005.01.053; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; McClellan AJ, 2005, NAT CELL BIOL, V7, P736, DOI 10.1038/ncb0805-736; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; PIND S, 1994, J BIOL CHEM, V269, P12784; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 2004, ESSAYS BIOCHEM, V40, P41, DOI 10.1042/bse0400041; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SARAH A, 2006, J MUSCLE RES CELL M, V27, P153; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; White SM, 2004, AM J PHYSIOL-HEART C, V286, pH823, DOI 10.1152/ajpheart.00986.2003; Wozniak MJ, 2006, EMBO J, V25, P5457, DOI 10.1038/sj.emboj.7601427; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Youker RT, 2004, MOL BIOL CELL, V15, P4787, DOI 10.1091/mbc.E04-07-0584; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	47	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23509	23516		10.1074/jbc.M701006200	http://dx.doi.org/10.1074/jbc.M701006200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17569659	hybrid			2022-12-25	WOS:000248577500052
J	Gong, P; Han, JH; Reddig, K; Li, HS				Gong, Ping; Han, Junhai; Reddig, Keith; Li, Hong-Sheng			A potential dimerization region of dCAMTA is critical for termination of fly visual response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CALMODULIN-BINDING PROTEIN; COMMONLY DELETED REGION; DNA-BINDING; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; CALCIUM; CAMTA1; NEUROBLASTOMA; ETHYLENE	CAMTAs are a group of Ca2+/calmodulin binding transcription activators that are implicated in brain tumor suppression, cardiac hypertrophy, and plant sensory responses. The sole fly CAMTA, dCAMTA, stimulates expression of an F-box gene, dFbxl4, to potentiate rhodopsin deactivation, which enables rapid termination of fly visual responses. Here we report that a dCAMTA fragment associated with a full-length protein in co-transfected human embryonic kidney 293 cells. The interaction site was mapped to a region within the DNA-binding CG-1 domain. With this potential dimerization site mutated, the full-length dCAMTA had defective nuclear localization. In transgenic flies, this mutant dCAMTA variant failed to stimulate expression of dFbxl4 and rescue the slow termination of light response phenotype of a dCAMTA null mutant fly. Our data suggest that dCAMTA may function as a dimer during fly visual regulation and that the CG-1 domain may mediate dimerization of CAMTA transcription factors.	Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Li, HS (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, 364 Plantat St, Worcester, MA 01605 USA.	Hong-Sheng.Li@umassmed.edu			NATIONAL INSTITUTE ON AGING [R01AG022508] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG022508] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Bouche N, 2002, J BIOL CHEM, V277, P21851, DOI 10.1074/jbc.M200268200; Chawla S, 2002, EUR J PHARMACOL, V447, P131, DOI 10.1016/S0014-2999(02)01837-X; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Cruzalegui FH, 2000, CELL MOL LIFE SCI, V57, P402, DOI 10.1007/PL00000702; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Han JH, 2006, CELL, V127, P847, DOI 10.1016/j.cell.2006.09.030; Hardingham GE, 1999, MICROSC RES TECHNIQ, V46, P348, DOI 10.1002/(SICI)1097-0029(19990915)46:6<348::AID-JEMT3>3.3.CO;2-1; Henrich KO, 2007, EUR J CANCER, V43, P607, DOI 10.1016/j.ejca.2006.09.023; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Ikura M, 2002, BIOESSAYS, V24, P625, DOI 10.1002/bies.10105; Katoh M, 2003, INT J ONCOL, V23, P1219; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Moorthy AK, 2003, J BIOL CHEM, V278, P556, DOI 10.1074/jbc.M207515200; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reddy ASN, 2000, BIOCHEM BIOPH RES CO, V279, P762, DOI 10.1006/bbrc.2000.4032; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; SILVA ODE, 1994, PLANT MOL BIOL, V25, P921, DOI 10.1007/BF00028887; Song K, 2006, CELL, V125, P453, DOI 10.1016/j.cell.2006.02.048; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Yang TB, 2002, J BIOL CHEM, V277, P45049, DOI 10.1074/jbc.M207941200; Yang TB, 2000, J BIOL CHEM, V275, P38467, DOI 10.1074/jbc.M003566200; Zaffran S, 2005, BIOCHEM BIOPH RES CO, V334, P361, DOI 10.1016/j.bbrc.2005.06.090; Zegzouti H, 1999, PLANT J, V18, P589, DOI 10.1046/j.1365-313x.1999.00483.x	30	12	12	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21253	21258		10.1074/jbc.M701223200	http://dx.doi.org/10.1074/jbc.M701223200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17537720	hybrid			2022-12-25	WOS:000248047500053
J	Sharma, M; George, AA; Singh, BN; Sahoo, NC; Rao, KVS				Sharma, Manish; George, Anuja A.; Singh, Badri N.; Sahoo, Naresh C.; Rao, Kanury V. S.			Regulation of transcript elongation through cooperative and ordered recruitment of cofactors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; C-TERMINAL DOMAIN; PROXIMAL REGION; PHOSPHORYLATION; ACTIVATION; PROMOTER; GENE	We studied the regulation of murine CD80, a gene whose basal transcriptional status was characterized by the presence of a stalled RNA polymerase II complex on the promoter-proximal region. Stimulus-induced activation of productive elongation involved a complex interplay of regulated events that included a synergy between ordered cofactor recruitment. This cascade of recruitments was initiated through the engagement of transcription factor NF-kappa B, leading to the temporal association of histone acetyltransferases and the consequent selective acetylation of a transcription start site downstream nucleosome. This in turn culminated into the nucleosomal association of Brd4-associated P-TEFb, a protein complex containing kinase specific for serine 2 of Rbp 1, the largest subunit of the carboxyl-terminal domain of RNA polymerase II. The consequent phosphorylation of serine 2 residues in CTD by CDK9 in the P-TEFb complex then facilitated escape of polymerase II into the productive elongation phase. Thus, the cooperative mechanisms that integrate between independent pathways characterize regulation of the elongation step of transcription, thereby providing another level at which specificity of gene regulation can be achieved.	Int Ctr Genet Engn & Biotechnol, Immunol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Rao, KVS (corresponding author), Int Ctr Genet Engn & Biotechnol, Immunol Grp, Aruna Asaf Ali Marg, New Delhi 110067, India.	kanury@icgeb.res.in	George, Anuja/C-5963-2017; Singh, Badri/P-5848-2015	George, Anuja/0000-0003-2643-6307; Singh, Badri/0000-0002-6100-7092				BORRIELLO F, 1994, J IMMUNOL, V153, P5038; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Donepudi M, 2001, J IMMUNOL, V166, P6491, DOI 10.4049/jimmunol.166.11.6491; George AA, 2006, EMBO J, V25, P811, DOI 10.1038/sj.emboj.7600966; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Marshall RM, 2006, FRONT BIOSCI-LANDMRK, V11, P2598, DOI 10.2741/1994; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; Schwartz BE, 2003, MOL CELL BIOL, V23, P6876, DOI 10.1128/MCB.23.19.6876-6886.2003; SELVAKUMAR A, 1993, IMMUNOGENETICS, V38, P292, DOI 10.1007/BF00188807; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7	22	16	18	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20887	20896		10.1074/jbc.M701420200	http://dx.doi.org/10.1074/jbc.M701420200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17535807	hybrid			2022-12-25	WOS:000248047500014
J	Drew, LJ; Rugiero, F; Cesare, P; Gale, JE; Abrahamsen, B; Bowden, S; Heinzmann, S; Robinson, M; Brust, A; Colless, B; Lewis, RJ; Wood, JN				Drew, Liam J.; Rugiero, Francois; Cesare, Paolo; Gale, Jonathan E.; Abrahamsen, Bjarke; Bowden, Sarah; Heinzmann, Sebastian; Robinson, Michelle; Brust, Andreas; Colless, Barbara; Lewis, Richard J.; Wood, John N.			High-Threshold Mechanosensitive Ion Channels Blocked by a Novel Conopeptide Mediate Pressure-Evoked Pain	PLOS ONE			English	Article								Little is known about the molecular basis of somatosensory mechanotransduction in mammals. We screened a library of peptide toxins for effects on mechanically activated currents in cultured dorsal root ganglion neurons. One conopeptide analogue, termed NMB-1 for noxious mechanosensation blocker 1, selectively inhibits (IC50 1 mu M) sustained mechanically activated currents in a subset of sensory neurons. Biotinylated NMB-1 retains activity and binds selectively to peripherin-positive nociceptive sensory neurons. The selectivity of NMB-1 was confirmed by the fact that it has no inhibitory effects on voltage-gated sodium and calcium channels, or ligand-gated channels such as acid-sensing ion channels or TRPA1 channels. Conversely, the tarantula toxin, GsMTx-4, which inhibits stretch-activated ion channels, had no effects on mechanically activated currents in sensory neurons. In behavioral assays, NMB-1 inhibits responses only to high intensity, painful mechanical stimulation and has no effects on low intensity mechanical stimulation or thermosensation. Unexpectedly, NMB-1 was found to also be an inhibitor of rapid FM1-43 loading (a measure of mechanotransduction) in cochlear hair cells. These data demonstrate that pharmacologically distinct channels respond to distinct types of mechanical stimuli and suggest that mechanically activated sustained currents underlie noxious mechanosensation. NMB-1 thus provides a novel diagnostic tool for the molecular definition of channels involved in hearing and pressure-evoked pain.	[Drew, Liam J.; Rugiero, Francois; Abrahamsen, Bjarke; Heinzmann, Sebastian; Robinson, Michelle; Wood, John N.] UCL, Dept Biol, London, England; [Gale, Jonathan E.] UCL, Ear Inst, Ctr Auditory Res, London, England; [Brust, Andreas; Colless, Barbara; Lewis, Richard J.] Xenome Ltd, Indooroopilly, Qld, Australia; [Lewis, Richard J.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia; [Lewis, Richard J.] Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia; [Cesare, Paolo] Fdn Santa Lucia, Ctr Europeo Ric Cervello, Rome, Italy; [Bowden, Sarah] Ionix Pharmaceut Ltd, Cambridge, England	University of London; University College London; University of London; University College London; University of Queensland; University of Queensland; IRCCS Santa Lucia	Wood, JN (corresponding author), UCL, Dept Biol, London, England.	j.wood@ucl.ac.uk	Gale, Jonathan/AAG-6874-2019; Lewis, Richard J/E-8674-2013; Abrahamsen, Bjarke/ABD-5874-2020; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Lewis, Richard/0000-0003-3470-923X; Brust, Andreas/0000-0003-4238-5706; Gale, Jonathan/0000-0003-4678-4878; Abrahamsen, Bjarke/0000-0002-6128-8269; Cesare, Paolo/0000-0003-1324-5974	MRC; Wellcome Trust; MRC [G9717869] Funding Source: UKRI; Medical Research Council [G9717869] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful for the support of The MRC and The in funding this work. We thank Ramin Raouf for help with toxin binding experiments.	Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Bode F, 2001, NATURE, V409, P35, DOI 10.1038/35051165; Cho HW, 2002, J NEUROSCI, V22, P1238, DOI 10.1523/JNEUROSCI.22-04-01238.2002; Corey DP, 2004, NATURE, V432, P723, DOI 10.1038/nature03066; Drew LJ, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-1; Drew LJ, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-8; Drew LJ, 2004, J PHYSIOL-LONDON, V556, P691, DOI 10.1113/jphysiol.2003.058693; Drew LJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-12-j0001.2002; Ernstrom GG, 2002, ANNU REV GENET, V36, P411, DOI 10.1146/annurev.genet.36.061802.101708; Gale JE, 2001, J NEUROSCI, V21, P7013, DOI 10.1523/JNEUROSCI.21-18-07013.2001; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Gottlieb P, 2006, BIOPHYS J, V90, P1545; Gottlieb P. A., 2004, CURRENT DRUG TARGETS, V3, P61; Hamill OP, 1996, PHARMACOL REV, V48, P231; Hu J, 2006, J PHYSIOL-LONDON, V577, P815, DOI 10.1113/jphysiol.2006.117648; HUSMARK I, 1971, J PHYSIOL-LONDON, V218, P257, DOI 10.1113/jphysiol.1971.sp009616; Kwan KY, 2006, NEURON, V50, P277, DOI 10.1016/j.neuron.2006.03.042; Lewin G.R., 2000, MOL BASIS PAIN INDUC, P129; Liedtke W, 2005, CELL MOL LIFE SCI, V62, P2985, DOI 10.1007/s00018-005-5181-5; Lin SY, 2005, CURR OPIN NEUROBIOL, V15, P350, DOI 10.1016/j.conb.2005.05.012; LOEWENSTEIN WR, 1966, J PHYSIOL-LONDON, V182, P346, DOI 10.1113/jphysiol.1966.sp007827; MARCOTTI W, 2001, INT J AUDIOL, V41, P231; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; McCarter GC, 1999, NEUROSCI LETT, V273, P179, DOI 10.1016/S0304-3940(99)00665-5; McCarter GC, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-28; Meyers JR, 2003, J NEUROSCI, V23, P4054; NAGY JI, 1983, J NEUROSCI, V3, P1145; SAUMET JL, 1982, PHARMACOL BIOCHEM BE, V16, P241, DOI 10.1016/0091-3057(82)90155-1; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; SHIR Y, 1990, NEUROSCI LETT, V115, P62, DOI 10.1016/0304-3940(90)90518-E; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P16586, DOI 10.1073/pnas.0606894103; Strassmaier M, 2002, CURR OPIN NEUROBIOL, V12, P380, DOI 10.1016/S0959-4388(02)00344-6; Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583	33	56	59	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e515	10.1371/journal.pone.0000515	http://dx.doi.org/10.1371/journal.pone.0000515			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565368	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451600003
J	Sumilo, D; Asokliene, L; Bormane, A; Vasilenko, V; Golovljova, I; Randolph, SE				Sumilo, Dana; Asokliene, Loreta; Bormane, Antra; Vasilenko, Veera; Golovljova, Irina; Randolph, Sarah E.			Climate Change Cannot Explain the Upsurge of Tick-Borne Encephalitis in the Baltics	PLOS ONE			English	Article							IXODES-RICINUS ACARI; LYME BORRELIOSIS; TEMPERATURE; FOCI	Background. Pathogens transmitted by ticks cause human disease on a greater scale than any other vector-borne infections in Europe, and have increased dramatically over the past 2-3 decades. Reliable records of tick-borne encephalitis (TBE) since 1970 show an especially sharp upsurge in cases in Eastern Europe coincident with the end of Soviet rule, including the three Baltic countries, Estonia, Latvia and Lithuania, where national incidence increased from 1992 to 1993 by 64, 175 and 1,065%, respectively. At the county level within each country, however, the timing and degree of increase showed marked heterogeneity. Climate has also changed over this period, prompting an almost universal assumption of causality. For the first time, we analyse climate and TBE epidemiology at sufficiently fine spatial and temporal resolution to question this assumption. Methodology/Principal Finding. Detailed analysis of instrumental records of climate has revealed a significant step increase in spring-time daily maximum temperatures in 1989. The seasonal timing and precise level of this warming were indeed such as could promote the transmission of TBE virus between larval and nymphal ticks co-feeding on rodents. These changes in climate, however, are virtually uniform across the Baltic region and cannot therefore explain the marked spatio-temporal heterogeneity in TBE epidemiology. Conclusions/Significance. Instead, it is proposed that climate is just one of many different types of factors, many arising from the socio-economic transition associated with the end of Soviet rule, that have acted synergistically to increase both the abundance of infected ticks and the exposure of humans to these ticks. Understanding the precise differential contribution of each factor as a cause of the observed epidemiological heterogeneity will help direct control strategies.	[Sumilo, Dana; Randolph, Sarah E.] Univ Oxford, Dept Zool, Oxford OX1 3PS, England; [Asokliene, Loreta] Ctr Communicable Dis Prevent & Control, Vilnius, Lithuania; [Bormane, Antra] State Agcy Publ Hlth Agcy, Riga, Latvia; [Vasilenko, Veera; Golovljova, Irina] Natl Inst Hlth Dev, Tallinn, Estonia	University of Oxford; Centre for Communicable Diseases & AIDS (ULAC) - Lithuania; National Institute for Health Development - Estonia	Randolph, SE (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	sarah.randolph@zoo.ox.ac.uk	Randolph, Sarah/AAR-9346-2021		Wellcome Trust [070696/Z/03/Z)]; Estonian Science Foundation [5963]; EU [GOCE-2003-010284]	Wellcome Trust(Wellcome TrustEuropean Commission); Estonian Science Foundation; EU(European Commission)	This study was funded principally by the Wellcome Trust (grant no. 070696/Z/03/Z) and also by the Estonian Science Foundation (grant 5963) and EU grant GOCE-2003-010284 EDEN; it is catalogued by the EDEN Steering Committee as EDEN41 (http://www.eden-fp6project.net/). The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views of the European Commission.	Daniel M, 2003, EUR J CLIN MICROBIOL, V22, P327, DOI 10.1007/s10096-003-0918-2; Daniel M., 2006, CLIMATE CHANGE ADAPT, P189; Dautel H, 1997, J INSECT PHYSIOL, V43, P843, DOI 10.1016/S0022-1910(97)00025-5; Davis J.C., 1986, STAT DATA ANAL GEOLO; Epstein PR, 2005, NEW ENGL J MED, V353, P1433, DOI 10.1056/NEJMp058079; Epstein PR, 2001, J URBAN HEALTH, V78, P367, DOI 10.1093/jurban/78.2.367; Gleason ACR, 2002, REMOTE SENS ENVIRON, V79, P147, DOI 10.1016/S0034-4257(01)00269-3; Hossell J, 2006, HDB CLIMATE TRENDS S; Houghton J. T., 2001, CLIMATE CHANGE 2001; Labuda M, 1999, ZBL BAKT-INT J MED M, V289, P513; Lindgren E, 2001, LANCET, V358, P16, DOI 10.1016/S0140-6736(00)05250-8; MacLEOD JOHN, 1935, PARASITOLOGY, V27, P123, DOI 10.1017/S0031182000015006; Menne Bettina, 2006, P1; Patz JA, 2002, P NATL ACAD SCI USA, V99, P12506, DOI 10.1073/pnas.212467899; Perret JL, 2000, PARASITOL RES, V86, P554, DOI 10.1007/s004360000209; Randolph S, 2006, INT J MED MICROBIOL, V296, P84, DOI 10.1016/j.ijmm.2005.12.008; Randolph SE, 2002, INT J PARASITOL, V32, P979, DOI 10.1016/S0020-7519(02)00030-9; Randolph SE, 2001, PHILOS T R SOC B, V356, P1045, DOI 10.1098/rstb.2001.0893; Randolph SE, 2004, PARASITOLOGY, V129, pS37, DOI 10.1017/S0031182004004925; Randolph SE, 2000, PARASITOLOGY, V121, P15, DOI 10.1017/S0031182099006083; REUTERSWARD A, 2003, LABOUR MARKETS SOCIA; Sharma S, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004331; *SKDS MARK PUBL OP, 2001, INV FACT HIND IMM PO; SUMILO D, 2007, EMERG INFEC IN PRESS; Sumilo D, 2006, INT J MED MICROBIOL, V296, P76, DOI 10.1016/j.ijmm.2005.12.006; Suss J, 2003, VACCINE, V21, pS19, DOI 10.1016/S0264-410X(02)00812-5; Suss J, 2002, INT J MED MICROBIOL, V291, P34; Talleklint L, 1998, J MED ENTOMOL, V35, P521, DOI 10.1093/jmedent/35.4.521; WHO, 2003, CLIM CHANG HUM HLTH; Wild M, 2005, SCIENCE, V308, P847, DOI 10.1126/science.1103215	30	111	117	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e500	10.1371/journal.pone.0000500	http://dx.doi.org/10.1371/journal.pone.0000500			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551580	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451500009
J	Visone, R; Pallante, P; Vecchione, A; Cirombella, R; Ferracin, M; Ferraro, A; Volinia, S; Coluzzi, S; Leone, V; Borbone, E; Liu, CG; Petrocca, F; Troncone, G; Calin, GA; Scarpa, A; Colato, C; Tallini, G; Santoro, M; Croce, CM; Fusco, A				Visone, R.; Pallante, P.; Vecchione, A.; Cirombella, R.; Ferracin, M.; Ferraro, A.; Volinia, S.; Coluzzi, S.; Leone, V.; Borbone, E.; Liu, C-G; Petrocca, F.; Troncone, G.; Calin, G. A.; Scarpa, A.; Colato, C.; Tallini, G.; Santoro, M.; Croce, C. M.; Fusco, A.			Specific microRNAs are downregulated in human thyroid anaplastic carcinomas	ONCOGENE			English	Article						microRNA; miR-30d; miR-125b; miR-26a; miR-30a-5p; thyroid anaplastic carcinoma	CHRONIC LYMPHOCYTIC-LEUKEMIA; MALIGNANT PHENOTYPE; GENE-EXPRESSION; CELL-LINES; OVEREXPRESSION; PROTEINS; RNA; DIFFERENTIATION; TRANSFORMATION; PROLIFERATION	Thyroid carcinomas comprise a broad spectrum of tumors with different clinical behaviors. On the one side, there are occult papillary carcinomas (PTC), slow growing and clinically silent, and on the other side, rapidly growing anaplastic carcinomas (ATC), which are among the most lethal human neoplasms. We have analysed the microRNA (miR) pro. le of ATC in comparison to the normal thyroid using a microarray (miRNACHIP microarray). By this approach, we found an aberrant miR expression pro. le that clearly differentiates ATC from normal thyroid tissues and from PTC analysed in previous studies. In particular, a significant decrease in miR-30d, miR-125b, miR-26a and miR-30a-5p was detected in ATC in comparison to normal thyroid tissue. These results were further confirmed by northern blots, quantitative reverse transcription-PCR analyses and in situ hybridization. The overexpression of these four miRs in two human ATC-derived cell lines suggests a critical role of miR-125b and miR-26a downregulation in thyroid carcinogenesis, since a cell growth inhibition was achieved. Conversely, no effect on cell growth was observed after the overexpression of miR-30d and miR-30a-5p in the same cells. In conclusion, these data indicate a miR signature associated with ATC and suggest the miR deregulation as an important event in thyroid cell transformation.	Univ Naples Federico II, Fac Med & Chirurg, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Pathol, I-80131 Naples, Italy; European Sch Mol Med, Biotechnol Avanzate Napoli & SEMM, NOGEC, CEINGE, Naples, Italy; Ohio State Univ, Columbus, OH 43210 USA; Univ Roma La Sapienza, Dip Istopathol, Osped St Andrea, Dipartimento Anat Umana & Istol, Rome, Italy; Univ Ferrara, Ctr Interdipartipartmental Ricerca Cancro, Dipartimento Med Sperimentale & Diagnost, Ferrara, Italy; Univ Naples 2, Fac Med & Chirurg, Dipartimoento Anat Patol & Citopatol, Naples, Italy; Univ Verona, Dipartimento Patol, Verona, Italy; Univ Bologna, Osped Bellaria, Dipartimento Patol Sperimentale, Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; University System of Ohio; Ohio State University; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Ferrara; Universita della Campania Vanvitelli; University of Verona; University of Bologna	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Pathol Cellulare & Mol, Via Pansini 5 80131, I-80131 Naples, Italy.	carlo.croce@osumc.edu; afusco@napoli.com	Calin, George/E-9390-2011; Volinia, Stefano/AAA-9264-2019; scarpa, aldo/K-6832-2016; Volinia, Stefano/A-3029-2010; Ferraro, Angelo/H-3193-2019; Pallante, Pierlorenzo/AAX-8758-2020; visone, rosa/K-7910-2016; Huang, H/E-9490-2010; Tallini, Giovanni/F-7850-2013; Ferraro, Angelo/A-4172-2014; Young, Richard A/F-6495-2012; Ferracin, Manuela/K-2097-2016	Volinia, Stefano/0000-0003-0910-3893; scarpa, aldo/0000-0003-1678-739X; Volinia, Stefano/0000-0003-0910-3893; Ferraro, Angelo/0000-0002-2044-7569; Tallini, Giovanni/0000-0003-0113-6682; Ferraro, Angelo/0000-0002-2044-7569; Young, Richard A/0000-0001-8855-8647; Ferracin, Manuela/0000-0002-1595-6887; Fusco, Alfredo/0000-0003-3332-5197; VISONE, Rosa/0000-0002-4993-0220; Calin, George/0000-0001-6704-5615; Coluzzi, Sabrina/0000-0003-4483-6232; Vecchione, Andrea/0000-0002-5497-6856				Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Califano D, 1998, CANCER RES, V58, P823; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; de Nigris F, 1998, CANCER RES, V58, P4745; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hunt JL, 2003, AM J SURG PATHOL, V27, P1559, DOI 10.1097/00000478-200312000-00009; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Martelli ML, 2000, EUR J ENDOCRINOL, V143, P515, DOI 10.1530/eje.0.1430515; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; Ros P, 1999, BIOCHIMIE, V81, P389, DOI 10.1016/S0300-9084(99)80086-8; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Weber F, 2006, J CLIN ENDOCR METAB, V91, P3584, DOI 10.1210/jc.2006-0693	31	316	348	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2007	26	54					7590	7595		10.1038/sj.onc.1210564	http://dx.doi.org/10.1038/sj.onc.1210564			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563749				2022-12-25	WOS:000251282100012
J	Kitisin, K; Ganesan, N; Tang, Y; Jogunoori, W; Volpe, EA; Kim, SS; Katuri, V; Kallakury, B; Pishvaian, M; Albanese, C; Mendelson, J; Zasloff, M; Rashid, A; Fishbein, T; Evans, SRT; Sidawy, A; Reddy, EP; Mishra, B; Johnson, LB; Shetty, K; Mishra, L				Kitisin, K.; Ganesan, N.; Tang, Y.; Jogunoori, W.; Volpe, E. A.; Kim, S. S.; Katuri, V.; Kallakury, B.; Pishvaian, M.; Albanese, C.; Mendelson, J.; Zasloff, M.; Rashid, A.; Fishbein, T.; Evans, S. R. T.; Sidawy, A.; Reddy, E. P.; Mishra, B.; Johnson, L. B.; Shetty, K.; Mishra, L.			Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation	ONCOGENE			English	Article						hepatocellular carcinoma; ELF; cyclin D1; transforming growth factor-beta; cell cycle	HEPATITIS-B-VIRUS; TGF-BETA; MICROSATELLITE INSTABILITY; CARCINOMA; EXPRESSION; RECEPTOR; GENE; CATENIN; TUMOR; P53	Transforming growth factor-beta (TGF-beta) signaling members, TGF-beta receptor type II ( TBRII), Smad2, Smad4 and Smad adaptor, embryonic liver fodrin ( ELF), are prominent tumor suppressors in gastrointestinal cancers. Here, we show that 40% of elf(-+/-) mice spontaneously develop hepatocellular cancer ( HCC) with markedly increased cyclin D1, cyclin-dependent kinase 4 (Cdk4), c-Myc and MDM2 expression. Reduced ELF but not TBRII, or Smad4 was observed in 8 of 9 human HCCs (P < 0.017). ELF and TBRII are also markedly decreased in human HCC cell lines SNU-398 and SNU-475. Restoration of ELF and TBRII in SNU-398 cells markedly decreases cyclin D1 as well as hyperphosphorylated-retinoblastoma ( hyperphosphorylated-pRb). Thus, we show that TGF-b signaling and Smad adaptor ELF suppress human hepatocarcinogenesis, potentially through cyclin D1 deregulation. Loss of ELF could serve as a primary event in progression toward a fully transformed phenotype and could hold promise for new therapeutic approaches in human HCCs.	Georgetown Univ, Sch Med, Dept Surg Sci, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Pathol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Med Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Dept Vet Affairs Med Ctr, Washington, DC USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Mishra, L (corresponding author), Georgetown Univ, Dept Surg, Med Dent Bldg,Room NW 207-213,Reservoir Rd,NW, Washington, DC 20007 USA.	lm229@georgetown.edu	Reddy, E. Premkumar/F-6233-2011; Ganesan, Natarajan/C-8080-2012; Volpe, Eugene A./D-2000-2012	Volpe, Eugene A./0000-0002-9128-754X; Mishra, Lopa/0000-0002-6850-0808	NATIONAL CANCER INSTITUTE [R01CA042857, P01CA095569, R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA095569, R01 CA4285718A, R01 CA106614A, P01 CA095569, R01 CA042857, R01 CA106614] Funding Source: Medline; NIDDK NIH HHS [R01 DK056111, R01 DK56111, R01 DK58637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; Ishizaki Y, 2004, INT J ONCOL, V24, P1077; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kiss A, 1997, CLIN CANCER RES, V3, P1059; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Longerich T, 2004, VIRCHOWS ARCH, V445, P589, DOI 10.1007/s00428-004-1118-x; Macdonald GA, 1998, HEPATOLOGY, V28, P90, DOI 10.1002/hep.510280114; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; Park YN, 2004, HEPATO-GASTROENTEROL, V51, P396; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pavio N, 2005, ONCOGENE, V24, P6119, DOI 10.1038/sj.onc.1208749; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; Sundarrajan M, 2002, CELL BIOL INT, V26, P699, DOI 10.1006/cbir.2002.0923; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; TINIAKOS D, 1993, HEPATO-GASTROENTEROL, V40, P37; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueta T, 2002, ONCOL REP, V9, P1197; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yamamoto H, 2000, INT J ONCOL, V16, P543; Zhang YJ, 2002, MOL CARCINOGEN, V33, P125, DOI 10.1002/mc.10028	44	100	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7103	7110		10.1038/sj.onc.1210513	http://dx.doi.org/10.1038/sj.onc.1210513			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17546056	Green Accepted			2022-12-25	WOS:000250715000004
J	Ost, A; Danielsson, A; Liden, M; Eriksson, U; Nystrom, FH; Stralfors, P				Ost, Anita; Danielsson, Anna; Liden, Martin; Eriksson, Ulf; Nystrom, Fredrik H.; Stralfors, Peter			Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes	FASEB JOURNAL			English	Article						insulin resistance; type 2 diabetes; adipokine; protein phosphorylation; MAP kinase	GLUCOSE-TRANSPORT; RECEPTOR SUBSTRATE-1; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; RESISTANCE; RETINOL-BINDING-PROTEIN-4; EXPRESSION; OBESITY; SERINE-307; METABOLISM	Reduced sensitivity to insulin in adipose, muscle, and liver tissues is a hallmark of type 2 diabetes. Animal models and patients with type 2 diabetes exhibit elevated levels of circulating retinol-binding protein (RBP4), and RBP4 can induce insulin resistance in mice. However, little is known about how RBP4 affects insulin signaling. We examined the mechanisms of action of RBP4 in primary human adipocytes. RBP4-treated adipocytes exhibited the same molecular defects in insulin signaling, via IRS1 to MAP kinase, as in adipocytes from patients with type 2 diabetes. Without affecting autophosphorylation of the insulin receptor, RBP4 blocked the insulin-stimulated phosphorylation of IRS1 at serine (307) [ corresponding to serine (302) in the murine sequence] and concomitantly increased the EC50 (from 0.5 to 2 nM) for insulin stimulation of IRS1 phosphorylation at tyrosine. The phosphorylation of IRS1 at serine (312) [ corresponding to serine (307) in the murine sequence] was not affected in cells from diabetic patients and was also not affected by RBP4. The EC50 for insulin stimulation of downstream phosphorylation of MAP kinase ERK1/2 was increased (from 0.2 to 0.8 nM) by RBP4. We show that ERK1/2 phosphorylation is similarly impaired in adipocytes from patients with type 2 diabetes. However, the sensitivity to insulin for downstream signaling to control of protein kinase B and glucose uptake was not affected by RBP4. When insulin-resistant adipocytes from patients with type 2 diabetes were incubated with antibodies against RBP4, insulin-induced phosphorylation of IRS1 at serine (307) was normalized and the EC50 for insulin stimulation of ERK1/2 phosphorylation was reduced. Endogenous levels of RBP4 were markedly reduced in adipocytes from obese or type 2 diabetic subjects, whereas expression levels of RBP4 mRNA were unaffected. These findings indicate that RBP4 may be released from diabetic adipocytes and act locally to inhibit phosphorylation of IRS1 at serine (307), a phosphorylation site that may integrate nutrient sensing with insulin signaling.	Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden; Linkoping Univ, Ctr Diabet Res, SE-58185 Linkoping, Sweden; Ludwig Inst Canc Res, S-10401 Stockholm, Sweden; Linkoping Univ, Dept Med & Care, Linkoping, Sweden	Linkoping University; Linkoping University; Ludwig Institute for Cancer Research; Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden.	peter.stralfors@ibk.liu.se		Nystrom, Fredrik/0000-0002-1680-1000; Stralfors, Peter/0000-0002-1196-1806				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Daniels Norman, 2001, American Journal of Bioethics, V1, P2, DOI 10.1162/152651601300168834; Danielsson A, 2006, BIOCHEM BIOPH RES CO, V342, P1183, DOI 10.1016/j.bbrc.2006.02.075; Danielsson A, 2005, J BIOL CHEM, V280, P34389, DOI 10.1074/jbc.C500230200; FROST SC, 1987, J BIOL CHEM, V262, P9872; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Janke J, 2006, DIABETES, V55, P2805, DOI 10.2337/db06-0616; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Liden M, 2005, EXP CELL RES, V310, P401, DOI 10.1016/j.yexcr.2005.08.002; MARINARI L, 1987, J LIPID RES, V28, P941; MELHUS H, 1995, BIOCHEM BIOPH RES CO, V210, P105, DOI 10.1006/bbrc.1995.1633; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Stenkula KG, 2004, MOL CELL ENDOCRINOL, V221, P1, DOI 10.1016/j.mce.2004.04.011; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; Thorn H, 2003, MOL BIOL CELL, V14, P3967, DOI 10.1091/mbc.E03-01-0050; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; Zick Y, 2004, BIOCHEM SOC T, V32, P812, DOI 10.1042/BST0320812	25	98	105	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3696	3704		10.1096/fj.07-8173com	http://dx.doi.org/10.1096/fj.07-8173com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17575262				2022-12-25	WOS:000250517800031
J	Zheng, H; Mckay, J; Buss, JE				Zheng, Hui; Mckay, Jodi; Buss, Janice E.			H-ras does not need COP I- or COP II-dependent vesicular transport to reach the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN FARNESYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; LIVE CELLS; K-RAS; TRAFFICKING; PALMITOYLATION; PATHWAY; GOLGI; LOCALIZATION	Although vesicular transport of the H-Ras protein from the Golgi to the plasma membrane is well known, additional trafficking steps, both to and from the plasma membrane, have also been described. Notably, both vesicular and nonvesicular transport mechanisms have been proposed. The initial trafficking of H-Ras to the plasma membrane was therefore examined in more detail. In untreated cells, H-Ras appeared at the plasma membrane more rapidly than a protein carried by the conventional exocytic pathway, and no H-Ras was visible on Golgi membranes in > 80% of the cells. H-Ras was still able to reach the plasma membrane when COP II-directed transport was disrupted by two different mutant forms of Sar1, when COP I-mediated vesicular traffic from the endoplasmic reticulum to the Golgi was inhibited with brefeldin A, or when microtubules were disrupted by nocodazole. Although some H-Ras was present in the secretory pathway, protein that reached the membranes of the endoplasmic reticulum-Golgi intermediate compartment was unable to move further in the presence of nocodozale. These results identify an alternative mechanism for H-Ras trafficking that circumvents conventional COPI-,COPII-,and microtubule dependent vesicular transport. Thus, H-Ras has two simultaneous but distinct means of transport and need not depend on vesicular trafficking for its delivery to the plasma membrane.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Buss, JE (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	jbuss2@email.uky.edu		Buss, Janice/0000-0002-8086-265X				Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Ashery U, 2006, TRAFFIC, V7, P1119, DOI 10.1111/j.1600-0854.2006.00459.x; Bannykh SI, 2005, TRAFFIC, V6, P803, DOI 10.1111/j.1600-0854.2005.00319.x; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Bergo MO, 2004, J BIOL CHEM, V279, P4729, DOI 10.1074/jbc.M310081200; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; Breuza L, 2004, J BIOL CHEM, V279, P47242, DOI 10.1074/jbc.M406644200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dong XW, 2003, MOL CELL BIOL, V23, P6574, DOI 10.1128/MCB.23.18.6574-6584.2003; Ducker CE, 2004, ONCOGENE, V23, P9230, DOI 10.1038/sj.onc.1208171; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; Fivaz M, 2005, J CELL BIOL, V170, P429, DOI 10.1083/jcb.200409157; Gomez GA, 2005, J BIOL CHEM, V280, P34997, DOI 10.1074/jbc.M506256200; Goodwin JS, 2005, J CELL BIOL, V170, P261, DOI 10.1083/jcb.200502063; Hauri HP, 2000, J CELL SCI, V113, P587; Hightower KE, 1998, BIOCHEMISTRY-US, V37, P15555, DOI 10.1021/bi981525v; Huang K, 2004, NEURON, V44, P977, DOI 10.1016/j.neuron.2004.11.027; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; Linder ME, 2007, NAT REV MOL CELL BIO, V8, P74, DOI 10.1038/nrm2084; Liu W, 2005, NAT STRUCT MOL BIOL, V12, P106, DOI 10.1038/nsmb0205-106; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Long SB, 2002, NATURE, V419, P645, DOI 10.1038/nature00986; Magee T, 2005, CURR OPIN CELL BIOL, V17, P190, DOI 10.1016/j.ceb.2005.02.003; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.e04-11-0960; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rotblat B, 2006, CANCER RES, V66, P1974, DOI 10.1158/0008-5472.CAN-05-3791; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; Roy S, 2005, MOL CELL BIOL, V25, P6722, DOI 10.1128/MCB.25.15.6722-6733.2005; Sang SLW, 2005, J PEPT RES, V66, P169, DOI 10.1111/j.1399-3011.2005.00285.x; Silvius JR, 2006, MOL BIOL CELL, V17, P192, DOI 10.1091/mbc.e05-05-0408; Silvius JR, 2002, J MEMBRANE BIOL, V190, P83, DOI 10.1007/s00232-002-1026-4; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Swarthout JT, 2005, J BIOL CHEM, V280, P31141, DOI 10.1074/jbc.M504113200; Watanabe R, 2004, CURR OPIN CELL BIOL, V16, P350, DOI 10.1016/j.ceb.2004.06.010; Watson RT, 2003, MOL CELL BIOL, V23, P961, DOI 10.1128/MCB.23.3.961-974.2003; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	44	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25760	25768		10.1074/jbc.M700437200	http://dx.doi.org/10.1074/jbc.M700437200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17588947	hybrid			2022-12-25	WOS:000249014100063
J	Coleman, ML; McDonough, MA; Hewitson, KS; Coles, C; Mecinovic, J; Edelmann, M; Cook, KM; Cockman, ME; Lancaster, DE; Kessler, BM; Oldham, NJ; Ratcliffe, PJ; Schofield, CJ				Coleman, Mathew L.; McDonough, Michael A.; Hewitson, Kirsty S.; Coles, Charlotte; Mecinovic, Jasmin; Edelmann, Mariola; Cook, Kristina M.; Cockman, Matthew E.; Lancaster, David E.; Kessler, Benedikt M.; Oldham, Neil J.; Ratcliffe, Peter J.; Schofield, Christopher J.			Asparaginyl hydroxylation of the notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR HIF; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CELL FATE; PROLYL; COACTIVATORS; ARCHITECTURE; RECOGNITION; ACTIVATION; PATHWAY	The stability and activity of hypoxia- inducible factor ( HIF) are regulated by the post- translational hydroxylation of specific prolyl and asparaginyl residues. We show that the HIF asparaginyl hydroxylase, factor inhibiting HIF ( FIH), also catalyzes hydroxylation of highly conserved asparaginyl residues within ankyrin repeat ( AR) domains ( ARDs) of endogenous Notch receptors. AR hydroxylation decreases the extent of ARD binding to FIH while not affecting signaling through the canonical Notch pathway. ARDproteins were found to efficiently compete with HIF for FIH- dependent hydroxylation. Crystallographic analyses of the hydroxylated Notch ARD ( 2.35 A) and of Notch peptides bound to FIH ( 2.4 - 2.6A) reveal the stereochemistry of hydroxylationon the AR and imply that significant conformational changes are required in the ARD fold in order to enable hydroxylation at the FIH active site. We propose that ARD proteins function as natural inhibitors of FIH and that the hydroxylation status of these proteins provides another oxygen- dependent interface that modulates HIF signaling.	Univ Oxford, Chem Res Lab, Oxford OX1 3TA, England; Univ Oxford, Henry Wellcome Bldg Mol Physiol, Oxford OX3 7BN, England	University of Oxford; University of Oxford	Schofield, CJ (corresponding author), Univ Oxford, Chem Res Lab, Oxford OX1 3TA, England.	christopher.schofield@chemistry.oxford.ac.uk	Cook, Kristina/B-8012-2008; Mecinovic, Jasmin/F-9694-2015; McDonough, Michael A/G-2744-2013; Coleman, Mathew L/C-1676-2014; Kessler, Benedikt/AAY-8614-2021; Cockman, Matthew/V-9619-2019; McDonough, Michael/N-8913-2019	Mecinovic, Jasmin/0000-0002-5559-3822; McDonough, Michael A/0000-0003-4664-6942; Coleman, Mathew L/0000-0001-6020-9023; Kessler, Benedikt/0000-0002-8160-2446; Cockman, Matthew/0000-0002-3310-4821; McDonough, Michael/0000-0003-4664-6942; Ratcliffe, Peter/0000-0002-2853-806X; Oldham, Neil/0000-0001-8024-4563; Cook, Kristina/0000-0002-0503-7166; Schofield, Christopher/0000-0002-0290-6565; Coles, Charlotte/0000-0003-4525-7144; Edelmann, Mariola/0000-0003-0459-7716	Biotechnology and Biological Sciences Research Council [BBS/B/07683] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bradley CM, 2005, J MOL BIOL, V352, P253, DOI 10.1016/j.jmb.2005.06.041; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brennan K, 2002, BIOESSAYS, V24, P405, DOI 10.1002/bies.10089; Cockman ME, 2006, P NATL ACAD SCI USA, V103, P14767, DOI 10.1073/pnas.0606877103; Croy CH, 2004, PROTEIN SCI, V13, P1767, DOI 10.1110/ps.04731004; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Diez H, 2007, EXP CELL RES, V313, P1, DOI 10.1016/j.yexcr.2006.09.009; Ehebauer MT, 2005, BIOCHEM J, V392, P13, DOI 10.1042/BJ20050515; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hirota K, 2005, BIOCHEM BIOPH RES CO, V338, P610, DOI 10.1016/j.bbrc.2005.08.193; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655; McNeill LA, 2002, BIOCHEM J, V367, P571, DOI 10.1042/BJ20021162; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Pahlman S, 2004, SEMIN CANCER BIOL, V14, P365, DOI 10.1016/j.semcancer.2004.04.016; Peet Daniel, 2006, Novartis Found Symp, V272, P37; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Sainson RCA, 2006, TRENDS MOL MED, V12, P141, DOI 10.1016/j.molmed.2006.02.001; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Stolze IP, 2004, J BIOL CHEM, V279, P42719, DOI 10.1074/jbc.M406713200; WALSH CT, 2006, POST TRANSLATIONAL M, P331; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Wu LZ, 2004, SEMIN CANCER BIOL, V14, P348, DOI 10.1016/j.semcancer.2004.04.014; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127; Zweifel ME, 2005, STRUCTURE, V13, P1599, DOI 10.1016/j.str.2005.07.015	33	171	183	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24027	24038		10.1074/jbc.M704102200	http://dx.doi.org/10.1074/jbc.M704102200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17573339	hybrid			2022-12-25	WOS:000248686600028
J	Kaler, G; Truong, DM; Khandelwal, A; Nagle, M; Eraly, SA; Swaan, PW; Nigam, SK				Kaler, Gregory; Truong, David M.; Khandelwal, Akash; Nagle, Megha; Eraly, Satish A.; Swaan, Peter W.; Nigam, Sanjay K.			Structural variation governs substrate specificity for organic anion transporter (OAT) homologs - Potential remote sensing by oat family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-AMINOHIPPURATE TRANSPORT; MAJOR HISTOCOMPATIBILITY COMPLEX; PROXIMAL TUBULE; RAT-KIDNEY; PAH TRANSPORT; OLFACTORY MUCOSA; ACIDS; IDENTIFICATION; REQUIREMENTS; BINDING	Organic anion transporters (OATs, SLC22) interact with a remarkably diverse array of endogenous and exogenous organic anions. However, little is known about the structural features that determine their substrate selectivity. We examined the substrate binding preferences and transport function of olfactory organic anion transporter, Oat6, in comparison with the more broadly expressed transporter, Oat1 ( first identified as NKT). In analyzing interactions of both transporters with over 40 structurally diverse organic anions, we find a correlation between organic anion potency (pK(i)) and hydrophobicity (logP) suggesting a hydrophobicity-driven association with transporter-binding sites, which appears particularly prominent for Oat6. On the other hand, organic anion binding selectivity between Oat6 and Oat1 is influenced by the anion mass and net charge. Smaller mono-anions manifest greater potency for Oat6 and di-anions for Oat1. Comparative molecular field analysis confirms these mechanistic insights and provides a model for predicting new OAT substrates. By comparative molecular field analysis, both hydrophobic and charged interactions contribute to Oat1 binding, although it is predominantly the former that contributes to Oat6 binding. Together, the data suggest that, although the three-dimensional structures of these two transporters may be very similar, the binding pockets exhibit crucial differences. Furthermore, for six radiolabeled substrates, we assessed transport efficacy (V-max) for Oat6 and Oat1. Binding potency and transport efficacy had little correlation, suggesting that different molecular interactions are involved in substrate binding to the transporter and translocation across the membrane. Substrate specificity for a particular transporter may enable design of drugs for targeting to specific tissues (e. g. olfactory mucosa). We also discuss how these data suggest a possible mechanism for remote sensing between OATs in different tissue compartments (e. g. kidney, olfactory mucosa) via organic anions.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cell & Mol Med, La Jolla, CA 92093 USA; Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Maryland; University of Maryland Baltimore	Nigam, SK (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Khandelwal, Akash/0000-0002-0472-7173; Swaan, Peter/0000-0003-1767-1487; Truong, David/0000-0002-5121-5111	NIAID NIH HHS [AI057695, R01 AI057695] Funding Source: Medline; NICHD NIH HHS [HD40011, R01 HD040011] Funding Source: Medline; NIDDK NIH HHS [DK075486, K08 DK064839, R03 DK075486, DK064839, DK61425, R01 DK061425, R01 DK061425-04] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK064839, R03DK075486, R01DK061425] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagger MA, 2004, EUR J PHARM SCI, V21, P235, DOI 10.1016/j.ejps.2003.10.012; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Burckhardt BC, 2003, REV PHYSIOL BIOCH P, V146, P95, DOI 10.1007/s10254-002-0003-8; Chang C, 2004, MOL PHARMACOL, V65, P558, DOI 10.1124/mol.65.3.558; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005; Dantzler WH, 2003, BBA-BIOMEMBRANES, V1618, P185, DOI 10.1016/j.bbamem.2003.08.015; Ekins S, 2005, PHARM RES-DORDR, V22, P512, DOI 10.1007/s11095-005-2505-y; Eraly SA, 2006, J BIOL CHEM, V281, P5072, DOI 10.1074/jbc.M508050200; Eraly SA, 2004, MOL PHARMACOL, V65, P479, DOI 10.1124/mol.65.3.479; Illum L, 2000, EUR J PHARM SCI, V11, P1, DOI 10.1016/S0928-0987(00)00087-7; Johnson BA, 2000, J COMP NEUROL, V426, P330, DOI 10.1002/1096-9861(20001016)426:2<330::AID-CNE12>3.0.CO;2-5; Kaler G, 2006, BIOCHEM BIOPH RES CO, V351, P872, DOI 10.1016/j.bbrc.2006.10.136; Lemieux MJ, 2004, CURR OPIN STRUC BIOL, V14, P405, DOI 10.1016/j.sbi.2004.06.003; Lemmen C, 1998, J MED CHEM, V41, P4502, DOI 10.1021/jm981037l; Lopez-Nieto C. E., 1996, Journal of the American Society of Nephrology, V7, P1301; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Monte JC, 2004, BIOCHEM BIOPH RES CO, V323, P429, DOI 10.1016/j.bbrc.2004.08.112; Nakamura T, 2000, COMP BIOCHEM PHYS A, V126, P17, DOI 10.1016/S1095-6433(00)00191-4; Schnabolk GW, 2006, AM J PHYSIOL-RENAL, V291, pF314, DOI 10.1152/ajprenal.00497.2005; Singer AG, 1997, P NATL ACAD SCI USA, V94, P2210, DOI 10.1073/pnas.94.6.2210; Suhre WM, 2005, MOL PHARMACOL, V67, P1067, DOI 10.1124/mol.104.004713; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; ULLRICH KJ, 1989, PFLUG ARCH EUR J PHY, V415, P342, DOI 10.1007/BF00370886; ULLRICH KJ, 1989, KIDNEY INT, V36, P78, DOI 10.1038/ki.1989.164; ULLRICH KJ, 1987, PFLUG ARCH EUR J PHY, V409, P547, DOI 10.1007/BF00584652; ULLRICH KJ, 1987, PFLUG ARCH EUR J PHY, V408, P38, DOI 10.1007/BF00581838; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V418, P360, DOI 10.1007/BF00550874; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V418, P371, DOI 10.1007/BF00550875; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; ULLRICH KJ, 1988, PFLUG ARCH EUR J PHY, V413, P134, DOI 10.1007/BF00582523; Vyas Tushar K., 2005, Current Drug Delivery, V2, P165, DOI 10.2174/1567201053586047; West IC, 1997, BBA-REV BIOMEMBRANES, V1331, P213, DOI 10.1016/S0304-4157(97)00007-5; Willse A, 2005, ANAL CHEM, V77, P2348, DOI 10.1021/ac048711t	35	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23841	23853		10.1074/jbc.M703467200	http://dx.doi.org/10.1074/jbc.M703467200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17553798	hybrid, Green Accepted			2022-12-25	WOS:000248686600012
J	Guo, HB; Randolph, M; Pierce, M				Guo, Hua-Bei; Randolph, Matthew; Pierce, Michael			Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes - Inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; HUMAN HEPATOCARCINOMA CELLS; ACETYLGLUCOSAMINYLTRANSFERASE-V; FACTOR RECEPTOR; SIGNALING PATHWAY; DOWN-REGULATION; E-CADHERIN; BETA-1,6-BRANCHED OLIGOSACCHARIDES; ABERRANT GLYCOSYLATION; EXPRESSION LEVELS	Changes in the expression of glycosyltransferases that branch N-linked glycans can alter the function of several types of cell surface receptors and a glucose transporter. To study in detail the mechanisms by which aberrant N-glycosylation caused by altered N-acetylglucosaminyltransferase V(GnT-V, GnT-Va, and Mgat5a) expression can regulate the invasiveness-related phenotypes found in some carcinomas, we utilized specific small interfering RNA (siRNA) to selectively knock down GnT-V expression in the highly metastatic and invasive human breast carcinoma cell line, MDA-MB231. Knockdown of GnT-V by siRNA expression had no effect on epidermal growth factor receptor expression levels but lowered expression of N-linked beta(1,6)-branching on epidermal growth factor receptor, as expected. Compared with control cells, knockdown of GnT-V caused significant inhibition of the morphological changes and cell detachment from matrix that is normally seen after stimulation with epidermal growth factor (EGF). Decreased expression of GnT-V caused a marked inhibition of EGF-induced dephosphorylation of focal adhesion kinase (FAK), consistent with the lack of cell morphology changes in the cells expressing GnT-V siRNA. The attenuation of EGF-mediated phosphorylation and activation of the tyrosine phosphatase SHP-2 was dramatically observed in GnT-V knockdown cells, and these effects could be rescued by reintroduction of GnT-V into these cells, indicating that reduced EGF-mediated activation of SHP-2 was GnT-V related. Concomitantly, knockdown of GnT-V caused reduced EGF-mediated ERK signaling and tumor cell invasiveness-related phenotypes, including effects on actin rearrangement and cell motility. No changes in EGF binding were observed, however, after knockdown of GnT-V. Our results demonstrate that decreased GnT-V activity due to siRNA expression in human breast carcinoma cells resulted in an inhibition of EGF-stimulated SHP-2 activation and, consequently, caused attenuation of the dephosphorylation of FAK induced by EGF. These effects suppressed EGF-mediated downstream signaling and invasiveness-related phenotypes and suggest GnT-V as a potential therapeutic target.	Univ Georgia, Dept Biochem & Mol Biol, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Pierce, M (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.	hawkeye@uga.edu						Abbott KL, 2006, EXP CELL RES, V312, P2837, DOI 10.1016/j.yexcr.2006.05.022; AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BROCKHAUSEN I, 1988, BIOCHEM CELL BIOL, V66, P1134, DOI 10.1139/o88-131; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 2006, J BIOL CHEM, V281, P15593, DOI 10.1074/jbc.R500030200; Caceres M, 2005, EXP CELL RES, V309, P229, DOI 10.1016/j.yexcr.2005.05.020; Chen L, 1998, ONCOGENE, V17, P2087, DOI 10.1038/sj.onc.1202124; Chen XN, 2006, BIOCHEM BIOPH RES CO, V343, P910, DOI 10.1016/j.bbrc.2006.03.046; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; Cunnick JM, 2002, J BIOL CHEM, V277, P9498, DOI 10.1074/jbc.M110547200; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; Dosaka-Akita H, 2004, CLIN CANCER RES, V10, P1773, DOI 10.1158/1078-0432.CCR-1047-3; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1611; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Granovsky M, 2000, NAT MED, V6, P306; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 2004, GLYCOCONJUGATE J, V21, P9, DOI 10.1023/B:GLYC.0000043741.47559.30; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Guo HB, 2005, J BIOL CHEM, V280, P8332, DOI 10.1074/jbc.M413532200; Guo HB, 2000, J CANCER RES CLIN, V126, P263, DOI 10.1007/s004320050341; Guo HB, 2003, J BIOL CHEM, V278, P52412, DOI 10.1074/jbc.M308837200; Guo HB, 1999, BIOCHEM BIOPH RES CO, V264, P509, DOI 10.1006/bbrc.1999.1303; Guo HB, 2002, CANCER RES, V62, P6837; Guo P, 2004, CELL MOL LIFE SCI, V61, P1795, DOI 10.1007/s00018-004-4122-z; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hakomori S, 1996, CANCER RES, V56, P5309; Handerson T, 2005, CLIN CANCER RES, V11, P2969, DOI 10.1158/1078-0432.CCR-04-2211; ILLIC D, 1995, NATURE, V377, P539; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Ishibashi Y, 2005, ONCOLOGY-BASEL, V69, P301, DOI 10.1159/000089680; Jaggi M, 2005, CANCER RES, V65, P483; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAX I, 1991, J BIOL CHEM, V266, P13828; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MacGillivray M, 2003, J BIOL CHEM, V278, P27190, DOI 10.1074/jbc.M213083200; Manes S, 1999, MOL CELL BIOL, V19, P3125; Ohtsubo K, 2005, CELL, V123, P1307, DOI 10.1016/j.cell.2005.09.041; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Pierce M, 1997, GLYCOCONJUGATE J, V14, P623, DOI 10.1023/A:1018592627696; Rafiq K, 2006, J BIOL CHEM, V281, P19781, DOI 10.1074/jbc.M513040200; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; Sato Y, 2001, J BIOL CHEM, V276, P11956, DOI 10.1074/jbc.M008551200; Schaller MD, 2004, J CELL BIOL, V166, P157, DOI 10.1083/jcb.200406151; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Seelentag WKF, 1998, CANCER RES, V58, P5559; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; Sieg DJ, 1999, J CELL SCI, V112, P2677; Stroop CJM, 2000, ARCH BIOCHEM BIOPHYS, V374, P42, DOI 10.1006/abbi.1999.1660; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang FM, 2005, BREAST CANCER RES TR, V89, P5, DOI 10.1007/s10549-004-1002-z; Wang XC, 2006, J BIOL CHEM, V281, P2572, DOI 10.1074/jbc.M510893200; Yamamoto H, 2000, CANCER RES, V60, P134; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhen YJ, 2003, BIOCHEMISTRY-US, V42, P5478, DOI 10.1021/bi027101p; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	79	78	82	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22150	22162		10.1074/jbc.M611518200	http://dx.doi.org/10.1074/jbc.M611518200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17537730	hybrid			2022-12-25	WOS:000248196800061
J	Guest, CB; Hartman, ME; O'Connor, JC; Chakour, KS; Sovari, AA; Freund, GG				Guest, Christopher B.; Hartman, Matthew E.; O'Connor, Jason C.; Chakour, Kenneth S.; Sovari, Ali A.; Freund, Gregory G.			Phagocytosis of Cholesteryl Ester Is Amplified in Diabetic Mouse Macrophages and Is Largely Mediated by CD36 and SR-A	PLOS ONE			English	Article								Type 2 diabetes (T2D) is associated with accelerated atherosclerosis, which accounts for approximately 75% of all diabetes-related deaths. Here we investigate the link between diabetes and macrophage cholesteryl ester accumulation. When diabetic (db/db) mice are given cholesteryl ester intraperitoneally (IP), peritoneal macrophages (PerM Phi s) recovered from these animals showed a 58% increase in intracellular cholesteryl ester accumulation over PerM Phi s from heterozygote control (db/+) mice. Notably, PerM Phi fluid-phase endocytosis and large particle phagocytosis was equivalent in db/+ and db/db mice. However, IP administration of CD36 and SR-A blocking antibodies led to 37% and 25% reductions in cholesteryl ester accumulation in PerM Phi. Finally, in order to determine if these scavenger receptors (SRs) were part of the mechanism responsible for the increased accumulation of cholesteryl esters observed in the diabetic mouse macrophages, receptor expression was quantified by flow cytometry. Importantly, db/db PerM Phi s showed a 43% increase in CD36 expression and an 80% increase in SR-A expression. Taken together, these data indicate that direct cholesteryl ester accumulation in mouse macrophages is mediated by CD36 and SR-A, and the magnitude of accumulation is increased in db/db macrophages due to increased scavenger receptor expression.	[Guest, Christopher B.; O'Connor, Jason C.; Freund, Gregory G.] Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; [Hartman, Matthew E.; Freund, Gregory G.] Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; [Freund, Gregory G.] Univ Illinois, Dept Pathol, Urbana, IL 61801 USA; [Guest, Christopher B.; Chakour, Kenneth S.; Sovari, Ali A.; Freund, Gregory G.] Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Freund, GG (corresponding author), Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA.	freun@uiuc.edu		Hartman, Matt/0000-0002-6238-1887	National Institutes of Health [DK064862, NS046227]; Ruth Kirschstein Institutional NRSA [5T32 DK59802]; American Heart Association; University of Illinois Agricultural Experiment Station; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK059802, R01DK064862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS046227] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth Kirschstein Institutional NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); University of Illinois Agricultural Experiment Station; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This research was supported by grants from the National Institutes of Health (DK064862 to G. G. F, NS046227 to M. E. H., Ruth Kirschstein Institutional NRSA 5T32 DK59802 to the Division of Nutritional Sciences and Predoctoral Fellowship to C. B. G.), American Heart Association (Established Investigator Award to G. G. F and Predoctoral Fellowship to J. C. O.), University of Illinois Agricultural Experiment Station (to G. G. F.).	Aronson D, 2002, CARDIOVASC DIABETOL, V1, DOI 10.1186/1475-2840-1-1; Askari B, 2002, HISTOL HISTOPATHOL, V17, P1317, DOI 10.14670/HH-17.1317; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BROWN MS, 1980, J BIOL CHEM, V255, P9344; Ceddia MA, 1999, J APPL PHYSIOL, V87, P2253, DOI 10.1152/jappl.1999.87.6.2253; de Villiers WJS, 1999, J LEUKOCYTE BIOL, V66, P740, DOI 10.1002/jlb.66.5.740; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; EPPS DE, 1995, CHEM PHYS LIPIDS, V77, P51, DOI 10.1016/0009-3084(95)02454-Q; Gargalovic P, 2003, J LIPID RES, V44, P11, DOI 10.1194/jlr.R200005-JLR200; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hiltunen TP, 1998, ATHEROSCLEROSIS, V137, pS81, DOI 10.1016/S0021-9150(97)00307-9; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Hurst RT, 2003, ANN INTERN MED, V139, P824, DOI 10.7326/0003-4819-139-10-200311180-00010; Jagasia Dinesh, 2003, Congest Heart Fail, V9, P133, DOI 10.1111/j.1527-5299.2002.00901.x; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; LESNIK P, 1992, P NATL ACAD SCI USA, V89, P10370, DOI 10.1073/pnas.89.21.10370; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; MAHLBERG FH, 1990, BIOCHIM BIOPHYS ACTA, V1045, P291, DOI 10.1016/0005-2760(90)90133-I; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Sampson MJ, 2003, ATHEROSCLEROSIS, V167, P129, DOI 10.1016/S0021-9150(02)00421-5; Silverstein RL, 2000, CURR OPIN LIPIDOL, V11, P483, DOI 10.1097/00041433-200010000-00006; SNOW JW, 1988, BIOCHEMISTRY-US, V27, P3640, DOI 10.1021/bi00410a018; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Takahashi Kiyoshi, 2002, Medical Electron Microscopy, V35, P179, DOI 10.1007/s007950200023; TANGIRALA RK, 1993, J BIOL CHEM, V268, P9653; Tyteca D, 2002, EXP CELL RES, V281, P86, DOI 10.1006/excr.2002.5613; WILLIAMS G, 1999, HDB DIABETES	34	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e511	10.1371/journal.pone.0000511	http://dx.doi.org/10.1371/journal.pone.0000511			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551591	Green Submitted, gold, Green Published			2022-12-25	WOS:000207451500020
J	Lima, MMS; Andersen, ML; Reksidler, AB; Vital, MABF; Tufik, S				Lima, Marcelo M. S.; Andersen, Monica L.; Reksidler, Angela B.; Vital, Maria A. B. F.; Tufik, Sergio			The Role of the Substantia Nigra Pars Compacta in Regulating Sleep Patterns in Rats	PLOS ONE			English	Article								Background. As of late, dopaminergic neurotransmission has been recognized to be involved in the generation of sleep disturbances. Increasing evidence shows that sleep disturbances in Parkinson's disease (PD) patients are mostly related to the disease itself, rather than being a secondary phenomenon. Evidence contained in the literature lends support to the hypothesis that the dopaminergic nigrostriatal pathway is closely involved in the regulation of sleep patterns. Methodology/Principal Findings. To test this hypothesis we examined the electrophysiological activity along the sleep-wake cycle of rats submitted to a surgically induced lesion of the SNpc by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We demonstrated that a 50% lesion of the substantia nigra pars compacta (SNpc) suffices to produce disruptions of several parameters in the sleep-wake pattern of rats. A robust and constant decrease in the latency to the onset of slow wave sleep (SWS) was detected throughout the five days of recording in both light [F-(22.16) = 72.46, p<0.0001] and dark [F-(22.16) = 75.0, p<0.0001] periods. Also found was a pronounced increase in the percentage of sleep efficiency during the first four days of recording [F-(21.15) = 21.48, p<0.0001], in comparison to the sham group. Additionally, the reduction in the SNpc dopaminergic neurons provoked an ablation in the percentage of rapid eye movement sleep (REM) during three days of the sleep-wake recording period with a strong correlation (r = 0.91; p<0.0001) between the number of dopaminergic neurons lost and the percentage decrease of REM sleep on the first day of recording. On day 4, the percentage of REM sleep during the light and dark periods was increased, [F-(22.16) = 2.46, p<0.0007], a phenomenon consistent with REM rebound. Conclusions/Significance. We propose that dopaminergic neurons present in the SNpc possess a fundamental function in the regulation of sleep processes, particularly in promoting REM sleep.	[Lima, Marcelo M. S.; Andersen, Monica L.; Tufik, Sergio] Univ Fed Sao Paulo, Dept Psicobiol, Sao Paulo, Brazil; [Reksidler, Angela B.; Vital, Maria A. B. F.] Univ Fed Parana, Dept Farmacol, BR-80060000 Curitiba, Parana, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal do Parana	Lima, MMS (corresponding author), Univ Fed Sao Paulo, Dept Psicobiol, Sao Paulo, Brazil.	mmeirasantoslima@psicobio.epm.br	Tufik, Sergio/D-7606-2012; Andersen, Monica L/C-7616-2012	Andersen, Monica L/0000-0002-1894-6748; M. S. Lima, Marcelo/0000-0001-9602-4880	AFIP; CAPES; FAPESP-CEPID [98/14.303-3]	AFIP; CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPESP-CEPID(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by AFIP, CAPES, FAPESP-CEPID (98/14.303-3 to ST). ST and MABFV are recipient of CNPq fellowships.	Adler CH, 2005, MOVEMENT DISORD, V20, pS23, DOI 10.1002/mds.20460; Arnulf I, 2002, NEUROLOGY, V58, P1019, DOI 10.1212/WNL.58.7.1019; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; DAHAN L, 2006, NEUROPSYCHOPHARMACOL, P1; De Cock VC, 2007, BRAIN, V130, P450, DOI 10.1093/brain/awl363; Lima MDS, 2006, BRAIN RES, V1101, P117, DOI 10.1016/j.brainres.2006.05.016; DZIRASA K, 2006, J NEUROSCI, V26, P1; Gagnon JF, 2002, NEUROLOGY, V59, P585, DOI 10.1212/WNL.59.4.585; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Hobson DE, 2002, JAMA-J AM MED ASSOC, V287, P455, DOI 10.1001/jama.287.4.455; Hobson JA, 1998, CURR OPIN NEUROBIOL, V8, P239, DOI 10.1016/S0959-4388(98)80146-3; JONES BE, 1973, BRAIN RES, V58, P157, DOI 10.1016/0006-8993(73)90830-5; JONES BE, 1969, CR SOC BIOL, V163, P176; JOUVET M, 1967, SCI AM, V216, P62, DOI 10.1038/scientificamerican0267-62; Larsen JP, 2001, CNS DRUGS, V15, P267, DOI 10.2165/00023210-200115040-00002; Lev N, 2003, PROG NEURO-PSYCHOPH, V27, P245, DOI 10.1016/S0278-5846(03)00019-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marsden CA, 2006, BRIT J PHARMACOL, V147, pS136, DOI 10.1038/sj.bjp.0706473; Monti JM, 2007, SLEEP MED REV, V11, P113, DOI 10.1016/j.smrv.2006.08.003; NUNES GP, 1994, BRAIN RES BULL, V34, P453, DOI 10.1016/0361-9230(94)90018-3; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V5th Edn, DOI 10.1016/c2009-0-63235-9; Poewe Werner, 2000, Current Opinion in Neurology, V13, P423, DOI 10.1097/00019052-200008000-00009; PUNGOR K, 1990, BRAIN RES, V525, P310, DOI 10.1016/0006-8993(90)90880-K; Reksidler AB, 2007, EUR J PHARMACOL, V560, P163, DOI 10.1016/j.ejphar.2006.12.032; Rye DB, 2002, NEUROLOGY, V58, P341, DOI 10.1212/WNL.58.3.341; Sandyk R, 1997, INT J NEUROSCI, V90, P75, DOI 10.3109/00207459709000627; TIMOIARIA C, 1970, PHYSIOL BEHAV, V5, P1057, DOI 10.1016/0031-9384(70)90162-9; TUFIK S, 1978, PHARMACOLOGY, V16, P98, DOI 10.1159/000136753; TUFIK S, 1981, PSYCHOPHARMACOLOGY, V72, P257, DOI 10.1007/BF00431826; Ulivelli M, 2002, NEUROLOGY, V58, P462, DOI 10.1212/WNL.58.3.462; WAUQUIER A, 1995, HDB EXPT PHARM	32	76	78	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e513	10.1371/journal.pone.0000513	http://dx.doi.org/10.1371/journal.pone.0000513			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551593	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451500022
J	Harada, H; Kizaka-Kondoh, S; Li, G; Itasaka, S; Shibuya, K; Inoue, M; Hiraoka, M				Harada, H.; Kizaka-Kondoh, S.; Li, G.; Itasaka, S.; Shibuya, K.; Inoue, M.; Hiraoka, M.			Significance of HIF-1-active cells in angiogenesis and radioresistance	ONCOGENE			English	Article						tumor hypoxia; angiogenesis; HIF-1; radiotherapy	UBIQUITIN-PROTEASOME PATHWAY; HYPOXIA-INDUCIBLE FACTOR-1; TUMOR-SUPPRESSOR PROTEIN; SELECTIVE CANCER-THERAPY; FACTOR 1-ALPHA; NECK-CANCER; TRANSCRIPTIONAL ACTIVATION; RADIATION ONCOLOGY; GROWTH; HEAD	Human solid tumors contain hypoxic regions that have considerably lower oxygen tension than the normal tissues. Hypoxia offers resistance to radiotherapy and anticancer chemotherapy, as well as predispose to increased tumor metastases. Furthermore, hypoxia induces hypoxia-inducible factor-1 (HIF-1), which in turn increases tumor angiogenesis. Thus, eradication of HIF-1-active/hypoxic tumor cells is very important for cancer therapy. We have previously reported that procaspase-3 fused with a von Hippel-Lindau (VHL)-mediated protein destruction motif of alpha subunit of HIF-1 (HIF-1 alpha) containing Pro564, named TAT-ODD-procaspase-3 (TOP3), specifically induced cell death to hypoxic cells in vivo as well as in vitro. We now report that TOP3 also eradicates the radiation-induced HIF-1-active tumor cells. HIF-1 activity in the xenografts of human tumor cells, which express luciferase under the transcriptional control of HIF-1, were monitored and quantified daily with an in vivo bioluminescence photon-counting device. HIF-1 activity in tumors was more rapidly increased by ionizing radiation (IR) compared to untreated tumors. TOP3 efficiently decreased the HIF-1-activity in irradiated tumors as well as unirradiated ones, indicating TOP3 eradicated tumor cells with HIF-1-activity induced by IR as well as hypoxia. Eradication of HIF-1-active/hypoxic cells in the xenografts during irradiation exhibited significant suppression in angiogenesis and strong enhancement in a long-term growth suppression of tumor xenografts. These results further strengthen the argument that HIF-1-active/hypoxic cells play crucial roles in angiogenesis and radioresistance.	Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto 6068507, Japan; Kyoto Univ, Nano Med Merger Educ Unit, Kyoto, Japan; Kyoto Univ, Grad Sch Med, COE Format Genom Anal Dis Model Anim Multiple Gen, Kyoto, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Biochem, Osaka, Japan	Kyoto University; Kyoto University; Kyoto University; Osaka Medical Center for Cancer & Cardiovascular Diseases	Kizaka-Kondoh, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, 54 Kawahara-cho, Kyoto 6068507, Japan.	skondoh@kuhp.kyoto-u.ac.jp	Kondoh, Shinae/AAF-8745-2020; Kondoh, Shinae/C-6937-2015	Kondoh, Shinae/0000-0003-3085-5782; Kondoh, Shinae/0000-0003-3085-5782				Abdollahi A, 2003, CANCER RES, V63, P3755; Brown JM, 1999, CANCER RES, V59, P5863; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; de Candia P, 2003, P NATL ACAD SCI USA, V100, P12337, DOI 10.1073/pnas.2031337100; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Geng L, 2001, CANCER RES, V61, P2413; Gorski DH, 1999, CANCER RES, V59, P3374; Harada H, 2002, CANCER RES, V62, P2013; Harada H, 2005, MOL IMAGING, V4, P182; Harada H, 2006, FEBS LETT, V580, P5718, DOI 10.1016/j.febslet.2006.09.025; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Inoue M, 2004, INT J ONCOL, V25, P713; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kizaka-Kondoh S, 2003, CANCER SCI, V94, P1021, DOI 10.1111/j.1349-7006.2003.tb01395.x; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Overgaard J, 2005, LANCET ONCOL, V6, P757, DOI 10.1016/S1470-2045(05)70292-8; Raleigh JA, 1998, CANCER RES, V58, P3765; Rapisarda A, 2002, CANCER RES, V62, P4316; Rischin D, 2005, J CLIN ONCOL, V23, P79, DOI 10.1200/JCO.2005.01.072; Rowinsky EK, 1999, ONCOLOGY-NY, V13, P61; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sobhanifar S, 2005, CANCER RES, V65, P7259, DOI 10.1158/0008-5472.CAN-04-4480; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008; VAUPEL P, 1989, CANCER RES, V49, P6449; Welsh SJ, 2003, MOL CANCER THER, V2, P235; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zackrisson B, 2003, ACTA ONCOL, V42, P443, DOI 10.1080/02841860310014886	38	109	112	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7508	7516		10.1038/sj.onc.1210556	http://dx.doi.org/10.1038/sj.onc.1210556			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563752				2022-12-25	WOS:000251282100002
J	Garate, M; Campos, EI; Bush, JA; Xiao, H; Li, G				Garate, Marco; Campos, Eric I.; Bush, Jason A.; Xiao, Hao; Li, Gang			Phosphorylation of the tumor suppressor p33(ING1b) at Ser-126 influences its protein stability and proliferation of melanoma cells	FASEB JOURNAL			English	Article						protein half-life; cell proliferation	NUCLEOTIDE EXCISION-REPAIR; UV-DAMAGED DNA; INDUCED APOPTOSIS; HUMAN CHK1; P53; CHECKPOINT; IDENTIFICATION; INHIBITION; SUBSTRATE; PATHWAY	ING (inhibitor of growth) tumor suppressors regulate cell-cycle checkpoints, apoptosis, and ultimately tumor suppression. Among the ING family members, p33(ING1b) is the most intensively studied and plays an important role in the cellular stress response to DNA damage. Here we demonstrate that there is basal phosphorylation of p33(ING1b) at Ser-126 in normal physiological conditions and that this phosphorylation is increased on DNA damage. The mutation of Ser-126 to alanine dramatically shortened the half-life of p33(ING1b). Furthermore, we found that both Chk1 and Cdk1 can phosphorylate this residue. Interestingly, while Cdk1 can phosphorylate p33(ING1b) at Ser-126 in nonstress conditions, Chk1 predominantly phosphorylates this residue on DNA damage, which suggests that p33(ING1b) is a downstream target of the ATM/ATR response cascade to genotoxic stress. More importantly, our data indicate that the Ser-126 residue plays a key role in regulating the expression of cyclin B1 and proliferation of melanoma cells.	Univ British Columbia, Vancouver Coastal Hlth Res Inst, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Calif State Univ Fresno, Dept Biol, Fresno, CA 93740 USA; ImmuneChem Pharmaceut Inc, Burnaby, BC, Canada	University of British Columbia; Vancouver Coastal Health Research Institute; California State University System; California State University Fresno	Li, G (corresponding author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011	Campos, Eric I./0000-0001-8152-3994				Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; BYERS HR, 1991, AM J PATHOL, V139, P423; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Campos EI, 2004, INT J ONCOL, V25, P73; Campos EI, 2004, J IMMUNOASS IMMUNOCH, V25, P71, DOI 10.1081/IAS-120027227; Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610; Cheung KJ, 2001, CANCER RES, V61, P4974; Cheung KJJ, 2000, BRIT J CANCER, V83, P1468, DOI 10.1054/bjoc.2000.1464; Chin MY, 2005, EXP CELL RES, V304, P531, DOI 10.1016/j.yexcr.2004.11.023; Clifford B, 2003, CANCER RES, V63, P4074; Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Ho CC, 2005, EXP CELL RES, V304, P1, DOI 10.1016/j.yexcr.2004.10.016; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffert JD, 2006, P NATL ACAD SCI USA, V103, P7159, DOI 10.1073/pnas.0600895103; JACK DB, 1995, MOL MED TODAY, V1, P2; KLEIN P, 1985, J BIOL CHEM, V260, P1757; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leung KM, 2002, CANCER RES, V62, P4890; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; Mone MJ, 2004, P NATL ACAD SCI USA, V101, P15933, DOI 10.1073/pnas.0403664101; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Scott M, 2001, J CELL SCI, V114, P3455; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Takahashi M, 2002, CANCER RES, V62, P2203; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Tsang FC, 2003, FEBS LETT, V553, P277, DOI 10.1016/S0014-5793(03)01024-X; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; VEGESNA RVK, 1988, MOL PHARMACOL, V33, P537; Wang J, 2006, CANCER RES, V66, P1906, DOI 10.1158/0008-5472.CAN-05-3444; Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200; Xu CF, 2005, MOL CELL PROTEOMICS, V4, P809, DOI 10.1074/mcp.T400019-MCP200; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; ZHANG W, 1994, CANCER RES, V54, P4448; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	50	42	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3705	3716		10.1096/fj.07-8069com	http://dx.doi.org/10.1096/fj.07-8069com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17585055				2022-12-25	WOS:000250517800032
J	Nath, A; Grinkova, YV; Sligar, SG; Atkins, WM				Nath, Abhinav; Grinkova, Yelena V.; Sligar, Stephen G.; Atkins, William M.			Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs - The effect of model membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; ALPHA-NAPHTHOFLAVONE; PHOSPHATIDYLCHOLINE VESICLES; FUNCTIONAL RECONSTITUTION; HOMOTROPIC COOPERATIVITY; LIPID-BILAYERS; P450 REDUCTASE; THERMODYNAMICS; SOLUBILIZATION; INHIBITION	The membrane-bound protein cytochrome P450 3A4 (CYP3A4) is a major drug-metabolizing enzyme. Most studies of ligand binding by CYP3A4 are currently carried out in solution, in the absence of a model membrane. Therefore, there is little information concerning the membrane effects on CYP3A4 ligand binding behavior. Phospholipid bilayer Nanodiscs are a novel model membrane system derived from high density lipoprotein particles, whose stability, monodispersity, and consistency are ensured by their self-assembly. We explore the energetics of four ligands (6-(p-toluidino)-2-naphthalenesulfonic acid (TNS), alpha-naphthoflavone (ANF), miconazole, and bromocriptine) binding to CYP3A4 incorporated into Nanodiscs. Ligand binding to Nanodiscs was monitored by a combination of environment-sensitive ligand fluorescence and ligand-induced shifts in the fluorescence of tryptophan residues present in the scaffold proteins of Nanodiscs; binding to the CYP3A4 active site was monitored by ligand-induced shifts in the heme Soret band absorbance. The dissociation constants for binding to the active site in CYP3A4-Nanodiscs were 4.0 mu M for TNS, 5.8 mu M for ANF, 0.45 mu M for miconazole, and 0.45 mu M for bromocriptine. These values are for CYP3A4 incorporated into a lipid bilayer and are therefore presumably more biologically relevant that those measured using CYP3A4 in solution. In some cases, affinity measurements using CYP3A4 in Nanodiscs differ significantly from solution values. We also studied the equilibrium between ligand binding to CYP3A4 and to the membrane. TNS showed no marked preference for either environment; ANF preferentially bound to the membrane, and miconazole and bromocriptine preferentially bound to the CYP3A4 active site.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Washington; University of Washington Seattle; University of Illinois System; University of Illinois Urbana-Champaign	Atkins, WM (corresponding author), Univ Washington, Dept Med Chem, Bos 357610, Seattle, WA 98195 USA.	winky@u.washington.edu		Nath, Abhinav/0000-0002-2895-2973	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033775, R01GM062284, P01GM032165] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-62284, GM-32165, GM-33775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abreu MSC, 2004, BIOPHYS J, V87, P353, DOI [10.1529/biophysj.104.040576, 10.1529/biophysi.104.040576]; Antollini SS, 1996, BIOPHYS J, V70, P1275, DOI 10.1016/S0006-3495(96)79684-4; Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; Bayburt TH, 2003, PROTEIN SCI, V12, P2476, DOI 10.1110/ps.03267503; Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k; Bayburt TH, 2006, ARCH BIOCHEM BIOPHYS, V450, P215, DOI 10.1016/j.abb.2006.03.013; BESCHIASCHVILI G, 1992, BIOCHEMISTRY-US, V31, P10044, DOI 10.1021/bi00156a026; Boldog T, 2006, P NATL ACAD SCI USA, V103, P11509, DOI 10.1073/pnas.0604988103; Cameron MD, 2005, BIOCHEMISTRY-US, V44, P14143, DOI 10.1021/bi051689t; Chiu SW, 1999, BIOPHYS J, V77, P2462, DOI 10.1016/S0006-3495(99)77082-7; Civjan NR, 2003, BIOTECHNIQUES, V35, P556, DOI 10.2144/03353rr02; Davydov DR, 2005, BIOCHEMISTRY-US, V44, P13902, DOI 10.1021/bi0509346; Denisov IG, 2005, J PHYS CHEM B, V109, P15580, DOI 10.1021/jp051385g; Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574; Duan H, 2004, ARCH BIOCHEM BIOPHYS, V424, P141, DOI 10.1016/j.abb.2004.02.010; Estronca LMBB, 2005, BIOPHYS J, V88, P557, DOI 10.1529/biophysj.104.047050; Fernando H, 2007, ARCH BIOCHEM BIOPHYS, V460, P129, DOI 10.1016/j.abb.2006.12.025; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; Gonen T, 2005, NATURE, V438, P633, DOI 10.1038/nature04321; Heerklotz H, 2000, BIOPHYS J, V78, P2435, DOI 10.1016/S0006-3495(00)76787-7; HEIRWEGH KPM, 1994, J BIOCHEM BIOPH METH, V29, P23, DOI 10.1016/0165-022X(94)90055-8; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; HUANG C, 1972, BIOCHEMISTRY-US, V11, P735, DOI 10.1021/bi00755a010; Isin EM, 2006, J BIOL CHEM, V281, P9127, DOI 10.1074/jbc.M511375200; Keller S, 2006, BIOPHYS J, V90, P4509, DOI 10.1529/biophysj.105.077867; Kim EY, 2004, TOXICOL LETT, V153, P239, DOI 10.1016/j.toxlet.2004.04.017; KOMINAMI S, 1986, J BIOL CHEM, V261, P2077; KUHNVELTEN WN, 1991, EUR J BIOCHEM, V197, P381, DOI 10.1111/j.1432-1033.1991.tb15922.x; Kumar S, 2005, DRUG METAB DISPOS, V33, P1131, DOI 10.1124/dmd.105.004606; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P52; Lee SY, 2004, NATURE, V430, P232, DOI 10.1038/nature02632; Leitz AJ, 2006, BIOTECHNIQUES, V40, P601, DOI 10.2144/000112169; Lin HL, 2002, J PHARMACOL EXP THER, V301, P160, DOI 10.1124/jpet.301.1.160; Margolis JM, 2003, DRUG METAB DISPOS, V31, P606, DOI 10.1124/dmd.31.5.606; MCLAUGHLIN S, 1976, BIOCHEMISTRY-US, V15, P1941, DOI 10.1021/bi00654a023; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; Nath A, 2007, BIOCHEMISTRY-US, V46, P2059, DOI 10.1021/bi602371n; PARRY G, 1976, FEBS LETT, V67, P123, DOI 10.1016/0014-5793(76)80348-1; Pearson JT, 2006, BIOCHEMISTRY-US, V45, P6341, DOI 10.1021/bi0600042; PEYRONNEAU MA, 1994, EUR J BIOCHEM, V223, P947, DOI 10.1111/j.1432-1033.1994.tb19072.x; Roberts AG, 2007, ARCH BIOCHEM BIOPHYS, V463, P89, DOI 10.1016/j.abb.2007.03.006; Schurholz T, 1996, BIOPHYS CHEM, V58, P87, DOI 10.1016/0301-4622(95)00088-7; SEELIG J, 1991, BIOCHEMISTRY-US, V30, P9354, DOI 10.1021/bi00102a031; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Shaw PM, 1997, ARCH BIOCHEM BIOPHYS, V348, P107, DOI 10.1006/abbi.1997.0378; SUGIHARA G, 1982, J PHYS CHEM-US, V86, P2784, DOI 10.1021/j100211a044; TALL AR, 1977, J BIOL CHEM, V252, P4701; Tsalkova TN, 2007, BIOCHEMISTRY-US, V46, P106, DOI 10.1021/bi061944p; Walter A, 2000, BBA-BIOMEMBRANES, V1508, P20, DOI 10.1016/S0304-4157(00)00005-8; Wynalda MA, 1997, DRUG METAB DISPOS, V25, P1211	50	57	57	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28309	28320		10.1074/jbc.M703568200	http://dx.doi.org/10.1074/jbc.M703568200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17573349	hybrid			2022-12-25	WOS:000249642100004
J	Covian, R; Zwicker, K; Rotsaert, FA; Trumpower, BL				Covian, Raul; Zwicker, Klaus; Rotsaert, Frederik A.; Trumpower, Bernard L.			Asymmetric and redox-specific binding of quinone and quinol at center N of the dimeric yeast cytochrome bc(1) complex - Consequences for semiquinone stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; BOVINE HEART-MITOCHONDRIA; C REDUCTASE COMPLEX; UBIQUINOL OXIDATION; RESPIRATORY-CHAIN; ELECTRON-TRANSFER; Q(O) SITE; THERMODYNAMIC PROPERTIES; CRYSTAL-STRUCTURE; B(6)F COMPLEX	The cytochrome bc(1) complex recycles one of the two electrons from quinol (QH(2)) oxidation at center P by reducing quinone ( Q) at center N to semiquinone ( SQ), which is bound tightly. We have analyzed the properties of SQ bound at center N of the yeast bc1 complex. The EPR- detectable signal, which reports SQ bound in the vicinity of reduced b(H) heme, was abolished by the center N inhibitors antimycin, funiculosin, and ilicicolin H, but was unchanged by the center P inhibitors myxothiazol and stigmatellin. After correcting for the EPR- silent SQ bound close to oxidized bH, we calculated a midpoint redox potential ( Em) of similar to 90 mV for all bound SQ. Considering the Em values for bH and free Q, this result indicates that center N preferentially stabilizes SQ center dot bH 3(+) complexes. This favors recycling of the electron coming from center P and also implies a > 2.5- fold higher affinity for QH2 than for Q at center N, which would potentially inhibit bH oxidation by Q. Using pre- steady- state kinetics, we show that Q does not inhibit the initial rate of bH reduction by QH2 through center N, but does decrease the extent of reduction, indicating that Q binds only when bH is reduced, whereas QH2 binds when bH is oxidized. Kinetic modeling of these results suggests that formation of SQ at one center N in the dimer allows stabilization of SQ in the other monomer by Q reduction after intradimer electron transfer. This model allows maximum SQ (center dot)bH 3(+) formation without inhibition of Q binding by QH2.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Goethe Univ Frankfurt, Zentrum Biol Chem, D-60590 Frankfurt, Germany	Dartmouth College; Goethe University Frankfurt	Trumpower, BL (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Berry EA, 2004, PHOTOSYNTH RES, V81, P251, DOI 10.1023/B:PRES.0000036888.18223.0e; Cooley JW, 2005, BIOCHEMISTRY-US, V44, P10520, DOI 10.1021/bi050571+; Covian R, 2005, J BIOL CHEM, V280, P22732, DOI 10.1074/jbc.M413592200; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Covian R, 2001, EUR J BIOCHEM, V268, P5783, DOI 10.1046/j.0014-2956.2001.02521.x; Covian R, 2006, J BIOL CHEM, V281, P30925, DOI 10.1074/jbc.M604694200; DELAROSA FF, 1983, FEBS LETT, V163, P140, DOI 10.1016/0014-5793(83)81181-8; DEVRIES S, 1980, FEBS LETT, V122, P143; Dutton P L, 1978, Methods Enzymol, V54, P411; DUTTON PL, 1972, EUR J BIOCHEM, V30, P495, DOI 10.1111/j.1432-1033.1972.tb02121.x; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Gutierrez-Cirlos EB, 2004, J BIOL CHEM, V279, P8708, DOI 10.1074/jbc.M311805200; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Kramer D, 2004, METHOD ENZYMOL, V382, P21; KROGER A, 1973, EUR J BIOCHEM, V34, P358, DOI 10.1111/j.1432-1033.1973.tb02767.x; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; TAKAMIYA KI, 1979, BIOCHIM BIOPHYS ACTA, V546, P1, DOI 10.1016/0005-2728(79)90166-X; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TSAI AL, 1983, BIOCHIM BIOPHYS ACTA, V722, P349, DOI 10.1016/0005-2728(83)90083-X; Valkova-Valchanova M, 2000, BIOCHEMISTRY-US, V39, P15484, DOI 10.1021/bi000751d; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Wenz T, 2007, J BIOL CHEM, V282, P3977, DOI 10.1074/jbc.M606482200; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU CA, 1972, J BIOL CHEM, V247, P1012; Zatsman AI, 2006, J AM CHEM SOC, V128, P14246, DOI 10.1021/ja065798m; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	40	19	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24198	24208		10.1074/jbc.M700662200	http://dx.doi.org/10.1074/jbc.M700662200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584742	hybrid			2022-12-25	WOS:000248686600045
J	Srinivasan, SV; Mayhew, CN; Schwemberger, S; Zagorski, W; Knudsen, ES				Srinivasan, Seetha V.; Mayhew, Christopher N.; Schwemberger, Sandy; Zagorski, William; Knudsen, Erik S.			RB loss promotes aberrant ploidy by deregulating levels and activity of DNA replication factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL-CYCLE CONTROL; ORIGIN RECOGNITION; TETRAPLOIDY CHECKPOINT; SIGNALING PATHWAYS; PROTEIN PATHWAY; E2F; PHASE; ANEUPLOIDY; PRB	The retinoblastoma tumor suppressor (RB) is functionally inactivated in many human cancers. Classically, RB functions to repress E2F-mediated transcription and inhibit cell cycle progression. Consequently, RB ablation leads to loss of cell cycle control and aberrant expression of E2F target genes. Emerging evidence indicates a role for RB in maintenance of genomic stability. Here, mouse adult fibroblasts were utilized to demonstrate that aberrant DNA content in RB-deficient cells occurs concomitantly with an increase in levels and chromatin association of DNA replication factors. Furthermore, following exposure to nocodazole, RB-proficient cells arrest with 4(N) DNA content, whereas RB-deficient cells bypass the mitotic block, continue DNA synthesis, and accumulate cells with higher ploidy and micronuclei. Under this condition, RB-deficient cells also retain high levels of tethered replication factors, MCM7 and PCNA, indicating that DNA replication occurs in these cells under nonpermissive conditions. Exogenous expression of replication factors Cdc6 or Cdt1 in RB-proficient cells does not recapitulate the RB-deficient cell phenotype. However, ectopic E2F expression in RB-proficient cells elevated ploidy and bypassed the response to nocodazole-induced cessation of DNA replication in a manner analogous to RB loss. Collectively, these results demonstrate that deregulated S phase control is a key mechanism by which RB-deficient cells acquire elevated ploidy.	Univ Cincinnati, Dept Cell & Canc Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Univ Cincinnati, Shriners Hosp Children, Coll Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Surg, Coll Med, Cincinnati, OH 45267 USA	University of Cincinnati; University of Cincinnati; University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Dept Cell & Canc Biol, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.	Erik.knudsen@uc.edu	Mayhew, Christopher N/AGB-4929-2022		NATIONAL CANCER INSTITUTE [R01CA106471, T32CA117846] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA117846, T32 CA117846-01A1, CA 106471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bermejo R, 2002, MOL BIOL CELL, V13, P3989, DOI 10.1091/mbc.E02-04-0217; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Black EP, 2005, P NATL ACAD SCI USA, V102, P15948, DOI 10.1073/pnas.0504300102; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bosco EE, 2005, NUCLEIC ACIDS RES, V33, P1581, DOI 10.1093/nar/gki283; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Braden WA, 2006, MOL CELL BIOL, V26, P7667, DOI 10.1128/MCB.00045-06; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DeGregori J, 2006, CURR MOL MED, V6, P739; Di Leonardo A, 1997, CANCER RES, V57, P1013; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Diffley JFX, 2002, J CELL SCI, V115, P869; Duensing A, 2005, BIOCHEM BIOPH RES CO, V331, P694, DOI 10.1016/j.bbrc.2005.03.157; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eguchi T, 2007, ONCOGENE, V26, P509, DOI 10.1038/sj.onc.1209810; Eward KL, 2004, J CELL SCI, V117, P5875, DOI 10.1242/jcs.01503; Fanning E, 2006, NUCLEIC ACIDS RES, V34, P4126, DOI 10.1093/nar/gkl550; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; Fujita M, 1997, J BIOL CHEM, V272, P10928; Fujita M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-22; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Gonzalo S, 2005, CELL CYCLE, V4, P752, DOI 10.4161/cc.4.6.1720; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Homesley L, 2000, GENE DEV, V14, P913; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; Isaac CE, 2006, MOL CELL BIOL, V26, P3659, DOI 10.1128/MCB.26.9.3659-3671.2006; Kaelin WG, 1997, ANN NY ACAD SCI, V833, P29, DOI 10.1111/j.1749-6632.1997.tb48589.x; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Khan SH, 1998, CANCER RES, V58, P396; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; Lentini L, 2006, CANCER LETT, V238, P153, DOI 10.1016/j.canlet.2005.07.005; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Machida YJ, 2005, CELL, V123, P13, DOI 10.1016/j.cell.2005.09.019; Maiorano D, 2006, CURR OPIN CELL BIOL, V18, P130, DOI 10.1016/j.ceb.2006.02.006; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Markey MP, 2002, CANCER RES, V62, P6587; Mayhew Christopher N, 2004, Methods Mol Biol, V281, P3; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Prasanth SG, 2004, PHILOS T R SOC B, V359, P7, DOI 10.1098/rstb.2003.1360; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stillman B, 2005, FEBS LETT, V579, P877, DOI 10.1016/j.febslet.2004.12.011; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; Tsuyama T, 2005, NUCLEIC ACIDS RES, V33, P765, DOI 10.1093/nar/gki226; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WEINBERG RA, 1992, CANCER SURV, V12, P43; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Wikman H, 2006, EXPERT REV ANTICANC, V6, P515, DOI 10.1586/14737140.6.4.515; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108; Yamasaki L, 2004, CURR OPIN CELL BIOL, V16, P623, DOI 10.1016/j.ceb.2004.08.005; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; Zheng L, 2002, ADV CANCER RES, V85, P13, DOI 10.1016/S0065-230X(02)85002-3; Zheng L, 2002, CANCER RES, V62, P2498; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	77	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23867	23877		10.1074/jbc.M700542200	http://dx.doi.org/10.1074/jbc.M700542200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17556357	hybrid			2022-12-25	WOS:000248686600014
J	Bish, RA; Myers, MP				Bish, Rebecca A.; Myers, Michael P.			Werner helicase-interacting protein 1 binds polyubiquitin via its zinc finger domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-KAPPA; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; MASS-SPECTROMETRY; DAMAGE TOLERANCE; UBIQUITIN LIGASE; HUMAN RAD18; YEAST; GENE; CHAPERONIN	DNA repair is regulated on many levels by ubiquitination. In order to identify novel connections between DNA repair pathways and ubiquitin signaling, we used mass spectrometry to identify proteins that interact with lysine 6-linked polyubiquitin chains. From this proteomic screen, we identified the DNA repair protein WRNIP1 (Werner helicase-interacting protein 1), along with nucleosome assembly protein 1, as novel ubiquitin-interacting proteins. We found that a small zinc finger domain at the N terminus of WRNIP1 is sufficient and necessary for noncovalent ubiquitin binding. This ubiquitin-binding zinc finger (UBZ) domain binds polyubiquitin but not monoubiquitin and appears to show no specificity for polyubiquitin chain linkage. A homologous zinc finger domain in RAD18 also binds polyubiquitin, suggesting a wider role for the UBZ domain in DNA repair. The WRNIP1 ubiquitin-binding function, along with its previously established ATPase activity, suggests that WRNIP1 plays a role in the metabolism of ubiquitinated proteins. Supporting this model, deletion of MGS1, the yeast homolog of WRNIP1, slows the rate of ubiquitin turnover, rendering yeast resistant to cycloheximide. We also find that WRNIP1 is heavily modified with ubiquitin and SUMO, revealing complex layers in the involvement of ubiquitin pathway proteins in the regulation of DNA repair. The novel ubiquitin-binding ability of WRNIP1 sheds light on the role of UBZ domain-containing proteins in postreplication DNA repair.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Myers, MP (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, POB 100,1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	myers@cshl.edu			NIGMS NIH HHS [GM 065094] Funding Source: Medline; PHS HHS [25603521, 25102067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065094] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Camasses A, 2003, MOL CELL, V12, P87, DOI 10.1016/S1097-2765(03)00244-2; Cannavo E, 2007, J BIOL CHEM, V282, P2976, DOI 10.1074/jbc.M609989200; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Gerlinger UM, 1997, MOL BIOL CELL, V8, P2487, DOI 10.1091/mbc.8.12.2487; GRAMATIKOFF K, 2004, FRONT BIOTECHNOL PHA, V4, P181; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hishida T, 2002, EMBO J, V21, P2019, DOI 10.1093/emboj/21.8.2019; Hishida T, 2001, P NATL ACAD SCI USA, V98, P8283, DOI 10.1073/pnas.121009098; Hishida T, 2006, MOL CELL BIOL, V26, P5509, DOI 10.1128/MCB.00307-06; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; Kaplun L, 2000, P NATL ACAD SCI USA, V97, P10077, DOI 10.1073/pnas.97.18.10077; Kawabe Y, 2001, J BIOL CHEM, V276, P20364, DOI 10.1074/jbc.C100035200; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; Marotti LA, 2002, BIOCHEMISTRY-US, V41, P5067, DOI 10.1021/bi015940q; MCCUSKER JH, 1988, GENETICS, V119, P303; Miyase S, 2005, J BIOL CHEM, V280, P515, DOI 10.1074/jbc.M409219200; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nakajima S, 2006, J BIOL CHEM, V281, P34687, DOI 10.1074/jbc.M605545200; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Ogi T, 2005, J CELL SCI, V118, P129, DOI 10.1242/jcs.01603; Plosky BS, 2006, EMBO J, V25, P2847, DOI 10.1038/sj.emboj.7601178; Powell DW, 2004, MOL CELL BIOL, V24, P7249, DOI 10.1128/MCB.24.16.7249-7259.2004; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; RASBAND WS, 2006, IMAGE J NATL I HLTH; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shiomi N, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl979; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Sugasawa K, 2005, CELL, V121, P387, DOI 10.1016/j.cell.2005.02.035; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; Tam S, 2006, NAT CELL BIOL, V8, P1155, DOI 10.1038/ncb1477; Tateishi S, 2000, P NATL ACAD SCI USA, V97, P7927, DOI 10.1073/pnas.97.14.7927; Tsurimoto T, 2005, GENES CELLS, V10, P13, DOI 10.1111/j.1365-2443.2004.00812.x; Villen J, 2007, P NATL ACAD SCI USA, V104, P1488, DOI 10.1073/pnas.0609836104; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Woelk T, 2006, NAT CELL BIOL, V8, P1246, DOI 10.1038/ncb1484; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yokota S, 2000, BIOCHEM BIOPH RES CO, V279, P712, DOI 10.1006/bbrc.2000.4011	57	56	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23184	23193		10.1074/jbc.M701042200	http://dx.doi.org/10.1074/jbc.M701042200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17550899	hybrid			2022-12-25	WOS:000248577500020
J	Li, B; Berman, J; Tang, JT; Lin, TJ				Li, Bo; Berman, Jason; Tang, Jin-Tian; Lin, Tong-Jun			The early growth response factor-1 is involved in stem cell factor (SCF)-induced interleukin 13 production by mast cells, but is dispensable for SCF-dependent mast cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR EGR-1; FACTOR RECEPTOR/C-KIT; FC-EPSILON-RI; C-KIT; HEMATOPOIETIC-CELLS; MACROPHAGE LINEAGE; MEDIATOR RELEASE; PROGENITOR CELLS; TYROSINE KINASE	The stem cell factor (SCF) plays a central role in the regulation of mast cell function and growth. However, roles of transcription factors involved in these processes remain incompletely defined. The early growth response factor-1 (Egr-1) is a member of the zinc finger transcription factor family. A role for Egr-1 in SCF-induced mast cell activation and growth was investigated in mouse bone marrow-derived mast cells (BMMC). The stimulation of BMMC with SCF induced a strong expression of Egr-1 mRNA. SCF-induced Egr-1 nuclear translocation and DNA binding were demonstrated by electrophoretic mobility shift assay (EMSA) and immunofluorescence assay. SCF-induced IL-13 expression was significantly reduced at both mRNA and protein levels in Egr-1-deficient BMMC. In addition, the synergy between IgE and SCF on IL-13 and IL-4 production was reduced in Egr-1-deficient mast cells. Interestingly, Egr-1 deficiency had little effect on SCF-induced mast cell growth. SCF-induced Egr activation likely requires tyrosine phosphorylation because a tyrosine kinase inhibitor PP2 blocked SCF-induced nuclear protein binding to Egr probe as determined by EMSA. Thus, Egr-1 is required for SCF-induced IL-13 expression, but not mast cell growth. Egr-1 represents a novel mechanism for SCF-induced mast cell activation.	Tsinghua Univ, Inst Med Phys & Engn, Beijing 100084, Peoples R China; Dalhousie Univ, Izaak Walton Killam Hlth Ctr, Dept Microbiol, Halifax, NS B3K 6R8, Canada; Dalhousie Univ, Izaak Walton Killam Hlth Ctr, Dept Immunol, Halifax, NS B3K 6R8, Canada; Dalhousie Univ, Izaak Walton Killam Hlth Ctr, Dept Pediat, Halifax, NS B3K 6R8, Canada	Tsinghua University; Dalhousie University; Dalhousie University; Dalhousie University	Lin, TJ (corresponding author), Tsinghua Univ, Inst Med Phys & Engn, Beijing 100084, Peoples R China.	tong-jun.lin@dal.ca						BECKMAN AM, 1997, NEUROCHEM INT, V31, P517; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; Berlin AA, 2006, LAB INVEST, V86, P557, DOI 10.1038/labinvest.3700419; Bondzi C, 2000, CELL GROWTH DIFFER, V11, P305; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Cho SJ, 2006, J BIOL CHEM, V281, P8161, DOI 10.1074/jbc.M506770200; COLEMAN JW, 1993, J IMMUNOL, V150, P556; COLUMBO M, 1992, J IMMUNOL, V149, P599; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; Faour WH, 2005, J BIOL CHEM, V280, P9536, DOI 10.1074/jbc.M414067200; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Gagari E, 1997, BLOOD, V89, P2654, DOI 10.1182/blood.V89.8.2654; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gibbs BF, 1997, EUR J PHARMACOL, V327, P73, DOI 10.1016/S0014-2999(97)89680-X; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Hundley TR, 2004, BLOOD, V104, P2410, DOI 10.1182/blood-2004-02-0631; Ingram JL, 2006, J IMMUNOL, V177, P4141, DOI 10.4049/jimmunol.177.6.4141; Jaffe JS, 1996, AM J RESP CELL MOL, V15, P473, DOI 10.1165/ajrcmb.15.4.8879181; Kanbe N, 1999, INT ARCH ALLERGY IMM, V119, P138, DOI 10.1159/000024189; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KITAMURA Y, 1979, BLOOD, V53, P492; Kobayashi H, 1998, CLIN EXP ALLERGY, V28, P1219, DOI 10.1046/j.1365-2222.1998.00377.x; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; LANGLEY KE, 1993, BLOOD, V81, P656; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Li B, 2006, BLOOD, V107, P2814, DOI 10.1182/blood-2005-09-3610; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; O'Laughlin-Bunner B, 2001, BLOOD, V98, P343, DOI 10.1182/blood.V98.2.343; Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; Silverman ES, 2001, AM J RESP CRIT CARE, V163, P778, DOI 10.1164/ajrccm.163.3.2003123; TAKAISHI T, 1994, ALLERGY, V49, P837, DOI 10.1111/j.1398-9995.1994.tb00784.x; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; TAYLOR AM, 1995, IMMUNOLOGY, V86, P427; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; VALENT P, 1992, BLOOD, V80, P2237; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	50	19	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22573	10.1074/jbc.M610859200	http://dx.doi.org/10.1074/jbc.M610859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17556359	hybrid			2022-12-25	WOS:000248354200035
J	Singh, M; Kesterson, RA; Jacobs, MM; Joers, JM; Gore, JC; Emeson, RB				Singh, Minati; Kesterson, Robert A.; Jacobs, Michelle M.; Joers, James M.; Gore, John C.; Emeson, Ronald B.			Hyperphagia-mediated obesity in transgenic mice misexpressing the RNA-editing enzyme ADAR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; HUMAN GROWTH-HORMONE; ADENOSINE-DEAMINASE; BODY-WEIGHT; CANDIDATE ENZYME; MESSENGER-RNA; LEPTIN; EXPRESSION; ACTIVATION; BINDING	ADAR2 is a double-stranded RNA-specific adenosine deaminase involved in the editing of mammalian RNAs by the site-specific conversion of adenosine to inosine. To examine the physiologic consequences resulting from ADAR2 misexpression, we have generated mutant mice expressing either wildtype or deaminase-deficient ADAR2 transgenes under the control of the human cytomegalovirus promoter. Transgenic mice expressing either wild-type or inactive ADAR2 isoforms demonstrated adult onset obesity characterized by hyperglycemia, hyperleptinemia, and increased adiposity. Paired feeding analysis revealed that mutant mice on caloric restriction had a growth rate and body composition indistinguishable from wild-type littermates, indicating that the observed obesity predominantly results from hyperphagia rather than a metabolic derangement. The observation that expression of catalytically inactive ADAR2 also is capable of producing an obese phenotype in mutant animals suggests that ADAR2 may possess additional biological activities beyond those required for the site-selective deamination of adenosine or may interfere with the actions of other double-stranded RNA-specific binding proteins in the cell.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Inst Imaging Sci, Nashville, TN 37232 USA; Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Alabama System; University of Alabama Birmingham	Emeson, RB (corresponding author), Vanderbilt Univ, Dept Pharmacol, 8160 Med Res Bldg 3, Nashville, TN 37232 USA.	ron.emeson@vanderbilt.edu		Emeson, Ronald/0000-0002-4585-1648; Singh, Minati/0000-0001-7307-2628; Joers, James/0000-0002-8444-2185	NINDS NIH HHS [NS33323] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033323] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Augustine KA, 1999, ANAT RECORD, V257, P64, DOI 10.1002/(SICI)1097-0185(19990415)257:2<64::AID-AR7>3.0.CO;2-G; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BaracNieto M, 1996, JMRI-J MAGN RESON IM, V6, P235, DOI 10.1002/jmri.1880060141; Bartolomucci A, 2003, PSYCHONEUROENDOCRINO, V28, P540, DOI 10.1016/S0306-4530(02)00039-2; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BAUDOUIN CJ, 1992, BRIT J RADIOL, V65, P132, DOI 10.1259/0007-1285-65-770-132; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bhalla T, 2004, NAT STRUCT MOL BIOL, V11, P950, DOI 10.1038/nsmb825; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Carlson CB, 2003, BIOPOLYMERS, V70, P86, DOI 10.1002/bip.10413; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Chen PL, 2004, J NEUROSCI, V24, P5091, DOI 10.1523/JNEUROSCI.0588-04.2004; DAVIS MG, 1988, BIOTECHNOL APPL BIOC, V10, P6; Dawson TR, 2004, J BIOL CHEM, V279, P4941, DOI 10.1074/jbc.M310068200; Elia M, 1992, World Rev Nutr Diet, V70, P68; Elmquist JK, 1998, LAB ANIM SCI, V48, P630; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; EMESON RB, 2000, RNA EDITING FRONTIER; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Feng Y, 2006, MOL CELL BIOL, V26, P480, DOI 10.1128/MCB.26.2.480-488.2006; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Fitzgerald LW, 1999, NEUROPSYCHOPHARMACOL, V21, pS82, DOI 10.1038/sj.npp.1395328; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Furuhata Y, 2000, EUR J ENDOCRINOL, V143, P535, DOI 10.1530/eje.0.1430535; Gan ZJ, 2006, J BIOL CHEM, V281, P33386, DOI 10.1074/jbc.M604484200; Gerber A, 1997, RNA, V3, P453; Giorgetti M, 2004, EUR J PHARMACOL, V488, P1, DOI 10.1016/j.ejphar.2004.01.036; GLAMOUR TS, 1995, AM J PHYSIOL-ENDOC M, V268, pE789, DOI 10.1152/ajpendo.1995.268.4.E789; Gott JM, 2000, ANNU REV GENET, V34, P499, DOI 10.1146/annurev.genet.34.1.499; HAMER DH, 1979, CELL, V18, P1299, DOI 10.1016/0092-8674(79)90240-X; Hayashi A, 2004, BRAIN RES, V1011, P221, DOI 10.1016/j.brainres.2004.03.032; Heisler LK, 2002, SCIENCE, V297, P609, DOI 10.1126/science.1072327; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Ikeda A, 1998, ENDOCRINOLOGY, V139, P3057, DOI 10.1210/en.139.7.3057; Jequier E, 2002, ANN NY ACAD SCI, V967, P379, DOI 10.1111/j.1749-6632.2002.tb04293.x; Jones JR, 2005, P NATL ACAD SCI USA, V102, P6207, DOI 10.1073/pnas.0306743102; Kesterson RA, 1997, MOL ENDOCRINOL, V11, P630, DOI 10.1210/me.11.5.630; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; King PJ, 2005, CURR DRUG TARGETS, V6, P225, DOI 10.2174/1389450053174587; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KURTZ TW, 1989, HYPERTENSION, V13, P896, DOI 10.1161/01.HYP.13.6.896; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; McGrew L, 2004, MOL PHARMACOL, V65, P252, DOI 10.1124/mol.65.1.252; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; Nonogaki K, 1998, NAT MED, V4, P1152, DOI 10.1038/2647; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; Price RD, 2001, J BIOL CHEM, V276, P44663, DOI 10.1074/jbc.M106745200; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sansam CL, 2003, P NATL ACAD SCI USA, V100, P14018, DOI 10.1073/pnas.2336131100; Sargent PA, 1997, PSYCHOPHARMACOLOGY, V133, P309, DOI 10.1007/s002130050407; Schaub M, 2002, BIOCHIMIE, V84, P791, DOI 10.1016/S0300-9084(02)01446-3; Schick F, 2005, EUR RADIOL, V15, P946, DOI 10.1007/s00330-005-2678-0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Sodhi MSK, 2005, MOL PHARMACOL, V68, P711, DOI 10.1124/mol.105.014134; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Tian B, 2004, NAT REV MOL CELL BIO, V5, P1013, DOI 10.1038/nrm1528; Tinsley FC, 2004, OBES RES, V12, P150, DOI 10.1038/oby.2004.20; Vaughan CH, 2003, PHYSIOL BEHAV, V79, P275, DOI 10.1016/S0031-9384(03)00094-5; Vickers SP, 1999, PSYCHOPHARMACOLOGY, V143, P309, DOI 10.1007/s002130050952; Wang QD, 2000, J NEUROCHEM, V74, P1290; Williams G, 2001, PHYSIOL BEHAV, V74, P683, DOI 10.1016/S0031-9384(01)00612-6; Yang WD, 2005, J BIOL CHEM, V280, P3946, DOI 10.1074/jbc.M407876200	73	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22448	22459		10.1074/jbc.M700265200	http://dx.doi.org/10.1074/jbc.M700265200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17567573	hybrid			2022-12-25	WOS:000248354200023
J	Aon, MA; Cortassa, S; Maack, C; O'Rourke, B				Aon, Miguel A.; Cortassa, Sonia; Maack, Christoph; O'Rourke, Brian			Sequential opening of mitochondrial ion channels as a function of glutathione redox thiol status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; MEMBRANE ANION CHANNEL; COMPLEX-I; NUCLEOTIDE TRANSHYDROGENASE; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; HEART-CELLS; ROLES; TRANSLOCATION; OSCILLATIONS	Mitochondrial membrane potential (Delta Psi(m)) depolarization contributes to cell death and electrical and contractile dysfunction in the post-ischemic heart. An imbalance between mitochondrial reactive oxygen species production and scavenging was previously implicated in the activation of an inner membrane anion channel (IMAC), distinct from the permeability transition pore (PTP), as the first response to metabolic stress in cardiomyocytes. The glutathione redox couple, GSH/GSSG, oscillated in parallel with Delta Psi(m) and the NADH/NAD(+) redox state. Here we show that depletion of reduced glutathione is an alternative trigger of synchronized mitochondrial oscillation in cardiomyocytes and that intermediate GSH/GSSG ratios cause reversible Delta Psi(m) depolarization, although irreversible PTP activation is induced by extensive thiol oxidation. Mitochondrial dysfunction in response to diamide occurred in stages, progressing from oscillations in Delta Psi(m) to sustained depolarization, in association with depletion of GSH. Mitochondrial oscillations were abrogated by 4'-chlorodiazepam, an IMAC inhibitor, whereas cyclosporin A was ineffective. In saponin-permeabilized cardiomyocytes, the thiol redox status was systematically clamped at GSH/GSSG ratios ranging from 300:1 to 20:1. At ratios of 150:1-100:1, Delta Psi(m) depolarized reversibly, and a matrix-localized fluorescent marker was retained; however, decreasing the GSH/GSSG to 50:1 irreversibly depolarized Delta Psi(m) and induced maximal rates of reactive oxygen species production, NAD(P)H oxidation, and loss of matrix constituents. Mitochondrial GSH sensitivity was altered by inhibiting either GSH uptake, the NADPH-dependent glutathione reductase, or the NADH/NADPH transhydrogenase, indicating that matrix GSH regeneration or replenishment was crucial. The results indicate that GSH/GSSG redox status governs the sequential opening of mitochondrial ion channels (IMAC before PTP) triggered by thiol oxidation in cardiomyocytes.	Johns Hopkins Univ, Inst Mol Cardiobiol, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	O'Rourke, B (corresponding author), Johns Hopkins Univ, Inst Mol Cardiobiol, Dept Med, 720 Rutland Ave,1059 Ross Bldg, Baltimore, MD 21205 USA.	bor@jhmi.edu	Aon, Miguel Antonio/A-6564-2008; Cortassa, Sonia/AAO-1633-2020	Aon, Miguel Antonio/0000-0002-4355-5431; Cortassa, Sonia/0000-0001-7224-9858; O'Rourke, Brian/0000-0002-5548-4853; Maack, Christoph/0000-0003-3694-4559	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054598, P01HL081427] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL054598-12, R37 HL54598, P01 HL081427, P01 HL081427-03, R37 HL054598, P01 HL081427-030001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Akar FG, 2005, J CLIN INVEST, V115, P3527, DOI 10.1172/JCI25371; Aon M, 2007, MOL SYSTEM BIOENERGE; Aon MA, 2006, BBA-MOL BASIS DIS, V1762, P232, DOI 10.1016/j.bbadis.2005.06.008; Aon MA, 2004, P NATL ACAD SCI USA, V101, P4447, DOI 10.1073/pnas.0307156101; Aon MA, 2003, J BIOL CHEM, V278, P44735, DOI 10.1074/jbc.M302673200; AON MA, 2007, CELLULAR OSCILLATORY; Aon MA, 2006, BIOPHYS J, V91, P4317, DOI 10.1529/biophysj.106.087817; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; Borecky J, 1997, J BIOL CHEM, V272, P19282; Bragg PD, 1999, BBA-BIOENERGETICS, V1413, P159, DOI 10.1016/S0005-2728(99)00090-0; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; Burwell LS, 2006, BIOCHEM J, V394, P627, DOI 10.1042/BJ20051435; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chernyak BV, 1997, BIOSCIENCE REP, V17, P293, DOI 10.1023/A:1027384628678; Cortassa S, 2004, BIOPHYS J, V87, P2060, DOI 10.1529/biophysj.104.041749; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Di Lisa F, 2005, CARDIOVASC RES, V66, P222, DOI 10.1016/j.cardiores.2005.02.009; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Follmann H, 1995, BIOFACTORS, V5, P147; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; HALLIWELL B, 1997, OXYGEN RADICALS DIS, P1; HARDY L, 1991, BIOCHEM J, V274, P133, DOI 10.1042/bj2740133; HOEK JB, 1988, BIOCHEM J, V254, P1; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jackson JB, 2003, FEBS LETT, V545, P18, DOI 10.1016/S0014-5793(03)00388-0; James AM, 2005, MECH AGEING DEV, V126, P982, DOI 10.1016/j.mad.2005.03.026; JENNER P, 2006, ACTA NEUROL SCAND SU, V394, P627; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P76; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Lash LH, 2006, CHEM-BIOL INTERACT, V163, P54, DOI 10.1016/j.cbi.2006.03.001; Lemar KM, 2005, MICROBIOL-SGM, V151, P3257, DOI 10.1099/mic.0.28095-0; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; Marczin N, 2003, ARCH BIOCHEM BIOPHYS, V420, P222, DOI 10.1016/j.abb.2003.08.037; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; O'Rourke B, 2000, J PHYSIOL-LONDON, V529, P23, DOI 10.1111/j.1469-7793.2000.00023.x; ONEILL P, 1982, BIOCHEM J, V205, P181, DOI 10.1042/bj2050181; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Powis G, 1997, Adv Pharmacol, V38, P329; Rebrin I, 2003, FREE RADICAL BIO MED, V35, P626, DOI 10.1016/S0891-5849(03)00388-5; Romashko DN, 1998, P NATL ACAD SCI USA, V95, P1618, DOI 10.1073/pnas.95.4.1618; Rydstrom J, 2006, TRENDS BIOCHEM SCI, V31, P355, DOI 10.1016/j.tibs.2006.05.003; Sadek HA, 2003, ARCH BIOCHEM BIOPHYS, V420, P201, DOI 10.1016/j.abb.2003.09.029; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schwaller M, 2003, J BIOL CHEM, V278, P7154, DOI 10.1074/jbc.M211036200; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Sheu SS, 2006, BBA-MOL BASIS DIS, V1762, P256, DOI 10.1016/j.bbadis.2005.10.007; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Vogel R, 1999, NEUROSCI LETT, V275, P97, DOI 10.1016/S0304-3940(99)00748-X; VUORINEN K, 1995, CIRCULATION, V91, P2810, DOI 10.1161/01.CIR.91.11.2810; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200	63	157	160	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21889	21900		10.1074/jbc.M702841200	http://dx.doi.org/10.1074/jbc.M702841200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17540766	Green Accepted, hybrid			2022-12-25	WOS:000248196800037
J	Azim-Zadeh, O; Hillebrecht, A; Linne, U; Marahiel, MA; Klebe, G; Lingelbach, K; Nyalwidhe, J				Azim-Zadeh, Omid; Hillebrecht, Alexander; Linne, Uwe; Marahiel, Mohamed A.; Klebe, Gerhard; Lingelbach, Klaus; Nyalwidhe, Julius			Use of biotin derivatives to probe conformational changes in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; CHEMICAL CROSS-LINKING; PLASMODIUM-FALCIPARUM; MASS-SPECTROMETRY; SERUM-ALBUMIN; PARASITOPHOROUS VACUOLE; CARBONIC-ANHYDRASE; ANION-EXCHANGER; MEMBRANE; AE1	Sulfosuccinimidyl-6-(biotinamido) hexanoate and derivatives thereof covalently bind to the epsilon-amino group of lysine residues. Our observation that access of the biotin derivative to specific lysine residues depends on conformational properties of the entire polypeptide chain prompted us to investigate whether differential biotinylation patterns of a protein can be used as indicators for conformational changes. Bovine serum albumin is a soluble protein with characteristic unfolding kinetics upon exposure to high temperature. First, we show that biotinylation patterns of proteins are highly reproducible. Second, we demonstrate by mass spectrometry and tandem mass spectrometry that unfolding of the protein correlates with the accessibility of the biotin derivative to specific lysine residues. We have applied this experimental strategy to the analysis of a cell-surface protein, viz. the human band 3 anion exchanger of erythrocytes infected with the malaria parasite Plasmodium falciparum. We found that Lys(826) in a highly flexible loop can be biotinylated in non-infected (but not infected) erythrocytes, confirming earlier observations (Winograd, E., and Sherman, I. W. (2004) Mol. Biochem. Parasitol. 138, 83-87) based on epitope-specific monoclonal antibodies suggesting that this region undergoes a conformational change upon infection.	Univ Marburg, Fachbereich Biol, D-35032 Marburg, Germany; Univ Marburg, Inst Pharmazeut Chem, D-35032 Marburg, Germany; Univ Marburg, Fachbereich Chem Biochem, D-35032 Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg	Lingelbach, K (corresponding author), Univ Marburg, Fachbereich Biol, Karl von Frisch Str 8, D-35032 Marburg, Germany.	lingelba@Staff.Uni-Marburg.de						Ahmad S, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-51; [Anonymous], 2005, SYBYL MOL MOD PACK; Back JW, 2002, ANAL CHEM, V74, P4417, DOI 10.1021/ac0257492; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Baumeister S, 2006, MOL MICROBIOL, V60, P493, DOI 10.1111/j.1365-2958.2006.05112.x; Baumeister S, 2003, MOL BIOCHEM PARASIT, V132, P35, DOI 10.1016/j.molbiopara.2003.08.003; Bennett KL, 2000, PROTEIN SCI, V9, P1503, DOI 10.1110/ps.9.8.1503; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; Cohn JV, 2003, MOL BIOCHEM PARASIT, V132, P27, DOI 10.1016/j.molbiopara.2003.08.001; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Frazar TF, 2003, MOL CELL BIOL, V23, P4753, DOI 10.1128/MCB.23.14.4753-4763.2003; Gao JP, 2006, ACTA BIOCH BIOPH SIN, V38, P611, DOI 10.1111/j.1745-7270.2006.00206.X; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Huang BX, 2004, J AM SOC MASS SPECTR, V15, P1237, DOI 10.1016/j.jasms.2004.05.004; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; Kopp J, 2004, NUCLEIC ACIDS RES, V32, pD230, DOI 10.1093/nar/gkh008; Nyalwidhe J, 2006, PROTEOMICS, V6, P1563, DOI 10.1002/pmic.200500379; Nyalwidhe J, 2002, J BIOL CHEM, V277, P40005, DOI 10.1074/jbc.M207077200; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; Popov M, 1999, BIOCHEM J, V339, P269, DOI 10.1042/0264-6021:3390269; Sarraf NS, 2004, ACTA BIOCHIM POL, V51, P665; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WETZEL R, 1980, EUR J BIOCHEM, V104, P469, DOI 10.1111/j.1432-1033.1980.tb04449.x; WILCHEK M, 1990, METHOD ENZYMOL, V184, P14; Winograd E, 2004, MOL BIOCHEM PARASIT, V138, P83, DOI 10.1016/j.molbiopara.2004.07.008; Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200	29	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21609	21617		10.1074/jbc.M610921200	http://dx.doi.org/10.1074/jbc.M610921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545162	hybrid			2022-12-25	WOS:000248196800007
J	Bonisch, C; Temme, C; Moritz, B; Wahle, E				Boenisch, Clemens; Temme, Claudia; Moritz, Bodo; Wahle, Elmar			Degradation of hsp70 and other mRNAs in Drosophila via the 5 '-3 ' pathway and its regulation by heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENTS; ACTIVATED PROTEIN-KINASE; POLY(A)-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; SELECTIVE TRANSLATION; MAMMALIAN EXOSOME; DISTINCT DOMAINS; DECAPPING ENZYME; POLY(A) NUCLEASE	Two general pathways of mRNA decay have been characterized in yeast. Both start with deadenylation. The major pathway then proceeds via cap hydrolysis and 5'-exonucleolytic degradation whereas the minor pathway consists of 3'-exonucleolytic decay followed by hydrolysis of the remaining cap structure. In higher eukaryotes, these pathways of mRNA decay are believed to be conserved but have not been well characterized. We have investigated the decay of the hsp70 mRNA in Drosophila Schneider cells. As shown by the use of reporter constructs, rapid deadenylation of this mRNA is directed by its 3'-untranslated region. The main deadenylase is the CCR4 center dot NOT complex; the PAN nuclease makes a lesser contribution. Heat shock prevents deadenylation not only of the hsp70 but also of bulk mRNA. A completely deadenylated capped hsp70 mRNA decay intermediate accumulates transiently and is degraded via cap hydrolysis and 5'-decay. Thus, decapping is a slow step in the degradation pathway. Cap hydrolysis is also inhibited during heat shock. Degradation of reporter RNAs from the 3'-end became detectable only upon inhibition of 5'-decay and thus represents a minor decay pathway. Because two reporter RNAs and at least two endogenous mRNAs were degraded primarily from the 5'-end with cap hydrolysis as a slow step, this pathway appears to be of general importance for mRNA decay in Drosophila.	Univ Halle, Inst Biochem & Biotechnol, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg	Wahle, E (corresponding author), Univ Halle, Inst Biochem & Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Germany.	ewahle@biochemtech.uni-halle.de		Wahle, Elmar/0000-0003-2504-0677				Alfieri RR, 2002, BBA-MOL CELL RES, V1592, P135, DOI 10.1016/S0167-4889(02)00291-4; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; Behm-Ansmant I, 2006, GENE DEV, V20, P1885, DOI 10.1101/gad.1424106; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Bollig F, 2002, EUR J BIOCHEM, V269, P5830, DOI 10.1046/j.1432-1033.2002.03300.x; Brewer G, 1999, J BIOL CHEM, V274, P16174, DOI 10.1074/jbc.274.23.16174; Brook M, 2006, MOL CELL BIOL, V26, P2408, DOI 10.1128/MCB.26.6.2408-2418.2006; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Cao D, 2001, RNA, V7, P1192, DOI 10.1017/S1355838201010330; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chou CF, 2006, MOL CELL BIOL, V26, P3695, DOI 10.1128/MCB.26.10.3695-3706.2006; Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Cougot N, 2004, TRENDS BIOCHEM SCI, V29, P436, DOI 10.1016/j.tibs.2004.06.008; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DELLAVALLE RP, 1994, MOL CELL BIOL, V14, P3646, DOI 10.1128/MCB.14.6.3646; Eulalio A, 2007, NAT REV MOL CELL BIO, V8, P9, DOI 10.1038/nrm2080; Fenger-Gron M, 2005, MOL CELL, V20, P905, DOI 10.1016/j.molcel.2005.10.031; Franks TM, 2007, GENE DEV, V21, P719, DOI 10.1101/gad.1494707; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Goldstrohm AC, 2006, NAT STRUCT MOL BIOL, V13, P533, DOI 10.1038/nsmb1100; Gowrishankar G, 2006, BIOL CHEM, V387, P323, DOI 10.1515/BC.2006.043; Gowrishankar G, 2005, BIOL CHEM, V386, P1287, DOI 10.1515/BC.2005.146; Hilgers V, 2006, RNA, V12, P1835, DOI 10.1261/rna.241006; Hitti E, 2006, MOL CELL BIOL, V26, P2399, DOI 10.1128/MCB.26.6.2399-2407.2006; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Kerwitz Y, 2003, EMBO J, V22, P3705, DOI 10.1093/emboj/cdg347; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kuhn U, 2003, J BIOL CHEM, V278, P16916, DOI 10.1074/jbc.M209886200; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LINDQUIST S, 1990, ENZYME, V44, P147, DOI 10.1159/000468754; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; PETERSEN R, 1988, GENE, V72, P161, DOI 10.1016/0378-1119(88)90138-2; PETERSEN RB, 1989, CELL REGUL, V1, P135, DOI 10.1091/mbc.1.1.135; SADIS S, 1988, J CELL PHYSIOL, V135, P377, DOI 10.1002/jcp.1041350304; Sambrook, 2001, MOL CLONING, V1; Semotok JL, 2005, CURR BIOL, V15, P284, DOI 10.1016/j.cub.2005.01.048; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Stoecklin G, 2006, EMBO REP, V7, P72, DOI 10.1038/sj.embor.7400572; Temme C, 2004, EMBO J, V23, P2862, DOI 10.1038/sj.emboj.7600273; Tharun S, 2001, MOL CELL, V8, P1075, DOI 10.1016/S1097-2765(01)00395-1; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; Till DD, 1998, MECH DEVELOP, V79, P51, DOI 10.1016/S0925-4773(98)00173-7; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uchida N, 2004, J BIOL CHEM, V279, P1383, DOI 10.1074/jbc.M309125200; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Wu MS, 2005, EMBO J, V24, P4082, DOI 10.1038/sj.emboj.7600869; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; Zaessinger S, 2006, DEVELOPMENT, V133, P4573, DOI 10.1242/dev.02649; Zhao MJ, 2002, J BIOL CHEM, V277, P44539, DOI 10.1074/jbc.M208408200; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	79	37	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21818	21828		10.1074/jbc.M702998200	http://dx.doi.org/10.1074/jbc.M702998200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545151	hybrid			2022-12-25	WOS:000248196800029
J	Gibbons, JA; Kozubowski, L; Tatchell, K; Shenolikar, S				Gibbons, Jennifer A.; Kozubowski, Lukasz; Tatchell, Kelly; Shenolikar, Shirish			Expression of human protein phosphatase-1 in Saccharomyces cerevisiae highlights the role of phosphatase isoforms in regulating eukaryotic functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; GLYCOGEN-METABOLISM; GLUCOSE REPRESSION; STRUCTURAL BASIS; CELL-CYCLE; TYPE-1; YEAST; MUSCLE; INHIBITION; DEPHOSPHORYLATION	Human (PP1) isoforms, PP1 alpha, PP1 beta, PP1 gamma 1, and PP1 gamma 2, differ in primary sequences atNandCtermini that potentially bind cellular regulators and define their physiological functions. The GLC7 gene encodes the PP1 catalytic subunit with >80% sequence identity to human PP1 and is essential for viability of Saccharomyces cerevisiae. In yeast, Glc7p regulates glycogen and protein synthesis, actin cytoskeleton, gene expression, and cell division. We substituted human PP1 for Glc7p in yeast to investigate the ability of individual isoforms to catalyze Glc7p functions. S. cerevisiae expressing human PP1 isoforms were viable. PP1 alpha-expressing yeast grew more rapidly than strains expressing other isoforms. On the other hand, PP1 alpha-expressing yeast accumulated less glycogen than PP1 beta- or PP1 gamma 1-expressing yeast. Yeast expressing human PP1 were indistinguishable from WT yeast in glucose derepression. However, unlike WT yeast, strains expressing human PP1 failed to sporulate. Analysis of chimeric PP1 alpha/beta subunits highlighted a critical role for their unique N termini in defining PP1 alpha and PP1 beta functions in yeast. Biochemical studies established that the differing association of PP1 isoforms with the yeast glycogen- targeting subunit, Gac1p, accounted for their differences in glycogen synthesis. In contrast to human PP1 expressed in Escherichia coli, enzymes expressed in yeast displayed in vitro biochemical properties closely resembling PP1 from mammalian tissues. Thus, PP1 expression in yeast should facilitate future structure-function studies of this protein serine/threonine phosphatase.	Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Pfizer; Duke University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Shenolikar, S (corresponding author), Pfizer Global Res & Dev, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	Shirish.Shenolikar@Pfizer.com	Tatchell, Kelly/A-9643-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047789] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52054] Funding Source: Medline; NIEHS NIH HHS [T32 ES07031] Funding Source: Medline; NIGMS NIH HHS [GM47789] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Andrews PD, 2000, J CELL SCI, V113, P507; Aschenbach WG, 2001, J BIOL CHEM, V276, P39959, DOI 10.1074/jbc.M105518200; Baker SH, 1997, GENETICS, V145, P615; BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Bloecher A, 2000, J CELL BIOL, V149, P125, DOI 10.1083/jcb.149.1.125; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; CANNON JF, 1994, GENETICS, V136, P485; Carmody LC, 2004, J BIOL CHEM, V279, P21714, DOI 10.1074/jbc.M402261200; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chakrabarti R, 2007, BIOL REPROD, V76, P992, DOI 10.1095/biolreprod.106.058610; Cheng C, 1997, YEAST, V13, P1; Chu YF, 1996, J BIOL CHEM, V271, P2574, DOI 10.1074/jbc.271.5.2574; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; De Wever V, 2005, EMBO J, V24, P4115, DOI 10.1038/sj.emboj.7600871; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; FRANCOIS J, 1987, EUR J BIOCHEM, V164, P369, DOI 10.1111/j.1432-1033.1987.tb11067.x; Genoux D, 2002, NATURE, V418, P970, DOI 10.1038/nature00928; Gibbons JA, 2005, J BIOL CHEM, V280, P15903, DOI 10.1074/jbc.M500871200; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Lesage B, 2005, FEBS LETT, V579, P5626, DOI 10.1016/j.febslet.2005.09.033; LIU HP, 1992, GENETICS, V132, P665; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MARTIN BL, 1991, FEBS LETT, V285, P6, DOI 10.1016/0014-5793(91)80712-C; Moorhead G, 1998, FEBS LETT, V438, P141, DOI 10.1016/S0014-5793(98)01276-9; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Ramaswamy NT, 1998, GENETICS, V149, P57; Reeder JE, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-12; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; Suzuki Y, 2001, MOL CELL BIOL, V21, P2683, DOI 10.1128/MCB.21.8.2683-2694.2001; Szoor B, 2001, ARCH BIOCHEM BIOPHYS, V396, P213; Tachikawa H, 2001, J CELL BIOL, V155, P797, DOI 10.1083/jcb.200107008; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TU JL, 1994, MOL CELL BIOL, V14, P6789, DOI 10.1128/MCB.14.10.6789; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; Weiser DC, 2004, J BIOL CHEM, V279, P48904, DOI 10.1074/jbc.M404416200; Williams-Hart T, 2002, GENETICS, V160, P1423; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301; Zheng JH, 2000, J BIOL CHEM, V275, P18070, DOI 10.1074/jbc.M000918200	52	25	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21838	21847		10.1074/jbc.M701272200	http://dx.doi.org/10.1074/jbc.M701272200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545157	hybrid			2022-12-25	WOS:000248196800031
J	Mal, TK; Takahata, S; Ki, S; Zheng, L; Kokubo, T; Ikura, M				Mal, Tapas K.; Takahata, Shinya; Ki, Sewon; Zheng, Le; Kokubo, Tetsuro; Ikura, Mitsuhiko			Functional silencing of TATA-binding protein (TBP) by a covalent linkage of the N-terminal domain of TBP-associated factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; GREEN FLUORESCENT PROTEIN; SHOW SYNTHETIC LETHALITY; PEPTIDE HYBRID MOLECULE; SACCHAROMYCES-CEREVISIAE; NMR-SPECTROSCOPY; IN-VIVO; TRANSACTIVATION DOMAIN; COACTIVATOR COMPLEXES; INHIBITORY DOMAIN	General transcription factor TFIID is comprised of TATA-binding protein (TBP) and TBP-associated factors (TAFs), together playing critical roles in regulation of transcription initiation. The TAF N-terminal domain (TAND) of yeast TAF1 containing two subdomains, TAND1 (residues 10-37) and TAND2 (residues 46-71), is sufficient to interact with TBP and suppress the TATA binding activity of TBP. However, the detailed structural analysis of the complex between yeast TBP and TAND12 (residues 6-71) was hindered by its poor solubility and stability in solution. Here we report a molecular engineering approach where the N terminus of TBP is fused to the C terminus of TAND12 via linkers of various lengths containing (GGGS)(n) sequence, (n = 1, 2, 3). The length of the linker within the TAND12-TBP fusion has a significant effect on solubility and stability (SAS). The construct with (GGGS)(3) linker produces the best quality single-quantum-coherence (HSQC) NMR spectrum with markedly improved SAS. In parallel to these observations, the TAND12-TBP fusion exhibits marked reduction of TBP function in binding to TAF1 as well as temperature sensitivity in in vivo yeast cell growth. Remarkably, the temperature sensitivity was proportional to the length of the linker in the fusions: the construct with (GGGS)(3) linker did not grow at 20 degrees C, while those with (GGGS)(1) and (GGGS)(2) linkers did. These results together indicate that the native interaction between TBP and TAND12 is well maintained in the TAND12-(GGGS)(3)-TBP fusion and that this fusion approach provides an excellent model system to investigate the structural detail of the TBP-TAF1 interaction.	Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Div Signalling Biol, Toronto, ON M5G 1L7, Canada; Yokohama City Univ, Int Grad Sch Arts & Sci, Div Cell & Mol Biol, Tsurumi Ku, Kanagawa 2300045, Japan	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Yokohama City University	Ikura, M (corresponding author), Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Div Signalling Biol, Toronto Med Discovery Towers,101 Coll St,4th Floo, Toronto, ON M5G 1L7, Canada.	mikura@uhnres.utoronto.ca	Mal, Tapas K/A-9453-2011	Mal, Tapas K/0000-0002-0625-2095; Ikura, Mitsuhiko/0000-0002-9524-1303				Bagby S, 2000, FEBS LETT, V468, P149, DOI 10.1016/S0014-5793(00)01213-8; Bagby S, 2001, METHOD ENZYMOL, V339, P20, DOI 10.1016/S0076-6879(01)39307-2; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Banik U, 2001, J BIOL CHEM, V276, P49100, DOI 10.1074/jbc.M109246200; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Cheng JX, 2002, CURR BIOL, V12, P1828, DOI 10.1016/S0960-9822(02)01257-5; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DALPORTO J, 1993, P NATL ACAD SCI USA, V90, P6671, DOI 10.1073/pnas.90.14.6671; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ducat T, 2006, J BIOMOL NMR, V34, P137, DOI 10.1007/s10858-006-0003-0; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Gardner KH, 1998, ANNU REV BIOPH BIOM, V27, P357, DOI 10.1146/annurev.biophys.27.1.357; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hilton TL, 2003, J BIOL CHEM, V278, P12992, DOI 10.1074/jbc.M300412200; Hoedemaeker FJ, 1997, J BIOL CHEM, V272, P29784, DOI 10.1074/jbc.272.47.29784; Howe PWA, 2004, J BIOMOL NMR, V30, P283, DOI 10.1007/s10858-004-3739-4; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Irvin JD, 2006, J BIOL CHEM, V281, P6404, DOI 10.1074/jbc.M513776200; Kasahara K, 2004, GENES CELLS, V9, P709, DOI 10.1111/j.1356-9597.2004.00762.x; Kobayashi A, 2003, NUCLEIC ACIDS RES, V31, P1261, DOI 10.1093/nar/gkg180; Kobayashi A, 2001, J BIOL CHEM, V276, P395, DOI 10.1074/jbc.M008208200; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; Kou HP, 2003, MOL CELL BIOL, V23, P3186, DOI 10.1128/MCB.23.9.3186-3201.2003; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lepre CA, 1998, J BIOMOL NMR, V12, P493, DOI 10.1023/A:1008353000679; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Mal TK, 2004, J MOL BIOL, V339, P681, DOI 10.1016/j.jmb.2004.04.020; Martel LS, 2002, MOL CELL BIOL, V22, P2788, DOI 10.1128/MCB.22.8.2788-2798.2002; Martin SR, 1996, BIOCHEMISTRY-US, V35, P3508, DOI 10.1021/bi952522a; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; PORUMB T, 1994, PROTEIN ENG, V7, P109, DOI 10.1093/protein/7.1.109; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Takahata S, 2004, MOL CELL BIOL, V24, P3089, DOI 10.1128/MCB.24.8.3089-3099.2004; Takahata S, 2003, J BIOL CHEM, V278, P45888, DOI 10.1074/jbc.M306886200; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Trinh R, 2004, MOL IMMUNOL, V40, P717, DOI 10.1016/j.molimm.2003.08.006; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Yang DW, 1999, J AM CHEM SOC, V121, P2571, DOI 10.1021/ja984056t; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976; Zhou P, 2001, J BIOMOL NMR, V20, P11, DOI 10.1023/A:1011258906244	61	10	10	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22228	22238		10.1074/jbc.M702988200	http://dx.doi.org/10.1074/jbc.M702988200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17553784	hybrid			2022-12-25	WOS:000248196800068
J	Chartier, FJM; Couture, M				Chartier, Francois J. M.; Couture, Manon			Substrate-specific interactions with the heme-bound oxygen molecule of nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN DETECTION; LIGAND-PROTEIN INTERACTIONS; N-G-HYDROXYARGININE; FE-S BOND; BACILLUS-SUBTILIS; STAPHYLOCOCCUS-AUREUS; MYCOBACTERIUM-TUBERCULOSIS; TRUNCATED HEMOGLOBIN; CATALYTIC MECHANISM; SINGLE-TURNOVER	We report the characterization by resonance Raman spectroscopy of the oxygenated complex ((FeO2)-O-II) of nitric-oxide synthases of Staphylococcus aureus (saNOS) and Bacillus subtilis (bsNOS) saturated with N-omega-hydroxy-L-arginine. The frequencies of the nu(Fe-O) and nu(O-O) modes were 530 and 1135 cm(-1), respectively, in both the presence and absence of tetrahydrobiopterin. On the basis of a comparison of these frequencies with those of saNOS and bsNOS saturated with L-arginine (nu(Fe-O) at 517 cm(-1) and nu(O-O) at 1123 cm(-1)) and those of substrate-free saNOS (nu(Fe-O) at 517 and nu(O-O) at 1135 cm(-1)) (Chartier, F. J. M., Blais, S. P., and Couture, M. (2006) J. Biol. Chem. 281, 9953 9962), we propose two models that account for the frequency shift of nu(Fe-O) (but not nu(O-O)) upon N-omega-hydroxy-L-arginine binding as well as the frequency shift of nu(O-O) (but not nu(Fe-O)) upon L-arginine binding. The implications of these substrate-specific interactions with respect to catalysis by NOSs are discussed.	Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1K 7P4, Canada; Univ Laval, CREFSIP, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Couture, M (corresponding author), Univ Laval, Dept Biochem & Microbiol, Pavillon Marchand,Rm 4165, Quebec City, PQ G1K 7P4, Canada.	manon.couture@bcm.ulaval.ca	Couture, Manon/F-8326-2015	Couture, Manon/0000-0001-8296-8055				Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2001, J INORG BIOCHEM, V83, P301, DOI 10.1016/S0162-0134(00)00176-8; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; BANGCHAROENPAURPONG O, 1986, J BIOL CHEM, V261, P8089; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; Chartier FJM, 2006, J BIOL CHEM, V281, P9953, DOI 10.1074/jbc.M513893200; Chartier FJM, 2004, BIOPHYS J, V87, P1939, DOI 10.1529/biophysj.104.042119; Chartier FJM, 2007, BIOCHEM J, V401, P235, DOI 10.1042/BJ20060913; Chen ZC, 2004, BIOCHEMISTRY-US, V43, P1798, DOI 10.1021/bi034920g; Cho KB, 2005, J PHYS CHEM B, V109, P23706, DOI 10.1021/jp054864o; Cho KB, 2004, J AM CHEM SOC, V126, P10267, DOI 10.1021/ja049186i; Cho KB, 2007, J AM CHEM SOC, V129, P3182, DOI 10.1021/ja066662r; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Couture M, 2001, J BIOL CHEM, V276, P38280; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; Gorren ACF, 2006, BBA-PROTEINS PROTEOM, V1764, P578, DOI 10.1016/j.bbapap.2005.11.005; Gorren ACF, 2005, METHOD ENZYMOL, V396, P456, DOI 10.1016/S0076-6879(05)96038-2; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Groves JT, 2000, CURR OPIN CHEM BIOL, V4, P687, DOI 10.1016/S1367-5931(00)00146-0; Harris DL, 1998, J AM CHEM SOC, V120, P8941, DOI 10.1021/ja981059x; HU SZ, 1991, J AM CHEM SOC, V113, P4815, DOI 10.1021/ja00013a016; Huang H, 2001, J AM CHEM SOC, V123, P2674, DOI 10.1021/ja005900u; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Ingledew WJ, 2005, BIOCHEMISTRY-US, V44, P4238, DOI 10.1021/bi047891y; Ingledew WJ, 2002, BIOCHEMISTRY-US, V41, P8377, DOI 10.1021/bi012101v; Jung C, 2000, BIOCHEMISTRY-US, V39, P10163, DOI 10.1021/bi0003792; Li D, 2007, J AM CHEM SOC, V129, P6943, DOI 10.1021/ja070683j; Li HY, 2006, J BIOL INORG CHEM, V11, P753, DOI 10.1007/s00775-006-0123-8; Li HY, 2002, BIOCHEMISTRY-US, V41, P13868, DOI 10.1021/bi020417c; Lu CY, 2007, J BIOL CHEM, V282, P13627, DOI 10.1074/jbc.M609397200; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Ogliaro F, 2002, J AM CHEM SOC, V124, P2806, DOI 10.1021/ja0171963; Ohta T, 2005, INORG CHEM, V44, P758, DOI 10.1021/ic0486318; Pant K, 2006, BIOCHEMISTRY-US, V45, P2537, DOI 10.1021/bi0518848; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Rosen GM, 2002, CHEM REV, V102, P1191, DOI 10.1021/cr010187s; Rousseau DL, 2005, J INORG BIOCHEM, V99, P306, DOI 10.1016/j.jinorgbio.2004.11.007; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Santolini M, 2006, BIOCHEMISTRY-US, V45, P1480, DOI 10.1021/bi051710q; Schelvis JPM, 2002, BIOCHEMISTRY-US, V41, P5695, DOI 10.1021/bi0118456; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Spiro TG, 2001, COORDIN CHEM REV, V219, P923, DOI 10.1016/S0010-8545(01)00384-8; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 2005, DALTON T, P3427, DOI 10.1039/b506355h; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Tosha T, 2006, BIOCHEMISTRY-US, V45, P5631, DOI 10.1021/bi060094a; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Wang ZQ, 2007, J BIOL CHEM, V282, P2196, DOI 10.1074/jbc.M608206200; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; Yoshimura H, 2006, BIOCHEMISTRY-US, V45, P8301, DOI 10.1021/bi060315c	63	27	28	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20877	20886		10.1074/jbc.M701800200	http://dx.doi.org/10.1074/jbc.M701800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17537725	hybrid			2022-12-25	WOS:000248047500013
J	Sullivan, PS; Campsmith, ML; Nakamura, GV; Begley, EB; Schulden, J; Nakashima, AK				Sullivan, Patrick S.; Campsmith, Michael L.; Nakamura, Glenn V.; Begley, Elin B.; Schulden, Jeffrey; Nakashima, Allyn K.			Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy	PLOS ONE			English	Article							HIV BEHAVIORAL SURVEILLANCE; MEDICATION ADHERENCE; VIRAL SUPPRESSION; CLINICAL-TRIALS; DRUG-USE; INFECTION; IMPACT; RISK; OUTCOMES; INDIVIDUALS	Background. Nonadherence to antiretroviral therapy (ARVT) is an important behavioral determinant of the success of ARVT. Nonadherence may lead to virological failure, and increases the risk of development of drug resistance. Understanding the prevalence of nonadherence and associated factors is important to inform secondary HIV prevention efforts. Methodology/Principal Findings. We used data from a cross-sectional interview study of persons with HIV conducted in 18 U. S. states from 2000-2004. We calculated the proportion of nonadherent respondents (took <95% of prescribed doses in the past 48 hours), and the proportion of doses missed. We used multivariate logistic regression to describe factors associated with nonadherence. Nine hundred and fifty-eight (16%) of 5,887 respondents reported nonadherence. Nonadherence was significantly (p<0.05) associated with black race and Hispanic ethnicity; age <40 years; alcohol or crack use in the prior 12 months; being prescribed >= 4 medications; living in a shelter or on the street; and feeling "blue" >= 14 of the past 30 days. We found weaker associations with having both male-male sex and injection drug use risks for HIV acquisition; being prescribed ARVT for >= 21 months; and being prescribed a protease inhibitor (PI)-based regimen not boosted with ritonavir. The median proportion of doses missed was 50%. The most common reasons for missing doses were forgetting and side effects. Conclusions/Significance. Self-reported recent nonadherence was high in our study. Our data support increased emphasis on adherence in clinical settings, and additional research on how providers and patients can overcome barriers to adherence.	[Sullivan, Patrick S.; Campsmith, Michael L.; Nakamura, Glenn V.; Begley, Elin B.; Schulden, Jeffrey; Nakashima, Allyn K.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Sullivan, PS (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.	pss0@cdc.gov		Sullivan, Patrick Sean/0000-0002-7728-0587	Centers for Disease Control and Prevention	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Funding support for data collection was provided to the project sites by the Centers for Disease Control and Prevention. No external funding was used to support the analysis of these data.	Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008; Ammassari A, 2004, PSYCHOSOMATICS, V45, P394, DOI 10.1176/appi.psy.45.5.394; Ammassari A, 2002, JAIDS, V31, pS123, DOI 10.1097/00126334-200212153-00007; Antinori A, 2004, ANTIVIR THER, V9, P291; Arnsten JH, 2002, J GEN INTERN MED, V17, P377, DOI 10.1007/s11606-002-0044-3; Bartenstein P, 2002, AKTUEL NEUROL, V29, P1, DOI 10.1055/s-2002-20000; Berg KM, 2004, J GEN INTERN MED, V19, P1111, DOI 10.1111/j.1525-1497.2004.30445.x; Bottonari KA, 2005, AIDS PATIENT CARE ST, V19, P719, DOI 10.1089/apc.2005.19.719; Buehler JW, 1996, PUBLIC HEALTH REP, V111, P133; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carrieri MP, 2006, JAIDS-J ACQ IMM DEF, V41, P477, DOI 10.1097/01.qai.0000186364.27587.0e; Chander G, 2006, DRUGS, V66, P769, DOI 10.2165/00003495-200666060-00004; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; COHEN M, 2006, 13 C RETR OPP INF DE; Fairley CK, 2005, HIV MED, V6, P366, DOI 10.1111/j.1468-1293.2005.00322.x; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; Fletcher CV, 2005, JAIDS-J ACQ IMM DEF, V40, P301, DOI 10.1097/01.qai.0000180078.53321.6a; Gallagher KM, 2007, PUBLIC HEALTH REP, V122, P32, DOI 10.1177/00333549071220S106; Glass TR, 2006, JAIDS-J ACQ IMM DEF, V41, P385, DOI 10.1097/01.qai.0000186371.95301.52; Gordillo V, 1999, AIDS, V13, P1763, DOI 10.1097/00002030-199909100-00021; GROSS R, 2006, 13 C RETR OPP INF DE; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Holmes WC, 2002, J GEN INTERN MED, V17, P677, DOI 10.1046/j.1525-1497.2002.00746.x; Howard AA, 2002, AIDS, V16, P2175, DOI 10.1097/00002030-200211080-00010; Kerr Thomas, 2005, Curr HIV/AIDS Rep, V2, P200, DOI 10.1007/s11904-005-0017-3; Lafeuillade A, 2001, INT J STD AIDS, V12, P18, DOI 10.1258/0956462011924290; Lansky A, 2007, PUBLIC HEALTH REP, V122, P16, DOI 10.1177/00333549071220S104; Lichtenstein KA, 2005, JAIDS-J ACQ IMM DEF, V39, P395, DOI 10.1097/01.qai.0000167478.28051.3a; Maggiolo F, 2005, CLIN INFECT DIS, V40, P158, DOI 10.1086/426595; Maisto SA, 2003, AM J ADDICTION, V12, pS12, DOI 10.1111/j.1521-0391.2003.tb00493.x; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Martini M, 2004, EUR J EPIDEMIOL, V19, P585, DOI 10.1023/B:EJEP.0000032353.03967.ef; Moss AR, 2004, CLIN INFECT DIS, V39, P1190, DOI 10.1086/424008; Murri R, 2004, J GEN INTERN MED, V19, P1104, DOI 10.1111/j.1525-1497.2004.30248.x; Nieuwkerk PT, 2005, JAIDS-J ACQ IMM DEF, V38, P445, DOI 10.1097/01.qai.0000147522.34369.12; NILSSON SL, 2006, AIDS CARE, V18, P246; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Piliero Peter J, 2003, J Am Acad Nurse Pract, V15, P305, DOI 10.1111/j.1745-7599.2003.tb01313.x; Reynolds NR, 2004, CURR HIV RES, V2, P207, DOI 10.2174/1570162043351309; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; Santos CP, 2005, AIDS, V19, pS14, DOI 10.1097/01.aids.0000191485.92285.c7; Selnes OA, 2002, JAIDS-J ACQ IMM DEF, V31, pS132, DOI 10.1097/00126334-200212153-00009; Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684; Simoni JM, 2006, AIDS BEHAV, V10, P227, DOI 10.1007/s10461-006-9078-6; Sledjeski EM, 2005, AIDS PATIENT CARE ST, V19, P728, DOI 10.1089/apc.2005.19.728; Smith RJ, 2006, P ROY SOC B-BIOL SCI, V273, P617, DOI 10.1098/rspb.2005.3352; Starace F, 2002, JAIDS, V31, pS136, DOI 10.1097/00126334-200212153-00010; Stirratt MJ, 2006, AIDS BEHAV, V10, P483, DOI 10.1007/s10461-006-9106-6; Trotta MP, 2003, AIDS, V17, P1099, DOI 10.1097/00002030-200305020-00026; *US DEP HHS, 2006, GUID US ANT AG HIV 1; Van Wijngaerden E, 2002, AIDS RES HUM RETROV, V18, P327, DOI 10.1089/088922202753519098; Vlahov D, 2001, AIDS, V15, P2311, DOI 10.1097/00002030-200111230-00013; Vrijens B, 2005, STAT MED, V24, P2719, DOI 10.1002/sim.2130; Wagner G, 2004, JAIDS-J ACQ IMM DEF, V35, P203, DOI 10.1097/00126334-200402010-00016; Wagner GJ, 2002, AIDS PATIENT CARE ST, V16, P599, DOI 10.1089/108729102761882134; Walsh JC, 2002, AIDS, V16, P269, DOI 10.1097/00002030-200201250-00017; Walster C. I., 1999, Fish Veterinary Journal, P54; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037; Weiser SD, 2004, HIV CLIN TRIALS, V5, P278, DOI 10.1310/LNHD-K1R7-HQP5-HJCQ; Wood E, 2004, JAIDS-J ACQ IMM DEF, V35, P261, DOI 10.1097/00126334-200403010-00006	60	54	56	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e552	10.1371/journal.pone.0000552	http://dx.doi.org/10.1371/journal.pone.0000552			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579723	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451700017
J	Plant, EP; Nguyen, P; Russ, JR; Pittman, YR; Nguyen, T; Quesinberry, JT; Kinzy, TG; Dinman, JD				Plant, Ewan P.; Nguyen, Phuc; Russ, Jonathan R.; Pittman, Yvette R.; Nguyen, Thai; Quesinberry, Jack T.; Kinzy, Terri Goss; Dinman, Jonathan D.			Differentiating between Near- and Non-Cognate Codons in Saccharomyces cerevisiae	PLOS ONE			English	Article								Background. Decoding of mRNAs is performed by aminoacyl tRNAs (aa-tRNAs). This process is highly accurate, however, at low frequencies (10(-3)-10(-4)) the wrong aa-tRNA can be selected, leading to incorporation of aberrant amino acids. Although our understanding of what constitutes the correct or cognate aa-tRNA: mRNA interaction is well defined, a functional distinction between near-cognate or single mismatched, and unpaired or non-cognate interactions is lacking. Methodology/Principal Findings. Misreading of several synonymous codon substitutions at the catalytic site of firefly luciferase was assayed in Saccharomyces cerevisiae. Analysis of the results in the context of current kinetic and biophysical models of aa-tRNA selection suggests that the defining feature of near-cognate aa-tRNAs is their potential to form mini-helical structures with A-site codons, enabling stimulation of GTPase activity of eukaryotic Elongation Factor 1A (eEF1A). Paromomycin specifically stimulated misreading of near-cognate but not of non-cognate aa-tRNAs, providing a functional probe to distinguish between these two classes. Deletion of the accessory elongation factor eEF1B gamma promoted increased misreading of near-cognate, but hyperaccurate reading of non-cognate codons, suggesting that this factor also has a role in tRNA discrimination. A mutant of eEF1B alpha, the nucleotide exchange factor for eEF1A, promoted a general increase in fidelity, suggesting that the decreased rates of elongation may provide more time for discrimination between aa-tRNAs. A mutant form of ribosomal protein L5 promoted hyperaccurate decoding of both types of codons, even though it is topologically distant from the decoding center. Conclusions/Signficance. It is important to distinguish between near-cognate and non-cognate mRNA: tRNA interactions, because such a definition may be important for informing therapeutic strategies for suppressing these two different categories of mutations underlying many human diseases. This study suggests that the defining feature of near-cognate aa-tRNAs is their potential to form mini-helical structures with A-site codons in the ribosomal decoding center. An aminoglycoside and a ribosomal factor can be used to distinguish between near-cognate and non-cognate interactions.	[Plant, Ewan P.; Nguyen, Phuc; Russ, Jonathan R.; Dinman, Jonathan D.] Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA; [Pittman, Yvette R.; Kinzy, Terri Goss] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA; [Nguyen, Thai] Eleanor Roosevelt High Sch, Ctr Sci & Technol, Greenbelt, MD USA; [Quesinberry, Jack T.] Huntington High Sch, Huntington, MD USA	University System of Maryland; University of Maryland College Park; Rutgers State University New Brunswick; Rutgers State University Medical Center	Dinman, JD (corresponding author), Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA.	dinman@umd.edu	Plant, Ewan/AAB-1911-2020	Plant, Ewan/0000-0003-0166-5939; Dinman, Jonathan/0000-0002-2402-9698; Kinzy, Terri/0000-0003-1394-9226	National Institutes of Health [GM058859, AI064307]; TGK [GM057483]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057483, R01GM058859] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); TGK; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the National Institutes of Health to JDD (GM058859 and AI064307), and to TGK (GM057483).	Agris PF, 2007, J MOL BIOL, V366, P1, DOI 10.1016/j.jmb.2006.11.046; AGRIS PF, 1991, BIOCHIMIE, V73, P1345, DOI 10.1016/0300-9084(91)90163-U; Anand M, 2003, J BIOL CHEM, V278, P6985, DOI 10.1074/jbc.M209224200; Anand M, 2001, COLD SPRING HARB SYM, V66, P439, DOI 10.1101/sqb.2001.66.439; Andersen CBF, 2006, NATURE, V443, P663, DOI 10.1038/nature05126; Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2001, NAT STRUCT BIOL, V8, P531, DOI 10.1038/88598; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BOUADLOUN F, 1983, EMBO J, V2, P1351, DOI 10.1002/j.1460-2075.1983.tb01591.x; Carr-Schmid A, 1999, MOL CELL BIOL, V19, P5257; Carr-Schmid A, 1999, J BIOL CHEM, V274, P30297, DOI 10.1074/jbc.274.42.30297; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Cochella L, 2005, CURR BIOL, V15, pR536, DOI 10.1016/j.cub.2005.07.018; Cochella L, 2007, NAT STRUCT MOL BIOL, V14, P30, DOI 10.1038/nsmb1183; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; Daviter T, 2006, BIOCHIMIE, V88, P1001, DOI 10.1016/j.biochi.2006.04.013; DESHMUKH M, 1995, J BIOL CHEM, V270, P30148; Dinman JD, 1997, RNA, V3, P870; DINMAN JD, 1994, GENETICS, V136, P75; Gromadski KB, 2006, MOL CELL, V21, P369, DOI 10.1016/j.molcel.2005.12.018; Hani J, 1998, NUCLEIC ACIDS RES, V26, P689, DOI 10.1093/nar/26.3.689; Harger JW, 2003, RNA, V9, P1019, DOI 10.1261/rna.5930803; HIRAGA K, 1993, FEBS LETT, V316, P165, DOI 10.1016/0014-5793(93)81208-H; Hobbie SN, 2006, BIOCHIMIE, V88, P1033, DOI 10.1016/j.biochi.2006.04.008; IKEMURA T, 1982, J MOL BIOL, V158, P573, DOI 10.1016/0022-2836(82)90250-9; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacobs JL, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh157; Jeppesen MG, 2003, J BIOL CHEM, V278, P47190, DOI 10.1074/jbc.M306630200; Kramer EB, 2007, RNA, V13, P87, DOI 10.1261/rna.294907; Lim VI, 2005, J MOL BIOL, V351, P470, DOI 10.1016/j.jmb.2005.06.019; Meskauskas A, 2001, RNA, V7, P1084, DOI 10.1017/S1355838201001480; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Najafabadi HS, 2007, GENE, V387, P150, DOI 10.1016/j.gene.2006.09.004; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; OLAREWAJU O, 2004, RNA BIOL, V1, P12; Percudani R, 1997, J MOL BIOL, V268, P322, DOI 10.1006/jmbi.1997.0942; PLEWNIAK F, 2007, GCG DOCUMENTATION; Rakwalska M, 2004, MOL CELL BIOL, V24, P9186, DOI 10.1128/MCB.24.20.9186-9197.2004; Rodnina MV, 2005, FEBS LETT, V579, P938, DOI 10.1016/j.febslet.2004.11.048; Salas-Marco J, 2005, J MOL BIOL, V348, P801, DOI 10.1016/j.jmb.2005.03.025; Sanbonmatsu KY, 2006, BIOCHIMIE, V88, P1075, DOI 10.1016/j.biochi.2006.07.002; Sanbonmatsu KY, 2006, BIOCHIMIE, V88, P1053, DOI 10.1016/j.biochi.2006.06.012; Sanbonmatsu KY, 2003, J MOL BIOL, V328, P33, DOI 10.1016/S0022-2836(03)00236-5; SANDBAKEN MG, 1988, GENETICS, V120, P923; Stansfield I, 1998, J MOL BIOL, V282, P13, DOI 10.1006/jmbi.1998.1976; Stoletzki N, 2007, MOL BIOL EVOL, V24, P374, DOI 10.1093/molbev/msl166; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998	53	41	41	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e517	10.1371/journal.pone.0000517	http://dx.doi.org/10.1371/journal.pone.0000517			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565370	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451600005
J	Yokoyama, S; Chen, CJ; Nguyen, T; Shively, JE				Yokoyama, S.; Chen, C-J; Nguyen, T.; Shively, J. E.			Role of CEACAM1 isoforms in an in vivo model of mammary morphogenesis: mutational analysis of the cytoplasmic domain of CEACAM1-4S reveals key residues involved in lumen formation	ONCOGENE			English	Article						CEACAM1-4S; phosphorylation; breast cancer; lumen formation; myofibroblast	CELL-ADHESION MOLECULE; BILIARY GLYCOPROTEIN CD66A; BREAST-CANCER CELLS; CARCINOEMBRYONIC ANTIGEN; EXPRESSION; GROWTH; SUPPRESSION; APOPTOSIS; FAMILY; GENE	CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1) is a type I transmembrane glycoprotein expressed in epithelial cells with three or four extracellular domains (ECDs) and either long or short cytoplasmic domain isoforms. We have previously shown that the four extracellular domains, short cytoplasmic domain isoform, CEACAM1-4S, plays an essential role in lumen formation in an in vitro model of mammary morphogenesis. In this study, we transfected MCF-7 cells with either the long or short cytoplasmic domain isoforms of CEACAM1, and grew the cells in humanized mammary mouse fat pads in NOD/SCID mice. In this in vivo model, only the long cytoplasmic domain isoform, CEACAM1-4L, formed glands with lumen. On the basis of other studies that revealed phosphorylation of key Thr and Ser residues in the short cytoplasmic domain, we introduced phosphorylation mimic ( for example, Thr or Ser to Asp) or null ( Thr or Ser to Ala) mutations into the cytoplasmic domain of CEACAM1-4S and tested them in the in vivo model. Mutation of either Thr or Ser to Asp or the double mutant Thr+Ser to Asp, but not the null mutants, induced gland formation with a central lumen-containing apoptotic cells. Moreover, the phosphorylation mimic mutants of CEACAM1-4S induced downregulation of beta 1-integrin, overexpression of beta 2-integrin, inhibited phosphorylation of focal adhesion kinase (pTyr-397) and resulted in myo.broblast differentiation as characterized by expression of vimentin, a-smooth muscle actin and beta 2-integrin, as well as the production of abundant extracellular matrix.	[Yokoyama, S.; Chen, C-J; Nguyen, T.; Shively, J. E.] City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Shively, JE (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, H138,Hilton Bldg,1500 E Duarte Rd, Duarte, CA 91010 USA.	jshively@coh.org						BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BRUMMER J, 1995, ONCOGENE, V11, P1649; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Chen CJ, 2007, J BIOL CHEM, V282, P5749, DOI 10.1074/jbc.M610903200; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Greenberg RS, 2006, FASEB J, V20, P1006, DOI 10.1096/fj.05-4838fje; Huang J, 1998, ANTICANCER RES, V18, P3203; Huang J, 1999, J CELL SCI, V112, P4193; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Kirshner J, 2003, J BIOL CHEM, V278, P50338, DOI 10.1074/jbc.M309115200; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Klein H, 1995, Violence Against Women, V1, P55, DOI 10.1177/1077801295001001004; Kleinerman DI, 1996, CANCER RES, V56, P3431; Kunath T, 1995, ONCOGENE, V11, P2375; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Laurie NA, 2005, CANCER RES, V65, P11010, DOI 10.1158/0008-5472.CAN-04-2841; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, CANCER RES, V57, P2354; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Peters KS, 2005, J PHYS ORG CHEM, V18, P1, DOI 10.1002/poc.849; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Schumann D, 2001, J BIOL CHEM, V276, P47421, DOI 10.1074/jbc.M109110200; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; SVENBERG T, 1979, CLIN EXP IMMUNOL, V36, P436; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; WAGENER C, 1983, J IMMUNOL, V130, P2302	35	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7637	7646		10.1038/sj.onc.1210577	http://dx.doi.org/10.1038/sj.onc.1210577			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17546042				2022-12-25	WOS:000251537800005
J	Satoh, K; Hovey, RC; Malewski, T; Warri, A; Goldhar, AS; Ginsburg, E; Saito, K; Lydon, JP; Vonderhaar, BK				Satoh, K.; Hovey, R. C.; Malewski, T.; Warri, A.; Goldhar, A. S.; Ginsburg, E.; Saito, K.; Lydon, J. P.; Vonderhaar, B. K.			Progesterone enhances branching morphogenesis in the mouse mammary gland by increased expression of Msx2	ONCOGENE			English	Article						progesterone; mammary gland; msx2; homeo-box genes; branching morphogenesis	EPITHELIAL-CELL PROLIFERATION; HEPATOCYTE GROWTH-FACTOR; SERUM-FREE CULTURE; HOMEOBOX GENES; BREAST-CANCER; RECEPTOR-B; IN-VITRO; HORMONE; MICE; PROLACTIN	Branching morphogenesis within the peripubertal mouse mammary gland is directed by progesterone (P). A role for the homeobox-containing transcription factor, Msx2, during branching morphogenesis is suggested from its ontogenic expression pro. le and hormonal regulation. Herein, we de. ne the spatio-temporal control of Msx2 expression, the regulation of its expression by P and its direct role in ductal branching morphogenesis. P induces Msx2 in the presence of estrogen (E) both in vitro and in vivo while absence of the P receptor (PR) decreased Msx2 expression. Stable transfection of PR into mouse mammary epithelial cells increased the endogenous expression of Msx2 and their ability to undergo branching morphogenesis in vitro. Furthermore, normal mammary cells stably-transfected with Msx2 demonstrated increased branching morphogenesis in vitro while transgenic mice expressing Msx2 in their mammary glands demonstrated enhanced lateral branching during early development. The action of P on branching morphogenesis appears to involve Bmp2/4. Together, these data demonstrate that P, acting through PR-A and the Bmp2/4 pathway, induces Msx2 to enhance ductal branching in the mammary glands.	Natl Canc Inst, Ctr Canc Res, Mammary Biol & Tumorigenesis Lab, Bethesda, MD USA; Baylor Coll Med, Dept Cell Biol, Houston, TX USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine	Vonderhaar, BK (corresponding author), NIH, Mol & Cellular Endocrinol Sect, Mammary Biol & Tumorigenesis Lab, Bldg 37 Room 1106a1,37 Convent Dr, Bethesda, MD 20892 USA.	bv10w@nih.gov	Malewski, Tadeusz/J-4930-2015; Malewski, Tadeusz/N-6883-2019; Malewski, Tadeusz/H-2915-2012	Malewski, Tadeusz/0000-0001-8061-435X; Malewski, Tadeusz/0000-0001-8061-435X; Warri, Anni/0000-0002-0535-847X	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC008226, Z01BC008226] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Alappat S, 2003, CELL RES, V13, P429, DOI 10.1038/sj.cr.7290185; Atwood CS, 2000, J ENDOCRINOL, V167, P39, DOI 10.1677/joe.0.1670039; Aupperlee MD, 2005, ENDOCRINOLOGY, V146, P3577, DOI 10.1210/en.2005-0346; Bamberger AM, 1996, P NATL ACAD SCI USA, V93, P6169, DOI 10.1073/pnas.93.12.6169; Brisken C, 2000, GENE DEV, V14, P650; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Daniel CW, 1999, J MAMMARY GLAND BIOL, V4, P3, DOI 10.1023/A:1018796301609; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; Fernandez-Valdivia R, 2005, SEMIN REPROD MED, V23, P22, DOI 10.1055/s-2005-864031; Friedmann Y, 1996, DEV BIOL, V177, P347, DOI 10.1006/dbio.1996.0168; Gupta IR, 2000, J CELL SCI, V113, P269; HASLAM SZ, 1988, J STEROID BIOCHEM, V31, P9, DOI 10.1016/0022-4731(88)90199-9; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; Kelly PA, 2002, MOL CELL ENDOCRINOL, V197, P127, DOI 10.1016/S0303-7207(02)00286-1; Lanari C, 2001, CANCER RES, V61, P293; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; Lydon JP, 1996, J STEROID BIOCHEM, V56, P67, DOI 10.1016/0960-0760(95)00254-5; Malewski T, 2005, CANCER INVEST, V23, P222, DOI 10.1081/CNV-200055958; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Ruan WF, 2005, ENDOCRINOLOGY, V146, P1170, DOI 10.1210/en.2004-1360; Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Sunil N, 2002, ENDOCRINOLOGY, V143, P2953, DOI 10.1210/en.143.8.2953; Wang WD, 1996, MECH DEVELOP, V58, P203, DOI 10.1016/S0925-4773(96)00562-X; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Zhang HZ, 2002, ENDOCRINOLOGY, V143, P3427, DOI 10.1210/en.2002-220007	38	28	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7526	7534		10.1038/sj.onc.1210555	http://dx.doi.org/10.1038/sj.onc.1210555			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546050				2022-12-25	WOS:000251282100004
J	Le Bras, A; Lionneton, F; Mattot, V; Lelievre, E; Caetano, B; Spruyt, N; Soncin, F				Le Bras, A.; Lionneton, F.; Mattot, V.; Lelievre, E.; Caetano, B.; Spruyt, N.; Soncin, F.			HIF-2 alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites	ONCOGENE			English	Article						angiogenesis; endothelium; gene transcription	VASCULAR-ENDOTHELIAL-CADHERIN; PAS DOMAIN PROTEIN-1; INDUCIBLE FACTOR-I; TRANSCRIPTION FACTOR; EMBRYONIC-DEVELOPMENT; GENE-TRANSCRIPTION; TUMOR-GROWTH; HIF-ALPHA; EXPRESSION; FACTOR-1-ALPHA	The mechanisms that are responsible for the restricted pattern of express ion of the VE-cadherin gene in endothelial cells are not clearly understood. Regulation of express ion is under the control of an approximately 140 bp proximal promoter that provides basal, non-endothelial specific expression. A larger region contained within the 2.5 kb genomic DNA sequence located ahead of the transcription start is involved in the specific expression of the gene in endothelial cells. We show here that the VE-cadherin promoter contains several putative hypoxia response elements (HRE) which are able to bind endothelial nuclear factors under normoxia. The VE-cadherin gene is not responsive to hypoxia but hypoxia-inducible factor (HIF)-2 alpha specifically activates the promoter while HIF-1 alpha does not. The HRE, that are involved in this activity have been identified. Further, we show that HIF2 alpha cooperates with the Ets-1 transcription factor for activation of the VE-cadherin promoter and that this synergy is dependent on the binding of Ets-1 to DNA. This cooperative action of HIF-2 a with Ets-1 most probably participates to the transcriptional regulation of express ion of the gene in endothelial cells. This mechanism may also be involved in the expression of the VE-cadherin gene by tumor cells in the process of vascular mimicry.	CNRS, UMR 8161, Lille, France; Univ Lille 1, Lille, France; Univ Lille 2, Lille, France; Inst Pasteur, Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Soncin, F (corresponding author), CNRS, Inst Biol Lille, UMR 8161, 1 Rue Calmette, BP 447, F-59021 Lille, France.	fabrice.soncin@ibl.fr	SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673; Lelievre, Etienne/0000-0003-0452-1578; Le Bras, Alexandra/0000-0001-7898-4618				Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008-5472.CAN-04-3246; Duan LJ, 2005, CIRCULATION, V111, P2227, DOI 10.1161/01.CIR.0000163580.98098.A3; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Hegen A, 2004, ARTERIOSCL THROM VAS, V24, P1803, DOI 10.1161/01.ATV.0000140819.81839.0e; Hisatsune H, 2005, BLOOD, V105, P4657, DOI 10.1182/blood-2004-09-3554; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Iurlaro M, 2004, AM J PATHOL, V165, P181, DOI 10.1016/S0002-9440(10)63287-7; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lelievre E, 2002, J BIOL CHEM, V277, P25143, DOI 10.1074/jbc.M201628200; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Lionneton F, 2003, ONCOGENE, V22, P9156, DOI 10.1038/sj.onc.1207241; Lofstedt T, 2007, CELL CYCLE, V6, P919, DOI 10.4161/cc.6.8.4133; May C, 2005, BLOOD, V105, P4337, DOI 10.1182/blood-2005-01-0010; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Sambrook J., 2002, MOL CLONING LAB MANU; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHWEIKI D, 1992, NATURE, V359, P845; Soncin F, 2003, EMBO J, V22, P5700, DOI 10.1093/emboj/cdg549; Sowter HM, 2003, CANCER RES, V63, P6130; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Teruyama K, 2001, FEBS LETT, V504, P1, DOI 10.1016/S0014-5793(01)02724-7; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	62	60	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7480	7489		10.1038/sj.onc.1210566	http://dx.doi.org/10.1038/sj.onc.1210566			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17563748				2022-12-25	WOS:000251282000009
J	Scheele, C; Nielsen, AR; Walden, TB; Sewell, DA; Fischer, CP; Brogan, RJ; Petrovic, N; Larsson, O; Tesch, PA; Wennmalm, K; Hutchinson, DS; Cannon, B; Wahlestedt, C; Pedersen, BK; Timmons, JA				Scheele, Camilla; Nielsen, Anders Rinnov; Walden, Tomas B.; Sewell, Dean A.; Fischer, Christian P.; Brogan, Robert J.; Petrovic, Natasa; Larsson, Ola; Tesch, Per A.; Wennmalm, Kristian; Hutchinson, Dana S.; Cannon, Barbara; Wahlestedt, Claes; Pedersen, Bente K.; Timmons, James A.			Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration?	FASEB JOURNAL			English	Article						metabolism; inactivity; mitochondria; alteredgene regulation	GLYCATION END-PRODUCTS; SKELETAL-MUSCLE MASS; GENE-EXPRESSION; ADIPOSE-TISSUE; MITOCHONDRIAL DYSFUNCTION; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; IN-VIVO; DISEASE; RECEPTOR	Mutations in PINK1 cause the mitochondrial-related neurodegenerative disease Parkinson's. Here we investigate whether obesity, type 2 diabetes, or inactivity alters transcription from the PINK1 locus. We utilized a cDNA-array and quantitative real-time PCR for gene expression analysis of muscle from healthy volunteers following physical inactivity, and muscle and adipose tissue from nonobese or obese subjects with normal glucose tolerance or type 2 diabetes. Functional studies of PINK1 were performed utilizing RNA interference in cell culture models. Following inactivity, the PINK1 locus had an opposing regulation pattern ( PINK1 was down-regulated while natural antisense PINK1 was up-regulated). In type 2 diabetes skeletal muscle, all transcripts from the PINK1 locus were suppressed and gene expression correlated with diabetes status. RNA interference of PINK1 in human neuronal cell lines impaired basal glucose uptake. In adipose tissue, mitochondrial gene expression correlated with PINK1 expression although remained unaltered following siRNA knockdown of Pink1 in primary cultures of brown preadipocytes. In conclusion, regulation of the PINK1 locus, previously linked to neurodegenerative disease, is altered in obesity, type 2 diabetes and inactivity, while the combination of RNAi experiments and clinical data suggests a role for PINK1 in cell energetics rather than in mitochondrial biogenesis.	Karolinska Inst, Ctr Genom & Bioinformat, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Univ Copenhagen, Rigshosp, Ctr Inflammat & Metab, DK-2100 Copenhagen, Denmark; Univ Stockholm, Wenner Gren Inst, Arrhenius Labs, S-11345 Stockholm, Sweden; Heriot Watt Univ, Sch Life Sci, Edinburgh, Midlothian, Scotland; Monash Univ, Dept Pharmacol, Clayton, Vic 3168, Australia; Scripps Res Inst, Dept Biochem, Jupiter, FL USA	Karolinska Institutet; Rigshospitalet; University of Copenhagen; Stockholm University; Heriot Watt University; Monash University; Scripps Research Institute	Timmons, JA (corresponding author), Karolinska Inst, Ctr Genom & Bioinformat, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden.	j.timmons@hw.ac.uk	Larsson, Ola/F-8151-2013; Timmons, James A/J-4698-2014; Scheele, Camilla/AAA-3599-2020; Wahlestedt, Claes/A-7039-2009; Pedersen, Bente Klarlund/AGR-3217-2022; Sewell, Dean A./C-3500-2009; Hutchinson, Dana/K-3795-2012; Timmons, James A/M-6350-2019; Cannon, Barbara/B-3089-2016	Timmons, James A/0000-0002-2255-1220; Scheele, Camilla/0000-0002-6055-9709; Pedersen, Bente Klarlund/0000-0001-6508-6288; Timmons, James A/0000-0002-2255-1220; Rinnov, Anders Rasmussen/0000-0003-3859-3289; Cannon, Barbara/0000-0001-6594-2363; Fischer, Christian/0000-0002-0657-9143; Hutchinson, Dana/0000-0001-9947-0106; Larsson, Ola/0000-0003-1412-1308				Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868; Asmann YW, 2006, DIABETES, V55, P3309, DOI 10.2337/db05-1230; Astrand PO, 2003, TXB WORK PHYSL PHYSL, V4th; Basta G, 2004, CARDIOVASC RES, V63, P582, DOI 10.1016/j.cardiores.2004.05.001; Beilina A, 2005, P NATL ACAD SCI USA, V102, P5703, DOI 10.1073/pnas.0500617102; BERG HE, 1993, CLIN PHYSIOL, V13, P337, DOI 10.1111/j.1475-097X.1993.tb00334.x; BERG HE, 1991, J APPL PHYSIOL, V70, P1882, DOI 10.1152/jappl.1991.70.4.1882; BERGSTROM J, 1966, SCAND J CLIN LAB INV, V18, P16, DOI 10.3109/00365516609065602; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Carey AL, 2006, DIABETOLOGIA, V49, P1000, DOI 10.1007/s00125-006-0178-7; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; FISCHER CP, 2006, SCAND J MED SCI SPOR, DOI DOI 10.1111/J.1066-0830.2006.00602.X; Gallagher D, 1997, J APPL PHYSIOL, V83, P229, DOI 10.1152/jappl.1997.83.1.229; Gandhi S, 2006, BRAIN, V129, P1720, DOI 10.1093/brain/awl114; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gesta S, 2006, P NATL ACAD SCI USA, V103, P6676, DOI 10.1073/pnas.0601752103; Gill JMR, 2006, CLIN SCI, V110, P409, DOI 10.1042/CS20050207; Haddad F, 2005, J APPL PHYSIOL, V98, P46, DOI 10.1152/japplphysiol.00553.2004; Hammarstedt A, 2003, BIOCHEM BIOPH RES CO, V301, P578, DOI 10.1016/S0006-291X(03)00014-7; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Harris TB, 2000, ANN NY ACAD SCI, V904, P462; Heilbronn LK, 2003, CURR PHARM DESIGN, V9, P1411, DOI 10.2174/1381612033454766; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Howell SJ, 2000, CLIN ENDOCRINOL, V52, P609, DOI 10.1046/j.1365-2265.2000.00997.x; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Kemmer D, 2004, COMP FUNCT GENOM, V5, P584, DOI 10.1002/cfg.443; Kuroda Y, 2006, HUM MOL GENET, V15, P883, DOI 10.1093/hmg/ddl006; Larsson O, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-129; Levy JC, 1998, DIABETES CARE, V21, P2191, DOI 10.2337/diacare.21.12.2191; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lu CY, 2004, P NATL ACAD SCI USA, V101, P11767, DOI 10.1073/pnas.0401588101; Lu Q, 2006, AGEING RES REV, V5, P449, DOI 10.1016/j.arr.2006.07.001; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; NECHAD M, 1987, AM J PHYSIOL, V253, pC889, DOI 10.1152/ajpcell.1987.253.6.C889; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Pedersen M, 2003, MECH AGEING DEV, V124, P495, DOI 10.1016/S0047-6374(03)00027-7; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200; Ristow M, 2004, J MOL MED, V82, P510, DOI 10.1007/s00109-004-0552-1; Rolo AP, 2006, TOXICOL APPL PHARM, V212, P167, DOI 10.1016/j.taap.2006.01.003; SANDRI M, 2006, P NATL ACAD SCI US; Sasaki N, 1998, AM J PATHOL, V153, P1149, DOI 10.1016/S0002-9440(10)65659-3; Scheele C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-74; Semple RK, 2004, INT J OBESITY, V28, P176, DOI 10.1038/sj.ijo.0802482; Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Steensberg A, 2003, J PHYSIOL-LONDON, V548, P631, DOI 10.1113/jphysiol.2002.032938; Stern DM, 2002, AGEING RES REV, V1, P1, DOI 10.1016/S0047-6374(01)00366-9; Tesch PA, 2004, J APPL PHYSIOL, V96, P1451, DOI 10.1152/japplphysiol.01051.2003; Timmons JA, 2006, GENOMICS, V87, P165, DOI 10.1016/j.ygeno.2005.09.007; Timmons JA, 2005, FASEB J, V19, P750, DOI 10.1096/fj.04-1980com; Timmons JA, 2007, P NATL ACAD SCI USA, V104, P4401, DOI 10.1073/pnas.0610615104; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Vlassara H, 2002, J INTERN MED, V251, P87, DOI 10.1046/j.1365-2796.2002.00932.x; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; Wang DF, 2006, P NATL ACAD SCI USA, V103, P13244, DOI 10.1073/pnas.0605551103; World Health Organization, 1999, DEF DIAGN CLASS DI 1; Wren JD, 2005, J BIOMED BIOTECHNOL, P104, DOI 10.1155/JBB.2005.104; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	67	75	81	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3653	3665		10.1096/fj.07-8520com	http://dx.doi.org/10.1096/fj.07-8520com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567565				2022-12-25	WOS:000250517800027
J	Walker, EA; Ahmed, A; Lavery, GG; Tomlinson, JW; Kim, SY; Cooper, MS; Ride, JP; Hughes, BA; Shackleton, CHL; McKiernan, P; Elias, E; Chou, JY; Stewart, PM				Walker, Elizabeth A.; Ahmed, Adeeba; Lavery, Gareth G.; Tomlinson, Jeremy W.; Kim, So Youn; Cooper, Mark S.; Ride, Jonathan P.; Hughes, Beverly A.; Shackleton, Cedric H. L.; McKiernan, Patrick; Elias, Elwyn; Chou, Janice Y.; Stewart, Paul M.			11 beta-hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose 6-phosphate provides evidence for a novel link between glucose metabolism and Hypothalamo-Pituitary-Adrenal axis function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; BONE-MINERAL DENSITY; HEXOSE-6-PHOSPHATE DEHYDROGENASE; ENDOPLASMIC-RETICULUM; SELECTIVE-INHIBITION; PYRIDINE-NUCLEOTIDES; CUSHINGS-DISEASE; CORTISOL; MICE; OBESITY	Microsomal glucose-6-phosphatase-alpha (G6Pase-alpha) and glucose 6-phosphate transporter (G6PT) work together to increase blood glucose concentrations by performing the terminal step in both glycogenolysis and gluconeogenesis. Deficiency of the G6PT in liver gives rise to glycogen storage disease type 1b (GSD1b), whereas deficiency of G6Pase-alpha leads to GSD1a. G6Pase-alpha shares its substrate (glucose 6-phosphate; G6P) with hexose-6-phosphate-dehydrogenase (H6PDH), a microsomal enzyme that regenerates NADPH within the endoplasmic reticulum lumen, thereby conferring reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). 11 beta-HSD1 interconverts hormonally active C11 beta-hydroxy steroids (cortisol in humans and corticosterone in rodents) to inactive C11-oxo steroids (cortisone and 11-dehydrocorticosterone, respectively). In vivo reductase activity predominates, generating active glucocorticoid. We hypothesized that substrate (G6P) availability to H6PDH in patients with GSD1b and GSD1a will decrease or increase 11 beta-HSD1 reductase activity, respectively. We investigated 11 beta-HSD1 activity in GSD1b and GSD1a mice and in two patients with GSD1b and five patients diagnosed with GSD1a. We confirmed our hypothesis by assessing 11 beta-HSD1 in vivo and in vitro, revealing a significant decrease in reductase activity in GSD1b animals and patients, whereas GSD1a patients showed a marked increase in activity. The cellular trafficking of G6P therefore directly regulates 11 beta-HSD1 reductase activity and provides a novel link between glucose metabolism and function of the hypothalamo-pituitary-adrenal axis.	Univ Birmingham, Div Med Sci & Biol Sci, Birmingham B15 2TH, W Midlands, England; NIH, NICHD, Bethesda, MD 20892 USA; Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England; Queen Elizabeth Hosp, Liver & Hepatobiliary Unit, Birmingham B15 2TH, W Midlands, England	University of Birmingham; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Birmingham; University of Birmingham	Stewart, PM (corresponding author), Univ Birmingham, Div Med Sci & Biol Sci, Birmingham B15 2TH, W Midlands, England.	p.m.stewart@bham.ac.uk	Lavery, Gareth/F-9346-2010; Cooper, Mark S/C-9529-2012	Tomlinson, Jeremy/0000-0002-3170-8533; Cooper, Mark/0000-0003-3112-7728	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER; Medical Research Council [G0100729, G84/6638] Funding Source: Medline; NICHD NIH HHS [1Z01 HD 000912-27] Funding Source: Medline; Wellcome Trust [074088] Funding Source: Medline; MRC [G0100729] Funding Source: UKRI	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Atanasov AG, 2004, FEBS LETT, V571, P129, DOI 10.1016/j.febslet.2004.06.065; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Banhegyi G, 2004, J BIOL CHEM, V279, P27017, DOI 10.1074/jbc.M404159200; Basu R, 2006, DIABETES, V55, P667, DOI 10.2337/diabetes.55.03.06.db05-1335; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; BRANDENBERGER G, 1982, J CLIN ENDOCR METAB, V54, P592, DOI 10.1210/jcem-54-3-592; Bujalska IJ, 2005, J MOL ENDOCRINOL, V34, P675, DOI 10.1677/jme.1.01718; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Cabrera-Abreu J, 2004, J INHERIT METAB DIS, V27, P1, DOI 10.1023/B:BOLI.0000016632.13234.56; Chen LY, 2003, HUM MOL GENET, V12, P2547, DOI 10.1093/hmg/ddg263; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; Clarke JL, 2003, ARCH BIOCHEM BIOPHYS, V415, P229, DOI 10.1016/S0003-9861(03)00229-7; Czegle I, 2006, MOL CELL ENDOCRINOL, V248, P24, DOI 10.1016/j.mce.2005.10.018; Ferguson SE, 1999, MOL CELL ENDOCRINOL, V158, P37, DOI 10.1016/S0303-7207(99)00186-0; FOLLENIUS M, 1982, J CLIN ENDOCR METAB, V55, P757, DOI 10.1210/jcem-55-4-757; Garty BZ, 1996, ISRAEL J MED SCI, V32, P1276; GITZELMANN R, 1993, EUR J PEDIATR, V152, P33; Hewitt KN, 2005, ENDOCRINOLOGY, V146, P2539, DOI 10.1210/en.2005-0117; KNOLL E, 1984, J CLIN CHEM CLIN BIO, V22, P597; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Krebs M, 2001, J CLIN ENDOCR METAB, V86, P2153, DOI 10.1210/jc.86.5.2153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; Lavery GG, 2006, J BIOL CHEM, V281, P6546, DOI 10.1074/jbc.M512635200; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Mason PJ, 1999, BLOOD CELL MOL DIS, V25, P30, DOI 10.1006/bcmd.1999.0224; McCormick KL, 2006, J BIOL CHEM, V281, P341, DOI 10.1074/jbc.M506026200; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; Palermo M, 1996, CLIN ENDOCRINOL, V45, P605, DOI 10.1046/j.1365-2265.1996.00853.x; Paterson JM, 2004, P NATL ACAD SCI USA, V101, P7088, DOI 10.1073/pnas.0305524101; Piccirella S, 2006, J BIOL CHEM, V281, P4671, DOI 10.1074/jbc.M509406200; Rake JP, 2003, J INHERIT METAB DIS, V26, P371, DOI 10.1023/A:1025111220095; Ricketts ML, 1998, J CLIN ENDOCR METAB, V83, P1325, DOI 10.1210/jc.83.4.1325; SHACKLETON C H L, 1990, P297; SHACKLETON CHL, 1993, J STEROID BIOCHEM, V45, P127, DOI 10.1016/0960-0760(93)90132-G; Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200; Stewart PM, 1999, J CLIN ENDOCR METAB, V84, P1022, DOI 10.1210/jc.84.3.1022; Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003-0031; Tomlinson JW, 2005, NAT CLIN PRACT ENDOC, V1, P92, DOI 10.1038/ncpendmet0023; Tomlinson JW, 2004, J CLIN ENDOCR METAB, V89, P2711, DOI 10.1210/jc.2003-031376; Tomlinson JW, 2002, J CLIN ENDOCR METAB, V87, P57, DOI 10.1210/jc.87.1.57; Valsamakis G, 2004, J CLIN ENDOCR METAB, V89, P4755, DOI 10.1210/jc.2003-032240; van de Werve G, 2000, EUR J BIOCHEM, V267, P1533, DOI 10.1046/j.1432-1327.2000.01160.x; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; Visser G, 2002, EUR J PEDIATR, V161, pS83, DOI 10.1007/s00431-002-1010-0; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200	48	47	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27030	27036		10.1074/jbc.M704144200	http://dx.doi.org/10.1074/jbc.M704144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17588937	hybrid			2022-12-25	WOS:000249304900044
J	Fulzele, K; DiGirolamo, DJ; Liu, Z; Xu, J; Messina, JL; Clemens, TL				Fulzele, Keertik; DiGirolamo, Douglas J.; Liu, Zhongyu; Xu, Jie; Messina, Joseph L.; Clemens, Thomas L.			Disruption of the insulin-like growth factor type 1 receptor in Osteoblasts enhances insulin signaling and action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; ALKALINE-PHOSPHATASE ACTIVITY; IGF-I; COLLAGEN-SYNTHESIS; DIABETES-MELLITUS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; TYROSINE KINASE; BONE-FORMATION; MESSENGER-RNA	Defective bone formation is common in patients with diabetes, suggesting that insulin normally exerts anabolic actions in bone. However, because insulin can cross-activate the insulinlike growth factor type 1 receptor ( IGF-1R), which also functions in bone, it has been difficult to establish the direct ( IGF-1independent) actions of insulin in osteoblasts. To overcome this problem, we examined insulin signaling and action in primary osteoblasts engineered for conditional disruption of the IGF-1 receptor ( Delta IGF-1R). Calvarial osteoblasts from mice carrying floxed IGF-1R alleles were infected with adenoviral vectors expressing the Cre recombinase (Ad-Cre) or green fluorescent protein (Ad-GFP) as control. Disruption of IGF-1RmRNA(> 90%) eliminated IGF-1R without affecting insulin receptor (IR) mRNA and protein expression and eliminated IGF-1R/IR hybrids. In Delta IGF-1R osteoblasts, insulin signaling was markedly increased as evidenced by increased phosphorylation of insulin receptor substrate 1/2 and enhanced ERK/Akt activation. Microarray analysis of RNA samples from insulin-treated, Delta IGF-1R osteoblasts revealed striking changes in several genes known to be downstream of ERK including Glut-1 and c-fos. Treatment of osteoblasts with insulin induced Glut-1 mRNA, increased 2-[ 1,2- H-3]-deoxy- D-glucose uptake, and enhanced proliferation. Moreover, insulin treatment rescued the defective differentiation and mineralization of Delta IGF-1R osteoblasts, suggesting that IR signaling can compensate, at least in part, for loss of IGF-1R signaling. We conclude that insulin exerts direct anabolic actions in osteoblasts by activation of its cognate receptor and that the strength of insulin-generated signals is tempered through interactions with the IGF-1R.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Clemens, TL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, 1670 Univ Blvd,VH G001, Birmingham, AL 35294 USA.	tclemens@path.uab.edu						Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; CANALIS E, 1983, METABOLISM, V32, P14, DOI 10.1016/0026-0495(83)90149-X; Ceddia RB, 2003, FEBS LETT, V555, P307, DOI 10.1016/S0014-5793(03)01261-4; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Denley A, 2006, ENDOCRINOLOGY, V147, P1029, DOI 10.1210/en.2005-0736; DIGIROLAMO DJ, 2005, 27 ANN M AM SOC BON; Entingh-Pearsall A, 2004, J BIOL CHEM, V279, P38016, DOI 10.1074/jbc.M313201200; Fatrai S, 2006, DIABETES, V55, P318, DOI 10.2337/diabetes.55.02.06.db05-0757; Gandhi A, 2005, BONE, V37, P482, DOI 10.1016/j.bone.2005.04.039; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; HAHN TJ, 1988, J BONE MINER RES, V3, P359; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Irwin R, 2006, ENDOCRINOLOGY, V147, P5760, DOI 10.1210/en.2006-0700; ITUARTE EA, 1989, CALCIFIED TISSUE INT, V45, P27, DOI 10.1007/BF02556657; Kaburagi Y, 2004, ENDOCRINOLOGY, V145, P5862, DOI 10.1210/en.2004-0199; Kemink SAG, 2000, J ENDOCRINOL INVEST, V23, P295, DOI 10.1007/BF03343726; Kim JJ, 2002, GROWTH HORM IGF RES, V12, P84, DOI 10.1054/ghir.2002.0265; Kitamura T, 2004, J CLIN INVEST, V113, P209, DOI 10.1172/JCI200417810; KREAM BE, 1985, ENDOCRINOLOGY, V116, P296, DOI 10.1210/endo-116-1-296; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEVY JR, 1986, ENDOCRINOLOGY, V119, P1786, DOI 10.1210/endo-119-4-1786; LODER RT, 1988, CLIN ORTHOP RELAT R, P210; Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002-220072; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MESSINA JL, 1999, HORMONAL CONTROL GRO, V5, P783; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; Mur C, 2002, DIABETES, V51, P743, DOI 10.2337/diabetes.51.3.743; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; PUN KK, 1989, J BONE MINER RES, V4, P853; ROSEN DM, 1983, ENDOCRINOLOGY, V112, P992, DOI 10.1210/endo-112-3-992; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; Taha C, 1999, J BIOL CHEM, V274, P33085, DOI 10.1074/jbc.274.46.33085; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Thomas DM, 1996, J BONE MINER RES, V11, P1312; Thrailkill KM, 2005, DIABETES, V54, P2875, DOI 10.2337/diabetes.54.10.2875; Thrailkill KM, 2005, AM J PHYSIOL-ENDOC M, V289, pE735, DOI 10.1152/ajpendo.00159.2005; TREADWAY JL, 1992, BIOCHEMISTRY-US, V31, P11801, DOI 10.1021/bi00162a018; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; VERHAEGHE J, 1990, DIABETES, V39, P477, DOI 10.2337/diabetes.39.4.477; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200; Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674; Zhou SH, 2004, J BONE MINER RES, V19, P1732, DOI 10.1359/JBMR.040702	53	107	108	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25649	25658		10.1074/jbc.M700651200	http://dx.doi.org/10.1074/jbc.M700651200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17553792	hybrid			2022-12-25	WOS:000249014100052
J	Hou, L; Honaker, MT; Shireman, LM; Balogh, LM; Roberts, AG; Ng, KC; Nath, A; Atkins, WM				Hou, Liming; Honaker, Matthew T.; Shireman, Laura M.; Balogh, Larissa M.; Roberts, Arthur G.; Ng, Kei-Cheuk; Nath, Abhinav; Atkins, William M.			Functional promiscuity correlates with conformational heterogeneity in A-class glutathione S-transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH CATALYTIC EFFICIENCY; FLUORESCENCE LIFETIME DISTRIBUTIONS; O-SUCCINYLBENZOATE SYNTHASE; EXCHANGE MASS-SPECTROMETRY; C-TERMINAL REGION; LIPID-PEROXIDATION; PROTEIN DYNAMICS; ENOLASE SUPERFAMILY; ENZYMATIC-ACTIVITY; HYDROGEN-EXCHANGE	The structurally related glutathione S-transferase isoforms GSTA1-1 and GSTA4-4 differ greatly in their relative catalytic promiscuity. GSTA1-1 is a highly promiscuous detoxification enzyme. In contrast, GSTA4-4 exhibits selectivity for congeners of the lipid peroxidation product 4-hydroxynonenal. The contribution of protein dynamics to promiscuity has not been studied. Therefore, hydrogen/deuterium exchange mass spectrometry ( H/DX) and fluorescence lifetime distribution analysis were performed with glutathione S-transferases A1-1 and A4-4. Differences in local dynamics of the C-terminal helix were evident as expected on the basis of previous studies. However, H/DX demonstrated significantly greater solvent accessibility throughout most of the GSTA1-1 sequence compared with GSTA4-4. APhe-111/Tyr-217 aromatic-aromatic interaction in A4-4, which is not present in A1-1, was hypothesized to increase core packing. "Swap" mutants that eliminate this interaction from A4-4 or incorporate it into A1-1 yield H/DX behavior that is intermediate between the wild type templates. In addition, the single Trp-21 residue of each isoform was exploited to probe the conformational heterogeneity at the intrasubunit domain-domain interface. Excited state fluorescence lifetime distribution analysis indicates that this core residue is more conformationally heterogeneous in GSTA1-1 than in GSTA4-4, and this correlates with greater stability toward urea denaturation for GSTA4-4. The fluorescence distribution and urea sensitivity of the mutant proteins were intermediate between the wild type templates. The results suggest that the differences in protein dynamics of these homologs are global. The results suggest also the possible importance of extensive conformational plasticity to achieve high levels of functional promiscuity, possibly at the cost of stability.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hou, L (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.	winky@u.washington.edu		Nath, Abhinav/0000-0002-2895-2973	NIGMS NIH HHS [T332 GM07750] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adman ET, 2001, PROTEINS, V42, P192, DOI 10.1002/1097-0134(20010201)42:2<192::AID-PROT60>3.0.CO;2-#; ALCALA JR, 1987, BIOPHYS J, V51, P925, DOI 10.1016/S0006-3495(87)83420-3; ALCALA JR, 1987, BIOPHYS J, V51, P597, DOI 10.1016/S0006-3495(87)83384-2; ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; Atkins WM, 1997, PROTEIN SCI, V6, P873; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; Bornscheuer UT, 2004, ANGEW CHEM INT EDIT, V43, P6032, DOI 10.1002/anie.200460416; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; Bull AW, 2002, BBA-GEN SUBJECTS, V1571, P77, DOI 10.1016/S0304-4165(02)00216-7; Busenlehner LS, 2005, ARCH BIOCHEM BIOPHYS, V433, P34, DOI 10.1016/j.abb.2004.09.002; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; Codreanu SG, 2005, BIOCHEMISTRY-US, V44, P10605, DOI 10.1021/bi050836k; Codreanu SG, 2002, BIOCHEMISTRY-US, V41, P15161, DOI 10.1021/bi026776p; Coles BF, 2005, METHOD ENZYMOL, V401, P9, DOI 10.1016/S0076-6879(05)01002-5; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Dimitrov JD, 2007, MOL IMMUNOL, V44, P1854, DOI 10.1016/j.molimm.2006.10.002; Dreij K, 2002, CHEM RES TOXICOL, V15, P825, DOI 10.1021/tx025519i; Ekroos M, 2006, P NATL ACAD SCI USA, V103, P13682, DOI 10.1073/pnas.0603236103; ERHARDT J, 1995, EUR J BIOCHEM, V230, P614; Eyles SJ, 2004, METHODS, V34, P88, DOI 10.1016/j.ymeth.2004.03.015; Fong DH, 2002, EMBO J, V21, P2323, DOI 10.1093/emboj/21.10.2323; Grubor NM, 2005, P NATL ACAD SCI USA, V102, P7453, DOI 10.1073/pnas.0502540102; Gustafsson A, 1999, BIOCHEMISTRY-US, V38, P16268, DOI 10.1021/bi991482y; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; Ibarra C, 2001, BIOCHEMISTRY-US, V40, P10614, DOI 10.1021/bi010672h; James LC, 2001, PROTEIN SCI, V10, P2600, DOI 10.1110/ps.ps.14601; Jimenez R, 2003, P NATL ACAD SCI USA, V100, P92, DOI 10.1073/pnas.262411399; Jimenez R, 2004, P NATL ACAD SCI USA, V101, P3803, DOI 10.1073/pnas.0305745101; Khersonsky O, 2006, CURR OPIN CHEM BIOL, V10, P498, DOI 10.1016/j.cbpa.2006.08.011; LAIBLE PD, 1994, BIOPHYS J, V66, P844, DOI 10.1016/S0006-3495(94)80861-6; Lairson LL, 2006, NAT CHEM BIOL, V2, P724, DOI 10.1038/nchembio828; Lasagna M, 1999, BIOPHYS J, V76, P443, DOI 10.1016/S0006-3495(99)77211-5; Mahajan SS, 2006, J AM CHEM SOC, V128, P8615, DOI 10.1021/ja061766n; Maier CS, 2005, METHOD ENZYMOL, V402, P312, DOI 10.1016/S0076-6879(05)02010-0; Mosebi S, 2003, BIOCHEMISTRY-US, V42, P15326, DOI 10.1021/bi035671z; Nieslanik BS, 1999, BIOCHEMISTRY-US, V38, P6971, DOI 10.1021/bi9829130; Nieslanik BS, 2001, BIOCHEMISTRY-US, V40, P3536, DOI 10.1021/bi001869x; Nilsson LO, 2000, P NATL ACAD SCI USA, V97, P9408, DOI 10.1073/pnas.150084897; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; O'Brien PJ, 2006, CHEM REV, V106, P720, DOI 10.1021/cr040481v; O'Loughlin TL, 2006, PROTEIN ENG DES SEL, V19, P439, DOI 10.1093/protein/gzl029; Pettersson PL, 2001, J BIOL CHEM, V276, P11698, DOI 10.1074/jbc.M009146200; Redinbo MR, 2004, DRUG DISCOV TODAY, V9, P431, DOI 10.1016/S1359-6446(04)03087-9; Ringia EAT, 2004, BIOCHEMISTRY-US, V43, P224, DOI 10.1021/bi035815+; Schmidt DMZ, 2003, BIOCHEMISTRY-US, V42, P8387, DOI 10.1021/bi034769a; Selley ML, 1998, FREE RADICAL BIO MED, V25, P169, DOI 10.1016/S0891-5849(98)00021-5; Sethi DK, 2006, IMMUNITY, V24, P429, DOI 10.1016/j.immuni.2006.02.010; Sharma R, 2004, ANTIOXID REDOX SIGN, V6, P289, DOI 10.1089/152308604322899350; Stella L, 1998, J BIOL CHEM, V273, P23267, DOI 10.1074/jbc.273.36.23267; Thoden JB, 2004, BIOCHEMISTRY-US, V43, P5716, DOI 10.1021/bi0497897; Thompson LC, 2006, BIOCHEMISTRY-US, V45, P2267, DOI 10.1021/bi0519506; Volkel W, 2005, FREE RADICAL BIO MED, V38, P1526, DOI 10.1016/j.freeradbiomed.2005.02.015; Wales TE, 2006, MASS SPECTROM REV, V25, P158, DOI 10.1002/mas.20064; Wallace LA, 1998, BIOCHEMISTRY-US, V37, P5320, DOI 10.1021/bi972936z; Wallace LA, 1999, BIOCHEMISTRY-US, V38, P16686, DOI 10.1021/bi991239z; WANG RW, 1993, PROTEIN SCI, V2, P2085, DOI 10.1002/pro.5560021209; Weis DD, 2006, J AM SOC MASS SPECTR, V17, P1498, DOI 10.1016/j.jasms.2006.05.014; Whitworth AJ, 2005, P NATL ACAD SCI USA, V102, P8024, DOI 10.1073/pnas.0501078102; Yang YZ, 2004, ATHEROSCLEROSIS, V173, P211, DOI 10.1016/j.atherosclerosis.2003.12.023; Zhan YP, 2004, BIOCHEMISTRY-US, V43, P7244, DOI 10.1021/bi0363329; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277; Zimmermann J, 2006, P NATL ACAD SCI USA, V103, P13722, DOI 10.1073/pnas.0603282103	66	51	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23264	23274		10.1074/jbc.M700868200	http://dx.doi.org/10.1074/jbc.M700868200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17561509	hybrid			2022-12-25	WOS:000248577500027
J	Song, H; Belcastro, M; Young, EJ; Sokolov, M				Song, Hongman; Belcastro, Marycharmain; Young, E. J.; Sokolov, Maxim			Compartment-specific phosphorylation of phosducin in rods underlies adaptation to various levels of illumination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DRIVEN TRANSLOCATION; BETA-GAMMA-SUBUNITS; G-PROTEIN; RETINAL RODS; TRANSDUCIN TRANSLOCATION; OUTER SEGMENTS; KINASE-II; BINDING; RHODOPSIN; PHOTORECEPTORS	Phosducin is a major phosphoprotein of rod photoreceptors that interacts with the G beta gamma subunits of heterotrimeric G proteins in its dephosphorylated state. Light promotes dephosphorylation of phosducin; thus, it was proposed that phosducin plays a role in the light adaptation of G protein-mediated visual signaling. Different functions, such as regulation of protein levels and subcellular localization of heterotrimeric G proteins, transcriptional regulation, and modulation of synaptic transmission have also been proposed. Although the molecular basis of phosducin interaction with G proteins is well understood, the physiological significance of light-dependent phosphorylation of phosducin remains largely hypothetical. In this study we quantitatively analyzed light dependence, time course, and subcellular localization of two principal light-regulated phosphorylation sites of phosducin, serine 54 and 71. To obtain physiologically relevant data, our experimental model exploited free-running mice and rats subjected to controlled illumination. We found that in the dark-adapted rods, phosducin phosphorylated at serine 54 is compartmentalized predominantly in the ellipsoid and outer segment compartments. In contrast, phosducin phosphorylated at serine 71 is present in all cellular compartments. The degree of phosducin phosphorylation in the dark appeared to be less than 40%. Dim light within rod operational range triggers massive reversible dephosphorylation of both sites, whereas saturating light dramatically increases phosphorylation of serine 71 in rod outer segment. These results support the role of phosducin in regulating signaling in the rod outer segment compartment and suggest distinct functions for phosphorylation sites 54 and 71.	W Virginia Univ, Inst Eye, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Dept Ophthalmol, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University	Sokolov, M (corresponding author), W Virginia Univ, Inst Eye, 1 Stadium Dr, Morgantown, WV 26506 USA.	sokolovm@rcbhsc.wvu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015574] Funding Source: NIH RePORTER; NCRR NIH HHS [2P20RR15574-06, P20 RR015574] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; Brown BM, 2002, BIOCHEMISTRY-US, V41, P13526, DOI 10.1021/bi0204490; Calvert PD, 2006, TRENDS CELL BIOL, V16, P560, DOI 10.1016/j.tcb.2006.09.001; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; Chen J, 2005, VISUAL NEUROSCI, V22, P19, DOI 10.1017/S0952523805221028; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Hauck SM, 2006, MOL CELL PROTEOMICS, V5, P324, DOI 10.1074/mcp.M500217-MCP200; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; Keller C, 2001, INVEST OPHTH VIS SCI, V42, P476; Kerov V, 2005, J BIOL CHEM, V280, P41069, DOI 10.1074/jbc.M508849200; KUO CH, 1989, NEUROSCI LETT, V103, P8, DOI 10.1016/0304-3940(89)90476-X; Lee BY, 2004, J BIOL CHEM, V279, P54008, DOI 10.1074/jbc.M405669200; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEE RH, 1992, J BIOL CHEM, V267, P25104; Lobanova ES, 2007, J NEUROSCI, V27, P1151, DOI 10.1523/JNEUROSCI.5010-06.2007; Lyubarsky AL, 2004, VISION RES, V44, P3235, DOI 10.1016/j.visres.2004.09.019; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; Nakano K, 2001, P NATL ACAD SCI USA, V98, P4693, DOI 10.1073/pnas.071067198; NAKATANI K, 1991, J GEN PHYSIOL, V97, P413, DOI 10.1085/jgp.97.3.413; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Sokolov M, 2004, J BIOL CHEM, V279, P19149, DOI 10.1074/jbc.M311058200; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; VONSCHANTZ M, 1994, INVEST OPHTH VIS SCI, V35, P3922; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	33	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23613	23621		10.1074/jbc.M701974200	http://dx.doi.org/10.1074/jbc.M701974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17569665	hybrid, Green Published			2022-12-25	WOS:000248577500063
J	Cha, HJ; Wang, XT; Li, HH; Fornace, A				Cha, Hyukjin; Wang, Xuetao; Li, Henghong; Fornace, Albert, Jr.			A functional role for p38 MAPK in modulating mitotic transit in the absence of stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYCLE CHECKPOINT KINASE; CELL-CYCLE; REGULATED KINASE; AURORA-A; PHOSPHORYLATION; MITOSIS; CENTROSOMES; INHIBITION; PATHWAY	Although p38 MAPK is known to be activated in response to various environmental stresses and to have inhibitory roles in cell proliferation and tumor progression, its role in cell cycle progression in the absence of stress is unknown in most cell types. In the case of G(2)/M cell cycle control, p38 activation has been shown to trigger a rapid G(2)/M cell cycle checkpoint after DNA damage stress and a spindle checkpoint after microtubule disruption. In the course of our studies, we observed that p38 became actively phosphorylated, and its kinase activity increased transiently during G(2)/Mcell cycle transition. Using an immunocytochemistry approach, the active form of p38 was found at the centrosome from late G(2) throughout mitosis, which suggests functional relevance for active p38 protein during mitotic entry. A closer examination reveals that p38 inhibition by pharmacologic inhibitors significantly accelerated the timing of mitotic entry. In addition, long term exposure of the inhibitor enhanced Cdc2 activity. These results indicate that p38 activity during G(2)/M may be involved in a mechanism for fine tuning the initiation of mitosis and perhaps transit of mitosis. Consistent with our previous findings, Cdc25B was phosphorylated on serine 309 at the centrosome during G(2)/M when p38 was active at this site; Cdc25B phosphorylation inhibits Cdc25B activity, and this phosphorylation was found to be p38-dependent. Taken together, our findings suggest that p38 regulates the timing of mitotic entry via modulation of Cdc25B activity under normal nonstress conditions.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; Harvard Univ, John B Little Ctr Radiat Sci & Environm Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Fornace, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	afornace@hsph.harvard.edu	Cha, Hyuk-Jin/AAB-8508-2020; Fornace, Albert J/A-7407-2008	Cha, Hyuk-Jin/0000-0001-9277-2662; Fornace, Albert J/0000-0001-9695-085X				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campos CBL, 2002, NEUROSCIENCE, V112, P583, DOI 10.1016/S0306-4522(02)00096-9; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; CAZALES M, 2005, CELL CYCLE, V4; Cha H, 2004, BIOCHEM J, V378, P857, DOI 10.1042/BJ20031173; Cha HJ, 2006, CELL SIGNAL, V18, P93, DOI 10.1016/j.cellsig.2005.03.028; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Dangi S, 2005, J BIOL CHEM, V280, P24524, DOI 10.1074/jbc.M414079200; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Engel FB, 2005, GENE DEV, V19, P1175, DOI 10.1101/gad.1306705; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jirmanova L, 2005, CELL CYCLE, V4, P1428, DOI 10.4161/cc.4.10.2055; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lopez-Aviles S, 2005, MOL CELL, V17, P49, DOI 10.1016/j.molcel.2004.11.043; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mirey G, 2005, CELL CYCLE, V4, P806, DOI 10.4161/cc.4.6.1716; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Salvador JM, 2005, NAT IMMUNOL, V6, P390, DOI 10.1038/ni1177; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Swenson KI, 2003, MOL BIOL CELL, V14, P156, DOI 10.1091/mbc.E02-02-0115; Tritarelli A, 2004, MOL BIOL CELL, V15, P3751, DOI 10.1091/mbc.E03-12-0900; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763	37	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22984	22992		10.1074/jbc.M700735200	http://dx.doi.org/10.1074/jbc.M700735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17548358	hybrid			2022-12-25	WOS:000248354200075
J	Hong, KM; Belperio, JA; Keane, MP; Burdick, MD; Strieter, RM				Hong, Kurt M.; Belperio, John A.; Keane, Michael P.; Burdick, Marie D.; Strieter, Robert M.			Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; DEPENDENT SMAD2/3 PHOSPHORYLATION; PERIPHERAL-BLOOD FIBROCYTES; HEPATIC STELLATE CELLS; HUMAN ADIPOSE-TISSUE; TGF-BETA; GENE-EXPRESSION; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; SIGNAL-TRANSDUCTION	Fibrocytes are a distinct population of fibroblast-like progenitor cells in peripheral blood that have recently been shown to possess plasticity to differentiate along mesenchymal lineages, including commitment to myofibroblast and adipocyte cells. Here, we demonstrated that transforming growth factor (TGF) beta 1 drives fibrocyte-to-myofibroblast differentiation through activating Smad2/3 and SAPK/JNK MAPK pathways, which in turn stimulates alpha-smooth muscle actin expression. We determined that SAPK/JNK signaling acts in a positive feedback loop to modulate Smad2/3 nuclear availability and Smad2/3-dependent transcription. Conversely, fibrocyte-to-adipocyte differentiation is driven by the peroxisome proliferator-activated receptor (PPAR) gamma agonist troglitazone, which is associated with cytoplasmic lipid accumulation and induction of aP2. Treatment with troglitazone also disrupted TGF beta 1-activated SAPK/JNK signaling, leading to decreased Smad2/3 transactivation activity and alpha-smooth muscle actin expression. Interestingly, TGF beta 1 was demonstrated to have reciprocal inhibition on fibrocyte differentiation to adipocytes. By activating SAPK/JNK signaling, which is normally suppressed during adipogenesis, PPAR gamma-dependent transactivation activity and induction of aP2 expression were disrupted. Taken together, within the context of the local microenvironmental niche, the delicate balance of PPAR gamma and TGF beta 1 activation drives the selection of an adipocyte or myofibroblast differentiation pathway through SAPK/JNK signaling.	Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Lab Med & Pathol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, Los Angeles, CA 90024 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	University of Virginia; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Virginia	Strieter, RM (corresponding author), POB 800466, Charlottesville, VA 22908 USA.	strieter@virginia.edu	Keane, Michael/R-6329-2019					Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ATFI A, 1999, EMBO J, V272, P1429; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Chesney J, 1998, J IMMUNOL, V160, P419; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Frey RS, 1997, CANCER RES, V57, P628; Fu MG, 2003, BIOCHEM J, V370, P1019, DOI 10.1042/BJ20021503; Gardner OS, 2005, MOL PHARMACOL, V68, P933, DOI 10.1124/mol.105.012260; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; Guo BL, 2005, KIDNEY INT, V68, P972, DOI 10.1111/j.1523-1755.2005.00491.x; Guo BL, 2004, DIABETES, V53, P200, DOI 10.2337/diabetes.53.1.200; Han SW, 2006, MOL CANCER THER, V5, P430, DOI 10.1158/1535-7163.MCT-05-0347; Hellemans K, 2003, GASTROENTEROLOGY, V124, P184, DOI 10.1053/gast.2003.50015; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hong KM, 2005, FASEB J, V19, P2029, DOI 10.1096/fj.05-4295fje; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; Kang YJ, 2005, J CELL BIOCHEM, V95, P1135, DOI 10.1002/jcb.20499; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Li MY, 2005, J CELL BIOCHEM, V96, P760, DOI 10.1002/jcb.20474; Maloo M, 2006, AM J TRANSPLANT, V6, P2212, DOI 10.1111/j.1600-6143.2006.01420.x; Metz CN, 2003, CELL MOL LIFE SCI, V60, P1342, DOI 10.1007/s00018-003-2328-0; MIYATA KS, 1994, GENE, V148, P327, DOI 10.1016/0378-1119(94)90707-2; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PETRUSCHKE T, 1994, INT J OBESITY, V18, P532; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Polikandriotis JA, 2005, ARTERIOSCL THROM VAS, V25, P1810, DOI 10.1161/01.ATV.0000177805.65864.d4; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Quan Timothy E, 2006, Curr Rheumatol Rep, V8, P145, DOI 10.1007/s11926-006-0055-x; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Rival Y, 2004, J PHARMACOL EXP THER, V311, P467, DOI 10.1124/jpet.104.068254; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schachtrup C, 2004, BIOCHEM J, V382, P239, DOI 10.1042/BJ20031340; Sitnicka E, 1996, BLOOD, V88, P82; Tanabe Y, 2004, J CELL SCI, V117, P3605, DOI 10.1242/jcs.01207; Varcoe RL, 2006, J THROMB HAEMOST, V4, P1125, DOI 10.1111/j.1538-7836.2006.01924.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Yoshida K, 2005, AM J PATHOL, V166, P1029, DOI 10.1016/S0002-9440(10)62324-3; Yue J, 2004, J CELL PHYSIOL, V199, P284, DOI 10.1002/jcp.10469	47	178	191	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22910	22920		10.1074/jbc.M703597200	http://dx.doi.org/10.1074/jbc.M703597200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17556364	hybrid			2022-12-25	WOS:000248354200068
J	Kirchberger, S; Leroch, M; Huynen, MA; Wahl, M; Neuhaus, HE; Tjaden, J				Kirchberger, Simon; Leroch, Michaela; Huynen, Martijn A.; Wahl, Markus; Neuhaus, H. Ekkehard; Tjaden, Joachim			Molecular and biochemical analysis of the plastidic ADP-glucose transporter (ZmBT1) from Zea mays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; ESCHERICHIA-COLI; STARCH SYNTHESIS; MAIZE ENDOSPERM; ADP/ATP CARRIER; EXPRESSION; GENE; PYROPHOSPHORYLASE; MITOCHONDRIAL; IDENTIFICATION	Physiological studies on the Brittle1 maize mutant have provided circumstantial evidence that ZmBT1 (Zea mays Brittle1 protein) is involved in the ADP-Glc transport into maize endosperm plastids, but up to now, no direct ADP-Glc transport mediated by ZmBT1 has ever been shown. The heterologous synthesis of ZmBT1 in Escherichia coli cells leads to the functional integration of ZmBT1 into the bacterial cytoplasmic membrane. ZmBT1 transports ADP-Glc in counterexchange with ADP with apparent affinities of about 850 and 465 mu M, respectively. Recently, a complete ferredoxin/thioredoxin system has been identified in cereal amyloplasts and BT1 has been proposed as a potential Trx target protein (Balmer, Y., Vensel, W. H., Cai, N., Manieri, W., Schurmann, P., Hurkman, W. J., and Buchanan, B. B. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 2988-2993). Interestingly, we revealed that the transport activity of ZmBT1 is reversibly regulated by redox reagents such as diamide and dithiothreitol. The expression of ZmBT1 is restricted to endosperm tissues during starch synthesis, whereas a recently identified BT1 maize homologue, the ZmBT1-2, exhibits a ubiquitous expression pattern in hetero- and autotrophic tissues indicating different physiological roles for both maize BT1 isoforms. BT1 homologues are present in both mono- and dicotyledonous plants. Phylogenetic analyses classify the BT1 family into two phylogenetically and biochemically distinct groups. The first group comprises BT1 orthologues restricted to cereals where they mediate the ADP-Glc transport into cereal endosperm storage plastids during starch synthesis. The second group occurs in mono- and dicotyledonous plants and is most probably involved in the export of adenine nucleotides synthesized inside plastids.	Tech Univ Kaiserslautern, Abteilung Pflanzenphysiol Fachbereich Biol, D-67653 Kaiserslautern, Germany; Ctr Mol & Biomol Informat, Nijmegen, Netherlands; Radboud Univ Nijmegen, Ctr Mol Life Sci, NL-6525 ED Nijmegen, Netherlands	University of Kaiserslautern; Radboud University Nijmegen	Tjaden, J (corresponding author), Tech Univ Kaiserslautern, Abteilung Pflanzenphysiol Fachbereich Biol, POB 3049, D-67653 Kaiserslautern, Germany.	tjaden@rhrk.uni-kl.de	Huijnen, M.A./H-8051-2014; Huynen, Martijn A/A-1530-2014	Huynen, Martijn A/0000-0001-6189-5491				AMORES MV, 1994, MOL CELL BIOCHEM, V137, P117, DOI 10.1007/BF00944073; Balmer Y, 2006, P NATL ACAD SCI USA, V103, P2988, DOI 10.1073/pnas.0511040103; Beckles DM, 2001, PLANT PHYSIOL, V125, P818, DOI 10.1104/pp.125.2.818; BHAVE MR, 1990, PLANT CELL, V2, P581, DOI 10.1105/tpc.2.6.581; Bowsher CG, 2007, J EXP BOT, V58, P1321, DOI 10.1093/jxb/erl297; CAO HP, 1995, PHYSIOL PLANTARUM, V95, P176, DOI 10.1111/j.1399-3054.1995.tb00825.x; Dean JD, 2002, PLANT MOL BIOL REP, V20, P347, DOI 10.1007/BF02772122; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; Denyer K, 1996, PLANT PHYSIOL, V112, P779, DOI 10.1104/pp.112.2.779; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; FLUGGE UI, 1992, BIOCHIM BIOPHYS ACTA, V1110, P112, DOI 10.1016/0005-2736(92)90301-2; Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352; Haferkamp I, 2004, NATURE, V432, P622, DOI 10.1038/nature03131; Haferkamp I, 2002, EUR J BIOCHEM, V269, P3172, DOI 10.1046/j.1432-1033.2002.02991.x; Heimpel S, 2001, J BIOL CHEM, V276, P11499, DOI 10.1074/jbc.M010586200; James MG, 2003, CURR OPIN PLANT BIOL, V6, P215, DOI 10.1016/S1369-5266(03)00042-6; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kammerer B, 1998, PLANT CELL, V10, P105, DOI 10.1105/tpc.10.1.105; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Klingenberg M, 1979, Methods Enzymol, V56, P245; KRAUSE DC, 1985, P NATL ACAD SCI USA, V82, P3015, DOI 10.1073/pnas.82.9.3015; Kruger NJ, 2003, CURR OPIN PLANT BIOL, V6, P236, DOI 10.1016/S1369-5266(03)00039-6; Leroch M, 2005, J BIOL CHEM, V280, P17992, DOI 10.1074/jbc.M412462200; LIU TTY, 1992, PLANT PHYSIOL, V99, pS39; MAHE A, 1992, MOL PLANT MICROBE IN, V5, P242, DOI 10.1094/MPMI-5-242; Mangelsdorf P.C., 1926, CONN AGR EXP STN B, V279, P509; MANGOLD HK, 1967, NUCL ACIDS NUCLEOTID, P749; Millar AH, 2003, PLANT PHYSIOL, V131, P443, DOI 10.1104/pp.009985; Mohlmann T, 1997, BIOCHEM J, V324, P503, DOI 10.1042/bj3240503; NELSON OE, 1962, BIOCHEM BIOPH RES CO, V9, P297, DOI 10.1016/0006-291X(62)90043-8; NEUHAUS HE, 1993, PLANT PHYSIOL, V101, P573, DOI 10.1104/pp.101.2.573; Patron NJ, 2004, PLANT PHYSIOL, V135, P2088, DOI 10.1104/pp.104.045203; Petsalaki Evangelia I., 2006, Genomics Proteomics & Bioinformatics, V4, P48, DOI 10.1016/S1672-0229(06)60016-8; PIEN FM, 1996, PLANT PHYSL S, V111, pS100; PREISS J, 1990, PLANT PHYSIOL, V92, P881, DOI 10.1104/pp.92.4.881; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sancenon V, 2004, J BIOL CHEM, V279, P15348, DOI 10.1074/jbc.M313321200; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; Shannon JC, 1996, PLANT PHYSIOL, V110, P835, DOI 10.1104/pp.110.3.835; Shannon JC, 1998, PLANT PHYSIOL, V117, P1235, DOI 10.1104/pp.117.4.1235; STUBBS M, 1981, INT ENCYCL PHARM TH, V107, P283; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sturzenbaum SR, 2001, COMP BIOCHEM PHYS B, V130, P281, DOI 10.1016/S1096-4959(01)00440-7; SULLIVAN TD, 1991, PLANT CELL, V3, P1337, DOI 10.1105/tpc.3.12.1337; SULLIVAN TD, 1995, PLANTA, V196, P477, DOI 10.1007/BF00203647; Tjaden J, 1998, PLANT J, V16, P531, DOI 10.1046/j.1365-313X.1998.00317.x; Tjaden J, 2004, MOL MICROBIOL, V51, P1439, DOI 10.1111/j.1365-2958.2004.03918.x; Tjaden J, 1998, J BIOL CHEM, V273, P9630, DOI 10.1074/jbc.273.16.9630; TOBIAS RB, 1992, PLANT PHYSIOL, V99, P146, DOI 10.1104/pp.99.1.146; Toyota K, 2006, PLANTA, V223, P248, DOI 10.1007/s00425-005-0128-5; TSAI CY, 1966, SCIENCE, V151, P341, DOI 10.1126/science.151.3708.341; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wenderoth I, 1997, J BIOL CHEM, V272, P26985, DOI 10.1074/jbc.272.43.26985; Wentz JB, 1926, J HERED, V17, P327, DOI 10.1093/oxfordjournals.jhered.a102744; WINKLER HH, 1986, METHOD ENZYMOL, V125, P253; Zrenner R, 2006, ANNU REV PLANT BIOL, V57, P805, DOI 10.1146/annurev.arplant.57.032905.105421	58	73	82	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22481	10.1074/jbc.M702484200	http://dx.doi.org/10.1074/jbc.M702484200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17562699	Green Published, hybrid			2022-12-25	WOS:000248354200026
J	Song, W; Levin, DS; Varkey, J; Post, S; Bermudez, VP; Hurwitz, J; Tomkinson, AE				Song, Wei; Levin, David S.; Varkey, Johnson; Post, Sean; Bermudez, Vladimir P.; Hurwitz, Jerard; Tomkinson, Alan E.			A conserved physical and functional interaction between the cell cycle checkpoint clamp loader and DNA ligase I of eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; IMMUNODEFICIENT PATIENT 46BR; REPLICATION FACTOR C; DAMAGE CHECKPOINT; NUCLEAR ANTIGEN; FLAP ENDONUCLEASE-1; COMPLEX; PCNA; PROTEINS; RAD9-RAD1-HUS1	DNA ligase I joins Okazaki fragments during DNA replication and completes certain excision repair pathways. The participation of DNA ligase I in these transactions is directed by physical and functional interactions with proliferating cell nuclear antigen, a DNA sliding clamp, and, replication factor C (RFC), the clamp loader. Here we show that DNA ligase I also interacts with the hRad17 subunit of the hRad17-RFC cell cycle checkpoint clamp loader, and with each of the subunits of its DNA sliding clamp, the heterotrimeric hRad9-hRad1-hHus1 complex. In contrast to the inhibitory effect of RFC, hRad17-RFC stimulates joining by DNA ligase I. Similar results were obtained with the homologous Saccharomyces cerevisiae proteins indicating that the interaction between the replicative DNA ligase and checkpoint clamp is conserved in eukaryotes. Notably, we show that hRad17 preferentially interacts with and specifically stimulates dephosphorylated DNA ligase I. Moreover, there is an increased association between DNA ligase I and hRad17 in S phase following DNA damage and replication blockage that occurs concomitantly with DNA damage-induced dephosphorylation of chromatin-associated DNA ligase I. Thus, our results suggest that the in vivo interaction between DNA ligase I and the checkpoint clamp loader is regulated by post-translational modification of DNA ligase	Univ Maryland, Sch Med, Mol Med Grad Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Health San Antonio; Memorial Sloan Kettering Cancer Center	Tomkinson, AE (corresponding author), 655 W Baltimore St, Baltimore, MD 21201 USA.	atomkinson@som.umaryland	Classen, Scott/AAY-8176-2020		NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057479, R37GM034559, R01GM034559] Funding Source: NIH RePORTER; NCI NIH HHS [CA92584] Funding Source: Medline; NIGMS NIH HHS [GM57479, GM034559] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Chang DY, 2005, J BIOL CHEM, V280, P408, DOI 10.1074/jbc.M406800200; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen X, 2006, METHOD ENZYMOL, V409, P39, DOI 10.1016/S0076-6879(05)09003-8; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Ferrari G, 2003, J BIOL CHEM, V278, P37761, DOI 10.1074/jbc.M304462200; Friedrich-Heineken F, 2005, J MOL BIOL, V353, P980, DOI 10.1016/j.jmb.2005.09.018; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; GALLINA A, 1995, BIOCHEM J, V312, P593, DOI 10.1042/bj3120593; Garg P, 2005, CELL CYCLE, V4, P221; Giannattasio M, 2004, EMBO J, V23, P429, DOI 10.1038/sj.emboj.7600051; Harrison C, 2002, CANCER RES, V62, P4065; Helt CE, 2005, CELL CYCLE, V4, P529, DOI 10.4161/cc.4.4.1598; HENDERSON LM, 1985, P NATL ACAD SCI USA, V82, P2044, DOI 10.1073/pnas.82.7.2044; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LEHMANN AR, 1988, CANCER RES, V48, P6343; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Levin DS, 2004, J BIOL CHEM, V279, P55196, DOI 10.1074/jbc.M409250200; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; LONN U, 1989, CARCINOGENESIS, V10, P981, DOI 10.1093/carcin/10.6.981; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; Majka J, 2006, MOL CELL, V24, P891, DOI 10.1016/j.molcel.2006.11.027; Majka J, 2006, J BIOL CHEM, V281, P27855, DOI 10.1074/jbc.M605176200; Montecucco A, 2001, MOL BIOL CELL, V12, P2109, DOI 10.1091/mbc.12.7.2109; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Pascal JM, 2006, MOL CELL, V24, P279, DOI 10.1016/j.molcel.2006.08.015; Post SM, 2003, NUCLEIC ACIDS RES, V31, P5568, DOI 10.1093/nar/gkg765; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Rossi R, 2006, CANCER RES, V66, P1675, DOI 10.1158/0008-5472.CAN-05-2741; Rossi R, 2002, CELL DEATH DIFFER, V9, P89, DOI 10.1038/sj.cdd.4400961; Shi GL, 2006, BIOCHEM J, V400, P53, DOI 10.1042/BJ20060774; Smirnova E, 2005, BIOCHEM J, V389, P13, DOI 10.1042/BJ20050211; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TEO IA, 1983, CARCINOGENESIS, V4, P559, DOI 10.1093/carcin/4.5.559; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tomkinson AE, 2006, CHEM REV, V106, P687, DOI 10.1021/cr040498d; Toueille M, 2004, NUCLEIC ACIDS RES, V32, P3316, DOI 10.1093/nar/gkh652; Uhlmann F, 1997, J BIOL CHEM, V272, P10065; Vijayakumar S, 2007, NUCLEIC ACIDS RES, V35, P1624, DOI 10.1093/nar/gkm006; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wang WS, 2006, J BIOL CHEM, V281, P20865, DOI 10.1074/jbc.M602289200; Wang WS, 2004, P NATL ACAD SCI USA, V101, P16762, DOI 10.1073/pnas.0407686101; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WEBSTER ADB, 1992, LANCET, V339, P1508, DOI 10.1016/0140-6736(92)91266-B; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100	58	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22721	22730		10.1074/jbc.M703774200	http://dx.doi.org/10.1074/jbc.M703774200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17561505	hybrid			2022-12-25	WOS:000248354200049
J	Gafencu, AV; Robciuc, MR; Fuior, E; Zannis, VI; Kardassis, D; Simionescu, M				Gafencu, Anca V.; Robciuc, Marius R.; Fuior, Elena; Zannis, Vassilis I.; Kardassis, Dimitris; Simionescu, Maya			Inflammatory signaling pathways regulating ApoE gene expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E GENE; NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; IN-VITRO; TRANSCRIPTION FACTORS; CELL BIOLOGY; APOPROTEIN-E; E SECRETION; LIPOPOLYSACCHARIDE	The atheroprotective role of apolipoprotein E (apoE) is well established. During inflammation, expression of apoE in macrophages is reduced leading to enhanced atheromatous plaque development. In the present study, we investigated the signaling pathways involved in the repression of apoE gene expression in response to lipopolysaccharide (LPS) treatment, a condition that mimics the inflammatory stress, in mouse macrophages RAW 264.7. We identified Tpl-2 and MEKK1 as the kinases that are primarily responsible for the down-regulation of apoE promoter activity by LPS. Using a dominant negative form of I kappa B, we established that Tpl-2 and MEKK1 signaling pathways converge to NF-kappa B acting on the apoE core promoter -55/+73. In addition to NF-kappa B activation, LPS also activated c-Jun via its phosphorylation by JNK. The activity of the apoE promoter was repressed by c-Jun, whereas small interference RNA-mediated inhibition of endogenous c-Jun expression reversed the inhibitory effect of Tpl-2 on the apoE promoter. Transfection experiments and DNA binding assays showed that the binding site for c-Jun is in the -55/+73 region of the apoE promoter. Finally, we showed that LPS inhibited apoE gene expression via activation of the Tpl-2/MEK/ERK pathway acting on a different apoE promoter region. In summary, LPS represses apoE gene expression in macrophages via signaling pathways that involve the upstream kinases Tpl-2 and MEKK1, the intermediate mitogenactivated protein kinases ERK and JNK, and the downstream transcription factors AP-1 and NF-kappa B that inhibit the apoE promoter activity via distinct regions.	Inst Cellular Biol & Pathol Nicolae Simionescu, Bucharest 050568, Romania; Univ Crete, Sch Med, GR-71110 Iraklion, Crete, Greece; Boston Univ, Sch Med, Boston, MA 02718 USA	Romanian Academy of Sciences; Nicolae Simionescu Institute of Cellular Biology & Pathology; University of Crete; Boston University	Gafencu, AV (corresponding author), Inst Cellular Biol & Pathol Nicolae Simionescu, 8 BP Hasdeu St,POB 35-14,Sect 5, Bucharest 050568, Romania.	anca.gafencu@icbp.ro	Fuior, Elena/AAP-2673-2020; Simionescu, Maya/C-4794-2011; Gafencu, Anca/AAP-8707-2020; Gafencu, Anca/C-3323-2011	Fuior, Elena/0000-0001-9166-8417; Gafencu, Anca/0000-0002-1290-1346; Simionescu, Maya/0000-0003-2077-0400; Zannis, Vassilis/0000-0002-1295-7155				Afonso V, 2006, FREE RADICAL BIO MED, V41, P709, DOI 10.1016/j.freeradbiomed.2006.05.014; Agelaki S, 2002, INFECT IMMUN, V70, P6068, DOI 10.1128/IAI.70.11.6068-6074.2002; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Bilsland AE, 2006, CANCER RES, V66, P1363, DOI 10.1158/0008-5472.CAN-05-1941; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROSATOS K, 2007, J BIOL CHEM     0424; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; Garcia MA, 1996, J NEUROSCI, V16, P7550; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Krappmann D, 2004, MOL CELL BIOL, V24, P6488, DOI 10.1128/MCB.24.14.6488-6500.2004; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; Nikolaidou-Neokosmidou V, 2006, BIOCHEM J, V398, P439, DOI 10.1042/BJ20060169; O'Reilly SM, 2003, BIOCHEM BIOPH RES CO, V303, P586, DOI 10.1016/S0006-291X(03)00389-9; OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526; PAIK YK, 1988, J BIOL CHEM, V263, P13340; Piquer BR, 2004, J CELL BIOCHEM, V91, P786, DOI 10.1016/jcb.10786; Prokova V, 2002, J BIOL CHEM, V277, P9342, DOI 10.1074/jbc.M109099200; Qiao XX, 2001, EUR J NEUROSCI, V14, P474, DOI 10.1046/j.0953-816x.2001.01666.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Salero E, 2003, BIOCHEM J, V370, P979, DOI 10.1042/BJ20021142; Salero E, 2001, J BIOL CHEM, V276, P1881, DOI 10.1074/jbc.M007008200; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; SMITH JD, 1988, J BIOL CHEM, V263, P8300; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; TSATSANIS C, 2006, UCSD NATURE MOL PAGE; WERB Z, 1983, J EXP MED, V158, P1272, DOI 10.1084/jem.158.4.1272; WERB Z, 1983, J CELL BIOL, V97, P1113, DOI 10.1083/jcb.97.4.1113; Zannis VI, 2001, CURR OPIN LIPIDOL, V12, P181, DOI 10.1097/00041433-200104000-00012; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414	41	56	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21776	21785		10.1074/jbc.M611422200	http://dx.doi.org/10.1074/jbc.M611422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17553793	hybrid			2022-12-25	WOS:000248196800025
J	Kalp, M; Sheri, A; Buynak, JD; Bethel, CR; Bonomo, RA; Carey, PR				Kalp, Matthew; Sheri, Anjaneyulu; Buynak, John D.; Bethel, Christopher R.; Bonomo, Robert A.; Carey, Paul R.			Efficient inhibition of class A and class D beta-lactamases by Michaelis complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROCYCLES; MECHANISM; CRYSTALS; BINDING	A 6-alkylidiene penam sulfone, SA-1-204, is an efficient inhibitor of both SHV-1 and OXA-1 beta-lactamases with K-I = 42 +/- 4nM and 1.0 +/- 0.1 mu M, respectively. To gain insight into the reaction chemistry of SA-1-204, the reactions between this inhibitor and SHV-1 and OXA-1 were studied by Raman spectroscopy in single crystals and in solution. Raman signatures characteristic of the unreacted beta-lactam ring show that in both phases the inhibitor binds as a noncovalent Michaelis-like complex. This complex is present as the major population for periods of up to an hour. On longer time scales, the Raman data show that beta-lactam ring opening eventually leads to a complex mixture of reaction products. However, the data clearly demonstrate that the key species for inhibition on the time scale of bacterial half-lives is the noncovalent complex preceding acylation.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Louis Stokes Cleveland Vet Affairs Med Ctr, Div Res, Cleveland, OH 44106 USA; So Methodist Univ, Dept Chem, Dallas, TX 75275 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Southern Methodist University	Carey, PR (corresponding author), Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.	paul.carey@case.edu			NIAID NIH HHS [5 R01 AI635172] Funding Source: Medline; NIGMS NIH HHS [GM54072, T32 GM07250, T32 GM007250] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250, R56GM054072, R01GM054072] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altose MD, 2001, P NATL ACAD SCI USA, V98, P3006, DOI 10.1073/pnas.061029598; Buynak JD, 1999, BIOORG MED CHEM LETT, V9, P1997, DOI 10.1016/S0960-894X(99)00325-X; Chen Y, 2006, J AM CHEM SOC, V128, P2970, DOI 10.1021/ja056806m; Crichlow GV, 2001, BIOCHEMISTRY-US, V40, P6233, DOI 10.1021/bi010131s; Dong J, 2001, BIOCHEMISTRY-US, V40, P9751, DOI 10.1021/bi010955+; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; FRISCH A, 2003, GAUSSIAN 03; Helfand MS, 2002, J BIOL CHEM, V277, P47719, DOI 10.1074/jbc.M207271200; Helfand MS, 2003, BIOCHEMISTRY-US, V42, P13386, DOI 10.1021/bi035716w; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Nukaga M, 2004, J BIOL CHEM, V279, P9344, DOI 10.1074/jbc.M312356200; Page MGF, 2000, DRUG RESIST UPDATE, V3, P109, DOI 10.1054/drup.2000.0137; Powers RA, 2002, STRUCTURE, V10, P1013, DOI 10.1016/S0969-2126(02)00799-2; STUBBS KA, 2007, J BIOL CHEM; Sun T, 2003, PROTEIN SCI, V12, P82, DOI 10.1110/ps.0224303; Tondi D, 2005, J AM CHEM SOC, V127, P4632, DOI 10.1021/ja042984o; Totir MA, 2006, BIOCHEMISTRY-US, V45, P11895, DOI 10.1021/bi060990m; Venkatesan AM, 2004, J MED CHEM, V47, P6556, DOI 10.1021/jm049680x; Venkatesan AM, 2006, J MED CHEM, V49, P4623, DOI 10.1021/jm060021p	19	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21588	21591		10.1074/jbc.C700080200	http://dx.doi.org/10.1074/jbc.C700080200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17561511	hybrid			2022-12-25	WOS:000248196800004
J	Lin, KR; Lee, SF; Hung, CM; Li, CL; Yang-Yen, HF; Yen, JJY				Lin, Kou-Ray; Lee, Shern-Fwu; Hung, Chien-Min; Li, Chung-Leung; Yang-Yen, Hsin-Fang; Yen, Jeffrey J. Y.			Survival factor withdrawal-induced apoptosis of TF-1 cells involves a TRB2-Mcl-1 axis-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; MEDIATED APOPTOSIS; LEUKEMIC-CELLS; GM-CSF; MCL-1; PROTEIN; BCL-2; DEATH; DROSOPHILA; INDUCTION	Tribbles, an atypical protein kinase superfamily member, coordinates cell proliferation, migration, and morphogenesis during the development of Drosophila and Xenopus embryos. Although Tribbles are highly conserved throughout evolution, the physiological functions of mammalian Tribbles family remain largely unclear. Here we report that human TRB2 is a pro-apoptotic molecule that induces apoptosis of cells mainly of the hematopoietic origin. TRB2 mRNA is selectively induced by removal of granulocyte macrophage colony-stimulating factor (GM-CSF) or interleukin-2 from human erythroleukemia-derived TF-1 cell line or activated primary CD4(+) T cells, respectively. It is, however, not induced by many other treatments that trigger apoptosis of these two cell types. Overexpression of TRB2 activates many apoptotic events observed in GM-CSF-deprived TF-1 cells, including loss of mitochondrial membrane potential, Mcl-1 cleavage/degradation, and activation of Bax and a number of caspases. Specific knockdown of TRB2 significantly suppresses GM-CSF deprivation-induced apoptosis and all apoptotic events mentioned above. Finally, we demonstrate that TRB2-induced cleavage and degradation of Mcl-1 are mediated via a caspase-dependent but proteasome-independent mechanism, and overexpression of Mcl-1 or its upstream activator Akt can markedly overcome the apoptogenic effect of TRB2. Altogether, these results suggest that the TRB2-Mcl-1 axis plays an important role in survival factor withdrawal-induced apoptosis of TF-1 cells.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 115, Taiwan; Taiwan Genome Sci Inc, Taipei 115, Taiwan; Acad Sinica, Gen Res Ctr, Inst Cellular & Organism Biol, Stem Cell Program, Taipei 115, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; Academia Sinica - Taiwan; Academia Sinica - Taiwan	Yen, JJY (corresponding author), Acad Sinica, Inst Biomed Sci, Acad Sinica 128,Sect 2,Yen Jiou Yuan Rd, Taipei 11529, Taiwan.	bmjyen@ibms.sinica.edu.tw	Lin, Kuo-Ray/V-6333-2019; Yen, Jeffrey Jong-Young/Q-5134-2018; Yang-Yen, Hsin-Fang/ABA-5808-2021	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Yang-Yen, Hsin-Fang/0000-0001-9048-4800; Lin, Kuo-Ray/0000-0002-6525-1674				Chen MC, 2000, J BIOL CHEM, V275, P38794, DOI 10.1074/jbc.M003292200; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chou CH, 2006, MOL BIOL CELL, V17, P3952, DOI 10.1091/mbc.E06-04-0319; Devireddy LR, 2003, MOL CELL BIOL, V23, P4532, DOI 10.1128/MCB.23.13.4532-4541.2003; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Everett H, 2000, J EXP MED, V191, P1487, DOI 10.1084/jem.191.9.1487; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; HAN JH, 1995, EXP HEMATOL, V23, P265; Huang HM, 1999, BLOOD, V93, P2569, DOI 10.1182/blood.V93.8.2569.408k08_2569_2577; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Kiss-Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Kostich M, 2002, GENOME BIOL, V3; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Prasad V, 2006, FREE RADICAL BIO MED, V41, P431, DOI 10.1016/j.freeradbiomed.2006.03.009; Rorth P, 2000, MOL CELL, V6, P23; Saka Y, 2004, DEV BIOL, V273, P210, DOI 10.1016/j.ydbio.2004.05.032; Sanz C, 2000, BLOOD, V95, P2742, DOI 10.1182/blood.V95.9.2742.009k24_2742_2747; Schwarzer R, 2006, CELL SIGNAL, V18, P899, DOI 10.1016/j.cellsig.2005.08.002; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	42	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21962	21972		10.1074/jbc.M701663200	http://dx.doi.org/10.1074/jbc.M701663200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545167	hybrid			2022-12-25	WOS:000248196800044
J	Zeniou-Meyer, M; Zabari, N; Ashery, U; Chasserot-Golaz, S; Haeberle, AM; Demais, V; Bailly, Y; Gottfried, I; Nakanishi, H; Neiman, AM; Du, GW; Frohman, MA; Bader, MF; Vitale, N				Zeniou-Meyer, Maria; Zabari, Naama; Ashery, Uri; Chasserot-Golaz, Sylvette; Haeberle, Anne-Marie; Demais, Valerie; Bailly, Yannick; Gottfried, Irit; Nakanishi, Hideki; Neiman, Aaron M.; Du, Guangwei; Frohman, Michael A.; Bader, Marie-France; Vitale, Nicolas			Phospholipase D1 production of phosphatidic acid at the plasma membrane promotes exocytosis of large dense-core granules at a late stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-REGULATED EXOCYTOSIS; MOUSE ADRENAL SLICES; PROTEIN-KINASE-C; CHROMAFFIN CELLS; MAST-CELLS; FUSION; HEMIFUSION; VESICLES; ARF6; SECRETION	Substantial efforts have recently been made to demonstrate the importance of lipids and lipid-modifying enzymes in various membrane trafficking processes, including calcium-regulated exocytosis of hormones and neurotransmitters. Among bioactive lipids, phosphatidic acid (PA) is an attractive candidate to promote membrane fusion through its ability to change membrane topology. To date, however, the bio-synthetic pathway, the dynamic location, and actual function of PA in secretory cells remain unknown. Using a short interference RNA strategy on chromaffin and PC12 cells, we demonstrate here that phospholipase D1 is activated in secreta-gogue-stimulated cells and that it produces PA at the plasma membrane at the secretory granule docking sites. We show that phospholipase D1 activation and PA production represent key events in the exocytotic progression. Membrane capacitance measurements indicate that reduction of endogenous PA impairs the formation of fusion-competent granules. Finally, we show that the PLD1 short interference RNA-mediated inhibition of exocytosis can be rescued by exogenous provision of a lipid that favors the transition of opposed bi-layer membranes to hemifused membranes having the outer leaflets fused. Our findings demonstrate that PA synthesis is required during exocytosis to facilitate a late event in the granule fusion pathway. We propose that the underlying mechanism is related to the ability of PA to alter membrane curvature and promote hemi-fusion.	CNRS, Inst Neurosci Cellulaires & Integrat, UMR 7168 LC2, Dept Neurotransmiss & Secret Neuroendocrine, F-67084 Strasbourg, France; Univ Strasbourg 1, F-67084 Strasbourg, France; Plateforme Imagerie Vitro, IFR37 Neurosci Strasbourg, F-67084 Strasbourg, France; Tel Aviv Univ, Inst Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tel Aviv University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Vitale, N (corresponding author), CNRS, Inst Neurosci Cellulaires & Integrat, UMR 7168 LC2, Dept Neurotransmiss & Secret Neuroendocrine, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	vitalen@neurochem.u-strasbg.fr	Bader, Marie-France/O-2098-2016; Chasserot-Golaz, Sylvette/K-7625-2017; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907; Neiman, Aaron/0000-0002-6600-6996; Du, Guangwei/0000-0003-4193-6975; Gottfried, Irit/0000-0002-5927-4626; Chasserot-Golaz, Sylvette/0000-0002-7437-2558; Ashery, Uri/0000-0001-6338-7888	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071520, R01GM071475] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM071520, GM071475] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Chasserot-Golaz S, 2005, MOL BIOL CELL, V16, P1108, DOI 10.1091/mbc.E04-07-0627; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; Chernomordik LV, 2006, J CELL BIOL, V175, P201, DOI 10.1083/jcb.200607083; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Choi SY, 2006, NAT CELL BIOL, V8, P1255, DOI 10.1038/ncb1487; Choi WS, 2002, J IMMUNOL, V168, P5682, DOI 10.4049/jimmunol.168.11.5682; Corrotte M, 2006, TRAFFIC, V7, P365, DOI 10.1111/j.1600-0854.2006.00389.x; de Barry J, 2006, J BIOL CHEM, V281, P18098, DOI 10.1074/jbc.M509842200; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; Giraudo CG, 2005, J CELL BIOL, V170, P249, DOI 10.1083/jcb.200501093; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Huang P, 2005, MOL BIOL CELL, V16, P2614, DOI 10.1091/mbc.E04-12-1124; Hughes WE, 2004, J BIOL CHEM, V279, P27534, DOI 10.1074/jbc.M403012200; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; Kishimoto T, 2006, EMBO J, V25, P673, DOI 10.1038/sj.emboj.7600983; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; Ktistakis NT, 2003, BIOCHEM SOC T, V31, P94, DOI 10.1042/bst0310094; Lu XB, 2005, J BIOL CHEM, V280, P30538, DOI 10.1074/jbc.M506862200; McDermott M, 2004, BIOCHEM CELL BIOL, V82, P225, DOI 10.1139/o03-079; Meyer MZ, 2006, J BIOL CHEM, V281, P7919, DOI 10.1074/jbc.M600081200; Nakanishi H, 2006, J CELL SCI, V119, P1406, DOI 10.1242/jcs.02841; Nakanishi H, 2004, MOL BIOL CELL, V15, P1802, DOI 10.1091/mbc.e03-11-0798; Nili U, 2006, NEUROSCIENCE, V143, P487, DOI 10.1016/j.neuroscience.2006.08.014; Peng Z, 2005, J IMMUNOL, V174, P5201, DOI 10.4049/jimmunol.174.9.5201; Reese C, 2005, NATURE, V436, P410, DOI 10.1038/nature03722; Reese C, 2005, J CELL BIOL, V171, P981, DOI 10.1083/jcb.200510018; Rigoni M, 2005, SCIENCE, V310, P1678, DOI 10.1126/science.1120640; Vicogne J, 2006, P NATL ACAD SCI USA, V103, P14761, DOI 10.1073/pnas.0606881103; Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Voets T, 2000, NEURON, V28, P537, DOI 10.1016/S0896-6273(00)00131-8; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; Waselle L, 2005, MOL ENDOCRINOL, V19, P3097, DOI 10.1210/me.2004-0530; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; Yi H, 2001, J HISTOCHEM CYTOCHEM, V49, P279, DOI 10.1177/002215540104900301; Yizhar O, 2004, P NATL ACAD SCI USA, V101, P2578, DOI 10.1073/pnas.0308700100; Zhang Y, 2004, GLIA, V46, P74, DOI 10.1002/glia.10322	43	157	160	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21746	21757		10.1074/jbc.M702968200	http://dx.doi.org/10.1074/jbc.M702968200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17540765	hybrid			2022-12-25	WOS:000248196800022
J	Jimenez-Juarez, N; Munoz-Garay, C; Gomez, I; Saab-Rincon, G; Damian-Almazo, JY; Gill, SS; Soberon, M; Bravo, A				Jimenez-Juarez, Nuria; Munoz-Garay, Carlos; Gomez, Isabel; Saab-Rincon, Gloria; Damian-Almazo, Juanita Y.; Gill, Sarjeet S.; Soberon, Mario; Bravo, Alejandra			Bacillus thuringiensis Cry1Ab mutants affecting oligomer formation are non-toxic to Manduca sexta larvae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; HELIOTHIS-VIRESCENS LARVAE; LINKED-IMMUNOSORBENT-ASSAY; AMINOPEPTIDASE-N-RECEPTOR; PORE-FORMING DOMAIN; DELTA-ENDOTOXIN; INSECTICIDAL TOXIN; PRE-PORE; PROTEIN TOXINS; PHAGE DISPLAY	Pore-forming toxins are biological weapons produced by a variety of living organisms, particularly bacteria but also by insects, reptiles, and invertebrates. These proteins affect the cell membrane of their target, disrupting permeability and leading eventually to cell death. The pore-forming toxins typically transform from soluble, monomeric proteins to oligomers that form transmembrane channels. The Cry toxins produced by Bacillus thuringiensis are widely used as insecticides. These proteins have been recognized as pore-forming toxins, and their primary action is to lyse midgut epithelial cells in their target insect. To exert their toxic effect, a pre-pore oligomeric intermediate is formed leading finally to membrane-inserted oligomeric pores. To understand the role of Cry oligomeric pre-pore formation in the insecticidal activity we isolated point mutations that affected toxin oligomerization but not their binding with the cadherin-like, Bt-R-1 receptor. We show the helix alpha-3 in domain I contains sequences that could form coiled-coil structures important for oligomerization. Some single point mutants in this helix bound Bt-R-1 receptors with similar affinity as the wild-type toxin, but were affected in oligomerization and were severally impaired in pore formation and toxicity against Manduca sexta larvae. These data indicate the pre-pore oligomer and the toxin pore formation play a major role in the intoxication process of Cry1Ab toxin in insect larvae.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92506 USA	Universidad Nacional Autonoma de Mexico; University of California System; University of California Riverside	Bravo, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Apdo 510-3,Av Univ 2002,Col Chamilpa, Cuernavaca 62250, Morelos, Mexico.	bravo@ibt.unam.mx	Saab-RIncon, Gloria/AFO-4892-2022; de la Parra, Maria Alejandra Bravo/R-6740-2017	Saab-RIncon, Gloria/0000-0002-5251-1000; Bravo, Alejandra/0000-0002-7573-7475; Munoz-Garay, Carlos/0000-0002-7218-4027				Aronson AI, 1999, APPL ENVIRON MICROB, V65, P2503; Bravo A, 2004, BBA-BIOMEMBRANES, V1667, P38, DOI 10.1016/j.bbamem.2004.08.013; Bravo A, 2007, TOXICON, V49, P423, DOI 10.1016/j.toxicon.2006.11.022; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Burton SL, 1999, J MOL BIOL, V287, P1011, DOI 10.1006/jmbi.1999.2649; CHEN XJ, 1995, J BIOL CHEM, V270, P6412, DOI 10.1074/jbc.270.11.6412; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; de Maagd RA, 2003, ANNU REV GENET, V37, P409, DOI 10.1146/annurev.genet.37.110801.143042; Dong L, 2003, BIOCHEM BIOPH RES CO, V301, P60, DOI 10.1016/S0006-291X(02)02933-9; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Genisset C, 2006, INFECT IMMUN, V74, P1786, DOI 10.1128/IAI.74.3.1786-1794.2006; Ghani EA, 1999, BIOCHEMISTRY-US, V38, P15204, DOI 10.1021/bi991678y; Gomez I, 2003, BIOCHEMISTRY-US, V42, P10482, DOI 10.1021/bi034440p; Gomez I, 2001, J BIOL CHEM, V276, P28906, DOI 10.1074/jbc.M103007200; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; Gomez I, 2006, J BIOL CHEM, V281, P34032, DOI 10.1074/jbc.M604721200; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Guereca L, 1999, BBA-PROTEIN STRUCT M, V1429, P342, DOI 10.1016/S0167-4838(98)00241-6; Hardy F, 1997, J IMMUNOL METHODS, V200, P155, DOI 10.1016/S0022-1759(96)00201-3; Herrero S, 2004, BIOCHEM J, V384, P507, DOI 10.1042/BJ20041094; Hua G, 2004, J BIOL CHEM, V279, P28051, DOI 10.1074/jbc.M400237200; Jenkins JL, 1999, FEBS LETT, V462, P373, DOI 10.1016/S0014-5793(99)01559-8; Jurat-Fuentes JL, 2004, EUR J BIOCHEM, V271, P3127, DOI 10.1111/j.1432-1033.2004.04238.x; Jurat-Fuentes JL, 2006, J INVERTEBR PATHOL, V92, P166, DOI 10.1016/j.jip.2006.01.010; Kammerer RA, 2001, J BIOL CHEM, V276, P13685, DOI 10.1074/jbc.M010492200; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; LERECLUS D, 1989, FEMS MICROBIOL LETT, V60, P211, DOI 10.1016/0378-1097(89)90511-9; Likitvivatanavong S, 2006, ARCH BIOCHEM BIOPHYS, V445, P46, DOI 10.1016/j.abb.2005.11.007; LORENCE A, 1995, FEBS LETT, V360, P217, DOI 10.1016/0014-5793(95)00092-N; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Melton-Witt JA, 2006, BIOCHEMISTRY-US, V45, P14347, DOI 10.1021/bi061334p; Menzies BE, 2000, FEMS IMMUNOL MED MIC, V29, P39, DOI 10.1016/S0928-8244(00)00185-1; Meza R, 1996, FEMS MICROBIOL LETT, V145, P333, DOI 10.1111/j.1574-6968.1996.tb08597.x; Mourez M, 2003, P NATL ACAD SCI USA, V100, P13803, DOI 10.1073/pnas.2436299100; Moussa LB, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/80101; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; Munoz-Garay C, 2006, J MEMBRANE BIOL, V212, P61, DOI 10.1007/s00232-006-0003-8; Nelson KL, 1999, CELL MICROBIOL, V1, P69, DOI 10.1046/j.1462-5822.1999.00009.x; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; Pardo-Lopez L, 2006, BIOCHEMISTRY-US, V45, P10329, DOI 10.1021/bi060297z; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Rausell C, 2004, J BIOL CHEM, V279, P55168, DOI 10.1074/jbc.M406279200; Rausell C, 2004, BBA-BIOMEMBRANES, V1660, P99, DOI 10.1016/j.bbamem.2003.11.004; Rausell C, 2004, BIOCHEMISTRY-US, V43, P166, DOI 10.1021/bi035527d; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; THOMAS WE, 1983, J CELL SCI, V60, P181; Tigue NJ, 2001, APPL ENVIRON MICROB, V67, P5715, DOI 10.1128/AEM.67.12.5715-5720.2001; Vachon V, 2002, BIOCHEMISTRY-US, V41, P6178, DOI 10.1021/bi011572e; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; WALTER B, 1995, J BIOL CHEM, V270, P23065; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WU D, 1992, J BIOL CHEM, V267, P2311; Zhang XB, 2006, P NATL ACAD SCI USA, V103, P9897, DOI 10.1073/pnas.0604017103; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	58	78	87	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21222	21229		10.1074/jbc.M701314200	http://dx.doi.org/10.1074/jbc.M701314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17537728	hybrid, Green Published			2022-12-25	WOS:000248047500049
J	Ozden, S; Huerre, M; Riviere, JP; Coffey, LL; Afonso, PV; Mouly, V; de Monredon, J; Roger, JC; El Amrani, M; Yvin, JL; Jaffar, MC; Frenkiel, MP; Sourisseau, M; Schwartz, O; Butler-Browne, G; Despres, P; Gessain, A; Ceccaldi, PE				Ozden, Simona; Huerre, Michel; Riviere, Jean-Pierre; Coffey, Lark L.; Afonso, Philippe V.; Mouly, Vincent; de Monredon, Jean; Roger, Jean-Christophe; El Amrani, Mohamed; Yvin, Jean-Luc; Jaffar, Marie-Christine; Frenkiel, Marie-Pascale; Sourisseau, Marion; Schwartz, Olivier; Butler-Browne, Gillian; Despres, Philippe; Gessain, Antoine; Ceccaldi, Pierre-Emmanuel			Human Muscle Satellite Cells as Targets of Chikungunya Virus Infection	PLOS ONE			English	Article								Background. Chikungunya (CHIK) virus is a mosquito-transmitted alphavirus that causes in humans an acute infection characterised by fever, polyarthralgia, head-ache, and myalgia. Since 2005, the emergence of CHIK virus was associated with an unprecedented magnitude outbreak of CHIK disease in the Indian Ocean. Clinically, this outbreak was characterized by invalidating poly-arthralgia, with myalgia being reported in 97.7% of cases. Since the cellular targets of CHIK virus in humans are unknown, we studied the pathogenic events and targets of CHIK infection in skeletal muscle. Methodology/Principal Findings. Immunohistology on muscle biopsies from two CHIK virus-infected patients with myositic syndrome showed that viral antigens were found exclusively inside skeletal muscle progenitor cells (designed as satelllite cells), and not in muscle fibers. To evaluate the ability of CHIK virus to replicate in human satellite cells, we assessed virus infection on primary human muscle cells; viral growth was observed in CHIK virus-infected satellite cells with a cytopathic effect, whereas myotubes were essentially refractory to infection. Conclusions/Significance. This report provides new insights into CHIK virus pathogenesis, since it is the first to identify a cellular target of CHIK virus in humans and to report a selective infection of muscle satellite cells by a viral agent in humans.	[Ozden, Simona; Afonso, Philippe V.; Gessain, Antoine; Ceccaldi, Pierre-Emmanuel] Inst Pasteur, CNRS, Unite Epidemiol & Physiopathol Virus Oncogenes, URA1930, Paris, France; [Huerre, Michel] Inst Pasteur, Unite Rech & Expertise Histotechnol & Pathol, Paris, France; [Riviere, Jean-Pierre] CHD Felix Guyon, Serv Anatomopathol, St Denis, Reunion, France; [Coffey, Lark L.; Frenkiel, Marie-Pascale; Despres, Philippe] Inst Pasteur, Unite Interact Mol Flavivirus Hotes, Paris, France; [Mouly, Vincent; Butler-Browne, Gillian] Univ Paris 06, INSERM, Inst Myol, U787, Paris, France; [de Monredon, Jean; Roger, Jean-Christophe; El Amrani, Mohamed] CHD Felix Guyon, Serv Neurol, St Denis, Reunion, France; [Yvin, Jean-Luc] CHD Felix Guyon, Serv Med Interne, St Denis, Reunion, France; [Jaffar, Marie-Christine] CHD Felix Guyon, Biol Lab, St Denis, Reunion, France; [Sourisseau, Marion; Schwartz, Olivier] Inst Pasteur, Unite Virus & Immunite, Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CHU Reunion; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU Reunion; CHU Reunion; CHU Reunion; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ceccaldi, PE (corresponding author), Inst Pasteur, CNRS, Unite Epidemiol & Physiopathol Virus Oncogenes, URA1930, Paris, France.	ceccaldi@pasteur.fr	CECCALDI, Pierre-Emmanuel/J-6628-2017; Mouly, Gillian/G-6595-2017; Afonso, Philippe/D-2234-2014; Afonso, Philippe V/ABB-5692-2021; Schwartz, Olivier/AAZ-3765-2021	CECCALDI, Pierre-Emmanuel/0000-0002-2736-2314; Afonso, Philippe/0000-0002-4828-3797; Afonso, Philippe V/0000-0002-4828-3797; Schwartz, Olivier/0000-0002-0729-1475; Mouly, Vincent/0000-0003-3809-4033; butler-browne, gillian/0000-0002-3431-242X; Coffey, Lark/0000-0002-0718-5146	French Minsitry of Research; Association Francaise contre les Myopathies; University Pierre-et-Marie Curie; Centre National de la Recherche Scientifique; ANR/MIME; INSERM; MYORES Network of Excellence; European Commission [511978]; Programmme Transversal de Recherches ``Chikungunya''	French Minsitry of Research; Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); University Pierre-et-Marie Curie; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); ANR/MIME(French National Research Agency (ANR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); MYORES Network of Excellence; European Commission(European CommissionEuropean Commission Joint Research Centre); Programmme Transversal de Recherches ``Chikungunya''	P. V. A. is a recipient from the French Minsitry of Research. This work is supported by the Association Francaise contre les Myopathies, the University Pierre-et-Marie Curie, the Centre National de la Recherche Scientifique, the ANR/MIME, INSERM, MYORES Network of Excellence from the European Commission (6thFP; contract 511978), and the Programmme Transversal de Recherches ``Chikungunya'' of the Pasteur Institute.	[Anonymous], 2006, Wkly Epidemiol Rec, V81, P409; BACHELET T, 2006, B SOC PATHOL EXOT, V99, P144; BISCHOFF R, 1975, ANAT REC, V182, P215, DOI 10.1002/ar.1091820207; Bodenmann P, 2006, LANCET, V368, P258, DOI 10.1016/S0140-6736(06)69046-6; Decary S, 1997, HUM GENE THER, V8, P1429, DOI 10.1089/hum.1997.8.12-1429; FINKELSTEIN S, 1987, PATHOLOGY INFECT DIS; GREISERWILKE I, 1989, J GEN VIROL, V70, P743, DOI 10.1099/0022-1317-70-3-743; Harley D, 2001, CLIN MICROBIOL REV, V14, P909, DOI 10.1128/CMR.14.4.909-932.2001; HIRUMA M, 1990, JPN J VET SCI, V52, P767; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Morrison TE, 2006, J VIROL, V80, P737, DOI 10.1128/JVI.80.2.737-749.2006; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Outbreak news, 2006, WKLY EPIDEMIOL REC, V81, P106; Ozden S, 2005, AM J PATHOL, V167, P1609, DOI 10.1016/S0002-9440(10)61245-X; Paquet C, 2006, EUROSURVEILLANCE, V11; PATTYN SR, 1975, ARCH VIROL, V49, P33, DOI 10.1007/BF02175593; Pfeffer M., 2006, EUROSURVEILLANCE, V11; Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263; SEAY AR, 1981, NEUROLOGY, V31, P656, DOI 10.1212/WNL.31.6.656; SOURISSEAU M, 2007, PLOS PATHOG IN PRESS; Taylor SF, 2005, SOUTH MED J, V98, P484, DOI 10.1097/01.SMJ.0000145879.14102.F4; TESH RB, 1982, ANNU REV MED, V33, P31, DOI 10.1146/annurev.me.33.020182.000335; Trgovcich J, 1996, VIROLOGY, V224, P73, DOI 10.1006/viro.1996.0508; UBOL S, 1991, J VIROL, V65, P6913, DOI 10.1128/JVI.65.12.6913-6921.1991; Villoing S, 2000, J VIROL, V74, P173, DOI 10.1128/JVI.74.1.173-183.2000; WEAVER SC, 2005, TOPLEY WILSONS MICRO, P1010	26	201	204	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e527	10.1371/journal.pone.0000527	http://dx.doi.org/10.1371/journal.pone.0000527			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565380	Green Published, gold			2022-12-25	WOS:000207451600015
J	Kumar, N; Mishra, J; Narang, VS; Waters, CM				Kumar, Narendra; Mishra, Jayshree; Narang, Vishal S.; Waters, Christopher M.			Janus kinase 3 regulates interleukin 2-induced mucosal wound repair through tyrosine phosphorylation of villin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; ULCERATIVE-COLITIS; GROWTH-FACTOR; T-CELLS; RECEPTOR; CHAIN; ACTIVATION; EXPRESSION; DISEASE; CLONING	Janus kinase 3 (Jak3) is a non-receptor tyrosine kinase known to be expressed in hematopoietic cells. Studies of whole organ homogenates show that Jak3 is also expressed in the intestines of both human and mice. However, neither its expression nor its function has been defined in intestinal epithelial enterocytes. The present studies demonstrate that functional Jak3 is expressed in human intestinal enterocytes HT-29 Cl-19A and Caco-2 and plays an essential role in the intestinal epithelial wound repair process in response to interleukin 2 (IL-2). Exogenous IL-2 enhanced the wound repair of intestinal enterocytes in a dose-dependent manner. Activation by IL-2 led to rapid tyrosine phosphorylation and redistribution of Jak3. IL-2-stimulated redistribution of Jak3 was inhibited by the Jak3-specific inhibitor WHI-P131. IL-2 also induced Jak3-dependent redistribution of the actin cytoskeleton in migrating cells. In these cells Jak3 interacted with the intestinal and renal epithelial cell-specific cytoskeletal protein villin in an IL-2-dependent manner. Inhibition of Jak3 activation resulted in loss of tyrosine phosphorylation of villin and a significant decrease in wound repair of the intestinal epithelial cells. Previously, we had shown that tyrosine phosphorylation of villin is important for cytoskeletal remodeling and cell migration. The present study demonstrates a novel pathway in intestinal enterocytes in which IL-2 enhances intestinal wound repair through mechanisms involving Jak3 and its interactions with villin.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Kumar, N (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	nkumar@utmem.edu	MISHRA, JAYSHREE/O-3468-2018	MISHRA, JAYSHREE/0000-0003-0619-0629; Kumar, Narendra/0000-0002-1193-0954	NHLBI NIH HHS [HL-064981, R01 HL064981] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064981] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CIACCI C, 1993, J CLIN INVEST, V92, P527, DOI 10.1172/JCI116598; Dignass AU, 1996, EXP CELL RES, V225, P422, DOI 10.1006/excr.1996.0193; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Hofmann SR, 2004, MOL CELL BIOL, V24, P5039, DOI 10.1128/MCB.24.11.5039-5049.2004; KAEMPFER R, 1994, P SOC EXP BIOL MED, V206, P176; KIKUCHI T, 1991, JPN J CANCER RES, V82, P339, DOI 10.1111/j.1349-7006.1991.tb01851.x; Kumar N, 2004, J BIOL CHEM, V279, P45036, DOI 10.1074/jbc.M405424200; Kumar N, 2004, J BIOL CHEM, V279, P24915, DOI 10.1074/jbc.C400110200; Kumar N, 2004, J BIOL CHEM, V279, P3096, DOI 10.1074/jbc.M308878200; Lin Q, 2005, AM J PATHOL, V167, P969, DOI 10.1016/S0002-9440(10)61187-X; Melgar S, 2003, CLIN EXP IMMUNOL, V134, P127, DOI 10.1046/j.1365-2249.2003.02268.x; Murata Y, 2002, INT IMMUNOL, V14, P627, DOI 10.1093/intimm/dxf031; Nishimura H, 1996, J IMMUNOL, V156, P663; REINECKER HC, 1995, P NATL ACAD SCI USA, V92, P8353, DOI 10.1073/pnas.92.18.8353; Rescigno M, 2005, NAT MED, V11, P254, DOI 10.1038/nm0305-254; RIMM DL, 1995, DIGEST DIS SCI, V40, P389, DOI 10.1007/BF02065426; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Safford MG, 1997, EXP HEMATOL, V25, P374; Sansonetti PJ, 2004, NAT REV IMMUNOL, V4, P953, DOI 10.1038/nri1499; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; Tomar A, 2004, MOL BIOL CELL, V15, P4807, DOI 10.1091/mbc.E04-05-0431; Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901; Wang R, 2003, ARCH BIOCHEM BIOPHYS, V410, P7, DOI 10.1016/S0003-9861(02)00637-9	24	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30341	30345		10.1074/jbc.C600319200	http://dx.doi.org/10.1074/jbc.C600319200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17537734	hybrid			2022-12-25	WOS:000250136300001
J	Waterland, RA; Travisano, M; Tahiliani, KG				Waterland, Robert A.; Travisano, Michael; Tahiliani, Kajal G.			Diet-induced hypermethylation at agouti viable yellow is not inherited transgenerationally through the female	FASEB JOURNAL			English	Article						transgenerational epigenetic inheritance; DNA; methylation; methyl supplementation; nutrition	EPIGENETIC INHERITANCE; GENE-EXPRESSION; DNA METHYLATION; MOUSE; MICE; MAMMALS; ALLELE; LOCUS	The effects of nonmutagenic environmental exposures can sometimes be transmitted for several generations, suggesting transgenerational inheritance of induced epigenetic variation. Methyl donor supplementation of female mice during pregnancy induces CpG hypermethylation at the agouti viable yellow ( A(vy)) allele in A(vy)/a offspring. Epigenetic inheritance occurs at A(vy); when passed through the female germ line, A(vy) epigenotype is not completely "reset." We therefore tested whether diet-induced epigenetic alterations at A(vy) are inherited transgenerationally. Female A(vy)/a mice were weaned onto either control ( n = 6) or a methyl-supplemented diet ( n = 5). These F0 dams were mated with a/a males. All F1 and F2 A(vy)/a females were weaned onto the same diet as their mothers, then mated with a/a males. F1, F2, and F3 A(vy)/a offspring were classified for coat color, an indicator of A(vy) methylation. In total, 62 F1, 98 F2, and 209 F3 A(vy)/a mice were studied. As expected, average A(vy)/a coat color was darker in the supplemented group ( P< 0.01). However, there was no cumulative effect of supplementation across successive generations. These results suggest that, in the female germ line, diet-induced A(vy) hypermethylation occurs in the absence of additional epigenetic modifications that normally confer transgenerational epigenetic inheritance at the locus. - Waterland, R. A., Travisano, M., Tahiliani, K. G. Diet-induced hypermethylation at agouti viable yellow is not inherited transgenerationally through the female.	Baylor Coll Med, Childrens Nutr Res Ctr, USDA, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Childrens Nutr Res Ctr, USDA, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Houston, Dept Biol & Biochem, Houston, TX USA; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine; United States Department of Agriculture (USDA); University of Houston System; University of Houston; University of Minnesota System; University of Minnesota Twin Cities	Waterland, RA (corresponding author), Baylor Coll Med, Childrens Nutr Res Ctr, USDA, Dept Pediat, Houston, TX 77030 USA.	waterland@bcm.edu	Travisano, Michael/AAI-4809-2020	Travisano, Michael/0000-0001-8168-0842	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK070007] Funding Source: NIH RePORTER; NIDDK NIH HHS [5K01DK070007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Blewitt ME, 2006, PLOS GENET, V2, P399, DOI 10.1371/journal.pgen.0020049; Chong SY, 2004, CURR OPIN GENET DEV, V14, P692, DOI 10.1016/j.gde.2004.09.001; Cropley JE, 2006, P NATL ACAD SCI USA, V103, P17308, DOI 10.1073/pnas.0607090103; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859; Lane N, 2003, GENESIS, V35, P88, DOI 10.1002/gene.10168; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538; Pembrey ME, 2002, EUR J HUM GENET, V10, P669, DOI 10.1038/sj.ejhg.5200901; Rakyan VK, 2006, CURR OPIN GENET DEV, V16, P573, DOI 10.1016/j.gde.2006.09.002; Rakyan VK, 2002, TRENDS GENET, V18, P348, DOI 10.1016/S0168-9525(02)02709-9; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; REIK W, 1993, DEVELOPMENT, V119, P933; Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; SPERGEL G, 1971, METABOLISM, V20, P401, DOI 10.1016/0026-0495(71)90102-8; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484; Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230; Wolff GL, 1996, FUND APPL TOXICOL, V29, P176, DOI 10.1006/faat.1996.0019; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949	23	140	146	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3380	3385		10.1096/fj.07-8229com	http://dx.doi.org/10.1096/fj.07-8229com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17551099				2022-12-25	WOS:000249781600038
J	Wooten-Blanks, LG; Song, PF; Senkal, CE; Ogretmen, B				Wooten-Blanks, Leslie G.; Song, Pengfei; Senkal, Can E.; Ogretmen, Besim			Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1	FASEB JOURNAL			English	Article						longevity assurance gene 1 ( LASS1); ceramide synthase; de novo ceramide generation; sphingolipids; lung cancer	LONGEVITY ASSURANCE GENE-1; ADENOCARCINOMA CELL-LINE; HTERT GENE; HUMAN HEAD; GROWTH; ACETYLATION; EXPRESSION; RNA; IDENTIFICATION; INHIBITION	In this study, distinct roles of de novo-generated endogenous ceramides and mechanisms by which deacetylated Sp3 regulates the hTERT promoter activity in response to ceramide signaling were explored. The generation of C-18-ceramide via the expression of ceramide synthase 1 ( CerS1), and not C-16-ceramide by CerS5 or CerS6 expression, resulted in repression of the hTERT promoter via deacetylation of Sp3 by histone deacetylase 1 ( HDAC1) in A549 human lung adenocarcinoma cells. Then roles and mechanisms of action of ceramide-mediated deacetylation of Sp3 in inhibiting the hTERT promoter were determined using constitutively deacetylated or acetylated Sp3 mutants at lysine ( K) 551. Expression of the deacetylated Sp3 mutant resulted in repression, whereas its acetylated mutant induced basal hTERT promoter activity in Drosophila S2 cells, which do not express any endogenous Sp3, and in A549 cells. Remarkably, chromatin immunoprecipitation data revealed that acetylated Sp3 mutant ( K551Q-Sp3) did not bind whereas deacetylated Sp3 ( K551R-Sp3) mutant bound strongly to the promoter DNA, resulting in the recruitment of histone deacetylase 1 ( HDAC1) and inhibition of the association of RNA polymerase II with the promoter. Mechanistically, increased generation of C-18-ceramide by hCerS1 expression, but not by its catalytically inactive mutant, mediated the association and recruitment of the deacetylated Sp3/HDAC1 complex to the hTERT promoter DNA, resulting in the local histone H3 deacetylation and repression of the promoter. - Wooten-Blanks, L. G., Song, P., Senkal, C. E., Ogretmen, B. Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Wooten-Blanks, LG (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	ogretmen@musc.edu			NCI NIH HHS [CA-88932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200; Beyne-Rauzy O, 2005, BLOOD, V106, P3200, DOI 10.1182/blood-2005-04-1386; Bilsland AE, 2006, CANCER RES, V66, P1363, DOI 10.1158/0008-5472.CAN-05-1941; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Crowe DL, 2005, INT J ONCOL, V27, P847; Davis W, 2003, NUCLEIC ACIDS RES, V31, P1097, DOI 10.1093/nar/gkg192; Ellis DJP, 2006, GENE, V379, P68, DOI 10.1016/j.gene.2006.04.015; FOX TE, 2007, IN PRESS J BIOL CHEM; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Gomez-Munoz A, 2005, FEBS LETT, V579, P3744, DOI 10.1016/j.febslet.2005.05.067; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Horikawa I, 1999, CANCER RES, V59, P826; Horikawa L, 2005, P NATL ACAD SCI USA, V102, P18437, DOI 10.1073/pnas.0508964102; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Mitra P, 2007, FEBS LETT, V581, P735, DOI 10.1016/j.febslet.2007.01.041; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Spassieva S, 2006, J BIOL CHEM, V281, P33931, DOI 10.1074/jbc.M608092200; Spengler ML, 2005, CELL SIGNAL, V17, P153, DOI 10.1016/j.cellsig.2004.06.007; Takakura M, 2005, MOL CELL BIOL, V25, P8037, DOI 10.1128/MCB.25.18.8037-8043.2005; Trapp S, 2006, J EXP MED, V203, P1307, DOI 10.1084/jem.20052240; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Wang SW, 2003, J BIOL CHEM, V278, P18842, DOI 10.1074/jbc.M209544200; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wijesinghe DS, 2005, J LIPID RES, V46, P2706, DOI 10.1194/jlr.M500313-JLR200; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Wooten LG, 2005, J BIOL CHEM, V280, P28867, DOI 10.1074/jbc.M413444200	43	50	56	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3386	3397		10.1096/fj.07-8621com	http://dx.doi.org/10.1096/fj.07-8621com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17548428				2022-12-25	WOS:000249781600039
J	Jahani-Asl, A; Cheung, ECC; Neuspiel, M; MacLaurin, JG; Fortin, A; Park, DS; McBride, HM; Slack, RS				Jahani-Asl, Arezu; Cheung, Eric C. C.; Neuspiel, Margaret; MacLaurin, Jason G.; Fortin, Andre; Park, David S.; McBride, Heidi M.; Slack, Ruth S.			Mitofusin 2 protects cerebellar granule neurons against injury-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL FISSION; BAX ACTIVATION; CYTOCHROME-C; FUSION; APOPTOSIS; MFN2; IDENTIFICATION; EXPRESSION; DYNAMICS; RELEASE	Of the GTPases involved in the regulation of the fusion machinery, mitofusin 2 (Mfn2) plays an important role in the nervous system as point mutations of this isoform are associated with Charcot Marie Tooth neuropathy. Here, we investigate whether Mfn2 plays a role in the regulation of neuronal injury. We first examine mitochondrial dynamics following different modes of injury in cerebellar granule neurons. We demonstrate that neurons exposed to DNA damage or oxidative stress exhibit extensive mitochondrial fission, an early event preceding neuronal loss. The extent of mitochondrial fragmentation and remodeling is variable and depends on the mode and the severity of the death stimuli. Interestingly, whereas mitofusin 2 loss of function significantly induces cell death in the absence of any cell death stimuli, expression of mitofusin 2 prevents cell death following DNA damage, oxidative stress, and K+ deprivation induced apoptosis. More importantly, whereas wild-type Mfn2 and the hydrolysis-deficient mutant of Mfn2 (Mfn2(RasG12V)) function equally to promote fusion and lengthening of mitochondria, the activated Mfn2(RasG12V) mutant shows a significant increase in the protection of neurons against cell death and release of proapoptotic factor cytochrome c. These findings highlight a signaling role for Mfn2 in the regulation of apoptosis that extends beyond its role in mitochondrial fusion.	Univ Ottawa, Univ Ottawa Heart Inst, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Dept Cell & Mol Med, Program Neurosci, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; Ottawa Hospital Research Institute	McBride, HM (corresponding author), Univ Ottawa, Univ Ottawa Heart Inst, 40 Ruskin St,Rm H445A, Ottawa, ON K1Y 4W7, Canada.	hmcbride@ottawaheart.ca; rslack@uottawa.ca	McBride, Heidi M./ABD-5774-2021; McBride, Heidi M/C-1162-2008	McBride, Heidi M./0000-0003-4666-2280; McBride, Heidi M/0000-0003-4666-2280; Jahani-Asl, Arezu/0000-0003-4002-3381; Park, David/0000-0002-4490-3784; Slack, Ruth/0000-0002-1552-2835				Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Cole K, 2004, INT J DEV NEUROSCI, V22, P485, DOI 10.1016/j.ijdevneu.2004.07.015; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Delivani P, 2006, MOL CELL, V21, P761, DOI 10.1016/j.molcel.2006.01.034; Detmer SA, 2007, J CELL BIOL, V176, P405, DOI 10.1083/jcb.200611080; Estaquier J, 2007, CELL DEATH DIFFER, V14, P1086, DOI 10.1038/sj.cdd.4402107; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; GOPING IS, 1995, FEBS LETT, V373, P45; Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; Jekabsons MB, 2006, CELL DEATH DIFFER, V13, P1595, DOI 10.1038/sj.cdd.4401851; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; McGahan L, 1998, MOL BRAIN RES, V56, P133, DOI 10.1016/S0169-328X(98)00038-2; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Parone PA, 2006, MOL CELL BIOL, V26, P7397, DOI 10.1128/MCB.02282-05; Piccioli P, 2001, J NEUROSCI RES, V66, P1064, DOI 10.1002/jnr.1251.abs; Pich S, 2005, HUM MOL GENET, V14, P1405, DOI 10.1093/hmg/ddi149; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; YUAN F, 2001, CHIN MED J, V113, P728; Yuan QJ, 2003, DEV NEUROSCI-BASEL, V25, P72, DOI 10.1159/000071470; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	35	155	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23788	23798		10.1074/jbc.M703812200	http://dx.doi.org/10.1074/jbc.M703812200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17537722	hybrid			2022-12-25	WOS:000248686600007
J	Krenz, M; Sadayappan, S; Osinska, HE; Henry, JA; Beck, S; Warshaw, DM; Robbins, J				Krenz, Maike; Sadayappan, Sakthivel; Osinska, Hanna E.; Henry, Jeffrey A.; Beck, Samantha; Warshaw, David M.; Robbins, Jeffrey			Distribution and structure-function relationship of myosin heavy chain isoforms in the adult mouse heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MYOSIN; ATPASE ACTIVITY; CARDIAC-HYPERTROPHY; ACTOMYOSIN ATPASE; MOLECULAR-BASIS; SURFACE LOOPS; EXPRESSION; ACTIN; SMOOTH; BINDING	The two cardiac myosin heavy chain isoforms, alpha and beta, exhibit distinct functional characteristics and therefore may be distributed regionally within the heart to match the functional demands of a specific region. In adult mouse hearts, which predominantly express alpha- myosin heavy chain, we observed high concentrations of beta- myosin in distinct areas such as at the tip of papillary muscles and at the base close to the valvular annulus. In light of these distinct distribution patterns of the myosin isoforms, we subsequently explored the isoform- specific structure function relationships of the myosins. The beta- and beta- isoforms are 93% identical in amino acid sequence, but it remains unclear which of the nonidentical residues determines isoform functionality. We hypothesized that residues situated within or close to the actin- binding interface of the myosin head influence actin binding and thereby modulate actin- activated ATPase activity. A chimeric myosin was created containing beta- sequence from amino acid 417 to 682 within the beta- backbone. In mice, similar to 70% of the endogenous cardiac protein was replaced with the chimeric myosin. Myofibrils containing chimeric myosin exhibited ATPase activities that were depressed to the levels observed in hearts expressing similar to 70% beta- myosin. In vitro motility assays showed that the actin filament sliding velocity generated by chimeric myosin was similar to that of beta- myosin, almost twice the velocities observed with beta- myosin. These data indicate that this large domain sequence switch conferred beta- like actin- activated ATPase activities to the chimeric myosin, suggesting that this region is responsible for the distinct hydrolytic properties of these myosin isoforms.	Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	Cincinnati Children's Hospital Medical Center; University of Vermont	Robbins, J (corresponding author), Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, 3333 Burnet Ave,Mail Locat Code 7020, Cincinnati, OH 45229 USA.	jeff.robbins@cchmc.org		Sadayappan, Sakthivel/0000-0003-2006-7678; Krenz, Maike/0000-0003-3784-287X	NHLBI NIH HHS [HL69799, HL60546, HL59408, HL56370, HL52318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059408, P50HL052318, R01HL056370, R01HL060546] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen DL, 2001, DEV BIOL, V229, P383, DOI 10.1006/dbio.2000.9974; Alpert NR, 2002, AM J PHYSIOL-HEART C, V283, pH1446, DOI 10.1152/ajpheart.00274.2002; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; Chen J, 2003, NUCLEIC ACIDS RES, V31, P474, DOI 10.1093/nar/gkg086; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; EVERETT AW, 1986, FASEB J, V45, P2568; Goodson HV, 1999, J MOL BIOL, V287, P173, DOI 10.1006/jmbi.1999.2565; Harada K, 1999, CIRCULATION, V100, P2093, DOI 10.1161/01.CIR.100.20.2093; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; HOLUBARSCH C, 1985, CIRC RES, V56, P78, DOI 10.1161/01.RES.56.1.78; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; James J, 2005, CIRCULATION, V111, P2339, DOI 10.1161/01.CIR.0000164233.09448.B1; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Krenz M, 2004, J AM COLL CARDIOL, V44, P2390, DOI 10.1016/j.jacc.2004.09.044; Krenz M, 2003, J BIOL CHEM, V278, P17466, DOI 10.1074/jbc.M210804200; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; MCAULIFFE JJ, 1990, CIRC RES, V66, P1204, DOI 10.1161/01.RES.66.5.1204; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Murphy CT, 2000, J MUSCLE RES CELL M, V21, P139, DOI 10.1023/A:1005610007209; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; Nguyen TTT, 1996, CIRC RES, V79, P222, DOI 10.1161/01.RES.79.2.222; Palmer BM, 2004, AM J PHYSIOL-HEART C, V287, pH91, DOI 10.1152/ajpheart.01015.2003; POPE B, 1981, EUR J BIOCHEM, V117, P201; POWERS PM, 1995, AM J PHYSIOL, V268, pC1348; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Sakthivel S, 2005, J BIOL CHEM, V280, P703, DOI 10.1074/jbc.M409513200; SCHIAFFINO S, 1989, CIRC RES, V64, P937, DOI 10.1161/01.RES.64.5.937; Sugiura S, 1998, CIRC RES, V82, P1029, DOI 10.1161/01.RES.82.10.1029; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; Tyska MJ, 2002, CELL MOTIL CYTOSKEL, V51, P1, DOI 10.1002/cm.10014; VANBUREN P, 1995, CIRC RES, V77, P439, DOI 10.1161/01.RES.77.2.439; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703	38	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24057	24064		10.1074/jbc.M704574200	http://dx.doi.org/10.1074/jbc.M704574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17575272	hybrid			2022-12-25	WOS:000248686600031
J	Pan, Q; Chathery, Y; Wu, Y; Rathore, N; Tong, RK; Peale, F; Bagri, A; Tessier-Lavigne, M; Koch, AW; Watts, RJ				Pan, Qi; Chathery, Yvan; Wu, Yan; Rathore, Nisha; Tong, Raymond K.; Peale, Franklin; Bagri, Anil; Tessier-Lavigne, Marc; Koch, Alexander W.; Watts, Ryan J.			Neuropilin-1 binds to VEGF(121) and regulates endothelial cell migration and sprouting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR VEGF; TUMOR-CELLS; RECEPTOR; IDENTIFICATION; ANGIOGENESIS; LETHALITY; SEQUENCE; ISOFORM; GENE	Neuropilin-1 (NRP1) was first described as a receptor for the axon guidance molecule, Semaphorin3A, regulating the development of the nervous system. It was later shown that NRP1 is an isoform- specific receptor for vascular endothelial growth factor ( VEGF), specifically VEGF(165). Much interest has been placed on the role of the various VEGF isoforms in vascular biology. Here we report that blocking NRP1 function, using a recently described antibody that inhibits VEGF(165) binding to NRP1, surprisingly reduces VEGF(121)-induced migration and sprout formation of endothelial cells. Intrigued by this observation, direct binding studies of NRP1 to various VEGF isoforms were performed. We show that VEGF(121) binds directly to NRP1; however, unlike VEGF165, VEGF(121) is not sufficient to bridge the NRP1 center dot VEGFR2 complex. Additionally, we show that VEGFR2 enhances VEGF(165), but not VEGF(121) binding to NRP1. We propose a new model for NRP1 interactions with various VEGF isoforms.	Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Tumor Biol, San Francisco, CA 94080 USA; Genentech Inc, Dept Angiogenesis, San Francisco, CA 94080 USA; Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Koch, AW (corresponding author), Genentech Inc, Dept Prot Chem, 1 DNA Way, San Francisco, CA 94080 USA.	akoch@gene.com; rwatts@gene.com						Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fuh G, 2000, J BIOL CHEM, V275, P26690; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Lei JX, 1998, BBA-GENE STRUCT EXPR, V1443, P400, DOI 10.1016/S0167-4781(98)00240-1; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shraga-Heled N, 2007, FASEB J, V21, P915, DOI 10.1096/fj.06-6277com; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1991, J BIOL CHEM, V266, P11947; von Wronski MA, 2006, J BIOL CHEM, V281, P5702, DOI 10.1074/jbc.M511941200; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang L, 2003, J BIOL CHEM, V278, P48848, DOI 10.1074/jbc.M310047200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200	33	169	177	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24049	24056		10.1074/jbc.M703554200	http://dx.doi.org/10.1074/jbc.M703554200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17575273	hybrid			2022-12-25	WOS:000248686600030
J	Schneiders, FI; Maertens, B; Bose, K; Li, Y; Brunken, WJ; Paulsson, M; Smyth, N; Koch, M				Schneiders, Fiona I.; Maertens, Barbara; Boese, Kerstin; Li, Yong; Brunken, William J.; Paulsson, Mats; Smyth, Neil; Koch, Manuel			Binding of netrin-4 to laminin short arms regulates basement membrane assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER DCC; C-ELEGANS; CHEMOATTRACTANT NETRIN-1; BRANCHING MORPHOGENESIS; AXON GUIDANCE; CELLS; EXPRESSION; GLYCOPROTEIN; RECEPTORS; UNC-5	Netrins were first identified as neural guidance molecules, acting through receptors that are members of the DCC and UNC-5 family. All netrins share structural homology to the laminin N-terminal domains and the laminin epidermal growth factor-like domains of laminin short arms. Laminins use these domains to self-assemble into complex networks. Here we demonstrate that netrin-4 is a component of basement membranes and is integrated into the laminin polymer via interactions with the laminin gamma 1 and gamma 3 short arms. The binding is mediated through the laminin N-terminal domain of netrin-4. In contrast to netrin-4, other members of the netrin family do not bind to these laminin short arms. Moreover, a truncated form of netrin-4 completely inhibits laminin-111 self-assembly in vitro, and full-length netrin-4 can partially disrupt laminin self-interactions. When added to explant cultures, netrin-4 retards salivary gland branching morphogenesis.	Univ Cologne, Ctr Biochem, Fac Med, D-50931 Cologne, Germany; Univ Cologne, Dept Dermatol, Fac Med, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med Cologne, Fac Med, D-50931 Cologne, Germany; Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA; Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England; Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA	University of Cologne; University of Cologne; University of Cologne; Tufts University; University of Southampton; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Koch, M (corresponding author), Univ Cologne, Ctr Biochem, Fac Med, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	Manuel.Koch@uni-koeln.de	Koch, Manuel/AAG-9914-2021	Koch, Manuel/0000-0002-2962-7814; Brunken, William J/0000-0001-7330-1814; Smyth, Neil/0000-0002-3734-2149				Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Dalvin S, 2003, GENE EXPR PATTERNS, V3, P279, DOI 10.1016/S1567-133X(03)00047-4; De Breuck S, 2003, DIABETOLOGIA, V46, P926, DOI 10.1007/s00125-003-1125-5; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hinck L, 2004, DEV CELL, V7, P783, DOI 10.1016/j.devcel.2004.11.002; Jiang Y, 2003, DEV BIOL, V258, P364, DOI 10.1016/S0012-1606(03)00136-2; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Koch M, 2000, J CELL BIOL, V151, P221, DOI 10.1083/jcb.151.2.221; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Liu Y, 2004, CURR BIOL, V14, P897, DOI 10.1016/j.cub.2004.05.020; Lu XW, 2004, NATURE, V432, P179, DOI 10.1038/nature03080; Meyerhardt JA, 1999, CELL GROWTH DIFFER, V10, P35; Nakashiba T, 2002, MECH DEVELOP, V111, P47, DOI 10.1016/S0925-4773(01)00600-1; Nakashiba T, 2000, J NEUROSCI, V20, P6540, DOI 10.1523/JNEUROSCI.20-17-06540.2000; Nguyen A, 2006, P NATL ACAD SCI USA, V103, P6530, DOI 10.1073/pnas.0511011103; Odenthal U, 2004, J BIOL CHEM, V279, P44504, DOI 10.1074/jbc.M402455200; Park KW, 2004, P NATL ACAD SCI USA, V101, P16210, DOI 10.1073/pnas.0405984101; Patel VN, 2006, DIFFERENTIATION, V74, P349, DOI 10.1111/j.1432-0436.2006.00088.x; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Srinivasan K, 2003, DEV CELL, V4, P371, DOI 10.1016/S1534-5807(03)00054-6; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VanRaay TJ, 1997, GENOMICS, V41, P279, DOI 10.1006/geno.1997.4659; Wang H, 1999, J NEUROSCI, V19, P4938; Yebra M, 2003, DEV CELL, V5, P695, DOI 10.1016/S1534-5807(03)00330-7; Yin Y, 2002, MOL CELL NEUROSCI, V19, P344, DOI 10.1006/mcne.2001.1089; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; Yurchenco PD, 2004, CURR OPIN CELL BIOL, V16, P572, DOI 10.1016/j.ceb.2004.07.013	39	67	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23750	23758		10.1074/jbc.M703137200	http://dx.doi.org/10.1074/jbc.M703137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17588941	hybrid			2022-12-25	WOS:000248686600003
J	Thomas, SR; Terentis, AC; Cai, H; Takikawa, O; Levina, A; Lay, PA; Freewan, M; Stocker, R				Thomas, Shane R.; Terentis, Andrew C.; Cai, Hong; Takikawa, Osamu; Levina, Aviva; Lay, Peter A.; Freewan, Mohammed; Stocker, Roland			Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN CATABOLISM; INTERFERON-GAMMA; DENDRITIC CELLS; KYNURENINE PATHWAY; SPECTRAL CHARACTERIZATION; CRYSTAL-STRUCTURE; HEME ENVIRONMENT; CARBON-MONOXIDE; EXPRESSION; METABOLISM	The heme protein indoleamine 2,3-dioxygenase (IDO) is induced by the proinflammatory cytokine interferon-gamma (IFN gamma) and plays an important role in the immune response by catalyzing the oxidative degradation of L-tryptophan (Trp) that contributes to immune suppression and tolerance. Here we examined the mechanism by which nitric oxide (NO) inhibits human IDO activity. Exposure of IFN gamma-stimulated human monocyte-derived macrophages (MDM) to NO donors had no material impact on IDO mRNA or protein expression, yet exposure of MDM or transfected COS-7 cells expressing active human IDO to NO donors resulted in reversible inhibition of IDO activity. NO also inhibited the activity of purified recombinant human IDO (rhIDO) in a reversible manner and this correlated with NO binding to the heme of rhIDO. Optical absorption and resonance Raman spectroscopy identified NO-inactivated rhIDO as a ferrous iron (Fe-II)-NO-Trp adduct. Stopped-flow kinetic studies revealed that NO reacted most rapidly with Fe-II rhIDO in the presence of Trp. These findings demonstrate that NO inhibits rhIDO activity reversibly by binding to the active site heme to trap the enzyme as an inactive nitrosyl-Fe-II enzyme adduct with Trp bound and O-2 displaced. Reversible inhibition by NO may represent an important mechanism in controlling the immune regulatory actions of IDO.	Univ New S Wales, Fac Med, Ctr Vasc Res, Sydney, NSW 2052, Australia; Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA; Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Aichi 4748522, Japan; Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia	University of New South Wales Sydney; State University System of Florida; Florida Atlantic University; National Center for Geriatrics & Gerontology; University of Sydney	Thomas, SR (corresponding author), Univ New S Wales, Fac Med, Ctr Vasc Res, Sydney, NSW 2052, Australia.	shane.thomas@unsw.edu.au	Terentis, Andrew/N-9188-2019; Stocker, Roland/AAV-4489-2021; Lay, Peter A/B-4698-2014	Terentis, Andrew/0000-0001-6137-8275; Lay, Peter A/0000-0002-3232-2720; Levina, Aviva/0000-0002-7311-3263				ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Aitken JB, 2004, BIOCHEMISTRY-US, V43, P4892, DOI 10.1021/bi049645s; AlberatiGiani D, 1997, J IMMUNOL, V159, P419; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Chon SY, 1996, J BIOL CHEM, V271, P17247, DOI 10.1074/jbc.271.29.17247; CHRISTEN S, 1994, J CLIN INVEST, V93, P2149, DOI 10.1172/JCI117211; Fallarino F, 2002, INT IMMUNOL, V14, P65, DOI 10.1093/intimm/14.1.65; Forouhar F, 2007, P NATL ACAD SCI USA, V104, P473, DOI 10.1073/pnas.0610007104; Fujigaki H, 2006, J IMMUNOL, V176, P372, DOI 10.4049/jimmunol.176.1.372; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; HIRATA F, 1977, J BIOL CHEM, V252, P4637; Hortelano S, 2003, J IMMUNOL, V171, P6059, DOI 10.4049/jimmunol.171.11.6059; Hucke C, 2004, INFECT IMMUN, V72, P2723, DOI 10.1128/IAI.72.5.2723-2730.2004; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; Khan S, 1997, J CELL SCI, V110, P2315; Konan KV, 1996, J BIOL CHEM, V271, P19140, DOI 10.1074/jbc.271.32.19140; Littlejohn TK, 2000, PROTEIN EXPRES PURIF, V19, P22, DOI 10.1006/prep.2000.1214; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Orabona C, 2005, J IMMUNOL, V174, P6582, DOI 10.4049/jimmunol.174.11.6582; Samelson-Jones BJ, 2006, BIOCHEMISTRY-US, V45, P8527, DOI 10.1021/bi060143j; Sanni LA, 1998, AM J PATHOL, V152, P611; SONO M, 1986, BIOCHEMISTRY-US, V25, P6089, DOI 10.1021/bi00368a038; SONO M, 1980, J BIOL CHEM, V255, P1339; SONO M, 1989, J BIOL CHEM, V264, P1616; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Sugimoto H, 2006, P NATL ACAD SCI USA, V103, P2611, DOI 10.1073/pnas.0508996103; SUGIMOTO H, 2006, P NATL ACAD SCI US; Takikawa O, 2005, BIOCHEM BIOPH RES CO, V338, P12, DOI 10.1016/j.bbrc.2005.09.032; Taoka S, 2001, J INORG BIOCHEM, V87, P245, DOI 10.1016/S0162-0134(01)00335-X; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; Terentis AC, 2002, J BIOL CHEM, V277, P15788, DOI 10.1074/jbc.M200457200; Terwel D, 2000, EUR J PHARMACOL, V400, P19, DOI 10.1016/S0014-2999(00)00379-4; Thomas DD, 2003, ANTIOXID REDOX SIGN, V5, P307, DOI 10.1089/152308603322110887; THOMAS SR, 1994, J BIOL CHEM, V269, P14457; Thomas SR, 2001, J IMMUNOL, V166, P6332, DOI 10.4049/jimmunol.166.10.6332; Thomas SR, 1999, REDOX REP, V4, P199, DOI 10.1179/135100099101534927; Wang J., 1996, METHODS NITRIC OXIDE, P427; Wang JL, 2003, J BIOL CHEM, V278, P2341, DOI 10.1074/jbc.M211131200; Zegarra-Moran O, 2004, J IMMUNOL, V173, P542, DOI 10.4049/jimmunol.173.1.542; Zhang Y, 2007, BIOCHEMISTRY-US, V46, P145, DOI 10.1021/bi0620095	43	82	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23778	23787		10.1074/jbc.M700669200	http://dx.doi.org/10.1074/jbc.M700669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17535808	hybrid			2022-12-25	WOS:000248686600006
J	Wiley, SE; Paddock, ML; Abresch, EC; Gross, L; van der Geer, P; Nechushtai, R; Murphy, AN; Jennings, PA; Dixon, JE				Wiley, Sandra E.; Paddock, Mark L.; Abresch, Edward C.; Gross, Larry; van der Geer, Peter; Nechushtai, Rachel; Murphy, Anne N.; Jennings, Patricia A.; Dixon, Jack E.			The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; PURIFICATION; DYSFUNCTION	The outer mitochondrial membrane protein mitoNEET was discovered as a binding target of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class used to treat type 2 diabetes (Colca, J. R., McDonald, W. G., Waldon, D. J., Leone, J. W., Lull, J. M., Bannow, C. A., Lund, E. T., and Mathews, W. R. (2004) Am. J. Physiol. 286, E252-E260). We have shown that mitoNEET is a member of a small family of proteins containing a 39-amino-acid CDGSH domain. Although the CDGSH domain is annotated as a zinc finger motif, mitoNEET was shown to contain iron (Wiley, S. E., Murphy, A. N., Ross, S. A., van der Geer, P., and Dixon, J. E. (2007) Proc. Natl. Acad. Sci. U. S. A. 104, 5318-5323). Optical and electron paramagnetic resonance spectroscopy showed that it contained a redox-active pH-labile Fe-S cluster. Mass spectrometry showed the loss of 2Fe and 2S upon cofactor extrusion. Spectroscopic studies of recombinant proteins showed that the 2Fe-2S cluster was coordinated by Cys-3 and His-1. The His ligand was shown to be involved in the observed pH lability of the cluster, indicating that loss of this ligand via protonation triggered release of the cluster. mitoNEET is the first identified 2Fe-2S-containing protein located in the outer mitochondrial membrane. Based on the biophysical data and domain fusion analysis, mitoNEET may function in Fe-S cluster shuttling and/or in redox reactions.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cell & Mol Med, La Jolla, CA 92093 USA; San Diego State Univ, Dept Chem & Biochem, San Diego, CA 92182 USA; Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Dept Plant & Environm Sci, IL-91904 Givat Ram, Israel	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; California State University System; San Diego State University; Hebrew University of Jerusalem	Dixon, JE (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jedixon@ucsd.edu	Murphy, Anne N/H-3217-2016	Murphy, Anne N/0000-0002-5222-9902; Wiley, Sandra/0000-0003-3979-2474	NATIONAL CANCER INSTITUTE [R01CA078629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041637, R01GM054038, R29GM054038] Funding Source: NIH RePORTER; NCI NIH HHS [(RO1)-CA078629] Funding Source: Medline; NIGMS NIH HHS [GM 41637, GM54038] Funding Source: Medline; PHS HHS [18024, 18849] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bogacka I, 2004, DIABETES CARE, V27, P1660, DOI 10.2337/diacare.27.7.1660; CAMMACK R, 1993, METHOD ENZYMOL, V227, P353, DOI 10.1016/0076-6879(93)27014-8; Colca JR, 2006, BIOCHEM PHARMACOL, V72, P125, DOI 10.1016/j.bcp.2006.01.002; Colca JR, 2004, AM J PHYSIOL-ENDOC M, V286, pE252, DOI 10.1152/ajpendo.00424.2003; FEE JA, 1984, J BIOL CHEM, V259, P124; Feinstein DL, 2005, BIOCHEM PHARMACOL, V70, P177, DOI 10.1016/j.bcp.2005.03.033; Fish A, 2003, ACTA CRYSTALLOGR D, V59, P734, DOI 10.1107/S0907444903002245; HOFMANN CA, 1992, DIABETES CARE, V15, P1075, DOI 10.2337/diacare.15.8.1075; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Lill R, 2006, BBA-MOL CELL RES, V1763, P652, DOI 10.1016/j.bbamcr.2006.05.011; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Maechler P, 2006, INT J BIOCHEM CELL B, V38, P696, DOI 10.1016/j.biocel.2005.12.006; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mehta JL, 2006, INT J BIOCHEM CELL B, V38, P794, DOI 10.1016/j.biocel.2005.12.008; Rees DC, 2003, SCIENCE, V300, P929, DOI 10.1126/science.1083075; Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8; Vasudevan Abu R, 2004, Diabetes Technol Ther, V6, P850, DOI 10.1089/dia.2004.6.850; Wiley SE, 2007, P NATL ACAD SCI USA, V104, P5318, DOI 10.1073/pnas.0701078104	19	120	124	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23745	23749		10.1074/jbc.C700107200	http://dx.doi.org/10.1074/jbc.C700107200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584744	hybrid			2022-12-25	WOS:000248686600002
J	Cho, YS; Jones, BF; Vermeire, JJ; Leng, L; DiFedele, L; Harrison, LM; Xiong, HB; Kwong, YKA; Chen, Y; Bucala, R; Lolis, E; Cappello, M				Cho, Yoonsang; Jones, Brian F.; Vermeire, Jon J.; Leng, Lin; DiFedele, Lisa; Harrison, Lisa M.; Xiong, Huabao; Kwong, Yuen-Kwan Amy; Chen, Yibang; Bucala, Richard; Lolis, Elias; Cappello, Michael			Structural and functional characterization of a secreted hookworm macrophage migration inhibitory factor (MIF) that interacts with the human MIF receptor CD74	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAUTOMERASE ACTIVE-SITE; MOLECULAR-CLONING; ANCYLOSTOMA-CEYLANICUM; PARASITIC NEMATODE; REGULATORY ROLE; PROTEIN; HOMOLOG; PURIFICATION; GROWTH; IMMUNIZATION	Hookworms, parasitic nematodes that infect nearly one billion people worldwide, are a major cause of anemia and malnutrition. We hypothesize that hookworms actively manipulate the host immune response through the production of specific molecules designed to facilitate infection by larval stages and adult worm survival within the intestine. A full-length cDNA encoding a secreted orthologue of the human cytokine, Macrophage Migration Inhibitory Factor (MIF) has been cloned from the hookworm Ancylostoma ceylanicum. Elucidation of the three-dimensional crystal structure of recombinant AceMIF (rAceMIF) revealed an overall structural homology with significant differences in the tautomerase sites of the human and hookworm proteins. The relative bioactivities of human and hookworm MIF proteins were compared using in vitro assays of tautomerase activity, macrophage migration, and binding to MIF receptor CD74. The activity of rAceMIF was not inhibited by the ligand ISO-1, which was previously determined to be an inhibitor of the catalytic site of human MIF. These data define unique immunological, structural, and functional characteristics of AceMIF, thereby establishing the potential for selectively inhibiting the hookworm cytokine as a means of reducing parasite survival and disease pathogenesis.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Program Int Child Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; CUNY Mt Sinai Sch Med, Immunobiol Ctr, Dept Pharmacol, New York, NY 10029 USA	Yale University; Yale University; Yale University; Yale University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Lolis, E (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	elias.lolis@yale.edu; michael.cappello@yale.edu		Lolis, Elias/0000-0002-7902-7868; Cappello, Michael/0000-0003-2255-8833; Leng, Lin/0000-0002-0605-358X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007404, R01AI058980, R01AI042310, R01AI065029, R01AI051306, R56AI042310] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI065029-02, R01 AI042310, R01 AI058980, R01 AI051306, T32 AI007404, AI42310, AI065029, AI058980, AI51306, R56 AI042310, AI007404, R01 AI065029] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aeberli D, 2006, RHEUMATOLOGY, V45, P937, DOI 10.1093/rheumatology/kel142; Al-Abed Y, 2005, J BIOL CHEM, V280, P36541, DOI 10.1074/jbc.C500243200; Augustijn KD, 2007, INFECT IMMUN, V75, P1116, DOI 10.1128/IAI.00902-06; Bacher M, 1997, AM J PATHOL, V150, P235; BEAVER PC, 1988, AM J TROP MED HYG, V39, P369, DOI 10.4269/ajtmh.1988.39.369; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Brown AC, 2007, MOL BIOCHEM PARASIT, V151, P141, DOI 10.1016/j.molbiopara.2006.10.017; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bungiro RD, 2004, INFECT IMMUN, V72, P2203, DOI 10.1128/IAI.72.4.2203-2213.2004; Bungiro RD, 2002, MOL BIOCHEM PARASIT, V119, P147, DOI 10.1016/S0166-6851(01)00408-X; Bungiro RD, 2001, J INFECT DIS, V183, P1380, DOI 10.1086/319867; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2003, SCAND J INFECT DIS, V35, P573, DOI 10.1080/00365540310016277; Cheng KF, 2006, BIOORG MED CHEM LETT, V16, P3376, DOI 10.1016/j.bmcl.2006.04.038; Culley FJ, 2000, J IMMUNOL, V165, P6447, DOI 10.4049/jimmunol.165.11.6447; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; Del Valle A, 2003, MOL BIOCHEM PARASIT, V129, P167, DOI 10.1016/S0166-6851(03)00121-X; DeLano WL, 2005, DRUG DISCOV TODAY, V10, P213, DOI 10.1016/S1359-6446(04)03363-X; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Falcone FH, 2001, J IMMUNOL, V167, P5348, DOI 10.4049/jimmunol.167.9.5348; Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1; Geiger SM, 2004, CLIN EXP IMMUNOL, V136, P334, DOI 10.1111/j.1365-2249.2004.02449.x; Jones B.F., 2004, DRUG DISCOV TODAY, V1, P217; Kasper G, 2001, PARASITE IMMUNOL, V23, P141, DOI 10.1046/j.1365-3024.2001.00366.x; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leng L, 2006, CELL RES, V16, P162, DOI 10.1038/sj.cr.7310022; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; LIN ECC, 1958, J BIOL CHEM, V233, P668; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Lue HQ, 2006, CELL SIGNAL, V18, P688, DOI 10.1016/j.cellsig.2005.06.013; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; Maaser C, 2002, GASTROENTEROLOGY, V122, P667, DOI 10.1053/gast.2002.31891; Marson AL, 2001, GENE, V278, P53, DOI 10.1016/S0378-1119(01)00706-5; McDevitt MA, 2006, J EXP MED, V203, P1185, DOI 10.1084/jem.20052398; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Milstone AM, 2000, J BIOL CHEM, V275, P29391, DOI 10.1074/jbc.M002715200; Miska KB, 2007, MOL BIOCHEM PARASIT, V151, P173, DOI 10.1016/j.molbiopara.2006.10.020; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; MOYLE M, 1994, J BIOL CHEM, V269, P10008; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oddo M, 2005, INFECT IMMUN, V73, P3783, DOI 10.1128/IAI.73.6.3783-3786.2005; Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Pastrana DV, 1998, INFECT IMMUN, V66, P5955, DOI 10.1128/IAI.66.12.5955-5963.1998; Rodriguez-Sosa M, 2003, INFECT IMMUN, V71, P1247, DOI 10.1128/IAI.71.3.1247-1254.2003; Sampey AV, 2001, ARTHRITIS RHEUM-US, V44, P1273, DOI 10.1002/1529-0131(200106)44:6<1273::AID-ART219>3.0.CO;2-8; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Shimizu T, 1996, FEBS LETT, V381, P199, DOI 10.1016/0014-5793(96)00120-2; Stavitsky AB, 2003, PARASITE IMMUNOL, V25, P369, DOI 10.1046/j.1365-3024.2003.00641.x; Stephenson LS, 2000, PARASITOLOGY, V121, pS23, DOI 10.1017/S0031182000006491; Sun HW, 1996, PROTEIN ENG, V9, P631, DOI 10.1093/protein/9.8.631; Tan THP, 2001, BIOCHEM J, V357, P373, DOI 10.1042/0264-6021:3570373; Umemiya R, 2007, EXP PARASITOL, V115, P135, DOI 10.1016/j.exppara.2006.07.006; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wu Z, 2003, J PARASITOL, V89, P507, DOI 10.1645/0022-3395(2003)089[0507:MEACOA]2.0.CO;2; Wylie T, 2004, NUCLEIC ACIDS RES, V32, pD423, DOI 10.1093/nar/gkh010; Zang XX, 2002, J BIOL CHEM, V277, P44261, DOI 10.1074/jbc.M204655200	64	77	87	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23447	23456		10.1074/jbc.M702950200	http://dx.doi.org/10.1074/jbc.M702950200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17567581	Green Accepted, hybrid			2022-12-25	WOS:000248577500045
J	Trybus, KM; Gushchin, MI; Lui, H; Hazelwood, L; Krementsova, EB; Volkmann, N; Hanein, D				Trybus, Kathleen M.; Gushchin, Marina I.; Lui, HongJun; Hazelwood, Larnele; Krementsova, Elena B.; Volkmann, Niels; Hanein, Dorit			Effect of calcium on calmodulin bound to the IQ motifs of myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON CRYOMICROSCOPY; CONFORMATIONAL-CHANGE; STRUCTURAL BASIS; APO-CALMODULIN; ATOMIC MODELS; BINDING; ACTIN; RECOGNITION; STATE; RECONSTRUCTIONS	The long neck of unconventional myosin V is composed of six tandem "IQ motifs," which are fully occupied by calmodulin (CaM) in the absence of calcium. Calcium regulates the activity, the folded-to-extended conformational transition, and the processive run length of myosin V, and thus, it is important to understand how calcium affects CaM binding to the IQ motifs. Here we used electron cryomicroscopy together with computer-based docking of crystal structures into three-dimensional reconstructions of actin decorated with a motor domain-two IQ complex to provide an atomic model of myosin V in the presence of calcium. Calcium causes a major rearrangement of the bound CaMs, dissociation of CaM bound to IQ motif 2, and propagated changes in the motor domain. Tryptophan fluorescence spectroscopy showed that calcium-CaM binds to IQ motifs 1, 3, and 5 in a different conformation than apoCaM. Proteolytic cleavage was consistent with CaM preferentially dissociating from the second IQ motif. The enzymatic and mechanical functions of myosin V can, therefore, be modulated both by calcium-dependent conformational changes of bound CaM as well as by CaM dissociation.	Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; Burnham Inst Med Res, Program Cell Adhes, La Jolla, CA 92037 USA	University of Vermont; Sanford Burnham Prebys Medical Discovery Institute	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, 149 Beaumont Ave, Burlington, VT 05405 USA.	kathleen.trybus@uvm.edu; niels@burnham.org			NHLBI NIH HHS [HL38113] Funding Source: Medline; NIAMS NIH HHS [AR47199] Funding Source: Medline; NIGMS NIH HHS [GM076503] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076503] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Hanein D, 1999, ULTRAMICROSCOPY, V76, P233, DOI 10.1016/S0304-3991(98)00086-2; Hanein D, 1997, J CELL BIOL, V139, P387, DOI 10.1083/jcb.139.2.387; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Houdusse A, 2006, P NATL ACAD SCI USA, V103, P19326, DOI 10.1073/pnas.0609436103; Koide H, 2006, BIOCHEMISTRY-US, V45, P11598, DOI 10.1021/bi0613877; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Liu J, 2006, NATURE, V442, P208, DOI 10.1038/nature04719; Lu HL, 2006, J BIOL CHEM, V281, P31987, DOI 10.1074/jbc.M605181200; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Martin SR, 2004, FEBS LETT, V567, P166, DOI 10.1016/j.febslet.2004.04.053; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nguyen H, 2005, NAT STRUCT MOL BIOL, V12, P127, DOI 10.1038/nsmb894; Owen CH, 1996, J STRUCT BIOL, V116, P167, DOI 10.1006/jsbi.1996.0027; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Rost LE, 1998, ULTRAMICROSCOPY, V72, P187, DOI 10.1016/S0304-3991(98)00017-5; Sellers JR, 2006, CURR OPIN CELL BIOL, V18, P68, DOI 10.1016/j.ceb.2005.12.014; Terrak M, 2003, EMBO J, V22, P362, DOI 10.1093/emboj/cdg058; Thirumurugan K, 2006, NATURE, V442, P212, DOI 10.1038/nature04865; Trybus KM, 2005, NAT CELL BIOL, V7, P854, DOI 10.1038/ncb0905-854; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Volkmann N, 2005, MOL CELL, V19, P595, DOI 10.1016/j.molcel.2005.07.015; Volkmann N, 2003, METHOD ENZYMOL, V374, P204, DOI 10.1016/S0076-6879(03)74010-5; Volkmann N, 2003, P NATL ACAD SCI USA, V100, P3227, DOI 10.1073/pnas.0536510100; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; Volkmann N, 1999, J STRUCT BIOL, V125, P176, DOI 10.1006/jsbi.1998.4074; Volkmann N, 2002, J STRUCT BIOL, V138, P123, DOI 10.1016/S1047-8477(02)00009-6; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Yuan T, 1998, BIOCHEMISTRY-US, V37, P3187, DOI 10.1021/bi9716579; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	38	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23316	23325		10.1074/jbc.M701636200	http://dx.doi.org/10.1074/jbc.M701636200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17562702	hybrid			2022-12-25	WOS:000248577500032
J	Bello, R; Feito, MJ; Ojeda, G; Portoles, P; Rojo, JM				Bello, Raquel; Jose Feito, Maria; Ojeda, Gloria; Portoles, Pilar; Rojo, Jose M.			Loss of N-terminal charged residues of mouse CD3 epsilon chains generates isoforms modulating antigen T cell receptor-mediated signals and T cell receptor-CD3 interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGE; BETA FG LOOP; CLASS-II MHC; MONOCLONAL-ANTIBODY; POSITIVE SELECTION; BIOCHEMICAL DIFFERENCES; CRYSTAL-STRUCTURE; PRESENTING CELLS; TCR-CD3 COMPLEX; TCR/CD3 COMPLEX	The antigen T cell receptor (TCR)-CD3 complexes present on the cell surface of CD4(+) T lymphocytes and T cell lines express CD3 epsilon chain isoforms with different isoelectric points (pI), with important structural and functional consequences. The pI values of the isoforms fit the predicted pI values of CD3 epsilon chains lacking one, two, and three negatively charged amino acid residues present in the N-terminal region. Different T cells have different ratios of CD3 epsilon chain isoforms. At a high pI, degraded CD3 epsilon isoforms can be better recognized by certain anti-CD3 monoclonal antibodies such as YCD3-1, the ability of which to bind to the TCR-CD3 complex is directly correlated with the pI of CD3 epsilon. The abundance of CD3 epsilon isoforms can be modified by treatment of T cells with the proteinase inhibitor phenanthroline. In addition, these CD3 epsilon isoforms have functional importance. This is shown, first, by the different structure of TCR-CD3 complexes in cells possessing different amounts of isoforms ( as observed in surface biotinylation experiments), by their different antigen responses, and by the stronger interaction between low pI CD3 epsilon isoforms and the TCR. Second, incubation of cells with phenanthroline diminished the proportion of degraded high pI CD3 epsilon isoforms, but also the ability of the cells to deliver early TCR activation signals. Third, cells expressing mutant CD3 epsilon chains lacking N-terminal acid residues showed facilitated recognition by antibody YCD3-1 and enhanced TCR-mediated activation. Furthermore, the binding avidity of antibody YCD3-1 was different in distinct thymus populations. These results suggest that changes in CD3 epsilon N-terminal chains might help to fine-tune the response of the TCR to its ligands in distinct activation situations or in thymus selection.	CSIC, Ctr Invest Biol, Dept Fisipatol Celular & Mol, E-28040 Madrid, Spain; Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Rojo, JM (corresponding author), CSIC, Ctr Invest Biol, Dept Fisipatol Celular & Mol, Ramiro Maeztu 9, E-28040 Madrid, Spain.	jmrojo@cib.csic.es	Rojo, Jose/ABH-1189-2020; Feito, Maria José/AAE-7813-2020; Portoles, Pilar/R-9492-2019	Feito, Maria José/0000-0001-8623-4913; Portoles, Pilar/0000-0001-6973-0835; Rojo, Jose M./0000-0001-9032-0072				Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; Alarcon B, 2003, IMMUNOL REV, V191, P38, DOI 10.1034/j.1600-065X.2003.00017.x; ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; Altan-Bonnet G, 2005, PLOS BIOL, V3, P1925, DOI 10.1371/journal.pbio.0030356; Arnett KL, 2004, P NATL ACAD SCI USA, V101, P16268, DOI 10.1073/pnas.0407359101; Backstrom BT, 1998, SCIENCE, V281, P835, DOI 10.1126/science.281.5378.835; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; Borroto A, 1998, J BIOL CHEM, V273, P12807, DOI 10.1074/jbc.273.21.12807; BORST J, 1984, NATURE, V312, P455, DOI 10.1038/312455a0; BRENNER MB, 1985, CELL, V40, P183, DOI 10.1016/0092-8674(85)90321-6; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Call ME, 2004, EMBO J, V23, P2348, DOI 10.1038/sj.emboj.7600245; Criado G, 2000, EUR J IMMUNOL, V30, P1469, DOI 10.1002/(SICI)1521-4141(200005)30:5<1469::AID-IMMU1469>3.0.CO;2-V; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; Dittel BN, 1997, J IMMUNOL, V158, P4065; Doucey MA, 2003, J BIOL CHEM, V278, P3257, DOI 10.1074/jbc.M208119200; Feito MJ, 2003, EUR J IMMUNOL, V33, P204, DOI 10.1002/immu.200390023; Ghendler Y, 1998, J EXP MED, V187, P1529, DOI 10.1084/jem.187.9.1529; Gil D, 2002, CELL, V109, P901, DOI 10.1016/S0092-8674(02)00799-7; Gil D, 2005, J EXP MED, V201, P517, DOI 10.1084/jem.20042036; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; Hayes SM, 2006, J EXP MED, V203, P47, DOI 10.1084/jem.20051886; Hayes SM, 2002, J EXP MED, V196, P1653; Hayes SM, 2002, IMMUNITY, V16, P827, DOI 10.1016/S1074-7613(02)00320-5; Hellwig S, 2005, IMMUNOBIOLOGY, V210, P685, DOI 10.1016/j.imbio.2005.07.002; Hogquist KA, 2005, NAT REV IMMUNOL, V5, P772, DOI 10.1038/nri1707; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hong SC, 1997, J IMMUNOL, V159, P4395; Jimenez-Perianez A, 2005, J LEUKOCYTE BIOL, V78, P1386, DOI 10.1189/jlb.1104642; JONES B, 1981, EUR J IMMUNOL, V11, P584, DOI 10.1002/eji.1830110712; Jose ES, 1998, EUR J IMMUNOL, V28, P12; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kjer-Nielsen L, 2003, IMMUNITY, V18, P53, DOI 10.1016/S1074-7613(02)00513-7; Kjer-Nielsen L, 2004, P NATL ACAD SCI USA, V101, P7675, DOI 10.1073/pnas.0402295101; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Kuhns MS, 2007, IMMUNITY, V26, P357, DOI 10.1016/j.immuni.2007.01.015; Kuhns MS, 2006, IMMUNITY, V24, P133, DOI 10.1016/j.immuni.2006.01.006; La Gruta NL, 2004, J IMMUNOL, V172, P3662, DOI 10.4049/jimmunol.172.6.3662; Lucas B, 1999, IMMUNITY, V10, P367, DOI 10.1016/S1074-7613(00)80036-9; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Minguet S, 2007, IMMUNITY, V26, P43, DOI 10.1016/j.immuni.2006.10.019; OJEDA G, 1995, CELL IMMUNOL, V164, P265, DOI 10.1006/cimm.1995.1170; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; PORTOLES P, 1990, J IMMUNOL METHODS, V129, P105, DOI 10.1016/0022-1759(90)90426-V; PORTOLES P, 1989, J IMMUNOL, V142, P4169; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Rabinowitz JD, 1996, IMMUNITY, V5, P125, DOI 10.1016/S1074-7613(00)80489-6; Risueno RM, 2005, BLOOD, V106, P601, DOI 10.1182/blood-2004-12-4763; Risueno RM, 2006, P NATL ACAD SCI USA, V103, P9625, DOI 10.1073/pnas.0601785103; ROJO JM, 1988, J IMMUNOL, V140, P1081; ROJO JM, 1989, EUR J IMMUNOL, V19, P2061, DOI 10.1002/eji.1830191114; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Sanchez A, 2004, EUR J IMMUNOL, V34, P2439, DOI 10.1002/eji.200324259; Schamel WWA, 2006, TRENDS IMMUNOL, V27, P176, DOI 10.1016/j.it.2006.02.005; Schamel WWA, 2005, J EXP MED, V202, P493, DOI 10.1084/jem.20042155; Sprent J, 2002, IMMUNOL REV, V185, P126, DOI 10.1034/j.1600-065X.2002.18512.x; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STAERZ UD, 1987, NATURE, V329, P449, DOI 10.1038/329449a0; Sun ZYJ, 2004, P NATL ACAD SCI USA, V101, P16867, DOI 10.1073/pnas.0407576101; Sun ZYJ, 2001, CELL, V105, P913, DOI 10.1016/S0092-8674(01)00395-6; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; Touma M, 2006, J IMMUNOL, V176, P6812, DOI 10.4049/jimmunol.176.11.6812; VONBOEHMER H, 1997, ANNU REV IMMUNOL, V13, P93; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; Werlen G, 2000, NATURE, V406, P422, DOI 10.1038/35019094; YAGI JJ, 1990, J IMMUNOL, V144, P892; YOON ST, 1994, IMMUNITY, V1, P563; Zapata DA, 1999, J BIOL CHEM, V274, P35119, DOI 10.1074/jbc.274.49.35119; Zapata DA, 2004, J BIOL CHEM, V279, P24485, DOI 10.1074/jbc.M311455200	72	7	7	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22324	22334		10.1074/jbc.M701875200	http://dx.doi.org/10.1074/jbc.M701875200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17561508	Green Published, hybrid			2022-12-25	WOS:000248354200010
J	Chai, SH; Li, MH; Lan, JQ; Xiong, ZG; Saugstad, JA; Simon, RP				Chai, Sunghee; Li, Minghua; Lan, JingQuan; Xiong, Zhi-Gang; Saugstad, Julie A.; Simon, Roger P.			A kinase-anchoring protein 150 and calcineurin are involved in regulation of acid-sensing ion channels ASIC1a and ASIC2a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; EPITHELIAL SODIUM-CHANNEL; HIPPOCAMPAL-NEURONS; CAENORHABDITIS-ELEGANS; ACTIVATED CURRENTS; MEMBRANE TOPOLOGY; GANGLION NEURONS; NMDA RECEPTORS; C INTERACTION; SUBUNIT	Acid-sensing ion channel (ASIC) 1a and ASIC2a are acid-sensing ion channels in central and peripheral neurons. ASIC1a has been implicated in long-term potentiation of synaptic transmission and ischemic brain injury, whereas ASIC2a is involved in mechanosensation. Although the biological role and distribution of ASIC1a and ASIC2a subunits in brain have been well characterized, little is known about the intracellular regulation of these ion channels that modulates their function. Using pulldown assays and mass spectrometry, we have identified A kinase-anchoring protein (AKAP)150 and the protein phosphatase calcineurin as binding proteins to ASIC2a. Extended pull-down and co-immunoprecipitation assays showed that these regulatory proteins also interact with ASIC1a. Transfection of rat cortical neurons with constructs encoding green fluorescent protein- or hemagglutinin-tagged channels showed expression of ASIC1a and ASIC2a in punctate and clustering patterns in dendrites that co-localized with AKAP150. Inhibition of protein kinase A binding to AKAPs by Ht-31 peptide reduces ASIC currents in cortical neurons and Chinese hamster ovary cells, suggesting a role of AKAP150 in association with protein kinase A in ASIC function. We also demonstrated a regulatory function of calcineurin in ASIC1a and ASIC2a activity. Cyclosporin A, an inhibitor of calcineurin, increased ASIC currents in Chinese hamster ovary cells and in cortical neurons, suggesting that activity of ASICs is inhibited by calcineurin-dependent dephosphorylation. These data imply that ASIC down-regulation by calcineurin could play an important role under pathological conditions accompanying intracellular Ca2+ overload and tissue acidosis to circumvent harmful activities mediated by these channels.	Robert S Dow Neurobiol Labs, Legacy Res, Portland, OR 97232 USA		Chai, SH (corresponding author), Robert S Dow Neurobiol Labs, Legacy Res, 1225 NE 2nd Ave, Portland, OR 97232 USA.	schai@downeurobiology.org			NATIONAL EYE INSTITUTE [R03EY015267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042926, R01NS050610] Funding Source: NIH RePORTER; NEI NIH HHS [R03 EY015267-03, R03 EY015267] Funding Source: Medline; NINDS NIH HHS [R01 NS050610, R01NS050610, R01NS42926, R42 NS065515, R01 NS042926] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Baron A, 2002, J BIOL CHEM, V277, P50463, DOI 10.1074/jbc.M208848200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Berdiev BK, 2002, J BIOL CHEM, V277, P45734, DOI 10.1074/jbc.M208995200; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CARR DW, 1992, J BIOL CHEM, V267, P16816; Chu XP, 2002, J NEUROPHYSIOL, V87, P2555, DOI 10.1152/jn.00741.2001; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Deval E, 2004, J BIOL CHEM, V279, P19531, DOI 10.1074/jbc.M313078200; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Ettaiche M, 2004, J NEUROSCI, V24, P1005, DOI 10.1523/JNEUROSCI.4698-03.2004; Farr CD, 2004, J NEUROCHEM, V91, P438, DOI 10.1111/j.1471-4159.2004.02735.x; Faux MC, 1999, BIOCHEM J, V343, P443, DOI 10.1042/0264-6021:3430443; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Gao J, 2005, NEURON, V48, P635, DOI 10.1016/j.neuron.2005.10.011; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; Hoshi N, 2003, NAT NEUROSCI, V6, P564, DOI 10.1038/nn1062; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Krupp JJ, 2002, NEUROPHARMACOLOGY, V42, P593, DOI 10.1016/S0028-3908(02)00031-X; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; Leonard AS, 2003, P NATL ACAD SCI USA, V100, P2029, DOI 10.1073/pnas.252782799; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; McIlwrath SL, 2005, NEUROSCIENCE, V131, P499, DOI 10.1016/j.neuroscience.2004.11.030; Peng BG, 2004, J NEUROSCI, V24, P10167, DOI 10.1523/JNEUROSCI.3196-04.2004; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2004, J BIOL CHEM, V279, P53886, DOI 10.1074/jbc.M407708200; RENARD S, 1994, J BIOL CHEM, V269, P12981; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100	49	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22668	22677		10.1074/jbc.M703624200	http://dx.doi.org/10.1074/jbc.M703624200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17548344	Green Accepted, hybrid			2022-12-25	WOS:000248354200044
J	DeVries-Seimon, TA; Ohm, AM; Humphries, MJ; Reyland, ME				DeVries-Seimon, Tracie A.; Ohm, Angela M.; Humphries, Michael J.; Reyland, Mary E.			Induction of apoptosis is driven by nuclear retention of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKC-DELTA; PROTEOLYTIC ACTIVATION; CELL APOPTOSIS; TRANSLOCATION; ABL; PHOSPHORYLATION; KERATINOCYTES; MITOCHONDRIA; INHIBITION; BINDING	Protein kinase C delta(PKC delta) mediates apoptosis downstream of many apoptotic stimuli. Because of its ubiquitous expression, tight regulation of the proapoptotic function of PKC delta is critical for cell survival. Full-length PKC delta is found in all cells, whereas the catalytic fragment of PKC delta, generated by caspase cleavage, is only present in cells undergoing apoptosis. Here we show that full-length PKC delta transiently accumulates in the nucleus in response to etoposide and that nuclear translocation precedes caspase cleavage of PKC delta. Nuclear PKC delta is either cleaved by caspase 3, resulting in accumulation of the catalytic fragment in the nucleus, or rapidly exported by a Crm1-sensitive pathway, thereby assuring that sustained nuclear accumulation of PKC delta is coupled to caspase activation. Nuclear accumulation of PKC delta is necessary for caspase cleavage, as mutants of PKC delta that do not translocate to the nucleus are not cleaved. However, caspase cleavage of PKC delta per se is not required for apoptosis, as an uncleavable form of PKC delta induces apoptosis when retained in the nucleus by the addition of an SV-40 nuclear localization signal. Finally, we show that kinase negative full-length PKC delta does not translocate to the nucleus in apoptotic cells but instead inhibits apoptosis by blocking nuclear import of endogenous PKC delta. These studies demonstrate that generation of the PKC delta catalytic fragment is a critical step for commitment to apoptosis and that nuclear import and export of PKC delta plays a key role in regulating the survival/death pathway.	Univ Colorado, Hlth Sci Ctr, Sch Dent, Dept Craniofac Biol, Aurora, CO 80045 USA; Columbia Univ, Dept Med, New York, NY 10032 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Columbia University	Reyland, ME (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Dent, Dept Craniofac Biol, 12801 E 17th Ave,Mail Stop 8120,POB 6511, Aurora, CO 80045 USA.	Mary.Reyland@uchsc.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE015648] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chattopadhyay A, 2002, J CELL SCI, V115, P2233; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; D'Costa AM, 2005, CELL DEATH DIFFER, V12, P224, DOI 10.1038/sj.cdd.4401558; da Rocha AB, 2002, ONCOLOGIST, V7, P17, DOI 10.1634/theoncologist.7-1-17; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mecklenbrauker I, 2004, NATURE, V431, P456, DOI 10.1038/nature02955; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Sitailo LA, 2006, J BIOL CHEM, V281, P29703, DOI 10.1074/jbc.M607351200; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Yoshida K, 2006, MOL CELL BIOL, V26, P3414, DOI 10.1128/MCB.26.9.3414-3431.2006; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	34	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22307	22314		10.1074/jbc.M703661200	http://dx.doi.org/10.1074/jbc.M703661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17562707	hybrid			2022-12-25	WOS:000248354200008
J	Milenkovic, D; Gabriel, K; Guiard, B; Schulze-Specking, A; Pfanner, N; Chacinska, A				Milenkovic, Dusanka; Gabriel, Kipros; Guiard, Bernard; Schulze-Specking, Agnes; Pfanner, Nikolaus; Chacinska, Agnieszka			Biogenesis of the essential Tim9-Tim10 chaperone complex of mitochondria - Site-specific recognition of cysteine residues by the intermembrane space receptor Mia40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; SMALL TIM PROTEINS; SACCHAROMYCES-CEREVISIAE; SULFHYDRYL OXIDASE; INNER-MEMBRANE; IMPORT; TRANSLOCATION; CARRIER; ERV1; SYSTEM	The mitochondrial intermembrane space (IMS) contains an essential machinery for protein import and assembly (MIA). Biogenesis of IMS proteins involves a disulfide relay between precursor proteins, the cysteine-rich IMS protein Mia40 and the sulfhydryl oxidase Erv1. How precursor proteins are specifically directed to the IMS has remained unknown. Here we systematically analyzed the role of cysteine residues in the biogenesis of the essential IMS chaperone complex Tim9-Tim10. Although each of the four cysteines of Tim9, as well as of Tim10, is required for assembly of the chaperone complex, only the most amino-terminal cysteine residue of each precursor is critical for translocation across the outer membrane and interaction with Mia40. Mia40 selectively recognizes cysteine-containing IMS proteins in a site-specific manner in organello and in vitro. Our results indicate that Mia40 acts as a trans receptor in the biogenesis of mitochondrial IMS proteins.	Univ Freiburg, Zentrum Biochem & Mol Zellforschung, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France	University of Freiburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Pfanner, N (corresponding author), Univ Freiburg, Zentrum Biochem & Mol Zellforschung, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	nikolaus.pfanner@biochemie.uni-freiburg.de	Pfanner, Nikolaus/AAV-7878-2021	Chacinska, Agnieszka/0000-0002-2832-2568				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Allen S, 2005, J MOL BIOL, V353, P937, DOI 10.1016/j.jmb.2005.08.049; Allen S, 2003, J BIOL CHEM, V278, P38505, DOI 10.1074/jbc.M306027200; Chacinska A, 2004, EMBO J, V23, P3735, DOI 10.1038/sj.emboj.7600389; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; de Marcos-Lousa C, 2006, TRENDS BIOCHEM SCI, V31, P259, DOI 10.1016/j.tibs.2006.03.006; Dolezal P, 2006, SCIENCE, V313, P314, DOI 10.1126/science.1127895; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Gabriel K, 2007, J MOL BIOL, V365, P612, DOI 10.1016/j.jmb.2006.10.038; Gerber J, 2001, J BIOL CHEM, V276, P23486, DOI 10.1074/jbc.M100134200; Herrmann JM, 2005, TRENDS BIOCHEM SCI, V30, P205, DOI 10.1016/j.tibs.2005.02.005; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Koehler CM, 2004, TRENDS BIOCHEM SCI, V29, P1, DOI 10.1016/j.tibs.2003.11.003; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Lu H, 2004, J BIOL CHEM, V279, P18952, DOI 10.1074/jbc.M313045200; Lu H, 2004, J BIOL CHEM, V279, P18959, DOI 10.1074/jbc.M313046200; Lutz T, 2003, EMBO J, V22, P4400, DOI 10.1093/emboj/cdg421; Matouschek A, 2001, NAT STRUCT BIOL, V8, P284, DOI 10.1038/86140; Meisinger Chris, 2006, Methods Mol Biol, V313, P33; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; Naoe M, 2004, J BIOL CHEM, V279, P47815, DOI 10.1074/jbc.M410272200; Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409; Oka T, 2005, MOL CELL, V18, P145, DOI 10.1016/j.molcel.2005.03.022; Prokisch H, 2004, PLOS BIOL, V2, P795, DOI 10.1371/journal.pbio.0020160; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Rissler M, 2005, J MOL BIOL, V353, P485, DOI 10.1016/j.jmb.2005.08.051; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Sevier CS, 2006, ANTIOXID REDOX SIGN, V8, P797, DOI 10.1089/ars.2006.8.797; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Terziyska N, 2005, FEBS LETT, V579, P179, DOI 10.1016/j.febslet.2004.11.072; Terziyska N, 2007, FEBS LETT, V581, P1098, DOI 10.1016/j.febslet.2007.02.014; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Webb CT, 2006, MOL CELL, V21, P123, DOI 10.1016/j.molcel.2005.11.010; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2006, MOL CELL, V21, P145, DOI 10.1016/j.molcel.2006.01.001; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017	51	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22472	22480		10.1074/jbc.M703294200	http://dx.doi.org/10.1074/jbc.M703294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553782	hybrid			2022-12-25	WOS:000248354200025
J	Fujita, Y; Xu, AN; Xie, L; Arunachalam, L; Chou, TC; Jiang, TD; Chiew, SK; Kourtesis, J; Wang, L; Gaisano, HY; Sugita, S				Fujita, Yoshihito; Xu, Ainan; Xie, Li; Arunachalam, Lakshmanan; Chou, Ting-Chieh; Jiang, Tiandan; Chiew, Soon-Kwang; Kourtesis, John; Wang, Li; Gaisano, Herbert Y.; Sugita, Shuzo			Ca2+-dependent activator protein for secretion 1 is critical for constitutive and regulated exocytosis but not for loading of transmitters into dense core vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-DEPENDENT EXOCYTOSIS; CAENORHABDITIS-ELEGANS; NEUROTROPHIN RELEASE; KINETIC COMPONENTS; CHROMAFFIN CELLS; SYNAPTOTAGMIN-I; CAPS; FUSION; MEMBRANE; BRAIN	Although CAPS1 was originally identified as a soluble factor that reconstitutes Ca2+ -dependent secretion from permeabilized neuroendocrine cells, its exact function in intact mammalian cells remains controversial. Here we investigate the role for CAPS1 by generating stable cell lines in which CAPS1 is strongly down-regulated. In these cells, Ca2+ -dependent secretion was strongly reduced not only of catecholamine but also of a transfected neuropeptide. These secretion defects were rescued by infusion of CAPS1-containing brain cytosol or by transfection-mediated expression of CAPS1. Whole cell patch clamp recording revealed significant reductions in slow burst and sustained release components of exocytosis in the knockdown cells. Unexpectedly, they also accumulated higher amounts of endogenous and exogenous transmitters, which were attributable to reductions in constitutive secretion. Electron microscopy did not reveal abnormalities in the number or docking of dense core vesicles. Our results indicate that CAPS1 plays critical roles not only in Ca2+ -dependent, regulated exocytosis but also in constitutive exocytosis downstream of vesicle docking. However, they do not support the role for CAPS1 in loading transmitters into dense core vesicles.	Univ Hlth Network, Toronto Western Res Inst, Div Fundamental Neurobiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Med, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Sugita, S (corresponding author), Univ Hlth Network, Toronto Western Res Inst, Div Fundamental Neurobiol, 399 Bathurst St,MC11-432, Toronto, ON M5T 2S8, Canada.	ssugita@uhnres.utoronto.ca		Sugita, Shuzo/0000-0002-9182-873X				Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; Avery Leon, 1993, Genetics, V134, P455; BRENNER S, 1974, GENETICS, V77, P71; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Charlie NK, 2006, GENETICS, V172, P943, DOI 10.1534/genetics.105.049577; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Elhamdani A, 1999, J NEUROSCI, V19, P7375, DOI 10.1523/JNEUROSCI.19-17-07375.1999; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grishanin RN, 2004, NEURON, V43, P551, DOI 10.1016/j.neuron.2004.07.028; Grishanin RN, 2002, J BIOL CHEM, V277, P22025, DOI 10.1074/jbc.M201614200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; Kang LJ, 2006, CELL METAB, V3, P463, DOI 10.1016/j.cmet.2006.04.012; Khvotchev MV, 2003, J NEUROSCI, V23, P10531; Lakshmana MK, 1997, ANAL BIOCHEM, V246, P166, DOI 10.1006/abio.1996.9997; Li G, 2005, J NEUROSCI, V25, P10188, DOI 10.1523/JNEUROSCI.3560-05.2005; Li G, 2007, J NEUROSCI, V27, P190, DOI 10.1523/JNEUROSCI.2537-06.2007; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Renden R, 2001, NEURON, V31, P421, DOI 10.1016/S0896-6273(01)00382-8; Rupnik M, 2000, P NATL ACAD SCI USA, V97, P5627, DOI 10.1073/pnas.090359097; Sadakata T, 2006, J COMP NEUROL, V495, P735, DOI 10.1002/cne.20947; Sadakata T, 2007, J NEUROSCI, V27, P2472, DOI 10.1523/JNEUROSCI.2279-06.2007; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sorensen JB, 2004, PFLUG ARCH EUR J PHY, V448, P347, DOI 10.1007/s00424-004-1247-8; Speidel D, 2005, NEURON, V46, P75, DOI 10.1016/j.neuron.2005.02.019; Speidel D, 2003, J BIOL CHEM, V278, P52802, DOI 10.1074/jbc.M304727200; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wang L, 2004, J BIOL CHEM, V279, P19875, DOI 10.1074/jbc.M400522200; Whim MD, 2006, J NEUROSCI, V26, P6637, DOI 10.1523/JNEUROSCI.5100-05.2006; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642	37	40	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21392	21403		10.1074/jbc.M703699200	http://dx.doi.org/10.1074/jbc.M703699200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17540763	hybrid			2022-12-25	WOS:000248047500067
J	Hardee, ME; Cao, YT; Fu, P; Jiang, XH; Zhao, YL; Rabbani, ZN; Vujaskovic, Z; Dewhirst, MW; Arcasoy, MO				Hardee, Matthew E.; Cao, Yiting; Fu, Ping; Jiang, Xiaohong; Zhao, Yulin; Rabbani, Zahid N.; Vujaskovic, Zeljko; Dewhirst, Mark W.; Arcasoy, Murat O.			Erythropoietin Blockade Inhibits the Induction of Tumor Angiogenesis and Progression	PLOS ONE			English	Article								Background. The induction of tumor angiogenesis, a pathologic process critical for tumor progression, is mediated by multiple regulatory factors released by tumor and host cells. We investigated the role of the hematopoietic cytokine erythropoietin as an angiogenic factor that modulates tumor progression. Methodology/Principal Findings. Fluorescently-labeled rodent mammary carcinoma cells were injected into dorsal skin-fold window chambers in mice, an angiogenesis model that allows direct, non-invasive, serial visualization and real-time assessment of tumor cells and neovascularization simultaneously using intravital microscopy and computerized image analysis during the initial stages of tumorigenesis. Erythropoietin or its antagonist proteins were co-injected with tumor cells into window chambers. In vivo growth of cells engineered to stably express a constitutively active erythropoietin receptor EPOR-R129C or the erythropoietin antagonist R103A-EPO were analyzed in window chambers and in the mammary fat pads of athymic nude mice. Co-injection of erythropoietin with tumor cells or expression of EPOR-R129C in tumor cells significantly stimulated tumor neovascularization and growth in window chambers. Co-injection of erythropoietin antagonist proteins (soluble EPOR or anti-EPO antibody) with tumor cells or stable expression of antagonist R103A-EPO protein secreted from tumor cells inhibited angiogenesis and impaired tumor growth. In orthotopic tumor xenograft studies, EPOR-R129C expression significantly promoted tumor growth associated with increased expression of Ki67 proliferation antigen, enhanced microvessel density, decreased tumor hypoxia, and increased phosphorylation of extracellular-regulated kinases ERK1/2. R103A-EPO antagonist expression in mammary carcinoma cells was associated with near-complete disruption of primary tumor formation in the mammary fat pad. Conclusions/Significance. These data indicate that erythropoietin is an important angiogenic factor that regulates the induction of tumor cell-induced neovascularization and growth during the initial stages of tumorigenesis. The suppression of tumor angiogenesis and progression by erythropoietin blockade suggests that erythropoietin may constitute a potential target for the therapeutic modulation of angiogenesis in cancer.	[Fu, Ping; Jiang, Xiaohong; Arcasoy, Murat O.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Hardee, Matthew E.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Cao, Yiting; Zhao, Yulin; Rabbani, Zahid N.; Vujaskovic, Zeljko; Dewhirst, Mark W.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA	Duke University; Duke University; Duke University	Arcasoy, MO (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	arcas001@mc.duke.edu	Dewhirst, Mark/Q-1302-2019	Dewhirst, Mark/0000-0003-3459-6546; Rabbani, zahid/0000-0002-4101-7947	National Institutes of Health (NCI) [CA40355, CA100844]; Department of Defense [DAMD17-03-1-0968, DAMD17-05-1-0294]; NATIONAL CANCER INSTITUTE [R01CA100844, R01CA040355] Funding Source: NIH RePORTER	National Institutes of Health (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was funded by grants from the National Institutes of Health (NCI) Duke SPORE in breast cancer CA40355 and CA100844, and the Department of Defense DAMD17-03-1-0968 and DAMD17-05-1-0294.	Arcasoy MO, 1997, MOL CELL BIOL, V17, P2076, DOI 10.1128/MCB.17.4.2076; Arcasoy MO, 2002, BLOOD, V99, P3066, DOI 10.1182/blood.V99.8.3066; Bahlmann FH, 2004, BLOOD, V103, P921, DOI 10.1182/blood-2003-04-1284; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blackwell KL, 2003, CANCER RES, V63, P6162; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Burns S, 2002, BLOOD, V99, P4400, DOI 10.1182/blood.V99.12.4400; Cao YT, 2005, CANCER RES, V65, P5498, DOI 10.1158/0008-5472.CAN-04-4553; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Feldman L, 2006, PROSTATE, V66, P135, DOI 10.1002/pros.20310; Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015; Folkman J, 2000, JNCI-J NATL CANCER I, V92, P94, DOI 10.1093/jnci/92.2.94; Gewirtz DA, 2006, CLIN CANCER RES, V12, P2232, DOI 10.1158/1078-0432.CCR-05-2287; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Hanlon PR, 2005, FASEB J, V19, P1323, DOI 10.1096/fj.04-3545fje; Hardee ME, 2006, CLIN CANCER RES, V12, P332, DOI 10.1158/1078-0432.CCR-05-1771; Hardee ME, 2005, BRIT J CANCER, V93, P1350, DOI 10.1038/sj.bjc.6602846; HARDEE ME, 2006, MOL CANCER THER, V5, P536; Haroon ZSA, 2003, AM J PATHOL, V163, P993, DOI 10.1016/S0002-9440(10)63459-1; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; Henke M, 2006, J CLIN ONCOL, V24, P4708, DOI 10.1200/JCO.2006.06.2737; Huang Q, 1999, NAT BIOTECHNOL, V17, P1033, DOI 10.1038/13736; Jaquet K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/mvre.2002.2426; Kertesz N, 2004, DEV BIOL, V276, P101, DOI 10.1016/j.ydbio.2004.08.025; LaMontagne KR, 2006, MOL CANCER THER, V5, P347, DOI 10.1158/1535-7163.MCT-05-0203; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lester RD, 2005, J BIOL CHEM, V280, P39273, DOI 10.1074/jbc.M509446200; Leyland-Jones B, 2005, J CLIN ONCOL, V23, P5960, DOI 10.1200/JCO.2005.06.150; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Menon MP, 2006, J CLIN INVEST, V116, P683, DOI 10.1172/JCI25227; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Moucadel V, 2005, J BIOL CHEM, V280, P13364, DOI 10.1074/jbc.M407326200; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; Qiu HW, 1998, J BIOL CHEM, V273, P11173, DOI 10.1074/jbc.273.18.11173; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Shan SQ, 2003, FASEB J, V17, P326, DOI 10.1096/fj.03-0765fje; Shikama Y, 1996, BLOOD, V88, P455, DOI 10.1182/blood.V88.2.455.bloodjournal882455; Tovari J, 2005, CANCER RES, V65, P7186, DOI 10.1158/0008-5472.CAN-04-2498; Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773; Wright JR, 2007, J CLIN ONCOL, V25, P1027, DOI 10.1200/JCO.2006.07.1514; Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060; Yasuda Y, 2002, CARCINOGENESIS, V23, P1797, DOI 10.1093/carcin/23.11.1797; Yasuda Y, 2001, BRIT J CANCER, V84, P836, DOI 10.1054/bjoc.2000.1666; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	51	83	86	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e549	10.1371/journal.pone.0000549	http://dx.doi.org/10.1371/journal.pone.0000549			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579721	Green Submitted, gold, Green Published			2022-12-25	WOS:000207451700015
J	Nickle, DC; Heath, L; Jensen, MA; Gilbert, PB; Mullins, JI; Pond, SLK				Nickle, David C.; Heath, Laura; Jensen, Mark A.; Gilbert, Peter B.; Mullins, James I.; Pond, Sergei L. Kosakovsky			HIV-Specific Probabilistic Models of Protein Evolution	PLOS ONE			English	Article								Comparative sequence analyses, including such fundamental bioinformatics techniques as similarity searching, sequence alignment and phylogenetic inference, have become a mainstay for researchers studying type 1 Human Immunodeficiency Virus (HIV-1) genome structure and evolution. Implicit in comparative analyses is an underlying model of evolution, and the chosen model can significantly affect the results. In general, evolutionary models describe the probabilities of replacing one amino acid character with another over a period of time. Most widely used evolutionary models for protein sequences have been derived from curated alignments of hundreds of proteins, usually based on mammalian genomes. It is unclear to what extent these empirical models are generalizable to a very different organism, such as HIV-1-the most extensively sequenced organism in existence. We developed a maximum likelihood model fitting procedure to a collection of HIV-1 alignments sampled from different viral genes, and inferred two empirical substitution models, suitable for describing between-and within-host evolution. Our procedure pools the information from multiple sequence alignments, and provided software implementation can be run efficiently in parallel on a computer cluster. We describe how the inferred substitution models can be used to generate scoring matrices suitable for alignment and similarity searches. Our models had a consistently superior fit relative to the best existing models and to parameter-rich data-driven models when benchmarked on independent HIV-1 alignments, demonstrating evolutionary biases in amino-acid substitution that are unique to HIV, and that are not captured by the existing models. The scoring matrices derived from the models showed a marked difference from common amino-acid scoring matrices. The use of an appropriate evolutionary model recovered a known viral transmission history, whereas a poorly chosen model introduced phylogenetic error. We argue that our model derivation procedure is immediately applicable to other organisms with extensive sequence data available, such as Hepatitis C and Influenza A viruses.	[Pond, Sergei L. Kosakovsky] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Nickle, David C.; Heath, Laura; Jensen, Mark A.; Mullins, James I.] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; [Gilbert, Peter B.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Gilbert, Peter B.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of California System; University of California San Diego; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Pond, SLK (corresponding author), Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.	spond@ucsd.edu	Nickle, David/ABF-2727-2020; Pond, Sergei LK/G-9830-2012	Pond, Sergei LK/0000-0003-4817-4029; Jensen, Mark/0000-0001-5215-101X	National Institutes of Health [AI43638, AI47745, AI57167, R01-GM66276, 5R01AI058894-03, 5P01AI057005-04, 2 RO1 AI054165-04]; University of California University wide AIDS Research Program [IS 02-SD-701]; University of California, San Diego Center for AIDS Research/NIAID Developmental Award [AI36214]; University of Washington Center for AIDS Research and STDs [P30-AI-27757]; Boeing Corporation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI043638, R01AI054165, P30AI027757, R56AI047745, P01AI057005, R01AI058894, R21AI047745, P30AI036214, R01AI057167, R01AI047745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066276] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California University wide AIDS Research Program(University of California System); University of California, San Diego Center for AIDS Research/NIAID Developmental Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); University of Washington Center for AIDS Research and STDs; Boeing Corporation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported in part by the National Institutes of Health (AI43638, AI47745, and AI57167, R01-GM66276), the University of California University wide AIDS Research Program (IS 02-SD-701), and by a University of California, San Diego Center for AIDS Research/NIAID Developmental Award to SLKP (AI36214). Additional support came from the National Institutes of Health (5R01AI058894-03, 5P01AI057005-04) and from the University of Washington Center for AIDS Research and STDs (P30-AI-27757) and a gift from Boeing Corporation all awarded to JIM and NIH award 2 RO1 AI054165-04 awarded to PBG. The funders had no influence on the preparation, review, or approval of the manuscript.	Adachi J, 1996, J MOL EVOL, V42, P459; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Burnham K.P., 2002, MODEL SELECTION MULT, DOI 10.1007/b97636; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Dimmic MW, 2002, J MOL EVOL, V55, P65, DOI 10.1007/s00239-001-2304-y; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Herbeck JT, 2006, J VIROL, V80, P1637, DOI 10.1128/JVI.80.4.1637-1644.2006; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KARLIN S, 1985, P NATL ACAD SCI USA, V82, P8597, DOI 10.1073/pnas.82.24.8597; Pond SLK, 2007, MOL BIOL EVOL, V24, P159, DOI 10.1093/molbev/msl144; Pond SLK, 2006, PLOS COMPUT BIOL, V2, P530, DOI 10.1371/journal.pcbi.0020062; Pond SLK, 2006, MOL BIOL EVOL, V23, P1891, DOI 10.1093/molbev/msl051; Leitner T, 1996, P NATL ACAD SCI USA, V93, P10864, DOI 10.1073/pnas.93.20.10864; Liu Y, 2006, J VIROL, V80, P9519, DOI 10.1128/JVI.00575-06; Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436; MUSE SV, 1994, MOL BIOL EVOL, V11, P715; Nachman MW, 2000, GENETICS, V156, P297; Nickle DC, 2003, SCIENCE, V299, P1515; Pond SLK, 2005, MOL BIOL EVOL, V22, P223, DOI 10.1093/molbev/msi009; Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079; POND SLK, 2006, MOL BIOL EVOL; Posada D, 2004, SYST BIOL, V53, P793, DOI 10.1080/10635150490522304; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Stanfel LE, 1996, J THEOR BIOL, V183, P195, DOI 10.1006/jtbi.1996.0213; SUGIURA N, 1978, COMMUN STAT A-THEOR, V7, P13, DOI 10.1080/03610927808827599; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Tang H, 2004, MOL BIOL EVOL, V21, P1548, DOI 10.1093/molbev/msh158; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; Yampolsky LY, 2005, GENETICS, V170, P1459, DOI 10.1534/genetics.104.039107; Yang ZH, 1998, MOL BIOL EVOL, V15, P1600, DOI 10.1093/oxfordjournals.molbev.a025888	37	72	75	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e503	10.1371/journal.pone.0000503	http://dx.doi.org/10.1371/journal.pone.0000503			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551583	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451500012
J	Pilkinton, M; Sandoval, R; Colamonici, OR				Pilkinton, M.; Sandoval, R.; Colamonici, O. R.			Mammalian Mip/LIN-9 interacts with either the p107, p130/E2F4 repressor complex or B-Myb in a cell cycle-phase-dependent context distinct from the Drosophila dREAM complex	ONCOGENE			English	Article						cell cycle; LIN-9; pocket proteins; CDK; cyclin; Myb	IN-VIVO; PROTEIN; TRANSCRIPTION; PHOSPHORYLATION; E2F; ACTIVATION; IDENTIFICATION; EXPRESSION; LIN-9; PRB	Mammalian Mip/LIN-9 is a cell cycle regulatory protein that is negatively regulated by CDK4/cyclin D. It has been demonstrated that Mip/LIN-9 collaborates with B-Myb during S and G2/M in the induction of cyclins A and B, and CDK1. The ortholog of Mip/LIN-9 in (D) under bar rosophila, Mip130, is part of a large multisubunit protein complex that includes (R) under bar BF, repressor (E) under bar 2Fs (a) under bar nd (M) under bar yb, in what was termed the dREAM complex. A similar complex, although lacking B-Myb, was also described in Caenorhabditis elegans. Here, we demonstrate that unlike Drosophila, Mip/LIN-9 has mutually exclusive and cell cycle-phasespeci. c interactions with the mammalian orthologs of the dREAM complex. In G(0)/early G(1), Mip/LIN-9 forms a complex with E2F4 and p107 or p130, while in late G(1)/S phase, it associates with B-Myb. The separation of Mip/LIN-9 from p107, p130/E2F4 is likely driven by phosphorylation of the pocket proteins by CDK4 since Mip/LIN-9 fails to interact with phosphorylated forms of p107, p130. Importantly, the repressor complex that Mip/LIN-9 forms with p107 takes functional precedence over the transcriptional activation linked to the Mip/LIN-9 and B-Myb interaction since expression of p107 blocks the activation of the cyclin B promoter triggered by B-Myb and Mip/LIN-9.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott,Room E403 M-C 868, Chicago, IL 60612 USA.	ocolamon@uic.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK07739] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Beall EL, 2004, GENE DEV, V18, P1667, DOI 10.1101/gad.1206604; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Beitel GJ, 2000, GENE, V254, P253, DOI 10.1016/S0378-1119(00)00296-1; Bhatt AM, 2004, GENE, V336, P219, DOI 10.1016/j.gene.2004.03.033; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Burgess A, 2006, J BIOL CHEM, V281, P9987, DOI 10.1074/jbc.M512714200; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; Ciemerych MA, 2005, ONCOGENE, V24, P2877, DOI 10.1038/sj.onc.1208608; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; FERGUSON EL, 1989, GENETICS, V123, P109; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gagrica S, 2004, EMBO J, V23, P4627, DOI 10.1038/sj.emboj.7600470; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Petrovas C, 2003, ONCOGENE, V22, P2011, DOI 10.1038/sj.onc.1206231; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; Sandoval R, 2006, EXP CELL RES, V312, P2465, DOI 10.1016/j.yexcr.2006.04.002; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Takahashi Y, 2000, GENE DEV, V14, P804; Vousden K H, 1990, Semin Cancer Biol, V1, P415; White-Cooper H, 1998, DEVELOPMENT, V125, P125; White-Cooper H, 2000, DEVELOPMENT, V127, P5463; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	51	87	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7535	7543		10.1038/sj.onc.1210562	http://dx.doi.org/10.1038/sj.onc.1210562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563750				2022-12-25	WOS:000251282100005
J	Glenn, JV; Beattie, JR; Barrett, L; Frizzell, N; Thorpe, SR; Boulton, ME; McGarvey, JJ; Stitt, AW				Glenn, Josephine V.; Beattie, J. Renwick; Barrett, Lindsay; Frizzell, Norma; Thorpe, Suzanne R.; Boulton, Mike E.; McGarvey, John J.; Stitt, Alan W.			Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging	FASEB JOURNAL			English	Article						RPE; Raman spectroscopy	MAILLARD REACTION-PRODUCTS; RETINAL-PIGMENT EPITHELIUM; HUMAN ARTICULAR-CARTILAGE; MACULAR DEGENERATION; SKIN COLLAGEN; DIABETIC-RETINOPATHY; LENS CRYSTALLINS; PROTEINS; ACCUMULATION; N-EPSILON-(CARBOXYMETHYL)LYSINE	The modification of proteins by nonenzymatic glycation leading to accumulation of advanced glycation end products ( AGEs) is a well-established phenomenon of aging. In the eyes of elderly patients, these adducts have been observed in retinal pigment epithelium (RPE), particularly within the underlying pentalaminar substrate known as Bruch's membrane. AGEs have also been localized to age-related subcellular deposits ( drusen and basal laminar deposits) and are thought to play a pathogenic role in progression of the major sight-threatening condition known as age-related macular degeneration (AMD). The current study has quantified AGEs in Bruch's membrane from postmortem eyes and established age-related correlations. In particular, we investigated the potential of confocal Raman microscopy to identify and quantify AGEs in Bruch's membrane in a nondestructive, analytical fashion. Bruch's membrane and the innermost layers of the underlying choroid (BM-Ch) were dissected from fresh postmortem eye-cups (n = 56). AGE adducts were quantified from homogenized tissue using reverse-phase HPLC and GC/MS in combination with immunohistochemistry. For parallel Raman analysis, BM-Ch was flat-mounted on slides and evaluated using a Raman confocal microscope and spectra analyzed by a range of statistical approaches. Quantitative analysis showed that the AGEs pentosidine, carboxymethyllysine (CML), and carboxyethyllysine (CEL) occurred at significantly higher levels in BM-Ch with age (P<0.05-0.01). Defined Raman spectral "fingerprints" were identified for various AGEs and these were observed in the clinical samples using confocal Raman microscopy. The Raman data set successfully modeled AGEs and not only provided quantitative data that compared with conventional analytical approaches, but also provided new and complementary information via a nondestructive approach with high spatial resolution. It was shown that the Raman approach could be used to predict chronological age of the clinical samples (P<0.001) and a difference in the Raman spectra between genders was highly significant (P<0.000001). With further development, this Raman-based approach has the potential for noninvasive examination of AGE adducts in living eyes and ultimately to assess their precise pathogenic role in age-related diseases.	Queens Univ Belfast, Fac Med & Hlth Sci, Sch Biomed Sci, Ctr Vis Sci, Belfast, Antrim, North Ireland; Queens Univ Belfast, Sch Chem & Chem Engn, Belfast, Antrim, North Ireland; Queens Univ Belfast, Ctr Clin Raman Microscopy, Belfast, Antrim, North Ireland; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ Texas, Med Branch, Dept Ophthalmol & Vis Sci, Galveston, TX 77550 USA	Queens University Belfast; Queens University Belfast; Queens University Belfast; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Texas System; University of Texas Medical Branch Galveston	Stitt, AW (corresponding author), Queens Univ Belfast, Royal Victoria Hosp, Ctr Vis Sci, Sch Biomed Sci, Belfast BT12 6BA, Antrim, North Ireland.	a.stitt@qub.ac.uk	Stitt, Alan/A-9842-2009; Beattie, Renwick/B-7810-2008; Beattie, James Renwick/I-4506-2015	Stitt, Alan/0000-0002-8647-9918; Beattie, James Renwick/0000-0002-0205-717X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; MRC [G0600053] Funding Source: UKRI; Medical Research Council [G0600053] Funding Source: Medline; NIDDK NIH HHS [DK19971] Funding Source: Medline; Wellcome Trust [WT066193] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust)		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; [Anonymous], 2001, NEAR INFRARED TECHNO; Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3; Beattie JR, 2005, MOL VIS, V11, P825; BEATTIE JR, 2007, IN PRESS MOL VISION; Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004; Cerami C, 1997, P NATL ACAD SCI USA, V94, P13915, DOI 10.1073/pnas.94.25.13915; COFFEY AJH, 1986, AM J OPHTHALMOL, V102, P164, DOI 10.1016/0002-9394(86)90138-8; Degenhardt TP, 1997, KIDNEY INT, V52, P1064, DOI 10.1038/ki.1997.429; Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Farboud B, 1999, MOL VIS, V5, pU1; Furic K, 2005, J MOL STRUCT, V744, P169, DOI 10.1016/j.molstruc.2004.10.041; Genuth S, 2005, DIABETES, V54, P3103, DOI 10.2337/diabetes.54.11.3103; Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775; Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404; Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629; ISHIBASHI T, 1986, OPHTHALMOLOGICA, V192, P179, DOI 10.1159/000309639; KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944; Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; Meerwaldt R, 2005, J AM SOC NEPHROL, V16, P3687, DOI 10.1681/ASN.2005020144; MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290; Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443; Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162; PALLIKARIS IG, 2000, AM J OPTHALMOL, V141, P611; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172; SCOTT WK, 2007, IN PRESS OPHTHALMOLO; SEBAG J, 1994, INVEST OPHTH VIS SCI, V35, P2976; Sell DR, 2005, ANN NY ACAD SCI, V1043, P118, DOI 10.1196/annals.1333.015; Sell DR, 2004, J BIOL CHEM, V279, P54173, DOI 10.1074/jbc.M408946200; Sell DR, 2000, FASEB J, V14, P145, DOI 10.1096/fasebj.14.1.145; SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47; Shih S, 2003, ARCH BIOCHEM BIOPHYS, V420, P79, DOI 10.1016/j.abb.2003.09.015; Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762; Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826; Stitt AW, 2005, DIABETES, V54, P785, DOI 10.2337/diabetes.54.3.785; Stitt AW, 1997, AM J PATHOL, V150, P523; Thomas MC, 2004, KIDNEY INT, V66, P1167, DOI 10.1111/j.1523-1755.2004.00868.x; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; Thorpe SR, 2003, AMINO ACIDS, V25, P275, DOI 10.1007/s00726-003-0017-9; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; Verzijl N, 2002, ARTHRITIS RHEUM, V46, P114, DOI 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; Wolffenbuttel BHR, 1998, P NATL ACAD SCI USA, V95, P4630, DOI 10.1073/pnas.95.8.4630; Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005; Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598	51	95	96	0	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3542	3552		10.1096/fj.06-7896com	http://dx.doi.org/10.1096/fj.06-7896com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567569				2022-12-25	WOS:000250517800017
J	Sasser, AK; Sullivan, NJ; Studebaker, AW; Hendey, LF; Axel, AE; Hall, BM				Sasser, A. Kate; Sullivan, Nicholas J.; Studebaker, Adam W.; Hendey, Lindsay F.; Axel, Amy E.; Hall, Brett M.			Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer	FASEB JOURNAL			English	Article						tumor microenvironment; IL-6; metastasis; mesenchymal stem cells; ER-alpha; STAT3; MSC	MESENCHYMAL STEM-CELLS; TUMOR-MICROENVIRONMENT; BONE; FIBROBLASTS; CYTOKINE; ESTROGEN; STAT3; MICE; CARCINOMA; DIFFERENTIATION	Bone is the primary anatomical site of breast cancer metastasis, and bone metastasis is associated with increased morbidity and mortality. Mesenchymal stem cells (MSC) are a predominant fibroblast cell population within the bone marrow, and metastatic breast cancer cells that seed within bone would predictably encounter MSC or their soluble factors. Therefore, we examined the impact of primary human MSC on a panel of estrogen receptor-alpha (ER alpha)-positive (MCF-7, T47D, BT474, and ZR-75-1) and ER alpha-negative (MDA-MB-231 and MDA-MB-468) human breast tumor cell lines. All ER alpha-positive breast tumor cell lines displayed low basal activation of signal transducer and activator of transcription 3 (STAT3) until exposed to MSC, which induced chronic phosphorylation of STAT3 on tyrosine-705. Paracrine IL-6 was found to be the principal mediator of STAT3 phosphorylation in coculture studies, and MSC induction of STAT3 phosphorylation was lost when IL-6 was depleted from MSC conditioned media or the IL-6 receptor was blocked on tumor cells. Enhanced tumor cell growth rates were observed in the ER alpha-positive mammary tumor cell line MCF-7 after paracrine and autocrine IL-6 exposure, where MCF-7 growth rates were enhanced by > 2-fold when cocultured with MSC in vitro and even more pronounced in vivo with autocrine IL-6 production.	Childrens Res Inst, Ctr Childhood Canc, Columbus, OH 43205 USA; Ohio State Univ, Sch Med & Publ Hlth, Dept Pediat, Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University	Hall, BM (corresponding author), Childrens Res Inst, Ctr Childhood Canc, WA5015,700 Childrens Dr, Columbus, OH 43205 USA.	hallb@ccri.net						Anderson WF, 2005, BREAST CANCER RES TR, V90, P127, DOI 10.1007/s10549-004-3777-3; Bachelot T, 2003, BRIT J CANCER, V88, P1721, DOI 10.1038/sj.bjc.6600956; Bennermo M, 2004, CLIN CHEM, V50, P2136, DOI 10.1373/clinchem.2004.037531; Boyce BF, 1999, ENDOCR-RELAT CANCER, V6, P333, DOI 10.1677/erc.0.0060333; Cat B, 2006, J CELL SCI, V119, P2727, DOI 10.1242/jcs.03011; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Conze D, 2001, CANCER RES, V61, P8851; DeMichele A, 2003, CANCER RES, V63, P8051; Hall BM, 2004, LEUKEMIA LYMPHOMA, V45, P35, DOI 10.1080/1042819031000139620; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hess KR, 2003, BREAST CANCER RES TR, V78, P105, DOI 10.1023/A:1022166517963; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; James JJ, 2003, BRIT J CANCER, V89, P660, DOI 10.1038/sj.bjc.6601198; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Kassem M, 1996, J CLIN ENDOCR METAB, V81, P513, DOI 10.1210/jc.81.2.513; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kim DH, 2005, CYTOKINE, V31, P119, DOI 10.1016/j.cyto.2005.04.004; KUNPFER H, 2006, BREAST CANC RES TREA, V102, P129; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Moinfar F, 2000, CANCER RES, V60, P2562; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; OKADA K, 1994, J GASTROEN HEPATOL, V9, P462, DOI 10.1111/j.1440-1746.1994.tb01275.x; Okamoto M, 1997, CANCER RES, V57, P141; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Parr C, 2004, CLIN CANCER RES, V10, P202, DOI 10.1158/1078-0432.CCR-0553-3; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Purohit A, 2002, BREAST CANCER RES, V4, P65, DOI 10.1186/bcr425; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; SASSER AK, 2007, IN PRESS CANC LETT; Selander KS, 2004, CANCER RES, V64, P6924, DOI 10.1158/0008-5472.CAN-03-2516; Studeny M, 2004, JNCI-J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Yasui Y, 1999, CANCER CAUSE CONTROL, V10, P431, DOI 10.1023/A:1008970121595; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995	39	166	174	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3763	3770		10.1096/fj.07-8832com	http://dx.doi.org/10.1096/fj.07-8832com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586727				2022-12-25	WOS:000250517800038
J	Guha, M; Xu, ZG; Tung, D; Lanting, L; Natarajan, R				Guha, Mausumee; Xu, Zhong-Gao; Tung, David; Lanting, Linda; Natarajan, Rama			Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes	FASEB JOURNAL			English	Article						diabetic nephropathy; CTGF; glomerular mesangial cells; antisense oligonucleotide	HUMAN MESANGIAL CELLS; HIGH GLUCOSE; FACTOR-BETA; GENE-EXPRESSION; TGF-BETA; EXTRACELLULAR-MATRIX; AUTOCRINE ACTIVATION; MESSENGER-RNA; FACTOR CTGF; CCN FAMILY	Diabetic nephropathy ( DN) remains a major complication in both type 1 and type 2 diabetes. Systemic administration of antitransforming growth factor-beta ( TGF-beta) antibody has shown some promise in mouse models of DN. However, chronic blockade of the multifunctional TGB-beta could be problematic. Several downstream effects of TGF-beta are mediated by connective tissue growth factor ( CTGF), which is up-regulated in several renal cells and secreted in the urine in the diabetic state. Using murine models of DN ( type 1 and type 2) and a CTGF antisense oligonucleotide ( ASO) of novel chimeric chemistry, we evaluated the specific role of this target in DN. In the type 1 model of DN, C57BL6 mice were made diabetic using streptozotocin injections and hyperglycemic animals were treated with CTGF ASOs ( 20 mg/kg/2 qw) for 4 months. ASO, but not mismatch control oligonucleotide, -treated animals showed significant reduction in target CTGF expression in the kidney with a concomitant decrease in proteinuria and albuminuria. Treatment with the CTGF ASO for 8 wk reduced serum creatinine and attenuated urinary albuminuria and proteinuria in diabetic db/db mice, a model of type 2 DN. The ASO also reduced expression of genes involved in matrix expansion such as fibronectin and collagen ( I and IV) and an inhibitor of matrix degradation, PAI-1, in the renal cortex, contributing to significant reversal of mesangial expansion in both models of DN. Pathway analyses demonstrated that diabetes-induced phosphorylation of p38 MAPK and its downstream target CREB was also inhibited by the ASO. Our results strongly suggest that blocking CTGF using a chimeric ASO holds substantial promise for the treatment of DN. - Guha, M., Xu, Z-G., Tung, D., Lanting, L., Natarajan, R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes.	Kalypsys Inc, Dept Pharmacol, San Diego, CA 92121 USA; Beckman Inst City Hope, Dept Diabet, Duarte, CA USA; Pfizer Inc, St Louis, MO USA	City of Hope; Beckman Research Institute of City of Hope; Pfizer	Guha, M (corresponding author), Kalypsys Inc, Dept Pharmacol, 10420 Wateridge Circle, San Diego, CA 92121 USA.	mguha@kalypsys.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058191] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK58191, R01 DK058191] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Adler SG, 2001, KIDNEY INT, V60, P2330, DOI 10.1046/j.1523-1755.2001.00073.x; Blom IE, 2001, NEPHROL DIAL TRANSPL, V16, P1139, DOI 10.1093/ndt/16.6.1139; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Breyer MD, 2005, J AM SOC NEPHROL, V16, P27, DOI [10.1681/ASN.2009070721, 10.1681/ASN.2004080648]; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; Gilbert RE, 2003, DIABETES CARE, V26, P2632, DOI 10.2337/diacare.26.9.2632; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Hoffman BB, 1998, KIDNEY INT, V54, P1107, DOI 10.1046/j.1523-1755.1998.00119.x; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Iglesias-de la Cruz MC, 2002, KIDNEY INT, V62, P901, DOI 10.1046/j.1523-1755.2002.00528.x; Kang SW, 2001, KIDNEY INT, V60, P543, DOI 10.1046/j.1523-1755.2001.060002543.x; Kim YS, 2005, J AM SOC NEPHROL, V16, P352, DOI 10.1681/ASN.2004070568; KREISBERG JI, 1993, KIDNEY INT, V43, P109, DOI 10.1038/ki.1993.18; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; McLennan SV, 2004, ENDOCRINOLOGY, V145, P5646, DOI 10.1210/en.2004-0436; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Okada H, 2005, J AM SOC NEPHROL, V16, P133, DOI 10.1681/ASN.2004040339; Peng B, 2001, ANTISENSE NUCLEIC A, V11, P15, DOI 10.1089/108729001750072092; Reddy MA, 2002, AM J PHYSIOL-RENAL, V283, pF985, DOI 10.1152/ajprenal.00181.2002; Reeves WB, 2000, P NATL ACAD SCI USA, V97, P7667, DOI 10.1073/pnas.97.14.7667; Riser BL, 2003, KIDNEY INT, V64, P451, DOI 10.1046/j.1523-1755.2003.00130.x; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Sakharova OV, 2001, CURR OPIN NEPHROL HY, V10, P727, DOI 10.1097/00041552-200111000-00001; Twigg SM, 2001, ENDOCRINOLOGY, V142, P1760, DOI 10.1210/endo.142.5.8141; Uchio K, 2004, WOUND REPAIR REGEN, V12, P60, DOI 10.1111/j.1067-1927.2004.012112.x-1; van Nieuwenhoven FA, 2005, NEPHROL DIAL TRANSPL, V20, P6, DOI 10.1093/ndt/gfh570; Wahab NA, 2002, J AM SOC NEPHROL, V13, P2437, DOI 10.1097/01.ASN.0000031828.58276.02; Wahab NA, 2001, BIOCHEM J, V359, P77, DOI 10.1042/0264-6021:3590077; Wang SN, 2001, KIDNEY INT, V60, P96, DOI 10.1046/j.1523-1755.2001.00776.x; Yokoi H, 2004, J AM SOC NEPHROL, V15, P1430, DOI 10.1097/01.ASN.0000130565.69170.85; Ziyadeh F N, 1997, Kidney Int Suppl, V60, pS7; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	41	160	182	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3355	3368		10.1096/fj.06-6713com	http://dx.doi.org/10.1096/fj.06-6713com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17554073				2022-12-25	WOS:000249781600036
J	Tang, CH; Lu, DY; Tan, TW; Fu, WM; Yang, RS				Tang, Chih-Hsin; Lu, Dah-Yuu; Tan, Tzu-Wei; Fu, Wen-Mei; Yang, Rong-Sen			Ultrasound induces hypoxia-inducible factor-1 activation and inducible nitric-oxide synthase expression through the integrin/integrin-linked kinase/Akt/mammalian target of rapamycin pathway in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTENSITY PULSED ULTRASOUND; CYCLIC RGD PEPTIDES; SIGNALING PATHWAY; PROTEIN-KINASE; CYCLOOXYGENASE-2 EXPRESSION; ACTIN CYTOSKELETON; BONE-FORMATION; CELL-ADHESION; SHEAR-STRESS; INTEGRIN	It has been shown that ultrasound (US) stimulation accelerates fracture healing in the animal models and clinical studies. Nitric oxide (NO) is a crucial early mediator in mechanically induced bone formation. Here we found that US stimulation increased NO formation and the protein level of inducible nitric-oxide synthase (iNOS). US-mediated iNOS expression was attenuated by anti-integrin alpha 5 beta 1 or beta 1 antibodies but not anti-integrin alpha v beta 3 or beta 3 antibodies or focal adhesion kinase mutant. Integrin-linked kinase (ILK) inhibitor (KP-392), Akt inhibitor (1L-6-hydroxymethyl-chiro-inositol2-[(R)-2-O-methyl-3-O-octadecylcarbonate]) or mammalian target of rapamycin (mTOR) inhibitor (rapamycin) also inhibited the potentiating action of US. US stimulation increased the kinase activity of ILK and phosphorylation of Akt and mTOR. Furthermore, US stimulation also increased the stability and activity of HIF-1 protein. The binding of HIF-1 alpha to the HRE elements on the iNOS promoter was enhanced by US stimulation. Moreover, the use of pharmacological inhibitors or genetic inhibition revealed that both ILK/Akt and mTOR signaling pathway were potentially required for US-induced HIF-1 alpha activation and subsequent iNOS up-regulation. Taken together, our results provide evidence that US stimulation up-regulates iNOS expression in osteoblasts by an HIF-1 alpha-dependent mechanism involving the activation of ILK/Akt and mTOR pathways via integrin receptor.	Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Dept Orthopaed, Taipei 100, Taiwan; China Med Univ, Coll Med, Dept Pharmacol, Taichung 404, Taiwan	National Taiwan University; National Taiwan University; China Medical University Taiwan	Fu, WM (corresponding author), Natl Taiwan Univ, Coll Med, Inst Pharmacol, 7 Chung shan S Rd, Taipei 100, Taiwan.	wenmei@ntu.edu.tw; rsyang@ntuh.gov.tw	Tang, Chih Hsin/O-5212-2015	Tang, Chih Hsin/0000-0002-7113-8352; FU, WEN-MEI/0000-0003-4157-8987; Yang, Rong-Sen/0000-0002-0553-4779				Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Cook SD, 1997, CLIN ORTHOP RELAT R, P198; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Deng WG, 2006, BLOOD, V108, P518, DOI 10.1182/blood-2005-09-3691; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; DUARTE LR, 1983, ARCH ORTHOP TRAUM SU, V101, P153, DOI 10.1007/BF00436764; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623-199401000-00004; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501; Lu DY, 2006, BIOCHEM PHARMACOL, V72, P992, DOI 10.1016/j.bcp.2006.06.038; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; PFAFF M, 1994, J BIOL CHEM, V269, P20233; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756-3282(02)00789-5; RUBIN CT, 1995, J BONE MINER RES, V10, P488; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; Saito M, 2004, BONE, V35, P644, DOI 10.1016/j.bone.2004.04.024; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHULTZ JF, 1995, J BIOL CHEM, V270, P11522, DOI 10.1074/jbc.270.19.11522; Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200; Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365-2567.2001.01261.x; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106; Warden SJ, 2001, BIOCHEM BIOPH RES CO, V286, P443, DOI 10.1006/bbrc.2001.5412; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940	43	61	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25406	25415		10.1074/jbc.M701001200	http://dx.doi.org/10.1074/jbc.M701001200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17588951	hybrid			2022-12-25	WOS:000249014100026
J	Dong, B; Valencia, CA; Liu, R				Dong, Biao; Valencia, C. Alexander; Liu, Rihe			Ca2+/Calmodulin directly interacts with the pleckstrin homology domain of AKT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; NF-KAPPA-B; FORKHEAD TRANSCRIPTION FACTOR; CALMODULIN-BINDING PROTEINS; SERINE-THREONINE KINASE; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; DEPENDENT PHOSPHORYLATION; INOSITOL PHOSPHATES; CRYSTAL-STRUCTURE; CELL-SURVIVAL	AKT kinase, also known as protein kinase B, is a key regulator of cell growth, proliferation, and metabolism. The activation of the AKT signaling pathway is one of the most frequent molecular alterations in a wide variety of human cancers. Dickson and coworkers recently observed that Ca2(+) center dot calmodulin ( Ca2(+) center dot CaM) may be a common regulator of AKT1 activation ( Deb, T. B., Coticchia, C. M., and Dickson, R. B. ( 2004) J. Biol. Chem. 279, 38903 - 38911). In our efforts to scan the mRNA-displayed proteome libraries for Ca2(+) center dot CaM- binding proteins, we found that both human and Caenorhabditis elegans AKT1 kinases bound to CaM in a Ca2(+)- dependent manner ( Shen, X., Valencia, C. A., Szostak, J., Dong, B., and Liu, R. ( 2005) Proc. Natl. Acad. Sci. U. S. A. 102, 5969 - 5974 and Shen, X., Valencia, C. A., Gao, W., Cotten, S. W., Dong, B., Chen, M., and Liu, R. ( 2007) submitted for publication). Here we demonstrate that Ca2 (+)center dot CaM and human AKT1 were efficiently co-immunoprecipitated, and their interaction was direct rather than mediated by other proteins. The binding is in part attributed to the first 42 residues of the pleckstrin homology ( PH) domain, a region that is critical for the recognition of its lipid ligands. The PH domain of human AKT1 can disrupt the complex of the full-length AKT1 with Ca2 (+) center dot CaM. In addition, Ca2(+) center dot CaM competes with phosphatidylinositol 3,4,5- trisphophate for interaction with the PH domain of human AKT1. Our findings suggest that Ca2(+) center dot CaM is directly involved in regulating the functions of AKT1, presumably by releasing the activated AKT1 from the plasma membrane and/ or prohibiting it from re-association with phosphoinositides on plasma membrane.	Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Liu, R (corresponding author), Univ N Carolina, Sch Pharm, CB 7360,Beard Hall 209, Chapel Hill, NC 27599 USA.	rliu@email.unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067480] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21DK067480] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deb TB, 2004, J BIOL CHEM, V279, P38903, DOI 10.1074/jbc.M405314200; DEL PL, 1997, SCIENCE, V278, P687; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Guilherme A, 1996, J BIOL CHEM, V271, P29533, DOI 10.1074/jbc.271.47.29533; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kumar CC, 2005, ONCOGENE, V24, P7493, DOI 10.1038/sj.onc.1209087; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; McCullar JS, 2003, J BIOL CHEM, V278, P33708, DOI 10.1074/jbc.M301940200; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Ozes ON, 1999, NATURE, V401, P82; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Shen XC, 2005, P NATL ACAD SCI USA, V102, P5969, DOI 10.1073/pnas.0407928102; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang TB, 2003, TRENDS PLANT SCI, V8, P505, DOI 10.1016/j.tplants.2003.09.004; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	60	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25131	25140		10.1074/jbc.M702123200	http://dx.doi.org/10.1074/jbc.M702123200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17580302	Green Published, hybrid			2022-12-25	WOS:000248933000068
J	Perez-Dorado, I; Campillo, NE; Monterroso, B; Hesek, D; Lee, M; Paez, JA; Garcia, P; Martinez-Ripoll, M; Garcia, JL; Mobashery, S; Menendez, M; Hermoso, JA				Perez-Dorado, Inmaculada; Campillo, Nuria E.; Monterroso, Begona; Hesek, Dusan; Lee, Mijoon; Paez, Juan A.; Garcia, Pedro; Martinez-Ripoll, Martin; Garcia, Jose L.; Mobashery, Shahriar; Menendez, Margarita; Hermoso, Juan A.			Elucidation of the molecular recognition of bacterial cell wall by modular pneumococcal phage endolysin CPL-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYTIC ENZYME CPL-1; STREPTOCOCCUS-PNEUMONIAE; CRYSTAL-STRUCTURE; PEPTIDOGLYCAN-BINDING; STRUCTURAL BASIS; FORCE FIELD; DOMAIN; PROTEINS; REPLACEMENT; MECHANISMS	Pneumococcal bacteriophage-encoded lysins are modular proteins that have been shown to act as enzymatic antimicrobial agents ( enzybiotics) in treatment of streptococcal infections. The first x- ray crystal structures of the Cpl- 1 lysin, encoded by the pneumococcal phage Cp- 1, in complex with three bacterial cell wall peptidoglycan ( PG) analogues are reported herein. The Cpl- 1 structure is folded in two well defined modules, one responsible for anchoring to the pneumococcal cell wall and the other, a catalytic module, that hydrolyzes the PG. Conformational rearrangement of Tyr- 127 is a critical event in molecular recognition of a stretch of five saccharide rings of the polymeric peptidoglycan ( cell wall). The PG is bound at a stretch of the surface that is defined as the peptidoglycan-binding sites 1 and 2, the juncture of which catalysis takes place. The peptidoglycan-binding site 1 binds to a stretch of three saccharides of the peptidoglycan in a conformation essentially identical to that of the peptidoglycan in solution. In contrast, binding of two peptidoglycan saccharides at the peptidoglycan-binding site 2 introduces a kink into the solution structure of the peptidoglycan, en route to catalytic turnover. These findings provide the first structural evidence on recognition of the peptidoglycan and shed light on the discrete events of cell wall degradation by Cpl- 1.	CSIC, Inst Quim Fis Rocasolano, Grp Cristalograf Macromol & Biol Estruct, E-28006 Madrid, Spain; CSIC, Inst Quim Med, Dept Quimioterap, E-28006 Madrid, Spain; CSIC, Inst Quim Fis Rocasolano, Dept Quim Fis Macromol Biol, E-28006 Madrid, Spain; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Medica (IQM); CSIC - Instituto de Quimica Organica General (IQOG); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); University of Notre Dame; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Hermoso, JA (corresponding author), CSIC, Inst Quim Fis Rocasolano, Grp Cristalograf Macromol & Biol Estruct, Serrano 119, E-28006 Madrid, Spain.	xjuan@iqfr.csic.es	Páez, Juan A./K-2938-2014; Pérez-Dorado, Inmaculada/AAP-2394-2021; Menendez, Margarita/M-1795-2014; Martinez-Ripoll, Martin/A-8313-2012; Monterroso, Begoña/J-9748-2014; García, Pedro/L-2808-2017; Lee, Mijoon/AFK-1543-2022; Hermoso, Juan/J-3433-2012; Campillo, Nuria E/J-8810-2014; Garcia Lopez, Jose Luis/G-9139-2015	Menendez, Margarita/0000-0002-3267-4443; Martinez-Ripoll, Martin/0000-0002-4019-0529; Monterroso, Begoña/0000-0003-2538-084X; García, Pedro/0000-0001-6717-8717; Lee, Mijoon/0000-0001-7432-0427; Hermoso, Juan/0000-0002-1862-8950; /0000-0002-9948-2665; Perez Dorado, J. Inmaculada/0000-0002-5213-5260; Garcia Lopez, Jose Luis/0000-0002-9238-2485				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; DAVID LZ, 2000, ACCOUNTS CHEM RES, V33, P11; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Djurkovic S, 2005, ANTIMICROB AGENTS CH, V49, P1225, DOI 10.1128/AAC.49.3.1225-1228.2005; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Dziarski R, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-232; Fernandez-Tornero C, 2001, NAT STRUCT BIOL, V8, P1020, DOI 10.1038/nsb724; GARCIA E, 1988, P NATL ACAD SCI USA, V85, P914, DOI 10.1073/pnas.85.3.914; Gosink KK, 2000, INFECT IMMUN, V68, P5690, DOI 10.1128/IAI.68.10.5690-5695.2000; Guan RJ, 2004, P NATL ACAD SCI USA, V101, P17168, DOI 10.1073/pnas.0407856101; Guan RJ, 2005, J MOL BIOL, V347, P683, DOI 10.1016/j.jmb.2005.01.070; Guan RJ, 2004, J BIOL CHEM, V279, P31873, DOI 10.1074/jbc.M404920200; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; Halgren TA, 1996, J COMPUT CHEM, V17, P553, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<553::AID-JCC3>3.0.CO;2-T; Hermoso JA, 2005, NAT STRUCT MOL BIOL, V12, P533, DOI 10.1038/nsmb940; Hermoso JA, 2003, STRUCTURE, V11, P1239, DOI 10.1016/j.str.2003.09.005; Hesek D, 2004, J ORG CHEM, V69, P778, DOI 10.1021/jo035397e; Hesek D, 2004, J ORG CHEM, V69, P2137, DOI 10.1021/jo035583k; Jado I, 2003, J ANTIMICROB CHEMOTH, V52, P967, DOI 10.1093/jac/dkg485; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Judson OP, 1999, J MOL EVOL, V49, P539, DOI 10.1007/PL00006575; Kristinsson KG, 1997, MICROB DRUG RESIST, V3, P117, DOI 10.1089/mdr.1997.3.117; Lavigne P, 2000, PROTEIN SCI, V9, P252; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Loeffler JM, 2001, SCIENCE, V294, P2170, DOI 10.1126/science.1066869; Loeffler JM, 2003, INFECT IMMUN, V71, P6199, DOI 10.1128/IAI.71.11.6199-6204.2003; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McCullers JA, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030028; Meroueh SO, 2006, P NATL ACAD SCI USA, V103, P4404, DOI 10.1073/pnas.0510182103; Monterroso B, 2002, ACTA CRYSTALLOGR D, V58, P1487, DOI 10.1107/S0907444902011563; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pelton SI, 2000, VACCINE, V19, pS96, DOI 10.1016/S0264-410X(00)00286-3; PEREZ S, 1995, MODELLING BIOMOLECUL; Porter CJ, 2007, J MOL BIOL, V366, P540, DOI 10.1016/j.jmb.2006.11.056; Rau A, 2001, J BIOL CHEM, V276, P31994, DOI 10.1074/jbc.M102591200; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANZ JM, 1992, BIOCHEMISTRY-US, V31, P8495, DOI 10.1021/bi00151a016; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang ZM, 2003, J BIOL CHEM, V278, P49044, DOI 10.1074/jbc.M307758200; Yuan YQ, 2007, P NATL ACAD SCI USA, V104, P5348, DOI 10.1073/pnas.0701160104	43	55	57	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24990	24999		10.1074/jbc.M704317200	http://dx.doi.org/10.1074/jbc.M704317200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17581815	Green Published, hybrid			2022-12-25	WOS:000248933000055
J	Fleige, A; Alberti, S; Grobe, L; Frischmann, U; Geffers, R; Muller, W; Nordheim, A; Schippers, A				Fleige, Anne; Alberti, Siegfried; Groebe, Lothar; Frischmann, Ursula; Geffers, Robert; Mueller, Werner; Nordheim, Alfred; Schippers, Angela			Serum response factor contributes selectively to lymphocyte development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE GROWTH; C-FOS OVEREXPRESSION; T-CELL-RECEPTOR; ZONE B-CELLS; TERNARY COMPLEX; TRANSCRIPTION FACTOR; GENE; SRF; ACTIVATION; MICE	Serum response factor (SRF), is a crucial transcription factor for murine embryonic development and for the function of muscle cells and neurons. Gene expression data show that SRF and its transcriptional cofactors are also expressed in lymphocyte precursors and mature lymphocytes. However, the role of SRF in lymphocyte development has not been addressed in vivo so far, attributed in part to early embryonic lethality of conventional Srf-null mice. To determine the in vivo role of SRF in developing lymphocytes, we specifically inactivated the murine Srf gene during T or B cell development using lymphocyte-specific Cre transgenic mouse lines. T cell-specific Srf deletion led to a severe block in thymocyte development at the transition from CD4/CD8 double to single positive stage. The few residual T cells detectable in the periphery retained at least one functional Srf allele, thereby demonstrating the importance of SRF in T cell development. In contrast, deletion of Srf in developing B cells did not interfere with the growth and survival of B cells in general, yet led to a complete loss of marginal zone B cells and a marked reduction of the CD5(+) B cell subset. Our study also revealed a contribution of SRF to the expression of the surface molecules IgM, CD19, and the chemokine receptor 4 in B lymphocytes. We conclude that SRF fulfills essential and distinct functions in the differentiation of different types of lymphocytes.	Helmholtz Ctr Infect Res, Dept Expt Immunol, D-38124 Braunschweig, Germany; Helmholtz Ctr Infect Res, Dept Mucosal Immun, D-38124 Braunschweig, Germany; Univ Tubingen, Dept Biol Mol, Interfac Inst Cell Biol, D-72076 Tubingen, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Eberhard Karls University of Tubingen	Schippers, A (corresponding author), Helmholtz Ctr Infect Res, Dept Expt Immunol, Inhoffenstr 7, D-38124 Braunschweig, Germany.	angela.schippers@helmholtz-hzi.de	Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725				Alberola-Ila J, 2003, IMMUNOL REV, V191, P79, DOI 10.1034/j.1600-065X.2003.00012.x; Alberti S, 2005, P NATL ACAD SCI USA, V102, P6148, DOI 10.1073/pnas.0501191102; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Bettini M, 2002, J IMMUNOL, V169, P1713, DOI 10.4049/jimmunol.169.4.1713; Buchwalter G, 2005, MOL CELL BIOL, V25, P10853, DOI 10.1128/MCB.25.24.10853-10862.2005; Carsetti R, 2004, IMMUNOL REV, V197, P179, DOI 10.1111/j.0105-2896.2004.0109.x; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Cesari F, 2004, GENESIS, V38, P87, DOI 10.1002/gene.20003; Chan YJ, 1996, J VIROL, V70, P8590, DOI 10.1128/JVI.70.12.8590-8605.1996; Charvet C, 2002, J BIOL CHEM, V277, P15376, DOI 10.1074/jbc.M111627200; Charvet C, 2006, MOL CELL BIOL, V26, P6664, DOI 10.1128/MCB.00138-06; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Costello PS, 2004, NAT IMMUNOL, V5, P289, DOI 10.1038/ni1038; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; Drewett V, 2001, J BIOL CHEM, V276, P33444, DOI 10.1074/jbc.M103877200; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; Hao SL, 2003, EMBO J, V22, P4166, DOI 10.1093/emboj/cdg401; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; JAMESON SC, 1994, NATURE, V369, P750, DOI 10.1038/369750a0; KAPTEIN JS, 1995, IMMUNOBIOLOGY, V193, P465, DOI 10.1016/S0171-2985(11)80431-6; Knoll B, 2006, NAT NEUROSCI, V9, P195, DOI 10.1038/nn1627; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Labuda T, 2000, INT IMMUNOL, V12, P253, DOI 10.1093/intimm/12.3.253; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Lopes-Carvalho T, 2004, IMMUNOL REV, V197, P192, DOI 10.1111/j.0105-2896.2004.0112.x; Lu TT, 2002, SCIENCE, V297, P409, DOI 10.1126/science.1071632; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; Martin D, 2002, BRILLS TIBET STU LIB, V2, P335; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; Miano JM, 2004, P NATL ACAD SCI USA, V101, P17132, DOI 10.1073/pnas.0406041101; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; Miyazaki T, 1998, J EXP MED, V188, P715, DOI 10.1084/jem.188.4.715; Mora-Garcia P, 2003, STEM CELLS, V21, P123, DOI 10.1634/stemcells.21-2-123; Mori S, 2004, INT IMMUNOL, V16, P1477, DOI 10.1093/intimm/dxh149; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nie YC, 2004, J EXP MED, V200, P1145, DOI 10.1084/jem.20041185; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Niu Z, 2005, J BIOL CHEM, V280, P32531, DOI 10.1074/jbc.M501372200; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ohkubo Y, 2005, J IMMUNOL, V174, P7703, DOI 10.4049/jimmunol.174.12.7703; Oliver AM, 1997, EUR J IMMUNOL, V27, P2366, DOI 10.1002/eji.1830270935; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Parlakian A, 2004, MOL CELL BIOL, V24, P5281, DOI 10.1128/MCB.24.12.5281-5289.2004; Pfoertner S, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r54; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; Preud'homme JL, 2000, MOL IMMUNOL, V37, P871, DOI 10.1016/S0161-5890(01)00006-2; Ramanan N, 2005, NAT NEUROSCI, V8, P759, DOI 10.1038/nn1462; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Shen CH, 2001, J IMMUNOL, V166, P411, DOI 10.4049/jimmunol.166.1.411; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sun Q, 2006, GENOME RES, V16, P197, DOI 10.1101/gr.4108706; Takahama Y, 1998, EUR J IMMUNOL, V28, P2159, DOI 10.1002/(SICI)1521-4141(199807)28:07<2159::AID-IMMU2159>3.0.CO;2-B; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wiebel FF, 2002, GENESIS, V32, P124, DOI 10.1002/gene.10049; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Yamashita K, 2005, MOL IMMUNOL, V42, P617, DOI 10.1016/j.molimm.2004.09.011; Zheng H, 2003, GENE DEV, V17, P2283, DOI 10.1101/gad.272503	73	30	30	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24320	24328		10.1074/jbc.M703119200	http://dx.doi.org/10.1074/jbc.M703119200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17591768	hybrid, Green Submitted			2022-12-25	WOS:000248686600058
J	Niranjan, T; Guo, XD; Victor, J; Lu, A; Hirsch, JP				Niranjan, Thiruvur; Guo, Xuedong; Victor, Jacob; Lu, Ailan; Hirsch, Jeanne P.			Kelch repeat protein interacts with the yeast G alpha subunit Gpa2p at a site that couples receptor binding to guanine nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PSEUDOHYPHAL DIFFERENTIATION; CRYSTAL-STRUCTURE; LIFE-SPAN; KINASE-A; G-BETA; GLUCOSE; GPR1; ACTIVATION; GROWTH	The kelch repeat-containing proteins Krh1p and Krh2p are negative regulators of the Gpa2p signaling pathway that directly interact with the G protein alpha- subunit Gpa2p in the yeast Saccharomyces cerevisiae. A screen was carried out to identify Gpa2p variants that are defective in their ability to bind Krh1p but retain the ability to bind another Gpa2p- interacting protein, Ime2p. This screen identified amino acids Gln- 419 and Asn- 425 as being important for the interaction between Gpa2p and Krh1p. Gpa2p variants with changes at these positions are defective for Krh1p binding in vivo. Cells containing these forms of Gpa2p display decreased heat shock resistance and increased expression of a gene required for pseudohyphal growth. These findings indicate that the substitutions at positions 419 and 425 confer a degree of constitutive activity to the Gpa2p alpha- subunit. Residues Gln- 419 and Asn- 425 are located in the beta 6-alpha 5 loop and alpha 5 helix of Gpa2p, which is the region that couples receptor binding to guanine nucleotide exchange. The results suggest that binding of Gpa2p to Krh1p does not resemble the binding of G alpha subunits to either G beta subunits or effectors, but it instead represents a novel type of functional interaction.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Hirsch, JP (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, Box 1603,1Gustave L Levy Pl, New York, NY 10029 USA.	jeanne.hirsch@mssm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM074242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Ansari K, 1999, J BIOL CHEM, V274, P30052, DOI 10.1074/jbc.274.42.30052; Batlle M, 2003, J CELL SCI, V116, P701, DOI 10.1242/jcs.00266; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; Donzeau M, 1999, MOL CELL BIOL, V19, P6110; Harashima T, 2005, MOL BIOL CELL, V16, P4557, DOI 10.1091/mbc.E05-05-0403; Harashima T, 2002, MOL CELL, V10, P163, DOI 10.1016/S1097-2765(02)00569-5; Harashima T, 2006, MOL CELL, V22, P819, DOI 10.1016/j.molcel.2006.05.011; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; James P, 1996, GENETICS, V144, P1425; Kaeberlein M, 2005, MECH AGEING DEV, V126, P491, DOI 10.1016/j.mad.2004.10.007; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kim J, 1999, MOL CELL BIOL, V19, P441; Kraakman L, 1999, MOL MICROBIOL, V32, P1002, DOI 10.1046/j.1365-2958.1999.01413.x; Kubler E, 1997, J BIOL CHEM, V272, P20321, DOI 10.1074/jbc.272.33.20321; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Lorenz MC, 2000, GENETICS, V154, P609; Lorenz MC, 1997, EMBO J, V16, P7008, DOI 10.1093/emboj/16.23.7008; Lu AL, 2005, EUKARYOT CELL, V4, P1794, DOI 10.1128/EC.4.11.1794-1800.2005; Marin EP, 2001, J BIOL CHEM, V276, P27400, DOI 10.1074/jbc.C100198200; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; Oldham WM, 2006, NAT STRUCT MOL BIOL, V13, P772, DOI 10.1038/nsmb1129; Peeters T, 2006, P NATL ACAD SCI USA, V103, P13034, DOI 10.1073/pnas.0509644103; Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Tamaki H, 2005, GENES CELLS, V10, P193, DOI 10.1111/j.1365-2443.2005.00828.x; Tamaki H, 2000, BIOCHEM BIOPH RES CO, V267, P164, DOI 10.1006/bbrc.1999.1914; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 2004, PLOS BIOL, V2, P610, DOI 10.1371/journal.pbio.0020128; Welton RM, 2000, GENETICS, V156, P513; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; Yun CW, 1997, BIOCHEM BIOPH RES CO, V240, P287, DOI 10.1006/bbrc.1997.7649	39	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24231	24238		10.1074/jbc.M702595200	http://dx.doi.org/10.1074/jbc.M702595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584745	hybrid			2022-12-25	WOS:000248686600048
J	Kim, K; Park, J; Rhee, S				Kim, Kwangsoo; Park, Jinseo; Rhee, Sangkee			Structural and functional basis for (S)-allantoin formation in the ureide pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSTHYRETIN-RELATED PROTEIN; URIC-ACID; HYDROXYISOURATE HYDROLASE; CRYSTAL-STRUCTURE; DEGRADATION; PRODUCT; 5-HYDROXYISOURATE; IDENTIFICATION; MECHANISM; INSIGHTS	The ureide pathway, which mediates the oxidative degradation of uric acid to (S)-allantoin, represents the late stage of purine catabolism in most organisms. The details of uric acid metabolism remained elusive until the complete pathway involving three enzymes was recently identified and characterized. However, the molecular details of the exclusive production of one enantiomer of allantoin in this pathway are still undefined. Here we report the crystal structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) decarboxylase, which catalyzes the last reaction of the pathway, in a complex with the product, (S)-allantoin, at 2.5-angstrom resolution. The homodimeric helical protein represents a novel structural motif and reveals that the active site in each monomer contains no cofactors, distinguishing this enzyme mechanistically from other cofactor-dependent decarboxylases. On the basis of structural analysis, along with site-directed mutagenesis, a mechanism for the enzyme is proposed in which a decarboxylation reaction occurs directly, and the invariant histidine residue in the OHCU decarboxylase family plays an essential role in producing (S)-allantoin through a proton transfer from the hydroxyl group at C4 to C5 at the re-face of OHCU. These results provide molecular details that address a longstanding question of how living organisms selectively produce (S)-allantoin.	Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea; Seoul Natl Univ, Ctr Agr Biomat, Seoul 151921, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Rhee, S (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, Room 7117, Seoul 151921, South Korea.	srheesnu@snu.ac.kr						Atkins C, 2000, PROKARYOTIC NITROGEN FIXATION, P559; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Begley TP, 2004, CURR OPIN CHEM BIOL, V8, P508, DOI 10.1016/j.cbpa.2004.08.004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cendron L, 2007, J BIOL CHEM, V282, P18182, DOI 10.1074/jbc.M701297200; Colloch N, 1997, NAT STRUCT BIOL, V4, P947, DOI 10.1038/nsb1197-947; Gabison L, 2006, FEBS LETT, V580, P2087, DOI 10.1016/j.febslet.2006.03.007; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hennebry SC, 2006, J MOL BIOL, V359, P1389, DOI 10.1016/j.jmb.2006.04.057; HOME L, 1998, NUCLEIC ACIDS RES, V26, P316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung DK, 2006, P NATL ACAD SCI USA, V103, P9790, DOI 10.1073/pnas.0600523103; Kahn K, 1997, J AM CHEM SOC, V119, P5435, DOI 10.1021/ja970375t; Lee Y, 2005, FEBS LETT, V579, P4769, DOI 10.1016/j.febslet.2005.07.056; Liu AM, 2006, BIOCHEMISTRY-US, V45, P10407, DOI 10.1021/bi061031v; Lundberg E, 2006, J STRUCT BIOL, V155, P445, DOI 10.1016/j.jsb.2006.04.002; Miller BG, 2002, ANNU REV BIOCHEM, V71, P847, DOI 10.1146/annurev.biochem.71.110601.135446; Miller BG, 2001, J BIOL CHEM, V276, P15174, DOI 10.1074/jbc.M011429200; Nam KH, 2004, PLANT CELL, V16, P2406, DOI 10.1105/tpc.104.023903; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramazzina I, 2006, NAT CHEM BIOL, V2, P144, DOI 10.1038/nchembio768; Raychaudhuri A, 2003, BIOCHEMISTRY-US, V42, P6848, DOI 10.1021/bi034137o; Raychaudhuri A, 2002, PLANT PHYSIOL, V130, P2061, DOI 10.1104/pp.011049; REYNOLDS PHS, 1982, TRENDS BIOCHEM SCI, V7, P366, DOI 10.1016/0968-0004(82)90116-5; Sarma AD, 1999, J BIOL CHEM, V274, P33863, DOI 10.1074/jbc.274.48.33863; Schultz AC, 2001, J BACTERIOL, V183, P3293, DOI 10.1128/JB.183.11.3293-3302.2001; Smith PMC, 2002, PLANT PHYSIOL, V128, P793, DOI 10.1104/pp.010912; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Todd CD, 2006, J EXP BOT, V57, P5, DOI 10.1093/jxb/erj013; TONEY MD, 1993, BIOCHEMISTRY-US, V32, P1471, DOI 10.1021/bi00057a010; Zanotti G, 2006, J MOL BIOL, V363, P1, DOI 10.1016/j.jmb.2006.07.079	32	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23457	23464		10.1074/jbc.M703211200	http://dx.doi.org/10.1074/jbc.M703211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17567580	hybrid			2022-12-25	WOS:000248577500046
J	Romanelli, RJ; LeBeau, AP; Fulmer, CG; Lazzarino, DA; Hochberg, A; Wood, TL				Romanelli, Robert J.; LeBeau, Andrew P.; Fulmer, Clifton G.; Lazzarino, Deborah A.; Hochberg, Alan; Wood, Teresa L.			Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; IGF-I; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; CELL-SURFACE; PROTEIN; BRAIN; ENDOCYTOSIS	Previously we demonstrated that insulin-like growth factor-I mediates the sustained phosphorylation of Akt, which is essential for long term survival and protection of glial progenitors from glutamate toxicity. These prosurvival effects correlated with prolonged activation and stability of the insulin like growth factor type-I receptor. In the present study, we investigated the mechanisms whereby insulin-like growth factor-I signaling, through the insulin-like growth factor type-I receptor, mediates the sustained phosphorylation of Akt. We showed that insulin-like growth factor-I stimulation induced loss of receptors from the cell surface but that surface receptors recovered over time. Blocking receptor internalization inhibited Akt phosphorylation, whereas inhibition of receptor trafficking blocked receptor recovery at the cell surface and the sustained phosphorylation of Akt. Moreover the insulin-like growth factor type-I receptor localized with the transferrin receptor and Rab11-positive endosomes in a ligand-dependent manner, further supporting the conclusion that this receptor follows a recycling pathway. Our results provide evidence that ligand stimulation leads to internalization of the insulin-like growth factor type-I receptor, which mediates Akt phosphorylation, and that receptor recycling sustains Akt phosphorylation in glial progenitors. Mathematical modeling of receptor trafficking further supports these results and predicts an additional kinetic state of the receptor consistent with sustained Akt phosphorylation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci H506, Newark, NJ 07103 USA; Penn State Univ, Coll Med, Dept Neurol & Behav Sci, Hershey, PA 17033 USA; ProSanos Corp, La Jolla, CA 92037 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Wood, TL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci H506, 185 S Orange Ave, Newark, NJ 07103 USA.	woodte@umdnj.edu		Wood, Teresa/0000-0002-4480-660X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050742, R01NS037560] Funding Source: NIH RePORTER; NINDS NIH HHS [NS050742, NS37560] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; Brismar H, 2006, PFLUG ARCH EUR J PHY, V451, P793, DOI 10.1007/s00424-005-1510-7; Cheng CM, 1998, J NEUROSCI, V18, P5673; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Cui QL, 2005, J BIOL CHEM, V280, P8918, DOI 10.1074/jbc.M414267200; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; D'Ercole AJ, 2002, NEUROPEPTIDES, V36, P209, DOI 10.1054/npep.2002.0893; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dore S, 1997, NEUROSCIENCE, V78, P373, DOI 10.1016/S0306-4522(96)00594-5; Haugh Jason M, 2002, Mol Interv, V2, P292, DOI 10.1124/mi.2.5.292; Haugsten EM, 2005, J CELL SCI, V118, P3869, DOI 10.1242/jcs.02509; Hendriks BS, 2005, J BIOL CHEM, V280, P6157, DOI 10.1074/jbc.M410491200; Jullien J, 2002, J BIOL CHEM, V277, P38700, DOI 10.1074/jbc.M202348200; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; LEVITZKI A, 1980, P NATL ACAD SCI-BIOL, V77, P2706, DOI 10.1073/pnas.77.5.2706; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Melikian HE, 1999, J NEUROSCI, V19, P7699; Ness JK, 2002, MOL CELL NEUROSCI, V20, P476, DOI 10.1006/mcne.2002.1149; Ness JK, 2004, GLIA, V46, P183, DOI 10.1002/glia.10360; Ness JK, 2002, DEV NEUROSCI-BASEL, V24, P437, DOI 10.1159/000069050; Penengo L, 2003, ONCOGENE, V22, P3669, DOI 10.1038/sj.onc.1206585; Popken GJ, 2004, EUR J NEUROSCI, V19, P2056, DOI 10.1111/j.0953-816X.2004.03320.x; Ranjan M, 1996, MOL CELL NEUROSCI, V7, P404, DOI 10.1006/mcne.1996.0029; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Romsicki Y, 2004, J BIOL CHEM, V279, P12868, DOI 10.1074/jbc.M309600200; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Touret N, 2003, J BIOL CHEM, V278, P25548, DOI 10.1074/jbc.M212374200; Toy-Miou-Leong M, 2004, J BIOL CHEM, V279, P12636, DOI 10.1074/jbc.M303384200; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang Y, 2004, J BIOL CHEM, V279, P8038, DOI 10.1074/jbc.M311494200; YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404; YE P, 1995, J NEUROSCI, V15, P7344; Ye P, 1995, NEUROSCI LETT, V201, P235, DOI 10.1016/0304-3940(95)12194-3; Ye P, 1996, DEV BRAIN RES, V95, P44; Ye P, 2004, J NEUROSCI RES, V78, P472, DOI 10.1002/jnr.20288; Ye P, 2002, J NEUROSCI, V22, P6041; ZAPF A, 1994, ENDOCRINOLOGY, V134, P2445, DOI 10.1210/en.134.6.2445; Zeger M, 2007, GLIA, V55, P400, DOI 10.1002/glia.20469; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	48	89	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22513	10.1074/jbc.M704309200	http://dx.doi.org/10.1074/jbc.M704309200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17545147	hybrid			2022-12-25	WOS:000248354200029
J	Toroian, D; Lim, JE; Price, PA				Toroian, Damon; Lim, Joo Eun; Price, Paul A.			The size exclusion characteristics of type I collagen - Implications for the role of noncollagenous bone constituents in mineralization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYAPATITE FORMATION; FUNCTIONAL IMPLICATIONS; PACKING; FIBRIL; TENDON; INHIBITION; PROTEIN; MATRIX; SERUM; SIALOPROTEIN	The mineral in bone is located primarily within the collagen fibril, and during mineralization the fibril is formed first and then water within the fibril is replaced with mineral. The collagen fibril therefore provides the aqueous compartment in which mineral grows. Although knowledge of the size of molecules that can diffuse into the fibril to affect crystal growth is critical to understanding the mechanism of bone mineralization, there have been as yet no studies on the size exclusion properties of the collagen fibril. To determine the size exclusion characteristics of collagen, we developed a gel filtration-like procedure that uses columns containing collagen from tendon and bone. The elution volumes of test molecules show the volume within the packed column that is accessible to the test molecules, and therefore reveal the size exclusion characteristics of the collagen within the column. These experiments show that molecules smaller than a 6-kDa protein diffuse into all of the water within the collagen fibril, whereas molecules larger than a 40-kDa protein are excluded from this water. These studies provide an insight into the mechanism of bone mineralization. Molecules and apatite crystals smaller than a 6-kDa protein can diffuse into all water within the fibril and so can directly impact mineralization. Although molecules larger than a 40-kDa protein are excluded from the fibril, they can initiate mineralization by forming small apatite crystal nuclei that diffuse into the fibril, or can favor fibril mineralization by inhibiting apatite growth everywhere but within the fibril.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Price, PA (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	pprice@ucsd.edu			NHLBI NIH HHS [HL58090] Funding Source: Medline; NIAMS NIH HHS [AR25921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025921] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; BHATNAGAR VM, 1969, CONTRIB MINERAL PETR, V22, P375, DOI 10.1007/BF00400132; BLITZ RM, 1969, J BONE JOINT SURG AM, V51, P456; Boivin G, 2002, CALCIFIED TISSUE INT, V70, P503, DOI 10.1007/s00223-001-2048-0; BONAR LC, 1985, J MOL BIOL, V181, P265, DOI 10.1016/0022-2836(85)90090-7; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; EINBINDER J, 1950, J BIOL CHEM, V188, P335; Ekani-Nkodo A, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.021909; FRASER RDB, 1983, J MOL BIOL, V167, P497, DOI 10.1016/S0022-2836(83)80347-7; FRATZL P, 1993, BIOPHYS J, V64, P260, DOI 10.1016/S0006-3495(93)81362-6; Fullerton GD, 2006, CELL BIOL INT, V30, P56, DOI 10.1016/j.cellbi.2005.09.008; Gutsmann T, 2003, BIOPHYS J, V84, P2593, DOI 10.1016/S0006-3495(03)75064-4; HALE JE, 1991, J BIOL CHEM, V266, P21145; Hamlin NJ, 2004, CALCIFIED TISSUE INT, V75, P231, DOI 10.1007/s00223-004-0190-1; Hemmelder MH, 1998, J LAB CLIN MED, V132, P390, DOI 10.1016/S0022-2143(98)90110-X; HODGE AJ, 1963, RECENT STUDIES ELECT, P289; Holmes DF, 2001, P NATL ACAD SCI USA, V98, P7307, DOI 10.1073/pnas.111150598; HULMES DJS, 1979, NATURE, V282, P878, DOI 10.1038/282878a0; HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756-3282(97)00279-2; LEES S, 1984, INT J BIOL MACROMOL, V6, P133, DOI 10.1016/0141-8130(84)90053-9; Midura RJ, 2004, J BIOL CHEM, V279, P25464, DOI 10.1074/jbc.M312409200; MOELLER HD, 1995, J ANAT, V187, P161; Orgel JPRO, 2006, P NATL ACAD SCI USA, V103, P9001, DOI 10.1073/pnas.0502718103; Orgel JPRO, 2001, STRUCTURE, V9, P1061, DOI 10.1016/S0969-2126(01)00669-4; Ottani V, 2001, MICRON, V32, P251, DOI 10.1016/S0968-4328(00)00042-1; Ottani V, 2002, MICRON, V33, P587, DOI 10.1016/S0968-4328(02)00033-1; PARRY DA, 1984, ULTRASTRUCTURE CONNE, V3, P34; PIEZ KA, 1981, BIOSCIENCE REP, V1, P801, DOI 10.1007/BF01114803; Price PA, 2004, J BIOL CHEM, V279, P19169, DOI 10.1074/jbc.M307880200; Price PA, 2003, J BIOL CHEM, V278, P22144, DOI 10.1074/jbc.M300744200; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; Price RI, 1997, INT J BIOL MACROMOL, V20, P23, DOI 10.1016/S0141-8130(97)01148-3; RASPANTI M, 1989, INT J BIOL MACROMOL, V11, P367, DOI 10.1016/0141-8130(89)90009-3; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; REVENKO I, 1994, BIOL CELL, V80, P67, DOI 10.1016/0248-4900(94)90019-1; ROBINSON RA, 1957, J BONE JOINT SURG AM, V39, P167, DOI 10.2106/00004623-195739010-00015; ROBINSON RA, 1958, P C OCT 30 31; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SCOTT TA, 1953, ANAL CHEM, V25, P1656, DOI 10.1021/ac60083a023; Skedros JG, 2005, CELLS TISSUES ORGANS, V181, P23, DOI 10.1159/000089966; Taha EA, 2003, CHEM PHARM BULL, V51, P1444, DOI 10.1248/cpb.51.1444; TORCHIA DA, 1982, METHOD ENZYMOL, V82, P174; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; Tzaphlidou M, 2005, MICRON, V36, P593, DOI 10.1016/j.micron.2005.05.009; VOET D, 2004, BIOCHEMISTRY-US, P136; Wess TJ, 2005, ADV PROTEIN CHEM, V70, P341, DOI 10.1016/S0065-3233(05)70010-3	49	176	187	4	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22437	22447		10.1074/jbc.M700591200	http://dx.doi.org/10.1074/jbc.M700591200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17562713	hybrid, Green Published			2022-12-25	WOS:000248354200022
J	Wu, ZH; Lauer, TW; Sick, A; Hackett, SF; Campochiaro, PA				Wu, Zhihao; Lauer, Thomas W.; Sick, Anna; Hackett, Sean F.; Campochiaro, Peter A.			Oxidative stress modulates complement factor H expression in retinal Pigmented epithelial cells by acetylation of FOXO3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTORS; GLOMERULONEPHRITIS TYPE-II; MACULAR DEGENERATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; DEPOSIT DISEASE; PROTEIN; KINASE; RISK; POLYMORPHISM; SURVIVAL	Age-related macular degeneration (AMD), the leading cause of severe vision loss in the elderly, is a complex disease that results from genetic modifications that increase susceptibility to environmental exposures. Smoking, a major source of oxidative stress, increases the incidence and severity of AMD, and antioxidants slow progression, suggesting that oxidative stress plays a major role. Polymorphisms in the complement factor H (CFH) gene that reduce activity of CFH increase the risk of AMD. In this study we demonstrate an interaction between these two risk factors, because oxidative stress reduces the ability of an inflammatory cytokine, interferon-gamma, to increase CFH expression in retinal pigmented epithelial cells. The interferon-gamma-induced increase in CFH is mediated by transcriptional activation by STAT1, and its suppression by oxidative stress is mediated by acetylation of FOXO3, which enhances FOXO3 binding to the CFH promoter, reduces its binding to STAT1, inhibits STAT1 interaction with the CFH promoter, and reduces expression of CFH. Expression of SIRT1, a mammalian homolog of NAD-dependent protein deacetylase sir2, attenuated FOXO3 recruitment to the CFH regulatory region and reversed the H2O2-induced repression of CFH gene expression. These data suggest an important interaction between environmental exposure and genetic susceptibility in the pathogenesis of AMD and, by elucidating molecular signaling involved in the interaction, provide potential targets for therapeutic intervention.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@jhmi.edu		Sick-Samuels, Anna/0000-0002-9247-9340	NATIONAL EYE INSTITUTE [P30EY001765] Funding Source: NIH RePORTER; NEI NIH HHS [P30EY1765, EY05951, P30EY0572] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Ceryak S, 2004, MOL CELL BIOCHEM, V255, P139, DOI 10.1023/B:MCBI.0000007270.82431.3e; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Gerritsma JSJ, 1997, CYTOKINE, V9, P276, DOI 10.1006/cyto.1996.0164; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Hayashi H, 2006, J BIOL CHEM, V281, P1332, DOI 10.1074/jbc.M505905200; HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751; Hu YY, 2005, MOL BIOL CELL, V16, P3705, DOI 10.1091/mbc.E05-04-0301; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jonsson H, 2005, NAT MED, V11, P666, DOI 10.1038/nm1248; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831; Lee KW, 2004, ANN NY ACAD SCI, V1030, P258, DOI 10.1196/annals.1329.032; Lee M, 2004, J CELL BIOCHEM, V93, P629, DOI 10.1002/jcb.20215; LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278; Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871; Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655; Matsuzaki H, 2005, J BIOCHEM, V138, P485, DOI 10.1093/jb/mvi146; MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912; Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353; Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012; Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Ward HM, 1997, IMMUNOL CELL BIOL, V75, P508, DOI 10.1038/icb.1997.79; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200; Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248	48	90	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22414	22425		10.1074/jbc.M702321200	http://dx.doi.org/10.1074/jbc.M702321200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17558024	hybrid			2022-12-25	WOS:000248354200020
J	Liu, Y; Li, ZJ; Lin, QS; Kosinski, J; Seetharaman, J; Bujnicki, JM; Sivaraman, J; Hew, CL				Liu, Yang; Li, Zhengjun; Lin, Qingsong; Kosinski, Jan; Seetharaman, J.; Bujnicki, Janusz M.; Sivaraman, J.; Hew, Choy-Leong			Structure and Evolutionary Origin of Ca2+-Dependent Herring Type II Antifreeze Protein	PLOS ONE			English	Article								In order to survive under extremely cold environments, many organisms produce antifreeze proteins (AFPs). AFPs inhibit the growth of ice crystals and protect organisms from freezing damage. Fish AFPs can be classified into five distinct types based on their structures. Here we report the structure of herring AFP (hAFP), a Ca2+-dependent fish type II AFP. It exhibits a fold similar to the C-type (Ca2+-dependent) lectins with unique ice-binding features. The 1.7 angstrom crystal structure of hAFP with bound Ca2+ and site-directed mutagenesis reveal an ice-binding site consisting of Thr96, Thr98 and Ca2+-coordinating residues Asp94 and Glu99, which initiate hAFP adsorption onto the [10-10] prism plane of the ice lattice. The hAFP-ice interaction is further strengthened by the bound Ca2+ through the coordination with a water molecule of the ice lattice. This Ca2+-coordinated ice-binding mechanism is distinct from previously proposed mechanisms for other AFPs. However, phylogenetic analysis suggests that all type II AFPs evolved from the common ancestor and developed different ice-binding modes. We clarify the evolutionary relationship of type II AFPs to sugar-binding lectins.	[Liu, Yang; Li, Zhengjun; Lin, Qingsong; Sivaraman, J.; Hew, Choy-Leong] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore; [Kosinski, Jan; Bujnicki, Janusz M.] Int Inst Mol & Cell Biol, Warsaw, Poland; [Kosinski, Jan; Bujnicki, Janusz M.] Brookhaven Natl Lab, Upton, NY 11973 USA	National University of Singapore; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; United States Department of Energy (DOE); Brookhaven National Laboratory	Sivaraman, J (corresponding author), Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore.	dbsjayar@nus.edu.sg; dbshewcl@nus.edu.sg	Sivaraman, J/H-8028-2012; Hew, Choy Leong/I-1501-2012; Kosinski, Jan/G-9971-2012; Kosinski, Jan/V-8540-2019; Lin, Qingsong/H-9794-2012	Hew, Choy Leong/0000-0002-9441-0064; Kosinski, Jan/0000-0002-3641-0322; Lin, Qingsong/0000-0001-9117-8514	National University of Singapore	National University of Singapore(National University of Singapore)	This work was supported by the office of life sciences and Academic research Fund (ARF), National University of Singapore (C. L. H and J. S.*).	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Blomme T, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-r43; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Ewart KV, 1999, CELL MOL LIFE SCI, V55, P271, DOI 10.1007/s000180050289; Ewart KV, 1996, J BIOL CHEM, V271, P16627, DOI 10.1074/jbc.271.28.16627; EWART KV, 1993, THESIS MEMORIAL U NE; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; Fletcher GL, 1999, CHEMTECH, V29, P17; FORTELLE EDL, 1997, METHOD ENZYMOL, P472; Frickey T, 2004, BIOINFORMATICS, V20, P3702, DOI 10.1093/bioinformatics/bth444; *FSANZ, 2006, TECHN REP SER, V42; Gilbert JA, 2005, FEMS MICROBIOL LETT, V245, P67, DOI 10.1016/j.femsle.2005.02.022; Graham LA, 2005, SCIENCE, V310, P461, DOI 10.1126/science.1115145; Gronwald W, 1998, BIOCHEMISTRY-US, V37, P4712, DOI 10.1021/bi972788c; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hew Choy L., 1992, Molecular Marine Biology and Biotechnology, V1, P309; Jia ZC, 2002, TRENDS BIOCHEM SCI, V27, P101, DOI 10.1016/S0968-0004(01)02028-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khanna HK, 2006, PLANT CELL REP, V25, P1336, DOI 10.1007/s00299-006-0191-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; Li ZJ, 2004, BIOCHEMISTRY-US, V43, P14547, DOI 10.1021/bi048485h; Li ZJ, 2001, PROTEIN EXPRES PURIF, V21, P438, DOI 10.1006/prep.2001.1395; Loewen MC, 1998, BIOCHEMISTRY-US, V37, P17745, DOI 10.1021/bi9820513; Marshall CB, 2004, NATURE, V429, P153, DOI 10.1038/429153a; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Meyer A, 2005, BIOESSAYS, V27, P937, DOI 10.1002/bies.20293; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SONNICHSEN FD, 1995, PROTEIN SCI, V4, P460; Taylor JS, 2001, CURR BIOL, V11, pR1005, DOI 10.1016/S0960-9822(01)00610-8; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Wang Renxue, 1995, Molecular Marine Biology and Biotechnology, V4, P20; Yamashita Y, 2003, BIOSCI BIOTECH BIOCH, V67, P461, DOI 10.1271/bbb.67.461; Zeng H, 2006, J AM CHEM SOC, V128, P2844, DOI 10.1021/ja0548182	41	52	55	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e548	10.1371/journal.pone.0000548	http://dx.doi.org/10.1371/journal.pone.0000548			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579720	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451700014
J	Zhao, LJ; Subramanian, T; Vijayalingam, S; Chinnadurai, G				Zhao, L-J; Subramanian, T.; Vijayalingam, S.; Chinnadurai, G.			PLDLS-dependent interaction of E1A with CtBP: regulation of CtBP nuclear localization and transcriptional functions	ONCOGENE			English	Article						E1A; CtBP; p300; acetylation; E-cadherin; c-fos	COREPRESSOR CTBP; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; FAMILY PROTEINS; TERMINAL DOMAIN; ACETYLATION; BINDING; TRANSFORMATION; TUMORIGENESIS; ASSOCIATION	C-terminal binding proteins (CtBPs) are cellular corepressors that are targeted by adenovirus E1A. A conserved motif of E1A (PLDLS) interacts with an N-terminal hydrophobic cleft of CtBPs. Many cellular cofactors also interact with CtBPs through PLDLS-like motifs. E1A interaction with CtBP2 changed the composition of the CtBP2 protein complex and enhanced CtBP2 acetylation. We have identified a mutant of CtBP2 (M48A) that fails to interact with cellular cofactors while interacting normally with E1A. Other cleft mutations in CtBP2 affected interaction of both cellular cofactors and E1A. The M48A mutant did not repress the cellular E-cadherin promoter but inhibited transactivation mediated by the E1A N-terminal region through interaction with the E1A PLDLS motif. In vitro, E1A enhanced CtBP2 acetylation by p300 via a mechanism involving dissociation of acetylated CtBP2 from p300. E1A enhanced nuclear localization of CtBP1 as well as a cytoplasmically localized acetylation-deficient mutant of CtBP2 (3KR-CtBP2) through PLDLS-dependent interaction. Chromatin immunoprecipitation assays revealed presence of CtBP2 on E-cadherin and c-fos promoters. While E1A did not significantly alter targeting of CtBP2 to the E-cadherin and c-fos promoters, it dramatically enhanced promoter targeting of 3KR-CtBP2. Our results raise a possibility that E1A may gain access to cellular promoters through PLDLS-dependent interaction with CtBPs.	Jewish Hosp St Louis, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Barnes-Jewish Hospital	Chinnadurai, G (corresponding author), Jewish Hosp St Louis, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NATIONAL CANCER INSTITUTE [R01CA033616, R01CA084941] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, R01 CA084941-07, R01 CA033616, R01 CA084941, CA-84941, R01 CA033616-27] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergman LM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-35; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; LUNDBLAD JR, 2006, CTBP FAMILY PROTEINS, P83; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Molloy D, 2006, VIROLOGY, V355, P115, DOI 10.1016/j.virol.2006.05.004; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhao LJ, 2006, J BIOL CHEM, V281, P36613, DOI 10.1074/jbc.M603550200; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200	22	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7544	7551		10.1038/sj.onc.1210569	http://dx.doi.org/10.1038/sj.onc.1210569			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546044	Green Accepted			2022-12-25	WOS:000251282100006
J	Bartkova, J; Horejsi, Z; Sehested, M; Nesland, JM; Rajpert-De Meyts, E; Skakkebaek, NE; Stucki, M; Jackson, S; Lukas, J; Bartek, J				Bartkova, J.; Horejsi, Z.; Sehested, M.; Nesland, J. M.; Rajpert-De Meyts, E.; Skakkebaek, N. E.; Stucki, M.; Jackson, S.; Lukas, J.; Bartek, J.			DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours	ONCOGENE			English	Article						DNA damage response; breast cancer; lung cancer; testicular cancer; MDC1 and 53BP1 defects; tumour suppressors	ONCOGENE-INDUCED SENESCENCE; CARCINOMA IN-SITU; GENOMIC INSTABILITY; CYCLE CHECKPOINTS; ATM ACTIVATION; PROTEIN; P53; CHK1; DIFFERENTIATION; TUMORIGENESIS	MDC1 and 53BP1 are critical components of the DNA damage response (DDR) machinery that protects genome integrity and guards against cancer, yet the tissue expression patterns and involvement of these two DDR adaptors/mediators in human tumours remain largely unknown. Here we optimized immunohistochemical analyses of human 53BP1 and MDC1 proteins in situ and identified their virtually ubiquitous expression, both in proliferating and quiescent, differentiated tissues. Focus formation by 53BP1 and/or MDC1 in human spermatogenesis and subsets of breast and lung carcinomas indicated physiological and 'pathological' activation of the DDR, respectively. Furthermore, aberrant reduction or lack of either protein in significant proportions of carcinomas supported the candidacy of 53BP1 and MDC1 for tumour suppressors. Contrary to carcinomas, almost no activation or loss of MDC1 or 53BP1 were found among testicular germ-cell tumours (TGCTs), a tumour type with unique biology and exceptionally low incidence of p53 mutations. Such concomitant presence ( in carcinomas) or absence ( in TGCTs) of DDR activation and DDR aberrations supports the roles of MDC1 and 53BP1 within the ATM/ATR-regulated checkpoint network which, when activated, provides an early anticancer barrier the pressure of which selects for DDR defects such as p53 mutations or loss of 53BP1/MDC1 during cancer progression.	Danish Canc Soc, Ctr Genotox Stress Res, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Acad Sci Czech Republ, Inst Mol Genet, Prague, Czech Republic; Copenhagen Univ Hosp, Dept Pathol, Copenhagen, Denmark; Univ Oslo, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway; Univ Copenhagen Hosp, Dept Growth & Reproduct, DK-2100 Copenhagen, Denmark; Univ Zurich, Inst Vet Biochem & Mol Biol, Zurich, Switzerland; Gurdon Inst, Cambridge, England	Danish Cancer Society; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Copenhagen; University of Oslo; University of Copenhagen; University of Zurich	Bartek, J (corresponding author), Danish Canc Soc, Ctr Genotox Stress Res, Inst Canc Biol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk	Dry, Kate/I-2328-2014; Rajpert-De Meyts, Ewa/H-6526-2019; Stucki, Manuel/H-4739-2017; Jackson, Stephen Philip/R-4548-2019; Bartek, Jiri/G-5870-2014	Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Jackson, Stephen Philip/0000-0001-9317-7937; Licenikova Horejsi, Zuzana/0000-0002-9943-1649; Lukas, Jiri/0000-0001-9087-506X				Albanell J, 1999, J NATL CANCER I, V91, P1321, DOI 10.1093/jnci/91.15.1321; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2006, CELL, V124, P888, DOI 10.1016/j.cell.2006.02.029; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2003, APMIS, V111, P252, DOI 10.1034/j.1600-0463.2003.1110129.x; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350-6361.2004; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Lukas C, 2001, CANCER RES, V61, P4990; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Mochan TA, 2003, CANCER RES, V63, P8586; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; Nowak R, 2000, ONCOGENE, V19, P4075, DOI 10.1038/sj.onc.1203746; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rajpert-de Meyts E, 2003, APMIS, V111, P267, DOI 10.1034/j.1600-0463.2003.11101301.x; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Xu XZ, 2003, FASEB J, V17, P1842, DOI 10.1096/fj.03-0310com	50	96	108	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7414	7422		10.1038/sj.onc.1210553	http://dx.doi.org/10.1038/sj.onc.1210553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546051				2022-12-25	WOS:000251282000003
J	Cui, F; Qu, H; Cong, J; Liu, XL; Qiao, CL				Cui, Feng; Qu, Hong; Cong, Jian; Liu, Xiao-Li; Qiao, Chuan-Ling			Do mosquitoes acquire organophosphate resistance by functional changes in carboxylesterases?	FASEB JOURNAL			English	Article						organophosphorus hydrolase; site-directed mutagenesis	AMINO-ACID SUBSTITUTION; INSECTICIDE RESISTANCE; LUCILIA-CUPRINA; CULEX-PIPIENS; SWISS-MODEL; ESTERASES; EVOLUTION; MECHANISM	Carboxylesterase-based metabolic resistance to organophosphates (OPs) in insects has been shown to originate either from mutations in esterase-encoding sequences or from amplification of esterase genes. This study aimed to test the hypothesis that mosquitoes can acquire OP resistance by functional changes in carboxylesterases. Mutations were introduced into the esterase B1 of mosquito Culex pipiens by site-directed mutagenesis at positions 110 and 224. Three single mutants (G110D, W224L, and W224S) and two double mutants ( G110D/W224L and G110D/W224S) were expressed and purified. All five mutants lost native carboxylesterase activity. Mutation W224L converted esterase B1 to an OP hydrolase and increased its malathion carboxylesterase activity. No obvious OP hydrolysis was observed by G110D or W224S. Our data strongly support our hypothesis and suggest that mutation W224L might occur in natural populations of mosquitoes. Sequence comparison shows that the site 224 is especially highly conserved among various insect carboxylesterases. This leads to another hypothesis: that the position 224 plays a key role in insect carboxylesterases' switching from their native physiological functions to other functional niches under selection pressure exerted by insecticides.	Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing 100080, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Shanghai Fisheries Univ, Coll Food Sci & Technol, Shanghai, Peoples R China; Shijiazhuang Pharmaceut Grp, Shijiazhuang, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; Peking University; Shanghai Ocean University	Qiao, CL (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing 100080, Peoples R China.	qiaocl@ioz.ac.cn	Liu, Xiaoli/HGE-7614-2022	Cui, Feng/0000-0001-6215-7159				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell PM, 1998, INSECT BIOCHEM MOLEC, V28, P139, DOI 10.1016/S0965-1748(97)00109-4; Claudianos C, 1999, INSECT BIOCHEM MOLEC, V29, P675, DOI 10.1016/S0965-1748(99)00035-1; CUANY A, 1993, PESTIC BIOCHEM PHYS, V45, P1, DOI 10.1006/pest.1993.1001; Davies AG, 1996, GENETICS, V143, P1321; DEVONSHIRE AL, 1991, BIOCHEM SOC T, V19, P755, DOI 10.1042/bst0190755; Devonshire AL, 2003, PESTIC BIOCHEM PHYS, V76, P1, DOI 10.1016/S0048-3575(03)00054-3; FOURNIER D, 1994, COMP BIOCHEM PHYS C, V108, P19, DOI 10.1016/1367-8280(94)90084-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hartley CJ, 2006, P NATL ACAD SCI USA, V103, P8757, DOI 10.1073/pnas.0509590103; Heidari R, 2004, INSECT BIOCHEM MOLEC, V34, P353, DOI 10.1016/j.ibmb.2004.01.001; Hemingway J, 1998, MED VET ENTOMOL, V12, P1, DOI 10.1046/j.1365-2915.1998.00082.x; Huang Jing, 2001, Acta Genetica Sinica, V28, P583; JARV J, 1984, BIOORG CHEM, V12, P259, DOI 10.1016/0045-2068(84)90010-5; JAYAWARDENA KGI, 1994, B ENTOMOL RES, V84, P39, DOI 10.1017/S000748530003220X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XF, 1986, SCI B, V19, P1505; Li XC, 2007, ANNU REV ENTOMOL, V52, P231, DOI 10.1146/annurev.ento.51.110104.151104; Newcomb RD, 1997, P NATL ACAD SCI USA, V94, P7464, DOI 10.1073/pnas.94.14.7464; Oakeshott JG, 1999, BIOESSAYS, V21, P1031; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Raymond M, 1998, PHILOS T R SOC B, V353, P1707, DOI 10.1098/rstb.1998.0322; Raymond M, 2001, GENETICA, V112, P287, DOI 10.1023/A:1013300108134; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520	24	24	33	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3584	3591		10.1096/fj.07-8237com	http://dx.doi.org/10.1096/fj.07-8237com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567568				2022-12-25	WOS:000250517800021
J	Telek, A; Biro, T; Bodo, E; Toth, BI; Borbiro, I; Kunos, G; Paus, R				Telek, Andrea; Biro, Tamas; Bodo, Eniko; Toth, Balazs I.; Borbiro, Istvan; Kunos, George; Paus, Ralf			Inhibition of human hair follicle growth by endo- and exocannabinoids	FASEB JOURNAL			English	Article						cannabinoid receptor; proliferation; apoptosis; hair cycle	TUMOR-GROWTH; ENDOGENOUS CANNABINOIDS; HEMODYNAMIC PROFILE; HPA AXIS; RECEPTOR; STRESS; SKIN; ANGIOGENESIS; INVOLVEMENT; ANANDAMIDE	Recent studies strongly suggest that the cannabinoid system is a key player in cell growth control. Since the organ-culture of human hair follicles (HF) offers an excellent, clinically relevant model for complex tissue interaction systems, we have asked whether the cannabinoid system plays a role in hair growth control. Here, we show that human scalp HF, intriguingly, are both targets and sources of endocannabinoids. Namely, the endocannabinoid N-arachidonoylethanolamide ( anandamide, AEA) as well as the exocannabinnoid Delta (9)-tetrahydrocannabinol dose-dependently inhibited hair shaft elongation and the proliferation of hair matrix keratinocytes, and induced intraepithelial apoptosis and premature HF regression (catagen). These effects were inhibited by a selective antagonist of cannabinoid receptor-1 (CB1). In contrast to CB2, CB1 was expressed in a hair cycle-dependent manner in the human HF epithelium. Since we successfully identified the presence of endocannabinoids in human HF, our data strongly suggest that human HF exploit a CB1-mediated endocannabinoid signaling system for negatively regulating their own growth. Clinically, CB1 agonists may therefore help to manage unwanted hair growth, while CB1 antagonists might counteract hair loss. Finally, human HF organ culture offers an instructive, physiologically relevant new research tool for dissecting "nonclassical" effects of endocannabinoids and their receptor-mediated signaling in general.	Univ Debrecen, Dept Physiol, Med & Hlth Sci Ctr, Res Ctr Mol Med, H-4032 Debrecen, Hungary; Univ Debrecen, Cell Physiol Res Grp, Hungarian Acad Sci, Res Ctr Mol Med,Med & Hlth Sci Ctr, H-4032 Debrecen, Hungary; Med Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany; NIAAA, NIH, Bethesda, MD USA	University of Debrecen; Hungarian Academy of Sciences; University of Debrecen; University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Biro, T (corresponding author), Univ Debrecen, Dept Physiol, Med & Hlth Sci Ctr, Res Ctr Mol Med, Nagyerdie Krt 98 POB 22, H-4032 Debrecen, Hungary.	biro@phys.dote.hu	Tóth, Balázs István/K-1214-2013; Paus, Ralf/F-6243-2011	Tóth, Balázs István/0000-0002-4103-4333; Borbiro, Istvan/0000-0002-8366-6881	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000350, ZIAAA000350] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Arck PC, 2005, J MOL MED, V83, P386, DOI 10.1007/s00109-004-0627-z; Arck PC, 2003, AM J PATHOL, V162, P803, DOI 10.1016/S0002-9440(10)63877-1; Arck PC, 2006, J INVEST DERMATOL, V126, P1697, DOI 10.1038/sj.jid.5700104; Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; BATKAI S, 2007, FASEB J; Bifulco M, 2004, FASEB J, V18, P1606, DOI 10.1096/fj.04-1754fje; Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547; Biro T, 2006, J INVEST DERMATOL, V126, P1909, DOI 10.1038/sj.jid.5700321; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Blazquez C, 2006, FASEB J, V20, P2633, DOI 10.1096/fj.06-6638fje; Bodo E, 2005, AM J PATHOL, V166, P985, DOI 10.1016/S0002-9440(10)62320-6; Botchkarev VA, 2003, AM J PATHOL, V162, P709, DOI 10.1016/S0002-9440(10)63866-7; Carrier EJ, 2005, CNS NEUROL DISORD-DR, V4, P657, DOI 10.2174/156800705774933023; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; De Vries TJ, 2001, NAT MED, V7, P1151, DOI 10.1038/nm1001-1151; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2006, ANNU REV MED, V57, P553, DOI 10.1146/annurev.med.57.011205.135648; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Felder CC, 2006, MOL INTERV, V6, P149, DOI 10.1124/mi.6.3.6; Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001; Foitzik K, 2006, AM J PATHOL, V168, P748, DOI 10.2353/ajpath.2006.050468; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Kogan N M, 2006, J Endocrinol Invest, V29, P3; Maccarrone M, 2003, J BIOL CHEM, V278, P33896, DOI 10.1074/jbc.M303994200; Pacher P, 2005, AM J PHYSIOL-HEART C, V289, pH533, DOI 10.1152/ajpheart.00107.2005; Pacher P, 2004, J PHYSIOL-LONDON, V558, P647, DOI 10.1113/jphysiol.2004.064824; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Paus R, 2006, J CLIN INVEST, V116, P1174, DOI 10.1172/JCI28553; Paus R, 2006, TRENDS IMMUNOL, V27, P32, DOI 10.1016/j.it.2005.10.002; Paus R, 2005, TRENDS IMMUNOL, V26, P32, DOI 10.1016/j.it.2004.09.014; Paus R, 2003, J INVEST DERM SYMP P, V8, P188, DOI 10.1046/j.1087-0024.2003.00807.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Peters EMJ, 2006, EXP DERMATOL, V15, P1, DOI 10.1111/j.0906-6705.2005.00372.x; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Piomelli Daniele, 2005, Curr Opin Investig Drugs, V6, P672; Portella G, 2003, FASEB J, V17, P1771, DOI 10.1096/fj.02-1129fje; SKOPP G, 2006, FORENSIC SCI INT; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2005, J INVEST DERMATOL, V124, P13, DOI 10.1111/j.0022-202X.2004.23528.x; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2007, MOL CELL ENDOCRINOL, V265, P143, DOI 10.1016/j.mce.2006.12.012; Stander S, 2005, J DERMATOL SCI, V38, P177, DOI 10.1016/j.jdermsci.2005.01.007; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Uhl M, 2004, FORENSIC SCI INT, V145, P143, DOI 10.1016/j.forsciint.2004.04.029; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Wilkinson JD, 2007, J DERMATOL SCI, V45, P87, DOI 10.1016/j.jdermsci.2006.10.009	53	71	74	2	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3534	3541		10.1096/fj.06-7689com	http://dx.doi.org/10.1096/fj.06-7689com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567570				2022-12-25	WOS:000250517800016
J	Freundlich, JS; Wang, F; Tsai, HC; Kuo, M; Shieh, HM; Anderson, JW; Nkrumah, LJ; Valderramos, JC; Yu, M; Kumar, TRS; Valderramos, SG; Jacobs, WR; Schiehser, GA; Jacobus, DP; Fidock, DA; Sacchettini, JC				Freundlich, Joel S.; Wang, Feng; Tsai, Han-Chun; Kuo, Mack; Shieh, Hong-Ming; Anderson, John W.; Nkrumah, Louis J.; Valderramos, Juan-Carlos; Yu, Min; Kumar, T. R. Santha; Valderramos, Stephanie G.; Jacobs, William R., Jr.; Schiehser, Guy A.; Jacobus, David P.; Fidock, David A.; Sacchettini, James C.			X-ray structural analysis of plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of Triclosan antimalarial efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; DIARYL ETHER INHIBITORS; ACP REDUCTASE; BIOLOGICAL-ACTIVITY; TOXOPLASMA-GONDII; CRYSTAL-STRUCTURE; ISONIAZID TARGET; DRUG TARGETS; INHA; TUBERCULOSIS	The x-ray crystal structures of five triclosan analogs, in addition to that of the isoniazid-NAD adduct, are described in relation to their integral role in the design of potent inhibitors of the malarial enzyme Plasmodium falciparum enoyl acyl carrier protein reductase ( PfENR). Many of the novel 5-substituted analogs exhibit low micromolar potency against in vitro cultures of drug-resistant and drug-sensitive strains of the P. falciparum parasite and inhibit purified PfENR enzyme with IC50 values of < 200 nM. This study has significantly expanded the knowledge base with regard to the structure-activity relationship of triclosan while affording gains against cultured parasites and purified PfENR enzyme. In contrast to a recent report in the literature, these results demonstrate the ability to improve the in vitro potency of triclosan significantly by replacing the suboptimal 5-chloro group with larger hydrophobic moieties. The biological and x-ray crystallographic data thus demonstrate the flexibility of the active site and point to future rounds of optimization to improve compound potency against purified enzyme and intracellular Plasmodium parasites.	Jacobus Pharmaceut Co, Dept Med Chem, Princeton, NJ 08544 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Texas A&M University System; Texas A&M University College Station; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Freundlich, JS (corresponding author), Princeton Univ, Dept Chem, Frick Chem Lab, Princeton, NJ 08544 USA.	joelf@princeton.edu	Gaw, Stephanie/K-4592-2019	Gaw, Stephanie/0000-0003-0891-6964; Fidock, David/0000-0001-6753-8938; Jacobs, William/0000-0003-3321-3080	NIAID NIH HHS [AI060342, AI43268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043268, R21AI043268, P01AI060342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin J, 2005, J BIOL CHEM, V280, P21847, DOI 10.1074/jbc.M501100200; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai D, 2002, TETRAHEDRON LETT, V43, P4285, DOI 10.1016/S0040-4039(02)00776-1; Chhibber M, 2006, BIOORGAN MED CHEM, V14, P8086, DOI 10.1016/j.bmc.2006.07.034; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P266; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; FOX HH, 1952, SCIENCE, V116, P129, DOI 10.1126/science.116.3006.129; Freundlich JS, 2006, TETRAHEDRON LETT, V47, P4275, DOI 10.1016/j.tetlet.2006.04.027; Freundlich JS, 2006, BIOORG MED CHEM LETT, V16, P2163, DOI 10.1016/j.bmcl.2006.01.051; Freundlich JS, 2005, BIOORG MED CHEM LETT, V15, P5247, DOI 10.1016/j.bmcl.2005.08.044; GEARY TG, 1983, AM J TROP MED HYG, V32, P221, DOI 10.4269/ajtmh.1983.32.221; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kapoor M, 2004, BIOCHEM J, V381, P719, DOI 10.1042/BJ20031821; Kapoor M, 2004, BIOCHEM J, V381, P725, DOI 10.1042/BJ20040228; Kapoor M, 2001, BIOCHEM BIOPH RES CO, V289, P832, DOI 10.1006/bbrc.2001.6061; Kirmizibekmez H, 2004, PLANTA MED, V70, P711, DOI 10.1055/s-2004-827200; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Kumar G, 2007, J MED CHEM, V50, P2665, DOI 10.1021/jm061257w; Kumar S, 2006, SYNTHETIC COMMUN, V36, P215, DOI 10.1080/00397910500334561; Kuo MR, 2003, J BIOL CHEM, V278, P20851, DOI 10.1074/jbc.M211968200; KURSANOV DN, 1974, SYNTHESIS-STUTTGART, P633; Lu JZQ, 2005, COMB CHEM HIGH T SCR, V8, P15, DOI 10.2174/1386207053328192; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; McLeod R, 2001, INT J PARASITOL, V31, P109, DOI 10.1016/S0020-7519(01)00111-4; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mi-ichi F, 2006, PARASITOLOGY, V133, P399, DOI 10.1017/S0031182006000540; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Netherton MR, 2001, ORG LETT, V3, P4295, DOI 10.1021/ol016971g; Nguyen M, 2002, ANTIMICROB AGENTS CH, V46, P2137, DOI 10.1128/AAC.46.7.2137-2144.2002; Nguyen M, 2001, CHEMBIOCHEM, V2, P877, DOI 10.1002/1439-7633(20011203)2:12<877::AID-CBIC877>3.0.CO;2-V; Nkrumah LJ, 2006, NAT METHODS, V3, P615, DOI 10.1038/NMETH904; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Sharma SK, 2007, J MED CHEM, V50, P765, DOI 10.1021/jm061154d; Sharma Shilpi, 2007, Antimicrob Agents Chemother, V51, P2552, DOI 10.1128/AAC.00124-07; Sindkhedkar MD, 2001, TETRAHEDRON, V57, P2991, DOI 10.1016/S0040-4020(01)00162-4; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Sullivan TJ, 2006, ACS CHEM BIOL, V1, P43, DOI 10.1021/cb0500042; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; Tasdemir D, 2006, J MED CHEM, V49, P3345, DOI 10.1021/jm0600545; Vilcheze C, 2006, NAT MED, V12, P1027, DOI 10.1038/nm1466; Waller RF, 2003, ANTIMICROB AGENTS CH, V47, P297, DOI 10.1128/AAC.47.1.297-301.2003; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wang LQ, 2004, DRUG METAB DISPOS, V32, P1162, DOI 10.1124/dmd.104.000273; Witkowski A, 2007, J BIOL CHEM, V282, P14178, DOI 10.1074/jbc.M701486200; Zhang L, 2005, J BIOL CHEM, V280, P12422, DOI 10.1074/jbc.M413686200; Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; Zhang YM, 2004, J BIOL CHEM, V279, P30994, DOI 10.1074/jbc.M403697200	63	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25436	25444		10.1074/jbc.M701813200	http://dx.doi.org/10.1074/jbc.M701813200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17567585	hybrid			2022-12-25	WOS:000249014100029
J	Qi, J; Forgac, M				Qi, Jie; Forgac, Michael			Cellular environment is important in controlling V-ATPase dissociation and its dependence on activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; IN-VIVO DISSOCIATION; PROTON-TRANSLOCATING ATPASE; COATED VESICLE (H+)-ATPASE; MEDIATED CROSS-LINKING; SACCHAROMYCES-CEREVISIAE; PREVACUOLAR COMPARTMENT; PLASMA-MEMBRANE; GENE ENCODES; SUBUNIT-C	One mechanism of regulating V-ATPase activity in vivo involves reversible dissociation into its component V-1 and V-0 domains, which in yeast occurs in response to glucose depletion. V-ATPase complexes containing the Vph1p isoform of subunit a (VCC) are targeted to the vacuole, and Stv1p-containing complexes (SCC) are targeted to the Golgi. Overexpression of Stv1p results in mistargeting of SCC to the vacuole. We have investigated the role of the a subunit isoform and cellular environment in controlling dissociation using vacuolar protein sorting (vps) mutants that accumulate proteins in either the prevacuolar compartment (PVC) (vps27 Delta) or a post-Golgi compartment (PGC) (vps21 Delta). Dissociation of both VCC and SCC depends upon cellular environment, with dissociation most complete in the vacuole and least complete in the PVC. The dependence of dissociation on V-ATPase activity was also investigated using both concanamycin and inactivating mutations. Concanamycin partly blocks dissociation of both VCC and SCC in all three compartments, with inhibition generally greater for SCC than VCC. The R735Q mutant of Vph1p results in loss of both ATPase and proton transport, whereas the R735K mutant lacks proton transport but has 10% of wild type ATPase activity. For VCC in the vacuole, dissociation is completely blocked for the R735Q but not the R735K mutant. Significant dissociation of VCC is observed for both mutants in the PVC and PGC, indicating that V-ATPase activity is not absolutely required for dissociation. Similar results were obtained for SCC, although dissociation of SCC is again generally more sensitive to activity than VCC. These results suggest that the cellular environment is important both in controlling in vivo dissociation of the V-ATPase and the dependence of this process on catalytic activity. Moreover, catalytic activity is not absolutely required for V-ATPase dissociation.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NIDDK NIH HHS [P30 DK034928, DK 34928] Funding Source: Medline; NIGMS NIH HHS [R37 GM034478-23, R37 GM034478-20, GM 34478, R37 GM034478, R37 GM034478-22, R37 GM034478-21, R01 GM034478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrami L, 2004, J CELL BIOL, V166, P645, DOI 10.1083/jcb.200312072; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; Bowers K, 2005, BBA-MOL CELL RES, V1744, P438, DOI 10.1016/j.bbamcr.2005.04.004; Conibear E, 2002, METHOD ENZYMOL, V351, P408; FENG Y, 1992, J BIOL CHEM, V267, P5817; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Gerrard SR, 2000, MOL BIOL CELL, V11, P613, DOI 10.1091/mbc.11.2.613; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Johnston M, 2002, METHOD ENZYMOL, V350, P290, DOI 10.1016/S0076-6879(02)50970-8; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kawasaki-Nishi S, 2003, J BIOL CHEM, V278, P41908, DOI 10.1074/jbc.M308026200; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; Liegeois S, 2006, J CELL BIOL, V173, P949, DOI 10.1083/jcb.200511072; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; Nelson N, 2003, J BIOENERG BIOMEMBR, V35, P281, DOI 10.1023/A:1025768529677; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peterson MR, 2001, TRAFFIC, V2, P476, DOI 10.1034/j.1600-0854.2001.20705.x; Pietrement C, 2006, BIOL REPROD, V74, P185, DOI 10.1095/biolreprod.105.043752; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Shao E, 2004, J BIOL CHEM, V279, P48663, DOI 10.1074/jbc.M408278200; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Wagner CA, 2004, PHYSIOL REV, V84, P1263, DOI 10.1152/physrev.00045.2003; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	49	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24743	24751		10.1074/jbc.M700663200	http://dx.doi.org/10.1074/jbc.M700663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17565997	hybrid, Green Accepted			2022-12-25	WOS:000248933000029
J	Johansen, ML; Brown, EJ				Johansen, Mette L.; Brown, Eric J.			Dual regulation of SIRP alpha phosphorylation by integrins and CD47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CADHERIN; TYROSINE-PHOSPHATASE SHP-2; FACTOR-I RECEPTOR; SMOOTH-MUSCLE-CELLS; RED-BLOOD-CELLS; GROWTH-FACTOR; NEGATIVE REGULATION; TRANSMEMBRANE GLYCOPROTEIN; SIGNAL-TRANSDUCTION; VE-CADHERIN	Signal regulatory protein alpha ( SIRP alpha, SHPS- 1) is a plasma membrane receptor for CD47 and a key regulator of phagocytosis, growth factor signaling, and migration. Phosphorylation of immunoreceptor tyrosine- based inhibition motifs in its cytoplasmic tail is essential for the functional effects of SIRP alpha, at least in part, because the phosphorylated immunoreceptor tyrosine-based inhibition motifs recruit Src homology 2 domain-containing tyrosine phosphatases. Ligation by CD47 and integrin engagement both have been thought to regulate SIRP alpha phosphorylation. However, their distinct contributions have not been distinguished. Here, we show that the importance of CD47 varies with cell type, since ligation of CD47 is not necessary for SIRP alpha phosphorylation in myeloid cells, whereas it is required in endothelial cells. In contrast, integrin- mediated adhesion is required for SIRP alpha phosphorylation in both cell types. This shows that SIRP alpha phosphorylation is dually regulated and demonstrates a new mechanism for functional cooperation between integrins and the integrin- associated protein CD47.	Univ Calif San Francisco, Program Microbial Pathogenesis & Host Defense, San Francisco, CA 94158 USA	University of California System; University of California San Francisco	Brown, EJ (corresponding author), Genentech Inc, 1 DNA Way,MS 33, San Francisco, CA 94080 USA.	brown.eric@gene.com			NIAID NIH HHS [P01 AI53194] Funding Source: Medline; NIGMS NIH HHS [R01 GM38330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amin ARMR, 2002, ONCOGENE, V21, P8871, DOI 10.1038/sj.onc.1206018; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Clemmons DR, 2003, ENDOCRINOLOGY, V144, P1664, DOI 10.1210/en.2002-221102; Comu S, 1997, J NEUROSCI, V17, P8702; Esser S, 1998, J CELL SCI, V111, P1853; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gresham HD, 2000, J EXP MED, V191, P515, DOI 10.1084/jem.191.3.515; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Ishikawa-Sekigami T, 2006, BIOCHEM BIOPH RES CO, V343, P1197, DOI 10.1016/j.bbrc.2006.03.094; Ishikawa-Sekigami T, 2006, BLOOD, V107, P341, DOI 10.1182/blood-2005-05-1896; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lambeng N, 2005, CIRC RES, V96, P384, DOI 10.1161/01.RES.0000156652.99586.9f; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Lee JW, 2004, MOL CELLS, V17, P188; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Ling Y, 2005, MOL BIOL CELL, V16, P3353, DOI 10.1091/mbc.E04-10-0918; Maile LA, 2003, MOL BIOL CELL, V14, P3519, DOI 10.1091/mbc.E03-04-0239; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Mocsai A, 2003, BLOOD, V101, P4155, DOI 10.1182/blood-2002-07-2346; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; Nelson CM, 2004, MOL BIOL CELL, V15, P2943, DOI 10.1091/mbc.E03-10-0745; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Okazawa H, 2005, J IMMUNOL, V174, P2004, DOI 10.4049/jimmunol.174.4.2004; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Oldenborg PA, 2004, LEUKEMIA LYMPHOMA, V45, P1319, DOI 10.1080/1042819042000201989; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; ROSEN H, 1987, J EXP MED, V166, P1685, DOI 10.1084/jem.166.6.1685; Sato R, 2003, BIOCHEM BIOPH RES CO, V309, P584, DOI 10.1016/j.bbrc.2003.08.031; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Stofega MR, 2000, J BIOL CHEM, V275, P28222; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Wallez Y, 2007, ONCOGENE, V26, P1067, DOI 10.1038/sj.onc.1209855; Wang YX, 2006, P NATL ACAD SCI USA, V103, P1774, DOI 10.1073/pnas.0510774103; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	49	46	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24219	24230		10.1074/jbc.M701565200	http://dx.doi.org/10.1074/jbc.M701565200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584740	hybrid			2022-12-25	WOS:000248686600047
J	Wall, SJ; Zhong, ZD; DeClerck, YA				Wall, Steven J.; Zhong, Zhi-Duan; DeClerck, Yves A.			The cyclin-dependent kinase inhibitors p15(INK4B) and p21(CIP1) are critical regulators of fibrillar collagen-induced tumor cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; G(2)/M ARREST; CANCER CELLS; PROLIFERATION; PROGRESSION; MELANOMA; GROWTH; INDUCTION; ADHESION; P21	The extracellular matrix is a crucial component in determining cell fate. Fibrillar collagen in its native form inhibits cell proliferation, whereas in its monomeric form it stimulates proliferation. The observation of elevated levels of p27(KIP1) in cells plated in the presence of fibrillar collagen has led to the assumption that this kinase inhibitor was responsible for cell cycle arrest on fibrillar collagen. Here we provide evidence that p15(INK4b), rather than p27(KIP1), is the cyclin-dependent kinase inhibitor responsible for G(0)/G(1) arrest of human melanoma cells grown on fibrillar collagen. Additionally, we demonstrate that fibrillar collagen can also arrest cells at the G(2) phase, which is mediated in part by p21(CIP1). Our data, in addition to identifying cyclin-dependent kinase inhibitors important in cell cycle arrest mediated by fibrillar collagen, demonstrate the complexity of cell cycle regulation and indicate that modulating a single cyclin-dependent kinase inhibitor does not disrupt cell proliferation in the presence of fibrillar collagen.	Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA; Univ So Calif, Dept Mol Biol, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Dept Biochem & Mol Biol, Dept Pediat, Los Angeles, CA 90027 USA; AmCyte Inc, Santa Monica, CA 90404 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California	DeClerck, YA (corresponding author), Childrens Hosp Los Angeles, Saban Res Inst, 4650 Sunset Blvd,Mail Stop 54, Los Angeles, CA 90027 USA.	declerck@usc.edu		DeClerck, Yves/0000-0002-3688-0113	NCI NIH HHS [R01 CA42919, R01 CA98469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042919, R01CA098469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacakova L, 1997, EXP MOL PATHOL, V64, P185, DOI 10.1006/exmp.1997.2219; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Dvory-Sobol H, 2006, EUR J CANCER, V42, P422, DOI 10.1016/j.ejca.2005.11.009; Elder D, 1999, ACTA ONCOL, V38, P535, DOI 10.1080/028418699431113; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Haass NK, 2005, PIGM CELL RES, V18, P150, DOI 10.1111/j.1600-0749.2005.00235.x; Han SW, 2005, CANCER LETT, V219, P71, DOI 10.1016/j.canlet.2004.07.040; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Herz DB, 2003, J UROLOGY, V170, P2072, DOI 10.1097/01.ju.0000091810.33953.13; Hodkinson PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Karsenty G, 1995, Int Rev Immunol, V12, P177, DOI 10.3109/08830189509056711; Kim HS, 2006, TOXICOL APPL PHARM, V215, P317, DOI 10.1016/j.taap.2006.03.011; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Luk Sharon Chui-Wah, 2005, Int J Med Sci, V2, P64; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Maeda T, 2005, BIOL PHARM BULL, V28, P849, DOI 10.1248/bpb.28.849; Nagaki M, 2000, J HEPATOL, V32, P488, DOI 10.1016/S0168-8278(00)80401-8; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Pilcher BK, 1998, ARCH DERMATOL RES, V290, pS37, DOI 10.1007/PL00007452; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; ROBERTS JM, 1990, EXP EYE RES, V50, P165, DOI 10.1016/0014-4835(90)90227-L; Satyamoorthy K, 2002, CANCER BIOL THER, V1, P14, DOI 10.4161/cbt.1.1.32; Sharma N, 2006, J BIOL CHEM, V281, P36124, DOI 10.1074/jbc.M604152200; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Wall SJ, 2005, J BIOL CHEM, V280, P40187, DOI 10.1074/jbc.M508226200; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Yamada KM, 2003, NATURE, V424, P889, DOI 10.1038/424889a; Zhou XY, 2006, J BIOL CHEM, V281, P39757, DOI 10.1074/jbc.M605621200	37	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24471	24476		10.1074/jbc.M702697200	http://dx.doi.org/10.1074/jbc.M702697200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17553787	hybrid			2022-12-25	WOS:000248686600074
J	Kallen, J; Lattmann, R; Beerli, R; Blechschmidt, A; Blommers, MJJ; Geiser, M; Ottl, J; Schlaeppi, JM; Strauss, A; Fournier, B				Kallen, Joerg; Lattmann, Rene; Beerli, Rene; Blechschmidt, Anke; Blommers, Marcel J. J.; Geiser, Martin; Ottl, Johannes; Schlaeppi, Jean-Marc; Strauss, Andre; Fournier, Brigitte			Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT TRANSCRIPTIONAL ACTIVATION; LIGAND-BINDING DOMAIN; ERR-ALPHA; GAMMA; IDENTIFICATION; ANTAGONISM; TARGETS; MODE; GENE	Inverse agonists of the constitutively active human estrogen-related receptor alpha(ERR alpha, NR3B1) are of potential interest for several disease indications (e. g. breast cancer, metabolic diseases, or osteoporosis). ERR alpha is constitutively active, because its ligand binding pocket (LBP) is practically filled with side chains (in particular with Phe(328), which is replaced by Ala in ERR beta and ERR gamma). We present here the crystal structure of the ligand binding domain of ERR alpha (containing the mutation C325S) in complex with the inverse agonist cyclohexylmethyl-(1-p-tolyl-1H-indol-3-ylmethyl)-amine (compound 1a), to a resolution of 2.3 angstrom. The structure reveals the dramatic multiple conformational changes in the LBP, which create the necessary space for the ligand. As a consequence of the new side chain conformation of Phe(328) (on helix H3), Phe(510)(H12) has to move away, and thus the activation helix H12 is displaced from its agonist position. This is a novel mechanism of H12 inactivation, different from ERR gamma, estrogen receptor (ER) alpha, and ER beta. H12 binds (with a surprising binding mode) in the coactivator groove of its ligand binding domain, at a similar place as a coactivator peptide. This is in contrast to ERR gamma but resembles the situation for ER alpha (raloxifene or 4-hydroxytamoxifen complexes). Our results explain the novel molecular mechanism of an inverse agonist for ERR alpha and provide the basis for rational drug design to obtain isotype-specific inverse agonists of this potential new drug target. Despite a practically filled LBP, the finding that a suitable ligand can induce an opening of the cavity also has broad implications for other orphan nuclear hormone receptors (e.g. the NGFI-B subfamily).	Novartis Inst BioMed Res, CH-4002 Basel, Switzerland	Novartis	Kallen, J (corresponding author), Novartis Inst BioMed Res, CH-4002 Basel, Switzerland.	Joerg.kallen@novartis.com						Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203, DOI 10.2174/1568026610606030203; Ariazi EA, 2002, CANCER RES, V62, P6510; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Bonnelye E, 2005, J CLIN ENDOCR METAB, V90, P3115, DOI 10.1210/jc.2004-2168; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Busch BB, 2004, J MED CHEM, V47, P5593, DOI 10.1021/jm049334f; Chao EYH, 2006, BIOORG MED CHEM LETT, V16, P821, DOI 10.1016/j.bmcl.2005.11.030; Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; DeLano W, 2002, PYMOL 0 99; Flaig R, 2005, J BIOL CHEM, V280, P19250, DOI 10.1074/jbc.M413175200; Gaillard S, 2007, MOL ENDOCRINOL, V21, P62, DOI 10.1210/me.2006-0179; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Greschik H, 2004, J BIOL CHEM, V279, P33639, DOI 10.1074/jbc.M402195200; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Horard B, 2003, J MOL ENDOCRINOL, V31, P349, DOI 10.1677/jme.0.0310349; Jahnke W, 2004, CELL MOL LIFE SCI, V61, P580, DOI 10.1007/s00018-003-3382-3; Jahnke W, 2002, CHEMBIOCHEM, V3, P167, DOI 10.1002/1439-7633(20020301)3:2/3<167::AID-CBIC167>3.0.CO;2-S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallen J, 2004, J BIOL CHEM, V279, P49330, DOI 10.1074/jbc.M407999200; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Renaud J, 2005, J MED CHEM, V48, P364, DOI 10.1021/jm040858p; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Stein R, 2006, DRUG FUTURE, V31, P427, DOI 10.1358/dof.2006.031.05.994706; Strauss A, 2003, J BIOMOL NMR, V26, P367, DOI 10.1023/A:1024013111478; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Wang L, 2006, J BIOL CHEM, V281, P37773, DOI 10.1074/jbc.M608410200; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101	41	64	68	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23231	23239		10.1074/jbc.M703337200	http://dx.doi.org/10.1074/jbc.M703337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17556356	Green Published, hybrid			2022-12-25	WOS:000248577500024
J	Kaznacheyeva, E; Glushankova, L; Bugaj, V; Zimina, O; Skopin, A; Alexeenko, V; Tsiokas, L; Bezprozvanny, I; Mozhayeva, GN				Kaznacheyeva, Elena; Glushankova, Lyuba; Bugaj, Vladislav; Zimina, Olga; Skopin, Anton; Alexeenko, Vadim; Tsiokas, Leonidas; Bezprozvanny, Ilya; Mozhayeva, Galina N.			Suppression of TRPC3 leads to disappearance of store-operated channels and formation of a new type of store-independent channels in A431 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CURRENT; PLASMA-MEMBRANE; TRANSIENT RECEPTOR; CA2+ INFLUX; FUNCTIONAL-PROPERTIES; CALCIUM-ENTRY; CRAC CHANNEL; DEPLETION; OSCILLATIONS; ACTIVATION	In most non-excitable cells, calcium (Ca2+) release from the inositol 1,4,5-trisphosphate (InsP(3))-sensitive intracellular Ca2+ stores is coupled to Ca2+ influx through the plasma membrane Ca2+ channels whose molecular composition is poorly understood. Several members of mammalian TRP-related protein family have been implicated to both receptor- and store-operated Ca2+ influx. Here we investigated the role of the native transient receptor potential 3(TRPC3) homologue in mediating the store- and receptor- operated calcium entry in A431 cells. We show that suppression of TRPC3 protein levels by small interfering RNA ( siRNA) leads to a significant reduction in store- operated calcium influx without affecting the receptoroperated calcium influx. With single-channel analysis, we further demonstrate that reduction of TRPC3 levels results in suppression of specific subtype of store- operated calcium channels and activation of store- independent channels. Our data suggest that TRPC3 is required for the formation of functional store-operated channels in A431 cells.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mozhayeva, GN (corresponding author), Russian Acad Sci, Inst Cytol, Tikhoretsky Ave 4, St Petersburg 194064, Russia.	gnmozh@mail.cytspb.rssi.ru	Glushankova, Lyubov/AAE-9361-2021; Kaznacheyeva, Elena V/I-7260-2017; Skopin, Anton Y/G-5457-2017	Glushankova, Lyubov/0000-0002-9995-1214; Kaznacheyeva, Elena V/0000-0003-1273-1188; Tsiokas, Leonidas/0000-0002-3659-1813; Skopin, Anton/0000-0002-9693-0098	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK059599, R01DK059599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038082] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59599] Funding Source: Medline; NINDS NIH HHS [NS38082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gusev K, 2003, J GEN PHYSIOL, V122, P81, DOI 10.1085/jgp.200308815; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kaznacheyeva E, 2000, J BIOL CHEM, V275, P4561, DOI 10.1074/jbc.275.7.4561; Kaznacheyeva E, 2001, P NATL ACAD SCI USA, V98, P148, DOI 10.1073/pnas.98.1.148; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Ma R, 2003, J BIOL CHEM, V278, P52763, DOI 10.1074/jbc.M309610200; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; MONTELL C, 2001, SCIENCES STKE; MOZHAYEVA GN, 1990, FEBS LETT, V277, P233, DOI 10.1016/0014-5793(90)80853-B; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Putney JW, 2001, J CELL SCI, V114, P2223; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; THEBAUT S, 2005, J CELL PHYSL, V240, P320; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; WU X, 2000, AM J PHYSIOL, V278, P536; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zubov AI, 1999, J BIOL CHEM, V274, P25983, DOI 10.1074/jbc.274.37.25983; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	46	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23655	23662		10.1074/jbc.M608378200	http://dx.doi.org/10.1074/jbc.M608378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17569672	hybrid			2022-12-25	WOS:000248577500068
J	Shen, T; Zheng, M; Cao, CM; Chen, CL; Tang, J; Zhang, WR; Cheng, HP; Chen, KH; Xiao, RP				Shen, Tao; Zheng, Ming; Cao, Chunmei; Chen, Chunlei; Tang, Jian; Zhang, Wanrui; Cheng, Heping; Chen, Kuang-Hueih; Xiao, Rui-Ping			Mitofusin-2 is a major determinant of oxidative stress-mediated heart muscle cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAILING HUMAN HEART; MITOCHONDRIAL FUSION; CARDIOMYOCYTE APOPTOSIS; MAMMALIAN HOMOLOGS; SIGNALING PATHWAY; CARDIAC MYOCYTES; DEATH; FAILURE; BAX; MFN2	An inexorable loss of terminally differentiated heart muscle cells is a crucial causal factor for heart failure. Here, we have provided several lines of evidence to demonstrate that mitofusin-2 (Mfn-2; also called hyperplasia suppressor gene), a member of the mitofusin family, is a major determinant of oxidative stress-mediated cardiomyocyte apoptosis. First, oxidative stress with H2O2 led to concurrent increases in Mfn-2 expression and apoptosis in cultured neonatal rat cardiomyocytes. Second, overexpression of Mfn-2 to a level similar to that induced by H2O2 was sufficient to trigger myocyte apoptosis, which is associated with profound inhibition of Akt activation without altering ERK1/2 signaling. Third, Mfn-2 silencing inhibited oxidative stress-induced apoptosis in H9C2 cells, a cardiac muscle cell line. Furthermore, Mfn-2-induced myocyte apoptosis was abrogated by inhibition of caspase-9 (but not caspase-8) and by overexpression of Bcl-x(L) or enhanced activation of phosphatidylinositol 3-kinase-Akt, suggesting that inhibition of Akt signaling and activation of the mitochondrial death pathway are essentially involved in Mfn-2-induced heart muscle cell apoptosis. These results indicate that increased cardiac Mfn-2 expression is both necessary and sufficient for oxidative stress-induced heart muscle cell apoptosis, suggesting that Mfn-2 deregulation may be a crucial pathogenic element and a potential therapeutic target for heart failure.	NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; Peking Univ, Inst Cardiovasc Sci, Beijing 100083, Peoples R China; Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Peking University; Peking University	Chen, KH (corresponding author), NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	chenku@grc.nia.nih.gov; Xiaor@grc.nia.nih.gov	cheng, heping/A-7299-2011; Xiao, Rui-Ping/AAE-2629-2019; Yimei, Wang/AAE-4083-2019; Heping, Cheng/AAE-2680-2019	Heping, Cheng/0000-0002-9604-6702; Shen, Tao/0000-0001-5856-0818	NATIONAL INSTITUTE ON AGING [Z01AG000289] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cesselli D, 2001, CIRC RES, V89, P279, DOI 10.1161/hh1501.094115; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Detmer SA, 2007, J CELL BIOL, V176, P405, DOI 10.1083/jcb.200611080; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Guerra S, 1999, CIRC RES, V85, P856, DOI 10.1161/01.RES.85.9.856; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Ide T, 1999, CIRC RES, V85, P357, DOI 10.1161/01.RES.85.4.357; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Konstam MA, 1998, PROG CARDIOVASC DIS, V41, P65, DOI 10.1016/S0033-0620(98)80033-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Pawlikowska P, 2007, CELL TISSUE RES, V327, P571, DOI 10.1007/s00441-006-0320-3; Rojo M, 2002, J CELL SCI, V115, P1663; Santel A, 2003, J CELL SCI, V116, P2763, DOI 10.1242/jcs.00479; Santel A, 2001, J CELL SCI, V114, P867; Saraste A, 1999, EUR J CLIN INVEST, V29, P380; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; Vander Heiden MG, 1999, MOL CELL, V3, P159; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	38	144	162	3	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23354	23361		10.1074/jbc.M702657200	http://dx.doi.org/10.1074/jbc.M702657200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17562700	hybrid			2022-12-25	WOS:000248577500036
J	Watanabe, J; Chou, KJ; Liao, JC; Miao, YN; Meng, HH; Ge, H; Grijalva, V; Hama, S; Kozak, K; Buga, G; Whitelegge, JP; Lee, TD; Farias-Eisner, R; Navab, M; Fogelman, AM; Reddy, ST				Watanabe, Junji; Chou, Katherine J.; Liao, James C.; Miao, Yunan; Meng, Hsiang-Hui; Ge, Helen; Grijalva, Victor; Hama, Susan; Kozak, Kathy; Buga, Georgette; Whitelegge, Julian P.; Lee, Terry D.; Farias-Eisner, Robin; Navab, Mohamad; Fogelman, Alan M.; Reddy, Srinivasa T.			Differential association of hemoglobin with proinflammatory high density lipoproteins in Atherogenic/Hyperlipidemic mice - A novel biomarker of atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE SCAVENGER RECEPTOR; CORONARY HEART-DISEASE; APOLIPOPROTEIN-A-I; NITRIC-OXIDE; OXIDIZED PHOSPHOLIPIDS; ERYTHROCYTE CONSUMPTION; CHOLESTEROL EFFLUX; OVARIAN-CANCER; CROSS-LINKING; INHIBITS 3	Studies in both mice and humans suggest that the anti-or proinflammatory nature of high density lipoprotein (HDL) may be a more sensitive predictor of risk for coronary heart disease events. In this study, we report the identification and characterization of two proteins (m/z 14,900 and 15,600) that are most dramatically associated with HDL in mouse models of atherosclerosis. Mass spectral analyses of proinflammatory HDL identified the two peaks to be hemoglobin (Hb) alpha and beta chains, respectively, with no apparent post-translational modification. Biochemical analysis confirmed the differential association of Hb with HDL from hyperlipidemic mice. We further show that HDL-associated Hb is predominantly in the oxyHb form with distinct physical and chemical properties. Furthermore oxyHb-containing proinflammatory HDL potently consumed nitric oxide and contracted arterial vessels ex vivo. Moreover Hb also was found differentially associated with HDL from coronary heart disease patients compared with healthy controls. Our data suggest that Hb contributes to the proinflammatory nature of HDL in mouse and human models of atherosclerosis and may serve as a novel biomarker for atherosclerosis.	Univ Calif Los Angeles, Dept Med Cardiol, Atherosclerosis Res Unit, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Bimol Engn, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; City of Hope; Beckman Research Institute of City of Hope	Reddy, ST (corresponding author), Univ Calif Los Angeles, Dept Med Cardiol, Atherosclerosis Res Unit, 650 Charles E Young Dr S,A8-131,CHS, Los Angeles, CA 90095 USA.	sreddy@mednet.ucla.edu		Liao, James/0000-0002-4580-7276	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, R01HL071776] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL71776, HL-30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alayash AI, 2001, ANTIOXID REDOX SIGN, V3, P313, DOI 10.1089/152308601300185250; Alayash AI, 1999, NAT BIOTECHNOL, V17, P545, DOI 10.1038/9849; ALTRUDA F, 1985, NUCLEIC ACIDS RES, V13, P3841, DOI 10.1093/nar/13.11.3841; Ansell BJ, 2003, CIRCULATION, V108, P2751, DOI 10.1161/01.CIR.0000103624.14436.4B; Balestrieri M, 2001, MOL REPROD DEV, V59, P186, DOI 10.1002/mrd.1021; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Cigliano L, 2001, STEROIDS, V66, P889, DOI 10.1016/S0039-128X(01)00124-6; de Valk B, 1999, ARCH INTERN MED, V159, P1542, DOI 10.1001/archinte.159.14.1542; Fabriek BO, 2005, IMMUNOBIOLOGY, V210, P153, DOI 10.1016/j.imbio.2005.05.010; Fung ET, 2001, CURR OPIN BIOTECH, V12, P65, DOI 10.1016/S0958-1669(00)00167-1; Garban HJ, 2004, J CARDIOVASC PHARM, V43, P638, DOI 10.1097/00005344-200405000-00005; Gomez SM, 2003, MOL CELL PROTEOMICS, V2, P1068, DOI 10.1074/mcp.M300062-MCP200; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V205, P1072, DOI 10.1006/bbrc.1994.2775; Hedrick CC, 2000, ARTERIOSCL THROM VAS, V20, P1946, DOI 10.1161/01.ATV.20.8.1946; Hunt RC, 1996, J CELL PHYSIOL, V168, P71, DOI 10.1002/(SICI)1097-4652(199607)168:1<71::AID-JCP9>3.0.CO;2-5; Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185; Issaq HJ, 2002, BIOCHEM BIOPH RES CO, V292, P587, DOI 10.1006/bbrc.2002.6678; Kozak KR, 2003, P NATL ACAD SCI USA, V100, P12343, DOI 10.1073/pnas.2033602100; Kozak KR, 2005, PROTEOMICS, V5, P4589, DOI 10.1002/pmic.200500093; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; KUNITAKE ST, 1994, BIOCHEMISTRY-US, V33, P1988, DOI 10.1021/bi00174a003; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Mackness Michael I, 2004, Am J Cardiovasc Drugs, V4, P211, DOI 10.2165/00129784-200404040-00002; Miller YI, 1996, ARCH BIOCHEM BIOPHYS, V326, P252, DOI 10.1006/abbi.1996.0073; Navab M, 2000, J LIPID RES, V41, P1481; Navab M, 2000, J LIPID RES, V41, P1495; Navab M, 2005, ANN MED, V37, P173, DOI 10.1080/07853890510007322; Navab M, 2004, CIRCULATION, V109, P3215, DOI 10.1161/01.CIR.0000134275.90823.87; Navab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200; Navab M, 2001, J LIPID RES, V42, P1308; Navab M, 2001, ARTERIOSCL THROM VAS, V21, P481, DOI 10.1161/01.ATV.21.4.481; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; PAGANGA G, 1992, FEBS LETT, V303, P154, DOI 10.1016/0014-5793(92)80508-E; Porta A, 1999, ZYGOTE, V7, P67, DOI 10.1017/S0967199499000416; PUPPO A, 1988, BIOCHEM J, V249, P185, DOI 10.1042/bj2490185; RADEMACHER BE, 1987, ANAL BIOCHEM, V160, P119, DOI 10.1016/0003-2697(87)90621-X; Ridker PM, 2002, CIRCULATION, V105, P2, DOI 10.1161/circ.105.1.2; Rubin R B, 2000, Am Clin Lab, V19, P28; Schaer DJ, 2006, BLOOD, V107, P373, DOI 10.1182/blood-2005-03-1014; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Shih DM, 1996, J CLIN INVEST, V97, P1630, DOI 10.1172/JCI118589; Spagnuolo MS, 2005, J BIOL CHEM, V280, P1193, DOI 10.1074/jbc.M411390200; Van Lenten BJ, 2001, CIRCULATION, V103, P2283; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; Vaughn MW, 2000, J BIOL CHEM, V275, P2342, DOI 10.1074/jbc.275.4.2342; Vaughn MW, 2001, NITRIC OXIDE-BIOL CH, V5, P18, DOI 10.1006/niox.2000.0328; Wagener FADTG, 2001, TRENDS PHARMACOL SCI, V22, P52, DOI 10.1016/S0165-6147(00)01609-6; Weinberger SR, 2002, CURR OPIN CHEM BIOL, V6, P86, DOI 10.1016/S1367-5931(01)00282-4; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986; Zhang RL, 2004, PROTEOMICS, V4, P244, DOI 10.1002/pmic.200300495; Ziouzenkova O, 1999, J BIOL CHEM, V274, P18916, DOI 10.1074/jbc.274.27.18916	54	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23698	23707		10.1074/jbc.M702163200	http://dx.doi.org/10.1074/jbc.M702163200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17556366	hybrid			2022-12-25	WOS:000248577500073
J	Zeisberg, M; Yang, CQ; Martino, M; Duncan, MB; Rieder, F; Tanjore, H; Kalluri, R				Zeisberg, Michael; Yang, Changqing; Martino, Margot; Duncan, Michael B.; Rieder, Florian; Tanjore, Harikrishna; Kalluri, Raghu			Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; GROWTH-FACTOR-BETA; RENAL FIBROSIS; EXTRACELLULAR-MATRIX; CRE RECOMBINASE; FIBROGENESIS; MORPHOGENESIS; REGENERATION; PROGRESSION; ACTIVATION	Activated fibroblasts are key contributors to the fibrotic extracellular matrix accumulation during liver fibrosis. The origin of such fibroblasts is still debated, although several studies point to stellate cells as the principal source. The role of adult hepatocytes as contributors to the accumulation of fibroblasts in the fibrotic liver is yet undetermined. Here, we provide evidence that the pro-fibrotic growth factor, TGF-beta 1, induces adult mouse hepatocytes to undergo phenotypic and functional changes typical of epithelial to mesenchymal transition (EMT). We perform lineage-tracing experiments using AlbCre. R26RstoplacZ double transgenic mice to demonstrate that hepatocytes which undergo EMT contribute substantially to the population of FSP1-positive fibroblasts in CCL4-induced liver fibrosis. Furthermore, we demonstrate that bone morphogenic protein-7 (BMP7), a member of the TGF beta superfamily, which is known to antagonize TGF beta signaling, significantly inhibits progression of liver fibrosis in these mice. BMP7 treatment abolishes EMT-derived fibroblasts, suggesting that the therapeutic effect of BMP7 was at least partially due to the inhibition of EMT. These results provide direct evidence for the functional involvement of adult hepatocytes in the accumulation of activated fibroblasts in the fibrotic liver. Furthermore, our findings suggest that EMT is a promising therapeutic target for the attenuation of liver fibrosis.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Matrix Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard MIT Div Hlth Sci & Technol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University	Kalluri, R (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Matrix Biol, 330 Brookline Ave,RW514, Boston, MA 02215 USA.	rkalluri@bidmc.harvard.edu	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK074558, R01DK061688, R01DK062987] Funding Source: NIH RePORTER; NIAID NIH HHS [AI53194] Funding Source: Medline; NIDDK NIH HHS [5K08DK074558-01, DK62987, DK55001, DK055001-07S1, DK61688] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bataller R, 2003, HEPATOLOGY, V37, P493, DOI 10.1053/jhep.2003.50127; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bissell DM, 1998, J GASTROENTEROL, V33, P295, DOI 10.1007/s005350050087; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Brenner DA, 2000, J HEPATOL, V32, P32, DOI 10.1016/S0168-8278(00)80413-4; Canbay A, 2002, GASTROENTEROLOGY, V123, P1323, DOI 10.1053/gast.2002.35953; Chagraoui J, 2003, BLOOD, V101, P2973, DOI 10.1182/blood-2002-05-1341; Duncan SA, 2001, GENE DEV, V15, P1879, DOI 10.1101/gad.920601; Friedman SL, 1999, SEMIN LIVER DIS, V19, P129, DOI 10.1055/s-2007-1007105; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gabele E, 2003, FRONT BIOSCI-LANDMRK, V8, pD69, DOI 10.2741/887; George J, 1999, P NATL ACAD SCI USA, V96, P12719, DOI 10.1073/pnas.96.22.12719; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Li D, 1999, J GASTROEN HEPATOL, V14, P618, DOI 10.1046/j.1440-1746.1999.01928.x; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; MARTINEZHERNANDEZ A, 1995, FASEB J, V9, P1401, DOI 10.1096/fasebj.9.14.7589981; Mehal WZ, 2006, GASTROENTEROLOGY, V130, P600, DOI 10.1053/j.gastro.2005.12.048; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Okada H, 2001, KIDNEY INT, V60, P597, DOI 10.1046/j.1523-1755.2001.060002597.x; Pagan R, 1997, HEPATOLOGY, V25, P598, DOI 10.1002/hep.510250318; Pavlova A, 1999, AM J PHYSIOL-RENAL, V277, pF650, DOI 10.1152/ajprenal.1999.277.4.F650; Peifer M, 2002, CELL, V109, P271, DOI 10.1016/S0092-8674(02)00739-0; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; SAPPINO AP, 1990, LAB INVEST, V63, P144; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Sugimoto H, 2007, FASEB J, V21, P256, DOI 10.1096/fj.06-6837com; Takemoto M, 1997, HYPERTENSION, V30, P1621, DOI 10.1161/01.HYP.30.6.1621; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsukamoto H, 1999, ALCOHOL CLIN EXP RES, V23, P911, DOI 10.1111/j.1530-0277.1999.tb04202.x; Wang YJ, 1998, WORLD J GASTROENTERO, V4, P74; Yang CQ, 2003, GASTROENTEROLOGY, V124, P147, DOI 10.1053/gast.2003.50012; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Zeisberg EM, 2005, J CLIN INVEST, V115, P1522, DOI 10.1172/JCI23769; Zeisberg M, 2004, J MOL MED, V82, P175, DOI 10.1007/s00109-003-0517-9; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7; Zeisberg M, 2002, AM J PATHOL, V160, P2001, DOI 10.1016/S0002-9440(10)61150-9; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zeisberg M, 2006, PLOS MED, V3, P535, DOI 10.1371/journal.pmed.0030100	50	633	689	0	63	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23337	23347		10.1074/jbc.M700194200	http://dx.doi.org/10.1074/jbc.M700194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17562716	hybrid			2022-12-25	WOS:000248577500034
J	Gloire, G; Horion, J; El Mjiyad, N; Bex, F; Chariot, A; Dejardin, E; Piette, J				Gloire, Geoffrey; Horion, Julie; El Mjiyad, Nadia; Bex, Francoise; Chariot, Alain; Dejardin, Emmanuel; Piette, Jacques			Promoter-dependent effect of IKK alpha on NF-kappa B/p65 DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SEVERE LIVER DEGENERATION; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; KINASE-ALPHA; MICE LACKING; OXIDATIVE STRESS; DEFICIENT MICE; BETA SUBUNIT; ACTIVATION	IKK alpha regulates many chromatin events in the nuclear phase of the NF-kappa B program, including phosphorylation of histone H3 and removal of co-repressors from NF-kappa B-dependent promoters. However, all of the nuclear functions of IKK alpha are not understood. In this study, using mouse embryonic fibroblasts IKK alpha knock-out and reexpressing IKK alpha after retroviral transduction, we demonstrate that IKK alpha contributes to NF-kappa B/p65 DNA binding activity on an exogenous kappa B element and on some, but not all, endogenous NF-kappa B-target promoters. Indeed, p65 chromatin immunoprecipitation assays revealed that IKK alpha is crucial for p65 binding on kappa B sites of icam-1 and mcp-1 promoters but not on i kappa b alpha promoter. The mutation of IKK alpha putative nuclear localization sequence, which prevents its nuclear translocation, or of crucial serines in the IKK alpha activation loop completely inhibits p65 binding on icam-1 and mcp-1 promoters and rather enhances p65 binding on the i kappa b alpha promoter. Further molecular studies demonstrated that the removal of chromatin-bound HDAC3, a histone deacetylase inhibiting p65 DNA binding, is differentially regulated by IKK alpha in a promoter-specific manner. Indeed, whereas the absence of IKK alpha induces HDAC3 recruitment and repression on the icam-1 promoter, it has an opposite effect on the i kappa b alpha promoter, where a better p65 binding occurs. We conclude that nuclear IKK alpha is required for p65 DNA binding in a gene-specific manner.	Univ Liege, GIGA Res B34, Virol & Immunol Unit, B-4000 Liege, Belgium; Univ Liege, Med Chem Unit, B-4000 Liege, Belgium; Free Univ Brussels, Inst Microbiol Res JM Wiame, B-1070 Brussels, Belgium; Free Univ Brussels, Microbiol Lab, B-1070 Brussels, Belgium	University of Liege; University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Piette, J (corresponding author), Univ Liege, GIGA Res B34, Virol & Immunol Unit, B-4000 Liege, Belgium.	jpiette@ulg.ac.be	Dejardin, Emmanuel/AAE-9076-2021	Chariot, Alain/0000-0002-1691-4347				Adam E, 2003, MOL CELL BIOL, V23, P6200, DOI 10.1128/MCB.23.17.6200-6209.2003; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Gao ZG, 2005, J BIOL CHEM, V280, P21091, DOI 10.1074/jbc.M500754200; Gloire G, 2006, ONCOGENE, V25, P5485, DOI 10.1038/sj.onc.1209542; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1081, DOI 10.1016/j.bcp.2006.06.017; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; PARK GY, 2006, J BIOL CHEM; Park GY, 2006, J BIOL CHEM, V281, P18684, DOI 10.1074/jbc.M600733200; Rudolph D, 2000, GENE DEV, V14, P854; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	42	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21308	21318		10.1074/jbc.M610728200	http://dx.doi.org/10.1074/jbc.M610728200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17537731	hybrid, Green Published			2022-12-25	WOS:000248047500059
J	Talbott, JR				Talbott, John R.			Size Matters: The Number of Prostitutes and the Global HIV/AIDS Pandemic	PLOS ONE			English	Article							MALE CIRCUMCISION; HIV-INFECTION; SEX; PREVALENCE; RISK; AFRICA	Background. HIV/AIDS prevalence rates across countries of the world vary more than 500-fold from .06% in Hungary to 33.4% in Swaziland. One of the most cited research papers in the field, utilizing cross country regression analysis to analyze other correlates with this HIV prevalence data, is flawed in that it weights each country's results by the country's population. Methodology/Principal Findings. Based on cross-country linear and multiple regressions using newly gathered data from UNAIDS, the number of female commercial sex workers as a percentage of the female adult population is robustly positively correlated with countrywide HIV/AIDS prevalence levels. Confirming earlier studies, female illiteracy levels, gender illiteracy differences and income inequality within countries are also significantly positively correlated with HIV/AIDS levels. Muslims as a percentage of the population, itself highly correlated with country circumcision rates and previously found to be negatively correlated with HIV/AIDS prevalence, is insignificant when the percentage of commercial sex workers in a population is included in the analysis. Conclusions/Significance. This paper provides strong evidence that when conducted properly, cross country regression data does not support the theory that male circumcision is the key to slowing the AIDS epidemic. Rather, it is the number of infected prostitutes in a country that is highly significant and robust in explaining HIV prevalence levels across countries. An explanation is offered for why Africa has been hit the hardest by the AIDS pandemic and why there appears to be very little correlation between HIV/AIDS infection rates and country wealth.	Africans Aids Inc, New York, NY USA		Talbott, JR (corresponding author), Africans Aids Inc, New York, NY USA.	johntalbs@hotmail.com						[Anonymous], 1985, THEORY PRACTICE ECON; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Cote AM, 2004, AIDS, V18, P917, DOI [10.1097/01.aids.0000111475.61782.98, 10.1097/00002030-200404090-00009]; Darby R, 2005, ARCH SEX BEHAV, V34, P707, DOI 10.1007/s10508-005-7930-9; DRAIN JK, 2004, J ACQUIR IMMUNE DEFI, V35; DRAIN PK, 2004, J ACQUIR IMMUNE DEFI, V35; EPSTEIN H, 2004, NY TIMES MAGAZI 0613, P54; Ferry B, 2001, AIDS, V15, pS41, DOI 10.1097/00002030-200108004-00005; Ghys PD, 2001, AIDS, V15, pS33, DOI 10.1097/00002030-200104003-00005; Gray PB, 2004, SOC SCI MED, V58, P1751, DOI 10.1016/S0277-9536(03)00367-8; Halperin DT, 2004, LANCET, V364, P4, DOI 10.1016/S0140-6736(04)16606-3; Halperin DT, 1999, LANCET, V354, P1813, DOI 10.1016/S0140-6736(99)03421-2; Harcourt C, 2005, SEX TRANSM INFECT, V81, P201, DOI 10.1136/sti.2004.012468; POTTERAT JJ, 1990, J SEX RES, V27, P233, DOI 10.1080/00224499009551554; Reynolds SJ, 2004, LANCET, V363, P1039, DOI 10.1016/S0140-6736(04)15840-6; ROLL R, 2002, END CLASS WARFARE EX; Siegfried N, 2005, LANCET INFECT DIS, V5, P165, DOI 10.1016/S1473-3099(05)01309-5; U.S. Census Bureau, 2006, HIV AIDS SURV DAT BA; *UN, 2005, DEV PROGR REP, P270; *UN STAT DIV, 2006, DEM SOC IND; UNAIDS, 2006, REP GLOB AIDS EP; United States Central Intelligence Agency, 2006, WORLD FACTB 2006; *USAID UNAIDS WHO, 2006, ANN TABL 6 PREV SERV; Vandepitte J, 2006, SEX TRANSM INFECT, V82, pIII18, DOI 10.1136/sti.2006.020081; Weiss HA, 2000, AIDS, V14, P2361, DOI 10.1097/00002030-200010200-00018; WESSA P, 2006, STAT SOFTWARE; *WORLD BANK, 2006, WORLD DEV IND 2006 D	27	52	52	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e543	10.1371/journal.pone.0000543	http://dx.doi.org/10.1371/journal.pone.0000543			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579715	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451700009
J	Ayoub, NA; Garb, JE; Tinghitella, RM; Collin, MA; Hayashi, CY				Ayoub, Nadia A.; Garb, Jessica E.; Tinghitella, Robin M.; Collin, Matthew A.; Hayashi, Cheryl Y.			Blueprint for a High-Performance Biomaterial: Full-Length Spider Dragline Silk Genes	PLOS ONE			English	Article							AMINO-ACID-COMPOSITION; NEPHILA-CLAVIPES TETRAGNATHIDAE; UTR SEQUENCE MOTIF; BLACK-WIDOW SPIDER; EGG CASE SILK; MECHANICAL-PROPERTIES; LATRODECTUS-HESPERUS; REGULATORY ELEMENTS; PROTEIN-COMPONENTS; MOLECULAR CLOCK	Spider dragline (major ampullate) silk outperforms virtually all other natural and manmade materials in terms of tensile strength and toughness. For this reason, the mass-production of artificial spider silks through transgenic technologies has been a major goal of biomimetics research. Although all known arthropod silk proteins are extremely large (> 200 kiloDaltons), recombinant spider silks have been designed from short and incomplete cDNAs, the only available sequences. Here we describe the first full-length spider silk gene sequences and their flanking regions. These genes encode the MaSp1 and MaSp2 proteins that compose the black widow's high-performance dragline silk. Each gene includes a single enormous exon (> 9000 base pairs) that translates into a highly repetitive polypeptide. Patterns of variation among sequence repeats at the amino acid and nucleotide levels indicate that the interaction of selection, intergenic recombination, and intragenic recombination governs the evolution of these highly unusual, modular proteins. Phylogenetic footprinting revealed putative regulatory elements in non-coding flanking sequences. Conservation of both upstream and downstream flanking sequences was especially striking between the two paralogous black widow major ampullate silk genes. Because these genes are co-expressed within the same silk gland, there may have been selection for similarity in regulatory regions. Our new data provide complete templates for synthesis of recombinant silk proteins that significantly improve the degree to which artificial silks mimic natural spider dragline fibers.	[Ayoub, Nadia A.; Garb, Jessica E.; Tinghitella, Robin M.; Collin, Matthew A.; Hayashi, Cheryl Y.] Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside	Ayoub, NA (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.	nadiaa@ucr.edu	Garb, Jessica E/J-4566-2015	Ayoub, Nadia/0000-0003-4404-1472; Tinghitella, Robin/0000-0002-0049-5539	Army Research Office [DAAD19-02-1-0358, W911NF-06-1-0455]; National Science Foundation [DEB-0236020]	Army Research Office; National Science Foundation(National Science Foundation (NSF))	The research was funded by the Army Research Office (DAAD19-02-1-0358 and W911NF-06-1-0455) and the National Science Foundation (DEB-0236020).	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSEN SO, 1970, COMP BIOCHEM PHYSIOL, V35, P705, DOI 10.1016/0010-406X(70)90988-6; Arcidiacono S, 1998, APPL MICROBIOL BIOT, V49, P31, DOI 10.1007/s002530051133; Arnason U, 2000, HEREDITAS, V133, P217, DOI 10.1111/j.1601-5223.2000.00217.x; Ayoub NA, 2007, MOL PHYLOGENET EVOL, V42, P394, DOI 10.1016/j.ympev.2006.07.018; BECKWITT R, 1994, J BIOL CHEM, V269, P6661; Beckwitt R, 1998, INSECT BIOCHEM MOLEC, V28, P121, DOI 10.1016/S0965-1748(97)00083-0; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; Bini E, 2006, BIOMACROMOLECULES, V7, P3139, DOI 10.1021/bm0607877; Blackledge TA, 2006, J EXP BIOL, V209, P2452, DOI 10.1242/jeb.02275; Blackledge TA, 2005, ZOOLOGY, V108, P41, DOI 10.1016/j.zool.2004.11.001; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Bram A, 1997, J APPL CRYSTALLOGR, V30, P390, DOI 10.1107/S0021889896012344; Bray N, 2003, GENOME RES, V13, P97, DOI 10.1101/gr.789803; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; Casem ML, 1999, INT J BIOL MACROMOL, V24, P103, DOI 10.1016/S0141-8130(98)00078-6; Castillo-Davis CI, 2002, NAT GENET, V31, P415, DOI 10.1038/ng940; Chaw SM, 2004, J MOL EVOL, V58, P424, DOI 10.1007/s00239-003-2564-9; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Coy JF, 1999, HUM MOL GENET, V8, P1253, DOI 10.1093/hmg/8.7.1253; Craig CL, 2000, MOL BIOL EVOL, V17, P1904, DOI 10.1093/oxfordjournals.molbev.a026292; De Bodt S, 2006, MOL BIOL EVOL, V23, P1293, DOI 10.1093/molbev/msk016; DELIDAKIS C, 1992, P NATL ACAD SCI USA, V89, P8731, DOI 10.1073/pnas.89.18.8731; Dicko C, 2004, BIOMACROMOLECULES, V5, P704, DOI 10.1021/bm034307c; DONG ZY, 1991, ARCH BIOCHEM BIOPHYS, V284, P53, DOI 10.1016/0003-9861(91)90262-H; Foelix R.F., 1996, BIOL SPIDERS, P336; Foo CWP, 2006, APPL PHYS A-MATER, V82, P193, DOI 10.1007/s00339-005-3425-8; Foo CWP, 2002, ADV DRUG DELIVER REV, V54, P1131; Frazer KA, 2004, NUCLEIC ACIDS RES, V32, pW273, DOI 10.1093/nar/gkh458; Garb JE, 2005, P NATL ACAD SCI USA, V102, P11379, DOI 10.1073/pnas.0502473102; Garb JE, 2006, SCIENCE, V312, P1762, DOI 10.1126/science.1127946; Gatesy J, 2001, SCIENCE, V291, P2603, DOI 10.1126/science.1057561; Goodwin EB, 1997, DEVELOPMENT, V124, P749; Gosline J, 2002, PHILOS T R SOC B, V357, P121, DOI 10.1098/rstb.2001.1022; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; Gosline JM, 1999, J EXP BIOL, V202, P3295; GRAUR D, 2000, FUNDAMENTALS MOL EVO; Gregory TR, 2003, J HERED, V94, P285, DOI 10.1093/jhered/esg070; Griswold CE, 1998, ZOOL J LINN SOC-LOND, V123, P1; Guerette PA, 1996, SCIENCE, V272, P112, DOI 10.1126/science.272.5258.112; Hardison RC, 2003, PLOS BIOL, V1, P156, DOI 10.1371/journal.pbio.0000058; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hayashi CY, 1999, INT J BIOL MACROMOL, V24, P271, DOI 10.1016/S0141-8130(98)00089-0; Hayashi CY, 2004, MOL BIOL EVOL, V21, P1950, DOI 10.1093/molbev/msh204; Hayashi CY, 2000, SCIENCE, V287, P1477, DOI 10.1126/science.287.5457.1477; Hayashi CY, 1998, J MOL BIOL, V275, P773, DOI 10.1006/jmbi.1997.1478; HINMAN M, 1992, SPIDER SILK MYSTERY, P227; HINMAN MB, 1992, J BIOL CHEM, V267, P19320; Hinman MB, 2000, TRENDS BIOTECHNOL, V18, P374, DOI 10.1016/S0167-7799(00)01481-5; Huemmerich D, 2004, BIOCHEMISTRY-US, V43, P13604, DOI 10.1021/bi048983q; Inada DC, 2003, GENOME RES, V13, P2030, DOI 10.1101/gr.1280703; Ittah S, 2006, BIOMACROMOLECULES, V7, P1790, DOI 10.1021/bm060120k; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kohler K, 2005, DNA CELL BIOL, V24, P371, DOI 10.1089/dna.2005.24.371; Kummerlen J, 1996, MACROMOLECULES, V29, P2920, DOI 10.1021/ma951098i; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lai EC, 1997, DEVELOPMENT, V124, P4847; Lai EC, 1998, DEVELOPMENT, V125, P4077; Lawrence BA, 2004, BIOMACROMOLECULES, V5, P689, DOI 10.1021/bm0342640; Lazaris A, 2002, SCIENCE, V295, P472, DOI 10.1126/science.1065780; Lee MSY, 1999, J MOL EVOL, V49, P385, DOI 10.1007/PL00006562; Leviten MW, 1997, DEVELOPMENT, V124, P4039; LOMBARDI SJ, 1990, J ARACHNOL, V18, P297; Marais G, 2005, GENETICS, V170, P481, DOI 10.1534/genetics.104.037333; Margulies EH, 2003, GENOME RES, V13, P2507, DOI 10.1101/gr.1602203; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Motriuk-Smith D, 2005, BIOMACROMOLECULES, V6, P3152, DOI 10.1021/bm050472b; O'Brien JP, 1998, ADV MATER, V10, P1185, DOI 10.1002/(SICI)1521-4095(199810)10:15<1185::AID-ADMA1185>3.0.CO;2-T; Parkhe AD, 1997, J MOL RECOGNIT, V10, P1, DOI 10.1002/(SICI)1099-1352(199701/02)10:1<1::AID-JMR338>3.0.CO;2-7; Pollard DA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-376; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Prakash A, 2005, NAT BIOTECHNOL, V23, P1249, DOI 10.1038/nbt1140; Rising A, 2006, BIOMACROMOLECULES, V7, P3120, DOI 10.1021/bm060693x; Rombauts S, 2003, PLANT PHYSIOL, V132, P1162, DOI 10.1104/pp.102.017715; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; RUIZGOMEZ M, 1993, EMBO J, V12, P1121, DOI 10.1002/j.1460-2075.1993.tb05753.x; Sakharkar MK, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-67; Sakharkar MK, 2002, BIOINFORMATICS, V18, P1266, DOI 10.1093/bioinformatics/18.9.1266; Sambrook J, 2001, MOL CLONING LAB MANU; Scheller J, 2004, TRANSGENIC RES, V13, P51, DOI 10.1023/B:TRAG.0000017175.78809.7a; Scheller J, 2001, NAT BIOTECHNOL, V19, P573, DOI 10.1038/89335; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; SELDEN PA, 1990, PALAEONTOLOGY, V33, P257; SIMMONS A, 1994, MACROMOLECULES, V27, P5235, DOI 10.1021/ma00096a060; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; Sinha S, 2005, MOL BIOL EVOL, V22, P874, DOI 10.1093/molbev/msi090; Sponner A, 2005, BIOCHEM BIOPH RES CO, V338, P897, DOI 10.1016/j.bbrc.2005.10.048; Sponner A, 2005, NAT MATER, V4, P772, DOI 10.1038/nmat1493; Sponner A, 2005, BIOCHEMISTRY-US, V44, P4727, DOI 10.1021/bi047671k; SPRAGUE KU, 1975, BIOCHEMISTRY-US, V14, P925, DOI 10.1021/bi00676a008; Swanson BO, 2006, APPL PHYS A-MATER, V82, P213, DOI 10.1007/s00339-005-3427-6; Swofford D.L., 2002, PAUP PHYLOGENETIC AN, DOI 10.1111/j.0014-3820.2002.tb00191.x; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Tian MZ, 2005, BIOCHEMISTRY-US, V44, P8006, DOI 10.1021/bi050366u; Urrutia AO, 2003, GENOME RES, V13, P2260, DOI 10.1101/gr.641103; van Beek JD, 2002, P NATL ACAD SCI USA, V99, P10266, DOI 10.1073/pnas.152162299; Vollrath F, 2001, NATURE, V410, P541, DOI 10.1038/35069000; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Wikstrom N, 2001, P ROY SOC B-BIOL SCI, V268, P2211, DOI 10.1098/rspb.2001.1782; Wong WSW, 2004, GENETICS, V167, P949, DOI 10.1534/genetics.102.010959; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; XU M, 1990, P NATL ACAD SCI USA, V87, P7120, DOI 10.1073/pnas.87.18.7120; Zhang JZ, 2003, TRENDS ECOL EVOL, V18, P292, DOI 10.1016/S0169-5347(03)00033-8; Zhao AC, 2006, BIOCHEMISTRY-US, V45, P3348, DOI 10.1021/bi052414g	108	271	294	5	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e514	10.1371/journal.pone.0000514	http://dx.doi.org/10.1371/journal.pone.0000514			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565367	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451600002
J	Cheng, K; Grisendi, S; Clohessy, JG; Majid, S; Bernardi, R; Sportoletti, P; Pandolfi, PP				Cheng, K.; Grisendi, S.; Clohessy, J. G.; Majid, S.; Bernardi, R.; Sportoletti, P.; Pandolfi, P. P.			The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence	ONCOGENE			English	Article						NPMc; E1A; Arf; senescence; cell transformation	TUMOR-SUPPRESSOR; GENE-EXPRESSION; ADENOVIRUS E1A; P53; INHIBITION; ACTIVATION; MUTATIONS; FUSION; NPM1	Mutations leading to aberrant cytoplasmic localization of Nucleophosmin 1 (NPM1) have been recently identified as the most frequent genetic alteration in acute myelogenous leukemia. However, the oncogenic potential of this nucleophosmin mutant (NPMc+) has never been established, which casts doubt on its role in leukemogenesis. By performing classical transformation assays, we find that NPMc+, but not wild-type NPM, cooperates specifically with adenovirus E1A to transform primary mouse embryonic. broblasts in soft agar. We demonstrate that NPMc+ blocks the p19(Arf) (Arf) induction elicited by E1A. Surprisingly, however, we find that NPMc+ induces cellular senescence and that E1A is able to overcome this response. We propose a model whereby the NPMc+ pro-senescence activity needs to be evaded for oncogenic transformation, even though NPMc+ can concomitantly blunt the Arf/p53 pathway. These findings identify for the first time NPMc+ as an oncogene and shed new unexpected light on its mechanism of action.	Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, New York, NY 10021 USA; Cornell Univ, Grad Program Biochem Mol & Cell Biol, Ithaca, NY 14853 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 110, New York, NY 10021 USA.	p-pandol@ski.mskcc.org	bernardi, rosa/B-1650-2013; Sportoletti, Paolo/AAE-5907-2020; SPORTOLETTI, PAOLO/K-6013-2016	bernardi, rosa/0000-0002-3607-6336; SPORTOLETTI, PAOLO/0000-0002-5630-9862; Clohessy, John/0000-0001-5186-9775				Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; den Besten W, 2005, CELL CYCLE, V4, P1593; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DYSON N, 1992, CANCER SURV, V12, P161; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lin CY, 2006, CELL SIGNAL, V18, P2041, DOI 10.1016/j.cellsig.2006.04.001; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; Mendes-da-Silva P, 2000, J CLIN PATHOL-MOL PA, V53, P184, DOI 10.1136/mp.53.4.184; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Olney HJ, 2002, BAS CLIN ON, V27, P89; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sauerbrey A, 1998, LEUKEMIA LYMPHOMA, V28, P275, DOI 10.3109/10428199809092683; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Thiede C, 2006, BLOOD, V107, P4011, DOI 10.1182/blood-2005-08-3167; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YonedaKato N, 1996, ONCOGENE, V12, P265; Zhang X, 2004, J BIOL CHEM, V279, P25122, DOI 10.1074/jbc.M403287200	36	35	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7391	7400		10.1038/sj.onc.1210549	http://dx.doi.org/10.1038/sj.onc.1210549			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546053				2022-12-25	WOS:000251282000001
J	Schreibelt, G; Kooij, G; Reijerkerk, A; van Doorn, R; Gringhuis, SI; van der Pol, S; Weksler, BB; Romero, IA; Couraud, PO; Piontek, J; Blasig, IE; Dijkstra, CD; Ronken, E; de Vries, HE				Schreibelt, Gerty; Kooij, Gijs; Reijerkerk, Arie; van Doorn, Ruben; Gringhuis, Sonja I.; van der Pol, Susanne; Weksler, Babette B.; Romero, Ignacio A.; Couraud, Pierre-Olivier; Piontek, Joerg; Blasig, Ingolf E.; Dijkstra, Christine D.; Ronken, Eric; de Vries, Helga E.			Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling	FASEB JOURNAL			English	Article						blood-brain barrier; claudin-5; occludin; protein kinase B	CENTRAL-NERVOUS-SYSTEM; BARRIER-SPECIFIC PROPERTIES; BLOOD-BRAIN; OXIDATIVE STRESS; IN-VITRO; MULTIPLE-SCLEROSIS; ACTIN CYTOSKELETON; PHOSPHATIDYLINOSITOL 3-KINASE; PARACELLULAR PERMEABILITY; POSSIBLE INVOLVEMENT	The blood-brain barrier (BBB) prevents the entrance of circulating molecules and immune cells into the central nervous system. The barrier is formed by specialized brain endothelial cells that are interconnected by tight junctions (TJ). A defective function of the BBB has been described for a variety of neuroinflammatory diseases, indicating that proper regulation is essential for maintaining brain homeostasis. Under pathological conditions, reactive oxygen species (ROS) significantly contribute to BBB dysfunction and inflammation in the brain by enhancing cellular migration. However, a detailed study about the molecular mechanism by which ROS alter BBB integrity has been lacking. Here we demonstrate that ROS alter BBB integrity, which is paralleled by cytoskeleton rearrangements and redistribution and disappearance of TJ proteins claudin-5 and occludin. Specific signaling pathways, including RhoA and PI3 kinase, mediated observed processes and specific inhibitors of these pathways prevented ROS-induced monocyte migration across an in vitro model of the BBB. Interestingly, these processes were also mediated by protein kinase B (PKB/Akt), a previously unknown player in cytoskeleton and TJ dynamics that acted downstream of RhoA and PI3 kinase. Our study reveals new insights into molecular mechanisms underlying BBB regulation and provides novel opportunities for the treatment of neuroinflammatory diseases.	Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, NL-1007 MB Amsterdam, Netherlands; Cornell Univ, Weill Med Coll, New York, NY USA; Open Univ, Dept Sci Biol, Milton Keynes MK7 6AA, Bucks, England; Inst Cochin, Dept Biol Cellulaire, Paris, France; Inst Mol Pharmacol, Berlin, Germany; Solvay Pharmaceut Res Labs, Weesp, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Cornell University; Open University - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Solvay SA	de Vries, HE (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	he.devries@vumc.nl	Kooij, Gijs/AAA-4268-2020; Horstmann, Britta/C-2154-2008; Piontek, Joerg/K-6305-2013; Romero, Ignacio/A-7381-2008; Schreibelt, Gerty/A-1260-2016; Piontek, Joerg/F-8549-2011	Piontek, Joerg/0000-0002-0880-8915; Schreibelt, Gerty/0000-0002-0156-8365; de Vries, Helga/0000-0001-7904-7124; Romero, Ignacio/0000-0002-0322-9180; Gringhuis, Sonja/0000-0003-0383-4978; Kooij, Gijs/0000-0002-9488-2918				Adamson P, 1999, J IMMUNOL, V162, P2964; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Basuroy S, 2003, J BIOL CHEM, V278, P11916, DOI 10.1074/jbc.M211710200; Blasig IE, 2006, CELL MOL LIFE SCI, V63, P505, DOI 10.1007/s00018-005-5472-x; Blasig IE, 2002, NEUROPHARMACOLOGY, V43, P1006, DOI 10.1016/S0028-3908(02)00180-6; Boven LA, 2000, NEUROPATH APPL NEURO, V26, P356, DOI 10.1046/j.1365-2990.2000.00255.x; Cenni V, 2003, CELL MOL LIFE SCI, V60, P2710, DOI 10.1007/s00018-003-3349-4; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; DeGroot CJA, 1997, J NEUROSCI RES, V49, P342, DOI 10.1002/(SICI)1097-4547(19970801)49:3<342::AID-JNR9>3.0.CO;2-C; Deli MA, 2005, CELL MOL NEUROBIOL, V25, P59, DOI 10.1007/s10571-004-1377-8; DeVries HE, 1996, J PHARMACOL EXP THER, V277, P1418; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fischer S, 2005, EUR J CELL BIOL, V84, P687, DOI 10.1016/j.ejcb.2005.03.002; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; Haorah J, 2005, J LEUKOCYTE BIOL, V78, P1223, DOI 10.1189/jlb.0605340; Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hendricks JJA, 2004, J EXP MED, V200, P1667, DOI 10.1084/jem.20040819; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Keese CR, 2004, P NATL ACAD SCI USA, V101, P1554, DOI 10.1073/pnas.0307588100; Kirk J, 2003, J PATHOL, V201, P319, DOI 10.1002/path.1434; Kooij G., 2005, BLOOD BRAIN BARRIER, P47; Lai CH, 2005, BRAIN RES REV, V50, P7, DOI 10.1016/j.brainresrev.2005.03.007; Lee HS, 2004, MICROVASC RES, V68, P231, DOI 10.1016/j.mvr.2004.07.005; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Massoumi R, 1998, EUR J CELL BIOL, V76, P185, DOI 10.1016/S0171-9335(98)80033-2; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Nguyen KT, 2002, J BIOL CHEM, V277, P11107, DOI 10.1074/jbc.M108166200; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Pachter JS, 2003, J NEUROPATH EXP NEUR, V62, P593, DOI 10.1093/jnen/62.6.593; Perez V, 2005, EUR J NEUROSCI, V21, P26, DOI 10.1111/j.1460-9568.2004.03845.x; Perriere N, 2005, J NEUROCHEM, V93, P279, DOI 10.1111/j.1471-4159.2004.03020.x; Persidsky Y, 2006, BLOOD, V107, P4770, DOI 10.1182/blood-2005-11-4721; Prasad R, 2005, J NEUROCHEM, V94, P204, DOI 10.1111/j.1471-4159.2005.03182.x; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Reijerkerk A, 2006, FASEB J, V20, P2550, DOI 10.1096/fj.06-6099fje; Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Schreibelt G, 2006, J IMMUNOL, V177, P2630, DOI 10.4049/jimmunol.177.4.2630; SHATOS MA, 1992, J BIOL CHEM, V267, P597; Shen L, 2005, MOL BIOL CELL, V16, P3919, DOI 10.1091/mbc.E04-12-1089; Sheth P, 2003, J BIOL CHEM, V278, P49239, DOI 10.1074/jbc.M305654200; Song L, 2004, MICROVASC RES, V67, P78, DOI 10.1016/j.mvr.2003.07.001; STEVENSON BR, 1994, J CELL SCI, V107, P367; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; van der Goes A, 2001, FASEB J, V15, P1852, DOI 10.1096/fj.00-0881fje; Vos CMP, 2005, NEUROBIOL DIS, V20, P953, DOI 10.1016/j.nbd.2005.06.012; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010	62	249	261	3	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3666	3676		10.1096/fj.07-8329com	http://dx.doi.org/10.1096/fj.07-8329com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586731				2022-12-25	WOS:000250517800028
J	Dominy, J; Simmons, CR; Hirschberger, LL; Hwang, J; Coloso, RM; Stipanuk, MH				E. Dominy, John, Jr.; Simmons, Chad R.; Hirschberger, Lawrence L.; Hwang, Jesse; Coloso, Relicardo M.; Stipanuk, Martha H.			Discovery and characterization of a second mammalian thiol dioxygenase, cysteamine dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYSTEINE DIOXYGENASE; INTRACELLULAR CYSTEINE; PANTOTHENATE KINASE; RAT; CYSTAMINE; EXPRESSION; PURIFICATION; DEGRADATION; HYPOTAURINE; INHIBITION	There are only two known thiol dioxygenase activities in mammals, and they are ascribed to the enzymes cysteine dioxygenase (CDO) and cysteamine (2-aminoethanethiol) dioxygenase ( ADO). Although many studies have been dedicated to CDO, resulting in the identification of its gene and even characterization of the tertiary structure of the protein, relatively little is known about cysteamine dioxygenase. The failure to identify the gene for this protein has significantly hampered our understanding of the metabolism of cysteamine, a product of the constitutive degradation of coenzyme A, and the synthesis of taurine, the final product of cysteamine oxidation and the second most abundant amino acid in mammalian tissues. In this study we identified a hypothetical murine protein homolog of CDO ( hereafter called ADO) that is encoded by the gene Gm237 and belongs to the DUF1637 protein family. When expressed as a recombinant protein, ADO exhibited significant cysteamine dioxygenase activity in vitro. The reaction was highly specific for cysteamine; cysteine was not oxidized by the enzyme, and structurally related compounds were not competitive inhibitors of the reaction. When overexpressed in HepG2/C3A cells, ADO increased the production of hypotaurine from cysteamine. Similarly, when endogenous expression of the human ADO ortholog C10orf22 in HepG2/C3A cells was reduced by RNA-mediated interference, hypotaurine production decreased. Western blots of murine tissues with an antibody developed against ADO showed that the protein is ubiquitously expressed with the highest levels in brain, heart, and skeletal muscle. Overall, these data suggest that ADO is responsible for endogenous cysteamine dioxygenase activity.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Stipanuk, MH (corresponding author), Cornell Univ, Div Nutr Sci, 227 Savage Hill, Ithaca, NY 14853 USA.	mhs6@cornell.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056649] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK056649] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bailey CDC, 2006, NEUROBIOL AGING, V27, P871, DOI 10.1016/j.neurobiolaging.2005.04.001; Berruyer C, 2004, MOL CELL BIOL, V24, P7214, DOI 10.1128/MCB.24.16.7214-7224.2004; Berruyer C, 2006, J EXP MED, V203, P2817, DOI 10.1084/jem.20061640; CAVALLINI D, 1963, J BIOL CHEM, V238, P2999; Chai SC, 2005, J BIOL CHEM, V280, P9865, DOI 10.1074/jbc.M413733200; Chai SC, 2006, J BIOL CHEM, V281, P15774, DOI 10.1074/jbc.M601269200; Coloso RM, 2006, ADV EXP MED BIOL, V583, P25; Dedeoglu A, 2002, J NEUROSCI, V22, P8942; Dominy J, 2004, NEUROCHEM RES, V29, P97, DOI 10.1023/B:NERE.0000010437.81860.d5; Dominy JE, 2006, BIOCHEM J, V394, P267, DOI 10.1042/BJ20051510; Dominy JE, 2007, AM J PHYSIOL-ENDOC M, V293, pE62, DOI 10.1152/ajpendo.00053.2007; Dominy JE, 2006, J BACTERIOL, V188, P5561, DOI 10.1128/JB.00291-06; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; EWETZ L, 1966, BIOCHIM BIOPHYS ACTA, V128, P296, DOI 10.1016/0926-6593(66)90176-7; Hirschberger LL, 2001, GENE, V277, P153, DOI 10.1016/S0378-1119(01)00691-6; HOSOKAWA Y, 1990, BIOCHEM BIOPH RES CO, V168, P473, DOI 10.1016/0006-291X(90)92345-Z; Lee JI, 2004, J NUTR BIOCHEM, V15, P112, DOI 10.1016/j.jnutbio.2003.10.005; Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001; Lesort M, 2003, J BIOL CHEM, V278, P3825, DOI 10.1074/jbc.M205812200; MCCANN KP, 1994, BBA-PROTEIN STRUCT M, V1209, P107, DOI 10.1016/0167-4838(94)90144-9; McCoy JG, 2006, P NATL ACAD SCI USA, V103, P3084, DOI 10.1073/pnas.0509262103; MICKELSON JK, 1995, HEPATOLOGY, V22, P866, DOI 10.1002/hep.1840220326; Qiu L, 2000, J INVEST DERMATOL, V114, P21, DOI 10.1046/j.1523-1747.2000.00826.x; RICHERSON RB, 1987, METHOD ENZYMOL, V143, P410; ROBISHAW JD, 1985, AM J PHYSIOL, V248, pE1, DOI 10.1152/ajpendo.1985.248.1.E1; ROBISHAW JD, 1984, AM J PHYSIOL, V246, pH532, DOI 10.1152/ajpheart.1984.246.4.H532; ROTILIO G, 1970, J BIOL CHEM, V245, P6235; SHARMA R, 1995, INT J BIOCHEM CELL B, V27, P655, DOI 10.1016/1357-2725(95)00038-Q; Simmons CR, 2006, J BIOL CHEM, V281, P18723, DOI 10.1074/jbc.M601555200; Simmons CR, 2006, PROTEIN EXPRES PURIF, V47, P74, DOI 10.1016/j.pep.2005.10.025; Stipanuk MH, 2006, J NUTR, V136, p1652S, DOI 10.1093/jn/136.6.1652S; Stipanuk MH, 2004, ANNU REV NUTR, V24, P539, DOI 10.1146/annurev.nutr.24.012003.132418; Stipanuk MH, 2004, AM J PHYSIOL-ENDOC M, V286, pE439, DOI 10.1152/ajpendo.00336.2003; Ye S, 2007, J BIOL CHEM, V282, P3391, DOI 10.1074/jbc.M609337200; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572	36	105	109	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25189	25198		10.1074/jbc.M703089200	http://dx.doi.org/10.1074/jbc.M703089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17581819	hybrid			2022-12-25	WOS:000249014100004
J	Czirr, E; Leuchtenberger, S; Dorner-Ciossek, C; Schneider, A; Jucker, M; Koo, EH; Pietrzik, CU; Baumann, K; Weggen, S				Czirr, Eva; Leuchtenberger, Stefanie; Dorner-Ciossek, Cornelia; Schneider, Anna; Jucker, Mathias; Koo, Edward H.; Pietrzik, Claus U.; Baumann, Karlheinz; Weggen, Sascha			Insensitivity to A beta 42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; IN-VIVO; TRANSGENIC MICE; ACTIVE-SITE; WILD-TYPE; COMPLEX; TARGET; ENDOPROTEOLYSIS; MODULATION; SUBSTRATE	A beta 42-lowering nonsteroidal anti-inflammatory drugs (NSAIDs) constitute the founding members of a new class of gamma-secretase modulators that avoid side effects of pan-gamma-secretase inhibitors on NOTCH processing and function, holding promise as potential disease-modifying agents for Alzheimer disease (AD). These modulators are active in cell-free gamma-secretase assays indicating that they directly target the gamma-secretase complex. Additional support for this hypothesis was provided by the observation that certain mutations in presenilin-1 (PS1) associated with early-onset familial AD (FAD) change the cellular drug response to A beta 42-lowering NSAIDs. Of particular interest is the PS1-Delta Exon9 mutation, which provokes a pathogenic increase in the A beta 42/A beta 40 ratio and dramatically reduces the cellular response to the A beta 42-lowering NSAID sulindac sulfide. This FAD PS1 mutant is unusual as a splice-site mutation results in deletion of amino acids Thr(291)-Ser(319) including the endoproteolytic cleavage site of PS1, and an additional amino acid exchange (S290C) at the exon 8/10 splice junction. By genetic dissection of the PS1-Delta Exon9 mutation, we now demonstrate that a synergistic effect of the S290C mutation and the lack of endoproteolytic cleavage is sufficient to elevate the A beta 42/A beta 40 ratio and that the attenuated response to sulindac sulfide results partially from the deficiency in endoproteolysis. Importantly, a wider screen revealed that a diminished response to A beta 42-lowering NSAIDs is common among aggressive FAD PS1 mutations. Surprisingly, these mutations were also partially unresponsive to gamma-secretase inhibitors of different structural classes. This was confirmed in a mouse model with transgenic expression of the PS1-L166P mutation, in which the potent gamma-secretase inhibitor LY-411575 failed to reduce brain levels of soluble A beta 42. In summary, these findings highlight the importance of genetic background in drug discovery efforts aimed at gamma-secretase, suggesting that certain AD mouse models harboring aggressive PS mutations may not be informative in assessing in vivo effects of gamma-secretase modulators and inhibitors.	Univ Mainz, Emmy Noether Res Grp, D-55128 Mainz, Germany; Univ Mainz, Inst Physiol Chem & Pathobiochem, Mol Neurodegenerat Grp, D-55128 Mainz, Germany; Boehringer Ingelheim Pharma GmbH & Co KG, Dept Cent Nervous Syst, D-88397 Biberach, Germany; Hertie Inst Clin Brain Res, Dept Cellular Neurol, D-72076 Tubingen, Germany; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; F Hoffmann La Roche & Co Ltd, Preclin Res Cent Nervous Syst, Div Pharmaceut, CH-4070 Basel, Switzerland	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Boehringer Ingelheim; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of California System; University of California San Diego; Roche Holding	Weggen, S (corresponding author), Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany.	sweggen@uni-duesseldorf.de						Beher D, 2005, EXPERT OPIN INV DRUG, V14, P1385, DOI 10.1517/13543784.14.11.1385; Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Citron M, 2004, NAT REV NEUROSCI, V5, P677, DOI 10.1038/nrn1495; Clarke EE, 2006, J BIOL CHEM, V281, P31279, DOI 10.1074/jbc.M605051200; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; Czirr E, 2006, NEURODEGENER DIS, V3, P298, DOI 10.1159/000095270; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Lewis HD, 2003, BIOCHEMISTRY-US, V42, P7580, DOI 10.1021/bi034310g; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x; Morohashi Y, 2006, J BIOL CHEM, V281, P14670, DOI 10.1074/jbc.M513012200; Mount C, 2006, NAT MED, V12, P780, DOI 10.1038/nm0706-780; Okochi M, 1997, FEBS LETT, V418, P162, DOI 10.1016/S0014-5793(97)01378-1; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Sato T, 2006, BIOCHEMISTRY-US, V45, P8649, DOI 10.1021/bi060597g; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Tanner L. I., 2000, PTC Int. Appl., Patent No. [0019210, WO 00 19. 210 A2]; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Tomita T, 2006, CURR PHARM DESIGN, V12, P661, DOI 10.2174/138161206775474206; Wang RS, 2006, J BIOL CHEM, V281, P15330, DOI 10.1074/jbc.M512574200; Weggen S, 2003, J BIOL CHEM, V278, P30748, DOI 10.1074/jbc.M304824200; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Wen PH, 2002, NEUROBIOL DIS, V10, P8, DOI 10.1006/nbdi.2002.0490; Wisniewski T, 1998, NEUROREPORT, V9, P217, DOI 10.1097/00001756-199801260-00008; Wolfe MS, 2006, BIOCHEMISTRY-US, V45, P7931, DOI 10.1021/bi060799c; WU J, 1998, Patent No. [09828268, 9828268]; Yamasaki A, 2006, J NEUROSCI, V26, P3821, DOI 10.1523/JNEUROSCI.5354-05.2006; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1	48	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24504	24513		10.1074/jbc.M700618200	http://dx.doi.org/10.1074/jbc.M700618200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17573346	hybrid			2022-12-25	WOS:000248933000004
J	Karamanlidis, G; Karamitri, A; Docherty, K; Hazlerigg, DG; Lomax, MA				Karamanlidis, Georgios; Karamitri, Angeliki; Docherty, Kevin; Hazlerigg, David G.; Lomax, Michael A.			C/EBP beta reprograms white 3T3-L1 preadipocytes to a brown adipocyte pattern of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; AMP RESPONSE ELEMENT; ADIPOSE-TISSUE; TRANSCRIPTION FACTORS; MICE LACKING; PPAR-GAMMA; DIFFERENTIATION; COACTIVATOR; ADIPOGENESIS; ACTIVATION	cAMP-dependent protein kinase induction of PPAR gamma coactivator-1 alpha (PGC-1 alpha) and uncoupling protein 1 (UCP1) expression is an essential step in the commitment of preadipocytes to the brown adipose tissue (BAT) lineage. We studied the molecular mechanisms responsible for differential expression of PGC-1 alpha in HIB1B (BAT) and 3T3-L1 white adipose tissue (WAT) precursor cell lines. In HIB1B cells PGC-1 alpha and UCP1 expression is cAMP-inducible, but in 3T3-L1 cells, expression is reduced and is cAMP-insensitive. A proximal 264-bp PGC-1 alpha reporter construct was cAMP-inducible only in HIB1B cells and was suppressed by site-directed mutagenesis of the proximal cAMP response element (CRE). In electrophoretic mobility shift assays, the transcription factors CREB and C/EBP beta, but not C/EBP alpha and C/EBP beta, bound to the CRE on the PGC-1 alpha promoter region in HIB1B and 3T3-L1 cells. Chromatin immuno-precipitation studies demonstrated that C/EBP beta and CREB bound to the CRE region in HIB1B and 3T3-L1 cell lysates. C/EBP alpha expression was induced by cAMP only in HIB1B cells, and overexpression of C/EBP beta rescued cAMP-inducible PGC-1 alpha and UCP1 expression in 3T3-L1 cells. These data demonstrate that differentiation of preadipocytes toward the BAT rather than the WAT phenotype is controlled in part by the action of C/EBP beta on the CRE in PGC-1 alpha proximal promoter.	Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Sch Biol Sci, Aberdeen AB24 5UH, Scotland; Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, Ashford TN25 5AH, Kent, England	University of Aberdeen; University of Aberdeen; Imperial College London	Lomax, MA (corresponding author), Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.	m.lomax@abdn.ac.uk		Karamitri, Angeliki/0000-0002-8397-5529; Docherty, Kevin/0000-0001-6765-2060				Bradbury DA, 2003, J BIOL CHEM, V278, P49954, DOI 10.1074/jbc.M307964200; Brenner S, 2003, J BIOL CHEM, V278, P5597, DOI 10.1074/jbc.M207448200; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Carmona MC, 2005, BIOCHEM J, V389, P47, DOI 10.1042/BJ20050009; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Chen YC, 2003, MOL CELL BIOL, V23, P4066, DOI 10.1128/MCB.23.12.4066-4082.2003; Dumais N, 2002, J IMMUNOL, V168, P274, DOI 10.4049/jimmunol.168.1.274; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lomax MA, 2007, ENDOCRINOLOGY, V148, P461, DOI 10.1210/en.2006-0918; Nedergaard J, 2005, BBA-MOL BASIS DIS, V1740, P293, DOI 10.1016/j.bbadis.2005.02.003; PARK EA, 1993, J BIOL CHEM, V268, P613; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; REHNMARK S, 1993, FEBS LETT, V318, P235, DOI 10.1016/0014-5793(93)80519-Z; Rim JS, 2004, J BIOL CHEM, V279, P25916, DOI 10.1074/jbc.M402102200; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	29	85	92	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24660	24669		10.1074/jbc.M703101200	http://dx.doi.org/10.1074/jbc.M703101200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17584738	hybrid			2022-12-25	WOS:000248933000021
J	Hernandez-Gonzalez, EO; Trevino, CL; Castellano, LE; de la Vega-Beltran, JL; Ocampo, AY; Wertheimer, E; Visconti, PE; Darszon, A				Hernandez-Gonzalez, Enrique O.; Trevino, Claudia L.; Castellano, Laura E.; de la Vega-Beltran, Jose L.; Ocampo, Ana Y.; Wertheimer, Eva; Visconti, Pablo E.; Darszon, Alberto			Involvement of cystic fibrosis transmembrane conductance regulator in mouse sperm capacitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; SENSITIVE FLUORESCENT INDICATORS; EPITHELIAL SODIUM-CHANNEL; K-ATP CHANNELS; SPERMATOGENIC CELLS; FERTILIZING-CAPACITY; MAMMALIAN SPERM; CA2+ CHANNELS; ION CHANNELS; INTRACELLULAR CHLORIDE	Mammalian sperm acquire fertilizing ability in the female tract during a process known as capacitation. In mouse sperm, this process is associated with increases in protein tyrosine phosphorylation, membrane potential hyperpolarization, increase in intracellular pH and Ca2+, and hyperactivated motility. The molecular mechanisms involved in these changes are not fully known. Present evidence suggests that in mouse sperm the capacitation-associated membrane hyperpolarization is regulated by a cAMP/protein kinase A-dependent pathway involving activation of inwardly rectifying K+ channels and inhibition of epithelial sodium channels (ENaCs). The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl- channel that controls the activity of several transport proteins, including ENaCs. Here we explored whether CFTR is involved in the regulation of ENaC inhibition in sperm and therefore is essential for the capacitation-associated hyperpolarization. Using reverse transcription-PCR, Western blot, and immunocytochemistry, we document the presence of CFTR in mouse and human sperm. Interestingly, the addition of a CFTR inhibitor (diphenylamine-2-carboxylic acid; 250 mu M) inhibited the capacitation-associated hyperpolarization, prevented ENaC closure, and decreased the zona pellucida-induced acrosome reaction without affecting the increase in tyrosine phosphorylation. In cubation of sperm in Cl-- free medium also eliminated the capacitation associated hyperpolarization. On the other hand, a CFTR activator (genistein; 5-10 mu M) promoted hyperpolarization in mouse sperm incubated under conditions that do not support capacitation. The addition of dibutyryl cyclic AMP to noncapacitated mouse sperm elevated intracellular Cl-. These results suggest that cAMP-dependent Cl- fluxes through CFTR are involved in the regulation of ENaC during capacitation and thus contribute to the observed hyperpolarization associated with this process.	Ctr Invest & Estudios Avanzados, Dept Biol Celular, IPN, Mexico City 07320, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Genet Desarrollo & Fisiol Mol, Cuernavaca 62210, Morelos, Mexico; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Universidad Nacional Autonoma de Mexico; University of Massachusetts System; University of Massachusetts Amherst	Hernandez-Gonzalez, EO (corresponding author), Ctr Invest & Estudios Avanzados, Dept Biol Celular, IPN, Ave Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico.	eoton@cell.cinvestav.mx	Hernández-González, Enrique/AAU-8526-2020	Trevino, Claudia L/0000-0002-7281-0534; Darszon, Alberto/0000-0002-2502-0505	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD038082, R01HD044044] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R03TW006121] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW 006121] Funding Source: Medline; NICHD NIH HHS [HD44044, HD38082] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		Acevedo JJ, 2006, DEV BIOL, V289, P395, DOI 10.1016/j.ydbio.2005.11.002; Andersson C, 2003, BIOCHEM BIOPH RES CO, V308, P518, DOI 10.1016/S0006-291X(03)01436-0; Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; Biasio W, 2004, J BIOL CHEM, V279, P5429, DOI 10.1074/jbc.M311155200; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; Calamita G, 2001, BIOL REPROD, V64, P1660, DOI 10.1095/biolreprod64.6.1660; Chan HC, 2006, MOL CELL ENDOCRINOL, V250, P106, DOI 10.1016/j.mce.2005.12.032; CROSS NL, 1989, BIOL REPROD, V41, P635, DOI 10.1095/biolreprod41.4.635; Darszon A, 2005, INT REV CYTOL, V243, P79, DOI 10.1016/S0074-7696(05)43002-8; Darszon A, 2006, REPRODUCTION, V131, P977, DOI 10.1530/rep.1.00612; Demarco IA, 2003, J BIOL CHEM, V278, P7001, DOI 10.1074/jbc.M206284200; Florman HM, 1998, BIOL REPROD, V59, P12, DOI 10.1095/biolreprod59.1.12; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gadsby DC, 1999, ADV SEC MESS PHOSPH, V33, P79; Gadsby DC, 2006, NATURE, V440, P477, DOI 10.1038/nature04712; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; Garcia MA, 1999, J ANDROL, V20, P88; GREGER R, 2001, PFLUGERS ARCH, V443, P3; Guggino WB, 2006, NAT REV MOL CELL BIO, V7, P426, DOI 10.1038/nrm1949; Henkel Ralf R, 2003, Reprod Biol Endocrinol, V1, P108, DOI 10.1186/1477-7827-1-108; Hernandez-Gonzalez EO, 2006, J BIOL CHEM, V281, P5623, DOI 10.1074/jbc.M508172200; Hernandez-Gonzalez EO, 2000, CELL MOTIL CYTOSKEL, V46, P43, DOI 10.1002/(SICI)1097-0169(200005)46:1&lt;43::AID-CM5&gt;3.0.CO;2-1; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hug MJ, 2003, NEWS PHYSIOL SCI, V18, P38, DOI 10.1152/nips.01412.2002; Inglefield JR, 1999, METHODS, V18, P197, DOI 10.1006/meth.1999.0772; Jarzabek Katarzyna, 2004, Reprod Biol, V4, P119; Jayaraman S, 1999, AM J PHYSIOL-CELL PH, V276, pC747, DOI 10.1152/ajpcell.1999.276.3.C747; Jentsch TJ, 2005, ANNU REV PHYSIOL, V67, P779, DOI 10.1146/annurev.physiol.67.032003.153245; KALAB P, 1994, J BIOL CHEM, V269, P3810; Kaneko H, 2004, J NEUROSCI, V24, P7931, DOI 10.1523/JNEUROSCI.2115-04.2004; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kunzelmann K, 1999, J MEMBRANE BIOL, V168, P1, DOI 10.1007/s002329900492; Kunzelmann K, 2003, PFLUG ARCH EUR J PHY, V445, P504, DOI 10.1007/s00424-002-0958-y; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lievano A, 1996, FEBS LETT, V388, P150, DOI 10.1016/0014-5793(96)00515-7; Liu XB, 1999, J BIOL CHEM, V274, P25121, DOI 10.1074/jbc.274.35.25121; MOORE GD, 1994, DEVELOPMENT, V120, P3313; Munoz-Garay C, 2001, DEV BIOL, V234, P261, DOI 10.1006/dbio.2001.0196; Nagel G, 2001, EMBO REP, V2, P249, DOI 10.1093/embo-reports/kve045; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; PARKKILA S, 1993, BIOL REPROD, V49, P326, DOI 10.1095/biolreprod49.2.326; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; Reddy MM, 2006, AM J PHYSIOL-CELL PH, V291, pC122, DOI 10.1152/ajpcell.00134.2005; Reisert J, 2005, NEURON, V45, P553, DOI 10.1016/j.neuron.2005.01.012; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Trevino CL, 2004, FEBS LETT, V563, P87, DOI 10.1016/S0014-5793(04)00257-1; VERKMAN AS, 1989, ANAL BIOCHEM, V178, P355, DOI 10.1016/0003-2697(89)90652-0; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Xu WM, 2007, P NATL ACAD SCI USA, V104, P9816, DOI 10.1073/pnas.0609253104; Yanagimachi R, 1994, PHYSL REPRODUCTION, V1, P189	57	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24397	24406		10.1074/jbc.M701603200	http://dx.doi.org/10.1074/jbc.M701603200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17588945	hybrid			2022-12-25	WOS:000248686600066
J	Kuo, MMC; Saimi, Y; Kung, C; Choe, S				Kuo, Mario Meng-Chiang; Saimi, Yoshiro; Kung, Ching; Choe, Senyon			Patch clamp and phenotypic analyses of a prokaryotic cyclic nucleotide-gated K+ channel using Escherichia coli as a host	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; FUNCTIONAL-CHARACTERIZATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; MODULATION; ACTIVATION; INWARD	Prokaryotic ion channels have been valuable in providing structural models for understanding ion filtration and channel-gating mechanisms. However, their functional examinations have remained rare and usually been carried out by incorporating purified channel protein into artificial lipid membranes. Here we demonstrate the utilization of Escherichia coli to host the functional analyses by examining a putative cyclic nucleotide-gated K+ channel cloned from Magnetospirillum magnetotacticum, MmaK. When expressed in wild-type E. coli cells, MmaK renders the host sensitive to millimolar concentrations of externally applied K+, indicating MmaK forms a functional K+ conduit in the E. coli membrane in vivo. After enlarging these cells into giant sphero-plasts, macro- and microscopic MmaK currents are readily detected in excised E. col imembrane patches by a patch clamp. We show that MmaK is indeed gated by submicromolar cAMP and similar to 10-fold higher concentration of cGMP and manifests as an inwardly rectified, K+ - specific current with a 10.8 pS unitary conductance at -100 mV. Additionally, MmaK is inactivated by slightly acidic pH only from the cytoplasmic side. Our in vitro biophysical characterizations of MmaK correlate with its in vivo phenotype in E. coli, implicating its critical role as an intracellular cAMP and pH sensor for modulating bacterial membrane potential. Exemplified by MmaK functional studies, we establish that E. coli and its giant spheroplast provide a convenient and versatile system to express foreign channels for biophysical analyses that can be further dovetailed with microbial genetics.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	Salk Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Choe, S (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA.	choe@salk.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047856, R01GM074821] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM074821, GM74821, R01 GM054867, R01 GM047856, GM054867, GM047856] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blount P, 1999, Methods Enzymol, V294, P458; BOTSFORD JL, 1981, MICROBIOL REV, V45, P620, DOI 10.1128/MMBR.45.4.620-642.1981; Clayton GM, 2004, CELL, V119, P615, DOI 10.1016/j.cell.2004.10.030; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Enkvetchakul D, 2004, J BIOL CHEM, V279, P47076, DOI 10.1074/jbc.C400417200; HAROLD FM, 1996, ESCHERICHIA COLI SAL, V1, P283; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hellmer J, 2003, FEBS LETT, V547, P165, DOI 10.1016/S0014-5793(03)00706-3; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kung C, 2005, NATURE, V436, P647, DOI 10.1038/nature03896; Kuo AL, 2005, STRUCTURE, V13, P1463, DOI 10.1016/j.str.2005.07.011; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Kuo MMC, 2007, P NATL ACAD SCI USA, V104, P2151, DOI 10.1073/pnas.0609085104; Kuo MMC, 2005, FEMS MICROBIOL REV, V29, P961, DOI 10.1016/j.femsre.2005.03.003; Kuo MMC, 2003, EMBO J, V22, P4049, DOI 10.1093/emboj/cdg409; KUO MMC, 2005, THESIS U WISCONSIN M; Li Y, 2007, J GEN PHYSIOL, V129, P109, DOI 10.1085/jgp.200609655; Loukin SH, 2005, J GEN PHYSIOL, V125, P521, DOI 10.1085/jgp.200509261; MacKinnon R, 1997, NAT STRUCT BIOL, V4, P877, DOI 10.1038/nsb1197-877; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Nakayama Y, 2007, P NATL ACAD SCI USA, V104, P5883, DOI 10.1073/pnas.0609996104; Nimigean CM, 2004, J GEN PHYSIOL, V124, P203, DOI 10.1085/jgp.200409133; Parfenova LV, 2006, J BIOL CHEM, V281, P21131, DOI 10.1074/jbc.M603109200; Ptak CP, 2005, BIOCHEMISTRY-US, V44, P62, DOI 10.1021/bi048390f; Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473; Santos JS, 2006, J GEN PHYSIOL, V128, P283, DOI 10.1085/jgp.200609572; Sesti F, 2003, NAT NEUROSCI, V6, P353, DOI 10.1038/nn1028; Shi N, 2006, NATURE, V440, P570, DOI 10.1038/nature04508; Sun S, 2006, PHYSIOL GENOMICS, V26, P1, DOI 10.1152/physiolgenomics.00026.2006; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; ZUFALL F, 1993, P NATL ACAD SCI USA, V90, P9335, DOI 10.1073/pnas.90.20.9335	33	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24294	24301		10.1074/jbc.M703618200	http://dx.doi.org/10.1074/jbc.M703618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17588940	hybrid, Green Accepted			2022-12-25	WOS:000248686600055
J	McCloskey, N; Hunt, J; Beavil, RL; Jutton, MR; Grundy, GJ; Girardi, E; Fabiane, SM; Fear, DJ; Conrad, DH; Sutton, BJ; Gould, HJ				McCloskey, Natalie; Hunt, James; Beavil, Rebecca L.; Jutton, Mark R.; Grundy, Gabrielle J.; Girardi, Enrico; Fabiane, Stella M.; Fear, David J.; Conrad, Daniel H.; Sutton, Brian J.; Gould, Hannah J.			Soluble CD23 monomers inhibit and oligomers stimulate IGE synthesis in human B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-AFFINITY RECEPTOR; IMMUNOGLOBULIN-E; INVITRO SYNTHESIS; HUMAN-LYMPHOCYTES; BINDING FACTORS; MONOCLONAL-ANTIBODIES; ANTIGEN RECEPTOR; HUMAN MONOCYTES; SERUM-LEVELS; FC	The low affinity IgE receptor, CD23, is implicated in IgE regulation and the pathogenesis of allergic disease. CD23 is a type II integral membrane protein, comprising a lectin " head," N- terminal " stalk," and C- terminal " tail" in the extracellular sequence. Endogenous proteases cleave CD23 in the stalk and the tail to release soluble fragments that either stimulate or inhibit IgE synthesis in human B cells. The molecular basis of these paradoxical activities is not understood. We have characterized three fragments of CD23, monomeric derCD23, monomeric exCD23, and oligomeric lzCD23. We show that the monomers inhibit and the oligomer stimulates IgE synthesis in human B cells after heavy chain switching to IgE. CD23 fragments could be targets for therapeutic intervention in allergic disease.	Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; Kings Coll London, MRC, Asthma UK Ctr Allerg Mech, London SE1 1UL, England; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA	University of London; King's College London; University of London; King's College London; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Virginia Commonwealth University	McCloskey, N (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunta House,Guys Campus,St Thomas St, London SE1 1UL, England.	natalie.mccloskey@kcl.ac.uk	Girardi, Enrico/AAD-2260-2020; Girardi, Enrico/L-4033-2014	Girardi, Enrico/0000-0003-3508-2723; Girardi, Enrico/0000-0003-3508-2723; Fear, David/0000-0003-0239-8385; Grundy, Gabrielle/0000-0003-1506-3664; Gould, Hannah/0000-0003-0411-688X	Medical Research Council [G0400503B] Funding Source: researchfish; Medical Research Council [G0400106, G0200486] Funding Source: Medline; Wellcome Trust [076343] Funding Source: Medline; MRC [G0200486, G0400106] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aberle N, 1997, ALLERGY, V52, P1238, DOI 10.1111/j.1398-9995.1997.tb02530.x; Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; AUBRY JP, 1994, J IMMUNOL, V152, P5806; BANSAL A, 1992, CLIN EXP IMMUNOL, V89, P452; BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BEAVIL RL, 1995, IMMUNOLOGY, V84, P202; Chen BH, 2002, IMMUNOLOGY, V107, P373, DOI 10.1046/j.1365-2567.2002.01512.x; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; DIERKS SE, 1993, J IMMUNOL, V150, P2372; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; Ferrajoli A, 2006, EXPERT REV ANTICANC, V6, P1231, DOI 10.1586/14737140.6.9.1231; FLORESROMO L, 1989, IMMUNOLOGY, V67, P547; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; GOULD HJ, 1997, IGE REGULATION MOL M; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Hermann P, 1999, J CELL BIOL, V144, P767, DOI 10.1083/jcb.144.4.767; Hibbert RG, 2005, J EXP MED, V202, P751, DOI 10.1084/jem.20050811; Huissoon AP, 2000, SCAND J RHEUMATOL, V29, P154; Karagiannis SN, 2003, EUR J IMMUNOL, V33, P1030, DOI 10.1002/eji.200323185; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; Kelly AE, 1998, J IMMUNOL, V161, P6696; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KljaicTurkalj M, 1996, INT ARCH ALLERGY IMM, V111, P188, DOI 10.1159/000237367; LecoanetHenchoz S, 1997, EUR J IMMUNOL, V27, P2290, DOI 10.1002/eji.1830270924; Lemieux GA, 2007, J BIOL CHEM, V282, P14836, DOI 10.1074/jbc.M608414200; LETELLIER M, 1989, MOL IMMUNOL, V26, P1105, DOI 10.1016/0161-5890(89)90054-0; LUDIN C, 1987, EMBO J, V6, P109, DOI 10.1002/j.1460-2075.1987.tb04726.x; Mongini PKA, 2003, J IMMUNOL, V171, P5244, DOI 10.4049/jimmunol.171.10.5244; Nakamura T, 2000, INT J IMMUNOPHARMACO, V22, P131, DOI 10.1016/S0192-0561(99)00068-5; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; PIRRON U, 1990, EUR J IMMUNOL, V20, P1547, DOI 10.1002/eji.1830200721; POCHON S, 1992, J EXP MED, V176, P389, DOI 10.1084/jem.176.2.389; RELIJIC R, 1996, THESIS U LONDON; Ribbens C, 2000, CLIN EXP IMMUNOL, V120, P194, DOI 10.1046/j.1365-2249.2000.01198.x; Roberts T, 1999, J IMMUNOL, V162, P4377; Rosenwasser LJ, 2005, CLIN REV ALLERG IMMU, V29, P61, DOI 10.1385/CRIAI:29:1:061; SARFATI M, 1984, IMMUNOLOGY, V53, P207; SARFATI M, 1984, IMMUNOLOGY, V53, P783; SARFATI M, 1984, IMMUNOLOGY, V53, P197; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Shi JG, 1997, BIOCHEMISTRY-US, V36, P2112, DOI 10.1021/bi961231e; SPIEGELBERG HL, 1984, ADV IMMUNOL, V35, P61, DOI 10.1016/S0065-2776(08)60574-X; Tanaka A, 1999, ANN OTO RHINOL LARYN, V108, P193, DOI 10.1177/000348949910800216; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; Weskamp G, 2006, NAT IMMUNOL, V7, P1293, DOI 10.1038/ni1399; Yabuuchi S, 2002, INT IMMUNOPHARMACOL, V2, P453, DOI 10.1016/S1567-5769(01)00187-4; YANAGIHARA Y, 1990, CLIN EXP ALLERGY, V20, P395, DOI 10.1111/j.1365-2222.1990.tb02800.x; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YOUNG RJ, 1995, PROTEIN ENG, V8, P193, DOI 10.1093/protein/8.2.193; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0	51	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24083	24091		10.1074/jbc.M703195200	http://dx.doi.org/10.1074/jbc.M703195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17576766	hybrid			2022-12-25	WOS:000248686600034
J	Xu, TH; Nie, LP; Zhang, Y; Mo, JL; Feng, WH; Wei, DG; Petrov, E; Calisto, LE; Kachar, B; Beisel, KW; Vazquez, AE; Yamoah, EN				Xu, Tonghui; Nie, Liping; Zhang, Yi; Mo, Jiling; Feng, Weihong; Wei, Dongguang; Petrov, Evgueni; Calisto, Lilian E.; Kachar, Bechara; Beisel, Kirk W.; Vazquez, Ana E.; Yamoah, Ebenezer N.			Roles of alternative splicing in the functional properties of inner ear-specific KCNQ4 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER HAIR-CELLS; DIFFERENTIAL EXPRESSION; SUBUNIT STOICHIOMETRY; POTASSIUM; CALMODULIN; GENE; EPILEPSY; MUTATION; MODULATION; DEAFNESS	The function of the KCNQ4 channel in the auditory setting is crucial to hearing, underpinned by the finding that mutations of the channel result in an autosomal dominant form of nonsyndromic progressive high frequency hearing loss. The precise function of KCNQ4 in the inner ear has not been established. However, recently we demonstrated that there is differential expression among four splice variants of KCNQ4 ( KCNQ4_v1-v4) along the tonotopic axis of the cochlea. Alternative splicing specifies the outcome of functional channels by modifying the amino acid sequences within the C terminus at a site designated as the membrane proximal region. We show that variations within the C terminus of splice variants produce profound differences in the voltage-dependent phenotype and functional expression of the channel. KCNQ4_v4 lacks exons 9-11, resulting in deletion of 54 amino acid residues adjacent to the S6 domain compared with KCNQ4_v1. Consequently, the voltage-dependent activation of KCNQ4_v4 is shifted leftward by similar to 20 mV, and the number of functional channels is increased severalfold compared with KCNQ4_v1. The properties of KCNQ4_v2 and KCNQ4_v3 fall between KCNQ4_v1 and KCNQ4_v4. Because of variations in the calmodulin binding domains of the splice variants, the channels are differentially modulated by calmodulin. Co-expression of these splice variants yielded current magnitudes suggesting that the channels are composed of heterotetramers. Indeed, a dominant negative mutant of KCNQ4_v1 cripples the currents of the entire KCNQ4 channel family. Furthermore, the dominant negative KCNQ4 mutant stifles the activity of KCNQ2-5, raising the possibility of a global disruption of KCNQ channel activity and the ensuing auditory phenotype.	Univ Calif Davis, Dept Otolaryngol, Ctr Neurosci, Davis, CA 95618 USA; Univ Calif Davis, Commun Sci Program, Davis, CA 95618 USA; NIDCD, Gene Struct Cell Biol, NIH, Bethesda, MD 20892 USA; Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA	University of California System; University of California Davis; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Creighton University	Nie, LP (corresponding author), Univ Calif Davis, Dept Otolaryngol, Ctr Neurosci, 1544 Newton Ct, Davis, CA 95618 USA.	lnie@ucdavis.edu; enyamoah@ucdavis.edu		Petrov, Evgeny/0000-0002-4055-6981	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005009, R01DC007592, Z01DC000002, R01DC004279, R01DC008649] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC07592, R01 DC005009, DC03828, DC05009, R01 DC004279, DC008649, DC04279] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BEGENISICH T, 1975, BIOPHYS J, V15, P843, DOI 10.1016/S0006-3495(75)85858-9; Beisel KW, 2005, J NEUROSCI, V25, P9285, DOI 10.1523/JNEUROSCI.2110-05.2005; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Casimiro MC, 2004, GENOMICS, V84, P555, DOI 10.1016/j.ygeno.2004.06.007; Chambard JM, 2005, PFLUG ARCH EUR J PHY, V450, P34, DOI 10.1007/s00424-004-1366-2; Chung HJ, 2006, P NATL ACAD SCI USA, V103, P8870, DOI 10.1073/pnas.0603376103; Chung WH, 2006, JARO-J ASSOC RES OTO, V7, P373, DOI 10.1007/s10162-006-0050-y; Cyr JL, 2002, J NEUROSCI, V22, P2487, DOI 10.1523/JNEUROSCI.22-07-02487.2002; Davies C, 2001, SYNAPSE, V40, P258, DOI 10.1002/syn.1048; Dedek K, 2001, P NATL ACAD SCI USA, V98, P12272, DOI 10.1073/pnas.211431298; Deschenes I, 2002, CIRC RES, V90, pE49, DOI 10.1161/01.RES.0000012502.92751.E6; EHRENSTEIN G, 1970, J GEN PHYSIOL, V55, P119, DOI 10.1085/jgp.55.1.119; Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/jgp.200208783; Herzog RI, 2003, J NEUROSCI, V23, P8261; HOUSLEY GD, 1992, J PHYSIOL-LONDON, V448, P73, DOI 10.1113/jphysiol.1992.sp019030; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Kharkovets T, 2006, EMBO J, V25, P642, DOI 10.1038/sj.emboj.7600951; Kharkovets T, 2000, P NATL ACAD SCI USA, V97, P4333, DOI 10.1073/pnas.97.8.4333; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim J, 2004, J BIOL CHEM, V279, P45004, DOI 10.1074/jbc.M407286200; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Kurokawa J, 2004, P NATL ACAD SCI USA, V101, P16374, DOI 10.1073/pnas.0405583101; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Lerche C, 2000, J BIOL CHEM, V275, P22395, DOI 10.1074/jbc.M002378200; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Mammano F, 1996, J PHYSIOL-LONDON, V496, P639, DOI 10.1113/jphysiol.1996.sp021715; Marcotti W, 1999, J PHYSIOL-LONDON, V520, P653, DOI 10.1111/j.1469-7793.1999.00653.x; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Oliver D, 2003, J NEUROSCI, V23, P2141; Richards MC, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.013938; Ruttiger L, 2004, P NATL ACAD SCI USA, V101, P12922, DOI 10.1073/pnas.0402660101; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; Wen H, 2002, J NEUROSCI, V22, P7991, DOI 10.1523/jneurosci.22-18-07991.2002; Yus-Najera E, 2002, J BIOL CHEM, V277, P28545, DOI 10.1074/jbc.M204130200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	39	35	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23899	23909		10.1074/jbc.M702108200	http://dx.doi.org/10.1074/jbc.M702108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17561493	hybrid			2022-12-25	WOS:000248686600017
J	Ma, ZJ; Huang, J; Sun, J; Wang, GN; Li, CZ; Xie, LP; Zhang, RQ				Ma, Zhuojun; Huang, Jing; Sun, Juan; Wang, Guannan; Li, Changzhong; Xie, Liping; Zhang, Rongqing			A novel extrapallial fluid protein controls the morphology of nacre lamellae in the pearl oyster, Pinctada fucata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-BINDING PROTEIN; AMORPHOUS CALCIUM-CARBONATE; MYTILUS-EDULIS; SHELL PROTEINS; MOLLUSK; MECHANISM; GROWTH; CRYSTALLIZATION; CALCIFICATION; PRECIPITATION	Mollusk shell nacre is known for its superior mechanical properties and precisely controlled biomineralization process. However, the question of how mollusks control the morphology of nacre lamellae remains unresolved. Here, a novel 38-kDa extrapallial fluid (EPF) protein, named amorphous calcium carbonate-binding protein (ACCBP), may partially answer this question. Although sequence analysis indicated ACCBP is a member of the acetylcholine-binding protein family, it is actively involved in the shell mineralization process. In vitro, ACCBP can inhibit the growth of calcite and induce the formation of amorphous calcium carbonate. When ACCBP functions were restrained in vivo, the nacre lamellae grew in a screw-dislocation pattern, and low crystallinity CaCO3 precipitated from the EPF. Crystal binding experiments further revealed that ACCBP could recognize different CaCO3 crystal phases and crystal faces. With this capacity, ACCBP could modify the morphology of nacre lamellae by inhibiting the growth of undesired aragonite crystal faces and meanwhile maintain the stability of CaCO3-supersaturated body fluid by ceasing the nucleation and growth of calcite. Furthermore, the crystal growth inhibition capacity of ACCBP was proved to be directly related to its acetylcholine-binding site. Our results suggest that a "safeguard mechanism" of undesired crystal growth is necessary for shell microstructure formation.	Tsing Hua Univ, Inst Marine Biotechnol, Dept Biol Sci, Beijing 100084, Peoples R China; Tsing Hua Univ, Minist Educ, Protein Sci Lab, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University	Xie, LP (corresponding author), Tsing Hua Univ, Inst Marine Biotechnol, Dept Biol Sci, Beijing 100084, Peoples R China.	lpxie@mail.tsinghua.edu.cn; rqzhang@mail.tsinghua.edu.cn						Albeck S, 1996, CHEM-EUR J, V2, P278, DOI 10.1002/chem.19960020308; Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; CLARKSON JR, 1992, J CHEM SOC FARADAY T, V88, P243, DOI 10.1039/ft9928800243; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CRENSHAW MA, 1972, BIOL BULL, V143, P506, DOI 10.2307/1540180; Donners JJJM, 2000, CHEM COMMUN, P1937, DOI 10.1039/b004867o; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; Gerbaud V, 2000, J BIOL CHEM, V275, P1057, DOI 10.1074/jbc.275.2.1057; GILES R, 1995, BIOL BULL, V188, P8, DOI 10.2307/1542062; Hansen SB, 2004, J BIOL CHEM, V279, P24197, DOI 10.1074/jbc.M402452200; Hattan SJ, 2001, J BIOL CHEM, V276, P4461, DOI 10.1074/jbc.M006803200; Koga N, 1998, THERMOCHIM ACTA, V318, P239, DOI 10.1016/S0040-6031(98)00348-7; Kono M, 2000, BIOCHEM BIOPH RES CO, V269, P213, DOI 10.1006/bbrc.2000.2274; Lowenstam HA, 1989, BIOMINERALIZATION; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Mann K, 2000, EUR J BIOCHEM, V267, P5257, DOI 10.1046/j.1432-1327.2000.01602.x; Mann S., 2001, BIOMINERALIZATION PR; Marin F, 2005, J BIOL CHEM, V280, P33895, DOI 10.1074/jbc.M506526200; Marin F, 2004, CR PALEVOL, V3, P469, DOI 10.1016/j.crpv.2004.07.009; MARSH ME, 1983, J EXP ZOOL, V226, P193, DOI 10.1002/jez.1402260204; MISOGIANES MJ, 1979, ANAL BIOCHEM, V100, P324, DOI 10.1016/0003-2697(79)90236-7; Miyamoto H, 1996, P NATL ACAD SCI USA, V93, P9657, DOI 10.1073/pnas.93.18.9657; Moradian-Oldak J, 2001, MATRIX BIOL, V20, P293, DOI 10.1016/S0945-053X(01)00154-8; Nair PS, 1998, BIOL BULL, V195, P43, DOI 10.2307/1542774; OGINO T, 1987, GEOCHIM COSMOCHIM AC, V51, P2757, DOI 10.1016/0022-0248(90)90618-U; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; PIETRZAK JE, 1976, HYDROBIOLOGIA, V50, P89, DOI 10.1007/BF00016846; Raz S, 2000, ADV MATER, V12, P38, DOI 10.1002/(SICI)1521-4095(200001)12:1<38::AID-ADMA38>3.0.CO;2-I; Rieger J, 2000, LANGMUIR, V16, P8300, DOI 10.1021/la0004193; Sanchez C, 2005, NAT MATER, V4, P277, DOI 10.1038/nmat1339; Schafer C, 2003, J CLIN INVEST, V112, P357, DOI 10.1172/JCI17202; Schlessinger A, 2005, PROTEINS, V61, P115, DOI 10.1002/prot.20587; Sellinger A, 1998, NATURE, V394, P256, DOI 10.1038/28354; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; Simkiss K, 1989, BIOMINERALIZATION CE; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Sudo S, 1997, NATURE, V387, P563, DOI 10.1038/42391; Treccani L, 2006, BIOPHYS J, V91, P2601, DOI 10.1529/biophysj.106.086108; VEIS A, 1981, CHEM BIOL MIN CONNEC; WADA K, 1999, PEARL SCI MINERALIZA; WEINER S, 2003, BIOMINERALIZATION FO; WILBUR KM, 1984, BIOL BULL, V166, P251, DOI 10.2307/1541446; WISE S JR, 1970, Eclogae Geologicae Helvetiae, V63, P775; Xu GF, 1998, J AM CHEM SOC, V120, P11977, DOI 10.1021/ja9819108; Yin Y, 2005, BIOCHEMISTRY-US, V44, P10720, DOI 10.1021/bi0505565; Zhang C, 2006, MAR BIOTECHNOL, V8, P572, DOI 10.1007/s10126-005-6029-6	48	86	97	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23253	23263		10.1074/jbc.M700001200	http://dx.doi.org/10.1074/jbc.M700001200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17558025	hybrid			2022-12-25	WOS:000248577500026
J	Tordjman, J; Leroyer, S; Chauvet, G; Quette, J; Chauvet, C; Tomkiewicz, C; Chapron, C; Barouki, R; Forest, C; Aggerbeck, M; Antoine, B				Tordjman, Joan; Leroyer, Stephanie; Chauvet, Genevieve; Quette, Joeelle; Chauvet, Caroline; Tomkiewicz, Celine; Chapron, Charles; Barouki, Robert; Forest, Claude; Aggerbeck, Martine; Antoine, Benedicte			Cytosolic aspartate aminotransferase, a new partner in adipocyte glyceroneogenesis and an atypical target of thiazolidinedione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; BROWN ADIPOSE-TISSUE; INSULIN-RESISTANCE; NUCLEAR RECEPTORS; HOUSEKEEPING GENE; RETINOIC ACID; MESSENGER-RNA; ROR-ALPHA; DIFFERENTIATION	We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [C-14] aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone. Conversely, the ratio of fatty acid to glycerol released into the medium decreased. Regulation of cAspAT gene expression was specific to differentiated adipocytes and did not require any peroxisome proliferator-activated receptor gamma (PPAR gamma)/retinoid X receptor-alpha direct binding. Nevertheless, PPAR gamma is indirectly necessary for both cAspAT basal expression and TZD responsiveness because they are, respectively, diminished and abolished by ectopic overexpression of a dominant negative PPAR gamma. The cAspAT TZD-responsive site was restricted to a single AGGACA hexanucleotide located at -381 to -376 bp whose mutation impaired the specific ROR alpha binding. ROR alpha ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by rosiglitazone treatment of adipocytes. Finally, the amounts of ROR alpha and cAspAT mRNAs were similarly increased by TZD treatment of human adipose tissue explants, confirming coordinated regulation. Our data identify cAspAT as a new member of glyceroneogenesis, transcriptionally regulated by TZD via the control of ROR alpha expression by PPAR gamma in adipocytes.	Univ Paris 06, INSERM U680, Fac Med, F-75012 Paris, France; Univ Paris 05, INSERM U530, F-75006 Paris, France; Univ Paris 05, INSERM U747, F-75006 Paris, France; Univ Paris 05, CHU Cochin, AP HP Grp Hosp Univ Quest, F-75006 Paris, France; CNRS, UPR 9078, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Antoine, B (corresponding author), Univ Paris 06, INSERM U680, Fac Med, 27 Rue Chaligny, F-75012 Paris, France.	antoine@st-antoine.inserm.fr	Chapron, Charles/O-8567-2017	Forest, Claude/0000-0003-3401-8148				AGGERBECK M, 1993, BIOCHEMISTRY-US, V32, P9065, DOI 10.1021/bi00086a011; ANTRASFERRY J, 1994, BIOCHEM J, V302, P943, DOI 10.1042/bj3020943; Austin S, 1998, CELL GROWTH DIFFER, V9, P267; BEALE EG, 1985, J BIOL CHEM, V260, P748; Beale EG, 2004, TRENDS ENDOCRIN MET, V15, P129, DOI 10.1016/j.tem.2004.02.006; Beale EG, 2003, TRENDS BIOCHEM SCI, V28, P402, DOI 10.1016/S0968-0004(03)00163-4; Beale EG, 2002, FASEB J, V16, P1695, DOI 10.1096/fj.02-0407rev; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Brito MN, 1999, AM J PHYSIOL-REG I, V276, pR1003, DOI 10.1152/ajpregu.1999.276.4.R1003; Chauvet C, 2005, MOL ENDOCRINOL, V19, P2517, DOI 10.1210/me.2005-0153; Chauvet C, 2002, BIOCHEM J, V364, P449, DOI 10.1042/BJ20011558; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; Chen JL, 2005, J BIOL CHEM, V280, P25396, DOI 10.1074/jbc.M413948200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Deng T, 2006, ENDOCRINOLOGY, V147, P875, DOI 10.1210/en.2005-0623; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Edgar AD, 1998, TOXICOL LETT, V98, P13, DOI 10.1016/S0378-4274(98)00042-3; Eubank DW, 2001, J BIOL CHEM, V276, P30561, DOI 10.1074/jbc.M103019200; FERRE P, 1988, BIOCHEM J, V263, P17459; Fontaine C, 2003, J BIOL CHEM, V278, P37672, DOI 10.1074/jbc.M304664200; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Franckhauser S, 2006, DIABETES, V55, P273, DOI 10.2337/diabetes.55.02.06.db05-0482; Franckhauser S, 2002, DIABETES, V51, P624, DOI 10.2337/diabetes.51.3.624; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hanson RW, 2003, BIOCHIMIE, V85, P1199, DOI 10.1016/j.biochi.2003.10.022; HORIO Y, 1988, J BIOCHEM-TOKYO, V103, P805, DOI 10.1093/oxfordjournals.jbchem.a122350; Jensen MD, 2001, AM J PHYSIOL-ENDOC M, V281, pE789; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Katunuma N, 1966, Adv Enzyme Regul, V4, P317, DOI 10.1016/0065-2571(66)90025-2; KREBS HA, 1967, BIOCHEM J, V102, P275, DOI 10.1042/bj1020275; Kurebayashi S, 1998, Nihon Rinsho, V56, P1729; LAUDET V, 1995, CURR BIOL, V5, P124, DOI 10.1016/S0960-9822(95)00031-5; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leroyer SN, 2006, J BIOL CHEM, V281, P13141, DOI 10.1074/jbc.M512943200; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; MeunierDurmort C, 1997, GENE THER, V4, P808, DOI 10.1038/sj.gt.3300450; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; PARLI JA, 1987, BIOCHIM BIOPHYS ACTA, V925, P175, DOI 10.1016/0304-4165(87)90107-3; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; Plee-Gautier E, 1998, ENDOCRINOLOGY, V139, P4936, DOI 10.1210/en.139.12.4936; Plee-Gautier E, 1998, BIOCHEM J, V329, P37, DOI 10.1042/bj3290037; RESHEF L, 1969, J BIOL CHEM, V244, P1994; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; ROGNSTAD R, 1970, BIOCHEM J, V116, P483, DOI 10.1042/bj1160483; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Tomkiewicz C, 2004, BIOCHEM PHARMACOL, V67, P213, DOI 10.1016/j.bcp.2003.07.018; Tordjman J, 2003, J BIOL CHEM, V278, P18785, DOI 10.1074/jbc.M206999200; VAUGHAN M, 1962, J BIOL CHEM, V237, P3354	57	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23591	23602		10.1074/jbc.M611111200	http://dx.doi.org/10.1074/jbc.M611111200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17545671	hybrid			2022-12-25	WOS:000248577500061
J	Heuck, AP; Savva, CG; Holzenburg, A; Johnson, AE				Heuck, Alejandro P.; Savva, Christos G.; Holzenburg, Andreas; Johnson, Arthur E.			Conformational changes that effect oligomerization and initiate pore formation are triggered throughout perfringolysin O upon binding to cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE BETA-HAIRPINS; DEPENDENT CYTOLYSIN; STREPTOLYSIN-O; ERYTHROCYTE-MEMBRANES; ELECTRON-MICROSCOPY; AQUEOUS-SOLUTION; PREPORE COMPLEX; LIPID-BILAYERS; THETA-TOXIN; PROTEIN	Pore formation by the cholesterol-dependent cytolysins (CDCs) requires the presence of cholesterol in the target membrane. Cholesterol was long thought to be the cellular receptor for these toxins, but not all CDCs require cholesterol for binding. Intermedilysin, secreted by Streptococcus intermedius, only binds to membranes containing the human protein CD59 but forms pores only if the membrane contains sufficient cholesterol. In contrast, perfringolysin O (PFO), secreted by Clostridium perfringens, only binds to membranes containing substantial amounts of cholesterol. Given that different steps in the assembly of various CDC pores require cholesterol, here we have analyzed to what extent cholesterol molecules, by themselves, can modulate the conformational changes associated with PFO oligomerization and pore formation. PFO binds to cholesterol when dispersed in aqueous solution, and this binding triggers the distant rearrangement of a beta-strand that exposes an oligomerization interface. Moreover, upon binding to cholesterol, PFO forms a prepore complex, unfolds two amphipathic transmembrane beta-hairpins, and positions their nonpolar surfaces so they associate with the hydrophobic cholesterol surface. The interaction of PFO with cholesterol is therefore sufficient to initiate an irreversible sequence of coupled conformational changes that extend throughout the toxin molecule.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Texas A&M Univ, Microscopy & Imaging Ctr, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Mol & Cellular Med, College Stn, TX 77843 USA	University of Massachusetts System; University of Massachusetts Amherst; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Heuck, AP (corresponding author), 710 N Pleasant St,Lederle GRT 816, Amherst, MA 01003 USA.	heuck@biochem.umass.edu	Johnson, Arthur E/G-3457-2012	Heuck, Alejandro/0000-0002-7786-3109	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037657, R01AI037657] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37657] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALOUF JE, 1991, SOURCEBOOK BACTERIOL; ALOUF JE, 1999, COMPREHENSIVE SOURCE, P443; ALVING CR, 1979, BIOCHIM BIOPHYS ACTA, V551, P224, DOI 10.1016/0005-2736(79)90368-7; ARRHENIUS S, 1907, IMMUNOCHEMISTRY, P187; CASTANHO MARB, 1992, BIOPHYS J, V63, P1455, DOI 10.1016/S0006-3495(92)81733-2; Christian AE, 1997, J LIPID RES, V38, P2264; COWELL JL, 1978, ARCH BIOCHEM BIOPHYS, V190, P603, DOI 10.1016/0003-9861(78)90316-8; Czajkowsky DM, 2004, EMBO J, V23, P3206, DOI 10.1038/sj.emboj.7600350; Dang TX, 2005, J STRUCT BIOL, V150, P100, DOI 10.1016/j.jsb.2005.02.003; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; Geva M, 2001, CHEMBIOCHEM, V2, P265, DOI 10.1002/1439-7633(20010401)2:4<265::AID-CBIC265>3.3.CO;2-M; Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862; Giddings KS, 2003, P NATL ACAD SCI USA, V100, P11315, DOI 10.1073/pnas.2033520100; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; Harris JR, 1998, J STRUCT BIOL, V121, P343, DOI 10.1006/jsbi.1998.3989; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; HAUGLAND RP, 2005, GUIDE FLURESCENT PRO, P93; Heuck AP, 2005, PROTEIN-LIPID INTERACTIONS: FROM MEMBRANE DOMAINS TO CELLULAR NETWORKS, P163; Heuck AP, 2000, MOL CELL, V6, P1233, DOI 10.1016/S1097-2765(00)00119-2; Heuck AP, 2003, J BIOL CHEM, V278, P31218, DOI 10.1074/jbc.M303151200; Heuck AP, 2002, CELL BIOCHEM BIOPHYS, V36, P89, DOI 10.1385/CBB:36:1:89; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; Huang JY, 1999, BIOPHYS J, V76, P2142, DOI 10.1016/S0006-3495(99)77369-8; Jacobs T, 1998, MOL MICROBIOL, V28, P1081, DOI 10.1046/j.1365-2958.1998.00858.x; Johnson AE, 2005, TRAFFIC, V6, P1078, DOI 10.1111/j.1600-0854.2005.00340.x; JOHNSON MK, 1980, INFECT IMMUN, V27, P97, DOI 10.1128/IAI.27.1.97-101.1980; Lange Y, 2004, P NATL ACAD SCI USA, V101, P11664, DOI 10.1073/pnas.0404766101; McConnell HM, 2003, BBA-BIOMEMBRANES, V1610, P159, DOI 10.1016/S0005-2736(03)00015-4; Miao L, 2002, BIOPHYS J, V82, P1429, DOI 10.1016/S0006-3495(02)75497-0; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V558, P307, DOI 10.1016/0005-2736(79)90265-7; Mouritsen OG, 2004, LIPIDS, V39, P1101, DOI 10.1007/s11745-004-1336-x; Nagamune H, 2004, MICROBIOL IMMUNOL, V48, P677, DOI 10.1111/j.1348-0421.2004.tb03479.x; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Nollmann M, 2004, BIOPHYS J, V86, P3141, DOI 10.1016/S0006-3495(04)74362-3; Ohno-Iwashita Y, 2004, ANAEROBE, V10, P125, DOI 10.1016/j.anaerobe.2003.09.003; OHNOIWASHITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1109, P81, DOI 10.1016/0005-2736(92)90190-W; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palmer M, 2004, FEMS MICROBIOL LETT, V238, P281, DOI 10.1016/j.femsle.2004.07.059; Polekhina G, 2005, P NATL ACAD SCI USA, V102, P600, DOI 10.1073/pnas.0403229101; Ramachandran R, 2004, NAT STRUCT MOL BIOL, V11, P697, DOI 10.1038/nsmb793; Ramachandran R, 2005, P NATL ACAD SCI USA, V102, P7139, DOI 10.1073/pnas.0500556102; Ramachandran R, 2002, NAT STRUCT BIOL, V9, P823, DOI 10.1038/nsb855; RENSHAW PF, 1983, J LIPID RES, V24, P47; ROSENQVIST E, 1980, BIOCHIM BIOPHYS ACTA, V600, P91, DOI 10.1016/0005-2736(80)90414-9; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Soltani CE, 2007, J BIOL CHEM, V282, P15709, DOI 10.1074/jbc.M701173200; TANFORD C, 1973, HYDROPHOBIC EFFECT F, P94; Tweten RK, 2001, CURR TOP MICROBIOL, V257, P15; VAZQUEZBOLAND JA, 1989, INFECT IMMUN, V57, P3928, DOI 10.1128/IAI.57.12.3928-3935.1989; VAZQUEZBOLAND JA, 1989, FEMS MICROBIOL LETT, V65, P95, DOI 10.1016/0378-1097(89)90372-8	54	42	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22629	22637		10.1074/jbc.M703207200	http://dx.doi.org/10.1074/jbc.M703207200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553799	hybrid			2022-12-25	WOS:000248354200040
J	Mamikonyan, G; Necula, M; Mkrtichyan, M; Ghochikyan, A; Petrushina, I; Movsesyan, N; Mina, E; Kiyatkin, A; Glabe, CG; Cribbs, DH; Agadjanyan, MG				Mamikonyan, Grigor; Necula, Mihaela; Mkrtichyan, Mikayel; Ghochikyan, Anahit; Petrushina, Irina; Movsesyan, Nina; Mina, Erene; Kiyatkin, Anatoly; Glabe, Charles G.; Cribbs, David H.; Agadjanyan, Michael G.			Anti-A beta(1-11) antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; TRIPLE-TRANSGENIC MODEL; TAU-FILAMENT FORMATION; ALZHEIMERS-DISEASE; A-BETA; MOUSE MODEL; ALPHA-SYNUCLEIN; IN-VITRO; IMMUNIZATION AN1792; COGNITIVE DECLINE	Different strategies proposed as therapy for Alzheimer disease (AD) have aimed to reduce the level of toxic forms of A beta peptide in the brain. Here, we directly analyze the therapeutic utility of the polyclonal anti-A beta(1-11) antibody induced in 3xTg-AD mice vaccinated with the second generation prototype epitope vaccine. Substoichiometric concentrations of purified anti-A beta(1-11) antibody prevented aggregation of A beta(42) and induced disaggregation of preformed A beta(42) fibrils down to non-filamentous and nontoxic species. Anti-A beta(1-11) antibody delayed A beta(42) oligomer formation but ultimately appeared to stabilize nonfibrillar conformations, including oligomer-like assemblies. The reduced oligomer-mediated cytotoxicity observed upon preincubation of A beta oligomers with the anti-A beta(1-11) antibody in the absence of oligomer disaggregation suggests a possible oligomer rearrangement in the presence of the antibody. These in vitro observations suggest that preventive vaccination may protect from AD or may delay the onset of the disease, whereas therapeutic vaccination cannot disrupt the toxic oligomers and may only minimally alleviate preexisting AD pathology.	Inst Mol Med, Dept Immunol, Huntington Beach, CA 92647 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA; Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19115 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Jefferson University	Agadjanyan, MG (corresponding author), Inst Mol Med, Dept Immunol, Huntington Beach, CA 92647 USA.	magadjanyan@immed.org	Kiyatkin, Anatoly/A-8707-2009	Kiyatkin, Anatoly/0000-0002-5060-6081; Ghochikyan, Anahit/0000-0001-5436-0616	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050895, R01NS031230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020241] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG020241, R01 AG020241-05, R01 AG20241] Funding Source: Medline; NINDS NIH HHS [NS3I230, R01 NS050895, R01 NS050895-02, R01 NS031230-07, R01 NS50895, R01 NS031230] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agadjanyan MG, 2005, J IMMUNOL, V174, P1580, DOI 10.4049/jimmunol.174.3.1580; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bayer AJ, 2005, NEUROLOGY, V64, P94, DOI 10.1212/01.WNL.0000148604.77591.67; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Chirita C, 2004, BIOCHEMISTRY-US, V43, P2879, DOI 10.1021/bi036094h; Chirita CN, 2004, BIOCHEMISTRY-US, V43, P1704, DOI 10.1021/bi036034b; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cribbs DH, 2003, INT IMMUNOL, V15, P505, DOI 10.1093/intimm/dxg049; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Fox NC, 2005, NEUROLOGY, V64, P1563, DOI 10.1212/01.WNL.0000159743.08996.99; Frenkel D, 2000, P NATL ACAD SCI USA, V97, P11455, DOI 10.1073/pnas.97.21.11455; Ghochikyan A, 2003, EUR J IMMUNOL, V33, P3232, DOI 10.1002/eji.200324000; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hock C, 2002, NAT MED, V8, P1270, DOI 10.1038/nm783; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Legleiter J, 2004, J MOL BIOL, V335, P997, DOI 10.1016/j.jmb.2003.11.019; Lemere CA, 2004, AM J PATHOL, V165, P283, DOI 10.1016/S0002-9440(10)63296-8; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Naiki H, 1998, BIOCHEMISTRY-US, V37, P17882, DOI 10.1021/bi980550y; Necula M, 2005, BIOCHEMISTRY-US, V44, P10227, DOI 10.1021/bi050387o; Necula M, 2003, J BIOL CHEM, V278, P46674, DOI 10.1074/jbc.M308231200; Nicoll JAR, 2004, NEUROBIOL AGING, V25, P589, DOI 10.1016/j.neurobiolaging.2004.02.003; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Oddo S, 2006, J BIOL CHEM, V281, P39413, DOI 10.1074/jbc.M608485200; Patton RL, 2006, AM J PATHOL, V169, P1048, DOI 10.2353/ajpath.2006.060269; Petrushina I, 2003, NEUROSCI LETT, V338, P5, DOI 10.1016/S0304-3940(02)01357-5; PRICE DL, 1994, ANNU REV MED, V45, P435; Racke MM, 2005, J NEUROSCI, V25, P629, DOI 10.1523/JNEUROSCI.4337-04.2005; Schenk D, 2004, CURR OPIN IMMUNOL, V16, P599, DOI 10.1016/j.coi.2004.07.012; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Solomon B, 1996, P NATL ACAD SCI USA, V93, P452, DOI 10.1073/pnas.93.1.452; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Zhu M, 2004, J BIOL CHEM, V279, P26846, DOI 10.1074/jbc.M403129200; Zlokovic BV, 2005, TRENDS NEUROSCI, V28, P202, DOI 10.1016/j.tins.2005.02.001	68	84	100	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22376	22386		10.1074/jbc.M700088200	http://dx.doi.org/10.1074/jbc.M700088200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17545160	Green Accepted, hybrid			2022-12-25	WOS:000248354200016
J	Wang, MD; Franklin, V; Sundaram, M; Kiss, RS; Ho, K; Gallant, M; Marcel, YL				Wang, Ming-Dong; Franklin, Vivian; Sundaram, Meenakshi; Kiss, Robert S.; Ho, Kenneth; Gallant, Michel; Marcel, Yves L.			Differential regulation of ATP binding cassette protein A1 expression and apoA-I lipidation by Niemann-Pick type C1 in murine hepatocytes and macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A1-MEDIATED CHOLESTEROL EFFLUX; CATHEPSIN-D; TRANSPORTER A1; DISEASE; TRAFFICKING; MOUSE; IDENTIFICATION; ESTER; GENE; HYPOALPHALIPOPROTEINEMIA	Niemann-Pick type C1 (Npc1) protein inactivation results in lipid accumulation in late endosomes and lysosomes, leading to a defect of ATP binding cassette protein A1 (Abca1)-mediated lipid efflux to apolipoprotein A-I (apoA-I) in macrophages and fibroblasts. However, the role of Npc1 in Abca1-mediated lipid efflux to apoA-I in hepatocytes, the major cells contributing to HDL formation, is still unknown. Here we show that, whereas lipid efflux to apoA-I in Npc1 null macrophages is impaired, the lipidation of endogenously synthesized apoA-I by low density lipoprotein-derived cholesterol or de novo synthesized cholesterol or phospholipids in Npc1-null hepatocytes is significantly increased by about 1-, 3-, and 8- fold, respectively. The increased cholesterol efflux reflects a major increase of Abca1 protein in Npc1- null hepatocytes, which contrasts with the decrease observed in Npc1- null macrophages. The increased Abca1 expression is largely post-transcriptional, because Abca1 mRNA is only slightly increased and Lxr alpha mRNA is not changed, and Lxr alpha target genes are reduced. This differs from the regulation of Abcg1 expression, which is up-regulated at both mRNA and protein levels in Npc1- null cells. Abca1 protein translation rate is higher in Npc1- null hepatocytes, compared with wild type hepatocytes as measured by [S-35] methionine incorporation, whereas there is no difference for the degradation of newly synthesized Abca1 in these two types of hepatocytes. Cathepsin D, which we recently identified as a positive modulator of Abca1, is markedly increased at both mRNA and protein levels by Npc1 inactivation in hepatocytes but not in macrophages. Consistent with this, inhibition of cathepsin D with pepstatin A reduced the Abca1 protein level in both Npc1- inactivated and WT hepatocytes. Therefore, Abca1 expression is specifically regulated in hepatocytes, where Npc1 activity modulates cathepsin D expression and Abca1 protein translation rate.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Microbiol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Immunol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Pathol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Lab Med, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Marcel, YL (corresponding author), 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	ylmarcel@ottawaheart.ca						Amigo L, 2002, HEPATOLOGY, V36, P819, DOI 10.1053/jhep.2002.35617; ANSORGE S, 1984, BIOMED BIOCHIM ACTA, V43, P1213; Bergeron J, 1997, BBA-LIPID LIPID MET, V1344, P139, DOI 10.1016/S0005-2760(96)00136-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boadu E, 2006, J BIOL CHEM, V281, P37081, DOI 10.1074/jbc.M606890200; Burgess JW, 2002, J BIOL CHEM, V277, P31318, DOI 10.1074/jbc.M204200200; Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656; Chang TY, 2005, J BIOL CHEM, V280, P20917, DOI 10.1074/jbc.R400040200; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; Costet P, 2000, J BIOL CHEM, V275, P28240; Erickson RP, 2005, AM J PHYSIOL-GASTR L, V289, pG300, DOI 10.1152/ajpgi.00568.2004; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; Haidar B, 2006, J BIOL CHEM, V281, P39971, DOI 10.1074/jbc.M605095200; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Imrie J, 2007, J INHERIT METAB DIS, V30, P51, DOI 10.1007/s10545-006-0384-7; Isoda K, 2007, ATHEROSCLEROSIS, V192, P298, DOI 10.1016/j.atherosclerosis.2006.07.023; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Kiss RS, 2003, J BIOL CHEM, V278, P10119, DOI 10.1074/jbc.M300137200; Kiss RS, 2005, J LIPID RES, V46, P1877, DOI 10.1194/jlr.M400482-JLR200; Kiss RS, 2006, J BIOL CHEM, V281, P12081, DOI 10.1074/jbc.M600621200; Kulinski A, 2007, J BIOL CHEM, V282, P1627, DOI 10.1074/jbc.M610001200; LANGE Y, 1994, J BIOL CHEM, V269, P3411; Le Goff W, 2006, ARTERIOSCL THROM VAS, V26, P527, DOI 10.1161/01.ATV.0000201042.00725.84; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; Liscum L, 2004, BBA-MOL CELL BIOL L, V1685, P22, DOI 10.1016/j.bbalip.2004.08.008; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MARCEL YL, 1987, J LIPID RES, V28, P768; Mari M, 2006, CELL METAB, V4, P185, DOI 10.1016/j.cmet.2006.07.006; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MAZZONE T, 1995, J LIPID RES, V36, P544; Mukhejee S, 2004, BBA-MOL CELL BIOL L, V1685, P28, DOI 10.1016/j.bbalip.2004.08.009; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Okuhira K, 2005, J BIOL CHEM, V280, P39653, DOI 10.1074/jbc.M510187200; Ory DS, 2004, TRENDS CARDIOVAS MED, V14, P66, DOI 10.1016/j.tcm.2003.12.003; Pentchev PG, 2004, BBA-MOL CELL BIOL L, V1685, P3, DOI 10.1016/j.bbalip.2004.08.005; Schmitz G, 2005, BBA-MOL CELL BIOL L, V1735, P1, DOI 10.1016/j.bbalip.2005.04.004; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Sevin M, 2007, BRAIN, V130, P120, DOI 10.1093/brain/awl260; Singaraja RR, 2006, ARTERIOSCL THROM VAS, V26, P1821, DOI 10.1161/01.ATV.0000229219.13757.a2; Sun Y, 2003, J BIOL CHEM, V278, P5813, DOI 10.1074/jbc.M208687200; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; Vainio S, 2005, BIOCHEM J, V391, P465, DOI 10.1042/BJ20050460; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang M, 2007, J LIPID RES, V48, P633, DOI 10.1194/jlr.M600470-JLR200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Witting SR, 2003, J BIOL CHEM, V278, P40121, DOI 10.1074/jbc.M305193200; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992; Yerushalmi B, 2002, J PEDIATR GASTR NUTR, V35, P44, DOI 10.1097/00005176-200207000-00011; Zhao B, 2007, AM J PHYSIOL-CELL PH, V292, pC405, DOI 10.1152/ajpcell.00306.2006; Zheng H, 2005, J BIOL CHEM, V280, P21612, DOI 10.1074/jbc.m502200200	58	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22525	10.1074/jbc.M700326200	http://dx.doi.org/10.1074/jbc.M700326200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553802	hybrid			2022-12-25	WOS:000248354200030
J	Lee, NY; Blobe, GC				Lee, Nam Y.; Blobe, Gerard C.			The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR-RESPONSES; RECEPTOR SYSTEM; PROTEIN-KINASE; III RECEPTOR; ARRESTINS; ANGIOGENESIS; ENDOCYTOSIS; DOMAIN; ROLES; SMAD	In endothelial cells, transforming growth factor beta (TGF-beta) signals through two distinct pathways to regulate endothelial cell proliferation and migration, the ALK-1/Smads 1/5/8 pathway and the ALK-5/Smads 2/3 pathway. TGF-beta signaling through these pathways is further regulated in endothelial cells by the endothelial specific TGF-beta superfamily co-receptor, endoglin. The importance of endoglin, ALK-1, and ALK-5 in endothelial biology is underscored by the embryonic lethal phenotypes of knock-outs in mice due to defects in angiogenesis, and by the presence of disease-causing mutations in these genes in human vascular diseases. However, the mechanism of action of endoglin is not well defined. Here we define a novel interaction between endoglin and the scaffolding protein beta-arrestin2. Both co-immunoprecipitation and fluorescence confocal studies demonstrate the specific interaction between endoglin and beta-arrestin2 in endothelial cells, enhanced by ALK-1 and to a lesser extent by the type II TGF-beta receptor. The endoglin/beta-arrestin2 interaction results in endoglin internalization and co-accumulation of endoglin and beta-arrestin2 in endocytic vesicles. Whereas endoglin did not have a direct impact on either Smad 2/3 or Smad 1/5/8 activation, endoglin antagonized TGF-beta-mediated ERK signaling, altered the subcellular distribution of activated ERK, and inhibited endothelial cell migration in a manner dependent on the ability of endoglin to interact with beta-arrestin2. Reciprocally, small interfering RNA-mediated silencing of endogenous beta-arrestin2 expression restored TGF-beta-mediated ERK activation and increased endothelial cell migration in an endoglin-dependent manner. These studies define a novel function for endoglin, and further expand the roles mediated by the ubiquitous scaffolding protein beta-arrestin2.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med, 221B MSRB Res Dr,Box 2631, Durham, NC 27710 USA.	blobe001@mc.duke.edu	Lee, Nam/H-3073-2016; Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NCI NIH HHS [R01-CA105255] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105255] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Koleva RI, 2006, J BIOL CHEM, V281, P25110, DOI 10.1074/jbc.M601288200; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; LENORMAND P, 1993, ADV SEC MESS PHOSPH, V28, P237; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Luttrell LM, 2002, J CELL SCI, V115, P455; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Pece-Barbara N, 2005, J BIOL CHEM, V280, P27800, DOI 10.1074/jbc.M503471200; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang X, 1999, DEVELOPMENT, V126, P1571	43	65	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21507	21517		10.1074/jbc.M700176200	http://dx.doi.org/10.1074/jbc.M700176200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17540773	hybrid			2022-12-25	WOS:000248047500078
J	Yamamoto, H; Kawada, M; Takeda, A; Igarashi, H; Matano, T				Yamamoto, Hiroyuki; Kawada, Miki; Takeda, Akiko; Igarashi, Hiroko; Matano, Tetsuro			Post-Infection Immunodeficiency Virus Control by Neutralizing Antibodies	PLOS ONE			English	Article								Background. Unlike most acute viral infections controlled with the appearance of virus-specific neutralizing antibodies (NAbs), primary HIV infections are not met with such potent and early antibody responses. This brings into question if or how the presence of potent antibodies can contribute to primary HIV control, but protective efficacies of antiviral antibodies in primary HIV infections have remained elusive; and, it has been speculated that even NAb induction could have only a limited suppressive effect on primary HIV replication once infection is established. Here, in an attempt to answer this question, we examined the effect of passive NAb immunization post-infection on primary viral replication in a macaque AIDS model. Methods and Findings. The inoculums for passive immunization with simian immunodeficiency virus mac239 (SIVmac239)-specific neutralizing activity were prepared by purifying polyclonal immunoglobulin G from pooled plasma of six SIVmac239-infected rhesus macaques with NAb induction in the chronic phase. Passive immunization of rhesus macaques with the NAbs at day 7 after SIVmac239 challenge resulted in significant reduction of set-point plasma viral loads and preservation of central memory CD4 T lymphocyte counts, despite the limited detection period of the administered NAb responses. Peripheral lymph node dendritic cell (DC)-associated viral RNA loads showed a remarkable peak with the NAb administration, and DCs stimulated in vitro with NAb-preincubated SIV activated virus-specific CD4 T lymphocytes in an Fc-dependent manner, implying antibody-mediated virion uptake by DCs and enhanced T cell priming. Conclusions. Our results present evidence indicating that potent antibody induction post-infection can result in primary immunodeficiency virus control and suggest direct and indirect contribution of its absence to initial control failure in HIV infections. Although difficulty in achieving requisite neutralizing titers for sterile HIV protection by prophylactic vaccination has been suggested, this study points out a possibility of non-sterile HIV control by prophylactic vaccine-induced, sub-sterile titers of NAbs post-infection, providing a rationale of vaccine-based NAb induction for primary HIV control.	[Yamamoto, Hiroyuki; Kawada, Miki; Takeda, Akiko; Matano, Tetsuro] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Tokyo, Japan; [Yamamoto, Hiroyuki; Kawada, Miki; Igarashi, Hiroko; Matano, Tetsuro] Univ Tokyo, Grad Sch Med, Tokyo, Japan; [Matano, Tetsuro] Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan; [Matano, Tetsuro] Natl Inst Biomed Innovat, Tsukuba Primate Res Ctr, Ibaraki, Japan	University of Tokyo; University of Tokyo; National Institute of Infectious Diseases (NIID); National Institute of Health Sciences - Japan	Matano, T (corresponding author), Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Tokyo, Japan.	matano@m.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology; Japan Health Sciences Foundation; Ministry of Health, Labor, and Welfare in Japan	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Health Sciences Foundation; Ministry of Health, Labor, and Welfare in Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported by a grant from the Ministry of Education, Culture, Sports, Science, and Technology, grants from the Japan Health Sciences Foundation, and grants from the Ministry of Health, Labor, and Welfare in Japan.	Arguello JR, 1998, TISSUE ANTIGENS, V52, P57, DOI 10.1111/j.1399-0039.1998.tb03024.x; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Castellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825; CHAKRABARTI L, 1994, AM J PATHOL, V144, P1226; Eitner F, 2000, AM J PATHOL, V156, P1197, DOI 10.1016/S0002-9440(10)64990-5; Frankel SS, 1998, J VIROL, V72, P9788, DOI 10.1128/JVI.72.12.9788-9794.1998; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; Hangartner L, 2006, NAT REV IMMUNOL, V6, P231, DOI 10.1038/nri1783; Huber M, 2006, PLOS MED, V3, P2078, DOI 10.1371/journal.pmed.0030441; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kawada M, 2006, J VIROL, V80, P1949, DOI 10.1128/JVI.80.4.1949-1958.2006; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Lore K, 2005, J EXP MED, V201, P2023, DOI 10.1084/jem.20042413; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Matano T, 2004, J EXP MED, V199, P1709, DOI 10.1084/jem.20040432; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Nishimura Y, 2004, P NATL ACAD SCI USA, V101, P12324, DOI 10.1073/pnas.0404620101; Nishimura Y, 2003, P NATL ACAD SCI USA, V100, P15131, DOI 10.1073/pnas.2436476100; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Picker LJ, 2005, NAT IMMUNOL, V6, P430, DOI 10.1038/ni0505-430; Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schuurhuis DH, 2002, J IMMUNOL, V168, P2240, DOI 10.4049/jimmunol.168.5.2240; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Thomas PG, 2006, P NATL ACAD SCI USA, V103, P2764, DOI 10.1073/pnas.0511185103; Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470	39	38	41	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e540	10.1371/journal.pone.0000540	http://dx.doi.org/10.1371/journal.pone.0000540			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579714	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451700008
J	Tian, KG; Yu, XL; Zhao, TZ; Feng, YJ; Cao, Z; Wang, CB; Hu, Y; Chen, XZ; Hu, DM; Tian, XS; Liu, D; Zhang, SO; Deng, XY; Ding, YQ; Yang, L; Zhang, YX; Xiao, HX; Qiao, MM; Wang, B; Hou, LL; Wang, XY; Yang, XY; Kang, LP; Sun, M; Jin, P; Wang, SJ; Kitamura, Y; Yan, JH; Gao, GF				Tian, Kegong; Yu, Xiuling; Zhao, Tiezhu; Feng, Youjun; Cao, Zhen; Wang, Chuanbin; Hu, Yan; Chen, Xizhao; Hu, Dongmei; Tian, Xinsheng; Liu, Di; Zhang, Shuo; Deng, Xiaoyu; Ding, Yinqiao; Yang, Lu; Zhang, Yunxia; Xiao, Haixia; Qiao, Mingming; Wang, Bin; Hou, Lili; Wang, Xiaoying; Yang, Xinyan; Kang, Liping; Sun, Ming; Jin, Ping; Wang, Shujuan; Kitamura, Yoshihiro; Yan, Jinghua; Gao, George F.			Emergence of Fatal PRRSV Variants: Unparalleled Outbreaks of Atypical PRRS in China and Molecular Dissection of the Unique Hallmark	PLOS ONE			English	Article							RESPIRATORY SYNDROME VIRUS; PORCINE EPIDEMIC ABORTION; MYSTERY SWINE DISEASE; CDNA INFECTIOUS CLONE; NORTH-AMERICAN; LELYSTAD VIRUS; GENOMIC CHARACTERIZATION; GENETIC-VARIATION; PROTEIN; VIRULENT	Porcine reproductive and respiratory syndrome (PRRS) is a severe viral disease in pigs, causing great economic losses worldwide each year. The causative agent of the disease, PRRS virus (PRRSV), is a member of the family Arteriviridae. Here we report our investigation of the unparalleled large-scale outbreaks of an originally unknown, but so-called ``high fever'' disease in China in 2006 with the essence of PRRS, which spread to more than 10 provinces (autonomous cities or regions) and affected over 2,000,000 pigs with about 400,000 fatal cases. Different from the typical PRRS, numerous adult sows were also infected by the ``high fever'' disease. This atypical PRRS pandemic was initially identified as a hog cholera-like disease manifesting neurological symptoms (e. g., shivering), high fever (40-42 degrees C), erythematous blanching rash, etc. Autopsies combined with immunological analyses clearly showed that multiple organs were infected by highly pathogenic PRRSVs with severe pathological changes observed. Whole-genome analysis of the isolated viruses revealed that these PRRSV isolates are grouped into Type II and are highly homologous to HB-1, a Chinese strain of PRRSV (96.5% nucleotide identity). More importantly, we observed a unique molecular hallmark in these viral isolates, namely a discontinuous deletion of 30 amino acids in nonstructural protein 2 (NSP2). Taken together, this is the first comprehensive report documenting the 2006 epidemic of atypical PRRS outbreak in China and identifying the 30 amino-acid deletion in NSP2, a novel determining factor for virulence which may be implicated in the high pathogenicity of PRRSV, and will stimulate further study by using the infectious cDNA clone technique.	[Tian, Kegong; Yu, Xiuling; Zhao, Tiezhu; Cao, Zhen; Wang, Chuanbin; Hu, Yan; Chen, Xizhao; Hu, Dongmei; Zhang, Shuo; Deng, Xiaoyu; Ding, Yinqiao; Yang, Lu; Zhang, Yunxia; Qiao, Mingming; Wang, Bin; Hou, Lili; Wang, Xiaoying; Yang, Xinyan; Kang, Liping; Sun, Ming; Jin, Ping] China Anim Dis Control Ctr, Beijing, Peoples R China; [Feng, Youjun; Tian, Xinsheng; Liu, Di; Xiao, Haixia; Wang, Shujuan; Kitamura, Yoshihiro; Yan, Jinghua; Gao, George F.] Chinese Acad Sci, Inst Microbiol, Ctr Mol Immunol, Beijing, Peoples R China; [Feng, Youjun; Tian, Xinsheng; Xiao, Haixia] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China; [Zhang, Yunxia; Qiao, Mingming; Wang, Bin; Hou, Lili; Wang, Shujuan] China Agr Univ, Coll Vet Med, Beijing 100094, Peoples R China; [Kitamura, Yoshihiro; Gao, George F.] Chinese Acad Sci, Inst Microbiol, China Japan Joint Lab Mol Immunol & Mol Microbiol, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; China Agricultural University; Chinese Academy of Sciences; Institute of Microbiology, CAS	Tian, KG (corresponding author), China Anim Dis Control Ctr, Beijing, Peoples R China.	tiankg@263.net; gaof@im.ac.cn	Gao, George Fu/ABD-5229-2021; Feng, Youjun/E-8386-2010; Liu, Di/ABD-2729-2021; Xiao, Haixia/AAZ-3374-2020; Liu, Di/G-6135-2014; yang, xin/HGU-9981-2022; Feng, Youjun/I-4134-2012	Liu, Di/0000-0003-3693-2726; Xiao, Haixia/0000-0003-0032-5430; Liu, Di/0000-0003-3693-2726; 	National Basic Research Program of China [2005CB523001]; National Key Technologies RD Programs [2006BAD06A04, 2006BAD06A01]; Natural Science Foundation in Beijing [5062028]; Japan MEXT (Ministry of Education, Culture, Sports, Science and Technology); National Natural Science Foundation of China [30525010]	National Basic Research Program of China(National Basic Research Program of China); National Key Technologies RD Programs(National Key Technology R&D Program); Natural Science Foundation in Beijing; Japan MEXT (Ministry of Education, Culture, Sports, Science and Technology)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Basic Research Program (Project 973) of China (2005CB523001), National Key Technologies R&D Programs (2006BAD06A04 & 2006BAD06A01) and Natural Science Foundation in Beijing (5062028). The China-Japan Joint Laboratory of Molecular Immunology and Molecular Microbiology is, in part, supported by Japan MEXT (Ministry of Education, Culture, Sports, Science and Technology). GEG is a distinguised young investigator of National Natural Science Foundation of China (NSFC) (Grant No.30525010).	Albina E, 1997, VET MICROBIOL, V55, P309, DOI 10.1016/S0378-1135(96)01322-3; Allende R, 1999, J GEN VIROL, V80, P307, DOI 10.1099/0022-1317-80-2-307; Blaha T, 2000, VET RES, V31, P77, DOI 10.1051/vetres:2000058; Botner A, 1999, VET MICROBIOL, V68, P187, DOI 10.1016/S0378-1135(99)00053-X; Botner A, 1997, VET REC, V141, P497, DOI 10.1136/vr.141.19.497; BROUWER J, 1994, VET QUART, V16, P95, DOI 10.1080/01652176.1994.9694427; Cavanagh D, 1997, ARCH VIROL, V142, P629; Chen J, 2006, BIOCHEM GENET, V44, P425, DOI 10.1007/s10528-006-9039-9; Dea S, 2000, ARCH VIROL, V145, P659, DOI 10.1007/s007050050662; Done SH, 1996, BRIT VET J, V152, P153, DOI 10.1016/S0007-1935(96)80071-6; ELAZHARY Y, 1991, VET REC, V129, P495, DOI 10.1136/vr.129.22.495-b; Faaberg KS, 2006, ADV EXP MED BIOL, V581, P73; Fang Y, 2004, VIRUS RES, V100, P229, DOI 10.1016/j.virusres.2003.12.026; Fang Y, 2006, ADV EXP MED BIOL, V581, P605; Fang Y, 2006, J VIROL, V80, P11447, DOI 10.1128/JVI.01032-06; GALINA L, 1994, VET REC, V134, P60, DOI 10.1136/vr.134.3.60; Gao ZQ, 2004, ARCH VIROL, V149, P1341, DOI 10.1007/s00705-004-0292-0; Grebennikova TV, 2004, VIROLOGY, V321, P383, DOI 10.1016/j.virol.2004.01.001; Han J, 2006, VIRUS RES, V122, P175, DOI 10.1016/j.virusres.2006.06.003; Hermann J, 2007, VET RES, V38, P81, DOI 10.1051/vetres:2006044; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Johnson W, 2004, VET IMMUNOL IMMUNOP, V102, P233, DOI 10.1016/j.vetimm.2004.09.010; Key KF, 2001, VET MICROBIOL, V83, P249, DOI 10.1016/S0378-1135(01)00427-8; Kwon B, 2006, VACCINE, V24, P7071, DOI 10.1016/j.vaccine.2006.07.010; Li H, 2003, VET MICROBIOL, V95, P295, DOI 10.1016/S0378-1135(03)00158-5; Mateu E, 2006, VIRUS RES, V115, P198, DOI 10.1016/j.virusres.2005.09.008; MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008; MURAKAMI Y, 1994, J VET MED SCI, V56, P891, DOI 10.1292/jvms.56.891; MURTAUGH MP, 1995, ARCH VIROL, V140, P1451, DOI 10.1007/BF01322671; Nelsen CJ, 1999, J VIROL, V73, P270, DOI 10.1128/JVI.73.1.270-280.1999; Nelson E A, 1995, Adv Exp Med Biol, V380, P321; NELSON EA, 1993, J CLIN MICROBIOL, V31, P3184, DOI 10.1128/JCM.31.12.3184-3189.1993; Nielsen HS, 2003, J VIROL, V77, P3702, DOI 10.1128/JVI.77.6.3702-3711.2003; Nielsen HS, 2001, J GEN VIROL, V82, P1263, DOI 10.1099/0022-1317-82-6-1263; Nielsen J, 2002, VET MICROBIOL, V84, P1, DOI 10.1016/S0378-1135(01)00450-3; Nodelijk G, 2003, PREV VET MED, V60, P37, DOI 10.1016/S0167-5877(03)00081-3; PATON DJ, 1991, VET REC, V128, P617, DOI 10.1136/vr.128.26.617; Pesch S, 2005, VET MICROBIOL, V107, P31, DOI 10.1016/j.vetmic.2005.01.028; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Schommer SK, 2006, ADV EXP MED BIOL, V581, P435; Shen S, 2000, ARCH VIROL, V145, P871, DOI 10.1007/s007050050680; SHIMIZU M, 1994, J VET MED SCI, V56, P389, DOI 10.1292/jvms.56.389; Stadejek T, 2002, J GEN VIROL, V83, P1861, DOI 10.1099/0022-1317-83-8-1861; Storgaard T, 1999, ARCH VIROL, V144, P2389, DOI 10.1007/s007050050652; Suarez P, 2000, VET RES, V31, P47, DOI 10.1051/vetres:2000056; TANG J, 2006, PLOS MED, V3; Thiel H J, 1993, Arch Virol Suppl, V7, P41; Wasilk A, 2004, J CLIN MICROBIOL, V42, P4453, DOI 10.1128/JCM.42.10.4453-4461.2004; WENSVOORT G, 1993, VET RES, V24, P117; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Yang L, 1999, ARCH VIROL, V144, P525, DOI 10.1007/s007050050523; Yang L, 2000, ARCH VIROL, V145, P1599, DOI 10.1007/s007050070079; Yoshii M, 2005, ARCH VIROL, V150, P2313, DOI 10.1007/s00705-005-0549-2; Zimmerman JJ, 1997, VET MICROBIOL, V55, P187, DOI 10.1016/S0378-1135(96)01330-2	54	730	914	5	94	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e526	10.1371/journal.pone.0000526	http://dx.doi.org/10.1371/journal.pone.0000526			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565379	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451600014
J	Balcan, D; Kabakcioglu, A; Mungan, M; Erzan, A				Balcan, Duygu; Kabakcioglu, Alkan; Mungan, Muhittin; Erzan, Ayse			The Information Coded in the Yeast Response Elements Accounts for Most of the Topological Properties of Its Transcriptional Regulation Network	PLOS ONE			English	Article								The regulation of gene expression in a cell relies to a major extent on transcription factors, proteins which recognize and bind the DNA at specific binding sites (response elements) within promoter regions associated with each gene. We present an information theoretic approach to modeling transcriptional regulatory networks, in terms of a simple "sequence-matching" rule and the statistics of the occurrence of binding sequences of given specificity in random promoter regions. The crucial biological input is the distribution of the amount of information coded in these cognate response elements and the length distribution of the promoter regions. We provide an analysis of the transcriptional regulatory network of yeast Saccharomyces cerevisiae, which we extract from the available databases, with respect to the degree distributions, clustering coefficient, degree correlations, rich-club coefficient and the k-core structure. We find that these topological features are in remarkable agreement with those predicted by our model, on the basis of the amount of information coded in the interaction between the transcription factors and response elements.	[Balcan, Duygu; Erzan, Ayse] Istanbul Tech Univ, Dept Phys, Fac Sci & Letters, TR-80626 Istanbul, Turkey; [Kabakcioglu, Alkan] Koc Univ, Dept Phys, Fac Arts & Sci, Istanbul, Turkey; [Mungan, Muhittin] Bogazici Univ, Dept Phys, Fac Arts & Sci, Istanbul, Turkey; [Mungan, Muhittin; Erzan, Ayse] Gursey Inst, Istanbul, Turkey	Istanbul Technical University; Koc University; Bogazici University; Bogazici University; Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)	Balcan, D (corresponding author), Istanbul Tech Univ, Dept Phys, Fac Sci & Letters, TR-80626 Istanbul, Turkey.	balcand@indiana.edu	Mungan, Muhittin/M-7991-2015	Mungan, Muhittin/0000-0002-0352-5422; Kabakcioglu, Alkan/0000-0002-9831-3632	Turkish Academy of Sciences	Turkish Academy of Sciences(Turkish Academy of Sciences)	AE is grateful for partial support from the Turkish Academy of Sciences.	Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; ALBERTS B, 2002, MOL BIOL CELL, pCH9; Almirantis Y, 1999, J STAT PHYS, V97, P233, DOI 10.1023/A:1004671119400; Balcan D, 2004, EUR PHYS J B, V38, P253, DOI 10.1140/epjb/e2004-00055-7; Banzhaf Wolfgang, 2004, Journal of Biological Physics and Chemistry, V4, P85, DOI 10.4024/2040405.jbpc.04.02; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bergmann S, 2004, PLOS BIOL, V2, P85, DOI 10.1371/journal.pbio.0020009; Bollobas B., 1998, MODERN GRAPH THEORY; Caldarelli G, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.258702; CARMI S, 2006, CONDMAT0601240ARXIV; Colizza V, 2006, NAT PHYS, V2, P110, DOI 10.1038/nphys209; Colizza V, 2005, PHYSICA A, V352, P1, DOI 10.1016/j.physa.2004.12.030; Dobrin R, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-10; Dorogovtsev SN, 2002, ADV PHYS, V51, P1079, DOI 10.1080/00018730110112519; GEARD N, 2003, P 2003 C EV COMP CEC; Guelzim N, 2002, NAT GENET, V31, P60, DOI 10.1038/ng873; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Huang Sui, 2004, Briefings in Functional Genomics & Proteomics, V2, P279, DOI 10.1093/bfgp/2.4.279; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Ihmels J, 2004, NAT BIOTECHNOL, V22, P86, DOI 10.1038/nbt918; Kauffman S, 2004, J THEOR BIOL, V230, P581, DOI 10.1016/j.jtbi.2003.12.017; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; KINIKOGLU B, 2006, IDENTIFYING PE UNPUB; KLEFFE J, 1992, COMPUT APPL BIOSCI, V8, P433; KULLBACK S, 1951, ANN MATH STAT, V22, P79, DOI 10.1214/aoms/1177729694; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Luscombe NM, 2004, NATURE, V431, P308, DOI 10.1038/nature02782; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; MOLLOY M, 1995, RANDOM STRUCT ALGOR, V6, P161, DOI 10.1002/rsa.3240060204; Mungan M, 2005, J PHYS A-MATH GEN, V38, P9599, DOI 10.1088/0305-4470/38/44/001; Pastor-Satorras R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.258701; Perelson AS, 1997, REV MOD PHYS, V69, P1219, DOI 10.1103/RevModPhys.69.1219; Reil T, 1999, LECT NOTES ARTIF INT, V1674, P457; SHANNON CE, 1949, P IRE, V37, P10, DOI 10.1109/JRPROC.1949.232969; SOLE RV, 2002, HDB GRAPHS NETWORKS; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Teixeira MC, 2006, NUCLEIC ACIDS RES, V34, pD446, DOI 10.1093/nar/gkj013; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; van Noort V, 2004, EMBO REP, V5, P280, DOI 10.1038/sj.embor.7400090; Vazquez A, 2004, P NATL ACAD SCI USA, V101, P17940, DOI 10.1073/pnas.0406024101; WAGNER A, 1994, P NATL ACAD SCI USA, V91, P4387, DOI 10.1073/pnas.91.10.4387; Wagner A, 2001, MOL BIOL EVOL, V18, P1283, DOI 10.1093/oxfordjournals.molbev.a003913; Watson J, 2004, BIOSYSTEMS, V76, P239, DOI 10.1016/j.biosystems.2004.05.016; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Zhou S, 2004, IEEE COMMUN LETT, V8, P180, DOI 10.1109/LCOMM.2004.823426	48	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e501	10.1371/journal.pone.0000501	http://dx.doi.org/10.1371/journal.pone.0000501			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551581	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451500010
J	Levine, SM; Lin, EA; Emara, W; Kang, J; DiBenedetto, M; Ando, T; Falush, D; Blaser, MJ				Levine, Steven M.; Lin, Edward A.; Emara, Walid; Kang, Josephine; DiBenedetto, Michael; Ando, Takafumi; Falush, Daniel; Blaser, Martin J.			Plastic cells and populations: DNA substrate characteristics in Helicobacter pylori transformation define a flexible but conservative system for genomic variation	FASEB JOURNAL			English	Article						bacterial genetics; microbiology; pathogenesis; molecular biology; colonization; microbial diversity	RESTRICTION-MODIFICATION SYSTEMS; NATURAL TRANSFORMATION; GENETIC-TRANSFORMATION; HEMOPHILUS-INFLUENZAE; MISMATCH-REPAIR; STREPTOCOCCUS-PNEUMONIAE; SALMONELLA-TYPHIMURIUM; NEISSERIA-GONORRHOEAE; MOLECULAR-MECHANISMS; GASTRIC COLONIZATION	Helicobacter pylori, bacteria that colonize the human gastric mucosa, are naturally competent for transformation by exogenous DNA, and show a panmictic population structure. To understand the mechanisms involved in its horizontal gene transfer, we sought to define the interval required from exposure to substrate DNA until DNA uptake and expression of a selectable phenotype, as well as the relationship of transforming fragment length, concentration, homology, symmetry, and strandedness, to the transformation frequency. We provide evidence that natural transformation in H. pylori differs in efficiency among wild-type strains but is saturable and varies with substrate DNA length, symmetry, strandedness, and species origin. We show that H. pylori cells can be transformed within one minute of contact with DNA, by DNA fragments as small as 50 bp, and as few as 5 bp on one flank of a selectable single nucleotide mutation is sufficient substrate for recombination of a transforming fragment, and that double-stranded DNA is the preferred (1000-fold > single-stranded) substrate. The high efficiency of double-stranded DNA as transformation substrate, in conjunction with strain-specific restriction endonucleases suggests a model of short-fragment recombination favoring closest relatives, consistent with the observed H. pylori population biology.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Nagoya, Aichi, Japan; Peter Medawar Bldg Pathogen Res, Dept Stat, Oxford, England	New York University; New York University; Nagoya University; University of Oxford	Blaser, MJ (corresponding author), NYU, Sch Med, Dept Med, 550 1st Ave, New York, NY 10016 USA.	martin.blaser@med.nyu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK007421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER; NIDDK NIH HHS [T35 DK007421] Funding Source: Medline; NIGMS NIH HHS [R01 GM63270] Funding Source: Medline; Wellcome Trust [069662] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Akopyants NS, 1998, P NATL ACAD SCI USA, V95, P13108, DOI 10.1073/pnas.95.22.13108; ALBRITTON WL, 1984, MOL GEN GENET, V193, P358, DOI 10.1007/BF00330693; ALM RA, 1999, HELICOBACTER PYLORI, V397, P176; Ando T, 2000, MOL MICROBIOL, V37, P1052, DOI 10.1046/j.1365-2958.2000.02049.x; Ando T, 1999, J BACTERIOL, V181, P5572, DOI 10.1128/JB.181.18.5572-5580.1999; Aras RA, 2002, NUCLEIC ACIDS RES, V30, P5391, DOI 10.1093/nar/gkf686; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Baltrus DA, 2006, FEMS MICROBIOL LETT, V255, P148, DOI 10.1111/j.1574-6968.2005.00066.x; BAROUKI R, 1986, J BIOL CHEM, V261, P8617; Bart A, 2000, MICROBIOL-UK, V146, P1255, DOI 10.1099/00221287-146-6-1255; Berg DE, 1997, CLIN INFECT DIS, V25, P996, DOI 10.1086/516081; Bik EM, 2006, P NATL ACAD SCI USA, V103, P732, DOI 10.1073/pnas.0506655103; CARLSON CA, 1983, J BACTERIOL, V153, P93, DOI 10.1128/JB.153.1.93-99.1983; Chen I, 2004, NAT REV MICROBIOL, V2, P241, DOI 10.1038/nrmicro844; Donahue JP, 2000, MOL MICROBIOL, V37, P1066, DOI 10.1046/j.1365-2958.2000.02036.x; Dubnau D, 2000, RES MICROBIOL, V151, P475, DOI 10.1016/S0923-2508(00)00166-2; Dubois A, 1999, GASTROENTEROLOGY, V116, P90, DOI 10.1016/S0016-5085(99)70232-5; Falush D, 2001, P NATL ACAD SCI USA, V98, P15056, DOI 10.1073/pnas.251396098; FERRERO RL, 1994, INFECT IMMUN, V62, P4981, DOI 10.1128/IAI.62.11.4981-4989.1994; Ghose C, 2005, J CLIN MICROBIOL, V43, P2635, DOI 10.1128/JCM.43.6.2635-2641.2005; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; Hoffman PS, 1996, J BACTERIOL, V178, P4822, DOI 10.1128/jb.178.16.4822-4829.1996; Hofreuter D, 2000, RES MICROBIOL, V151, P487, DOI 10.1016/S0923-2508(00)00164-9; Hofreuter D, 1998, MOL MICROBIOL, V28, P1027, DOI 10.1046/j.1365-2958.1998.00879.x; Hofreuter D, 2001, MOL MICROBIOL, V41, P379, DOI 10.1046/j.1365-2958.2001.02502.x; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Israel DA, 2000, FEMS MICROBIOL LETT, V186, P275, DOI 10.1016/S0378-1097(00)00156-7; Israel DA, 2001, J CLIN INVEST, V107, P611, DOI 10.1172/JCI11450; Kamba M, 2001, INT J PHARM, V228, P209, DOI 10.1016/S0378-5173(01)00844-4; Kang J, 2005, J BACTERIOL, V187, P3528, DOI 10.1128/JB.187.10.3528-3537.2005; Kang J, 2004, J BACTERIOL, V186, P7704, DOI 10.1128/JB.186.22.7704-7713.2004; Kang J, 2006, NAT REV MICROBIOL, V4, P826, DOI 10.1038/nrmicro1528; Kong HM, 2000, NUCLEIC ACIDS RES, V28, P3216, DOI 10.1093/nar/28.17.3216; Kuipers EJ, 2000, J INFECT DIS, V181, P273, DOI 10.1086/315173; Kuipers EJ, 1998, J BACTERIOL, V180, P2901, DOI 10.1128/JB.180.11.2901-2905.1998; LORENZ MG, 1994, MICROBIOL REV, V58, P563, DOI 10.1128/MMBR.58.3.563-602.1994; Lundstrom AM, 2001, HELICOBACTER, V6, P44, DOI 10.1046/j.1523-5378.2001.00006.x; MATHIS LS, 1982, J GEN MICROBIOL, V128, P1159; McGowan CC, 1998, MOL MICROBIOL, V30, P19, DOI 10.1046/j.1365-2958.1998.t01-1-01079.x; MEJEAN V, 1988, MOL GEN GENET, V213, P444, DOI 10.1007/BF00339614; MORRISON DA, 1972, J BACTERIOL, V112, P220, DOI 10.1128/JB.112.1.220-223.1972; NEDENSKOVSORENSEN P, 1990, J INFECT DIS, V161, P365, DOI 10.1093/infdis/161.2.365; Normark S, 2003, ADV CANCER RES, V90, P63, DOI 10.1016/S0065-230X(03)90002-9; Oh JD, 2006, P NATL ACAD SCI USA, V103, P9999, DOI 10.1073/pnas.0603784103; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Pasta F, 1999, P NATL ACAD SCI USA, V96, P2943, DOI 10.1073/pnas.96.6.2943; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pinto AV, 2005, MOL CELL, V17, P113, DOI 10.1016/j.molcel.2004.11.035; POSTEL EH, 1966, J MOL BIOL, V16, P317, DOI 10.1016/S0022-2836(66)80175-4; Pot RGJ, 2001, ANTIMICROB AGENTS CH, V45, P2975, DOI 10.1128/AAC.45.10.2975-2976.2001; Pride DT, 2002, J MOL BIOL, V316, P629, DOI 10.1006/jmbi.2001.5311; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Sambrook J., 2002, MOL CLONING LAB MANU; Saunders NJ, 1999, MICROBIOL-SGM, V145, P3523, DOI 10.1099/00221287-145-12-3523; SCHMID EN, 1990, J MED MICROBIOL, V32, P101, DOI 10.1099/00222615-32-2-101; Schofield MJ, 2003, ANNU REV MICROBIOL, V57, P579, DOI 10.1146/annurev.micro.57.030502.090847; SCOCCA JJ, 1974, J BACTERIOL, V118, P369, DOI 10.1128/JB.118.2.369-373.1974; Smeets LC, 2000, J BACTERIOL, V182, P3948, DOI 10.1128/JB.182.14.3948-3954.2000; Smeets LC, 2002, TRENDS MICROBIOL, V10, P159, DOI 10.1016/S0966-842X(02)02314-4; Smeets LC, 2000, FEMS IMMUNOL MED MIC, V27, P99; STEIN DC, 1991, CAN J MICROBIOL, V37, P345, DOI 10.1139/m91-056; Suerbaum S, 1998, P NATL ACAD SCI USA, V95, P12619, DOI 10.1073/pnas.95.21.12619; Takata T, 2002, NUCLEIC ACIDS RES, V30, P2444, DOI 10.1093/nar/30.11.2444; THOMPSON SA, 1995, INFECT IMMUN, V63, P2185, DOI 10.1128/IAI.63.6.2185-2193.1995; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSUDA M, 1993, MICROBIOL IMMUNOL, V37, P85, DOI 10.1111/j.1348-0421.1993.tb03184.x; WANG Y, 1993, J GEN MICROBIOL, V139, P2485, DOI 10.1099/00221287-139-10-2485; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; Xu Q, 2000, P NATL ACAD SCI USA, V97, P9671, DOI 10.1073/pnas.97.17.9671; Yeh YC, 2003, INFECT IMMUN, V71, P5427, DOI 10.1128/IAI.71.9.5427-5431.2003; Zahrt TC, 1997, P NATL ACAD SCI USA, V94, P9786, DOI 10.1073/pnas.94.18.9786	72	44	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3458	3467		10.1096/fj.07-8501com	http://dx.doi.org/10.1096/fj.07-8501com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17567566				2022-12-25	WOS:000250517800009
J	Pederson, T				Pederson, Thoru			Ribosomal protein mutations in Diamond-Blackfan anemia: might they operate upstream from protein synthesis?	FASEB JOURNAL			English	Article						pediatric hematology; nucleolus; cell cycle control	S19 GENE; NUCLEOLUS; RNA	The inherited bone marrow failure syndromes are clinically distinct but share some common features. Difficult to treat and typified by a poor prognosis, their pathogenesis is unknown. Recent findings that some patients with the erythroblastopenia Diamond-Blackfan anemia (DBA) have mutations in ribosomal proteins have led to the idea that this and perhaps other bone marrow failure disorders result from an inadequate supply of normally functioning ribosomes. According to this hypothesis, an insufficiency of the protein synthetic capacity limits the replicative potential of cells, with the DBA disease phenotype in particular arising from a block of one or more of the two to four critical, temporally compressed cell divisions in the differentiation program of the erythroid lineage in the fetal liver and the postnatal bone marrow. Here I propose an alternative ( but not mutually exclusive) hypothesis centered on nucleoli: the specialized intranuclear domains within which ribosomes are assembled. It was recently discovered that the nucleoli contain cell cycle machinery in close proximity to nascent ribosomes. Although mutations in ribosomal proteins might be expected to negatively influence the cell's protein synthetic capacity, I suggest it is also possible that the DBA mutations directly affect the nucleolus to destabilize or otherwise deregulate the coresident cell cycle machinery. This hypothesis envisions that the ribosomal protein mutations discovered in DBA act upstream from ribosome assembly by interfering with the staging of cell cycle progression machinery in the nucleolus, in a pretranslational mode of pathogenesis.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, 377 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021595] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-21595] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alter BP, 1998, NATHAN OSKIS HEMATOL, P237; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Choesmel V, 2007, BLOOD, V109, P1275, DOI 10.1182/blood-2006-07-038372; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Ebert BL, 2005, BLOOD, V105, P4620, DOI 10.1182/blood-2004-08-3313; GAULDEN ME, 1958, P NATL ACAD SCI USA, V44, P553, DOI 10.1073/pnas.44.6.553; Gazda HT, 2006, AM J HUM GENET, V79, P1110, DOI 10.1086/510020; Gazda HT, 2006, BRIT J HAEMATOL, V135, P149, DOI 10.1111/j.1365-2141.2006.06268.x; Gazda HT, 2004, BRIT J HAEMATOL, V127, P105, DOI 10.1111/j.1365-2141.2004.05152.x; Giordano E, 1999, J CELL BIOL, V144, P1123, DOI 10.1083/jcb.144.6.1123; Lipton JM, 2006, SEMIN HEMATOL, V43, P167, DOI 10.1053/j.seminhematol.2006.04.002; Ma HH, 2007, MOL BIOL CELL, V18, P2630, DOI 10.1091/mbc.E07-03-0244; Matsson H, 2006, BLOOD CELL MOL DIS, V36, P259, DOI 10.1016/j.bcmd.2005.12.002; Matsson H, 2004, MOL CELL BIOL, V24, P4032, DOI 10.1128/MCB.24.9.4032-4037.2004; Matsson H, 1999, HUM GENET, V105, P496, DOI 10.1007/s004390051136; Oliver ER, 2004, DEVELOPMENT, V131, P3907, DOI 10.1242/dev.01268; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PEDERSON T, 1970, J CELL BIOL, V45, P183, DOI 10.1083/jcb.45.1.183; Pederson T, 2002, TRENDS BIOCHEM SCI, V27, P111, DOI 10.1016/S0968-0004(02)02063-7; Politz JC, 2002, J CELL BIOL, V159, P411, DOI 10.1083/jcb.200208037; Politz JCR, 2005, MOL BIOL CELL, V16, P3401, DOI 10.1091/mbc.E05-02-0106; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Willig TN, 1999, BLOOD, V94, P4294	24	13	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3442	3445		10.1096/fj.07-8766hyp	http://dx.doi.org/10.1096/fj.07-8766hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17586729				2022-12-25	WOS:000250517800006
J	Oh, YK; Palsson, BO; Park, SM; Schilling, CH; Mahadevan, R				Oh, You-Kwan; Palsson, Bernhard O.; Park, Sung M.; Schilling, Christophe H.; Mahadevan, Radhakrishnan			Genome-scale reconstruction of metabolic network in Bacillus subtilis based on high-throughput phenotyping and gene essentiality data	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GLYCINE OXIDASE; D-ALANINE; RIBOFLAVIN; GROWTH; OPERON; CARBON; MODEL; ACID; IDENTIFICATION	In this report, a genome-scale reconstruction of Bacillus subtilis metabolism and its iterative development based on the combination of genomic, biochemical, and physiological information and high-throughput phenotyping experiments is presented. The initial reconstruction was converted into an in silico model and expanded in a four-step iterative fashion. First, network gap analysis was used to identify 48 missing reactions that are needed for growth but were not found in the genome annotation. Second, the computed growth rates under aerobic conditions were compared with high-throughput phenotypic screen data, and the initial in silico model could predict the outcomes qualitatively in 140 of 271 cases considered. Detailed analysis of the incorrect predictions resulted in the addition of 75 reactions to the initial reconstruction, and 200 of 271 cases were correctly computed. Third, in silico computations of the growth phenotypes of knock-out strains were found to be consistent with experimental observations in 720 of 766 cases evaluated. Fourth, the integrated analysis of the large-scale substrate utilization and gene essentiality data with the genome-scale metabolic model revealed the requirement of 80 specific enzymes ( transport, 53; intracellular reactions, 27) that were not in the genome annotation. Subsequent sequence analysis resulted in the identification of genes that could be putatively assigned to 13 intracellular enzymes. The final reconstruction accounted for 844 open reading frames and consisted of 1020 metabolic reactions and 988 metabolites. Hence, the in silico model can be used to obtain experimentally verifiable hypothesis on the metabolic functions of various genes.	Genomatica Inc, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Mahadevan, R (corresponding author), Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3E5, Canada.	mahadevan@chem-eng.utoronto.ca	Oh, You-Kwan/R-9528-2019; Oh, You-Kwan/AAO-9487-2020; Mahadevan, Radhakrishnan/A-8502-2008	Oh, You-Kwan/0000-0001-9076-7931; Mahadevan, Radhakrishnan/0000-0002-1270-9063; Palsson, Bernhard/0000-0003-2357-6785				ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Arkin A, 1998, GENETICS, V149, P1633; Auger S, 2002, J BACTERIOL, V184, P5179, DOI 10.1128/JB.184.18.5179-5186.2002; BLOOM FR, 1975, J BACTERIOL, V121, P1078, DOI 10.1128/JB.121.3.1078-1084.1975; Bochner BR, 2001, GENOME RES, V11, P1246, DOI 10.1101/gr.186501; Bryan EM, 1996, J BACTERIOL, V178, P4778, DOI 10.1128/jb.178.16.4778-4786.1996; Burns KE, 2005, J AM CHEM SOC, V127, P3682, DOI 10.1021/ja042792t; CHAUDHURI A, 1982, FOLIA MICROBIOL, V27, P73, DOI 10.1007/BF02879762; Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Dauner M, 2001, BIOTECHNOL BIOENG, V76, P132, DOI 10.1002/bit.1153; Dauner M, 2002, APPL ENVIRON MICROB, V68, P1760, DOI 10.1128/AEM.68.4.1760-1771.2002; Duarte NC, 2004, GENOME RES, V14, P1298, DOI 10.1101/gr.2250904; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Eymann C, 2004, PROTEOMICS, V4, P2849, DOI 10.1002/pmic.200400907; Feist AM, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100046; Fischer S.H., 2002, BACILLUS SUBTILIS IT, P181; FISHER SH, 2002, BACILLUS SUBTILIS IT, P181; Foster S.J., 2002, BACILLUS SUBTILIS IT, P21; Fraenkel D., 1996, ESCHERICHIA COLI SAL, P189; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Liu XM, 1998, J BACTERIOL, V180, P6154; Loew LM, 2001, TRENDS BIOTECHNOL, V19, P401, DOI 10.1016/S0167-7799(01)01740-1; Losick R., 2002, BACILLUS SUBTILIS IT, P163; Matsumoto K, 1998, J BACTERIOL, V180, P100, DOI 10.1128/JB.180.1.100-106.1998; Molla G, 2003, EUR J BIOCHEM, V270, P1474, DOI 10.1046/j.1432-1033.2003.03513.x; Mortl M, 2004, J BIOL CHEM, V279, P29718, DOI 10.1074/jbc.M401224200; Moszer I, 2002, NUCLEIC ACIDS RES, V30, P62, DOI 10.1093/nar/30.1.62; Nakano MM, 1999, J BACTERIOL, V181, P7087, DOI 10.1128/JB.181.22.7087-7097.1999; Nishibori A, 2005, J BACTERIOL, V187, P2163, DOI 10.1128/JB.187.6.2163-2174.2005; Njau RK, 2000, J BIOL CHEM, V275, P38780, DOI 10.1074/jbc.M007432200; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; Petersohn A, 2001, J BACTERIOL, V183, P5617, DOI 10.1128/JB.183.19.5617-5631.2001; Reed JL, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r54; Reed JL, 2006, NAT REV GENET, V7, P130, DOI 10.1038/nrg1769; Sakai A, 2001, J BIOSCI BIOENG, V91, P147, DOI 10.1263/jbb.91.147; SANTANA M, 1992, J BIOL CHEM, V267, P10225; Sauer U, 1997, NAT BIOTECHNOL, V15, P448, DOI 10.1038/nbt0597-448; Sauer U, 1999, BIOTECHNOL BIOENG, V64, P750, DOI 10.1002/(SICI)1097-0290(19990920)64:6<750::AID-BIT15>3.0.CO;2-S; Sauer U, 1998, BIOTECHNOL BIOENG, V59, P227, DOI 10.1002/(SICI)1097-0290(19980720)59:2<227::AID-BIT10>3.0.CO;2-B; Sekowska A, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-8; Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m; Sonenshein A. L., 2002, BACILLUS SUBTILIS IT, P151; SONENSHEIN AL, 1993, BACILLUS SUBTILIS IT; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Ploeg JR, 1998, MICROBIOL-SGM, V144, P2555, DOI 10.1099/00221287-144-9-2555; Varner J, 1999, CURR OPIN BIOTECH, V10, P146, DOI 10.1016/S0958-1669(99)80025-1; Wecke J, 1996, MICROB DRUG RESIST, V2, P123, DOI 10.1089/mdr.1996.2.123; WILLECKE K, 1971, J BIOL CHEM, V246, P5264; Winstedt L, 1998, J BACTERIOL, V180, P6571, DOI 10.1128/JB.180.24.6571-6580.1998; Yoshida KI, 2002, J BACTERIOL, V184, P983, DOI 10.1128/jb.184.4.983-991.2002; You CH, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-57; Zhou L, 2003, J BACTERIOL, V185, P4956, DOI 10.1128/JB.185.16.4956-4972.2003	53	290	313	4	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28791	28799		10.1074/jbc.M703759200	http://dx.doi.org/10.1074/jbc.M703759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17573341	hybrid			2022-12-25	WOS:000249642100053
J	Gourlay, LJ; Angelucci, F; Baiocco, P; Boumis, G; Brunori, M; Bellelli, A; Miele, AE				Gourlay, Louise J.; Angelucci, Francesco; Baiocco, Paola; Boumis, Giovanna; Brunori, Maurizio; Bellelli, Andrea; Miele, Adriana E.			The three-dimensional structure of two redox states of cyclophilin a from Schistosoma mansoni - Evidence for redox regulation of peptidyl-prolyl cis-trans isomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE; PARASITE; PROTEIN	Treatment of schistosomiasis, a widespread human parasitic disease caused by the helminth parasites of the genus Schistosoma, relies mainly on one chemotherapeutic agent, praziquantel, although several other compounds exert antiparasitic effects. One such compound is the immunosuppressant cyclosporin A, which has been shown to significantly diminish worm burden in mice infected with Schistosoma mansoni. Given the well established interaction between cyclosporin A and the cyclophilin superfamily of peptidylprolyl cis-trans isomerases, we solved the structure of cyclophilin A from S. mansoni (SmCypA) by x-ray crystallography in the reduced and oxidized states at 1.5 and 1.8 angstrom of resolution, respectively. Oxidized SmCypA contains a disulfide bridge between two C-terminal cysteines (Cys-122 and Cys-126). This is the first example of a cyclophilin containing this disulfide bridge. Parallel functional studies suggest a mechanism for regulation of SmCypA activity via oxidation of its thiol groups; in fact, whereas oxidized SmCypA is inactive, reduced SmCypA is an efficient isomerase active at nanomolar levels with a k(cat)/K-m of 1.1 X 10(7) M-1 s(-1), and it is inhibited by cyclosporin A (IC50 of 14 +/- 4 nM). The lack of conservation of this cysteine couple within the CypA superfamily, their close proximity to the active site, and the importance of thiol groups for peptidyl-prolyl cis-trans isomerase activity render this structural feature a challenge for the development of alternative and more effective anti-schistosomiasis inhibitors and may in addition imply an alternative function of SmCypA in the schistosome.	Univ Roma La Sapienza, Dept Biochim, I-00185 Rome, Italy; Consiglio Nazl Richerche Inst Mol Biol, Inst Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy	Sapienza University Rome; Fondazione Cenci Bolognetti	Bellelli, A (corresponding author), Univ Roma La Sapienza, Dept Biochim, P le A Moro 5, I-00185 Rome, Italy.	andrea.bellelli@uniroma1.it	baiocco, paola/K-4599-2016; Bellelli, Andrea/D-2785-2009; Baiocco, Paola/Q-4413-2019; Miele, Adriana E./F-4083-2011	baiocco, paola/0000-0002-1084-5694; Baiocco, Paola/0000-0002-1084-5694; Miele, Adriana E./0000-0002-4637-2606; Brunori, Maurizio/0000-0002-7795-1635; GOURLAY, LOUISE JANE/0000-0002-6369-2230; BOUMIS, Giovanna/0000-0001-5323-7288				BACHAR O, 1993, PROTEIN ENG, V6, P279, DOI 10.1093/protein/6.3.279; Bell A, 1996, GEN PHARMACOL-VASC S, V27, P963, DOI 10.1016/0306-3623(95)02148-5; Berriman M, 1998, BIOCHEM J, V334, P437, DOI 10.1042/bj3340437; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; Bugli F, 1998, PROTEIN EXPRES PURIF, V12, P340, DOI 10.1006/prep.1997.0852; CAVALLINI D, 1969, ARCH BIOCHEM BIOPHYS, V130, P354, DOI 10.1016/0003-9861(69)90044-7; Chapman CR, 2005, GENET ENG NEWS, V25, P40; DAVIS RE, 1995, J BIOL CHEM, V270, P21813, DOI 10.1074/jbc.270.37.21813; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Fischer G, 2004, REV PHYSIOL BIOCH P, V148, P105, DOI 10.1007/s10254-003-0011-3; Ghezzi P, 2006, PROTEOMICS, V6, P817, DOI 10.1002/pmic.200500177; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Hammerschmid F, 1996, ANN NY ACAD SCI, V782, P456, DOI 10.1111/j.1749-6632.1996.tb40583.x; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; Khattab A, 1998, EXP PARASITOL, V90, P103, DOI 10.1006/expr.1998.4307; Klinkert MQ, 1996, MOL BIOCHEM PARASIT, V81, P239, DOI 10.1016/0166-6851(96)02692-8; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163; Mi HF, 1996, FEBS LETT, V398, P201, DOI 10.1016/S0014-5793(96)01248-3; Motohashi K, 2003, J BIOL CHEM, V278, P31848, DOI 10.1074/jbc.M304258200; MUNRO GH, 1990, PARASITOLOGY, V100, P19, DOI 10.1017/S0031182000060078; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE AP, 1995, PARASITOL TODAY, V11, P385, DOI 10.1016/0169-4758(95)80007-7; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; Senkevich TG, 2002, P NATL ACAD SCI USA, V99, P6667, DOI 10.1073/pnas.062163799; Sokolskaja E, 2006, J VIROL, V80, P2855, DOI 10.1128/JVI.80.6.2855-2862.2006; Wang T, 2005, BIOCHEM BIOPH RES CO, V333, P845, DOI 10.1016/j.bbrc.2005.06.006; 1994, ACTA CRYSTALLOGR D, V50, pD760	32	24	24	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24851	24857		10.1074/jbc.M702714200	http://dx.doi.org/10.1074/jbc.M702714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17591771	hybrid			2022-12-25	WOS:000248933000041
J	Lyukmanova, EN; Shenkarev, ZO; Schulga, AA; Ermolyuk, YS; Mordvintsev, DY; Utkin, YN; Shoulepko, MA; Hogg, RC; Bertrand, D; Dolgikh, DA; Tsetlin, VI; Kirpichnikov, MP				Lyukmanova, Ekaterina N.; Shenkarev, Zakhar O.; Schulga, Alexey A.; Ermolyuk, Yaroslav S.; Mordvintsev, Dmitry Yu.; Utkin, Yurii N.; Shoulepko, Mikhail A.; Hogg, Ron C.; Bertrand, Daniel; Dolgikh, Dmitry A.; Tsetlin, Victor I.; Kirpichnikov, Mikhail P.			Bacterial expression, NMR, and electrophysiology analysis of chimeric short/long-chain alpha-neurotoxins acting on neuronal nicotinic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-BINDING-PROTEIN; CRYSTAL-STRUCTURE; CURAREMIMETIC TOXINS; TORPEDO-CALIFORNICA; KAPPA-BUNGAROTOXIN; HOMOLOG ACHBP; SNAKE; COMPLEX; REVEALS; RESOLUTION	Different snake venom neurotoxins block distinct subtypes of nicotinic acetylcholine receptors (nAChR). Short-chain alpha-neurotoxins preferentially inhibit muscle-type nAChRs, whereas long-chain alpha-neurotoxins block both muscle-type and alpha 7 homooligomeric neuronal nAChRs. An additional disulfide in the central loop of alpha-and kappa-neurotoxins is essential for their action on the alpha 7 and alpha 3 beta 2nAChRs, respectively. Design of novel toxins may help to better understand their subtype specificity. To address this problem, two chimeric toxins were produced by bacterial expression, a short-chain neurotoxin II Naja oxiana with the grafted disulfide-containing loop from long-chain neurotoxin I from N. oxiana, while a second chimera contained an additional A29K mutation, the most pronounced difference in the central loop tip between long-chain alpha-neurotoxins and kappa-neurotoxins. The correct folding and structural stability for both chimeras were shown by H-1 and H-1-N-15 NMR spectroscopy. Electrophysiology experiments on the nAChRs expressed in Xenopus oocytes revealed that the first chimera and neurotoxin I block alpha 7 nAChRs with similar potency (IC50 6.1 and 34 nM, respectively). Therefore, the disulfide-confined loop endows neurotoxin II with full activity of long-chain alpha-neurotoxin and the C-terminal tail in neurotoxin I is not essential for binding. The A29K mutation of the chimera considerably diminished the affinity for alpha 7 nAChR (IC50 126 nM) but did not convey activity at alpha 3 beta 2nAChRs. Docking of both chimeras to alpha 7 and alpha 3 beta 2nAChRs was possible, but complexes with the latter were not stable at molecular dynamics simulations. Apparently, some other residues and dimeric organization of kappa-neurotoxins underlie their selectivity for alpha 3 beta 2nAChRs.	Russian Acad Sci, Shemyakin Ovkchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Moscow MV Lomonosov State Univ, Moscow 119899, Russia; Ctr Med Univ Geneva, Dept Neurosci, Fac Med, CH-1211 Geneva, Switzerland	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Lomonosov Moscow State University; University of Geneva	Dolgikh, DA (corresponding author), Russian Acad Sci, Shemyakin Ovkchinnikov Inst Bioorgan Chem, 16-10 Miklukho Maklaya St, Moscow 117997, Russia.	dolgikh@nmr.ru	Shulepko, Mikhail/N-9124-2016; Shenkarev, Zakhar O./P-1808-2015; Utkin, Yuri/L-2952-2019; Dolgikh, Dmitry A/F-2369-2014; Utkin, Yuri N./F-1958-2014; Tsetlin, Victor/X-2491-2018; Schulga, Alexey/T-3856-2018; Lyukmanova, Ekaterina/F-2340-2014	Shenkarev, Zakhar O./0000-0003-1383-3522; Utkin, Yuri/0000-0002-4609-970X; Utkin, Yuri N./0000-0002-4609-970X; Schulga, Alexey/0000-0003-3425-0828; Lyukmanova, Ekaterina/0000-0002-9728-9407; Dolgikh, Dmitry/0000-0002-9880-7202				Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; Antil-Delbeke S, 2000, J BIOL CHEM, V275, P29594, DOI 10.1074/jbc.M909746199; Bertrand Daniel, 2002, Epilepsy Curr, V2, P191, DOI 10.1046/j.1535-7597.2002.00072.x; Bocharov EV, 2003, APPL MAGN RESON, V24, P247, DOI 10.1007/BF03166664; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; DEWAN JC, 1994, BIOCHEMISTRY-US, V33, P13147, DOI 10.1021/bi00248a026; Dohrman DP, 2003, BRAIN RES, V975, P90, DOI 10.1016/S0006-8993(03)02593-9; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; GRANT GA, 1988, BIOCHEMISTRY-US, V27, P3794, DOI 10.1021/bi00410a041; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; Hogg RC, 2004, BIOORG MED CHEM LETT, V14, P1859, DOI 10.1016/j.bmcl.2003.10.075; Hogg RC, 2003, J BIOL CHEM, V278, P26908, DOI 10.1074/jbc.M212628200; Hogg RC, 1999, J BIOL CHEM, V274, P36559, DOI 10.1074/jbc.274.51.36559; Hucho F, 2001, ANGEW CHEM INT EDIT, V40, P3101, DOI 10.1002/1521-3773(20010903)40:17<3100::AID-ANIE3100>3.0.CO;2-A; Johnson DA, 2005, BIOPHYS CHEM, V116, P213, DOI 10.1016/j.bpc.2005.03.010; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Li XW, 2006, LIFE SCI, V78, P1863, DOI 10.1016/j.lfs.2005.08.031; Lindstrom JM, 2003, ANN NY ACAD SCI, V998, P41, DOI 10.1196/annals.1254.007; Liukmanova E N, 2004, Bioorg Khim, V30, P30; Martin-Ruiz C, 2002, NEUROSCI LETT, V335, P134, DOI 10.1016/S0304-3940(02)01183-7; Martin-Ruiz CM, 2004, MOL BRAIN RES, V123, P81, DOI 10.1016/j.molbrainres.2004.01.003; Martin-Ruiz CM, 2003, BIOL PSYCHIAT, V54, P1222, DOI 10.1016/S0006-3223(03)00348-2; Martin-Ruiz CM, 1999, J NEUROCHEM, V73, P1635, DOI 10.1046/j.1471-4159.1999.0731635.x; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; Mordvintsev DY, 2005, COMPUT BIOL CHEM, V29, P398, DOI 10.1016/j.compbiolchem.2005.08.007; Mourier G, 2000, PROTEIN ENG, V13, P217, DOI 10.1093/protein/13.3.217; OSWALD RE, 1991, BIOCHEMISTRY-US, V30, P4901, DOI 10.1021/bi00234a010; Plummer HK, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-29; Samson AO, 2002, NEURON, V35, P319, DOI 10.1016/S0896-6273(02)00773-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Servent D, 2000, EUR J PHARMACOL, V393, P197, DOI 10.1016/S0014-2999(00)00095-9; Servent D, 1998, TOXICOL LETT, V103, P199, DOI 10.1016/S0378-4274(98)00307-5; Shen XM, 2003, J CLIN INVEST, V111, P497, DOI 10.1172/JC1200316997; Sixma TK, 2003, ANNU REV BIOPH BIOM, V32, P311, DOI 10.1146/annurev.biophys.32.110601.142536; Spura A, 2000, J BIOL CHEM, V275, P22452, DOI 10.1074/jbc.M001283200; Tapper AR, 2004, SCIENCE, V306, P1029, DOI 10.1126/science.1099420; Teixeira-Clerc F, 2002, J BIOL CHEM, V277, P25741, DOI 10.1074/jbc.M200534200; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Tsetlin VI, 2004, FEBS LETT, V557, P9, DOI 10.1016/S0014-5793(03)01454-6; Ulens C, 2006, P NATL ACAD SCI USA, V103, P3615, DOI 10.1073/pnas.0507889103; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang Y, 2001, MOL PHARMACOL, V60, P1201, DOI 10.1124/mol.60.6.1201; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200	54	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24784	24791		10.1074/jbc.M611263200	http://dx.doi.org/10.1074/jbc.M611263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17576769	hybrid			2022-12-25	WOS:000248933000034
J	Zeller, CE; Parnell, SC; Dohlman, HG				Zeller, Corinne E.; Parnell, Stephen C.; Dohlman, Henrik G.			The RACK1 ortholog Asc1 functions as a G-protein beta subunit coupled to glucose responsiveness in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KELCH-REPEAT PROTEINS; G-ALPHA SUBUNIT; SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; FILAMENTOUS GROWTH; INVASIVE GROWTH; MAP KINASE; INTRACELLULAR ACIDIFICATION; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION	According to the prevailing paradigm, G- proteins are composed of three subunits, an alpha subunit with GTPase activity and a tightly associated beta gamma subunit complex. In the yeast Saccharomyces cerevisiae there are two known G alpha proteins ( Gpa1 and Gpa2) but only one G beta gamma, which binds only to Gpa1. Here we show that the yeast ortholog of RACK1 ( receptor for activated protein kinase C1) Asc1 functions as the G beta for Gpa2. As with other known G beta proteins, Asc1 has a 7-WD domain structure, interacts directly with the G alpha in a guanine nucleotide-dependent manner, and inhibits G alpha guanine nucleotide exchange activity. In addition, Asc1 binds to the effector enzyme adenylyl cyclase ( Cyr1), and diminishes the production of cAMP in response to glucose stimulation. Thus, whereas Gpa2 promotes glucose signaling through elevated production of cAMP, Asc1 has opposing effects on these same processes. Our findings reveal the existence of an unusual G beta subunit, one having multiple functions within the cell in addition to serving as a signal transducer for cell surface receptors and intracellular effectors.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Dohlman, HG (corresponding author), 405 Mary Ellen Jones Bldg,Campus Box 7260, Chapel Hill, NC 27599 USA.	henrik_dohlman@med.unc.edu		Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [R01 GM080739, GM080739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson J, 2004, EMBO J, V23, P2564, DOI 10.1038/sj.emboj.7600250; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Bardwell L, 2004, PEPTIDES, V25, P1465, DOI 10.1016/j.peptides.2003.10.022; Batlle M, 2003, J CELL SCI, V116, P701, DOI 10.1242/jcs.00266; Baum S, 2004, BIOCHEM J, V380, P823, DOI 10.1042/BJ20031962; Baur M, 1997, MOL CELL BIOL, V17, P4330, DOI 10.1128/MCB.17.8.4330; Broach JR, 1991, CURR OPIN GENET DEV, V1, P370, DOI 10.1016/S0959-437X(05)80302-8; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; Chantrel Y, 1998, GENETICS, V148, P559; Chasse SA, 2006, EUKARYOT CELL, V5, P330, DOI 10.1128/EC.5.2.330-346.2006; Chasse SA, 2004, METHOD ENZYMOL, V389, P399; Chen SH, 2005, J BIOL CHEM, V280, P33445, DOI 10.1074/jbc.M505422200; Chen SH, 2004, J MOL CELL CARDIOL, V37, P399, DOI 10.1016/j.yjmcc.2004.04.019; Chen SH, 2004, J BIOL CHEM, V279, P17861, DOI 10.1074/jbc.M313727200; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Colombo S, 2004, J BIOL CHEM, V279, P46715, DOI 10.1074/jbc.M405136200; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Cullen PJ, 2000, P NATL ACAD SCI USA, V97, P13619, DOI 10.1073/pnas.240345197; Dell EJ, 2002, J BIOL CHEM, V277, P49888, DOI 10.1074/jbc.M202755200; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; Gerbasi VR, 2004, MOL CELL BIOL, V24, P8276, DOI 10.1128/MCB.24.18.8276-8287.2004; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Goddard A, 2006, FUNGAL GENET BIOL, V43, P840, DOI 10.1016/j.fgb.2006.06.005; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Harashima T, 2005, MOL BIOL CELL, V16, P4557, DOI 10.1091/mbc.E05-05-0403; Harashima T, 2002, MOL CELL, V10, P163, DOI 10.1016/S1097-2765(02)00569-5; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HOFFMAN CS, 2007, SCI STKE; Ivey FD, 2005, P NATL ACAD SCI USA, V102, P6108, DOI 10.1073/pnas.0502270102; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Kleinschmidt M, 2006, CURR GENET, V49, P218, DOI 10.1007/s00294-005-0049-7; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; Kubler E, 1997, J BIOL CHEM, V272, P20321, DOI 10.1074/jbc.272.33.20321; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lemaire K, 2004, MOL CELL, V16, P293, DOI 10.1016/j.molcel.2004.10.004; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lorenz MC, 2000, GENETICS, V154, P609; Lorenz MC, 1997, EMBO J, V16, P7008, DOI 10.1093/emboj/16.23.7008; Lu AL, 2005, EUKARYOT CELL, V4, P1794, DOI 10.1128/EC.4.11.1794-1800.2005; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; McEwen DP, 2002, METHOD ENZYMOL, V344, P403; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; Palmer DA, 2006, J BIOL CHEM, V281, P32596, DOI 10.1074/jbc.M602768200; Peeters T, 2006, P NATL ACAD SCI USA, V103, P13034, DOI 10.1073/pnas.0509644103; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sklan EH, 2006, PROG NEUROBIOL, V78, P117, DOI 10.1016/j.pneurobio.2005.12.002; Slessareva JE, 2006, CELL, V126, P191, DOI 10.1016/j.cell.2006.04.045; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; Thevelein JM, 2005, BIOCHEM SOC T, V33, P253, DOI 10.1042/BST0330253; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; THEVELEIN JM, 1992, ANTON LEEUW INT J G, V62, P109, DOI 10.1007/BF00584466; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; UNO I, 1985, P NATL ACAD SCI USA, V82, P7855, DOI 10.1073/pnas.82.23.7855; Versele M, 1999, EMBO J, V18, P5577, DOI 10.1093/emboj/18.20.5577; Wang Y, 2004, PLOS BIOL, V2, P610, DOI 10.1371/journal.pbio.0020128; Wang YQ, 2006, J BIOL CHEM, V281, P1964, DOI 10.1074/jbc.M508985200; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; Yun CW, 1998, BIOCHEM BIOPH RES CO, V252, P29, DOI 10.1006/bbrc.1998.9600	79	77	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25168	25176		10.1074/jbc.M702569200	http://dx.doi.org/10.1074/jbc.M702569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17591772	Green Published, hybrid			2022-12-25	WOS:000248933000072
J	Grampp, T; Sauter, K; Markovic, B; Benke, D				Grampp, Thomas; Sauter, Kathrin; Markovic, Branko; Benke, Dietmar			gamma-aminobutyric acid type B receptors are constitutively internalized via the clathrin-dependent pathway and targeted to lysosomes for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GABA(B) RECEPTOR; COATED VESICLE FORMATION; CELL-SURFACE EXPRESSION; BINDING PROTEIN; PIT FORMATION; RAT-BRAIN; DESENSITIZATION; ENDOCYTOSIS; SUBUNIT; PHOSPHORYLATION	Receptor internalization is recognized as an important mechanism for rapidly regulating cell surface numbers of receptors. However, there are conflicting results on the existence of rapid endocytosis of gamma- aminobutyric acid, type B ( GABAB) receptors. Therefore, we analyzed internalization of GABAB receptors expressed in HEK 293 cells qualitatively and quantitatively using immunocytochemical, cell surface enzyme- linked immunosorbent assay, and biotinylation methods. The data indicate the existence of rapid constitutive receptor internalization, with the first endocytosed receptors being observed in proximity of the plasma membrane after 10 min. After 120 min, a loss of about 40 - 50% of cell surface receptors was detected. Stimulation of GABA(B) receptors with GABA or baclofen did not enhance endocytosis of receptors, indicating the lack of agonist-induced internalization. The data suggest that GABA(B) receptors were endocytosed via the classical dynamin- and clathrin- dependent pathway and accumulated in an endosomal sorting compartment before being targeted to lysosomes for degradation. No evidence for recycling of receptors back to the cell surface was found. In conclusion, the results indicate the presence of constitutive internalization of GABAB receptors via clathrin-coated pits, which resulted in lysosomal degradation of the receptors.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland	University of Zurich	Benke, D (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthuresstr 190, CH-8057 Zurich, Switzerland.	benke@pharma.unizh.ch						Becher A, 2004, BIOCHEM BIOPH RES CO, V321, P981, DOI 10.1016/j.bbrc.2004.07.057; Benke D, 1999, J BIOL CHEM, V274, P27323, DOI 10.1074/jbc.274.38.27323; Benke D, 2002, J RECEPT SIGNAL TR R, V22, P253, DOI 10.1081/RRS-120014600; Bettler B, 2004, PHYSIOL REV, V84, P835, DOI 10.1152/physrev.00036.2003; Cuitino L, 2005, TRAFFIC, V6, P820, DOI 10.1111/j.1600-0854.2005.00320.x; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DEAN RT, 1984, BIOCHEM J, V217, P27, DOI 10.1042/bj2170027; Enna SJ, 2004, BIOCHEM PHARMACOL, V68, P1541, DOI 10.1016/j.bcp.2004.06.037; Fairfax BP, 2004, J BIOL CHEM, V279, P12565, DOI 10.1074/jbc.M311389200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fritschy JM, 2004, J COMP NEUROL, V477, P235, DOI 10.1002/cne.20188; Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Gonzalez-Maeso J, 2003, EUR J PHARMACOL, V481, P15, DOI 10.1016/j.ejphar.2003.09.002; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kanaide M, 2007, J CELL PHYSIOL, V210, P237, DOI 10.1002/jcp.20863; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Luttrell LM, 2002, J CELL SCI, V115, P455; Malitschek B, 1998, MOL CELL NEUROSCI, V12, P56, DOI 10.1006/mcne.1998.0698; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Martin SC, 1999, MOL CELL NEUROSCI, V13, P180, DOI 10.1006/mcne.1999.0741; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mutneja M, 2005, PFLUG ARCH EUR J PHY, V450, P61, DOI 10.1007/s00424-004-1367-1; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Pontier SM, 2006, EMBO J, V25, P2698, DOI 10.1038/sj.emboj.7601157; Puckerin A, 2006, J BIOL CHEM, V281, P31131, DOI 10.1074/jbc.M605000200; Richards DS, 2005, J NEUROENDOCRINOL, V17, P413, DOI 10.1111/j.1365-2826.2005.01324.x; Sauter K, 2005, J BIOL CHEM, V280, P33566, DOI 10.1074/jbc.M503482200; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Steiger JL, 2004, J NEUROSCI, V24, P6115, DOI 10.1523/JNEUROSCI.1200-04.2004; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354	36	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24157	24165		10.1074/jbc.M702626200	http://dx.doi.org/10.1074/jbc.M702626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17581821	hybrid			2022-12-25	WOS:000248686600041
J	Chen, YT; Tian, DH; Ku, L; Osterhout, DJ; Feng, Y				Chen, Yuntao; Tian, Donghua; Ku, Li; Osterhout, Donna J.; Feng, Yue			The selective RNA-binding protein quaking I (QKI) is necessary and sufficient for promoting oligodendroglia differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MORPHOLOGICAL-DIFFERENTIATION; SIGNAL-TRANSDUCTION; MAP1B EXPRESSION; NERVOUS-SYSTEM; CELL DIVISIONS; RAT-BRAIN; DYSMYELINATION; P27(KIP1); GENE	Quaking I ( QKI) is a selective RNA-binding protein essential for myelination of the central nervous system. Three QKI isoforms with distinct C termini and subcellular localization, namely QKI-5, QKI-6, and QKI-7, are expressed in oligodendroglia progenitor cells (OPCs) prior to the initiation of myelin formation and implicated in promoting oligodendrocyte lineage development. However, the functional requirement for each QKI isoform and the mechanisms by which QKI isoforms govern OPC development still remain elusive. We report here that exogenous expression of each QKI isoform is sufficient to enhance differentiation of OPCs with different efficiency, which is abolished by a point mutation that abrogates the RNA binding activity of QKI. Reciprocally, small interfering RNA-mediated QKI knockdown blocks OPC differentiation, which can be partly rescued by QKI-5 and QKI-6 but not by QKI-7, indicating the differential requirement of QKI isoform function in advancing OPC differentiation. Furthermore, we found that abrogation of OPC differentiation, as a result of QKI deficiency, is not due to altered proliferation capacity or cell cycle progression. These results indicate that QKI isoforms are necessary and sufficient for promoting OPC development, which must involve direct influence of QKI on differentiation/ maturation of OPCs independent of cell cycle exit, likely via regulating the expression of the target mRNAs of QKI that support OPC differentiation.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	Emory University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Feng, Y (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	yfeng@emory.edu		Feng, Yue/0000-0002-7905-2182	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039551, R01NS056097] Funding Source: NIH RePORTER; NINDS NIH HHS [NS056097, NS39551] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aberg K, 2006, P NATL ACAD SCI USA, V103, P7482, DOI 10.1073/pnas.0601213103; Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; BANSAL R, 1989, J NEUROSCI RES, V24, P548, DOI 10.1002/jnr.490240413; BARRES BA, 1994, DEVELOPMENT, V120, P1097; Casaccia-Bonnefil P, 1999, DEVELOPMENT, V126, P4027; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Cox RD, 1999, GENOMICS, V57, P333, DOI 10.1006/geno.1999.5804; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; FISCHER I, 1990, J NEUROSCI RES, V27, P112, DOI 10.1002/jnr.490270117; FRANKLIN RJM, 1995, GLIA, V13, P39, DOI 10.1002/glia.440130105; Galarneau A, 2005, NAT STRUCT MOL BIOL, V12, P691, DOI 10.1038/nsmb963; Gao FB, 1997, CURR BIOL, V7, P152, DOI 10.1016/S0960-9822(06)00060-1; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Hardy RJ, 1998, J NEUROSCI RES, V51, P417, DOI 10.1002/(SICI)1097-4547(19980215)51:4<417::AID-JNR1>3.0.CO;2-F; Hardy RJ, 1996, J NEUROSCI, V16, P7941; Hardy RJ, 1998, J NEUROSCI RES, V54, P46, DOI 10.1002/(SICI)1097-4547(19981001)54:1<46::AID-JNR6>3.0.CO;2-H; Haroutunian V, 2006, AM J PSYCHIAT, V163, P1834, DOI 10.1176/appi.ajp.163.10.1834; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kondo T, 1999, MAMM GENOME, V10, P662; Larocque D, 2005, NAT NEUROSCI, V8, P27, DOI 10.1038/nn1359; Larocque D, 2002, NEURON, V36, P815, DOI 10.1016/S0896-6273(02)01055-3; Li ZZ, 2000, J NEUROSCI, V20, P4944; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; McInnes LA, 2006, NEUROSCI BIOBEHAV R, V30, P551, DOI 10.1016/j.neubiorev.2005.10.003; McMahon AP, 2000, GENE DEV, V14, P2261, DOI 10.1101/gad.840800; Meixner A, 2000, J CELL BIOL, V151, P1169, DOI 10.1083/jcb.151.6.1169; Noveroske JK, 2005, MAMM GENOME, V16, P672, DOI 10.1007/s00335-005-0035-x; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; Song J, 1999, J NEUROCYTOL, V28, P671, DOI 10.1023/A:1007060832459; Tabu K, 2006, J CELL SCI, V119, P1433, DOI 10.1242/jcs.02854; Tang XM, 2000, J CELL BIOCHEM, V76, P270, DOI 10.1002/(SICI)1097-4644(20000201)76:2<270::AID-JCB10>3.0.CO;2-6; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; VOUYIOUKLIS DA, 1993, J NEUROSCI RES, V35, P257, DOI 10.1002/jnr.490350305; Wu HY, 2001, MOL CELL NEUROSCI, V17, P292, DOI 10.1006/mcne.2000.0941; Wu JI, 2002, P NATL ACAD SCI USA, V99, P4233, DOI 10.1073/pnas.072090399; Zhang YY, 2003, EMBO J, V22, P1801, DOI 10.1093/emboj/cdg171; Zhao LX, 2006, J NEUROSCI, V26, P11278, DOI 10.1523/JNEUROSCI.2677-06.2006; Zhao LX, 2006, MOL BIOL CELL, V17, P4179, DOI 10.1091/mbc.E06-04-0355	43	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23553	23560		10.1074/jbc.M702045200	http://dx.doi.org/10.1074/jbc.M702045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17575274	hybrid			2022-12-25	WOS:000248577500057
J	Fontayne, A; De Maeyer, B; De Maeyer, M; Yamashita, M; Matsushita, T; Deckmyn, H				Fontayne, Alexandre; De Maeyer, Bauke; De Maeyer, Marc; Yamashita, Mayo; Matsushita, Tadashi; Deckmyn, Hans			Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN DOCKING; VON-WILLEBRAND-DISEASE; MONOCLONAL-ANTIBODIES; IX-V; ACTIVATION; MECHANISMS; ADHESION; BINDING	The monoclonal antibody 6B4 has a potent antithrombotic effect in nonhuman primates by binding to the flexible loop, also known as the beta-switch region ( amino acids 230-242), of glycoprotein Ib alpha(GPIb alpha). This interaction blocks, in high shear stress conditions, the specific interaction between GPIb alpha and von Willebrand factor suppressing platelet deposition to the damaged vessel wall, a key event in the pathogenesis of arterial thrombosis. To understand the interactions between this antibody and its antigen at the amino acid level, we here report the identification of the paratope and epitope in 6B4 and GPIb alpha, respectively, by using computer modeling and site-directed mutagenesis. The docking programs ZDOCK ( rigid body docking) and HADDOCK ( flexible docking) were used to model the interaction of 6B4 with GPIb alpha mutants were constructed and assayed for their capacity to bind GPIb alpha and 6B4, respectively. From these data, it is found that the paratope of 6B4 is mainly formed by five residues: Tyr(27D), Lys(27E), Asp(28), and Glu(93) located in light chain CDR1and -3, respectively, and Tyr(100C) of the heavy chain CDR3. These residues form a valley, where the GPIb alpha flexible loop can bind via residues Asp(235) and Lys(237). The experimental results were finally used to build a more accurate docking model. Taken together, this information provides guidelines for the design of new derivatized lead compounds with antithrombotic properties.	Katholieke Univ Leuven, Interdisciplinary Res Ctr, Lab Thrombosis Res, B-8500 Kortrijk, Belgium; Katholieke Univ Leuven, Interdisciplinary Res Ctr, Dept Chem, Lab Biomol Modeling, B-8500 Kortrijk, Belgium; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Grad Sch Med, Dept Hematol, Nagoya, Aichi 4668560, Japan	KU Leuven; KU Leuven; Nagoya University; Nagoya University	Deckmyn, H (corresponding author), Katholieke Univ Leuven, Interdisciplinary Res Ctr, Lab Thrombosis Res, KU Leuven Campus Kortrijk,E Sabbelaan 53, B-8500 Kortrijk, Belgium.	Hans.Deckmyn@kuleuven-kortrijk.be	Deckmyn, Hans/L-9434-2015; Matsushita, Tadadshi/I-7349-2014; Deckmyn, Hans/N-8932-2019	Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; FONTAYNE, Alexandre/0000-0002-0097-2294				Andrews RK, 2003, INT J BIOCHEM CELL B, V35, P1170, DOI 10.1016/S1357-2725(02)00280-7; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; Bonvin AM, 2006, CURR OPIN STRUC BIOL, V16, P194, DOI 10.1016/j.sbi.2006.02.002; Cauwenberghs N, 2000, HAEMOSTASIS, V30, P139; Cauwenberghs N, 2000, ARTERIOSCL THROM VAS, V20, P1347, DOI 10.1161/01.ATV.20.5.1347; Chen R, 2002, PROTEINS, V47, P281, DOI 10.1002/prot.10092; DELHAISE P, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80028-3; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Feng SJ, 2003, BLOOD, V102, P2122, DOI 10.1182/blood-2002-12-3805; Fontayne A, 2006, THROMB HAEMOSTASIS, V96, P671, DOI 10.1160/TH06-06-0297; GAUWENBERGHS N, 2001, BLOOD, V98, P652; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; Miller JL, 1996, THROMB HAEMOSTASIS, V75, P865; Nakamura F, 2006, BLOOD, V107, P1925, DOI 10.1182/blood-2005-10-3964; Ruggeri ZM, 1997, THROMB HAEMOSTASIS, V78, P611; Russell RB, 2004, CURR OPIN STRUC BIOL, V14, P313, DOI 10.1016/j.sbi.2004.04.006; Shimizu A, 2004, J BIOL CHEM, V279, P16285, DOI 10.1074/jbc.M307230200; Whitelegg NRJ, 2000, PROTEIN ENG, V13, P819, DOI 10.1093/protein/13.12.819; Wu DM, 2002, ARTERIOSCL THROM VAS, V22, P323, DOI 10.1161/hq0202.102321; Wu YL, 2004, BIOPHYS J, V87, P105, DOI 10.1529/biophysj.103.039156; Yip J, 2005, IUBMB LIFE, V57, P103, DOI 10.1080/15216540500078962	24	17	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23517	23524		10.1074/jbc.M701826200	http://dx.doi.org/10.1074/jbc.M701826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17569666	Green Published, hybrid			2022-12-25	WOS:000248577500053
J	Nagarajavel, V; Madhusudan, S; Dole, S; Rahmouni, AR; Schnetz, K				Nagarajavel, V.; Madhusudan, S.; Dole, Sudhanshu; Rahmouni, A. Rachid; Schnetz, Karin			Repression by binding of H-NS within the transcription unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; NUCLEOID STRUCTURING PROTEIN; CONTROLLED PROU OPERON; RNA-POLYMERASE; SALMONELLA-TYPHIMURIUM; DNA-BINDING; GENE-EXPRESSION; BGL OPERON; BACTERIAL CHROMATIN; RIFAMPICIN INHIBITION	H-NS inhibits transcription by forming repressing nucleoprotein complexes next to promoters. We investigated repression by binding of H-NS within the transcription unit using the bgl and proU operons. Repression of both operons requires a downstream regulatory element (DRE) in addition to an upstream element (URE). In bgl, H-NS binds to a region located between 600 to 700 bp downstream of the transcription start site, whereas in proU the DRE extends up to position +270. We show that binding of H-NS to the bgl-DRE inhibits transcription initiation at a step before open complex formation, as shown before for proU. This was shown by determining the occupancy of the bgl transcription unit by RNA polymerases, expression analysis of bgl and proU reporter constructs, and chloroacetaldehyde footprinting of RNA polymerase promoter complexes. The chloroacetaldehyde footprinting also revealed that RNA polymerase is "poised" at the osmoregulated sigma 70- dependent proU promoter at low osmolarity, whereas at high osmolarity poising of RNA polymerase and repression by H-NS are reduced. Furthermore, repression by H-NS via the URE and DRE is synergistic, and the efficiency of repression by H-NS via the DRE inversely correlates with the promoter activity. Repression is high for a promoter of low activity, whereas it is low for a strong promoter. Inefficient repression of strong promoters by H-NS via a DRE may account for high induction levels of proU at high osmolarity and for bgl upon disruption of the URE.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; CNRS, Ctr Biophys Mol, F-45071 Orleans, France	University of Cologne; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS)	Schnetz, K (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.	schnetz@uni-koeln.de		Schnetz, Karin/0000-0003-4693-6202				Amit R, 2003, BIOPHYS J, V84, P2467, DOI 10.1016/S0006-3495(03)75051-6; AYMERICH S, 1992, P NATL ACAD SCI USA, V89, P10410, DOI 10.1073/pnas.89.21.10410; Badaut C, 2002, J BIOL CHEM, V277, P41657, DOI 10.1074/jbc.M206037200; Bloch V, 2003, NAT STRUCT BIOL, V10, P212, DOI 10.1038/nsb904; Bouffartigues E, 2007, NAT STRUCT MOL BIOL, V14, P441, DOI 10.1038/nsmb1233; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; CSONKA LN, 1994, J BACTERIOL, V176, P6324, DOI 10.1128/jb.176.20.6324-6333.1994; CSONKA LN, 1982, J BACTERIOL, V151, P1433, DOI 10.1128/JB.151.3.1433-1443.1982; Dame RT, 2006, NATURE, V444, P387, DOI 10.1038/nature05283; Dame RT, 2005, MOL MICROBIOL, V56, P858, DOI 10.1111/j.1365-2958.2005.04598.x; Dame RT, 2000, NUCLEIC ACIDS RES, V28, P3504, DOI 10.1093/nar/28.18.3504; Dame RT, 2002, J BIOL CHEM, V277, P2146, DOI 10.1074/jbc.C100603200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DATTANANDA CS, 1991, J BACTERIOL, V173, P7481, DOI 10.1128/jb.173.23.7481-7490.1991; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; Deckert J, 2002, MOL CELL BIOL, V22, P6458, DOI 10.1128/MCB.22.18.6458-6470.2002; DERSCH P, 1993, MOL MICROBIOL, V8, P875, DOI 10.1111/j.1365-2958.1993.tb01634.x; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; Dole S, 2004, MOL MICROBIOL, V52, P589, DOI 10.1111/j.1365-2958.2004.04001.x; Dole S, 2002, MOL MICROBIOL, V43, P217, DOI 10.1046/j.1365-2958.2002.02734.x; Dorman CJ, 2007, NAT REV MICROBIOL, V5, P157, DOI 10.1038/nrmicro1598; Dorman CJ, 2004, NAT REV MICROBIOL, V2, P391, DOI 10.1038/nrmicro883; Esposito D, 2002, J MOL BIOL, V324, P841, DOI 10.1016/S0022-2836(02)01141-5; Giel M, 1996, GENETICS, V143, P627; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; GOWRISHANKAR J, 1986, J BACTERIOL, V168, P1197, DOI 10.1128/jb.168.3.1197-1204.1986; Gralla JD, 2006, EMBO J, V25, P1515, DOI 10.1038/sj.emboj.7601041; Guerin M, 1996, EMBO J, V15, P5397, DOI 10.1002/j.1460-2075.1996.tb00923.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; Jordi BJAM, 1997, J BIOL CHEM, V272, P12083, DOI 10.1074/jbc.272.18.12083; Jordi JAM, 2000, J BIOL CHEM, V275, P12123, DOI 10.1074/jbc.275.16.12123; JOVANOVICH SB, 1988, J BACTERIOL, V170, P534, DOI 10.1128/jb.170.2.534-539.1988; JOVANOVICH SB, 1989, J BIOL CHEM, V264, P7821; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lee SJ, 2004, MOL CELL, V14, P153, DOI 10.1016/S1097-2765(04)00202-3; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; LOPILATO J, 1990, BACTERIAL CHROMOSOME, P435; Lucchini S, 2006, PLOS PATHOG, V2, P746, DOI 10.1371/journal.ppat.0020081; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Luijsterburg MS, 2006, J STRUCT BIOL, V156, P262, DOI 10.1016/j.jsb.2006.05.006; Madhusudan S, 2005, MICROBIOL-SGM, V151, P3349, DOI 10.1099/mic.0.28080-0; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Navarre WW, 2006, SCIENCE, V313, P236, DOI 10.1126/science.1128794; Olekhnovich IN, 2006, J MOL BIOL, V357, P373, DOI 10.1016/j.jmb.2006.01.007; Oshima T, 2006, DNA RES, V13, P141, DOI 10.1093/dnares/dsl009; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PRINCE WS, 1990, J BIOL CHEM, V265, P17673; Prosseda G, 2004, MOL MICROBIOL, V51, P523, DOI 10.1046/j.1365-2958.2003.03848.x; RAMIREZ RM, 1989, P NATL ACAD SCI USA, V86, P1153, DOI 10.1073/pnas.86.4.1153; REYNOLDS AE, 1986, J MOL BIOL, V191, P85, DOI 10.1016/0022-2836(86)90424-9; Rimsky S, 2001, MOL MICROBIOL, V42, P1311, DOI 10.1046/j.1365-2958.2001.02706.x; SCHNETZ K, 1992, P NATL ACAD SCI USA, V89, P1244, DOI 10.1073/pnas.89.4.1244; Schnetz K, 1996, NUCLEIC ACIDS RES, V24, P2422, DOI 10.1093/nar/24.12.2422; SCHNETZ K, 1995, EMBO J, V14, P2545, DOI 10.1002/j.1460-2075.1995.tb07252.x; Schroder O, 2002, BIOL CHEM, V383, P945, DOI 10.1515/BC.2002.101; Shin M, 2005, GENE DEV, V19, P2388, DOI 10.1101/gad.1316305; SHINDO H, 1995, FEBS LETT, V360, P125, DOI 10.1016/0014-5793(95)00079-O; Shindo H, 1999, FEBS LETT, V455, P63, DOI 10.1016/S0014-5793(99)00862-5; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; Toulme F, 2005, J MOL BIOL, V351, P39, DOI 10.1016/j.jmb.2005.05.052; Ueguchi C, 1997, J MOL BIOL, V274, P145, DOI 10.1006/jmbi.1997.1381; Ueguchi C, 1996, J MOL BIOL, V263, P149, DOI 10.1006/jmbi.1996.0566; Ueguchi C, 1998, J BACTERIOL, V180, P190, DOI 10.1128/JB.180.1.190-193.1998; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; Wolf T, 2006, J BACTERIOL, V188, P6728, DOI 10.1128/JB.00586-06	69	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23622	23630		10.1074/jbc.M702753200	http://dx.doi.org/10.1074/jbc.M702753200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17569663	hybrid			2022-12-25	WOS:000248577500064
J	Wirth, J; Chopin, F; Santoni, V; Viennois, G; Tillard, P; Krapp, A; Lejay, L; Daniel-Vedele, F; Gojon, A				Wirth, Judith; Chopin, Franck; Santoni, Veronique; Viennois, Gaeelle; Tillard, Pascal; Krapp, Anne; Lejay, Laurence; Daniel-Vedele, Francoise; Gojon, Alain			Regulation of root nitrate uptake at the NRT2.1 protein level in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER GENES ATNRT2.1; NO3-UPTAKE; UPTAKE SYSTEM; POSTTRANSLATIONAL REGULATION; NICOTIANA-PLUMBAGINIFOLIA; PHOSPHATE TRANSPORTER; PLASMA-MEMBRANE; AFFINITY; EXPRESSION; PLANT	In Arabidopsis the NRT2.1 gene encodes a main component of the root high-affinity nitrate uptake system ( HATS). Its regulation has been thoroughly studied showing a strong correlation between NRT2.1 expression and HATS activity. Despite its central role in plant nutrition, nothing is known concerning localization and regulation of NRT2.1 at the protein level. By combining a green fluorescent protein fusion strategy and an immunological approach, we show that NRT2.1 is mainly localized in the plasma membrane of root cortical and epidermal cells, and that several forms of the protein seems to co-exist in cell membranes ( the monomer and at least one higher molecular weight complex). The monomer is the most abundant form of NRT2.1, and seems to be the one involved in NO3- transport. It strictly requires the NAR2.1 protein to be expressed and addressed at the plasma membrane. No rapid changes in NRT2.1 abundance were observed in response to light, sucrose, or nitrogen treatments that strongly affect both NRT2.1 mRNA level and HATS activity. This suggests the occurrence of post-translational regulatory mechanisms. One such mechanism could correspond to the cleavage of NRT2.1 C terminus, which results in the presence of both intact and truncated proteins in the plasma membrane.	INRA CNRS SupAgro UM2, Biochim & Phhysiol Mol Plantes, UMR 5004, Inst Biol Integrat Plantes, F-34060 Montpellier, France; INRA, Unite Nutr Azotee Plantes, F-78026 Versailles, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Lejay, L (corresponding author), INRA CNRS SupAgro UM2, Biochim & Phhysiol Mol Plantes, UMR 5004, Inst Biol Integrat Plantes, F-34060 Montpellier, France.	lejay@supagro.inra.fr	Wirth, Judith/J-4992-2019; Krapp, Anne/E-8372-2013; Lejay, Laurence/AAC-9544-2021; Lejay, Laurence/GLS-1491-2022	Krapp, Anne/0000-0003-2034-5615; Lejay, Laurence/0000-0003-0785-3893; 				BEHL R, 1988, PLANTA, V176, P235, DOI 10.1007/BF00392450; Bolte S, 2004, J MICROSC-OXFORD, V214, P159, DOI 10.1111/j.0022-2720.2004.01348.x; Boursiac Y, 2005, PLANT PHYSIOL, V139, P790, DOI 10.1104/pp.105.065029; Cerezo M, 2001, PLANT PHYSIOL, V127, P262, DOI 10.1104/pp.127.1.262; Chiou TJ, 2001, PLANT J, V25, P281, DOI 10.1046/j.1365-313x.2001.00963.x; CHOPIN F, IN PRESS PLANT PHYSL; Clarkson DT, 1996, PLANT CELL ENVIRON, V19, P859, DOI 10.1111/j.1365-3040.1996.tb00422.x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Connolly EL, 2002, PLANT CELL, V14, P1347, DOI 10.1105/tpc.001263; Crawford NM, 1998, TRENDS PLANT SCI, V3, P389, DOI 10.1016/S1360-1385(98)01311-9; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; Daniel-Vedele F, 1998, CURR OPIN PLANT BIOL, V1, P235, DOI 10.1016/S1369-5266(98)80110-6; DELHON P, 1995, J EXP BOT, V46, P1585, DOI 10.1093/jxb/46.10.1585; Dharmasiri S, 2006, SCIENCE, V312, P1218, DOI 10.1126/science.1122847; Filleur S, 1999, PLANTA, V207, P461, DOI 10.1007/s004250050505; Filleur S, 2001, FEBS LETT, V489, P220, DOI 10.1016/S0014-5793(01)02096-8; Finnemann J, 2000, PLANT J, V24, P171, DOI 10.1046/j.1365-313x.2000.00863.x; Forde BG, 2000, BBA-BIOMEMBRANES, V1465, P219, DOI 10.1016/S0005-2736(00)00140-1; Fraisier V, 2000, PLANT J, V23, P489, DOI 10.1046/j.1365-313x.2000.00813.x; Galvan A, 2001, CELL MOL LIFE SCI, V58, P225, DOI 10.1007/PL00000850; Gansel X, 2001, PLANT J, V26, P143, DOI 10.1046/j.1365-313x.2001.01016.x; Gao-Rubinelli F, 2004, BIOCHEM GENET, V42, P21, DOI 10.1023/B:BIGI.0000012141.51114.23; GIANNINI JL, 1987, PLANT PHYSIOL, V85, P1129, DOI 10.1104/pp.85.4.1129; Gibon Y, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-r76; Gonzalez E, 2005, PLANT CELL, V17, P3500, DOI 10.1105/tpc.105.036640; Guo FQ, 2001, PLANT CELL, V13, P1761, DOI 10.1105/tpc.13.8.1761; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Hawkesford MJ, 2000, ADV BOT RES, V33, P159, DOI 10.1016/S0065-2296(00)33043-9; Kaiser WM, 2001, J EXP BOT, V52, P1981, DOI 10.1093/jexbot/52.363.1981; Koltermann M, 2003, PLANT MOL BIOL, V52, P855, DOI 10.1023/A:1025024821832; Krouk G, 2006, PLANT PHYSIOL, V142, P1075, DOI 10.1104/pp.106.087510; Lejay L, 1999, PLANT J, V18, P509, DOI 10.1046/j.1365-313X.1999.00480.x; Lejay L, 2003, PLANT CELL, V15, P2218, DOI 10.1105/tpc.013516; Li WB, 2007, PLANT PHYSIOL, V143, P425, DOI 10.1104/pp.106.091223; Little DY, 2005, P NATL ACAD SCI USA, V102, P13693, DOI 10.1073/pnas.0504219102; Liu KH, 2003, EMBO J, V22, P1005, DOI 10.1093/emboj/cdg118; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; Loque D, 2006, PLANT J, V48, P522, DOI 10.1111/j.1365-313X.2006.02887.x; Montanini B, 2006, BIOCHEM J, V394, P125, DOI 10.1042/BJ20051199; Muchhal US, 1999, P NATL ACAD SCI USA, V96, P5868, DOI 10.1073/pnas.96.10.5868; Munos S, 2004, PLANT CELL, V16, P2433, DOI 10.1105/tpc.104.024380; Navarro FJ, 2006, J BIOL CHEM, V281, P13268, DOI 10.1074/jbc.M601253200; Nazoa P, 2003, PLANT MOL BIOL, V52, P689, DOI 10.1023/A:1024899808018; Okamoto M, 2006, PLANT PHYSIOL, V140, P1036, DOI 10.1104/pp.105.074385; Okamoto M, 2003, PLANT CELL PHYSIOL, V44, P304, DOI 10.1093/pcp/pcg036; Orsel M, 2004, PLANTA, V219, P714, DOI 10.1007/s00425-004-1266-x; Orsel M, 2002, J EXP BOT, V53, P825, DOI 10.1093/jexbot/53.370.825; Orsel M, 2006, PLANT PHYSIOL, V142, P1304, DOI 10.1104/pp.106.085209; Perez MD, 1997, BIOCHEM J, V321, P397, DOI 10.1042/bj3210397; Quesada A, 1997, PLANT MOL BIOL, V34, P265, DOI 10.1023/A:1005872816881; QUESADA A, 1994, PLANT J, V5, P407, DOI 10.1111/j.1365-313X.1994.00407.x; Remans T, 2006, PLANT PHYSIOL, V140, P909, DOI 10.1104/pp.105.075721; Rohila JS, 2004, PLANT J, V38, P172, DOI 10.1111/j.1365-313X.2004.02031.x; Santoni V, 2003, BIOCHEM J, V373, P289, DOI 10.1042/BJ20030159; SANTONI V, 1994, PLANTA, V192, P557, DOI 10.1007/BF00203594; Schneidereit A, 2003, PLANT PHYSIOL, V133, P182, DOI 10.1104/pp.103.026674; Stitt M, 1999, CURR OPIN PLANT BIOL, V2, P178, DOI 10.1016/S1369-5266(99)80033-8; Tamura K, 2003, PLANT J, V35, P545, DOI 10.1046/j.1365-313X.2003.01822.x; Tong Y, 2005, PLANT J, V41, P442, DOI 10.1111/j.1365-313X.2004.02310.x; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; Unkles SE, 2001, EMBO J, V20, P6246, DOI 10.1093/emboj/20.22.6246; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Vidmar JJ, 2000, PLANT PHYSIOL, V123, P307, DOI 10.1104/pp.123.1.307; Williams LE, 2001, ANNU REV PLANT PHYS, V52, P659, DOI 10.1146/annurev.arplant.52.1.659; Zhou JJ, 2000, FEBS LETT, V466, P225, DOI 10.1016/S0014-5793(00)01085-1; Zhou JJ, 2000, J BIOL CHEM, V275, P39894, DOI 10.1074/jbc.M004610200; Zhuo DG, 1999, PLANT J, V17, P563, DOI 10.1046/j.1365-313X.1999.00396.x	67	110	122	0	62	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23541	23552		10.1074/jbc.M700901200	http://dx.doi.org/10.1074/jbc.M700901200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17573350	Green Published, hybrid			2022-12-25	WOS:000248577500056
J	Zhou, Z; Yin, J; Dou, Z; Tang, JX; Zhang, CZ; Cao, YJ				Zhou, Zhuo; Yin, Jie; Dou, Zhixun; Tang, Jun; Zhang, Cuizhu; Cao, Youjia			The calponin homology domain of Vav1 associates with calmodulin and is prerequisite to T cell antigen receptor-induced calcium release in Jurkat T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; SIGNAL-TRANSDUCTION; CA2+-INDEPENDENT INHIBITION; TRISPHOSPHATE RECEPTORS; PROTOONCOGENE PRODUCT; EXCHANGE FACTOR; ACTIN-BINDING; ACTIVATION	Vav1 is a guanine nucleotide exchange factor that is expressed specifically in hematopoietic cells and plays important roles in T cell development and activation. Vav1 consists of multiple structural domains so as to facilitate both its guanine nucleotide exchange activity and scaffold function following T cell antigen receptor (TCR) engagement. Previous studies demonstrated that the calponin homology ( CH) domain of Vav1 is required for TCR-stimulated calcium mobilization and thus downstream activation of nuclear factor of activated T cells. However, it remained obscure how Vav1 functions in regulating calcium flux. In an effort to explore molecules interacting with Vav1, we found that calmodulin bound to Vav1 in a calcium-dependent and TCR activation-independent manner. The binding site was mapped to the CH domain of Vav1. Reconstitution of vav1-null Jurkat T cells (J.Vav1) with CH-deleted Vav1 exhibited a severe deficiency in calcium release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells. The defect persisted even when phospholipase-C gamma 1 was fully activated, indicating a prerequisite role of Vav1 CH domain in calcium signaling. The results suggest that Vav1 and calmodulin function cooperatively to potentiate TCR-induced calcium release. This study unveiled a mechanism by which the Vav1CH domain is involved in calcium signaling and provides insight into our understanding of the role of Vav1 in T cell activation.	Nankai Univ, Coll Life Sci, Dept Biochem & Mol Biol, Tianjin 300071, Peoples R China; Nankai Univ, Coll Life Sci, Minist Educ, Key Lab Bioact Mat, Tianjin 300071, Peoples R China	Nankai University; Nankai University	Cao, YJ (corresponding author), Nankai Univ, Coll Life Sci, Dept Biochem & Mol Biol, 94 Weijin Rd, Tianjin 300071, Peoples R China.	caoyj@nankai.edu.cn		Tang, Jun/0000-0002-8285-5111; zhou, zhuo/0000-0001-5862-9854				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Bare DJ, 2005, J BIOL CHEM, V280, P15912, DOI 10.1074/jbc.M414212200; Billadeau DD, 2000, J IMMUNOL, V164, P3971, DOI 10.4049/jimmunol.164.8.3971; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Braiman A, 2006, EMBO J, V25, P774, DOI 10.1038/sj.emboj.7600978; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Cardy TJA, 1998, BIOCHEM J, V334, P447, DOI 10.1042/bj3340447; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Cui J, 2004, J BIOL CHEM, V279, P16311, DOI 10.1074/jbc.M400206200; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; Groysman M, 2002, J BIOL CHEM, V277, P50121, DOI 10.1074/jbc.M204299200; Groysman M, 2000, FEBS LETT, V467, P75, DOI 10.1016/S0014-5793(00)01121-2; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; HILL TD, 1988, J BIOL CHEM, V263, P16479; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kasri NN, 2006, J BIOL CHEM, V281, P8332, DOI 10.1074/jbc.M510971200; Kasri NN, 2004, BIOL RES, V37, P577; Katzav S, 2004, BLOOD, V103, P2443, DOI 10.1182/blood-2003-08-2834; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li ZG, 2003, J BIOL CHEM, V278, P4347, DOI 10.1074/jbc.M208579200; Medvedeva MV, 1996, BIOCHEM J, V315, P1021, DOI 10.1042/bj3151021; Missiaen L, 1999, J BIOL CHEM, V274, P13748, DOI 10.1074/jbc.274.20.13748; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Nolz JC, 2006, CURR BIOL, V16, P24, DOI 10.1016/j.cub.2005.11.036; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Serrano CJ, 2005, J IMMUNOL, V174, P6233, DOI 10.4049/jimmunol.174.10.6233; Stoica B, 1998, J IMMUNOL, V160, P1059; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WILLS FL, 1994, PROTEIN SCI, V3, P2311, DOI 10.1002/pro.5560031216; WINDER SJ, 1993, BIOCHEMISTRY-US, V32, P13327, DOI 10.1021/bi00211a046; Wulfing C, 1997, J EXP MED, V185, P1815, DOI 10.1084/jem.185.10.1815; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	58	25	27	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23737	23744		10.1074/jbc.M702975200	http://dx.doi.org/10.1074/jbc.M702975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17550897	hybrid			2022-12-25	WOS:000248577500077
J	Li, YJ; Brodsky, B; Baum, J				Li, Yingjie; Brodsky, Barbara; Baum, Jean			NMR shows hydrophobic interactions replace glycine packing in the triple helix at a natural break in the (Gly-X-Y)(n) repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-LIKE PEPTIDE; AMINO-ACID-SEQUENCE; IV COLLAGEN; N-15-C-13-LABELED PROTEINS; MOLECULAR-STRUCTURE; HIGH-SENSITIVITY; LARGER PROTEINS; CHEMICAL-SHIFTS; RESONANCE NMR; GFT NMR	Little is known about the structural consequences of the more than 20 breaks in the (Gly-X-Y)(n) repeating sequence found in the long triple helix domain of basement membrane type IV collagen. NMR triple resonance studies of doubly labeled residues within a set of collagen model peptides provide distance and dihedral angle restraints that allow determination of model structures of both a standard triple helix and of a triple helix with a break in solution. Although the standard triple helix cannot continue when Gly is not every third residue, the NMR data support rod-like molecules that have standard triple-helical structures on both sides of a well defined and highly localized perturbation. The GAAVM break region may be described as a "pseudo triple helix," because it preserves the standard one-residue stagger of the triple helix but introduces hydrophobic interactions at the position normally occupied by the much smaller and hydrogen-bonded Gly residue of the repeating (Gly-X-Y)(n) sequence. This structure provides a rationale for the consensus presence of hydrophobic residues in breaks of similar length and defines a novel variant of a triple helix that could be involved in recognition.	Rutgers State Univ, BIOMAPS Inst, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Baum, J (corresponding author), Rutgers State Univ, BIOMAPS Inst, Dept Chem & Biol Chem, 610 Taylor Rd, Piscataway, NJ 08854 USA.	baum@rutgers.edu			NIGMS NIH HHS [GM45302, GM60048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045302, R01GM060048, R29GM045302] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baum Jean, 1999, Current Opinion in Structural Biology, V9, P122, DOI 10.1016/S0959-440X(99)80016-5; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Bella J, 2006, J MOL BIOL, V362, P298, DOI 10.1016/j.jmb.2006.07.014; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P518; CLUBB RT, 1992, J MAGN RESON, V97, P213, DOI 10.1016/0022-2364(92)90252-3; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1991, J MAGN RESON, V91, P84, DOI 10.1016/0022-2364(91)90410-U; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; Kim S, 2004, J BIOMOL NMR, V28, P117, DOI 10.1023/B:JNMR.0000013827.20574.46; Kim S, 2003, J AM CHEM SOC, V125, P1385, DOI 10.1021/ja028197d; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; Liu XY, 1998, BIOCHEMISTRY-US, V37, P15528, DOI 10.1021/bi981147u; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MESSERLE BA, 1989, J MAGN RESON, V85, P608, DOI 10.1016/0022-2364(89)90252-7; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; Mohs A, 2006, J BIOL CHEM, V281, P17197, DOI 10.1074/jbc.M601763200; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27; Ramachandran G N., 1967, TREATISE COLLAGEN; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Schittny JC, 1989, CURR OPIN CELL BIOL, V1, P983, DOI 10.1016/0955-0674(89)90069-0; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YURCHENCO PD, 1988, AM J PATHOL, V132, P278; ZHOU J, 1992, J BIOL CHEM, V267, P12475; ZHU GA, 1992, J MAGN RESON, V98, P192, DOI 10.1016/0022-2364(92)90124-P	39	30	30	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22699	22706		10.1074/jbc.M702910200	http://dx.doi.org/10.1074/jbc.M702910200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17550894	hybrid			2022-12-25	WOS:000248354200047
J	Park, PH; McMullen, MR; Huang, HL; Thakur, V; Nagy, LE				Park, Pil-hoon; McMullen, Megan R.; Huang, Honglian; Thakur, Varsha; Nagy, Laura E.			Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression - Role of TNF-alpha in adiponectin-stimulated interleukin-10 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTIC CELLS; INDUCED LIVER-INJURY; RAT KUPFFER CELLS; ANTIINFLAMMATORY CYTOKINES; TRANSCRIPTION FACTORS; PROTEIN; MICE; LPS; RECEPTORS; FAMILY	Adiponectin is an adipokine with potent anti-inflammatory properties. However, the mechanisms by which adiponectin suppresses macrophage function are not well understood. Treatment of RAW264.7 macrophages with adiponectin for 18 h decreased lipopolysaccharide (LPS)-stimulated tumor necrosis factor-alpha (TNF-alpha) production. Here we demonstrate that globular adiponectin (gAcrp) initially increased TNF-alpha expression in RAW264.7 macrophages; this TNF-alpha then contributed to increased expression of interleukin-10, which in turn was required for the development of tolerance to subsequent LPS exposure. gAcrp-mediated increases in TNF-alpha mRNA accumulation were associated with increased TNF-alpha promoter activity. gAcrp increased the DNA binding activity of both Egr-1 and NF kappa B; mutation of either the Egr-1 or NF kappa B binding sites in the TNF-alpha promoter decreased gAcrp-stimulated promoter activity. Further, co-transfection with either dominant negative Egr-1 or the I kappa B super-repressor prevented gAcrp-stimulated TNF-alpha promoter activity. gAcrp also increased Egr-1 promoter activity, mRNA accumulation, and DNA binding activity. Inhibition of ERK1/2 with U0126 potently suppressed gAcrp-stimulated Egr-1 promoter activity, as well as TNF-alpha promoter activity. In summary, these data demonstrate that adiponectin initially increases TNF-alpha production by macrophages via ERK1/2 -> Egr-1 and NF kappa B-dependent mechanisms; these increases in TNF-alpha in turn lead to increased expression of interleukin-10 and an eventual dampening of LPS-mediated cytokine production in macrophages.	Cleveland Clin Fdn, Dept Pathobiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Gastroenterol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Nagy, LE (corresponding author), Cleveland Clin Fdn, Dept Pathobiol, LRI NE40,9500 Euclid Ave, Cleveland, OH 44195 USA.	laura.nagy@case.edu	huang, Honglian/E-8679-2010		NIAAA NIH HHS [AA011975, R56 AA011975, R01 AA011975, R01 AA013868, AA013868, R01 AA011975-10] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013868, R01AA011975, R56AA011975] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Braddock M, 2001, ANN MED, V33, P313, DOI 10.3109/07853890109002083; Calandra T, 1997, CRIT REV IMMUNOL, V17, P77, DOI 10.1615/CritRevImmunol.v17.i1.30; Chinetti G, 2004, BIOCHEM BIOPH RES CO, V314, P151, DOI 10.1016/j.bbrc.2003.12.058; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Dobrovolskaia MA, 2002, MICROBES INFECT, V4, P903, DOI 10.1016/S1286-4579(02)01613-1; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Furukawa K, 2004, BIOCHEM BIOPH RES CO, V317, P831, DOI 10.1016/j.bbrc.2004.03.123; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Goldstein BJ, 2004, J CLIN ENDOCR METAB, V89, P2563, DOI 10.1210/jc.2004-0518; Grutz G, 2005, J LEUKOCYTE BIOL, V77, P3, DOI 10.1189/jlb.0904484; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kishore R, 2002, AM J PHYSIOL-GASTR L, V282, pG6, DOI 10.1152/ajpgi.00328.2001; Masaki T, 2004, HEPATOLOGY, V40, P177, DOI 10.1002/hep.20282; Matsumoto H, 2006, WORLD J GASTROENTERO, V12, P3352, DOI 10.3748/wjg.v12.i21.3352; Means TK, 2000, J LEUKOCYTE BIOL, V67, P885, DOI 10.1002/jlb.67.6.885; Moore MJ, 2001, SCIENCE, V294, P1841, DOI 10.1126/science.1067676; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Papanikolaou NA, 2000, J BIOL CHEM, V275, P26683; Sato TA, 2003, J IMMUNOL, V170, P158, DOI 10.4049/jimmunol.170.1.158; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shi L, 2002, AM J PHYSIOL-CELL PH, V282, pC1205, DOI 10.1152/ajpcell.00511.2001; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Thakur V, 2006, AM J PHYSIOL-GASTR L, V290, pG998, DOI 10.1152/ajpgi.00553.2005; Tilg H, 2006, GASTROENTEROLOGY, V131, P934, DOI 10.1053/j.gastro.2006.05.054; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Tsatsanis C, 2005, BIOCHEM BIOPH RES CO, V335, P1254, DOI 10.1016/j.bbrc.2005.07.197; Waki H, 2005, ENDOCRINOLOGY, V146, P790, DOI 10.1210/en.2004-1096; Wang Y, 2004, PROTEOMICS, V4, P3933, DOI 10.1002/pmic.200400826; Wolf AM, 2004, BIOCHEM BIOPH RES CO, V323, P630, DOI 10.1016/j.bbrc.2004.08.145; Wulster-Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Yamaguchi N, 2005, FEBS LETT, V579, P6821, DOI 10.1016/j.febslet.2005.11.019; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723	42	122	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21695	21703		10.1074/jbc.M701419200	http://dx.doi.org/10.1074/jbc.M701419200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17537727	hybrid, Green Accepted			2022-12-25	WOS:000248196800016
J	Patel, A; Fondrk, MK; Kaftanoglu, O; Emore, C; Hunt, G; Frederick, K; Amdam, GV				Patel, Avani; Fondrk, M. Kim; Kaftanoglu, Osman; Emore, Christine; Hunt, Greg; Frederick, Katy; Amdam, Gro V.			The Making of a Queen: TOR Pathway Is a Key Player in Diphenic Caste Development	PLOS ONE			English	Article							HONEY-BEE; APIS-MELLIFERA; SIGNALING PATHWAY; VITELLOGENIN; DIFFERENTIATION; EXPRESSION; INSECT; NUMBER; TARGET; GROWTH	Background. Honey bees (Apis mellifera) provide a principal example of diphenic development. Excess feeding of female larvae results in queens (large reproductives). Moderate diet yields workers (small helpers). The signaling pathway that links provisioning to female developmental fate is not understood, yet we reasoned that it could include TOR (target of rapamycin), a nutrient-and energy-sensing kinase that controls organismal growth. Methodology/Principal Findings. Here, the role of Apis mellifera TOR (amTOR) in caste determination is examined by rapamycin/FK506 pharmacology and RNA interference (RNAi) gene knockdown. We show that in queen-destined larvae, the TOR inhibitor rapamycin induces the development of worker characters that are blocked by the antagonist FK506. Further, queen fate is associated with elevated activity of the Apis mellifera TOR encoding gene, amTOR, and amTOR gene knockdown blocks queen fate and results in individuals with worker morphology. Conclusions/Significance. A much-studied insect dimorphism, thereby, can be governed by the TOR pathway. Our results present the first evidence for a role of TOR in diphenic development, and suggest that adoption of this ancestral nutrient-sensing cascade is one evolutionary pathway for morphological caste differentiation in social insects.	[Patel, Avani; Fondrk, M. Kim; Kaftanoglu, Osman; Frederick, Katy; Amdam, Gro V.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; [Emore, Christine; Hunt, Greg] Purdue Univ, Dept Entomol, W Lafayette, IN 47907 USA; [Amdam, Gro V.] Norwegian Univ Life Sci, Anim & Aquacultural Sci Dept, As, Norway	Arizona State University; Arizona State University-Tempe; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Norwegian University of Life Sciences	Amdam, GV (corresponding author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.	Gro.Amdam@asu.edu			Norwegian Research Council [171958, 175413]; U.S. National Science Foundation [0615502]; National Institute on Aging [PO1 AG22500]; Pew Foundation; NATIONAL INSTITUTE ON AGING [P01AG022500] Funding Source: NIH RePORTER	Norwegian Research Council(Research Council of NorwayEuropean Commission); U.S. National Science Foundation(National Science Foundation (NSF)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Pew Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Support was provided by the Norwegian Research Council # 171958, # 175413, U.S. National Science Foundation # 0615502, National Institute on Aging PO1 AG22500 and the Pew Foundation.	Aase ALTO, 2005, APIDOLOGIE, V36, P293, DOI 10.1051/apido:2005003; Amdam GV, 2006, BEHAV BRAIN RES, V169, P201, DOI 10.1016/j.bbr.2006.01.006; Amdam GV, 2004, P NATL ACAD SCI USA, V101, P11350, DOI 10.1073/pnas.0403073101; Amdam GV, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-1; Amdam GV, 2003, P NATL ACAD SCI USA, V100, P1799, DOI 10.1073/pnas.0333979100; Aronstein K, 2006, J APICULT RES, V45, P20, DOI 10.1080/00218839.2006.11101307; Berrigan D, 1998, EVOL ECOL, V12, P535, DOI 10.1023/A:1006552608754; BERRIGAN D, 1991, OIKOS, V60, P313, DOI 10.2307/3545073; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Cristino AS, 2006, INSECT MOL BIOL, V15, P703, DOI 10.1111/j.1365-2583.2006.00696.x; Dedej S, 1998, J APICULT RES, V37, P183, DOI 10.1080/00218839.1998.11100970; ENGELS W, 1990, SOCIAL INSECTS EVOLU, P264; Guertin DA, 2006, CURR BIOL, V16, P958, DOI 10.1016/j.cub.2006.03.084; Guidugli KR, 2005, ARCH INSECT BIOCHEM, V59, P211, DOI 10.1002/arch.20061; Hafen E, 2003, CURR TOP MICROBIOL, V279, P153; Hansen IA, 2004, P NATL ACAD SCI USA, V101, P10626, DOI 10.1073/pnas.0403460101; Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Maeterlinck Maurice, 1901, LIFE BEE; MICHELETTE ERD, 1993, APIDOLOGIE, V24, P431, DOI 10.1051/apido:19930410; Nelson CM, 2007, PLOS BIOL, V5, P673, DOI 10.1371/journal.pbio.0050062; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Page RE, 2007, BIOESSAYS, V29, P334, DOI 10.1002/bies.20549; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Reiss M.J., 1989, ALLOMETRY GROWTH REP; REMBOLD H, 1981, J APICULT RES, V20, P165, DOI 10.1080/00218839.1981.11100492; Rembold H, 1964, Hoppe Seylers Z Physiol Chem, V339, P251, DOI 10.1515/bchm2.1964.339.1.251; REMBOLD H, 1974, J INSECT PHYSIOL, V20, P1193, DOI 10.1016/0022-1910(74)90225-X; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; VANDENBERG JD, 1987, J APICULT RES, V26, P90, DOI 10.1080/00218839.1987.11100743; West-Eberhard M.J., 1987, P35; Wheeler DE, 2006, INSECT MOL BIOL, V15, P597, DOI 10.1111/j.1365-2583.2006.00681.x; Winston M.L., 1991, BIOL HONEY BEE; WIRTZ P, 1972, ENTOMOL EXP APPL, V15, P517, DOI 10.1007/BF00293616; WOYKE J, 1977, J APICULT RES, V16, P84, DOI 10.1080/00218839.1977.11099866	35	209	227	3	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e509	10.1371/journal.pone.0000509	http://dx.doi.org/10.1371/journal.pone.0000509			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551589	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451500018
J	Sampath, R; Russell, KL; Massire, C; Eshoo, MW; Harpin, V; Blyn, LB; Melton, R; Ivy, C; Pennella, T; Li, F; Levene, H; Hall, TA; Libby, B; Fan, N; Walcott, DJ; Ranken, R; Pear, M; Schink, A; Gutierrez, J; Drader, J; Moore, D; Metzgar, D; Addington, L; Rothman, R; Gaydos, CA; Yang, S; St George, K; Fuschino, ME; Dean, AB; Stallknecht, DE; Goekjian, G; Yingst, S; Monteville, M; Saad, MD; Whitehouse, CA; Baldwin, C; Rudnick, KH; Hofstadler, SA; Lemon, SM; Ecker, DJ				Sampath, Rangarajan; Russell, Kevin L.; Massire, Christian; Eshoo, Mark W.; Harpin, Vanessa; Blyn, Lawrence B.; Melton, Rachael; Ivy, Cristina; Pennella, Thuy; Li, Feng; Levene, Harold; Hall, Thomas A.; Libby, Brian; Fan, Nancy; Walcott, Demetrius J.; Ranken, Raymond; Pear, Michael; Schink, Amy; Gutierrez, Jose; Drader, Jared; Moore, David; Metzgar, David; Addington, Lynda; Rothman, Richard; Gaydos, Charlotte A.; Yang, Samuel; St. George, Kirsten; Fuschino, Meghan E.; Dean, Amy B.; Stallknecht, David E.; Goekjian, Ginger; Yingst, Samuel; Monteville, Marshall; Saad, Magdi D.; Whitehouse, Chris A.; Baldwin, Carson; Rudnick, Karl H.; Hofstadler, Steven A.; Lemon, Stanley M.; Ecker, David J.			Global Surveillance of Emerging Influenza Virus Genotypes by Mass Spectrometry	PLOS ONE			English	Article								Background. Effective influenza surveillance requires new methods capable of rapid and inexpensive genomic analysis of evolving viral species for pandemic preparedness, to understand the evolution of circulating viral species, and for vaccine strain selection. We have developed one such approach based on previously described broad-range reverse transcription PCR/electrospray ionization mass spectrometry (RT-PCR/ESI-MS) technology. Methods and Principal Findings. Analysis of base compositions of RT-PCR amplicons from influenza core gene segments (PB1, PB2, PA, M, NS, NP) are used to provide subspecies identification and infer influenza virus H and N subtypes. Using this approach, we detected and correctly identified 92 mammalian and avian influenza isolates, representing 30 different H and N types, including 29 avian H5N1 isolates. Further, direct analysis of 656 human clinical respiratory specimens collected over a seven-year period (1999-2006) showed correct identification of the viral species and subtypes with >97% sensitivity and specificity. Base composition derived clusters inferred from this analysis showed 100% concordance to previously established clades. Ongoing surveillance of samples from the recent influenza virus seasons (2005-2006) showed evidence for emergence and establishment of new genotypes of circulating H3N2 strains worldwide. Mixed viral quasispecies were found in approximately 1% of these recent samples providing a view into viral evolution. Conclusion/Significance. Thus, rapid RT-PCR/ESI-MS analysis can be used to simultaneously identify all species of influenza viruses with clade-level resolution, identify mixed viral populations and monitor global spread and emergence of novel viral genotypes. This high-throughput method promises to become an integral component of influenza surveillance.	[Sampath, Rangarajan; Massire, Christian; Eshoo, Mark W.; Harpin, Vanessa; Blyn, Lawrence B.; Melton, Rachael; Ivy, Cristina; Pennella, Thuy; Li, Feng; Levene, Harold; Hall, Thomas A.; Libby, Brian; Fan, Nancy; Walcott, Demetrius J.; Ranken, Raymond; Pear, Michael; Schink, Amy; Gutierrez, Jose; Drader, Jared; Moore, David; Hofstadler, Steven A.; Ecker, David J.] Ibis Biosci Inc, Carlsbad, CA USA; [Russell, Kevin L.; Metzgar, David; Addington, Lynda] USN, Hlth Res Ctr, Resp Dis Lab, San Diego, CA 92152 USA; [Rothman, Richard; Gaydos, Charlotte A.; Yang, Samuel] Johns Hopkins Med Inst, Dept Emergency Med & Med, Baltimore, MD 21205 USA; [St. George, Kirsten; Fuschino, Meghan E.; Dean, Amy B.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA; [Stallknecht, David E.; Goekjian, Ginger] Univ Georgia, Coll Vet Med, Athens, GA USA; [Yingst, Samuel; Monteville, Marshall; Saad, Magdi D.] Naval Med Res Unit 3, Cairo, Egypt; [Whitehouse, Chris A.; Baldwin, Carson] USA, Ft Detrick, MD USA; [Rudnick, Karl H.] Sci Applicat Int Corp, San Diego, CA 92121 USA; [Lemon, Stanley M.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX USA	United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); Johns Hopkins University; Johns Hopkins Medicine; State University of New York (SUNY) System; Wadsworth Center; University System of Georgia; University of Georgia; Naval Medical Research Center (NMRC); Naval Medical Research Unit - No. 3 (NAMRU-3); Science Applications International Corporation (SAIC); University of Texas System; University of Texas Medical Branch Galveston	Sampath, R (corresponding author), Ibis Biosci Inc, Carlsbad, CA USA.	rsampath@ibisbio.com	Saad, Magdi/H-5561-2013; Gaydos, Charlotte A./E-9937-2010	Saad, Magdi/0000-0003-2111-8115; Ecker, David/0000-0003-4350-9037; Yang, Samuel/0000-0003-1123-9036; Rothman, Richard/0000-0002-1017-9505	DARPA; U.S. Department of Defense; CDC [R01-CI-000099]; NIAID, NIH [IUCIAI067232-01]	DARPA(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); U.S. Department of Defense(United States Department of Defense); CDC(Centre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The RT-PCR/ESI-MS technology development was funded by DARPA, a division of the U.S. Department of Defense. Funding from the CDC and NIAID supported the influenza surveillance assay development and screening described here. The sponsors had no role in the design, implementation or conlusions of the assay.; The author thank the CDC (Extramural Grant: R01-CI-000099) and NIAID (NIH Grant IUCIAI067232-01) for financial support.	Barr IG, 2005, J MED VIROL, V76, P391, DOI 10.1002/jmv.20374; Brownstein MJ, 1996, BIOTECHNIQUES, V20, P1004, DOI 10.2144/96206st01; Chen H, 2006, P NATL ACAD SCI USA, V103, P2845, DOI 10.1073/pnas.0511120103; Ecker D, 2006, J ASS LAB AUTOM, P341; Ecker DJ, 2005, P NATL ACAD SCI USA, V102, P8012, DOI 10.1073/pnas.0409920102; Hofstadler SA, 2005, INT J MASS SPECTROM, V242, P23, DOI 10.1016/j.ijms.2004.09.014; Holmes EC, 2005, PLOS BIOL, V3, P1579, DOI 10.1371/journal.pbio.0030300; Jiang Y, 2003, ANAL BIOCHEM, V316, P50, DOI 10.1016/S0003-2697(03)00024-1; Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254; Kilbourne ED, 2004, VIRAL IMMUNOL, V17, P350, DOI 10.1089/0882824041857076; Li CJ, 2005, VIROLOGY, V340, P70, DOI 10.1016/j.virol.2005.06.025; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Muddiman DC, 1997, ANAL CHEM, V69, P1543, DOI 10.1021/ac961134r; Puthavathana P, 2005, J GEN VIROL, V86, P423, DOI 10.1099/vir.0.80368-0; Ruest A, 2003, J CLIN MICROBIOL, V41, P3487, DOI 10.1128/JCM.41.8.3487-3493.2003; Sampath R, 2005, EMERG INFECT DIS, V11, P373, DOI 10.3201/eid1103.040629; Sampath R, 2007, ANN NY ACAD SCI, V1102, P109, DOI 10.1196/annals.1408.008; Schweiger B, 2000, J CLIN MICROBIOL, V38, P1552, DOI 10.1128/JCM.38.4.1552-1558.2000; Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320; Smith GJD, 2006, P NATL ACAD SCI USA, V103, P16936, DOI 10.1073/pnas.0608157103; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; van Elden LJR, 2001, BRIT J GEN PRACT, V51, P630; van Elden LJR, 2001, J CLIN MICROBIOL, V39, P196, DOI 10.1128/JCM.39.1.196-200.2001; WRIGHT KE, 1995, J CLIN MICROBIOL, V33, P1180, DOI 10.1128/JCM.33.5.1180-1184.1995; Xu XY, 2002, J INFECT DIS, V186, P1490, DOI 10.1086/344738	26	107	152	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e489	10.1371/journal.pone.0000489	http://dx.doi.org/10.1371/journal.pone.0000489			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534439	Green Published, Green Submitted, gold			2022-12-25	WOS:000207448800019
J	Capel, E; Flejou, JF; Hamelin, R				Capel, E.; Flejou, J-F; Hamelin, R.			Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis	ONCOGENE			English	Article						microsatellite instability; HNPCC; MLH1; promoter; methylation	MICROSATELLITE INSTABILITY; DNA; HMLH1; CPG; CANCER; HYPERMETHYLATION; PREDISPOSITION; MUTATIONS; REGION; TUMORS	About 15% of colorectal cancers are called MSI because they demonstrate microsatellite instability. In most sporadic MSI cases, the DNA mismatch repair (MMR) defect is due to methylation of the MLH1 promoter. In hereditary MSI cases, it is the consequence of germline mutations of one of the MMR genes. We analysed the MLH1 promoter for methylation using the methylation-specific PCR technique. With a previously described and widely used primer set, a number of samples with an intact MMR system were found to have methylated MLH1 promoter, a finding normally associated with lack of MLH1 expression. Another primer set, specific for a more proximal region of the promoter, gave results that correlated more closely with loss of MLH1 expression. We then conducted a survey of the literature on the subject, and a total of 161 articles were examined. Although it was shown as early as 1999 that absence of MLH1 expression correlated with methylation of the proximal but not distal regions of the MLH1 promoter, 60% of published studies analysed nonspecific regions. Our findings suggest that these studies are likely to have wrongly estimated the association between methylation of the MLH1 gene and the lack of its protein expression.	INSERM, U762, F-75010 Paris, France; Univ Paris 06, IFR65, Paris, France; Hop St Antoine, Serv Anat Pathol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Hamelin, R (corresponding author), INSERM, U762, 27 rue Juliette Dodu, F-75010 Paris, France.	richard.hamelin@cephb.fr		Capel, Emilie/0000-0001-8396-2843				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Boland CR, 1998, CANCER RES, V58, P5248; Brennetot C, 2005, INT J CANCER, V113, P446, DOI 10.1002/ijc.20586; Deng GR, 1999, CANCER RES, V59, P2029; Eads CA, 1999, CANCER RES, V59, P2302; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fiegl H, 2004, CANCER EPIDEM BIOMAR, V13, P882; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Grady WM, 2001, CANCER RES, V61, P900; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Kane MF, 1997, CANCER RES, V57, P808; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Park SJ, 2003, AM J PATHOL, V162, P815, DOI 10.1016/S0002-9440(10)63878-3; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamamoto H, 2001, CANCER RES, V61, P3139	28	50	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7596	7600		10.1038/sj.onc.1210581	http://dx.doi.org/10.1038/sj.onc.1210581			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546041				2022-12-25	WOS:000251282100013
J	Bruton, RK; Rasti, M; Mapp, KL; Young, N; Carter, RZ; Abramowicz, IA; Sedgwick, GG; Onion, DF; Shuen, M; Mymryk, JS; Turnell, AS; Grand, RJA				Bruton, R. K.; Rasti, M.; Mapp, K. L.; Young, N.; Carter, R. Z.; Abramowicz, I. A.; Sedgwick, G. G.; Onion, D. F.; Shuen, M.; Mymryk, J. S.; Turnell, A. S.; Grand, R. J. A.			C-terminal-binding protein interacting protein binds directly to adenovirus early region 1A through its N-terminal region and conserved region 3	ONCOGENE			English	Article						adenovirus E1A; C-terminal-binding protein; interacting protein; CtIP; C-terminal-binding protein; CtBP	E1A PROTEIN; DNA-DAMAGE; ONCOGENIC TRANSFORMATION; STRUCTURAL DETERMINANTS; TRANSCRIPTIONAL ADAPTER; CELLULAR PHOSPHOPROTEIN; SIMIAN ADENOVIRUSES; NEGATIVE MODULATION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS	C-terminal-binding protein interacting protein (CtIP) was first isolated as a binding partner of C-terminal-binding protein (CtBP). It is considered to contribute to the transcriptional repression and cell cycle regulatory properties of the retinoblastoma (Rb) family of proteins and to have a role in the cellular response to DNA damage. Here, we have shown that CtIP is a novel target for the adenovirus oncoprotein early region 1A (AdE1A). AdE1A associates with CtIP in both Ad5E1-transformed cells and Ad5-infected cells and binds directly in glutathione-S-transferase pull-down assays. Two binding sites have been mapped on Ad5E1A - the N-terminal alpha-helical region ( residues 1 - 30) and conserved region 3(CR3) - the transcriptional activation domain. CtIP can bind AdE1A and CtBP independently, raising the possibility that ternary complexes exist in Ad-transformed and - infected cells. Significantly, reduction of CtIP expression with small interfering RNAs results in reduction of the ability of a Gal4 DNA-binding domain-CR3 construct to transactivate a Gal 4-responsive luciferase reporter and this effect is reversed by reduction of CtBP expression. Therefore, in this model, CtIP acts as a transcriptional co-activator of AdE1A when dissociated from CtBP, through the action of AdE1A. These data are consistent with observations that CtIP expression is induced by AdE1A during viral infection and that reduction of CtIP expression with RNA interference can retard virus replication. In addition, AdE1A causes disruption of the CtIP/Rb complex during viral infection by its interaction with CtIP, possibly contributing to transcriptional derepression.	Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Western Ontario, Dept Oncol & Microbiol & Immunol, London, ON N6A 3K7, Canada	Cancer Research UK; University of Birmingham; Western University (University of Western Ontario)	Grand, RJA (corresponding author), Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	R.J.A.Grand@bham.ac.uk		Onion, David/0000-0002-4522-2307	Breast Cancer Now [2001:218] Funding Source: Medline	Breast Cancer Now		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; Barral PM, 2005, FEBS LETT, V579, P2752, DOI 10.1016/j.febslet.2005.03.095; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; Chinnadurai G, 2006, BBA-REV CANCER, V1765, P67, DOI 10.1016/j.bbcan.2005.09.002; Chinnadurai G, 2004, CURR TOP MICROBIOL, V273, P139; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; CHINNADURAI G, 2007, IN PRESS INT J BIOCH; Chinnadurai G., 2006, CTBP FAMILY PROTEINS, P1; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 2006, LANDES BIOSCIENCE, P44; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELMSA TN, 1989, VIROLOGY, V171, P120; JONES N, 1995, CURR TOP MICROBIOL I, V199, P58; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; Molloy DP, 2001, BBA-PROTEIN STRUCT M, V1546, P55, DOI 10.1016/S0167-4838(00)00071-6; Murakami P, 1999, ANAL BIOCHEM, V274, P283, DOI 10.1006/abio.1999.4282; Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005; Rasti M, 2006, EMBO J, V25, P2710, DOI 10.1038/sj.emboj.7601169; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang G, 2002, J VIROL, V76, P9186, DOI 10.1128/JVI.76.18.9186-9193.2002; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Yu XC, 2006, GENE DEV, V20, P1721, DOI 10.1101/gad.1431006	50	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7467	7479		10.1038/sj.onc.1210551	http://dx.doi.org/10.1038/sj.onc.1210551			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546052				2022-12-25	WOS:000251282000008
J	Hasegawa, K; Watanabe, T; Suzuki, T; Yamano, A; Oikawa, T; Sato, Y; Kouguchi, H; Yoneyama, T; Niwa, K; Ikeda, T; Ohyama, T				Hasegawa, Kimiko; Watanabe, Toshihiro; Suzuki, Tomonori; Yamano, Akihito; Oikawa, Tetsuo; Sato, Yasuhiko; Kouguchi, Hirokazu; Yoneyama, Tohru; Niwa, Koichi; Ikeda, Toshihiko; Ohyama, Tohru			A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C PROGENITOR TOXIN; HEMAGGLUTININ COMPONENT; EPITHELIAL-CELLS; NEUROTOXIN; BINDING; INTERNALIZATION; IDENTIFICATION; MODEL; GENE	The botulinum neurotoxins (BoNTs) are the most potent toxins known in nature, causing the lethal disease known as botulism in humans and animals. The BoNTs act by inhibiting neurotransmitter release from cholinergic synapses. Clostridium botulinum strains produce large BoNTs toxin complexes, which include auxiliary non-toxic proteins that appear not only to protect BoNTs from the hostile environment of the digestive tract but also to assist BoNT translocation across the intestinal mucosal layer. In this study, we visualize for the first time a series of botulinum serotype D toxin complexes using negative stain transmission electron microscopy (TEM). The complexes consist of the 150-kDa BoNT, 130-kDa nontoxic non-hemagglutinin (NTNHA), and three kinds of hemagglutinin (HA) subcomponents: 70-kDa HA-70, 33-kDa HA-33, and 17-kDa HA-17. These components assemble sequentially to form the complex. A novel TEM image of the mature L-TC revealed an ellipsoidal-shaped structure with "three arms" attached. The "body" section was comprised of a single BoNT, a single NTNHA and three HA-70 molecules. The arm section consisted of a complex of HA-33 and HA-17 molecules. We determined the x-ray crystal structure of the complex formed by two HA-33 plus one HA-17. On the basis of the TEM image and biochemical results, we propose a novel 14-mer subunit model for the botulinum toxin complex. This unique model suggests how non-toxic components make up a "delivery vehicle" for BoNT.	Tokyo Univ Agr, Fac BioInd, Dept Food Sci & Technol, Abashiri 0992493, Japan; PharmAxess Inc, Tokyo 1968666, Japan; JEOL Ltd, Akishima, Tokyo 1968558, Japan; Hokkaido Inst Publ Hlth, Sapporo, Hokkaido, Japan; Sankyo Co Ltd, Tokyo 1408710, Japan	Tokyo University of Agriculture; Jeol Ltd; JEOL Japan; Daiichi Sankyo Company Limited	Ohyama, T (corresponding author), Tokyo Univ Agr, Fac BioInd, Dept Food Sci & Technol, 196 Yasaka, Abashiri 0992493, Japan.	t-oyama@bioindustry.nodai.ac.jp	Yoneyama, Tohru/ABG-2670-2020; Yoneyama, Tohru/P-7820-2016	Yoneyama, Tohru/0000-0002-1098-407X				Adachi H, 2003, ACTA CRYSTALLOGR D, V59, P194, DOI 10.1107/S0907444902019741; Arndt JW, 2005, J MOL BIOL, V346, P1083, DOI 10.1016/j.jmb.2004.12.039; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bigalke H, 2000, HANDB EXP PHARM, V145, P407; BOROFF DA, 1972, INFECT IMMUN, V6, P1003, DOI 10.1128/IAI.6.6.1003-1007.1972; Burkard F, 1997, J STRUCT BIOL, V120, P78, DOI 10.1006/jsbi.1997.3910; Consky E, 1994, THERAPY BOTULINUM TO, P211; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DOLLY JO, 1984, NATURE, V307, P457, DOI 10.1038/307457a0; Fujinaga Y, 2004, MICROBIOL-SGM, V150, P1529, DOI 10.1099/mic.0.26805-0; Fujinaga Y, 1997, MICROBIOL-UK, V143, P3841, DOI 10.1099/00221287-143-12-3841; Fujinaga Y, 2000, FEBS LETT, V467, P179, DOI 10.1016/S0014-5793(00)01147-9; Hasegawa K, 2004, PROTEIN J, V23, P371, DOI 10.1023/B:JOPC.0000039551.42676.4c; HAUSER D, 1994, MOL GEN GENET, V243, P631, DOI 10.1007/BF00279572; Inoue K, 2003, MICROBIOL-SGM, V149, P3361, DOI 10.1099/mic.0.26586-0; Kouguchi H, 2002, J BIOL CHEM, V277, P2650, DOI 10.1074/jbc.M106762200; Kouguchi H, 2006, J MICROBIOL METH, V67, P416, DOI 10.1016/j.mimet.2006.04.013; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MCREE DE, 1993, PRACTICAL PROTEIN CR, P271; Minton NP, 1995, CURR TOP MICROBIOL, V195, P161; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mutoh S, 2005, MICROBIOL-SGM, V151, P3847, DOI 10.1099/mic.0.28323-0; Mutoh S, 2003, BIOCHEMISTRY-US, V42, P10991, DOI 10.1021/bi034996c; Nishikawa A, 2004, BIOCHEM BIOPH RES CO, V319, P327, DOI 10.1016/j.bbrc.2004.04.183; Niwa K, 2007, FEMS IMMUNOL MED MIC, V49, P346, DOI 10.1111/j.1574-695X.2006.00205.x; OHISHI I, 1977, INFECT IMMUN, V16, P107, DOI 10.1128/IAI.16.1.107-109.1977; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SAKAGUCHI G, 1984, BACTERIAL PROTEIN TO, P435; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; Suzuki T, 2005, MICROBIOL-SGM, V151, P1475, DOI 10.1099/mic.0.27801-0; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; Uotsu N, 2006, BBA-MOL CELL RES, V1763, P120, DOI 10.1016/j.bbamcr.2005.11.014; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780	37	89	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24777	24783		10.1074/jbc.M703446200	http://dx.doi.org/10.1074/jbc.M703446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17581814	hybrid			2022-12-25	WOS:000248933000033
J	Choi, WG; Roberts, DM				Choi, Won-Gyu; Roberts, Daniel M.			Arabidopsis NIP2;1, a major intrinsic protein transporter of lactic acid induced by anoxic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL PERMEASE ACTIVITY; CYTOPLASMIC PH REGULATION; WATER PERMEABILITY; GENE-EXPRESSION; ROOT-TIPS; AQUAPORIN; FAMILY; MEMBRANE; LACTATE; MEMBERS	Nodulin 26 intrinsic proteins ( NIPs) are plant- specific, highly conserved water and solute transport proteins with structural and functional homology to soybean nodulin 26. Arabidopsis thaliana contains nine NIP genes. In this study, it is shown that one of these, AtNIP2; 1, is exquisitely sensitive to water logging and anoxia stress. Based on quantitative PCR and promoter:: GUS experiments, AtNIP2; 1 is expressed at a low basal level in the root tips and the vascular bundle of differentiated roots. Transcript levels are elevated acutely and rapidly upon water logging of root or leaf tissues, increasing 70- fold in roots within the 1st h of submersion. After this large initial increase, mRNA levels decline to steady state levels that remain over 10- fold higher by 6 h post- submersion. An even greater induction of AtNIP2; 1 expression was observed upon anoxia challenge of Arabidopsis seedlings, with a 300- fold increase in AtNIP2; 1 transcript observed by 2 h after the initiation of oxygen deprivation. Functional analysis of AtNIP2; 1 expressed in Xenopus oocytes shows that the protein differs from soybean nodulin 26, showing minimal water and glycerol transport. Instead, AtNIP2; 1 displays transport of lactic acid, with a preference for the protonated acidic form of this weak acid. Overall, the data suggest that AtNIP2; 1 is an anaerobic- induced gene that encodes a lactic acid transporter and may play a role in adaptation to lactic fermentation under anaerobic stress.	Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Roberts, DM (corresponding author), Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA.	drobert2@utk.edu		Roberts, Daniel/0000-0002-0780-7056				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Alexandersson E, 2005, PLANT MOL BIOL, V59, P469, DOI 10.1007/s11103-005-0352-1; Armstrong W., 1979, Advances in Botanical Research, V7, P225, DOI 10.1016/S0065-2296(08)60089-0; Cabello-Hurtado F, 2004, PLANT SCI, V166, P633, DOI 10.1016/j.plantsci.2003.11.001; Chaumont F, 2000, PLANT PHYSIOL, V122, P1025, DOI 10.1104/pp.122.4.1025; Ciavatta VT, 2001, PLANT PHYSIOL, V127, P1556, DOI 10.1104/pp.010793; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Czechowski T, 2004, PLANT J, V38, P366, DOI 10.1111/j.1365-313X.2004.02051.x; DAVIES DD, 1974, PLANTA, V118, P297, DOI 10.1007/BF00385580; Dean RM, 1999, BIOCHEMISTRY-US, V38, P347, DOI 10.1021/bi982110c; DOLFERUS R, 1994, PLANT PHYSIOL, V105, P1075, DOI 10.1104/pp.105.4.1075; Drew MC, 1997, ANNU REV PLANT PHYS, V48, P223, DOI 10.1146/annurev.arplant.48.1.223; Felle HH, 2005, ANN BOT-LONDON, V96, P519, DOI 10.1093/aob/mci207; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; FRISCH DA, 1995, PLANT MOL BIOL, V27, P405, DOI 10.1007/BF00020193; Gonen T, 2005, NATURE, V438, P633, DOI 10.1038/nature04321; Guenther JF, 2000, PLANTA, V210, P741, DOI 10.1007/s004250050675; Guenther JF, 2003, PLANT CELL, V15, P981, DOI 10.1105/tpc.009787; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; JEFFERSON RA, 1987, EMBO J, V6, P3901; Johanson U, 2001, PLANT PHYSIOL, V126, P1358, DOI 10.1104/pp.126.4.1358; Klebl F, 2003, FEBS LETT, V547, P69, DOI 10.1016/S0014-5793(03)00671-9; Klok EJ, 2002, PLANT CELL, V14, P2481, DOI 10.1105/tpc.004747; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Kursteiner O, 2003, PLANT PHYSIOL, V132, P968, DOI 10.1104/pp.102.016907; Ma JF, 2006, NATURE, V440, P688, DOI 10.1038/nature04590; Mizutani M, 2006, PLANT CELL PHYSIOL, V47, P1420, DOI 10.1093/pcp/pcl004; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; Niemietz CM, 2000, FEBS LETT, V465, P110, DOI 10.1016/S0014-5793(99)01729-9; Noda Y, 2006, BBA-BIOMEMBRANES, V1758, P1117, DOI 10.1016/j.bbamem.2006.03.004; Ober ES, 1996, J EXP BOT, V47, P447, DOI 10.1093/jxb/47.3.447; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rivers RL, 1997, J BIOL CHEM, V272, P16256, DOI 10.1074/jbc.272.26.16256; RIVOAL J, 1993, PLANT PHYSIOL, V101, P553, DOI 10.1104/pp.101.2.553; ROBERTS JKM, 1984, P NATL ACAD SCI-BIOL, V81, P6029, DOI 10.1073/pnas.81.19.6029; ROBERTS JKM, 1984, P NATL ACAD SCI-BIOL, V81, P3379, DOI 10.1073/pnas.81.11.3379; Sachs MM, 1996, J EXP BOT, V47, P1, DOI 10.1093/jxb/47.1.1; SACHS MM, 1980, CELL, V20, P761, DOI 10.1016/0092-8674(80)90322-0; Sakurai J, 2005, PLANT CELL PHYSIOL, V46, P1568, DOI 10.1093/pcp/pci172; Schuurmans JAMJ, 2003, PLANT MOL BIOL, V53, P655, DOI 10.1023/B:PLAN.0000019070.60954.77; Subramanian C, 2004, P NATL ACAD SCI USA, V101, P6798, DOI 10.1073/pnas.0307964101; Takano J, 2006, PLANT CELL, V18, P1498, DOI 10.1105/tpc.106.041640; Tornroth-Horsefield S, 2006, NATURE, V439, P688, DOI 10.1038/nature04316; Tournaire-Roux C, 2003, NATURE, V425, P393, DOI 10.1038/nature01853; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; van Dongen JT, 2003, PLANT PHYSIOL, V131, P1529, DOI 10.1104/pp.102.017202; Wallace IS, 2006, BBA-BIOMEMBRANES, V1758, P1165, DOI 10.1016/j.bbamem.2006.03.024; Wallace IS, 2005, BIOCHEMISTRY-US, V44, P16826, DOI 10.1021/bi0511888; Wallace IS, 2004, PLANT PHYSIOL, V135, P1059, DOI 10.1104/pp.103.033415; WEAVER CD, 1991, PLANT PHYSIOL, V95, P222, DOI 10.1104/pp.95.1.222; Weig A, 1997, PLANT PHYSIOL, V114, P1347, DOI 10.1104/pp.114.4.1347; Weig AR, 2000, FEBS LETT, V481, P293, DOI 10.1016/S0014-5793(00)02027-5; XIA JH, 1994, PLANT PHYSIOL, V105, P651, DOI 10.1104/pp.105.2.651; XIA JH, 1992, PLANT PHYSIOL, V81, P3379; Yoo SD, 2007, NAT PROTOC, V2, P1565, DOI 10.1038/nprot.2007.199	56	130	143	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24209	24218		10.1074/jbc.M700982200	http://dx.doi.org/10.1074/jbc.M700982200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17584741	hybrid			2022-12-25	WOS:000248686600046
J	Tan, W; Wang, YH; Gold, B; Chen, JS; Dean, M; Harrison, PJ; Weinberger, DR; Law, AJ				Tan, Wei; Wang, Yanhong; Gold, Bert; Chen, Jingshan; Dean, Michael; Harrison, Paul J.; Weinberger, Daniel R.; Law, Amanda J.			Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ALTERNATIVE PROMOTERS; DOMAIN; CELLS; DISORDER; DISEASE; SYSTEM; CANCER	Neuregulin 1 (NRG1) is essential for the development and function of multiple organ systems, and its dysregulation has been linked to diseases such as cancer and schizophrenia. Recently, altered expression of a novel isoform (type IV) in the brain has been associated with schizophrenia-related genetic variants, especially rs6994992 (SNP8NRG243177). Here we have isolated and characterized full-length NRG1 type IV cDNAs from the adult and fetal human brain and identified novel splice variants of NRG1. Full-length type IV spans 1.8 kb and encodes a putative protein of 590 amino acids with a predicted molecular mass of similar to 66 kDa. The transcript consists of 11 exons with an Ig-like domain, an epidermal growth factor-like (EGF) domain, a beta-stalk, a transmembrane domain, and a cytoplasmic "a-tail," placing it in the beta 1a NRG1 subclass. NRG1 type IV was not detected in any tissues except brain and a putative type IV NRG1 protein of 66 kDa was similarly brain-specific. Type IV transcripts are more abundantly expressed in the fetal brain, where, in addition to the full-length structure, two novel type IV variants were identified. In vitro luciferase-reporter assays demonstrate that the 5' promoter region upstream of type IV is functional, with differential activity associated with genetic variation at rs6994992, and that promoter competition may impact on type IV expression. Our data suggest that type IV is a unique brain- specific NRG1 that is differentially expressed and processed during early development, is translated, and its expression regulated by a schizophrenia risk-associated functional promoter or single nucleotide polymorphism (SNP).	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; NCI, SAIC Frederick, Frederick, MD 21702 USA; NCI, NIH, Lab Genome Divers, Frederick, MD 21702 USA; NIMH, Intramural Res Program, Clin Brain Disorders Branch, Bethesda, MD 20892 USA	University of Oxford; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Law, AJ (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	amanda.law@psych.ox.ac.uk	Dean, Michael C/G-8172-2012; Tan, Weihong/A-5412-2008; Dean, Michael/R-7501-2019; McIntosh, Andrew M/B-9379-2008; Law, Amanda J/G-6372-2012; Tan, Weihong/AAA-4536-2020	Dean, Michael C/0000-0003-2234-0631; Tan, Weihong/0000-0002-8066-1524; McIntosh, Andrew M/0000-0002-0198-4588; Law, Amanda J/0000-0002-2574-1564; Harrison, Paul/0000-0002-6719-1126	Intramural NIH HHS Funding Source: Medline; Medical Research Council [G120/997] Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002906, Z01MH002734, Z01MH002904] Funding Source: NIH RePORTER; MRC [G120/997] Funding Source: UKRI	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Amin DN, 2005, EXP CELL RES, V309, P12, DOI 10.1016/j.yexcr.2005.04.034; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Bao JX, 2003, J CELL BIOL, V161, P1133, DOI 10.1083/jcb.200212085; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; Conte C, 2002, EMBO J, V21, P3908, DOI 10.1093/emboj/cdf367; De Gobbi M, 2006, SCIENCE, V312, P1215, DOI 10.1126/science.1126431; Falls DL, 2003, J NEUROCYTOL, V32, P619, DOI 10.1023/B:NEUR.0000020614.83883.be; Frenzel KE, 2001, J NEUROCHEM, V77, P1; Hall J, 2006, NAT NEUROSCI, V9, P1477, DOI 10.1038/nn1795; Harrison PJ, 2006, BIOL PSYCHIAT, V60, P132, DOI 10.1016/j.biopsych.2005.11.002; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Hashimoto R, 2004, MOL PSYCHIATR, V9, P299, DOI 10.1038/sj.mp.4001434; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jablensky A, 2001, ARCH GEN PSYCHIAT, V58, P579, DOI 10.1001/archpsyc.58.6.579; Law AJ, 2006, P NATL ACAD SCI USA, V103, P6747, DOI 10.1073/pnas.0602002103; Levav I, 2007, BRIT J PSYCHIAT, V190, P156, DOI 10.1192/bjp.bp.106.024943; Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754; Li DW, 2006, HUM MOL GENET, V15, P1995, DOI 10.1093/hmg/ddl122; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Montero JC, 2007, MOL BIOL CELL, V18, P380, DOI 10.1091/mbc.E06-06-0511; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; Ohler U, 2006, NUCLEIC ACIDS RES, V34, P5943, DOI 10.1093/nar/gkl608; Rimer M, 2003, J NEUROCYTOL, V32, P665, DOI 10.1023/B:NEUR.0000020615.79831.51; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; STEFANIS NC, 2007, IN PRESS BIOL PSYCHI; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Steinthorsdottir V, 2004, GENE, V342, P97, DOI 10.1016/j.gene.2004.07.029; Wang JY, 2001, J BIOL CHEM, V276, P2841, DOI 10.1074/jbc.M005700200; WEINBERGER D R, 1986, P397; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Zhang ZY, 2006, J NEUROSCI RES, V84, P1, DOI 10.1002/jnr.20861	36	114	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24343	24351		10.1074/jbc.M702953200	http://dx.doi.org/10.1074/jbc.M702953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17565985	hybrid			2022-12-25	WOS:000248686600060
J	Aprikian, P; Tchesnokova, V; Kidd, B; Yakovenko, O; Yarov-Yarovoy, V; Trinchina, E; Vogel, V; Thomas, W; Sokurenko, E				Aprikian, Pavel; Tchesnokova, Veronika; Kidd, Brian; Yakovenko, Olga; Yarov-Yarovoy, Vladimir; Trinchina, Elena; Vogel, Viola; Thomas, Wendy; Sokurenko, Evgeni			Interdomain interaction in the FimH adhesin of Escherichia coli regulates the affinity to mannose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATCH BONDS; STRUCTURAL BASIS; P-SELECTIN; FIMBRIAL ADHESIN; BINDING; DOMAIN; FLOW; TRANSITION; THRESHOLD; CHAPERONE	FimH is a mannose-specific adhesin located on the tip of type 1 fimbriae of Escherichia coli that is capable of mediating shear-enhanced bacterial adhesion. FimH consists of a fimbria-associated pilin domain and a mannose-binding lectin domain, with the binding pocket positioned opposite the interdomain interface. By using the yeast two-hybrid system, purified lectin and pilin domains, and docking simulations, we show here that the FimH domains interact with one another. The affinity for mannose is greatly enhanced (up to 300-fold) in FimH variants in which the interdomain interaction is disrupted by structural mutations in either the pilin or lectin domains. Also, affinity to mannose is dramatically enhanced in isolated lectin domains or in FimH complexed with the chaperone molecule that is wedged between the domains. Furthermore, FimH with native structure mediates weak binding at low shear stress but shifts to strong binding at high shear, whereas FimH with disrupted interdomain contacts ( or the isolated lectin domain) mediates strong binding to mannose-coated surfaces even under low shear. We propose that interactions between lectin and pilin domains decrease the affinity of the mannose-binding pocket via an allosteric mechanism. We further suggest that mechanical force at high shear stress separates the two domains, allowing the lectin domain to switch from a low affinity to a high affinity state. This shift provides a mechanism for FimH-mediated shear-enhanced adhesion by enabling the adhesin to form catch bond-like interactions that are longer lived at high tensile force.	Univ Washington, Dept Microbiol, Seattle, WA 98105 USA; Univ Washington, Dept Bioengn, Seattle, WA 98105 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98105 USA; Univ Washington, Nanotechnol Ctr, Seattle, WA 98105 USA; ETH, Swiss Fed Inst Technol, Dept Mat, Lab Biol Oriented Mat, CH-8093 Zurich, Switzerland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Swiss Federal Institutes of Technology Domain; ETH Zurich	Thomas, W (corresponding author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.	wendyt@u.washington.edu; evs@u.washington.edu	Vogel, Viola/O-8025-2015; Yarov-Yarovoy, Vladimir/ABE-5454-2020	Vogel, Viola/0000-0003-2898-7671; Yarov-Yarovoy, Vladimir/0000-0002-2325-4834; Thomas, Wendy/0000-0001-8602-0819; Kidd, Brian/0000-0003-2110-1145				Barnhart MM, 2000, P NATL ACAD SCI USA, V97, P7709, DOI 10.1073/pnas.130183897; Barnhart MM, 2003, J BACTERIOL, V185, P2723, DOI 10.1128/JB.185.9.2723-2730.2003; Barsegov V, 2005, P NATL ACAD SCI USA, V102, P1835, DOI 10.1073/pnas.0406938102; Bouckaert J, 2005, MOL MICROBIOL, V55, P441, DOI 10.1111/j.1365-2958.2004.04415.x; Bouckaert J, 2006, MOL MICROBIOL, V61, P1556, DOI 10.1111/j.1365-2958.2006.05352.x; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Chang KC, 1999, BIOPHYS J, V76, P1280, DOI 10.1016/S0006-3495(99)77291-7; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Deller MC, 2000, CURR OPIN STRUC BIOL, V10, P213, DOI 10.1016/S0959-440X(00)00072-5; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Doggett TA, 2002, BIOPHYS J, V83, P194, DOI 10.1016/S0006-3495(02)75161-8; Dwir O, 2003, J CELL BIOL, V163, P649, DOI 10.1083/jcb.200303134; Evans E, 2004, P NATL ACAD SCI USA, V101, P11281, DOI 10.1073/pnas.0401870101; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Forero M, 2006, PLOS BIOL, V4, P1509, DOI 10.1371/journal.pbio.0040298; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Gray JJ, 2003, J MOL BIOL, V331, P281, DOI 10.1016/S0022-2836(03)00670-3; Guo B, 2006, P NATL ACAD SCI USA, V103, P9844, DOI 10.1073/pnas.0601255103; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hung CS, 2002, MOL MICROBIOL, V44, P903, DOI 10.1046/j.1365-2958.2002.02915.x; Isberg RR, 2002, CELL, V110, P1, DOI 10.1016/S0092-8674(02)00821-8; JONES CH, 1993, P NATL ACAD SCI USA, V90, P8397, DOI 10.1073/pnas.90.18.8397; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Konstantopoulos K, 2003, CURR BIOL, V13, pR611, DOI 10.1016/S0960-9822(03)00529-3; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; Lou JZ, 2007, BIOPHYS J, V92, P1471, DOI 10.1529/biophysj.106.097048; Lou JZ, 2006, J CELL BIOL, V174, P1107, DOI 10.1083/jcb.200606056; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Marchese P, 1999, P NATL ACAD SCI USA, V96, P7837, DOI 10.1073/pnas.96.14.7837; Marshall BT, 2003, NATURE, V423, P190, DOI 10.1038/nature01605; Miller E, 2006, BIOPHYS J, V91, P3848, DOI 10.1529/biophysj.106.088989; Nilsson LM, 2006, J BIOL CHEM, V281, P16656, DOI 10.1074/jbc.M511496200; Pereverzev YV, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.010903; Pereverzev YV, 2005, BIOPHYS J, V89, P1446, DOI 10.1529/biophysj.105.062158; Phan UT, 2006, NAT IMMUNOL, V7, P883, DOI 10.1038/ni1366; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; Salas A, 2006, J BIOL CHEM, V281, P10876, DOI 10.1074/jbc.M512472200; Sarangapani KK, 2004, J BIOL CHEM, V279, P2291, DOI 10.1074/jbc.M310396200; Schembri MA, 2000, INFECT IMMUN, V68, P2638, DOI 10.1128/IAI.68.5.2638-2646.2000; Schembri MA, 2000, FEMS MICROBIOL LETT, V188, P147, DOI 10.1111/j.1574-6968.2000.tb09186.x; Sokurenko EV, 2004, MOL BIOL EVOL, V21, P1373, DOI 10.1093/molbev/msh136; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; Sokurenko EV, 2001, MOL MICROBIOL, V41, P675, DOI 10.1046/j.1365-2958.2001.02545.x; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Thomas W, 2006, BIOPHYS J, V90, P753, DOI 10.1529/biophysj.105.066548; Thomas WE, 2004, MOL MICROBIOL, V53, P1545, DOI 10.1111/j.1365-2958.2004.04226.x; Thomas WE, 2002, CELL, V109, P913, DOI 10.1016/S0092-8674(02)00796-1; Thomas W, 2006, J CELL BIOL, V174, P911, DOI 10.1083/jcb.200609029; Ulrichts H, 2006, J BIOL CHEM, V281, P4699, DOI 10.1074/jbc.M513314200; Vetsch M, 2004, NATURE, V431, P329, DOI 10.1038/nature02891; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weissman SJ, 2006, MOL MICROBIOL, V59, P975, DOI 10.1111/j.1365-2958.2005.04985.x; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Zhu Cheng, 2005, Molecular & Cellular Biomechanics, V2, P91	57	110	114	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23437	23446		10.1074/jbc.M702037200	http://dx.doi.org/10.1074/jbc.M702037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17567583	hybrid			2022-12-25	WOS:000248577500044
J	Yin, YI; Bassit, B; Zhu, L; Yang, X; Wang, CY; Li, YM				Yin, Ye Ingrid; Bassit, Bhramdeo; Zhu, Lei; Yang, Xia; Wang, Chunyu; Li, Yue-Ming			gamma-secretase substrate concentration modulates the A beta 42/A beta 40 ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; TRANSMEMBRANE DOMAIN; PRESENILIN MUTATIONS; CLEAVAGE SITE; BETA-PROTEIN; DEPOSITION; INHIBITORS; A-BETA-42; SPECIFICITY	Mutation of the amyloid precursor protein (APP), presenilin 1, or presenilin-2 results in the development of early onset autosomal dominant forms of Alzheimer disease ( AD). These mutations lead to an increased A beta 42/A beta 40 ratio that correlates with the onset of disease. However, it remains unknown how these mutations affect gamma-secretase, a protease that generates the termini of A beta 40 and A beta 42. Here we have determined the reaction mechanism of gamma-secretase with wild type and three mutated APP substrates. Our findings indicate that despite the overall outcome of an increased A beta 42/A beta 40 ratio, these mutations each display rather distinct reactivity to gamma-secretase. Intriguingly, we found that the ratio of A beta 42/A beta 40 is variable with substrate concentration; increased substrate concentrations result in higher ratios of A beta 42/A beta 40. Moreover, we demonstrated that reduction of gamma-secretase substrate concentration by BACE1 inhibition in cells decreased the A beta 42/A beta 40 ratio. This study indicates that biological factors affecting targets such as BACE1 and APP, which ultimately cause an increased concentration of gamma-secretase substrate, can augment the A beta 42/A beta 40 ratio and may play a causative role in sporadic AD. Therefore, strategies lowering the A beta 42/A beta 40 ratio through partial reduction of gamma-secretase substrate production may introduce a practical therapeutic modality for treatment of AD.	Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA; Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA	Memorial Sloan Kettering Cancer Center; Rensselaer Polytechnic Institute	Li, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, 1275 York Ave,Box 459, New York, NY 10021 USA.	liy2@mskcc.org	Wang, Chunyu/AAH-5952-2019; LI, Yue/GRS-8071-2022					Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Clarke EE, 2006, J BIOL CHEM, V281, P31279, DOI 10.1074/jbc.M605051200; De Jonghe C, 2001, HUM MOL GENET, V10, P1665, DOI 10.1093/hmg/10.16.1665; De Strooper B, 2007, EMBO REP, V8, P141, DOI 10.1038/sj.embor.7400897; Deng Y, 2006, J NEUROSCI, V26, P3845, DOI 10.1523/JNEUROSCI.5384-05.2006; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; Kim J, 2007, J NEUROSCI, V27, P627, DOI 10.1523/JNEUROSCI.4849-06.2007; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kumar-Singh S, 2006, HUM MUTAT, V27, P686, DOI 10.1002/humu.20336; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Maruyama K, 1996, BIOCHEM BIOPH RES CO, V227, P730, DOI 10.1006/bbrc.1996.1577; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Xie J, 2005, J BIOL CHEM, V280, P13824, DOI 10.1074/jbc.M411933200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhang X, 2007, J BIOL CHEM, V282, P10873, DOI 10.1074/jbc.M608856200; Zhao GJ, 2004, J BIOL CHEM, V279, P50647, DOI 10.1074/jbc.C400473200	30	95	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23639	23644		10.1074/jbc.M704601200	http://dx.doi.org/10.1074/jbc.M704601200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17556361	hybrid			2022-12-25	WOS:000248577500066
J	Cheng, B; Price, DH				Cheng, Bo; Price, David H.			Properties of RNA polymerase II elongation complexes before and after the P-TEFb-mediated transition into productive elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPT RELEASE FACTOR; BROMODOMAIN PROTEIN BRD4; IN-VITRO; DEPENDENT TRANSCRIPTION; CAPPING ENZYME; HELA-CELLS; HIV-1 TAT; FACTOR-B; PHOSPHORYLATION; KINASE	The positive transcription elongation factor, P-TEFb, controls the fraction of initiated RNA polymerase II molecules that enter into the productive mode of elongation necessary to generate mRNAs. To better understand the mechanism of this transition into productive elongation we optimized a defined in vitro transcription system and compared results obtained with it to those obtained with a crude system. We found that controlling the function of TFIIF is a key aspect of RNA polymerase II elongation control. Before P-TEFb function, early elongation complexes under the control of negative factors are completely unresponsive to the robust elongation stimulatory activity of TFIIF. P-TEFb-mediated phosphorylation events, targeting the elongation complex containing DSIF and NELF, reverse the negative effect of DSIF and NELF and simultaneously facilitate the action of TFIIF. We also found that productive elongation complexes are completely resistant to negative elongation factors. Our data suggest that an additional factor(s) is involved in establishing the unique resistance activities of the elongation complexes before and after P-TEFb function. Furthermore, we provide evidence for the existence of another positive activity required for efficient function of P-TEFb. A model of the mechanism of P-TEFb-mediated elongation control is proposed in which P-TEFb induces the transition into productive elongation by changing the accessibility of elongation factors to elongation complexes. Our results have uncovered important properties of elongation complexes that allow a more complete understanding of how P-TEFb controls the elongation phases of transcription by RNA polymerase II.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Mol & Cellular Biol Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Price, DH (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.	david-price@uiowa.edu	Cheng, Bo/C-7217-2014; Cheng, Bo/B-7575-2012; Price, David H/F-6173-2010; Cheng, Bo/J-5569-2014	Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamson TE, 2003, METHOD ENZYMOL, V371, P264; Aida M, 2006, MOL CELL BIOL, V26, P6094, DOI 10.1128/MCB.02366-05; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Bird G, 2004, MOL CELL BIOL, V24, P8963, DOI 10.1128/MCB.24.20.8963-8969.2004; Byers SA, 2005, J BIOL CHEM, V280, P16360, DOI 10.1074/jbc.M500424200; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Fujinaga K, 2004, MOL CELL BIOL, V24, P787, DOI 10.1128/MCB.24.2.787-795.2004; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Guiguen A, 2007, EMBO J, V26, P1552, DOI 10.1038/sj.emboj.7601627; GUO HL, 1993, J BIOL CHEM, V268, P18762; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Kim HJ, 2004, MOL CELL BIOL, V24, P6184, DOI 10.1128/MCB.24.14.6184-6193.2004; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kulkarni PA, 2004, RECENT PROG HORM RES, V59, P125, DOI 10.1210/rp.59.1.125; Lindstrom DL, 2003, MOL CELL BIOL, V23, P1368, DOI 10.1128/MCB.23.4.1368-1378.2003; Lis JT, 2000, GENE DEV, V14, P792; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Mandal SS, 2004, P NATL ACAD SCI USA, V101, P7572, DOI 10.1073/pnas.0401493101; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; Palangat M, 2005, P NATL ACAD SCI USA, V102, P15036, DOI 10.1073/pnas.0409405102; Peng J, 1998, COLD SPRING HARB SYM, V63, P365, DOI 10.1101/sqb.1998.63.365; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; PRICE DH, 1987, J BIOL CHEM, V262, P3244; Qiang Z, 2006, MICROBIOL MOL BIOL R, V70, P646, DOI 10.1128/MMBR.00011-06; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; TAMM I, 1980, BIOCHEMISTRY-US, V19, P2743, DOI 10.1021/bi00553a032; UCKER DS, 1984, J BIOL CHEM, V259, P7416; Ujvari A, 2004, J BIOL CHEM, V279, P49773, DOI 10.1074/jbc.M409087200; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1998, J BIOL CHEM, V273, P3771, DOI 10.1074/jbc.273.6.3771; Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024; Yamaguchi Y, 2002, MOL CELL BIOL, V22, P2918, DOI 10.1128/MCB.22.9.2918-2927.2002; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Zhang ZQ, 2004, J BIOL CHEM, V279, P23223, DOI 10.1074/jbc.M402956200; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	54	108	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21901	21912		10.1074/jbc.M702936200	http://dx.doi.org/10.1074/jbc.M702936200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17548348	hybrid			2022-12-25	WOS:000248196800038
J	Galownia, NC; Kushiro, K; Gong, Y; Asthagiri, AR				Galownia, Niki C.; Kushiro, Keiichiro; Gong, Yuan; Asthagiri, Anand R.			Selective desensitization of growth factor signaling by cell adhesion to fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYCLIN D1 EXPRESSION; PDGF BETA-RECEPTOR; GRB2-SOS COMPLEX; CULTURED-CELLS; RAS ACTIVATION; G1 PHASE; PHOSPHORYLATION; INSULIN; TRANSDUCTION	Cell adhesion to the extracellular matrix is required to execute growth factor (GF)-mediated cell behaviors, such as proliferation. A major underlying mechanism is that cell adhesion enhances GF-mediated intracellular signals, such as extracellular signal-regulated kinase (Erk). However, because GFs use distinct mechanisms to activate Ras-Erk signaling, it is unclear whether adhesion-mediated enhancement of Erk signaling is universal to all GFs. We examined this issue by quantifying the dynamics of Erk signaling induced by epidermal growth factor, basic fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF) in NIH-3T3 fibroblasts. Adhesion to fibronectin-coated surfaces enhances Erk signaling elicited by epidermal growth factor but not by bFGF or PDGF. Unexpectedly, adhesion is not always a positive influence on GF-mediated signaling. At critical subsaturating doses of PDGF or bFGF, cell adhesion ablates Erk signaling; that is, adhesion desensitizes the cell to GF stimulation, rendering the signaling pathway unresponsive to GF. Interestingly, the timing of growth factor stimulation proved critical to the desensitization process. Erk activation significantly improved only when pre-exposure to adhesion was completely eliminated; thus, concurrent stimulation by GF and adhesion was able to partially rescue adhesion-mediated desensitization of PDGF- and bFGF-mediated Erk and Akt signaling. These findings suggest that adhesion-mediated desensitization occurs with rapid kinetics and targets a regulatory point upstream of Ras and proximal to GF receptor activation. Thus, adhesion-dependent Erk signaling is not universal to all GFs but, rather, is GF-specific with quantitative features that depend strongly on the dose and timing of GF exposure.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Asthagiri, AR (corresponding author), CALTECH, Div Chem & Chem Engn, 1200 E California Blvd,MC 210-41, Pasadena, CA 91125 USA.	anand@cheme.caltech.edu			NIBIB NIH HHS [EB005214] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R03EB005214] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Asthagiri AR, 2000, J CELL SCI, V113, P4499; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; BUDAY L, 1995, ONCOGENE, V11, P1327; Budowle B, 2001, BIOTECHNIQUES, V30, P680, DOI 10.2144/01303pf01; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; DANIEL TO, 1985, P NATL ACAD SCI USA, V82, P2684, DOI 10.1073/pnas.82.9.2684; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fucini RV, 1999, J BIOL CHEM, V274, P18651, DOI 10.1074/jbc.274.26.18651; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HERREN B, 1993, J BIOL CHEM, V268, P15088; Hupfeld CJ, 2005, J BIOL CHEM, V280, P1016, DOI 10.1074/jbc.M403674200; Ji SN, 2002, J BIOL CHEM, V277, P28384, DOI 10.1074/jbc.M111723200; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lauffenburger DA, 1993, RECEPTORS MODELS BIN, P30; Lee JW, 2004, MOL CELLS, V17, P188; Lin TH, 1997, J BIOL CHEM, V272, P8849; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN CS, 1994, J BIOLUM CHEMILUM, V9, P145, DOI 10.1002/bio.1170090308; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwartz MA, 2001, J CELL SCI, V114, P2553; Walker JL, 2005, CANCER METAST REV, V24, P383, DOI 10.1007/s10555-005-5130-7; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Wijelath ES, 2006, CIRC RES, V99, P853, DOI 10.1161/01.RES.0000246849.17887.66; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899	51	4	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21758	21766		10.1074/jbc.M703577200	http://dx.doi.org/10.1074/jbc.M703577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17540764	Green Accepted, hybrid			2022-12-25	WOS:000248196800023
J	Leiros, HKS; Pey, AL; Innselset, M; Moe, E; Leiros, I; Steen, IH; Martinez, A				Leiros, Hanna-Kirsti S.; Pey, Angel L.; Innselset, Marte; Moe, Elin; Leiros, Ingar; Steen, Ida Helene; Martinez, Aurora			Structure of phenylalanine hydroxylase from Colwellia psychrerythraea 34H, a monomeric cold active enzyme with local flexibility around the active site and high overall stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID HYDROXYLASES; DIFFERENTIAL SCANNING CALORIMETRY; RESOLUTION CRYSTAL-STRUCTURES; NATIVE-STATE ENSEMBLE; PSEUDOMONAS-AERUGINOSA; CHROMOBACTERIUM-VIOLACEUM; SUBSTRATE-BINDING; CATALYTIC DOMAIN; PSYCHROPHILIC BACTERIUM; ALLOSTERIC REGULATION	The characteristic of cold-adapted enzymes, high catalytic efficiency at low temperatures, is often associated with low thermostability and high flexibility. In this context, we analyzed the catalytic properties and solved the crystal structure of phenylalanine hydroxylase from the psychrophilic bacterium Colwellia psychrerythraea 34H (CpPAH). CpPAH displays highest activity with tetrahydrobiopterin (BH4) as cofactor and at 25 degrees C (15 degrees C above the optimal growth temperature). Although the enzyme is monomeric with a single L-Phe-binding site, the substrate binds cooperatively. In comparison with PAH from mesophilic bacteria and mammalian organisms, CpPAH shows elevated [S-0.5](L-Phe) (= 1.1 +/- 0.1 mM) and K-m(BH4) (= 0.3 +/- 0.1 mM), as well as high catalytic efficiency at 10 degrees C. However, the half-inactivation and denaturation temperature is only slightly lowered (T-m similar to 52 degrees C; where T-m is half-denaturation temperature), in contrast to other cold-adapted enzymes. The crystal structure shows regions of local flexibility close to the highly solvent accessible binding sites for BH4 (Gly(87)/Phe(88)/Gly(89)) and L-Phe (Tyr(114)-Pro(118)). Normal mode and COREX analysis also detect these and other areas with high flexibility. Greater mobility around the active site and disrupted hydrogen bonding abilities for the cofactor appear to represent cold-adaptive properties that do not markedly affect the thermostability of CpPAH.	Univ Bergen, Dept Biomed, N-5009 Bergen, Norway; Univ Tromso, Dept Chem, Norwegian Struct Biol Ctr, Norstruct, N-9037 Tromso, Norway; Univ Bergen, Dept Biol, N-5020 Bergen, Norway	University of Bergen; UiT The Arctic University of Tromso; University of Bergen	Martinez, A (corresponding author), Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.	aurora.martinez@biomed.uib.no	Martinez, Aurora/M-3088-2019; Moe, Elin/J-4367-2013; Leiros, Hanna-Kirsti S/E-4000-2016; Steen, Ida Helene/HGD-1549-2022; Leiros, Ingar/AAM-2940-2020; Moe, Elin/Q-6131-2019	Martinez, Aurora/0000-0003-1643-6506; Moe, Elin/0000-0002-7923-1471; Leiros, Hanna-Kirsti S/0000-0002-2726-6322; Moe, Elin/0000-0002-7923-1471; Leiros, Ingar/0000-0001-9333-4541; Flydal, Marte/0000-0002-4070-8367; Pey, Angel Luis/0000-0001-7706-3243				ABITA JP, 1984, J BIOL CHEM, V259, P4560; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Andersen OA, 2003, J MOL BIOL, V333, P747, DOI 10.1016/j.jmb.2003.09.004; Andersen OA, 2001, J MOL BIOL, V314, P279, DOI 10.1006/jmbi.2001.5061; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Arias-Barrau E, 2004, J BACTERIOL, V186, P5062, DOI 10.1128/jb.186.15.5062-5077.2004; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Chen DW, 1998, J BIOL CHEM, V273, P25594, DOI 10.1074/jbc.273.40.25594; CORNISHBOWDEN A, 1987, J THEOR BIOL, V124, P1, DOI 10.1016/S0022-5193(87)80248-5; CORNISHBOWDEN A, 1986, BIOCHEM J, V240, P293, DOI 10.1042/bj2400293; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; Duffy B, 2003, ANNU REV PHYTOPATHOL, V41, P501, DOI 10.1146/annurev.phyto.41.052002.095606; Ekstrom F, 2003, ACTA CRYSTALLOGR D, V59, P1310, DOI 10.1107/S090744490301014X; Erlandsen H, 2004, P NATL ACAD SCI USA, V101, P16903, DOI 10.1073/pnas.0407256101; Erlandsen H, 2002, J MOL BIOL, V320, P645, DOI 10.1016/S0022-2836(02)00496-5; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; Fitzpatrick PF, 2003, BIOCHEMISTRY-US, V42, P14083, DOI 10.1021/bi035656u; Georlette D, 2004, FEMS MICROBIOL REV, V28, P25, DOI 10.1016/j.femsre.2003.07.003; Gianese G, 2001, PROTEIN ENG, V14, P141, DOI 10.1093/protein/14.3.141; Gjetting T, 2001, AM J HUM GENET, V68, P1353, DOI 10.1086/320604; Gu W, 1998, MICROBIOL-SGM, V144, P3127, DOI 10.1099/00221287-144-11-3127; Heredia VV, 2006, BIOCHEMISTRY-US, V45, P7553, DOI 10.1021/bi060253q; Hilser V J, 2001, Methods Mol Biol, V168, P93; Hilser VJ, 1998, P NATL ACAD SCI USA, V95, P9903, DOI 10.1073/pnas.95.17.9903; Hollup SM, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-52; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; Huston AL, 2000, ENVIRON MICROBIOL, V2, P383, DOI 10.1046/j.1462-2920.2000.00118.x; Huston AL, 2004, APPL ENVIRON MICROB, V70, P3321, DOI 10.1128/AEM.70.6.3321-3328.2004; Ibarra-Molero B, 1999, BIOCHEMISTRY-US, V38, P8138, DOI 10.1021/bi9905819; Ikemoto K, 2002, BIOL CHEM, V383, P325, DOI 10.1515/BC.2002.035; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamata K, 2004, STRUCTURE, V12, P429, DOI 10.1016/j.str.2004.02.005; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; KOTOB SI, 1995, APPL ENVIRON MICROB, V61, P1620, DOI 10.1128/AEM.61.4.1620-1622.1995; Kumar S, 2004, CHEMBIOCHEM, V5, P280, DOI 10.1002/cbic.200300627; Leiros HKS, 2000, EUR J BIOCHEM, V267, P1039; Liberles JS, 2005, AMINO ACIDS, V28, P1, DOI 10.1007/s00726-004-0152-y; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; Maki S, 2006, EXTREMOPHILES, V10, P237, DOI 10.1007/s00792-005-0493-9; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Methe BA, 2005, P NATL ACAD SCI USA, V102, P10913, DOI 10.1073/pnas.0504766102; Miranda FF, 2002, J BIOL CHEM, V277, P40937, DOI 10.1074/jbc.M112197200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAKATA H, 1979, J BIOL CHEM, V254, P1829; NEET KE, 1990, BIOCHEMISTRY-US, V29, P770, DOI 10.1021/bi00455a026; Nosanchuk JD, 2006, ANTIMICROB AGENTS CH, V50, P3519, DOI 10.1128/AAC.00545-06; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; PARNIAK MA, 1981, J BIOL CHEM, V256, P6876; Pey AL, 2004, J AM CHEM SOC, V126, P13670, DOI 10.1021/ja047713s; Plonka PM, 2006, ACTA BIOCHIM POL, V53, P429, DOI 10.18388/abp.2006_3314; Polen I, 2005, J BIOTECHNOL, V115, P221, DOI 10.1016/j.jbiotec.2004.08.017; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; Rocchia W, 2002, J COMPUT CHEM, V23, P128, DOI 10.1002/jcc.1161; Sanchez-Amat A, 1998, COMP BIOCHEM PHYS B, V119, P557, DOI 10.1016/S0305-0491(98)00028-5; Sanchez-Ruiz JM, 2001, TRENDS BIOTECHNOL, V19, P132, DOI 10.1016/S0167-7799(00)01548-1; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SCRIVER CR, 2001, METABOLIC MOL BASES, P1667; Siddiqui KS, 2006, ANNU REV BIOCHEM, V75, P403, DOI 10.1146/annurev.biochem.75.103004.142723; Smalas A O, 2000, Biotechnol Annu Rev, V6, P1, DOI 10.1016/S1387-2656(00)06018-X; Song J, 1996, MOL MICROBIOL, V22, P497, DOI 10.1046/j.1365-2958.1996.00131.x; Song J, 1999, J BACTERIOL, V181, P2789, DOI 10.1128/JB.181.9.2789-2796.1999; Teigen K, 1999, J MOL BIOL, V294, P807, DOI 10.1006/jmbi.1999.3288; Teigen K, 2005, PTERIDINES, V16, P27; Teigen K, 2007, CURR MED CHEM, V14, P455, DOI 10.2174/092986707779941023; Thorolfsson M, 2003, BIOCHEMISTRY-US, V42, P3419, DOI 10.1021/bi034021s; Thorolfsson M, 2002, BIOCHEMISTRY-US, V41, P7573, DOI 10.1021/bi0160720; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vertrees J, 2005, BIOINFORMATICS, V21, P3318, DOI 10.1093/bioinformatics/bti520; Volner A, 2003, J BIOL INORG CHEM, V8, P121, DOI 10.1007/s00775-002-0395-6; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Werner-Felmayer G, 2002, CURR DRUG METAB, V3, P159, DOI 10.2174/1389200024605073; Xie G, 1999, Microb Comp Genomics, V4, P5, DOI 10.1089/omi.1.1999.4.5; Yumoto I, 1998, INT J SYST BACTERIOL, V48, P1357, DOI 10.1099/00207713-48-4-1357; ZHAO GS, 1994, P NATL ACAD SCI USA, V91, P1366, DOI 10.1073/pnas.91.4.1366; Zoidakis J, 2005, J INORG BIOCHEM, V99, P771, DOI 10.1016/j.jinorgbio.2004.12.017	80	62	64	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21973	21986		10.1074/jbc.M610174200	http://dx.doi.org/10.1074/jbc.M610174200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17537732	hybrid			2022-12-25	WOS:000248196800045
J	Shiryaev, SA; Remacle, AG; Ratnikov, BI; Nelson, NA; Savinov, AY; Wei, G; Bottini, M; Rega, MF; Parent, A; Desjardins, R; Fugere, M; Day, R; Sabet, M; Pellecchia, M; Liddington, RC; Smith, JW; Mustelin, T; Guiney, DG; Lebl, M; Strongin, AY				Shiryaev, Sergey A.; Remacle, Albert G.; Ratnikov, Boris I.; Nelson, Nicholas A.; Savinov, Alexei Y.; Wei, Ge; Bottini, Massimo; Rega, Michele F.; Parent, Amelie; Desjardins, Roxane; Fugere, Martin; Day, Robert; Sabet, Mojgan; Pellecchia, Maurizio; Liddington, Robert C.; Smith, Jeffrey W.; Mustelin, Tomas; Guiney, Donald G.; Lebl, Michal; Strongin, Alex Y.			Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA EXOTOXIN-A; ANTHRAX LETHAL FACTOR; D-ARGININE; PEPTIDE-SYNTHESIS; INFLUENZA-VIRUS; IN-VIVO; INHIBITORS; CLEAVAGE; HEMAGGLUTININ; ACTIVATION	Pathogens or their toxins, including influenza virus, Pseudomonas, and anthrax toxins, require processing by host proprotein convertases (PCs) to enter host cells and to cause disease. Conversely, inhibiting PCs is likely to protect host cells from multiple furin-dependent, but otherwise unrelated, pathogens. To determine if this concept is correct, we designed specific nanomolar inhibitors of PCs modeled from the extended cleavage motif TPQRERRRKKR down arrow GL of the avian influenza H5N1 hemagglutinin. We then confirmed the efficacy of the inhibitory peptides in vitro against the fluorescent peptide, anthrax protective antigen (PA83), and influenza hemagglutinin substrates and also in mice in vivo against two unrelated toxins, anthrax and Pseudomonas exotoxin. Peptides with Phe/Tyr at P1' were more selective for furin. Peptides with P1' Thr were potent against multiple PCs. Our strategy of basing the peptide sequence on a furin cleavage motif known for an avian flu virus shows the power of starting inhibitor design with a known substrate. Our results confirm that inhibiting furin-like PCs protects the host from the distinct furin-dependent infections and lay a foundation for novel, host cell-focused therapies against acute diseases.	Burnham Inst Med Res, La Jolla, CA 92037 USA; Illumina Inc, San Diego, CA 92121 USA; Univ Sherbrooke, Dept Pharmacol, Sherbrooke, PQ J1H SN4, Canada; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Illumina; University of Sherbrooke; University of California System; University of California San Diego	Strongin, AY (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019; Lebl, Michal/GZG-9703-2022; Pellecchia, Maurizio/Y-7072-2018	Strongin, Alex/0000-0003-3765-3016; Bottini, Massimo/0000-0001-9237-8972; Mustelin, Tomas/0000-0001-5912-8840	NCRR NIH HHS [RR020843] Funding Source: Medline; NIAID NIH HHS [AI061139] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI061139] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Basak A, 2001, BIOCHEM J, V353, P537, DOI 10.1042/0264-6021:3530537; Bottini M, 2006, J NANOSCI NANOTECHNO, V6, P1381, DOI 10.1166/jnn.2006.164; Bradley KA, 2003, BIOCHEM PHARMACOL, V65, P309, DOI 10.1016/S0006-2952(02)01455-7; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; Chiron MF, 1997, J BIOL CHEM, V272, P31707, DOI 10.1074/jbc.272.50.31707; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Fogle MR, 2002, J SURG RES, V106, P86, DOI 10.1006/jsre.2002.6433; Forino M, 2005, P NATL ACAD SCI USA, V102, P9499, DOI 10.1073/pnas.0502733102; Fugere M, 2005, TRENDS PHARMACOL SCI, V26, P294, DOI 10.1016/j.tips.2005.04.006; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; Fugere M, 2007, MOL PHARMACOL, V71, P323, DOI 10.1124/mol.106.027946; GILL DM, 1982, MICROBIOL REV, V46, P86, DOI 10.1128/MMBR.46.1.86-94.1982; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; Hachmann J, 2006, BIOPOLYMERS, V84, P340, DOI 10.1002/bip.20482; Hachmann J, 2006, J COMB CHEM, V8, P149, DOI 10.1021/cc050123l; Jiao GS, 2006, P NATL ACAD SCI USA, V103, P19707, DOI 10.1073/pnas.0606555104; Kacprzak MM, 2004, J BIOL CHEM, V279, P36788, DOI 10.1074/jbc.M400484200; Kandel R, 2005, EXPERT OPIN THER TAR, V9, P1, DOI 10.1517/14728222.9.1.1; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Kozlov IA, 2006, COMB CHEM HIGH T SCR, V9, P481, DOI 10.2174/138620706777698535; Lebl Michal, 2005, V298, P167; Leikina E, 2002, EMBO J, V21, P5701, DOI 10.1093/emboj/cdf559; Peinado JR, 2004, BIOCHEM BIOPH RES CO, V321, P601, DOI 10.1016/j.bbrc.2004.07.012; Remacle AG, 2006, ONCOGENE, V25, P5648, DOI 10.1038/sj.onc.1209572; Sabet M, 2006, FEMS IMMUNOL MED MIC, V47, P369, DOI 10.1111/j.1574-695X.2006.00096.x; Sarac MS, 2004, INFECT IMMUN, V72, P602, DOI 10.1128/IAI.72.1.602-605.2004; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; Scamuffa N, 2006, FASEB J, V20, P1954, DOI 10.1096/fj.05-5491rev; Shiryaev SA, 2006, BIOCHEM J, V393, P503, DOI 10.1042/BJ20051374; Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Wu CCN, 2007, P NATL ACAD SCI USA, V104, P3990, DOI 10.1073/pnas.0611624104; Yang HH, 2005, ANAL CHEM, V77, P354, DOI 10.1021/ac048351+	35	80	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20847	20853		10.1074/jbc.M703847200	http://dx.doi.org/10.1074/jbc.M703847200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17537721	hybrid			2022-12-25	WOS:000248047500010
J	Thuy, TT; Shah, NS; Mai, HA; Do, TN; Duong, T; Truong, L; Dinh, NS; Bui, DD; Luu, TMC; Phung, TPM; Wells, CD; Laserson, KF; Varma, JK				Thuy, Trinh Thanh; Shah, N. Sarita; Mai Hoang Anh; Do Trong Nghia; Duong Thom; Truong Linh; Dinh Ngoc Sy; Bui Duc Duong; Luu Thi Minh Chau; Phung Thi Phuong Mai; Wells, Charles D.; Laserson, Kayla F.; Varma, Jay K.			HIV-Associated TB in An Giang Province, Vietnam, 2001-2004: Epidemiology and TB Treatment Outcomes	PLOS ONE			English	Article								Background. Mortality is high in HIV-infected TB patients, but few studies from Southeast Asia have documented the benefits of interventions, such as co-trimoxazole (CTX), in reducing mortality during TB treatment. To help guide policy in Vietnam, we studied the epidemiology of HIV-associated TB in one province and examined factors associated with outcomes, including the impact of CTX use. Methodology/Principal Findings. We retrospectively abstracted data for all HIV-infected persons diagnosed with TB from 2001-2004 in An Giang, a province in southern Vietnam in which TB patients receive HIV counseling and testing. We used standard WHO definitions to classify TB treatment outcomes. We conducted multivariate analysis to identify risk factors for the composite outcome of death, default, or treatment failure during TB treatment. From 2001-2004, 637 HIV-infected TB patients were diagnosed in An Giang. Of these, 501 (79%) were male, 321 (50%) were aged 25-34 years, and the most common self-reported HIV risk factor was sex with a commercial sex worker in 221 (35%). TB was classified as smear-positive in 531 (83%). During TB treatment, 167 (26%) patients died, 9 (1%) defaulted, and 6 (1%) failed treatment. Of 454 patients who took CTX, 116 (26%) had an unsuccessful outcome compared with 33 (70%) of 47 patients who did not take CTX (relative risk, 0.4; 95% confidence interval [CI], 0.3-0.5). Adjusting for male sex, rural residence, TB smear status and disease location, and the occurrence of adverse events during TB treatment in multivariate analysis, the benefit of CTX persisted (adjusted odds ratio for unsuccessful outcome 0.1; CI, 0.1-0.3). Conclusions/Significance. In An Giang, Vietnam, HIV-associated TB was associated with poor TB treatment outcomes. Outcomes were significantly better in those taking CTX. This finding suggests that Vietnam should consider applying WHO recommendations to prescribe CTX to all HIV-infected TB patients.	[Thuy, Trinh Thanh] US Ctr Dis Control & Prevent, Global AIDS Program, Hanoi, Vietnam; [Shah, N. Sarita; Wells, Charles D.; Laserson, Kayla F.; Varma, Jay K.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; [Mai Hoang Anh; Duong Thom; Truong Linh] An Giang Prov Prevent Med Ctr, Long Xuyen City, Vietnam; [Do Trong Nghia; Dinh Ngoc Sy; Bui Duc Duong] Minist Hlth, Vietnam Natl TB Program, Natl Hosp TB & Lung Dis, Hanoi, Vietnam; [Luu Thi Minh Chau; Phung Thi Phuong Mai] Minist Hlth, LIFE GAP Off, Hanoi, Vietnam; [Varma, Jay K.] US Ctr Dis Control Collaborat, Thailand Minist Publ Hlth, Bangkok, Thailand	Centers for Disease Control & Prevention - USA; Ministry of Public Health - Thailand	Varma, JK (corresponding author), US Ctr Dis Control & Prevent, Global AIDS Program, Hanoi, Vietnam.	jvarma@cdc.gov			U.S. Agency for International Development; U.S. Centers for Disease Control and Prevention	U.S. Agency for International Development(United States Agency for International Development (USAID)); U.S. Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	U.S. Agency for International Development and U.S. Centers for Disease Control and Prevention. USAID was not involved in: study design, collection, analysis, interpretation of data; or the decision to submit for publication.	Apers L, 2004, INT J TUBERC LUNG D, V8, P945; Boeree MJ, 2005, TROP MED INT HEALTH, V10, P723, DOI 10.1111/j.1365-3156.2005.01433.x; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010; Dheda K, 2004, J INFECT DIS, V190, P1670, DOI 10.1086/424676; Freudenberg N, 2006, AM J PUBLIC HEALTH, V96, P424, DOI 10.2105/AJPH.2005.063511; Grimwade K, 2005, AIDS, V19, P163, DOI 10.1097/00002030-200501280-00008; GRIMWADE K, 2004, COCHRANE LIB; Hargreaves NJ, 2001, INT J TUBERC LUNG D, V5, P847; *JOINT UN PROGR HI, 2006, REP GLOB AIDS EP 200; Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002; MWAUNGULU FB, 2004, B WORLD HEALTH ORGAN, V82, P854; Quy HT, 2006, INT J TUBERC LUNG D, V10, P45; Tuan NA, 2007, B WORLD HEALTH ORGAN, V85, P35, DOI 10.2471/BLT.05.026153; *WHO, 2006, GLOB TUB CONTR SURV; *WHO, 2004, INT POL COLL TB HIV; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization, 2003, TREATM TUB GUID NAT, DOI DOI 10.1016/S0035-9203(99)90185-2	18	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e507	10.1371/journal.pone.0000507	http://dx.doi.org/10.1371/journal.pone.0000507			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551587	gold, Green Published			2022-12-25	WOS:000207451500016
J	Edwards, KA; Doescher, LT; Kaneshiro, KY; Yamamoto, D				Edwards, Kevin A.; Doescher, Linden T.; Kaneshiro, Kenneth Y.; Yamamoto, Daisuke			A Database of Wing Diversity in the Hawaiian Drosophila	PLOS ONE			English	Article								Background. Within genus Drosophila, the endemic Hawaiian species offer some of the most dramatic examples of morphological and behavioral evolution. The advent of the Drosophila grimshawi genome sequence permits genes of interest to be readily cloned from any of the hundreds of species of Hawaiian Drosophila, offering a powerful comparative approach to defining molecular mechanisms of species evolution. A key step in this process is to survey the Hawaiian flies for characters whose variation can be associated with specific candidate genes. The wings provide an attractive target for such studies: Wings are essentially two dimensional, and genes controlling wing shape, vein specification, pigment production, and pigment pattern evolution have all been identified in Drosophila. Methodology/Principal Findings. We present a photographic database of over 180 mounted, adult wings from 73 species of Hawaiian Drosophila. The image collection, available at FlyBase.org, includes 53 of the 112 known species of "picture wing'' Drosophila, and several species from each of the other major Hawaiian groups, including the modified mouthparts, modified tarsus, antopocerus, and haleakalae (fungus feeder) groups. Direct image comparisons show that major wing shape changes can occur even between closely related species, and that pigment pattern elements can vary independently of each other. Among the 30 species closest to grimshawi, diverse visual effects are achieved by altering a basic pattern of seven wing spots. Finally, we document major pattern variations within species, which appear to result from reduced diffusion of pigment precursors through the wing blade. Conclusions/Significance. The database highlights the striking variation in size, shape, venation, and pigmentation in Hawaiian Drosophila, despite their generally low levels of DNA sequence divergence. In several independent lineages, highly complex patterns are derived from simple ones. These lineages offer a promising model system to study the evolution of complexity.	[Edwards, Kevin A.] Illinois State Univ, Dept Biol Sci, Normal, IL 61761 USA; [Doescher, Linden T.; Kaneshiro, Kenneth Y.] Univ Hawaii Manoa, Ctr Conservat Res & Training, Honolulu, HI 96822 USA; [Yamamoto, Daisuke] Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi 980, Japan	Illinois State University; University of Hawaii System; University of Hawaii Manoa; Tohoku University	Edwards, KA (corresponding author), Illinois State Univ, Dept Biol Sci, Normal, IL 61761 USA.	kaedwar@ilstu.edu	Edwards, Kevin Andrew/GOE-3539-2022; Vanrolleghem, Peter A/E-1784-2011	Edwards, Kevin Andrew/0000-0003-4721-5626; Vanrolleghem, Peter A/0000-0003-1695-1313; , Daisuke/0000-0002-4623-0106	ERATO; Japan Science and Technology; NIH [GM062185]; Illinois State University; MEXT [1802012]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM062185] Funding Source: NIH RePORTER	ERATO(Japan Science & Technology Agency (JST)); Japan Science and Technology(Japan Science & Technology Agency (JST)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Illinois State University; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funded by Yamamoto Behavior Genes Project, ERATO, Japan Science and Technology (to DY); NIH GM062185 (to KAE); and Illinois State University. DY was supported by Specially Promoted Research grant # 1802012 from MEXT.	Ashburner M., 2004, DROSOPHILA LAB HDB; Boake CRB, 1998, HEREDITY, V80, P642, DOI 10.1046/j.1365-2540.1998.00317.x; Bonacum J, 2005, MOL PHYLOGENET EVOL, V37, P73, DOI 10.1016/j.ympev.2005.03.008; BRENNAN MD, 1984, CELL, V38, P147, DOI 10.1016/0092-8674(84)90535-X; Carson Hampton L., 1995, P14; Carson Hampton L., 1992, P407; CARSON HL, 1976, ANNU REV ECOL SYST, V7, P311, DOI 10.1146/annurev.es.07.110176.001523; CARSON HL, 1970, SCIENCE, V168, P1414, DOI 10.1126/science.168.3938.1414; Carson HL, 1997, J HERED, V88, P343, DOI 10.1093/oxfordjournals.jhered.a023115; CARSON HL, 1967, P NATL ACAD SCI USA, V57, P1280, DOI 10.1073/pnas.57.5.1280; CARSON HL, 1983, GENETICS, V103, P465; Craddock EM, 2000, EVOL BIOL, V31, P1; Crosby MA, 2007, NUCLEIC ACIDS RES, V35, pD486, DOI 10.1093/nar/gkl827; Davis T, 2000, HEREDITAS, V132, P67, DOI 10.1111/j.1601-5223.2000.00067.x; Davis T, 2000, HEREDITAS, V132, P257, DOI 10.1111/j.1601-5223.2000.00257.x; de Celis JF, 2003, BIOESSAYS, V25, P443, DOI 10.1002/bies.10258; Dworkin I, 2006, GENETICS, V173, P1417, DOI 10.1534/genetics.105.053868; Gompel N, 2005, NATURE, V433, P481, DOI 10.1038/nature03235; GREENE E, 1987, SCIENCE, V236, P310, DOI 10.1126/science.236.4799.310; GRIMSHAW PH, 1901, FAUNA HAWAIIENSIS, V3, P1; Grumbling G, 2006, NUCLEIC ACIDS RES, V34, pD484, DOI 10.1093/nar/gkj068; Handler AM, 2001, INSECT BIOCHEM MOLEC, V31, P111, DOI 10.1016/S0965-1748(00)00159-4; Hardy D.E., 1972, U TEXAS PUBLICATION, V7213, P155; HARDY DE, 1979, P HAWAII ENTOMOL SOC, V13, P71; HARDY DE, 1968, U TEXAS PUBL, V6818, P171; HARDY DE, 1971, U TEXAS PUBL 2, V7103, P151; HARDY DE, 1965, DIPTERA CYCLORRAPHA, V2; Hardy DE., 1969, U TEXAS PUBLICATION, V6918, P39; Held LI., 2002, IMAGINAL DISCS GENET; HOY RR, 1988, SCIENCE, V240, P217, DOI 10.1126/science.3127882; Joron M, 2006, PLOS BIOL, V4, P1831, DOI 10.1371/journal.pbio.0040303; KAMBYSELLIS MP, 1995, CURR BIOL, V5, P1129, DOI 10.1016/S0960-9822(95)00229-6; Kaneshiro K, 2005, J HERED, V96, P285, DOI 10.1093/jhered/esi049; KANESHIRO KY, 1988, BIOSCIENCE, V38, P258, DOI 10.2307/1310849; KANESHIRO KY, 1987, TRENDS ECOL EVOL, V2, P207, DOI 10.1016/0169-5347(87)90022-X; KANESHIRO KY, 1977, DROS INFORM SERV, V52, P85; Kopp A, 2002, EVOL DEV, V4, P278, DOI 10.1046/j.1525-142X.2002.02017.x; Mezey JG, 2005, GENETICS, V169, P2101, DOI 10.1534/genetics.104.036988; O'Connor MB, 2006, DEVELOPMENT, V133, P183; O'Grady P.M., 2002, Bishop Museum Occasional Papers, V69, P36; O'Grady Patrick M., 2004, Bishop Museum Bulletins in Entomology, V12, P117; O'Grady PM, 2001, BMC EVOL BIOL, V1, DOI 10.1186/1471-2148-1-6; O'Grady PM, 2003, ANN ENTOMOL SOC AM, V96, P12, DOI 10.1603/0013-8746(2003)096[0012:ROTDMS]2.0.CO;2; Prud'homme B, 2006, NATURE, V440, P1050, DOI 10.1038/nature04597; Remsen J, 1998, MOL PHYLOGENET EVOL, V9, P225, DOI 10.1006/mpev.1997.0484; SPIETH HT, 1975, ANN ENTOMOL SOC AM, V68, P506, DOI 10.1093/aesa/68.3.506; Stark J, 1999, ANNU REV ENTOMOL, V44, P97, DOI 10.1146/annurev.ento.44.1.97; True JR, 1999, CURR BIOL, V9, P1382, DOI 10.1016/S0960-9822(00)80083-4; VAL FC, 1977, EVOLUTION, V31, P611, DOI 10.1111/j.1558-5646.1977.tb01051.x; Weber K, 2005, GENETICS, V169, P1461, DOI 10.1534/genetics.104.027748; Wheeler M.R., 1965, DROS INFORM SERV, V40, P98; Wittkopp PJ, 2003, TRENDS GENET, V19, P495, DOI 10.1016/S0168-9525(03)00194-X; Wittkopp PJ, 2002, DEVELOPMENT, V129, P1849; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5; YANG H, 1969, U TEXAS PUBL, V6918, P133; Yeh SD, 2006, HEREDITY, V96, P383, DOI 10.1038/sj.hdy.6800814; ASSEMBLY ALIGNMENT A	57	39	39	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e487	10.1371/journal.pone.0000487	http://dx.doi.org/10.1371/journal.pone.0000487			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534437	Green Published, gold, Green Submitted			2022-12-25	WOS:000207448800017
J	Hehl, AB; Regos, A; Schraner, E; Schneider, A				Hehl, Adrian B.; Regos, Attila; Schraner, Elisabeth; Schneider, Andre			Bax Function in the Absence of Mitochondria in the Primitive Protozoan Giardia lamblia	PLOS ONE			English	Article								Bax-induced permeabilization of the mitochondrial outer membrane and release of cytochrome c are key events in apoptosis. Although Bax can compromise mitochondria in primitive unicellular organisms that lack a classical apoptotic machinery, it is still unclear if Bax alone is sufficient for this, or whether additional mitochondrial components are required. The protozoan parasite Giardia lamblia is one of the earliest branching eukaryotes and harbors highly degenerated mitochondrial remnant organelles (mitosomes) that lack a genome. Here we tested whether human Bax expressed in Giardia can be used to ablate mitosomes. We demonstrate that these organelles are neither targeted, nor compromised, by Bax. However, specialized compartments of the regulated secretory pathway are completely ablated by Bax. As a consequence, maturing cyst wall proteins that are sorted into these organelles are released into the cytoplasm, causing a developmental arrest and cell death. Interestingly, this ectopic cargo release is dependent on the carboxy-terminal 22 amino acids of Bax, and can be prevented by the Bax-inhibiting peptide Ku70. A C-terminally truncated Bax variant still localizes to secretory organelles, but is unable to permeabilize these membranes, uncoupling membrane targeting and cargo release. Even though mitosomes are too diverged to be recognized by Bax, off-target membrane permeabilization appears to be conserved and leads to cell death completely independently of mitochondria.	[Hehl, Adrian B.; Regos, Attila] Univ Zurich, Inst Parasitol, CH-8057 Zurich, Switzerland; [Schraner, Elisabeth] Univ Zurich, Inst Vet Anat, CH-8057 Zurich, Switzerland; [Schneider, Andre] Univ Fribourg, Dept Cell & Dev Biol, CH-1700 Fribourg, Switzerland	University of Zurich; University of Zurich; University of Fribourg	Hehl, AB (corresponding author), Univ Zurich, Inst Parasitol, Winterthurerstr 266A, CH-8057 Zurich, Switzerland.	Adrian.Hehl@access.uzh.ch		Hehl, Adrian/0000-0002-2110-4445	Swiss National Science Foundation [31-100270/1, 3100A0112327]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Swiss National Science Foundation, Grants nr. 31-100270/1 and 3100A0112327	Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; Arisue N, 2002, PARASITOL INT, V51, P9, DOI 10.1016/S1383-5769(01)00093-9; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Chanez AL, 2006, J CELL SCI, V119, P2968, DOI 10.1242/jcs.03023; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dolezal P, 2005, P NATL ACAD SCI USA, V102, P10924, DOI 10.1073/pnas.0500349102; Epand RF, 2002, BIOCHEM BIOPH RES CO, V298, P744, DOI 10.1016/S0006-291X(02)02544-5; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Esseiva AC, 2004, EMBO REP, V5, P268, DOI 10.1038/sj.embor.7400095; Ferrier DEK, 2001, EVOL DEV, V3, P263, DOI 10.1046/j.1525-142x.2001.003004263.x; Figarella K, 2005, CELL DEATH DIFFER, V12, P335, DOI 10.1038/sj.cdd.4401564; Gerwig GJ, 2002, GLYCOBIOLOGY, V12, P499, DOI 10.1093/glycob/cwf059; Hedges SB, 2001, BMC EVOL BIOL, V1, DOI 10.1186/1471-2148-1-4; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; Lanfredi-Rangel A, 1998, J STRUCT BIOL, V123, P225, DOI 10.1006/jsbi.1998.4035; Lee N, 2002, CELL DEATH DIFFER, V9, P53, DOI 10.1038/sj.cdd.4400952; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marti M, 2003, TRENDS PARASITOL, V19, P440, DOI 10.1016/S1471-4922(03)00201-0; Marti M, 2003, J BIOL CHEM, V278, P24837, DOI 10.1074/jbc.M302082200; Marti M, 2003, MOL BIOL CELL, V14, P1433, DOI 10.1091/mbc.E02-08-0467; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nohynkova E, 2006, EUKARYOT CELL, V5, P753, DOI 10.1128/EC.5.4.753-761.2006; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Regoes A, 2005, J BIOL CHEM, V280, P30557, DOI 10.1074/jbc.M500787200; REINER DS, 1990, EUR J CELL BIOL, V53, P142; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Sagolla MS, 2006, J CELL SCI, V119, P4889, DOI 10.1242/jcs.03276; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Silberman JD, 2002, MOL BIOL EVOL, V19, P777, DOI 10.1093/oxfordjournals.molbev.a004135; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Sun CH, 2003, J BIOL CHEM, V278, P21701, DOI 10.1074/jbc.M302023200; Tovar J, 2003, NATURE, V426, P172, DOI 10.1038/nature01945; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zha HB, 1996, MOL CELL BIOL, V16, P6494	39	12	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e488	10.1371/journal.pone.0000488	http://dx.doi.org/10.1371/journal.pone.0000488			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534438	gold, Green Published, Green Submitted			2022-12-25	WOS:000207448800018
J	Gudmundsdottir, K; Lord, CJ; Ashworth, A				Gudmundsdottir, K.; Lord, C. J.; Ashworth, A.			The proteasome is involved in determining differential utilization of double-strand break repair pathways	ONCOGENE			English	Article						DSS1; BRCA2; proteasome; double-strand break	SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; USTILAGO-MAYDIS; DNA-REPAIR; DSS1; STABILITY; YEAST; BRCA2; RECOMBINATION; PROTEIN	The DSS1 protein interacts with the breast cancer susceptibility protein BRCA2 that plays an integral role in the repair of DNA double-strand breaks (DSBs). DSS1 has also been shown to interact with components of the 26S proteasome in Saccharomyces cerevisiae and in human tumour cells. This raises the possibility of functional interplay between the DNA repair machinery and the proteasome. We show here that human DSS1 interacts with the RPN3 and RPN7 proteasome subunits and de. ne regions of DSS1 important for the interactions with RPN3, RPN7 and BRCA2. We also show that BRCA2 interacts with RPN3 and RPN7 and that the BRCA2/RPN7 interaction is independent of DSS1. Finally, and most significantly, we demonstrate that the proteolytic activity of the proteasome is a determinant of the choice of DSB repair pathway; inhibition of proteasome proteolytic activity results in an increase in the utilization of potentially mutagenic single-strand annealing at the expense of a reduction in the level of error-free gene conversion. This confirms a functional link between DSB repair and proteasomal activity.	Canc Res Inst, Breakthrough Breast Canc Res Ctr, Gene Funct Lab, London, England	University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Fulham Rd, London SW3 6JB, England.	alan.ashworth@icr.ac.uk	Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021	Lord, Christopher J/0000-0002-3226-0515; 	Cancer Research UK [A8363] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Breast Cancer Now		Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Funakoshi M, 2004, J CELL SCI, V117, P6447, DOI 10.1242/jcs.01575; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Isono E, 2005, J BIOL CHEM, V280, P6537, DOI 10.1074/jbc.M409364200; Josse L, 2006, BIOCHEM J, V393, P303, DOI 10.1042/BJ20051238; Kojic M, 2005, MOL CELL BIOL, V25, P2547, DOI 10.1128/MCB.25.7.2547-2557.2005; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; Li J, 2006, ONCOGENE, V25, P1186, DOI 10.1038/sj.onc.1209153; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sin N, 1999, BIOORG MED CHEM LETT, V9, P2283, DOI 10.1016/S0960-894X(99)00376-5; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	16	44	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2007	26	54					7601	7606		10.1038/sj.onc.1210579	http://dx.doi.org/10.1038/sj.onc.1210579			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563742				2022-12-25	WOS:000251282100014
J	Hines, JK; Kruesel, CE; Fromm, HJ; Honzatko, RB				Hines, Justin K.; Kruesel, Claire E.; Fromm, Herbert J.; Honzatko, Richard B.			Structure of inhibited fructose-1,6-bisphosphatase from Escherichia coli - Distinct allosteric inhibition sites for AMP and glucose 6-phosphate and the characterization of a gluconeogenic switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE 1,6-BISPHOSPHATASE; RECOMBINANT PORCINE; MECHANISM; PHOSPHOFRUCTOKINASE; BISPHOSPHATASE; PURIFICATION; 6-PHOSPHATE; ACTIVATION; TRANSITION; PROGRAM	Allosteric activation of fructose-1,6-bisphosphatase (FBPase) from Escherichia coli by phosphoenolpyruvate implies rapid feed-forward activation of gluconeogenesis in heterotrophic bacteria. But how do such bacteria rapidly down-regulate an activated FBPase in order to avoid futile cycling? Demonstrated here is the allosteric inhibition of E. coli FBPase by glucose 6-phosphate (Glc-6-P), the first metabolite produced upon glucose transport into the cell. FBPase undergoes a quaternary transition from the canonical R-state to a T-like state in response to Glc-6-P and AMP ligation. By displacing Phe(15), AMP binds to an allosteric site comparable with that of mammalian FBPase. Relative movements in helices H1 and H2 perturb allosteric activator sites for phosphoenolpyruvate. Glc-6-P binds to allosteric sites heretofore not observed in previous structures, perturbing subunits that in pairs form complete active sites of FBPase. Glc-6-P and AMP are synergistic inhibitors of E. coli FBPase, placing AMP/Glc-6-P inhibition in bacteria as a possible evolutionary predecessor to AMP/fructose 2,6-bisphosphate inhibition in mammalian FBPases. With no exceptions, signature residues of allosteric activation appear in bacterial sequences along with key residues of the Glc-6-P site. FBPases in such organisms may be components of metabolic switches that allow rapid changeover between gluconeogenesis and glycolysis in response to nutrient availability.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, 4206 Mol Biol Bldg, Ames, IA 50011 USA.	honzatko@iastate.edu			NINDS NIH HHS [NS 10546, R01 NS010546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABUL J, 1983, ARCH BIOCHEM BIOPHYS, V225, P944, DOI 10.1016/0003-9861(83)90109-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAMBOST JP, 1980, J BIOL CHEM, V255, P2867; CHIN AM, 1989, J BACTERIOL, V171, P2424, DOI 10.1128/jb.171.5.2424-2434.1989; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; Choe JY, 2003, J BIOL CHEM, V278, P51176, DOI 10.1074/jbc.M308396200; DALDAL F, 1983, J BACTERIOL, V153, P390, DOI 10.1128/JB.153.1.390-394.1983; Donahue JL, 2000, J BACTERIOL, V182, P5624, DOI 10.1128/JB.182.19.5624-5627.2000; DRUECKES P, 1995, ANAL BIOCHEM, V230, P173, DOI 10.1006/abio.1995.1453; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS P, 1992, PDBSET; FERRARI RICHARD A., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P372, DOI 10.1016/0003-9861(59)90264-4; FRAENKEL DG, 1966, ARCH BIOCHEM BIOPHYS, V114, P4, DOI 10.1016/0003-9861(66)90298-0; FRAENKEL DG, 1968, J BIOL CHEM, V243, P6451; FRAENKEL DG, 1965, J BACTERIOL, V90, P837, DOI 10.1128/JB.90.4.837-842.1965; FRAENKEL DG, 1996, ESCHERICHIA COLI SAL, P189; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Hines JK, 2007, J BIOL CHEM, V282, P11696, DOI 10.1074/jbc.M611104200; Hines JK, 2006, J BIOL CHEM, V281, P18386, DOI 10.1074/jbc.M602553200; Iancu CV, 2005, J BIOL CHEM, V280, P19737, DOI 10.1074/jbc.M501011200; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEDERER B, 1981, BIOCHEM BIOPH RES CO, V103, P1281, DOI 10.1016/0006-291X(81)90261-8; LIU F, 1990, J BIOL CHEM, V265, P7401; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; REEVES RE, 1973, BIOCHEM BIOPH RES CO, V50, P459, DOI 10.1016/0006-291X(73)90862-0; Sato T, 2004, J BACTERIOL, V186, P5799, DOI 10.1128/JB.186.17.5799-5807.2004; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	45	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24697	24706		10.1074/jbc.M703580200	http://dx.doi.org/10.1074/jbc.M703580200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17567577	hybrid			2022-12-25	WOS:000248933000025
J	Fritsch, RM; Schneider, G; Saur, D; Scheibel, M; Schmid, RM				Fritsch, Ralph M.; Schneider, Guenter; Saur, Dieter; Scheibel, Melanie; Schmid, Roland M.			Translational repression of MCL-1 couples stress-induced eIF2 alpha phosphorylation to mitochondrial apoptosis initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ALPHA-SUBUNIT; EUKARYOTIC INITIATION-FACTOR-2; PROTEIN-SYNTHESIS; GENE-EXPRESSION; BCL2 FAMILY; ACTIVATION; KINASE; DEATH; BAX	The integrated stress response (ISR) integrates a broad range of environmental and endogenous stress signals to the phosphorylation of the alpha-subunit of eukaryotic translation initiation factor 2 (eIF2 alpha). Although intense or prolonged activation of this pathway is known to induce apoptosis, the molecular mechanisms coupling stress-induced eIF2 alpha phosphorylation to the cell death machinery have remained incompletely understood. In this study, we characterized apoptosis initiation in response to classical activators of the ISR (tunicamycin, UVC, elevated osmotic pressure, arsenite). We found that all applied stress stimuli activated a mitochondrial pathway of apoptosis initiation. Rapid and selective down-regulation of the anti-apoptotic BCL-2 family protein MCL-1 preceded the activation of BAX, BAK, and caspases. Stabilization of MCL-1 blocked apoptosis initiation, while cells with reduced MCL-1 protein content were strongly sensitized to stress-induced apoptosis. Stress-induced elimination of MCL-1 occurred with unchanged protein turnover and independently of MCL-1 mRNA levels. In contrast, stress-induced phosphorylation of eIF2 alpha at Ser(51) was both essential and sufficient for the down-regulation of MCL-1 protein in stressed cells. These findings indicate that stress-induced phosphorylation of eIF2 alpha is directly coupled to mitochondrial apoptosis regulation via translational repression of MCL-1. Down-regulation of MCL-1 enables but not enforces apoptosis initiation in stressed cells.	Tech Univ Munich, Dept Med 2, Klinikum Rechts Isar, D-81675 Munich, Germany	Technical University of Munich	Schmid, RM (corresponding author), Tech Univ Munich, Dept Med 2, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany.	roland.schmid@lrz.tum.de	Saur, Dieter/O-8355-2015; Fritsch, Ralph/Q-8836-2019; Saur, Dieter/G-4629-2011	Saur, Dieter/0000-0001-5874-0210; Fritsch, Ralph/0000-0001-9639-3213				Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brunelle JK, 2007, MOL CELL BIOL, V27, P1222, DOI 10.1128/MCB.01535-06; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Gil J, 1999, MOL CELL BIOL, V19, P4653; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Kazemi S, 2004, MOL CELL BIOL, V24, P3415, DOI 10.1128/MCB.24.8.3415-3429.2004; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Perkins DJ, 2004, MOL CELL BIOL, V24, P2025, DOI 10.1128/MCB.24.5.2025-2040.2004; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Schneider G, 2006, EMBO J, V25, P3801, DOI 10.1038/sj.emboj.7601259; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	44	79	86	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22551	10.1074/jbc.M702673200	http://dx.doi.org/10.1074/jbc.M702673200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553788	hybrid			2022-12-25	WOS:000248354200033
J	Goni-Oliver, P; Lucas, JJ; Avila, J; Hernandez, F				Goni-Oliver, Paloma; Lucas, Jose J.; Avila, Jesus; Hernandez, Felix			N-terminal cleavage of GSK-3 by calpain - A new form of GSK-3 regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ALZHEIMERS-DISEASE; BETA-CATENIN; TAU-PROTEIN; TRANSGENIC MICE; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; MAMMALIAN-CELLS; LITHIUM; PROTEOLYSIS	Although GSK-3 activity can be regulated by phosphorylation and through interaction with GSK-3-binding proteins, here we describe N-terminal proteolysis as a novel way to regulate GSK-3. When brain extracts were exposed to calcium, GSK-3 was truncated, generating two fragments of similar to 40 and 30 kDa, a proteolytic process that was inhibited by specific calpain inhibitors. Interestingly, instead of inhibiting this enzyme, GSK-3 truncation augmented its kinase activity. When we digested recombinant GSK-3 alpha and GSK-3 alpha protein with calpain, each isoform was cleaved differently, yet the truncated GSK-3 isoforms were still active kinases. We also found that lithium, a GSK-3 inhibitor, inhibits full-length and cleaved GSK-3 isoforms with the same IC50 value. Calpain removed the N-terminal ends of His-tagged GSK-3 isoenzymes, and exposing cultured cortical neurons with ionomycin, glutamate, or N-methyl-D-aspartate led to the truncation of GSK-3. This truncation was blocked by the calpain inhibitor calpeptin, at the same concentration at which it inhibits calpain-mediated cleavage of NMDAR-2B and of p35 (the regulatory subunit of CDK5). Together, our data demonstrate that calpain activation produces a truncation of GSK-3 that removes an N-terminal inhibitory domain. Furthermore, we show that GSK-3 alpha and GSK-3 alpha isoenzymes have a different susceptibility to this cleavage, suggesting a means to specifically regulate these isoenzymes. These data provide the first direct evidence that calpain promotes GSK-3 truncation in a way that has implications in signal transduction, and probably in pathological disorders such as Alzheimer disease.	Univ Autonoma Madrid, Fac Ciencias, CSIC UAM, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Hernandez, F (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC UAM, Ctr Biol Mol Severo Ochoa, Cantoblanco, Madrid 28049, Spain.	fhernandez@cbm.uam.es	Lucas, Jose J./U-6543-2019; Avila, Jesus/I-2610-2015; Hernandez, Felix/L-2114-2015	Avila, Jesus/0000-0002-6288-0571; Hernandez, Felix/0000-0001-8753-8249; Lucas, Jose J./0000-0003-1597-3916				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; Hajimohammadreza I, 1997, J NEUROCHEM, V69, P1006; Hansen L, 1997, DIABETOLOGIA, V40, P940, DOI 10.1007/s001250050771; Hernandez F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x; Hernandez F, 2004, J BIOL CHEM, V279, P3801, DOI 10.1074/jbc.M311512200; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lau KF, 1999, GENOMICS, V60, P121, DOI 10.1006/geno.1999.5875; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Li T, 2006, BIOCHEMISTRY-US, V45, P3134, DOI 10.1021/bi051635j; Lochhead PA, 2006, MOL CELL, V24, P627, DOI 10.1016/j.molcel.2006.10.009; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Mukai F, 2002, J NEUROCHEM, V81, P1073, DOI 10.1046/j.1471-4159.2002.00918.x; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Russ C, 2001, MOL PSYCHIATR, V6, P320, DOI 10.1038/sj.mp.4000852; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Sengupta A, 1997, MOL CELL BIOCHEM, V167, P99, DOI 10.1023/A:1006883924775; Shaw PC, 1998, GENOME, V41, P720, DOI 10.1139/gen-41-5-720; Shea TB, 1996, J NEUROCHEM, V66, P1539; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Simpkins KL, 2003, J NEUROSCI, V23, P11322; SINGH TJ, 1995, FEBS LETT, V358, P4, DOI 10.1016/0014-5793(94)01383-C; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; WANG QM, 1994, J BIOL CHEM, V269, P14566; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200	49	109	114	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22406	22413		10.1074/jbc.M702793200	http://dx.doi.org/10.1074/jbc.M702793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17569662	hybrid, Green Published			2022-12-25	WOS:000248354200019
J	Zimina, EP; Fritsch, A; Schermer, B; Bakulina, AY; Bashkurov, M; Benzing, T; Bruckner-Tuderman, L				Zimina, Elena P.; Fritsch, Anja; Schermer, Bernhard; Bakulina, Anastasia Yu.; Bashkurov, Mikhail; Benzing, Thomas; Bruckner-Tuderman, Leena			Extracellular phosphorylation of collagen XVII by ecto-casein kinase 2 inhibits ectodomain shedding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING-ENZYME; PROTEIN-KINASE CK2; BULLOUS PEMPHIGOID ANTIGEN; CELL-SURFACE; METALLOPROTEINASE INHIBITORS; ECTOPROTEIN KINASES; RBL-2H3 CELLS; RELEASE; ATP; MATRIX	Ecto-phosphorylation is emerging as an important mechanism to regulate cellular ligand interactions and signal transduction. Here we show that extracellular phosphorylation of the cell surface receptor collagen XVII regulates shedding of its ectodomain. Collagen XVII, a member of the novel family of collagenous transmembrane proteins and component of the hemidesmosomes, mediates adhesion of the epidermis to the dermis in the skin. The ectodomain is constitutively shed from the cell surface by metalloproteinases of the ADAM (a disintegrin and metalloproteinase) family, mainly by tumor necrosis factor-alpha converting enzyme (TACE). We used biochemical, mutagenesis, and structural modeling approaches to delineate mechanisms controlling ectodomain cleavage. A standard assay for extracellular phosphorylation, incubation of intact keratinocytes with cell-impermeable [gamma-P-32]ATP, led to collagen XVII labeling. This was significantly diminished by both broad-spectrum extracellular kinase inhibitor K252b and a specific casein kinase 2 (CK2) inhibitor. Collagen XVII peptides containing a putative CK2 recognition site were phosphorylated by CK2 in vitro, disclosing Ser(542) and Ser(544) in the ectodomain as phosphate group acceptors. Phosphorylation of Ser(544) in vivo and in vitro was confirmed by immunoblotting of epidermis and HaCaT keratinocyte extracts with phosphoepitopespecific antibodies. Functionally, inhibition of CK2 kinase activity or mutation of the phosphorylation acceptor Ser(544) to Ala significantly increased ectodomain shedding, whereas overexpression of CK2 alpha inhibited cleavage of collagen XVII. Structural modeling suggested that the phosphorylation of serine residues prevents binding of TACE to its substrate. Thus, extracellular phosphorylation of collagen XVII by ecto-CK2 inhibits its shedding by TACE and represents novel mechanism to regulate adhesion and motility of epithelial cells.	Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; Univ Freiburg, Div Nephrol, D-79104 Freiburg, Germany; State Res Ctr Virol & Biotechnol Vector, Novosibirsk 630559, Russia	University of Freiburg; University of Freiburg; University of Freiburg; State Research Center of Virology & Biotechnology VECTOR	Bruckner-Tuderman, L (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	bruckner-tuderman@uniklinik-freiburg.de	Benzing, Thomas/X-5476-2019; Bakulina, Anastasia/A-6215-2014; Schermer, Bernhard/E-9972-2014	Schermer, Bernhard/0000-0002-5194-9000				BENOREPARSONS M, 1989, ARCH BIOCHEM BIOPHYS, V272, P274, DOI 10.1016/0003-9861(89)90220-8; Bissell MJ, 2005, COLD SH Q B, V70, P343, DOI 10.1101/sqb.2005.70.013; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Black RA, 1996, BIOCHEM BIOPH RES CO, V225, P400, DOI 10.1006/bbrc.1996.1186; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Burrell HE, 2005, J BIOL CHEM, V280, P29667, DOI 10.1074/jbc.M505381200; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Elomaa O, 2001, HUM MOL GENET, V10, P953, DOI 10.1093/hmg/10.9.953; Fluhrer R, 2004, J BIOL CHEM, V279, P1585, DOI 10.1074/jbc.M306653200; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2004, J BIOL CHEM, V279, P24521, DOI 10.1074/jbc.M308835200; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Hu X, 2004, J MOL GRAPH MODEL, V22, P293, DOI 10.1016/j.jmgm.2003.11.002; Hu X, 2003, J MOL GRAPH MODEL, V22, P115, DOI 10.1016/S1093-3263(03)00153-0; Kitajima Y, 1995, EPITHELIAL CELL BIOL, V4, P70; Lambert MH, 2005, COMB CHEM HIGH T SCR, V8, P327, DOI 10.2174/1386207054020840; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Morgenstern E, 2001, EUR J CELL BIOL, V80, P87, DOI 10.1078/0171-9335-00138; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Redegeld FA, 1999, TRENDS PHARMACOL SCI, V20, P453, DOI 10.1016/S0165-6147(99)01399-1; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Rodriguez F, 2005, P NATL ACAD SCI USA, V102, P4718, DOI 10.1073/pnas.0501074102; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Schumann H, 2000, AM J PATHOL, V156, P685, DOI 10.1016/S0002-9440(10)64772-4; Stepanova V, 2002, J BIOL CHEM, V277, P10265, DOI 10.1074/jbc.M109057200; Teshima R, 1997, J IMMUNOL, V159, P964; Teshima R, 1999, IMMUNOL LETT, V68, P369, DOI 10.1016/S0165-2478(99)00086-3; Trachana V, 2005, INT J BIOCHEM CELL B, V37, P478, DOI 10.1016/j.biocel.2004.08.001; Vaisanen MR, 2004, BIOCHEM J, V380, P685, DOI 10.1042/BJ20031974; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; WALTER J, 1994, CELL MOL BIOL RES, V40, P473; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; Walter J, 2000, J BIOL CHEM, V275, P23523, DOI 10.1074/jbc.M002850200; Yin XY, 2001, CELL COMMUN ADHES, V8, P373, DOI 10.3109/15419060109080756; Zhang ZL, 2001, FASEB J, V15, P303; Zhu SL, 1997, BIOCHEM J, V323, P637, DOI 10.1042/bj3230637; Zien P, 2003, BIOCHEM BIOPH RES CO, V306, P129, DOI 10.1016/S0006-291X(03)00928-8; Zimina EP, 2005, J BIOL CHEM, V280, P34019, DOI 10.1074/jbc.M503751200	49	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22737	22746		10.1074/jbc.M701937200	http://dx.doi.org/10.1074/jbc.M701937200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17545155	hybrid			2022-12-25	WOS:000248354200051
J	Peshenko, IV; Dizhoor, AM				Peshenko, Igor V.; Dizhoor, Alexander M.			Activation and inhibition of photoreceptor guanylyl cyclase by guanylyl cyclase activating protein 1 (GCAP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; DOMINANT CONE DEGENERATION; EF-HAND; VERTEBRATE PHOTORECEPTORS; 3-DIMENSIONAL STRUCTURE; CA2+-BINDING PROTEINS; MOLECULAR-MECHANISMS; RHODOPSIN KINASE; OUTER SEGMENTS; MUTATION	Guanylyl cyclase activating protein 1 (GCAP-1), a Ca2+/Mg2+ sensor protein that accelerates retinal guanylyl cyclase (RetGC) in the light and decelerates it in the dark, is inactive in cation-free form. Binding of Mg2+ in EF-hands 2 and 3 was essential for RetGC activation in the conditions mimicking light adaptation. Mg2+ binding in EF-hand 2 affected the conformation of a neighboring non-metal binding domain, EF-hand-1, and increased GCAP-1 affinity for RetGC nearly 40-fold compared with the metal-free EF-hand 2. Mg2+ binding in EF-hand 3 increased GCAP-1 affinity for RetGC 5-fold and its maximal RetGC stimulation 2-fold. Mg2+ binding in EF-hand 4 affected neither GCAP-1 affinity for RetGC, nor RetGC activation. Inactivation of Ca2+ binding in EF-hand 4 was sufficient to render GCAP-1 a constitutive activator of RetGC, whereas the EF-hand 3 role in Ca2+-dependent deceleration of RetGC was likely to be through the neighboring EF-hand 4. Inactivation of Ca2+ binding in EF-hand 2 affected cooperativity of RetGC inhibition by Ca2+, but did not prevent the inhibition. We conclude that 1) Mg2+ binding in EF-hands 2 and 3, but not EF-hand 4, is essential for the ability of GCAP-1 to activate RetGC in the light; 2) Mg2+ or Ca2+ binding in EF-hand 3 and especially in EF-hand 2 is required for high-affinity interaction with the cyclase and affects the conformation of the neighboring EF-hand 1, a domain required for targeting RetGC; and 3) RetGC inhibition is likely to be primarily caused by Ca2+ binding in EF-hand 4.	Penn Coll Optometry, Hafter Res Labs, Elkins Pk, PA 19027 USA		Dizhoor, AM (corresponding author), 8360 Old York Rd, Elkins Pk, PA 19027 USA.	adizhoor@pco.edu		Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011522-12, R01 EY011522, EY11522] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allouche D, 1999, J MOL BIOL, V285, P857, DOI 10.1006/jmbi.1998.2329; Ames JB, 2006, J BIOL CHEM, V281, P37237, DOI 10.1074/jbc.M606913200; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BABU A, 1992, J BIOL CHEM, V267, P15469; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Burgoyne RD, 2004, TRENDS NEUROSCI, V27, P203, DOI 10.1016/j.tins.2004.01.010; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Cates MS, 2002, BIOPHYS J, V82, P1133, DOI 10.1016/S0006-3495(02)75472-6; Chen CH, 2003, J PHYSIOL-LONDON, V553, P125, DOI 10.1113/jphysiol.2003.053280; DESILVA AC, 1995, J BIOL CHEM, V270, P6773; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; Ermilov AN, 2001, J BIOL CHEM, V276, P48143, DOI 10.1074/jbc.M107539200; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Hwang JY, 2004, EUR J BIOCHEM, V271, P3785, DOI 10.1111/j.1432-1033.2004.04320.x; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; Nishiguchi KM, 2004, INVEST OPHTH VIS SCI, V45, P3863, DOI 10.1167/iovs.04-0590; Olshevskaya EV, 2004, J NEUROSCI, V24, P6078, DOI 10.1523/JNEUROSCI.0963-04.2004; Olshevskaya EV, 2002, MOL CELL BIOCHEM, V230, P139, DOI 10.1023/A:1014248208584; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Peshenko IV, 2006, J BIOL CHEM, V281, P23830, DOI 10.1074/jbc.M600257200; Peshenko IV, 2004, BIOCHEMISTRY-US, V43, P13796, DOI 10.1021/bi048943m; Peshenko IV, 2004, J BIOL CHEM, V279, P16903, DOI 10.1074/jbc.C400065200; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sokal I, 2005, INVEST OPHTH VIS SCI, V46, P1124, DOI 10.1167/iovs.04-1431; Sokal I, 2001, J BIOL CHEM, V276, P43361, DOI 10.1074/jbc.M103614200; Stephen R, 2006, J MOL BIOL, V359, P266, DOI 10.1016/j.jmb.2006.03.042; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Tachibanaki S, 2000, J BIOL CHEM, V275, P3313, DOI 10.1074/jbc.275.5.3313; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Wilkie SE, 2001, AM J HUM GENET, V69, P471, DOI 10.1086/323265; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5	51	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21645	21652		10.1074/jbc.M702368200	http://dx.doi.org/10.1074/jbc.M702368200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17545152	Green Accepted, hybrid			2022-12-25	WOS:000248196800011
J	Meisel, RP; Schaeffer, SW				Meisel, Richard P.; Schaeffer, Stephen W.			Meiotic Transmission of Drosophila pseudoobscura Chromosomal Arrangements	PLOS ONE			English	Article								Drosophila pseudoobscura harbors a rich gene arrangement polymorphism on the third chromosome generated by a series of overlapping paracentric inversions. The arrangements suppress recombination in heterokaryotypic individuals, which allows for the selective maintenance of coadapted gene complexes. Previous mapping experiments used to determine the degree to which recombination is suppressed in gene arrangement heterozygotes produced non-recombinant progeny in non-Mendelian ratios. The deviations from Mendelian expectations could be the result of viability differences between wild and mutant chromosomes, meiotic drive because of achiasmate pairing of homologues in heterokaryotypic females during meiosis, or a combination of both mechanisms. The possibility that the frequencies of the chromosomal arrangements in natural populations are affected by mechanisms other than adaptive selection led us to consider these hypotheses. We performed reciprocal crosses involving both heterozygous males and females to determine if the frequency of the non-recombinant progeny deviates significantly from Mendelian expectations and if the frequencies deviate between reciprocal crosses. We failed to observe non-Mendelian ratios in multiple crosses, and the frequency of the non-recombinant classes differed in only one of five pairs of reciprocal crosses despite sufficient power to detect these differences in all crosses. Our results indicate that deviations from Mendelian expectations in recombination experiments involving the D. pseudoobscura inversion system are most likely due to fitness differences of gene arrangement karyotypes in different environments.	[Meisel, Richard P.] Penn State Univ, Inst Mol Evolutionary Genet, Intercoll Grad Program Genet, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Meisel, RP (corresponding author), Penn State Univ, Inst Mol Evolutionary Genet, Intercoll Grad Program Genet, University Pk, PA 16802 USA.	meisel@psu.edu	Meisel, Richard/J-3410-2013; Schaeffer, Stephen W/B-1662-2010; Schaeffer, Stephen/AAA-2303-2021	Meisel, Richard/0000-0002-7362-9307; Schaeffer, Stephen/0000-0003-2070-5342				ANDERSON WW, 1991, P NATL ACAD SCI USA, V88, P10367, DOI 10.1073/pnas.88.22.10367; ANDERSON WW, 1968, GENET RES, V12, P317, DOI 10.1017/S0016672300011903; DOBZHANSKY T, 1948, GENETICS, V33, P158; DOBZHANSKY T, 1948, P NATL ACAD SCI USA, V34, P137, DOI 10.1073/pnas.34.4.137; DOBZHANSKY T, 1950, GENETICS, V35, P288; HAWLEY RS, 1993, ANNU REV GENET, V27, P281; Kovacevic M, 2000, GENETICS, V156, P155; LEVINE L, 1955, GENETICS, V40, P832; LEVINE RP, 1955, GENETICS, V40, P399; LEVINE RP, 1956, AM NAT, V90, P41, DOI 10.1086/281905; ORRWEAVER TL, 1995, P NATL ACAD SCI USA, V92, P10443, DOI 10.1073/pnas.92.23.10443; Popadic A, 1996, MOL BIOL EVOL, V13, P883, DOI 10.1093/oxfordjournals.molbev.a025648; Powell Jeffrey R., 1992, P73; Richards S, 2005, GENOME RES, V15, P1, DOI 10.1101/gr.3059305; RILEY MA, 1989, GENETICS, V123, P359; Schaeffer SW, 2005, GENETICS, V171, P1729, DOI 10.1534/genetics.105.041947; Schaeffer SW, 2003, P NATL ACAD SCI USA, V100, P8319, DOI 10.1073/pnas.1432900100; SCHAEFFER SW, 1992, GENETICS, V132, P471; Sokal RR, 1995, BIOMETRY; STRICKBERGER MW, 1963, EVOLUTION, V17, P40, DOI 10.2307/2406334; Sturtevant AH, 1937, J GENET, V34, P415, DOI 10.1007/BF02982303; Sturtevant AH, 1936, GENETICS, V21, P444; WATANABE T, 1970, GENET RES, V15, P123, DOI 10.1017/S0016672300001427; WRIGHT S, 1946, GENETICS, V31, P125	24	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e530	10.1371/journal.pone.0000530	http://dx.doi.org/10.1371/journal.pone.0000530			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565383	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451600018
J	Ceballos-Cancino, G; Espinosa, M; Maldonado, V; Melendez-Zajgla, J				Ceballos-Cancino, G.; Espinosa, M.; Maldonado, V.; Melendez-Zajgla, J.			Regulation of mitochondrial Smac/DIABLO-selective release by survivin	ONCOGENE			English	Article						antineoplastic drugs; cancer; DNA damage; inhibitor of apoptosis proteins; mitochondria	CYTOCHROME-C; INDUCED APOPTOSIS; IN-VITRO; SMAC; CELLS; ACTIVATION; EXPRESSION; PROTEIN; CANCER; BAX	The intrinsic apoptotic pathway is characterized by the release of several mitochondrial intermembrane proteins into the cytosol of dying cells. It is unclear whether the release of these proteins follows a common or specific pathway. In the present report we show that survivin and, to a lesser extent, the survivin splice variant survivin DeltaEx3 regulate the specific liberation of second mitochondria-derived activator of caspase/direct IAP binding protein with low pI (Smac/DIABLO), an inhibitor of apoptosis proteins binding protein, during apoptosis induced by etoposide, a DNA damaging agent. This antineoplastic drug induced posttranscriptional upregulation of survivin and survivin DeltaEx3. In turn, mitochondrial survivin associated with Smac/DIABLO, delaying its release. In addition, cytosolic survivin also stabilized the cytosolic levels of released Smac/DIABLO. These results provide an explanation for the observed differences in the release of mitochondrial intermembrane proteins in various apoptotic models and present a new mechanism for the anti-apoptotic effects of survivin in cancer cells.	Inst Nacl Cancerol, Subdirecc Invest Basica, Mol Biol Lab, Mexico City 14080, DF, Mexico	Instituto Nacional de Cancerologia (INCAN)	Maldonado, V (corresponding author), Inst Nacl Cancerol, Subdirecc Invest Basica, Mol Biol Lab, Av San Fernando 22, Mexico City 14080, DF, Mexico.	vilmaml@gmail.com; jorgezajgla@salud.gob.mx	Melendez-Zajgla, Jorge/A-5708-2008					Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518; Kandasamy K, 2003, CANCER RES, V63, P1712; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Lim MLR, 2006, EXP CELL RES, V312, P1174, DOI 10.1016/j.yexcr.2006.01.026; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martinez-Velazquez M, 2007, CELL SIGNAL, V19, P1212, DOI 10.1016/j.cellsig.2007.01.001; McNeish IA, 2005, EXP CELL RES, V302, P69, DOI 10.1016/j.yexcr.2004.08.029; Morizane Y, 2005, J BIOCHEM, V137, P125, DOI 10.1093/jb/mvi029; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Tirro E, 2006, CANCER RES, V66, P4263, DOI 10.1158/0008-5472.CAN-05-3248; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Wall NR, 2003, CANCER RES, V63, P230; Yamamoto S, 2002, J PHYS CHEM SOLIDS, V63, P1489, DOI 10.1016/S0022-3697(02)00032-X; Zhang WG, 2002, J EUR CERAM SOC, V22, P2869, DOI 10.1016/S0955-2219(02)00063-8; Zhou LL, 2005, APOPTOSIS, V10, P289, DOI 10.1007/s10495-005-0803-9	21	75	77	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7569	7575		10.1038/sj.onc.1210560	http://dx.doi.org/10.1038/sj.onc.1210560			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546047	Bronze			2022-12-25	WOS:000251282100009
J	Julien, S; Puig, I; Caretti, E; Bonaventure, J; Nelles, L; van Roy, F; Dargemont, C; Garcia de Herreros, A; Bellacosa, A; Larue, L				Julien, S.; Puig, I.; Caretti, E.; Bonaventure, J.; Nelles, L.; van Roy, F.; Dargemont, C.; Garcia de Herreros, A.; Bellacosa, A.; Larue, L.			Activation of NF-kappa B by Akt upregulates Snail expression and induces epithelium mesenchyme transition	ONCOGENE			English	Article						E-cadherin; metastasis; Zeb; slug; migration	E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; REPRESSES E-CADHERIN; GENE-EXPRESSION; BREAST-CANCER; SUPPRESSOR GENE; CELL INVASION; TUMOR-CELLS; BINDING; TARGET	Carcinoma progression is associated with the loss of epithelial features, and the acquisition of mesenchymal characteristics and invasive properties by tumour cells. The loss of cell-cell contacts may be the. first step of the epithelium mesenchyme transition (EMT) and involves the functional inactivation of the cell-cell adhesion molecule E-cadherin. Repression of E-cadherin expression by the transcription factor Snail is a central event during the loss of epithelial phenotype. Akt kinase activation is frequent in human carcinomas, and Akt regulates various cellular mechanisms including EMT. Here, we show that Snail activation and consequent repression of E- cadherin may depend on AKT-mediated nuclear factor-kappa B (NF-kappa B) activation, and that NF-kappa B induces Snail expression. Expression of the NF-kappa B subunit p65 is suficient for EMT induction, validating this signalling module during EMT. NF-kappa B pathway activation is associated with tumour progression and metastasis of several human tumour types; E-cadherin acts as a metastasis suppressor protein. Thus, this signalling and transcriptional network linking AKT, NF-kappa B, Snail and E-cadherin during EMT is a potential target for antimetastatic therapeutics.	CNRS, Inst Curie, Dev Genet Melanocytes, UMR 146, F-91405 Orsay, France; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA USA; Univ Leuven, VIB7, Fladers Interuniv Ins Biotechnol, Lab Mol Biol Dept Dev Biol, Louvain, Belgium; Univ Ghent VIB, Dept Mol Biomed Res, Ghent, Belgium; Univ Paris 06, Inst Jacques Monod, Dept Biol Cellulaire, UMR 7592 CNRS, Paris, France; Univ Pompeu Fabra, Ins Municipal Invest Med, Unit Biol Cellular Mol, Barcelona, Spain; Regina Elena Inst Canc Res, Lab Dev Therapeut, Rome, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Fox Chase Cancer Center; KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Pompeu Fabra University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Larue, L (corresponding author), CNRS, Inst Curie, Dev Genet Melanocytes, UMR 146, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr	de Herreros, A Garcia/H-3104-2014; Larue, Lionel/F-7355-2013; van Roy, Frans M/C-6123-2009; Larue, Lionel/I-6532-2016	de Herreros, A Garcia/0000-0001-5270-0808; van Roy, Frans M/0000-0003-4358-1039; Puig Borreil, Isabel/0000-0001-5614-4298				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Grille SJ, 2003, CANCER RES, V63, P2172; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gustin JA, 2006, J BIOL CHEM, V281, P16473, DOI 10.1074/jbc.M507373200; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Misra J, 2002, GENOME RES, V12, P1112, DOI 10.1101/gr.225302; Morali OG, 2005, MOL B INT U, P12; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Nelles L, 2003, GENOMICS, V82, P460, DOI 10.1016/S0888-7543(03)00169-1; NIETO MA, 1992, DEVELOPMENT, V116, P227; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Ozes ON, 1999, NATURE, V401, P82; Park BK, 2001, CANCER RES, V61, P7647; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Stoyanova R, 2004, CANCER BIOL THER, V3, P1313, DOI 10.4161/cbt.3.12.1459; Stoyanova R, 2004, J CELL PHYSIOL, V201, P359, DOI 10.1002/jcp.20074; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang HD, 2004, WORLD J GASTROENTERO, V10, P3088; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	66	383	398	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7445	7456		10.1038/sj.onc.1210546	http://dx.doi.org/10.1038/sj.onc.1210546			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17563753				2022-12-25	WOS:000251282000006
J	Perez, CA; Ott, J; Mays, DJ; Pietenpol, JA				Perez, C. A.; Ott, J.; Mays, D. J.; Pietenpol, J. A.			p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm	ONCOGENE			English	Article						SELEX; consensus DNA-binding site; p63MH; ING1; PTPN14	P53 FAMILY; BIOLOGICAL FUNCTIONS; HUMAN GENOME; GENES; PROTEIN; DELTA-NP63-ALPHA; TRANSCRIPTION; EXPRESSION; SEQUENCE; DISTINCT	p53 and p63 belong to a family of sequence-specific transcription factors regulating key cellular processes. Differential composition of the p53 and p63 DNA-binding sites may contribute to distinct functions of these protein homologues. We used SELEX (systematic evolution of ligands by exponential enrichment) methodology to identify nucleic acid ligands for p63. We found that p63 bound preferentially to DNA fragments conforming to the 20 bp sequence 5'- RRRC(A/G)(A/T)GYYYRRRC(A/T) (C/T)GYYY-3'. Relative to the p53 consensus, the p63 consensus DNA-binding site (DBS) was more degenerate, particularly at positions 10 and 11, and was enriched for A/G at position 5 and C/T at position 16 of the consensus. The differences in DNA-binding site preferences between p63 and p53 influenced their ability to activate transcription from select response elements (REs) in cells. A computer algorithm, p63MH, was developed to find candidate p63-binding motifs on input sequences. We identified genes responsive to p63 regulation that contain functional p63 REs. Our results suggest that the sequence composition of REs could be one contributing factor to target gene discrimination between p63 and p53.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Biochem, Nashville, TN 37203 USA; Rockefeller Univ, Lab Stat Gen, New York, NY 10021 USA	Vanderbilt University; Rockefeller University	Pietenpol, JA (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37203 USA.	j.pietenpol@vanderbilt.edu			NCI NIH HHS [CA105436, CA68485, CA70856] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIMH NIH HHS [MH44292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070856, R01CA105436, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044292, R37MH044292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; BLACKWELL TK, 1995, METHOD ENZYMOL, V254, P604; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; Caserta TM, 2006, MOL CANCER RES, V4, P759, DOI 10.1158/1541-7786.MCR-05-0149; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hearnes JM, 2005, MOL CELL BIOL, V25, P10148, DOI 10.1128/MCB.25.22.10148-10158.2005; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; MCKAY R, 1981, NATURE, V289, P810, DOI 10.1038/289810a0; Moll UM, 2004, MOL CANCER RES, V2, P371; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Perez CA, 2007, CELL CYCLE, V6, P246, DOI 10.4161/cc.6.3.3801; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; Ponassi R, 2006, BIOCHEM PHARMACOL, V72, P1417, DOI 10.1016/j.bcp.2006.07.031; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Shimada A, 1999, CANCER RES, V59, P2781; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Thijs G, 2002, J COMPUT BIOL, V9, P447, DOI 10.1089/10665270252935566; Tomso DJ, 2005, P NATL ACAD SCI USA, V102, P6431, DOI 10.1073/pnas.0501721102; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005	35	74	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7363	7370		10.1038/sj.onc.1210561	http://dx.doi.org/10.1038/sj.onc.1210561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17563751				2022-12-25	WOS:000250955700008
J	Lee, SS; Gao, W; Mazzola, S; Thomas, MN; Csizmadia, E; Otterbein, LE; Bach, FH; Wang, H				Lee, Soo Sun; Gao, Wenda; Mazzola, Silvia; Thomas, Michael N.; Csizmadia, Eva; Otterbein, Leo E.; Bach, Fritz H.; Wang, Hongjun			Heme oxygenase-1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells	FASEB JOURNAL			English	Article						islet transplantation; allograft survival	CUTTING EDGE; IN-VIVO; TRANSPLANTATION TOLERANCE; DIABETES-MELLITUS; NOD MICE; TGF-BETA; CD4(+)CD25(+); PROTECTION; IMMUNOSUPPRESSION; INFLAMMATION	Heme oxygenase-1 (HO-1) induction in, or carbon monoxide (CO), or bilirubin administration to, donors and/or recipients frequently lead to long-term survival (> 100 days) of DBA/2 islets into B6AF1 recipients. We tested here whether similar treatments show value in a stronger immunogenetic combination, i.e., BALB/c to C57BL/6, and attempted to elucidate the mechanism accounting for tolerance. Induction of HO-1, administering CO or bilirubin to the donor, the islets or the recipient, prolonged islet allograft survival to different extents. Combining all the above treatments (the "combined" protocol) led to survival for > 100 days and antigen-specific tolerance to 60% of the transplanted grafts. A high level of forkhead box P3 (Foxp3) and transforming growth factor beta (TGF-beta) expression was detected in the long-term surviving grafts. With the combined protocol, significantly more T regulatory cells (Tregs) were observed surrounding islets 7 days following transplantation. No prolongation of graft survival was observed using the combined protocol when CD4(+) CD25(+) T cells were predepleted from the recipients before transplantation. In conclusion, our combined protocol led to long-term survival and tolerance to islets in the BALB/c to C57BL/6 combination by promoting Foxp3(+) Tregs; these cells played a critical role in the induction and maintenance of tolerance in the recipient.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA; Univ Milan, Dipartimento Patol Anim, I-20122 Milan, Italy	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Milan	Wang, H (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, 99 Brookline Ave, Boston, MA 02215 USA.	hwang3@bidmc.harvard.edu	Wang, Hongjun/AAA-1319-2021; Mazzola, Silvia Michela/J-8137-2012	Mazzola, Silvia Michela/0000-0001-8131-4340	NHLBI NIH HHS [HL077721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077721] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benghiat FS, 2005, TRANSPLANTATION, V79, P648, DOI 10.1097/01.TP.0000155179.61445.78; Bertuzzi F, 2006, CURR MOL MED, V6, P369, DOI 10.2174/156652406777435453; Choi BM, 2005, BIOCHEM BIOPH RES CO, V327, P1066, DOI 10.1016/j.bbrc.2004.12.106; Dai ZH, 2004, J CLIN INVEST, V113, P310, DOI 10.1172/JCI200419727; Emerich DF, 2002, EXPERT OPIN BIOL TH, V2, P793, DOI 10.1517/14712598.2.8.793; Erdmann K, 2005, AAPS J, V7, pE195, DOI 10.1208/aapsj070118; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Graca L, 2002, J IMMUNOL, V168, P5558, DOI 10.4049/jimmunol.168.11.5558; Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080; Kohyama M, 2004, P NATL ACAD SCI USA, V101, P4192, DOI 10.1073/pnas.0400214101; Koksoy S, 2005, TRANSPLANTATION, V79, P1492, DOI 10.1097/01.TP.0000159870.01567.02; Kryczek I, 2006, J IMMUNOL, V177, P40, DOI 10.4049/jimmunol.177.1.40; Kumagai N, 2002, TRANSPLANTATION, V74, P1223, DOI 10.1097/00007890-200211150-00005; Lee K, 2004, J IMMUNOL, V172, P6539, DOI 10.4049/jimmunol.172.11.6539; Li M, 2007, CELL CYCLE, V6, P567, DOI 10.4161/cc.6.5.3917; Maerten P, 2005, J AUTOIMMUN, V25, P112, DOI 10.1016/j.jaut.2005.04.001; Molano RD, 2003, DIABETES, V52, P957, DOI 10.2337/diabetes.52.4.957; Nakao A, 2005, AM J TRANSPLANT, V5, P282, DOI 10.1111/j.1600-6143.2004.00695.x; Nanji SA, 2004, BIODRUGS, V18, P315, DOI 10.2165/00063030-200418050-00004; Pace L, 2006, J IMMUNOL, V176, P3900, DOI 10.4049/jimmunol.176.7.3900; Pileggi A, 2001, DIABETES, V50, P1983, DOI 10.2337/diabetes.50.9.1983; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; RICORDI C, 1990, ACTA DIABETOL LAT, V27, P185, DOI 10.1007/BF02581331; Ryan Edmond A, 2004, Curr Diab Rep, V4, P304, DOI 10.1007/s11892-004-0083-8; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143; Trani J, 2003, J IMMUNOL, V170, P279, DOI 10.4049/jimmunol.170.1.279; Wang HJ, 2006, ENDOCRINOLOGY, V147, P762, DOI 10.1210/en.2005-0632; Wang HJ, 2005, DIABETES, V54, P1400, DOI 10.2337/diabetes.54.5.1400; Xia ZW, 2006, J IMMUNOL, V177, P5936, DOI 10.4049/jimmunol.177.9.5936; YAMASHITA K, 2006, FASEB J, DOI DOI 10.1096/05-4791FJE; Zelenay S, 2007, INT IMMUNOL, V19, P11, DOI 10.1093/intimm/dxl116; Zhang N, 2006, DIABETES, V55, P2429, DOI 10.2337/db06-0173	39	77	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3450	3457		10.1096/fj.07-8472com	http://dx.doi.org/10.1096/fj.07-8472com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17551098				2022-12-25	WOS:000250517800008
J	Rigamonti, D; Bolognini, D; Mutti, C; Zuccato, C; Tartari, M; Sola, F; Valenza, M; Kazantsev, AG; Cattaneo, E				Rigamonti, Dorotea; Bolognini, Daniele; Mutti, Cesare; Zuccato, Chiara; Tartari, Marzia; Sola, Francesco; Valenza, Marta; Kazantsev, Aleksey G.; Cattaneo, Elena			Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIC FACTOR; TARGET GENES; RAT-BRAIN; EXPRESSION; TRANSCRIPTION; DISEASE; BDNF; REST/NRSF; NEURONS; MODEL	Increased levels of the repressor element 1/neuron restrictive silencer element (RE1/NRSE) silencing activity promoter, and a consequent reduction in the transcription of many RE1/NRSE-bearing neuronal genes, including brain-derived neurotrophic factor (BDNF), have been demonstrated in Huntington disease (HD) and represent one possible effector of its selective neuronal vulnerability. Restoring the expression levels of neuronal genes in diseased neurons therefore seems to be an attractive therapeutic approach. To this end, we have developed a cell-based reporter assay for monitoring RE1/NRSE silencing activity and validated it by genetically inactivating the RE1/NRSE or pharmacologically stimulating global transcription. In a pilot compound screen, we identified three closely related structural analogues that up-regulate reporter expression at low nanomolar concentrations, and follow-up studies have shown that they efficaciously increase endogenous BDNF levels in HD cells. Moreover, one of the compounds increases the viability of HD cells. Our findings suggest a new avenue for the development of drugs for HD and other neurodegenerative disorders based on the pharmacological up-regulation of the production of the neuronal survival factor BDNF and of other RE1/NRSE-regulated neuronal genes.	Univ Milan, Ctr Stem Cell Res, I-20133 Milan, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Dialect Srl, I-20014 Nerviano Mi, Italy; Nerviano Med Sci Srl, Dept Biol, I-20014 Nerviano Mi, Italy; Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA	University of Milan; University of Milan; Nerviano Medical Sciences S.r.l; Harvard University; Massachusetts General Hospital	Cattaneo, E (corresponding author), Univ Milan, Ctr Stem Cell Res, Via Balzaretti 9, I-20133 Milan, Italy.	elena.cattaneo@unimi.it	Bolognini, Daniele/AAF-7892-2020; VALENZA, MARTA/B-7763-2017	VALENZA, MARTA/0000-0002-7048-9257; ZUCCATO, CHIARA/0000-0003-1771-3392; CATTANEO, ELENA/0000-0002-0755-4917	Telethon [GGP06250] Funding Source: Medline	Telethon(Fondazione Telethon)		Altar CA, 1999, TRENDS PHARMACOL SCI, V20, P59, DOI 10.1016/S0165-6147(99)01309-7; Bahn S, 2002, LANCET, V359, P310, DOI 10.1016/S0140-6736(02)07497-4; Baquet ZC, 2004, J NEUROSCI, V24, P4250, DOI 10.1523/JNEUROSCI.3920-03.2004; Bemelmans AP, 1999, HUM GENE THER, V10, P2987, DOI 10.1089/10430349950016393; Borrell-Pages M, 2006, J CLIN INVEST, V116, P1410, DOI 10.1172/JCI27607; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Calderone A, 2003, J NEUROSCI, V23, P2112; Canals JM, 2004, J NEUROSCI, V24, P7727, DOI 10.1523/JNEUROSCI.1197-04.2004; Cattaneo E, 1998, J NEUROSCI RES, V53, P223, DOI 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7; Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806; CONDORELLI DF, 1994, J NEUROCHEM, V63, P509; Di Prospero NA, 2005, NAT REV GENET, V6, P756, DOI 10.1038/nrg1690; Djouma E, 2006, EUR J NEUROSCI, V23, P3319, DOI 10.1111/j.1460-9568.2006.04864.x; GULY D, 2002, PHARM EXP THER, V301, P322; Hersch SM, 2003, CURR OPIN NEUROL, V16, P501, DOI 10.1097/01.wco.0000084229.82329.03; Johnson R, 2006, NUCLEIC ACIDS RES, V34, P3862, DOI 10.1093/nar/gkl525; KAZANTSEV AG, 2007, PROG NEUROBIOL  0223; Kells AP, 2004, MOL THER, V9, P682, DOI 10.1016/j.ymthe.2004.02.016; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Ma YL, 1999, CHINESE J PHYSIOL, V42, P73; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Palm K, 1998, J NEUROSCI, V18, P1280; Perez-Navarro E, 2000, J NEUROCHEM, V75, P2190, DOI 10.1046/j.1471-4159.2000.0752190.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Ryu Hoon, 2005, Expert Opin Emerg Drugs, V10, P345, DOI 10.1517/14728214.10.2.345; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; Sipione S, 2001, MOL NEUROBIOL, V23, P21; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; Timmusk T, 1999, J BIOL CHEM, V274, P1078; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Wood IC, 2003, J MOL BIOL, V334, P863, DOI 10.1016/j.jmb.2003.10.017; XU G, 2006, NEUROSCIENCE; Zhang G, 2003, J PHARMACOL EXP THER, V305, P57, DOI 10.1124/jpet.102.046128; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581; Zuccato C, 2007, J NEUROSCI, V27, P6972, DOI 10.1523/JNEUROSCI.4278-06.2007	44	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24554	24562		10.1074/jbc.M609885200	http://dx.doi.org/10.1074/jbc.M609885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17565993	Green Published, hybrid			2022-12-25	WOS:000248933000009
J	Asanoma, K; Kato, H; Yamaguchi, S; Shin, CH; Liu, ZP; Kato, K; Inoue, T; Miyanari, Y; Yoshikawa, K; Sonoda, K; Fukushima, K; Wake, N				Asanoma, Kazuo; Kato, Hidenori; Yamaguchi, Shinichiro; Shin, Chong Hyun; Liu, Zhi-Ping; Kato, Kiyoko; Inoue, Takafumi; Miyanari, Yoko; Yoshikawa, Koji; Sonoda, Kenzo; Fukushima, Kotaro; Wake, Norio			HOP/NECC1, a novel regulator of mouse trophoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; PLACENTAL LACTOGEN-I; GENE-EXPRESSION; GIANT-CELLS; TRANSCRIPTION; PROTEIN; KINASE; HOP; PHOSPHORYLATES; PROLIFERATION	Homeodomain-only protein/ not expressed in choriocarcinoma clone 1 ( HOP/ NECC1) is a newly identified gene that modifies the expression of cardiac- specific genes and thereby regulates heart development. More recently, HOP/ NECC1 was reported to be a suppressor of choriocarcinogenesis. Here, we examined the temporal expression profile of HOP/ NECC1 in wild- type mouse placenta. We found that E8.5 - E9.5 wild- type placenta expressed HOP/ NECC1 in the giant cell and spongiotrophoblast layers. HOP/ NECC1 ( -/- ) placenta exhibited marked propagation of giant cell layers and, in turn reduction of spongiotrophoblast formation. We demonstrated SRF transcriptional activity increased in the differentiating trophoblasts and forced expression of SRF in a trophoblast stem ( TS) cell line induces the differentiation into giant cells. Negative regulation of SRF ( serum response factor) by the binding of HOP/ NECC1 protein contributed at least in part to the generation of these placental defects. Gradual induction of HOP/ NECC1 in response to differentiation stimuli may result in the decision to differentiate into a particular type of trophoblastic cell lineage and result in non- lethal defects shown by the HOP/ NECC1 ( -/- ) placentas.	Kyushu Univ, Dept Mol Genet, Div Mol & Cell Therapeut, Fukuoka 812, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Pathol, Fukuoka 812, Japan; Kyushu Univ, Fac Med, Dept Obstet & Gynecol, Higashi Ku, Fukuoka 8128582, Japan; Hokkaido Canc Ctr, Dept Gynecol, Shiraishi Ku, Sapporo, Hokkaido 003000, Japan; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	Kyushu University; Kyushu University; Kyushu University; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Asanoma, K (corresponding author), Kyushu Univ, Dept Mol Genet, Div Mol & Cell Therapeut, Fukuoka 812, Japan.	asanoma@med.kyushu-u.ac.jp						Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Asanoma K, 2003, GENOMICS, V81, P15, DOI 10.1016/S0888-7543(02)00011-3; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Camoretti-Mercado B, 2000, J BIOL CHEM, V275, P30387, DOI 10.1074/jbc.M000840200; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Cheng YH, 2005, BIOL REPROD, V73, P500, DOI 10.1095/biolreprod.105.039941; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Ding W, 2001, J CELL SCI, V114, P1011; FARIA TN, 1991, BIOL REPROD, V44, P327, DOI 10.1095/biolreprod44.2.327; FARIA TN, 1991, ENDOCRINOLOGY, V129, P2895, DOI 10.1210/endo-129-6-2895; Fluck M, 2000, BIOCHEM BIOPH RES CO, V270, P488, DOI 10.1006/bbrc.2000.2457; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; Hemberger M, 2001, TRENDS ENDOCRIN MET, V12, P162, DOI 10.1016/S1043-2760(01)00375-7; Hughes M, 2004, DEV BIOL, V271, P26, DOI 10.1016/j.ydbio.2004.03.029; Ismat FA, 2005, CIRC RES, V96, P898, DOI 10.1161/01.RES.0000163108.47258.f3; Iyer D, 2006, P NATL ACAD SCI USA, V103, P4516, DOI 10.1073/pnas.0505338103; KOOK H, 2003, J CLIN INVEST, V112, P683; LEE SJ, 1988, ENDOCRINOLOGY, V122, P1761, DOI 10.1210/endo-122-5-1761; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; Ma GT, 1997, DEVELOPMENT, V124, P907; MacAuley A, 1998, MOL BIOL CELL, V9, P795, DOI 10.1091/mbc.9.4.795; Ohgane J, 1998, DEV GENET, V22, P132, DOI 10.1002/(SICI)1520-6408(1998)22:2<132::AID-DVG3>3.0.CO;2-7; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; REECY J, 1998, HEART DEV, P273; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Rossant Janet, 1995, Seminars in Developmental Biology, V6, P237, DOI 10.1016/S1044-5781(06)80049-6; RUDERT F, 1992, MAMM GENOME, V3, P262, DOI 10.1007/BF00292154; SHIDA MM, 1993, MOL ENDOCRINOL, V7, P181, DOI 10.1210/me.7.2.181; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Wheaton K, 2004, MOL CELL BIOL, V24, P7298, DOI 10.1128/MCB.24.16.7298-7311.2004; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	36	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24065	24074		10.1074/jbc.M701380200	http://dx.doi.org/10.1074/jbc.M701380200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17576768	hybrid			2022-12-25	WOS:000248686600032
J	Leppanen, VM; Tossavainen, H; Permi, P; Lehtio, L; Ronnholm, G; Goldman, A; Kilpelainen, I; Pihlajamaa, T				Leppanen, Veli-Matti; Tossavainen, Helena; Permi, Perttu; Lehtio, Lari; Ronnholm, Gunilla; Goldman, Adrian; Kilpelainen, Ilkka; Pihlajamaa, Tero			Crystal structure of the N-terminal NC4 domain of collagen IX, a zinc binding member of the laminin-neurexin-sex hormone binding globulin (LNS) domain family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; OLIGOMERIC MATRIX PROTEIN; C-REACTIVE PROTEIN; ALPHA-DYSTROGLYCAN; EXTRACELLULAR-MATRIX; NONCOLLAGENOUS DOMAIN; LIGAND-BINDING; A-DOMAIN; CARTILAGE; HEPARIN	Collagen IX, located on the surface of collagen fibrils, is crucial for cartilage integrity and stability. The N-terminal NC4 domain of the alpha 1(IX) chain is probably important in this because it interacts with various macromolecules such as proteoglycans and cartilage oligomeric matrix protein. At least 17 distinct collagen polypeptides carry an NC4-like unit near their N terminus, but this report, describing the crystal structure of NC4 at 1.8-angstrom resolution, represents the first atomic level structure for these domains. The structure is similar to previously characterized laminin-neurexin-sex hormone binding globulin (LNS) structures, dominated by an antiparallel beta-sheet sandwich. In addition, a zinc ion was found in a position similar to that of the metal binding site of other LNS domains. A partial backbone NMR assignment of NC4 was obtained and utilized in NMR titration studies to investigate the zinc binding in solution state and to quantitate the affinity of metal binding. The K-d of 11.5 mM suggests a regulatory rather than a structural role for zinc in solution. NMR titration with a heparin tetrasaccharide revealed the presence of a secondary binding site for heparin on NC4, showing structural and functional conservation with thrombospondin-1, but a markedly reduced affinity for the ligand. Also the overall arrangement of the N and C termini of NC4 resembles most closely the N-terminal domain of thrombospondin-1, distinguishing the two from the majority of the published LNS structures.	Univ Helsinki, Inst Biotechnol, NMR Lab, Program Struct Biol & Biophys, FI-00014 Helsinki, Finland; Univ Helsinki, Dept Chem, Organ Chem Lab, FI-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Pihlajamaa, T (corresponding author), Univ Helsinki, Inst Biotechnol, NMR Lab, Program Struct Biol & Biophys, POB 65, FI-00014 Helsinki, Finland.	Tero.Pihlajamaa@helsinki.fi		Goldman, Adrian/0000-0001-8032-9700; Leppanen, Veli-Matti/0000-0001-7100-965X; Lehtio, Lari/0000-0001-7250-832X				Aitio H, 2001, PROTEIN SCI, V10, P74, DOI 10.1110/ps.31201; Avvakumov GV, 2000, J BIOL CHEM, V275, P25920, DOI 10.1074/jbc.M004484200; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Budde B, 2005, MOL CELL BIOL, V25, P10465, DOI 10.1128/MCB.25.23.10465-10478.2005; Calzada MJ, 2003, J BIOL CHEM, V278, P40679, DOI 10.1074/jbc.M302014200; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Chapman KL, 2001, NAT GENET, V28, P393, DOI 10.1038/ng573; Coleman JE, 1998, CURR OPIN CHEM BIOL, V2, P222, DOI 10.1016/S1367-5931(98)80064-1; Czarny-Ratajczak M, 2001, AM J HUM GENET, V69, P969, DOI 10.1086/324023; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fallahi A, 2005, PROTEIN SCI, V14, P1526, DOI 10.1110/ps.051363105; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Goddard T. D. and Kneller D. G ., 2002, SPARKY; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; Guo Y, 1998, EMBO J, V17, P5265, DOI 10.1093/emboj/17.18.5265; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jackson GC, 2004, J MED GENET, V41, P52, DOI 10.1136/jmg.2003.011429; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kapyla J, 2004, J BIOL CHEM, V279, P51677, DOI 10.1074/jbc.M409412200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishnan VV, 2000, BIOCHEMISTRY-US, V39, P9119, DOI 10.1021/bi000296l; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Paassilta P, 1999, AM J HUM GENET, V64, P1036, DOI 10.1086/302328; Pihlajamaa T, 2004, J BIOL CHEM, V279, P24265, DOI 10.1074/jbc.M402865200; Ricard-Blum S, 2005, PATHOL BIOL, V53, P430, DOI 10.1016/j.patbio.2004.12.024; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; Sasaki T, 2002, J BIOL CHEM, V277, P44164, DOI 10.1074/jbc.M207340200; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Savontaus M, 1998, HISTOCHEM CELL BIOL, V110, P149, DOI 10.1007/s004180050276; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Sheckler LR, 2006, J BIOL CHEM, V281, P22896, DOI 10.1074/jbc.M603464200; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Stetefeld J, 2004, STRUCTURE, V12, P503, DOI 10.1016/j.str.2004.02.001; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; SWIDERSKI RE, 1992, DEVELOPMENT, V115, P169; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Tan K, 2006, STRUCTURE, V14, P33, DOI 10.1016/j.str.2005.09.017; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tossavainen H, 2006, PROTEIN SCI, V15, P1760, DOI 10.1110/ps.052068506; Warner LR, 2006, J BIOL CHEM, V281, P39507, DOI 10.1074/jbc.M608551200; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888	64	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23219	23230		10.1074/jbc.M702514200	http://dx.doi.org/10.1074/jbc.M702514200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17553797	hybrid			2022-12-25	WOS:000248577500023
J	Tanaka, KI; Namba, T; Arai, Y; Fujimoto, M; Adachi, H; Sobue, G; Takeuchi, K; Nakai, A; Mizushima, T				Tanaka, Ken-Ichiro; Namba, Takushi; Arai, Yasuhiro; Fujimoto, Mitsuaki; Adachi, Hiroaki; Sobue, Gen; Takeuchi, Koji; Nakai, Akira; Mizushima, Tohru			Genetic evidence for a protective role for heat shock factor 1 and heat shock protein 70 against colitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVATION; ADHESION MOLECULE EXPRESSION; SODIUM-INDUCED COLITIS; ACID-INDUCED COLITIS; TNBS-INDUCED COLITIS; NUCLEAR-FACTOR; NITRIC-OXIDE; TNF-ALPHA; DUAL ROLE	Inflammatory bowel disease (IBD) involves infiltration of leukocytes into intestinal tissue, resulting in intestinal damage induced by reactive oxygen species (ROS). Pro-inflammatory cytokines and cell adhesion molecules (CAMs) play important roles in this infiltration of leukocytes. The roles of heat shock factor 1 (HSF1) and heat shock proteins (HSPs) in the development of IBD are unclear. In this study, we examined the roles of HSF1 and HSPs in an animal model of IBD, dextran sulfate sodium (DSS)-induced colitis. The colitis worsened or was ameliorated in HSF1-null mice or transgenic mice expressing HSP70 (or HSF1), respectively. Administration of DSS up-regulated the expression of HSP70 in colonic tissues in an HSF1-dependent manner. Expression of pro-inflammatory cytokines and CAMs and the level of cell death observed in colonic tissues were increased or decreased in DSS-treated HSF1-null mice or transgenic mice expressing HSP70, respectively, relative to control wild-type mice. Relative to macrophages from control wildtype mice, macrophages prepared from HSF1-null mice or transgenic mice expressing HSP70 displayed enhanced or reduced activity, respectively, for the generation of pro-inflammatory cytokines in response to lipopolysaccharide stimulation. Suppression of HSF1 or HSP70 expression in vitro stimulated lipopolysaccharide induced up-regulation of CAMs or ROS-induced cell death, respectively. This study provides the first genetic evidence that HSF1 and HSP70 play a role in protecting against DSS-induced colitis. Furthermore, this protective role seems to involve various mechanisms, such as suppression of expression of pro-inflammatory cytokines and CAMs and ROS-induced cell death.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan; Yamaguchi Univ, Sch Med, Yamaguchi 7558505, Japan; Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4668550, Japan; Kyoto Pharmaceut Univ, Kyoto 6078414, Japan	Kumamoto University; Yamaguchi University; Nagoya University; Kyoto Pharmaceutical University	Mizushima, T (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan.	mizu@gpo.kumamoto-u.ac.jp	Adachi, Hiroaki/AAM-7812-2020; Tanaka, Ken-ichiro/J-8557-2013	Adachi, Hiroaki/0000-0002-9302-4663; 				Adachi H, 2003, J NEUROSCI, V23, P2203; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Barton SGRG, 2003, CELL STRESS CHAPERON, V8, P329, DOI 10.1379/1466-1268(2003)008<0329:EOHSPH>2.0.CO;2; Bendjelloul F, 2000, CLIN EXP IMMUNOL, V119, P57, DOI 10.1046/j.1365-2249.2000.01090.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan JYH, 2004, CIRCULATION, V110, P3560, DOI 10.1161/01.CIR.0000143082.63063.33; Chen HQ, 2006, FEBS LETT, V580, P3145, DOI 10.1016/j.febslet.2006.04.066; COLLINS T, 1993, LAB INVEST, V68, P499; COOPER HS, 1993, LAB INVEST, V69, P238; Cuzzocrea Salvatore, 2003, Expert Opin Emerg Drugs, V8, P339, DOI 10.1517/14728214.8.2.339; Danese S, 2005, DIGEST LIVER DIS, V37, P811, DOI 10.1016/j.dld.2005.03.013; ELSAGHIER A, 1992, CLIN EXP IMMUNOL, V89, P305, DOI 10.1111/j.1365-2249.1992.tb06950.x; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Guzhova IV, 1997, CELL STRESS CHAPERON, V2, P132, DOI 10.1379/1466-1268(1997)002<0132:MSPHIW>2.3.CO;2; Hirakawa T, 1996, GASTROENTEROLOGY, V111, P345, DOI 10.1053/gast.1996.v111.pm8690199; Inouye S, 2004, J BIOL CHEM, V279, P38701, DOI 10.1074/jbc.M405986200; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jurjus Abdo R., 2004, Journal of Pharmacological and Toxicological Methods, V50, P81, DOI 10.1016/j.vascn.2003.12.002; Kinoshita K, 2006, NEUROGASTROENT MOTIL, V18, P578, DOI 10.1111/j.1365-2982.2006.00784.x; KOIZUMI M, 1992, GASTROENTEROLOGY, V103, P840, DOI 10.1016/0016-5085(92)90015-Q; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; Kubisch C, 2004, GASTROENTEROLOGY, V127, P275, DOI 10.1053/j.gastro.2004.04.005; Ludwig D, 1999, DIGEST DIS SCI, V44, P1440, DOI 10.1023/A:1026616221950; Mathew A, 1998, ANN NY ACAD SCI, V851, P99, DOI 10.1111/j.1749-6632.1998.tb08982.x; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nakai A, 2000, EMBO J, V19, P1545, DOI 10.1093/emboj/19.7.1545; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ohkawara T, 2005, SCAND J GASTROENTERO, V40, P1049, DOI 10.1080/00365520510023161; Ohkawara T, 2002, GASTROENTEROLOGY, V123, P256, DOI 10.1053/gast.2002.34236; Ohkawara T, 2006, INT J MOL MED, V17, P229; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petrof Elaine O, 2004, Chin J Dig Dis, V5, P45, DOI 10.1111/j.1443-9573.2004.00154.x; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174; Rumi G, 2004, J PHYSIOL PHARMACOL, V55, P823; Rumi G, 2004, DIGEST DIS SCI, V49, P1466, DOI 10.1023/B:DDAS.0000042248.48819.ad; Salimuddin, 1999, AM J PHYSIOL-ENDOC M, V277, pE110, DOI 10.1152/ajpendo.1999.277.1.E110; Sans M, 1999, GASTROENTEROLOGY, V116, P874, DOI 10.1016/S0016-5085(99)70070-3; Segui J, 2004, J LEUKOCYTE BIOL, V76, P537, DOI 10.1189/jlb.0304196; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; Singh-Jasuja H, 2001, BIOL CHEM, V382, P629, DOI 10.1515/BC.2001.074; Sun DX, 2005, J SURG RES, V129, P114, DOI 10.1016/j.jss.2005.05.028; Tanaka KI, 2007, MOL PHARMACOL, V71, P985, DOI 10.1124/mol.106.033282; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Tomita N, 2000, GENE THER, V7, P1326, DOI 10.1038/sj.gt.3301243; Venkatraman A, 2003, AM J PHYSIOL-GASTR L, V285, pG177, DOI 10.1152/ajpgi.00307.2002; Wang WP, 2001, AM J PHYSIOL-GASTR L, V281, pG586, DOI 10.1152/ajpgi.2001.281.2.G586; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; Yoo HY, 1999, J BIOL CHEM, V274, P23887, DOI 10.1074/jbc.274.34.23887	55	113	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23240	23252		10.1074/jbc.M704081200	http://dx.doi.org/10.1074/jbc.M704081200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17556362	hybrid			2022-12-25	WOS:000248577500025
J	Qiu, Y; Loh, HH; Law, PY				Qiu, Yu; Loh, Horace H.; Law, Ping-Yee			Phosphorylation of the delta-opioid receptor regulates its beta-arrestins selectivity and subsequent receptor internalization and adenylyl cyclase desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INTRACELLULAR TRAFFICKING; CONFORMATIONAL-CHANGES; CLATHRIN ADAPTER; VISUAL ARRESTIN; XENOPUS OOCYTES; KINASE 2; MU; ENDOCYTOSIS; ACTIVATION	In the current study, we investigated the role of receptor phosphorylation and beta-arrestins in delta-opioid receptor (DOR) signaling and trafficking by using a DOR mutant in which all Ser/Thr residues in the C terminus were mutated to Ala (DTS). We demonstrated that the DOR agonist D-[Pen(2),Pen(5)] enkephalin could induce receptor internalization and adenylyl cyclase (AC) desensitization of DTS, but with comparatively slower kinetics than those observed with wild type DOR. Blockade of the internalization of DTS by the dominant-negative mutant dynamin, dynamin K44E, did not affect AC desensitization. However, depletion of beta-arrestins almost totally blocked both internalization and AC desensitization of DTS. A BRET assay suggested that DOR phosphorylation promotes receptor selectivity for beta-arrestin 2 over beta-arrestin 1. Furthermore, in mouse embryonic fibroblast (MEF) cells lacking either beta-arrestin 1 (beta arr1(-/-)) or beta-arrestin 2 (beta arr2(-/-)), agonist-induced DTS desensitization and internalization were similar to that observed in wild type MEFs. In contrast, although DOR internalization decreased in both beta arr1(-/-) MEFs and beta arr2(-/-) MEFs, DPDPE-induced DOR desensitization was significantly reduced in beta arr2(-/-) MEFs, but not in beta arr1(-/-) MEFs. Additionally, the BRET assay suggested that depletion of phosphorylation did not influence the stability of the receptor-beta-arrestin complex. Consistent with this observation, DTS did not recycle after internalization, which is like wild type DOR. Taken together, these results indicate that receptor phosphorylation confers DOR selectivity for beta-arrestin 2 without affecting the stability of the receptor-beta-arrestin complex and the fate of the internalized receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Qiu, Y (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321Church St,SE, Minneapolis, MN 55455 USA.	qiuxx014@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA011806, K05-DA00513, DA016674, DA007339, DA000564, K05-DA70544] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA000564, R56DA000564, R01DA016674, K05DA000513, R01DA007339, P50DA011806] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Cen B, 2001, MOL PHARMACOL, V59, P758, DOI 10.1124/mol.59.4.758; Charest PG, 2005, EMBO REP, V6, P334, DOI 10.1038/sj.embor.7400373; Claude-Geppert PA, 2005, J PHARMACOL EXP THER, V313, P216, DOI 10.1124/jpet.104.076505; Deng HB, 2001, BRAIN RES, V898, P204, DOI 10.1016/S0006-8993(01)02179-5; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; Ferguson G, 2000, MOL PHARMACOL, V57, P546, DOI 10.1124/mol.57.3.546; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Guo J, 2000, MOL PHARMACOL, V58, P1050, DOI 10.1124/mol.58.5.1050; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hanson SM, 2006, J BIOL CHEM, V281, P3458, DOI 10.1074/jbc.M512148200; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Hasbi A, 1998, J NEUROCHEM, V70, P2129; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Law PY, 2000, J BIOL CHEM, V275, P32057, DOI 10.1074/jbc.M002395200; Law PY, 2004, NEUROPHARMACOLOGY, V47, P300, DOI 10.1016/j.neuropharm.2004.07.013; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lowe JD, 2002, J BIOL CHEM, V277, P15729, DOI 10.1074/jbc.M200612200; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nair KS, 2005, NEURON, V46, P555, DOI 10.1016/j.neuron.2005.03.023; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pan L, 2003, J BIOL CHEM, V278, P11623, DOI 10.1074/jbc.M209532200; PEI G, 1995, MOL PHARMACOL, V48, P173; Qiu Y, 2003, J BIOL CHEM, V278, P36733, DOI 10.1074/jbc.M305857200; Richardson MD, 2003, J NEUROCHEM, V84, P854, DOI 10.1046/j.1471-4159.2003.01577.x; Stalheim L, 2005, MOL PHARMACOL, V67, P78, DOI 10.1124/mol.104.006072; Terrillon S, 2004, EMBO J, V23, P3950, DOI 10.1038/sj.emboj.7600387; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Wang CH, 1998, BIOCHEM BIOPH RES CO, V249, P321, DOI 10.1006/bbrc.1998.9080; Wang W, 2003, J BIOL CHEM, V278, P36848, DOI 10.1074/jbc.M301540200; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; Xiao KH, 2004, J BIOL CHEM, V279, P55744, DOI 10.1074/jbc.M409785200; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhang X, 2005, J NEUROCHEM, V95, P169, DOI 10.1111/j.1471-4159.2005.03352.x	52	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22315	22323		10.1074/jbc.M611258200	http://dx.doi.org/10.1074/jbc.M611258200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17565992	hybrid			2022-12-25	WOS:000248354200009
J	Somanath, PR; Kandel, ES; Hay, N; Byzova, TV				Somanath, Payaningal R.; Kandel, Eugene S.; Hay, Nissim; Byzova, Tatiana V.			Akt1 signaling regulates integrin activation, matrix recognition, and fibronectin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL 3-KINASE; PATHOLOGICAL ANGIOGENESIS; BETA-1 CHAIN; IN-VIVO; CELL; KINASE; FIBRILLOGENESIS; AKT/PKB; PROTEIN	Akt, a serine-threonine kinase, regulates multiple cellular processes in vascular cells. We have previously documented that Akt activates integrins and Akt1 deficiency results in matrix abnormalities in skin and blood vessels in vivo. Based on these observations, we hypothesized that Akt1 is necessary for integrin activation and matrix assembly by fibroblasts. In this study, using various cell systems, we show that Akt1 is essential for the inside-out activation of integrins in endothelial cells and fibroblasts, which in turn, mediates matrix assembly. Fibronectin is a major extracellular matrix component of the skin and the vascular basement membrane, which possesses binding sites for many integrins and extracellular matrix proteins. Akt1(-)/(-) fibroblasts and NIH fibroblasts expressing dominant negative Akt1 (K179M-Akt1) showed impaired fibronectin assembly compared with control fibroblasts. In contrast, expression of constitutively active Akt1 (myrAkt1) resulted in enhanced fibronectin assembly. Although increased fibronectin assembly by myrAkt1-expressing human foreskin fibroblasts was abolished by treatment with anti-integrin beta(1) blocking antibodies, treatment with beta(1)-stimulating antibodies rescued the impaired fibronectin assembly that was due to lack of Akt activity. Finally, expression of myrAkt1 corrected the phenotype of Akt1(-/-) fibroblasts thus showing that Akt1 regulates fibronectin assembly through activation of integrin alpha(5)beta(1).	Cleveland Clin, Lerner Res Inst, JJ Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin, Lerner Res Inst, Dept Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Byzova, TV (corresponding author), Cleveland Clin, Lerner Res Inst, JJ Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org		Byzova, Tatiana/0000-0002-2615-875X; Rammohan Shenoy, Somanath/0000-0003-3017-0230	NATIONAL CANCER INSTITUTE [K01CA098176] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL073311, R01HL071625] Funding Source: NIH RePORTER; NCI NIH HHS [CA098176, K01 CA098176] Funding Source: Medline; NHLBI NIH HHS [R01 HL071625-05, R01 HL071625, HL071625, P01 HL073311-050004, P01 HL073311] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chen JH, 2005, NAT MED, V11, P1188, DOI 10.1038/nm1307; Chen JH, 2004, BLOOD, V104, P1703, DOI 10.1182/blood-2003-10-3428; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Christopher RA, 1997, J CELL SCI, V110, P569; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fujio Y, 2001, CELL DEATH DIFFER, V8, P1207, DOI 10.1038/sj.cdd.4400919; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hynes RO, 2004, MATRIX BIOL, V23, P333, DOI 10.1016/j.matbio.2004.08.001; Jacob MP, 2003, BIOMED PHARMACOTHER, V57, P195, DOI 10.1016/S0753-3322(03)00065-9; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kirk RI, 2000, J BIOL CHEM, V275, P30901, DOI 10.1074/jbc.M001908200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; Lim IJ, 2003, J BIOL CHEM, V278, P40851, DOI 10.1074/jbc.M305759200; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Mahabeleshwar GH, 2006, J EXP MED, V203, P2495, DOI 10.1084/jem.20060807; Mao Y, 2005, MATRIX BIOL, V24, P389, DOI 10.1016/j.matbio.2005.06.008; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004; Ruoslahti E, 1997, J CLIN INVEST, V100, pS53; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Somanath PR, 2006, CELL CYCLE, V5, P512, DOI 10.4161/cc.5.5.2538; Sun JF, 2005, P NATL ACAD SCI USA, V102, P128, DOI 10.1073/pnas.0403198102; Tsuchida J, 1997, FEBS LETT, V416, P212, DOI 10.1016/S0014-5793(97)01206-4; Wierzbicka-Patynowski I, 2002, J BIOL CHEM, V277, P19703, DOI 10.1074/jbc.M200270200; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235; Zhao J H, 2000, Prog Mol Subcell Biol, V25, P37	45	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22964	22976		10.1074/jbc.M700241200	http://dx.doi.org/10.1074/jbc.M700241200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17562714	Green Accepted, hybrid			2022-12-25	WOS:000248354200073
J	Wong, AW; Scales, SJ; Reilly, DE				Wong, Athena W.; Scales, Suzie J.; Reilly, Dorothea E.			DNA internalized via Caveolae requires microtubule-dependent, Rab7-independent transport to the late endocytic pathway for delivery to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC LIPID FORMULATIONS; NONVIRAL GENE DELIVERY; MEDIATED ENDOCYTOSIS; INTRACELLULAR TRAFFICKING; PLASMA-MEMBRANE; LATE ENDOSOMES; PROTEIN RILP; TRANSFECTION; CLATHRIN; RAB7	Using cationic liposomes to mediate gene delivery by transfection has the advantages of improved safety and simplicity of use over viral gene therapy. Understanding the mechanism by which cationic liposome: DNA complexes are internalized and delivered to the nucleus should help identify which transport steps might be manipulated in order to improve transfection efficiencies. We therefore examined the endocytosis and trafficking of two cationic liposomes, DMRIE-C and Lipofectamine LTX, in CHO cells. We found that DMRIE-C-transfected DNA is internalized via caveolae, while LTX-transfected DNA is internalized by clathrin-mediated endocytosis, with both pathways converging at the late endosome or lysosome. Inhibition of microtubule-dependent transport with nocodazole revealed that DMRIE-C: DNA complexes cannot enter the cytosol directly from caveosomes. Lysosomal degradation of transfected DNA has been proposed to be a major reason for poor transfection efficiency. However, in our system dominant negatives of both Rab7 and its effector RILP inhibited late endosome to lysosome transport of DNA complexes and LDL, but did not affect DNA delivery to the nucleus. This suggests that DNA is able to escape from late endosomes without traversing lysosomes and that caveosome to late endosome transport does not require Rab7 function. Lysosomal inhibition with chloroquine likewise had no effect on transfection product titers. These data suggest that DMRIE-C and LTX transfection complexes are endocytosed by separate pathways that converge at the late endosome or lysosome, but that blocking lysosomal traffic does not improve transfection product yields, identifying late endosome/lysosome to nuclear delivery as a step for future study.	Genentech Inc, Dept Early Stage Cell Culture, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Wong, AW (corresponding author), Genentech Inc, Dept Early Stage Cell Culture, San Francisco, CA 94080 USA.	wong.athena@gene.com	Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283				Andersen DC, 2004, CURR OPIN BIOTECH, V15, P456, DOI 10.1016/j.copbio.2004.08.002; Apodaca G, 2002, AM J PHYSIOL-RENAL, V282, pF179, DOI 10.1152/ajprenal.2002.282.2.F179; Austin CD, 2006, P NATL ACAD SCI USA, V103, P10283, DOI 10.1073/pnas.0604044103; Austin CD, 2005, P NATL ACAD SCI USA, V102, P17987, DOI 10.1073/pnas.0509035102; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683; Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180; Ciftci K, 2001, INT J PHARM, V218, P81, DOI 10.1016/S0378-5173(01)00623-8; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Dean DA, 1999, EXP CELL RES, V253, P713, DOI 10.1006/excr.1999.4716; Dinneen JL, 2004, EXP CELL RES, V294, P509, DOI 10.1016/j.yexcr.2003.12.006; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; Elouahabi A, 2005, MOL THER, V11, P336, DOI 10.1016/j.ymthe.2004.12.006; ElOuahabi A, 1997, FEBS LETT, V414, P187, DOI 10.1016/S0014-5793(97)00973-3; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Felgner PL, 1995, ANN NY ACAD SCI, V772, P126, DOI 10.1111/j.1749-6632.1995.tb44738.x; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Gourbatsi E, 2006, MOL BIOTECHNOL, V33, P1; Grosse S, 2005, J GENE MED, V7, P1275, DOI 10.1002/jgm.772; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Howell DPG, 2003, MOL THER, V8, P957, DOI 10.1016/j.ymthe.2003.09.011; Jordens I, 2001, CURR BIOL, V11, P1680, DOI 10.1016/S0960-9822(01)00531-0; Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200; Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; Meresse S, 1997, ELECTROPHORESIS, V18, P2682, DOI 10.1002/elps.1150181425; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Norkin LC, 2001, ADV DRUG DELIVER REV, V49, P301, DOI 10.1016/S0169-409X(01)00143-0; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Pelkmans L, 2005, BBA-MOL CELL RES, V1746, P295, DOI 10.1016/j.bbamcr.2005.06.009; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Peters PJ, 2003, J CELL BIOL, V162, P703, DOI 10.1083/jcb.200304140; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; Rejman J, 2005, MOL THER, V12, P468, DOI 10.1016/j.ymthe.2005.03.038; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; Rejman J, 2006, J LIPOSOME RES, V16, P237, DOI 10.1080/08982100600848819; Renigunta A, 2006, BIOCONJUGATE CHEM, V17, P327, DOI 10.1021/bc050263o; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Russell MRG, 2006, CURR OPIN CELL BIOL, V18, P422, DOI 10.1016/j.ceb.2006.06.002; Smisterova J, 2001, J BIOL CHEM, V276, P47615, DOI 10.1074/jbc.M106199200; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; van der Aa MAEM, 2006, PHARM RES-DORDR, V23, P447, DOI 10.1007/s11095-005-9445-4; VANDERAA MA, 2007, IN PRESS PHARM RES; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; Wasungu L, 2006, J CONTROL RELEASE, V116, P255, DOI 10.1016/j.jconrel.2006.06.024; Wattiaux R, 1997, FEBS LETT, V417, P199, DOI 10.1016/S0014-5793(97)01283-0; Wattiaux R, 2000, ADV DRUG DELIVER REV, V41, P201, DOI 10.1016/S0169-409X(99)00066-6; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200; Zuhorn IS, 2002, J BIOL CHEM, V277, P18021, DOI 10.1074/jbc.M111257200	63	55	57	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22953	22963		10.1074/jbc.M611015200	http://dx.doi.org/10.1074/jbc.M611015200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17562704	hybrid			2022-12-25	WOS:000248354200072
J	Zhuang, SF; Kelo, LS; Nardi, JB; Kanost, MR				Zhuang, Shufei; Kelo, Lisha; Nardi, James B.; Kanost, Michael R.			An integrin-tetraspanin interaction required for cellular innate immune responses of an insect, Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM; LIGAND-BINDING; BETA-INTEGRIN; ADHESION; PROTEIN; IDENTIFICATION; ENCAPSULATION; ASSOCIATION; SUPERFAMILY; ATTACHMENT	In their encounters with foreign intruders, the cells of the insect innate immune system, like those of the mammalian immune system, exhibit both humoral and cell-mediated responses. Some intruders can be dispatched by the humoral immune system alone, but many must be phagocytosed by individual hemocytes or encapsulated by interacting hemocytes. Surface proteins of hemocytes control the abrupt transition of hemocytes from resting, nonadherent cells to activated, adherent cells during these cell-mediated responses. Two of these surface proteins, an integrin and a tetraspanin, interact during this adhesive transition. As demonstrated with a hemocyte adhesion assay and a surface plasmon resonance assay, the large extracellular loop of tetraspanin D76 binds to a hemocyte-specific integrin of Manduca sexta. The interaction between the large extracellular loop domain and hemocyte-specific integrin is interrupted not only by a monoclonal antibody (MS13) that binds to a domain of beta-integrin known to be a ligand-binding site for cell adhesion but also by double-stranded beta-integrin RNA. Transfected S2 cells expressing tetraspanin mediate adhesion of hemocytes. A monoclonal antibody to tetraspanin D76 perturbs the cell-mediated immune response of encapsulation. These studies involving antibody blocking, RNA interference, and binding assays imply a trans interaction of integrin and tetraspanin on hemocyte surfaces.	Univ Illinois, Dept Entomol, Urbana, IL 61801 USA; Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	University of Illinois System; University of Illinois Urbana-Champaign; Kansas State University	Nardi, JB (corresponding author), Univ Illinois, Dept Entomol, 320 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.	j-nardi@uiuc.edu		Kanost, Michael/0000-0002-6827-0061	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064657] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berditchevski F, 2001, J CELL SCI, V114, P4143; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Brower DL, 2003, CURR OPIN CELL BIOL, V15, P607, DOI 10.1016/S0955-0674(03)00102-9; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Holmblad T, 1997, J EXP ZOOL, V277, P255, DOI 10.1002/(SICI)1097-010X(19970215)277:3<255::AID-JEZ6>3.0.CO;2-N; Hughes AL, 2001, J MOL EVOL, V52, P63, DOI 10.1007/s002390010134; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Irving P, 2005, CELL MICROBIOL, V7, P335, DOI 10.1111/j.1462-5822.2004.00462.x; Kanost MR, 2004, IMMUNOL REV, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; Lavine MD, 2003, INSECT MOL BIOL, V12, P441, DOI 10.1046/j.1365-2583.2003.00428.x; Levin DM, 2005, INSECT BIOCHEM MOLEC, V35, P369, DOI 10.1016/j.ibmb.2005.01.003; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Liu WH, 2002, ANAL BIOCHEM, V302, P52, DOI 10.1006/abio.2001.5530; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Moita LF, 2006, INSECT BIOCHEM MOLEC, V36, P282, DOI 10.1016/j.ibmb.2006.01.004; Nardi JB, 2006, DEV COMP IMMUNOL, V30, P447, DOI 10.1016/j.dci.2005.06.026; Nishiuchi R, 2005, P NATL ACAD SCI USA, V102, P1939, DOI 10.1073/pnas.0409493102; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Retta SF, 2001, MOL BIOL CELL, V12, P3126, DOI 10.1091/mbc.12.10.3126; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; SMITH JW, 1994, J BIOL CHEM, V269, P32788; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011; Todres E, 2000, INSECT MOL BIOL, V9, P581, DOI 10.1046/j.1365-2583.2000.00222.x; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; Wiegand C, 2000, ARCH INSECT BIOCHEM, V45, P95, DOI 10.1002/1520-6327(200011)45:3&lt;95::AID-ARCH1&gt;3.0.CO;2-0; WILLOTT E, 1994, EUR J CELL BIOL, V65, P417; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yu XQ, 2003, DEV COMP IMMUNOL, V27, P189, DOI 10.1016/S0145-305X(02)00099-X; ZHUANG S, 2007, IN PRESS DEV COMP IM	50	47	53	2	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22563	10.1074/jbc.M700341200	http://dx.doi.org/10.1074/jbc.M700341200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553801	hybrid			2022-12-25	WOS:000248354200034
J	Gale, AJ; Yegneswaran, S; Xu, X; Pellequer, JL; Griffin, JH				Gale, Andrew J.; Yegneswaran, Subramanian; Xu, Xiao; Pellequer, Jean-Luc; Griffin, John H.			Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C cleavage site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR XA; PEPTIDE-BOND CLEAVAGES; FACTOR-VIIIA; HEAVY-CHAIN; PROTHROMBIN ACTIVATION; CATALYZED INACTIVATION; COFACTOR ACTIVITY; INTERACTIVE SITE; FACTOR VA(R506Q); AUTOLYSIS LOOP	Prothrombin is proteolytically activated by the prothrombinase complex comprising the serine protease Factor (F) Xa complexed with its cofactor, FVa. Based on inhibition of the prothrombinase complex by synthetic peptides, FVa residues 493-506 were proposed as a FXa binding site. FVa is homologous to FVIIIa, the cofactor for the FIXa protease, in the FX-activating complex, and FVIIIa residues 555-561 ( homologous to FVa residues 499-506) are recognized as a FIXa binding sequence. To test the hypothesis that FVa residues 499-505 contribute to FXa binding, we created the FVa loop swap mutant (designated 499-505(VIII) FV) with residues 499-505 replaced by residues 555-561 of FVIIIa, which differ at five of seven positions. Based on kinetic measurements and spectroscopic titrations, this FVa loop swap mutant had significantly reduced affinity for FXa. The fully formed prothrombinase complex containing this FVa mutant had fairly normal kinetic parameters (k(cat) and K-m) for cleavage of prothrombin at Arg-320. However, small changes in both Arg-320 and Arg-271 cleavage rates result together in a moderate change in the pathway of prothrombin activation. Although residues 499-505 directly precede the Arg-506 cleavage site for activated protein C (APC), the 499-505(VIII) FVa mutant was inactivated entirely normally by APC. These results suggest that this A2 domain sequence of the FVa and FVIIIa cofactors evolved to have different specificity for binding FXa and FIXa while retaining compatibility as substrate for APC. In an updated three-dimensional model for the FVa structure, residues 499-505, along with Arg-506, Arg-306, and other previously suggested FXa binding sequences, delineate a continuous surface on the A2 domain that is strongly implicated as an extended FXa binding surface in the prothrombinase complex.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; DSV iBEB SBTN LIRM, Inst Biotechnol & Environm Biol, Commissariat Energie Atom Valrho, F-30207 Bagnols Sur Ceze, France	Scripps Research Institute; CEA	Gale, AJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-286,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	agale@scripps.edu	Pellequer, Jean-Luc/L-6855-2013	Pellequer, Jean-Luc/0000-0002-8944-2715; Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082588, R01HL021544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07695, HL82588, HL21544] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams TE, 2004, P NATL ACAD SCI USA, V101, P8918, DOI 10.1073/pnas.0403072101; Autin L, 2006, PROTEINS, V63, P440, DOI 10.1002/prot.20848; Brufatto N, 2003, J BIOL CHEM, V278, P6755, DOI 10.1074/jbc.M206413200; Bukys MA, 2006, J BIOL CHEM, V281, P39194, DOI 10.1074/jbc.M604482200; Chen SWW, 2004, CURR MED CHEM, V11, P595, DOI 10.2174/0929867043455891; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; Fay PJ, 2005, BLOOD REV, V19, P15, DOI 10.1016/j.blre.2004.02.003; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P20139; Gale AJ, 2006, J THROMB HAEMOST, V4, P1315, DOI 10.1111/j.1538-7836.2006.01951.x; Gale AJ, 2000, BLOOD, V96, P585; Gale AJ, 2002, PROTEIN SCI, V11, P2091, DOI 10.1110/ps.0210002; Heeb MJ, 1999, EUR J BIOCHEM, V260, P64, DOI 10.1046/j.1432-1327.1999.00137.x; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; Jenkins PV, 2002, BLOOD, V100, P501, DOI 10.1182/blood-2001-12-0361; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; Koppaka V, 1996, BIOCHEMISTRY-US, V35, P7482, DOI 10.1021/bi952063d; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Orcutt SJ, 2004, J BIOL CHEM, V279, P54927, DOI 10.1074/jbc.M410866200; Pellequer JL, 2000, THROMB HAEMOSTASIS, V84, P849, DOI 10.1055/s-0037-1614127; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Singh LS, 2003, J BIOL CHEM, V278, P28335, DOI 10.1074/jbc.M300233200; Steen M, 2002, J BIOL CHEM, V277, P50022, DOI 10.1074/jbc.M205609200; Toso R, 2006, J BIOL CHEM, V281, P8773, DOI 10.1074/jbc.M511419200; Varfaj F, 2006, BIOCHEM J, V396, P355, DOI 10.1042/BJ20060117; Walsh PN, 2002, ESSAYS BIOCHEM, V38, P95, DOI 10.1042/bse0380095; Yegneswaran S, 2002, CHEM BIOL, V9, P485, DOI 10.1016/S1074-5521(02)00132-1; Yegneswaran S, 2004, J BIOL CHEM, V279, P49019, DOI 10.1074/jbc.M406645200; Yegneswaran S, 2003, J BIOL CHEM, V278, P33312, DOI 10.1074/jbc.M305906200	44	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21848	21855		10.1074/jbc.M702192200	http://dx.doi.org/10.1074/jbc.M702192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17553804	hybrid			2022-12-25	WOS:000248196800032
J	Ke, B; Oh, E; Thurmond, DC				Ke, Ban; Oh, Eunjin; Thurmond, Debbie C.			Doc2 beta is a novel Munc18c-interacting partner and positive effector of syntaxin 4-mediated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; PANCREATIC BETA-CELLS; DOUBLE C2 PROTEIN; T-SNARE; GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; VESICLE EXOCYTOSIS; TARGET MEMBRANE; TRANSGENIC MICE; RAT-BRAIN	The widely expressed Sec/Munc18 (SM) protein Munc18c is required for SNARE-mediated insulin granule exocytosis from islet beta cells and GLUT4 vesicle exocytosis in skeletal muscle and adipocytes. Although Munc18c function is known to involve binding to the t-SNARE Syntaxin 4, a paucity of Munc18c-binding proteins has restricted elucidation of the mechanism by which it facilitates these exocytosis events. Toward this end, we have identified the double C2 domain protein Doc2 beta as a new binding partner for Munc18c. Unlike its granule/vesicle localization in neuronal cells, Doc2 beta was found principally in the plasma membrane compartment in islet beta cells and adipocytes. Moreover, co-immunoprecipitation and GST interaction assays showed Doc2 beta-Munc18c binding to be direct and complexes to be devoid of Syntaxin 4. Supporting the notion of Munc18c binding with Syntaxin 4 and Doc2 beta in mutually exclusive complexes, in vitro competition with Syntaxin 4 effectively displaced Munc18c from binding to Doc2 beta. The second C2 domain (C2B) of Doc2 beta and an N-terminal region of Munc18c were sufficient to confer complex formation. Disruption of endogenous Munc18c-Doc2 beta complexes by addition of the Doc2 beta binding domain of Munc18c ( residues 173-255) was found to selectively inhibit glucose-stimulated insulin release. Moreover, increased expression of Doc2 beta enhanced glucose-stimulated insulin secretion by similar to 40%, whereas siRNA-mediated depletion of Doc2 beta attenuated insulin release. All changes in secretion correlated with parallel alterations in VAMP2 granule docking with Syntaxin 4. Taken together, these data support a model wherein Munc18c transiently switches from association with Syntaxin 4 to association with Doc2 beta at the plasma membrane to facilitate exocytosis.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Thurmond, DC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Ctr Diabet Res, 635 Barnhill Dr,MS4053, Indianapolis, IN 46202 USA.	dthurmon@iupui.edu			NIDDK NIH HHS [R01 DK067912, DK067912, R01 DK067912-04] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; Ballew N, 2005, MOL BIOL CELL, V16, P1839, DOI 10.1091/mbc.E04-08-0725; Chan CB, 1999, DIABETES, V48, P997, DOI 10.2337/diabetes.48.5.997; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Duncan RR, 1999, J BIOL CHEM, V274, P27347, DOI 10.1074/jbc.274.39.27347; Duncan RR, 2000, BIOCHIMIE, V82, P421, DOI 10.1016/S0300-9084(00)00214-5; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Grabowski R, 1997, FEBS LETT, V411, P169, DOI 10.1016/S0014-5793(97)00720-5; Groffen AJA, 2004, J BIOL CHEM, V279, P23740, DOI 10.1074/jbc.M400731200; Hori T, 1999, J NEUROSCI, V19, P7262, DOI 10.1523/JNEUROSCI.19-17-07262.1999; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; Kwan EP, 2006, DIABETES, V55, P1421, DOI 10.2337/db05-1263; Latham CF, 2006, TRAFFIC, V7, P1408, DOI 10.1111/j.1600-0854.2006.00474.x; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Malkinson G, 2006, CELL CALCIUM, V39, P85, DOI 10.1016/j.ceca.2005.10.007; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Mochida S, 1998, P NATL ACAD SCI USA, V95, P11418, DOI 10.1073/pnas.95.19.11418; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; Nagamatsu S, 1999, DIABETES, V48, P2367, DOI 10.2337/diabetes.48.12.2367; Nevins AK, 2005, J BIOL CHEM, V280, P1944, DOI 10.1074/jbc.M409528200; Oh E, 2005, DIABETES, V54, P638, DOI 10.2337/diabetes.54.3.638; Oh E, 2006, J BIOL CHEM, V281, P17624, DOI 10.1074/jbc.M601581200; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; Rickman C, 2007, J BIOL CHEM, V282, P12097, DOI 10.1074/jbc.M700227200; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Saito T, 2003, J BIOL CHEM, V278, P36718, DOI 10.1074/jbc.M305114200; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; Shen JS, 2007, CELL, V128, P183, DOI 10.1016/j.cell.2006.12.016; Spurlin BA, 2006, MOL ENDOCRINOL, V20, P183, DOI 10.1210/me.2005-0157; Spurlin BA, 2004, DIABETES, V53, P2223, DOI 10.2337/diabetes.53.9.2223; Spurlin BA, 2003, DIABETES, V52, P1910, DOI 10.2337/diabetes.52.8.1910; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; Thurmond DC, 2000, EMBO J, V19, P3565, DOI 10.1093/emboj/19.14.3565; Thurmond DC, 2003, MOL ENDOCRINOL, V17, P732, DOI 10.1210/me.2002-0333; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; THURMOND DC, 2006, MECH INSULIN ACTION, P52; Tsuboi T, 2006, MOL BIOL CELL, V17, P2101, DOI 10.1091/mbc.E05-11-1047; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yang CM, 2001, J CLIN INVEST, V107, P1311, DOI 10.1172/JCI12274; Zilly FE, 2006, PLOS BIOL, V4, P1789, DOI 10.1371/journal.pbio.0040330	51	50	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21786	21797		10.1074/jbc.M701661200	http://dx.doi.org/10.1074/jbc.M701661200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17548353	hybrid			2022-12-25	WOS:000248196800026
J	Thevissen, K; Ayscough, KR; Aerts, AM; Du, W; De Brucker, K; Meert, EMK; Ausma, J; Borgers, M; Cammue, BPA; Francois, IEJA				Thevissen, Karin; Ayscough, Kathryn R.; Aerts, An M.; Du, Wei; De Brucker, Katrijn; Meert, Els M. K.; Ausma, Jannie; Borgers, Marcel; Cammue, Bruno P. A.; Francois, Isabelle E. J. A.			Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; MECHANISMS; INHIBITORS; APOPTOSIS; AZOLES	The antifungal compound miconazole inhibits ergosterol biosynthesis and induces reactive oxygen species (ROS) in susceptible yeast species. To further uncover the mechanism of miconazole antifungal action and tolerance mechanisms, we screened the complete set of haploid Saccharomyces cerevisiae gene deletion mutants for mutants with an altered miconazole sensitivity phenotype. We identified 29 S. cerevisiae genes, which when deleted conferred at least 4-fold hypersensitivity to miconazole. Major functional groups encode proteins involved in tryptophan biosynthesis, membrane trafficking including endocytosis, regulation of actin cytoskeleton, and gene expression. With respect to the antifungal activity of miconazole, we demonstrate an antagonism with tryptophan and a synergy with a yeast endocytosis inhibitor. Because actin dynamics and induction of ROS are linked in yeast, we further focused on miconazole-mediated changes in actin cytoskeleton organization. In this respect, we demonstrate that miconazole induces changes in the actin cytoskeleton, indicative of increased filament stability, prior to ROS induction. These data provide novel mechanistic insights in the mode of action of a ROS-inducing azole.	Katholieke Univ Leuven, Ctr Microbial & Plant Genet, B-3001 Heverlee, Belgium; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; BarrierTherapeut NV, B-2440 Geel, Belgium	KU Leuven; University of Sheffield	Cammue, BPA (corresponding author), Katholieke Univ Leuven, Ctr Microbial & Plant Genet, B-3001 Heverlee, Belgium.	bruno.cammue@biw.kuleuven.be	Cammue, Bruno/M-9575-2013; Thevissen, Karin/B-7003-2015	Thevissen, Karin/0000-0003-0275-9072	Medical Research Council [G117/394] Funding Source: Medline; MRC [G117/394] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ayscough KR, 2000, CURR BIOL, V10, P1587, DOI 10.1016/S0960-9822(00)00859-9; Cornet M, 2006, ANTIMICROB AGENTS CH, V50, P3492, DOI 10.1128/AAC.00391-06; Edlind T, 2002, MOL MICROBIOL, V46, P257, DOI 10.1046/j.1365-2958.2002.03165.x; Flaherty P, 2005, BIOINFORMATICS, V21, P3286, DOI 10.1093/bioinformatics/bti515; FONZI WA, 1993, GENETICS, V134, P717; Francois Isabelle E. J. A., 2006, Anti-Infective Agents in Medicinal Chemistry, V5, P3, DOI 10.2174/187152106774755554; Gourlay CW, 2006, MOL MICROBIOL, V62, P1515, DOI 10.1111/j.1365-2958.2006.05486.x; Gourlay CW, 2005, J CELL SCI, V118, P2119, DOI 10.1242/jcs.02337; Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148; Hagan IM, 2000, PRACT APPROACH SER, V218, P179; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; Jain P, 2003, ANTIMICROB AGENTS CH, V47, P3195, DOI 10.1128/AAC.47.10.3195-3201.2003; Kobayashi D, 2002, ANTIMICROB AGENTS CH, V46, P3113, DOI 10.1128/AAC.46.10.3113-3117.2002; Kontoyiannis DP, 2003, MYCOSES, V46, P183, DOI 10.1046/j.1439-0507.2003.00876.x; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Rodriguez-Hernandez CJ, 2003, J BIOL CHEM, V278, P33887, DOI 10.1074/jbc.M305220200; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; Smith WL, 2002, ANTIMICROB AGENTS CH, V46, P3532, DOI 10.1128/AAC.46.11.3532-3539.2002; Thorpe GW, 2004, P NATL ACAD SCI USA, V101, P6564, DOI 10.1073/pnas.0305888101; Toenjes KA, 2005, ANTIMICROB AGENTS CH, V49, P963, DOI 10.1128/AAC.49.3.963-972.2005; Tucker CL, 2004, COMP FUNCT GENOM, V5, P216, DOI 10.1002/cfg.391; VANDENBOSSCHE H, 1990, MYCOSES, V33, P335, DOI 10.1111/myc.1990.33.7-8.335	23	49	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21592	21597		10.1074/jbc.M608505200	http://dx.doi.org/10.1074/jbc.M608505200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17553796	hybrid			2022-12-25	WOS:000248196800005
J	Xiang, Y; Seemann, J; Bisel, B; Punthambaker, S; Wang, YZ				Xiang, Yi; Seemann, Joachim; Bisel, Blaine; Punthambaker, Sukanya; Wang, Yanzhuang			Active ADP-ribosylation factor-1 (ARF1) is required for mitotic golgi fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COP-COATED VESICLES; POLO-LIKE KINASE; ENDOPLASMIC-RETICULUM; HELA-CELLS; BREFELDIN-A; GTP HYDROLYSIS; CDC2 KINASE; PROTEIN; MITOSIS; TRANSPORT	In mammalian cells the Golgi apparatus undergoes an extensive disassembly process at the onset of mitosis that is believed to facilitate equal partitioning of this organelle into the two daughter cells. However, the underlying mechanisms for this fragmentation process are so far unclear. Here we have investigated the role of the ADP-ribosylation factor-1 (ARF1) in this process to determine whether Golgi fragmentation in mitosis is mediated by vesicle budding. ARF1 is a small GTPase that is required for COPI vesicle formation from the Golgi membranes. Treatment of Golgi membranes with mitotic cytosol or with purified coatomer together with wild type ARF1 or its constitutive active form, but not the inactive mutant, converted the Golgi membranes into COPI vesicles. ARF1-depleted mitotic cytosol failed to fragment Golgi membranes. ARF1 is associated with Golgi vesicles generated in vitro and with vesicles in mitotic cells. In addition, microinjection of constitutive active ARF1 did not affect mitotic Golgi fragmentation or cell progression through mitosis. Our results show that ARF1 is active during mitosis and that this activity is required for mitotic Golgi fragmentation.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Michigan System; University of Michigan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, YZ (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	yzwang@umich.edu	Punthambaker, Sukanya/AAR-9166-2020; Wang, Yanzhuang/AAE-5299-2019	Wang, Yanzhuang/0000-0002-1864-7094	NIGMS NIH HHS [R01 GM087364, R01 GM087364-03, R01 GM087364-02, R01 GM087364-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087364] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altan-Bonnet N, 2004, CURR OPIN CELL BIOL, V16, P364, DOI 10.1016/j.ceb.2004.06.011; Altan-Bonnet N, 2003, P NATL ACAD SCI USA, V100, P13314, DOI 10.1073/pnas.2234055100; Altan-Bonnet N, 2006, MOL BIOL CELL, V17, P990, DOI 10.1091/mbc.E05-02-0155; Antonny B, 2005, BIOCHEM SOC T, V33, P619, DOI 10.1042/BST0330619; Axelsson MAB, 2004, MOL BIOL CELL, V15, P1843, DOI 10.1091/mbc.E03-07-0459; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Futatsumori M, 2000, J BIOCHEM-TOKYO, V128, P793, DOI 10.1093/oxfordjournals.jbchem.a022817; Gromley A, 2005, CELL, V123, P75, DOI 10.1016/j.cell.2005.07.027; Happe S, 1998, J CELL BIOL, V140, P511, DOI 10.1083/jcb.140.3.511; HO WC, 1989, EUR J CELL BIOL, V48, P250; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; Kano F, 2000, J CELL BIOL, V149, P357, DOI 10.1083/jcb.149.2.357; Keryer G, 1998, J BIOL CHEM, V273, P34594, DOI 10.1074/jbc.273.51.34594; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kuai J, 2000, J BIOL CHEM, V275, P4022, DOI 10.1074/jbc.275.6.4022; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; Ludford RJ, 1924, P R SOC LOND B-CONTA, V97, P50, DOI 10.1098/rspb.1924.0043; Malsam J, 2005, SCIENCE, V307, P1095, DOI 10.1126/science.1108061; MAUL GG, 1970, CANCER RES, V30, P2326; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Nickel W, 1997, FEBS LETT, V413, P395, DOI 10.1016/S0014-5793(97)00939-3; Nickel W, 1998, J CELL SCI, V111, P3081; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1995, METHOD ENZYMOL, V257, P128; SERAFINI T, 1992, METHOD ENZYMOL, V219, P286; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Taguchi T, 2003, TRAFFIC, V4, P344, DOI 10.1034/j.1600-0854.2003.00091.x; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; Wang Y., 2006, CELL BIOL LAB HDB, P33; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; Wang YZ, 2003, EMBO J, V22, P3279, DOI 10.1093/emboj/cdg317; Zaal KJM, 1999, CELL, V99, P589, DOI 10.1016/S0092-8674(00)81548-2	49	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21829	21837		10.1074/jbc.M611716200	http://dx.doi.org/10.1074/jbc.M611716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17562717	hybrid, Green Accepted			2022-12-25	WOS:000248196800030
J	Brodsky, LI; Wahed, AS; Li, J; Tavis, JE; Tsukahara, T; Taylor, MW				Brodsky, Leonid I.; Wahed, Abdus S.; Li, Jia; Tavis, John E.; Tsukahara, Takuma; Taylor, Milton W.			A Novel Unsupervised Method to Identify Genes Important in the Anti-viral Response: Application to Interferon/Ribavirin in Hepatitis C Patients	PLOS ONE			English	Article								Background. Treating hepatitis C with interferon/ribavirin results in a varied response in terms of decrease in viral titer and ultimate outcome. Marked responders have a sharp decline in viral titer within a few days of treatment initiation, whereas in other patients there is no effect on the virus (poor responders). Previous studies have shown that combination therapy modifies expression of hundreds of genes in vitro and in vivo. However, identifying which, if any, of these genes have a role in viral clearance remains challenging. Aims. The goal of this paper is to link viral levels with gene expression and thereby identify genes that may be responsible for early decrease in viral titer. Methods. Microarrays were performed on RNA isolated from PBMC of patients undergoing interferon/ribavirin therapy. Samples were collected at pre-treatment (day 0), and 1, 2, 7, 14 and 28 days after initiating treatment. A novel method was applied to identify genes that are linked to a decrease in viral titer during interferon/ribavirin treatment. The method uses the relationship between inter-patient gene expression based proximities and inter-patient viral titer based proximities to define the association between microarray gene expression measurements of each gene and viral-titer measurements. Results. We detected 36 unique genes whose expressions provide a clustering of patients that resembles viral titer based clustering of patients. These genes include IRF7, MX1, OASL and OAS2, viperin and many ISG's of unknown function. Conclusion. The genes identified by this method appear to play a major role in the reduction of hepatitis C virus during the early phase of treatment. The method has broad utility and can be used to analyze response to any group of factors influencing biological outcome such as antiviral drugs or anti-cancer agents where microarray data are available.	[Tsukahara, Takuma; Taylor, Milton W.] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; [Brodsky, Leonid I.] Univ Haifa, Inst Evolut, IL-31999 Haifa, Israel; [Wahed, Abdus S.; Li, Jia] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA USA; [Tavis, John E.] St Louis Univ, St Louis, MO 63103 USA	Indiana University System; Indiana University Bloomington; University of Haifa; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Saint Louis University	Taylor, MW (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	taylor@indiana.edu	Taylor, Milton W./R-7549-2019	Wahed, Abdus/0000-0001-6911-7221	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Cancer Institute (NCI) [U01 DK60329, U01 DK60340, U01 DK60324, U01 DK60344, U01 DK60327, U01 DK60335, U01 DK60352, U01 DK60342, U01 DK60345, U01 DK60309, U01 DK60346, U01 DK60349, U01 DK60341]; National Center for Research Resources (NCRR) [M01 RR00645, M02 RR000079, M01 RR16500, M01 RR000042, M01 RR00046]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645, M01RR000079, M01RR000046, M01RR000042, M01RR016500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK060345, U01DK060341, U01DK060342, U01DK060346, U01DK060349, U01DK060329, U01DK060344, U01DK060340, U01DK060309, U01DK060324, U01DK060352, U01DK060327, U01DK060335] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was funded as a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) with co-support from the Intramural Research Program of the National Cancer Institute (NCI) with further support under a Cooperative Research and Development Agreement (CRADA) with Roche Laboratories, Grant numbers: U01 DK60329, U01 DK60340, U01 DK60324, U01 DK60344, U01 DK60327, U01 DK60335, U01 DK60352, U01 DK60342, U01 DK60345, U01 DK60309, U01 DK60346, U01 DK60349, U01 DK60341. Other support: National Center for Research Resources (NCRR) General Clinical Research Centers Program grants: M01 RR00645 (New York Presbyterian), M02 RR000079 (University of California, San Francisco), M01 RR16500 (University of Maryland), M01 RR000042 (University of Michigan), M01 RR00046 (University of North Carolina).	Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Barnes BJ, 2004, J BIOL CHEM, V279, P45194, DOI 10.1074/jbc.M400726200; COX T, 2003, MULTIDIMENSIONAL SCA; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Dong BH, 2004, J VIROL, V78, P8983, DOI 10.1128/JVI.78.17.8983-8993.2004; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fried MW, 2000, AM J GASTROENTEROL, V95, P3225, DOI 10.1111/j.1572-0241.2000.03433.x; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Gertz J, 2003, BIOINFORMATICS, V19, P2039, DOI 10.1093/bioinformatics/btg278; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Hartnell A, 2001, BLOOD, V97, P288, DOI 10.1182/blood.V97.1.288; Helbig KJ, 2005, HEPATOLOGY, V42, P702, DOI 10.1002/hep.20844; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; JAIL A, 1988, ALGORITHMS CLUSTERIN; Ji XH, 2003, HEPATOLOGY, V37, P610, DOI 10.1053/jhep.2003.50105; Johnson CL, 2006, TRENDS IMMUNOL, V27, P1, DOI 10.1016/j.it.2005.11.004; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Lim W, 2005, J IMMUNOL, V175, P5690, DOI 10.4049/jimmunol.175.9.5690; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Oetke C, 2006, MOL CELL BIOL, V26, P1549, DOI 10.1128/MCB.26.4.1549-1557.2006; Okochi K, 2005, GENES CELLS, V10, P151, DOI 10.1111/j.1365-2443.2005.00826.x; Pazos F, 2001, PROTEIN ENG, V14, P609, DOI 10.1093/protein/14.9.609; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sanda C, 2006, J INTERF CYTOK RES, V26, P462, DOI 10.1089/jir.2006.26.462; Schoenemeyer A, 2005, J BIOL CHEM, V280, P17005, DOI 10.1074/jbc.M412584200; Snedecor G.W., 1989, AMES IOWA STATE U PR; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Su AI, 2002, P NATL ACAD SCI USA, V99, P15669, DOI 10.1073/pnas.202608199; Tahara E, 2005, CANCER IMMUNOL IMMUN, V54, P729, DOI 10.1007/s00262-004-0645-2; Tan H, 2005, J INTERF CYTOK RES, V25, P632, DOI 10.1089/jir.2005.25.632; Taylor MW, 2007, J VIROL, V81, P3391, DOI 10.1128/JVI.02640-06; Taylor MW, 2004, J INTERF CYTOK RES, V24, P107, DOI 10.1089/107999004322813354; van den Berg TK, 2001, J IMMUNOL, V166, P3637, DOI 10.4049/jimmunol.166.6.3637; YANG HD, 1995, MOL CELL BIOL, V15, P6770; Zeuzem S, 2001, GASTROENTEROLOGY, V120, P1438, DOI 10.1053/gast.2001.24006	39	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e584	10.1371/journal.pone.0000584	http://dx.doi.org/10.1371/journal.pone.0000584			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17589564	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451900004
J	Lucas, KA; Filley, JR; Erb, JM; Graybill, ER; Hawes, JW				Lucas, Kerry A.; Filley, Jessica R.; Erb, Jeremy M.; Graybill, Eric R.; Hawes, John W.			Peroxisomal metabolism of propionic acid and isobutyric acid in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; BETA-OXIDATION; COENZYME-A; LEUCINE 2,3-AMINOMUTASE; ARABIDOPSIS-THALIANA; VALINE CATABOLISM; FAT METABOLISM; ANIMAL TISSUES; DEHYDROGENASE; MITOCHONDRIAL	The subcellular sites of branched-chain amino acid metabolism in plants have been controversial, particularly with respect to valine catabolism. Potential enzymes for some steps in the valine catabolic pathway are clearly present in both mitochondria and peroxisomes, but the metabolic functions of these isoforms are not clear. The present study examined the possible function of these enzymes in metabolism of isobutyryl- CoA and propionyl- CoA, intermediates in the metabolism of valine and of odd-chain and branched-chain fatty acids. Using C-13 NMR, accumulation of beta- hydroxypropionate from [ 2- C-13] propionate was observed in seedlings of Arabidopsis thaliana and a range of other plants, including both monocots and dicots. Examination of coding sequences and subcellular targeting elements indicated that the completed genome of A. thaliana likely codes for all the enzymes necessary to convert valine to propionyl- CoA in mitochondria. However, Arabidopsis mitochondria may lack some of the key enzymes for metabolism of propionyl- CoA. Known peroxisomal enzymes may convert propionyl- CoA to beta- hydroxypropionate by a modified beta- oxidation pathway. The chy1-3 mutation, creating a defect in a peroxisomal hydroxyacyl-CoA hydrolase, abolished the accumulation of beta- hydroxyisobutyrate from exogenous isobutyrate, but not the accumulation of beta- hydroxypropionate from exogenous propionate. The chy1 -3 mutant also displayed a dramatically increased sensitivity to the toxic effects of excess propionate and isobutyrate but not of valine. 13C NMR analysis of Arabidopsis seedlings exposed to [ U-C-13] valine did not show an accumulation of beta- hydroxypropionate. No evidence was observed for a modified beta- oxidation of valine. 13C NMR analysis showed that valine was converted to leucine through the production of alpha- ketoisovalerate and isopropylmalate. These data suggest that peroxisomal enzymes for a modified beta- oxidation of isobutyryl- CoA and propionyl-CoA could function for metabolism of substrates other than valine.	Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA	University System of Ohio; Miami University	Hawes, JW (corresponding author), Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA.	hawesjw@muohio.edu						Adham AR, 2005, PLANT J, V41, P859, DOI 10.1111/j.1365-313X.2005.02343.x; BECK WS, 1957, J BIOL CHEM, V229, P997; BUCKEL W, 1974, J BACTERIOL, V117, P1248, DOI 10.1128/JB.117.3.1248-1260.1974; Daschner K, 1999, PLANT MOL BIOL, V39, P1275; Daschner K, 2001, PLANT PHYSIOL, V126, P601, DOI 10.1104/pp.126.2.601; Diebold R, 2002, PLANT PHYSIOL, V129, P540, DOI 10.1104/pp.001602; DieuaideNoubhani M, 1997, BIOCHEM J, V325, P367, DOI 10.1042/bj3250367; DUNFORD R, 1990, PHYTOCHEMISTRY, V29, P41, DOI 10.1016/0031-9422(90)89006-U; Eastmond PJ, 2000, J BIOL CHEM, V275, P34375, DOI 10.1074/jbc.M004945200; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Faivre-Nitschke SE, 2001, EUR J BIOCHEM, V268, P1332, DOI 10.1046/j.1432-1327.2001.01999.x; FLAVIN M, 1957, J BIOL CHEM, V229, P965; Froman BE, 2000, PLANT PHYSIOL, V123, P733, DOI 10.1104/pp.123.2.733; Fujiki Y, 2000, J BIOL CHEM, V275, P6007, DOI 10.1074/jbc.275.8.6007; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; GERBLING H, 1989, BIOL ROLE PLANT LIPI, P21; GIOVANELLI J, 1958, J BIOL CHEM, V231, P411; Goepfert S, 2005, PLANT PHYSIOL, V138, P1947, DOI 10.1104/pp.105.064311; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; HALARNKAR PP, 1988, PHYTOCHEMISTRY, V27, P997, DOI 10.1016/0031-9422(88)80259-0; HALARNKAR PP, 1989, COMP BIOCHEM PHYS B, V92, P227, DOI 10.1016/0305-0491(89)90270-8; HATCH MD, 1962, ARCH BIOCHEM BIOPHYS, V96, P193, DOI 10.1016/0003-9861(62)90398-3; Hawes JW, 1996, J BIOL CHEM, V271, P26430, DOI 10.1074/jbc.271.42.26430; Hayashi H, 1999, J BIOL CHEM, V274, P12715, DOI 10.1074/jbc.274.18.12715; Herter S, 2001, J BACTERIOL, V183, P4305, DOI 10.1128/JB.183.14.4305-4316.2001; Hooks MA, 1999, PLANT J, V20, P1, DOI 10.1046/j.1365-313X.1999.00559.x; Horswill AR, 1999, J BACTERIOL, V181, P5615, DOI 10.1128/JB.181.18.5615-5623.1999; Kirch HH, 2004, TRENDS PLANT SCI, V9, P371, DOI 10.1016/j.tplants.2004.06.004; Lange PR, 2004, FEBS LETT, V571, P147, DOI 10.1016/j.febslet.2004.06.071; Lawand S, 2002, PLANT CELL, V14, P2161, DOI 10.1105/tpc.002485; Ludwig-Muller J, 2000, PLANT GROWTH REGUL, V32, P219, DOI 10.1023/A:1010746806891; Lutziger I, 2001, PLANT PHYSIOL, V127, P615, DOI 10.1104/pp.010321; MENON GKK, 1960, BIOCHIM BIOPHYS ACTA, V44, P602, DOI 10.1016/0006-3002(60)91619-X; MIERNYK JA, 1991, PLANT PHYSIOL, V95, P564, DOI 10.1104/pp.95.2.564; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; POSTON JM, 1978, PHYTOCHEMISTRY, V17, P401, DOI 10.1016/S0031-9422(00)89324-3; POSTON JM, 1977, SCIENCE, V195, P301, DOI 10.1126/science.195.4275.301; REEVES HC, 1962, J BACTERIOL, V84, P186, DOI 10.1128/JB.84.1.186-187.1962; Reumann S, 2004, PLANT PHYSIOL, V136, P2587, DOI 10.1104/pp.104.043695; Richmond TA, 1999, PLANT CELL, V11, P1911, DOI 10.1105/tpc.11.10.1911; ROUGRAFF PM, 1990, ANAL BIOCHEM, V184, P317, DOI 10.1016/0003-2697(90)90687-5; Schuster J, 2005, PLANT MOL BIOL, V57, P241, DOI 10.1007/s11103-004-7533-1; Shimomura Y, 2000, METHOD ENZYMOL, V324, P229; SHIMOMURA Y, 1994, J BIOL CHEM, V269, P14248; Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776; Snell KD, 2002, METAB ENG, V4, P29, DOI 10.1006/mben.2001.0214; WU K, 1994, PLANTA, V192, P249, DOI 10.1007/BF01089041; WURTELE ES, 1990, ARCH BIOCHEM BIOPHYS, V278, P179, DOI 10.1016/0003-9861(90)90246-U; YANAI Y, 1995, PLANT CELL PHYSIOL, V36, P779, DOI 10.1093/oxfordjournals.pcp.a078822; Zolman BK, 2001, J BIOL CHEM, V276, P31037, DOI 10.1074/jbc.M104679200	50	32	35	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24980	24989		10.1074/jbc.M701028200	http://dx.doi.org/10.1074/jbc.M701028200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17580301	hybrid			2022-12-25	WOS:000248933000054
J	Pan, XY; Hussain, MM				Pan, Xiaoyue; Hussain, M. Mahmood			Diurnal regulation of microsomal triglyceride transfer protein and plasma lipid levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTRAINED CIRCADIAN-RHYTHMS; HMG-COA REDUCTASE; APOLIPOPROTEIN-B; MESSENGER-RNA; CHOLESTEROL-BIOSYNTHESIS; IN-VIVO; TRANSCRIPTIONAL REGULATION; INSULIN-RESISTANCE; FASTED RATS; APO-B	Plasma lipids are maintained within a narrow physiologic range and exhibit circadian rhythmicity. Plasma triglyceride and cholesterol levels were high in the night due to changes in apolipoprotein B-lipoproteins in ad libitum fed rats and mice maintained in a 12-h photoperiod. Absorption of [H-3] triolein or [H-3] cholesterol was higher at 2400 h than at 1200 h, indicating that intestinal lipoprotein production shows diurnal variation. Moreover, intestinal microsomal triglyceride transfer protein (MTP) activity, protein, mRNA, and gene transcription showed diurnal variations and were high at 2400 h. Similar to the small intestine, hepatic MTP activity, protein, and mRNA levels also changed significantly within a day. MTP was induced in fasted animals soon after refeeding. When mice were subjected to restricted feeding, MTP expression was high at the expected time of food availability. In contrast, extended exposures to light and dark completely abolished rhythmicity in MTP expression and plasma lipid levels. These studies show that MTP expression and plasma lipid undergo diurnal regulation and exhibit peaks and nadirs at similar times and suggest that diurnal modulation of MTP is a major determinant of daily changes in plasma lipids. Furthermore, environmental factors, such as food and light, play an important role in MTP regulation.	Suny Downstate Med Ctr, Dept Cell Biol & Anat, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Cell Biol & Anat, Dept Anat, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Hussain, MM (corresponding author), Suny Downstate Med Ctr, Dept Cell Biol & Anat, 450 Clarkson Ave,Box 5, Brooklyn, NY 11203 USA.	mahmood.hussain@downstate.edu			NHLBI NIH HHS [HL-64272] Funding Source: Medline; NIDDK NIH HHS [DK-46700] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ameen C, 2005, J BIOL CHEM, V280, P1224, DOI 10.1074/jbc.M412107200; Athar H, 2004, J LIPID RES, V45, P764, DOI 10.1194/jlr.D300026-JLR200; BACK P, 1969, ARCH BIOCHEM BIOPHYS, V133, P11, DOI 10.1016/0003-9861(69)90482-2; Bakillah A, 2003, FRONT BIOSCI-LANDMRK, V8, pD294; BALASUBRAMANIAM S, 1994, BIOCHEM J, V298, P39, DOI 10.1042/bj2980039; BENNETT AJ, 1995, BIOCHEM BIOPH RES CO, V212, P473, DOI 10.1006/bbrc.1995.1994; Bennett AJ, 1996, FEBS LETT, V394, P247, DOI 10.1016/0014-5793(96)00962-3; BERKOWITZ CM, 1995, HEPATOLOGY, V21, P1658, DOI 10.1002/hep.1840210626; BRUCKDORFER KR, 1974, HORM METAB RES, V6, P99, DOI 10.1055/s-0028-1093890; Chateau D, 2005, J CELL PHYSIOL, V202, P767, DOI 10.1002/jcp.20173; Davidson AJ, 2003, GENES BRAIN BEHAV, V2, P32, DOI 10.1034/j.1601-183X.2003.00005.x; Davidson AJ, 2001, PHYSIOL BEHAV, V74, P349, DOI 10.1016/S0031-9384(01)00567-4; Davidson AJ, 2000, AM J PHYSIOL-REG I, V278, pR1296, DOI 10.1152/ajpregu.2000.278.5.R1296; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; EDWARDS PA, 1972, J LIPID RES, V13, P396; GOO RH, 1987, GASTROENTEROLOGY, V93, P515, DOI 10.1016/0016-5085(87)90913-9; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; Haidari M, 2002, J BIOL CHEM, V277, P31646, DOI 10.1074/jbc.M200544200; HAMPRECHT B, 1969, FEBS LETT, V4, P117, DOI 10.1016/0014-5793(69)80210-3; HO K-J, 1979, International Journal of Chronobiology, V6, P39; HO KJ, 1975, P SOC EXP BIOL MED, V150, P271, DOI 10.3181/00379727-150-39018; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 2003, FRONT BIOSCI, V8, pS500, DOI 10.2741/1071; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Iqbal J, 2005, J LIPID RES, V46, P1491, DOI 10.1194/jlr.M500023-JLR200; Iqbal J, 2003, J BIOL CHEM, V278, P31610, DOI 10.1074/jbc.M301177200; Juo SHH, 2000, ARTERIOSCL THROM VAS, V20, P1316, DOI 10.1161/01.ATV.20.5.1316; Jurevics H, 2000, J LIPID RES, V41, P1048; KRIEGER DT, 1977, SCIENCE, V197, P398, DOI 10.1126/science.877566; LIN MCM, 1995, J LIPID RES, V36, P1073; Lu S, 2002, J LIPID RES, V43, P1303, DOI 10.1194/jlr.M200035-JLR200; Maillot F, 2005, DIABETES METAB, V31, P69, DOI 10.1016/S1262-3636(07)70169-6; MAYER D, 1976, ARCH TOXICOL, V36, P267, DOI 10.1007/BF00340534; MIRANIOOSTDIJK CP, 1983, EUR J CLIN INVEST, V13, P301, DOI 10.1111/j.1365-2362.1983.tb00105.x; MISTLBERGER RE, 1994, NEUROSCI BIOBEHAV R, V18, P171, DOI 10.1016/0149-7634(94)90023-X; MONDOLA P, 1995, PHYSIOL BEHAV, V58, P175, DOI 10.1016/0031-9384(95)00016-C; Mortimer BC, 1998, COMP BIOCHEM PHYS A, V120, P671, DOI 10.1016/S1095-6433(98)10085-5; Oishi K, 2005, BIOCHEM J, V386, P575, DOI 10.1042/BJ20041150; Pan XY, 2007, J BIOL CHEM, V282, P17078, DOI 10.1074/jbc.M701742200; Pan XY, 2004, J NUTR, V134, P2211, DOI 10.1093/jn/134.9.2211; Pan XY, 2003, J PHARMACOL EXP THER, V307, P626, DOI 10.1124/jpet.103.055939; Pan XY, 2002, AM J PHYSIOL-GASTR L, V283, pG57, DOI 10.1152/ajpgi.00545.2001; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Phillips C, 2002, ATHEROSCLEROSIS, V160, P355, DOI 10.1016/S0021-9150(01)00721-3; Rava P, 2006, J BIOL CHEM, V281, P11019, DOI 10.1074/jbc.M512823200; Rava P, 2005, J LIPID RES, V46, P1779, DOI 10.1194/jlr.D400043-JLR200; SHAPIRO DJ, 1969, BIOCHEM BIOPH RES CO, V37, P867, DOI 10.1016/0006-291X(69)90972-3; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; Sheena V, 2005, J LIPID RES, V46, P328, DOI 10.1194/jlr.M400371-JLR200; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Shelton JM, 2000, J LIPID RES, V41, P532; Shen L, 2005, AM J PHYSIOL-GASTR L, V288, pG48, DOI 10.1152/ajpgi.00064.2004; Stephan FK, 2002, J BIOL RHYTHM, V17, P284, DOI 10.1177/074873002129002591; STEPHAN FK, 1983, BEHAV BRAIN RES, V7, P81, DOI 10.1016/0166-4328(83)90006-2; Terada T, 2005, BIOCHEM PHARMACOL, V70, P1756, DOI 10.1016/j.bcp.2005.09.027; Tietge UJF, 1999, J LIPID RES, V40, P2134; WETTERAU JR, 1992, SCIENCE, V258, P999; Zhang H, 2005, BLOOD, V105, P3286, DOI 10.1182/blood-2004-06-2101; Zhang JQ, 2002, AM J PHYSIOL-ENDOC M, V283, pE267, DOI 10.1152/ajpendo.00567.2001	60	101	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24707	24719		10.1074/jbc.M701305200	http://dx.doi.org/10.1074/jbc.M701305200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17575276	hybrid			2022-12-25	WOS:000248933000026
J	Cagnac, O; Leterrier, M; Yeager, M; Blumwald, E				Cagnac, Olivier; Leterrier, Marina; Yeager, Mark; Blumwald, Eduardo			Identification and characterization of vnx1p, a novel type of vacuolar monovalent Cation/H+ antiporter of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+-ANTIPORTER; ARABIDOPSIS-THALIANA; TRANSPORT ACTIVITY; NHA1 ANTIPORTER; BUDDING YEAST; ION-TRANSPORT; K+ TRANSPORT; EXCHANGER; GENE; SODIUM	We identified and characterized Vnx1p, a novel vacuolar monovalent cation/H+ antiporter encoded by the open reading frame YNL321w from Saccharomyces cerevisiae. Despite the homology of Vnx1p with other members of the CAX ( calcium exchanger) family of transporters, Vnx1p is unable to mediate Ca2+ transport but is a low affinity Na+/H+ and K+/H+ antiporter with a K-m of 22.4 and 82.2 mM for Na+ and K+, respectively. Sequence analyses of Vnx1p revealed the absence of key amino acids shown to be essential for Ca2+/H+ exchange. vnx1 Delta cells displayed growth inhibition when grown in the presence of hygromycin B or NaCl. Vnx1p activity was found in the vacuoles and shown to be dependent on the electrochemical potential gradient of H+ generated by the action of the V-type H+-ATPase. The presence of Vnx1p at the vacuolar membrane was further confirmed with cells expressing a VNX1::GFP chimeric gene. Similar to Nhx1p, the prevacuolar compartment-bound Na+/H+ antiporter, the vacuole-bound Vnx1p appears to play roles in the regulation of ion homeostasis and cellular pH.	Univ Calif Davis, Dept Plant Sci, Davis, CA 95616 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of California System; University of California Davis; Scripps Research Institute	Blumwald, E (corresponding author), Univ Calif Davis, Dept Plant Sci, Davis, CA 95616 USA.	eblumwald@ucdavis.edu	Blumwald, Eduardo/Y-2751-2019					Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; Banuelos MA, 1998, J BIOL CHEM, V273, P1640, DOI 10.1074/jbc.273.3.1640; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; BLUMWALD E, 1987, METHOD ENZYMOL, V148, P115; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Brett CL, 2005, MOL BIOL CELL, V16, P1396, DOI 10.1091/mbc.E04-11-0999; Cai XJ, 2004, MOL BIOL EVOL, V21, P1692, DOI 10.1093/molbev/msh177; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Darley CP, 2000, BIOCHEM J, V351, P241, DOI 10.1042/0264-6021:3510241; Eide DJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r77; Flis K, 2005, BIOCHEM J, V390, P655, DOI 10.1042/BJ20050480; Froissard Marine, 2006, Biotechnology Journal, V1, P308, DOI 10.1002/biot.200500034; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; Hirata T, 2002, J BIOCHEM, V131, P261, DOI 10.1093/oxfordjournals.jbchem.a003097; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; IVEY DM, 1993, J BIOL CHEM, V268, P11296; Kamiya T, 2004, J BIOL CHEM, V279, P812, DOI 10.1074/jbc.M309726200; Kinclova-Zimmermannova O, 2006, FEMS YEAST RES, V6, P792, DOI 10.1111/j.1567-1364.2006.00062.x; KO CH, 1990, GENETICS, V125, P305; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Maresova L, 2005, MOL MICROBIOL, V55, P588, DOI 10.1111/j.1365-2958.2004.04410.x; Martinez-Munoz GA, 2005, YEAST, V22, P689, DOI 10.1002/yea.1238; Michel B, 2006, YEAST, V23, P581, DOI 10.1002/yea.1376; Nass R, 1999, MICROBIOL-SGM, V145, P3221, DOI 10.1099/00221287-145-11-3221; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; Ohgaki R, 2005, BBA-BIOMEMBRANES, V1712, P185, DOI 10.1016/j.bbamem.2005.03.011; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Sambrook J, 2001, MOL CLONING LAB MANU; Shigaki T, 2006, J MOL EVOL, V63, P815, DOI 10.1007/s00239-006-0048-4; Shigaki T, 2005, J BIOL CHEM, V280, P30136, DOI 10.1074/jbc.M503610200; Simon E, 2001, J BIOL CHEM, V276, P29740, DOI 10.1074/jbc.M101992200; SRINIVASAN J, 1995, BIOCHEM J, V309, P927, DOI 10.1042/bj3090927; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Wipf D, 2003, GENOME, V46, P177, DOI [10.1139/g02-121, 10.1139/G02-121]; Yamaguchi T, 2003, P NATL ACAD SCI USA, V100, P12510, DOI 10.1073/pnas.2034966100	49	65	71	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24284	24293		10.1074/jbc.M703116200	http://dx.doi.org/10.1074/jbc.M703116200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17588950	hybrid			2022-12-25	WOS:000248686600054
J	Frielingsdorf, S; Klosgen, RB				Frielingsdorf, Stefan; Kloesgen, Ralf Bernd			Prerequisites for terminal processing of thylakoidal tat substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B(6)/F COMPLEX; ARGININE SIGNAL PEPTIDE; RIESKE FE/S PROTEIN; ESCHERICHIA-COLI; TRANSLOCATION PATHWAY; ARABIDOPSIS-THALIANA; DEPENDENT PATHWAY; MEMBRANE-PROTEINS; LEADER PEPTIDASE; EXPORT PATHWAY	In bacteria and chloroplasts, the Tat (twin arginine translocation) system is capable of translocating folded passenger proteins across the cytoplasmic and thylakoidal membranes, respectively. Transport depends on signal peptides that are characterized by a twin pair of arginine residues. The signal peptides are generally removed after transport by specific processing peptidases, namely the leader peptidase and the thylakoidal processing peptidase. To gain insight into the prerequisites for such signal peptide removal, we mutagenized the vicinity of thylakoidal processing peptidase cleavage sites in several thylakoidal Tat substrates. Analysis of these mutants in thylakoid transport experiments showed that the amino acid composition of both the C-terminal segment of the signal peptide and the N-terminal part of the mature protein plays an important role in the maturation process. Efficient removal of the signal peptide requires the presence of charged or polar residues within at least one of those regions, whereas increased hydrophobicity impairs the process. The relative extent of this effect varies to some degree depending on the nature of the precursor protein. Unprocessed transport intermediates with fully translocated passenger proteins are found in membrane complexes of high molecular mass, which presumably represent Tat complexes, as well as free in the lipid bilayer. This seems to indicate that the Tat substrates can be laterally released from the complexes prior to processing and that membrane transport and terminal processing of Tat substrates are independent processes.	Univ Halle Wittenberg, Inst Biol Plant Physiol, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg	Klosgen, RB (corresponding author), Univ Halle Wittenberg, Inst Biol Plant Physiol, Weinbergweg 10, D-06120 Halle, Germany.	klosgen@pflanzenphys.uni-halle.de	Frielingsdorf, Stefan/AAD-8065-2019	Frielingsdorf, Stefan/0000-0002-4141-7836				Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Berghofer J, 1999, FEBS LETT, V460, P328, DOI 10.1016/S0014-5793(99)01365-4; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DeLisa MP, 2003, P NATL ACAD SCI USA, V100, P6115, DOI 10.1073/pnas.0937838100; Gerard F, 2006, J BIOL CHEM, V281, P6130, DOI 10.1074/jbc.M512733200; Gerard F, 2007, J BIOL CHEM, V282, P5263, DOI 10.1074/jbc.M610337200; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; Hou B, 2006, J MOL BIOL, V355, P957, DOI 10.1016/j.jmb.2005.11.029; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; Karnauchov I, 1997, FEBS LETT, V408, P206, DOI 10.1016/S0014-5793(97)00427-4; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; KIRWIN PM, 1987, J BIOL CHEM, V262, P16386; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma XY, 2006, PHYTOCHEMISTRY, V67, P1629, DOI 10.1016/j.phytochem.2006.04.008; Marques JP, 2004, J EXP BOT, V55, P1697, DOI 10.1093/jxb/erh191; Marques JP, 2003, MOL GENET GENOMICS, V269, P381, DOI 10.1007/s00438-003-0846-y; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; Molik S, 2001, J BIOL CHEM, V276, P42761, DOI 10.1074/jbc.M106690200; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; Pratap J, 1998, MOL GEN GENET, V258, P326, DOI 10.1007/s004380050738; Richter S, 2005, J BIOL CHEM, V280, P42723, DOI 10.1074/jbc.M509570200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; Shanmugham A, 2006, BIOCHEMISTRY-US, V45, P2243, DOI 10.1021/bi052188a; Summer EJ, 2000, J BIOL CHEM, V275, P23483, DOI 10.1074/jbc.M004137200; Tissier C, 2002, EUR J BIOCHEM, V269, P3131, DOI 10.1046/j.1432-1033.2002.02943.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635	38	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24455	24462		10.1074/jbc.M702630200	http://dx.doi.org/10.1074/jbc.M702630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17581816	hybrid			2022-12-25	WOS:000248686600072
J	Lee, JW; Fang, XH; Dolganov, G; Fremont, RD; Bastarache, JA; Ware, LB; Matthay, MA				Lee, Jae W.; Fang, Xiaohui; Dolganov, Gregory; Fremont, Richard D.; Bastarache, Julie A.; Ware, Lorraine B.; Matthay, Michael A.			Acute lung injury edema fluid decreases net fluid transport across human alveolar epithelial type II cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; PULMONARY-EDEMA; SODIUM-CHANNEL; IN-VITRO; BIOPHYSICAL PROPERTIES; CFTR TRAFFICKING; DOWN-REGULATION; MESSENGER-RNA; NA+ TRANSPORT; ION-TRANSPORT	Most patients with acute lung injury ( ALI) have reduced alveolar fluid clearance that has been associated with higher mortality. Several mechanisms may contribute to the decrease in alveolar fluid clearance. In this study, we tested the hypothesis that pulmonary edema fluid from patients with ALI might reduce the expression of ion transport genes responsible for vectorial fluid transport in primary cultures of human alveolar epithelial type II cells. Following exposure to ALI pulmonary edema fluid, the gene copy number for the major sodium and chloride transport genes decreased. By Western blot analyses, protein levels of alpha ENaC, alpha 1Na, K- ATPase, and cystic fibrosis transmembrane conductance regulator decreased as well. In contrast, the gene copy number for several inflammatory cytokines increased markedly. Functional studies demonstrated that net vectorial fluid transport was reduced for human alveolar type II cells exposed to ALI pulmonary edema fluid compared with plasma ( 0.02 +/- 0.05 versus 1.31 +/- 0.56 mu l/ cm2/ h, p< 0.02). An inhibitor of p38 MAPK phosphorylation ( SB202190) partially reversed the effects of the edema fluid on net fluid transport as well as gene and protein expression of the main ion transporters. In summary, alveolar edema fluid from patients with ALI induced a significant reduction in sodium and chloride transport genes and proteins in human alveolar epithelial type II cells, effects that were associated with a decrease in net vectorial fluid transport across human alveolar type II cell monolayers.	Univ Calif San Francisco, Dept Anesthesiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pilmonary & Crit Care Med, Nashville, TN 37232 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Vanderbilt University	Lee, JW (corresponding author), Univ Calif San Francisco, Dept Anesthesiol, 505 Parnassus Ave,Box 0648, San Francisco, CA 94143 USA.	leejw@anesthesia.ucsf.edu	Ware, Lorraine/AAJ-9307-2021; Lee, Jae W/G-7717-2012	Ware, Lorraine/0000-0002-9429-4702; Lee, Jae/0000-0002-6521-8647; Lee, Jae W/0000-0002-8756-0195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051856, R01HL051854, U01HL081332, R37HL051856] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL081332, U01 HL081332, R01 HL051854, R37 HL051856, R01 HL051856, HL-51854, HL-51856, R37 HL051856-14] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; Brochiero E, 2004, AM J PHYSIOL-LUNG C, V287, pL382, DOI 10.1152/ajplung.00320.2002; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Dagenais A, 2004, AM J PHYSIOL-LUNG C, V286, pL301, DOI 10.1152/ajplung.00326.2002; Dickie AJ, 2000, PEDIATR RES, V48, P304, DOI 10.1203/00006450-200009000-00007; Ding JW, 1998, AM J PHYSIOL-LUNG C, V274, pL378, DOI 10.1152/ajplung.1998.274.3.L378; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Eaton Douglas C, 2004, Proc Am Thorac Soc, V1, P10, DOI 10.1513/pats.2306008; Elia N, 2003, AM J RESP CRIT CARE, V168, P1043, DOI 10.1164/rccm.200206-618OC; ELIAS N, 2007, IN PRESS AM J PHYSL; Fang XH, 2006, AM J PHYSIOL-LUNG C, V290, pL242, DOI 10.1152/ajplung.00178.2005; Fang XH, 2004, AM J PHYSIOL-LUNG C, V287, pL104, DOI 10.1152/ajplung.00176.2003; Folkesson HG, 2006, AM J RESP CELL MOL, V35, P10, DOI 10.1165/rcmb.2006-0080SF; Frank J, 2003, J BIOL CHEM, V278, P43939, DOI 10.1074/jbc.M304882200; Frank JA, 2002, AM J RESP CRIT CARE, V165, P242, DOI 10.1164/ajrccm.165.2.2108087; Fukuda N, 2001, AM J PHYSIOL-LUNG C, V280, pL1258, DOI 10.1152/ajplung.2001.280.6.L1258; Geiser T, 2004, AM J PHYSIOL-LUNG C, V287, pL448, DOI 10.1152/ajplung.00177.2003; Geiser T, 2001, AM J RESP CRIT CARE, V163, P1384, DOI 10.1164/ajrccm.163.6.2006131; Howe K, 2002, AM J PHYSIOL-CELL PH, V283, pC1667, DOI 10.1152/ajpcell.00414.2001; Howe KL, 2004, EXP CELL RES, V298, P473, DOI 10.1016/j.yexcr.2004.04.026; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; JIAN L, 2001, AM J PHYSIOL-LUNG C, V280, pL646; Johnson MD, 2006, P NATL ACAD SCI USA, V103, P4964, DOI 10.1073/pnas.0600855103; LESCALEMATYS L, 1990, J BIOL CHEM, V265, P17935; Matalon S, 2002, J APPL PHYSIOL, V93, P1852, DOI 10.1152/japplphysiol.01241.2001; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Mutlu G, 2005, CIRC RES, V96, P999, DOI 10.1161/01.RES.0000164554.21993.AC; Mutlu GM, 2005, AM J PHYSIOL-LUNG C, V289, pL685, DOI 10.1152/ajplung.00247.2005; Olman MA, 2004, J IMMUNOL, V172, P2668, DOI 10.4049/jimmunol.172.4.2668; Pittet JF, 2001, J IMMUNOL, V166, P6301, DOI 10.4049/jimmunol.166.10.6301; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Pruliere-Escabasse V, 2005, AM J PHYSIOL-LUNG C, V288, pL77, DOI 10.1152/ajplung.00048.2004; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; Rafii B, 2002, J PHYSIOL-LONDON, V544, P537, DOI 10.1113/jphysiol.2002.024612; Roux J, 2005, J BIOL CHEM, V280, P18579, DOI 10.1074/jbc.M410561200; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Sakuma T, 2006, CRIT CARE MED, V34, P676, DOI 10.1097/01.CCM.0000201403.70636.0F; Shao Y, 2004, AM J PHYSIOL-CELL PH, V286, pC580, DOI 10.1152/ajpcell.00117.2003; Skinn AC, 2005, AM J PHYSIOL-GASTR L, V289, pG739, DOI 10.1152/ajpgi.00425.2004; Vadasz I, 2005, AM J RESP CELL MOL, V33, P343, DOI 10.1165/rcmb.2004-0407OC; Vivona ML, 2001, AM J RESP CELL MOL, V25, P554, DOI 10.1165/ajrcmb.25.5.4420; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035	49	70	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24109	24119		10.1074/jbc.M700821200	http://dx.doi.org/10.1074/jbc.M700821200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17580309	Green Accepted, hybrid			2022-12-25	WOS:000248686600037
J	Cohen, SE; Kokkotou, E; Biddinger, SB; Kondo, T; Gebhardt, R; Kratzsch, J; Mantzoros, CS; Kahn, CR				Cohen, Shmuel E.; Kokkotou, Efi; Biddinger, Sudha B.; Kondo, Tatsuya; Gebhardt, Rolf; Kratzsch, Juergen; Mantzoros, Christos S.; Kahn, C. Ronald			High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; GENE-EXPRESSION; ADIPOSE-TISSUE; ENERGY-BALANCE; SERUM LEPTIN; RESISTANCE; OBESITY; MODULATION; IDENTIFICATION; GROWTH	Liver-specific insulin receptor knock-out (LIRKO) mice display hyperinsulinemia, abnormal glucose metabolism, and progressive liver dysfunction. In addition, circulating leptin levels appear to be increased more than 10-fold. However, food intake, body weight, and adipose mass are not significantly altered in LIRKO mice compared with wild-type littermates. Using a ligand immunofunctional assay, we found that the apparent increase in circulating leptin in LIRKO mice is because of an 80-fold increased serum level of soluble leptin receptor. Gene expression analysis by microarray and real time PCR reveals the liver as the source of soluble leptin receptor in LIRKO mice, with an increase in expression of the short (Ob-Ra), long (Ob-Rb), and soluble (Ob-Re) forms of the leptin receptor. Direct control of leptin receptor expression by insulin could also be demonstrated in isolated hepatocytes from normal mice. Despite the markedly increased levels of leptin receptor in their circulation, LIRKO mice exhibit normal or even enhanced leptin sensitivity, as assessed by their physiological and molecular responses to exogenous leptin administration and their lower base-line hypothalamic levels of SOCS3 mRNA. Thus, insulin signaling in the liver plays an important role in control of leptin receptor expression and shedding. In the LIRKO mouse, this is lost, leading to markedly increased leptin receptors into the circulation. These high levels of circulating leptin receptor bind leptin and likely alter its clearance, but do not inhibit leptin action and may actually potentiate leptin action. In this manner, insulin signaling in liver plays an important role in leptin homeostasis and fine modulation of leptin action.	Joslin Diabet Ctr, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Leipzig, Inst Biochem, D-04103 Leipzig, Germany; Univ Hosp, Inst Lab Med Clin Chem & Mol Diagnost, D-04103 Leipzig, Germany	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Leipzig University; Leipzig University	Kahn, CR (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	Mantzoros, Christos/Y-2902-2019; Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; Kondo, Tatsuya/0000-0003-4830-8955	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, R01DK031036, R37DK031036, R01DK033201] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK040561, P30 DK040561-12, P30-DK040561, DK31036, DK33201] Funding Source: Medline; PHS HHS [R01-58785] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ahima RS, 2006, OBESITY, V14, P242, DOI 10.1038/oby.2006.317; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Biddinger SB, 2006, DIABETES, V55, P2032, DOI 10.2337/db05-0742; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Brabant G, 2004, EUR J CLIN INVEST, V34, P831, DOI 10.1111/j.1365-2362.2004.01427.x; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Ceddia RB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0158rev; Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Dong XC, 2006, J CLIN INVEST, V116, P101, DOI 10.1172/JCI25735; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Ge HF, 2002, J BIOL CHEM, V277, P45898, DOI 10.1074/jbc.M205825200; GEBHARDT R, 1990, CANCER RES, V50, P4407; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Howard JK, 2006, TRENDS ENDOCRIN MET, V17, P365, DOI 10.1016/j.tem.2006.09.007; Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Kratzsch J, 2006, EUR J ENDOCRINOL, V155, P609, DOI 10.1530/eje.1.02261; Kratzsch J, 2002, J CLIN ENDOCR METAB, V87, P4587, DOI 10.1210/jc.2002-020001; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; Lahlou N, 2000, DIABETES, V49, P1347, DOI 10.2337/diabetes.49.8.1347; Lahlou N, 2002, DIABETES, V51, P1980, DOI 10.2337/diabetes.51.6.1980; Lammert A, 2002, BIOCHEM BIOPH RES CO, V298, P798, DOI 10.1016/S0006-291X(02)02575-5; Lammert A, 2001, BIOCHEM BIOPH RES CO, V283, P982, DOI 10.1006/bbrc.2001.4885; Lindell K, 2001, MOL CELL ENDOCRINOL, V172, P37, DOI 10.1016/S0303-7207(00)00382-8; Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389; MEWES K, 1993, CANCER RES, V53, P5135; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Monteleone P, 2002, MOL PSYCHIATR, V7, P641, DOI 10.1038/sj.mp.4001043; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; Munzberg H, 2005, NAT NEUROSCI, V8, P566, DOI 10.1038/nn1454; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogawa T, 2004, METABOLISM, V53, P879, DOI 10.1016/j.metabol.2004.02.009; Otte C, 2004, EXP CLIN ENDOCR DIAB, V112, P10, DOI 10.1055/s-2004-815720; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; van Dielen FMH, 2002, J CLIN ENDOCR METAB, V87, P1708, DOI 10.1210/jc.87.4.1708; Wilsey J, 2004, J ENDOCRINOL, V181, P297, DOI 10.1677/joe.0.1810297; Yang GQ, 2004, MOL ENDOCRINOL, V18, P1354, DOI 10.1210/me.2004-0027; Yechoor VK, 2004, P NATL ACAD SCI USA, V101, P16525, DOI 10.1073/pnas.0407574101; Zastrow O, 2003, INT J OBESITY, V27, P1472, DOI 10.1038/sj.ijo.0802432	48	49	53	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23672	23678		10.1074/jbc.M704053200	http://dx.doi.org/10.1074/jbc.M704053200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17556363	Green Published, hybrid			2022-12-25	WOS:000248577500070
J	Galardi, S; Mercatelli, N; Giorda, E; Massalini, S; Frajese, GV; Ciafre, SA; Farace, MG				Galardi, Silvia; Mercatelli, Neri; Giorda, Ezio; Massalini, Simone; Frajese, Giovanni Vanni; Ciafre, Silvia Anna; Farace, Maria Giulia			miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27(Kip1)*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; PROGNOSTIC-SIGNIFICANCE; MICRORNA SIGNATURE; HUMAN CANCER; SMALL RNAS; P27; CARCINOGENESIS; ADENOCARCINOMA; GLIOBLASTOMA; DEREGULATION	MicroRNAs are short regulatory RNAs that negatively modulate protein expression at a post-transcriptional level and are deeply involved in the pathogenesis of several types of cancers. Here we show that miR-221 and miR-222, encoded in tandem on chromosome X, are overexpressed in the PC3 cellular model of aggressive prostate carcinoma, as compared with LNCaP and 22Rv1 cell line models of slowly growing carcinomas. In all cell lines tested, we show an inverse relationship between the expression of miR-221 and miR- 222 and the cell cycle inhibitor (p)27(Kip1). We recognize two target sites for the microRNAs in the 3' untranslated region of (p)27 mRNA, and we show that miR221/222 ectopic overexpression directly results in p27 downregulation in LNCaP cells. In those cells, we demonstrate that the ectopic overexpression of miR-221/222 strongly affects their growth potential by inducing a G(1) to S shift in the cell cycle and is sufficient to induce a powerful enhancement of their colony-forming potential in soft agar. Consistently, miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27Kip1 in PC3 cells and strongly reduces their clonogenicity in vitro. Our results suggest that miR-221/222 can be regarded as a new family of oncogenes, directly targeting the tumor suppressor p27Kip1, and that their overexpression might be one of the factors contributing to the oncogenesis and progression of prostate carcinoma through p27Kip1 down-regulation.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med & Endocrinol, I-00133 Rome, Italy; Ospedale Bambino Gesu, Res Ctr, I-00165 Rome, Italy; Univ Cassino, Dept Hlth & Sports Sci, I-03043 Cassino, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Bambino Gesu; University of Cassino	Ciafre, SA (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.	ciafre@uniroma2.it	ciafrè, silvia anna/G-1783-2012; Giorda, Ezio/AAH-9950-2019	ciafrè, silvia anna/0000-0001-6467-8396; Giorda, Ezio/0000-0002-5875-832X; GALARDI, SILVIA/0000-0002-3646-4064				Belletti B, 2005, CURR MED CHEM, V12, P1589, DOI 10.2174/0929867054367149; Bracarda S, 2005, CRIT REV ONCOL HEMAT, V56, P379, DOI 10.1016/j.critrevonc.2005.03.010; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Cheville JC, 1998, MODERN PATHOL, V11, P324; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hsu PWC, 2006, NUCLEIC ACIDS RES, V34, pD135, DOI 10.1093/nar/gkj135; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kim VN, 2005, MOL CELLS, V19, P1; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsihlias J, 1998, CANCER RES, V58, P542; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Webber MM, 1997, PROSTATE, V30, P58; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5	30	587	651	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23716	23724		10.1074/jbc.M701805200	http://dx.doi.org/10.1074/jbc.M701805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17569667	hybrid			2022-12-25	WOS:000248577500075
J	Leskela, TT; Markkanen, PMH; Pietila, EM; Tuusa, JT; Petaja-Repo, UE				Leskela, Tarja T.; Markkanen, Piia M. H.; Pietila, E. Maritta; Tuusa, Jussi T.; Petaja-Repo, Ulla E.			Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; LUTEINIZING-HORMONE RECEPTOR; CELL-SURFACE EXPRESSION; DOMINANT RETINITIS-PIGMENTOSA; PROTEIN-COUPLED RECEPTORS; V2 VASOPRESSIN RECEPTORS; STRUCTURAL INSTABILITY; ALPHA(2A)-ADRENERGIC RECEPTOR; HYPOGONADOTROPIC HYPOGONADISM; CONFORMATIONAL STABILITY	Accumulating evidence has indicated that membrane-permeable G protein-coupled receptor ligands can enhance cell surface targeting of their cognate wild-type and mutant receptors. This pharmacological chaperoning was thought to result from ligand-mediated stabilization of immature receptors in the endoplasmic reticulum (ER). In the present study, we directly tested this hypothesis using wild-type and mutant forms of the human delta-opioid receptor as models. ER-localized receptors were isolated by expressing the receptors in HEK293 cells under tightly controlled tetracycline induction and blocking their ER export with brefeldin A. The ER-retained delta-opioid receptor precursors were able to bind [H-3] diprenorphine with high affinity, and treatment of cells with an opioid antagonist naltrexone led to a 2-fold increase in the number of binding sites. After removing the transport block, the antagonist-mediated increase in the number of receptors was detectable at the cell surface by flow cytometry and cell surface biotinylation assay. Importantly, opioid ligands, both antagonists and agonists, were found to stabilize the ER-retained receptor precursors in an in vitro heat inactivation assay and the treatment enhanced dissociation of receptor precursors from the molecular chaperone calnexin. Thus, we conclude that pharmacological chaperones facilitate plasma membrane targeting of delta-opioid receptors by binding and stabilizing receptor precursors, thereby promoting their release from the stringent ER quality control.	Univ Oulu, Dept Anat & Cell Biol, FI-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FI-90014 Oulu, Finland	University of Oulu; University of Oulu	Petaja-Repo, UE (corresponding author), Univ Oulu, Dept Anat & Cell Biol, POB 5000, FI-90014 Oulu, Finland.	Petaja-Repo@oulu.fi	Markkanen, Piia/ABD-8843-2020; Petäjä-Repo, Ulla/AAV-6115-2021	Markkanen, Piia/0000-0002-7200-6490				Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Apaja PM, 2006, MOL BIOL CELL, V17, P2243, DOI 10.1091/mbc.E05-09-0875; Apaja PM, 2005, ENDOCRINOLOGY, V146, P3224, DOI 10.1210/en.2005-0073; Bernier V, 2004, CURR OPIN PHARMACOL, V4, P528, DOI 10.1016/j.coph.2004.08.001; Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003; Bernier V, 2004, MOL ENDOCRINOL, V18, P2074, DOI 10.1210/me.2004-0080; Bernier V, 2006, J AM SOC NEPHROL, V17, P232, DOI 10.1681/ASN.2005080854; Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643; Celej MS, 2003, PROTEIN SCI, V12, P1496, DOI 10.1110/ps.0240003; Chaipatikul V, 2003, MOL PHARMACOL, V64, P32, DOI 10.1124/mol.64.1.32; Chen Y, 2006, J PHARMACOL EXP THER, V319, P765, DOI 10.1124/jpet.106.107987; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; Fan J, 2005, MOL ENDOCRINOL, V19, P2579, DOI 10.1210/me.2004-0301; Fortin JP, 2006, MOL PHARMACOL, V69, P1146, DOI 10.1124/mol.105.019976; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Griesenbach U, 2003, CURR OPIN MOL THER, V5, P489; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hurt CM, 2000, J BIOL CHEM, V275, P35424, DOI 10.1074/jbc.M006241200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Janovick JA, 2003, J PHARMACOL EXP THER, V305, P608, DOI 10.1124/jpet.102.048454; Janovick JA, 2002, J CLIN ENDOCR METAB, V87, P3255, DOI 10.1210/jc.87.7.3255; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P8829, DOI 10.1021/bi00152a020; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; Li J, 2001, MOL PHARMACOL, V60, P1064, DOI 10.1124/mol.60.5.1064; Li J, 2001, BIOCHEMISTRY-US, V40, P12039, DOI 10.1021/bi0100945; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Maya-Nunez G, 2002, J CLIN ENDOCR METAB, V87, P2144, DOI 10.1210/jc.87.5.2144; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Noorwez SM, 2004, J BIOL CHEM, V279, P16278, DOI 10.1074/jbc.M312101200; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Perlmutter DH, 2002, PEDIATR RES, V52, P832, DOI 10.1203/01.PDR.0000036878.28942.14; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Petaja-Repo UE, 2006, J BIOL CHEM, V281, P15780, DOI 10.1074/jbc.M602267200; Pietila EM, 2005, J BIOL CHEM, V280, P26622, DOI 10.1074/jbc.M413815200; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Robben JH, 2006, MOL BIOL CELL, V17, P379, DOI 10.1091/mbc.E05-06-0579; Robert J, 2005, J BIOL CHEM, V280, P42198, DOI 10.1074/jbc.M510180200; Saliba RS, 2002, J CELL SCI, V115, P2907; Samama P, 1997, P NATL ACAD SCI USA, V94, P137, DOI 10.1073/pnas.94.1.137; Schoneberg T, 1997, J CLIN INVEST, V100, P1547, DOI 10.1172/JCI119678; Schoneberg T, 2004, PHARMACOL THERAPEUT, V104, P173, DOI 10.1016/j.pharmthera.2004.08.008; Schulein R, 2001, J BIOL CHEM, V276, P8384, DOI 10.1074/jbc.M007045200; Tan CM, 2003, J BIOL CHEM, V278, P35678, DOI 10.1074/jbc.M301888200; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Van Craenenbroeck K, 2005, J BIOL CHEM, V280, P19350, DOI 10.1074/jbc.M414043200; van Meer G, 2005, EMBO J, V24, P3159, DOI 10.1038/sj.emboj.7600798; Villaverde J, 1997, EUR J BIOCHEM, V244, P441, DOI 10.1111/j.1432-1033.1997.t01-2-00441.x; Wilson MH, 2000, BIOCHEMISTRY-US, V39, P693, DOI 10.1021/bi9920275; Wilson MH, 2001, MOL PHARMACOL, V59, P929, DOI 10.1124/mol.59.4.929; Wuller S, 2004, J BIOL CHEM, V279, P47254, DOI 10.1074/jbc.M408154200	58	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23171	23183		10.1074/jbc.M610896200	http://dx.doi.org/10.1074/jbc.M610896200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17550902	hybrid			2022-12-25	WOS:000248577500019
J	Osborn, SL; Sohn, SJ; Winoto, A				Osborn, Stephanie L.; Sohn, Sue J.; Winoto, Astar			Constitutive phosphorylation mutation in Fas-associated death domain (FADD) results in early cell cycle defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; INDUCED APOPTOSIS; CD95 FAS/APO-1; T-LYMPHOCYTES; C-MYC; PROTEIN; FADD/MORT1; PROLIFERATION; PROGRESSION; ACTIVATION	Fas-associated death domain (FADD) is an adaptor molecule for the death receptor subfamily of the tumor necrosis factor receptor superfamily, but it is also required for cell proliferation. Cell cycle-specific regulation of FADD phosphorylation plays an important role in FADD proliferative function since mice with a mutant form of FADD mimicking constitutive phosphorylation at serine 191 (FADD-D) exhibit defective T cell proliferation. Here we characterized these mice in detail and found that T cell development in 2-4-week-old mice is relatively normal, although mature FADD-DT cells manifest defective G(0) and G(1) to S transition with abnormalities in regulation of p130, p27 degradation, retinoblastoma protein phosphorylation, and CDK2 kinase activity. These downstream defects are further associated with the failure to up-regulate the forkhead box M1 cell cycle transcription factor, FoxM1. FADD-D protein is also mislocalized during cell cycle progression. Thus, regulation of FADD phosphorylation is crucial for proper cell cycle entry.	Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Winoto, A (corresponding author), Univ Calif Berkeley, Canc Res Lab, 465 LSA, Berkeley, CA 94720 USA.	winoto@berkeley.edu						Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Alappat EC, 2005, MOL CELL, V19, P321, DOI 10.1016/j.molcel.2005.06.024; Berns A, 2005, NATURE, V436, P787, DOI 10.1038/436787a; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chau H, 2005, J EXP MED, V202, P405, DOI 10.1084/jem.20050118; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHINNAIYAN AM, 1995, CELL, V81, P512; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Costa RH, 2005, CURR OPIN GENET DEV, V15, P42, DOI 10.1016/j.gde.2004.12.007; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; Dominguez-Sola D, 2004, NAT CELL BIOL, V6, P288, DOI 10.1038/ncb0404-288; Frisch S, 2004, CELL DEATH DIFFER, V11, P1361, DOI 10.1038/sj.cdd.4401512; Fung TK, 2005, SEMIN CELL DEV BIOL, V16, P335, DOI 10.1016/j.semcdb.2005.02.014; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Hua ZC, 2003, IMMUNITY, V18, P513, DOI 10.1016/S1074-7613(03)00083-9; Imtiyaz HZ, 2006, J IMMUNOL, V176, P6852, DOI 10.4049/jimmunol.176.11.6852; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LUCAS B, 1994, J IMMUNOL, V153, P53; Mayol X, 1996, ONCOGENE, V13, P237; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; O'Reilly L, 2004, CELL DEATH DIFFER, V11, P1362, DOI 10.1038/sj.cdd.4401513; O'Reilly LA, 2004, CELL DEATH DIFFER, V11, P724, DOI 10.1038/sj.cdd.4401408; Plas DR, 2002, NAT IMMUNOL, V3, P515, DOI 10.1038/ni0602-515; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Suda T, 1996, J IMMUNOL, V157, P3918; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhang J, 2001, J BIOL CHEM, V276, P29815, DOI 10.1074/jbc.M103838200; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	49	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22786	22792		10.1074/jbc.M703163200	http://dx.doi.org/10.1074/jbc.M703163200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17553783	hybrid			2022-12-25	WOS:000248354200056
J	Yang, R; Wilcox, DM; Haasch, DL; Jung, PM; Nguyen, PT; Voorbach, MJ; Doktor, S; Brodjian, S; Bush, EN; Lin, E; Jacobson, PB; Collins, CA; Landschulz, KT; Trevillyan, JM; Rondinone, CM; Surowy, TK				Yang, Ruojing; Wilcox, Denise M.; Haasch, Deanna L.; Jung, Paul M.; Nguyen, Phong T.; Voorbach, Martin J.; Doktor, Stella; Brodjian, Sevan; Bush, Eugene N.; Lin, Emily; Jacobson, Peer B.; Collins, Christine A.; Landschulz, Katherine T.; Trevillyan, James M.; Rondinone, Cristina M.; Surowy, Terry K.			Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; BINDING-PROTEIN; GLUCOKINASE EXPRESSION; HEPATIC EXPRESSION; MICROARRAY DATA; POTENTIAL ROLE; IN-VIVO; KINASES; RESISTANCE; ADENOVIRUS	The c-Jun N-terminal kinases (JNKs) have been implicated in the development of insulin resistance, diabetes, and obesity. Genetic disruption of JNK1, but not JNK2, improves insulin sensitivity in diet-induced obese (DIO) mice. We applied RNA interference to investigate the specific role of hepatic JNK1 in contributing to insulin resistance in DIO mice. Adenovirus-mediated delivery of JNK1 short-hairpin RNA (Ad-shJNK1) resulted in almost complete knockdown of hepatic JNK1 protein without affecting JNK1 protein in other tissues. Liver-specific knockdown of JNK1 resulted in significant reductions in circulating insulin and glucose levels, by 57 and 16%, respectively. At the molecular level, JNK1 knockdown mice had sustained and significant increase of hepatic Akt phosphorylation. Furthermore, knockdown of JNK1 enhanced insulin signaling in vitro. Unexpectedly, plasma triglyceride levels were robustly elevated upon hepatic JNK1 knockdown. Concomitantly, expression of proliferator-activated receptor gamma coactivator 1 beta, glucokinase, and microsomal triacylglycerol transfer protein was increased. Further gene expression analysis demonstrated that knockdown of JNK1 up-regulates the hepatic expression of clusters of genes in glycolysis and several genes in triglyceride synthesis pathways. Our results demonstrate that liver-specific knockdown of JNK1 lowers circulating glucose and insulin levels but increases triglyceride levels in DIO mice.	Abbott Labs, Dept Metab Dis Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Yang, R (corresponding author), Abbott Labs, Dept Metab Dis Res, 100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	ruojingyang@yahoo.com		Jung, Paul/0000-0001-9168-6738				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bennett BL, 2003, CURR OPIN PHARMACOL, V3, P420, DOI 10.1016/S1471-4892(03)00068-7; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Desai UJ, 2001, DIABETES, V50, P2287, DOI 10.2337/diabetes.50.10.2287; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Farese RV, 2005, EXP BIOL MED, V230, P593; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Huang A, 2004, FEBS LETT, V558, P69, DOI 10.1016/S0014-5793(03)01499-6; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; Nakatani Y, 2004, J BIOL CHEM, V279, P45803, DOI 10.1074/jbc.M406963200; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; Ono H, 2003, DIABETES, V52, P2905, DOI 10.2337/diabetes.52.12.2905; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Spann NJ, 2006, J BIOL CHEM, V281, P33066, DOI 10.1074/jbc.M607148200; Tietge UJF, 1999, J LIPID RES, V40, P2134; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wheeler DL, 2005, NUCLEIC ACIDS RES, V33, pD39, DOI 10.1093/nar/gki062; Wilcox DM, 2007, J RNAI GENE SILENCIN, V3, P225; Wolfrum C, 2006, CELL METAB, V3, P99, DOI 10.1016/j.cmet.2006.01.001; Yang RJ, 2003, J BIOL CHEM, V278, P23418, DOI 10.1074/jbc.M213112200; Yang RJ, 2002, J BIOL CHEM, V277, P1514, DOI 10.1074/jbc.M107001200	33	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22765	22774		10.1074/jbc.M700790200	http://dx.doi.org/10.1074/jbc.M700790200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17550900	hybrid			2022-12-25	WOS:000248354200054
J	Mazina, OM; Rossi, MJ; Thoma, NH; Mazin, AV				Mazina, Olga M.; Rossi, Matthew J.; Thomae, Nicolas H.; Mazin, Alexander V.			Interactions of human Rad54 protein with branched DNA molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING ENZYME; HOLLIDAY JUNCTION COMPLEX; SINGLE-STRANDED-DNA; RECOMBINATIONAL REPAIR; NUCLEOPROTEIN FILAMENT; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DEPENDENT ATPASE; HOMOLOGOUS RECOMBINATION; YEAST RAD51	The Rad54 protein plays an important role during homologous recombination in eukaryotes. The protein belongs to the Swi2/Snf2 family of ATP-dependent DNA translocases. We previously showed that yeast and human Rad54 (hRad54) specifically bind to Holliday junctions and promote branch migration. Here we examined the minimal DNA structural requirements for optimal hRad54 ATPase and branch migration activity. Although a 12-bp double-stranded DNA region of branched DNA is sufficient to induce ATPase activity, the minimal substrate that gave rise to optimal stimulation of the ATP hydrolysis rate consisted of two short double-stranded DNA arms, 15 bp each, combined with a 45-nucleotide single-stranded DNA branch. We showed that hRad54 binds preferentially to the open and not to the stacked conformation of branched DNA. Stoichiometric titration of hRad54 revealed formation of two types of hRad54 complexes with branched DNA substrates. The first of them, a dimer, is responsible for the ATPase activity of the protein. However, branch migration activity requires a significantly higher stoichiometry of hRad54, similar to 10 +/- 2 protein monomers/DNA molecule. This pleomorphism of hRad54 in formation of oligomeric complexes with DNA may correspond to multiple functions of the protein in homologous recombination.	Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; Friedrich Miescher Inst, Dept Growth Control, CH-4058 Basel, Switzerland	Drexel University; Friedrich Miescher Institute for Biomedical Research	Mazin, AV (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th St,NCB,Rm 10103, Philadelphia, PA 19102 USA.	amazin@drexelmed.edu		Rossi, Matthew/0000-0002-7796-919X	NCI NIH HHS [CA100839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100839, R56CA100839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Amitani I, 2006, MOL CELL, V23, P143, DOI 10.1016/j.molcel.2006.05.009; Ariyoshi M, 2000, P NATL ACAD SCI USA, V97, P8257, DOI 10.1073/pnas.140212997; Bugreev DV, 2006, NATURE, V442, P590, DOI 10.1038/nature04889; BUGREEV DV, 2006, NATURE PROT, DOI DOI 10.1038/NPROT.2006.217; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Chi P, 2006, J BIOL CHEM, V281, P26268, DOI 10.1074/jbc.M602983200; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Durr H, 2005, CELL, V121, P363, DOI 10.1016/j.cell.2005.03.026; Game JC, 2000, MUTAT RES-FUND MOL M, V451, P277, DOI 10.1016/S0027-5107(00)00055-5; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; GUO Q, 1990, BIOCHEMISTRY-US, V29, P10927, DOI 10.1021/bi00501a010; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kiianitsa K, 2006, P NATL ACAD SCI USA, V103, P9767, DOI 10.1073/pnas.0604240103; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Lilley DMJ, 2000, Q REV BIOPHYS, V33, P109, DOI 10.1017/S0033583500003590; Liu YL, 2004, NAT REV MOL CELL BIO, V5, P937, DOI 10.1038/nrm1502; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Mazina OM, 2004, J BIOL CHEM, V279, P52042, DOI 10.1074/jbc.M410244200; McClure W R, 1980, Methods Enzymol, V64, P277; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; PARSONS CA, 1995, EMBO J, V14, P5736, DOI 10.1002/j.1460-2075.1995.tb00260.x; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Roe SM, 1998, MOL CELL, V2, P361, DOI 10.1016/S1097-2765(00)80280-4; ROSEN MA, 1993, BIOCHEMISTRY-US, V32, P6563, DOI 10.1021/bi00077a010; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Snowden T, 2004, MOL CELL, V15, P437, DOI 10.1016/j.molcel.2004.06.040; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; Soultanas P, 2002, NUCLEIC ACIDS RES, V30, P4051, DOI 10.1093/nar/gkf527; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 2003, DNA REPAIR, V2, P787, DOI 10.1016/S1568-7864(03)00070-3; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tanaka K, 2002, NUCLEIC ACIDS RES, V30, P1346, DOI 10.1093/nar/30.6.1346; Thoma NH, 2005, NAT STRUCT MOL BIOL, V12, P350, DOI 10.1038/nsmb919; Tudyka T, 1997, PROTEIN SCI, V6, P2180; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Wesoly J, 2006, MOL CELL BIOL, V26, P976, DOI 10.1128/MCB.26.3.976-989.2006; Wolner B, 2005, J BIOL CHEM, V280, P10855, DOI 10.1074/jbc.M414388200; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	57	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21068	21080		10.1074/jbc.M701992200	http://dx.doi.org/10.1074/jbc.M701992200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17545145	hybrid			2022-12-25	WOS:000248047500033
J	Ghosh, JG; Houck, SA; Clark, JI				Ghosh, Joy G.; Houck, Scott A.; Clark, John I.			Interactive Domains in the Molecular Chaperone Human alpha B Crystallin Modulate Microtubule Assembly and Disassembly	PLOS ONE			English	Article								Background. Small heat shock proteins regulate microtubule assembly during cell proliferation and in response to stress through interactions that are poorly understood. Methodology. Novel functions for five interactive sequences in the small heat shock protein and molecular chaperone, human alpha B crystallin, were investigated in the assembly/disassembly of microtubules and aggregation of tubulin using synthetic peptides and mutants of human alpha B crystallin. Principal Findings. The interactive sequence 113FISREFHR120 exposed on the surface of alpha B crystallin decreased microtubule assembly by similar to 45%. In contrast, the interactive sequences, (131)LTITSSLSSDGV(142) and 156ERTIPITRE164, corresponding to the beta 8 strand and the C-terminal extension respectively, which are involved in complex formation, increased microtubule assembly by similar to 34-45%. The alpha B crystallin peptides, 113FISREFHR120 and 156ERTIPITRE164, inhibited microtubule disassembly by similar to 26-36%, and the peptides 113FISREFHR120 and (131)LTITSSLSSDGV(142) decreased the thermal aggregation of tubulin by similar to 42-44%. The (131)LTITSSLSSDGV(142) and 156ERTIPITRE164 peptides were more effective than the widely used anti-cancer drug, Paclitaxel, in modulating tubulin <-> microtubule dynamics. Mutagenesis of these interactive sequences in wt human alpha B crystallin confirmed the effects of the alpha B crystallin peptides on microtubule assembly/disassembly and tubulin aggregation. The regulation of microtubule assembly by alpha B crystallin varied over a narrow range of concentrations. The assembly of microtubules was maximal at alpha B crystallin to tubulin molar ratios between 1:4 and 2:1, while molar ratios >2:1 inhibited microtubule assembly. Conclusions and Significance. Interactive sequences on the surface of human alpha B crystallin collectively modulate microtubule assembly through a dynamic subunit exchange mechanism that depends on the concentration and ratio of alpha B crystallin to tubulin. These are the first experimental results in support of the functional importance of the dynamic subunit model of small heat shock proteins.	[Ghosh, Joy G.; Houck, Scott A.; Clark, John I.] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; [Clark, John I.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Clark, JI (corresponding author), Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA.	clarkji@u.washington.edu			NEI NIH HHS [NEI EY04542, R01 EY004542] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004542] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arai H, 1997, CELL STRUCT FUNCT, V22, P539, DOI 10.1247/csf.22.539; Atomi Y, 2001, Biol Sci Space, V15, P206; Attard G, 2006, PATHOL BIOL, V54, P72, DOI 10.1016/j.patbio.2005.03.003; BAI R, 1990, BIOCHEM PHARMACOL, V39, P1941, DOI 10.1016/0006-2952(90)90613-P; Bauer NG, 2006, J MOL NEUROSCI, V29, P153, DOI 10.1385/JMN:29:2:153; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BERKOWITZ SA, 1981, J BIOL CHEM, V256, P1216; BONNE D, 1985, J BIOL CHEM, V260, P2819; Clavarezza M, 2006, ANN ONCOL, V17, pVII22, DOI 10.1093/annonc/mdl944; Day RM, 2003, CELL STRESS CHAPERON, V8, P183, DOI 10.1379/1466-1268(2003)008<0183:ASHCPF>2.0.CO;2; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Djabali K, 1999, EXP CELL RES, V253, P649, DOI 10.1006/excr.1999.4679; Fujita Y, 2004, J CELL SCI, V117, P1719, DOI 10.1242/jcs.01021; Ghosh JG, 2005, PROTEIN SCI, V14, P684, DOI 10.1110/ps.041152805; Ghosh JG, 2005, BIOCHEMISTRY-US, V44, P14854, DOI 10.1021/bi0503910; GHOSH JG, 2007, BIOCHEMISTRY; Ghosh JG, 2006, BIOCHEMISTRY-US, V45, P13847, DOI 10.1021/bi061471m; Ghosh JG, 2006, CELL STRESS CHAPERON, V11, P187, DOI 10.1379/CSC-186.1; Ghosh JG, 2006, BIOCHEMISTRY-US, V45, P9878, DOI 10.1021/bi060970k; Gopalakrishnan S., 1993, Transactions of the Kansas Academy of Science, V96, P7, DOI 10.2307/3628308; Gruvberger-Saal SK, 2006, J CLIN INVEST, V116, P30, DOI 10.1172/JCI27462; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Hardy J, 2003, J MOL NEUROSCI, V20, P203, DOI 10.1385/JMN:20:2:203; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hardy John, 2006, Current Alzheimer Research, V3, P71, DOI 10.2174/156720506775697098; Head MW, 2000, NEUROREPORT, V11, P361, DOI 10.1097/00001756-200002070-00028; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Jordan A, 1998, MED RES REV, V18, P259, DOI 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.3.CO;2-T; Kato K, 1996, J BIOL CHEM, V271, P26989, DOI 10.1074/jbc.271.43.26989; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; LAUDANSKI K, 2006, ARCH IMMUNOL THER EX; LAUNAY N, 2006, EXP CELL RES; Liang JJ, 2006, PROTEIN SCI, V15, P1619, DOI 10.1110/ps.062216006; Liang P, 1997, J CELL SCI, V110, P1431; LIESKA N, 1980, BIOCHIM BIOPHYS ACTA, V626, P136, DOI 10.1016/0005-2795(80)90205-6; Liu LY, 2006, ANAL BIOCHEM, V350, P186, DOI 10.1016/j.ab.2005.12.019; Maglara AA, 2003, J PHYSIOL-LONDON, V548, P837, DOI 10.1113/jphysiol.2002.034520; Mao JJ, 2001, NEUROPATH APPL NEURO, V27, P180, DOI 10.1046/j.1365-2990.2001.00310.x; Minami M, 2003, ACTA NEUROPATHOL, V105, P549, DOI 10.1007/s00401-003-0679-0; MITRA G, 2007, PROTEINS; Montero A, 2005, LANCET ONCOL, V6, P229, DOI 10.1016/S1470-2045(05)70094-2; Muchowski PJ, 1999, INVEST OPHTH VIS SCI, V40, P951; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; Pasta SY, 2004, MOL VIS, V10, P655; Prescott AR, 1996, OPHTHALMIC RES, V28, P58, DOI 10.1159/000267946; Quinlan Roy, 2002, Prog Mol Subcell Biol, V28, P219; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SAKURAI T, 2005, FASEB J; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHINOHARA H, 1993, J NEUROL SCI, V119, P203, DOI 10.1016/0022-510X(93)90135-L; Simmons TL, 2005, MOL CANCER THER, V4, P333; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; THOMPSON WC, 1981, CELL MOTIL CYTOSKEL, V1, P445, DOI 10.1002/cm.970010405; TOMOKANE N, 1991, AM J PATHOL, V138, P875; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; WANG J, 2007, NEUROBIOL AGING; Wang XJ, 2003, CIRC RES, V93, P998, DOI 10.1161/01.RES.0000102401.77712.ED; Wilhelmus MMM, 2006, NEUROPATH APPL NEURO, V32, P119, DOI 10.1111/j.1365-2990.2006.00689.x; Wisniewski T, 1998, NEUROCHEM RES, V23, P385, DOI 10.1023/A:1022465702518; Xi JH, 2006, FASEB J, V20, P846, DOI 10.1096/fj.05-5532com	61	58	59	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e498	10.1371/journal.pone.0000498	http://dx.doi.org/10.1371/journal.pone.0000498			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551579	Green Submitted, gold, Green Published			2022-12-25	WOS:000207451500008
